

ADVANCES IN MEDICAL IMAGING, DETECTION, AND DIAGNOSIS

edited by


Raj Bawa | Gerald F. Audette | S. R. Bawa

Bela Patel | Bruce D. Johnson

Rajeev Khanna



ADVANCES IN MEDICAL IMAGING, DETECTION, AND DIAGNOSIS



Current Issues in Medicine

Series Editor

Raj Bawa

Titles in the Series

Vol. 1

Advances in Medical Biochemistry, Genomics, Physiology, and Pathology

Raj Bawa, Esther H. Chang, Gerald F. Audette, Anil Diwan, and Saadia A. Faiz, eds.

2022

978-981-4877-44-2 (Hardcover)

978-1-003-18044-9 (eBook)

Vol. 2

Advances in Clinical Immunology, Medical Microbiology, COVID-19, and Big Data

Raj Bawa, ed.

2022

978-981-4877-84-8 (Hardcover)

978-1-003-18043-2 (eBook)

Vol. 3

Advances in Surgical and Medical Specialties

Raj Bawa, ed.

2023

978-981-4877-45-9 (Hardcover)

978-1-003-29830-4 (eBook)

Vol. 4

Advances in Medical Imaging, Detection, and Diagnosis

Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna, eds.

2023

978-981-4877-46-6 (Hardcover)

978-1-003-29803-8 (eBook)

Vol. 5

Advances in Medicine: Critical Issues, Current Perspectives, and Editorials

Raj Bawa, ed.

2024

Vol. 6

Advances in Therapies and Clinical Applications

Raj Bawa, Gerald F. Audette, eds.

2024

Vol. 7

Advances in Drug Delivery

Raj Bawa, ed.

2024

Current Issues in Medicine Vol. 4

Advances in Medical Imaging, Detection, and Diagnosis

edited by

Raj Bawa, PhD, MD

Patent Agent, Bawa Biotech LLC, Ashburn, Virginia, USA
VP and Chief IP Officer, Guanine Inc., Rensselaer, New York, USA
Scientific Advisor, Teva Pharmaceutical Industries, Ltd., Israel

Gerald F. Audette, PhD

Associate Dean, Faculty of Science
Professor of Chemistry, York University
Toronto, Canada

S. R. Bawa, MSc, PhD

Scientific Advisor, Bawa Biotech LLC, Ashburn, Virginia, USA

Bela Patel, MD

Professor of Medicine, Graham Distinguished University Chair
Vice Dean of Healthcare Quality, McGovern Medical School
The University of Texas Health Science Center
Houston, Texas, USA

Bruce D. Johnson, PhD

Professor of Medicine, Professor of Physiology
Department of Cardiovascular Medicine, Mayo Clinic
Rochester, Minnesota, USA

Rajeev Khanna, MD

Medical Director, Virginia Medical Arts Clinic, PC
Sterling, Virginia, USA



JENNY STANFORD
PUBLISHING

Published by

Jenny Stanford Publishing Pte. Ltd.
101 Thomson Road
#06-01, United Square
Singapore 307591
Email: editorial@jennystanford.com
Web: www.jennystanford.com

Note from the Series Editor and the Publisher

Extensive efforts have been made to make the information provided herein as accurate and up-to-date as possible. It is important to note that knowledge and best practices in the various fields represented in this book (pathology, clinical microbiology, vaccines, nutrition, surgical tools and procedures, stem cell research, biochemistry, drug delivery, nanomedicine, precision medicine, genomics, tissue engineering, pharmaceutical sciences, etc.) are constantly evolving. This book is no substitute for individual patient assessment based on health care professionals' examination of each patient and consideration of specific factors unique to that patient. These include, but are not limited to, the following: age, weight, height, gender, current and past medical history, family medical data, laboratory data, etc. Therefore, it is imperative that the reader not rely solely on the information presented herein. The reader should always consult: (i) appropriate medical professionals (physicians, dentists, pharmacists, licensed healthcare professionals, etc.), (ii) federal agencies (FDA, CDC, NIH, NIOSH, CPSC, etc.), and/or (iii) product manufacturer, including drug/device product labels (regarding use, warnings, directions, etc.) before consuming any drug product, using any medical device, selecting any diagnostic procedure, or undergoing any surgery. To the fullest extent of the law, the publisher, the editors, and the authors make no representations or warranties, express or implied, with respect to the information presented in this book, for its use or misuse, or interpretation thereof. In this regard, they assume no liability for any injury and/or damage to persons or property as a matter of product liability, negligence, or otherwise.

A catalogue record for this book is available from the Library of Congress and the British Library.

Advances in Medical Imaging, Detection, and Diagnosis

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd. All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage and retrieval system now known or to be invented, without written permission from the publisher. For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case, permission to photocopy is not required from the publisher.

ISBN 978-981-4877-46-6 (Hardcover)

ISBN 978-1-003-29803-8 (eBook)

Dedication

It is an honor and privilege to dedicate this volume to our friend, colleague, mentor, and collaborator

Prof. Howard E. Gendelman, MD

For demonstrating the determination and ingenuity to not only revolutionize the field of neuroimmunology but to develop the cross section between pharmacology and neuroscience in the novel therapies for neurodegenerative disorders.

For his pioneering leadership and ceaseless energy as a physician-scientist, and as a mentor to countless young professionals dedicated to building the next generation of scientific leaders.

For his innovative research in therapeutics for Parkinson's and Alzheimer's diseases that serve to slow or improve clinical disease outcomes.

For the co-development of ultra-long-acting antiretroviral and CRISPR excision therapies for treatment, prevention, and elimination of viral infections.

And for serving as a tenacious advocate for building collaborations, and being an inspirational role-model of the power of never accepting 'no' as the final answer.
Today but not tomorrow.



*Margaret R. Larson Professor of Internal Medicine and Infectious Diseases
Professor and Chair, Department of Pharmacology and Experimental Neuroscience
Head, Carol Swarts MD Laboratory of Innovative Neuroscience
Co-Director of the Center for Neurodegenerative Disorders
University of Nebraska Medical Center, Omaha, Nebraska, USA*

The Editors



Raj Bawa, PhD, MD, is president of Bawa Biotech LLC (founded in 2002), a biotech/pharma consultancy and patent law firm based in Ashburn, Virginia, USA. Trained as a microbiologist and biochemist, he is an inventor, author, entrepreneur, professor, and registered patent agent (since 2002) licensed to practice before the US Patent & Trademark Office. He is currently a scientific advisor to Teva Pharmaceutical Industries, Israel (since 2010), and full professor (adjunct) at Northern Virginia Community College, Annandale, Virginia (since 2004). He is vice president and chief IP officer at Guanine, Inc., Rensselaer, New York (since 2017), a company focused on rapid, accurate detection of infective pathogens. He has served as a principal investigator of various National Cancer Institute (NCI) research grants; most recently as a principal investigator of a Centers for Disease Control and Prevention (CDC) grant to develop an assay for *Klebsiella pneumoniae* carbapenemase (KPC)-producing bacteria. He was an adjunct professor at Rensselaer Polytechnic Institute, Troy, New York, from 1998 to 2018. After earning a BSc (Honors School) in microbiology, he earned an MS in cancer biology, a PhD in biophysics/biochemistry, and an MD. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner from 1996–2002. Currently, he is a life member of Sigma Xi, cochair of the nanotech and precision medicine committees of the American Bar Association, and founding director of the American Society for Nanomedicine (established in 2008). He has authored over 100 publications, edited 10 texts, and serves on the editorial boards of numerous peer-reviewed journals, including serving as an associate editor of *Nanomedicine* (Elsevier).



Gerald F. Audette, PhD, is associate dean, Faculty of Science, professor of chemistry, and member of the Centre for Research on Biomolecular Interactions at York University, Toronto, Canada. His research focuses on the correlation between protein structure and biological activity of proteins involved in bacterial conjugation, in particular, the type 4 secretion system from the conjugative F-plasmid of *Escherichia coli*. In addition, his research targets the type IV pilins and associated assembly systems from multiple bacterial pathogens and is exploring the adaptation of these protein systems for applications in bionanotechnology and nanomedicine. Dr. Audette is the co-editor of volumes 1–4 of the *Jenny Stanford Series on Nanomedicine* and is a subject editor of structural chemistry and crystallography for the journal *FACETS*.



S. R. Bawa, MSc, PhD, is currently scientific advisor at Bawa Biotech LLC, a biotechnology and patent law firm founded in 2002 and based in Ashburn, Virginia. Previously, he was Founding Chairman and Professor of Biophysics at Panjab University, Chandigarh, India (1964–1992). At Panjab University, he also served as Dean of Foreign Students (1986–1988) and Coordinator of the Biotechnology Center (1986–1988). He was president of the

Electron Microscopy Society of India (1986–1992), Secretary of the Indian Biophysical Society (1986–1988), and Founding Secretary of the Northern India Science Association (1966–1992). Dr. Bawa received his BSc (University Gold Medal), MSc (University Gold Medal), and PhD degrees in 1949, 1951, and 1954, respectively, from Panjab University. He was a Fulbright Fellow and Instructor (1958–1960) and a Boese Postdoctoral Research Fellow (1959–1960), both at Columbia University. He was an Instructor (1961–1963) in the Department of Anatomy at Cornell University Medical College. In 1964, at the age of 34, he assumed the position of Founding Head and Reader of the newly established Biophysics Department at Panjab University, Chandigarh, India. He was promoted to Professor and Head in 1969. After retiring from Panjab University in 1992, Dr. Bawa joined the David Axelrod Institute of the New York State Department of Health in Albany, New York, from where he retired in 1999. Dr. Bawa has published over 150 scientific papers in peer-reviewed journals, books, and conference proceedings. His numerous accolades include Alexander von Humboldt Fellowship, Germany (five times); Fulbright Fellowship, US; US Alumni Research Travel Grant, US; Boese Postdoctoral Fellowship, Columbia University, US; British Council Invitee, UK; Diatome Award of the Electron Microscope Society of America; PL-480 Research Project and Appreciation Award, US Department of Agriculture; Kazato Research Award, Japan; and National Lectureship, India. He is an elected member or life member of various professional societies and organizations. He has served on various international scientific committees, advisory boards, government expert panels, and held visiting professorships in the US, Canada, and Europe. He has been a member of various peer-reviewed international journal editorial boards, including *Ultramicroscopy* (1986–1995, Elsevier), *Andrologia* (1993–1995, Blackwell/Wiley), *Acta Anatomica* (1974–1977, Karger), *Journal of Ultrastructure Research* (1969–1985, Elsevier) and *Journal of Submicroscopic Cytology* (1970–1977, Università di Bologna). Since 2004, the *Dr. S. R. Bawa Merit Scholarship* is awarded by Panjab University to a student standing first in the BSc (Honors School) class in biophysics. In 2022, Panjab University presented Dr. Bawa the *Distinguished Alumnus Award*.



Bela Patel, MD, is a professor of medicine, vice dean of Healthcare Quality, and division director for Pulmonary, Critical Care and Sleep Medicine at the McGovern Medical School at the University of Texas Health Science Center in Houston. She is regional chief medical officer and executive medical director of Critical Care for Memorial Hermann Hospital Texas Medical Center. Dr. Patel attended the University of Texas in Austin and the University of Texas McGovern Medical School in Houston. She completed her training in internal medicine in 1996 and subsequently a fellowship in pulmonary, critical care and sleep medicine in 1999 also at the University of Texas Health Science Center in Houston. Dr. Patel was appointed as the chief of Pulmonary, Critical Care and Sleep Medicine in 2002 and later appointed the chief of Medicine at Lyndon B. Johnson General Hospital and vice chair of the Department of Medicine in 2007. In 2009, she became the assistant chief medical officer and subsequently regional chief medical officer in 2017 for Memorial Hermann Hospital Texas Medical Center. Through her work in quality and patient safety, she was inducted as a fellow in Clinical Safety and Effectiveness by the University of Texas System. Dr. Patel was appointed as the assistant dean of Healthcare Quality in 2011 and the vice dean in 2017 and supports the 18 vice chairs of quality in Medicine at McGovern Medical School. Dr. Patel's research interest includes sepsis, ARDS, pulmonary hypertension, cognitive complexity and error reduction in critical care, and quality improvement implementation.



Bruce D. Johnson, PhD, is a professor of medicine, professor of physiology, and a consultant in the Department of Cardiovascular Medicine at the Mayo Clinic, Rochester, Minnesota. Additionally, he has joint appointments in the Division of Preventive, Occupational and Aerospace Medicine and in the Department of Physiology and Biomedical Engineering. He is the director of the Mayo Clinical Research Unit's Energy Balance Core Laboratory and directs his own research laboratory in human integrative and environmental physiology. The majority of his research has focused on factors limiting human performance in various clinical syndromes, in athletes, and under extreme environmental conditions. He has led field studies in Antarctica, funded through the National Science Foundation (NSF), and on Mount Aconcagua in Argentina, Mount Everest, and Mount Kilimanjaro. His research has involved studying unique populations such as breath-hold divers in Croatia and F-22 pilots from the US Air Force. His clinical research focuses on novel methods for the detection and tracking of chronic disease as well as environmental factors that may be involved in disease risk. His laboratory also works closely with consumer and medical device companies that track health status through wearable or passive sensing as well as with early-phase supplement and pharmaceutical company products. His research has been funded by the NIH, DOD, NSF, State of Minnesota, and industry.



Rajeev Khanna, MD, is an internal medicine consultant practicing in a group practice in Northern Virginia, as a part of Loudoun Medical Group. He is an internist with interest in long-term management of chronic health problems such as diabetes, high blood pressure, heart disease, and heart failure. He obtained his MBBS and MD in internal medicine from Dayanand Medical College, Ludhiana, Punjab, India, Dr. Khanna was in training for neurology postgraduation (DM) at the Postgraduate Institute of Medical Education and Research, Chandigarh, India before moving to the United States. He completed his residency in internal medicine at PG Hospital Center, Maryland, USA, in 1994. He has been published in multiple peer-reviewed journals.

Contents

<i>Corresponding Authors</i>	xxvii
<i>Note from the Series Editor</i>	xxxiii
1. Medical Imaging, Detection, and Diagnosis: A Journey in Pictures	1
<i>Raj Bawa, PhD, MD</i>	
2. Techniques and Technologies for Medical Imaging, Detection and Diagnosis: An Introduction	133
<i>National Institutes of Health</i>	
2.1 Studying Cells	134
2.2 Structural Biology	138
2.3 Optical Imaging	144
2.4 X-Rays	147
2.5 Mammography	154
2.6 Nuclear Medicine	157
2.7 Computed Tomography	161
2.8 Magnetic Resonance Imaging	165
2.9 Ultrasound	169
2.10 Sensors	173
2.11 Artificial Intelligence	176
2.12 Telehealth	178
2.13 Glossary of Terms	181
3. Progress in Viral Imaging by Super-Resolution Fluorescence Microscopy	197
<i>Stefania Castelletto, PhD, and Alberto Boretti, PhD</i>	
4. Ultra-Rapid Detection of SARS-CoV-2 in Public Workspace Environments	211
<i>Ozlem Yaren, PhD, Jacquelyn McCarter, Nikhil Phadke, PhD, Kevin M. Bradley, Benjamin Overton, Zunyi Yang, PhD, Shatakshi Ranade, MSc, Kunal Patil, Rishikesh Bangale, MSc, and Steven A. Benner, PhD</i>	
4.1 Introduction	211
4.2 Material and Methods	213
4.3 Results	217
4.4 Discussion	225

5. Saliva as a Testing Specimen with or without Pooling for SARS-CoV-2 Detection by Multiplex RT-PCR Test	233
<i>Qing Sun, PhD, Jonathan Li, PhD, Hui Ren, PhD, Larry Pastor, Yulia Loginova, PhD, Roberta Madej, PhD, Kristopher Taylor, Joseph K. Wong, MD, Zhao Zhang, PhD, Aiguo Zhang, PhD, Chuanyi M. Lu, MD, and Michael Y. Sha, PhD</i>	
5.1 Introduction	233
5.2 Methods	235
5.3 Results	238
5.4 Discussion	245
6. Theranostics: Simultaneous Treatment and Diagnosis Made Possible by Nanotechnology	251
<i>João Albuquerque, PhD, Ana Rute Neves, PhD, and Salette Reis, PhD</i>	
6.1 Introduction	251
6.2 Nanotechnology-Based Approaches	252
6.3 Concluding Remarks	263
7. Current Issues in Diagnosis and Staging of Cancer	269
<i>National Institutes of Health</i>	
7.1 Symptoms of Cancer	270
7.2 How Cancer Is Diagnosed	271
7.3 Cancer Staging	275
7.4 Understanding Cancer Prognosis	278
7.5 Questions to Ask Your Doctor about Your Diagnosis	281
7.6 Diagnosis and Staging Research	281
8. Diagnostic Ability of Radiofrequency Ultrasound in Parkinson's Disease Compared to Conventional Transcranial Sonography and Magnetic Resonance Imaging	285
<i>Mindaugas Baranauskas, PhD, Rytis Jurkonis, PhD, Arūnas Lukoševičius, PhD, Vaidas Matijošaitis, Rymantė Gleiznienė, PhD, and Daiva Rastenytė, PhD</i>	
8.1 Introduction	285
8.2 Materials and Methods	286
8.3 Results	292
8.4 Discussion	296
8.5 Conclusions	298
9. An Overview of Immunoassays	303
<i>Caroline Murphy, PhD, Sarah Gilgunn, PhD, and Richard O'Kennedy, PhD</i>	
9.1 Introduction to Antibodies and Immunoassays	303
9.2 Types of Immunoassays	308
9.3 Choosing a Suitable Immunoassay Technique	309

9.4	Signal Generation in Immunoassays	313
9.5	Next Generation Signal Transduction Systems	319
9.6	Conclusions and Key Issues	322
10.	My Personal and Professional Journey: <i>Reflections, Memories and Confessions</i>	331
	<i>S. R. Bawa, MSc, PhD</i>	
10.1	My Life: An Overview	331
10.2	Early Days in Lahore, British India	341
10.3	Punjab: Land of Five Rivers and India's Gatekeeper	347
10.4	Lahore	349
10.5	Urdu: The Language of Love	355
10.6	India: The Economic Jewel in the Crown	356
10.7	India's Independence, Partition of Punjab, and My Exodus from Lahore	358
10.8	Divide-and-Rule: A British Specialty	370
10.9	The Second Partition of Punjab	372
10.10	My Education in Independent India	375
10.11	My Life with Microscopes: An Ongoing Affair	380
10.12	The Passage from India	393
10.13	From Cornell to Panjab University	406
10.14	A Glimpse of Home Life at the University	438
10.15	International Travel and Research Collaborations	441
10.16	Future of the Research Enterprise	447
10.17	Concluding Remarks: Moving toward the Future while Reflecting on the Past	449
11.	Quantitative Polymerase Chain Reaction and Precision Medicine	473
	<i>Joel L. Ramirez, MD, and Johannes R. Kratz, MD</i>	
11.1	A Brief History of qPCR	473
11.2	What Is qPCR?	474
11.3	Current Uses of qPCR in Precision Medicine	475
11.4	qPCR in Oncology	475
11.5	qPCR in Infectious Disease	479
11.6	Limitations of qPCR	481
11.7	Future Use of qPCR in Precision Medicine	482
12.	Protein Biomarker Signatures in Precision Diagnostics of Cancer	487
	<i>Henrik Winther, PhD, and Carl Borrebaeck, PhD</i>	
12.1	Early Diagnosis and Biomarker Profiling within Cancer	487
12.2	Technology Requirements for Precision Diagnostic Medical Devices	488

12.3	Biomarker Multiplexing Provides Higher Diagnostic Accuracies	491
12.4	Regulatory Considerations	494
12.5	Other Prerequisites to the Successful Release of Protein Biomarker Signatures for Precision Diagnostics	496
12.6	Future Perspectives	499
13.	Next-Generation Sequencing for Companion Diagnostics and Precision Medicine	507
	<i>Il-Jin Kim, PhD, Pedro Mendez, PhD, and David Jablons, MD</i>	
13.1	Introduction	507
13.2	Platforms of Next-Generation Sequencing	508
13.3	Bioinformatics	520
13.4	NGS Applications for CDx and Clinical Laboratory Analysis	521
13.5	Potential Issues and Future Directions	524
14.	Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based <i>In Vitro</i> Diagnostics	531
	<i>U.S. Food and Drug Administration</i>	
14.1	Introduction	531
14.2	Background	532
14.3	Scope	534
14.4	Definitions	535
14.5	Recommendations	535
14.6	FDA's Genetic Variant Database Recognition Process	540
15.	Innovating the Concept and Practice of Two-Dimensional Gel Electrophoresis in the Analysis of Proteomes at the Proteoform Level	545
	<i>Xianquan Zhan, MD, PhD, Biao Li, Xiaohan Zhan, Hartmut Schlüter, PhD, Peter R. Jungblut, MD, and Jens R. Coorsen, PhD</i>	
15.1	Introduction	545
15.2	Definition of Spots and Pixels	549
15.3	Relationship between Proteoform, Protein, and Proteome	550
15.4	A 2DE Spot Contains Many Proteoforms Derived from Different Genes	551
15.5	Proteoforms from One Gene Are Distributed within Different 2DE Spots	551
15.6	Most Proteoforms in a 2DE Spot Are of Low-Abundance	553
15.7	Stable Isotope-Labeled 2DE-LC-MS/MS for the Large-Scale Analysis of Proteoforms	554
15.8	Conclusions	557

16. Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer	567
<i>Siew-Wai Pang, Noel Jacques Awi, Subasri Armon, MD, Wendy Wan-Dee Lim, MD, John Seng-Hooi Low, MD, Kaik-Boo Peh, MD, Suat-Cheng Peh, MD, PhD, and Sin-Yeang Teow, PhD</i>	
16.1 Colorectal Cancer and Its Treatment	567
16.2 Molecular Biomarkers	569
16.3 Current Molecular Diagnostic Technologies	575
16.4 Challenges and Limitations	581
16.5 Conclusions and Future Perspectives	582
17. Fully Electronic Urine Dipstick Probe for Combinatorial Detection of Inflammatory Biomarkers	597
<i>Vikramshankar Kamakoti, PhD, David Kinnamon, MS, Kang Hyeok Choi, Badrinath Jagannath, MS, Mohanraj Ramasamy, MS, and Shalini Prasad, PhD</i>	
17.1 Introduction	597
17.2 Materials and Methods	600
17.3 FTIR Characterization of Surface Chemistry	601
17.4 Surface Charge Characterization with ζ -Potential	601
17.5 Experimental Protocol for Biosensing Experiments	602
17.6 Portable Electronic Dipstick Interface	602
17.7 Results	603
17.8 Comparison of Impedance Response with Portable Electronic Hardware Prototype	608
17.9 Discussion	610
17.10 Conclusions	611
17.11 Future Perspectives	612
17.12 Summary Points	612
18. Nanosensor Diagnostics	619
<i>Sourav Bhattacharjee, PhD</i>	
18.1 Introduction	619
18.2 AuNPs	620
18.3 CNTs	629
18.4 QDs	637
18.5 MNPs	638
18.6 Summary and Outlook	639
19. Measuring Microbiome Effectiveness: A Role for Ingestible Sensors	655
<i>David Smith and Sohan Jheeta, PhD</i>	
19.1 Introduction: The Microbiome in Health and Disease	655
19.2 Horizontal Gene Transfer	656

19.3	Microbiome Diversity: Probiotics and Sentinel Cells	656
19.4	Detecting Diversity and Overall Composition of the Microbiome	658
19.5	The Mutualistic Microbiome: Dysbiosis	658
19.6	Ingestible Sensing Capsules in the Context of Microbiome Studies	660
19.7	Target Metabolites: A Surrogate Marker for Microbiome Effectiveness	661
19.8	What Is the Story So Far...?	662
20.	In-Ear Blood Oxygen Saturation: A Tool for Wearable, Unobtrusive Monitoring of Core Blood Oxygen Saturation	667
	<i>Harry J. Davies, MSc, Ian Williams, PhD, Nicholas S. Peters, PhD, and Danilo P. Mandic, PhD</i>	
20.1	Introduction	667
20.2	Materials and Methods	669
20.3	Results	674
20.4	Discussion	677
20.5	Conclusions	679
21.	Nanomaterials in Imaging	683
	<i>Sourav Bhattacharjee, PhD</i>	
21.1	Introduction	683
21.2	Gold Nanoparticles	684
21.3	Quantum Dots	695
21.4	Carbon Nanotubes	696
21.5	Magnetic Nanoparticles	700
21.6	Dendrimers	701
21.7	Polyelectrolyte Complex Nanoparticles	702
21.8	Silicon Nanoparticles	702
21.9	Summary and Outlook	703
22.	In vivo Imaging as a Tool to Noninvasively Study Nanosystems	725
	<i>George Loudos, PhD, and Maria Tina Rouchota, PhD</i>	
22.1	Introduction	725
22.2	X-Ray Imaging	726
22.3	Magnetic Resonance Imaging	729
22.4	Ultrasound	731
22.5	Scintigraphic and SPECT Imaging	732
22.6	Coincidence and PET Imaging	734

22.7	Optical Imaging	736
22.8	Multimodal Imaging	737
23.	Assessment and Quantification of the Core Muscles in Individuals with and without Achilles Tendon Pathology by Ultrasound Imaging	747
	<i>Carlos Romero-Morales, MSc, PT, PhD, César Calvo-Lobo, MSc, PT, PhD, Marta San-Antolín, PhD, PHYSC, Pedro Martín-Llantino, MSc, PT, PhD, David Rodríguez-Sanz, MSc, DP, PT, PhD, María Bravo-Aguilar, MSc, PT, PhD, and Daniel López-López, MSc, DP, MPH, PhD</i>	
23.1	Background	747
23.2	Material and Methods	749
23.3	Results	750
23.4	Discussion	751
23.5	Conclusions	752
24.	Loop-Mediated Isothermal Amplification: An Advanced Molecular Point-of-Care Technique for the Detection of <i>Leishmania</i> Infection	755
	<i>Chukwunonso O. Nzelu, PhD, Hirotomo Kato, DVM, PhD, and Nathan C. Peters, PhD</i>	
24.1	Introduction	755
24.2	LAMP Technique: Its Developments and Features	758
24.3	Application of LAMP Technique to Leishmaniasis	760
24.4	Molecular Xenomonitoring/Surveillance Potentials of LAMP for Leishmaniasis	767
24.5	LAMP Amplicon End-Point Closed Detection System	769
24.6	Cost and Hands-On Time of the <i>Leishmania</i> LAMP Test	771
24.7	Concluding Remarks and Future Directions	772
25.	Are Nanobiosensors an Improved Solution for Diagnosis of <i>Leishmania</i>?	783
	<i>Sona Jain, PhD, Wanessa Santana, Silvio S. Dolabella, PhD, André L. S. Santos, PhD, Eliana B. Souto, PhD, and Patrícia Severino, PhD</i>	
25.1	Introduction	783
25.2	Current Diagnostic Methods and Limitations	785
25.3	Emerging Nanomaterial-Based Detection Technologies	787
25.4	Conclusions	802
26.	Carbapenem-Resistant <i>Enterobacteriaceae</i> Testing in 45 Minutes Using Oligonucleotide Detection Tags	813
	<i>Neil Gordon, BEng, MBA, Raj Bawa, PhD, MD, Garry Palmateer, MSc, Mehdi Rajabi, PhD, Jesse B. Gordon, PhD, Noor M. Koth, BS, Rakshika Balasubramaniam, and Benjamin R. Gordon, BSc</i>	
26.1	Introduction	813
26.2	Materials and Methods	817

26.3	Results	821
26.4	Discussion	823
26.5	Conclusion	824
27.	Ultrasonography of the Kidney: A Pictorial Review	829
	<i>Kristoffer Linkdskov Hansen, MD, PhD, Michael Bachmann Nielsen, MD, PhD, and Caroline Ewertsen, MD, PhD</i>	
27.1	Introduction	829
27.2	Examination Technique	830
27.3	Findings in the Normal Kidney	830
27.4	Cystic Renal Masses	833
27.5	Solid Renal Masses	835
27.6	Hydronephrosis	838
27.7	Renal Calculi	841
27.8	Chronic Kidney Disease	843
27.9	Acute Renal Injury	845
27.10	US-Guided Intervention	846
27.11	CEUS, Image Fusion and Elastography	847
27.12	Conclusions	849
28.	The Accuracy of Lung Auscultation in the Practice of Physicians and Medical Students	853
	<i>Honorata Hafke-Dys, PhD, Anna Bręborowicz, PhD, Paweł Kleka, PhD, Jędrzej Kociński, PhD, and Adam Biniakowski, PhD</i>	
28.1	Introduction	853
28.2	Study Objectives	854
28.3	Materials and Methods	855
28.4	Results	858
28.5	Discussion	866
28.6	Conclusions	868
29.	PCR for the Detection of Pathogens in Neonatal Early Onset Sepsis	873
	<i>Clarissa Oeser, MSc, Marcus Pond, PhD, Philip Butcher, PhD, Alison Bedford Russell, MD, Philipp Henneke, MD, PhD, Ken Laing, PhD, Timothy Planche, MD, PhD, Paul T. Heath, MD, PhD, and Kathryn Harris, PhD</i>	
29.1	Introduction	873
29.2	Materials and Methods	874
29.3	Culture Methods	875
29.4	Results	879
29.5	Discussion	883
29.6	Conclusions	885

30. Multiplex qPCR Discriminates Variants of Concern to Enhance Global Surveillance of SARS-CoV-2	891
<i>Chantal B. F. Vogels, PhD, Mallery I. Breban, Isabel M. Ott, Tara Alpert, PhD, et al.</i>	
30.1 Introduction	892
30.2 Results	894
30.3 Discussion	897
30.4 Materials and Methods	898
30.5 Supporting Information	901
31. Diagnosing Point-of-Care Diagnostics for Neglected Tropical Diseases	907
<i>Mitasha Bharadwaj, PhD, Michel Bengtson, PhD, Mirte Golverdingen, MSc, Loulotte Waling, MSc, and Cees Dekker, PhD</i>	
31.1 Point-of-Care Diagnostics	907
31.2 Three Different Approaches for PoC Diagnostics	910
31.3 PoC Tests for Neglected Tropical Diseases	913
31.4 Discussion and Conclusions	922
31.5 Methods	925
32. Capture and Visualization of Live <i>Mycobacterium tuberculosis</i> Bacilli from Tuberculosis Patient Bioaerosols	935
<i>Ryan Dinkele, Sophia Gessner, PhD, Andrea McKerry, Bryan Leonard, MPH, et al.</i>	
32.1 Introduction	935
32.2 Results	937
32.3 Discussion	944
32.4 Materials and Methods	947
33. Diagnostic Accuracy of a Novel Tuberculosis Point-of-Care Urine Lipoarabinomannan Assay for People Living with HIV: A Meta-Analysis of Individual In- and Outpatient Data	955
<i>Tobias Broger, MSc, Mark P. Nicol, PhD, Rita Székely, PhD, Stephanie Bjerrum, MD, PhD, et al.</i>	
33.1 Introduction	956
33.2 Methods	957
33.3 Results	960
33.4 Discussion	965
34. History of Thermal Imaging from 1960	973
<i>Kurt Ammer, MD, PhD, and Francis Ring, DSc</i>	
34.1 Development of Imaging Systems	973
34.2 Development of Applications	975

35. A Novel Deep Learning-Based Point-of-Care Diagnostic Method for Detecting <i>Plasmodium falciparum</i> with Fluorescence Digital Microscopy	979
<i>Oscar Holmström, MD, PhD, Sebastian Stenman, MD, Antti Suutala, MScEng, Hannu Moilanen, Hakan Küçükkel, Billy Ngasala, MD, PhD, Andreas Mårtensson, PhD, Lwidiko Mhamilawa, PhD, Berit Aydin-Schmidt, PhD, Mikael Lundin, MD, Vinod Diwan, PhD, Nina Linder, MD, PhD, and Johan Lundin, PhD</i>	
35.1 Introduction	979
35.2 Materials and Methods	981
35.3 Results	989
35.4 Discussion	993
35.5 Conclusion	995
35.6 Hardware, Software and Data Availability Statement	995
36. Positron Emission Tomography and Magnetic Resonance Imaging in Experimental Human Malaria to Identify Organ-Specific Changes in Morphology and Glucose Metabolism: A Prospective Cohort Study	1001
<i>John Woodford, PhD, Ashley Gillman, PhD, Peter Jenvey, MBBS, Jennie Roberts, MBBS, Stephen Woolley, MSc, Bridget E. Barber, PhD, Melissa Fernandez, Stephen Rose, MD, Paul Thomas, PhD, Nicholas M. Anstey, PhD, and James S. McCarthy, PhD</i>	
36.1 Introduction	1001
36.2 Methods	1003
36.3 Results	1004
36.4 Discussion	1009
37. Chemical Tools for Decoding Redox Signaling at the Host–Microbe Interface	1017
<i>Elizabeth M. Gordon, MSc, and Stavroula K. Hatzios, PhD</i>	
37.1 Introduction	1017
37.2 How Are ROS Generated at the Host–Microbe Interface?	1018
37.3 How Do ROS Modulate Cell Signaling at the Posttranslational Level?	1018
37.4 Why Are Chemical Approaches Useful for Detecting Redox Signaling?	1019
37.5 Future Directions	1022
38. The CRISPR Toolbox in Medical Mycology: State of the Art and Perspectives	1025
<i>Florent Morio, PhD, Lisa Lombardi, PhD, and Geraldine Butler, PhD</i>	
38.1 Introduction	1025
38.2 The CRISPR–Cas9 Toolbox: How Does It Work?	1026

38.3	Tips and Tricks of CRISPR–Cas9 in Fungi	1027
38.4	Current Methods Available for Genome Editing in Fungal Pathogens	1028
38.5	Perspectives and Future Directions	1040
38.6	Conclusions	1043
39.	The Potential Impact of Urine-LAM Diagnostics on Tuberculosis Incidence and Mortality: A Modelling Analysis	1053
	<i>Saskia Ricks, PhD, Claudia M. Denkinger, MD, PhD, Samuel G. Schumacher, PhD, Timothy B. Hallett, PhD, and Nimalan Arinaminpathy, PhD</i>	
39.1	Introduction	1053
39.2	Methods	1055
39.3	Results	1066
39.4	Discussion	1069
39.5	Conclusions	1071
40.	Development of a Multiplex Loop-Mediated Isothermal Amplification Assay for On-Site Diagnosis of SARS CoV-2	1081
	<i>Woong Sik Jang, Da Hye Lim, Jung Yoon, MD, Ahran Kim, Minsup Lim, Jeonghun Nam, PhD, Richard Yanagihara, MD, MPH, Sook-Won Ryu, MD, Bo Kyeong Jung, PhD, Nam-Hee Ryoo, MD, PhD, and Chae Seung Lim, MD, PhD</i>	
40.1	Introduction	1081
40.2	Materials and Methods	1082
40.3	Results	1086
40.4	Discussion	1093
41.	A Proteomics-Based Method for Identifying Antigens within Immune Complexes	1099
	<i>Stephanie Menikou, PhD, Andrew J. McArdle, MD, Ming-Shi Li, PhD, Myrsini Kaforou, PhD, Paul R. Langford, PhD, and Michael Levin, PhD</i>	
41.1	Introduction	1099
41.2	Materials and Methods	1101
41.3	Results	1105
41.4	Discussion	1111
42.	Avidin-Biotin Complex-Based Capture Coating Platform for Universal Influenza Virus Immobilization and Characterization	1119
	<i>Micaela Trexler, PhD, Michelle Brusatori, PhD, and Gregory Auner, PhD</i>	
42.1	Introduction	1119
42.2	Materials and Methods	1122
42.3	Results and Discussion	1124

43. Visualization of Sympathetic Neural Innervation in Human White Adipose Tissue	1137
<i>Aliki Perdikari, PhD, Tessa Cacciottolo, MD, PhD, Elana Henning, RN, Edson Mendes de Oliveira, PhD, Julia M. Keogh, and I. Sadaf Farooqi, PhD</i>	
43.1 Introduction	1137
43.2 Results	1138
43.3 Discussion	1141
43.4 Material and Methods	1143
43.5 Ethics	1146
44. Brainstem fMRI	1151
<i>Pengxu Wei, PhD, Zhi Lan, PhD, Zeping Lv, PhD, and Yubo Fan, PhD</i>	
44.1 Introduction	1151
44.2 Technical Challenges of Brainstem fMRI	1152
44.3 Advances in Brainstem fMRI	1156
44.4 Further Directions	1157
45. Electrodes for Neural Stimulation and Monitoring	1163
<i>Jonathan R. Tomshine, PhD, and Kevin E. Bennet, PhD</i>	
45.1 Introduction	1163
45.2 Electrode Design Considerations	1164
45.3 Neural Electrode Examples	1167
45.4 Summary	1172
46. Imaging and Visualizing SARS-CoV-2 in a New Era for Structural Biology	1175
<i>Kendra E. Leigh, PhD, and Yorgo Modis, PhD</i>	
46.1 Introduction	1175
46.2 Background	1176
46.3 The Resolution Spectrum	1176
46.4 Finding and Tracking SARS-CoV-2 in the Cell	1179
46.5 The Cryo-EM Revolution—Impact on SARS-CoV-2 Imaging	1180
46.6 X-Ray Crystallography	1185
46.7 Outlook	1187
47. Super-Resolution Microscopy: A Brief History and New Avenues	1195
<i>Kirti Prakash, PhD, Benedict Diederich, PhD, Rainer Heintzmann, PhD, and Lothar Schermelleh, PhD</i>	
47.1 Introduction	1195
47.2 A Brief History of Super-Resolution Microscopy	1196
47.3 New Avenues for Super-Resolution Microscopy	1200

47.4	Biological Application of SRM: What Have We Learned?	1201
47.5	Open Technology Developments for Super-Resolution Microscopy	1203
48.	End-to-End System for Rapid and Sensitive Early-Detection of SARS-CoV-2 for Resource-Poor and Field-Test Environments Using a \$51 Lab-in-a-Backpack	1213
	<i>E. Emily Lin, MSc, Umar A. Razzaque, MSc, Stephen A. Burrows, PhD, and Stoyan K. Smoukov, PhD</i>	
48.1	Introduction/Background	1213
48.2	Equipment/Materials and Methods	1216
48.3	Modified RT-LAMP Reaction Components	1217
48.4	Results	1218
48.5	Conclusions	1222
49.	A Review of the Leishmanin Skin Test: A Neglected Test for a Neglected Disease	1227
	<i>Jessica Carstens-Kass, Kayla Paulini, Patrick Lypaczewski, MSc, and Greg Matlashewski, PhD</i>	
49.1	Introduction	1227
49.2	History of the Leishmanin Skin Test	1229
49.3	Potential Application of Leishmanin to the Interferon- γ Release Assay	1235
49.4	Future Directions	1237
50.	Current Issues in Age-Related Macular Degeneration	1249
	<i>National Institutes of Health</i>	
50.1	What Is AMD?	1250
50.2	Who Is at Risk?	1251
50.3	How Is AMD Detected?	1251
50.4	What Are the Stages of AMD?	1253
50.5	How Is AMD Treated?	1254
50.6	What Are Some Low Vision Devices?	1257
50.7	What Is Charles Bonnet Syndrome?	1257
50.8	Byooviz	1258
51.	On-Chip Liquid Chromatography	1261
	<i>Makoto Tsunoda, PhD</i>	
51.1	Introduction	1261
51.2	Approaches	1262
51.3	Conclusions	1268

52. Studying Metabolism with Multi-Organ Chips: New Tools for Disease Modelling, Pharmacokinetics and Pharmacodynamics	1273
<i>Tanvi Shroff, MSc, Kehinde Aina, MSc, Christian Maass, PhD, Madalena Cipriano, PhD, Joeri Lambrecht, PhD, Frank Tacke, MD, PhD, Alexander Mosig, PhD, and Peter Loskill, PhD</i>	
52.1 Introduction	1274
52.2 Concepts for Linking Multi-Organ Chips	1279
52.3 Multi-Organ Chips to Study Metabolism	1282
52.4 Applications of Metabolism-Focused Multi-Organ Chips	1284
52.5 <i>In silico</i> Modelling of Multi-Organ Chips and <i>in vitro</i> – <i>in vivo</i> Translation	1294
52.6 Outlook	1301
53. From <i>Animaculum</i> to Single Molecules: 300 Years of the Light Microscope	1317
<i>Adam J. M. Wollman, D. Phil., Richard Nudd, PhD, Erik G. Hedlund, PhD, and Mark C. Leake, PhD</i>	
53.1 Summary	1317
53.2 Antonj van Leeuwenhoek and Invention of the Microscope	1318
53.3 The Development of the Microscope and Its Theoretical Underpinnings	1320
53.4 Increasing Optical Contrast	1321
53.5 The Fluorescence Microscope	1324
53.6 Improving Resolution in Length and Time	1326
53.7 The Future	1330
54. Ultrastructure Expansion Microscopy in <i>Trypanosoma Brucei</i>	1339
<i>Ana Kalichava, MSc, and Torsten Ochseneiter, PhD</i>	
54.1 Introduction	1339
54.2 Results and Discussion	1342
54.3 Material and Methods	1348
55. Pathogenic Prion Structures at High Resolution	1355
<i>Byron Caughey, PhD, Heidi G. Standke, Efrosini Artikis, PhD, Forrest Hoyt, MSc, and Allison Kraus, PhD</i>	
55.1 What Structures Allow Prions to Propagate as Deadly Infectious Pathogens?	1356
55.2 What Is the Structural Basis of Prion Strain Variation?	1358
55.3 How Might Prion Structures Explain Prion Transmission Barriers?	1359

55.4	How Might GPI Anchors and N-Linked Glycans Affect Prion Structure and Interactions with Tissue Environments?	1359
55.5	What Are Structural Determinants of Prion Transmissibility and Pathogenicity?	1360
	<i>Index</i>	1363

Corresponding Authors

Kurt Ammer, MD, PhD

Faculty of Advanced Technology
University of South Wales
Pontypridd, UK

Mindaugas Baranauskas, PhD

Biomedical Engineering Institute
Kaunas University of Technology
Kaunas, Lithuania
m.baranauskas@ktu.lt

Raj Bawa, PhD, MD

Bawa Biotech LLC, Ashburn, Virginia,
USA
Guanine Inc., Rensselaer, New York, USA
Teva Pharma Industries Ltd., Israel
bawa@bawabiotech.com

S. R. Bawa, MSc, PhD

Bawa Biotech LLC
Ashburn, Virginia, USA
bawa@bawabiotech.com

Steven A. Benner, PhD

Foundation for Applied Molecular
Evolution
Alachua, Florida, USA
sbenner@ffame.org

Kevin E. Bennet, PhD

Department of Neurologic Surgery
Mayo Clinic
Rochester, Minnesota, USA
kbennet@mayo.edu

Sourav Bhattacharjee, PhD

University College Dublin
Dublin, Ireland
sourav.bhattacharjee@ucd.ie

Geraldine Butler, PhD

School of Biomolecular and Biomedical
Science, Conway Institute

University College Dublin
Belfield, Dublin, Ireland
geraldine.butler@ucd.ie

César Calvo-Lobo, MSc, PT, PhD

Facultad de Enfermería
Fisioterapia y Podología
Universidad Complutense de Madrid
Madrid, Spain
cescalvo@ucm.es

Stefania Castelletto, PhD

RMIT University
Melbourne, Australia
stefania.castelletto@rmit.edu.au

Byron Caughey, PhD

Rocky Mountain Laboratories
National Institutes of Health
Hamilton, Montana, USA
bcaughey@nih.gov

Harry J. Davies, MSc

Department of Electrical and Electronic
Engineering
Imperial College London
London, UK
harry.davies14@imperial.ac.uk

Cees Dekker, PhD

Department of Bionanoscience
Kavli Institute of Nanoscience Delft
Delft University of Technology
Delft, The Netherlands
c.dekker@tudelft.nl

Yubo Fan, PhD

School of Biological Science and Medical
Engineering
Beihang University
Haidian District, Beijing, China
yubofan@buaa.edu.cn

I. Sadaf Farooqi, PhD

Wellcome-MRC Institute of Metabolic
Science
University of Cambridge Metabolic
Research Laboratories
Addenbrooke's Hospital
Cambridge, UK
isf20@cam.ac.uk

Joseph R. Fauver, PhD

Department of Epidemiology of
Microbial Diseases
Yale School of Public Health
New Haven, Connecticut, USA
joseph.fauver@yale.edu

Neil Gordon, BEng, MBA

Guanine, Inc.
Rensselaer, New York, USA
neil.gordon@guanineinc.com

Nathan D. Grubaugh, PhD

Department of Epidemiology of
Microbial Diseases
Yale School of Public Health
New Haven, Connecticut, USA
nathan.grubaugh@yale.edu

Honorata Hafke-Dys, PhD

Institute of Acoustics, Faculty of Physics
Adam Mickiewicz University in Poznań
Uniwersytetu Poznańskiego, Poland
h.hafke@amu.edu.pl

Kristoffer L. Hansen, MD, PhD

Department of Radiology
Copenhagen University Hospital
Copenhagen, Denmark
lindskov@gmail.com

Stavroula K. Hatzios, PhD

Department of Molecular, Cellular, and
Developmental Biology
Yale University
New Haven, Connecticut, USA
stavroula.hatzios@yale.edu

Oscar Holmström, MD, PhD

Institute for Molecular Medicine Finland
University of Helsinki
Helsinki, Finland
oscar.holmstrom@helsinki.fi

Sona Jain, PhD

Postgraduate Program in Industrial
Biotechnology
Universidade Tiradentes
Aracaju, Brazil
sona.arun@souunit.com.br

Sohan Jheeta, PhD

NoR CEL
Leeds, UK
sohan@sohanjheeta.com

Il-Jin Kim, PhD

Guardant Health
Redwood City, California, USA
ijkimsf@gmail.com

Johannes R. Kratz, MD

Division of Cardiothoracic Surgery
University of California
San Francisco, California, USA
johannes.kratz@ucsf.edu

Allison Kraus, PhD

Department of Pathology and Cleveland
Center for Membrane and Structural
Biology
Case Western Reserve University School
of Medicine
Cleveland, Ohio, USA
alk127@case.edu

Mark C. Leake, PhD

Biological Physical Sciences Institute
Departments of Physics and Biology
University of York
York, UK
mark.leake@york.ac.uk

Chae Seung Lim, MD, PhD

Departments of Laboratory Medicine
College of Medicine
Korea University Guro Hospital
Seoul, Korea
malarim@korea.ac.kr

Peter Loskill, PhD

NMI Natural and Medical Sciences
Institute
University of Tübingen
Reutlingen, Germany
peter.loskill@uni-tuebingen.de

George Loudos, PhD

Technological Educational Institute of
Athens
Attiki, Athens, Greece
gloudos@teiath.gr

Chuanyi M. Lu, MD

University of California and VA
Healthcare System
San Francisco, California, USA
mark.lu@va.gov

Greg Matlashewski, PhD

Department of Microbiology and
Immunology
McGill University
Montreal, Canada
greg.matlashewski@mcgill.ca

Stephanie Menikou, PhD

Department of Infectious Disease
Section of Paediatric Infectious Disease
Imperial College London
London, UK
s.menikou@imperial.ac.uk

Yorgo Modis, PhD

Molecular Immunity Unit
Department of Medicine
MRC Laboratory of Molecular Biology
University of Cambridge

Cambridge, UK
ymodis@mrc-lmb.cam.ac.uk

Alexander Mosig, PhD

Institute of Biochemistry II
Center for Sepsis Control and Care
Jena University Hospital
Jena, Germany
alexander.mosig@med.uni-jena.de

Caroline Murphy, PhD

School of Biotechnology
Dublin City University
Dublin, Ireland
caroline.s.murphy@dcu.ie

Chukwunonso O. Nzelu, PhD

Snyder Institute for Chronic Diseases
Cumming School of Medicine and
Comparative Biology and Experimental
Medicine
Faculty of Veterinary Medicine
University of Calgary
Calgary, Canada
chukwunonso.nzelu@ucalgary.ca

Torsten Ochsenreiter, PhD

Institute of Cell Biology
University of Bern
Switzerland
torsten.ochsenreiter@izb.unibe.ch

Clarissa Oeser, MSc

Paediatric Infectious Diseases
Institute of Infection and Immunity
St George's, University of London
London, UK
clarissa_oeser@yahoo.com

Siew-Wai Pang

Department of Medical Sciences
Sunway University
Jalan University
Subang Jaya, Malaysia
15035363@imail.sunway.edu.my

Nathan C. Peters, PhD

Snyder Institute for Chronic Diseases
Cumming School of Medicine and
Comparative Biology and Experimental
Medicine
Faculty of Veterinary Medicine
University of Calgary
Calgary, Canada
ncpeters@ucalgary.ca

Kirti Prakash, PhD

Integrated Pathology Unit
Centre for Molecular Pathology
The Royal Marsden Trust and Institute
of Cancer Research
Sutton, UK
kirtiprakash2.71@gmail.com

Shalini Prasad, PhD

Department of Bioengineering
University of Texas at Dallas
Richardson, Texas, USA
shalini.prasad@utdallas.edu

Daiva Rastenytė, PhD

Department of Neurology
Medical Academy
Lithuanian University of Health Sciences
Kaunas, Lithuania
daiva.rastenyte@ismuni.lt

Salette Reis, PhD

Department of Chemical Sciences
Faculty of Pharmacy
University of Porto
Porto, Portugal
shreis@ff.up.pt

Saskia Ricks, PhD

MRC Centre for Global Infectious Disease
Analysis
Imperial College London
London, UK
saskia.ricks12@imperial.ac.uk

Maria Tina Rouchota, PhD

Technological Educational Institute of
Athens

Attiki, Athens, Greece
m.rouchota@upatras.gr

Nam-Hee Ryoo, MD, PhD

Department of Laboratory Medicine
Dongsan Medical Center
Keimyung University
Daegu, Korea
nhryoo@dsmc.or.kr

Lothar Schermelleh, PhD

Department of Biochemistry
University of Oxford
Oxford, UK
lothar.schermelleh@bioch.ox.ac.uk

Samuel G. Schumacher, PhD

FIND
Geneva, Switzerland
Samuel.Schumacher@finddx.org

Michael Y. Sha, PhD

DiaCarta, Inc.
Richmond, California, USA
msha@diacarta.com

David Smith

NoR CEL
Leeds, UK
dave.smithathome@gmail.com

Stoyan K. Smoukov, PhD

School of Engineering and Materials
Science
Queen Mary University of London
London, UK
s.smoukov@qmul.ac.uk

Eliana B. Souto, PhD

CEB—Centre of Biological
Engineering
University of Minho
Campus de Gualtar
Braga, Portugal
eliana.souto@ceb.uminho.pt

Qing Sun, PhD

DiaCarta, Inc.
Richmond, California, USA
qsun@diacarta.com

Sin-Yeang Teow, PhD

Department of Medical Sciences
Sunway University
Jalan University
Subang Jaya, Malaysia
ronaltdt@sunway.edu.my

Micaela Trexler, PhD

Smart Sensors and Integrated
Microsystems
Wayne State University
Detroit, Michigan, USA
mtrexler@wayne.edu

Makoto Tsunoda, PhD

Graduate School of Pharmaceutical
Sciences
University of Tokyo
Tokyo, Japan
makotot@mol.f.u-tokyo.ac.jp

Chantal B. F. Vogels, PhD

Department of Epidemiology of
Microbial Diseases
Yale School of Public Health
New Haven, Connecticut, USA
chantal.vogels@yale.edu

Digby F. Warner, PhD

Department of Pathology
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
digby.warner@uct.ac.za

Henrik Winther, PhD

Immunovia AB
Medicon Village
Lund, Sweden
henrik.winther@immunovia.com

Robin Wood, PhD

Institute of Infectious Disease and
Molecular Medicine
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
robin.wood@hiv-research.org.za

John Woodford, PhD

Clinical Tropical Medicine Laboratory
QIMR-Berghofer Medical Research
Institute
Brisbane, Australia
john.woodford@uqconnect.edu.au

Ozlem Yaren, PhD

Foundation for Applied Molecular
Evolution
Alachua, Florida, USA
oyaren@ffame.org

Xianquan Zhan, MD, PhD

University Creative Research
Initiatives Center
Shandong First Medical University
Jinan, China
yjzhan2011@gmail.com

Note from the Series Editor

A hallmark of medicine is that it is continuously evolving, its knowledge base continuously expanding. Clearly, the pace and sophistication of advances in medicine in the past two decades have been truly breathtaking. This has necessitated a growing need for a comprehensive reference that highlights the current issues in specific sectors of medicine. Keeping this in mind, each volume in the *Current Issues in Medicine series* is a stand-alone text that provides a broad survey of various critical topics in a focused area of medicine—all accomplished in a user-friendly yet interconnected format. The series not only highlights current issues and advances but also explores related topics such as translational medicine, precision medicine, nanomedicine, regulatory science, neglected global diseases, emerging pandemics, FDA and patent law, immunotoxicology, theranostics, big data, artificial intelligence, novel medical instrumentation, clinical procedures, combination drug products, and novel therapies. While bridging the gap between basic research and clinical medicine, this series provides a thorough understanding of medicine's potential to address health problems from both the patient's and the provider's perspectives in a healthcare setting. Each volume is an excellent resource for medical practitioners, medical students, nurses, fellows, residents, undergraduate and graduate students, educators, venture capitalists, policymakers, and biomedical researchers. The multidisciplinary approach of the series makes it a valuable reference for health care systems, the pharmaceutical and device industry, academia, and governments. However, unlike other series on medicine or medical texts, this series focuses on current trends, perspectives, and critical issues in medicine that are central to healthcare delivery in the 21st century.

The first two volumes in this series focus on the current issues in basic medical sciences, subjects that are fundamental to the practice of medicine. These subjects, traditionally taught in the first two years of medical school that precede clinical instruction, provide a core of basic knowledge crucial for the success in clinical medicine during rotations, training, and medical practice. The subsequent volumes are dedicated to clinical topics or specialties in medicine. A separate volume on medical history and another on perspectives/editorials are part of the series.

Medical imaging, detection, and diagnosis have all aided in treatment and prevention of disease throughout human history. Technological innovations in these critical sectors of medicine continue to provide for safer, more accurate and faster diagnosis for patients. They have revolutionized medicine. Hence, it is critical that practitioners stay current with these latest advances to provide the best care for nursing and clinical practices. Given this backdrop, the current volume focuses on the tools, technologies, techniques, and testing protocols related to diagnostics and imaging that currently impact medicine. Fundamental coverage

on the use of technology in clinical practice is highlighted. The range of topics covered here and the expertise of the contributing authors accurately reflect the rapidly evolving areas within medical diagnostics and imaging.

A handwritten signature in blue ink, appearing to read 'R. Bawa', is positioned above the printed name.

Raj Bawa, PhD, MD
Series Editor

Chapter 1

Medical Imaging, Detection, and Diagnosis: *A Journey in Pictures*

Raj Bawa, PhD, MD

Patent Law Department, Bawa Biotech LLC, Ashburn, Virginia, USA

Guanine Inc., Rensselaer, New York, USA

Teva Pharmaceutical Industries Ltd., Israel

bawa@bawabiotech.com



Medical imaging, detection, and diagnosis have all aided in treatment and prevention of disease throughout human history. We as humans would certainly not exist in the capacity that we do in 2023 without these medical advancements. This chapter looks at the best and brightest minds of medicine as well as the instruments, devices, and techniques that have revolutionized it. Historical images have been sprinkled throughout the chapter to provide context and perspective while highlighting the long span of medical advances and patient care. Also detailed are some of the greatest medical inventions and discoveries so far in the context of medical imaging, detection, and diagnosis. In summary, this chapter shows how much of an impact medicine has had on our lives by exploring the evolution of medical imaging and diagnosis. I have tried telling this vivid story via photographs, paintings, etches, and images. Let's discover the origins of some of the greatest medical innovations in history as we embark on this fascinating journey in pictures. Many of the medical marvels pertaining to imaging, detection, and diagnosis included here appeal to me personally. However, my bias and intellectual shortcomings will be apparent. Since this is an ongoing project and the subject of a future volume in this series, I welcome suggestions and criticisms.

Copyright © 2023 Raj Bawa. All rights reserved. As a service to authors and researchers, as copyright holder, I permit unrestricted use, distribution, online posting, and reproduction of this chapter or unaltered excerpts therefrom, in any medium, provided the original source is clearly identified and properly credited.

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Raj Bawa

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)


www.jennystanford.com



René Théophile Hyacinthe Laënnec. A painting depicting Laënnec (1781–1826) auscultating a tuberculosis patient, a disease which he himself succumbed to at the age of 45. Laënnec, a French physician and professor of medicine at the Collège de France, in 1816 invented the stethoscope (Greek, *stethos*, chest; *skopos*, examination). The painting depicts Laënnec with his original apparatus, a grey cylinder that enabled him to listen with one end on the patient's chest and the other on his ear. Laënnec also coined the terms “rhonchi” and “crepittance” in the diagnosis of respiratory conditions. The familiar binaural stethoscope, with rubber tubing going to both ears, was not developed until the 1850s. Regarded as the “father of chest medicine,” Laënnec demonstrated the importance of the instrument in diagnosing diseases of the lungs, heart, and vascular systems. The first flexible versions of the stethoscope were invented in 1851 by Arthur Leared (binaural stethoscope), which fitted into both ears. The design was standardized in 1852 by George Philip Cammann. The above painting is by Théobald Chartran: “Laënnec à l'hôpital Necker ausculte un phtisique devant ses élèves (1816)” (“Laënnec examines a consumptive patient with a stethoscope in front of his students at the Necker Hospital”). Photo of painting kindly provided by the Wellcome Library.




Laënnec's original stethoscope. One of the original stethoscopes belonging to Laënnec constructed of wood and brass. It consists of a single hollow tube. Photo courtesy of the Science Museum, London.



Laënnec's stethoscope details. Components above shown are: instrument assembled (Fig. 1); two portions of the instrument in longitudinal section (Fig. 2 and Fig. 3); detachable chest piece (Fig. 4); earpiece unscrewed (Fig. 5); and transverse section (Fig. 6). Photo kindly provided by the US National Library of Medicine.



Physician auscultating. Cartoon dated 1906 depicting a physician who has placed a Laënnec wooden stethoscope between his left ear and the patient's back. "A contemporary cartoon depicts a physician of fashion placing his stethoscope wherever he found a spot on her body which was not covered by her corset. Undressing and redressing would have been too time-consuming had women shed their corsets in their doctor's office. The corseted patient became a way of life for the average physician." Source: G. S. Schwarz. (1979). Society, physicians, and the corset. *Bulletin of the New York Academy of Medicine* 55(6):551-590.



The thermometer and the Fahrenheit (°F) scale. Daniel Gabriel Fahrenheit (1686–1736), who helped lay the foundations for the era of precision thermometry by inventing the mercury-in-glass thermometer and the Fahrenheit scale. There are many claimants to have invented the thermometer and its development came in several stages over the course of almost 2,000 years. It included Philo of Byzantium who lived during the 3rd century BC, Galileo Galilei in the 16th century, Ferdinand II, and Grand Duke of Tuscany. However, it is Fahrenheit who today is credited with creating the first reliable modern thermometer in 1714, which used mercury instead of water or alcohol. With the improved accuracy of a mercury thermometer, he originally took as the zero of his scale the temperature of an equal ice-salt mixture and selected the values of 30°F and 90°F for the freezing point of water and normal human body temperature, respectively (later revised to 32°F and 98.6°F). Sketch courtesy of Wikimedia.



Mercury thermometer. A photo of the original mercury thermometer of Fahrenheit.



Doctor examining his patient. Jan Steen's *The Sick Woman*, c. 1663–1666. “Faint from fever, the young woman rests her head on a pillow. Is she perhaps lovesick? Is she pregnant? To find out, a quack would put a strip of his patient’s clothing in a brazier to smoulder – the scent would disclose her secret. Jan Steen here presents such a charlatan making a diagnosis. His old-fashioned attire characterizes him as a comic character.” The above featured oil painting is at the Rijksmuseum in Amsterdam, Netherlands. Photo of painting kindly provided by Wikimedia.



Inexperienced medical student taking the pulse of a patient. I firmly believe that the center of medical education is the patient. The great medical educator, William Osler said that medical education at its best “begins with the patient, continues with the patient, and ends with the patient.” In my view, no matter how knowledgeable and skilled medical school faculty are, medical education centers less on what they seek to teach than on what patients need future physicians to learn. Borrowing from Socrates, “...we are but medical education’s midwives.” Experiential education, that is training through interaction with patients, is a constant of a physician’s initial and continual training. Learning from observation and experience, and the wherewithal to understand the difference, is essential for a physician. Often such images tell a story that is educative and professionally self-deprecating: We learn from experience and, in order to gain expertise, we sometimes must struggle in learning while looking to care for the patient. This color etching titled *Physician and Pupil*, dated 1806 is by A. M. Mills and printed by Bowles & Carver, London. The image is courtesy of the Wellcome Library.



Five doctors discussing their patient, Napoléon. Note that one of the physicians is examining his rear end. Napoléon says to the doctors: “My dear doctors – do tell me what is the matter with me I felt the first symptoms – directly I heard the ambassador was fairly off – it is a very odd sensation.” The doctor who is examining his backside replies: “Beggar me have found it out – your heart be in your breeches.” This colored etching from 1803 is by an unknown artist. Courtesy of the Wellcome Library.



Multiple stethoscope. Prior to the advent of high-resolution imaging, a physician's skill in auscultation was critical, and something learned via repeated practice. In the photograph above from the 1920s, medical students are seen employing a multiple stethoscope to listen to their heartbeats. It is an example of technology-enhanced learning, which is critical to the ongoing training of physicians and clinicians with the advancement of new methodologies and technologies. Photo courtesy of the Wellcome Library.



Collective stethoscope. This photograph from the early twentieth century provides an excellent example of technology-enhanced learning, that has *not* stood the test of time. It depicts a bedside demonstration of the collective stethoscope. Source: Heartbeats by Radio. A new use for wireless. The hospital and health review. Published in 1924, New series volume 3, p. 272. Photo courtesy of the Wellcome Library.



Madam Curie. Marie Salomea Skłodowska Curie (1867–1922), the Polish-French physicist, was most well known for her discovery of radium and polonium and her contributions to the treatment of cancers using radioisotopes. In 1920 and 1932, Madame Curie founded the Curie Institutes in Paris and Warsaw, respectively, as centers for medical research. She also developed mobile radiography units for field hospitals during the first World War. Marie Curie was the first woman to win a Nobel Prize in Physics (in 1903, shared with Pierre Curie and Antoine Henri Becquerel), and a second Nobel Prize in Chemistry (in 1911). She is the only woman to win two Nobel Prizes in two separate scientific fields. Photograph of Marie Curie above (c. 1920) is by Henri Manuel. Photo kindly provided by Wikipedia.




Chevalier Jackson. American laryngologist, Chevalier Jackson (1865–1958), was a founder of modern endoscopy. The endoscopic methods he developed were a significant advance in the safe removal of objects from the airways of patients. A professor at numerous leading American medical schools, Jackson was an engaging instructor often using props, examples of foreign bodies removed from patients during endoscopies', to engage the students. In my view, it is critical to value medical teaching with equal importance to patient care and research. Medical teaching is an art. I fondly recall that some of my best professors presented complex concepts in an amazing manner, which etched the information in my mind. I am proud to pass on that information to my students using the very same examples, analogies, props, etc. Photo courtesy of the Wellcome Library.



Chevalier Jackson with staff at the Jefferson Bronchoscope Clinic. This photo, taken in 1927, shows Jackson with his colleagues and bimanually drawn chalk illustrations at his Bronchoscopy Clinic. Photo courtesy of Thomas Jefferson University Archives, Art/Photo Collection. Open access by the Jefferson Digital Commons.



Chevalier Jackson with his patient object collection. From brain tissue to gallstones, doctors have long preserved specimens from their patients sometimes as trophies, sometimes as teaching tools, sometimes as curiosities or even art. Jackson preserved more than 2,000 objects that people had swallowed or inhaled: nails and bolts, miniature binoculars, a radiator key, a child's perfect-attendance pin, a medallion that says "Carry me for good luck." His remarkable collection of objects removed from his patients is now housed at the Mutter Museum in Philadelphia. Photo courtesy of Thomas Jefferson University Archives, Art/Photo Collection. Open access by the Jefferson Digital Commons.



Prognosis for a case. A colored drawing of a professor and medical student. The question-and-answer style of a presented case and symptoms remains important in medical education, though this particular format is now anachronistic. The employment of multiple and varied forms of case assessment provides a more robust and rounded diagnosis, and better patient outcomes. Image shown above was published by the Antikamnia Chemical Co., St Louis, Missouri, c. 1900, and is courtesy of the Wellcome Library.



The London School of Tropical Medicine. First located at the Albert Dock Hospital (Seaman's Hospital Society), it is now known as London School of Hygiene & Tropical Medicine (LSHTM). Founded in 1899 at the London Docks by Patrick Manson, the LSHTM fosters education in the medical laboratory sciences, and has grown to be a world-leading institution for the study of public health and infectious disease. In 1902, the benefactor Petit wrote the following about the institution in a letter to the school: "This institution, whilst according ample scope to students of diseases that well nigh devastate the East, will be the means of bringing the Western and Eastern minds together to afford help to the suffering East, and thus cementing that union of hearts." This image from 1910 shows students at the London School of Tropical Medicine engaged in active learning through examination of specimens and discussion with fellow scientists. Photo courtesy of the Wellcome Library.




Sir Ronald Ross, C. S. Sherrington, and R. W. Boyce in a laboratory at the Liverpool School of Tropical Medicine. The Liverpool School of Tropical Medicine was founded in 1899. Boyce was the first Dean. Sherrington was Holt Professor of Physiology at University College, Liverpool, from 1895. Ross was the first Lecturer in Tropical Diseases and, from 1903 to 1912, Alfred Jones Professor of Tropical Medicine. Gouache in grisaille on paper by W. T. Maud, 1899. Photo courtesy of the Wellcome Library.




Karl Landsteiner. For centuries, biomedical knowledge and pathologies of blood were mysteries to physicians and patients alike. In fact, in the 17th century, the still-dangerous practice of blood transfusions (used since at least the Middle Ages) was banned in many parts of Western Europe. In 1900 Landsteiner (1868–1943), Austrian American immunologist and pathologist, discovered that the blood of two people under contact agglutinates. In 1901, he found that this effect was due to contact of blood with blood serum. As a result, he succeeded in identifying the three blood groups, which he labeled A, B, and C (later changed to O). A fourth blood type, later named AB, was identified a year later. In my humble opinion, this discovery is one of the major medical breakthroughs of the century. Landsteiner, in this 1930 photo taken in Stockholm, also discovered that blood transfusion between persons with the same blood group did not result in the destruction of blood cells, whereas this occurred between persons of different blood groups. Based on his findings, the first successful blood transfusion was performed by Reuben Ottenberg at Mount Sinai Hospital in New York in 1907. In 1910, Emil Freiherr von Dungern and Ludwig Hirschfeld of the University of Zurich put forth the first hypothesis for the Mendelian inheritance of blood groups, which lead to the use of the ABO system in paternity legal cases. In 1913, Richard Lewisohn of Mount Sinai Hospital discovered that adding citrates to blood prevents coagulation. Landsteiner made numerous contributions to pathological anatomy, histology, and immunology, all of which showed, not only his meticulous care in observation and description, but also his biological understanding. In 1940, at the age of 70, he announced the discovery of the rhesus (Rh) factor, then responsible for the serious illness or death of 1 in 200 white babies. He also introduced dark field microscopy for the diagnosis of primary syphilis and worked on the characteristics of *Spirochaeta pallida*. He, along with colleagues, was able to describe the mechanism that resulted in the Wassermann reaction. But Landsteiner, no doubt, always will be honored for his discovery in 1901: his brilliant work on blood groups for which he was given the Nobel Prize for Physiology or Medicine in 1930. Photo kindly provided by Wikimedia.




Bedside blood grouping card. A bedside blood grouping card showing agglutination of blood with anti-A and anti-Rh(D), but not with anti-B. Hence, this patient's blood type is A+ because Anti-A serum (i.e., serum with antibody A against antigen a) and Anti-D (i.e., serum with antibodies against the Rh antigen) agglutinated the patient's blood. Courtesy of Wikimedia.




Iron-deficiency anemia. Peripheral blood smear from a person with iron-deficiency anemia, displaying characteristic red blood cell morphology. The red blood cells are abnormally small (microcytosis), have large areas of central pallor (hypochromia), and vary greatly in size (anisocytosis). Courtesy of Wikimedia.




Angiography with coronary stenosis. Coronary angiography of a critical sub-occlusion of the common trunk of the left coronary artery and the circumflex artery (red arrows). A coronary angiogram is a procedure that uses X-ray imaging to see heart's blood vessels. The test generally is done to see if there is a restriction in blood flow going to the heart. Coronary angiograms are part of a general group of procedures known as heart (cardiac) catheterizations. Cardiac catheterization procedures can both diagnose and treat heart and blood vessel conditions. A coronary angiogram, which can help diagnose heart conditions, is the most common type of cardiac catheterization procedure. During a coronary angiogram, a type of dye that's visible by an X-ray machine is injected into the blood vessels of your heart. The X-ray machine rapidly takes a series of images (angiograms), offering a look at your blood vessels. If necessary, a cardiothoracic surgeon can open clogged heart arteries (angioplasty) during your coronary angiogram. Courtesy of Wikimedia.



Small blood vessel in alveoli. Computer-colored scanning electron micrograph (SEM) of small blood vessel in alveoli. Courtesy of David Gregory and Debbie Marshall. CC BY 4.0.




Human liver biopsy sample. A small quantity of tissue is sampled from the liver when doing a biopsy, which is then examined under a microscope. Courtesy of Wikimedia.




Fine needle aspiration (FNA) of pancreatic tissue. An adenocarcinoma is seen on the left, normal ductal epithelium is on the right. FNA is a diagnostic procedure used to investigate lumps or masses. In this technique, a thin (23–25 gauge), hollow needle is inserted into the mass for sampling of cells that, after being stained, are examined under a microscope (biopsy). The sampling and biopsy considered together are called fine-needle aspiration biopsy (FNAB) or fine-needle aspiration cytology (FNAC) (the latter to emphasize that any aspiration biopsy involves cytopathology, not histopathology). FNA biopsies are very safe minor surgical procedures. Often, a major surgical (excisional or open) biopsy can be avoided by performing a needle aspiration biopsy instead, eliminating the need for hospitalization. Today, this procedure is widely used in the diagnosis of cancer and inflammatory conditions. Aspiration is safer and far less traumatic than an open biopsy; complications beyond bruising and soreness are rare. However, the few problematic cells can be too few (inconclusive) or missed entirely (a false negative). This type of sampling is performed for one of two reasons: (a) a biopsy is performed on a lump or a tissue mass when its nature is in question; or (b) for known tumors, this biopsy is performed to assess the effect of treatment or to obtain tissue for special studies. When the lump can be felt, the biopsy is usually performed by a cytopathologist or a surgeon. In this case, the procedure is usually short and simple. Otherwise, it may be performed by an interventional radiologist, a doctor with training in performing such biopsies under x-ray or ultrasound guidance. In this case, the procedure may require more extensive preparation and take more time to perform. Also, fine-needle aspiration is the main method used for chorionic villus sampling, as well as for many types of body fluid sampling. It is also used for ultrasound-guided aspiration of breast abscess, of breast cysts, and of seromas. Courtesy of Wikimedia.




Physical examination of urine. A physician examining a urine-flask brought by a woman; oil painting after Caspar Netscher (1639–1684). Courtesy of the Wellcome Library.




Urinary casts. Examples of urinary casts: (a) renal tubular epithelial (RTE) cell cast, (b) muddy granular cast, (c) white blood cell cast, (d) red blood cell cast. Courtesy of Wikimedia.




Formed elements of urine. Microscopic examination of centrifuged urine showing various elements of the urine: (i) squamous epithelial cells, (ii) red blood cells, (iii) white blood cells, (iv) bacteria, (v) yeast, (vi) calcium oxalate crystals, (vii) triple phosphate crystals, (viii) granular casts, and (ix) yeast with pseudohyphae. Courtesy of Wikimedia.




Enterococcus pneumoniae. This histological photomicrograph reveals cocci-shaped *Enterococcus sp.* bacteria taken from a pneumonia patient. *Enterococcus sp.* is a common, Gram-positive bacterium that can normally be found in the bowel and female genital tract. These bacteria can be spread by the fecal-oral transmission route, contact with infected body fluids, or contact with contaminated surfaces. Courtesy of the Centers for Disease Control and Prevention.




Methicillin-resistant *Staphylococcus aureus* (MRSA). Scanning electron micrograph of methicillin-resistant *Staphylococcus aureus* (MRSA, brown) surrounded by cellular debris. MRSA resists treatment with many antibiotics. MRSA is usually spread in the community by contact with infected people or things that are carrying the bacteria. This includes contact with a contaminated wound or by sharing personal items, such as towels or razors, that have touched infected skin. MRSA is resistant to all beta-lactam antibiotics. This includes all penicillins (e.g., amoxicillin) and cephalosporins (e.g., keflex). The first documented MRSA outbreak in the US occurred at a Boston hospital in 1968. MRSA lives harmlessly on the skin of around 1 in 30 people, usually in the nose, armpits, groin or buttocks. This is known as "colonization" or "carrying" MRSA. You can get MRSA on your skin by touching someone who has it. Courtesy of the National Institute of Allergy and Infectious Diseases.




Mammogram procedure. Courtesy of Blausen.com. “Medical gallery of Blausen Medical 2014”. *WikiJournal of Medicine* 1(2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436.




Breast cancer diagnosis. Normal (left) versus cancerous (right) mammography image. Images kindly provided by the National Cancer Institute.




Breast cancer. A polyloid giant cancer cell (PGCC) from triple-negative breast cancer. Courtesy of the National Cancer Institute.




Colon cancer cells. Cultured colon cancer cells showing the nuclei stained with DAPI in blue, the actin cytoskeleton in red and plectin (isoform 1k) in green. Plectin interacts with cytoskeletal actin, affecting its behavior. This subtype of plectin promotes the migration of cells and may affect metastasis. Courtesy of Lorna McInroy. CC BY.



Papanicolaou stain showing a low-grade squamous intraepithelial lesion (LSIL) from a Pap test. LSIL is an abnormality found on a pap test that consists of cells that are abnormal and may develop into cervical cancer. Abnormal cells have an enlarged nucleus, irregular chromatin, and relatively abundant cytoplasm. Binucleation (two nuclei in one cell) and peri-nuclear glycogen are commonly seen. Courtesy of Wikipedia.




Pap stain of adenocarcinoma in peritoneal fluid. Cytopathology of peritoneal fluid in a case of peritoneal carcinomatosis, showing typical features of adenocarcinoma. Papanicolaou stain (or Pap stain) is a multichromatic cytological staining technique developed by George Papanicolaou in 1942. The Pap stain is one of the most widely used stains in cytology, where it is used to aid pathologists in making a diagnosis. Although most notable for its use in the Pap test or Pap smear as a reliable technique in cervical cancer screening in gynecology, it is also used to stain non-gynecological specimen preparations from a variety of bodily secretions and from small needle biopsies of organs and tissues. Courtesy of Wikimedia.



Lumbar puncture procedure. Illustration depicting common positions for lumbar puncture procedure. Courtesy of Blausen.com. "Medical gallery of Blausen Medical 2014". *WikiJournal of Medicine* 1(2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436.



Lumbar puncture in a meningitis patient. This photograph illustrates the operation of lumbar puncture and the technique in injecting the anti-meningitis serum. The patient is lying on his left side over the right side of the bed. His back is bowed by the physician in the middle of the photograph by flexing the hips on his abdomen and bending his head forward. The skin at the site of the operation has been painted with tincture of iodine. The site of the operation is draped off with sterile towels. The needle has been inserted at the level of the crest of the ileum, which is marked with tincture of iodine. The assistant at the head of the patient is taking blood pressure observations. The medical team is relying on the force of gravity to inject the serum. Photo kindly provided by Wikimedia.




The Hooke microscope. This sketch shows a 17th-century compound microscope and illumination system used by Robert Hooke (1635–1703), one of the best such microscopes of his time. The image is from an engraving in his book *Micrographia*, published in 1665, which was primarily a review of a series of observations that he had made while following the development and improvement of the microscope. It is in *Micrographia*, that he coined the term "cell" (suggesting plant structure's resemblance to honeycomb cells) which spurred microscopic investigations. By observing microscopic fossils, Hooke presaged the theory of biological evolution. He is known as a "Renaissance Man" of 17th century England for his superb work in astronomy, physics, and biology. Sketch kindly provided by Wikimedia.



Robert Hooke. No known portrait of Robert Hooke survives. Hooke approximated the experimental confirmation that gravity heeds an inverse square law, and first hypothesized the relation of the inverse square law to planetary motion – a principle furthered and formalized by Isaac Newton via Newton's Law of Universal Gravitation. Claim to this discovery contributed to the rivalry between Hooke and Newton, who called Hooke's legacy into question. It is argued that knowledge of the identity of the sitter in the above painting was suppressed by Isaac Newton's influence, as Hooke's theories might take precedence over Newton's.



The Hooke microscope. The hand-crafted, leather and gold-tooled microscope Hooke used is shown above. It was originally manufactured by Christopher White of London. Hooke is believed to have used it for the observations that formed the basis of his book *Micrographia*. Photographed at the National Museum of Health and Medicine, US Armed Forces Institute of Pathology.



Microscopy. General view of an early light microscope with various attachments.



Antonie van Leeuwenhoek. Leeuwenhoek (1632–1723) is considered to be the first acknowledged microscopist and microbiologist. The Dutch pioneer is best known for his work in the field of microscopy and for his contributions toward the establishment of microbiology as a scientific discipline. For the first time, he described spermatozoa from insects and humans, striations in muscles, and the mouthparts of insects. He also advanced Malpighi's demonstration of the blood capillaries in 1660 by giving the first accurate description of red blood cells. In 1702, Leeuwenhoek remarked that “in all falling rain, carried from gutters into water-butts, animalcules are to be found; and that in all kinds of water, standing in the open air, animalcules can turn up. For these animalcules can be carried over by the wind, along with the bits of dust floating in the air.” These animalcules, whose sizes he calculated, were microorganisms, including bacteria. Photo of painting kindly provided by Jan Verkolje – <http://www.rijksmuseum.nl/collectie/SK-A-957>. Public Domain, <https://commons.wikimedia.org/w/index.php?curid=34320547>.




Wilhelm Conrad von Röntgen. Röntgen (1845–1923), shown above with his wife Anna Bertha Röntgen (1839–1919), discovered X-rays by accident while experimenting with cathode rays. He realized that a new kind of ray was being created that was capable of passing through the heavy paper; he referred to it as 'X-rays'. He discovered that these rays could pass through human tissue, but not through bones and metal objects. In late 1895, he took the first X-ray image ever captured – of his wife's hand (second photo from top).




Taking an X-ray image with early Crookes tube apparatus, late 1800s. The Crookes tube is visible in center. The standing man is viewing his hand with a fluoroscope screen. The seated man is taking a radiograph of his hand by placing it on a photographic plate. No precautions against radiation exposure were taken as its hazards were unknown at the time. Source: W. J. Morton and E. W. Hammer. (1896). *The X-ray, or Photography of the Invisible and Its Value in Surgery*. American Technical Book Co., New York, fig. 54. Public Domain, <https://commons.wikimedia.org/w/index.php?curid=3272036>.



X-ray of hip replacement. Implants, such as artificial hip joints, generally are regulated extensively due to the invasive nature of such devices. Hip replacement surgery (hip arthroplasty) is a surgical procedure performed by an orthopedic surgeon that involves removal of the diseased parts of the hip joint and replacement with new, artificial parts, as shown in this X-ray. Courtesy of the National Institutes of Health.




X-ray of normal congruous vertebral lines. Cervical lines are annotations used in medical imaging of the cervical vertebrae. These are useful in the detection of cervical fractures. Incongruities indicate cervical fracture, spondylolisthesis, and/or ligament injury. X-ray image kindly provided by Mikael Häggström.




Vertebral lines on a computerized tomography (CT) scan of the neck. Again, as indicated in the adjacent X-ray image, these lines are useful in the detection of cervical fractures. It is important to note that CT scans or X-ray images are evaluated for the presence or absence of directly visible fractures. In addition, indirect signs of injury by the vertebral column are incongruities of the vertebral lines, and/or increased thickness of the prevertebral space. CT scan image kindly provided by Mikael Häggström.




Willem Einthoven with his galvanometer. This photograph taken in a hospital in London in 1916 shows Willem Einthoven (1860–1927), a Dutch physiologist, testing the string galvanometer he developed on a patient with the patient's one foot and hands immersed in saline to improve electrical conductivity. For Einthoven, who won the Nobel Prize for the development of the electrocardiogram in 1924, one of the most rewarding aspects of the high fidelity recording of the human electrocardiogram was its validation of his earlier theoretical predictions regarding the electrical activity of the heart. Einthoven's main achievements in electrophysiology were the description of the normal ECG, some physiological effects on the ECG, the three ECG leads, and the triangle rule. Photograph source: <https://www.youtube.com/watch?v=yJvkfHDuw1c>.




Early commercial ECG. This photo does not represent the ECG machine built by Willem Einthoven and his team. Rather it shows an early commercial ECG machine, built in 1911 by the Cambridge Scientific Instrument Company, to measure the human electrocardiogram according to the standards developed by Einthoven. Courtesy of Wikipedia.




An electrocardiogram (ECG or EKG). A 12-lead ECG of a 26-year-old male with an incomplete right bundle branch block (RBBB). Courtesy of Wikimedia.



Normal electrocardiogram (ECG) trace. Schematic representation of a normal ECG trace showing sinus rhythm; an example of widely used clinical medical equipment. Diagram kindly provided by Agateller (Anthony Atkielski). Public Domain, <https://commons.wikimedia.org/w/index.php?curid=1560893>.



The first ECG tracings. The first electrocardiogram is shown above. The initial attempts to record the human heart electrical activity were performed with a mercury capillary electrometer by Augustus Waller in 1887 in London. This capillary electrometer consisted of a glass tube containing mercury with one end drawn out into a fine capillary and immersed vertically in dilute sulfuric acid (Fig. 1 above). The tracings were poor, however, and exhibited only two distorted deflections.



ECG Tracing with Heart Contraction. Besides the stethoscope, the electrocardiogram (ECG) is the oldest and most enduring tool of the cardiologist. At every beat, the heart is depolarized to trigger its contraction. This electrical activity is transmitted throughout the body and can be picked up on the skin. This is the principle behind the ECG. An ECG machine records this activity via electrodes on the skin and displays it graphically. An ECG involves attaching 10 electrical cables to the body: one to each limb and six across the chest. ECG terminology has two meanings for the word "lead:" (i) the cable used to connect an electrode to the ECG recorder; and (ii) the electrical view of the heart obtained from any one combination of electrodes. Courtesy of Wikimedia.



Ophthalmoscope (left) and otoscope combination by Welch Allyn. Hermann Ludwig Ferdinand von Helmholtz (1821–1894) developed a way for physicians to illuminate the retina and observe it at the same time. He invented one of medicine’s most important instruments – the ophthalmoscope. This medical instrument enables opticians and physicians to closely examine the interior surface of the eye, which is useful not only for accurately prescribing glasses, but can also be used to examine retinal blood

vessels and detect high blood pressure, arterial disease, glaucoma, and tumors. The genius made significant contributions to medicine: mathematics of the eye, theories of vision, concepts on visual perception of space, color vision research, as well as research on the sensation of tone, and perception of sound. In 1915, Francis A. Welch and William Noah Allyn invented the world’s first handheld direct illuminating ophthalmoscope. Photo courtesy of Wikimedia.

Fundus photograph of the right eye.

The image shows a fundus with no sign of disease or pathology. It is seen from front so that left in the image is to the person’s right. (The fundus of the eye is the interior surface of the eye opposite the lens and includes the retina, optic disc, macula, fovea, and posterior pole. It can be examined by ophthalmoscopy and/or fundus photography.) The gaze is into the camera, so the macula is in the center of the image, and the optic disk is located towards the nose (right in image). The optic disk has some pigmentation at the perimeter of the lateral side, which is considered non-pathological. Veins are darker and slightly wider than corresponding arteries. Major nerve pathways are seen as white striped patterns radiating from the optic disk. In addition, there are also lighter areas close to larger vessels seen mainly at upper left in the image (person’s upper right), which is regarded as a normal finding in younger people. Photo is taken at Gävle Hospital in Sweden in 2012 on a healthy 25-year old male volunteer. M. Häggström. (2014). Medical gallery of Mikael Häggström 2014. *Wikijournal of Medicine* 1(2). DOI:10.15347/wjm/2014.008. ISSN 2002-4436.






The electroretinogram (ERG). The ERG is a diagnostic test that measures the electrical activity of the retina in response to a light stimulus. The ERG arises from currents generated directly by retinal neurons in combination with contributions from retinal glia. Importantly, the ERG is an objective measure of retinal function that can be recorded non-invasively under physiological conditions. ERGs are often recorded using a thin fiber electrode that is placed in contact with the cornea or an electrode that is embedded within a corneal contact lens. These electrodes permit the electrical activity generated by the retina to be recorded at the corneal surface. The ERG has important clinical utility in that it provides diagnostic information concerning a variety of inherited and acquired retinal disorders. Moreover, the ERG can be used to monitor disease progression and evaluate retinal toxicity due to various drugs or retained intraocular foreign bodies. The first known ERG was recorded from amphibian retina in 1865 by the Swedish physiologist, Alarik Frithiof Holmgren (1831–1897). James Dewar (1842–1923) of Scotland subsequently recorded the ERG in humans in 1877. In 1908, Einthoven and Jolly separated the ERG response into three components: a-wave, b-wave, and c-wave, which are further described below. Despite the early discovery of the ERG, widespread application did not occur until 1941, when American psychologist Lorin Riggs introduced a contact-lens electrode for ERG recording. Many of the observations that serve as the basis for our understanding of the ERG were conducted by Ragnar Granit (1900–1991).




Hermann Ludwig Ferdinand von Helmholtz. Helmholtz (1821–1894), a German physicist and physician, made significant contributions in several scientific fields. In physiology and psychology, he is known for his theories of vision and sound, visual perception of space, and empiricism in the physiology of perception. In physics, he is known for his theories on the conservation of energy, work in electrodynamics, chemical thermodynamics, and on a mechanical foundation of thermodynamics. As a philosopher, he is known for his philosophy of science, ideas on the relation between the laws of perception and the laws of nature, the science of aesthetics, and ideas on the civilizing power of science. The photo above is that of Helmholtz’s statue in front of Humboldt University in Berlin. Courtesy of Wikimedia.



White matter connections obtained with magnetic resonance imaging (MRI) tractography. MRI diffusion tensor imaging of white matter tracts. In neuroscience, tractography is a 3D modeling technique used to visually represent nerve tracts using data collected by diffusion MRI. It uses special techniques of MRI and computer-based diffusion MRI. The results are presented in two- and three-dimensional images called tractograms. Courtesy of Wikimedia.




Proton CT of a human head. 3D rendering of the head of an adult male receiving X-ray radiotherapy, viewed from the side. The patient is wearing a conventional restrictive mesh mask to prevent any movement during treatment. No data is available for the tip of the nose. A clinical proton CT has not yet been produced to date. This is a simulation using X-ray data of a patient receiving radiotherapy, where every X-ray event has been converted to its proton equivalent. 180 image projections were then processed using a new algorithm to create the image seen here. Using a digital model created in this way, external tissue can also be digitally stripped away to reveal the bare skull inside. Proton beam radiotherapy is rapidly becoming a recognized treatment for certain cancers, especially in children and young people. To target the tumor site while minimizing the exposure to healthy surrounding tissue it is necessary to image using the same particles (protons) that are used for therapy. The advantage of using high-energy treatment protons to construct the CT scan instead of much lower energy X-ray photons is that registration errors are reduced from $\pm 4\%$ to less than $\pm 1\%$. Proton therapy could be used in many more cases and with better outcomes. Courtesy of Nigel Allinson, University of Lincoln; CC BY 4.0.



3D human skull from computerized tomography (CT) data. A CT scan, formerly called Computed Axial Tomography scanning or CAT scanning) is a medical imaging technique used to obtain detailed internal images of the human body. Based on the variable absorption of X-rays by different tissues, CT imaging, provides a different form of imaging known as cross-sectional imaging (Greek, *tomos* meaning "slice" or "section" and *graphie* meaning "drawing"). A CT imaging system produces cross-sectional images or "slices" of anatomy used for a variety of diagnostic and therapeutic purposes. Most CT systems are also capable of "spiral" (i.e., "helical") scanning, as well as scanning in the formerly more conventional "axial" mode. In addition, many CT systems are capable of imaging multiple slices simultaneously, allowing relatively larger volumes of anatomy to be imaged in relatively short time. Courtesy of Prof. Dr. Michael Tsokos, FAL, <https://commons.wikimedia.org/w/index.php?curid=22886395>.




Calculation of bone age analysis by BoneXpert. X-ray of the hand of a 7.60-year-old female is shown with automatic calculation of bone age by the BoneXpert software. The bone age is 7.38 by the Greulich and Pyle algorithm, and 8.16 by the second Tanner Whitehouse algorithm. BoneXpert software analyzes the image completely automatically, independently of the rotation of the hand. Both left and right hands are accepted. BoneXpert analyses the following 21 bones: radius, ulna, metacarpals, and phalanges. These are used for the overall bone age formed as a simple average over these 21 bones. In addition, the seven carpals are considered, and a carpal bone age is computed for the group of all visible carpals. Thus, the carpal bone age is not averaged into the overall bone age. Carpal bone age is usually not determined for boys with bone age above 12 years and for girls with bone age above 10 years, because the carpals develop very little above these bone ages. Bone age is considered the most important and most representative criterion of biological maturity. In fact, bone age indicates the level of biological and structural maturity better than the chronological age calculated from the date of birth. Bone age determination is carried out for the purpose of evaluating growth in pediatric patients and for the diagnosis of many endocrine disorders and pediatric syndromes. (Conventionally this is determined from an X-ray image of the hand.) It also allows for growth prediction; determining skeletal age is important for orthopedic procedures in which it is essential to know potential future longitudinal growth. In rare cases, skeletal age determination is also required in judicial proceedings to determine, for example, whether a suspect should be charged as a juvenile or an adult. Automated methods like this one for evaluation of hand and wrist radiographs have been developed which reduce inter-rater variability compared to manual methods. Courtesy of BoneXpert and Wikimedia.




PET, MRI, and overlaid images of a human brain. Courtesy of Mco44. Public Domain, <https://commons.wikimedia.org/w/index.php?curid=3587922>.




Scintigraphy. Lung scintigraphy evaluating lung cancer. Courtesy of Wikimedia.




Positron emission tomography (PET). Computer representation of false-color image of a cross section of human brain, based on scintillography in Positron-Emission Tomography (PET). This is a transaxial slice of the brain of a 56 year old patient (male) taken with PET. The injected dose was 282 MBq of ^{18}F -FDG and the image was generated from a 20-minutes measurement with an ECAT Exact HR+ PET Scanner. Red areas show more accumulated tracer substance (^{18}F -FDG) and blue areas are regions where low to no tracer have been accumulated. PET image courtesy of Jens Maus (<http://jens-maus.de/>). Public Domain, <https://commons.wikimedia.org/w/index.php?curid=404690>.




Computerized tomography (CT) scan of the chest with contrast. The red arrows depict bilateral near occlusive pulmonary emboli. Source: N. Epperla, E. Peterson, and P. Foy, (2015). An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. *BMC Hematol* 15:7. <https://doi.org/10.1186/s12878-015-0025-5>. Open access.




Fused CT-PET. These scans more clearly show tumors and are therefore often used to diagnose and monitor the growth of cancerous tumors. Courtesy of the National Institutes of Health.




Computerized tomography (CT) scans. (A) CT scan of the chest with contrast. Coronal section showing bilateral, bilobed lungs (yellow arrows depict the major fissure). (B) CT scan of the abdomen. The arrow points to multiple splenic lobules suggestive of polysplenia. (C) CT scan of the abdomen. Coronal section showing azygous continuation of inferior vena cava. Source: N. Epperla, E. Peterson, and P. Foy, (2015). An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. *BMC Hematol* 15:7. <https://doi.org/10.1186/s12878-015-0025-5>. Open access.




Laser microscopy. This image of the hippocampus was taken with an ultra-widefield high-speed multiphoton laser microscope. Tissue was stained to reveal the organization of glial cells (cyan), neurofilaments (green) and DNA (yellow). Courtesy of the National Center for Microscopy and Imaging Research.



Cell ultrastructure. Fibroblast cells with nuclei (blue, circular, center), mitochondria (green, surrounding the nucleus), and the actin cytoskeleton (red, outermost). Courtesy of the National Institutes of Health.



Villi in the small intestine. 3D reconstruction of villi in the small intestine of the mouse. Villi are small finger like projection that cover the internal surface of the small intestine to increase the surface area and assist in digestion. This image was created from a wholmount that had a fluorescent stain applied to mark different cellular components. The tips of the villi have been cropped away to show the internal morphology. The red shows the F-actin (stained with rhodamine phalloidin), which cover the surface of each villus. Cell nuclei are labelled blue (stained with DAPI). Image courtesy of Paul Appleton; CC BY.



Actin filaments. Multiple actin filaments (magenta) are organized around a dynamin helical polymer (rainbow colored) in this model derived from cryo-electron tomography. By bundling actin, dynamin increases the strength of a cell's skeleton and plays a role in cell-cell fusion, a process involved in conception, development, and regeneration. Courtesy of Elizabeth Chen, University of Texas Southwestern Medical Center and the National Institute of Diabetes and Digestive and Kidney Diseases.




FIG. 1. Section through the middle piece showing the mitochondria (*M*) and an outer row of 9 coarse fibers with numbers 1, 5, 6, and 9 larger than the rest. Electron dense medulla and electron lucent cortex of the coarse fibers can be discerned. Human testis. $\times 80,000$.






FIG. 2. Section through the middle piece reveals 5 supernumerary coarse fibers around the usual set of 9. Of the supernumerary ones, fibers 11, 12, and 13 reveal contact with the adjacent coarse fibers of the inner set. Human ejaculate. $\times 25,000$.

FIG. 3. Section through the main piece. Note the homogeneously dense nature of the coarse fibers in the micrograph as well as in the preceding figure. One small supernumerary coarse fiber is indicated by an arrow. Human ejaculate. $\times 39,000$.


Examples of early electron microscopy. Text and electron micrographs kindly provided by Prof. Dr. S. R. Bawa. Further details: S. R. Bawa. (1963). Outer coarse fibers of the mammalian sperm tail – an electron microscope study. *Journal of Ultrastructure Research* 9:475–483.




Nuclear medicine. Myocardial perfusion scans with thallium-201 for the rest images (bottom rows) and Tc-Sestamibi for the stress images (top rows). The nuclear medicine myocardial perfusion scan plays a pivotal role in the noninvasive evaluation of coronary artery disease. The study not only identifies patients with coronary artery disease, but it also provides overall prognostic information or overall risk of adverse cardiac events for the patient. Courtesy of Wikimedia.




Bone scan. A nuclear medicine whole body bone scan. This type of scan is generally used in evaluations of various bone-related pathology, such as bone pain, stress fracture, nonmalignant bone lesions, bone infections, or the spread of cancer to the bone. Courtesy of Myohan, CC BY 3.0.




Parathyroid subtraction. A nuclear medicine parathyroid scan demonstrates a parathyroid adenoma adjacent to the left inferior pole of the thyroid gland. The above study was performed with Technetium-Sestamibi (1st column) and iodine-123 (2nd column) simultaneous imaging and the subtraction technique (3rd column). Courtesy of Myohan, CC BY 3.0.




Iodine-123 whole body scan for thyroid cancer evaluation. The study above was performed after the total thyroidectomy and TSH stimulation with thyroid hormone medication withdrawal. The study shows a small residual thyroid tissue in the neck and a mediastinum lesion, consistent with the thyroid cancer metastatic disease. The observable uptakes in the stomach and bladder are normal physiologic findings. Courtesy of Wikipedia.




Carotid ultrasound. Ultrasound of carotid artery. Courtesy of the National Heart Lung and Blood Institute.



Ultrasonographic measurement of aortic diameter. Abdominal ultrasound in the axial plane at the level of the navel of a 31 year old man, showing normal anatomy. It uses compression to decrease the distance to the aorta for better visualization, resulting in flat shapes of the inferior mesenteric vein and the inferior vena cava. It shows measurement of the aorta, as applied in detecting abdominal aortic aneurysm (not present in this case). Courtesy of Mikael Häggström.



Ventricular septal defect. An abnormal echocardiogram: the image shows a mid-muscular ventricular septal defect. The trace in the lower left shows the cardiac cycle and the red mark during the time in the cardiac cycle when the image was captured. Colors are used to represent the velocity and direction of blood flow. Courtesy of Kjetil Lenes. Public Domain.



Echocardiogram. An echocardiography, echocardiogram, cardiac echo or simply an echo, is an ultrasound of the heart. In this parasternal long-axis view, a measurement of the heart's left ventricle is shown. Public Domain.




Santiago Ramón y Cajal in his laboratory. Cajal (1852–1934) was a brilliant Spanish neuroscientist, pathologist, and histologist specializing in neuroanatomy and the central nervous system. He is often called the “father of neuroscience.” He and Camillo Golgi received the Nobel Prize in Physiology or Medicine in 1906 for his theory that became known as the neuron doctrine. I find it remarkable that in 1873, after five years at medical school, Cajal graduated and was now qualified to practice medicine. He was just 21. Cajal made several major classic contributions to neuroanatomy. He discovered the axonal growth cone, and demonstrated experimentally that the relationship between nerve cells was not continuous or a single system, as per extant reticular theory. Rather, he determined that the relationship between nerve cells is contiguous, and that there are gaps between neurons. This provided definitive evidence for what Heinrich Waldeyer would name “neuron theory,” now widely considered the foundation of modern neuroscience. In 1894, Cajal stated to the Royal Society of London: “The ability of neurons to grow in an adult and their power to create new connections can explain learning.” This statement is considered to be the origin of the synaptic theory of memory. He was a proponent of polarization of nerve cell function. By producing excellent depictions of neural structures and their connectivity, and providing detailed descriptions of cell types he discovered a new type of cell, which was subsequently named after him, the interstitial cell of Cajal (ICC). Courtesy of Wikimedia.




Ramón y Cajal in Zaragoza, Spain, c. 1870, auto-portrait. Cajal was a pioneering neuroanatomist who, over the course of five decades, combined cutting-edge scientific research with consummate draftsmanship to create groundbreaking drawings of the human brain and other nerve tissues.


“Is the brain’s grey matter a continuous network of fibres? At the end of the nineteenth century, this was a contentious question, with high-stakes implications: an opposing theory that the grey matter was made of separate cells had gained traction by 1906, when the Nobel prize honoured two giants of neuroscience for work on the structure of the nervous system. The laureates embodied the hostile extremes of the dispute, a feud that has gone down in the annals of science history. Camillo Golgi, who clung to the continuous-web theory, abused his Nobel acceptance speech to attack his younger co-laureate, Santiago Ramón y Cajal. Cajal behaved himself at the ceremony, but elsewhere, he had described Golgi’s stubbornness as “a typical case of the crippling influence of theoretical prejudice”. Cajal was proved right. His delicate tissue preparations clearly showed tiny gaps between individual brain cells. His work has been compared to that of Andreas Vesalius, the Renaissance physician whose exquisite drawings of his own anatomical dissections revolutionized medicine. Cajal’s immense artistic skills similarly led him to profound insights into brain development and function, most of which have stood the test of time.” Source: B. Ehrlich. (2022). *The Brain in Search of Itself: Santiago Ramón y Cajal and the Story of the Neuron*. Farrar, Straus and Giroux, New York, New York.



Ramón y Cajal's sketch of the retina. Painting made by Cajal showing the schematics of the structure of the mammalian retina. The various numbers in Cajal's original sketch above refer to: 1. Rod and cone layer; 2. External limiting membrane; 3. Outer granular layer; 4. Outer plexiform layer; 5. Inner granular layer; 6. Inner plexiform layer; 7. Ganglion cell layer; 8. Optic nerve fibre layer; 9. Internal limiting membrane; A. Pigmented cells; B. Epithelial cells; a. Rods; b. Cones; c. Rod nucleus; d. Cone Nucleus; e. Large horizontal cell; f. Cone-associated bipolar cell; g. Rod-associated bipolar cell; h. Amacrine cells; i. Giant ganglion cell; and j. Small ganglion cells. Obtained from Santiago Ramon y Cajal's *Structure of the Mammalian Retina*, c. 1900. Open Access.




Histopathology of the thalamus. A normal neuron is shown at left, and in an infarction at approximately 24 hours at right on H&E stain, with a hyper-eosinophilic neuron, as well as an infiltrate of neutrophils. The surrounding neuropil has slight edema and loss of the normal architecture. Courtesy of Mikael Häggström.




Diffusion tractography: 3D-printed reconstruction of the arcuate fasciculus. The brain is composed of two types of matter: grey and white. The grey matter contains cell bodies, and is responsible for processing information. White matter connects these grey matter areas, allowing signalling (and information transfer) between remote areas of the brain. Language is considered a uniquely human cognitive ability. Its anatomical foundation in the brain has primarily been mapped to two distant brain regions in the frontal and temporal lobes. This image shows a 3D-printed reconstruction of the arcuate fasciculus, the white matter pathway connecting these two areas. Although discovered in the 19th century using postmortem dissection methods, it is only with the advent of new technologies that this connection could be visualized in the living human brain. To create this work, a type of MRI called diffusion tractography was used to generate a 3D map of the arcuate fasciculus. The data were then converted to a file compatible with 3D printing. The 3D print is made from clear resin, and is illuminated using colored light in a darkroom for this photograph. Image courtesy of Stephanie J. Forkel and Ahmad Beyh, Natbrainlab, King's College London; Alfonso de Lara Rubio, King's College London; CC BY.




Healthy adult human brain. Sagittal view of a healthy adult, living human brain, virtually sliced down a vertical axis dividing it into left and right halves. The anterior portion of the brain is facing towards the left side of the image. Information on neural tracts or pathways of white matter in the brain were collected by a type of magnetic resonance imaging (MRI), which tracks the movement of water molecules within tissue, similar to diffusion tensor imaging (DTI). This was used to reconstruct a digital model in the style of a Joseph Jules Dejerine anatomical drawing. The rostral/anterior portion of the brain is facing. Field of view is 256×140 mm. Image courtesy of Dr. Flavio Dell'Acqua; CC BY.



CT scan; papilloma, choroid plexus. CT scan of 9-year-old child showing papilloma of choroid plexus. This is usually a benign neoplasm that arises from the cuboidal epithelium of the choroid plexus and takes the form of an enlarged choroid plexus which may be associated with oversecretion of CSF. The tumor usually presents in the first decade of life with signs of increased intracranial pressure including headaches, ataxia, diplopia, and alterations of mental status. In children it is most common in the lateral ventricles and in adults it tends to arise in the fourth ventricle. Malignant transformation to choroid plexus carcinomas may rarely occur. CC BY 4.0.




Diffusion magnetic resonance imaging (MRI): Healthy human brain from a young adult. Coronal view of nerve fibres in the brain of a young healthy adult, which has been virtually sliced down a vertical axis to divide it into front and back. The brain is viewed from behind, with the left side of the brain on the left of the image. This image was created by virtually dissecting the brain using data obtained from diffusion MRI. Diffusion weighted imaging is a specialised type of MRI scan which measures water diffusion in many directions in order to reconstruct the orientation of bundles of nerve fibres. Tractography is used to indirectly model these nerve fibres, which transmit information between different regions of the brain. These have been color-coded to help distinguish between different tracts which pass close to each other. For example, fibres connecting the left and right hemispheres (red), fibers travelling from top to bottom (blue) connecting to the spinal cord, and fibers running from front to back (green) are visible here. Reconstructing these connections between different parts of the brain will aid our understanding of how the brain functions in health and disease, and could ultimately become a tool in the same way as the human genome. Width of image is approximately 165 mm. Image courtesy of Alfred Anwander, Max Planck Institute for Human Cognitive and Brain Sciences; CC BY.




Monkeypox virus. The color-enhanced SEM shows the MPox virus (orange) in infected cells. Courtesy of the National Institute of Allergy and Infectious Diseases.



Monkeypox virus. Colorized scanning electron micrograph of Mpxv virus (orange) on the surface of infected VERO E6 cells (green). Courtesy of the National Institute of Allergy and Infectious Diseases.



Monkeypox virus particles. This digitally-colored electron microscopic (EM) image depicts Mpox virus particles, obtained from a clinical sample associated with the 2003 prairie dog outbreak. It was a thin section image from a human skin sample. In the micrograph on the left are mature, oval-shaped virus particles, and on the right are the crescents, and spherical particles of immature virions. Courtesy of Cynthia S. Goldsmith and Russell Regnery, Centers for Disease Control and Prevention.




Measles virus particles. This illustration provides a 3D graphic representation of a spherical-shaped, measles virus particle, that is studded with glycoprotein tubercles. Those tubercular studs colored maroon, are known as H-proteins (hemagglutinin), while the colorized gray, represent what are referred to as F-proteins (fusion). The F-protein is responsible for fusion of the virus and host cell membranes, viral penetration, and hemolysis. The H-protein is responsible for the binding of virions to cells. Both types of proteinaceous studs are embedded in the particle envelope's lipid bilayer. Kindly provided by the Centers for Disease Control and Prevention.



Instruction in physical diagnosis. Demonstration in an amphitheater of techniques for diagnosis through physical examination (PE). Only one of the medical students present is a woman. Courtesy of the National Library of Medicine.



A doctor checks a patient's pulse in Meiji-era Japan. This photograph depicts a doctor checking a patient's pulse. The photo was taken by Kusakabe Kimbei in the 1870–1890s and the monochrome albumen silver print was hand-colored.




Chest palpitation. Making a diagnosis in a case of disease of the lungs. Clinic scene, in New York Polyclinic Medical School.




Attending surgeon's office. An examination room in Washington, DC during World War I (1910s). Courtesy of Otis Historical Archives National Museum of Health and Medicine (originally posted to Flickr as Reeve 978, CC BY 2.0, <https://commons.wikimedia.org/w/index.php?curid=5790312>).




The Doctor. This is an 1891 painting by Luke Fildes that depicts a Victorian doctor observing the critical stage in a child's illness, while the parents gaze on helplessly from the periphery. This classic painting was commissioned in 1890 by Sir Henry Tate from Fildes, the subject of which was left to his own discretion. The subject matter relates to a bereavement suffered by Fildes, when in 1877 his first son died at home at the age of one. The painting has been used to portray the values of the ideal physician and the inadequacies of the medical profession. It is a beautiful panorama of the traditional medical profession. Here, the figure of the doctor stands as a symbol of quiet professional devotion, capturing, as Fildes put it, "the status of the doctor of our time." Basically, the doctor is contemplating his patient, intrigued, trying to scrutinize the pathophysiology to achieve an effective therapy. We also see the sick girl, possibly victim of some of the terrible incurable infectious febrile diseases in the pre-antibiotic era, pale, weak, asleep. Behind the child, a working class father and mother anxiously await the doctor's assessment. We see the dismayed mother, worried, hoping for the best. Also notable is the expression of the father, who cannot contain his concern about his daughter's illness, but who has to remain calm to give comfort to the grieving mother. The sliver of dawn light at the window suggests renewed hope in the face of near-tragedy. Painting and text courtesy of Tate Gallery, London, and Wikipedia.




Human immunodeficiency virus (HIV). Internal structure of an HIV particle showing the capsid surrounding the RNA-containing core in red and the membrane in blue. The yellow area is electron dense material, including proteases, between the core and the membrane. Courtesy of Stephen Fuller; CC BY.




Transmission electron microscope (TEM) image of human immunodeficiency virus (HIV). This TEM image reveals some of the ultrastructural features exhibited by a number of HIV particles, which had been co-cultivated along with human lymphocytes. Courtesy of the Centers for Disease Control and Prevention.




SEM of *Escherichia coli* (*E. coli*). Low-temperature electron micrograph of a cluster of *E. coli*, magnified 10,000 \times . *E. coli* is a Gram-negative, facultative anaerobic, rod-shaped, coliform bacterium that is commonly found in the lower intestine of warm-blooded organisms. There are six classic pathotypes of *E. coli*: enteropathogenic *E. coli* (EPEC), shiga toxin-producing *E. coli* (STEC), enteroaggregative *E. coli* (EAEC), enterotoxigenic *E. coli* (ETEC), enteroinvasive *E. coli* (EIEC), and diffusely adherent *E. coli* (DAEC). Most *E. coli* strains are harmless, but some serotypes (EPEC, ETEC etc.) can cause serious disease. The harmless strains are part of the normal microbiome of the gut, and can benefit their hosts by producing vitamin K2, and preventing colonization of the intestine with pathogenic bacteria by having a mutualistic relationship. *E. coli* is expelled into the environment within fecal matter. Courtesy of the Agricultural Research Service, US Department of Agriculture and Wikipedia.




Enteropathogenic (EPEC) *E. coli* on human intestinal cells. The small red dots are enteropathogenic *E. coli* bacteria attaching to the surface of human intestinal cells in culture. During this process they sequester the actin (green) in the host cell to form actin-rich pedestals. This tends to give the appearance of a green halo around the bacteria. Once attached, the bacteria cause the tight junctions (blue) between the cells to break down, leading to the leakage of water into the intestine and consequent diarrhea. Courtesy of S. Schuller; CC BY.



Fragile X chromosome and the atomic force microscope. Fragile X chromosome made visible by atomic force microscopy (AFM). The arrow indicates the fragile site. Courtesy of Dr. Ben Oostra; CC0.




Fluorescence *in situ* hybridization (FISH) of Duchenne muscular dystrophy control. Human chromosomes highlighted by fluorescent probes which bind to specific sequences of DNA. This FISH study shows a female not deleted for a cosmid (red) from within the Duchenne muscular dystrophy (DMD) gene. A cosmid is a type of hybrid plasmid that contains a Lambda phage *cos* sequence. In a carrier female, this signal would be missing from one of the X chromosomes. Courtesy of Dr. John Crolla, Wessex Reg. Genetics Centre; CC BY.




Astrocytes and blood vessels of the retina. A large-scale high-resolution montage of the entire surface of a mouse retina generated by the use of antibody labeling and laser scanning confocal imaging. The montage is comprised of more than 400 tiled images acquired sequentially across the retinal surface and seamlessly stitched together using specialized software to form one large image. Since the original image tiles were taken at high resolution, details at the cellular level can be viewed at any point on the montage by zooming into the selected area. Complete networks of both astrocytes and blood vessels on the retinal surface are shown in the montage by virtue of their different antibody labeling properties: astrocyte cell bodies are red; the star-shaped extensions from the astrocyte cell bodies are green; and blood vessels are blue. Courtesy of Gabriel Luna, Neuroscience Research Institute, University of California Santa Barbara; CC BY.



Human blastocyst hatching. A human embryo at the blastocyst stage, about six days after fertilization, viewed under a light microscope. The embryo is in the process of “hatching” out of the zona pellucida – the tough outer membrane – just before implanting in the wall of the uterus. The actual size of the embryo is about 0.3 mm. Courtesy of K. Hardy; CC BY.



Human cells showing the stages of cell division. The stages of cell division showing the DNA in blue, the tubulin in green and the kinetochores in pink. Starting with interphase at the top and progressing anticlockwise, the stages shown are: prophase, prometaphase (incomplete chromosome attachment), metaphase (chromosomes all attached and aligned), early anaphase (chromosome separation), anaphase, and telophase. Courtesy of Matthew Daniels; CC BY.




MRI of a fetus with Pentalogy of Cantrell (POC). Fetal MRI using single shot turbo spin echo, shows the heart in an ectopic position (*) and eventration of a part of the liver at the midline (arrow). Notice the small thoracic cavity (t). No malformation of the central nervous system could be seen. POC is a collection of five congenital midline birth anomalies that present a distinctive challenge for providers and surgeons. Those five defects are of the heart, pericardium, diaphragm, sternum, and abdominal wall. Source: M. Leyder, *et al.* (2014). Ultrasound meets magnetic resonance imaging in the diagnosis of Pentalogy of Cantrell with complete ectopy of the heart. *Gynecology & Obstetrics* 04(01). DOI:10.4172/2161-0932.1000200, CC BY 4.0.



Radiocontrast-enhanced median plane CT scan of a pregnancy at 37 weeks of gestational age. CT scan in the median plane using radiocontrast, of a 30-year-old woman who was involved in a high-speed traffic accident. She was pregnant at 37 weeks of gestational age, and it was decided that the risk of traumatic injury to the mother or child outweighed the risks of a CT scan, which was therefore performed, and showed no traumatic injury. Courtesy of Mikael Häggström.



Transmission electron microscope (TEM). This historic 1965 image depicts a Centers for Disease Control (CDC) transmission electron microscope (TEM), which uses a beam of electrons that is passed through an extremely thin specimen, and on to an imaging surface, at which point the image becomes visible. Sometimes a fluorescent surface is used, and at other times a sheet of photographic film, or in the case of modern day technology, a digital camera captures the image. The electron microscope is capable of revealing details that are tens of thousands of times smaller than can be seen by even the highest quality light microscope. Courtesy of the Centers for Disease Control and Prevention.




Giants of Electron Microscopy. Photographs of Nobelist George Palade (1912–2008) (top) and Nobelist Ernst Ruska (1906–1988) (lower left). Ruska’s high resolution electron microscope from around 1934 (lower right). Image collage courtesy of Prof. Dr. S. R. Bawa.



Prof. Dr. S. R. Bawa with Prof. Dr. Fritiof S. Sjöstrand. Sjöstrand (1912–2011) was a pioneer of electron microscopy and a giant of biomedical research. He invented the Sjöstrand Microtome for ultra-sectioning biological tissue, produced the first high-resolution electron micrographs of biological tissue, was the first to describe the mitochondrial inner membrane in detail, and was the first to describe the electron transport proteins in mitochondria. His work in the field of biological electron microscopy led to several pioneering developments and discoveries. Sjöstrand founded the *Journal of Ultrastructure Research* in 1957 (now *Journal of Structural Biology*). In recognition of his remarkable contributions to the development of electron microscopy, the Annual Sjöstrand Lecture series was set up in 2018 in Sweden. Prof. Dr. S. R. Bawa and Sjöstrand collaborated since the 1960s when Dr. Bawa was a faculty member in the anatomy department at Cornell University Medical College (now Weill Cornell Medicine). Sjöstrand, Dr. Keith Porter and Nobelist George Palade constituted the “big three” in the 1950’s for their pioneering use of the electron microscope to describe details of cellular structure that anchored the burgeoning field of cell biology. Text and photo courtesy of Prof. Dr. S. R. Bawa.




Sjöstrand's ultramicrotome. It dramatically improved ultrathin sectioning with minimal distortion. Courtesy of Prof. Dr. S. R. Bawa.



Prototype of Sjöstrand's original ultramicrotome, 1952. Courtesy of Prof. Dr. S. R. Bawa.




Hans Ris. Prof. Dr. Hans Ris. (1914–2004), a cytologist and pioneer electron microscopist, revealed the importance of non-histone proteins in chromosomes, was one of the first to recognize that blue-green algae were a special type of bacteria and provided remarkable high-resolution images of the nuclear pore complex. He was a founding member of the American Society for Cell Biology. In 1972, he established the High Voltage Electron Microscopy (HVEM) laboratory at the University of Wisconsin-Madison, which his successor dismantled after his retirement. The Center for Quantitative Cell Imaging at the University of Wisconsin-Madison hosts an annual seminar series honoring him. In his biographical memoir published in 2011 by the National Academies, Michael Dolan, and Lynn Margulis, accurately describe his monumental contributions to science and remarkable career: “Hans Ris occupied a unique historical position: he was a cytologist (student of the cell) at the beginning of the molecular biological revolution and a superb electron microscopist when “biochemical and biophysical cytology” was renamed “cell biology. [H]e influenced the careers of scores of scientists as he generously collaborated to produce a massive collection of remarkably informative micrographs. He was a naturalist on a mission of investigation, an observer-researcher his entire life.” Text and photo courtesy of Prof. Dr. S. R. Bawa.




Freeze-fracture electron microscopy. Freeze-fracture is a technique for examining the ultrastructure of rapidly frozen biological samples via transmission electron microscopy. Courtesy of Prof. Dr. S. R. Bawa.



Freeze-fracture replica of sperm. The micrograph shown above represents a freeze-fracture replica of water buffalo sperm. Intramembrane particles (IMPs) are present on the major portion of the acrosome (A). The post acrosome (PA) is densely populated with IMPs. 'Cords' demarcating the posterior boundary of the sperm head are visible (arrowheads). 31,000 \times . Further details: H. K. Bains, M. A. Pabst, G. Werner, and S. R. Bawa. (1993). *Journal of Submicroscopic Cytology and Pathology* 25(4):465–470. Courtesy of Prof. Dr. S. R. Bawa.




Eight Ishihara charts for testing color blindness, Europe, 1917–1959. Color blindness is tested using eight placards (one shown). They are known as Ishihara charts. They are named after their inventor, Japanese ophthalmologist Shinobu Ishihara (1897–1963). Each image consists of closely packed colored dots and a number. The patient must identify the number or image he or she can see. The type of color blindness a patient has is identified using the range of charts. There are several types of color blindness. These range in severity. In dichromatism, there is difficulty seeing one of the three primary colors: red, blue or green. In anomalous trichomatosis, there is reduced sensitivity to certain colors. In the rarer monochromatism, there is no color vision and the world is seen in white, black and grey shades. Ishihara devised his test in 1917. It is still used. Courtesy of the Science Museum, London and the Wellcome Collection.




TEM of mitochondrion. An electron micrograph depicting sperm mitochondria essential for sperm motility. Mitochondria are organelles surrounded by double membranes, distributed in the cytosol of most eukaryotic cells and convert the potential energy of pyruvate molecules into ATP. Sperm cells contain around 50–75 pieces of mitochondria in its midpiece. The structure and function of the mitochondria in sperm and somatic cells is basically similar. The sperm mitochondria generate ATP for the movement of the sperm. Mitochondria contain their own DNA (mitochondrial DNA, mtDNA), are semiautonomous, and have the capacity to replicate, divide, and fuse independent of the somatic nuclear division cycle.


Electron microscopes were developed in the 1930s, as the collaborative product of innumerable scientists and a truly international endeavor. The first electron micrographs were published in 1940 in Germany and they were of bacteriophages. The first electron micrographs of biological (histological) tissue were that of mitochondria, published in *Nature* in the early 1950s, independently by Fritiof Sjöstrand and George Palade. This electron micrograph and text is courtesy of my 93-year-old-father, Prof. Dr. S. R. Bawa, from his personal slide collection.




SEM of *Staphylococcus aureus*. Scanning electron micrograph of methicillin-resistant *Staphylococcus aureus* (MRSA) and a dead human neutrophil. Courtesy of the National Institute of Allergy and Infectious Diseases.




Scanning electron microscopic (SEM) image. This digitally-colored image depicts a number of corkscrew-shaped *Leptospira sp.* bacteria atop a 0.1 μm polycarbonate filter. Courtesy of Janice Haney Carr, Centers for Disease Control and Prevention.




SARS-CoV-2 and the cell. (a) Electron microscopy plays an important confirmatory role in diagnosis and determining subcellular localization. A false-color transmission electron micrograph of SARS-CoV-2 isolated from a patient. Coronaviruses are approximately 80–120 nm in diameter. (b) A false-color scanning electron micrograph of an apoptotic cell (green) infected with SARS-CoV-2 isolated from a patient. The virions can be observed as small yellow spheres. (a) and (b) are courtesy of NIAID. (c) Fluorescence microscopy can show subcellular localization. Co-localization of FLAG-tagged SARS-CoV-2 protein Orf6 with nuclear pore complex protein Nup358 in HEK293T cells, as imaged by stimulated emission depletion (STED) super-resolution microscopy. Scale bar in the left-most panel is 5 μm . Scale bar in the magnified panels is 1 μm . This panel is adapted from L. Miorin, *et al.* (2020). *Proc Natl Acad Sci USA*. 117:28344–28354; CC BY 4.0.




Structural view of a coronavirus. Source: https://commons.wikimedia.org/wiki/File:3D_medical_animation_coronavirus_structure.jpg; CC BY-SA 4.0.




Digitally colored transmission electron micrograph of SARS-CoV-2 virions. Virion nanoparticles, isolated from a patient in the US, are shown emerging from the surface of cells cultured in the lab. The coronae (bluish) are visible on the surface of the virus (yellow-red). Courtesy of the National Institutes of Health.




The peplomers of a SARS-CoV-2. This illustration reveals the surface morphology/topography of the virus nanoparticle. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding it, when viewed electron microscopically. A peplomer (Greek, *peplos*, 'robe', '[woman's] dress' + *meros*, 'part') is one of the knoblike spike structures (red, orange, yellow), generally composed of glycoproteins (spike protein) and projecting from the lipid bilayer of the surface envelope of an enveloped virus. Peplomers play important roles in the infection process. Courtesy of the Centers for Disease Control and Prevention.




Digitally colorized scanning electron micrograph of SARS-CoV-2 virions. Virion nanoparticles (yellow), isolated from a patient in the US, are shown emerging from the surface of cells cultured in a lab. Courtesy of the Centers for Disease Control and Prevention.



False-color transmission electron micrograph of the UK B.1.1.7 variant coronavirus. The variant's increased transmissibility is believed to be due to changes in the structure of the spike proteins, shown here in green. The prominent projections (green) seen on the outside of the virus particle (yellow) are spike proteins. This fringe of proteins enables the virus to attach to and infect host cells, then replicate. Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Courtesy of the Centers for Disease Control and Prevention.




Negative stain electron microscopy. Image of a negatively stained particle of SARS-CoV-2, causative agent of COVID-19. Note the prominent spikes from which the coronavirus gets its name for “corona” or “crown-like.” Courtesy of Cynthia S. Goldsmith and A. Tamin, the Centers for Disease Control and Prevention.




Transmission electron microscope (TEM) image of human coronavirus 229E particles. This digitally colored TEM image from 1975, depicts four human coronavirus 229E particles, which are members of the Coronaviridae family. Coronaviruses possess a helical genome, composed of non-segmented, positive-sense single-stranded RNA ((+) ssRNA). This is an enveloped virus, which means that its outermost covering is derived from the host cell membrane. The coronavirus derives its name from the fact that under electron microscopic examination, each virion is surrounded by a corona, or halo, due to the presence of viral spike peplomers emanating from its proteinaceous envelope. Courtesy of the Centers for Disease Control and Prevention.

CRACKING THE COVID-19 CODE

Finding treatments or vaccines starts with understanding the protein structure of a virus. Here's how it happens at the Advanced Photon Source (APS) at Argonne National Laboratory.




Understanding the protein structure of SARS-CoV-2. Courtesy of Argonne National Laboratory.




Ultrasonography. A normal appendix without (left) and with compression (right). Absence of compressibility indicates appendicitis. Courtesy of Wikimedia.




Panoramic ultrasonography of a proximal biceps tendon rupture. Top image shows the contralateral normal side, and lower image shows a retracted muscle with a hematoma filling out the proximal space. Courtesy of Mikael Haggström.




Angiogram. A transverse projection of the vertebral, basilar, and posterior cerebral circulation. Courtesy of Lipothymia. Public Domain, <https://commons.wikimedia.org/w/index.php?curid=1577168>.




Volume segmentation of a 3D-rendered CT scan of the thorax. The anterior thoracic wall, the airways and the pulmonary vessels anterior to the root of the lung have been digitally removed in order to visualize thoracic contents: – blue: pulmonary arteries – red: pulmonary veins (and also the abdominal wall) – yellow: the mediastinum – violet: the diaphragm. Courtesy of Mikael Häggström.




Examples of T1-weighted, T2-weighted and PD-weighted MRI scans. Courtesy of KieranMaher at English Wikibooks - Adapted, with permission, by Kieran Maher using Graphic Converter from Applied Imaging Technology by Heggie, Liddell & Maher (2000). Public Domain, <https://commons.wikimedia.org/w/index.php?curid=12766438>.




Effective T2-weighted MRI of hemosiderin deposits after subarachnoid hemorrhage. Enhanced gradient echo effective T2 (T2*) weighted angiography (ESWAN) image of the brain of a 54-year-old man who experienced a traumatic brain injury with right frontotemporal SAH (Fisher Grade 4) with bilateral frontal contusions and intracerebral hematoma. This follow-up MRI (1.5T) image was obtained 26 weeks following the head injury. The axial ESWAN image displays a rim of hypointensity (arrowheads) with hemosiderin deposits forming along the cerebral convexity. H. Zhao *et al.* (2015). *PLOS ONE* 10(2):e0116632, CC BY 4.0, <https://commons.wikimedia.org/w/index.php?curid=71956986>.




Double inversion recovery (DIR) MRI in the axial plane of the brain. Image shows lesions by multiple sclerosis. White circles surround two cortical lesions and one juxtacortical lesion. A separate PSIR MRI confirmed these, and also disclosed six more lesions (white arrows) that were not identified on DIR prior to PSIR. A. Favaretto *et al.* (2015). *PLOS ONE* 10(5):e0127805, CC BY 4.0, <https://commons.wikimedia.org/w/index.php?curid=63344691>.




Vastly undersampled Isotropic Projection Reconstruction (VIPR) of a Phase Contrast (PC) MRI sequence. Separation of the arterial wall layers results in dissection. A false lumen arises in the space where blood seeps into the vessel wall. The blood that accumulates inside this false lumen can generate blood clots or otherwise block blood flow. In this 56 year-old male, dissections of the celiac artery (upper) and the superior mesenteric artery (lower) are seen. Laminar flow is present in the true lumen (closed arrow), and helical flow is present in the false lumen (open arrow). M. Häggström. (2011). *Journal of Cardiovascular Magnetic Resonance* 13(1):19, CC BY 2.0, <https://commons.wikimedia.org/w/index.php?curid=63390956>.



Magnetic resonance imaging (MRI) of a meningioma. A T1 weighted MR image of the brain of a patient with a meningioma after injection of an MRI contrast agent (top left), and the same image with the result of an interactive segmentation overlaid in green (3D model of the segmentation on the top right, axial, and coronal views at the bottom). Using an interactive segmentation approach this MR image of a meningioma was segmented. Courtesy of Wikipedia.



Computed tomography (CT) brain scan showing oligodendroglioma. This is a relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle(s). They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. Courtesy of the Wellcome Library.




Computed tomography of human brain from base of the skull to top. Taken with intravenous contrast medium. Commons: Scrollable computed tomography images of a normal brain. Courtesy of Mikael Häggström, Radiology, Uppsala University Hospital, <https://commons.wikimedia.org/w/index.php?curid=3479321>.



CT scanner. Courtesy of daveynin, CC BY 2.0, <https://commons.wikimedia.org/w/index.php?curid=20326407>.



Gantry of an MRI scanner. An MRI gantry remains fixed, and contains cryogenically cooled superconducting electromagnets and radio transmitters that flip protons in hydrogen atoms in the human body via proton nuclear magnetic resonance. The machine then listens and processes the signals given off by the hydrogen atoms as the protons flip back in order to produce a 3D image of the interior of the patient's body. Courtesy of Liz West from Boxborough, MA, CC BY 2.0, <https://commons.wikimedia.org/w/index.php?curid=24632735>.




Normal whole body Positron Emission Tomography-Computerized Tomography (PET-CT) scan with FDG-18. The PET-CT imaging is a highly advanced, non-invasive test that allows detection of tumors earlier, and sometimes more reliably, than other imaging methods. The whole body PET-CT scan is commonly used in the detection, staging, and follow-up of various cancers.

Many imaging centers combine nuclear medicine images with computed tomography (CT) or magnetic resonance imaging (MRI) to produce special views (image fusion or co-registration), which allows physicians to connect and interpret information from two different exams on one image. While a PET scan measures important body functions, such as metabolism and helps evaluate how well organs and tissues are functioning, CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple internal images of tissue. Now-a-days, this “hybrid” PET-CT imaging technique can perform both tests almost simultaneously thereby greatly improving diagnostic accuracy and may help prevent additional examinations. In summary, these combined scans help pinpoint abnormal metabolic activity and generally provide more accurate diagnoses than the two scans performed separately. In fact, today, these combined PET-CT scanners perform virtually all PET scans. Image courtesy of Myohan, CC BY 3.0, <https://commons.wikimedia.org/w/index.php?curid=17271087>.



Fluoroscope. <https://commons.wikimedia.org/w/index.php?-curid=2530717>.



Thoracic fluoroscopy using handheld fluorescent screen, 1909. No radiation protection is used, as the dangers of X-rays were not yet recognized. Source: Edwin J. Houston. *Elementary Electricity*, Ch. 13: The X-rays; in *Popular Electricity Magazine*, Vol. 2, No. 1, May 1908, p. 6, Fig. 87.



WWI fluoroscope operation. Surgical operation during World War I using a fluoroscope to find embedded bullets, 1917. J. P. Hoguet – Retrieved 12 October 2013 from A. M. Jungmann, “X-rays: Samaritans of war” in Waldemar Kaempffert, Ed., *The Book of Modern Marvels*, Leslie Judge Co., New York, p. 172. <https://commons.wikimedia.org/w/index.php?curid=28986607>.




Thoracic fluoroscopy in 1940. Courtesy of the National Cancer Institute.




Fluoroscopy. Fluoroscopic image showing dilatation of the pancreatic duct during endoscopic retrograde cholangiopancreatography (ERCP) investigation. The endoscope is visible. ERCP, a minimally invasive interventional procedure that is part of the diagnostic and treatment plan for a number of gastrointestinal conditions, is an investigation used to view and if necessary biopsy the gallbladder, bile duct, pancreas, and pancreatic duct. Minor surgery can also be carried out during the procedure. Courtesy of DrM!KEY, <https://commons.wikimedia.org/w/index.php?curid=6723923>.



Raynaud's phenomenon (RP). Named after the French physician, Auguste Gabriel Maurice Raynaud (1834–1881), who first described it in his doctoral thesis in 1862. The Raynaud phenomenon (RP) is a medical condition in which the spasm of small arteries causes episodes of reduced blood flow to end arterioles. RP occurs in 3–5% of the population. The Raynaud's episodes classically result in the affected part turning white and then blue. As blood flow returns, the area turns red and burns. Numbness or pain are symptoms that may be noted in some patients. The condition has been visualized using thermal infrared which allows us to see thermal energy or radiation more commonly referred to as heat. The image shows the hand of a person experiencing symptoms of Raynaud's against that of a person who is unaffected. The hand affected with Raynaud's is on the right, the other hand is unaffected. This image shows both hands after exposure to cold water for 2 minutes, both hands appear to emit low levels of radiation. This image illustrates how the unaffected hand warms considerably quicker and begins to emit higher levels of radiation (heat) soon after exposure, whilst the affected hand continues to emit lower levels. Image courtesy of Matthew Clavey (TVR) and Carly Dakin (Wellcome).




Underlying mechanism of Raynaud's syndrome/phenomenon. Figure A shows typical digital arteries with normal blood flow to the fingers. The inset images show cross-sections of a normal artery. Figure B shows white discoloration of the fingertips caused by blocked blood flow. Figure C shows narrowed digital arteries, causing blocked blood flow and purple discoloration of the fingertips. The inset images show cross-sections of a narrowed artery blocking the flow of blood. Diagram courtesy of the National Heart, Lung, and Blood Institute.




Dual energy computed tomography angiography (DECT) of a human chest.

The scan was performed with an extremely low radiation dose on a patient who had received a mechanical heart pump (blue) while waiting for a heart transplant. The image was rendered with a 3D volume rendering technique to check the wiring of the pump to the left side of the diseased heart and to the aorta. The pump connection to the heart was faultless. DECT has two sources of x-rays (dual source CT) at different energies, which are used simultaneously to scan the patient. The patient is scanned in a series of virtual x-ray “slices,” which are then digitally reconstructed to produce a 3D image. Colors and degree of transparency then can be applied to the various tissues. DECT provides higher quality images than conventional CT without the need for exposure to additional radiation. Angiograph courtesy of Anders Persson; CC BY.




Human aortic valve tissue displaying calcification. Calcification of the aortic valve is an active, proliferative process that results from inflammation, fibrosis, and bone matrix formation, mediated by the signaling pathways common to valvulogenesis and osteogenesis. Often the main therapeutic option is open heart surgery and replacement with a valve prosthesis. Shown here is a density-dependent color scanning electron micrograph of the surface of aortic valve tissue displaying calcification in the form of spherical particles. The orange color identifies denser material (calcified material composed of calcium phosphate), while structures that appear in green are less dense (corresponding to the organic component of the tissue). Micrographs were colored in post-processing by combining images acquired by two modes of image acquisition that use different kinds of electron microscope detector (Secondary electron and Backscatter electron detectors). Horizontal field width is 64 microns. Micrograph courtesy of Sergio Bertazzo, Department of Materials, Imperial College London; CC BY.




Kidney stone. Scanning electron micrograph of a kidney stone (nephrolithiasis). Kidney stones form when salts, minerals, and chemicals in the urine (for example calcium, oxalate, and uric acid) crystallize and solidify. Small kidney stones are often passed naturally but larger stones can sometimes get lodged in the kidney or other parts of the urinary tract. Size of stone is 2 mm. Micrograph courtesy of Kevin Mackenzie, University of Aberdeen; CC BY.



Head louse egg attached to a strand of hair. False-colored scanning electron micrograph of a head louse egg (green) attached to a strand of human hair (brown). Head lice (*Pediculus*) feed on human blood and live in close proximity to the scalp. They lay eggs (nits) in sacs which firmly attach to individual strands of hair near the base of the shaft. Horizontal image width is 1.5 mm. Micrograph courtesy of Kevin Mackenzie, University of Aberdeen; CC BY.




3D structured illumination microscope (3D SIM). Super-resolution optical micrograph of DNA stain in a human fetal lung fibroblast nucleus acquired with 3D SIM. A rare phenomenon has occurred in this image; the majority of the genome has been caught in misreplication. If a single chromosome becomes caught and pulled between the two new cells, it can lead to the presence of small chromatin threads/bridges joining adjacent nuclei. This leads to clearly demarcated chromatin fibres visible throughout the interior of the nucleus, and as the new cells move apart the tension distributed by the cable-like chromatin has deformed the entire nuclear envelope. The width of the image is 84 micrometers. Micrograph courtesy of Ezequiel Miron, University of Oxford; CC BY.




Seminiferous tubule. Cross section through a seminiferous tubule showing the developing sperm with their tails pointing into the lumen of the tubule. The nuclei are stained blue with DAPI and mitochondria red with mitotracker. Sperm have a large number of mitochondria to power their swim towards the egg. The image has been volume rendered using Imaris. Courtesy of Kate Sullivan/NIMR, Francis Crick Institute; CC BY.




ECAT Exact HR PET scanner. This image shows a picture taken from a typical PET facility equipped with an ECAT Exact HR+ PET scanner. PET scanners such as this are steadily being replaced by systems that combine both PET and CT scanners into a single PET/CT imaging device. Courtesy of Jens Maus (<http://jens-maus.de/>), <https://commons.wikimedia.org/w/index.php?curid=404712>.



Schema of a PET acquisition process. Courtesy of Jens Maus (<http://jens-maus.de/>), <https://commons.wikimedia.org/w/index.php?curid=401252>.




Brain PET-MRI fusion image. Courtesy of Mco44 at en.wikipedia, <https://commons.wikimedia.org/w/index.php?curid=18102518>.



Light Microscopy (histopathology) of small-cell lung carcinoma cells. About 13% of people with lung cancer have a type called small-cell lung cancer (SCLC). It's one of the most aggressive and deadly tumor types, often proving completely resistant to chemotherapy. Even if SCLC shrinks after initial treatment, it can be fatal within weeks of recurrence. Courtesy of Dr. Parth Desai, National Cancer Institute.




Endoscopy surgery. U.S. Navy photo by Mass Communication Specialist 2nd Class Marc Rockwell-Pate. Public Domain.




An anoscope, a proctoscope, and a rectoscope with approximate lengths. Image courtesy of Mikael Häggström.



Light microscopy of ureter. Microscopic cross-section of the ureter, showing the epithelium (purple cells) sitting next to the lumen. A large amount of muscle fibres can be seen surrounding the epithelium, and the adventitia sits beyond this. Courtesy of OpenStax (<https://openstax.org>).



MRI of herniated spinal disc. Left: Illustration of herniated spinal disc, superior view. Right: MRI showing herniated L5-S1 disc (red arrow tip), sagittal view. Courtesy of OpenStax (<https://openstax.org>).



Magnetic resonance images of sacroiliac joints: psoriatic arthritis. Shown are T1-weighted semi-coronal magnetic resonance images through the sacroiliac joints (a) before and (b) after intravenous contrast injection. Enhancement is seen at the right sacroiliac joint (arrow), indicating active sacroiliitis. Source: F. McQueen, M. Lassere, and M. Østergaard. (2006). Magnetic resonance imaging in psoriatic arthritis: a review of the literature. *Arthritis Res. Ther.* 8:207. <https://doi.org/10.1186/ar1934>.




Scanning electron microscope (SEM) image of *Legionella pneumophila*.


Magnified 10,000X, this digitally colorized SEM image depicts a group of *Legionella pneumophila* bacteria. It appeared that a few were completing their reproductive process (cell division). Note the presence of flagellar appendages, as well as an elongated-rod morphology in some organisms. *L. pneumophila* frequently elongate when grown in broth, when plate-grown cells age, or when refrigerated, as in this case. Usually, *L. pneumophila* are stout, fat bacilli, which was the morphology displayed by the majority of these organisms. These bacteria originated on a 1 week-old culture plate (+/- 1 day), forming a single colony, at 37°C, on a buffered charcoal yeast extract (BCYE) medium with no antibiotics. The original sample was acid-treated for 15 minutes, to minimize fungal impurities, which would have inhibited the visualization of these organisms. Courtesy of the Centers for Disease Control and Prevention.



Scanning electron microscope (SEM) image of *Borrelia hermsii*. This digitally colorized SEM image, depicts a green-colored, spiral shaped, *Borrelia hermsii* bacterium, set atop a number of red-colored red blood cells (RBCs). *B. hermsii* is the causative agent of the illness, tick-borne relapsing fever (TBRF). Courtesy of the National Institute of Allergy and Infectious Diseases, and the Centers for Disease Control and Prevention.



Transmission electron microscope (TEM) image shows recreated 1918 influenza virions. This digitally-colored negative-stained TEM image shows recreated 1918 influenza virions that were collected from supernatants of 1918-infected Madin-Darby Canine Kidney (MDCK) cell cultures 18 hours after infection. Courtesy of the Centers for Disease Control and Prevention.



Structured-illumination micrograph (SIM) of *Toxoplasma gondii*. SIM of three tachyzoites, a developmental stage in the *Toxoplasma gondii* parasite life cycle. The plasma membrane (red), an apical protein (black) and DNA (blue) is visible in each. *Toxoplasma gondii* is a parasitic protozoa that causes toxoplasmosis. Toxoplasmosis is a common infection in birds and mammals. If infected during pregnancy (for example from eating raw or undercooked meat or from contact with cats), the mother can pass the infection onto her unborn child (congenital toxoplasmosis). This can result in serious health complications for the child. Each parasite measures 10 micrometers. Structured-illumination microscopy (SIM) is one type of super-resolution microscopy. Courtesy of Leandro Lemgruber, University of Glasgow; CC BY.



Blood glucose meters. Top left: Reflolux S (Accu-Chek III in the U.S.) by Boehringer Mannheim, introduced 1991. (Reflolux series introduced 1983.) 2 minute read time, based on reflectance. Top right: ExacTech Card, by MediSense (now Abbott). Introduced 1987. 30 second read time, electrochemical test stripe. Used much less blood and capillary fill. Bottom left: FreeStyle, by TheraSense (now Abbott). Introduced 2003. 15 second test time, electrochemical. Bottom right: Freestyle Mini, by Abbott. Introduced 2004, this is a smaller version of the FreeStyle. 7 second test time. Courtesy of Christopher Tidy and Wikipedia.



Blood glucose meter FreeStyle Libre from Abbott. The white sensor is fixed to the upper arm and scanned with the reader. The reader is showing (top to bottom time (13:46), days to replacement of sensor (11), current BG (7,4) and change (-> i.e. steady) and a diagram of the latest blood glucose levels. Courtesy of Sjö and Wikipedia.

"In September 2016, the U.S. Food and Drug Administration (FDA) approved the Freestyle Libre Pro Glucose Monitoring System, a continuous glucose monitoring (CGM) system for blinded professional use in clinics. In September 2017, the FDA approved a Freestyle Libre for personal use by patients. The system's disposable sensor is applied to the back of a patient's arm and can be worn for 10 days with the personal device and up to 14 days with the Pro version. Providers and patients use a handheld device to download the blood glucose information stored in the sensor. The retrospective information then can be used by providers to make therapy changes to improve patients' glycemic control. Alternatively, patients can use the data in daily life to get on demand glucose readings without having to perform a fingerstick to obtain blood for use with a glucose meter. The FDA has identified inaccuracies of the system at lower glucose levels, as seen in the clinical trials of the system. In 40% of instances in which the device indicated that a patient's glucose was <60 mg/dL, the patient's glucose was actually in range (81–160 mg/dL). Although CGM devices in general tend to lose accuracy at lower blood glucose numbers, the Freestyle Libre is less accurate than previously approved CGM systems." Source: A. Blum. (2018). Freestyle Libre Glucose Monitoring System. *Clin Diabetes* 36(2):203–204.



3D Optical Coherence Tomography of Choroid, Zone of Haller. Shown is a three dimensional Optical Coherence Tomography (Swept Source OCT) of a healthy human choroid in the center of the retina (fovea). The picture shows converging vascular channels with their inner ceiling and outer ground. Blood cells are not depicted, since they flow too quickly. The height of the imaged channels is about 100 micrometers. The "zone of Haller" or "Haller's layer" is the outermost layer of the choroid consisting of larger diameter blood vessels. Named after the Swiss anatomist Albrecht (Victor) von Haller. Optical Coherence Tomography or OCT is a non-invasive, non-touch imaging technique that is based on coherent laser waves which produce optical cross sectional images. OCT is used in the diagnosis of diabetes, glaucoma and age-related macular degeneration (AMD). These images are produced by a lab which has developed a new noise filter, that allows 'speckle noise' freed imaging, which is said to enhance the imaging of the retinal structures. This image has been created by extracting the three dimensional structures from the OCT scans. The vessels were extracted from the 3D data stack using a semi-automatic rolling-marble method. From these data, a 3D digital model of the outer choroid was calculated. Colors and textures were added to highlight the choroidal walls. In ophthalmology, the introduction of new, non-invasive and non-touch imaging modalities such as OCT has increased the visualization of the *in vivo* structures of the eye and provided crucial insights into the early diagnosis and monitoring of diseases. OCT can be compared to ultrasound. Instead of soundwaves, a coherent 1050 nm laser light may be used to obtain 256 high resolution cross sectional images of a human retina. The retina has a vital role in vision. Permanent blindness can be caused by damage to the retina in diseases such as diabetes, glaucoma or age-related-macular degeneration. The unique function of the retina is supported by the blood flow, of which approximately 70 percent goes through the choroid. The choroid shows the highest perfusion of any tissue in the human body. The center most part of the retina is called fovea and is responsible for central, sharpest vision. This avascular fovea receives metabolites and oxygen to 100 percent from the choroidal circulation, emphasizing the extraordinary importance of the choroid. Courtesy of Peter Maloca and the Wellcome Collection.



Pohl Omniskop X-ray apparatus, Germany, 1925–1935. This impressive machine is known as an “Omniskop.” During the 1920s, it belonged to Ernst Rachwalsky, a doctor working in Berlin who specialized in the treatment of stomach problems. Both his family and his highly successful practice were firmly established in the German capital, yet in 1936 Dr. Rachwalsky felt compelled to emigrate and take his chances in London. Why did he feel he had to go and why was he so keen to take this device with him? By the early 1930s the Nazi Party was in power in Germany. Life became increasingly dangerous for Jewish people like Rachwalsky and his family. Eventually, rather than stay and face the growing threat he decided get out of the country and travel to England. His family joined him shortly afterwards. Rather than leaving his machine behind, Rachwalsky shipped the Omniskop over in parts to England. There he carried on using it in the new London medical practice he established until his retirement in 1962. Rachwalsky had bought this cutting edge, very expensive, machine to assist his work on stomach disorders. Using counterweights and a motor, the Omniskop could position patients at a variety of angles. This meant Dr. Rachwalsky could take x-ray images of many different views of his patient’s stomachs, for more effective diagnosis. Some patients apparently found it a frightening experience. Others found it a fascinating machine to ride in. In its own retirement, the Omniskop has been the centerpiece of exhibitions and inspired Hollywood movie set designers. It certainly seems to be a machine that people get very attached to. It was manufactured by Ernst Pohl, Kiel, Schleswig-Holstein, Germany. Courtesy of the Science Museum, London and the Wellcome Collection.



Blood transfusion apparatus, UK, 1914–1918. It's 1917, and you are a wounded soldier at a casualty clearing station on the Western Front. You are bleeding badly and going into shock. You are in danger of dying and urgently need blood – where's the nearest blood bank? It is right next to you. Your blood transfusion will come directly from another patient. Is it safe? It's the best method available at the time, particularly if your surgeon is Lieutenant Geoffrey Keynes of the Royal Army Medical Corps. He designed and pioneered this portable blood transfusion kit with a special device in the flask for regulating flow. Why didn't Keynes use stored blood? It didn't keep very well. It needed to be refrigerated – a difficult task in field hospitals, and it clotted into lumps unless an anticoagulant was added. While it became technically possible to do this during the First World War, the patient-to-patient method was still more widely used. Matching of blood groups was recommended, but there was not always time. The first blood banks stored O type blood – suitable for all recipients. But in the meantime, you were lucky to have reached a casualty clearing station, to take your chances with an emergency transfusion. And who better than with Lieutenant Geoffrey Keynes? In 1921 he co-founded London's Blood Transfusion Service, and a year later published Britain's first textbook on the subject. Courtesy of the Science Museum, London and the Wellcome Collection.



Plesch type tonoscillograph, London, 1931–1940. A tonoscillograph measures and records blood pressure. The device was invented by Jonas Plesch (1878–1957), a Hungarian physiologist and pathologist. This machine was used in medical health checks at the Pioneer Health Centre in Peckham, London during the 1930s. The Pioneer Health Centre took overall health and wellbeing rather than simply disease as its focus of study. Graphs or tonoscillograms of members of the same family were kept together. They created a picture of a family's general health. The tonoscillograph shown here was manufactured by Hawksley and Sons Limited, London. Photo courtesy of the Science Museum, London and the Wellcome Collection.



Otosporin drops, 1968. One of a series of leaflets (traditional remedies) issued by Burroughs Wellcome & Co. advertising Otosporin, a remedy for otitis. This photo shows a man undergoing a traditional medical procedure to his ear by a woman at the dinner table. Courtesy of Burroughs Wellcome & Co. and the Wellcome Collection.




Hemacytometer, Paris, 1874. This early hemacytometer is a simple device. It consists of a microscope slide marked into squares. A blood sample was diluted and placed on the slide. The red cells in the squares are then counted through a microscope. An increase or decrease in blood cells in the blood can indicate disease within the body. A low level of red blood cells is called anemia. A high level of red blood cells is called polycythemia. The hemacytometer was devised by French physiologist Louis-Charles Malassez. This example is the original instrument described by Malassez. It was manufactured by Verick in Paris, France. Courtesy of the Science Museum, London and the Wellcome Collection.



Self-administering enema syringe, Europe, before 1935. Enema syringes vary in shape and material but they are all intended to introduce liquids such as medications or purgatives into the body via the rectum – a once very common medical procedure. After the ivory nozzle was inserted into the anus, liquid was pumped through the metal tubing from the metal reservoir. It allowed a person to give themselves the enema rather than relying on a physician or nurse and so was probably used in the home. It was produced somewhere in Europe but the manufacturer is unknown. Courtesy of the Science Museum, London and the Wellcome Collection.



Simpson type obstetrical forceps, London, 1871–1900. These long obstetrical forceps are made of steel and ebony. They follow a forceps design by James Young Simpson (1811–1870), a Scottish physician and obstetrician. The forceps are longer and heavier than his short type forceps. They delivered babies from higher up the birth canal. Simpson's long and short forceps were adapted in many later designs. They were manufactured by Mayer and Melzer, London. Courtesy of the Science Museum, London and the Wellcome Collection.




Heart-lung machine, London, 1955–1960. The heart-lung machine performs the functions of the heart and lungs during surgery. A pump takes over the action of the heart, supplying the body with blood. The heart can then be stopped, making it easier to operate on. The patient's blood flows over the rotating discs where oxygen is blown across it, effectively taking over the action of the lungs. This machine with a pump oxygenator was conceived by Denis Melrose (1921–2007) at the Postgraduate Medical School in Hammersmith in London, in the early 1950s. Melrose also developed a way to stop the heart beating during heart surgery using potassium citrate. The technique is still used today and is called cold cardioplegia. The machine shown here was the first to be used in open heart surgery operations at the Postgraduate Medical School. It was manufactured by New Electronic Products, London. Courtesy of the Science Museum, London and the Wellcome Collection.




Surgical instrument set, Germany, 1939. This extensive steel surgical instrument set contains a wide range of the equipment an army surgeon may have needed at a German field hospital. Some of the instruments, such as the amputation knives and saw, are for specific tasks. Other instruments, such as the forceps for clamping bones, arteries, and intestines, have a more general use. The kit is labelled with the German word *Hauptbesteck* and the date. *Hauptbesteck* translates as “main cutlery,” “cutlery” being another word for surgical instruments. The use of steel for the case as well as the instruments ensured that this equipment could be sterilized easily. It was manufactured by Jetter and Scheerer, Tuttlingen, Baden-Württemberg, Germany. Courtesy of the Science Museum, London and the Wellcome Collection.



Lithotomy set, Paris, 1820–1860. Lithotomy was a procedure where a stone in the bladder or urethra was removed by means of surgery. This thirty-piece instrument set contained all the necessary instruments to carry out the operation, including four gorges, specialized knives used in lithotomy, and six lithotomy staffs, which are grooved to guide the gorge towards the stone. This set was made by Charrière, a surgical instrument maker based in Paris, France. Courtesy of the Science Museum, London and the Wellcome Collection.




Photomicrograph of smallpox skin histopathology. Hematoxylin and Eosin (H&E)-stained tissue sample, reveals some of the histopathologic changes found in a human skin tissue sample from the site of a variola (smallpox) virus lesion. Courtesy of Public Health Image Library, the Centers for Disease Control and Prevention.




Transmission electron micrograph of an Ebola virus. Ebola is the cause of a viral hemorrhagic fever disease (Ebola virus disease, or EVD). It does not pose a significant risk to the U.S. public as the viruses that cause EVD are located mainly in sub-Saharan Africa. People can get EVD through direct contact with an infected animal (bat or nonhuman primate) or a sick or dead person infected with Ebola virus. On December 19, 2019, FDA announced the approval of Ervebo, the first FDA-approved vaccine for the prevention of EVD, caused by Zaire ebolavirus in individuals 18 years of age and older. The CDC recommends supportive therapy for patients as the primary treatment for Ebola. This includes balancing the patient's fluids and electrolytes, maintaining their oxygen status and blood pressure and treating them for any complicating infections. On December 21, 2020, FDA approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebola virus) infection in adults and children. On October 14, 2020, FDA announced the approval of Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients. Courtesy of Cynthia Goldsmith, the Centers for Disease Control and Prevention.



Edward Jenner vaccinating patients. Jenner is seen in the Smallpox and Inoculation Hospital at St. Pancras: the patients develop features of cows. Patients are spoon-fed “opening mixture” as they come through the door. A boy standing next to Jenner is holding his pot labelled “vaccine pock hot from ye cow” on his jacket is a badge saying “Pancras” and in his pocket a paper entitled “Benefits of the vaccine process.” Colored etching by J. Gillray, 1802. Courtesy of the Wellcome Library.




Histopathology of smallpox vaccination lesions. Cytoarchitectural pathologic changes found in a sample of skin tissue from an eczema vaccinatum lesion, which had manifested itself after this patient had received a smallpox vaccination. Courtesy of Public Health Image Library, the Centers for Disease Control and Prevention.



Scanning electron micrograph of tooth enamel. If you went out and asked folks what they're seeing in this colorized scanning electron micrograph, most would probably guess an elegantly woven basket, or a soft, downy feather. But what this scanning electron micrograph actually shows isn't at all soft: it is the hardest substance in the mammalian body—tooth enamel! Before placing a sample of mouse dental enamel under the microscope, it was briefly treated with acid in order to reveal how the tissue's mineralized rods are interwoven in a manner that gives teeth both strength and flexibility. Courtesy of Olivier Duverger and Maria I. Morasso, National Institute of Arthritis and Musculoskeletal and Skin Diseases.



Scanning electron micrograph of carbapenem-resistant *Klebsiella pneumoniae*. Colorized scanning electron micrograph showing carbapenem-resistant *Klebsiella pneumoniae* interacting with a human neutrophil. Trillions of microbes, like bacteria, fungi, and other microbes, are living on or in your body right now. Together, they make up your microbiota. Most don't cause any harm. In fact, many protect you from harmful infections. Bacteria live in colonies. This lets them work together to form defenses against other bacteria. But how they defend themselves from infiltrating bacteria isn't fully understood. A better understanding of how they do so could help scientists find alternatives to antibiotics, which harm beneficial microbes and can become less effective as pathogens develop drug resistance. Courtesy of Apollo Stacey and Yasmine Belkaid, National Institute of Allergy and Infectious Diseases.




Thomas Clifford Allbutt. English Physician Allbutt (1839–1925) was an advocate for the reform of medical education and a pioneer for new medical tools. He invented the pocket medical thermometer, introduced the use of the ophthalmoscopy and microscopy to hospitals, and was an outspoken advocate of teaching fewer things well, than more things cursorily and/or poorly. A medical thermometer (also called clinical thermometer) is a device which is used for measuring human or animal body temperature. The tip of the thermometer is inserted into the mouth under the tongue (oral or sub-lingual temperature), under the armpit (axillary temperature), into the rectum via the anus (rectal temperature), into the ear (tympanic temperature), or on the forehead (temporal temperature). Portrait courtesy of the Wellcome Library.




Kary Banks Mullis and the polymerase chain reaction (PCR). PCR is a method widely used to rapidly make millions to billions of copies (complete or partial) of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it (or a part of it) to a large enough amount to study in detail. PCR was invented in 1983 by the American biochemist Kary Banks Mullis (1944–2019) at Cetus Corporation. Mullis and biochemist Michael Smith, who had developed other essential ways of manipulating DNA, were jointly awarded the Nobel Prize in Chemistry in 1993. Applications of the technique include DNA cloning for sequencing, gene cloning and manipulation, gene mutagenesis; construction of DNA-based phylogenies, or functional analysis of genes; diagnosis and monitoring of genetic disorders; amplification of ancient DNA; analysis of genetic fingerprints for DNA profiling (for example, in forensic science and parentage testing); and detection of pathogens in nucleic acid tests for the diagnosis of infectious diseases. I would like to add that outrageous misinformation about PCR, which in my view is the “gold standard” for COVID-19 diagnosis, continues to circulate online.


The photograph above shows Dr. Raj Bawa with Dr. Mullis at the US Department of Commerce in Washington, DC, on the occasion of the *American Innovator Award* ceremony on October 14, 1998: "I was lucky to spend the day with Dr. Mullis and his wife Nancy. It was a fascinating experience where Dr. Mullis delighted me with tales of his remarkable personal and scientific life. Some of these I can disclose. Dr. Mullis briefly left science to write fiction before accepting his graduate fellowship; he practiced clandestine chemistry (synthesis and self-testing of novel psychoactive substances) throughout his graduate school studies; he managed a bakery for two years during his postdoctoral work; he sold jewelry containing the amplified DNA of deceased famous people; he referred to the Empress of Japan as “sweetie” at a palace dinner; etc. And, yes, he recounted in detail with bitterness at receiving a mere \$10,000 bonus from Cetus for the invention of PCR; Cetus later sold the PCR patent to Roche for \$300 million.”




Lab-on-a-chip. This technology allows immunological assays to be miniaturized so tests can be done rapidly with minimum quantities of expensive reagents. The chips contain tiny flow tubes to allow movement of fluids by capillary action, reactions sites with embedded reagents, and data output through electronic sensors. Courtesy of Maggie Bartlett, NHGRI and OpenStax (<https://openstax.org>).



Monoclonal antibodies (mAbs). These antibodies are produced by introducing an antigen to a mouse and then fusing polyclonal B cells from the mouse's spleen to myeloma cells. The resulting hybridoma cells are cultured and continue to produce antibodies to the antigen. Hybridomas producing the desired mAb are then grown in large numbers on a selective medium that is periodically harvested to obtain the desired mAbs. Courtesy of OpenStax (<https://openstax.org>).



Minimum Inhibitory Concentration (MIC) measurement. A microdilution tray can also be used to determine MICs of multiple antimicrobial drugs in a single assay. In this example, the drug concentrations increase from left to right and the rows with clindamycin, penicillin, and erythromycin have been indicated to the left of the plate. For penicillin and erythromycin, the lowest concentrations that inhibited visible growth are indicated by red circles and were 0.06 µg/mL for penicillin and 8 µg/mL for erythromycin. For clindamycin, visible bacterial growth was observed at every concentration up to 32 µg/mL and the MIC is interpreted as >32 µg/mL. Courtesy of the Centers for Disease Control and Prevention and OpenStax (<https://openstax.org>).




Measuring MIC with a Etest strip. The Etest can be used to determine the MIC of an antibiotic. In this Etest, vancomycin is shown to have a MIC of 1.5 µg/mL against *Staphylococcus aureus*. Courtesy of OpenStax (<https://openstax.org>).



The iron-lung ward, 1953. Polio was once a common disease with potentially serious consequences, including paralysis. Vaccination has all but eliminated the disease from most countries around the world. An iron-lung ward, such as the one shown in this 1953 photograph, housed patients paralyzed from polio and unable to breathe for themselves.

People living in developed nations and born in the 1960s or later may have difficulty understanding the once heavy burden of devastating infectious diseases. For example, smallpox, a deadly viral disease, once destroyed entire civilizations, but has since been eradicated. Thanks to the vaccination efforts by multiple groups, including the World Health Organization, Rotary International, and the United Nations Children's Fund (UNICEF), smallpox has not been diagnosed in a patient since 1977. Polio is another excellent example. This crippling viral disease paralyzed patients, who were often kept alive in "iron lung wards" as recently as the 1950s. Today, vaccination against polio has nearly eradicated the disease. Vaccines have also reduced the prevalence of once-common infectious diseases such as chickenpox, German measles, measles, mumps, and whooping cough. The success of these and other vaccines is due to the very specific and adaptive host defenses. Courtesy of OpenStax (<https://openstax.org>).




Size matters. The relative sizes of various microscopic and nonmicroscopic objects. Note that a typical virus measures about 100 nm, 10 times smaller than a typical bacterium (~1 μm), which is at least 10 times smaller than a typical plant or animal cell (~10–100 μm). An object must measure about 100 μm to be visible without a microscope.

Most microbes are unicellular and small enough that they require artificial magnification to be seen. However, there are some unicellular microbes that are visible to the naked eye, and some multicellular organisms that are microscopic. An object must measure about 100 micrometers (μm) to be visible without a microscope, but most microorganisms are many times smaller than that. For some perspective, consider that a typical animal cell measures roughly 10 μm across but is still microscopic. Bacterial cells are typically about 1 μm, and viruses can be 10 times smaller than bacteria. Courtesy of OpenStax (<https://openstax.org>).




Using delayed hypersensitivity to test for TB. The modern version of Pirquet's scarification is the tine test, which uses devices like this to administer tuberculin antigen into the skin, usually on the inside of the forearm. The tine test is considered less reliable than the Mantoux test. Courtesy of the Centers for Disease Control and Prevention and OpenStax (<https://openstax.org>).

Austrian pediatrician Clemens von Pirquet (1874–1929) first described allergy mechanisms, including type III serum sickness. His interest led to the development of a test for tuberculosis (TB), using the tuberculin antigen, based on earlier work identifying the TB pathogen performed by Robert Koch. Pirquet's method involved scarification, which results in simultaneous multiple punctures, using a device with an array of needles to break the skin numerous times in a small area. The device Pirquet used was similar to the tine test device with four needles seen in the figure above. The tips of all the needles in the array are coated with tuberculin, a protein extract of TB bacteria, effectively introducing the tuberculin into the skin. One to three days later, the area can be examined for a delayed hypersensitivity reaction, signs of which include swelling and redness. As you can imagine, scarification was not a pleasant experience, and the numerous skin punctures put the patient at risk of developing bacterial infection of the skin. Mantoux modified Pirquet's test to use a single subcutaneous injection of purified tuberculin material. A positive test, which is indicated by a delayed localized swelling at the injection site, does not necessarily mean that the patient is currently infected with active TB. Because type IV (delayed-type) hypersensitivity is mediated by reactivation of memory T cells, such cells may have been created recently (due to an active current infection) or years prior (if a patient had TB and had spontaneously cleared it, or if it had gone into latency). However, the test can be used to confirm infection in cases in which symptoms in the patient or findings on a radiograph suggest its presence.




The complement fixation (CF) test. The CF test is used to determine whether a patient's serum contains antibodies to a specific antigen. If it does, complement fixation will occur, and there will be no complement available to lyse the antibody-bound sheep red blood cells that are added to the solution in the next step. If the sample does not contain antibodies to the antigen, hemolysis of the sheep blood cells will be observed. Courtesy of OpenStax (<https://openstax.org>).



Polyclonal antisera. This diagram illustrates the process for harvesting polyclonal antibodies produced in response to an antigen.

Polyclonal antisera are used in many clinical tests that are designed to determine whether a patient is producing antibodies in response to a particular pathogen. While these tests are certainly powerful diagnostic tools, they have their limitations, because they are an indirect means of determining whether a particular pathogen is present. Tests based on a polyclonal response can sometimes lead to a false-positive result—in other words, a test that confirms the presence of an antigen that is, in fact, not present. Antibody-based tests can also result in a false-negative result, which occurs when the test fails to detect an antibody that is, in fact, present. The accuracy of antibody tests can be described in terms of test sensitivity and test specificity. Test sensitivity is the probability of getting a positive test result when the patient is indeed infected. If a test has high sensitivity, the probability of a false negative is low. Test specificity, on the other hand, is the probability of getting a negative test result when the patient is not infected. If a test has high specificity, the probability of a false positive is low. False positives often occur due to cross-reactivity, which can occur when epitopes from a different pathogen are similar to those found on the pathogen being tested for. For this reason, antibody-based tests are often used only as screening tests; if the results are positive, other confirmatory tests are used to make sure that the results were not a false positive. Courtesy of OpenStax (<https://openstax.org>).



Atherosclerotic Coronary Arteries. In this coronary angiogram (x-ray), the dye makes visible two occluded coronary arteries. Such blockages can lead to decreased blood flow (ischemia) and insufficient oxygen (hypoxia) delivered to the cardiac tissues. If uncorrected, this can lead to cardiac muscle death (myocardial infarction).


Coronary artery disease is the leading cause of death worldwide. It occurs when the buildup of plaque—a fatty material including cholesterol, connective tissue, white blood cells, and some smooth muscle cells—within the walls of the arteries obstructs the flow of blood and decreases the flexibility or compliance of the vessels. This condition is called atherosclerosis, a hardening of the arteries that involves the accumulation of plaque. As the coronary blood vessels become occluded, the flow of blood to the tissues will be restricted, a condition called ischemia that causes the cells to receive insufficient amounts of oxygen, called hypoxia. The figure above shows the blockage of coronary arteries highlighted by the injection of dye. Some individuals with coronary artery disease report pain radiating from the chest called angina pectoris, but others remain asymptomatic. If untreated, coronary artery disease can lead to MI or a heart attack. The disease progresses slowly and often begins in children and can be seen as fatty “streaks” in the vessels. It then gradually progresses throughout life. Well-documented risk factors include smoking, family history, hypertension, obesity, diabetes, high alcohol consumption, lack of exercise, stress, and hyperlipidemia or high circulating levels of lipids in the blood. Treatments may include medication, changes to diet and exercise, angioplasty with a balloon catheter, insertion of a stent, or coronary bypass procedure. Angioplasty is a procedure in which the occlusion is mechanically widened with a balloon. A specialized catheter with an expandable tip is inserted into a superficial vessel, normally in the leg, and then directed to the site of the occlusion. At this point, the balloon is inflated to compress the plaque material and to open the vessel to increase blood flow. Then, the balloon is deflated and retracted. A stent consisting of a specialized mesh is typically inserted at the site of occlusion to reinforce the weakened and damaged walls. Stent insertions have been routine in cardiology for more than 40 years.

Chapter 2

Techniques and Technologies for Medical Imaging, Detection and Diagnosis: An Introduction¹

*National Institute of Biomedical Imaging and Bioengineering,
National Institutes of Health, Bethesda, Maryland, USA*

Keywords: 3D mammography, acoustic radiation force impulse imaging (ARFI), adenosine triphosphate (ATP), artificial intelligence (AI), atrial fibrillation (AF), breast CT scanner (bCT), computed tomography (CT), congestive heart failure (HF), contrast agents, cross-sectional images, cryo-electron microscopy (cryo-EM), cyber-physically assistive clothing (CPAC), deep learning, deep-vein thrombosis (DVT), diagnostic ultrasound, diffuse optical tomography (DOT), digital breast tomosynthesis, endoplasmic reticulum (ER), endoscopy, fluoroscopy, functional magnetic resonance imaging (fMRI), high intensity focused ultrasound (HIFU), HIV protease, lab-on-a-chip, machine learning, magnetic resonance elastography (MRE), mammography, neural networks, nuclear magnetic resonance (NMR), optical coherence tomography (OCT), optical imaging, photoacoustic, photoacoustic imaging, point-of-care (POC), positron emission tomography (PET), pulse oximeter, Raman spectroscopy, remote patient monitoring (RPM), super-resolution microscopy, telehealth, terahertz tomography, therapeutic ultrasound, wearable sensors, X-ray crystallography, X-rays



¹This chapter is organized and edited by the Series Editor, Raj Bawa, PhD, MD. It is based on information and materials kindly provided to Dr. Bawa by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The mission of the NIBIB is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care.


Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com



2.1 Studying Cells

2.1.1 What Are Cells?

Cells provide structure and function for all living things, from microorganisms to humans. Scientists consider them the smallest form of life. Cells house the biological machinery that makes the proteins, chemicals, and signals responsible for everything that happens inside our bodies.


2.1.2 What Do Cells Look Like?

Cells come in different shapes—round, flat, long, star-like, cubed, and even shapeless. Most cells are colorless and see-through. The size of a cell also varies. Some of the smallest are one-celled bacteria, which are too small to see with the naked eye, at 1-millionth of a meter (micrometer) across. Plants have some of the largest cells, 10–100 micrometers across. The human cell with the biggest diameter is the egg. It is about the same diameter as a hair strand (80 micrometers).

2.1.3 How Many Different Types of Human Cells Are There?

The trillions of cells that make up a human are organized into about 200 major types. All of a person's cells contain the same set of genes (see more on genes: <https://ghr.nlm.nih.gov/primer/basics/gene>). However, each cell type “switches on” a different pattern of genes, and this determines which proteins the cell

produces. The unique set of proteins in different cell types allows them to perform specialized tasks. For instance, red blood cells carry oxygen throughout the body. White blood cells kill germ invaders. Intestinal cells release molecules that help digest food. Nerve cells send chemical and electrical messages that produce thoughts and movement. And heart cells contract in unison to pump blood.



Fibroblast cells with nuclei (blue, circular, center), energy factories (green, surrounding the nucleus), and the actin cytoskeleton (red, outermost). *Credit:* Dylan Burnette and Jennifer Lippincott-Schwartz, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.

2.1.4 What Are Eukaryotic and Prokaryotic Cells, and How Are They Different?

When putting cells into categories, scientists can tell eukaryotic cells apart from prokaryotic cells because they look different. Eukaryotic cells make up animals, plants, fungi, and some single-celled organisms. And they have a number of structures inside them, called organelles. The most prominent organelle is the nucleus, which contains the cell's genetic material, or DNA (see more on DNA: <https://biobeat.nigms.nih.gov/2017/04/six-things-to-know-about-dna-and-dna-repair/>). Prokaryotic cells don't have a nucleus or other organelles. They are single-celled microorganisms that tend to be smaller than eukaryotic cells. There are two types of prokaryotic cells—bacteria and archaea.


2.1.5 What Are Some of the Major Organelles in a Human Cell?

In addition to the nucleus, the most prominent organelles include the following:

- Mitochondria, the cell's power plants, convert energy from food into the body's main energy source, adenosine triphosphate (ATP).
- Ribosomes are molecular factories that make proteins.
- The endoplasmic reticulum (ER), a network of interconnected sacs, processes newly made secreted and membrane proteins and produces fatty substances called lipids.
- The Golgi complex receives proteins and lipids from the ER, packages them, and sends them to their final destinations inside the cell, within the cell membrane, or outside the cell.
- Lysosomes, the cell's garbage dumps, break down waste materials and dispose of them or recycle them.

2.1.6 How Do Cells Move?

Many types of cells can move. Single-celled organisms move to find food. And even cells inside multicellular organisms may need to get around. For example, immune system cells must move toward invaders. And sperm needs to "swim" to fertilize eggs.



This is a pig cell in the process of dividing. The image shows the chromosomes (purple, shorter, center) and the cell skeleton (green, fibrous, outer). *Credit:* Nasser Rusan, National Heart, Lung, and Blood Institute, National Institutes of Health.

Cells move in several ways. Some simply float through water or other liquids. Some push themselves along using long, thin proteins, called flagella, and cilia that stick outside the cell membrane and wave around. Some “crawl” along, using what’s called amoeboid movements, in which cytoplasm-filled protrusions scoot the cell forward.

Within cells, nutrients and organelles move around to carry out various cellular functions. This kind of internal movement is called cyclosis, or cytoplasmic streaming. The internal structure of cells, which is called the cytoplasm, creates a directional flow that pushes the contents of the cells around.

Scientists study cell movement to better understand how cells work, including how cancer cells move from one tissue to another and how white blood cells move to heal wounds and attack invaders.

2.1.7 How Do Scientists Study Cells?

Cell biologists rely on an array of tools to peer into the body and examine cells. Imaging techniques magnify organelles and track cells as they divide, grow, interact, and carry out other vital tasks. Biochemical or genetic tests allow researchers to study how cells respond to environmental stressors, such as rising temperatures or toxins. These tests can also label specific proteins using fluorescent tags and other chemicals that allow scientists to visualize proteins at work inside cells. Sophisticated computational tools then integrate and analyze all the data.

2.1.8 How Do Our Bodies Make More Cells?

One cell divides into two in a process called mitosis. Mitosis produces two genetically identical “daughter” cells from a single parent cell. Another type of cell division, meiosis, creates four daughter cells that are genetically distinct from one another and from the original parent cell. Only a few special cells can perform meiosis: those that will become eggs in females and sperm in males.

2.1.9 How and Why Do Cells Die?

Cells come equipped with what they need to self-destruct. This is called programmed cell death, or apoptosis. And it serves a healthy and protective role in our bodies. For example, it helps shape our fingers and toes before birth, and it kills off diseased cells during our lives. Another kind of cell death, called necrosis, is unplanned and not protective. Necrosis can happen after a sudden traumatic injury, infection, or exposure to a toxic chemical.

2.1.10 What Are Stem Cells?

Stem cells can renew themselves millions of times. Other cells in the body, such as muscle and nerve cells, cannot do this. Embryonic stem cells are undifferentiated,

meaning they can turn into any type of cell in the body. Tissue-specific stem cells (sometimes called adult or somatic stem cells) arise later in development. They also can replenish cells. The primary role of tissue-specific stem cells is to maintain and repair the tissue in which they're found.

2.1.11 How Do Problems in Cells Lead to Disease?

Changes to the genes inside a cell, called mutations, can alter the cell's ability to divide, make proteins, remove waste, or perform other tasks. These genetic mutations can lead to birth defects, cancer, and other diseases. Cells that are damaged through physical trauma or infection can, in extreme cases, contribute to harmful inflammation and organ malfunction.

2.1.12 How Does Studying Cells Aid Our Understanding of Human Health and Disease?

Learning about how cells work—and what happens when they don't work properly—teaches us about the biological processes that keep us healthy. It also uncovers new ways to treat disease. Cellular research has already led to cancer treatments, antibiotics, medicine that lowers cholesterol, and improved methods for delivering drugs. However, much more remains to be discovered. For example, understanding how stem cells and certain other cells regenerate could offer insight on how to repair damaged or lost tissue.

2.2 Structural Biology

2.2.1 What Is Structural Biology?

Structural biology is the study of how biological molecules are built. Using a variety of imaging techniques, scientists view molecules in three dimensions to see how they are assembled, how they function, and how they interact. That has helped researchers understand how the thousands of different molecules in each of our cells work together to keep us healthy. Structural studies have also shown how misshapen molecules make us sick, and as a result, these studies have prompted new treatments for many diseases.

2.2.2 What Are Molecules?


Molecules are groups of two or more atoms held together by chemical bonds. Molecules include DNA, RNA, proteins, carbohydrates (sugars), and lipids (fats). Structural biologists are particularly interested in proteins because they do so much of the work in the body. Increasingly, biologists are investigating large molecules made up of combinations of RNA and proteins, called RNA-protein complexes.

2.2.3 What Are Proteins?

Proteins are molecules that contribute to virtually every activity in the body. They form hair and fingernails, carry oxygen in the blood, allow muscles to move, and much more.



Top: Protein molecules are made up of amino acids hooked together like beads on a string. Bottom: To become active, proteins must twist and fold into their final, or “native,” configuration. *Credit:* NIGMS.



A mix of alpha helices (red; curled ribbon forming a six-sided star) and beta sheets (blue; thinner, tangled strands). *Credit:* RCSB Protein Data Bank.

2.2.4 What Are Proteins Made of?

Proteins are made of long strands of small molecules called amino acids. There are 20 amino acids that are commonly found in proteins, and each protein contains a unique combination of a few dozen to many thousand amino acids. Some proteins are made of a single strand of amino acids, while some are made up of multiple strands that come together to form the final structure of the protein.

2.2.5 How Does a Protein Get Its Shape?

Even though proteins are strings of amino acids, they do not remain in a straight line. The strands twist, bend, and fold into specific shapes. The way they fold depends in part on the way the amino acids interact with each other. Some sections of proteins form standard “motifs”: corkscrew-like coils called alpha helices and flat sections called beta sheets.


Researchers can easily determine a protein’s amino acid sequence. The trick has been figuring out how and why the proteins fold. Scientists are beginning to solve that puzzle with research into how amino acids interact, and they are using powerful new computer programs that help predict protein motifs. Researchers are even starting to design their own brand-new proteins that perform specific jobs. This new work helps scientists understand not only how proteins fold but also how they misfold and malfunction in diseases such as Alzheimer’s and cystic fibrosis. Knowing more about these processes might allow researchers to design new treatments.

2.2.6 Why Does a Protein’s Shape Matter?

A protein’s structure allows it to perform its job. For instance, antibodies are shaped like a Y. This helps these immune-system proteins bind to foreign molecules such as bacteria or viruses with one end while recruiting other immune-system proteins with the other. DNA polymerase III is donut shaped. This helps it form a ring around DNA as it copies its genetic information. And proteins called enzymes have grooves and pockets that help them hold onto other molecules to speed chemical reactions. Misfolded, or misshapen, proteins can cause diseases. They often stop working properly and can build up in tissues. Alzheimer’s disease, Parkinson’s disease, and cystic fibrosis are examples of diseases caused by misfolded proteins.

2.2.7 What Kinds of Proteins Are There?

There are many different kinds of proteins. For example, many proteins are enzymes that aid biochemical reactions. Others have shapes or specific functions that help cells hold their shape and move, as described in the previous answer. Another type, called transporter proteins, are embedded in the cell’s outer membrane and form channels that help vital substances such as sodium or potassium pass into or out of the cell.



Knowing that HIV protease—an enzyme that breaks down HIV—has two symmetrical halves, pharmaceutical researchers initially attempted to block the enzyme with symmetrical, naturally occurring small molecules. They made these by chopping in half molecules of the natural substrate, then making a new molecule by fusing together two identical halves of the natural substrate. *Credit: NIGMS.*

2.2.8 How Do Scientists Use Protein Structures to Develop New Drugs?

Drugs typically work by either blocking or supporting the activity of specific proteins in the body. Using an approach called structure-based drug design, scientists can make a template for a protein and use that blueprint for creating new medicines. They start with a computerized model of the protein structure they're interested in studying. For example, the computer model would allow researchers to examine how two proteins work together. Then, if scientists wanted to turn off one protein, they would try to design a molecule that would block or alter that interaction.

2.2.9 What's an Example of a Medicine Developed Using Structure-Based Drug Design?

Researchers used structure-based drug design to develop some anti-HIV drugs. HIV protease is an enzyme that keeps the virus alive. Knowing its structure allowed researchers to determine the kinds of molecules that could stop HIV protease from working. Scientists used computer models to fine tune molecules that could halt virus production. This work led to medicines called protease inhibitors.

2.2.10 How Do Scientists Determine Protein Structures?

Researchers use several imaging techniques to determine the structure of proteins and other complex molecules. Cryo-electron microscopy (cryo-EM) allows scientists to “see” individual proteins as well as larger structures such as molecular complexes (groups of proteins that combine and function as a unit), viruses, or organelles (specialized structures within the cell that perform specific functions). X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy also make it possible for researchers to view proteins. The Protein Data Bank (PDB; <https://www.rcsb.org/>) stores these structures and gives scientists access to them; as of February 23, 2022, there are 187,423 structures available in the PDB from studies using X-ray crystallography, NMR and cryo-EM approaches.

2.2.11 What Is Cryo-EM, and How Does It Work?

In cryo-EM, researchers rapidly freeze a cell, virus, molecular complex, or other structure so that water molecules do not have time to form crystals. This preserves the sample in its natural state. Scientists use an electron microscope to blast the frozen sample with an electron beam. This creates a two-dimensional projection of the sample on a digital detector. By creating hundreds of projections of the sample from many different angles and then taking the average of these angles, scientists generate a three-dimensional model of its structure. Recent advances in cryo-EM provide highly detailed images of proteins and other biological structures, including larger structures such as RNA-protein complexes.

2.2.12 What Is X-Ray Crystallography, and How Does It Work?

X-ray crystallography shoots a beam of X-rays through a tiny crystal made up of trillions of identical protein molecules. The crystal scatters the X-rays onto an electronic detector, similar to the way images are captured in a digital camera. A computer measures the intensities of the scattered X-rays to assign a position to each atom in the crystallized molecule. The result is a three-dimensional digital image. This method has been used to determine more than 85 percent of known protein structures.

2.2.13 What Is NMR Spectroscopy, and How Does It Work?

NMR spectroscopy works using the natural magnets—the nuclei of certain atoms—inside proteins. Those natural cellular magnets interact with a big magnet inside the NMR instrument. The big magnet forces the protein's magnets to line up. Researchers then hit the sample with a series of split-second radio-wave pulses and observe how the protein's nuclei respond. Scientists use several sets of these NMR pulses and combine the data to get a more complete picture of the protein. Although X-ray crystallography can examine larger proteins than NMR is able to do, NMR technology can study proteins in liquid solutions. In contrast, X-ray crystallography requires that proteins be organized into crystals.

2.2.14 Can Scientists View How Proteins Act?

New technology is beginning to allow researchers to progress from creating static pictures of proteins and other molecules to making movies of their actions. Images provide snapshots of what these cellular elements are doing at specific points in time. Although they supply valuable information, these still pictures don't capture how proteins and other molecules inside cells are constantly moving and changing, folding and unfolding as they interact. Understanding these dynamics is critical to unlocking how life works. In addition, there is a whole class of proteins, called intrinsically disordered proteins, that do not hold a specific shape. Their shape adapts to what's going on inside the cell, making it nearly impossible to take a still picture of them.

Scientists are now using powerful computer models to make molecular movies so they can see the full range of proteins in live action. By feeding in information from various imaging techniques about how amino acids and other building blocks interact, scientists can create moving pictures. Such movies help researchers understand how proteins work in their natural state and allow them to design highly specific drugs.

2.2.15 What Does the Future Hold for Structural Biology?


Researchers on the frontier of structural biology are merging multiple imaging techniques – X-ray crystallography, NMR, cryo-EM, and others, to understand what proteins and other molecules look like, and to create more precise models of how they interact to effect their function in the cell. Scientists can create a single image that zooms in to see specific protein and zooms out to see how they interact within the larger cellular structure. In addition to combining existing techniques, scientists are developing ever more powerful methods. For example, new X-ray lasers allow insights into processes that occur in less than one tenth of a trillion of a second, much faster timescales than that captured by other sources of X-rays.

Scientists use super-efficient methods to determine protein structures more quickly than ever before. They also use sophisticated techniques to predict three-

dimensional structures of proteins. And they use high-powered computer models to design and create new proteins not found in nature that have useful functions, such as discovering and combating disease. This work will continue to increase our understanding of the diverse roles molecules play in biology and to spur advances in medicine.

2.3 Optical Imaging

2.3.1 What Is Optical Imaging?



Optical imaging is a technique for non-invasively looking inside the body, as is done with X-rays. But, unlike X-rays, which use ionizing radiation, optical imaging uses visible light and the special properties of photons to obtain detailed images of organs and tissues as well as smaller structures including cells and even molecules. These images are used by scientists for research and by clinicians for disease diagnosis and treatment.

2.3.2 What Are the Advantages of Optical Imaging?

Optical imaging offers several advantages over other radiological imaging techniques:

Optical imaging significantly reduces patient exposure to harmful radiation by using non-ionizing radiation, which includes visible, ultraviolet, and infrared light. These types of light generate images by exciting electrons without causing the damage that can occur with ionizing radiation used in some other imaging techniques. Because it is much safer for patients, and significantly faster, optical imaging can be used for lengthy and repeated procedures over time to monitor the progression of disease or the results of treatment.

Optical imaging is particularly useful for visualizing soft tissues. Soft tissues can be easily distinguished from one another due to the wide variety of ways different tissues absorb and scatter light.

Because it can obtain images of structures across a wide range of sizes and types, optical imaging can be combined with other imaging techniques, such as MRI or X-rays, to provide enhanced information for doctors monitoring complex diseases or researchers working on intricate experiments.

Optical imaging takes advantage of the various colors of light to see and measure many different properties of an organ or tissue at the same time. Other imaging techniques are limited to just one or two measurements.

2.3.3 What Types of Optical Imaging Are There and What Are They Used for?


Optical imaging includes a variety of techniques that use light to obtain images from inside the body, tissues, or cells.

- **Endoscopy:** The simplest and most widely recognized type of optical imaging is endoscopy. An endoscope consists of a flexible tube with a system to deliver light to illuminate an organ or tissue. For example, a physician can insert an endoscope through a patient's mouth to see the digestive cavity to find the cause of symptoms such as abdominal pain, difficulty swallowing, or gastrointestinal bleeding. Endoscopes are also used for minimally invasive robotic surgery to allow a surgeon to see inside the patient's body while remotely manipulating the thin robotic arms that perform the procedure.
- **Optical Coherence Tomography (OCT):** Optical coherence tomography is a technique for obtaining sub-surface images such as diseased tissue just below the skin. OCT is a well-developed technology with commercially available systems now in use in a variety of applications, including art conservation and diagnostic medicine. For example, ophthalmologists use OCT to obtain detailed images from within the retina. Cardiologists also use it to help diagnose coronary artery disease.
- **Photoacoustic Imaging:** During photoacoustic imaging, laser pulses are delivered to a patient's tissues; the pulses generate heat, expanding the tissues and enabling their structure to be imaged. The technique can be used for a number of clinical applications including monitoring blood vessel growth in tumors, detecting skin melanomas, and tracking blood oxygenation in tissues.
- **Diffuse Optical Tomography (DOT):** DOT can be used to obtain information about brain activity. A laser that uses near-infrared light is positioned on the scalp. The light goes through the scalp and harmlessly traverses the brain. The absorption of light reveals information about chemical concentrations in the brain. The scattering of the light reflects physiological characteristics such as the swelling of a neuron upon activation to pass on a neural signal.
- **Raman Spectroscopy:** This technique relies on what is known as Raman scattering of visible, near-infrared, or near-ultraviolet light that is delivered

by a laser. The laser light interacts with molecular vibrations in the material being examined and shifts in energy are measured that reveal information about the properties of the material. The technique has a wide variety of applications including identifying chemical compounds and characterizing the structure of materials and crystals. In medicine, Raman gas analyzers are used to monitor anesthetic gas mixtures during surgery.

- **Super-resolution Microscopy:** This form of light microscopy encompasses several techniques used in research to obtain very high-resolution images of individual cells, at a level of detail not feasible using normal microscopy. One example is a technique called photoactivated localization microscopy (PALM), which uses fluorescent markers to pinpoint single molecules. PALM can be performed sequentially to create a super-resolution image from the series of molecules isolated in the sample tissue.
- **Terahertz Tomography:** This relatively new, experimental technique involves sectional imaging using terahertz radiation. Terahertz radiation consists of electromagnetic waves, which are found on the spectrum between microwaves and infrared light waves. They are of great interest to scientists because terahertz radiation can “see” what visible and infrared light cannot and holds great promise for detecting unique information unavailable via other optical imaging methods.

2.3.4 What Are NIBIB-Funded Researchers Developing in the Area of Optical Imaging to Improve Biomedical Research and Medical Care?



Source: Hari Shroff, NIBIB.

Scanning laser microscopes to identify cancer of the epithelium without painful biopsies: Scientists are building a miniature scanning laser microscope that can identify skin cancer cells and can also be attached to an endoscope (a thin illuminated tube) to examine cells on the epithelium of the oral cavity, GI tract and elsewhere. The device combines high resolution images showing cellular detail, with wide-field color video images of the surrounding tissue. The two views will allow the clinician to see the exact position in the tissue where the microscopic images are being taken, which is essential for accurately identifying and sampling the cells most likely to be cancerous. The instrument will improve early cancer diagnosis leading to higher survival rates at lower health care costs.


Near infrared brain imaging for guiding treatment in children with cerebral palsy: Cerebral palsy affects a child's ability to develop typical motor skills and to engage fully in play, and routine daily activities. Currently, treatments are tried blindly and as a result many pediatric patients undergo futile, prolonged, and taxing treatments that have no benefit. This project uses functional near infrared (fNIR) imaging to detect brain activation patterns in the cortex, located at the top of the skull. The images will allow researchers to identify strong cortical activation patterns, which indicate a positive response to therapies. Ultimately, the scientists hope to refine the system so that physicians can readily use it to assess the initial severity of cerebral palsy and help them decide which specific treatment is likely to have a positive outcome for each individual patient.

Digital holograms to test response to therapies for ovarian cancer: Ovarian cancer is often not detected until late stages, when it is difficult to treat and can be fatal. Scientists are using a new technique called tissue dynamics imaging (TDI) to measure the sensitivity of ovarian tumors to chemotherapy and biological treatments. TDI constructs 3D holograms inside ovarian cancer tissue samples that measure cellular function and growth of tumors in response to drug treatments. The method predicts the clinical outcome expected following each round of treatment and determines the best subsequent treatment. The approach of analyzing the changing cellular properties of ovarian tumor tissue is designed to determine the optimal therapy for each patient. The ultimate goal is to establish TDI as a novel drug-response monitoring system that could transform personalized ovarian cancer care.

2.4 X-Rays

2.4.1 What Are Medical X-Rays?

X-rays are a form of electromagnetic radiation, similar to visible light. Unlike light, however, X-rays have higher energy and can pass through most objects, including the body. Medical X-rays are used to generate images of tissues and structures inside the body. If X-rays travelling through the body also pass through an X-ray detector on the other side of the patient, an image will be formed that represents the "shadows" formed by the objects inside the body.




Caption Challenge


Complete the captions for these microscopic images using concepts you've picked up in class.




Model of a bacterial _____ created using cryo-electron tomography.




A time-lapse sequence of mitosis in a flower cell. Also known as _____, this process was captured with a light microscope.



These thin, fibrous tubulin proteins help to make up a cell's skeleton, also known as a _____.



Scientific illustration shows an enzyme wrapping around a broken strand of _____ to repair it.



The dendrites of this _____ located in the brain's hippocampus transfer electrochemical signals to the body's central nervous system.

Word Bank

Cytoskeleton

Cell Division

Neuron

DNA

Cell

One type of X-ray detector is photographic film, but there are many other types of detectors that are used to produce digital images. The X-ray images that result from this process are called radiographs.

2.4.2 How Do Medical X-Rays Work?



X-ray of the lumbar spine.

To create a radiograph, a patient is positioned so that the part of the body being imaged is located between an X-ray source and an X-ray detector. When the machine is turned on, X-rays travel through the body and are absorbed in different amounts by different tissues, depending on the radiological density of the tissues they pass through. Radiological density is determined by both the density and the atomic number (the number of protons in an atom's nucleus) of the materials being imaged. For example, structures such as bone contain calcium, which has a higher atomic number than most tissues. Because of this property, bones readily absorb X-rays and, thus, produce high contrast on the X-ray detector. As a result, bony structures appear whiter than other tissues against the black background of a radiograph. Conversely, X-rays travel more easily through less radiologically dense tissues such as fat and muscle, as well as through air-filled cavities such as the lungs. These structures are displayed in shades of gray on a radiograph.

The Colorful World of Imaging Technology

Check out some of the ways color and contrast can help scientists better visualize tiny specimens, and how this research can help human health!



Staining and Colorizing Specimens

Cryo-ET image before and after colorizing

Specimen: Caulobacter bacterium

Color key: In the second image, cell membranes are highlighted in red and blue, protein shell in green, ribosomes in yellow, and storage granules in orange.

Why study this? By studying this bacterium, scientists learn more about asymmetric cell division—an important factor in our understanding of human disease and the growth of tumors.




Light sheet fluorescence microscope

Specimen: Jellyfish

Color key: Nervous system is stained green. Musculature is stained red. Cell nuclei are stained blue.

Why study this? By studying jellyfish tissues, scientists learn more about the evolution of animals, including humans!



Confocal microscope + fluorescence

Specimen: Fruit fly brain

Color key: To create this digital, 3D color-coded map, scientists labeled the brain's parts with fluorescence, then captured and combined thousands of photos.

Why study this? By studying the brain of fruit flies, researchers aim to learn more about the functions and structures of the human brain.




Scanning electron microscope

Specimen: Leg muscle

Color key: Blood vessels are colored pink (with red blood cells at the bottom). The light brown marks the extracellular matrix (ECM), made up of molecules like proteins that physically support the muscle.

Why study this? Disruption of the ECM is associated with many muscle disorders. Scientists hope to learn more about how the ECM functions and how muscle disorders can be treated.



X-ray fluorescence technology

Specimen: Leaf

Color key: The levels of zinc in the leaf from lowest to highest are marked in blue, green, red, and white.

Why study this? Zinc is required for the function of more than 300 enzymes in the human body. With a goal of improving human health, researchers are investigating how plants distribute zinc to find ways of increasing the zinc content of crops.

2.4.3 When Are Medical X-Rays Used?

Listed below are examples of examinations and procedures that use X-ray technology to either diagnose or treat disease:

2.4.3.1 Diagnostic

X-ray radiography: Detects bone fractures, certain tumors and other abnormal masses, pneumonia, some types of injuries, calcifications, foreign objects, dental problems, etc.

Mammography: A radiograph of the breast that is used for cancer detection and diagnosis. Tumors tend to appear as regular or irregular-shaped masses that are somewhat brighter than the background on the radiograph (i.e., whiter on a black background or blacker on a white background). Mammograms can also detect tiny bits of calcium, called microcalcifications, which show up as very bright specks on a mammogram. While usually benign, microcalcifications may occasionally indicate the presence of a specific type of cancer.

Computed Tomography (CT): Combines traditional X-ray technology with computer processing to generate a series of cross-sectional images of the body that can later be combined to form a three-dimensional X-ray image. CT images are more detailed than plain radiographs and give doctors the ability to view structures within the body from many different angles.

Fluoroscopy: Uses X-rays and a fluorescent screen to obtain real-time images of movement within the body or to view diagnostic processes, such as following the path of an injected or swallowed contrast agent. For example, fluoroscopy is used to view the movement of the beating heart, and, with the aid of radiographic contrast agents, to view blood flow to the heart muscle as well as through blood vessels and organs. This technology is also used with a radiographic contrast agent to guide an internally threaded catheter during cardiac angioplasty, which is a minimally invasive procedure for opening clogged arteries that supply blood to the heart.

2.4.3.2 Therapeutic

X-rays and other types of high-energy radiation can be used to destroy cancerous tumors and cells by damaging their DNA. The radiation dose used for treating cancer is much higher than the radiation dose used for diagnostic imaging. Therapeutic radiation can come from a machine outside of the body or from a radioactive material that is placed in the body, inside or near tumor cells, or injected into the blood stream. [Click here for more information on radiation therapy for cancer.](#)

2.4.4 Are There Risks?

When used appropriately, the diagnostic benefits of X-ray scans significantly outweigh the risks. X-ray scans can diagnose possibly life-threatening conditions such as blocked blood vessels, bone cancer, and infections. However, X-rays

produce ionizing radiation—a form of radiation that has the potential to harm living tissue. This is a risk that increases with the number of exposures added up over the life of the individual. However, the risk of developing cancer from radiation exposure is generally small.

An X-ray in a pregnant woman poses no known risks to the baby if the area of the body being imaged isn't the abdomen or pelvis. In general, if imaging of the abdomen and pelvis is needed, doctors prefer to use exams that do not use radiation, such as MRI or ultrasound. However, if neither of those can provide the answers needed, or there is an emergency or other time constraint, an X-ray may be an acceptable alternative imaging option.

Children are more sensitive to ionizing radiation and have a longer life expectancy and, thus, a higher relative risk for developing cancer than adults. Parents may want to ask the technologist or doctor if their machine settings have been adjusted for children.

2.4.5 What Are NIBIB-Funded Researchers Developing in the Field of X-Ray Technology?

Current research of X-ray technology focuses on ways to reduce radiation dose, improve image resolution, and enhance contrast materials and methods.

Dedicated Breast CT (bCT): Research funded by NIBIB has led to the development of a breast CT scanner (bCT) that allows radiologists to view the breast in three dimensions and has the potential to reveal small tumors obscured behind dense breast tissue. The scanner uses a radiation dose comparable to mammography by sending X-rays only through the breast and not the chest. At present, more than 600 women have been imaged using bCT in clinical trials. Results from these trials suggest that bCT is significantly better at detecting tumors than mammography, though mammography is better at detecting microcalcifications. Recently, positron emission tomography (PET) technology has been incorporated into the bCT platform. A PET scan highlights areas of increased metabolic activity, which could indicate the presence of a tumor. Additionally, injection of a contrast agent has been shown to improve bCT's ability to detect microcalcifications and could help radiologists distinguish benign from malignant tumors. Research is currently focused on ways in which bCT could be used to provide real-time image guidance for biopsy needle placement and minimally invasive ablation of tumors.

Near-Infrared, Diffuse Light Imaging with Ultrasonic Guidance: Researchers funded by NIBIB have developed a novel, hand-held breast imaging system that uses visible light to distinguish benign lesions from early-stage cancer. The system creates maps of tissue density in a local area of the breast based on how the tissue scatters light; the denser the tissue, the more light is scattered, and the greater the likelihood that the tissue is cancerous. The method is currently being tested in a large number of patients undergoing surgery to remove a breast tumor. Early results indicate that the imaging system may be a promising adjunct to mammography for diagnosing breast cancer and determining disease prognosis.

In addition, the system could allow surgeons to determine tumor margins more rapidly during surgery compared to methods used over the past twenty years. This could potentially reduce surgeries that need to be repeated because not all cancerous tissue was removed initially.

2.5 Mammography

2.5.1 What Is a Mammogram?

Mammography is an X-ray imaging method used to examine the breast for the early detection of cancer and other breast diseases. It is used as both a diagnostic and screening tool.

2.5.2 How Does It Work?

During a mammogram, a patient's breast is placed on a flat support plate and compressed with a parallel plate called a paddle. An X-ray machine produces a small burst of X-rays that pass through the breast to a detector located on the opposite side. The detector can be either a photographic film plate, which captures the X-ray image on film, or a solid-state detector, which transmits electronic signals to a computer to form a digital image. The images produced are called mammograms.

On a film mammogram, low density tissues, such as fat, appear translucent (i.e., darker shades of gray approaching the black background), whereas areas of dense tissue, such as connective and glandular tissue or tumors, appear whiter on a gray background. In a standard mammogram, both a top and a side view are taken of each breast, although extra views may be taken if the physician is concerned about a suspicious area of the breast.

2.5.3 What Will the Results Look Like?

A radiologist will carefully examine a mammogram to search for high density regions or areas of unusual configuration that look different from normal tissue. These areas could represent many different types of abnormalities, including cancerous tumors, non-cancerous masses called benign tumors, fibroadenomas, or complex cysts. Radiologists look at the size, shape, and contrast of an abnormal region, as well as the appearance of the edges or margins of such an area, all of which can indicate the possibility of malignancy (i.e., cancer). They also look for tiny bits of calcium, called microcalcifications, which show up as very bright specks on a mammogram. While usually benign, sites of microcalcifications may occasionally signal the presence of a specific type of cancer. If a mammogram shows one or more suspicious regions that are not definitive for cancer, the radiologist may order additional mammogram views, with or without additional magnification or compression, or they may order a biopsy. Another alternative may be referral for another type of non-invasive imaging study.

2.5.4 Why Does the Breast Need to Be Compressed?

Compression holds the breast in place to minimize blurring of the X-ray image that can be caused by patient motion. Also, compression evens out the shape of the breast so that the X-rays can travel through a shorter path to reach the detector. This reduces the radiation dose and improves the quality of the X-ray image. Finally, compression allows all the tissues to be visualized in a single plane so that small abnormalities are less likely to be obscured by overlying breast tissue.

2.5.5 What Is Digital Mammography?

A digital mammogram uses the same X-ray technology as conventional mammograms, but instead of using film, solid-state detectors are used to record the X-ray pattern passing through the breast. These detectors convert the X-rays that pass through them into electronic signals that are sent to a computer. The computer then converts these electronic signals into images that can be displayed on a monitor and also stored for later use. Several advantages of using digital mammography over film mammography include: the ability to manipulate the image contrast for better clarity, the ability to use computer-aided detection of abnormalities, and the ability to easily transmit digital files to other experts for a second opinion. In addition, digital mammograms may decrease the need for the re-takes, which are common with film mammography due to incorrect exposure techniques or problems with film development. As a result, digital mammography can lead to lower X-ray exposures. To date, there is no evidence that digital mammography is better than film mammography for reducing a woman's risk of dying from breast cancer, however, digital screening may be more accurate for finding cancers in younger women or women with dense breasts.

2.5.6 What Is Tomosynthesis (3D Mammography)?

Digital Breast Tomosynthesis, also known as 3D mammography, is an FDA-approved method for breast cancer screening in which X-rays of the breast are taken at different angles to generate thin cross-sections. The 3D representation of the breast is like the 3D images created by standard CT technology. Tomosynthesis differs from CT technology in that significantly fewer X-ray beams are projected through the breast than with CT and the X-ray exposure to the rest of the chest is dramatically reduced. Hence, the radiation dose delivered to the breast by tomosynthesis is similar to that delivered 2D mammography. While tomosynthesis uses very low-dose X-rays, it is currently most often used in addition to 2D mammography, making the total radiation dose higher than standard mammography. Early evaluations of 3D mammography suggest an improved detection of breast cancers than seen with 2D mammography, but extensive large-scale comparisons of tomosynthesis with 2D mammography

in randomized studies are still in process. Therefore, researchers do not know with full certainty whether 3D mammography is better or worse than standard mammography at avoiding false-positive results and identifying early cancers in all types of patients.

2.5.7 Are There Risks?

Because mammography uses X-rays to produce images of the breast, patients are exposed to a small amount of ionizing radiation. For most women, the benefits of regular mammograms outweigh the risks posed by this amount of radiation. The risk associated with this dose appears to be greater among younger women (under age 40). However, in some cases, the benefits of using mammography to detect breast cancer under age 40 may outweigh the risks of radiation exposure. For example, a mammogram may reveal that a suspicious mass is benign and, therefore, doesn't need to be treated. Additionally, if a tumor is malignant and is caught early by mammogram, a surgeon may be able to remove it before it spreads and requires more aggressive treatment such as chemotherapy.

2.5.8 When should I Get a Mammogram?

Several organizations and professional societies have developed guidelines for mammography screening including the United States Preventive Services Task Force, the American Cancer Society, and the American College of Radiology. You can read more about these recommendations on their websites. All recommend that women talk with their doctor about the benefits and potential harms of mammography, when to start screening, and how often to be screened.

2.5.9 What Are Examples of NIBIB-Funded Projects in Breast Cancer Screening?

Dedicated Breast CT (dbCT): Research funded by NIBIB has led to the development of a dedicated breast CT scanner (dbCT) that allows radiologists to view the breast in three dimensions and has the potential to reveal small tumors obscured behind dense breast tissue. The scanner uses a radiation dose comparable to mammography by sending X-rays only through the breast and not the chest. At present, more than 600 women have been imaged using dbCT in clinical trials. Results from these trials suggest that dbCT is significantly better at detecting tumors than mammography, though mammography is better at detecting microcalcifications. Recently, positron emission tomography (PET) technology has been incorporated into the dbCT platform. A PET scan highlights areas of increased metabolic activity, which could indicate the presence of a tumor. Additionally, injection of a contrast agent has been shown to improve dbCT's ability to detect microcalcifications and could help radiologists distinguish benign from malignant tumors. Research is currently focused on ways in which dbCT


could be used to provide real-time image guidance for biopsy needle placement and minimally invasive ablation of tumors.

Near-Infrared, Diffuse Light Imaging with Ultrasonic Guidance: Researchers funded by NIBIB have developed a novel hybrid ultrasound/optical breast imaging system that uses simultaneous optical (infrared) and ultrasound sensors in a hand-held probe. The method provides accurate detection of tumor angiogenesis (i.e., formation of new blood vessels) and the distribution of these new blood vessels, which can help distinguish benign lesions from early-stage cancers. The method is being tested in many patients who will also receive ultrasound-guided biopsy. Early results indicate that this may be a promising adjunct to mammography and may help to reduce the number of benign breast biopsies compared to methods that have been in use over the past 20 years. It may also be useful in evaluating the effectiveness of chemotherapy treatments.

2.6 Nuclear Medicine

2.6.1 What Is Nuclear Medicine?

Nuclear medicine is a medical specialty that uses radioactive tracers (radiopharmaceuticals) to assess bodily functions and to diagnose and treat disease. Specially designed cameras allow doctors to track the path of these radioactive tracers. Single Photon Emission Computed Tomography or SPECT and Positron Emission Tomography or PET scans are the two most common imaging modalities in nuclear medicine.




2.6.2 What Are Radioactive Tracers?

Radioactive tracers are made up of carrier molecules that are bonded tightly to a radioactive atom. These carrier molecules vary greatly depending on the purpose of the scan. Some tracers employ molecules that interact with a specific protein or sugar in the body and can even employ the patient's own cells. For example, in cases where doctors need to know the exact source of intestinal bleeding, they may radiolabel (add radioactive atoms) to a sample of red blood cells taken from the patient. They then reinject the blood and use a SPECT scan to follow the path of the blood in the patient. Any accumulation of radioactivity in the intestines informs doctors of where the problem lies.

For most diagnostic studies in nuclear medicine, the radioactive tracer is administered to a patient by intravenous injection. However, a radioactive tracer may also be administered by inhalation, by oral ingestion, or by direct injection into an organ. The mode of tracer administration will depend on the disease process that is to be studied.

Approved tracers are called radiopharmaceuticals since they must meet FDA's exacting standards for safety and appropriate performance for the approved


clinical use. The nuclear medicine physician will select the tracer that will provide the most specific and reliable information for a patient's particular problem. The tracer that is used determines whether the patient receives a SPECT or PET scan.



Researchers demonstrate that combined PET/CT (right) of a mouse provides a more complete view of the spine than CT (left) or PET (middle) alone.

2.6.3 What Is Single Photon Emission Computed Tomography (SPECT)?


SPECT imaging instruments provide three-dimensional (tomographic) images of the distribution of radioactive tracer molecules that have been introduced into the patient's body. The 3D images are computer generated from many projection images of the body recorded at different angles. SPECT imagers have gamma camera detectors that can detect the gamma ray emissions from the tracers that have been injected into the patient. Gamma rays are a form of light that moves at a different wavelength than visible light. The cameras are mounted on a rotating gantry that allows the detectors to be moved in a tight circle around a patient who is lying motionless on a pallet.



2.6.4 What Is Positron Emission Tomography (PET)?

PET scans also use radiopharmaceuticals to create three-dimensional images. The main difference between SPECT and PET scans is the type of radiotracers used. While SPECT scans measure gamma rays, the decay of the radiotracers used with PET scans produce small particles called positrons. A positron is a

particle with roughly the same mass as an electron but oppositely charged. These react with electrons in the body and when these two particles combine, they annihilate each other. This annihilation produces a small amount of energy in the form of two photons that shoot off in opposite directions. The detectors in the PET scanner measure these photons and use this information to create images of internal organs.




2.6.5 What Are Nuclear Medicine Scans Used for?

SPECT scans are primarily used to diagnose and track the progression of heart disease, such as blocked coronary arteries. There are also radiotracers to detect disorders in bone, gall bladder disease and intestinal bleeding. SPECT agents have recently become available for aiding in the diagnosis of Parkinson's disease in the brain and distinguishing this malady from other anatomically-related movement disorders and dementias.

The major purpose of PET scans is to detect cancer and monitor its progression, response to treatment, and to detect metastases. Glucose utilization depends on the intensity of cellular and tissue activity, so it is greatly increased in rapidly dividing cancer cells. In fact, the degree of aggressiveness for most cancers is roughly paralleled by their rate of glucose utilization. In the last 15 years, slightly modified radiolabeled glucose molecules (F-18 labeled deoxyglucose or FDG) have been shown to be the best available tracer for detecting cancer and its metastatic spread in the body.

A combination instrument that produces both PET and CT scans of the same body regions in one examination (PET/CT scanner) has become the primary imaging tool for the staging of most cancers worldwide.



Fused CT-PET scans more clearly show tumors and are therefore often used to diagnose and monitor the growth of cancerous tumors.

Recently, a PET probe was approved by the FDA to aid in the accurate diagnosis of Alzheimer's disease, which previously could be diagnosed with accuracy only after a patient's death. In the absence of this PET imaging test, Alzheimer's disease can be difficult to distinguish from vascular dementia or other forms of dementia that affect older people.

2.6.6 Are There Risks?

The total radiation dose conferred to patients by most radiopharmaceuticals used in diagnostic nuclear medicine studies is no more than what is conferred during routine chest X-rays or CT exams. There are legitimate concerns about possible cancer induction even by low levels of radiation exposure from cumulative medical imaging examinations, but this risk is accepted to be quite small in contrast to the expected benefit derived from a medically needed diagnostic imaging study.


Like radiologists, nuclear medicine physicians are strongly committed to keeping radiation exposure to patients as low as possible, giving the least amount of radiotracer needed to provide a diagnostically useful examination.

2.6.7 How Are NIBIB-Funded Researchers Advancing Nuclear Medicine?

Research in nuclear medicine involves developing new radio tracers as well as technologies that will help physicians produce clearer pictures.

2.6.8 Developing New Tracers


A bacterial infection is a common complication of implanting a medical device into the body. With more patients receiving device implants than ever before, infections from implants are a growing problem. Currently, these types of infections are diagnosed based on physical exam results and microbial cultures. However, such techniques are only useful for detecting late-stage infections, which usually have already become difficult to treat. Conversely, medical devices may be needlessly removed when doctors mistake inflammation that is a normal consequence of surgery with inflammation due to an infection. NIBIB is currently supporting research to develop a new family of PET imaging contrast agents that are taken up specifically by bacterial cells, but not human cells. Such imaging agents would allow doctors to visualize early-stage bacterial infections so they can be easily treated, thereby reducing the number of implanted devices that are unnecessarily removed. They also have the potential to be used for diagnosing infections not associated with medical devices, for example, those affecting the heart or lungs.



PET contrast agents designed to detect bacterial infections reveal *E. coli* in a rat.

2.6.9 Creating New Technology

A SPECT tracer is currently available for accurate diagnosis of Parkinson's disease. However, the small region in the brain that must be imaged requires a dedicated brain SPECT imager with special gamma cameras to provide high resolution, which adds to the cost of the procedure. NIBIB is supporting research to create an inexpensive adapter for the conventional SPECT imagers that most hospitals already have. The adapter would allow standard clinical SPECT cameras to provide the same high resolution that currently only dedicated SPECT brain imaging systems can produce. These improvements would make Parkinson's diagnosis less costly and more widely available.



This simulated image shows how an inexpensive adapter for a SPECT camera could provide higher resolution images of the part of the brain affected in Parkinson's disease.

2.7 Computed Tomography (CT)

2.7.1 What Is a Computed Tomography (CT) Scan?

The term "computed tomography", or CT, refers to a computerized X-ray imaging procedure in which a narrow beam of X-rays is aimed at a patient and quickly

rotated around the body, producing signals that are processed by the machine's computer to generate cross-sectional images—or “slices”—of the body. These slices are called tomographic images and contain more detailed information than conventional X-rays. Once a number of successive slices are collected by the machine's computer, they can be digitally “stacked” together to form a three-dimensional image of the patient that allows for easier identification and location of basic structures as well as possible tumors or abnormalities.

2.7.2 How Does CT Work?

Unlike a conventional X-ray—which uses a fixed X-ray tube—a CT scanner uses a motorized X-ray source that rotates around the circular opening of a donut-shaped structure called a gantry. During a CT scan, the patient lies on a bed that slowly moves through the gantry while the X-ray tube rotates around the patient, shooting narrow beams of X-rays through the body. Instead of film, CT scanners use special digital X-ray detectors, which are located directly opposite the X-ray source. As the X-rays leave the patient, they are picked up by the detectors and transmitted to a computer.

Each time the X-ray source completes one full rotation, the CT computer uses sophisticated mathematical techniques to construct a 2D image slice of the patient. The thickness of the tissue represented in each image slice can vary depending on the CT machine used, but usually ranges from 1-10 millimeters. When a full slice is completed, the image is stored, and the motorized bed is moved forward incrementally into the gantry. The X-ray scanning process is then repeated to produce another image slice. This process continues until the desired number of slices is collected.



Image slices can either be displayed individually or stacked together by the computer to generate a 3D image of the patient that shows the skeleton, organs, and tissues as well as any abnormalities the physician is trying to identify. This method has many advantages including the ability to rotate the 3D image in space

or to view slices in succession, making it easier to find the exact place where a problem may be located.

2.7.3 What Is a CT Contrast Agent?

As with all X-rays, dense structures within the body—such as bone—are easily imaged, whereas soft tissues vary in their ability to stop X-rays and, thus, may be faint or difficult to visualize. For this reason, contrast agents have been developed that are highly visible in an X-ray or CT scan and are safe to use in patients. Contrast agents contain substances that are better at stopping X-rays and, thus, are more visible on an X-ray image. For example, to examine the circulatory system, a contrast agent based on iodine is injected into the bloodstream to help illuminate blood vessels. This type of test is used to look for possible obstructions in blood vessels, including those in the heart. Other contrast agents, such as barium-based compounds, are used for imaging the digestive system, including the esophagus, stomach, and GI tract.



2.7.4 When Would I Get a CT Scan?

CT scans can be used to identify disease or injury within various regions of the body. For example, CT has become a useful screening tool for detecting possible tumors or lesions within the abdomen. A CT scan of the heart may be ordered when various types of heart disease or abnormalities are suspected. CT can also be used to image the head in order to locate injuries, tumors, clots leading to stroke, hemorrhage, and other conditions. It can image the lungs in order to reveal the presence of tumors, pulmonary embolisms (blood clots), excess fluid, and other conditions such as emphysema or pneumonia. A CT scan is particularly useful when imaging bone fractures, joints, cartilage, or tendons since it usually produces more detail than would be possible with a conventional X-ray.

2.7.5 Are There Risks?

All X-rays produce ionizing radiation, which has the potential to cause biological effects in the human body. For patients, these biological effects can range from an increased lifetime risk of cancer to possible allergic reactions or kidney failure due to contrast agents. Under some rare circumstances of prolonged, high-dose exposure, X-rays can cause adverse health effects such as skin reddening, skin tissue injury, hair loss, cataracts, or birth defects (if scanning conducted during pregnancy).

For conventional X-rays, the amount of radiation delivered to a patient is extremely small. However, for a CT exam, such as a study of the abdomen, the radiation delivered to the patient can be equivalent to as many as 400 chest X-rays. Similarly, a CT exam of the head can produce the equivalent of about 100 chest X-rays. For this reason, it's important that CT exams are limited only to those cases where the benefit to be gained greatly outweighs the increased risk. This is especially true for children, who are more sensitive to ionizing radiation and have a longer life expectancy and, thus, have a higher relative risk for developing cancer than adults. Also, a child's smaller size affects the amount of radiation dose received. For this reason, when scanning children, equipment settings need to be adjusted to reduce the radiation dose while maintaining high image quality.

2.7.6 What Are Examples of NIBIB-Funded Projects Using Computed Tomography?

Dedicated Breast CT Scanner: NIBIB is funding research for the development of a dedicated breast CT scanner that allows the breast to be imaged in 3D and could help radiologists detect hard-to-find tumors. The scanner produces a radiation dose comparable to that of a standard X-ray mammogram and doesn't require compression of the breast. In this breast CT scanner, a woman lies prone in a specially designed large table with her breast suspended in an opening in the scanning bed. The scanner rotates only around the breast without passing X-rays through the chest, thus reducing the radiation that would be delivered to the chest in a conventional CT scanner.

Reduction in Radiation from Routine CT scans: NIBIB has put out a call for researchers to submit groundbreaking ideas that will help to radically decrease the amount of radiation used in CT scans. This new funding opportunity [PAR-12-206] is intended to inspire innovation and creativity and allow researchers to try new approaches that might not be funded otherwise. The funding opportunity calls for new research in CT scanner technology and CT image reconstruction methods and/or algorithm developments and improvements that could realistically reduce patient radiation exposure, while maintaining high image quality.

2.8 Magnetic Resonance Imaging (MRI)

2.8.1 What Is MRI?

MRI is a non-invasive imaging technology that produces three dimensional detailed anatomical images without the use of damaging radiation. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.



2.8.2 How Does MRI Work?

MRIs employ powerful magnets which produce a strong magnetic field that forces protons in the body to align with that field. When a radiofrequency current is then pulsed through the patient, the protons are stimulated, and spin out of equilibrium, straining against the pull of the magnetic field. When the radiofrequency field is turned off, the MRI sensors can detect the energy released as the protons realign with the magnetic field. The time it takes for the protons to realign with the magnetic field, as well as the amount of energy released, changes depending on the environment and the chemical nature of the molecules. Physicians are able to tell the difference between various types of tissues based on these magnetic properties.



MRI of a knee.


To obtain an MRI image, a patient is placed inside a large magnet and must remain very still during the imaging process in order not to blur the image. Contrast agents (often containing the element Gadolinium) may be given to a patient intravenously before or during the MRI to increase the speed at which protons realign with the magnetic field. The faster the protons realign, the brighter the image.

2.8.3 What Is MRI Used for?

MRI scanners are particularly well suited to image the non-bony parts or soft tissues of the body. They differ from computed tomography (CT), in that they do not use the damaging ionizing radiation of X-rays. The brain, spinal cord and nerves, as well as muscles, ligaments, and tendons are seen much more clearly with MRI than with regular X-rays and CT; for this reason, MRI is often used to image knee and shoulder injuries.

In the brain, MRI can differentiate between white matter and grey matter and can also be used to diagnose aneurysms and tumors. Because MRI does not use X-rays or other radiation, it is the imaging modality of choice when frequent imaging is required for diagnosis or therapy, especially in the brain. However, MRI is more expensive than X-ray imaging or CT scanning.

One kind of specialized MRI is functional Magnetic Resonance Imaging (fMRI). This is used to observe brain structures and determine which areas of the brain “activate” (consume more oxygen) during various cognitive tasks. It is used to advance the understanding of brain organization and offers a potential new standard for assessing neurological status and neurosurgical risk.



New diffusion MRI technology provides unprecedented detail of the connections in the brain.

2.8.4 Are There Risks?

Although MRI does not emit the damaging ionizing radiation that is found in X-ray and CT imaging, it does employ a strong magnetic field. The magnetic field extends beyond the machine and exerts very powerful forces on objects of iron, some steels, and other magnetizable objects; it is strong enough to fling a wheelchair across the room. Patients should notify their physicians of any form of medical or implant prior to an MR scan.

When having an MRI scan, the following should be taken into consideration:

- *People with implants, particularly those containing iron*—pacemakers, vagus nerve stimulators, implantable cardioverter-defibrillators, loop recorders, insulin pumps, cochlear implants, deep brain stimulators, and capsules from capsule endoscopy—should not enter an MRI machine.
- *Noise*—loud noise commonly referred to as clicking and beeping, as well as sound intensity up to 120 decibels in certain MR scanners, may require special ear protection.
- *Nerve Stimulation*—a twitching sensation sometimes results from the rapidly switched fields in the MRI.
- *Contrast agents*—patients with severe renal failure who require dialysis may risk a rare but serious illness called nephrogenic systemic fibrosis that may be linked to the use of certain gadolinium-containing agents, such as gadodiamide and others. Although a causal link has not been established, current guidelines in the United States recommend that dialysis patients should only receive gadolinium agents when essential, and that dialysis should be performed as soon as possible after the scan to remove the agent from the body promptly.
- *Pregnancy*—while no effects have been demonstrated on the fetus, it is recommended that MRI scans be avoided as a precaution especially in the first trimester of pregnancy when the fetus' organs are being formed and contrast agents, if used, could enter the fetal bloodstream.
- *Claustrophobia*—people with even mild claustrophobia may find it difficult to tolerate long scan times inside the machine. Familiarization with the machine and process, as well as visualization techniques, sedation, and anesthesia provide patients with mechanisms to overcome their discomfort. Additional coping mechanisms include listening to music or watching a video or movie, closing, or covering the eyes, and holding a panic button.

The open MRI is a machine that is open on the sides rather than a tube closed at one end, so it does not fully surround the patient. It was developed to accommodate the needs of patients who are uncomfortable with the narrow tunnel and noises of the traditional MRI and for patients whose size or weight make the traditional MRI impractical. Newer open MRI technology provides high quality images for many but not all types of examinations.



2.8.5 What Are Examples of NIBIB-Funded Projects in MRI?

2.8.5.1 Replacing biopsies with sound

Chronic liver disease and cirrhosis affect more than 5.5 million people in the United States. NIBIB-funded researchers have developed a method to turn sound waves into images of the liver, which provides a new non-invasive, pain-free approach to find tumors or tissue damaged by liver disease. The Magnetic Resonance Elastography (MRE) device is placed over the liver of the patient before he enters the MRI machine. It then pulses sound waves through the liver, which the MRI can detect and use to determine the density and health of the liver tissue. This technique is safer and more comfortable for the patient as well as being less expensive than a traditional biopsy. Since MRE is able to recognize very slight differences in tissue density, there is the potential that it could also be used to detect cancer.



New open MRI machine.

2.8.5.2 Determining the aggressiveness of a tumor

Traditional MRI, unlike PET or SPECT, cannot measure metabolic rates. However, researchers funded by NIBIB have discovered a way to inject specialized

compounds (hyperpolarized carbon 13) into prostate cancer patients to measure the metabolic rate of a tumor. This information can provide a fast and accurate picture of the tumor's aggressiveness. Monitoring disease progression can improve risk prediction, which is critical for prostate cancer patients who often adopt a wait and watch approach.

2.9 Ultrasound

2.9.1 What Is Medical Ultrasound?

Medical ultrasound falls into two distinct categories: diagnostic and therapeutic.

Diagnostic ultrasound is a non-invasive diagnostic technique used to image inside the body. Ultrasound probes, called transducers, produce sound waves that have frequencies above the threshold of human hearing (above 20 KHz), but most transducers in current use operate at much higher frequencies (in the megahertz (MHz) range). Most diagnostic ultrasound probes are placed on the skin. However, to optimize image quality, probes may be placed inside the body via the gastrointestinal tract, vagina, or blood vessels. In addition, ultrasound is sometimes used during surgery by placing a sterile probe into the area being operated on.

Diagnostic ultrasound can be further sub-divided into anatomical and functional ultrasound. Anatomical ultrasound produces images of internal organs or other structures. Functional ultrasound combines information such as the movement and velocity of tissue or blood, softness or hardness of tissue, and other physical characteristics, with anatomical images to create "information maps." These maps help doctors visualize changes/differences in function within a structure or organ.



Therapeutic ultrasound also uses sound waves above the range of human hearing but does not produce images. Its purpose is to interact with tissues in the body such that they are either modified or destroyed. Among the modifications possible are moving or pushing tissue, heating tissue, dissolving blood clots, or delivering drugs to specific locations in the body. These destructive, or ablative, functions

are made possible by use of very high-intensity beams that can destroy diseased or abnormal tissues such as tumors. The advantage of using ultrasound therapies is that, in most cases, they are non-invasive. No incisions or cuts need to be made to the skin, leaving no wounds or scars.

2.9.2 How Does It Work?

Ultrasound waves are produced by a transducer, which can both emit ultrasound waves, as well as detect the ultrasound echoes reflected back. In most cases, the active elements in ultrasound transducers are made of special ceramic crystal materials called piezoelectric. These materials are able to produce sound waves when an electric field is applied to them, but can also work in reverse, producing an electric field when a sound wave hits them. When used in an ultrasound scanner, the transducer sends out a beam of sound waves into the body. The sound waves are reflected back to the transducer by boundaries between tissues in the path of the beam (e.g., the boundary between fluid and soft tissue or tissue and bone). When these echoes hit the transducer, they generate electrical signals that are sent to the ultrasound scanner. Using the speed of sound and the time of each echo's return, the scanner calculates the distance from the transducer to the tissue boundary. These distances are then used to generate two-dimensional images of tissues and organs. During an ultrasound exam, the technician will apply a gel to the skin. This keeps air pockets from forming between the transducer and the skin, which can block ultrasound waves from passing into the body.



An ultrasound transducer.

2.9.3 What Is Ultrasound Used for?

Diagnostic ultrasound. Diagnostic ultrasound is able to non-invasively image internal organs within the body. However, it is not good for imaging bones or any tissues that contain air, like the lungs. Under some conditions, ultrasound can image bones (such as in a fetus or in small babies) or the lungs and lining around the lungs, when they are filled or partially filled with fluid. One of the most common uses of ultrasound is during pregnancy, to monitor the growth and development of the fetus, but there are many other uses, including imaging the heart, blood vessels, eyes, thyroid, brain, breast, abdominal organs, skin, and muscles. Ultrasound images are displayed in either 2D, 3D, or 4D (which is 3D in motion).

Functional ultrasound. Functional ultrasound applications include Doppler and color Doppler ultrasound for measuring and visualizing blood flow in vessels within the body or in the heart. It can also measure the speed of the blood flow and direction of movement. This is done using color-coded maps called color Doppler imaging. Doppler ultrasound is commonly used to determine whether plaque build-up inside the carotid arteries is blocking blood flow to the brain.

Another functional form of ultrasound is elastography, a method for measuring and displaying the relative stiffness of tissues, which can be used to differentiate tumors from healthy tissue. This information can be displayed as either color-coded maps of the relative stiffness; black-and white maps that display high-contrast images of tumors compared with anatomical images; or color-coded maps that are overlaid on the anatomical image. Elastography can be used to test for liver fibrosis, a condition in which excessive scar tissue builds up in the liver due to inflammation.

Ultrasound is also an important method for imaging interventions in the body. For example, ultrasound-guided needle biopsy helps physicians see the position of a needle while it is being guided to a selected target, such as a mass or a tumor in the breast. Also, ultrasound is used for real-time imaging of the location of the tip of a catheter as it is inserted in a blood vessel and guided along the length of the vessel. It can also be used for minimally invasive surgery to guide the surgeon with real-time images of the inside of the body.




Figure A shows how the ultrasound probe (transducer) is placed over the carotid artery. Figure B is a color ultrasound image showing blood flow (the red color in the image) in the carotid artery. Figure C is a waveform image showing the sound of flowing blood in the carotid artery.

Therapeutic or interventional ultrasound. Therapeutic ultrasound produces high levels of acoustic output that can be focused on specific targets for the purpose

of heating, ablating, or breaking up tissue. One type of therapeutic ultrasound uses high-intensity beams of sound that are highly targeted, is called High Intensity Focused Ultrasound (HIFU). HIFU is being investigated as a method for modifying or destroying diseased or abnormal tissues inside the body (e.g., tumors) without having to open or tear the skin or cause damage to the surrounding tissue. Either ultrasound or MRI is used to identify and target the tissue to be treated, guide and control the treatment in real time, and confirm the effectiveness of the treatment. HIFU is currently FDA approved for the treatment of uterine fibroids, to alleviate pain from bone metastases, and most recently for the ablation of prostate tissue. HIFU is also being investigated as a way to close wounds and stop bleeding, to break up clots in blood vessels, and to temporarily open the blood brain barrier so that medications can pass through.

2.9.4 Are There Risks?

Diagnostic ultrasound is generally regarded as safe and does not produce ionizing radiation like that produced by X-rays. Still, ultrasound can produce some biological effects in the body under specific settings and conditions. For this reason, the FDA requires that diagnostic ultrasound devices operate within acceptable limits. The FDA, as well as many professional societies, discourage the casual use of ultrasound (e.g., for keepsake videos) and recommend that it be used only when there is a true medical need.

What are examples of NIBIB-funded projects using ultrasound?

The following are examples of current research projects funded by NIBIB that are developing new applications of ultrasound that are already in use or that will be in use in the future:

Acoustic Radiation Force Impulse Imaging (ARFI). ARFI is a new technique developed by researchers at Duke University with NIBIB support that uses ultrasound elastography to differentiate liver tumors from healthy tissue, as well as identify the presence of fibrosis. This non-invasive method could reduce unnecessary liver biopsies, which can be painful and sometimes dangerous. ARFI has received FDA approval and is now commercially available in the U.S.

Low-cost, miniature transducers and arrays. By using new transducer materials and new manufacturing methods, ultrasound arrays can be produced in a manner like the production of computer chips. One type of new transducer, called CMUTs, (capacitive micromachined ultrasound transducers) are less expensive to produce, easier to manufacture as arrays, and have several advantages over standard transducers.

This new CMUT technology was recently used in a device developed using NIBIB funding called the GE Vscan. The Vscan is a palm-size ultrasound scanner, which has both anatomical imaging and color Doppler capability. The device is currently in clinical use and costs considerably less than a full-sized ultrasound scanner. Its small size and low cost, as well as range of applications, allow it to be used

in ambulances, emergency rooms, field hospitals, or other remote locations. It is currently being used in 100 countries around the world.

Histotripsy technique for dissolving blood clots. Researchers at the University of Michigan are investigating the clot-dissolving capabilities of a high intensity ultrasound technique, called histotripsy, for the non-invasive treatment of deep-vein thrombosis (DVT). This technique uses short, high-intensity pulses of ultrasound to cause clot breakdown. The researchers are currently experimenting on pigs, in which they have successfully demonstrated the effectiveness of this technique, and its possible use in humans. They are currently working on new methods to avoid inadvertent vessel damage during clot treatment, and to provide real-time imaging feedback to monitor the treatment. This research could have a significant impact, since current conventional treatments for DVT involve drug therapy and sometimes invasive removal of the clots, which requires a several-day hospital stay, and may result in complications after treatment. In contrast, the non-invasive histotripsy technique is 50 times faster than the current technique, does not require drugs or external agents, and if successful, could be used as an outpatient procedure.

2.10 Sensors

2.10.1 What Are Sensors?

In medicine and biotechnology, sensors are tools that detect specific biological, chemical, or physical processes and then transmit or report this data. Some sensors work outside the body while others are designed to be implanted within the body.

Some monitoring devices consist of multiple sensors that measure a number of physical or biological parameters. Other devices may be multifunctional, incorporating sensors and then delivering a drug or intervention based on the sensor data obtained. Sensors may also be components in systems that process clinical samples, such as increasingly common “lab-on-a-chip” devices.

Sensors help health care providers and patients monitor health conditions and ensure that they can make informed decisions about treatment. Sensors are also often used to monitor the safety of medicines, food, environmental conditions, and other substances we may encounter.

2.10.2 How Are Sensors Used in Current Medical Practice?

Many different types of sensors are already used in health care, including self-care at home. Thermometers translate the expansion of a fluid or bending of a metal strip in response to heat into a number corresponding to body temperature. Paper-based home pregnancy tests contain a substance that changes color in the presence of hormones indicating pregnancy. In hospitals and other provider-based settings, you can find more complex types of sensors like pulse oximeters

(also known as blood-oxygen monitors), which measure changes in the body's absorption of special types of light to provide information on a patient's heart rate and the amount of oxygen in the blood.



Thermometers are a type of sensor commonly used in health care.

2.10.3 How Might Novel Sensors Improve Medical Care or Biomedical Research?

Advances in technology, engineering, and materials science have opened the door for increasingly sophisticated sensors to be used in medical research. For example, a group of NIBIB-funded researchers developed a compact, wireless, implantable brain sensor that can record and transmit brain activity data. Building on previously developed brain-computer interfaces that used wired connections, this new sensor may someday lead to unobtrusive, thought-controlled prosthetics and other assistive devices for people with amputated limbs, paralysis, or other movement impairments.

Researchers at NIBIB aim to improve existing sensors through a variety of means, such as making fluorescent probes easier to see and increasing the capabilities and enhancing efficiency of individual sensors.

While many advanced sensors aren't practical for routine medical care, they allow researchers to study the basic foundations of disease in more detail than previously possible, and to develop new technologies that could dramatically improve the quality of life of people with severe disabilities.

2.10.4 What Technologies Are NIBIB-Funded Researchers Developing with Sensors?

Sensors play key roles in all aspects of health care—prevention, diagnosis, disease monitoring, treatment monitoring—and the range of research involving sensors is equally broad. In addition to health-related applications, NIBIB funds studies to test new materials and technologies for building sensors, to develop new sensors that can advance medical research, and to promote healthy independent living through home-based and wearable sensors.



Test tubes containing purified proteins made to fluoresce in different colors. *Source:* NIBIB.

2.10.5 New Materials and Technologies

Good health requires not only protecting our bodies but safeguarding things we put into our bodies as well. NIBIB-funded researchers developed a sensor using a thin membrane made from of a special kind of plastic. The researchers loaded the membrane with a compound that creates a voltage difference across the membrane in the presence of oversulfated chondroitin sulfate (OSCS), a potentially deadly contaminant sometimes found in preparations of the commonly used blood thinner heparin. By measuring the voltage, scientists can quickly identify OSCS-contaminated samples before the heparin is administered to a patient. The reaction between OSCS and the membrane is also reversible, so the sensors can be used repeatedly.

2.10.6 Advancing Medical Research

Many illnesses develop and progress as a result of faulty regulation or dysfunction of a range of hormones, neurotransmitters, or other important body chemicals. Tracking such chemical activity is key to unraveling disease processes. NIBIB-funded researchers seek to improve on biosensors in a variety of ways, such as creating novel types of coatings that improve sensor sensitivity, selectivity, and stability; and developing a fluorescence-based strategy to detect proteins in living organisms and in real time.

2.10.7 Healthy Independent Living

Environmental and mobile sensors are already a part of many people's everyday lives, including things like faucets that automatically start when you place your hands under them and shut off when you're done washing. NIBIB supports initiatives to develop improved sensor and related information technologies for home and mobile use that will sustain wellness and facilitate coordinated management of chronic diseases. For example, one research team is working to improve the ability of "smart homes" to make sense of real-time sensor data and to recognize

changes in a resident's activity patterns that may signal changes in well-being, such as a fall or disrupted meal schedule.

2.10.8 What Are Important Areas for Future Research on Sensors?

The types of sensors being developed and studied currently may play key roles in expanding and greatly changing the delivery of health care. One area that may benefit from sensor research is point-of-care (POC) technologies.

Point-of-care refers to the place where patients receive health care, which may be anywhere from primary care offices or community clinics to emergency rooms or even patients' own homes. POC research seeks to address barriers to health care that have arisen from the concentration of services in highly specialized medical centers and labs. POC technologies may allow providers to diagnose and treat a particular health condition in a single visit, so patients don't need to make additional appointments or wait for test results.

NIBIB-funded efforts are already underway to develop cost-effective POC solutions for detecting a range of medical conditions, including H5N1 influenza and allergies and other autoimmune diseases. Integrating compact, wireless sensing technologies into medical devices or chronic treatments like long-term oxygen therapy may help lower treatment costs and be easier for patients to use. Such technologies may also be compatible with mobile devices, allowing for remote monitoring and assessments in real-time.

Some of the challenges to sensor research include simplifying and automating the preparation of patient samples to be used at the point-of-care and overcoming the body's natural rejection response to implantable or minimally invasive sensors.

2.11 Artificial Intelligence (AI)

2.11.1 What Are the Types of AI and How Do They Differ?

2.11.1.1 Artificial intelligence

A feature where machines learn to perform tasks, rather than simply carrying out computations that are input by human users.

Early applications of AI included machines that could play games such as checkers and chess, and programs that could reproduce language.

2.11.1.2 Machine learning

An approach to AI in which a computer algorithm (a set of rules and procedures) is developed to analyze and make predictions from data that is fed into the system.

Machine learning-based technologies are routinely used every day, such as personalized news feeds and traffic prediction maps.

2.11.1.3 Neural networks

A machine learning approach modeled after the brain in which algorithms process signals via interconnected nodes called artificial neurons.

Mimicking biological nervous systems, artificial neural networks have been used successfully to recognize and predict patterns of neural signals involved in brain function.

2.11.1.4 Deep learning

A form of machine learning that uses many layers of computation to form what is described as a deep neural network, capable of learning from large amounts of complex, unstructured data.

Deep neural networks are responsible for voice-controlled virtual assistants as well as self-driving vehicles, which learn to recognize traffic signs.

2.11.2 How Is AI Being Used to Improve Medical Care and Biomedical Research?

2.11.2.1 Radiology

The ability of AI to interpret imaging results may aid in detecting a minute change in an image that a clinician might accidentally miss.

2.11.2.2 Telehealth

Wearable devices allow for constant monitoring of a patient and the detection of physiological changes that may provide early warning signs of an event such as an asthma attack.

2.11.2.3 Imaging

One example is the use of AI to evaluate how an individual will look after facial and cleft palate surgery.

2.11.2.4 Clinical care

A large focus of AI in the healthcare sector is in clinical decision support systems, which use health observations and case knowledge to assist with treatment decisions.

2.11.3 How Are NIBIB-Funded Researchers Using AI in Their Biomedical Research?

2.11.3.1 Early diagnosis of Alzheimer's disease (AD) using analysis of brain networks

AD-related neurological degeneration begins long before the appearance of clinical symptoms. Information provided by functional MRI (fMRI) neuroimaging data,

which can detect changes in brain tissue during the early phases of AD, holds potential for early detection and treatment. The researchers are combining the ability of fMRI to detect subtle brain changes with the ability of machine learning to analyze multiple brain changes over time. This approach aims to improve early detection of AD, as well as other neurological disorders including schizophrenia, autism, and multiple sclerosis.

2.11.3.2 Prediction of blood glucose levels using wearable sensors

NIBIB-funded researchers are building machine learning models to better manage blood glucose levels by using data obtained from wearable sensors. New portable sensing technologies provide continuous measurements that include heart rate, skin conductance, temperature, and body movements. The data will be used to train an artificial intelligence network to help predict changes in blood glucose levels before they occur. Anticipating and preventing blood glucose control problems will enhance patient safety and reduce costly complications.

2.11.3.3 Enhanced image analysis for improved colorectal cancer screening

This project aims to develop an advanced image scanning system with high detection sensitivity and specificity for colon cancers. The researchers will develop deep neural networks that can analyze a wider field on the radiographic images obtained during surgery. The wider scans will include the suspected lesion areas and more surrounding tissue. The neural networks will compare patient images with images of past diagnosed cases. The system is expected to outperform current computer-aided systems in the diagnosis of colorectal lesions. Broad adoption could advance the prevention and early diagnosis of cancer.

2.11.3.4 Smart clothing to reduce low back pain

Smart, cyber-physically assistive clothing (CPAC) is being developed in an effort to reduce the high prevalence of low back pain. Forces on back muscles and discs that occur during daily tasks are major risk factors for back pain and injury. The researchers are gathering a public data set of more than 500 movements measured from each subject to inform a machine learning algorithm. The information will be used to develop assistive clothing that can detect unsafe conditions and intervene to protect low back health. The long-term vision is to create smart clothing that can monitor lumbar loading; train safe movement patterns; directly assist wearers to reduce incidence of low back pain; and reduce costs related to health care expenses and missed work.

2.12 Telehealth

2.12.1 What Is Telehealth?

Telehealth is broadly defined as the use of communications technologies to provide health care at a distance. Telehealth has become a valuable tool thanks

to combined advances in communications, computer science, informatics, and medical technologies.

Telehealth often involves remote monitoring of blood pressure, heart rate, and other measurements obtained by a device worn by the patient and electronically sent to medical personnel. Smartphones and other smart personal devices are increasingly utilized for the collection, dissemination and even analysis of health status due to their increasing presence around the globe, even in remote, underserved communities.

In the last several years virtual visits between doctors and patients have become very common, especially with the onset of the COVID-19 pandemic. The willingness of physicians, patients, and insurers to embrace virtual medicine is likely to cause it to remain a popular option in healthcare.

2.12.2 How Can Telehealth Technologies Improve Medical Care?

Teleconsultations allow a physician in a remote area to receive advice from a specialist at a distant location about special or complex patient conditions. Such consultations can be as simple as a phone call. Increasingly, they involve sophisticated sharing of medical information such as CT, MRI or ultrasound scans. These images can be taken by the local physician, incorporated into an electronic medical record and sent to the specialist for diagnosis and treatment recommendations.

Point-of-care (POC) medicine relies on diagnostic devices that can perform at the time and place of patient care, which includes at home, in doctor's offices and clinics, and in remote areas without electricity or laboratory equipment. POC devices can detect micronutrient deficiencies, anemia, infectious agents and even some cancers. Combined with telehealth, POC technologies allow health care workers to test patients and rapidly obtain results without the need for a complex laboratory setting, which can result in significant cost-reduction.

Remote patient monitoring (RPM) enables patient monitoring outside of clinical settings, such as in the home. Patients use or wear sensors that wirelessly collect and transmit physiological data to health professionals. RPM can significantly improve an individual's quality of life. For example, in diabetes management, the real-time transmission of blood glucose readings enables healthcare providers to intervene when needed and avoid acute events and hospitalizations.

Telehomecare provides the remote care needed to allow people with chronic conditions, dementia, or those at high risk of falling to remain living in their own homes. The approach focuses on reacting to emergency events and raising a help response quickly. Sensors monitor changes in chronic conditions as well as other risks including floods, fires, and gas leaks. Sensors can also alert caregivers if a person with dementia leaves the house. When a sensor is activated, a monitoring center is alerted to take appropriate action such as contacting a caregiver or sending emergency services.

2.12.3 What Telehealth/POC Technologies Are Researchers Creating to Improve Healthcare?

2.12.3.1 15-minute paper-based viral diagnostic

Diagnoses of HIV viral load requires RNA amplification from blood in a centralized laboratory, which can delay diagnosis and treatment for weeks. NIBIB scientists are developing a paper-based diagnostic that can quantify HIV viral load in whole blood in 15 minutes. A mobile phone is used to power and control the paper-based RNA extraction and reaction; analyze the fluorescent readout indicating viral load; and store the results in the cloud where they can be accessed by a physician. The \$10 test will be broadly applicable for infectious disease diagnosis at the point-of-care.

2.12.3.2 Wearable mHealth system to improve therapy for knee osteoarthritis

Knee osteoarthritis (OA) is a leading cause of disability because of pain, stiffness, and decreased range of motion. Studies have shown that too excessive or too limited levels of clinically recommended therapy often increase pain, suggesting that everyone has an optimal treatment level. NIBIB-funded engineers have developed a flexible wearable system with one sensor attached to the knee sleeve and a second sensor under the foot insole. The system will gather and assess a patient's movement biomechanics that affect pain, quality of life, and rehabilitation progression; this will generate clinical data that will enable the development of personalized OA therapy.

2.12.3.3 Smartphone-based test to diagnose anemia

More than 1.6 billion people have anemia, which increases risk of maternal and infant mortality and impairs cognition in children and adults. Inflammation and iron and B vitamin deficiency each cause anemia, and incorrect treatments may exacerbate the condition. NIBIB-funded researchers are developing AnemiaPhone to assess inflammation, B vitamin, and iron status in one test. A smartphone accessory analyzes a drop of blood on a test strip. The phone camera captures and quantitates the results, which are catalogued so healthcare workers can administer the correct treatment to everyone. The technology is designed to perform in remote settings where anemia is a persistent, debilitating health problem.

2.12.3.4 Mobile device to avoid heart congestion hospitalization

Atrial fibrillation (AF) and congestive heart failure (HF) are common conditions that frequently occur together and often result in hospitalizations when patients experience shortness of breath. Early warning of congestion would allow cardiologists to adjust patient medications and avoid the need for hospitalization. NIBIB scientists are developing smartphone and smart wearable devices for

monitoring patients with AF and HF for early stages of worsening heart congestion. The technology will consist of a smart wrist band and smart ring that will detect heartbeat frequency and amplitude changes that are indicative of impending heart congestion. The data will be submitted by smart phone to cardiologists enabling therapy adjustments to avoid hospitalization and significantly reduce progression to heart failure and the associated morbidity, mortality, and expense.

2.13 Glossary of Terms

- **Acoustic radiation force impulse imaging**

An imaging technique that shoots short pulses of ultrasound at targeted tissues and then monitors the tissue response in the form of shear waves that can be measured and displayed as elastography images. These measurements and images can be used to diagnose or monitor the possible presence of diseased or cancerous tissue, based on the measured stiffness properties of tissues such as breast or liver where areas of increased stiffness may indicate the presence of tumors, fibrosis, scar tissue, and other types of disease or damage.

- **Angiography**

A diagnostic X-ray imaging procedure used to see how blood flows through the blood vessels and organs of the body. This is done by injecting special dyes, known as contrast agents, into the blood vessel and using X-ray techniques such as fluoroscopy to monitor blood flow. Examples include coronary angiography (heart), cerebral angiography (brain), and peripheral angiography (hands, arms, feet and legs).

- **Artificial intelligence (AI)**

A feature where machines learn to perform tasks, rather than simply carrying out computations that are input by human users. Early applications of AI included machines that could play games such as checkers and chess, and programs that could reproduce language.

- **Biocompatibility**

A measure of how a biomaterial interacts in the body with the surrounding cells, tissues and other factors. A biomaterial is considered to have good biocompatibility if it does not generate a vigorous immune response, resists build-up of proteins and other substances on its surface that would hinder its function, and is resistant to infection.

- **Bioengineering**

The application of concepts and methods of engineering, biology, medicine, physiology, physics, materials science, chemistry, mathematics, and computer

sciences to develop methods and technologies to solve health problems in humans.

- **Bioinformatics**

The branch of biology that is concerned with the acquisition, storage, display and analysis of biological information. Analysis of biological information includes statistical and computational methods to model biological processes.

- **Biomaterial**

Any matter, surface, or construct that interacts with biological systems. Biomaterials can be derived from nature or synthesized in the laboratory using metallic components, polymers, ceramics, or composite materials. Medical devices made of biomaterials are often used to replace or augment a natural function. Examples include heart valves, hip replacements, and materials used regularly in dentistry and surgery.

- **Biomedical imaging**

The science and the branch of medicine concerned with the development and use of imaging devices and techniques to obtain internal anatomic images and to provide biochemical and physiological analysis of tissues and organs.

- **Biomimetics**

Using biological form and function seen in nature to inspire the design of solutions to engineering problems.

- **Bioreactor**

A manufactured or engineered device that provides an environment that supports biological processes. Many bioreactors are used to grow cells or tissues for use in tissue engineering.

- **Biosensors**

A device that uses biological material, such as DNA, enzymes and antibodies, to detect specific biological, chemical, or physical processes and then transmits or reports this data.

- **Blood-brain barrier**

A highly selective, semi-impermeable boundary that divides the brain from the rest of the body. It allows the passage of vital molecules through specialized transport proteins and diffusion mechanisms.

- **Brachytherapy**

A form of radiation therapy in which one or more small radioactive sources is placed in or adjacent to an area requiring treatment. The dose rate and

longevity of the radiation source is chosen to reflect the treatment plan and whether the radioactive material is left in place temporarily or permanently. A key feature of brachytherapy is that the radiation affects only a very localized area around the radiation source. Brachytherapy is commonly used to treat prostate, cervical and breast cancers.

- **Brain-Computer Interface**

A system that uses the brain's electrical signals to allow individuals with limited mobility to learn to use their thoughts to move a computer cursor or other devices like a robotic arm or a wheelchair.

- **Cell reprogramming**

Changing the function of a cell using chemical, protein or even mechanical force. Most commonly, a cell, like a skin cell, may be treated with protein factors that reprogram it to become a stem cell that can then be reprogrammed, with various protein or chemical factors, to function as a different type of cell such as a liver, heart or nerve cell.

- **Chemical gradient**

The amount of a chemical changes over a specified distance, generally increasing from a lower to higher amount. The gradual increase in the amount of a chemical drives many processes in our body that allow cell growth.

- **Clinical decision support system**

An interactive software-based system designed to assist physicians and other health professionals as well as patients with diagnostic and treatment decisions and reminders. The system compiles and analyzes medical information from raw data, health observations, and other medical information sources.

- **Computational modeling**

The use of mathematics, statistics, physics and computer science to study the mechanism and behavior of complex systems by computer simulation. A computational model contains numerous variables that characterize the system being studied. Simulation is done by adjusting these variables and observing how the changes affect the outcomes predicted by the model.

- **Computed tomography**

A computerized X-ray imaging procedure in which a narrow beam of X-rays is aimed at a patient and quickly rotated around the body, producing signals that are processed by the machine's computer to generate cross-sectional images—or "slices"—of the body. These slices are called tomographic images and contain more detailed information about the internal organs than conventional X-rays.

- **Contrast agent**

A substance used to enhance the imaged appearance of structures, processes or fluids within the body in biomedical imaging.

- **COVID-19 RT-PCR test**

The COVID-19 RT-PCR test is a real-time reverse transcription polymerase chain reaction test for the qualitative detection of nucleic acid from SARS-CoV-2.

- **Deep brain stimulation**

A neurosurgical treatment utilizing a neurostimulator placed in the brain to deliver electrical signals to specific parts of the brain to help control unwanted movements such as in Parkinson's disease or regulate the firing of neurons in the brain to help control the symptoms of disorders such as epilepsy or depression.

- **Deep learning (DL)**

A form of machine learning that uses many layers of computation to form what is described as a deep neural network, capable of learning from large amounts of complex, unstructured data. Deep neural networks are responsible for voice-controlled virtual assistants as well as self-driving vehicles, which learn to recognize traffic signs.

- **Drug delivery systems**

Engineered technologies for the targeted delivery and/or controlled release of therapeutic agents.

- **Elastography**

A medical imaging technique that measures the elasticity or stiffness of a tissue. The technique captures snapshots of shear waves, a special type of sound wave, as they move through the tissue. The stiffness of the tissue gives information about the possible presence of disease. For example, tumors are harder than the surrounding normal tissue and disease livers are stiffer than healthy ones.

- **Electroencephalography (EEG)**

The recording of electrical activity along the scalp resulting from current flowing within the neurons of the brain. EEG can be used to diagnose epilepsy and other disorders associated with altered brain electrical activity.

- **Electromagnetic radiation**

A kind of radiation including visible light, radio waves, gamma rays, and X-rays, in which electric and magnetic fields vary simultaneously. The different forms are differentiated by their wavelength and energy. For instance, visible light has relatively long wavelengths and less energy compared to X-rays or gamma rays with short wavelengths and high energy.

- **Electroporation**

Application of an external electrical field to increase the permeability of the cell membrane. It is usually used in molecular biology as a way of introducing some substance into a cell such as a drug, protein, or piece of DNA that can change the cell's function.

- **Endoscope**

A thin illuminated flexible or rigid tube-like optical system used to examine the interior of a hollow organ or body cavity by direct insertion. Instruments can be attached for biopsy and surgery. Similar technology is used in a laparoscope.

- **Exoskeleton**

The external skeleton that supports and protects an animal's body in contrast to the bones of an internal skeleton. Rehabilitation engineers have used this design in nature to develop exoskeletons that attach to the outside of the body and assist individuals with functions like arm and leg movement.

- **Extracellular matrix (ECM)**

The ECM is a collection of extracellular molecules secreted by support cells that provides structural and biochemical support to the surrounding cells.

- **Extracellular vesicles**

Extracellular vesicles (EVs) are nanosized, membrane-bound vesicles released from cells that can transport cargo—including DNA, RNA, and proteins—between cells as a form of intercellular communication. For example, EVs released from healthy cells can carry DNA, RNA or proteins that help to direct repair of damaged tissues. EVs released from tumor cells can carry DNA, RNA, and proteins that act to help the tumor to metastasize to other tissues.

- **Fluorescence**

The emission of light by a substance that has absorbed light or other electromagnetic radiation. The absorbed and emitted light are usually different wavelengths and therefore produce different colors.

- **Fluorophore**

A fluorescent chemical compound that can re-emit light upon light excitation. Fluorophores are usually bonded to a molecule serving as a marker to stain tissues, cells, or materials in methods including fluorescent imaging and spectroscopy.

- **Focused ultrasound**

A non-invasive therapeutic technique that directs ultrasonic waves to a specific location.

- **Focused ultrasound blood-brain barrier disruption**

A non-invasive technology that uses high-frequency sound waves and microbubbles to reversibly open the blood-brain barrier. The ultrasound waves are emitted from a device called a transducer.

- **Functional magnetic resonance imaging (fMRI)**

An MRI-based technique for measuring brain activity. It works by detecting the changes in blood oxygenation and flow that occur in response to neural activity—when a brain area is more active it consumes more oxygen and to meet this increased demand blood flow increases to the active area. fMRI can be used to produce activation maps showing which parts of the brain are involved in a particular mental process.

- **Gamma ray**

Electromagnetic radiation of the shortest wavelength and the highest energy.

- **Glycosaminoglycans (GAGs)**

GAGs are a main component of the ECM and are linked to the fibrous proteins in the ECM which include collagen, elastin, fibronectin, and laminin.

- **Haptic technology**

A technology that provides the sense of touch to the user through forces, vibrations or motions. For medical procedures, haptic interfaces can improve minimally-invasive surgery by relaying the sense of pressure and touch through the instruments used by the surgeon. Haptic technology has been introduced into the design of prosthetics to provide sensory feedback to the user.

- **Hydrogel**

A biomaterial made up of a network of polymer chains that are highly absorbent and as flexible as natural tissue. Hydrogels have a number of uses including as scaffolds for tissue engineering, as sustained release drug delivery systems, and as biosensors that are sensitive to specific molecules such as glucose.

- **Image-guided robotic interventions**

Medical procedures, primarily minimally invasive surgery, performed through a small incision or natural orifice using robotic tools operated remotely by a surgeon with visualization by devices such as cameras small enough to fit into a minimal incision.

- **Immunofluorescence**

A biological staining technique in which the fluorescent signaling molecule is bound to an antibody to a protein of interest. When the “fluorescently tagged”

antibody binds to its target protein the site or distribution of that protein can be visualized with the appropriate imaging devices.

- **Implantable devices**

Man-made medical devices implanted in the body to replace or augment biological functions. Such devices range from those that provide structural support, such as a hip replacement to those that contain electronics, such as pacemakers. Some implants are bioactive such as a drug-eluting stent used to open a blocked artery.

- **In vitro**

A laboratory experiment or process performed in a test tube, culture dish, or elsewhere outside a living animal.

- **Induced pluripotent stem cell (iPSC)**

A stem cell that is formed by the introduction of stem-cell inducing factors into a differentiated cell of the body, typically a skin cell.

- **Ionizing radiation**

A type of electromagnetic radiation that can strip electrons from an atom or molecule—a process called ionization. Ionizing radiation has a relatively short wavelength on the electromagnetic spectrum. Examples of ionizing radiation include gamma rays, and X-rays. Lower energy ultraviolet, visible light, infrared, microwaves, and radio waves are considered non-ionizing radiation.

- **Laparoscope**

A thin, lighted telescope-like viewing instrument that is inserted through a small incision or natural orifice to examine and operate on abdominal and pelvic structures. Similar technology is used in an endoscope. “Laparo” is derived from the Greek root for abdomen and pelvis; however, devices similar to laparoscopes are used for other parts of the body such as thoroscopes for chest surgery.

- **Laser Doppler imaging**

A technique used to measure the total local microcirculatory blood perfusion including the perfusion in capillaries, arterioles, venules, and shunting vessels. The technique is based on the emission of a scanning beam of laser light and the Doppler shift that occurs when light particles hit moving blood cells.

- **Machine learning (ML)**

An approach to AI in which a computer algorithm (a set of rules and procedures) is developed to analyze and make predictions from data that is fed into the system. Machine learning-based technologies are routinely used every day, such as personalized news feeds and traffic prediction maps.

- **Magnetic resonance elastography (MRE)**

A special MRI technique to capture snapshots of shear waves that move through the tissue and create “elastograms” or images that show tissue stiffness. MRE is used to non-invasively detect hardening of the liver caused by chronic liver disease. MRE also has the potential to diagnose diseases in other parts of the body.

- **Magnetic resonance IMAGING (MRI)**

A non-invasive imaging technology used to investigate anatomy and function of the body in both health and disease without the use of damaging ionizing radiation. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects changes in protons found in the water that makes up living tissues.

- **Magnetic resonance spectroscopy (MRS)**

A non-invasive analytic imaging technique used to study metabolic changes in diseases affecting the brain, including tumors, strokes, and seizures. The technique is also used to study the metabolism of other organs. MRS complements MRI as a non-invasive means for the characterization of tissue, by providing measure of the concentration of different chemical components within the tissue.

- **Mammography**

An X-ray imaging method used to image the breast for the early detection of cancer and other breast diseases. It is used as both a diagnostic and screening tool.

- **Mesenchymal stem cells**

A term used to define non-blood adult stem cells from a variety of tissues. However, it is not clear whether mesenchymal stem cells from different tissues are the same.

- **mHealth**

An abbreviation for mobile health, which is the practice of medicine and public health supported with mobile devices such as mobile phones for health services and information.

- **Microbubbles**

Microscopic, preformed bubbles composed of varying materials that enable widespread applications. One application of microbubbles in medicine is as a contrast agent to help obtain clearer ultrasound images.

- **Microfluidics**

A multidisciplinary field including engineering, physics, chemistry and biotechnology involving the design of systems for the precise control and

manipulation of fluids on a small, sub-millimeter scale. Typically fluids are moved, mixed, separated or processed in various ways.

- **Microparticle**

Particles between 0.1 and 100 μm in size. A μm is a micrometer, which is one-millionth of a meter. Man-made microparticles include ceramics, glass, polymers and metals. In biological systems, microparticles are small membrane-bound vesicles derived from cells circulating in the bloodstream. Microparticles are generally 1000 times larger than nanoparticles.

- **Microscopy**

Using microscopes to view samples and objects that cannot be seen with the unaided eye.

- **Minimally invasive surgery**

A surgical procedure typically utilizing one or more small incisions through which laparoscopic surgical tools are inserted and manipulated by a surgeon. Minimally invasive surgery can reduce damage to surrounding healthy tissue, decrease the need for pain medication, and reduce patient recovery time.

- **Molecular imaging**

A discipline that involves the visualization of molecular processes and cellular functions in living organisms. With the inclusion of a biomarker, which interacts chemically with tissues and structures of interest, many imaging techniques can be used for molecular imaging including ultrasound, X-rays, magnetic resonance imaging, optical imaging, positron emission tomography, and single photon emission computed tomography.

- **Morphometry**

The measurement of the form of living systems or their parts. In medicine, morphometry is often used to study changes in brain structure during development, aging and in response to disease. Researchers can measure anatomical features of the brain in terms of shape, mass and volume and derive various measures such as grey matter density and white matter connectivity using neuroimaging techniques and neuroinformatics.

- **Multiphoton microscopy**

An imaging technique that uses two or three-photon excitation of a fluorophore in a specimen. Fluorescence occurs when two or more photons of excitation light are absorbed by the specimen at the same time. Because excitation occurs only where photons coincide, there is reduced phototoxicity and photobleaching and greater depth penetration. Because of the reduced toxicity, the method is ideal for imaging living specimens especially when deep imaging is required.

- **Multiscale modeling**

Multiscale modeling uses mathematics and computation to quantitatively represent and simulate a system at more than one scale while functionally linking the mathematical models across these scales. Biological and behavioral scales include atomic, molecular, molecular complexes, sub-cellular, cellular, multi-cell systems, tissue, organ, multi-organ systems, organism/individual, group, organization, market, environment, and populations.

- **Nanoparticle**

Ultrafine particles between 1 and 100 nanometers in size. The size is similar to that of most biological molecules and structures. Nanoparticles can be engineered for a wide variety of biomedical uses including diagnostic devices, contrast agents, physical therapy applications, and drug delivery vehicles. A nanoparticle is approximately 1/10,000 the width of a human hair. Nanoparticles are generally 1000 times smaller than microparticles.

- **Nanotechnology**

The manipulation of matter with at least one dimension sized from 1 to 100 nanometers. Research areas include surface science, molecular biology, semiconductor physics, and microfabrication. Applications are diverse and include device physics, molecular self-assembly, and precisely manipulating atoms and molecules.

- **Near infrared spectroscopy (NIRS)**

A spectroscopic method that uses the near-infrared region of the electromagnetic spectrum for pharmaceutical and medical diagnostics, typically measurements of blood sugar and blood oxygen levels.

- **Neural networks**

A machine learning approach modeled after the brain in which algorithms process signals via interconnected nodes called artificial neurons. Mimicking biological nervous systems, artificial neural networks have been used successfully to recognize and predict patterns of neural signals involved in brain function.

- **Neuroimaging**

Includes the use of a number of techniques to image the structure and function of the brain, spinal cord, and associated structures.

- **Neuroprosthetics**

A broad discipline of neuroscience and biomedical engineering concerned with developing devices that can substitute a motor, sensory or cognitive

function lost due to injury or disease. Examples encompass a wide range including cochlear implants, visual prosthetics, and brain-computer interfaces for conscious control of movement in paralyzed individuals.

- **Nuclear medicine**

A medical specialty that uses radioactive tracers (radiopharmaceuticals) to assess bodily functions and to diagnose and treat disease. Diagnostic nuclear medicine relies heavily on imaging techniques that measure cellular function and physiology.

- **Oncoprotein**

A protein encoded by an oncogene which can cause the transformation of a cell into a tumor cell if introduced into it.

- **Optical coherence tomography (OCT)**

A technique for obtaining sub-surface images such as diseased tissue just below the skin. For example, ophthalmologists use OCT to obtain detailed images from within the retina. Cardiologists also use it to help diagnose coronary artery disease.

- **Optical imaging**

A technique for non-invasively looking inside the body, as is done with X-rays. Unlike X-rays, which use ionizing radiation, optical imaging uses visible light and the special properties of photons to obtain detailed images of organs and tissues as well as smaller structures including cells and molecules.

- **Perfusable**

The movement of fluid through blood vessels to a cell tissue or an organ, generally referring to blood.

- **Photon**

A particle of light or electromagnetic radiation. The energies of photons range from high-energy gamma rays and X-rays to low-energy radio waves.

- **Piezoelectric crystals**

Crystals in the transducer of an ultrasound device that vibrate when an electric signal is applied, emitting high-frequency sound pressure waves. The crystals are the crucial component of an ultrasound device both producing and detecting the ultrasound waves used to image structures inside of the body.

- **Point-of-care**

Testing and treating of patients at sites close to where they live. Rapid diagnostic tests are used to obtain immediate, on-site results. The success of the concept relies on portable, rapid diagnostic devices that provide results

directly to the user, which allows health care workers in remote areas to test and treat patients at the time of the visit.

- **Polymer**

A large molecule composed of many repeating subunits. Polymers range from familiar synthetic plastics such as polystyrene to natural biopolymers such as DNA. Polymers have unique physical properties, including strength, flexibility, and elasticity.

- **Positron emission tomography (PET)**

PET scans use radiopharmaceuticals to create 3 dimensional images. The decay of the radiotracers used with PET scans produce small particles called positrons. When positrons react with electrons in the body, they annihilate each other. This annihilation produces two photons that shoot off in opposite directions. The detectors in the PET scanner measure these photons and use this information to create images of internal organs.

- **Progenitor cells**

Progenitor cells are cells that are similar to stem cells but instead of the ability to become any type of cell, they are already predisposed to develop into a particular type of cell.

- **Prosthetics**

The design, fabrication, and fitting of artificial body parts.

- **Radiation**

The emission of energy as electromagnetic waves or as moving subatomic particles, especially high-energy particles that cause ionization.

- **Radiopharmaceuticals/radioactive tracers**

Radioactive tracers are made up of carrier molecules that are bonded tightly to a radioactive atom. The carrier molecule is designed to bind to the tissue being examined so that the radioactive atom can be scanned to produce an image from inside the body.

- **Raman spectroscopy**

This technique relies on inelastic scattering of visible, near-infrared, or near-ultraviolet light that is delivered by a laser. The laser light interacts with molecular vibrations in the material being examined and shifts in energy are measured that reveal information about the properties of the material. The technique has a wide variety of applications including identifying chemical compounds and characterizing the structure of materials and crystals. In medicine, Raman gas analyzers are used to monitor anesthetic gas mixtures during surgery.

- **Rapid diagnostic test**

Rapid diagnostic tests (RDTs) are medical diagnostic tests that provide quick results and can be used in various settings. Results are typically indicated in an hour or less. Pregnancy testing is one example of an RDT, producing results within several minutes. RDTs have become a widely used method to detect a range of infections using blood, saliva, or urine samples. Examples of infections for which RDTs have been developed include malaria, strep throat, STDs, and HIV. Reliable and accurate COVID-19 RDTs are a goal of NIBIB's Rapid Acceleration of Diagnostics Tech (RADx Tech) initiative.

- **Regenerative medicine**

A broad field that includes tissue engineering but also incorporates research on self-healing—where the body uses its own systems, sometimes with the help of foreign biological material to rebuild tissues and organs.

- **Rehabilitation engineering**

The use of engineering science and principles to develop technological solutions and devices to assist individuals with disabilities and aid the recovery of physical and cognitive functions lost because of disease or injury.

- **Robotic Surgery**

Surgery performed through very small incisions or natural orifices using thin finger-like robotic tools controlled remotely by the surgeon through a telemanipulator or computer interface.

- **Scaffold**

A structure of artificial or natural materials on which tissue is grown to mimic a biological process outside the body or to replace a disease or damaged tissue inside the body.

- **Sensors**

In medicine and biotechnology, sensors are tools that detect specific biological, chemical, or physical processes and then transmit or report this data. Some sensors work outside the body while others are designed to be implanted within the body. Sensors help health care providers and patients monitor health conditions. Sensors are also used to monitor the safety of medicines, foods and other environmental substances we may encounter.

- **Single photon emission computed tomography (SPECT)**

A nuclear medicine imaging technique using gamma rays. SPECT imaging instruments provide 3 dimensional images of the distribution of radioactive tracer molecules that have been introduced into the patient's body. The 3D images are computer generated from many images of the body recorded at different angles by cameras that rotate around the patient.

- **Spectroscopy**

The branch of science concerned with the investigation and measurement of spectra produced when matter interacts with or emits electromagnetic radiation.

- **Stem cell**

An undifferentiated cell of a multicellular organism that is capable of giving rise to more of the same cell type indefinitely and has the ability to differentiate into many other types of cells that form the structures of the body.

- **Structural biology**

The study of the structure of large biomolecules like proteins and nucleic acids, how the structure relates to the function of the molecule, and how alterations in structure affect function. Various methods such as crystallography are used to gain information about the structure of a molecule. This information is often analyzed with bioinformatics techniques to obtain or solve the structure of the molecule.

- **Structured illumination microscopy (SIM)**

A form of super high-resolution microscopy designed to capture extremely clear images of cells and molecules, even when they are moving quickly. The sophisticated technique uses a number of filters and other light processors to rapidly scan images, combine multiple images, and eliminate out of focus light in order to obtain super-resolution images of cells and subcellular structures in motion.

- **Synchrotron**

A large circular facility/device that accelerates sub-atomic particles in a magnetic field in a circular path that generates electromagnetic radiation with a defined exit (beam line). One type of synchrotron (a synchrotron light source) converts a high-energy beam of electrons into high-energy X-rays that can be used in a number of applications including biomedical imaging.

- **Telehealth**

The use of communications technologies to provide and support health care at a distance.

- **Tesla**

An international unit to describe the strength of a magnetic field.

- **Theranostics**

The relatively experimental science of combining therapy and diagnosis into a single procedure or molecule. Towards this end, bioengineers are building

multi-functional nanoparticles that can be introduced into a patient, find the site of disease, diagnose the condition, and deliver the appropriate, personalized therapy.

- **Tissue engineering**

An interdisciplinary and multidisciplinary field that aims at the development of biological substitutes that restore, maintain, or improve tissue function.

- **Ultrasound**

A form of acoustic energy, or sound, that has a frequency that is higher than the level of human hearing. As a medical diagnostic technique, high frequency sound waves are used to provide real-time medical imaging image inside the body without exposure to ionizing radiation. As a therapeutic technique, high frequency sound waves interact with tissues to destroy diseased tissue such as tumors, or to modify tissues, or target drugs to specific locations in the body.

- **Virion**

A complete, infectious virus particle that exists outside of the host cell.

- **X-rays**

A form of high energy electromagnetic radiation that can pass through most objects, including the body. X-rays travel through the body and strike an X-ray detector (such as radiographic film, or a digital X-ray detector) on the other side of the patient, forming an image that represents the “shadows” of objects inside the body.

Abbreviations

AD:	Alzheimer’s disease
AF:	atrial fibrillation
AI:	artificial intelligence
ARFI:	acoustic radiation force impulse imaging
ATP:	adenosine triphosphate
bCT:	breast computed tomography
CPAC:	cyber-physically assistive clothing
cryo-EM:	cryo-electron microscopy
CT:	computed tomography
dbCT:	dedicated breast computed tomography
DL:	deep learning
DOT:	diffuse optical tomography
DVT:	deep-vein thrombosis
ECM:	extracellular matrix
EEG:	electroencephalography

ER:	endoplasmic reticulum
EVs:	extracellular vesicles
fMRI:	functional magnetic resonance imaging
fNIR:	functional near infrared
GAGs:	glycosaminoglycans
HF:	congestive heart failure
HIFU:	high intensity focused ultrasound
iPSC:	induced pluripotent stem cell
ML:	machine learning
MRE:	magnetic resonance elastography
MRI:	magnetic resonance imaging
MRS:	magnetic resonance spectroscopy
NIRS:	near infrared spectroscopy
NMR:	nuclear magnetic resonance
OA:	osteoarthritis
OCT:	optical coherence tomography
ORC:	origin recognition complex
OSCS:	oversulfated chondroitin sulfate
PALM:	photoactivated localization microscopy
PDB:	Protein Data Bank
PET:	positron emission tomography
POC:	point-of-care
RADx Tech:	Rapid Acceleration of Diagnostics Tech
RDTs:	rapid diagnostic tests
RPM:	remote patient monitoring
SIM:	structured illumination microscopy
SPECT:	single photon emission computed tomography
TDI:	tissue dynamics imaging

Chapter 3

Progress in Viral Imaging by Super-Resolution Fluorescence Microscopy

Stefania Castelletto, PhD,^a and Alberto Boretti, PhD^b

^a*RMIT University, Melbourne, Australia*

^b*Prince Mohammad Bin Fahad University, Al Khobar, Saudi Arabia*

stefania.castelletto@rmit.edu.au

Keywords: broadly neutralizing antibodies (bnABs), fluorescence, fluorescence super-resolution (FSR), green fluorescent protein (GFP), imaging, infection, membrane-proximal external region (MPER), microscopy, photo-activation localization microscopy (PALM), photo-bleaching, photo-toxicity, quantum dots, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), single-molecule switching microscopy (SMSM), spatial resolution, stimulated emission depletion microscopy (STEC), stochastic optical reconstruction microscopy (STORM), temporal resolution, total internal reflection fluorescence (TIRF), viral dynamics

Cell and molecular biologists, virologists, and immunologists need novel technologies to better understand or uncover how inactive viral substances transform into live substances that start an infection. Visualization of the way the virus enters the cell and transports the viral genome needed for its reproduction is of paramount importance to viral studies. There is therefore significant interest in imaging and tracking of viruses at the single virus level. Most current studies on virus imaging are focused on uncovering the mechanism of assembly and cell interaction and infection.

The recent outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has brought even more attention towards the need of imaging virus with the desired resolution to uncover the specific mechanisms associated with the cell infection process. The total dimension of the SARS-CoV-2 virus is 50 to 200 nm (Fig. 3.1). However, the dimension of some of the features of the virus requires a spatial resolution at the nanometer level and

below. These features must be monitored with minimal interference over the relevant time scales. High-resolutions imaging techniques have been applied, however, providing only partial information.




Figure 3.1 Top left: Transmission electron microscope (TEM) image shows SARS-CoV-2. Credit: NIAID. Top right: TEM of SARS-CoV-2 virus particles. Credit: NIAID. Bottom: Colorized scanning electron micrograph of an apoptotic cell infected with SARS-CoV-2 virus particles. The cell is in green and the virus particles are in purple. Credit: NIAID.

In the mechanism proposed in ref. [1] and depicted in Fig. 3.2, a spike protein on the surface of the virus permits the virus access into cells. Receptor binding and protease activation of this spike protein were investigated in ref. [1] by using a technique based on biochemical and pseudovirus entry assays, which is described in ref. [2].

This technique, despite being very insightful to provide a model of the virus cell's entry mechanism, leaves a significant margin of arbitration, and it would

require the support of a direct method to image the actual viral infection process, as well the virus maturation with the necessary spatial and temporal resolution of the process. Likewise, for the development of antivirals of the enhanced safety-to-efficacy profile, it would be necessary to image the details of the virus-to-cell interaction, as it is not yet possible. The question is whether current methods of high spatial resolution imaging could provide such a possibility and what has been done in the space of virus imaging of cells' entry so far that could aid in their future application to SARS-CoV-2.




Figure 3.2 (A) Different stages of SARS-CoV-2 virus entry. (B) Scheme of the 3D structure of the SARS-CoV-2 virus spike. S₁ is the receptor-binding subunit, S₂ the membrane fusion subunit, TM the transmembrane anchor, IC the intracellular tail). (C) Scheme of the 1D structure of the SARS-CoV-2 virus spike S₂. NTD is the N-terminal domain, FP the fusion peptide, HR₁ the heptad repeat, HR₂ the heptad repeat. (D) Sequence comparison of SARS-CoV-2, SARS-CoV-1, and two bat SARS-like coronaviruses spike proteins in a region at the S₁/S₂ boundary. Image from [1]. This open-access article is distributed under Creative Commons Attribution License 4.0(CC BY). Further details are provided in the reference.

Viruses such as HIV, influenza, and SARS-CoV-2 are approximately 100 nm in diameter, thus considerably smaller than cells even if some of them can reach the size of bacterial cells [3]. Due to this small size, super-resolution (SR) imaging techniques as well as high localization for their tracking are necessary. A better knowledge of the mechanisms of virus assembly and infection is needed for treatment by antivirals. The ultimate quest is to image a single virus with high resolution and to track single virus dynamics in living cells, with minimal

interference with the viral process by the imaging technique. To this end, several methods have been adopted which can address either resolution or tracking, either in ensemble measurements or at the single level, mostly *in vitro*. These methods are meant to overcome electron microscopy which provides enough resolution with, however, a lack of dynamic imaging and limited applicability to *in vivo* imaging due to the vacuum operation conditions and/or complex sample preparation.

From the early approaches to image viruses based on electron microscopy such as TEM to today's methods, the world of viruses' imaging has been enriched by fluorescence microscopy approaches, providing a facile imaging methodology and potentials for imaging and tracking viruses in living cells and for a prolonged time without inducing cell damage and consequent death [4]. However, fluorescence microscopy has a limited resolution generally in the 250 nm range, which appears insufficient to image viruses. Recently fluorescence super-resolution (FSR) microscopy methods [5] circumvented the diffraction limit [6] associated with conventional fluorescence microscopy, to provide new insights in the possibility to image viruses surfaces details and follow their dynamics [7]. These techniques, an extension of fluorescence microscopy and alternative to electron microscopy, established over the past twenty years, have permitted the visualization of some virus components and have the potentials for live imaging.

In the specific context of virology studies and live-cell imaging, the most known FSR methods have advantages and disadvantages. Technological progress is needed in labeling, imaging speed, photo-bleaching, depth of imaging.

At present, none of the imaging and tracking techniques can accomplish all the requirements for viruses' studies; however, by learning from the current demonstrations of FSR techniques in specific viruses, further development can be envisioned to achieve some of these quests.

The virology world's major quest of observing *in vivo* and in real-time the interaction of the nanometric scale virions with the molecular cell biology is currently barely within reach. This is due to the different spatial scales involved, the time scale within which current high-resolution imaging can be achieved and the difficulty to image for a long time due to either methods toxicity responsible to cells death or tags photo-bleaching.

Regardless of the possibility of live-cell imaging studies, most to-date virus studies using FSR microscopy and single virus tracking have been carried out only on fixed samples. For virology research *in vivo*, these technologies necessitate in addition to a higher resolution than current capabilities for *in vivo* imaging, also low photo-bleaching and photo-toxicity, higher imaging speed, and the possibility to achieve imaging of the sample with depth penetration and specific labeling. In particular, the acquisition of cells and viruses dynamics in the time scale of ms, requires high imaging speed, while their interaction should allow long tracking times, and this is everything but simple to achieve due to short life fluorescent labels and photo-toxicity leading to cells death.

FSR microscopy techniques recently established [8, 9] comprise among the most notable, single-molecule switching microscopy (SMSM) divided into photo-

activation localization microscopy (PALM) [10, 11]) and stochastic optical reconstruction microscopy (STORM) [12, 13], and stimulated emission depletion microscopy (STED) [14]. We refer the reader for details of these techniques principle of operation and schematics to the many reviews such as the example in refs. [5, 15]. As a common feature, these methods permit us to achieve spatial resolution below 100 nm, enabling the imaging of viruses for the examination of their architectural details and their interactions with the cell constituents throughout virus replication, spread, and infection. These methods have permitted to resolve images better than 20 nm and achieve 10 nm localization accuracy. While high resolution can be achieved with these methods, they suffer from slow acquisition time and/or post-processing of images, as well in some cases of photo-toxicity or photo-bleaching of fluorescent tags that make volumetric time elapse imaging of living samples impractical.

To date, only a few demonstrations of the application of the above FSR methods to study the bio-functionalities of viruses even in fixed cells can be accounted for, with the principal focus been human immunodeficiency virus (HIV) [8, 16]. FSR microscopy studies of HIV have been reviewed in refs. [8, 17]. The latest applications of these techniques in HIV-1 may be found in refs. [7, 18]. Other viruses and methodology have been recently implemented. These studies, together with examples applied to Rotavirus [19], Hendra virus [20], VSV-like particles [21], Influenza A virus [22–24], ZIKA virus [25], Herpes simplex virus [26], Ebola virus [27], Nipah virus [28], and Newcastle disease virus [29], while in still limited demonstrations, illustrate the perspective of FSR imaging to bring a better understanding of cell-virus biological processes and their dynamics with nanoscale resolution.

One of the key issues of all FSR microscopy-based methods applied to the virus is the labeling or fluorescence tags. The size of the fluorescent tags is of paramount importance to directly target the biological structures of interest and track cellular processes in specific locations without introducing artifacts. Besides, they must have photophysical properties that are compatible with the microscopy and SR principles described below, and ideally, they should not photo-bleach to provide access to extended time for tracking. As such several tags have been used for fluorescence microscopy of viruses such as covalent labeling, intercalating and lipophilic dyes, for single virus imaging, fluorescent proteins, fluorescent nanoparticles such as quantum dots (QDs) and metal nanoparticles, as discussed in ref. [4]. So far, virions have been conjugated with organic fluorophores or genetically combined to a green fluorescent protein (GFP). An engineered particle with a GFP segment can be bond to a protein of interest associated with another GFP segment [30]. A review of the type of fluorescent-labeled viruses and fluorescence microscopy methods to image them so far is reported in ref. [3].

The advantage of STED microscopy is the direct creation of the image in real-time with a simple acquisition process, without the need of image frame post-processing, which may induce potential post-processing image artifacts. However, achieving high resolution and high speed comes at the expense of photo-toxicity.

When exposing samples with high laser intensities as with the STED-beam, radicals or singlet oxygen can be generated causing photo-bleaching and photo-toxicity in living systems with subsequent cell death. The typical STED laser intensities are in \sim GW cm^{-2} thus creating photo-bleaching and photo-toxicity for biological samples. This drawback has been mitigated by various methods [8] eventually showing the applicability of STED to living cells [31]. Nevertheless, STED microscopy is not suitable for a long period of imaging of live-cell imaging. The maximum temporal resolution of STED-microscopy of 5–10 ms was achieved in the investigation of HIV-1 acceptance into HeLa cells [8], even if at the expense of a reduced field of view.

For HIV-1 to achieve a morphologically mature fully infectious virus particle status, it undergoes a process called maturation with the release of individual proteins. The maturation is a critical step to understand the HIV-1 replication cycle and to develop anti-HIV-1 therapy. The HIV-1 maturation and how the virus evolves into a lipid environment were studied using STED. The study permitted to visualize the protein on the surface of individual HIV-1 particles. The first visualization of the viral envelope (Env, the trimeric viral envelope surface glycoprotein) glycoprotein distribution on the surface- with features of 40 nm of individual HIV-1 particles was achieved with STED using anti-gp120 antibodies as reporters [32, 33]. This study revealed that the maturation was induced by clustering determined by the Gag-interacting Env tail on the virus surface of the Env proteins [32]. STED was able to visualize these proteins on the viruses' surface in different stages as it was not possible with confocal fluorescent microscopy [32].

It was also studied in more detail how the virus assembles in the plasma membranes [7]. The study permitted to determine the mobility of the protein on the surface of individual HIV-1 particles. It was confirmed that during its assembly, HIV-1 includes duplicates of Env, and the main structural protein Gag3. This is a polyprotein firstly accumulating into immature virus particles [16]. To achieve this, STED was combined with another method called fluorescence correlation spectroscopy (FCS). This method is constructed on the correlation analysis of the fluorescence intensity fluctuations of the tagged molecules over time while they diffuse. From the correlation of their intensity fluctuations, it is possible to determine the molecular transit times and their diffusion coefficient. FCS can be combined with STED (known as STED-FCS) where the determination of the molecular diffusion can be achieved with high spatial localization at the level of an individual molecule. STED-FCS also improves temporal resolution [34] to make it more applicable to virus study.

The membrane-proximal external region (MPER) of the HIV-1 Env has been identified as a potential vaccine target [35]. The MPER accessibility is limited making its native structure poorly understood, as such different and exclusive models are explaining the molecular mechanism of MPER used by broadly neutralizing antibodies (bnAbs) to recognize it. Ref. [36] studies the accessibility of antibodies to the native Env MPER on single HIV virions using STED.

Broadly neutralizing antibodies 10E8 and 4E10 Fabs were conjugated with the KK114, the fluorescent probe Abberior STAR RED, to analyze MPER accessibility through STED microscopy in the native Env complex.

STED imaging of fluorescently labeled Fabs reveals a common pattern of native Env recognition for HIV-1 antibodies targeting MPER or the surface subunit gp120. Figure 3.3 presents the model of HIV virions, and Fig. 3.4 the visualization of these HIV virions by STED microscopy super-resolution.

SMSM uses simpler optical setups and provides a higher resolution than STED with 10–20 nm localization precision. It makes use of laser intensities in the $\sim\text{kW cm}^{-2}$, much lower compared to STED. However, photo-switching often requires UV laser irradiation, which can cause pronounced photo-toxicity. Currently, SMSM approaches encompass higher image resolution and lower photo-toxicity if it is compared to the other methods; however, the downfall is the requirement for the acquisition of many camera frames and the use of post-processing algorithms to create a final highly resolved image which limits the temporal speed. SMSM techniques in general feature a very high spatial resolution at the expensed of reduced imaging speed due to the acquisition of thousands of photo-switching cycles necessary to build up the final image. Due to a several seconds typical acquisition time associated with SMLM, the technique appears less suitable for live-cell imaging while it is better applicable to fixed samples requiring the highest possible, molecular level resolution.




Figure 3.3 Model for MPER accessibility within native Env complexes based on Cryo-EM reconstructions. The contours in the top image show the exposure of the MPER helix in native Env (green) to 10E8 and no-10E8. The sketches in the bottom show the different Env components. The positions of the neutralizing epitopes for bnAbs used PGT145 (V1/V2), VRC01 and b12 (CD4bs) and 10E8/4E10 (MPER) are also shown. Image from [36]. This open-access article is distributed under Creative Commons Attribution License 4.0 (CC BY). Further details are provided in the reference.




Figure 3.4 (a) MPER Env site visualized by the signal of 10E8-KK114 bound to HIV-1 virions acquired in confocal or STED modes (top and bottom images respectively). (b) STED images of 2G12, 10E8-KK114, 4E10-KK114, and Annexin V-ATTO 647 bound to HIV-1 virions and corresponding pixel areas below. (c) HIV virions incubated with 10E8-KK114 and distribution analysis of Fab STED foci number upon incubation with 2G12 or directly labeled 10E8 and 4E10 Fab-KK114 conjugates. (d) Distribution of Fab STED foci detected on virions. Images from [36]. This open-access article is distributed under Creative Commons Attribution License 4.0(CC BY). Further details are provided in the reference.

PALM microscopy has also demonstrated the ability to observe the virus assembly at the host cells with nanoscale resolution. In particular, PALM has been applied to immune system living host CD4+ T cells. HIV assembly and budding, the part of the processes of new HIV formation in infected host cells, was studied at the plasma membrane of the cells in refs. [16, 18]. It has been implemented so-called live PALM, consisting of combining PALM and total internal reflection fluorescence microscopy (TIRF) [37], with analysis methods based on hidden Markov statistical analyses and Bayesian inference. This approach permitted to achieve a description of the virus formation at the plasma membrane of individual cells, with 50 nm spatial resolution and millisecond temporal resolution. HIV-1 particle assembly at the host cell plasma membrane occurs via thousands of viral

Gag proteins forming particles with a diameter of 100–130 nm. By introducing into the HIV-1 Gag precursor and derivatives a photoactive fluorescent protein mEOS2 to form Gag(i)mEOS2, PALM imaging was achieved.

The modality of assembly for the Nipah virus was for the first time revealed by using an SMSM similar to a STORM combined with TIRF, showing the virus assembly model previously undetermined using biochemical analyses and electron microscopy [28].

Single virus tracking (SVT) is another method to image viruses [38]. While FSR microscopy can provide nanometric resolution in imaging viruses, their trajectory tracking can be achieved without the need for SR methods by simply using wide-field microscopy, TIRF microscopy, confocal microscopy, and spectroscopy. These methods allow for the imaging of virions labeled with photo-stable organic fluorescent dyes or fluorescent proteins and permit tracking their position with highly accurate particle localization in the nanometer range better than the resolution of microscopes images. For example, in ref. [27], Ebola virus dynamic entry and internalization into live cells were visualized by fluorescent virus labeling using SVT at the single virus level. This for the first time permitted to observe that Ebola virus internalization in cells occurs through lipid rafts.

SVT has been combined with FSR microscopy to increase the temporal resolution of PALM and STORM. Combining Single-particle tracking with PALM (known as SPT-PALM) enabled monitoring of the molecular diffusion of single-molecule Gag and tsO45 proteins from the vesicular stomatitis virus G (VSVG) [21].

Finally, the combination of FSR and electron microscopy methods continues to be the object of interest to correlate different SR microscopy methods.

Correlative fluorescence light microscopy and SEM has been applied to a variety of cellular targets, included the influenza virus [22, 24], where 3D STORM and SEM are combined.

Some of the recent demonstrations encompassing the combination of different SR approaches have provided at least partial answers to open questions as an example in the HIV replication [8, 16, 17] and from these experiences, further progress can be envisaged to reveal other viruses, such as the SARS-CoV-2 coronavirus that is now monopolizing research efforts.

In conclusion, FSR methods have largely progressed from the time of their inception, at a current stage of development and deployment which has provided many commercial systems, that are progressively becoming of common use in biomedical imaging laboratories. However, for virus imaging, there is not yet one perfect approach, as the above-described techniques have a unique set of advantages and disadvantages. These approaches are evolving to combine more than one imaging method to mitigate disadvantages and leverage on the respective advantages or simplicity of use. There are open problems associated with FSR methods impeding to reach *in vivo* single virus imaging [4]. In particular, the development of FSR methods for virus imaging, while have reached a high level of resolution ideal for viruses, have been impacted by common open limitations such as accurate labeling, imaging speed, sample depth penetration, photo-bleaching, and photo-toxicity.

Nevertheless, current virology studies employing FSR imaging have contributed to many novel insights even if still achieved in fixed cells environment and *in vitro* cell cultures. As such of their potentials to study the dynamic behavior of viruses' components and their interactions with living cells or tissues environment, is not yet accomplished. The new development of FSR methods has recently seen the combination of STED and STORM (MINFLUX) [39], merging the advantages of both methods. Due to MINFLUX recent application in 3D imaging in fixed and live cells [40], it could be further applied in observing the virus components dynamics in living cells. However, one of the major problems for expanding the use of FSR imaging in live-cells virology is the need for biosafety containment level 3 or 4 (BSL-3 and BSL-4 laboratories), which are not very common. In this regards the development of commercial nano imagers could mitigate safety requirements as well the use of pseudovirus that can be handled in biosafety level 2 laboratories in place of wild-type viruses. Pseudovirus [41], deprived of the certain virulent genome, can only replicate once, and are obtained by combining proteins from the surfaces of other viruses, as an example for Sars-Cov-2 virus with replication-defective HIV or another retrovirus [42], could advance the *in vivo* FSR microscopy application to a virus.

So far from Ebola and HIV-1 viruses studies the key components of the viruses and the cells allowing interaction and internalization to be investigated, can be expanded towards the development of drugs that specifically prevent this interaction.

It can be finally concluded that the above-mentioned techniques could be implemented not only to advance virions' imaging and motion analyses to provide information about biological mechanisms, as it has been shown now in some examples but also to facilitate the development of antiviral therapeutics and vaccines. This seems to be possible at the current stage of development and even better when their full potential could be reached, which is *in vivo* imaging and single-particle tracking could be implemented in cultured cells with different therapeutics.

Abbreviations

FCS:	fluorescence correlation spectroscopy
FSR:	fluorescence super-resolution microscopy
GFP:	green fluorescent protein
HIV:	human immunodeficiency
MPER:	membrane-proximal external region
PALM:	photo-activation localization microscopy
QDs:	quantum dots
SMSM:	single-molecule switching microscopy
SR:	super-resolution
STED:	stimulated emission depletion microscopy
STORM:	stochastic optical reconstruction microscopy

SVT:	single virus tracking
TEM:	transmission electron microscope
TIRF:	total internal reflection fluorescence microscopy
VSVG:	vesicular stomatitis virus G

Disclosures and Conflict of Interest

Author Contributions: Conceptualization, A.B.; Methodology, S.C. and A.B.; Formal Analysis, S.C. and A.B.; Investigation, S.C.; Resources, S.C., and A.B.; Writing–Original Draft Preparation, S.C.; Writing – Review & Editing, S.C. and A.B.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., Li, F. Cell entry mechanisms of SARS-CoV-2. *Proceedings of the National Academy of Sciences* **2020**, *117*, 11727–11734.
2. Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., Li, F. Structural basis of receptor recognition by SARS-CoV-2. *Nature* **2020**, *581*, 221–224.
3. Wang, I.H., Burckhardt, C.J., Yakimovich, A., Greber, U.F. Imaging, tracking and computational analyses of virus entry and egress with the cytoskeleton. *Viruses* **2018**, *10*, 166.
4. Liu, S.-L., Wang, Z.-G., Xie, H.-Y., Liu, A.-A., Lamb, D.C., Pang, D.-W. Single-virus tracking: From imaging methodologies to virological applications. *Chemical Reviews* **2020**, *120*, 1936–1979.
5. Schermelleh, L., Ferrand, A., Huser, T., Eggeling, C., Sauer, M., Biehlmaier, O., Drummen, G.P.C. Super-resolution microscopy demystified. *Nature Cell Biology* **2019**, *21*, 72–84.
6. Abbe, E. Beiträge zur Theorie des Mikroskops und der mikroskopischen Wahrnehmung. *Archiv für mikroskopische Anatomie* **1873**, *9*, 413–468.
7. Chojnacki, J., Waithe, D., Carravilla, P., Huarte, N., Galiani, S., Enderlein, J., Eggeling, C. Envelope glycoprotein mobility on HIV-1 particles depends on the virus maturation state. *Nature Communications* **2017**, *8*, 545.
8. Chojnacki, J., Eggeling, C. Super-resolution fluorescence microscopy studies of human immunodeficiency virus. *Retrovirology* **2018**, *15*, 41–41.
9. Huang, B., Babcock, H., Zhuang, X. Breaking the diffraction barrier: super-resolution imaging of cells. *Cell* **2010**, *143*, 1047–1058.
10. Betzig, E., Patterson, G.H., Sougrat, R., Lindwasser, O.W., Olenych, S., Bonifacio, J.S., Davidson, M.W., Lippincott-Schwartz, J., Hess, H.F. Imaging intracellular fluorescent proteins at nanometer resolution. *Science* **2006**, *313*, 1642.
11. Hess, S.T., Girirajan, T.P.K., Mason, M.D. Ultra-high resolution imaging by fluorescence photoactivation localization microscopy. *Biophysical Journal* **2006**, *91*, 4258–4272.
12. Rust, M.J., Bates, M., Zhuang, X. Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). *Nature Methods* **2006**, *3*, 793–796.

13. Heilemann, M., van de Linde, S., Schüttelpe, M., Kasper, R., Seefeldt, B., Mukherjee, A., Tinnefeld, P., Sauer, M. Subdiffraction-resolution fluorescence imaging with conventional fluorescent probes. *Angewandte Chemie International Edition* **2008**, *47*, 6172–6176.
14. Hell, S.W., Wichmann, J. Breaking the diffraction resolution limit by stimulated emission: stimulated-emission-depletion fluorescence microscopy. *Optics Letters* **1994**, *19*, 780–782.
15. Huang, B., Bates, M., Zhuang, X. Super-resolution fluorescence microscopy. *Annual Review of Biochemistry* **2009**, *78*, 993–1016.
16. Inamdar, K., Floderer, C., Favard, C., Muriaux, D. Monitoring HIV-1 assembly in living cells: Insights from dynamic and single molecule microscopy. *Viruses* **2019**, *11*, 72.
17. Müller, B., Heilemann, M. Shedding new light on viruses: Super-resolution microscopy for studying human immunodeficiency virus. *Trends in Microbiology* **2013**, *21*(10), 522–533.
18. Floderer, C., Masson, J.-B., Boilley, E., Georgeault, S., Merida, P., El Beheiry, M., Dahan, M., Roingard, P., Sibarita, J.-B., Favard, C. Single molecule localisation microscopy reveals how HIV-1 Gag proteins sense membrane virus assembly sites in living host CD4 T cells. *Scientific Reports* **2018**, *8*, 1–15.
19. Willig, K.I., Kellner, R.R., Medda, R., Hein, B., Jakobs, S., Hell, S.W. Nanoscale resolution in GFP-based microscopy. *Nature Methods* **2006**, *3*, 721–723.
20. Monaghan, P., Green, D., Pallister, J., Klein, R., White, J., Williams, C., McMillan, P., Tilley, L., Lampe, M., Hawes, P., et al. Detailed morphological characterisation of Hendra virus infection of different cell types using super-resolution and conventional imaging. *Virology Journal* **2014**, *11*, 200.
21. Manley, S., Gillette, J.M., Patterson, G.H., Shroff, H., Hess, H.F., Betzig, E., Lippincott-Schwartz, J. High-density mapping of single-molecule trajectories with photoactivated localization microscopy. *Nature Methods* **2008**, *5*, 155–157.
22. Kim, D., Deerinck, T., Sigal, Y., Babcock, H., Ellisman, M., Zhuang, X. Correlative stochastic optical reconstruction microscopy and electron microscopy. *PLOS ONE* **2015**, *10*, e0124581.
23. Qin, C., Li, W., Li, Q., Yin, W., Zhang, X., Zhang, Z., Zhang, X.-E., Cui, Z. Real-time dissection of dynamic uncoating of individual influenza viruses. *Proceedings of the National Academy of Sciences* **2019**, *116*, 2577–2582.
24. Kolpe, A., Arista-Romero, M., Schepens, B., Pujals, S., Saelens, X., Albertazzi, L. Super-resolution microscopy reveals significant impact of M2e-specific monoclonal antibodies on influenza A virus filament formation at the host cell surface. *Scientific Reports* **2019**, *9*, 4450.
25. Caldas, L.A., Azevedo, R.C., da Silva, J.L., de Souza, W. Microscopy analysis of Zika virus morphogenesis in mammalian cells. *Scientific Reports* **2020**, *10*, 8370.
26. Bosse, J.B., Hogue, I.B., Feric, M., Thiberge, S.Y., Sodeik, B., Brangwynne, C.P., Enquist, L.W. Remodeling nuclear architecture allows efficient transport of herpesvirus capsids by diffusion. *Proceedings of the National Academy of Sciences* **2015**, *112*, E5725.
27. Jin, C., Che, B., Guo, Z., Li, C., Liu, Y., Wu, W., Wang, S., Li, D., Cui, Z., Liang, M. Single virus tracking of Ebola virus entry through lipid rafts in living host cells. *Biosafety and Health* **2020**, *2*, 25–31.

28. Liu, Q., Chen, L., Aguilar, H.C., Chou, K.C. A stochastic assembly model for Nipah virus revealed by super-resolution microscopy. *Nature Communications* **2018**, *9*, 3050.
29. Laine, R.F., Goodfellow, G., Young, L.J., Travers, J., Carroll, D., Dibben, O., Bright, H., Kaminski, C.F. Structured illumination microscopy combined with machine learning enables the high throughput analysis and classification of virus structure. *eLife* **2018**, *7*, e40183.
30. Kamiyama, D., Sekine, S., Barsi-Rhyne, B., Hu, J., Chen, B., Gilbert, L.A., Ishikawa, H., Leonetti, M.D., Marshall, W.F., Weissman, J.S., et al. Versatile protein tagging in cells with split fluorescent protein. *Nature Communications* **2016**, *7*, 11046.
31. Urban, N.T., Willig, K.I., Hell, S.W., Nägerl, U.V. STED nanoscopy of actin dynamics in synapses deep inside living brain slices. *Biophysical Journal* **2011**, *101*, 1277–1284.
32. Chojnacki, J., Staudt, T., Glass, B., Bingen, P., Engelhardt, J., Anders, M., Schneider, J., Müller, B., Hell, S.W., Kräusslich, H.-G. Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. *Science* **2012**, *338*, 524.
33. Hanne, J., Göttfert, F., Schimer, J.f., Anders-Össwein, M., Konvalinka, J., Engelhardt, J., Müller, B., Hell, S.W., Kräusslich, H.-G. Stimulated emission depletion nanoscopy reveals time-course of human immunodeficiency virus proteolytic maturation. *ACS Nano* **2016**, *10*, 8215–8222.
34. Eggeling, C., Ringemann, C., Medda, R., Schwarzmann, G., Sandhoff, K., Polyakova, S., Belov, V.N., Hein, B., von Middendorff, C., Schönle, A., et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. *Nature* **2009**, *457*, 1159–1162.
35. Molinos-Albert, L.M., Clotet, B., Blanco, J., Carrillo, J. Immunologic insights on the membrane proximal external region: A major human immunodeficiency virus type-1 vaccine target. *Frontiers in Immunology* **2017**, *8*, 1154.
36. Carravilla, P., Chojnacki, J., Rujas, E., Insausti, S., Largo, E., Waithe, D., Apellaniz, B., Sicard, T., Julien, J.-P., Eggeling, C., et al. Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions. *Nature Communications* **2019**, *10*, 78.
37. Fish, K.N. Total internal reflection fluorescence (TIRF) microscopy. *Current Protocols in Cytometry* **2009**, Chapter 12, *50*, 12.18.1–12.18.13.
38. Parveen, N., Borrenberghs, D., Rocha, S., Hendrix, J. Single viruses on the fluorescence microscope: imaging molecular mobility, interactions and structure sheds new light on viral replication. *Viruses* **2018**, *10*(250), 250.
39. Balzarotti, F., Eilers, Y., Gwosch, K., Gynnå, A., Westphal, V., Stefani, F., Elf, J., Hell, S. Nanometer resolution imaging and tracking of fluorescent molecules with minimal photon fluxes. *Science* **2017**, *355*(6325), 606–612.
40. Gwosch, K.C., Pape, J.K., Balzarotti, F., Hoess, P., Ellenberg, J., Ries, J., Hell, S.W. MINFLUX nanoscopy delivers 3D multicolor nanometer resolution in cells. *Nature Methods* **2020**, *17*, 217–224.
41. Li, Q., Liu, Q., Huang, W., Li, X., Wang, Y. Current status on the development of pseudoviruses for enveloped viruses. *Reviews in Medical Virology* **2018**, *28*(1), e1963.
42. Huang, S.-W., Tai, C.-H., Hsu, Y.-M., Cheng, D., Hung, S.-J., Chai, K.M., Wang, Y.-F., Wang, J.-R. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development. *Biomedical Journal* **2020**, *43*(4), 375–387.

Chapter 4

Ultra-Rapid Detection of SARS-CoV-2 in Public Workspace Environments

Ozlem Yaren, PhD,^a Jacquelyn McCarter,^a Nikhil Phadke, PhD,^{b,c} Kevin M. Bradley,^a Benjamin Overton,^a Zunyi Yang, PhD,^{a,d} Shatakshi Ranade, MSc,^c Kunal Patil,^c Rishikesh Bangale, MSc,^c and Steven A. Benner, PhD^{a,d}

^aFoundation for Applied Molecular Evolution, Alachua, Florida, USA

^bGenePath Diagnostics Inc., Ann Arbor, Michigan, USA

^cGenePath Diagnostics India Pvt. Ltd., Pune, Maharashtra, India

^dFirebird Biomolecular Sciences LLC, Alachua, Florida, USA

oyaren@ffame.org, sbenner@ffame.org

Keywords: antivirals, asymptomatic carrier, backward internal primer (BIP), coronaviruses, detection, displaceable probe (DP), DP-RT-LAMP, ease of use, field-deployable, forward internal primer (FIP), heat-inactivated virus isolate, limit of detection (LOD), loop primers, Middle East Respiratory Syndrome (MERS), multiplex detection, nasopharyngeal (NP), pandemic, quantitative polymerase chain reaction (qPCR), reverse transcription loop-mediated isothermal amplification (RT-LAMP), sample manipulation, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), sensitivity, testing, viral transport medium (VTM)

4.1 Introduction

Once again, the world is facing a coronavirus pandemic, this time from SARS-CoV-2 that emerged in Wuhan, China in late 2019 [1]. Previous coronaviral threats include the SARS coronavirus that emerged in southern China in 2003 as the causative pathogen of severe acute respiratory syndrome [2, 3], and a coronavirus that causes Middle East respiratory syndrome (MERS) [4–6]. However, unlike these homologous coronaviruses, SARS-CoV-2 creates a remarkable range of medical outcomes, from lethality to mild (or no) symptoms in infected

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

individuals [7, 8]. Further, it appears to be transmissible via asymptomatic carriers. This, in turn, has caused economic disruption across the globe that is measured in the trillions of dollars [9].

At present, no single event seems likely to resolve this pandemic cleanly. Coronaviruses have generally been poor targets for vaccines [10, 11], although novel routes may make this view obsolete [12]. Antivirals that are effective against other viruses [13] may have activity against SARS-CoV-2 [14], but their ability to manage the pandemic remain in doubt. Treatments that mitigate disease symptoms may save lives, but are not likely to be effective at preventing virus spread [15, 16].

All of these factors create an urgency for tests that identify, in minutes, low- or asymptomatic infected individuals as they enter public spaces, such as workspaces, schools, points of entry, and commercial business establishments. To be useful, such tests must (a) require no sample transport, (b) require minimal sample manipulation, (c) can be performed by unlicensed individuals, (d) return results on the spot in much less than 1 h, and (e) cost no more than a few dollars. They cannot involve RNA extraction or other sample preparation steps found in assays typically used in reference laboratories.

Such specs are demanding. However, the demands are mitigated by the fact that to meet its societal purpose, the test need not be ultra-sensitive. To identify carriers who have the potential to infect individuals in public spaces, tests need only be sensitive enough to catch perhaps 10^4 – 10^5 virions per sample from the nasal or oral cavities. While these numbers remain to be better defined (and on-site tests are likely to help to define them), it is clear that the necessary speed, simplicity, and frugality can be more easily obtained by trading off unneeded sensitivity. False positives are managed by re-testing. While false negatives remain (either by failure of low resource sampling or failure of the test itself), the absence of a work-place test effectively makes all untested low- or asymptomatic carries “false negatives”.

Using various nucleic acid based architectural innovations, we have developed a variety of kits that meet these specs with untrained and unlicensed users outside of traditional laboratory settings, including in the field [17–19]. These have focused on detecting environmental pathogens, including detecting arboviral RNA in infected insects and ticks [20] since these require no regulatory supervision. We have established many collaborations, including TrakItNow (which builds mosquito traps) [21], immediate care facilities [22], LynxDx in Ann Arbor, MI, and Achira Labs in Bangalore, India [23].

Here, we report the application of these architectures to the detection of the SARS-CoV-2 coronavirus in nasal and oral cavity samples. The architectures that we report here:

- a. Operate on dry swabbed samples, without extensive sample preparation,
- b. Require no temperature cycling, and do not require expensive instruments,
- c. Have ~\$3.00 in disposable costs, and therefore are routinely usable,
- d. Produce an easily read signal in less than 30 min,

- e. Have limits of detection of ~ 200 viral RNA per assay when minimal sample preparation was sought, and
- f. Are easy to run, not requiring a trained medical professional.

4.2 Material and Methods

4.2.1 Primers and Displaceable Probes for Displaceable Probe RT-LAMP

RT-LAMP primers were designed as described previously [17, 18]. The primers and displaceable probes for displaceable probe RT-LAMP (DP-RT-LAMP) primers and strand displaceable probes were purchased from Integrated DNA Technologies (IDT, Coralville, IA). Strand-displaceable probes were 5'-labeled with Iowa Black-FQ (IBFQ) and 3'-labeled with FAM. For multiplexed LAMP, internal control probes targeting the human RNase P gene were 5'-labeled with IBFQ and 3'-labeled with JOE. The duplex segment of the displaceable probes was screened against viral and human genomic overlaps (see Table S1 in S1 File).

4.2.2 DP-RT-LAMP Assay

12.5 μL of 2X WarmStart LAMP master mix (NEB) was combined with 2.5 μL of 10X LAMP primer set, 1 μL of excess B3 primer (300 μM), 0.2 μL of dUTP (100 mM, Promega), 0.5 μL of Antarctic Thermolabile UDG (1U/ μL , NEB), 0.5 μL of RNase inhibitor (40U/ μL , NEB), and 8 μL of sample (consisting of either heat-inactivated virus or nasal/saliva samples spiked with heat-inactivated virus). No template control used nuclease-free water to replace the sample.

10X LAMP primer set consists of 16 μM each of FIP and BIP, 2 μM each of F3 and B3, 5 μM LF (or LB for CoV2-v2-4 set), 4 μM LB (or LF for CoV2-v2-4 set), 150 nM quencher-bearing probe, and 100 nM of fluorophore-bearing probe.

Reactions were monitored in real-time using either a LightCycler[®] 480 (Roche Life Science, US) or a Genie[®] II (Optigene, UK) instrument. 8-strip PCR tubes were first incubated at 55°C for 10 min followed by incubation at 65°C for 45–60 min. During the 65°C incubation, fluorescence signal was recorded every 30 s using FAM/SYBR channel of the instrument.

End-point observation of the fluorescence signal was enabled by blue LED light (excitation at 470 nm) through orange filter of SafeBlue Illuminator/Electrophoresis System, MBE-150-PLUS (Major Science, US) or 3D printed observation box (Firebird Biomolecular Sciences, US).

4.2.3 Sample Preparation

Heat-inactivated SARS-CoV-2 isolate. Authentic SARS-CoV-2, isolate USA-WA 1/2020, was obtained through BEI Resources (cat no. NR-52286, 1.16×10^9 genome equivalents/mL). This virus has been inactivated by heating at 65°C for 30 min.

Target dilutions were made in 1 mM Na citrate pH 6.5, 0.4 U/ μ L RNase inhibitor (NEB, Ipswich, MA) and aliquots (100 μ L) were stored at -80°C . This material was used for LOD experiments and spiking nasal swabs and saliva samples to create a positive control.

Nasal swab testing. CleanWIPE Swab, 3" Semi-Flexible bulb tip (HT1802-500, Foamtec International) was used for nasal sampling. Each nostril was swabbed for at least 10 s using the same swab. Swab was placed in sterile 15 mL falcon tube and stored at 4°C until processing. Swabs were processed within 1 h.

Nasal swabs were eluted in 200 μ L of buffer solution (1 mM Na citrate pH 6.5, 2.5 mM TCEP, 1 mM EDTA, 10 mM LiCl, 15% Chelex-100) by brief vortexing. Swabs were then removed and elution solution was briefly spun down. An aliquot of the elution was added to DP-RT-LAMP assay.

Saliva samples. About 1 mL of saliva was collected in sterile 5 mL falcon tube and stored at 4°C until processing and samples were processed within 1h. A suspension (100 μ L) of 15% Chelex-100 in 1.6 mL microcentrifuge tube was spun down briefly and supernatant was removed. To this was added 100 μ L of saliva mixed with 1 μ L of concentrated sample preparation solution (0.1 M Na citrate pH 6.5, 1M LiCl, 0.25 M TCEP, 0.1 M EDTA). Each sample was briefly vortexed and spun down to settle the Chelex-100. An aliquot of the sample was added to DP-RT-LAMP assay.

Collecting saliva on Q-paper. Q-paper was first dipped into saliva samples and soaked for 5 s, then air dried for 5 min. Saliva soaked Q-paper was directly inserted into 50 μ L of DP-RT-LAMP mixture (see S1 File for Q-paper preparation).

Evaluation of clinical samples. Nasopharyngeal (NP) swabs, previously stored in VTM media, were eluted in 200 μ L buffer solution (1 mM Na citrate pH 6.5, 2.5 mM TCEP, 1 mM EDTA, 10 mM LiCl, 15% Chelex-100) by brief vortexing. Swabs were then removed and elution solution was briefly spun down. 5 μ L of sample was added to DP-RT-LAMP assay.

Reactions were monitored in real-time using Rotor Gene Q (Qiagen, US). FAM and JOE channels were used for SARS-CoV-2 and RNase P detection, respectively.

Ethical statement. Nasal and Saliva samples. For contrived samples, nasal and saliva samples were collected from healthy volunteers and spiked with heat-inactivated virus. Samples were collected according to IntegReview IRB procedure (protocol number: 2020001). Study was advertised through written communication and samples were accepted from adult volunteers (18 years old or older) during the month of September in 2020. Since it is not a clinical evaluation of active infection, study group consisted of only adults. Each participant was provided with information sheet explaining the details of the study along with the consent form to sign. Participant signed the form in the presence of a witness at the start of the study and a copy of the informed consent form has been provided to the participant.

All volunteers were screened for fever immediately prior to donating samples. Criteria that would exclude potential volunteers from participating include fever and signs of illness not within the nature of seasonal allergies (that is, respiratory congestion in combination with a fever). Exclusion from one round

of sample collection will not disqualify a volunteer from future participation or sample collection. Upon each round of collections, the inclusion/exclusion criteria evaluation will be performed, and any volunteers that qualify may participate, even if they have been excluded from previous collections. Participants contributed to this study may not be considered representative of a larger population. Table of relevant demographic details are provided below. Collected samples were then spiked in with heat-inactivated SARS-CoV-2 virus at varying concentrations and remaining of the samples were disposed in a biohazard bag containing 10% bleach at the end of the experiment.

IRB procedure 2020001

Gender	Race	Age	Gender	Race	Age
Male	Caucasian	25	Male	Asian	46
Male	Hispanic	44	Female	Caucasian	40
Male	Caucasian	43	Female	Caucasian	33
Male	Asian	51	Female	Hispanic	44
Male	Caucasian	51	Female	Caucasian	65
Male	Asian	45	Female	Caucasian	38
Male	Caucasian	27	Female	Hispanic	27

In addition to IRB approved saliva collection, some of the saliva samples were purchased from BioIVT (human saliva, 5 mL) and received as de-identified. Donor information sheet with gender, age and race was provided (see table below).

BioIVT human saliva

Gender	Race	Age	Gender	Race	Age
Male	Caucasian	35	Female	Caucasian	49
Male	Asian	29	Female	Hispanic	30
Male	Caucasian	31	Female	Caucasian	38
Male	Asian	28	Female	Caucasian	31
Male	Caucasian	33	Female	Hispanic	29
Male	Caucasian	27	Female	Hispanic	31
Male	Caucasian	30	Female	Caucasian	28
Male	Caucasian	35	Female	Asian	25
Male	Caucasian	27	Female	Caucasian	24
Female	Hispanic	26	Female	Hispanic	22

Clinical nasopharyngeal (NP) samples collected by GenePath Dx. Samples were collected and tested under a protocol reviewed and approved by GenePath Dx/Causeway Healthcare's Independent Ethics Committee/Institutional Review

Board which is registered with the Central Drugs Standard Control Organization (CDSCO), Office of Drugs Controller General (DCG), Directorate General of Health Services, Ministry of Health and Family Welfare (MoHFW), Government of India (with registration number ECR/225/Indt/MH/2015). Nasopharyngeal and oropharyngeal swabs for routine Covid-19 testing were collected either at a drive-through facility or during a home visit. The demographics included individuals of all ages who were referred for Covid-19 testing by their physician on account of symptoms or potential exposure, or individuals who requested self-testing on account of symptoms, exposure or need for a test result for travel or other similar purposes. Individuals availing of these facilities were explained about the potential for use of leftover samples for test improvement, new test development, and statistical analysis in a manner where no personally identifiable information would be revealed. All individuals were informed that this work had been approved by a government approved ethics committee and no information from these tests would be communicated back to them. Verbal consent was obtained from individuals, who expressed interest in participating in this work, prior to sample collection. Samples collected between June–September 2020 were used in this work. The tubes of individuals who consented to such use of their samples were marked with an additional symbol. Consent was witnessed by the second collector from the collection team. Only samples from individuals who could directly give consent (i.e., no minors) were collected. There were no other inclusion or exclusion criteria. The samples may be considered as a representative of the larger population in the geographical area that they were collected in but cannot be considered a representation of a larger global population. Within the testing laboratory, samples are only marked with codes that cannot be decoded by the testing laboratory. Matching of samples by the reference method and novel method is only made through the codes and no individual names and IDs are available.

GenePath Dx samples from India

Gender	Age	Gender	Age
Female	26	Female	75
Male	34	Female	30
Female	29	Male	41
Female	53	Male	32
Male	79	Male	41
Male	26		

4.2.4 Multiplexed DP-RT-LAMP to Detect SARS-CoV-2 and RNase P (Internal Control)

For simultaneous detection of virus and internal control, total amount of LAMP primers was kept the same and half the amounts of primer mix was used

for virus and internal control detection. For proof of concept, varying amounts of heat-inactivated virus was first tested in the presence of human RNA (440 copies).

Nasal and saliva samples were treated with an additional heat step (95°C for 5 min) after spiked with inactivated virus and treated with buffers described in sample preparation section. Multiplexed LAMP was analyzed on LightCycler® 480 (Roche Life Science, US) using FAM channel (483–533) for SARS-CoV-2 detection and JOE channel (558–610) for RNase P detection.

4.3 Results

4.3.1 Assay Architecture

In recent years, reverse transcription loop-mediated isothermal amplification (RT-LAMP) has become an alternative to RT-PCR due to its high sensitivity and specificity, its tolerance for inhibitory substances, and operation at constant temperatures. Together, these lower assay complexity and cost, making LAMP often considered for COVID-19 diagnostics [24–26].

In its classical form, RT-LAMP uses six primers binding eight distinct regions within a target RNA. It runs at constant temperatures ranging from 62°C to 72°C, and uses a reverse transcriptase and a DNA polymerase with strong strand displacing activity (e.g., Bst DNA polymerase). Initially, forward and backward internal primers (FIP and BIP), with outer forward and backward primers (F3 and B3), form a double loop structure. This structure facilitates exponential amplification by formation of multiple repeating loops and improvement in amplification time is usually obtained by additional loop primers (LB and LF) [27].

Classical LAMP generates signals by the precipitation of the magnesium salt as one of its byproducts, pyrophosphate; the turbidity from this precipitation is detected. Alternatively formation of high molecular weight amplicons allows an intercalating dye to create a fluorescent signal [28, 29] or non-fluorescent signal [30, 31]. Alternatively, the pH change arising during the amplification is detected by the change in the color of an indicator [32–34].

None of these are well suited for workplace detection of pathogen RNA, such as that from SARS-CoV-2. These detection architectures can easily be deceived by off-target amplicons, and are therefore susceptible to generation of false-positive results. Confirming the nature of the amplicon by measuring melting temperatures, very useful in PCR, is difficult with LAMP amplicons whose lengths mature over the time of the process, and where off-target amplicons have unpredictable melting temperatures [35–37]. Assimilating probes have been introduced to allow the high molecular weight amplicon to contain a fluorophore, where the assimilation separates the fluorophore from a fluorescence quencher [38].

To manage these issues, we offer an alternative architecture that exploits a displaceable probe (DP). This is a short oligonucleotide carrying a 3'-fluorophore

that is displaced from a complementary oligonucleotide as the desired amplification proceeds. Complementary oligonucleotide has a 5'-quencher, and carries a tag that is a primer that binds to one of the loops in the LAMP double loop structure (Fig. 4.1A). Thus, each probe is delivered to the amplification mixture as a target-sequence-independent double-strand probe region and a single-stranded target-priming region. This architecture allows to measure the fluorescent signal in real-time (Fig. 4.1B). Alternatively, end-point visualization of the fluorescent signal can be realized through an orange filter by exciting the fluorophore with blue LED (Fig. 4.1C).




Figure 4.1 Displaceable probe LAMP to detect SARS-CoV-2. (A) Classical RT-LAMP utilizes six primers hybridizing to eight regions within the viral genome. These primers form a dumbbell structure through self-hybridization of FIP and BIP and addition of two loop primers improves the amplification rate. To allow simultaneous detection of several targets in real-time, displaceable probe architecture was employed by tagging one of the loop primers with a quencher and supplementing with a partially complementary probe containing a fluorophore tag. (B) Positive results can be analyzed in real-time and process manifests itself as sigmoidal curve as it would be in RT-qPCR using TaqMan probes. (C) End-point fluorescence is then observed through orange filter coupled with blue LED (exc. 470 nm, Firebird Biomolecular Sciences LLC, US).

4.3.2 DP-RT-LAMP Assays Using Heat-Inactivated Virus Isolate

We assessed the LOD with heat-inactivated SARS-CoV-2 isolate after running initial test with synthetic RNA (Fig. S1 in S1 File). This was also used to “spike” nasal swabs and saliva samples. Among three conditions tested (Fig S2 in S1 File), the




Figure 4.2 Limit of detection using DP-RT-LAMP primers using heat-inactivated SARS-COV-2 or human RNA (for internal control). (A) Real-time analysis of CoV2-W3 primer set (targeting S gene) with LOD of 10 RNA copies/assay. (B) End-point visualization of LAMP products with primer set CoV2-W3. (C) Real-time analysis of CoV2-v2-4 primer set (targeting N gene) with LOD of 25 RNA copies/assay. (D) Real-time analysis of internal control RNaseP-2 primer set (targeting human RNase P gene) with LOD of 44 copies of human RNA/assay. (E) Time to threshold (Tt) values of each LAMP primer set was determined for each target copy number/assay and similar values were obtained when compared to RT-qPCR test (Ct values were also converted to their corresponding Tt values for convenience).

best sensitivity was achieved with using WS-RTx and excess B3 primer with incubation at 55°C for 10 min followed by incubation at 65°C 50 min. This protocol was used to assess the sensitivity of another SARS-CoV-2 primer set targeting N gene and internal control primer set targeting RNase P. The primer set targeting S gene (CoV2-W3) gave an LOD of 10 copies/assay within 16 min (Fig. 4.2A); the fluorescence signal arising from fluorescence was visible to naked eye (Fig. 4.2B). The primer set targeting the N gene had an LOD of 25 copies/assay within a 12 min (Fig. 4.2C). The primer set targeting the human RNase P gene had an LOD of 44 copies/assay, within a 16 min (Fig. 4.2D). Threshold times were compared to RT-qPCR where N gene and RNase P gene were detected in multiplex format (Yang et al., manuscript in preparation). For this comparison, Ct values from PCR assay were converted to their corresponding Tt values; RT-LAMP was found to be outperforming over multiplex RT-qPCR in terms of assay rapidity (Fig. 4.2E).

4.3.3 Simple Sample Preparation of Nasal Swabs and Saliva Samples

For a test that can be used at the entrance to a public space to identify carriers who present an environmental risk, sample preparation must be minimal, and any instrumentation involved must be “field-deployable”. To be fool-proof, end-point analysis is demanded. Several research groups have also sought low sample preparation workflows, as RNA purification from biological samples is time consuming and timely delivery of test results can be impaired due to limited supplies of sample purification kits [24, 25, 39–42]. To meet these specs, we generated three protocols for SARS-CoV-2 testing.

First, the behavior of the virus itself defines the sampling procedure. False negatives arising from defective sampling are often as problematic as (or more problematic than) false negatives arising from failure of the assay. Fortunately, the life cycle of SARS-CoV-2 appears to allow simple sampling, with mid-turbinate sampling being adequate, as well as saliva sampling [43, 44].

Therefore, our first protocol uses dry mid-turbinate or anterior nasal swabbing as a collection method, and relied on the positive control targeting human RNase P to ensure that the collection was adequately aggressive. Post sampling, swabs were eluted in various elution/inactivation buffers. An aliquot from the elution solution was added directly to the DP-RT-LAMP mixture, and analyzed in real-time using portable Genie[®] II instrument, available from Optigene and by visualization of end-point fluorescence (Fig. 4.3A and Fig. S3A in S1 File). Genie[®] II processes 16 samples simultaneously using the FAM-channel (483–533 nm). The data outputs are similar to those obtained with the more expensive real-time PCR instrument. Genie[®] II offers positive/negative results with Tt values as good as obtained with the PCR instrument, but at a fraction of the cost and useable in the lobby of a workplace, a courtroom, or a school (Fig. 4.3D).




Figure 4.3 Sampling work-flow and results output. (A) Dry nasal swabs were used as sampling method. Swabs were first eluted in a sample preparation buffer and aliquot from that was added into RT-LAMP mixture. End-point results were visualized using blue LED and orange filter. (B) Direct saliva was mixed with a sample preparation buffer briefly and aliquot from that was added into RT-LAMP mixture. End-point results were visualized using the same method for nasal swab sampling. (C) Q-paper was combined with saliva and Q-paper coated with saliva was directly introduced into RT-LAMP mixture without further manipulation. End-point fluorescent signal was visualized using blue LED and orange filter. Note that the square of Q-paper is observable, but does not compromise the real-time or end-point analysis. (D) In addition to end-point visualization, RT-LAMP experiments were also run in real-time using Genie® II (Optigene, UK) which can operate on battery therefore enabling its use in low-resource settings.

The sensitivity of the preferred nasal sampling method was determined with a small set of samples using heat-inactivated virus to spike nasal swabs from healthy volunteers. Here, 1000 RNA copies/assay were detected consistently at 100%. Ca. 200 copies/assay were detected with 90% efficiency, and 100 copies of RNA/assay were detected at 50% efficiency. The internal control that targets the RNase P gene was detected at 100%, indicating that the sample collection was sufficiently aggressive (Fig. 4.4A).




Figure 4.4 Further evaluation of presently preferred sampling methods and sensitivity analysis with contrived samples using heat-inactivated SARS-CoV-2 template from BEI. (A) Varying amounts of RNA was spiked into nasal swab samples from healthy individuals. 200 copies of RNA were detected with consistency and RNase P gene was used as sampling control. (B) and (C) Varying amounts of RNA was spiked into saliva samples or saliva that was deposited onto Q-paper, respectively. 200 copies of RNA were detected with consistency and RNase P gene was detected successfully. (D) Mean Tt values in minutes and numbers of positive results versus total number of samples were displayed in the table.

Additionally, inactivated virus-spiked saliva (with saliva alone as the negative control) was diluted with several inactivation buffers (1:100 ratio of buffer to saliva) and an aliquot of the resulting mixture was added to the DP-RT-LAMP mixture and analyzed similarly (Fig. 4.3B and Fig S3B in S1 File). Alternatively, saliva can be placed on “Q-paper”, a cellulose filter paper that carries quaternary ammonium groups. Q-paper has been previously used to capture arboviral RNA from single mosquitoes after a drop of ammonia is added to the carcasses [18]. In this work, the Q-paper holding the viral RNA could be added directly to the RT-LAMP mixture without any sample preparation. The fluorescence can be analyzed in real-time or by end-point visualization (Fig. 4.3C).

The sensitivities of the assay with two saliva sampling methods were further analyzed using contrived saliva samples of healthy volunteers. Here, 200 copies of RNA/assay could be detected by both methods with 100% detection rate with a

small sample size (5 to 10 cases); 100 copies of RNA were detected with 100% efficiency using 100X inactivation solution, and with 40% efficiency using Q-paper for sampling. Additionally, the internal control targeting RNase P gene was detected at 90–100% in both methods (Fig. 4.4B–4.4D).

4.3.4 Validation of DP-RT-LAMP Assay on Clinical Samples

Previously collected nasopharyngeal (NP) swabs samples that were stored in viral transport medium (VTM) were first eluted at room temperature without a heating step in sample elution buffer used for DP-RT-LAMP assay. SARS-CoV-2 specific primer set and internal control targeting RNase P gene was run in parallel and signal threshold times were determined. LAMP assay results were also compared to a CLIA notified and ICMR (Indian Council for Medical Research) approved PCR assay from GenePath Diagnostics (GPDx CoViDx One PCR). This is a 4-plex real-time RT-qPCR assay targets RdRP, N and E gene of SARS-CoV-2 and uses RNase P gene as sample extraction control. It uses a commercial sample extraction kit to purify and concentrate viral RNA from VTM whereas LAMP method uses minimal sample preparation through simple swab elution. Out of 11 samples tested, LAMP assay results are in 100% agreement with PCR assay with average Tt value of 17 min for SARS-CoV-2 target and 18 min for RNase P targets (Table 4.1).

Table 4.1 Clinical evaluation of DP-RT-LAMP assay and comparable PCR assay

Sample	LAMP Tt (min)			GPDx CoViDx One PCR Ct				
	CoV2-W3	RNase P	Result	RdRP	N	R	RNase P	Result
1	32.7	24.0	Positive	33.13	35.78	33.26	29.15	Low Positive
2	10.9	18.0	Positive	25.56	27.45	25.25	28.21	Positive
3	41.5	16.2	Positive	30.99	34.24	31.65	25.55	Positive
4	12.4	16.5	Positive	30.85	32.75	31.31	29.81	Positive
5	11.0	16.9	Positive	29.62	31.84	29.72	29.82	Positive
6	16.7	17.7	Positive	31.49	33.73	32.18	31.14	Positive
7	12.7	14.7	Positive	30.6	32.12	30.99	29.25	Positive
8	23.7	15.0	Positive	32.65	35.73	33.31	29.5	Low Positive
9	10.3	15.6	Positive	25.67	27.71	25.75	28.99	Positive
10	13.0	16.7	Positive	31.94	34.87	32.9	27.35	Positive
11	9.0	29.0	Positive	23.77	25.29	23.62	27.51	Positive

4.3.5 Multiplex Detection of SARS-CoV-2 and RNase P

An assay robust for workplace use must incorporate a signal to indicate that sampling is sufficiently aggressive. Our displaceable probe architecture allows

the simultaneous detection of viral RNA and the human RNase P gene in single tube assay. To show this, we spiked varying amounts of viral RNA into human RNA background and 10 copies of SARS-CoV-2 RNA could be detected in the presence human RNA in two-plex format when equal amount of the two LAMP primer sets were present. When viral RNA was present in higher amounts, the signal for RNase P was delayed to 32.5 min, instead of appearing between 21–23 min. This is presumed to reflect the two amplification processes competing for some of the LAMP amplification resources. A similar degree of sensitivity for both targets was achieved when viral RNA was ~ 1000 copies/assay (Fig. 4.5A).




Figure 4.5 Multiplexed detection of SARS-CoV-2 RNA and RNase P (internal control). (A) Varying amounts of heat-inactivated SARS-CoV-2 (BEI resources) spiked with human RNA (440 cp). Fluorescence signals from three channels were recorded every 30 s using LightCycler® 480. Channel 483–533 is specific for SARS-CoV-2 RNA, channel 523–568 can detect signals from both targets (ladder formation manifests itself), and channel 558–610 is specific for RNase P. Corresponding Tt values were shown on the table. (B) 10⁴, 10³ and 10² copies of SARS-CoV-2 RNA was spiked into processed nasal swab and saliva samples and analyzed simultaneously.

We then applied the same process to nasal swabs and explored the effect of brief heating step (95°C 5 min) on the assay sensitivity. When no heating step was involved, only 10^4 and 10^3 copies of viral RNA could be detected and Tt value of RNase P decreases with the decreasing order of viral RNA input. When samples were heated, more uniform co-amplification of both targets was observed (Fig. 4.5B, left panel).

Similar outcomes were observed when saliva samples were used. When there was no heating, 10^4 and 10^3 copies of RNA could be detected within 16 min, but signal was delayed to 20 min for 100 copies of RNA. Similar to nasal swabs, RNase P detection was significantly delayed in higher viral load. This is expected of LAMP since the viral amplifications consumed LAMP resources in general (e.g., dNTPs). When saliva samples were heated, more uniform co-amplification of both targets was observed with Tt ranging from 15 to 20 min for CoV-2 and 15 to 25 min for RNase P (Fig. 4.5B, right panel).

4.4 Discussion

The SARS-CoV-2 has been especially successful in having itself transmitted worldwide by its ability to cause a wide range of symptoms, ranging from lethality to no recognizable symptoms at all. Further, multiple anecdotal examples show clear transfer of the virus from one symptomatic patient to another symptomatic patient via an individual who displayed no symptoms at all, neither at the time of transmission nor forever after [45]. This makes SARS-CoV-2 virtually unique among pathogens, while presenting an unprecedented challenge to those charged to manage the resulting pandemic. While classical 2003 SARS could be tracked by monitoring symptoms (e.g., fever, which can be remotely tested), SARS-CoV-2 cannot.

This makes the current testing regime totally inadequate. Reports from hospitals and New York City, for example, show the time between sampling, sample transport, and return of sample results ranging from two days to 22 days, with costs per assay generally in excess of \$100. Neither this time of delay nor the cost are adequate to determine whether or not the individual being sampled is likely to forward infect other individuals at a workplace, courtroom, jail, or schoolhouse. Indeed, as Thomas Frieden of the CDC pointed out, if the test requires days to resolve an outcome, the test might as well not be taken at all, except for curiosity or for larger epidemiological public health [46].

Compounding this is the fact that the asymptomatic carrier has no particular reason to present himself/herself for testing. The most common way in which such asymptomatic carriers are identified is by broad testing of individuals who have been in contact with asymptomatic patient. However, for serious epidemiological work to be done given the peculiarities of this particular virus, large-scale random testing must be done. Again, the standard procedures involving days to result and \$100 per assay are not compatible with this.

It is easy to identify preferred workplace assay; however, it must cost just a few dollars to run. Further, the assay must be run without the need to transport samples or it should survive the transport and storage in amateur hands. Essentially all “home assay” kits are not home assays at all, but rather are home sampling kits.

Further, the results must be returned in minutes, not hours, and certainly not days. Rather, the assay must be usable at the entrance to a workplace, a courtroom, an airport, or schoolyard, and return results in 30 min. If the assay is positive, the individual is referred off campus to a reference laboratory. If the assay is negative, to the extent that it does not indicate a risk for forward infection, the individual is allowed to enter the public space.

These specs make certain demands on assay design. First, they must not involve any of the classical sample preparation tests that are used in assays, and reference laboratories. They must be workable by a nonprofessional who need not be licensed, in an environment that must not need CLIA certification. Indeed, they cannot involve a reference laboratory at all.

These demanding specifications may be offset in part by the absence of a need for ultra-high sensitivity. For example, when treating HIV, even 10 virions in a sample indicate that the patient has an infection that demands medical attention. For workplace use, however, an assay need be only as sensitive as necessary to ensure that the individual does not present a forward contamination risk. While the viral load of saliva necessary for that risk is not known, emerging data suggest that this requires hundreds of thousands or millions of viral particles per milliliter for upper respiratory track samples [47].

The assay presented here meets all the requirements for use it in an entrance to a public space, such as a schoolyard, a workplace, or an airport. To ease the need for transport without a chain of refrigeration, assay components were lyophilized and shown to perform similar to their non-lyophilized counterparts. Further, this assay has shown a potential to be used as one-step LAMP where a nasal/saliva swab can be directly eluted into the assay mixture for rapid (<30 min) screening of individuals entering in public spaces (Fig. S5 and Table S4 in S1 File). It detects virus if it is present at approximately 200 copies per nasal swab assay, representing approximately 8,000 copies of RNA per nasal swab, and 100 copies per saliva assay, representing approximately 20,000 copies of RNA per mL of saliva. This is currently believed to be below the level of mean viral load in upper respiratory specimens [48, 49] and below the level required for a forward infection risk [47, 50].

Supporting Information

S1 File. The supplementary information file contains information about primer and probe sequences (S1), initial SARS-CoV-2 templates (S2), optimization of nasal swab sampling (S3), optimization of saliva sampling (S4), lyophilization of DP-RT-LAMP reagents (S5), and one-step LAMP assay using nasal/saliva swabs (S6).

Available at: <https://journals.plos.org/plosone/article/file?type=supplementary&id=info:doi/10.1371/journal.pone.0240524.s001>.

Abbreviations

BIP:	backward internal primer
DP:	displaceable probe
DP-RT-LAMP:	displaceable probe RT-LAMP
FIP:	forward internal primer
IBFQ:	Iowa Black-FQ
LOD:	limit of detection
MERS:	Middle East Respiratory Syndrome
NP:	nasopharyngeal
qPCR:	quantitative polymerase chain reaction
RT-LAMP:	reverse transcription loop-mediated isothermal amplification
VTM:	viral transport medium

Disclosures and Conflict of Interest

This chapter was originally published as: Yaren, O., McCarter, J., Phadke, N., Bradley, K. M., Overton, B., Yang, Z., et al. (2021). Ultra-rapid detection of SARS-CoV-2 in public workspace environments. *PLoS ONE* **16**(2), e0240524, <https://doi.org/10.1371/journal.pone.0240524>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: All relevant data are within the chapter and its Supporting Information files (<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0240524#sec019>).

Funding: This project was made possible through the support of a grant from Dynamic Combinatorial Chemistry, LLC, The funder provided support in the form of salaries and supplies for authors OY, ZY, JM, and BO, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the chapter. The specific roles of these authors are articulated in the ‘author contributions’ section. The opinions expressed in this publication are those of the author(s) and do not necessarily reflect the views of DCC. Firebird Biomolecular Sciences, LLC, GenePath Diagnostics, Inc., and GenePath Diagnostics India Pvt. Ltd. employ the indicated authors and the specific roles of these authors are articulated in the ‘author contributions’ section.

Competing interests: Firebird Biomolecular Sciences, LLC, GenePath Diagnostics, Inc., and GenePath Diagnostics India Pvt. Ltd. employ the indicated authors and the specific roles of these authors are articulated in the ‘author contributions’ section. OY, ZY, SAB and their institutions own intellectual property associated with the assay. Some of the items mentioned here are sold by Firebird

Biomolecular Sciences, LLC, which employs the indicated authors and is owned by SAB. This does not alter the authors' and institutions' adherence to PLOS ONE policies on sharing data and materials.

Acknowledgments: The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Heat Inactivated, NR-52286.

Author Contributions

Conceptualization: Ozlem Yaren, Steven A. Benner; **Funding acquisition:** Steven A. Benner; **investigation:** Ozlem Yaren, Steven A. Benner; **methodology:** Ozlem Yaren, Jacquelyn McCarter, Nikhil Phadke; **project administration:** Ozlem Yaren; **resources:** Steven A. Benner; **software:** Kevin M. Bradley; **supervision:** Ozlem Yaren, Nikhil Phadke; **validation:** Benjamin Overton, Zunyi Yang, Shatakshi Ranade, Kunal Patil, Rishikesh

Bangale; **visualization:** Ozlem Yaren, Jacquelyn McCarter; **writing – original draft:** Ozlem Yaren; **writing – review & editing:** Ozlem Yaren, Nikhil Phadke, Kevin M. Bradley, Zunyi Yang, Steven A. Benner.

References

1. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Euro Surveill.* 2020;25(4):2000058.
2. Hu B, Zeng L-P, Yang X-L, Ge X-Y, Zhang W, Li B, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. *PLoS Pathog.* 2017;13(11):e1006698.
3. Benner SA, Gaucher EA, Li T. Post-genomic evolutionary analyses of the severe acute respiratory syndrome (SARS) virus genome using the Master Catalog[R] interpretive proteomics platform. *PharmaGenomics.* 2003;3:S17.
4. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. *Clin Microbiol Rev.* 2015;28:1098–6618.
5. Chan JF-W, Lau SK-P, Woo PC-Y. The emerging novel Middle East respiratory syndrome coronavirus: The “knowns” and “unknowns”. *J Formos Med Assoc.* 2013;112(7):372–81.
6. Yaren O, Glushakova LG, Bradley KM, Hoshika S, Benner SA. Standard and AEGIS nicking molecular beacons detect amplicons from the Middle East respiratory syndrome coronavirus. *J Virol Methods.* 2016;236:54–61.
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497–506.
8. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507–513.
9. Salterio SE. Accounting for the unaccountable—perspectives on the economic effects of the Coronavirus 19 pandemic (April 17, 2020). Available at: <https://ssrn.com/>

- abstract=3581243 or <http://dx.doi.org/10.2139/ssrn.3581243> (accessed on September 30, 2022).
10. Choy W-Y, Lin S-G, Chan PK-S, Tam JS-L, Lo YMD, Chu IM-T, et al. Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine development. *Clin Chem*. 2004;50(6):1036–1042.
 11. Qu D, Zheng B, Yao X, Guan Y, Yuan Z-H, Zhong N-S, et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. *Vaccine*. 2005;23(7):924–931.
 12. Chen W-H, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. *Curr Trop Med Rep*. 2020;7(2):61–64.
 13. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *J Biol Chem*. 2020;295(15):4773–4779.
 14. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. *J Biol Chem*. 2020;295(20):6785–6797.
 15. Villar J, Confalonieri M, Pastores SM, Meduri GU. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by Coronavirus Disease 2019. *Crit Care Explor*. 2020;2(4):e0111.
 16. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. *bioRxiv*. 2020:2020.03.11.987016.
 17. Yaren O, Alto BW, Bradley KM, Moussatche P, Glushakova L, Benner SA. Multiplexed isothermal amplification based diagnostic platform to detect Zika, chikungunya, and dengue 1. *JoVE*. 2018;(133):e57051.
 18. Yaren O, Alto BW, Gangodkar PV, Ranade SR, Patil KN, Bradley KM, et al. Point of sampling detection of Zika virus within a multiplexed kit capable of detecting dengue and chikungunya. *BMC Infect Dis*. 2017;17(1):293.
 19. Yaren O, Bradley KM, Moussatche P, Hoshika S, Yang Z, Zhu S, et al. A norovirus detection architecture based on isothermal amplification and expanded genetic systems. *J Virol Methods*. 2016;237:64–71.
 20. Yaren O. Point-of-sampling detection of Lyme and other tick-borne pathogens. 1R21AI135296-01. 2020. Available at: <https://grantome.com/grant/NIH/R21-AI135296-01> (accessed on September 30, 2022).
 21. TrackItNow. Available at: www.trakitnow.com (accessed on September 30, 2022).
 22. OneStop. Available at: https://www.onestopmedcenter.com/?fbclid=IwAR2LCZfFRPq-q_6b-g_laizDMZ2kv0y-N4wM8U-bXDPYE5dpAJa0BEHcc9Y (accessed on September 30, 2022).
 23. Lynxdx (www.lynxdx.com) and Achiralabs (<https://achiralabs.com/>) (accessed on September 30, 2022).
 24. Bhadra S, Riedel TE, Lakhotia S, Tran ND, Ellington AD. High-surety isothermal amplification and detection of SARS-CoV-2, including with crude enzymes. *bioRxiv*.

- 2020:2020.04.13.039941. Available at: <https://www.biorxiv.org/content/10.1101/2020.04.13.039941v2> (accessed on September 30, 2022).
25. Joung J, Ladha A, Saito M, Segel M, Bruneau R, Huang M-IW, et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv. 2020:2020.05.04.20091231. Available at: <https://www.medrxiv.org/content/10.1101/2020.05.04.20091231v1> (accessed on September 30, 2022).
 26. Butler DJ, Mozsary C, Meydan C, Danko D, Foox J, Rosiene J, et al. Shotgun transcriptome and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. bioRxiv. 2020:2020.04.20.048066. Available at: <https://www.biorxiv.org/content/10.1101/2020.04.20.048066v5> (accessed on September 30, 2022).
 27. Nagamine K, Hase T, Notomi T. Accelerated reaction by loop-mediated isothermal amplification using loop primers. *Mol Cell Probes*. 2002;16(3):223–229.
 28. Yan C, Cui J, Huang L, Du B, Chen L, Xue G, et al. Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect*. 2020;26(6):773–779.
 29. Lamb LE, Bartolone SN, Ward E, Chancellor MB. Rapid detection of novel coronavirus/ Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification. *PLoS ONE*. 2020;15(6):e0234682.
 30. El-Tholoth M, Bau HH, Song J. A single and two-stage, closed-tube, molecular test for the 2019 Novel Coronavirus (COVID-19) at home, clinic, and points of entry. ChemRxiv. 2020:60c74829f96a0042bd28702a. Available at: <https://chemrxiv.org/engage/chemrxiv/article-details/60c74829f96a0042bd28702a> (September 30, 2022).
 31. Park G-S, Ku K, Baek S-H, Kim S-J, Kim SI, Kim B-T, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *J Mol Diagn*. 2020;22(6):729–735.
 32. Zhang Y, Odiwuor N, Xiong J, Sun L, Nyaruaba RO, Wei H, et al. Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP. medRxiv. 2020:2020.02.26.20028373. Available at: <https://www.medrxiv.org/content/10.1101/2020.02.26.20028373v1> (accessed on September 30, 2022).
 33. Kellner MJ, Ross JJ, Schnabl J, Dekens MPS, Heinen R, Tanner NA, et al. Scalable, rapid and highly sensitive isothermal detection of SARS-CoV-2 for laboratory and home testing. bioRxiv. 2020:2020.06.23.166397. Available at: <https://www.biorxiv.org/content/10.1101/2020.06.23.166397v2> (accessed on September 30, 2022).
 34. Schermer B, Fabretti F, Damagnez M, Di Cristanziano V, Heger E, Arjune S, et al. Rapid SARS-CoV-2 testing in primary material based on a novel multiplex LAMP assay. medRxiv. 2020:2020.06.18.20130377. Available at: <https://www.medrxiv.org/content/10.1101/2020.06.18.20130377v1> (accessed on September 30, 2022).
 35. Liu N, Zou D, Dong D, Yang Z, Ao D, Liu W, et al. Development of a multiplex loop-mediated isothermal amplification method for the simultaneous detection of *Salmonella* spp. and *Vibrio parahaemolyticus*. *Sci Rep*. 2017;7:45601.
 36. Abildgaard A, Tovbjerg SK, Giltay A, Detemmerman L, Nissen PH. Lactase persistence genotyping on whole blood by loop-mediated isothermal amplification and melting curve analysis. *Clin Chim Acta*. 2018;482:50–56.

37. Fowler VL, Armson B, Gonzales JL, Wise EL, Howson ELA, Vincent-Mistiaen Z, et al. A reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for the rapid detection of SARS-CoV-2 within nasopharyngeal and oropharyngeal swabs at Hampshire Hospitals NHS Foundation Trust. medRxiv. 2020:2020.06.30.20142935. Available at: <https://www.medrxiv.org/content/10.1101/2020.06.30.20142935v4> (accessed on September 30, 2022).
38. Kubota K, Jenkins DM, Alvarez AM, Su WW. FRET-based assimilating probe for sequence-specific real-time monitoring of loop-mediated isothermal amplification (LAMP). *Biol Eng Trans.* 2011;4:81–100.
39. Anahtar MN, McGrath GEG, Rabe BA, Tanner NA, White BA, Lennerz JKM, et al. Clinical assessment and validation of a rapid and sensitive SARS-CoV-2 test using reverse-transcription loop-mediated isothermal amplification. medRxiv. 2020:2020.05.12.20095638. Available at: <https://www.medrxiv.org/content/10.1101/2020.05.12.20095638v1> (accessed on September 30, 2022).
40. Dao Thi VL, Herbst K, Boerner K, Meurer M, Kremer LPM, Kirrmaier D, et al. Screening for SARS-CoV-2 infections with colorimetric RT-LAMP and LAMP sequencing. medRxiv. 2020:2020.05.05.20092288. Available at: <https://www.medrxiv.org/content/10.1101/2020.05.05.20092288v1> (accessed on September 30, 2022).
41. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR–Cas12-based detection of SARS-CoV-2. *Nat Biotechnol.* 2020;38(7):870–874.
42. Rabe BA, Cepko C. SARS-CoV-2 detection using an isothermal amplification reaction and a rapid, inexpensive protocol for sample inactivation and purification. medRxiv. 2020:2020.04.23.20076877. Available at: <https://www.medrxiv.org/content/10.1101/2020.04.23.20076877v1> (accessed on September 30, 2022).
43. Srivatsan S, Han PD, van Raay K, Wolf CR, McCulloch DJ, Kim AE, et al. Preliminary support for a “dry swab, extraction free” protocol for SARS-CoV-2 testing via RT-qPCR. bioRxiv. 2020:2020.04.22.056283. Available at: <https://www.biorxiv.org/content/10.1101/2020.04.22.056283v1> (accessed on September 30, 2022).
44. Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. Evaluation of heating and chemical protocols for inactivating SARS-CoV-2. bioRxiv. 2020:2020.04.11.036855. Available at: <https://www.biorxiv.org/content/10.1101/2020.04.11.036855v2> (accessed on September 30, 2022).
45. Lu J, Gu J, Li K, Xu C, Su W, Lai Z, et al. COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020. *Emerg Infect Dis.* 2020;26(7):1628–1631.
46. Tom Frieden – Weekly Blog. Available at: <https://www.drtomfrieden.net/blog> (accessed on September 30, 2022).
47. Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *J Infect.* 2020;81(3):357–371.
48. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20(5):565–574.

49. Kleiboeker S, Cowden S, Grantham J, Nutt J, Tyler A, Berg A, et al. SARS-CoV-2 viral load assessment in respiratory samples. *J Clin Virol.* 2020;129:104439.
50. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, Parker R. Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. *Sci Adv.* 2020;7(1):eabd5393.

Chapter 5

Saliva as a Testing Specimen with or without Pooling for SARS-CoV-2 Detection by Multiplex RT-PCR Test

Qing Sun, PhD,^a Jonathan Li, PhD,^a Hui Ren, PhD,^a Larry Pastor,^a Yulia Loginova, PhD,^a Roberta Madej, PhD,^a Kristopher Taylor,^b Joseph K. Wong, MD,^b Zhao Zhang, PhD,^a Aiguo Zhang, PhD,^a Chuanyi M. Lu, MD,^b and Michael Y. Sha, PhD^a

^a*DiaCarta, Inc., Richmond, California, USA*

^b*University of California and VA Healthcare System, San Francisco, California, USA*

qsun@diacarta.com, mark.lu@va.gov, msha@diacarta.com

Keywords: coefficient of variation (CV), confidence interval (CI), coronavirus disease 2019 (COVID-19), cross reactivity, cycle threshold (Ct), extraction control (EC), high-throughput, institutional review board (IRB), internal control (IC), limit of detection (LOD), molecular detection, multiplex, nasopharyngeal swab (NPS), negative percentage agreement (NPA), negative predictive value (NPV), oropharyngeal swab (OPS), pandemic, personal protective equipment (PPE), positive percentage agreement (PPA), positive predictive value (PPV), QuantiVirus™, real-time reverse transcription polymerase chain reaction (RT-qPCR), reproducibility, sample pooling, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)

5.1 Introduction

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously provisionally named 2019 novel coronavirus or 2019-nCoV), has been identified as the cause of respiratory infection including severe pneumonia outbreak that started in Wuhan, China in late 2019 [1, 2], and has since become a global pandemic. The disease was named the coronavirus disease of 2019 (COVID-19) by the World Health Organization in February 2020. It has been

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

determined that SARS-CoV-2 can be transmitted from person-to-person (symptomatic or asymptomatic) and is more transmissible than SARS-CoV [3–5].

Nasopharyngeal swab (NPS) and oropharyngeal swab (OPS) samples are widely accepted as specimens for the detection of SARS-CoV-2 since the start of the COVID-19 pandemic. However, the collection procedures for NPS and OPS specimens may cause discomfort and, in some people, sneezing and coughing. The latter in turn can generate droplets or aerosol particles that place healthcare workers collecting these specimens at risk [6], requiring heavy use of personal protective equipment (PPE). Poor tolerability of NPS and OPS sampling can result in false-negative tests due to inadequate or poor quality of specimen collection [7–10]. Recent investigations by Wyllie et al. [11] and Hanson et al. [12] suggested that saliva is a viable and even more sensitive alternative to NPS specimens, and could also enable at-home self-administered sample collection for large-scale SARS-CoV-2 molecular testing. Other researchers [13] also reported that SARS-CoV-2 was detected in 91.7% ($n = 11$) of the initial saliva specimens from confirmed COVID-19 patients. All saliva specimens ($n = 33$) collected from patients whose NPS specimens tested negative for COVID-19 also tested negative. It is apparent that detection of SARS-CoV-2 in saliva can be used as a more appealing and cost-effective alternative for the diagnosis of COVID-19. Indeed, a molecular test using saliva samples was first approved for FDA under EUA on May 8, 2020 [14].

The use of saliva specimens might decrease the risk of nosocomial transmission of COVID-19 and is ideal for situations in which NPS or OPS specimen collection may be impractical [15–18]. Collecting saliva is easy and more tolerable to patients, can reduce risk of cross-infection, and can be used in settings where PPE is not readily available. It will also be useful for testing infants and young children in daycare facilities and schools.

The QuantiVirus™ SARS-CoV-2 Test is a real-time reverse transcription polymerase chain reaction (RT-qPCR) test that includes the assay controls for the qualitative detection of viral RNA from SARS-CoV-2 in NPS, OPS, saliva or sputum specimens collected from patients who are suspected of COVID-19 infection. Extracted RNA is reverse-transcribed and amplified in a single reaction. In this multiplex qPCR method, the Orf1ab, N, and E genes of the SARS-CoV-2 genome are targeted in the RT-PCR assay (Fig. 5.1A). Primers and TaqMan probes designed for conserved regions of the SARS-CoV-2 virus genome allow specific amplification and detection of the viral RNA from all variants of SARS-CoV-2 from respiratory specimens. The Human RNase P gene is used as an Internal Control (IC) to monitor viral RNA extraction efficiency and assess amplifiable RNA in the samples to be tested. The test is a multiplex RT-PCR assay consisting of one reaction with primers and probes for the viral gene targets (Orf1ab, N and E genes) and IC in one tube, designed to increase assay throughput.

We demonstrate here that saliva sampling is an adequate alternative to NPS and OPS sampling and can be used for COVID-19 testing using the QuantiVirus SARS-CoV-2 test.




Figure 5.1 (A) SARS-CoV-2 genome structure and assay target genes. Republished from FDA EUA [14] under a CC BY license, with permission from Diacarta Inc, original copyright [2020]. (B) A high-throughput workflow for SARS-COV-2 detection from sample collection to result availability within about 4 h.

5.2 Methods

5.2.1 Study Design and Ethics

Besides contrived saliva samples, deidentified leftover patient NPS and saliva samples were used in the study. All patient specimens were collected in May-September 2020 and previously tested at UCSF affiliated San Francisco VAMC clinical laboratories and DiaCarta's CLIA laboratory for clinical diagnostic or screening purpose. Other than qualitative RT-PCR results (positive or negative), only PCR cycle threshold (Ct) values were included in study analysis and no patient clinical chart reviews were performed. This study was approved by the institutional review board (IRB) at UCSF (UCSF IRB #11-05207) as a no-subject contact study with waiver of consent and as exempt under category 4.

5.2.2 Clinical Specimens

Clinical samples were collected from patients who had previously been tested positive for SARS-CoV-2. Paired NPS and saliva samples were collected at the same time. The QuantiVirus™ Saliva Collection Kit (DiaCarta, Inc. cat# DC-11-0021) was used for saliva collection, following the kit insert instructions and under the supervision of healthcare providers. No eat or drink 30 min before saliva sample collection.

Each saliva sample contains about 2 mL liquid saliva and 2 mL viral transport media. The NPS and saliva samples are refrigerated and processed for testing within 24 h after collection.

5.2.3 Sample Pooling

Positive saliva and negative saliva samples were pooled together according to the experiment design for 1:6 (i.e., 1 positive mixed with 5 negatives) and 1:12 (i.e., 1 positive mixed with 11 negatives) pooling, respectively. A total of 77 positive patient samples and 385 negative samples were used for pooling at 1:6 ratio to create 77 pooled positive samples and 54 pooled negative samples. After mixing the pooled samples, RNA was extracted for RT-PCR according to the testing protocol.

5.2.4 Viral RNA Extraction

MGI's automatic RNA/DNA extraction instrument MGISP-960 (MGI Tech Co., Ltd, China) was used for the SARS-CoV-2 viral RNA extraction according to the manufacturer's instructions, for which 200 μ L of each NPS VTM or saliva sample was used. For each batch of clinical samples to be tested, an extraction control (EC) was included (spike 20 μ L of EC from the QuantiVirus™ SARS-CoV-2 kit into 180 μ L sterile RNase-free water). The clinical samples and spiked EC were processed and extracted on the MGI platform. The extraction output is RNA in 30–50 μ L RNase-free water, 5.5 μ L of which is used for the PCR reaction per test. The turnaround time from sample extraction to PCR final report is around 4 h (Fig. 5.1B). Precautions were taken while handling extracted RNA samples to avoid RNA degradation. Extracted RNA samples were stored at -80°C if not immediately used for RT-PCR.

5.2.5 Multiplex Primer and Probe Design

Target gene sequences in the SARS-CoV-2 genome, the N gene, E gene and ORF1ab gene were identified and selected for test development. The gene sequences were retrieved from GenBank and GISAID databases for primer and probe designs to ensure coverage of all SARS-CoV-2 strains. Multiple alignments of the collected sequences were performed using Qiagen CLC Main Workbench 20.0.4, and

conserved regions in each target gene were identified using BioEditor 7.2.5. prior to primer and probe designs. Primers and probes were designed to target the most conserved regions of each of the target genes of the viral genome, using Primer3plus software and following general rules of real-time PCR design. All primers were designed with a melting temperature (T_m) of approximately 60°C and the probes were designed with a T_m of about 65°C. The amplicon sizes were kept as short as possible within the range of 70 bp to 150 bp for each primer pair to achieve better amplification efficiency and detection sensitivity. All primers and probes were synthesized by Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) and LGC Biosearch Technologies (Novato, CA, USA), respectively.

5.2.6 Real-Time Reverse-Transcription PCR

The total volume of one RT-PCR reaction for all targets is 10 μ L, including 5.5 μ L of RNA, 2.0 μ L of 5x primer and probe mixture (final concentration of 0.2 μ M and 0.1 μ M, respectively), and 2.5 μ L of 4x TaqPath™ 1-Step RT-qPCR Master Mix (Catalog number A28526, Thermo Fisher, Waltham, MA) or 4x Inhibitor-Tolerant RT-qPCR mix (MDX016-50, Meridian Bioscience, Tennessee). Thermal cycling was performed at 25°C for 2 min for uracil-N-glycosylase gene (UNG) incubation and 53°C for 10 min for reverse transcription, followed by 95°C for 2 min and then 45 cycles of 95°C for 3 sec, and 60°C for 30 sec. QuantStudio™ 5 Real-Time PCR System (Thermo Fisher, USA), Applied Biosystems™ 7500 Fast Dx Real-Time PCR Instrument (Thermo Fisher, USA), BioRad CFX384 (Bio-Rad, USA) and Roche LightCycler 480 II (Roche, USA) were used for real-time reverse-transcription PCR (rRT-PCR) amplification and detection.

5.2.7 Analytical Sensitivity and Limit of Detection

To determine the Limit of Detection (LoD) and analytical sensitivity of the QuantiVirus SARS CoV-2 Test kit, studies using empirical method were performed using serial dilutions of analyte and the LoD was determined to be the lowest concentration of template that could reliably be detected with 95% of all tested positive. LoD of each target assay in the QuantiVirus™ SARS-CoV-2 Test were conducted and verified using SeraCare AccuPlex SARS-CoV-2 Reference Material Kit (Cat# 0505-0126). Non-infectious viral particles from the AccuPlex SARS-CoV-2 Reference Material Kit were spiked in saliva at various concentrations (50 copies/mL, 100 copies/mL, and 200 copies/mL) diluted from the stock concentration of 5000 copies/mL. Real-time RT-PCR assay was performed with the provided kit reagents and tested triplicate on ABI QS5, ABI 7500 Fast Dx, Bio-Rad CFX 384 PCR and Roche LightCycler 480 II instruments. Then the LOD was confirmed by testing 1xLoD of viral RNA with 20 replicates. The LoD was determined to be the lowest concentration (copies/ml) at which $\geq 95\%$ (19/20) of the 20 replicates were tested as positive.

5.2.8 Precision

Precision studies include intra-run, inter-run, instrument, and operator variability evaluation. The assay precision was assessed by the repeat testing of samples with three or more different template concentrations. (1) Inter-assay %CV was established for same lot of reagents tested on the same instrument by the same user; (2) Intra-assay %CV was established through performance of kit on reference samples run in replicates of nine; and (3) Operator variability was evaluated with one lot of reagents by two operators. Reproducibility is demonstrated based on %CV of Ct values.

5.2.9 Microorganism Panel for Cross-Reactivity

MERS-coronavirus, SARS-CoV coronavirus samples were ordered from IDT. NATtrol Respiratory Validation Panel was ordered from ZeptoMetrix (cat# NATRVP-3, Buffalo, NY). RNA/DNA were extracted from high titer stocks of the potentially cross-reacting microorganisms.

5.2.10 Statistical Data Analysis

Average cycle threshold (Ct), standard deviation (SD) and coefficient of variation (CV) were calculated using Microsoft Office Excel 365 software (Microsoft, Redmond, WA). Clinical sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) at two-sided 95% confidence interval (CI) were analyzed using MedCalc software Version 19.3.1. NP and saliva pair analysis was conducted by Wilcoxon signed rank test.

5.3 Results

5.3.1 Validation of QuantiVirus™ SARS-CoV-2 Test Kit

Analytical sensitivity. Non-infectious viral particles from the AccuPlex SARS-CoV-2 Reference Material Kit (SeraCare Bioscience) were spiked in saliva at various concentrations (50, 100 and 200 copies/mL). Real-time RT-PCR assay was performed with the provided kit reagents. The assessment of individual assay result is that sample Ct<40 indicates positive and Ct>40 indicates negative. Therefore, 100 copies/mL were determined as a tentative LOD due to 50 copies/mL sample was undetectable from E gene target (Table S1).

We then validated the QuantiVirus™ SARS-CoV-2 kit on four qPCR instruments from different vendors, using contrived saliva samples by 20 measurements. The overall analytical sensitivity (lower limit of detection or LOD) is around 100–200 copies/mL under 95% confidence interval (Table 5.1).

Table 5.1 (a) Results of twenty replicates for analytical sensitivity confirmation on the ABI 7500 Dx; (b) results of 20 replicates for analytical sensitivity confirmation on the BioRad CFX 384; (c) results of 20 replicates for analytical sensitivity confirmation on the Roche LC 480. (d) results of 20 replicates for analytical sensitivity confirmation on the ABI QS5

Target	RNA (copy/mL)	No. Replicates (N)	Avg Ct	SD	CV	Positive	Negative	Call Rate
a								
ORF1ab gene	100 copies/mL	20	34.28	1.05	3.08%	20	0	100%
N gene	100 copies/mL	20	35.73	1.12	3.13%	20	0	100%
E gene	200 copies/mL	20	34.24	0.98	2.87%	20	0	100%
b								
ORF1ab gene	100 copies/mL	20	33.76	0.97	2.87%	20	0	100%
N gene	100 copies/mL	20	35.97	1.02	2.85%	20	0	100%
E gene	100 copies/mL	20	37.87	0.58	1.52%	20	0	100%
c								
ORF1ab gene	100 copies/mL	20	32.85	0.57	1.7%	20	0	100%
N gene	200 copies/mL	20	35.04	0.58	1.7%	20	0	100%
E gene	100 copies/mL	20	36.13	0.59	1.6%	20	0	100%
d								
ORF1ab gene	200 copies/mL	20	34.09	0.66	1.92%	20	0	100%
N gene	200 copies/mL	20	35.11	1.81	5.14%	20	0	100%
E gene	200 copies/mL	20	34.99	1.68	4.82%	20	0	100%

Note: Table 5.1a–5.1d were republished from FDA EUA [14] under a CC BY license, with permission from Diacarta Inc, original copyright [2020].

The validation data established that the LOD of the assay is 200 copies/mL on ABI 7500 Fast Dx (Table 5.1a), 100 copies/mL on Bio-Rad CFX 384 (Table 5.1b), 200 copies/mL on Roche LightCycler 480 II (Table 5.1c), and 200 copies/mL on the ThermoFisher ABI QuantStudio 5 (Table 5.1d).

Assay precision. *Intra-Assay.* QuantiVirus SARS CoV-2 assay at four different sample template concentrations (100, 200, 300 and 500 copies/mL) was repeated 10 times and run on the sample 384-well plate on BioRadCFX instrument. Average Ct and CV were calculated and summarized in Table S2a. The Intra assay overall CV was <3% and acceptable for this assay.

Operator reproducibility. The QuantiVirus SARS CoV-2 Test reactions were set up by two operators using the same lot of reagent and run on the ABI QuantStudio 5 instrument. Average Ct and CV were calculated and summarized in Table S2b. Overall CV for two operators is <3% and is acceptable for this assay.

Inter-instrument reproducibility. The QuantiVirus SARS CoV-2 Assay reactions were set up with three replicates and run on three different qPCR instruments including Bio-Rad CFX 384, ABI QS5 and ABI 7500 Fast Dx. Average Ct and CV were calculated and summarized in Table S2c. The results indicate that three instruments have <5% CV and is acceptable.

Cross-reactivity (assay specificity). We tested the cross-reactivity as part of the assay development. MERS-coronavirus and SARS-CoV coronavirus samples were ordered from IDT and NATtrol Respiratory Verification Panel from ZeptoMetrix (cat#NATRVP-3). RNA/DNA were extracted from high titer stocks of the potentially cross-reacting microorganisms (estimated $1.0E+05$ units/mL) and were extracted from 100 μ L microorganisms' stocks using the Thermo Fisher viral RNA extraction kit (PureLink™ Viral RNA/DNA Mini Kit) or Qiagen QIAamp DNA Mini Kit. Extracted RNA/DNA were eluted to 100 μ L with sterile RNase-free water. 5.5 μ L of the purified RNA/DNA samples was used for each reaction and tested using the QuantiVirus™ SARS-CoV-2 Test Kit. The cross-reactivity testing results are summarized in Table S3.

The cross-reactivity tests were run in triplicate, and all test controls passed (Positive controls Ct<25, No target control Ct>45, Extraction control has RP Ct<28). The tested organisms were all negative for the targeted N, E and ORF1ab genes of SARS-CoV-2 and human RP gene, indicating there is no cross-reactivity between SARS-CoV-2 primers & probes and any of the comparison organisms tested. The cross reactivity with common Human coronaviruses and MERS-coronavirus was also tested, and there was no cross reactivity at 10^5 PFU/mL.

5.3.2 Assay Sensitivity Verification

We spiked non-infectious viral particles (SeraCare AccuPlex SARS-CoV-2 Reference Material Kit) into healthy donor saliva which were confirmed by SARS-CoV-2 qPCR test to be negative, and tested each using three different qPCR instruments, ABI QuantStudio 5, ABI 7500 Fast Dx and BioRad CFX 384.

Clinical evaluation of the QuantiVirus™ SARS-CoV-2 Test was conducted with saliva specimens including 40 contrived positive and 30 negative samples. Saliva samples collected from healthy donors were mixed with the MGI RNA extraction kit's lysis buffer at 1:1 ratio before spiking in non-infectious viral particles for contrived positive sample (SeraCare AccuPlex SARS-CoV-2 Reference Material Kit) (Table S4a–S4c).

20 contrived positive saliva samples were created with the addition of non-infectious viral particles templates at 1x estimated LOD (1×200 copies/mL), 10 saliva samples were spiked at 1.5xLoD (300 copies/mL), and another 10 saliva samples were spiked at 2.5xLoD (500 copies/mL). Viral RNA was extracted from spiked samples and tested with the QuantiVirus™ SARS-CoV-2 test kit. The results showed that all 40 spiked saliva samples tested positive and all 30 control saliva samples tested negative on all three PCR instruments (Table S4a–S4c) with 100% (95% CI: 0.76–0.99) for positive call rate and 100% (95% CI: 0.91–1.00) for negative call rate.

5.3.3 Clinical Evaluation on NPS Samples

Using the QuantiVirus™ SARS-CoV-2 Test, we tested clinical NPS samples including 85 positive samples and 90 negative samples which previously had been tested on Abbott m2000 molecular system using Abbott Real-Time SARS-CoV-2 testing kits (Table 5.2). The data shows that the clinical sensitivity of QuantiVirus™ SARS-CoV-2 test is 98.8% (95% CI: 92.7%–99.9%) and specificity is 100% (95% CI: 94.9%–100%). Its PPV is 100% (95% CI: 94.6%–100%) and NPV is 98.9% (95% CI: 93.1%–99.9%).

Table 5.2 Results of clinical NPS sample evaluation using QuantiVirus™ SARS-CoV-2 test

Patients samples	N	SARS-CoV-2		Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
		Detected	Not Detected				
Positive	85	84	1	98.8% (0.927–0.999)	100% (0.949–1.00)	100% (0.946–1.00)	98.9% (0.931–0.999)
Negative	90	0	90				

Note: ABI QuantStudio 5 qPCR instrument was used for this test.

5.3.4 Clinical Evaluation of Paired NPS and Saliva Sample

We tested and evaluated the concordance between paired NPS and saliva samples collected from patients by QuantiVirus™ SARS-CoV-2 tests. Among the 20 pairs of nasopharyngeal swabs (NPS) and saliva samples, the test results were the same for 16 pairs (16/20, 80% concordance rate), including 5 positive pairs and 11 negative pairs. There were four samples for which the results were discordant (Table S5). Of these four pairs, one pair was NPS positive and saliva negative, whereas the other three pairs were NPS negative and saliva positive. Nevertheless, we compared NPS and saliva specimens by Wilcoxon matched pair signed rank test. The two samples types show 80% concordance with no significant differences ($p = 0.13$, Fig. 5.2A), and its RP were similar between two types of specimens ($p = 0.06$, Fig. 5.2B).

5.3.5 Comparison of QuantiVirus™ SARS-CoV-2 Multiplex Kit with FDA EUA Approved Abbott Realtime SARS-CoV-2 Kit

We tested 24 saliva samples of recovering COVID-19 patients with the QuantiVirus™ SARS-CoV-2 kit in comparison with the Abbott m2000 RealTime SARS-CoV-2 PCR kit in parallel (Table 5.3). Data showed a concordance of the assays of about 88%. There were three samples detected by QuantiVirus™ SARS-CoV-2 kit, but not detectable with the Abbott kit (patients #8, 11 and 12), consistent with the reported higher sensitivity of QuantiVirus™ SARS-CoV-2 PCR assay [22].




Figure 5.2 Clinical evaluation of paired nasopharyngeal and saliva samples. Cycle threshold (Ct) values for target gene and RP gene of NPS and saliva specimens were compared by Wilcoxon matched pairs signed rank test. Cycle threshold (Ct) values for viral E gene, N gene, O gene (ORF1ab), and human RNase P gene (RP) for NP and saliva specimens. (A) E, N, and O Ct values for paired NP and saliva samples. Pairs are connected by a line. The Ct was set to 42 for samples in which signal was not detected. Ct values of E, N, and O were comparable between the two types of samples by Wilcoxon signed rank test. NPS and saliva concordance is about 80% with no significant differences ($p = 0.13$). (B) RP Ct values for NP and saliva specimens were similar between the two types of samples by Wilcoxon signed rank test.

Table 5.3 Comparison of Abbott m2000 SARS-CoV-2 PCR test and DiaCarta QuantiVirus™ SARS-CoV-2 PCR test for SARS-CoV-2 detection in clinical saliva samples

Method Comparison	Abbott m2000 Real-time SARS-CoV-2		DiaCarta QuantiVirus SARS-CoV-2 multiplex				
	Accession #	Detection & qPCR Ct	Detection	ROX (E-Gene)	Cy5 (N-Gene)	FAM (ORF 1ab gene)	VIC (RP Gene)
Patient 1	Saliva 1	Not detected	Not detected	Undetermined	Undetermined	Undetermined	21.6
Patient 2	Saliva 2	Not detected	Not detected	Undetermined	undetermined	Undetermined	22.9
Patient 3	Saliva 3	Not detected	Not detected	Undetermined	undetermined	Undetermined	22.1
Patient 4	Saliva 4	Not detected	Not detected	Undetermined	undetermined	Undetermined	21.6
Patient 5	Saliva 5	Detected (Ct 18.21)	Detected	32.1	31.7	30.0	20.7
Patient 6	Saliva 6	Detected (Ct 31.00)	Detected	Undetermined	37.8	Undetermined	23.7
Patient 7	Saliva 7	Not detected	Not detected	Undetermined	Undetermined	Undetermined	19.7
Patient 8	Saliva 8	Not detected	Detected	37.4	37.3	42.4	23.3

Method Comparison	Abbott m2000 Real-time SARS-CoV-2		Diacarta QuantiVirus SARS-CoV-2 multiplex				
	Accession #	Detection & qPCR Ct	Detection	ROX (E-Gene)	Cy5 (N-Gene)	FAM (ORF 1ab gene)	VIC (RP Gene)
Patient 9	Saliva 9	Detected (Ct 23.89)	Detected	Undetermined	24.4	undetermined	21.8
Patient 10	Saliva 10	Not detected	Not detected	Undetermined	undetermined	Undetermined	22.3
Patient 11	Saliva 11	Not detected	Detected	32.8	33.9	31.5	23.9
Patient 12	Saliva 12	Not detected	Detected	35.7	38.5	33.9	24.2
Patient 13	Saliva 13	Not detected	Not detected	Undetermined	43.5	Undetermined	24.5
Patient 14	Saliva 14	Detected (Ct 20.77)	Detected	36.1	37.0	34.0	26.1
Patient 15	Saliva 15	Detected	Detected	35.6	35.1	34.2	23.6
Patient 16	Saliva 16	Not detected	Not detected	Undetermined	37.7	Undetermined	23.6
Patient 17	Saliva 17	Not detected	Not detected	Undetermined	Undetermined	41.2	32.7
Patient 18	Saliva 18	Not detected	Not detected	Undetermined	Undetermined	Undetermined	24.9
Patient 19	Saliva 19	Not detected	Not detected	Undetermined	Undetermined	33.5	29.1
Patient 20	Saliva 20	Detected (Ct. 21.40)	Detected	Undetermined	39.4	36.8	26.6
Patient 21	Saliva 21	Not detected	Not detected	Undetermined	Undetermined	Undetermined	25.1
Patient 22	Saliva 22	Not detected	Not detected	Undetermined	43.5	Undetermined	23.6
Patient 23	Saliva 23	Not detected	Not detected	Undetermined	Undetermined	Undetermined	29.1
Patient 24	Saliva 24	Not detected	Not detected	Undetermined	Undetermined	Undetermined	25.2

5.3.6 Population Screening Using Saliva Samples

We tested 389 total saliva specimens collected from the general population of asymptomatic individuals (i.e., asymptomatic screening) in Los Angeles and the San Francisco Bay Area counties. The screened population was represented by African Americans, White, Asian, and Latinx, with ages ranging from 18 to 80 (average 41) years old. From May 8 to Aug 26, 2020, 301 saliva samples were tested, and 5 samples were tested positive for SARS-CoV-2 by the QuantiVirus™ SARS-CoV-2 test. The 5 positives corresponded to 4 males of ages 19, 51, 52 and 54, and 1 female of age 34. Overall detection rate was 1.66% (Table 5.4). In another testing run of 88 saliva samples, 2 samples were positive and 86 were negative, with an overall positive detection rate of 2.27%. Together, we had screened 389 people from the general population and found that 7 people were positive for SARS-CoV-2 with an overall detection rate of 1.8%, consistent with the reported average positive testing rate from the same periods in the two metropolitan regions.

Table 5.4 Summary of saliva-based COVID-19 screening using QuantiVirus™ SARS-CoV-2 test in local communities

Date	Total (N)	Positive	Negative	Detection rate (%)
May 8-Aug. 26, 2020	301	5	296	1.66%
Aug. 28, 2020	88	2	86	2.27%
Total	389	7	382	1.80%

5.3.7 Evaluation of Pooling Saliva Samples for SARS-CoV-2 Screening

To test the feasibility of pooling saliva specimens for screening asymptomatic patients, we pooled negative and positive saliva samples, and tested a total of 77 pooled positive samples (1 patient sample mixed with 5 healthy saliva samples; 1:6 ratio) and 54 pooled negative samples (mixed 6 healthy samples) (Table 5.5). Of the 77 pooled positive saliva samples, 73 were tested positive (average Ct of three genes: O gene Ct ~29.8; E gene 30.9 and N gene Ct ~31.0) and 4 was reported as undetected. The average internal control (IC) RP Ct was 21.9 for all 131 pooled samples. Positive predictive value (PPV) is 100% (95% CI: 93.8%-100%). Negative predictive value (NPV) is 93.1% (95% CI: 82.5-97.8%). Additionally, we tested a total of 49 pooled positive saliva samples, created by mixing 1 patient sample with 11 healthy samples (1:12 ratio). Of the 49 pooled positive samples, 44 were tested positive (O gene, E gene and N gene average Ct 31.8, 32.1 and 31.9) and 5 was reported as undetected. Its IC RP average Ct was 22.3 for all 49 pooled saliva samples and additional 20 pooled healthy saliva samples. PPV is 100% (95% CI: 89.9%-100%) and NPV is 80.0% (95% CI: 58.7%-92.4%), respectively.

Table 5.5 Saliva sample pooling for SARS-CoV-2 detection by QuantiVirus™ SARS-COV-2 test kit.

Saliva sample pooling	Sample test (N)	Positive	Negative	Total screen sample (N)	Sensitivity	Specificity	PPV (%)	NPV (%)
1 positive + 5 negative pooling	77	73	4	462	94.8% (95% CI: 0.865-0.983)	100% (95% CI: 0.917-1.00)	100% (95% CI: 0.938-1.00)	93.1% (95% CI: 0.825-0.978)
6 negative pooling	54	0	54	324				
1 positive + 11 negative pooling	49	44	5	588	89.8% (95% CI: 0.769-0.962)	100% (95% CI: 0.799-1.00)	100% (95% CI: 0.899-1.00)	80.0% (95% CI: 0.587-0.924)
12 negative pooling	20	0	20	240				

*Single positive sample Mean Ct~30.3 at ORF1ab, Ct~22.3 RP; 1:6 ratio positive samples Mean Ct~31.1 at ORF1ab, Ct 21.9 at RP; 1:12 ratio positive sample Mean Ct~32.3 at ORF1ab, Ct 23.3 at RP.

**Total screen sample (N) = pooling samples number x pooling ratio.

5.4 Discussion

We have developed and validated a multiplex rRT-PCR assay for SARS-CoV-2 detection in saliva samples with clinical sensitivity of 98.8% (95% CI: 92.7%–99.9%) and specificity of 100% (95% CI: 94.9%–100%). Its PPV is 100% (95% CI: 94.6%–100%) and NPV is 98.9% (95% CI: 93.1%–99.9%). The detection of three viral target genes in one PCR tube enables a high throughput test using RT-qPCR. For these validated 384-well plate PCR platforms, 381 patient samples can be tested in each run (plus 3 controls). We have validated and integrated MGISP-960 high-throughput Automated Sample Preparation System, which can extract 192 samples (2x96) in about 80 min. For a CLIA laboratory with two MGI-960 machines, 380 samples can be tested with results available within 4 h (Fig. 5.1B).

We spiked SARS-CoV-2 viral particles into healthy donor saliva and confirmed that the analytical sensitivity (LOD) of the QuantiVirus™ RT-qPCR test is ~100 copies/mL for Bio-Rad CFX 384 and ~200 copies/mL for ABI QS5, ABI 7500Dx and Roche LC 480. Comparing to other FDA approved test kits, we have confirmed that our test kit has 600 NAAT Detectable Units/mL (NDU/mL) by FDA Reference Panel Testing and is among the top of all FDA approved SARS-CoV-2 test kits (Table S6 and FDA EUA website [19]). The multiplex RT-qPCR test can simultaneously detect three viral gene targets, which can minimize false negative results as chances of simultaneous mutations in all three target genes in the viral genome are highly unlikely. Furthermore, the results confirm that human saliva samples do not inhibit the RT-qPCR reaction, possibly due to the fact that inhibitor-tolerant RT-PCR master mix was used in the QuantiVirus™ SARS-CoV-2 test kit.

Leung et al. [6] analyzed 95 patient-matched paired samples from 62 patients including 29 confirmed patients with COVID-19 and 33 COVID-19 negative patients. The concordance rate was 78.9% (75/95 samples) between NP and saliva. Vogels et al. [20] reported a positive agreement of 83.8% (31/37 positive samples) for nasopharyngeal swabs and saliva when using TaqPath COVID-19 combo kit. Our data showed 80% concordance and no significant differences between NP and saliva, which is consistent with Leung's & Vogels's reports. Interestingly, for patient #4, the viral RNA was detected in the NPS sample by both Abbott m2000 test and DiaCarta test, but viral RNA was not detected in the saliva by either test. For patient #6, viral RNA was not detected in the NPS sample by either test, whereas viral RNA was detected in the saliva by both tests. This observation suggests that sample collection variabilities such as the time of collection and NPS sample quality do matter in SARS-CoV-2 PCR testing.

The 20 paired NPS-saliva samples were collected from recovering patients being evaluated prior to their release from self-quarantine. Consequently, their viral loads were much lower (100–1000 copies/mL), compared to the viral loads expected for the initial diagnostic testing. For patients with active SARS-CoV-2 infection (viral loads typically are above 10,000 copies/mL), there should be no problem detecting the virus in adequately collected saliva samples.

Landry et al. [21] described that most of saliva samples from sick patients were thick, stringy, and difficult to pipet. Since we used the QuantiVirus™ SARS-CoV-2 saliva sample collection kit which has VTM solution in the collection tube, the saliva was diluted 2-fold and therefore much easier to process. Matic et al. [22] used PBS at a 1:2 dilution that also helped resolve highly viscous saliva samples; however, manual dilution after collection may be associated with pipetting errors and cross contamination.

The QuantiVirus™ SARS-CoV-2 test results were 87.5% in concordance with FDA EUA approved Abbott RealTime SARS-CoV-2 results for saliva samples, with a higher detection rate overall. In fact, this observation is consistent with recently reported test sensitivity among various SARS-CoV-2 molecular tests. FDA published its SARS-CoV-2 Reference Panel Comparative Data on its website on Sept 15, 2020 [19]. It reported that QuantiVirus™ SARS-CoV-2 Kit has LOD of 600 NDU/mL whereas Abbott Realtime SARS-CoV-2 assay has LOD of 2700 NDU/mL. Accordingly, the reason for the observation that SARS-CoV-2 viral RNA was detected in three patient samples by the QuantiVirus™ SARS-CoV-2 test but not by Abbott RealTime SARS-CoV-2 assay was likely due to the higher sensitivity of the QuantiVirus™ SARS-CoV-2 assay. It also demonstrated that saliva specimens represent a viable specimen type that can be easily applied for COVID-19 testing when using more sensitive tests.

A total of 389 saliva specimens from the general population were tested and demonstrated the feasibility of using saliva for large scale population screening. Saliva is a non-invasive and easily collectable specimen for COVID-19 screening. Given the drawbacks of nasopharyngeal and oropharyngeal swab sample collection, saliva sampling could be applied as an acceptable alternative [23].

With saliva pooling strategy, we have demonstrated that 6-samples pooling (1 patient mixed with 5 healthy saliva samples, or 1:6 ratio) has 94.8% sensitivity (95% CI: 86.5–98.3%) and 100% specificity (95% CI:91.7–100%), As noted, of the 77 pooled saliva samples, 4 pooling samples were tested negative. In fact, for these 4 pooled samples, the individual positive samples used for the pooling had Ct of 34.4, 34.8, 35.7 and 37.5 for ORF1ab gene, respectively, consistent with low viral loads to start with (less than 100–200 copies/mL) (see Table 5.1a–5.1d). Therefore, in order to detect weakly positive patient in pooled samples, a RT-PCR test with LOD at 100–200 copies/mL or higher is required. If pooling testing is considered, each clinical laboratory should establish laboratory-specific pooling protocol based on the LOD of SARS-CoV-2 molecular test. One advantage of pooling testing is its cost-effectiveness, allowing population-based asymptomatic screening or monitoring even when testing supplies are limited.

In summary, we have demonstrated that saliva specimens can be reliably used for SARS-CoV-2 detection, and saliva-based large-scale population screening for COVID-19 with or without pooling is feasible.

Supporting Information

S1 Table Tentative LOD determination by series dilution. <https://doi.org/10.1371/journal.pone.0243183.s001>.

S2 Table (a) Intra assay precision of the QuantiVirus SARS-Cov-2 test kit. (b) Operator reproducibility of the QuantiVirus SARS Cov-2 test kit. (c) Inter-instrument precision of the QuantiVirus SARS CoV-2 test kit. <https://doi.org/10.1371/journal.pone.0243183.s002>.

S3 Table Results of cross-reactivity evaluation of the QuantiVirus™ SARS CoV-2 test kit. <https://doi.org/10.1371/journal.pone.0243183.s003>.

S4 Table (a) Evaluation of contrived saliva samples with added non-infectious viral particles (Bio-Rad CFX 384). (b) Evaluation of contrived saliva samples with added non-infectious viral particles (ABI QuantStudio 5). (c) Evaluation of contrived saliva samples with added non-infectious viral particles (ABI 7500 Fast Dx). <https://doi.org/10.1371/journal.pone.0243183.s004>.

S5 Table Paired NPS and saliva samples tested by QuantiVirus™ SARS-CoV-2 test. <https://doi.org/10.1371/journal.pone.0243183.s005>.

S6 Table Assay sensitivity evaluation of various FDA EUA approved SARS-CoV-2 RT-PCR test kits. <https://doi.org/10.1371/journal.pone.0243183.s006>.

Abbreviations

CI:	confidence interval
CV:	coefficient of variation
COVID-19:	Coronavirus Disease 2019
Ct:	cycle threshold
EC:	extraction control
IC:	internal control
IRB:	institutional review board
LOD:	limit of detection
NPA:	negative percentage agreement
NPS:	nasopharyngeal swab
NPV:	negative predictive value
OPS:	oropharyngeal swab
PPE:	personal protective equipment
PPA:	positive percentage agreement
PPV:	positive predictive value
rRT-PCR:	reverse-transcription PCR
RT-qPCR:	real-time reverse transcription polymerase chain reaction
SARS-CoV2:	Severe Acute Respiratory Syndrome Coronavirus 2
SD:	standard deviation

T_m : melting temperature
UNG: uracil-N-glycosylase gene

Disclosures and Conflict of Interest

This chapter was originally published as: Sun, Q., Li, J., Ren, H., Pastor, L., Loginova, Y., Madej, R., et al. (2021). Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test. *PLoS ONE*, **16**(2), e0243183, <https://doi.org/10.1371/journal.pone.0243183>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: All relevant data are within the chapter and its Supporting information files.

Funding: The authors received no specific funding for this work. This study was conducted by DiaCarta R&D and does not involve extramural funding. JW, KT and CML provided leftover and deidentified clinical specimens including testing validation samples and helped data analysis and chapter preparation. DiaCarta didn't provided financial compensation to JW, KT and CML. The funder Diacarta Inc provided support in the form of salaries for authors [QS, HR, JL, LP, RM, YL, ZZ, AZ and MS], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the chapter. The specific roles of these authors are articulated in the 'author contributions' section.

Competing interests: This commercial affiliation (to Diacarta Inc) does not alter our adherence to PLOS ONE policies on sharing data and materials.

Acknowledgments: The authors thank Dr. Ramanathan Vairavan and Eric Chu for reviewing and editing this chapter, and Christopher Teixeira, Fady Etnas, Enas Eltarazy and Eric Abbott for their technical contributions.

Author Contributions

Conceptualization: Chuanyi M. Lu, Michael Y. Sha; Data curation: Jonathan Li, Hui Ren, Larry Pastor, Yulia Loginova, Kristopher Taylor; Formal analysis: Zhao Zhang; Investigation: Jonathan Li, Hui Ren, Larry Pastor, Yulia Loginova, Joseph K. Wong, Aiguo Zhang, Michael Y. Sha; Methodology: Qing Sun, Michael Y. Sha;

Project administration: Aiguo Zhang; Software: Zhao Zhang; Supervision: Qing Sun, Roberta Madej, Joseph K. Wong, Aiguo Zhang, Chuanyi M. Lu, Michael Y. Sha; Validation: Roberta Madej, Michael Y. Sha; Writing – original draft: Qing Sun, Chuanyi M. Lu, Michael Y. Sha; Writing – review & editing: Joseph K. Wong, Aiguo Zhang, Chuanyi M. Lu, Michael Y. Sha.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 382 (2020) 727–733.

2. World Health Organization (WHO). Coronavirus. Geneva: WHO; 2020. Available at: <https://www.who.int/health-topics/coronavirus> (accessed on September 30, 2022).
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-infected pneumonia. *N Engl J Med.* 382 (2020) 1199–1207.
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 395(2020) 507–514.
5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet.* 395 (2020) 514–523.
6. Leung EC, Chow VC, Lee MK and Lai RW. Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2. *J Med Virol.* 93(1) (2020) 533–536.
7. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA et al. Virological assessment of hospitalized patients with COVID-2019. *Nature.* 581 (2020) 465–469.
8. He X, Lau EH, Wu P, Deng X, Wang J, Hao X et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med.* 26 (2020) 672–675.
9. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T et al. Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19. *J Clin Microbiol.* 58 (2020) e01438–20.
10. Kinloch N, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T et al. Suboptimal biological sampling as a probable cause of false-negative COVID-19 diagnostic test results. *J Infect Dis.* 222(2020) 899–902.
11. Wyllie A, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P., et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. medRxiv (2020). Available at: <https://doi.org/10.1101/2020.04.16.20067835> (accessed on September 30, 2022).
12. Hanson KE, Barker AP, Hillyard D.R, Gilmore N, Barrett JW, Orlandi RR et al. Self-collected anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. *J Clin Microbiol.* 58(11) (2020) e01824-20.
13. Centre for Health Protection. Severe respiratory disease associated with a novel infectious agent—letters to doctors. (2020). Available at: <https://www.chp.gov.hk/en/miniweb/letters/100063.html> (accessed on November 20, 2022).
14. FDA EUA, Individual EUAs for molecular diagnostic tests for SARS-CoV-2. Available at: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#umbrella-molecular> (accessed on November 20, 2022).
15. Sri Santosh T, Parmar R, Anand H, Srikanth K, Saritha M. A review of salivary diagnostics and its potential implication in detection of COVID-19. *Cureus.* 12 (2020) e7708.
16. To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM., et al. Consistent detection of 2019 Novel Coronavirus in saliva. *Clin Infect Dis.* 71 (2020) 841–843.

17. Chen L, Zhao J, Peng J, Li X, Deng X, Geng Z., et al. Detection of 2019-nCoV in saliva and characterization of oral symptoms in COVID-19 patients. (2020). Available at: <https://ssrn.com/abstract=3557140> (accessed on November 20, 2022).
18. Xu R, Cui B, Duan X, Zhang P, Zhou X and Yuan Q. 2020. Saliva: potential diagnostic value and transmission of 2019-nCoV. *Int J Oral Sci.* 12 (2020) 11.
19. FDA SARS-CoV-2 Reference Panel Comparative Data. Available at: <https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data?from=singlemessage&isappinstalled=0> (accessed on September 30, 2022).
20. Vogels C, Watkins A, Harden C, Brackney D, Shafer J, Wang J., et al. SalivaDirect: simple and sensitive molecular diagnostic test for SARS-COV-2 surveillance. *MedRxiv* (2020). Available at: <https://doi.org/10.1101/2020.08.03.20167791> (accessed on September 30, 2022).
21. Landy M, Criscuolo J and Peaper D. Challenges in use of saliva for detection of SARS-COV-2 RNA in symptomatic outpatients. *J Clin Virol.* 130 (2020) 104567.
22. Matic N, Lawson T, Ritchie G, Stefanovic A, Leung V, Champagne S., et al. Automated molecular testing of saliva for SARS-COV-2 detection. *MedRxiv* (2020). Available at: <https://doi.org/10.1101/2020.08.11.20170613> (accessed on September 30, 2022).
23. Fakheran O, Dehghannejad M and Khademi A. Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review. *Infect Dis Poverty.* 9 (2020) 100–107.

Chapter 6

Theranostics: Simultaneous Treatment and Diagnosis Made Possible by Nanotechnology

João Albuquerque, PhD, Ana Rute Neves, PhD, and Salette Reis, PhD

Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Portugal

shreis@ff.up.pt

Keywords: apomorphine, arginine-glycine-aspartic acid (RGD), bioavailability, cancer theranostics, cisplatin, dendrimers, diagnostics, DNA transfection, Doxorubicin, drug delivery, encapsulation, fluorescein isothiocyanate (FITC), gene silencing, gold nanoparticles (AuNPs), graphene, imaging, iron oxide nanoparticles (IONPs), laser ablation, lipid nanoparticles, liposome, magnetic resonance imaging (MRI), methotrexate, nanocage, nanocarbons, nanocarriers, nanocrystals, nanomedicine, nanoparticles (NPs), nanorod, nanosphere, nanostructured lipid carriers (NLCs), nanotechnology, near-infrared (NIR), optical properties, Paclitaxel, personalized treatment, photodynamic therapy, plasmid DNA, poly(ethylene glycol) (PEG), polyamidoamine (PAMAM), polymeric nanoparticles, quantum dots (QDs), rheumatoid arthritis, small interfering RNA, solid lipid nanoparticles (SLNs), superparamagnetic, surface functionalization, theranostics, treatment

6.1 Introduction

There is confusion over the definition of nanotechnology and, partly because of a lack of any standard nomenclature, various inconsistent definitions have sprung up over the years. One widely employed definition that is unconstrained by an arbitrary size limitation or dimensionality is listed below [1a]: “The design, characterization, production, and application of structures, devices, and systems by controlled manipulation of size and shape at the nanometer scale (atomic, molecular, and macromolecular scale) that produces structures, devices, and systems with at least one novel/superior characteristic or property.”

Recently in the field of nanotechnology, the understanding and manipulation of materials with dimensions within the nanoscale have been on the rise and have led to the emergence of several more specific fields. The application of nanotechnology in medicine, for example, has opened up a wide variety of

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

possibilities for new treatments and diagnosis methods. Nanomedicine takes advantage of nanotechnology to propose alternatives to current or even past treatments. For instance, it allows the encapsulation of therapeutic agents into nanoparticles (NPs) that can be tailored and even targeted at a specific application, organ, or tissue. This nanomedicine approach increases the bioavailability of the drugs and lowers their toxicity by decreasing the overall amount that has to be used while also increasing the percentage that reaches the desired site, thus increasing the efficacy of the treatment. The same approach can be applied to imaging or contrasting agents, increasing the specificity and, therefore, the detail and reliability of the obtained imaging results.

Nowadays, nanomedicine can go even further when considering nanocarrier approaches. In fact, instead of encapsulating either therapeutic or imaging agents, nanotechnology is able to encapsulate both of them within the same particle. This coencapsulation allows for simultaneous treatment and imaging, this being a new concept known as theranostics: the combination of therapy with diagnosis. This concept has recently caught the attention of many researchers across the world, and much effort has been put into attempting to use it in the clinic, from the encapsulation of drugs for systemic diseases with iron as a magnetic resonance imaging (MRI) contrast agent, to the use of magnetic NPs that act as both therapeutic agent and imaging contrast agent.

This chapter will focus on the nanotechnology applications for theranostic-based approaches in medicine, reviewing what is already being researched in the labs and their possible applications in the clinics, as well as other possibilities in the future of medicine and health care.

The term “theranostic” was first used in 2002 and was described as the capability of a compound or methodology to function simultaneously as a diagnostic and a therapeutic agent. This emerging novel field arose with the acceptance that a universal elixir that can treat all diseases and conditions simply does not exist and that most diseases, even for different patients with the same disease, sometimes require individualized treatment [1b–3]. The main goal of theranostics is to develop methodologies that allow treatment and simultaneous follow-up of every patient, with the hope that in the long term the treatment can be tuned for each individual, increasing its efficacy and improving the prognosis [1b–4].

6.2 Nanotechnology-Based Approaches

Nanotechnology is a scientific field that encompasses the understanding and manipulation of materials with dimensions in the nanoscale [5–10]. It comprises knowledge from fundamental physics, chemistry, biology, and engineering, with applications spreading to a wide variety of scientific areas, from computer engineering and electronics to medicine and food products [3, 8, 11–13].

Within the field of nanotechnology, several more specific subfields exist, such as the application of nanotechnology to the medicine and health sciences (nanomedicine). In the past few years, nanomedicine has taken advantage of different strategies and materials in an attempt to improve diagnosis, imaging, and treatment of several diseases and conditions [1, 4, 5, 14, 15]. These attempts include drug delivery to bypass toxicity and improve bioavailability [16], the use of iron NPs that can be guided to a specific location and ablate tumors via application of magnetic field [17], and the double encapsulation of a therapeutic and an imaging agent within surface-modified NPs for targeted theranostics [18].

Prior to the concept of theranostics, nanomedicine had already used NPs to encapsulate drugs and imaging agents, although in separate carriers [6, 19, 20]. This earlier and independent concept was achieved through drug delivery, and its main objectives [6, 19, 20] were:

- *Increased overall bioavailability*, by encapsulating the agent within nanocarriers that are able to avoid recognition in the blood and improve the stability of these agents in the body
- *Reduced toxicity to healthy organs/tissues*, by using selective or targeted nanocarriers that only accumulate in the intended organ or tissue, allowing reduction in the total amount of drugs

Nowadays, nanomedicine has gone a step further in the field of drug delivery by altering the NPs to improve their applications and the efficacy of the proposed formulation. The surface of the particles can be functionalized with different molecules to achieve different goals, such as immune system avoidance, specific targeting, and increased cell uptake [21–23].

Figure 6.1 is a schematic representation of a nanoparticle to be used in drug delivery, including some examples of surface functionalization and a summary of the possibilities that nanomedicine provides.




Figure 6.1 Schematic representation of multifunctional NPs for drug delivery applications.

6.2.1 Coencapsulation/Association of Therapeutic and Imaging Agents

Theranostics brought a new light to the drug delivery concept. In fact, if we can encapsulate a therapeutic agent or an imaging agent inside a NP, why can't we encapsulate both of them at the same time and inside the same NP? In this context, theranostic approaches based on the coencapsulation of a therapeutic and an imaging agent arose.

There are numerous agents that have already been successfully coencapsulated inside a wide variety of NPs. In this section, some of these proposed formulations will be presented, grouped by NP type.

6.2.1.1 Lipid nanoparticles

Lipid NPs can be divided into three major types. Solid lipid nanoparticles (SLNs) are NPs composed of lipids that are solid at body temperature (37°C) and that arrange themselves in spherical solid particles with a crystal-like matrix [24, 25]; nanostructured lipid carriers (NLCs) are NPs composed of a mixture of lipids that are solid and liquid at body temperature (37°C) and arrange themselves in spherical solid particles with an amorphous matrix [24, 25]; and liposomes are NPs composed of amphiphilic lipids that arrange themselves in a thin, spherical bilayer of lipids, containing an aqueous phase inside, similar to a cellular membrane [13, 24, 26, 27].

All these NPs have proven to be biocompatible and are capable of therapeutic and imaging agent coencapsulation within their matrix or membrane and core [24, 27, 28]. It is also possible to functionalize the surface of these NPs either by taking advantage of existing functional groups or by altering the surface to present additional available groups [18, 29, 30]. These properties, combined with the possibility to scale up lipid NP production, make these NPs promising candidates for theranostic applications. Table 6.1 presents some examples of theranostic applications based on lipid NPs.

Table 6.1 List of some theranostic applications of lipid NPs

Type of NPs	Therapeutic agent	Imaging agent	Application	Ref.
SLN	Paclitaxel and small interfering RNA	Quantum dots	Cancer theranostics	[31]
SLN	Methotrexate	Superparamagnetic iron oxide NPs	Rheumatoid arthritis treatment	[18]
NLC	DIM-C-pPhC6H5	XenolightDiR	Lung cancer treatment	[32]
Liposome	Small interfering RNA	Quantum dots	Improved and monitored gene silencing	[33]
Liposome	Doxorubicin	Quantum dots	Cancer treatment	[34]
Liposome	Plasmid DNA	Gold NPs	DNA transfection	[35]

6.2.1.2 Polymeric nanoparticles

Polymeric NPs can be composed of a wide variety of polymers, both synthetic—poly(lactic-co-glycolic) acid (PLGA), poly(ϵ -caprolactone) (PCL), etc.—and natural (chitosan, alginate, etc.) and produced by several different methods, depending on the needs of the encapsulated agent [1, 36]. The polymer PLGA has inclusively been approved by the Food and Drug Administration (FDA). But regardless of the method used, the production of these NPs relies on condensation reaction between monomers, which can all be the same molecule or different molecules. In the latter case, the ratio between different monomers can vary and this variation influences molecular weight and other properties [36]. The research performed with polymeric NPs for drug delivery and theranostic purposes is extensive and widespread. Some examples of the suggested applications are listed in Table 6.2.

Table 6.2 List of some theranostic applications of polymeric NPs

Polymer	Therapeutic agent	Imaging agent	Application	Ref.
PLGA	Meso-tetraphenylporpholactol	Meso-tetraphenylporpholactol	Dual imaging/photodynamic therapy of tumors	[37]
PLGA	Methotrexate	Superparamagnetic iron oxide NPs	Rheumatoid arthritis treatment	[38]
PLA or PCL	Doxorubicin	Perfluoropentane	Ultrasound-assisted drug delivery and imaging in cancer	[39]
HPMA	Doxorubicin	(123I or 125I) iodine	Treatment and imaging in melanomas and mammary carcinomas	[40]
Chitosan	Paclitaxel	Cy5.5	Cancer treatment and imaging	[41]

Abbreviations: PLGA, poly(lactic-co-glycolic) acid; PLA, poly(L-lactide); PCL, poly(ϵ -caprolactone); HPMA, N-(2-hydroxypropyl)methacrylamide.

6.2.1.3 Dendrimers

A dendrimer is synthetic macromolecule composed of a central core and surrounded by several repeated branches of dendrons. This composition and organization results in a nearly perfect three-dimensional geometric shape, and its size and molecular weight depend on the generation of the dendrimer [42]. Dendrimers are produced by stepwise chemical methods, which allow for different levels of branches to be produced. Every level or generation consists of a “layer” of dendrons linked to the previous layer, the first level being linked to the central core [13, 42]. Due to their production mechanism, dendrimers have a uniform size, shape, and molecular weight. Since the generations are produced in a stepwise manner, it is also relatively easy to incorporate functional groups on the surface of dendrimer NPs and ensure they are well distributed [13].

The most commonly studied dendrimers for theranostic applications are composed of polyamidoamine (PAMAM), coated or not with poly(ethylene glycol) (PEG), but other molecules have also been suggested. These dendrimer-based approaches have been proposed for several theranostic applications, as shown in Table 6.3.

For instance, G5 PAMAM dendrimers modified with fluorescein isothiocyanate (FITC) and arginine-glycine-aspartic acid (RGD) with a terminal PEG have been developed to encapsulate doxorubicin. FITC functions as a fluorescent imaging agent, RGD-PEG was used as a targeting molecule, and doxorubicin is a well-known anticancer drug. These agents conferred theranostic and targeting capabilities on the dendrimers that have been studied for applications in glioblastomas [43]. Besides that, G5 PAMAM dendrimers loaded with gold NPs and surface-modified with folic acid and α -tocopheryl succinate, both with PEG spacers, have also been established. The gold NPs were used in computed tomography imaging, with folic acid as a targeting agent, and α -tocopheryl succinate is known as an anticancer drug. The different agents combined resulted in theranostic capabilities for the dendrimers and were suggested for cancer treatment and imaging [44].

Table 6.3 List of some theranostic applications of dendrimers

Dendrimer	Therapeutic agent	Imaging agent	Application	Ref.
G5 PAMAM	Doxorubicin	FITC	Glioblastoma treatment	[43]
G5 PAMAM	α -Tocopheryl succinate	Gold NPs	Cancer treatment and imaging	[44]
G3.5 PAMAM	Doxorubicin	Superparamagnetic iron oxide NPs	Tumor treatment	[45]

Finally, G3.5 PAMAM dendrimers modified with PEG and folic acid, with a core consisting of superparamagnetic iron oxide nanoparticles (SPIONs) and conjugated with doxorubicin have also been produced. SPIONs were used as contrast agents in MRI, folic acid enabled the active targeting of folic receptors, and doxorubicin is a well-known anticancer drug. The combination of these agents enabled targeted theranostics when using these dendrimers, proposed for use in tumors [45].

6.2.1.4 Silica nanoparticles

Silica is considered a safe material and has inclusively been used in surgical implants in the past. Silica NPs can be synthesized by both chemical and physical methods, and their size and morphology have been reported to be accurately controlled by the production parameters [1, 3, 46]. It is also possible to include functional groups on the surface by adding coprecursors during NP synthesis, such as aminopropyltrimethoxysilane and mercaptopropylmethoxysilane, which

supply amine and thiol groups, respectively [46]. Biomolecules or smaller NPs can then be integrated either by previous coupling to the precursor molecules or by direct encapsulation within the silica matrix [1, 3, 46]. Silica NPs with highly porous matrices have also been reported, with the advantage of allowing a postencapsulation plugging through the pores, slowing agent release [46].

Molecules can be easily introduced into silica NPs during their production. For example, the coencapsulation of 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide (HPPH) and 9,10-bis(4'-[4''-aminostyryl]styryl)anthracene (BDSA) within silica NPs using such methods has been proposed for cancer treatment [47]. HPPH is a fluorescent compound that has been shown to have increased fluorescent activity when encapsulated in silica NPs. BDSA is a two-photon absorbing dye that can absorb near-infrared (NIR) rays and transfer the energy to HPPH, which, in turn, enables its photodynamic therapeutic properties [47]. Another approach consisted in using luminescent silica NPs to deliver doxorubicin to tumors. The luminescence was generated by the defects located at the interfaces of Si-SiO₂ and by quantum confinement effects [48].

6.2.1.5 Iron oxide nanoparticles

Iron oxide nanoparticles (IONPs) are nanocrystals of magnetite or hematite usually coated with other molecules that depend on the production method and alter the colloidal properties of the NPs [17, 46, 49]. IONPs smaller than 20 nm have been shown to be superparamagnetic, a state where particles show zero magnetism unless subjected to a magnetic field [49].

Traditionally, IONPs have been synthesized in aqueous solution by the coprecipitation of iron ions (II and III), where additives have been added to confer colloidal properties to the formulations. More recently, other methods, such as high-temperature decomposition, have been proposed and proven to have a more accurate control of the NPs' size and increased crystallinity, which translates into better magnetic properties. However, the latter method presents the disadvantage of NPs being coated with a thick alkyl layer, which may have to be substituted by ligand exchange or ligand addition for some applications [46, 49].

Regardless of the production method IONPs have been shown to be biocompatible and relatively cheap. They also possess superior magnetic properties and have been surface-functionalized to allow the coupling of biomolecules to their surface [17, 46, 49]. Considering this latter case, IONPs can be used in theranostics with two main approaches for conjugation: (i) the IONPs can be coencapsulated within a larger NP together with a therapeutic agent and (ii) a therapeutic agent can be coupled to the surface of IONPs. In both cases, the IONPs are the imaging agents commonly used as contrast agents in MRI [17, 46]. Examples of the proposed theranostic approaches already implemented are shown in Table 6.4.

Table 6.4 List of some theranostic applications of IONPs

Type of NPs	Therapeutic agent	Imaging agent	Application	Ref.
IONPs	Cisplatin	IONPs	Breast cancer treatment	[50]
IONPs	Small interfering RNA	IONPs	Gastric cancer treatment	[51]
Lipid	Small interfering RNA	IONPs	Proof of concept	[52]
Polymeric	Doxorubicin	IONPs	Lung carcinoma treatment	[53]

For instance, porous IONPs have been produced by controlled oxidation at 250°C followed by acid etching. The NPs have been loaded with cisplatin and coupled with herceptin for targeted delivery and controlled release in breast cancer. Cisplatin is an anticancer drug and was adsorbed in the pores of the IONPs, while herceptin provided targeting capability to the NPs [50]. IONPs coated with cationic lipids and coupled with small interfering RNA have also been developed, which outperformed the existing commercial particles in gastric cancer models. The IONPs were guided using external magnetic fields and accumulation and increased efficacy were observed at the targeted site [51]. Moreover, small interfering RNA and PEGylated cyclic RGD peptide have been also conjugated to IONPs as a promising strategy. The RGD functioned as the targeting agent, and the small interfering RNA was successfully transfected in a proof-of-concept study [52]. Furthermore, doxorubicin has been loaded into nonfouling polymer-coated IONPs for applications in lung carcinomas. In this case, the polymer was poly ([3-(trimethoxysilyl) propyl]-*r*-[poly(ethylene glycol) methyl ether methacrylate]) (poly(TMSMA-*r*-PEGMA), the IONPs were used as MRI contrast agents, and doxorubicin was the therapeutic agent [53].

6.2.1.6 Gold nanoparticles

Gold nanoparticles (AuNPs) are metallic NPs that have been shown to possess unique properties in imaging applications [46, 54, 55]. They can be produced in many sizes and shapes, and both of these parameters will result in NPs with different optical properties. AuNPs can be produced by several methods, both chemical and physical (such as laser ablation), and the production parameters can be fine-tuned to accurately control the NP size and morphology, both of which influence the absorption spectrum of the NPs [54, 55]. Additionally, Au surfaces have a high affinity for thiol groups, enabling simple and effective surface functionalization of these NPs. The affinity arises by use of molecules with a thiol group on one end or even by simply adding a thiol tag to a selected molecule [21, 54].

This tunable absorption spectrum and ease of surface functionalization, coupled with a good biodistribution and a low toxicity, have made AuNPs good candidates for several proposed bioapplications with theranostic approaches [13, 46, 54, 55]. These theranostic approaches have strategies similar to those for IONPs. The AuNP can be either coencapsulated with a therapeutic agent inside a

bigger NP or directly coupled to a therapeutic agent, with the AuNP also functioning as the imaging agent [54]. Some examples can be found in Table 6.5.

Table 6.5 List of some theranostic applications using AuNPs

Shape of NPs	Therapeutic agent	Imaging agent	Application	Refs.
Nanospheres	Hairpin DNA labeled with a fluorophore	AuNPs	Colorectal carcinoma treatment	[56]
Nanospheres	Plasmonic AuNPs covered by a thin layer of medium	AuNPs	Prostate cancer treatment	[57, 58]
Nanospheres	Insulin	AuNPs	Diabetes management	[59]
Nanocages	Yb-2,4-dimethoxy-hematoporphyrin	Yb-2,4-dimethoxy-hematoporphyrin	Photothermic and photodynamic therapy simultaneously with imaging of cervical tumors	[60]
Nanorods	Doxorubicin	AuNPs	Cancer treatment	[61]
Nanostars	Methylene blue	Methylene blue	Breast cancer treatment	[62]

6.2.1.7 Quantum dots

Quantum dots (QDs) consist of nanocrystals formed by semiconductor materials that have been shown to possess unique optical properties [21, 46, 63]. QDs are brighter, have a narrower emission spectrum, and are more photostable when compared to organic dyes and fluorescent proteins [46, 63]. The first QDs developed showed emissions around the visible spectrum, but recently QDs have been created that emit light mainly in the infrared and NIR region, making them more promising for bioimaging considering the low tissue penetration of visible light. Moreover, the optical properties of QDs can be accurately adjusted by tuning their size and composition [46, 63].

The production method of QDs is very similar to the previously described method of pyrolysis for IONP production [46]. The selected metallic precursors are heated in organic solvents to achieve particle formation, and adequate surfactants are added to control particle growth. These particles are also usually coated with a ZnS layer, which has been proven to enhance optical properties and also provides a shell that prevents leakage of the toxic core constituents. As a result of the production method, QDs are coated with a thick alkyl layer, rendering them hydrophobic [46, 63]. This layer can be replaced using ligand exchange or ligand addition, again similar to IONPs [46]. Recently, the production of magnetic QDs has also been reported. These magnetic QDs consist of an Fe_3O_4 core and a ZnO shell and may provide QDs with alternative targeting and functional capabilities [64].

QDs' unique and superior optical properties as well as their proven considerable renal clearance have made them a promising candidate for in vivo imaging approaches. QDs can also be used in theranostic applications if we apply strategies similar to those used for IONPs and AuNPs, either by coencapsulation with a therapeutic agent or by direct coupling of a therapeutic agent [21, 46, 63]. Several theranostic approaches, comprising both previously mentioned strategies, using QDs have been proposed and studied (Table 6.6).

Table 6.6 List of some theranostic applications using QDs

Type of NP	Therapeutic agent	Imaging agent	Application	Refs.
QDs	Doxorubicin or mitoxantrone	QDs	Tumor treatment	[65, 66]
Liposomes	Apomorphine	QDs	Brain tumor treatment	[67, 68]
Polymeric	Small interfering RNA	QDs	Cancer treatment	[69]

For instance, QDs functionalized with A10 RNA aptamer loaded with doxorubicin, by intercalation of the drug with the aptamer sequence, have been studied. The A10 RNA aptamer recognizes the prostate cell membrane and together with doxorubicin acts as a fluorescence-quencher, resulting in the attenuation of the fluorescence activity of the formulation. However, when the QDs enter cells, doxorubicin begins to be gradually released and the fluorescent properties of the QDs are recovered, resulting in both therapy and imaging of the targeted tumor cells [65]. A similar attempt with positive results has been proposed involving direct binding of mitoxantrone to QDs [66]. PEGylated QDs can also be loaded into the aqueous core of cationic liposomes. The liposomes increase the uptake by tumor cells, resulting in superior staining of the tumor cells. It is also possible to surface-functionalize the liposome and load therapeutic agents in order to achieve theranostic effects [67]. A similar approach has also shown improved treatment and imaging in mouse brain tumors; the approach involves loading QDs inside the bilayer of liposomes while dissolving apomorphine in the aqueous core of the liposomes [68]. Hydrophobic triblock biodegradable copolymers, composed of PEG, PCL, and poly(ethylene imine), have been coloaded with QDs and fluorescently labeled "small interfering RNA." The polymeric NPs increased cellular uptake of the agents, and the coencapsulated agents acted as a prototype pair for fluorescence resonance energy transfer (also known as Förster resonance energy transfer [FRET]) with considerable efficiency [69].

6.2.1.8 Nanocarbons

Carbon nanomaterials, or nanocarbons, are structures composed solely of carbon and can be zero-dimensional (fullerene and carbon dots [CDs]), one-dimensional (carbon nanotubes [CNTs]), two-dimensional (graphene), or three-dimensional (nanodiamonds) [70]. Many of these nanocarbons possess inherent optical properties, making them useful in imaging, and some of them, like CNTs and

graphene, also present exceptional electrical properties that could make them very useful in sensing applications of biomedicine. Moreover, nanocarbons, especially single-walled nanocarbons, have a very high surface area available for functionalization or therapy/imaging agent coupling. This functionalization and coupling can occur by both covalent and noncovalent methods [13, 46, 70, 71].

Table 6.7 List of some theranostic applications using nanocarbons

Type of NP	Therapeutic agent	Imaging agent	Application	Refs.
Carbon nanotubes	Small interfering RNA	Carbon nanotubes	Human T cells and primary cells applications	[72, 73]
Nanodiamonds	Doxorubicin	Radiation-damaged nanodiamonds	Colorectal carcinoma treatment	[74, 75]
Fullerene	Fullerene	Gd ³⁺	Tumor treatment	[76, 77]
Carbon dots	Oxaliplatin(IV)-COOH derivative	Carbon dots	Cancer treatment	[78]
Graphene	Graphene	Cu	Endothelial tumor treatment	[79]

However, some nanocarbons, like CNTs, have been found to be toxic to the organism as well as nonbiodegradable, which could limit their use in bioapplications [46, 70]. New studies have shown that nanocarbon's toxicity is greatly influenced by their surface and that surface functionalized nanocarbons have much lower toxicity than nonfunctionalized ones [71]. Still, more studies are required to assess long-term complications of nanocarbons before their safety can be correctly evaluated.

Regardless, the inherent properties and the ease of their functionalization combined with their ability to be taken up by cells make them promising candidates in future theranostic applications [46, 71]. In fact, some theranostic approaches based on nanocarbons have already been proposed and studied, as can be seen in Table 6.7.

6.2.2 Theranostic Agents and Nanoparticles

In the previous section, theranostic approaches that relied on the association of a therapeutic agent and an imaging agent were presented. This section will focus on NPs and agents that can simultaneously function as therapeutic and imaging agents themselves.

6.2.2.1 Theranostic nanoparticles

Some of the NPs described in the previous chapter have the potential to be theranostic agents on their own. For example, besides the imaging potential described in the previous section, IONPs can be used for hyperthermia [17, 46].

A magnetic field can be used to guide the IONPs to the targeted area and once there, if an alternate magnetic field is applied, the IONPs will convert the electromagnetic energy into heat, resulting in the thermal ablation of the surrounding tissue [2, 17]. Considering gold nanoshells, these NPs are gold shells, each NP having a silica core (60 nm) and a gold outer shell (10–12 nm) [1, 55]. They have been shown to both absorb and scatter incident light, resulting in the rise of the temperature around the NPs. Therefore, these NPs are capable of functioning as both imaging contrasting agents and photothermic actuators [55]. QDs have also great potential for imaging applications coupled with photodynamic therapy (PDT) [46, 63]. It has been found that QDs can be activated by light and then transfer their triplet state energy to oxygen molecules in the proximity, resulting in reactive oxygen radicals that damage the surrounding tissues [46]. Finally, nanocarbons also present optical properties that can be used for theranostic applications. CNTs and graphene derivatives with strong absorbance in the NIR region can be useful for photothermic ablation [80], and fullerenes can be used for photodynamic and photothermic therapies and as contrasting agents in MRI [77].

The discovery of these theranostic NPs brings new possibilities to the future of medicine, such as a potential simultaneous diagnosis, treatment, and imaging without the use of toxic drugs with adverse side effects for the patients.

6.2.2.2 Theranostic compounds

Similar to NPs that can have potential theranostic applications on their own some bioactive compounds and molecules also have this capability. For example, photosensitizers are capable of being both imaging and therapeutic agents. Photosensitizers are molecules that are able to produce changes in other molecules when subjected to light [81, 82]. They are essential in PDT since when excited by light (the wavelength depends on the compound) the photosensitizers produce highly reactive singlet oxygen, which then reacts with and destroys nearby molecules, cells, and tissues. Most photosensitizers are also bright fluorophores by nature, and almost all of them tend to emit light in the NIR spectra, making them useful in imaging applications [81, 82]. There are also recent reports about the existence of activatable molecules that only gain photosensitizer properties when activated, by either temperature, pH, or another chemical agent [81]. These latter photosensitizers are proposed to be used as smart drugs in the future [81].

Examples of such compounds are porphyrins, molecules consisting of four pyrrole subunits linked together by four methine bridges [83]. These molecules have well-described photosensitizing properties and have also been shown to be capable of passively accumulating in tumor tissues and residing there for a considerable period of time. Considering these properties, porphyrins have been considered for several imaging approaches, such as fluorescence and acoustic imaging and MRI, as well as for different therapies, such as photo- and sonodynamic

therapy [83]. These approaches can be combined to create theranostic strategies using only one agent, which is simultaneously an imaging and therapeutic one.

However, porphyrins, and many other photosensitizers, such as bacteriochlorophyll- α , methylene blue, silicon naphthalocyanine, rose Bengal, and Chlorin- e_6 , all of which are commonly used [81], have been found to have poor tumor selectivity and accumulate at high rates in the skin [83]. This limitation can be overcome by using nanotechnology approaches. Photosensitizers can be encapsulated in or coupled to one of the NPs described in the previous sections to increase their bioavailability and to promote a targeted and more specific delivery to the intended site [83]. Overall, the combination of a theranostic agent with nanotechnology can greatly improve the efficacy of the formulation.

6.3 Concluding Remarks

Nowadays, nanotechnology has been largely applied to medicine and biomedical applications. Nanomedicine has brought the possibility to achieve better treatment and imaging capabilities to the clinic and even to achieve both of them at the same time. As was shown, the studies regarding the application of NPs toward theranostic are very widespread and comprise a considerable variety of NPs, therapeutic agents, and imaging agents. Much work and understanding are still required, but these days, when a need for individualized medicine is on the rise, nanotechnology may potentiate existing treatments and imaging methods and result in an overall superior life span and quality.

Abbreviations

AuNPs:	gold nanoparticles
BDSA:	9,10-bis(4'-[4''-aminostyryl]styryl)anthracene
CDs:	carbon dots
CNTs:	carbon nanotubes
RGD:	arginine-glycine-aspartic acid
FDA:	US Food and Drug Administration
FITC:	fluorescein isothiocyanate
FRET:	Förster resonance energy transfer
HPMA:	N-(2-hydroxypropyl)methacrylamide
HPPH:	2-devinyl-2-(1-hexyloxyethyl)pyrophephorbide
IONPs:	iron oxide nanoparticles
MRI:	magnetic resonance imaging
NIR:	near-infrared
NLCs:	nanostructured lipid carriers
NPs:	nanoparticles
PAMAM:	polyamidoamine
PCL:	poly(ϵ -caprolactone)

PDT:	photodynamic therapy
PEG:	poly(ethylene glycol)
PLA:	poly(L-lactide)
PLGA:	poly(lactic-co-glycolic) acid
QDs:	quantum dots
SLNs:	solid lipid nanoparticles
SPIONs:	superparamagnetic iron oxide nanoparticles

Disclosures and Conflict of Interest

This chapter was originally published as: Albuquerque, J., Neves, A. R., and Reis, S. (2018). Theranostics: Simultaneous treatment and diagnosis made possible by nanotechnology. In: Neves, A. R., Reis, S., eds. *Nanoparticles in Life Sciences and Biomedicine*, Jenny Stanford Publishing, Singapore, chapter 15, pp. 443–465. It appears here, with edits and updates, by kind permission of the publisher.

Acknowledgments: The work reflected in this chapter received financial support from the European Union (FEDER funds) and National Funds (*Fundação para a Ciência e Tecnologia* and *Ministério da Educação e Ciência* [FCT/MEC]) under the partnership agreement PT2020 UID/MULTI/04378/2013-POCI/01/0145/FEDER/007728. João Albuquerque thanks FCT, SANFEED Doctoral Programme, and PREMIX® for his PhD grant reference PD/BDE/114426/2016. Ana Rute Neves also thanks ICETA for her postdoctoral grant (FOOD_RL3_PHD_GABAI_02) under the project NORTE-01-0145-FEDER-00001.

References

- 1a. Bawa, R. What's in a Name? Defining "Nano" in the Context of Drug Delivery. In: *Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy, and Clinical Applications* (Bawa, R., Audette, G. F., and Rubinstein, I., eds), Jenny Stanford Publishing, Singapore, 2016, pp. 127–168.
- 1b. Kelkar, S.S., et al. Theranostics: combining imaging and therapy. *Bioconjug Chem*, 2011, **22**(10):1879–1903.
2. Xie, J., et al. Magnetic nanoparticle-based theranostics. *Theranostics*, 2012, **2**:122–124.
3. Choi, K.Y., et al. Theranostic nanoplatfoms for simultaneous cancer imaging and therapy: current approaches and future perspectives. *Nanoscale*, 2012, **4**(2):330–342.
4. Prabhu, P., et al. The upcoming field of theranostic nanomedicine: an overview. *J Biomed Nanotechnol*, 2012, **8**(6):859–882.
5. Bamrungsap, S., et al. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. *Nanomedicine (Lond)*, 2012, **7**(8):1253–1271.
6. Sehgal, R. Nanotechnology and its applications in drug delivery: a review. *Int J Med Mol Med*, 2013, **3**(1):WMC002867.
7. Sanna, V., et al. Targeted therapy using nanotechnology: focus on cancer. *Int J Nanomed*, 2014, **9**:467–483.

8. Westesen, K., et al. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. *J Controlled Release*, 1997, **48**(2-3):223-236.
9. Svenson, S., et al. *Multifunctional Nanoparticles for Drug Delivery Applications: Imaging, Targeting, and Delivery*. Springer, New York, 2012.
10. Shang, L., et al. Engineered nanoparticles interacting with cells: size matters. *J Nanobiotechnol*, 2014, **12**:5.
11. Panyam, J., et al. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Adv Drug Deliv Rev*, 2003, **55**(3):329-347.
12. Scott, N.R. Nanotechnology and animal health. *Rev Sci Tech Off Int Epiz*, 2005, **24**(1): 425-432.
13. Chan, W.C.W. *Bio-Applications of Nanoparticles*. Springer Science + Business Media, New York; Landes Bioscience, Austin, Texas, 2007.
14. Moghimi, S.M., et al. Nanomedicine: current status and future prospects. *FASEB J*, 2005, **19**(3):311-330.
15. Sumer, B., et al. Theranostic nanomedicine for cancer. *Nanomedicine*, 2008, **3**(2): 137-140.
16. Zhang, Z.H., et al. Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin. *Int J Nanomed*, 2012, **7**(1):3333-3339.
17. Kandasamy, G., et al. Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics. *Int J Pharm*, 2015, **496**(2): 191-218.
18. Albuquerque, J., et al. Solid lipid nanoparticles: a potential multifunctional approach towards rheumatoid arthritis theranostics. *Molecules*, 2015, **20**(6):11103-11118.
19. Couvreur, P. Nanoparticles in drug delivery: past, present and future. *Adv Drug Deliv Rev*, 2013, **65**(1):21-23.
20. Sun, T.M., et al. Engineered nanoparticles for drug delivery in cancer therapy. *Angew Chem Int Ed*, 2014, **53**(46):12320-12364.
21. Sperling, R.A., et al. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. *Philos Trans A Math Phys Eng Sci*, 2010, **368**(1915): 1333-1383.
22. Sapsford, K.E., et al. Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. *Chem Rev*, 2013, **113**(3):1904-2074.
23. Pan, H., et al. Programmable nanoparticle functionalization for in vivo targeting. *FASEB J*, 2013, **27**(1):255-264.
24. Mashaghi, S., et al. Lipid nanotechnology. *Int J Mol Sci*, 2013, **14**(2):4242-4282.
25. Weber, S., et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. *Eur J Pharm Biopharm*, 2013, **86**(1):7-22.
26. Charron, D.M., et al. Theranostic lipid nanoparticles for cancer medicine. *Cancer Treat Res*, 2015, **166**:103-127.
27. Al-Jamal, W.T., et al. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. *Acc Chem Res*, 2011, **44**(10): 1094-1104.

28. Ekambaram, P., et al. Solid lipid nanoparticles: review. *Sci Rev Chem Commun*, 2012, **2**(1):80–102.
29. Mehnert, W., et al. Solid lipid nanoparticles: production, characterization and applications. *Adv Drug Deliv Rev*, 2001, **47**(2–3):165–196.
30. Shastri, V., et al. Functionalized solid lipid nanoparticles and methods of making and using same, 2006. United States Patent Application 20060083781 (publication date: April 20, 2006).
31. Bae, K.H., et al. Optically traceable solid lipid nanoparticles loaded with sirna and paclitaxel for synergistic chemotherapy with in situ imaging. *Adv Healthcare Mater*, 2013, **2**(4):576–584.
32. Patel, A.R., et al. Theranostic tumor homing nanocarriers for the treatment of lung cancer. *Nanomedicine*, 2014, **10**(5):1053–1063.
33. Chen, A.A., et al. Quantum dots to monitor RNAi delivery and improve gene silencing. *Nucleic Acids Res*, 2005, **33**(22):e190.
34. Weng, K.C., et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. *Nano Lett*, 2008, **8**(9):2851–2857.
35. Li, D., et al. The enhancement of transfection efficiency of cationic liposomes by didodecyldimethylammonium bromide coated gold nanoparticles. *Biomaterials*, 2010, **31**(7):1850–1857.
36. Wang, Z., et al. Polymeric materials for theranostic applications. *Pharm Res*, 2014, **31**(6):1358–1376.
37. McCarthy, J.R., et al. Polymeric nanoparticle preparation that eradicates tumors. *Nano Lett*, 2005, **5**(12):2552–2556.
38. Moura, C.C., et al. Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application. *Int J Nanomed*, 2014, **9**(1):4911–4922.
39. Rapoport, N., et al. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. *J Natl Cancer Inst*, 2007, **99**(14):1095–1106.
40. Pimm, M.V., et al. Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. *J Drug Target*, 1996, **3**(5):375–383.
41. Kim, K., et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. *J Controlled Release*, 2010, **146**(2):219–227.
42. Sk, U.H., et al. Dendrimers for theranostic applications. *Biomol Concepts*, 2015, **6**(3): 205–217.
43. He, X., et al. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells. *Colloids Surf B*, 2015, **125**:82–89.
44. Zhu, J., et al. Targeted cancer theranostics using alpha-tocopheryl succinate-conjugated multifunctional dendrimer-entrapped gold nanoparticles. *Biomaterials*, 2014, **35**(26):7635–7646.
45. Chang, Y., et al. Synthesis and characterization of DOX-conjugated dendrimer-modified magnetic iron oxide conjugates for magnetic resonance imaging, targeting, and drug delivery. *J Mater Chem*, 2012, **22**(19):9594–9601.

46. Xie, J., et al. Nanoparticle-based theranostic agents. *Adv Drug Deliv Rev*, 2010, **62**(11): 1064–1079.
47. Roy, I., et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. *J Am Chem Soc*, 2003, **125**(26):7860–7865.
48. Park, K., et al. New generation of multifunctional nanoparticles for cancer imaging and therapy. *Adv Funct Mater*, 2009, **19**(10):1553–1566.
49. Lin, M.M., et al. Development of superparamagnetic iron oxide nanoparticles (SPIONS) for translation to clinical applications. *IEEE Trans Nanobiosci*, 2008, **7**(4):298–305.
50. Cheng, K., et al. Porous hollow Fe(3)O(4) nanoparticles for targeted delivery and controlled release of cisplatin. *J Am Chem Soc*, 2009, **131**(30):10637–10644.
51. Namiki, Y., et al. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. *Nat Nanotechnol*, 2009, **4**(9):598–606.
52. Lee, J.H., et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. *Angew Chem Int Ed Engl*, 2009, **48**(23): 4174–4179.
53. Yu, M.K., et al. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. *Angew Chem Int Ed Engl*, 2008, **47**(29):5362–5365.
54. Ashraf, S., et al. Gold-Based nanomaterials for applications in nanomedicine. *Top Curr Chem*, 2016, **370**:169–202.
55. Bardhan, R., et al. Theranostic nanoshells: from probe design to imaging and treatment of cancer. *Acc Chem Res*, 2011, **44**(10):936–946.
56. Conde, J., et al. Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. *Biomaterials*, 2013, **34**(10):2516–2523.
57. Wagner, D.S., et al. The in vivo performance of plasmonic nanobubbles as cell theranostic agents in zebrafish hosting prostate cancer xenografts. *Biomaterials*, 2010, **31**(29): 7567–7574.
58. Lukianova-Hleb, E.Y., et al. Cell-specific multifunctional processing of heterogeneous cell systems in a single laser pulse treatment. *ACS Nano*, 2012, **6**(12):10973–10981.
59. Bhumkar, D.R., et al. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. *Pharm Res*, 2007, **24**(8):1415–1426.
60. Khlebtsov, B., et al. Nanocomposites containing silica-coated gold-silver nanocages and Yb-2,4-dimethoxyhematoporphyrin: multifunctional capability of IR-luminescence detection, photosensitization, and photothermolysis. *ACS Nano*, 2011, **5**(9):7077–7089.
61. Venkatesan, R., et al. Doxorubicin conjugated gold nanorods: A sustained drug delivery carrier for improved anticancer therapy. *J Mater Chem B*, 2013, **1**(7):1010–1018.
62. Fales, A.M., et al. Silica-coated gold nanostars for combined surface-enhanced Raman scattering (SERS) detection and singlet-oxygen generation: a potential nanoplatform for theranostics. *Langmuir*, 2011, **27**(19):12186–12190.
63. Ho, Y.P., et al. Quantum dot-based theranostics. *Nanoscale*, 2010, **2**(1):60–68.
64. Singh, S.P. Multifunctional magnetic quantum dots for cancer theranostics. *J Biomed Nanotechnol*, 2011, **7**(1):95–97.

65. Bagalkot, V., et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. *Nano Lett*, 2007, **7**(10):3065–3070.
66. Yuan, J., et al. Anticancer drug-DNA interactions measured using a photoinduced electron-transfer mechanism based on luminescent quantum dots. *Anal Chem*, 2009, **81**(1):362–368.
67. Al-Jamal, W.T., et al. Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. *Small*, 2008, **4**(9):1406–1415.
68. Wen, C.J., et al. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. *Int J Nanomed*, 2012, **7**:1599–1611.
69. Endres, T., et al. Amphiphilic biodegradable PEG-PCL-PEI triblock copolymers for FRET-capable in vitro and in vivo delivery of siRNA and quantum dots. *Mol Pharm*, 2014, **11**(4):1273–1281.
70. Liu, Z., et al. Nano-carbons as theranostics. *Theranostics*, 2012, **2**(3):235–237.
71. Yang, S.T., et al. Pharmacokinetics, metabolism and toxicity of carbon nanotubes for biomedical purposes. *Theranostics*, 2012, **2**(3):271–282.
72. Kam, N.W., et al. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. *J Am Chem Soc*, 2005, **127**(36):12492–12493.
73. Liu, Z., et al. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. *Angew Chem Int Ed Engl*, 2007, **46**(12):2023–2027.
74. Huang, H., et al. Active nanodiamond hydrogels for chemotherapeutic delivery. *Nano Lett*, 2007, **7**(11):3305–3314.
75. Vijayanthimala, V., et al. Functionalized fluorescent nanodiamonds for biomedical applications. *Nanomedicine (Lond)*, 2009, **4**(1):47–55.
76. Liu, J., et al. Preparation of PEG-conjugated fullerene containing Gd³⁺ ions for photodynamic therapy. *J Controlled Release*, 2007, **117**(1):104–110.
77. Chen, Z., et al. Applications of functionalized fullerenes in tumor theranostics. *Theranostics*, 2012, **2**(3):238–250.
78. Zheng, M., et al. Integrating oxaliplatin with highly luminescent carbon dots: An unprecedented theranostic agent for personalized medicine. *Adv Mater*, 2014, **26**(21):3554–3560.
79. Shi, S., et al. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. *Biomaterials*, 2013, **34**(12):3002–3009.
80. Yang, K., et al. The influence of surface chemistry and size of nanoscale graphene oxide on photothermal therapy of cancer using ultra-low laser power. *Biomaterials*, 2012, **33**(7):2206–2214.
81. Lovell, J.F., et al. Activatable photosensitizers for imaging and therapy. *Chem Rev*, 2010, **110**(5):2839–2857.
82. Cengel, K.A., et al. PDT: what's past is prologue. *Cancer Res*, 2016, **76**(9):2497–2499.
83. Zhou, Y., et al. Porphyrin-loaded nanoparticles for cancer theranostics. *Nanoscale*, 2016, **8**(25):12394–12405.

Chapter 7

Current Issues in Diagnosis and Staging of Cancer¹

*National Cancer Institute,
National Institutes of Health, Bethesda, Maryland, USA*

Keywords: artificial intelligence (AI), biomarkers, biopsy, bone scans, bronchoscopy, cancer staging, colonoscopy, companion diagnostic, computed tomography (CT), endoscopy, Surveillance, Epidemiology and End Results (SEER) Program, Genomic Data Commons, image-guided biopsy, imaging, jaundice, liquid biopsy, magnetic resonance imaging (MRI), metastatic bone tumors, Tumor, Node and Metastasis (TNM) Staging System, nuclear scans, pathology reports, PDQ[®] cancer treatment summaries, positron emission tomography (PET), radionuclide scan, sentinel lymph node biopsy, sentinel lymph nodes, TMN staging system, tumor grade, tumor markers, ultrasound

Cancer can cause many different symptoms. Most often these symptoms are not caused by cancer, but by benign tumors or other problems. If you have symptoms that last for a couple of weeks, your doctor will do a physical exam and order tests or other procedures to find out what is causing your symptoms.

If you do find out you have cancer, your doctor will order another set of tests or procedures to figure out its stage. Stage refers to the extent of your cancer and is based on factors such as how large the tumor is and if it has spread. Once your doctor knows the stage of your cancer, he will be able to suggest treatment and discuss your prognosis with you. Understanding your cancer and knowing what to expect can help you and your loved ones feel more in control and cope with your diagnosis.

¹This chapter is organized and edited by the Series Editor, Raj Bawa, PhD, MD. It is based on information and materials kindly provided to Dr. Bawa by the National Cancer Institute (NCI) at the National Institutes of Health (NIH). The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship. NCI is the oldest and has the largest budget and research program of the 27 institutes and centers of the NIH.

7.1 Symptoms of Cancer

Cancer can cause many symptoms, but these symptoms are most often caused by illness, injury, benign tumors, or other problems. If you have symptoms that do not get better after a few weeks, see your doctor so that problems can be diagnosed and treated as early as possible. Often, cancer does not cause pain, so do not wait to feel pain before seeing a doctor.

To learn more about symptoms for a specific cancer, see:

1. List of PDQ® cancer treatment summaries for adult. Available at: <https://www.cancer.gov/publications/pdq/information-summaries/adult-treatment> (accessed on September 25, 2022)
2. Childhood Cancers. Available at: <https://www.cancer.gov/publications/pdq/information-summaries/pediatric-treatment> (accessed on September 25, 2022).

Each summary includes detailed information about symptoms caused by a specific cancer.

Some of the symptoms that cancer may cause include:

Breast changes

- Lump or firm feeling in your breast or under your arm
- Nipple changes or discharge
- Skin that is itchy, red, scaly, dimpled, or puckered

Bladder changes

- Trouble urinating
- Pain when urinating
- Blood in the urine

Bleeding or bruising, for no known reason

Bowel changes

- Blood in the stools
- Changes in bowel habits

Cough or hoarseness that does not go away

Eating problems

- Pain after eating (heartburn or indigestion that doesn't go away)
- Trouble swallowing
- Belly pain
- Nausea and vomiting
- Appetite changes

Fatigue that is severe and lasts

Fever or night sweats for no known reason

Mouth changes

- A white or red patch on the tongue or in your mouth
- Bleeding, pain, or numbness in the lip or mouth

Neurological problems

- Headaches
- Seizures
- Vision changes
- Hearing changes
- Drooping of the face

Skin changes

- A flesh-colored lump that bleeds or turns scaly
- A new mole or a change in an existing mole
- A sore that does not heal
- Jaundice

Swelling or lumps anywhere such as in the neck, underarm, stomach, and groin

Weight gain or weight loss for no known reason

7.2 How Cancer Is Diagnosed

If you have a symptom or a screening test result that suggests cancer, your doctor must find out whether it is due to cancer or some other cause. The doctor may start by asking about your personal and family medical history and do a physical exam. The doctor also may order lab tests, imaging tests (scans), or other tests or procedures. You may also need a biopsy, which is often the only way to tell for sure if you have cancer.

This section covers tests that are often used to help diagnose cancer. Depending on the symptoms you have, you may have other tests, too. To learn more about how specific cancers are diagnosed, see the PDQ[®] cancer treatment summaries for adult and childhood cancers. These summaries include detailed information about and pictures of diagnostic tests and procedures for each specific type of cancer.

7.2.1 Lab Tests

High or low levels of certain substances in your body can be a sign of cancer. So, lab tests of your blood, urine, or other body fluids that measure these substances can help doctors make a diagnosis. However, abnormal lab results are not a sure sign of cancer. Learn more about laboratory tests and how they are used to diagnose cancer (<https://www.cancer.gov/about-cancer/diagnosis-staging/understanding-lab-tests-fact-sheet>).

Some lab tests involve testing blood or tissue samples for tumor markers. Tumor markers are substances that are produced by cancer cells or by other cells of the body in response to cancer. Most tumor markers are made by normal cells and cancer cells but are produced at much higher levels by cancer cells. Learn more about tumor markers and how they are used to diagnose cancer (<https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet>).

7.2.2 Imaging tests

Imaging tests create pictures of areas inside your body that help the doctor see whether a tumor is present. These pictures can be made in several ways:

Computed tomography (CT) scan

A CT scan uses an x-ray machine linked to a computer to take a series of pictures of your organs from different angles. These pictures are used to create detailed 3-D images of the inside of your body.

Sometimes, you may receive a dye or other contrast material before you have the scan. You might swallow the dye, or it may be given by a needle into a vein. Contrast material helps make the pictures easier to read by highlighting certain areas in the body.

During the CT scan, you will lie still on a table that slides into a donut-shaped scanner. The CT machine moves around you, taking pictures. Learn more about CT scans and how they are used to diagnose cancer.

Magnetic resonance imaging (MRI)

An MRI uses a powerful magnet and radio waves to take pictures of your body in slices. These slices are used to create detailed images of the inside of your body, which can show the difference between healthy and unhealthy tissue.

When you have an MRI, you lie still on a table that is pushed into a long, round chamber. The MRI machine makes loud thumping noises and rhythmic beats.

Sometimes, you might have a special dye injected into your vein before or during your MRI exam. This dye, called a contrast agent, can make tumors show up brighter in the pictures.

Nuclear scan

A nuclear scan uses radioactive material to take pictures of the inside of the body. This type of scan may also be called radionuclide scan.

Before this scan, you receive an injection of a small amount of radioactive material, which is sometimes called a tracer. It flows through your bloodstream and collects in certain bones or organs.

During the scan, you lie still on a table while a machine called a scanner detects and measures the radioactivity in your body, creating pictures of bones or organs on a computer screen or on film.

After the scan, the radioactive material in your body will lose its radioactivity over time. It may also leave your body through your urine or stool.

Bone scan

Bone scans are a type of nuclear scan that check for abnormal areas or damage in the bones. They may be used to diagnose bone cancer or cancer that has spread to the bones (also called metastatic bone tumors).

Before this test, a very small amount of radioactive material is injected into your vein. As it travels through the blood, the material collects in abnormal areas in the bone. Areas where the material collects show up on pictures taken by a special scanner. These areas are called “hot spots.”

Positron emission tomography (PET)

A PET scan is a type of nuclear scan that makes detailed 3-D pictures of areas inside your body where glucose is taken up. Because cancer cells often take up more glucose than healthy cells, the pictures can be used to find cancer in the body.

Before the scan, you receive an injection of a tracer called radioactive glucose. During the scan, you will lie still on a table that moves back and forth through a scanner.

Ultrasound

An ultrasound exam uses high-energy sound waves that people cannot hear. The sound waves echo off tissues inside your body. A computer uses these echoes to create pictures of areas inside your body. This picture is called a sonogram.

During an ultrasound exam, you will lie on a table while a tech slowly moves a device called a transducer on the skin over the part of the body that is being examined. The transducer is covered with a warm gel that makes it easier to glide over the skin.

X-rays

X-rays use low doses of radiation to create pictures inside your body. An x-ray tech will put you in position and direct the x-ray beam to the correct part of your body. While the images are taken, you will need to stay very still and may need to hold your breath for a second or two.

7.2.3 Biopsy

In most cases, doctors need to do a biopsy to diagnose cancer. A biopsy is a procedure in which the doctor removes a sample of tissue. A pathologist looks at the tissue under a microscope and runs other tests to see if the tissue is cancer. The pathologist describes the findings in a pathology report, which contains details about your diagnosis. Pathology reports play an important role in diagnosing cancer and helping decide treatment options. Learn more about pathology

reports and the type of information they contain (<https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet>).

The biopsy sample may be obtained in several ways.

With a needle: The doctor uses a needle to withdraw tissue or fluid. This method is used for bone marrow aspirations, spinal taps, and some breast, prostate, and liver biopsies.

With endoscopy: The doctor uses a thin, lighted tube called an endoscope to examine areas inside the body. Endoscopes go into natural body openings, such as the mouth or anus. If the doctor sees abnormal tissue during the exam, he will remove the abnormal tissue along with some of the surrounding normal tissue through the endoscope.

Examples of endoscopy exams include

- **Colonoscopy**, which is an exam of the colon and rectum. In this type of exam, an endoscope goes through the anus, allowing the doctor to examine the rectum and colon. If the doctor sees polyps, she will remove them and send them to a lab for testing.
- **Bronchoscopy**, which is an exam of the trachea, bronchi, and lungs. In this type of exam, an endoscope goes through the mouth or nose and down the throat.

With surgery: A surgeon removes an area of abnormal cells during an operation. Surgery may be excisional or incisional.

In an excisional biopsy, the surgeon removes the entire area of abnormal cells. Often some of the normal tissue around these cells is also removed.

In an incisional biopsy, the surgeon removes just part of the abnormal area.

Some biopsies may require a sedative or anesthesia.

Sedatives are medicine that help you relax and stay very still or sleep during a biopsy.

Anesthesia keeps you from feeling pain. It refers to drugs or other substances that cause you to lose feeling or awareness. There are three types of anesthesia.

- **Local Anesthesia**, which causes loss of feeling in one small area of the body
- **Regional Anesthesia**, which causes loss of feeling in a part of the body, such as an arm or leg
- **General Anesthesia**, which causes loss of feeling and a complete loss of awareness that seems like a very deep sleep

7.2.4 After Cancer Is Diagnosed

If the biopsy and other tests show that you have cancer, you may have more tests to help your doctor plan treatment. For instance, your doctor will need to figure out the stage of your cancer. For some cancers, knowing the grade of the tumor

or risk group that you fall into are important for deciding on the best treatment. Your tumor may also be tested further for other tumor or genetic markers.

To learn more about other tests that may be used to plan treatment for your cancer, see the PDQ® cancer treatment summaries for adult and childhood cancers for your type of cancer.

7.2.5 Related Resources

- Pathology Reports. Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet> (accessed on September 25, 2022).
- Tumor Markers. Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet> (accessed on September 25, 2022).
- Understanding Laboratory Tests. Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/understanding-lab-tests-fact-sheet> (accessed on September 25, 2022).
- Sentinel Lymph Node Biopsy. Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/staging/sentinel-node-biopsy-fact-sheet> (accessed on September 25, 2022).
- FDA Approves Blood Tests That Can Help Guide Cancer Treatment. Available at: <https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-guardant-360-foundation-one-cancer-liquid-biopsy> (accessed on September 25, 2022).

7.3 Cancer Staging

Stage refers to the extent of your cancer, such as how large the tumor is, and if it has spread. Knowing the stage of your cancer helps your doctor:

- Understand how serious your cancer is and your chances of survival
- Plan the best treatment for you
- Identify clinical trials that may be treatment options for you

A cancer is always referred to by the stage it was given at diagnosis, even if it gets worse or spreads. New information about how a cancer has changed over time gets added on to the original stage. So, the stage doesn't change, even though the cancer might.

7.3.1 How Stage Is Determined

To learn the stage of your disease, your doctor may order x-rays, lab tests, and other tests or procedures. See Section 7.2 to learn more about these tests.

7.3.2 Systems That Describe Stage

There are many staging systems. Some, such as the tumor, node and metastasis (TNM) staging system (<https://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=CDR0000672851&version=Patient&language=English>), are used for many types of cancer. Others are specific to a particular type of cancer. Most staging systems include information about:

- Where the tumor is located in the body
- The cell type (such as, adenocarcinoma or squamous cell carcinoma)
- The size of the tumor
- Whether the cancer has spread to nearby lymph nodes
- Whether the cancer has spread to a different part of the body
- Tumor grade, which refers to how abnormal the cancer cells look and how likely the tumor is to grow and spread

7.3.3 The Tumor, Node and Metastasis (TNM) Staging System

The TNM system is the most widely used cancer staging system. Most hospitals and medical centers use the TNM system as their main method for cancer reporting. You are likely to see your cancer described by this staging system in your pathology report, unless you have a cancer for which a different staging system is used. Examples of cancers with different staging systems include brain and spinal cord tumors and blood cancers.

In the TNM system:

- The T refers to the size and extent of the main tumor. The main tumor is usually called the primary tumor.
- The N refers to the number of nearby lymph nodes that have cancer.
- The M refers to whether the cancer has metastasized. This means that the cancer has spread from the primary tumor to other parts of the body.

When your cancer is described by the TNM system, there will be numbers after each letter that give more details about the cancer—for example, T1N0MX or T3N1M0. The following explains what the letters and numbers mean:

Primary tumor (T)

- TX: Main tumor cannot be measured.
- T0: Main tumor cannot be found.
- T1, T2, T3, T4: Refers to the size and/or extent of the main tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b.

Regional lymph nodes (N)

- NX: Cancer in nearby lymph nodes cannot be measured.

- N0: There is no cancer in nearby lymph nodes.
- N1, N2, N3: Refers to the number and location of lymph nodes that contain cancer. The higher the number after the N, the more lymph nodes that contain cancer.

Distant metastasis (M)

- MX: Metastasis cannot be measured.
- M0: Cancer has not spread to other parts of the body.
- M1: Cancer has spread to other parts of the body.

7.3.4 Other Ways to Describe Stage

The TNM system helps describe cancer in great detail. But, for many cancers, the TNM combinations are grouped into five less-detailed stages. When talking about your cancer, your doctor or nurse may describe it as one of these stages:

Stage	What it means
Stage 0	Abnormal cells are present but have not spread to nearby tissue. Also called carcinoma <i>in situ</i> , or CIS. CIS is not cancer, but it may become cancer.
Stage I, Stage II, and Stage III	Cancer is present. The higher the number, the larger the cancer tumor and the more it has spread into nearby tissues.
Stage IV	The cancer has spread to distant parts of the body.

Another staging system that is used for all types of cancer groups the cancer into one of five main categories. This staging system is more often used by cancer registries than by doctors. But, you may still hear your doctor or nurse describe your cancer in one of the following ways:

- **In situ**—Abnormal cells are present but have not spread to nearby tissue.
- **Localized**—Cancer is limited to the place where it started, with no sign that it has spread.
- **Regional**—Cancer has spread to nearby lymph nodes, tissues, or organs.
- **Distant**—Cancer has spread to distant parts of the body.
- **Unknown**—There is not enough information to figure out the stage.

To learn more about staging for your type of cancer, see the PDQ® cancer treatment summaries for adult and childhood cancers.

7.3.5 Related Resources

- Tumor Grade: Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-grade> (accessed on September 25, 2022).

- Pathology Reports: Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet> (accessed on September 25, 2022).

7.4 Understanding Cancer Prognosis

If you have cancer, you may have questions about how serious your cancer is and your chances of survival. The estimate of how the disease will go for you is called prognosis. It can be hard to understand what prognosis means and also hard to talk about, even for doctors.

7.4.1 Many Factors Can Affect Your Prognosis

Some of the factors that affect prognosis include:

- The type of cancer and where it is in your body
- The stage of the cancer, which refers to the size of the cancer and if it has spread to other parts of your body
- The cancer's grade, which refers to how abnormal the cancer cells look under a microscope. Grade provides clues about how quickly the cancer is likely to grow and spread.
- Certain traits of the cancer cells
- Your age and how healthy you were before cancer
- How you respond to treatment

7.4.2 Seeking Information About Your Prognosis Is a Personal Decision

When you have cancer, you and your loved ones face many unknowns. Understanding your cancer and knowing what to expect can help you and your loved ones make decisions. Some of the decisions you may face include:

- Which treatment is best for you
- If you want treatment
- How to best take care of yourself and manage treatment side effects
- How to deal with financial and legal matters

Many people want to know their prognosis. They find it easier to cope when they know more about their cancer. You may ask your doctor about survival statistics or search for this information on your own. Or, you may find statistics confusing and frightening, and think they are too impersonal to be of value to you. It is up to you to decide how much information you want.

If you do decide you want to know more, the doctor who knows the most about your situation is in the best position to discuss your prognosis and explain what the statistics may mean.

If you need help coping with your prognosis, you may find our information on Coping With Cancer helpful (<https://www.cancer.gov/about-cancer/coping>).

7.4.3 Understanding Statistics about Survival

Doctors estimate prognosis by using statistics that researchers have collected over many years about people with the same type of cancer. Several types of statistics may be used to estimate prognosis. The most commonly used statistics include:

- **Cancer-specific survival**

This is the percentage of patients with a specific type and stage of cancer who have not died from their cancer during a certain period of time after diagnosis. The period of time may be 1 year, 2 years, 5 years, etc., with 5 years being the time period most often used. Cancer-specific survival is also called disease-specific survival. In most cases, cancer-specific survival is based on causes of death listed in medical records.

- **Relative survival**

This statistic is another method used to estimate cancer-specific survival that does not use information about the cause of death. It is the percentage of cancer patients who have survived for a certain period of time after diagnosis compared to people who do not have cancer.

- **Overall survival**

This is the percentage of people with a specific type and stage of cancer who have not died from any cause during a certain period of time after diagnosis.

- **Disease-free survival**

This statistic is the percentage of patients who have no signs of cancer during a certain period of time after treatment. Other names for this statistic are recurrence-free or progression-free survival.

Because statistics are based on large groups of people, they cannot be used to predict exactly what will happen to you. Everyone is different. Treatments and how people respond to treatment can differ greatly. Also, it takes years to see the benefit of new treatments and ways of finding cancer. So, the statistics your doctor uses to make a prognosis may not be based on treatments being used today.

Still, your doctor may tell you that you have a good prognosis if statistics suggest that your cancer is likely to respond well to treatment. Or, he may tell you that you have a poor prognosis if the cancer is harder to control. Whatever your doctor tells you, keep in mind that a prognosis is an educated guess. Your doctor cannot be certain how it will go for you.

7.4.4 Where to Find Cancer Statistics

NCI collects and reports on cancer statistics through its SEER Program, which stands for Surveillance, Epidemiology, and End Results. From the Cancer Stat Facts page

(<https://seer.cancer.gov/statfacts>) on the SEER web site, you can find answers to the most commonly asked questions about cancer statistics for many cancer types. You can also browse the latest SEER Cancer Statistics Review (https://seer.cancer.gov/csr/1975_2016/).

7.4.5 If You Decide Not to Have Treatment

If you decide not to have treatment, the doctor who knows your situation best is in the best position to discuss your prognosis.

Survival statistics most often come from studies that compare treatments with each other, rather than treatment with no treatment. So, it may not be easy for your doctor to give you an accurate prognosis.

7.4.6 Understanding the Difference between Cure and Remission

Cure means that there are no traces of your cancer after treatment and the cancer will never come back.

Remission means that the signs and symptoms of your cancer are reduced. Remission can be partial or complete. In a complete remission, all signs and symptoms of cancer have disappeared.

If you remain in complete remission for 5 years or more, some doctors may say that you are cured. Still, some cancer cells can remain in your body for many years after treatment. These cells may cause the cancer to come back one day. For cancers that return, most do so within the first 5 years after treatment. But, there is a chance that cancer will come back later. For this reason, doctors cannot say for sure that you are cured. The most they can say is that there are no signs of cancer at this time.

Because of the chance that cancer can come back, your doctor will monitor you for many years and do tests to look for signs of cancer's return. They will also look for signs of late side effects from the cancer treatments you received.

Video Series

The following video series explores three cancer patients' and their doctor's thoughts and feelings about prognosis: https://youtu.be/_0YvVNjWNWI. The videos explain key points about prognosis and how doctors and patients can talk about it in a clear and supportive way. Two viewer guides are also available:

1. For patients. Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/patient-viewer-guide.pdf> (accessed on September 25, 2022)
2. For provider care teams. Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/provider-viewer-guide.pdf> (accessed on September 25, 2022).

7.5 Questions to Ask Your Doctor about Your Diagnosis

Learning that you have cancer can be a shock and you may feel overwhelmed at first. When you meet with your doctor, you will hear a lot of information. These questions may help you learn more about your cancer and what you can expect next.

- What type of cancer do I have?
- What is the stage of my cancer?
- Has it spread to other areas of my body?
- Will I need more tests before treatment begins? Which ones?
- Which types of doctors do I need to see for my cancer treatment?
- Will you help me find a doctor to give me another opinion on the best treatment plan for me?
- How serious is my cancer?
- What are my chances of survival?

For questions about other topics, see our complete list of Questions to Ask Your Doctor about Cancer (<https://www.cancer.gov/about-cancer/coping/questions>).

7.5.1 Related Resources

- Finding Health Care Services: Available at: <https://www.cancer.gov/about-cancer/managing-care/services> (accessed on September 25, 2022).
- Taking Time: Support for People with Cancer: Available at: <https://www.cancer.gov/publications/patient-education/taking-time> (accessed on September 25, 2022).

7.6 Diagnosis and Staging Research

- Can Artificial Intelligence Help See Cancer in New, and Better, Ways?

Researchers have been developing artificial intelligence (AI) tools that could make cancer imaging faster, more accurate, and more informative. But there are also questions about whether these tools are ready for doctors' offices, whether they will actually help people, and whether that benefit will reach all—or only some—patients.

Available at: <https://www.cancer.gov/news-events/cancer-currents-blog/2022/artificial-intelligence-cancer-imaging> (accessed on September 25, 2022)

- Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval

FDA has expanded the approved uses of the FoundationOne Liquid CDx blood test, known as a liquid biopsy, that can help doctors pick specific

treatments for some people with cancer. When used in this way, the test is known as a companion diagnostic.

Available at: <https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-foundation-one-cancer-liquid-biopsy-expanded-approval> (accessed on September 25, 2022)

- **Artificial Intelligence Expedites Brain Tumor Diagnosis during Surgery**

A method that combines artificial intelligence with an advanced imaging technology can accurately diagnose brain tumors in fewer than 3 minutes during surgery, a new study shows. The approach can also accurately distinguish tumor from healthy tissue.

Available at: <https://www.cancer.gov/news-events/cancer-currents-blog/2020/artificial-intelligence-brain-tumor-diagnosis-surgery> (accessed on September 25, 2022)

- **Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations**

Cancer researchers have trained a computer program to scan images of tissue samples to differentiate normal lung tissue from the two most common forms of lung cancer. The program also learned to detect cancer-related genetic mutations in the samples.

Available at: <https://www.cancer.gov/news-events/cancer-currents-blog/2018/artificial-intelligence-lung-cancer-classification> (accessed on September 25, 2022)

- **Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer**

Research studies show tests that analyze tumor DNA in blood, called liquid biopsies, may help detect cancer early, guide precision cancer treatment, and track treatment response.

Available at: <https://www.cancer.gov/news-events/cancer-currents-blog/2017/liquid-biopsy-detects-treats-cancer> (accessed on September 25, 2022)

- **Image-guided biopsy for diagnosis of prostate cancer can increase detection of high-risk tumors**

In the largest prospective study to date of image-guided technology for identifying suspicious regions of the prostate to biopsy, researchers compared the ability of this technology to detect high-risk prostate cancer with that of the current standard of unguided prostate biopsy.

Available at: <https://www.cancer.gov/news-events/press-releases/2015/prostatefusiontargetedbiopsyjama> (accessed on September 25, 2022)

- **NCI establishes Genomic Data Commons to facilitate identification of molecular subtypes of cancer and potential drug targets**

NCI is establishing the Genomic Data Commons to store, analyze and distribute cancer genomics data generated by NCI and other research organizations. The GDC will provide an interactive system for researchers to access

data, with the goal of advancing the molecular diagnosis of cancer and suggest potential therapeutic targets based on genomic information.

Available at: <https://www.cancer.gov/news-events/press-releases/2014/genomicdatacommonsnewsnote> (accessed on September 25, 2022)

Chapter 8

Diagnostic Ability of Radiofrequency Ultrasound in Parkinson's Disease Compared to Conventional Transcranial Sonography and Magnetic Resonance Imaging

Mindaugas Baranauskas, PhD,^a Rytis Jurkonis, PhD,^a Arūnas Lukoševičius, PhD,^a
Vaidas Matijošaitis,^b Rymantė Gleiznienė, PhD,^c and Daiva Rastenytė, PhD^b

^a*Biomedical Engineering Institute, Kaunas University of Technology, Kaunas, Lithuania*

^b*Department of Neurology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania*

^c*Department of Radiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania*

m.baranauskas@ktu.lt, daiva.rastenyte@ismuni.lt

Keywords: area under the curve (AUC), brain tissue micromovements, conventional TCS (cTCS), cross-sectional B-mode imaging, displacement waveform, dominant frequency (FreqD), frequency of high-end spectra peak (FreqHP), healthy controls (HC), interquartile range (IQR), logistic regression (LR), magnetic resonance imaging (MRI), neurological deficit, Parkinson's disease (PD), radiofrequency (RF), radiofrequency ultrasound, receiver operating characteristic (ROC), region of interest (ROI), root mean square (RMS), standard deviation (SD), substantia nigra (SN), transcranial sonography (TCS), ultrasound (US), Unified Parkinson's Disease Rating Scale (UPDRS)

8.1 Introduction

Parkinson's disease (PD) is the second most common progressive neurodegenerative disease whose main neuropathological feature is the loss of dopaminergic neurons of the substantia nigra (SN) located in the midbrain [1, 2] and the deposition of α -synuclein in neurons [3]. Despite huge achievements in contemporary neurology and neuroimaging, a definitive diagnostic test for PD is not yet available [4]. Positron emission tomography and single-photon emission computed tomography are currently the most common functional radionuclide diagnostic methods used in degenerative extrapyramidal disorders; however, their application in clinical

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

practice remains limited due to high price, the relatively short half-life of the radioisotopes, radiation exposure to patients, and the discrepant data on their reliability in differential diagnosis [4–6]. Advanced magnetic resonance imaging (MRI) techniques and post-processing procedures are also being extensively explored to enhance diagnostic accuracy for PD [7, 8], nevertheless, these novel techniques are also rather costly and not easily accessible.

Transcranial sonography (TCS) is a relatively new method for assessment of the deep brain structures, including midbrain and SN [9–11]. Hyperechogenicity of SN in a cross-sectional B-mode (Brightness or Grayscale mode) image of the midbrain is treated as a main PD biomarker [4]. Nevertheless, TCS needs to be performed by an experienced examiner to be reliable and support the diagnosis for the patient. Therefore, additive techniques are acknowledgeable in order to improve diagnostic reliability of TCS, especially if they are inexpensive, non-invasive, safe and easily accessible.

TCS modification opens up the possibility to track the brain tissue displacements at the scale of micrometers caused by the endogenous quasi-periodic pulsatility in the intracranial basin. Endogenous characteristics of brain tissue displacements are supposedly related with the biomechanical features of pulsating tissue and are likely affected by evolving pathology and correlated with tissue stiffness [12]. These brain tissue displacements can be evaluated by detailed analysis of raw ultrasound (US) radiofrequency (RF) signal changes of the same tissue region over time [13]. We developed such an approach further [14] and in our recent study [15] we demonstrated that evaluation of complex interactions between the set of radiofrequency transcranial sonography (RF TCS)-based brain tissue displacement parameters allows us to discern the medial temporal lobe of an Alzheimer's disease patient from that of a healthy control (HC) subject with excellent diagnostic ability.

The aim of this study was to estimate tissue displacement parameters in midbrain using backscattered US RF signals and to compare the diagnostic ability of RF US-based dynamic features of disease affected tissues with conventional TCS (cTCS) and MRI while differentiating patients with PD from HC.

8.2 Materials and Methods

The design and consent procedures of this exploratory study were approved by the Ethics Committee for Biomedical Research at the Lithuanian University of Health Sciences (decision on 19 December 2017, No. BE-2-728), Kaunas, Lithuania. All participants gave signed informed consent prior to inclusion in the study. All procedures were in accordance with the Declaration of Helsinki.

8.2.1 Patients and Control Group

Twenty PD patients were prospectively selected from both outpatient and inpatient units of the Department of Neurology at the Hospital of Lithuanian

University of Health Sciences Kaunas Clinics (Kaunas, Lithuania) from March 2018 until March 2019.

Neurologists who consulted the patients for a movement disorder performed an initial selection of potential study subjects. Patients were included in the study if they: (1) were diagnosed with idiopathic or familial PD, which was based on the United Kingdom Brain Bank criteria [16]; (2) provided written consent; (3) had satisfactory acoustic window properties on at least one side for TCS; (4) were 18 years or older; (5) were eligible for MRI. Patients were excluded from the study if they: (1) had an uncertain diagnosis; (2) had a major somatic disease (decompensated heart failure, terminal renal or hepatic dysfunction, active cancer, had diagnosed hemodynamically significant intracranial/extracranial artery stenosis or thrombosis); (3) had a severe mental disorder (psychotic type, severe depression); (4) had a prominent neurological deficit (severe visual disturbance, aphasia, severe paresis, ataxia).

Twenty age- and sex-matched HC subjects were recruited from healthy relatives of the patients, provided they did not have any major somatic illness as listed above, cognitive impairment or any structurally abnormal findings in brain MRI and were not under investigation or treatment for any neurodegenerative diseases. All participants were Caucasians and most of them were Lithuanians.

All participants completed a questionnaire on general demographic information and risk factors. Education was evaluated by the duration of formal education in years. Family history was considered positive if there was at least one known PD case among first- or second-degree relatives. The Motor section of the Unified Parkinson's Disease Rating Scale (UPDRS) [17] was applied while assessing functionality of the patient.

8.2.2 Radiofrequency Transcranial Sonography

RF TCS imaging for endogenous brain tissue motion data collection was performed using a research-dedicated ultrasound scanner, Ultrasonix Sonix Touch (Analogic Ultrasound, Richmond, BC, Canada, 2013), equipped with a phased array sector probe (SA 4-2, 64 acoustic elements). The main parameters of ultrasonic scanning and RF signal digitization were as follows: sampling frequency $f_s = 40$ MHz, analog-to-digital converter resolution 16 bits, number of post-beam formed scanning lines—131, angle of phased array transducer sector— 60° , scanning depth—11 cm, frequency of ultrasound waves 2.5 MHz, frame rate—45 Hz, transmit focal single depth—7 cm. The sequences for recording B-mode scans (259 frames in total) and raw B scan forming RF signals were acquired and stored for off-line analysis.

All US scans were performed by an experienced neurosonologist (Vaidas Matijošaitis) with 13 years of experience in intracranial vascular and structural ultrasound. All study subjects were asked to stay calm and relaxed in a supine position for 5 min and remain motionless and speechless during the examination. First scans were made in a midbrain (axial) scanning plane in B-mode through a right temporal bone acoustic window. The position of the transducer was fixed

by closing the dedicated spherical bearing of the bracket during insonation of the midbrain. After recording the sequence of B-mode scan images, the butterfly shape midbrain was marked as a region of interest (ROI) for further investigation (see Fig. 8.1a), and 6-s length US RF signal sequences were stored in the computer memory. The investigator had no contact with the patient, US transducer or the patient's bed during US RF signal recording. All procedures described above were repeated while making scans through a left temporal bone window. Thus, two ROIs—one from the left and another from the right side of the head—were investigated separately for each study subject.

The classical 1D cross-correlation [18–20] was used to obtain spatial point displacements in ROI along the scanning line from the acquired US RF signals. The calculation options used at this step were the same as described in our earlier article [14]. The displacement signal processing was the same as in our recent study [15]: the coordinate system was changed into Lagrangian [21], the median for each scanning frame's line was subtracted separately and high-pass filtered with cutoff at 0.75 Hz and only confidently repeatable moving spatial points were selected for further analysis.

The waveforms of displacement signals were quantified using four groups of the displacement parameters for each individual confident spatial point:

1. Amplitude parameters:

- Root mean square (RMS)—represents displacement intensity over an entire recorded time (6-s). RMS of each individual confident spatial point depicted in Fig. 8.1b.
- Peak-to-peak amplitude of a mean repeated movement; this parameter was called “pulse amplitude” by Kucewicz et al. [19].

2. Strain parameter—Lagrangian strain as module of the derivative of amplitudes of a mean repeated movement calculated along the ultrasound scanning line's direction.

3. Morphology parameter—frequency of high-end spectra peak (shortly-FreqHP) was calculated from the entire displacement signal length (6-s). FreqHP was estimated at the peak of the power spectra observed in the frequency range from $1.5 \times \text{FreqD}$ to 22.5 Hz, where FreqD is the dominant frequency in displacement low-end spectra (from 0.67 to 2.00 Hz interval) supposedly caused by heart beats.

4. Energy parameter—relative energy within the 4–6 Hz frequency band normalized to total energy of displacement signal. This parameter was introduced to control the Parkinsonian 4–6 Hz rest tremor [22, 23]. Distribution of this energy parameter was evaluated only by its statistical mode.

The distributions of remaining parameters—amplitude, strain and morphology group parameters of all displacement signals of individual points—were quantified by their minimal and maximal values, median, first (Q1) and third quartiles (Q3), interquartile range (IQR) and the most frequent value (statistical mode); in addition, amplitude group parameters were also evaluated by ex-Gaussian

estimates μ , σ , τ , also ex-Gaussian distribution mean and standard deviation (SD) using the DISTRIB toolbox for MATLAB [24]; as strain has similar to exponential distribution, only the ex-Gaussian distribution τ estimate was added from the ex-Gaussian estimates. Most of above-mentioned parameters and their distributions were described in more a detailed manner in our previous study [15].




Figure 8.1 Regions of interest (ROI) examples in axial scanning plane images co-registered by different methods for the same healthy participant: (a) half of the midbrain in radiofrequency (RF) transcranial sonography (TCS) data-based B-mode image, (b) analyzed half of the midbrain and not-analyzed half of the midbrain mapped as root mean square (RMS) of confident displacements detected from RF TCS signal sequences; (c) substantia nigra (SN) in conventional TCS (cTCS) image of midbrain (d) SN by magnetic resonance imaging (MRI) of midbrain, T2W/TSE/2 mm sequences. Contours of ROI depicted in colorful lines (see online version). In the sonography examples, the ultrasound transducer was on the left side of the head or at the top of images.

8.2.3 Conventional TCS

All PD patients and HC subjects underwent cTCS with a commercially available ultrasound system, Voluson 730 Expert BT08 (General Electric (GE) Healthcare, Zipf, Austria). The ultrasound system was equipped with an electronic sectored PA2-5P phased array transducer, which has a working frequency range of 1.3 to 4.0 MHz, 128 piezoelectric elements, a modifiable 90-degree visual angle. B-mode images have 8-bit depth (i.e., 256 gray tones), a dynamic range of 180 dB and a maximum depth of 30 cm. The system comes installed with algorithms to reduce noise and artifacts.

TCS imaging was done using the PA2-5P/NEURO transducer mode. Scans were done in B-mode without any color coding or Doppler mode. Amplitude gain was changed manually, which was done by observing the live TCS image. The brightest point on the screen was used as a reference point for amplitude gain. Regulator sliders of time gain compensation were used and placed in a semicircle with convexity to the right so that the ROI, the midbrain along with its structures—SN, the red nucleus, raphe nuclei—could be seen the brightest.

All subjects were supine in a darkened room, scans were performed by placing the transducer at the level of the eyebrows with the front part pointed upwards, i.e., to the side of face at the pre-auricular temporal bone area. Scans were performed in two standard planes: (a) the mesencephalic or the midbrain plane, and (b) the diencephalic plane or the third ventricle plane. In the mesencephalic plane, the area of the SN projection was measured (in cm^2) at the level of the transducer (see Fig. 8.1c). Measurement of the height of the third ventricle in the segment neighboring brain stem was also performed.

All participants had quantitative measurements of the size of the third ventricle and the SN performed twice on each side by the same neurosonologist who performed RF TCS. The penetration depth of TCS was usually 16.8 cm, while the zoom was 1.6 times to measure the SN and third ventricle dimensions. The normative threshold values of the SN area calculated in our laboratory for Voluson 730 Expert BT08 were $< 0.20 \text{ cm}^2$ (mean + 1 SD) and $< 0.26 \text{ cm}^2$ (mean + 2 SD) [25]. For the third ventricle diameter, the normative value was $< 1.0 \text{ cm}$ (mean + 2 SD) [26].

8.2.4 MRI Acquisition

All MRI scans were obtained using a 1.5 T Siemens MAGNETOM Avanto (Erlangen, Germany) scanner within 2 to 4 weeks from the examination by TCS. The imaging protocol included axial T2W/TSE/2mm (TR 4740 ms, TE 3.37 ms, TI 1100 ms, flip angle 120), T1W/mpr/p2/iso (TR 3000 ms, TE 89 ms), T2W/fl2d/hemo (TR800 ms, TE 26 ms, flip angle 20), coronal T2W/TSE (TR 5000 ms, TE 93 ms, flip angle 150), DW/ADC (TR 3000 ms, TE 89 ms), axial and coronal T2W/FLAIR (TR 9000 ms, TE 98 ms, TI 2500 ms, flip angle 150) and sagittal T2W/spc2d/iso

(TR 3200 ms, TE 379 ms) sequences of the entire brain. No contrast media were injected. No hardware or software upgrades of the MRI scanner were done during the study period.

All sequences (T2W/FLAIR, T2W, T2W/fl2d/hemo, DW/ADC) were used to eliminate intra- and extra-axial lesions (tumors, vascular pathology, etc.). For the measurements of the SN, T2W/TSE/2 mm axial images of midbrain were used in all PD patients and in HC. In the axial plane, SN is as crescent-shaped region (see Fig. 8.1d); therefore, two quantitative measurements—ventral and dorsal—were taken. The ventral measurement was a maximum width of the visible SN in the cerebral peduncle near the interpeduncular cistern and 1.5 mm proximal from the inner corner of the midbrain. The dorsal measurement was a maximum width of the visible SN in the cerebral peduncle near the peripontine cistern and 2.0 mm distal from the inner corner of the midbrain. The area of SN was evaluated in the same sequence and scan level using the JiveX Diagnostics Advanced 5.2.0.3 system (VISUS Health IT GmbH, Bochum, Germany) measurement tool (Polygon statistic measurement).

8.2.5 Statistical Analysis

RF TCS, cTCS and MRI data were made quantitative in this study. This allowed us to provide detailed statistical analysis.

Normality of data distributions were examined using the Shapiro–Wilk test. Since majority of RF TCS-based parameter estimates were not normally distributed, they were compared between HC subjects and patients with PD using the non-parametric Mann–Whitney U test; remaining variables were compared between groups by a parametric Student t test for independent samples. Variables that achieved a p value of less than 0.20 were examined with multivariate analysis using logistic regression (LR) for three methods—RF TCS, cTCS and MRI—based measures separately. Forward and backward stepwise LR was applied to assess the predictive characteristics of the amplitude, strain and morphology (FreqHP) groups of parameters between PD patients and control subjects, with age (for all three methods based quantitative measures) and relative energy in the 4–6 Hz frequency band (only for RF TCS-based quantitative measures) included as a covariate.

Receiver operating characteristic (ROC) analysis was used to evaluate the performance of the diagnostic ability of the analyzed parameter estimates and—more generally—to evaluate the accuracy of the LR model that classified subjects into sick or healthy. An optimal diagnostic cut-off point was determined via the Youden index. ROC curves were analyzed to define a cut-off value for the highest sensitivity and specificity of predicted probability of LR models and the RF US parameter estimates, which achieved $p \leq 0.05$ using a Mann–Whitney U test.

The significance level α was set at 0.05. Statistical analysis was performed using IBM SPSS Statistics 22.0 (IBM Corp., Armonk, NY, USA) software.

8.3 Results

8.3.1 Demographic Data and Single TCS and MRI Quantitative Measures

Initially, among PD patients 12 (60%) were men, 11 (50%) of HC subjects were men, and, thus, groups were similar regarding sex (χ^2 test, $p = 1.00$, $p > 0.05$). Age and education of the initial sample did not differ statistically between the HC and PD groups (see Table 8.1: all subjects).

Table 8.1 Demographic characteristics, conventional transcranial sonography and magnetic resonance imaging quantitative measures

Variable	Mean \pm standard deviation		p Value
	HC	PD	
All subjects			
Age, years	68.5 \pm 6.8	64.1 \pm 10.1	0.17
Education, years	15.2 \pm 3.2	14.7 \pm 2.9	0.61
Motor section of UPDRS	–	33.2 \pm 12.9	–
Subjects with repeatable waveforms in RF TCS recordings			
Age, years	68.1 \pm 6.8	62.9 \pm 10.7	0.123
Education, years	15.0 \pm 3.2	14.9 \pm 3.2	0.99
Motor section of UPDRS	–	31.6 \pm 10.7	–
SN dorsal width by MRI, mm	4.29 \pm 1.29	3.08 \pm 1.77	0.007
SN ventral width by MRI, mm	5.35 \pm 1.31	4.05 \pm 1.44	0.002
SN area by MRI, mm ²	55.4 \pm 7.9	33.1 \pm 10.9	<0.001
SN area by cTCS, mm ²	10.8 \pm 2.74	24.4 \pm 7.49	<0.001
Width of 3rd ventricle by MRI, mm	6.19 \pm 2.80	6.53 \pm 1.98	0.70
Width of 3rd ventricle by cTCS, mm	5.89 \pm 1.89	6.58 \pm 2.38	0.36

Note: Statistically significant differences according to the Student t test marked in bold.

Abbreviations: cTCS, conventional transcranial sonography; MRI, magnetic resonance imaging; HC, healthy controls; PD, Parkinson's disease; RF TCS, radiofrequency transcranial sonography; UPDRS, the Unified Parkinson's Disease Rating Scale.

Once the US RF data were processed, six subjects from the PD patient group and one subject from the HC group were excluded due to an insufficient number of repeated waveforms in displacement signals (see Table 8.1: subjects with repeatable waveforms in RF TCS recordings). Therefore, US RF data of 19 control subjects (the ROIs of both sides for 10 subjects, only right ROI for three subjects, only left ROI for six subjects—29 ROIs in total) and of 14 PD patients (the ROIs of both sides for six patients, only right ROI for four patients, only left ROI for four patients—20 ROIs in total) were used for the final analyses. Ten persons

(52.6%) of the control group were men, and nine (64.2%) were men in the PD group; however, groups did not differ by sex (χ^2 test, $p = 0.72$). Age and education of the remaining subjects did not differ statistically between the HC and PD groups (see Table 8.1) too.

The morphology parameter FreqHP Q3 was the only parameter from RF US-based parameters that significantly differed statistically between HC (Me = 2.37, Q1 = 1.95, Q3 = 2.62, IQR = 0.68) and PD groups (Me = 2.71, Q1 = 2.20, Q3 = 3.30, IQR = 1.10) according to the Mann–Whitney U test ($p = 0.018$). The area under the curve (AUC) of ROC for FreqHP Q3 was 70.0% (95% confidence interval: 55.1–84.9%); at cut-off of 2.62 Hz, sensitivity was 65.0%, specificity was 75.9%. Besides, there was tendency that maximal FreqHP value ($p = 0.076$), RMS ex-Gaussian SD ($p = 0.080$) and RMS IQR ($p = 0.091$) was higher in PD group too. The dominant frequency (FreqD) of the low-end spectrum peak (expected heart rate) did not differ between groups (Mann–Whitney $p = 0.282$). Relative energy in 4–6 Hz frequency band did not differ between HC and PD groups too (Mann–Whitney $p = 0.222$).

The SN area had remarkable discrepancy between quantitative measures by MRI and by cTCS, these measures had moderate negative correlation (Pearson $r = -0.498$, $p < 0.001$). Scores on Motor section of UPDRS did not correlate with size of the SN area neither by MRI ($p = 0.752$), nor by cTCS measures ($p = 0.487$).

8.3.2 Models of Logistic Regression Analysis

To assess the predictive power of multiple parameters together for the likelihood that the subject had PD, forward and backward stepwise LR was applied.

From all 40 RF TCS-based parameter estimates, nine had a Mann–Whitney p value of less than 0.20, and thus initially we tried to pass them into LR; however, both forward and backward stepwise LR analysis produced models without RF TCS-based variables (i.e., both models only contained an intercept).

Then, we evaluated multiple sets of RF TCS-based variables (four variables having a Mann–Whitney p value of less than 0.10) with their interactions manually. Only variables not exceeding 0.5 value of Spearman correlation were included into the one set for the LR model. According to ROC analysis, the most optimal LR model was with two single variables (FreqHP Q3 and RMS ex-Gaussian SD) and their interaction (see RF TCS 1st model in Table 8.2 and Fig. 8.2). After adding age covariate into this LR model, age became a statistically significant variable; however, two RF TCS-based components (one single variable and interaction) remained statistically significant (see RF TCS 2nd model in Table 8.2). Relative energy in the 4–6 Hz frequency band was not a statistically significant variable after adding it as a covariate; however, then only one RF TCS-based component (interaction) remained at the threshold of statistical significance (see RF TCS 3rd model in Table 8.2). All these three models were statistically significant ($p < 0.005$) and had a good classification ability (AUC > 80%) according to the ROC analysis (see Table 8.3 for more details).

Table 8.2 The predictive power of the midbrain tissue displacement signal parameters or size of substantia nigra area for the likelihood that the subject has Parkinson's disease

Parameter estimate	β	Exp(β)	Exp(β) 95% CI	<i>p</i> Value
RF TCS 1st model				
RMS_exG_SD	-3.490	0.030	[0.001, 0.684]	0.028
FreqHP_Q3	-4.392	0.012	[0.000, 0.857]	0.042
FreqHP_Q3 \times RMS_exG_SD	1.806	6.084	[1.352, 27.37]	0.019
Constant	7.235	1387.2	-	0.112
RF TCS 2nd model				
RMS_exG_SD	-2.807	0.060	[0.004, 0.917]	0.043
FreqHP_Q3	-3.627	0.027	[0.001, 1.364]	0.071
FreqHP_Q3 \times RMS_exG_SD	1.527	4.606	[1.212, 17.50]	0.025
Age	-0.120	0.887	[0.811, 0.971]	0.010
Constant	12.873	3.898×10^5	-	0.012
RF TCS 3rd model				
RMS_exG_SD	-2.895	0.055	[0.002, 1.433]	0.081
FreqHP_Q3	-3.915	0.020	[0.000, 2.249]	0.104
FreqHP_Q3 \times RMS_exG_SD	1.599	4.946	[0.986, 24.806]	0.052
Age	-0.135	0.873	[0.791, 0.964]	0.007
Relative energy in 4-6 Hz	163.25	7.917×10^{70}	[0.000, 1.083×10^{180}]	0.203
Constant	13.448	6.923×10^5	-	0.018
cTCS 1st model				
TCS_SN_area	0.731	2.076	[1.319, 3.267]	0.002
Constant	-11.868	0.000	-	0.001
cTCS 2nd model				
TCS_SN_area	0.808	2.243	[1.239, 4.063]	0.008
Age	-0.119	0.888	[0.694, 1.136]	0.345
Constant	-5.084	0.006	-	0.463
MRI 1st model				
MRI_SN_area	-0.225	0.798	[0.706, 0.902]	<0.001
Constant	9.633	1.526×10^4	-	0.001
MRI 2nd model				
MRI_SN_area	-0.264	0.768	[0.652, 0.905]	0.002
Age	-0.202	0.817	[0.680, 0.981]	0.031
Constant	23.973	2.578×10^{10}	-	0.006

Note: Results of logistic regression analyses. β , logistic regression coefficient; Exp(β), odds ratios; CI, confidence interval; RF TCS, radiofrequency transcranial sonography; cTCS, conventional transcranial sonography; MRI, magnetic resonance imaging; FreqHP_Q3, frequency of high-end spectra peak, third quartile, Hz; RMS_exG_SD, root mean square, standard deviation of ex-Gaussian distribution, μm ; TCS_SN_area, area of substantia nigra by conventional transcranial sonography, mm^2 ; MRI_SN_area, area of substantia nigra by magnetic resonance imaging, mm^2 .

Table 8.3 ROC analysis of the predicted probability of logistic regression models for the likelihood that the subject has Parkinson's disease

Model	AUC, %	95% CI	<i>p</i> Value	Cut-Off, %	Sensitivity, %	Specificity, %	Overall Correct Classification, %
RF TCS 1st	80.9	[69.1, 92.7]	<0.001	29.9	85.0	69.0	75.5
RF TCS 2nd	86.2	[74.9, 97.6]	<0.001	44.6	80.0	86.2	83.7
RF TCS 3rd	88.3	[78.6, 97.9]	<0.001	42.7	80.0	86.2	83.7
cTCS 1st	98.2	[94.9, 100.0]	<0.001	77.7	90.0	100.0	95.9
cTCS 2nd	98.7	[96.5, 100.0]	<0.001	70.8	90.0	100.0	95.9
MRI 1st	94.1	[86.5, 100.0]	0.039	54.1	90.0	96.6	93.9
MRI 2nd	97.8	[94.3, 100.0]	0.018	43.3	95.0	96.6	95.9

Abbreviations: AUC, area under the curve; CI, confidence interval; cTCS, conventional transcranial sonography; MRI, magnetic resonance imaging; RF TCS, radiofrequency transcranial sonography.




Figure 8.2 Visualization of radiofrequency ultrasound-based displacement parameter estimates that were included in the first logistic regression model. Sub-images represent distributions of displacement parameters of confidently repeatable moving individual points, from midbrain: (a) frequency of high-end spectra peak (FreqHP) and (b) root mean square (RMS). FreqHP_Q3—FreqHP third quartile, Hz; RMS_exG_SD—RMS standard deviation of ex-Gaussian distribution, µm.

The predicted probability of these RF TCS data-based LR models did correlate with the size of the SN area as measured by cTCS (from Spearman $\rho = 0.459$ and $p = 0.002$ for RF TCS 1st Model to Spearman $\rho = 0.531$ and $p < 0.001$ for RF TCS 2nd Model) and MRI (from Spearman $\rho = -0.347$ and $p = 0.015$ for RF TCS 1st Model to Spearman $\rho = -0.517$ and $p < 0.001$ for RF TCS 3rd Model). Predicted probability of these LR models did not correlate on the Scores on Motor section of UPDRS ($p > 0.05$).

Meanwhile cTCS and MRI quantitative data based LR models had an excellent classification ability (AUC > 90%) even with a single variable—size of SN area, independent of age (see Tables 8.2 and 8.3).

8.4 Discussion

We aimed to assess the diagnostic ability of endogenous brain tissue displacement parameters in a midbrain using US RF signals and compare it with a diagnostic ability of the measurements of the SN area by cTCS and by MRI for the differentiation of patients with PD from HC subjects. The model constructed of RF TCS-based tissue displacement parameters—FreqHP and RMS—demonstrated quite good diagnostic ability in the evaluation of the midbrain.

The interaction between one morphology parameter (FreqHP) distribution estimate and one amplitude parameter (RMS) distribution estimate had the highest influence in the RF US-based model (RF TCS 1st Model). FreqHP reflects the distribution of frequency values by finding a peak with the maximum power within high-end spectra for every spatial point separately. Since this displacement waveform morphology parameter estimate Q3 was the only one from all US RF-based variables differing between HC subjects and PD patients (only Q3 of FreqHP became higher in PD patients), we can hypothesize that the registered micromovements in most parts of the midbrain did not significantly change with the disease, and the changes occurred only in part of the midbrain which had a relatively sharper micromovements pattern. The same FreqHP parameter-captured disease affected other brain structures in our previous study [15]. There, a set of brain tissue displacement signal parameters (FreqHP maximum, mode and IQR, and strain) worked together well while differentiating the medial temporal lobe of an Alzheimer's disease patient from that of an HC subject with an excellent diagnostic ability [15]. The observed tendency that PD has wider RMS dispersion (as evaluated by ex-Gaussian SD and IQR) also suggest increased anisotropy in the midbrain.

The obvious difference in the results using the method under investigation could be caused by differences of the constitutive properties of tissue between various regions of the brain, between white matter and gray matter [27–29], by the specificities of the underlying neurodegenerative process, by cardiovascular pulsatility [30] and cerebral autoregulation [31] and by the method itself.

The brainstem, including the midbrain, is globally stiffer than the cerebral hemispheres [27], and is anisotropic [32, 33] because the largest part of brainstem consists of ascending and descending axons forming major tracts, and white matter tissue is found to be stiffer than gray matter [29]. In the case of PD, a neurodegenerative process in the midbrain affects mainly dopaminergic neurons of the compact part of the SN which forms a less-stiff gray matter nucleus. The SN is a very small part (small percentage) of the entire midbrain and, in contrast to Alzheimer's disease, does not result in apparent atrophy or other changes on conventional neuroimaging modalities such as computed tomography or MRI [34]. Deformation-based morphometry and independent component analysis, however,

identified PD-specific atrophy in the midbrain, basal ganglia, basal forebrain, medial temporal lobe and discrete cortical regions [35]. Since the SN area is taking a relatively small part in the midbrain scanning plane, therefore, observed changes by our RF TCS-based micromovements tracking method are relatively subtle; however, they are still captured by this method.

Besides, according to our data, the midbrain is located about 1.5 times deeper than the medial temporal lobe assessed in our previous study. Therefore, the US scanning inter-line gaps are increased from 0.54 to 0.73 mm, although this loss of resolution is hardly influencing our results. However, transtemporal scanning perpendicular to the cranio-caudal axis of the pulsating brain [36, 37] might limit the possibility of detecting the endogenous deformations more significantly.

Despite all the conditions mentioned above, diagnostic ability findings for the RF TCS of the midbrain (when age included as covariate, sensitivity is 80.0%, specificity is 86.2%) appear to be similar to that recently published for the cTCS of the SN (sensitivity: 85%, specificity: 89% respectively) [38], as well as to our previously published results (sensitivity: 90%, specificity: 82.4%, respectively [25].

To our knowledge, our study is the first one providing quantitative measures obtained by RF TCS (with high amount of various parameter estimates), cTCS and MRI methods simultaneously. In our present study, the predicted probability of PD was excellent (ROC AUC \geq 90%) with a sensitivity of 90–95% and a specificity of 96.6–100% for both structural TCS and MRI measurements of the SN area, i.e., a bit higher compared to that reported by other researchers. Conventional T1- and T2-weighted MRI measurements of the SN area were criticized for poor delineation of the SN and we found just two published studies looking at the differences of the measurements of the SN area between PD patients and HC subjects with conflicting results [39, 40]. In a study by Minati et al. [39], the SN area of the PD patients was significantly smaller compared to that of HC subjects while no difference was found in a study by Oikawa et al [40]. Recently the SN pars compacta T1w/T2w ratio value on 3T MRI was proposed as a novel, parsimonious *in vivo* biomarker for the PD [41].

It should be noted, however, that our current study was not designed as a diagnostic accuracy study, the number of participants was quite small and investigators were not blinded to the clinical status of the subject, and this might have had some influence on the results. A high percentage of PD patients' data were excluded due to non-repeated movement of the brain tissue.

We believe that an assessment of endogenous brain tissue displacement parameters in order to detect pathologic changes specific for PD in a midbrain using backscattered US RF signals still has a future, as it has potential for the improvement in respect of sonography scanning planes and transcranial acoustic windows, enabling detection of stronger displacement of midbrain endogenous motion along the cranio-caudal axis. Furthermore, more parameters, for instance, relative strain could be informative in the semi-longitudinal section of a midbrain. Future studies could validate our results using larger samples of participants to try to achieve a better balance between temporal and spatial resolution with the RF TCS method, which could ideally open the possibility to locate the small

SN structure and simultaneously capture its micromovements to try to better integrate data while evaluating SN or midbrain properties by simultaneously using several methods such as RF TCS and cTCS.

8.5 Conclusions

The model constructed of RF TCS-based brain tissue displacement parameters—FreqHP and RMS—revealed, presumably increased anisotropy in the midbrain and demonstrated rather good diagnostic ability in the PD evaluation, although it was not superior to that of the structural cTCS or MRI. Future studies are needed in order to establish a true place of US RF signal-based displacement parameters for the detection of pathologically affected brain tissue.

Abbreviations

AUC:	area under the curve
cTCS:	conventional TCS
FreqD:	dominant frequency
FreqHP	frequency of high-end spectra peak
HC:	healthy controls
IQR	interquartile range
LR:	logistic regression
MRI:	magnetic resonance imaging
PD:	Parkinson's disease
RF:	radiofrequency
RMS:	root mean square
ROI:	region of interest
ROC:	receiver operating characteristic
RMS:	root mean square
SD:	standard deviation
SN:	substantia nigra
TCS:	transcranial sonography
UPDRS:	Unified Parkinson's disease rating scale
US:	ultrasound

Disclosures and Conflict of Interest

This chapter was originally published as: Baranauskas, M., Jurkonis, R., Lukoševičius, A., Matijošaitis, V., Gleiznienė, R., Rastenytė, D. (2020). Diagnostic ability of radiofrequency ultrasound in Parkinson's disease compared to conventional transcranial sonography and magnetic resonance imaging. *Diagnostics*, **10**, 778, <https://doi.org/10.3390/diagnostics10100778>, under the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates, by kind permission of the copyright holders.

Author Contributions: Conceptualization: A.L. and D.R.; data curation: V.M., M.B. and R.J.; funding acquisition: D.R.; investigation: V.M., R.J. and R.G.; methodology: A.L., R.J., M.B., V.M. and D.R.; project administration: R.J. and D.R.; resources: R.J. and V.M.; software: M.B.; supervision: A.L. and D.R.; validation: M.B. and R.J.; visualization: M.B.; writing—original draft: M.B., D.R. and R.J.; writing—review and editing: A.L., D.R. and V.M. All authors have read and agreed to the published version of the chapter.

Funding: This study was performed within a framework of a project funded by the Research Council of Lithuania “Radiofrequency Ultrasound-based Brain Tissue Assessment Method for the Diagnostics of Early Neurodegeneration (NeuroRD)” Reg. No.: MIP-17-457.

Acknowledgments: We thank Kristina Jurėnienė for her consultations regarding logistic regression models and ROC analyses.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the chapter, or in the decision to publish the results.

References

1. Fearnley, J.M., Lees, A.J. Ageing and Parkinson’s disease: Substantia nigra regional selectivity. *Brain* **1991**, *114*, 2283–2301.
2. Hornykiewicz, O. Basic research on dopamine in Parkinson’s disease and the discovery of the nigrostriatal dopamine pathway: The view of an eyewitness. *Neurodegener. Dis.* **2008**, *5*, 114–117.
3. Braak, H., Tredici, K.D., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. *Neurobiol. Aging* **2003**, *24*, 197–211.
4. Berardelli, A., Wenning, G.K., Antonini, A., Berg, D., Bloem, B.R., Bonifati, V., Brooks, D., Burn, D.J., Colosimo, C., Fanciulli, A., et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. *Eur. J. Neurol.* **2013**, *20*, 16–34.
5. O’Brien, J.T., Oertel, W.H., McKeith, I.G., Grosset, D.G., Walker, Z., Tatsch, K., Tolosa, E., Sherwin, P.F., Grachev, I.D. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. *BMJ Open* **2014**, *4*, e005122.
6. Vlaar, A.M., de Nijs, T., van Kroonenburgh, M.J., Mess, W.H., Winogrodzka, A., Tromp, S.C., Weber, W.E. The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: Comparison with SPECT scans. *BMC Neurol.* **2008**, *8*, 42.
7. Chau, M.T., Todd, G., Wilcox, R., Agzarian, M., Bezak, E. Diagnostic accuracy of the appearance of Nigrosome-1 on magnetic resonance imaging in Parkinson’s disease: A systematic review and meta-analysis. *Parkinsonism Relat. Disord.* **2020**, *78*, 12–20.
8. Tuite, P. Magnetic resonance imaging as a potential biomarker for Parkinson’s disease. *Transl. Res.* **2016**, *175*, 4–16.

9. Berg, D., Godau, J., Walter, U. Transcranial sonography in movement disorders. *Lancet Neurol.* **2008**, *7*, 1044–1055.
10. Berg, D., Behnke, S., Walter, U. Application of transcranial sonography in extrapyramidal disorders: Updated recommendations. *Ultraschall Med. Eur. J. Ultrasound* **2006**, *27*, 12–19.
11. Walter, U., Behnke, S., Eyding, J., Niehaus, L., Postert, T., Seidel, G., Berg, D. Transcranial brain parenchyma sonography in movement disorders: State of the art. *Ultrasound Med. Biol.* **2007**, *33*, 15–25.
12. Ince, J., Alharbi, M., Minhas, J.S., Chung, E.M. Ultrasound measurement of brain tissue movement in humans: A systematic review. *Ultrasound* **2020**, *28*, 70–81.
13. Kucewicz, J.C., Dunmire, B., Leotta, D.F., Panagiotides, H., Paun, M., Beach, K.W. Functional tissue pulsatility imaging of the brain during visual stimulation. *Ultrasound Med. Biol.* **2007**, *33*, 681–690.
14. Jurkonis, R., Makūnaitė, M., Baranauskas, M., Lukoševičius, A., Sakalauskas, A., Matijošaitis, V., Rastenytė, D. Quantification of endogenous brain tissue displacement imaging by radiofrequency ultrasound. *Diagnostics* **2020**, *10*, 57.
15. Baranauskas, M., Jurkonis, R., Lukoševičius, A., Makūnaitė, M., Matijošaitis, V., Gleiznienė, R., Rastenytė, D. Ultrasonic assessment of the medial temporal lobe tissue displacements in Alzheimer's disease. *Diagnostics* **2020**, *10*, 452.
16. Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. *J. Neurol. Neurosurg. Psychiatry* **1992**, *55*, 181–184.
17. Fahn, S., Elton, R. Unified Parkinson's disease rating scale. In *Recent Developments in Parkinson's Disease*, Fahn, S., Marsden, C., Calne, D., Goldstein, M., Eds., Macmillan Health Care Information: Florham Park, NJ, USA, 1987, pp. 153–164.
18. Desmidt, T., Brizard, B., Dujardin, P.-A., Ternifi, R., Réméniéras, J.-P., Patat, F., Andersson, F., Cottier, J.-P., Vierron, E., Gissot, V., et al. Brain tissue pulsatility is increased in midlife depression: A comparative study using ultrasound tissue pulsatility imaging. *Neuropsychopharmacology* **2017**, *42*, 2575–2582.
19. Kucewicz, J.C., Dunmire, B., Giardino, N.D., Leotta, D.F., Paun, M., Dager, S.R., Beach, K.W. Tissue pulsatility imaging of cerebral vasoreactivity during hyperventilation. *Ultrasound Med. Biol.* **2008**, *34*, 1200–1208.
20. Ternifi, R., Cazals, X., Desmidt, T., Andersson, F., Camus, V., Cottier, J.-P., Patat, F., Remenieras, J.-P. Ultrasound measurements of brain tissue pulsatility correlate with the volume of MRI white-matter hyperintensity. *J. Cereb. Blood Flow Metab.* **2014**, *34*, 942–944.
21. Maurice, R.L., Bertrand, M. Lagrangian speckle model and tissue-motion estimation-theory [ultrasonography]. *IEEE Trans. Med. Imaging* **1999**, *18*, 593–603.
22. Gibb, W.R., Lees, A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* **1988**, *51*, 745–752.
23. Marsili, L., Rizzo, G., Colosimo, C. Diagnostic criteria for Parkinson's disease: From James Parkinson to the concept of prodromal disease. *Front. Neurol.* **2018**, *9*, 156.

24. Lacouture, Y., Cousineau, D. How to use MATLAB to fit the ex-Gaussian and other probability functions to a distribution of response times. *Tutor. Quant. Methods Psychol.* **2008**, *4*, 35–45.
25. Laučkaitė, K., Rastenytė, D., Šurkienė, D., Vaitkus, A., Sakalauskas, A., Lukoševičius, A., Gleiznienė, R. Specificity of transcranial sonography in parkinson spectrum disorders in comparison to degenerative cognitive syndromes. *BMC Neurol.* **2012**, *12*, 12.
26. Laučkaitė, K., Rastenytė, D., Šurkienė, D., Vaidelytė, B., Dambrauskaitė, G., Sakalauskas, A., Vaitkus, A., Gleiznienė, R. Ultrasonographic (TCS) and clinical findings in overlapping phenotype of essential tremor and Parkinson's disease (ET-PD). *BMC Neurol.* **2014**, *14*, 54.
27. Arbogast, K.B., Margulies, S.S. Material characterization of the brainstem from oscillatory shear tests. *J. Biomech.* **1998**, *31*, 801–807.
28. Budday, S., Nay, R., de Rooij, R., Steinmann, P., Wyrobek, T., Ovaert, T.C., Kuhl, E. Mechanical properties of gray and white matter brain tissue by indentation. *J. Mech. Behav. Biomed. Mater.* **2015**, *46*, 318–330.
29. van Dommelen, J.A.W., van der Sande, T.P.J., Hrapko, M., Peters, G.W.M. Mechanical properties of brain tissue by indentation: Interregional variation. *J. Mech. Behav. Biomed. Mater.* **2010**, *3*, 158–166.
30. Rektor, I., Goldemund, D., Sheardová, K., Rektorová, I., Michálková, Z., Dufek, M. Vascular pathology in patients with idiopathic Parkinson's disease. *Parkinsonism Relat. Disord.* **2009**, *15*, 24–29.
31. Vokatch, N., Grötzsch, H., Mermillod, B., Burkhard, P.R., Sztajzel, R. Is cerebral autoregulation impaired in Parkinson's disease? A transcranial Doppler study. *J. Neurol. Sci.* **2007**, *254*, 49–53.
32. Feng, Y., Okamoto, R.J., Namani, R., Genin, G.M., Bayly, P.V. Measurements of mechanical anisotropy in brain tissue and implications for transversely isotropic material models of white matter. *J. Mech. Behav. Biomed. Mater.* **2013**, *23*, 117–132.
33. Velardi, F., Fraternali, F., Angelillo, M. Anisotropic constitutive equations and experimental tensile behavior of brain tissue. *Biomech. Model. Mechanobiol.* **2006**, *5*, 53–61.
34. Pyatigorskaya, N., Gallea, C., Garcia-Lorenzo, D., Vidailhet, M., Lehericy, S. A review of the use of magnetic resonance imaging in Parkinson's disease. *Ther. Adv. Neurol. Disord.* **2014**, *7*, 206–220.
35. Zeighami, Y., Ulla, M., Iturria-Medina, Y., Dadar, M., Zhang, Y., Larcher, K.M.-H., Fonov, V., Evans, A.C., Collins, D.L., Dagher, A. Network structure of brain atrophy in de novo Parkinson's disease. *eLife* **2015**, *4*, e08440.
36. Barry, R.L., Coaster, M., Rogers, B.P., Newton, A.T., Moore, J., Anderson, A.W., Zald, D.H., Gore, J.C. On the origins of signal variance in fMRI of the human midbrain at high field. *PLoS ONE* **2013**, *8*, e62708.
37. Reese, T.G., Feinberg, D.A., Dou, J., Wedeen, V.J. Phase contrast MRI of myocardial 3D strain by encoding contiguous slices in a single shot. *Magn. Reson. Med.* **2002**, *47*, 665–676.

38. Tao, A., Chen, G., Deng, Y., Xu, R. Accuracy of transcranial sonography of the substantia nigra for detection of Parkinson's disease: A systematic review and meta-analysis. *Ultrasound Med. Biol.* **2019**, *45*, 628–641.
39. Minati, L., Grisoli, M., Carella, F., De Simone, T., Bruzzone, M.G., Savoiaro, M. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. *AJNR Am. J. Neuroradiol.* **2007**, *28*, 309–313.
40. Oikawa, H., Sasaki, M., Tamakawa, Y., Ehara, S., Tohyama, K. The substantia nigra in Parkinson disease: Proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. *AJNR Am. J. Neuroradiol.* **2002**, *23*, 1747–1756.
41. Du, G., Lewis, M.M., Sica, C., Kong, L., Huang, X. Magnetic resonance T1w/T2w ratio: A parsimonious marker for Parkinson disease: Midbrain T1w/T2w Ratio in PD. *Ann. Neurol.* **2019**, *85*, 96–104.

Chapter 9

An Overview of Immunoassays

Caroline Murphy, PhD, Sarah Gilgunn, PhD, and Richard O’Kennedy, PhD

School of Biotechnology, Dublin City University, Dublin, Ireland

caroline.s.murphy@dcu.ie

Keywords: antibody, antibody fragment, antibody labels, antibody purification, antibody structure, bioluminescence, chemiluminescence, competitive assay, enzyme-linked immunosorbent assay (ELISA), epitope, fluorescence, fluorescence polarisation immunoassay (FPIA), fluorescence protein (FP), fluorescence resonance energy transfer (FRET), gold nanoparticles (GNPs), immobilisation, immunoassay, immunogen, immunoglobulin (Ig), immunosensing, monoclonal, nanomaterials, nanomechanical sensors, phage display, piezoelectric mass sensors, point-of-care (POC), polyclonal, quantum dots (QDs), recombinant, sandwich assay, signal generation, signal transduction, time-resolved fluorescence

9.1 Introduction to Antibodies and Immunoassays

The aim of this chapter is to provide a detailed and practical introduction to immunoassays. The production of antibodies, various antibody structures and their fundamental role in immunoassays are outlined. Comprehensive guides to different immunoassay formats ranging from direct to competitive are provided, and subsequently, important signalling systems, including colorimetric and fluorescence-based approaches, are examined. Finally, electrical, mechanical and optical signal transduction mechanisms that are used in immunoassays are described.

Immunoassays are biochemical tests that utilise immunoglobulins (Igs) (antibodies) as high sensitivity binders to detect the presence of molecules that are present at low concentrations. Antibodies are an integral part of the humoral immune system and are nature’s major recognition devices. They are found on the surface of B-cells (B-lymphocytes) and recognise the presence of foreign antigens. The B-cell can detect and signal the presence of an extensive range of

antigens, consisting of molecules ranging from prions to viruses, drugs, toxins and aberrant biomolecules that invade our bodies. Immunoglobulin proteins exist in many different formats, the five main isotypes of immunoglobulin are IgG (shown in Fig. 9.1), IgM, IgD, IgA and IgE.




Figure 9.1 Structure of immunoglobulin G (IgG). IgG is made up of two heavy chains (composed of constant domains C_{H1} , C_{H2} and C_{H3} and variable heavy domain, V_H), and two light chains (composed of the constant light domain, C_L and the variable light domain, V_L), connected by disulphide bonds. The antigen-binding region is composed of a variable heavy chain and a variable light chain, which recognises the epitope (specific area where binding occurs) of the antigen.

Antibodies are at the forefront of targeted therapeutics and diagnostics due to their natural high affinities and excellent half-lives. They can be readily manipulated using standard molecular biological techniques into customised antibodies that are tailored to perform efficiently in their chosen end-point application. The biopharmaceutical industry has heavily invested in antibody-based diagnostics and therapeutics, and the latter currently represents the largest and fastest growing class of biopharmaceuticals [1, 2].

Antibodies are generally represented in three forms: (i) polyclonal (produced from a mixture of various B-cell clones), (ii) monoclonal (secreted from a single clone of B-cells) and (iii) recombinant antibodies (the product of the genetic manipulation of antibody genes) [3, 4].

9.1.1 Polyclonal Antibody Production

Polyclonal antibody production involves the immunisation of animals with an antigen and adjuvant (immune system stimulating material) mixture, resulting in the activation of multiple B-cells targeting different antigen epitopes. This produces a vast number of antibodies with different specificities and epitope affinities [3]. These polyclonal antibodies are purified from the serum of immunised animals. Polyclonal antisera can be obtained relatively quickly (6–12 weeks for highly immunogenic antigens) but the time may be antigen-dependent. Methods of

purification are generally associated with the antibody type and the intended application(s) for the antibody. These are listed in Table 9.1 [5].

Several key steps need to be considered for the production of polyclonal antibodies, including (i) preparation/availability of antigen, (ii) choice of host species, (iii) injection regime, (iv) monitoring antibody response to immunogen and (v) collection/purification of antibodies. The choice of host is of particular importance when developing polyclonal antibodies against human derived targets, as a large number of proteins are highly conserved throughout mammalian evolution, and, are therefore, common to many mammalian species. Hence, immunisation of such proteins into rabbits and mice, may generate a limited immune response [6]. The use of a species more phylogenetically distant from humans such as chickens (that diverged from mammalian genomes some 310 million years ago [7]) is an ideal alternative for immunisation and selection of antibodies against highly conserved human proteins [6, 8].

Table 9.1 Polyclonal antibody purification methods [5]

Purification type	Methodologies involved in the purification
Crude	Precipitation of a subset of total serum proteins that includes immunoglobulins
General	Affinity purification of certain antibody classes (e.g. IgG)
Specific	Affinity purification of only those antibodies in a sample that bind to a particular antigen

9.1.2 Production of Monoclonal Antibodies

The development of ‘hybridoma technology’ won Georges Köhler and César Milstein the Nobel Prize in Physiology or Medicine in 1984. They created an immortal cell line capable of producing an endless supply of identical antibodies with known specificity called ‘monoclonal antibodies’ signifying the fact that they were derived from a single hybrid cell [9]. The production of monoclonal antibodies is shown in Fig. 9.2 [3].

9.1.3 Recombinant Antibody Fragments

Recombinant antibodies are highly attractive for customised antibody development as genetic manipulations can be easily employed to precisely tailor their specificity and biophysical properties [10–14]. The ability to readily generate bulk quantities of recombinant proteins, with low production costs in *Escherichia coli*, has fuelled the emergence of an assortment of distinct antibody constructs that can be employed in a wide variety of applications. Some common recombinant antibody constructs are shown in Fig. 9.3.

The smallest antibody fragment that retains the full monovalent antigen binding capabilities of a human IgG is the variable fragment (Fv) and it is comprised of the variable heavy (V_H) and variable light (V_L) domains held together by non-covalent interactions [12, 13].




Figure 9.2 Production of monoclonal antibodies by hybridoma technology. B-cells from an immunised mouse are isolated and fused with a myeloma cell line creating hybridomas (generally mediated by the addition of polyethylene glycol (PEG)). Cloning and selection of a specific hybridoma is carried out by ‘limiting dilution’. The clones are screened for reactivity and specific antibody-producing clones are further characterised and expanded for generation of the desired antibody.




Figure 9.3 Antibody fragment constructs. The mammalian IgG construct (150 kDa) consists of two heavy and two light polypeptide chains linked together by disulphide bonds. The heavy chain consists of variable heavy (V_H) and three constant (C_{H1}, C_{H2}, and C_{H3}) regions. The scFv consists of the V_H and V_L chains joined together by a flexible linker. A single chain antibody (scAb) fragment consists of a scFv with an additional constant chain (either heavy or light). The Fab (antigen-binding fragment) contains the full light chain with V_H and C_{H1}. F(ab')₂ is comprised of two Fab fragments held together by disulphide bonds.

The single chain fragment variable (scFv) is more stable than the Fv (which is more prone to aggregation than the scFv) and typically, a flexible 15 residue glycine/serine ((Gly₄Ser)₃) linker is incorporated to link the chains together and aid antibody folding and stability during bacterial expression [14].

The antigen-binding fragment (Fab) is a larger, more stable fragment of approximately 50 kDa. The Fab fragment consists of the variable heavy, variable light, constant heavy and constant light chains (V_H & C_{H1} and V_L & C_L). An interchain disulphide bond exists between the C_{H1} and C_L (Fig. 9.3) [15].

There are various advantages and disadvantages associated with the different types of recombinant antibody structures that can be engineered. It should also be noted that antibody fragments can be relatively easily reformatted for improved characteristics such as expression [16], reduction in non-specific binding [17] and enhanced specificity [18]. The selection of superlative antigen-specific recombinant fragments can be achieved using a process known as phage display technology.

9.1.3.1 Production of recombinant antibodies by phage display technology

When George P. Smith first demonstrated in 1985, that the link between phenotype and genotype could be established in filamentous bacteriophage, the advent of phage display technology emerged [19]. Over the last few decades an increased understanding of antibody structure and function has allowed phage display to become one of the most powerful tools in the controlled selection of unique antibodies with properties unattainable from conventional hybridoma methods [20, 21].




Figure 9.4 Selection of antibodies by phage display. The process of ‘panning’ is a means of selection of defined clones through binding of the phage library to the target, washing to remove unbound phage and elution of the target-specific phage. This process is repeated for a number of ‘rounds’ to enrich for a high affinity binder.

Phage display can be used with naive, immunised or synthetic repertoires [22] and allows for the controlled selection and screening of antibodies against defined antigen conformations from a highly diverse combinatorial library of antibody fragments [23]. Selection involves subjecting the phage library to successive rounds of antigen exposure, allowing antigen-specific phage-displayed antibodies to bind to their targets, in a process known as 'panning'. The antigen-specific phage are recovered and subsequently infected into bacteria for re-amplification [21]. Ideally, a high affinity antibody would be selected for in the initial round. However, non-specific binding of phage confines the enrichment that can be achieved during each round. Hence, 2–5 rounds of panning are necessary to identify high affinity binders [23]. One round of panning is outlined in Fig. 9.4.

9.2 Types of Immunoassays

Following the production of the antibody of choice, the most ideal immunoassay format must be selected. Immunoassays can be divided into homogenous and heterogeneous formats. A homogenous immunoassay does not require the physical separation of the antibody bound to the analyte from free analyte. An example of a homogenous immunoassay is a fluorescence polarisation immunoassay (FPIA). A heterogeneous immunoassay involves the separation of free analyte from antibody-bound analyte, an example of which is an enzyme-linked immunosorbent assay (ELISA).

Immunoassay methods can be further subdivided into 'immunometric' and 'competitive' immunoassays (Fig. 9.5). Immunometric assays require the use of two specific detection molecules (normally antibodies) and are also referred to as sandwich assays. The immobilised antibody captures the analyte by binding to one of its epitopes. A second labelled antibody then binds and the amount of signal generated, due to the label, is directly proportional to the concentration of the analyte in the sample (Fig. 9.5).

In the competitive assay, labelled ('tracer') antigen and free antigen (from the sample to be analysed) compete for binding to the immobilised antibody. The greater the level of analyte in the sample, the smaller the amount of labelled antigen available for binding. Hence, the signal generated is inversely proportional to the concentration of the free antigen, as demonstrated by the curve in Fig. 9.5.

Immunometric immunoassays are commonly used for the detection of molecules such as proteins and viruses, as these entities have the capacity to facilitate the binding of two or more antibodies.

Competitive immunoassays are commonly used to detect small molecules such as drugs and toxins. Competitive immunoassays use an analyte-specific detection antibody and a 'tracer' molecule, which is a labelled version of the target analyte. The tracer is frequently labelled with an enzyme or fluorophore which can generate a detectable signal.




Figure 9.5 Schematic representation of immunometric and competitive immunoassay systems. An example of a typical response curve for each assay format is also shown.

9.3 Choosing a Suitable Immunoassay Technique

In order to determine the concentration of analyte present in a sample, several techniques can be used. Each technique has its own unique properties, which renders it suitable for recognising different types of analyte, ranging from bacteria to endogenous proteins to viruses and toxins. The nature of analyte to be detected (size, structure, and whether cytoplasmic, periplasmic or membrane bound) must also be considered.

9.3.1 Detection of Target Analyte: An Immunometric Approach

A number of different immunometric immunoassay formats that can be used, and these are outlined in the following subsections.

9.3.1.1 Direct immunoassay

A direct antibody immunoassay involves coating analyte either passively or actively onto a solid surface, as shown in Fig. 9.6. Antigen standards of known concentration are serially diluted and added to the plate, which is then incubated for a set time and temperature (e.g. 4°C overnight, room temperature for 2 h or 37°C for 1 h). The surface is blocked and washed to eliminate non-specific binding and

any unbound analyte is removed. Antigen-specific-labelled antibodies are added and the signal produced is measured.




Figure 9.6 Direct immunoassay. (A) Sample analyte is applied and binds to the solid surface. Following blocking and washing steps, (B) a specific detection antibody is introduced which produces a signal.

9.3.1.2 Indirect immunoassay

Indirect immunoassays may be used to detect antibodies in a sample that bind to an antigen (Fig. 9.7). Target antigen is first coated onto a solid surface. Appropriately diluted serum samples are applied to the coated antigen and any antigen specific antibodies present in the sample will bind. A wash step (e.g. 3 washes with phosphate buffered saline (PBS)) is incorporated to remove any unbound antibody and any non-specific antibody-antigen interactions. A species-specific enzyme-linked antibody is then applied, the enzyme's substrate is added, the enzyme converts the substrate into colored or fluorescent product and the signal is measured.

For example, the indirect immunoassay has been used to detect the presence of antibody to human immunodeficiency virus (HIV) [24]. Since the 1980s, the indirect ELISA was employed to detect anti-HIV antibodies. In 2015, a modern version of the indirect immunoassay called a 'reverse-indirect' immunoassay was developed by Jeong and Ahn using DNA-encoded gold-nanoparticles (GNPs) to detect multiple viral analytes [25]. Their system is called a 'gold nanoparticle-enhanced oligo-nucleotide-linked immunosorbent assay' (GNP-OLISA). DNA strands surround the GNP and bind to antigen from HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV), yielding Ag-GNP-DNA particles. Spiked human serum samples (containing antibodies against HIV, HCV and HBV) were added to the multiplex assay. Meanwhile, a 96-well plate was coated with anti-human-IgG and the samples were added to the wells for capture. Three different RNA fluorogenic probes were used and cleavage by RNase H generated a fluorescent signal that was linearly proportional to the amount of antibody to the respective virus present. Nanoparticles (which will be discussed in more detail later in this chapter) were incorporated for increased screening efficiency and greater detection sensitivities.




Figure 9.7 Indirect immunoassay. (A) The analyte of interest is first bound to a solid surface (e.g. to the well of a microtiter plate), followed by blocking and washing steps. (B) Serum containing the antibody of interest is diluted in a suitable buffer. This is followed by a second wash step and non-specifically bound antibodies are washed away. (C) Enzyme-labelled species-specific antibody is added to detect serum antibodies. (D) The plate is washed again, an enzyme substrate is added, and a signal is generated and measured.

9.3.1.3 Sandwich immunoassay

The key principle of the sandwich immunoassay is the use of an antibody that captures antigen, followed by the addition of a detection antibody that binds to a separate epitope. In order for efficient measurement to occur, the antigen must be large enough to contain two antigenic sites (epitopes) where each antibody has sufficient unimpeded access. It allows both the detection and the quantitation of sample analyte (Fig. 9.8) [26]. For quantification, a standard curve composed of standards of known concentration of the analyte to be measured must be included. A range of at least eight analyte dilutions and a negative control should be included and each determination should be performed in triplicate.




Figure 9.8 Sandwich immunoassay. (A) A capture antibody is applied and binds to the solid surface. The surface is blocked and washed to remove any non-specifically bound antibody and to prevent non-specific binding. (B) Sample analyte is applied and incubated, followed by a second wash step. (C) An enzyme-labelled specific detection antibody is introduced, and a substrate is added which produces a measurable signal.

The fundamental steps of a sandwich immunoassay include firstly, the surface immobilisation of analyte-specific antibody, followed by blocking and washing steps. The sample analyte is applied for a suitable length of time and is detected using an enzyme-linked detection antibody. If sample analyte is present, the detection antibody binds, the enzymic substrate is introduced and a signal is produced and measured.

9.3.2 Detection of Small Molecules Using a Competitive Approach

Competitive immunoassays are commonly used to measure the presence and concentration of small molecules such as drugs, hormones and toxins [27–29]. They require the use of only one specific antibody. This is beneficial, as small molecules do not have sufficient epitopes to facilitate binding of more than one detection antibody. Competitive assays require a ‘tracer’, which is composed of the analyte in question conjugated to either a signal generating enzyme, a fluorophore, a nanoparticle or a radiolabel. Competitive assays are effective in determining cross-reactivity to other antigens. In a competitive immunoassay, the analyte competes with a pre-titrated ‘tracer’ of known concentration. A competition curve is generated. The higher the concentration of analyte in the sample the lower the signal generated. Conversely, the lower the concentration of analyte the higher the signal generated, thus the intensity of signal generated is inversely proportional to the concentration of analyte present. A competitive immunoassay approach was utilised to measure the presence of a small (<1 kDa) algal-toxin molecule called microcystin-LR [30]. Due to the diminutive size of the algal-toxin a competitive immunoassay was chosen as microcystin-LR could only facilitate the binding of one specific antibody to a single epitope.




Figure 9.9 Competitive immunoassay. (A) Conjugated small molecules are applied at an optimal concentration onto a solid surface. The assay surface is blocked and washed to reduce non-specific binding. (B) A mixture of sample analyte (to be detected) and pre-titrated enzyme-labelled antibody are applied and incubated. The free analyte (small molecule) competes with surface bound analyte for antibody binding. This is followed by a second wash step. (C) Unbound antibody is washed away. The substrate for the enzyme label is added and the signal produced is measured and is inversely proportional to the concentration of analyte present.

Figure 9.9 outlines the fundamental steps in a competitive immunoassay. A predefined optimised concentration of antigen is coated onto the surface of a 96-well plate and the plate is washed and blocked using appropriate blocker. Sample analyte of unknown concentration and a pre-defined amount of antibody are mixed, incubated and added to the plate. The plate is incubated for a defined length of time. Following washing, an enzyme-conjugated secondary antibody may be added and, following the addition of chromogenic or fluorescence substrate, a signal is generated and measured [31].

9.4 Signal Generation in Immunoassays

Detection approaches can be divided into 'labelled' and 'label-free' signalling systems. Immunoassays that use an antibody linked to either an enzyme, fluorescent label, radiolabel, colorimetric marker or nanoparticle are classified as 'labelled' (Tables 9.2 and 9.3).

9.4.1 Signal Generation

The first ever antibody detection systems employed the use of radiolabels [32]. Rosalyn Yalow and Solomon Aaron Berson reported the first use of radiolabels in an assay to detect insulin in the 1950s [32, 33]. The hazardous working conditions, waste disposal and potential health issues associated with working with radioactivity lead to the accelerated development of alternative detection systems. Current technologies are safer, do not pose major health risks to the user and waste generated can be disposed of with minimal inconvenience. Today, radiolabels have been substantially replaced with detection methodologies that provide high sensitivities using much safer methodologies and these will be discussed in greater detail in the following subsections.

9.4.1.1 Colorimetry as a method of immuno-detection

Colorimetry is a technique that is used to measure colored compounds in a solution. Upon enzymatic action, chromogenic substrates produce colored compounds. Peroxidase is a small enzyme (approximately 40 kDa), which can be used to produce a readable signal in the presence of its substrate and the oxidising agent, hydrogen peroxide. Peroxidase can be used to aid generation of both chromogenic substrates (using 3,3',5,5'-tetramethylbenzidine (TMB) or 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (APTS)) or light (using enhanced chemiluminescence (ECL) substrate). Peroxidase enzymes exist in many isoforms and the most commonly used in biotechnological and biochemical applications are plant peroxidases e.g., horse radish peroxidase (HRP) and soybean peroxidase (SRP). To further enhance the utility of peroxidases in industrial settings, an interesting study was carried out by Loughran et al. The authors resurrected a 110 million year old active ancestral plant peroxidase gene called 'Grandparent' (GP). It was thought that in 110 million years of evolution, some enzymatic properties may have been lost. Loughran et al. compared the properties of GP to

the existing peroxidases, HRP isoenzyme A2, HRP isoenzyme C and SBP. The results found that GP displays moderate thermal stability but exceeded the extant peroxidases in increased tolerance to H_2O_2 , a desirable attribute in the biotechnological industries [56]. An advantage of using peroxidase as an enzymatic label is its small size, which rarely causes steric hindrance when conjugated to antibodies (usually at a 4:1 ratio). Its limitation lies in the fact that the peroxidase reaction requires a substrate for H_2O_2 and is incompatible with buffers that contain sodium azide or metals, as they inactivate peroxidase.

Table 9.2 Immunoassay signalling systems

Labels	Examples	Ref.
Radioactive labels	Iodine 125 (^{125}I); tritium (3H)	[32, 33]
Enzyme labels	Alkaline phosphatase (AP); glucose oxidase; horse radish peroxidase (HRP); soybean peroxidase (SBP); glucose-6-phosphate dehydrogenase and xanthine oxidase	[34–36]
Chemiluminescence	Acridinium sulphonamides; acridinium esters; luminol; HRP; coelenterazine; dioxetanes and peroxyoxalic acid	[37, 38]
Enhanced chemiluminescence	HRP, in presence of its substrate H_2O_2 ; in the presence of enhancer molecules or phenols.	[38–40]
Fluorescence	Fluorescein isothiocyanate (FITC); lanthanide cryptates; rhodamine; Texas red; semiconductor nanocrystal quantum dots; ethidium bromide and Alexa fluor dyes	[41]
Bioluminescence	Aequorin (from Jellyfish, <i>Aequoria victoria</i>); luciferase (from firefly and sea pansy, <i>Renilla reniformis</i>)	[42–47]
Phosphorescence	Phosphors–Europium-activated yttrium oxisulphide	[48, 49]
Time-resolved fluorescence	Dissociation-Enhanced Lanthanide Fluorescent Immunoassay (DELFI [®]) from Perkin Elmer Europium (lanthanide)-conjugated antibodies or antigen in sandwich or competitive immunoassays	[50, 51]
Nano- and microparticle labels	Fluorescent quantum dots—typically 2–8 nm in size and coated in a layer of organic material to facilitate functionalisation, e.g. Quantum dots (QDs) Qdots [®] available from Invitrogen Hydrophilic magnetic beads (2.8 μm) coated with amine, carboxyl, epoxy or tosyl groups, e.g. Dynabeads from Invitrogen Polystyrene latex beads—commonly used in agglutination tests Colloidal gold nanoparticles—used for visualisation in electron microscopy, Immunoliposomes—antibody-targeted liposomes	[52–54]
Electro-chemiluminophore	Ruthenium tris(bipyridyl)	[55]

Table 9.3 Commonly used colorimetric, fluorescent and chemiluminescent signalling reagents

Antibody conjugate enzyme		Substrate	Signalling properties	Read-out
Enzyme-linked immunosorbent (ELISA)-colorimetric	Alkaline phosphatase (AP)	<i>p</i> -nitrophenyl phosphate disodium salt (<i>p</i> -NPP)	Hydrolysis of <i>p</i> -NPP to chromogenic <i>p</i> -nitrophenol	Absorbs at 405 nm; yellow colored product
	Horse radish peroxidase (HRP)	H ₂ O ₂ coupled to 3,3',5,5'-tetramethylbenzidine (TMB)	Very sensitive; fast color development; may have high background if too much analyte used	Absorbs at 650 nm; Blue colored product
		H ₂ O ₂ coupled to 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS))	Slow color development	Absorbs at 410 nm and 650 nm; green colored product
		H ₂ O ₂ coupled to <i>o</i> -phenylenediamine (OPD)	Slightly less sensitive than TMB	Absorbs at 492 nm; yellow-orange colored product
Fluorescence-linked immunosorbent assay (FLISA)-fluorescent	Alkaline phosphatase (AP)	4-methylumbelliferyl phosphate (4-MUP), dissolved in 0.1 to 0.2 mg mL ⁻¹ in 100 mM diethanolamine, 1 mM MgCl ₂ , pH 9.6 (Merck) AttoPhos® (Promega)	Fluorescence-based assays are only slightly more sensitive than colorimetric assays; however, fluorescence-based read-outs can give a wider dynamic range	Excitation 360 nm, emission 440 nm
	β-galactosidase	4-methylumbelliferyl galactosidase (4-MUG) (Merck)		Excitation 360 nm Emission 440 nm
	Peroxidase (e.g. horse radish peroxidase (HRP))	Hydroxyphenylacetic acid (HPA) and 3- <i>p</i> -hydroxyphenylproprionic acid (HPPA), addition of H ₂ O ₂ is necessary (Merck) Quantibluo (Fisher Scientific)		Excitation 320 nm Emission 404 nm
Chemiluminescent ELISA		QuantaRed (Fisher Scientific)		Excitation 325 nm Emission 420 nm
	HRP	Supersignal ELISA Pico Chemiluminescent substrate (Fisher Scientific)	Full compatibility with all formats of immunoassay	Excitation 570 nm Emission 585 nm
	AP, HRP	Supersignal ELISA Femto Maximum sensitivity from Fisher Scientific Lumigen®	Range of different products that will generate chemiluminescence in the presence of AP or HRP	Light output should be measured

The enzyme, alkaline phosphatase (AP), is an alternative signal-producing enzymatic label. It has an approximate molecular weight of 86 kDa. Due to its larger size, care must be taken when labelling antibodies with AP, to ensure that the conjugation level does not hinder access for antigen binding. AP is more expensive than peroxidase but it is more stable. A disadvantage associated with using AP is that it is rendered inactive in acidic conditions ($\text{pH} < 4.5$), in chelating agents or in inorganic buffers. However, these attributes may be advantageously used as reaction stopping mechanisms. The substrates of AP are non-toxic and relatively stable; for example, *p*-nitrophenyl phosphate (*p*-NPP) is stable for months at 4°C (Table 9.3).

9.4.1.2 Luminescence as a method of immuno-detection

Luminescence refers to the release of energy from an electronically excited molecule in the form of visible light. When the excited molecule returns to the ground state it releases a photon of light. The 'catch-all' title of luminescence covers a range of detection systems, including chemiluminescence, phosphorescence, bioluminescence and fluorescence.

9.4.1.2.1 Chemiluminescence

Chemiluminescence refers to the release of energy from chemical reactions in the form of light and does not require a light source for excitation (unlike fluorescence) [44]. The photons generated from luminescent compounds can be triggered in a very short period of time and the sensitivity reached can be higher than that achieved with conventional labelling [37, 57]. Examples of chemical labels were previously given in Table 9.3 [37, 58].

Two methods can be chosen: (i) using a chemically labelled substrate which converts to a chemiluminescent product, (ii) using a chemiluminescent molecule directly attached to the antibody. The labelling of a ligand (e.g. an antibody) with an enzyme that generates chemiluminescence is frequently used as it can initiate multiple chemiluminescent reactions making the reaction highly sensitive. Alternatively, the chemiluminescent compound can be covalently labelled to one of the complementary binding partners. This is a straightforward approach, however, not many chemiluminescent tags exist and there is usually limited surface space on the antibody to fit multiple tags.

Advantages of chemiluminescent detection systems include, fast emission of light, wide dynamic range, high stability of reagents and low consumption of expensive reagents, short incubation times, high sensitivity, elimination of background effects and low toxicity [58, 59].

9.4.1.2.2 Bioluminescence, a natural form of signal generation

Bioluminescence refers to the phenomena whereby biological reactions produce light [42]. Bioluminescence has often proven advantageous when used in immunoassays due to its unique properties, since unlike fluorescence, there is virtually no associated background, and it has a high quantum yield and rapid kinetics of reaction [44].

Many bright photoproteins have been discovered in the darkest places. Aequorin was originally found in the jellyfish *Aequoria victoria* [43] and is a stable complex composed of an apoprotein (apoaequorin), a chromophore (coelenterazine) and molecular oxygen [60]. Recombinant aequorin has successfully been used in immunoassays to detect the hormone cortisol [61]. Recombinant aequorin is chemically conjugated to cortisol at different molar ratios, and the resulting conjugates are assessed for the highest level of bioluminescence [61]. The development of a chimeric antibody incorporating aequorin has also been shown to be useful. The apoaequorin gene was sub-cloned into a mammalian expression vector and the constant domain of the antibody replaced by the photoprotein. This method is more reliable than chemically linking the photoprotein to the antibody as chemical modifications can often lead to 'batch-to-batch' variations or loss of antibody binding activity [45]. When aequorin was first discovered in 1962, Shimomura et al. simultaneously discovered a second protein that has also become a fundamental bioimaging tool [43]. Green fluorescence protein (GFP) has been frequently used as a genetically encoded fluorescence marker. The fluorescence protein (FP) family has expanded to over 1000 variant forms, each exhibiting different excitation and emission wavelengths, thus, all displaying different colors (e.g. monomeric Orange (mOrange) (excitation 548 nm/emission 562 nm) to mRuby (ex. 558 nm/em. 605 nm)). A review by Nienhaus and colleagues contains a selection of some of the most widely used FPs [62].

9.4.1.2.3 Fluorescence, a widely used method of immunoassay signal generation

Fluorescence is a phenomenon that occurs when electromagnetic energy (a photon of light) is absorbed by a substance, thus activating its electrons and elevating them into higher energy states. The return to ground state energy causes the release of energy in the form of light, called fluorescence. Fluorescence only occurs for as long as the substance is absorbing light, however, the fluorescent molecule can be excited again, thus continuing the cycle. Emitted fluorescence occurs at a longer wavelength than the wavelength for excitation and the change in wavelength is referred to as the 'Stokes shift'. This change in wavelength occurs due to a loss of energy between the excitation of the electron and the release of the energy as fluorescence. The degree of 'Stokes shift' depends on the inherent electronic structure of the fluorophore.

A fluorophore is excited over a range of wavelengths. The wavelength at which the molecule is excited most optimally is called the excitation maximum. Likewise, the fluorophore emits fluorescence over a range of wavelengths. The emission maximum is the wavelength at which the fluorophore emits light (fluorescence) most intensely. Since the fluorophores absorb and emit over a range of wavelengths, it is important to choose two fluorophores with distinct excitation and emission peaks, so that they do not overlap and can be detected individually.

Fluorescent molecules can be used in fluorescence immunoassays as an alternative to colorimetric readouts. Fluorescent substrates can be utilised in place of TMB or PNPP as substrates for AP, β -galactosidase and HRP detection

enzymes (previously listed in Table 9.3). The production of a fluorescent signal is influenced by many different parameters including pH, temperature, ion concentration, drying, light scattering, quenching and bleaching, and all must be accounted for during experimentation [63, 64].

9.4.2 Nanomaterials, for Signal Generation and Immobilisation

Nano-sized entities (between 1–100 nanometres) are becoming increasingly prevalent in immunoassays for use in both detection and immobilisation. They permit very low levels of detection, and are increasingly being utilised in ‘point-of-care’ diagnostics.

Quantum dots (QDs) are fluorescent nanostructures composed of semiconducting materials that are now being used in a wide range of biological imaging techniques [65–67]. They were first discovered in 1980 by Ekimov and Onushchenko who found that QDs could produce a range of fluorescence signals based on their size [68]. Currently, QDs can be classified into three different categories based on their composition. The first, ‘core-type’ QDs are composed of a single material e.g. cadmium selenide (CdSe) or cadmium sulphide (CdS) [69]. Secondly, ‘core-shell’ QDs are composed of two semiconducting materials, one ‘core’ material embedded within a ‘shell’ material (Fig. 9.10). These ‘core-shell’ QDs display improved brightness and quantum-yields over ‘core-type’ QDs. Finally, the third type of QD is the ‘alloy’ QD, composed of zinc selenium-cadmium selenide (ZnSe-CdSe). Alloy QDs are unique, as their fluorescence properties can be altered without changing the size of the QD. The change in the ratio of alloy components facilitates the change in color [69]. QDs have become a new resource in the field of disease detection and diagnosis and have been used in many biological assays such as fluorescence resonance energy transfer (FRET)-based sensing, cellular imaging and immunoassays [66, 70–72].

Numerous QD attributes have been identified to differentiate them from fluorescent organic dyes or protein fluorophores [73]. These include:

- wide excitation spectra
- narrow-size-tuneable photo-luminescent emission spectra
- large Stokes shifts
- high quantum yields
- increased photostability (over fluorescent dyes)
- highly suitable to multicolor applications
- distinct populations of QDs can be excited by a single excitation wavelength
- higher resistance to photobleaching under continuous illumination

Gold nanoparticles (AuNPs or GNPs), have increased in popularity due to their stability over long periods of time. Their inherently high electron densities renders them easily detectable by a wide range analytical technologies, e.g. atomic force microscopy (AFM), Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). Depending on their size, AuNPs produce

different colors; if less than 100 nm, AuNPs are red, while greater than 100 nm, AuNPs are yellowish in color [74]. AuNPs non-covalently linked to antibodies, have been successfully integrated into lateral flow immunoassays, due to their robust nature, stability and ability to produce an intense color [74].




Figure 9.10 Quantum dot (QD) structure displaying inner core and outer shell. Inner core materials that can be used in QDs include zinc sulphide (ZnS), cadmium sulphide (CdS), zinc selenide (ZnSe), cadmium telluride (CdTe), lead sulphide (PbS), PbSe/Te and CdSe/Te and cadmium mercury/tellurium (CdHg/Te) alloys. The outer core is usually ZnS. The QD is surrounded by a polymer coating which increases water solubility and facilitates binding of antibody/antigen.

Carbon nanotubes (CNTs) are cylinders of carbon composed of one (single walled nanotubes (SWNT)) or more layers of graphene (multiwall nanotubes (MWNT)) [75]. Increasingly, CNTs are being used for industrial applications displaying up to 10-fold greater tensile strength than typical industrial fibres. CNTs can be metallic or semiconducting in nature [76] and can act as antibody supports. Wan and colleagues have exploited their potential use as immunosensing labels as well as availing of their signal transducing capabilities [77]. A universal MWNT, covalently coated in HRP and goat anti-rabbit, was used as a universal electrochemical-based detector for the presence of cancer markers, prostate specific antigen (PSA) and interleukin-8 (IL-8). The system provided the detection of very low levels of PSA and IL-8 (5 pg mL^{-1} and 8 pg mL^{-1} , respectively). However, the numerous steps involved rendered it quite labour intensive.

9.5 Next Generation Signal Transduction Systems

In a concerted effort to simplify detection mechanisms, shorten assay times, reduce the number of assay steps and to facilitate multiplexing of immunoassays, signal transduction methods employing electrochemical, mechanical and optical mechanisms have increased in popularity. The following section will investigate these signal transduction mechanisms in more detail.

9.5.1 Electrochemical Transducers for Immunoassay Applications

Electrochemical transducers are an integral part of immunoassay signalling. Electrochemistry relates to the production of an electric current during a chemical reaction. The most common type of electrochemical reaction used in biotechnology is the reduction/oxidation reaction or redox reaction, during which electrons are transferred between two interacting species. Electrochemical techniques are often employed for use in colored and turbid media [78, 79]. Additional advantages that apply to electrochemical immunoassay transducers are the high sensitivities that can be achieved, and the instruments used for measurement are relatively inexpensive. Electrochemical immunosensors generally have low power requirements and are capable of being incorporated into automated detection platforms [78].

9.5.2 Nanomechanical Sensors/Piezoelectric Mass Sensors

Nanomechanical transducers detect changes in mass, pressure or resonance frequency. Nanomechanical immunosensors differ from traditional fluorescence-based immuno-detection systems in that they do not require labelling of analytes or antibodies [80]. These sensors have been used to measure a range of analytes such as bacteria, viruses, oligonucleotides, disease markers and inflammatory mediators such as PSA and interleukins [81, 82].

The piezoelectric effect was first described by Jacques and Pierre Curie in 1880. The term is derived from the Greek word *piezein* meaning to press [83]. When a voltage is applied across a piezoelectric quartz crystal (SiO_2), it induces stress in the material and the quartz undergoes a change in volume, conversely, when the quartz undergoes a change in volume it generates a voltage [83,84]. Piezoelectricity facilitates the 'label-free' detection of analytes at a surface by measuring a change in mass, and, in the case of immuno-sensing, a change in mass is observed when an analyte binds to an antibody or an antibody binds to immobilised antigen [85]. Two different types of acoustic sensor have been developed, a bulk acoustic wave (BAW) device and a surface acoustic wave (SAW) device and these will be discussed further in the next two sections.

Bulk acoustic wave devices or quartz crystal microbalances (QCMs) can be used for the 'label-free' detection of analytes. A BAW device consists of a thin layer of quartz crystal embedded between two electrodes. The quartz crystal produces a characteristic resonant frequency when an alternating current (AC) is applied; this frequency is based on the total oscillating mass of the quartz crystal, and changes when a biomolecule attaches. Comprehensive reviews of the fundamental principles of quartz crystal microbalances and their uses in biological detection have been published by Ferreria et al. and by Ferrier et al. [84, 85]; in addition, the applications of quartz microbalances have been extensively described [86–88]. A study by Seo and colleagues described the use of a novel QCM immunosensor for the detection of alpha-fetoprotein (AFP) developed using TiO_2 nanoparticle-based immunoassay incorporating a silver enhancement reaction

[80]. Their system used a sandwich-immunoassay format. The quartz crystal was immobilised with anti-AFP antibody, AFP was added and bound to the antibody, a second anti-AFP antibody conjugated to TiO_2 was then added and bound. A silver enhancement reaction was subsequently carried out; the complex was photo-irradiated (exposed to UV light) in the presence of silver nitrate (AgNO_3). Silver (Ag) molecules bound to titanium oxide (TiO_2) enhanced the mass of the complex by three orders of magnitude, thus making the variations in the resonant frequency of the quartz crystals easier to observe (measured using a QCM200, Stanford Research Systems Sunnyvale CA, USA) [80].

Surface acoustic waves sensors (SAWS) exploit the piezoelectric properties of certain crystalline materials e.g. quartz (SiO_2), lithium niobate (LiNbO_3) or lithium tantalate (LiTaO_3). SAWS detect changes in mass along the surface of the crystal. Interdigitated electrodes (IDEs) on the surface of the crystal generate acoustic waves, which travel parallel to the surface and are sensitive to changing mass. SAWS have been easily incorporated into 'point-of-care' (POC) or microfluidic devices. Lee and colleagues developed a microfluidic CD device encasing whole blood, wash buffer and assay reagents in a microfluidic compact disc (CD) [89].

The main advantages of acoustic wave sensors is their 'label-free' capabilities, fast assay times (<10 min), high sensitivities and the ability to perform assays in turbid and colored solutions with little pre-assay clean-up required, making them highly applicable to 'real-time', POC *in vitro* diagnostics [90]. Lee and colleagues also developed a POC device that uses SAWS to detect the presence of cardiac disease markers cardiac troponin I (cTnI), creatine kinase-MB and myoglobin [89] below the clinical 'cut-off' level required. The SAW relied on changes in mass to generate its signal, however, this rendered it susceptible to changes in density and viscosity of the sample medium. Another limitation to SAW sensing is sensitivity to temperature and mechanical stress, which need to be controlled during experiments [84].

Cantilevers can be manufactured at micro- or nano-scale depending on the requirements of the detection system [91]. The first cantilevers were 'deflection' or 'static' mode cantilevers. They operate on the basis that the cantilever physically bends upon the binding of an analyte to an antibody [92–95]. These were followed by the introduction of 'resonant' or 'dynamic' mode cantilevers, which operate by generating an oscillating signal [96–98]. Both are efficient at measuring the presence of molecules in solution and in air, thus, making them applicable to both biological (e.g. proteins, viruses, bacteria, small molecules and gases) and environmental sensing (e.g. temperature and pH) [84]. Micro-cantilevers are usually made of 1 μm thick rectangular silicon sheets that are anchored at one end. Upon binding of specific sample analyte to an immobilised antibody (or similar binding molecule e.g. cDNA for oligonucleotide detection), a surface stress is imposed on the micro-cantilever, causing it to bend. Deflection of a laser beam detects the bending cantilever. Advantages of micro-cantilevers include their 'label-free' configurations, 'ease-of-functionalisation', 'low-cost', 'ease-of-detection', their potential for miniaturisation and multiplexing. Some drawbacks that arise during the use of cantilever-based sensors include their sensitivity to temperature

and changes in refractive index as well as sensitivity to the flow of fluid in the sample medium [99]. Micro-cantilevers have been successfully applied to the detection of tumour markers e.g. angiopoietin-1, a potential marker for tumour progression and to detect small molecules such as mycotoxins [100, 101].

9.5.3 Optical Signal Transduction

Optical biosensors utilise light properties such as refraction, production of evanescent waves and reflection, and measure changes in these properties during biomolecular interactions.

9.6 Conclusions and Key Issues

The myriad of immunosensing possibilities presented in this chapter are just a taste of the sensing capabilities that are on offer today. Firstly, the type of antibody for a particular application must be taken into account, and, due to their 'ease-of-manipulation' and capacity for sensitivity improvement, recombinant antibodies may be considered.

The strategy used for the immobilisation of antibodies is crucial to maximise stability, enhance sensitivity by ensuring antibodies are correctly orientated and available for binding and to maximise reproducibility.

It is also clear that 'label-free' immunosensing has become an important element in analyte monitoring. Despite the technologies available, there are still the fundamental issues of sensitivity, 'signal-to-noise' ratios and aggregation that afflict solid surfaces in use today. The elimination of non-specific binding is key to optimum performance and must be carefully controlled in complex matrices.

Ultimately, a system that requires little pre-assay preparation, is fully integrated, with the ability to multiplex, can be carried out *in situ* with minimum user intervention, and is affordable will always be the gold standard in immunosensing. 'Lab-on-a-chip' immunoassay systems are currently revolutionising diagnostics with both fluorescence and colorimetric-based detection systems but also with cantilever-based approaches. They facilitate the combination and reduction of assay steps, reagents are encased within the system (which addresses safety issues) and the microfluidics allows the reduction of assay reagent volumes required to complete a test. 'Lab-on-a-chip' can permit the analysis of a number of different analytes in parallel; for an example, please refer to Maguire et al. [102].

Immunoassays should not solely be chosen based on analytical sensitivity but must address the detection requirements for each situation. For example, an immunoassay may need to generate quantitative data or generate a simple yes/no read-out. The question should also be asked, can multi-component analysis be integrated into the system, as this will greatly increase the value of the immunoassay.

Finally, the translation from laboratory to commercially available systems is an important step and must be pursued so that detection systems can be distributed and used to address global monitoring issues e.g. in remote and resource-limited locations.

Abbreviations

AC:	alternating current
AFM:	atomic force microscopy
AFP:	alpha-fetoprotein
AP:	alkaline phosphatase
APTS:	2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid
AuNPs:	gold nanoparticles
BAW:	bulk acoustic wave
CNTs:	carbon nanotubes
cTnI:	cardiac troponin I
DELFI A:	dissociation-enhanced lanthanide fluorescent immunoassay
ECL:	enhanced chemiluminescence
ELISA:	enzyme-linked immunosorbent assay
FITC:	fluorescein isothiocyanate
FP:	fluorescence protein
FPIA:	fluorescence polarisation immunoassay
FRET:	fluorescence resonance energy transfer
FT-IR:	Fourier transform infrared spectroscopy
GFP:	green fluorescence protein
GNP-OLISA:	gold nanoparticle-enhanced oligo-nucleotide-linked immunosorbent assay
GNPs:	gold-nanoparticles
HBV:	hepatitis B virus
HCV:	hepatitis C virus
HIV:	human immunodeficiency virus
HRP:	horse radish peroxidase
IDEs:	interdigitated electrodes
IgG:	immunoglobulin G
IL-8:	interleukin-8
MWNT	multiwall nanotubes
<i>p</i> -NPP:	<i>p</i> -nitrophenyl phosphate disodium salt
PBS:	phosphate buffered saline
PEG:	polyethylene glycol
PSA:	prostate specific antigen
QCMs:	quartz crystal microbalances
QDs:	quantum dots
SAW:	surface acoustic wave
SAWS:	surface acoustic waves sensors
SBP:	soybean peroxidase
SEM:	scanning electron microscopy
SRP:	soybean peroxidase
SWNT:	single walled nanotubes
TMB:	3,3',5,5'-tetramethylbenzidine

Disclosures and Conflict of Interest

This chapter was originally published as: Murphy, C., Gilgunn, S., O’Kennedy, R. (2017). An Overview of Immunoassays. In: O’Kennedy, R., Murphy, C., eds. *Immunoassays: Development, Applications and Future Trends*, Jenny Stanford Publishing, Singapore, chapter 1, pp. 1–36, and appears here, with edits and updates, by kind permission of the publisher.

Acknowledgments: The authors would like to acknowledge the support of Dublin City University and Science Foundation Ireland (through grants 08/US/I1512, 10/CE/B1821, 14/IA/2646 and 19/IFA/7416), and The Irish Cancer Society Programme grant (PCI11WAT) as part of the Prostate Cancer Research Consortium, Dublin, Ireland.

References

1. Finlay, W.J.J., and J.C. Almagro, Natural and man-made V-gene repertoires for antibody discovery. *Front Immunol*, 2012. **3**, doi: 10.3389/fimmu.2012.00342.
2. Conroy, P.J., et al., Reconciling the structural attributes of avian antibodies. *J Biol Chem*, 2014. **289**(22):15384–15392.
3. Leenaars, M., and C.F. Hendriksen, Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. *ILARJ*, 2005. **46**(3):269–279.
4. Zhu, K., et al., Recent developments in antibody-based assays for the detection of bacterial toxins. *Toxins (Basel)*, 2014. **6**(4):1325–1348.
5. Howard, G.C., and M.R. Kaser, eds. *Making and Using Antibodies: A Practical Handbook*. 2nd. 2013, CRC Press: Florida.
6. Andris-Widhopf, J., et al., Methods for the generation of chicken monoclonal antibody fragments by phage display. *J Immunol Methods*, 2000. **242**:159–181.
7. International Chicken Genome Sequencing Consortium, Sequence and comparative analysis of the chicken genome provide unique perspectives on vertebrate evolution. *Nature*, 2004. **432**(7018):695–716.
8. Narat, M., Production of antibodies in chickens. *Food Technol Biotechnol*, 2003. **41**(3): 259–267.
9. Kohler, G., and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature*, 1975. **256**(5517):495–497.
10. Conroy, P.J., et al., Antibody production, design and use for biosensor-based applications. *Semin Cell Dev Biol*, 2009. **20**(1):10–26.
11. Hayes, C.J., P. Leonard, and R. O’Kennedy, Overcoming antibody expression and screening limitations by smart design: applications to PSA immunoassay development. *Protein Expr Purif*, 2012. **83**(1):84–91.
12. Hudson, P.J., Recombinant antibody fragments. *Curr Opin Biotechnol*, 1998. **9**(4): 395–402.
13. Holliger, P., and P.J. Hudson, Engineered antibody fragments and the rise of single domains. *Nat Biotechnol*, 2005. **23**(9):1126–1136.

14. Barbas, C.F., et al., *Phage Display: A Laboratory Manual*. 2001, Cold Spring Harbour Press, New York.
15. Joosten, V., et al., The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. *Microb Cell Fact*, 2003. **2**:1–15.
16. Hayhurst, A., et al., Isolation and expression of recombinant antibody fragments to the biological warfare pathogen *Brucella melitensis*. *J Immunol Methods*, 2003. **276** (1-2):185–196.
17. Birtalan, S., et al., The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. *J Mol Biol*, 2008. **377**(5):1518–1528.
18. Muller, B.H., et al., *In vitro* affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay. *J Mol Biol*, 2011. **414**(4):545–562.
19. Smith, G.P., Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. *Science*, 1985. **228**(4705):1315–1317.
20. McCafferty, J., et al., Phage antibodies: filamentous phage displaying antibody variable domains. *Nature*, 1990. **348**(6301):552–554.
21. Hoogenboom, H.R., Selecting and screening recombinant antibody libraries. *Nat Biotech*, 2005. **23**(9):1105–1116.
22. Bradbury, A.R.M., et al., Beyond natural antibodies: the power of *in vitro* display technologies. *Nat Biotech*, 2011. **29**(3):245–254.
23. Bradbury, A.R., and J.D. Marks, Antibodies from phage antibody libraries. *J Immunol Methods*, 2004. **290**(1-2):29–49.
24. Nuwayhid, N.F., Laboratory tests for detection of human immunodeficiency virus type 1 infection. *Clin Diagn Lab Immunol*, 1995. **2**(6):637–645.
25. Jeong, M.S., and D.R. Ahn, A microwell plate-based multiplex immunoassay for simultaneous quantitation of antibodies to infectious viruses. *Analyst*, 2015. **140**(6): 1995–2000.
26. Abcam. Available at: <http://www.abcam.com> (accessed on September 30, 2022).
27. Byrne, B., et al., Antibody-based sensors: principles, problems and potential for detection of pathogens and associated toxins. *Sensors (Basel)*, 2009. **9**(6):4407–4445.
28. Uraipong, C., V. Wong, and N.A. Lee, A testosterone-specific competitive enzyme immunoassay for monitoring water quality. *Bull Environ Contam Toxicol*, 2013. **90**(5): 585–590.
29. Czeh, A., et al., A flow cytometry-based competitive fluorescent microsphere immunoassay (CFIA) system for detecting up to six mycotoxins. *J Immunol Methods*, 2012. **384**(1-2): 71–80.
30. Murphy, C., et al., Detection of the cyanobacterial toxin, microcystin-LR, using a novel recombinant antibody-based optical-planar waveguide platform. *Biosens Bioelectron*, 2015. **67**:708–714.
31. Gan, S.D., and K.R. Patel, Enzyme immunoassay and enzyme-linked immunosorbent assay. *J Invest Dermatol*, 2013. **133**(9):e12.
32. Yalow, R.S., and S.A. Berson, Assay of plasma insulin in human subjects by immunological methods. *Nature*, 1959. **184**(Suppl 21):1648–1649.
33. Yalow, R.S., and S.A. Berson, Immunoassay of endogenous plasma insulin in man. *J Clin Invest*, 1960. **39**:1157–1175.

34. Kuznetsov, et al., On applicability of laccase as label in the mediated and mediatorless electroimmunoassay: effect of distance on the direct electron transfer between laccase and electrode. *Biosens Bioelectron*, 2001. **16**(1-2):73-84.
35. Du, D., et al., Immunological assay for carbohydrate antigen 19-9 using an electrochemical immunosensor and antigen immobilization in titania sol-gel matrix. *J Immunol Methods*, 2003. **283**(1-2):67-75.
36. Liu, Y., and Y. Li, An antibody-immobilized capillary column as a bioseparator/bioreactor for detection of *Escherichia coli* O157:H7 with absorbance measurement. *Anal Chem*, 2001. **73**(21):5180-5183.
37. Dodeigne, C., L. Thunus, and R. Lejeune, Chemiluminescence as a diagnostic tool. A review. *Talanta*, 2000. **51**(3):415-439.
38. Kricka, L.J., G.H.G. Thorpe, and R.A.W. Stott, Enhanced chemiluminescence enzyme-immunoassay. *Pure Appl Chem*, 1987. **59**(5):651-654.
39. Alegria-Schaffer, A., A. Lodge, and K. Vattem, Performing and optimizing Western blots with an emphasis on chemiluminescent detection. *Methods Enzymol*, 2009. **463**: 573-599.
40. Kamidate, T., et al., Application of 4-iodophenol-enhanced luminol chemiluminescence to direct detection of horseradish peroxidase encapsulated in liposomes. *Anal Sci*, 2009. **25**(9):1163-1166.
41. Hicks, J.M., Fluorescence immunoassay. *Hum Pathol*, 1984. **15**(2):112-116.
42. Shim, Y.N., and I.R. Paeng, Development of bioluminescence immunoassay using photoprotein, aequorin and site-directed immobilization. *Bull Korean Chem Soc*, 2003. **24**(1):70-74.
43. Shimomura, O., F.H. Johnson, and Y. Saiga, Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, *Aequorea*. *J Cell Comp Physiol*, 1962. **59**(3):223-239.
44. Roda, A., et al., Biotechnological applications of bioluminescence and chemiluminescence. *Trends Biotechnol*, 2004. **22**(6):295-303.
45. Casadei, J., M.J. Powell, and J.H. Kenten, Expression and secretion of aequorin as a chimeric antibody by means of a mammalian expression vector. *Proc Natl Acad Sci USA*, 1990. **87**(6):2047-2051.
46. Naylor, L.H., Reporter gene technology: The future looks bright. *Biochem Pharmacol*, 1999. **58**(5):749-757.
47. Alam, J., and J.L. Cook, Reporter genes: Application to the study of mammalian gene transcription. *Anal Biochem*, 1990. **188**(2):245-254.
48. Jia-Ming, L., et al., Determination of human IgG by solid substrate room temperature phosphorescence immunoassay based on an antibody labeled with nanoparticles containing Rhodamine 6G luminescent molecules. *Spectrochim Acta A Mol Biol Spectrosc*, 2005. **61**(5):923-927.
49. Goldman, E.R., et al., Conjugation of luminescent quantum dots with antibodies using an engineered adaptor protein to provide new reagents for fluoroimmunoassays. *Anal Chem*, 2002. **74**(4):841-847.
50. Maple, P.A., et al., Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison

- with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. *Clin Vaccine Immunol*, 2006. **13**(2):214–218.
51. Maple, P.A.C., C.S. Jones, and N.J. Andrews, Time resolved fluorometric immunoassay, using Europium labelled antihuman IgG, for the detection of human tetanus antitoxin in serum. *J Clin Pathol*, 2001. **54**(10):812–815.
 52. Tully, E., et al., The development of rapid fluorescence-based immunoassays, using quantum dot-labelled antibodies for the detection of *Listeria monocytogenes* cell surface proteins. *Int J Biol Macromol*, 2006. **39**(1–3):127–134.
 53. Kozłowska, D., et al., Molecular and magnetic resonance imaging: The value of immunoliposomes. *Adv Drug Deliv Rev*, 2009. **61**(15):1402–1411.
 54. Xing, Y., et al., Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. *Nat Protoc*, 2007. **2**(5):1152–1165.
 55. Doeven, E.H., et al., Selective excitation of concomitant electrochemiluminophores: tuning emission color by electrode potential. *Angew Chem Int Ed Engl*, 2012. **51**(18): 4354–4357.
 56. Loughran, N.B., et al., Stability properties of an ancient plant peroxidase. *Biochimie*, 2014. **104**:156–159.
 57. Girotti, S., et al., Trace analysis of pollutants by use of honeybees, immunoassays, and chemiluminescence detection. *Anal Bioanal Chem*, 2013. **405**(2–3):555–571.
 58. Rongen, H.A.H., et al., Chemiluminescence and immunoassays. *J Pharm Biomed Anal*, 1994. **12**(4):433–462.
 59. Bi, S., H. Zhou, and S. Zhang, Multilayers enzyme-coated carbon nanotubes as biolabel for ultrasensitive chemiluminescence immunoassay of cancer biomarker. *Biosens Bioelectron*, 2009. **24**(10):2961–2966.
 60. Ohmiya, Y., and T. Hirano, Shining the light: The mechanism of the bioluminescence reaction of calcium-binding photoproteins. *Chem Biol*, 1996. **3**(5):337–347.
 61. Mirasoli, M., et al., Bioluminescence immunoassay for cortisol using recombinant aequorin as a label. *Anal Biochem*, 2002. **306**(2):204–211.
 62. Nienhaus, K., and G.U. Nienhaus, Fluorescent proteins for live-cell imaging with super-resolution. *Chem Soc Rev*, 2014. **43**(4):1088–1106.
 63. Brand, L., and M.L. Johnson, eds. Fluorescence spectroscopy. *Methods Enzymol*. Vol. 450. 2008, Academic Press.
 64. Albani, J.R., ed. *Principles and Applications of Fluorescence Spectroscopy*. 2007, Wiley-Blackwell.
 65. Bruchez, M., Jr., et al., Semiconductor nanocrystals as fluorescent biological labels. *Science*, 1998. **281**(5385):2013–2016.
 66. Medintz, I.L., et al., Quantum dot bioconjugates for imaging, labelling and sensing. *Nat Mater*, 2005. **4**(6):435–446.
 67. Smith, A.M., and S. Nie, Next-generation quantum dots. *Nat Biotechnol*, 2009. **27**(8): 732–733.
 68. Ekimov, A.I., and A.A. Onushchenko, Quantum size effect in three-dimensional microscopic semiconductor crystals. *JETP Letters*, 1981. **34**(6):345–349.

69. Groeneveld, E., et al., Tailoring ZnSe-CdSe colloidal quantum dots via cation exchange: from core/shell to alloy nanocrystals. *ACS Nano*, 2013. **7**(9):7913–7930.
70. Michalet, X., et al., Quantum dots for live cells, *in vivo* imaging, and diagnostics. *Science*, 2005. **307**(5709):538–544.
71. Xing, Y., and J. Rao, Quantum dot bioconjugates for *in vitro* diagnostics & *in vivo* imaging. *Cancer Biomark*, 2008. **4**(6):307–319.
72. Jamieson, T., et al., Biological applications of quantum dots. *Biomaterials*, 2007. **28**(31):4717–4732.
73. Goldman, E.R., I.L. Medintz, and H. Mattoussi, Luminescent quantum dots in immunoassays. *Anal Bioanal Chem*, 2006. **384**(3):560–563.
74. Omidfar, K., F. Khorsand, and M. Darziani Azizi, New analytical applications of gold nanoparticles as label in antibody-based sensors. *Biosens Bioelectron*, 2013. **43**: 336–347.
75. De Volder, M.F.L., et al., Carbon nanotubes: present and future commercial applications. *Science*, 2013. **339**(6119):535–539.
76. Kurkina, T., and K. Balasubramanian, Towards *in vitro* molecular diagnostics using nanostructures. *Cell Mol Life Sci*, 2012. **69**(3):373–388.
77. Wan, Y., et al., Carbon nanotube-based ultrasensitive multiplexing electrochemical immunosensor for cancer biomarkers. *Biosens Bioelectron*, 2011. **30**(1):93–99.
78. Ghindilis, A.L., et al., Immunosensors: electrochemical sensing and other engineering approaches. *Biosens Bioelectron*, 1998. **13**(1):113–131.
79. Sharma, M.K., et al., Highly sensitive amperometric immunosensor for detection of *Plasmodium falciparum* histidine-rich protein 2 in serum of humans with malaria: comparison with a commercial kit. *J Clin Microbiol*, 2008. **46**(11):3759–3765.
80. Seo, H., et al., Photocatalytic silver enhancement reaction for gravimetric immuno-sensors. *Nanotechnology*, 2010. **21**(50):505502.
81. Uludag, Y., and I.E. Tothill, Cancer biomarker detection in serum samples using surface plasmon resonance and quartz crystal microbalance sensors with nanoparticle signal amplification. *Anal Chem*, 2012. **84**(14):5898–5904.
82. Godber, B., et al., Direct quantification of analyte concentration by resonant acoustic profiling. *Clin Chem*, 2005. **51**(10):1962–1972.
83. Ward, M.D., and D.A. Buttry, *In situ* interfacial mass detection with piezoelectric transducers. *Science*, 1990. **249**(4972):1000–1007.
84. Ferrier, D.C., M.P. Shaver, and P.J. Hands, Micro and nano structure-based oligonucleotide sensors. *Biosens Bioelectron*, 2015. **68**:798–810.
85. Ferreira, G.N., A.C. da-Silva, and B. Tome, Acoustic wave biosensors: physical models and biological applications of quartz crystal microbalance. *Trends Biotechnol*, 2009. **27**(12):689–697.
86. Becker, B., and M.A. Cooper, A survey of the 2006–2009 quartz crystal microbalance biosensor literature. *J Mol Recognit*, 2011. **24**(5):754–787.
87. Cooper, M.A., and V.T. Singleton, A survey of the 2001 to 2005 quartz crystal microbalance biosensor literature: applications of acoustic physics to the analysis of biomolecular interactions. *J Mol Recognit*, 2007. **20**(3):154–184.

88. Speight, R.E., and M.A. Cooper, A survey of the 2010 quartz crystal microbalance literature. *J Mol Recognit*, 2012. **25**(9):451–473.
89. Lee, W., et al., A centrifugally actuated point-of-care testing system for the surface acoustic wave immunosensing of cardiac troponin I. *Analyst*, 2013. **138**(9):2558–2566.
90. Arruda, D.L., et al., Microelectrical sensors as emerging platforms for protein biomarker detection in point-of-care diagnostics. *Expert Rev Mol Diagn*, 2009. **9**(7): 749–755.
91. Lang, H.P., M. Hegner, and C. Cerber, Cantilever array sensors. *Mater Today*, 2005. **8**: 30–36.
92. Fritz, J., Cantilever biosensors. *Analyst*, 2008. **133**(7):855–863.
93. Hansen, K.M., and T. Thundat, Microcantilever biosensors. *Methods*, 2005. **37**(1):57–64.
94. Hwang, K.S., et al., Micro- and nanocantilever devices and systems for biomolecule detection. *Annu Rev Anal Chem*, 2009. **2**:77–98.
95. Ziegler, C., Cantilever-based biosensors. *Anal Bioanal Chem*, 2004. **379**(7–8):946–959.
96. Lange, D., et al., Complementary metal oxide semiconductor cantilever arrays on a single chip: mass-sensitive detection of volatile organic compounds. *Anal Chem*, 2002. **74**(13):3084–3095.
97. Ilic, B., et al., Mechanical resonant immunospecific biological detector. *Appl Phys Lett*, 2000. **77**(3):450–452.
98. Ilic, B., et al., Enumeration of DNA molecules bound to a nanomechanical oscillator. *Nano Lett*, 2005. **5**(5):925–929.
99. Arlett, J.L., E.B. Myers, and M.L. Roukes, Comparative advantages of mechanical biosensors. *Nat Nanotechnol*, 2011. **6**(4):203–215.
100. Ricciardi, C., et al., Development of a microcantilever-based immunosensing method for mycotoxin detection. *Biosens Bioelectron*, 2013. **40**(1):233–239.
101. Ricciardi, C., et al., Development of microcantilever-based biosensor array to detect angiopoietin-1, a marker of tumor angiogenesis. *Biosens Bioelectron*, 2010. **25**(5): 1193–1198.
102. Maguire, I., et al. Novel microfluidic analytical sensing platform for the simultaneous detection of three algal toxins in water. *ACS Omega*. 2018. **3**(6):6624–6634.

Chapter 10

My Personal and Professional Journey: *Reflections, Memories and Confessions*

S. R. Bawa, MSc, PhD¹

Bawa Biotech LLC, Ashburn, Virginia, USA

bawa@bawabiotech.com

10.1 My Life: An Overview

Hereby, too, I shall indulge the inclination so natural in old men, to be talking of themselves and their own past actions.

—Benjamin Franklin (1706–1790), American Statesman and Scientist, *Memoirs*

یہ دولت بھی لے لو، یہ شہرت بھی لے لو بھلے چہین لو مجھ سے میری جوانی
مگر مجھ کو لوٹا دو، بچپن کا ساون وہ کاغذ کی کشتی، وہ بارش کا پانی

*...take this wealth too, take this fame too, take away my youth from me,
but give me back the dawn of my childhood, that paper boat, that rainwater...*

—Mirza Ghalib (1797–1869), Indian Poet of Urdu and Persian

*...we are not given a short life but we make it short, and we are not ill-supplied but wasteful
of it...Life is long if you know how to use it.*

—Lucius Seneca (4 BC–65 AD), Roman Philosopher

¹This chapter is in the public domain. As a service to authors and researchers, unrestricted use, circulation, distribution, online posting, and reproduction of this chapter or unaltered excerpts therefrom, in any medium, are encouraged provided the original source is clearly identified/properly credited. The author's most recent affiliations were the David Axelrod Institute, New York State Department of Health, Albany, New York, USA, and the Department of Biophysics, Panjab University, Chandigarh, India.

I always have lived my way; I did it my way (“*Your time is limited, so don’t waste it living someone else’s life. Don’t be trapped by dogma—which is living with the results of other people’s thinking. Don’t let the noise of others’ opinions drown out your own inner voice. And most important, have the courage to follow your heart and intuition.*”—Steve Jobs). This chapter serves as an autobiographical memoir. It relates my experiences of the past 75 years in science, education, research, teaching, and administration; each has held equal importance in my professional life. This chapter also sheds some light on my youth under British colonial rule (1929–1947). The traumatic British partition of my beloved Punjab and loss of its ancient capital city of Lahore that resulted in me becoming a refugee in my own country is covered in detail (August 1947). I will reflect on my early life through the lens of historical events, nostalgia, and loss. It will then trace my undergraduate and graduate education (1947–1954), marriage to the sunshine of my life at the age of 24 (1954), and subsequent relocation with my young family to New York City (1958–1963). There, I was a Fulbright Scholar and Lecturer at Columbia University (1958–1960) and, later, a Lecturer (1961–1963) at Cornell University Medical College (now Weill Cornell Medicine). These venerable institutions provided me a firm foundation of scientific knowledge and academic tradition. New York City was a global epicenter of groundbreaking research in cell biology, biomedicine, and microscopy from the 1940s until the 1960s. I was lucky to have witnessed and participated in some of it with the giants of science and medicine. This resulted in a publication record of a dozen single-author papers in *Nature*, *Journal of Cell Biology*, *Journal of Ultrastructure Research*, *Journal of Morphology*, and many more. Lahore of the 1930s and 1940s was the old world to me—steeped in tradition, culture, architecture, poetry, and history. New York City of the 1950s and 1960s was the new world to me—stunning skyscrapers, limitless human creativity, optimism, diversity, modernism, and education. Both great cities will always occupy a tender corner in my heart.

The chapter is dedicated to my late-wife, Sudesh (Photos 1–3). Although she was an angel, I only referred to her as *Rani* (Punjabi, “Queen”). She was this and much more: kind, beautiful inside and out, thoughtful, gentle to the core, always smiling, exuding warmth, and helpful to all. She made my soul blossom (“*The best and most beautiful things in the world cannot be seen or even touched—they must be felt with the heart.*”—*Helen Keller*). I feel her absence every second of every minute. It is a void that nothing, and no one else, ever can fill. This chapter is also dedicated to my teachers, students, and colleagues, who taught me much and whose efforts are responsible primarily for what has been accomplished in our work—that is, the research focused on the “why” behind the problems that I have encountered over the past 75 years. These reciprocal relationships formed throughout my research and teaching career have fostered a depth of thinking and problem solving.






Photo 1. My wife “Rani” at age 12 in Lahore, Punjab, British India (c. 1947).

(आपकी नज़रों ने समझा प्यार के काबिल मुझे दिल की ऐ धड़कन ठहर जा मिल गयी मंज़िल मुझे/Aapki nazaron ne samjha, pyaar ke kabil mujhe, dil ki ai dhadkan thaher ja, mil gayee manzil mujhe. Translation from Hindi: Your eyes have found me worthy of your love; Oh, beats of my heart stop now, I have found my destiny.—Raja Mehdi Ali Khan)



Photo 2. Wedding photo following ceremony, 1954.

(कभी-कभी मेरे दिल में ख्याल आता है कि जैसे तुझ को बनाया गया है मेरे लिए तू अब से पहले सितारों में बस रही थी कहीं तुझे ज़मीं पे बुलाया गया है मेरे लिए / *Kabhi kabhi mere dil me khayaal aataa hai ke jaise tujhko banaaya gayaa hai mere liye; Tu ab se pahle sitaaron me bas rahee thee kahin, tujhe zameen pe bulaaya gayaa hai mere liye.* Translation from Hindi: *Sometimes, in my heart a feeling emerges that you've been created just for me; Until now you were living among the stars somewhere, you've been called down to earth just for me.*—Sahir Ludhianvi)



Photo 3. Photograph taken at home a few months after our wedding in 1954 in Hoshiarpur, Punjab, India. I was 24 and Rani was 19.

(ਰਲ ਗਈ ਸੀ ਇਸ ਚਿੱਚ ਇਕ ਬੂੰਦ ਤੇਰੇ ਇਸ਼ਕ ਦੀ, ਏਸੇ ਲਈ ਮੈਂ ਜਿੰਦਗੀ ਦੀ ਸਾਰੀ ਕੁੜੱਤਣ ਪੀ ਲਈ / *Rall gai si es vich ik boond tere ishq di; Esse layi main zindagi di saari kudattan pee layi.* Translation from Punjabi: *Because a drop of your love had blended in, that is why I drank the entire bitterness of life.*—Amrita Pritam)

The great city of Lahore, the ancient and beloved city of the Punjabis, had shaped my youth. Colonialism and the partition of Punjab had shaken my faith in humanity. America and New York City had reestablished that lost hope and reshaped my life. In 1958, there were few Indians in the New York City and only a handful at Cornell.² In fact, minorities were rare in the higher strata of American academia of the 1950s. They were especially scant at Ivy League schools such as Cornell and Columbia. After spending five gloriously happy years in New York City—where I learned how to manage a laboratory, write grants, lecture medical students, present at major conferences, and conduct top-notch biomedical research—I was ready to embark on a solo academic career. I had my sights set on MD Anderson Cancer Center in Houston, Texas. I had a wonderful visit there and, subsequently, was offered a position. However, my wife did not prefer Houston due to its stifling heat and humidity. Family has always been most important to me (*“A man should never neglect his family for business.”*—Walt Disney). So, I reapplied and finally accepted the position of assistant professor in the Anatomy Department at Georgetown University School of Medicine in Washington, DC. Along with this position came the coveted Green Card.³

This was an era without the Internet, Skype, or Facetime. Long hours in the research lab and teaching meant that I was away at work from early morning until late evening without access to my family. I almost always worked on the weekends. When I accepted the position at Georgetown, I requested the department chair for a leave of absence to visit the extended family (my wife’s and mine) in India after five long years. The department chair kindly agreed and even encouraged that we spend at least six months there prior to joining Georgetown. His gracious gesture left a deep impression on me. I would return the favor to my colleagues and students throughout my career. With his blessings and a tenure-track appointment letter in my pocket, we boarded the gorgeous RMS Queen Elizabeth, a luxury ocean liner operated by the Cunard Line, for London (Photos 4 and 5). Following a month at sea on another luxury liner, we finally arrived in India to the delight of our families.

²From humble beginnings, Indian immigrants have overcome great odds to become one of the most influential communities in American society today. Indians trickled into the US beginning in 1790, when the first settlers from the subcontinent landed in Massachusetts. Only 523 Indians immigrated between 1820 and 1898. In 1900, only 2,050 people of Indian heritage resided in the US. In 1946, the Luce-Cellar bill was signed into law that provided for the admission of 100 Indians per year and allowed them to become citizens. As a result, 6,474 East Indians entered between 1948 and 1965. Indians in the New York Metropolitan Area now constitute one of the largest Indian communities in the US. (Data cited here is courtesy of the US Census Bureau of the US Department of Commerce.)

³A Green (or Permanent Resident) Card holder is a US resident who has been granted authorization to live and work in the US on a permanent basis. US immigration laws provide a variety of ways for people to apply for a Green Card, including through one’s family, a job offer/employment, refugee/asylum status, or several other special provisions. Someone else usually must file (sponsor) the petition, although one may be eligible to file it themselves in some cases.



Photo 4. My wife and I, photographed in 1963 on board the ocean liner RMS Queen Elizabeth, *en route* from New York Harbor to Southampton in the UK. Operated by Cunard Line, it provided weekly luxury transatlantic service between New York City and Southampton, via Cherbourg in France. At that time, it was the largest passenger liner.



Photo 5. RMS Queen Elizabeth approaching her berth at Pier 90 in the North River at New York City in the late 1940s. Photograph of the painting by Robert Lloyd.

I was 33 years old and felt that I already had experienced a lifetime of upheaval during India's partition when I was forced to flee Lahore. I also felt the weight of responsibility having married at age 24. I had tasted professional success after working at some of the planet's most prestigious universities in a country that I had always admired. Naturally, I felt a huge sense of personal and professional achievement. However, little did I know that I was just a rookie and life was just beginning!

A few months after arriving in India, I was approached by Dr. A. C. Joshi, the Vice-Chancellor⁴ of Panjab University in Chandigarh, a city that did not even exist prior to 1947. I was heavily recruited and given an impressive initial offer to serve as Founding Head and Reader of the Department of Biophysics at the newly founded university. Frankly, I was not interested at all to stay in India and was eagerly looking forward to joining Georgetown to start my research and teaching activities. My wife was in contact with a realtor in Washington, DC, for the purchase of a small house near the campus. I also was reluctant to stay in India, fearing that I would not be able to conduct cutting-edge biomedical research in a university that was barely getting off the ground. Moreover, the department had no faculty, instruments, or staff. The Basic Medical Sciences (BMS) building (Photo 6), where the department would be eventually based, was still under construction. Nevertheless, I decided to visit the university and meet the Vice-Chancellor. I had two meetings with him and, during the second meeting, was seated next to other highly-sought-after recruits to lead various departments. I was impressed to learn the credentials of the other candidates as we were seated in the ornate waiting room. One of them was Dr. Manmohan Singh, who had completed his doctorate at Oxford in 1962 and was slated to be the Economics Chair.⁵ Dr. Singh ultimately would serve as the Prime Minister of India from 2004 to 2014. Dr. Joshi sealed the deal once he offered to construct a new Electron Microscope Facility for me, only the fourth or fifth one in India at that time. The closest one was in Delhi at the prestigious All India Institute of Medical Sciences (AIIMS), under the charge of my colleague, Dr. R. K. Misra, who was the Professor and Head of the Biophysics Department there. I accepted the position at Panjab University in Chandigarh in spring 1964. By then, my parents also had resettled in Chandigarh, having built a beautiful home there. Thus, the first part of my professional journey began in Lahore ("The City of Gardens"), unfolded via New York City ("The City that Never Sleeps"), and ended in Chandigarh ("The City Beautiful").

⁴The chief academic and administrative officer of the university, equivalent to a president at a US university.

⁵A year later in 1965, I purchased a new car, a rare event in India at that time. In fact, there were a handful of motor vehicles on the sprawling Panjab University campus in the 1960s. Dr. Singh, who had taken over as the economics department chair, rode a bicycle to work. Since our office buildings were close by, often we would pass each other; he would wave at me as I drove by.



Photo 6. The Basic Medical Sciences (BMS) building where my Department of Biophysics was housed for 50 years from its founding in 1964 until 2014. The Electron Microscope Laboratories occupied the basement of the building. The distinct modern architectural style of Pierre Jeanneret is evident.



I became a scientist in 1951 and, in a sense, continue to pursue that profession to this day. At 93, though, it takes me a bit longer to read and hear. Perhaps I need more time to grasp cutting-edge concepts and novel scientific terminology. While these developments about my diminishing abilities are topics of interest and concern to some, I am less bothered by them. In my view, these are normal and to be expected with aging as the brain atrophies and the ventricular width increases. Since my retirement in 1992, there have been numerous advancements in the tools and techniques in the areas of my research that often mystify me. Frankly, I am astounded at the explosion of information, which leaves me in a state of “information overload.” There was a time when I was on top of publications and literature pertaining to my research. Now, there are so many more journals and publications than when I was a young scientist.

Not everything is positive in biomedical research. I notice some trends that I am not too pleased about: plagiarism, recycling of data, scientific fraud, sloppy science, non-disclosure of financial research support, improper or incomplete oversight of researchers by professors/advisors, broken peer-review system, marketing of basic research as translational, rise of provocative statements on university or company websites, misinformation journalism, and so on. The current pervasive culture of science rewards flashy, eye-catching, and positive findings.

Negative data is often shielded from peer reviewers and the scientific community. Over the past 30 years, I have noticed that the drive to succeed, ambition, and pride cloud scientific judgement. The distinction between creative thinking and biased interpretation is a narrow one. There is also the negative impact of the rise of predatory journals (i.e., publications that accept articles and payments from authors, while bypassing scientific due diligence and fact-checking)—all contributing to the pollution of scientific literature. The honor system in academia—by which I have abided religiously—is in a shambles. I will shed further light on these troubling issues later (Section 10.16).

In addition to my academic endeavors summarized above, and detailed ahead, this chapter should give the reader some insight into my personal life. I hope it provides a glimpse into my strong motivation and powers of survival under suppressive conditions. My life's joys, tribulations, confessions, and twists are highlighted. While my journey may have had its share of potholes and roadblocks, there have been many more sun shines and rainbows. My intentions are always good; this is paramount to me. I believe that if you have good intentions and are honest in your actions, the results will reflect your sincerity. Remember that failures and successes are relative, one often leading to the other. Always keep your focus on the prize; ignore background chatter. Value life, love, and time. Learn to forgive and forget. I always have treated everyone with respect—faculty members, staff, students, children, family members, and strangers—even if they did not appreciate or reciprocate (*"I've learned that people will forget what you said, people will forget what you did, but people will never forget how you made them feel."*—Maya Angelou).

We all forget how fragile we are. When I used to teach anatomy, I often incorporated parts of my colleague Dr. Vid Persaud's classic *The Developing Human: Clinically Oriented Embryology*⁶ into my lectures. I was constantly reminded of the numerous human embryonic and fetal syndromes that can appear before the miracle of birth. We arrive on this planet with odds stacked against us. And, when we are here, we are so temporary in the grand scheme of things. Plans and dreams can alter in a flash. As I reflect on my history, I realize that life is full of contradictions and extremes, including ups and downs. I have slept on the cold ground of a refugee camp, yet also walked the hallowed halls of the Ivy League. I have gained much in professional life and yet felt that there was nothing much left when I lost my young son. I have endured the betrayal of false friends and certain family members and yet have been embraced by the unconditional love of many more. Nevertheless, I continue to seek the best in mankind (*"I believe in the sun, even when it is not shining. I believe in love, even when feeling it not. I believe in God, even when God is silent."*—Anonymous).⁷ I strive to make an honest effort and difference each day, providing a bit of

⁶Moore, K. L., Persaud, T. V. N., Torchia, M. G. (2019). *The Developing Human: Clinically Oriented Embryology*. 11th edition. Elsevier, Philadelphia, Pennsylvania, USA.

⁷Horvath, M. (1988). Even when God is silent. University of Houston. Available at: <https://www.houstonpublicmedia.org/articles/arts-culture/2018/02/01/263905/composer-michael-horvit-talks-about-his-piece-even-when-god-is-silent/> (accessed on April 30, 2023).

bliss to those around me. I believe that we all contribute to the world's problems and, therefore, have a moral obligation to respond—a sense of duty to make a difference, even if it is tiny (“*To leave the world a bit better...To know even one life has breathed easier because you have lived. This is to have succeeded.*”—Ralph Waldo Emerson). I continue to press on because, in the words of Robert Frost, “*I have promises to keep, And miles to go before I sleep, And miles to go before I sleep.*”⁸

10.2 Early Days in Lahore, British India

I was born in Lahore, in the prosperous state of Punjab in British India (Map 1), on Christmas Day 1929 to a family that greatly valued education, culture, philosophy, music, and poetry. I lived in Lahore until August 15, 1947, when Punjab was partitioned by the British colonists as they made a clumsy and hasty exit out of India.⁹ Both of my parents were Punjabis—my mother a Sikh and my father a Hindu. Their ancestors possibly could be traced to Western Punjab, bordering Persia and Afghanistan. Discipline, honor, truth, love, and spiritual growth shaped my youth and adult life. Prior to August 15, 1947, Punjab, the “Land of Five Rivers,” had the shape of a beautiful butterfly (Map 2).

A year before my birth, in November 1928, the prominent freedom fighter Lala Lajpat Rai, the “Lion of Punjab,” had been brutally beaten in Lahore during a peaceful protest, which ultimately led to his death.¹⁰ Six days after I was born, on December 31, 1929, Pandit Jawaharlal Nehru (1889–1964) as Congress President at its Lahore session unfurled the tricolor (Indian national flag) on the banks of the river Ravi and gave the call for *Purna Swaraj* (Hindi, “complete self-rule or sovereignty”) from British colonial rule in India. The year 1929 also marked the 10th anniversary of a horrific episode in world history, which lasted a mere ten minutes but reverberates to this day in the conscious of every Punjabi.¹¹ It is the *Jallianwala Bagh* (Punjabi, “the garden of the Jallah-man”) massacre in Amritsar, the sister city of and only 34 miles from Lahore. Here, 150 British troops (British India Army) assumed positions on elevated ground towards the main entrance of the Jallianwala Bagh. Then, at six minutes to sunset, they cold-bloodedly opened

⁸Frost, R. (1923). Stopping by woods on a snowy evening. *The Poetry of Robert Frost: The Collected Poems*. Lathem, E. C. (editor), Henry Holt and Co., New York, USA.


⁹Punjab Province (British India). Available at: <https://www.youtube.com/watch?v=a216QAFnaFE> (accessed on April 30, 2023).

¹⁰Lala Lajpat Rai. Available at: <https://www.youtube.com/watch?v=-cJtrZSWsM0> (accessed on April 30, 2023).

¹¹The Irish War for Independence (*Cogadh na Saoirse*) started in 1919. The summer of 2022 marked the 75th anniversary of The Partition of India and the 100th anniversary of the Irish Civil War (*Cogadh Cathartha na hÉireann*). The British were involved in both horrible events; their leadership even involved a few of the same players. In the case of India, they partitioned the country as they made a hasty retreat. In the case of Ireland, they forced it to cede six northern counties.



Map 1. Map of India under British occupation prior to August 1947. It shows British India in two shades of pink and Princely States in yellow. The Partition was the parting gift of the British colonists that tore India into three pieces—West Pakistan (now Pakistan), India, and East Pakistan (now Bangladesh). Burma and Ceylon (now Sri Lanka) at one time were also part of India. On the eve of independence in 1947, India comprised nearly 600 states, each with its own maharaja, nizam, or prince. The process of their absorption brought many problems, including their reluctance to cede power as well as the integration of administrative/legal systems into a common and secular national structure.



Map 2. Map depicting Punjab province, with its five rivers, on the north-western front of India as it existed in 1909 prior to its partition in August 1947. Bengal Presidency in the eastern front of India was similarly carved out in 1947 by the British imperialists as East Pakistan (now Bangladesh). Therefore, among Punjabis and Bengalis, The Partition resonates at an almost visceral level as a moral tragedy. In this chapter, I focus entirely on Punjab's partition although the enormous Bengali story runs parallel to and intersects with it, which I have neither skill nor space to address.

fire without warning on an unarmed crowd of 20,000 Punjabis celebrating Baisakhi.¹² They continued shooting until their ammunition was exhausted, thus killing and wounding hundreds.¹³ In the end, roughly 1,650 rounds were fired. The bullet marks still can be seen on the walls of Jallianwala Bagh, which is now a national memorial. This monstrous episode¹⁴ marked the beginning of the end of the British rule in India. Shamefully, no British government official or member of the British monarchy has ever apologized for the massacre (*“One cannot and must not try to erase the past merely because it does not fit the present.”*—Golda Meir). Hopefully, the current UK Prime Minister Rishi Sunak, whose parents are Punjabis, can ease the century-old grief of the Punjabi people by offering an official apology. I was born into this climate of freedom and patriotic fervor. I was named “Sukhdev”¹⁵ as a homage to a Punjabi freedom-fighter by the same name.

Both my parents had a strong work ethic. At an early age, I too acquired this characteristic and was motivated to do my best at whatever task I encountered. My father was Secretary of Education at Lahore Corporation, a prestigious government position. His massive library, including the *Encyclopedia Britannica* and *National Geographic* magazines, opened my eyes to the outside world at a young age (*“A room without books is like a body without a soul.”*—Cicero). He was a sensitive, calm man, who always was open to new ideas. His most impressive trait was that he was a good listener—patient and never interrupting (*“Nature hath given men one tongue but two ears, that we may hear from others twice as much as we speak.”*—Epictetus). The only times I witnessed anger on his otherwise

¹²*Baisakhi*, also pronounced *Vaisakhi*, marks the first day of the month of *Vaisakh* and traditionally falls on April 13th or April 14th as a celebration of the spring harvest, primarily in North India. It is also known as the harvest festival of Punjab and is celebrated by people across religions.

¹³The Indian philosopher-poet Rabindranath Tagore, who had been awarded the Nobel Prize for literature in 1913 and subsequently was knighted by the British government, returned his knighthood as a sign of dismay. In his letter to the Viceroy, he summed up the fury of the Indian people: *“The time has come when the badges of honour make our shame glaring in their incongruous context of humiliation and I for my part wish to stand shorn of all special distinctions, by the side of those of my countrymen, who for their so-called insignificance, are liable to suffer a degradation not fit for human beings.”* Source: Jallianwala Bagh Massacre: 103 years of Tragedy. Available at: <https://www.jagranjosh.com/general-knowledge/jallianwala-bagh-massacre-causes-and-its-impact-1446016915-1> (accessed on April 30, 2023).

¹⁴100 Years of Jallianwala Bagh: How the massacre unfolded. Available at: <https://www.youtube.com/watch?v=IYpgHP7hjjg> (accessed on April 30, 2023).

¹⁵Sukhdev Thapar was a major Indian freedom fighter who along with his best friends and partners, Bhagat Singh (1907–1931) and Shivaram Rajguru (1908–1931), swore to avenge the murder of Lala Lajpat Rai, as well as the Jallianwala Bagh massacre (and they did). He, along with Bhagat Singh and Rajguru, was hanged in Lahore Jail in 1931 by the British government at the age of 23. This trial is an important event in Indian history, as it went contrary to the fundamental doctrine of criminal jurisprudence. An *ex-parte* trial was against the principles of natural justice according to which no man shall be held guilty unless given an opportunity to defend in a hearing. The Communist Party of Great Britain condemned the case at that time: *“The history of this case, of which we do not come across any example in relation to the political cases, reflects the symptoms of callousness and cruelty which is the outcome of bloated desire of the imperialist government of Britain so that fear can be instilled in the hearts of the repressed people.”* Source: Rana, B. S. (2008). *Bhagat Singh: An Immortal Revolutionary of India*. Diamond Pocket Books, New Delhi, India.

smiling face was when he suspected deception or distortion. It is a wonderful characteristic, one which I wish I had inherited from him. At various points in his life, he taught and published textbooks on mathematics and physics. My mother was a homemaker, who rose early to clean and cook for the entire household. She was the glue that held everything and everyone together. She was fair yet firm, which was the only way to keep our large brood in check. My mother liked to entertain and invite guests to eat with us. She was exceptionally good in the kitchen. While my father's features almost always were composed, those of my mother rarely were. Moods and humor slipped across her face like images passing across the waters of a lake.

Ours was a joint family that lived in a magnificent home in one of Lahore's impressive neighborhoods. I grew up surrounded by my ten siblings, loving parents, deep friendships, and a feeling of community. Our cohesiveness was characterized with love, kindness, honesty, honor, and generosity—important features of the Punjabi culture that are gradually eroding (*"Kindness is the language which the deaf can hear and the blind can see."*—Mark Twain). I made several very close friends, a few of whom still keep in touch; most are gone now. Our infrequent conversations generally are hard to decipher over the phone, given our poor hearing and other issues associated with advanced age. One of our neighbors was a widow with two young children, a boy and a girl. The widow had returned from Kenya, where she had lost her husband, a civil engineer employed by British Rail. Her daughter was Sudesh, who was born near Nairobi and became my wife in 1954. I was 24 then and a newly minted PhD; she was 19.

Ours was city life with amenities found on prosperous farms. Milk, eggs, vegetables, honey, meat, and fruit all were obtained from the massive garden on the rear of our property. At an early age, I learned to herd cows into the courtyard, milk them, and clean their udders. Life was carefree, and I relished daily chores. It felt as though we lived in a cocoon in contrast to our surroundings. British treatment of the tough Punjabis was especially harsh, because we were perceived as a major threat to Britain's precarious hold on India. Central Lahore Jail (also called Kot Lakhpat Jail) was the site of frequent hangings of Punjabi freedom fighters.

Our schooling was supplemented with regular private lessons at home, often by my father from his math and physics textbooks. He felt that such home schooling was important to take control of the narrative of our own country's history, art, culture, philosophy, and poetry, which had hitherto been dominated by European voices. I became fluent in English, Punjabi, Hindi, and Urdu. I also studied Farsi (Persian)¹⁶ and Sanskrit. Gurmukhi and Shahmukhi as Urdu and

¹⁶Persian is known as Farsi in Iran, Dari in Afghanistan, and Tajik in Tajikistan. Note that Punjabi and Urdu were our languages in the western part of Punjab province in British India. The languages of the Indian Punjab state (called East Punjab in 1947 at the time of The Partition) today are primarily Hindi, Punjabi, and English. The languages of the Pakistani Punjab province (called West Punjab in 1947 at the time of The Partition) today are primarily Punjabi, Urdu, and English. In other words, Punjabi continues to be the language of Punjabis today, whether they reside in India or Pakistan.

Farsi were compulsory subjects at the primary level in public schools of the pre-partitioned Punjab.¹⁷ Relative to the lives of my peers, it certainly was a life of luxury and comfort, though I did not fully appreciate it at the time. Listening to music was my refuge and escape from loneliness (“*Music expresses that which cannot be put into words.*”—Victor Hugo).

Being quite athletic, I learned horseback riding and archery. However, kite flying or *patang* (Hindi, “fighter kite”) was a passion of mine. I especially enjoyed this ancient Indian tradition during Basant. Basant is a springtime kite-flying event during the Basant Panchami festival in Punjab. It is no exaggeration to say that the sky used to turn into a rainbow and that there used to be no space for the birds to fly. Brought into the country by Chinese travelers, the earlier kites were used for measuring distances, signaling and for communicating military operations. The kites I used in Lahore and later in Hoshiarpur were delicate ones made of paper and wooden sticks. I hear that they are now made with flexible materials that make them more resilient. Kites were generally shaped like a diamond, with a center spine and a bow shaped intersecting the spine that gives them their shape. In addition to other typical rural Punjabi childhood games like *Punjabi Kabaddi* (*Circle Kabaddi*), *Gilli-Danda*, and *Pittu Garam* (*Seven Stones*), I played field hockey and cricket. Field hockey and cricket are part of growing up in Punjab, like ice hockey in Canada or soccer in Germany. Field hockey and cricket were sports of obvious choice, given the dominance of Punjabi players on the national teams of both sports as well as their impressive performance at international events. The Indian teams dominated the international hockey scene, winning six straight Olympic gold medals and 24 consecutive matches between 1928 and 1956 and two more gold medals in 1964 and 1980. There are historical records that suggest early forms of hockey were played in Egypt and Persia around 2000 BC. A game like field hockey was played in the 17th century in Punjab under the name, *khido khundi* (*khido*, Punjabi, “woolen ball”; *khundi*, Punjabi, “to the stick”). “*Hockey, more than any other game, is etched in the Indian psyche. It is hockey that brings out the magic and mystery, the poetry and prose in Indian sport.*”¹⁸ In the 1980s, the international governing body introduced AstroTurf, which provided an edge to European teams. It was a carefully crafted move. I feel that this took the beauty and finesse out of the game. Political clout and money have corrupted international sports whether it is the Olympic Games, test cricket, or the FIFA World Cup.

¹⁷The two scripts used for Punjabi are Gurmukhi and Shahmukhi. Shahmukhi came in use by Punjabi Sufi poets to write the Punjabi language, starting in the 12th century. Shahmukhi script is the standard script in Pakistani Punjab province used for Punjabi while Gurmukhi script is used in the Indian Punjab state. Shahmukhi is generally written in the Nasta’liq calligraphic hand, which is also used for Urdu. Shahmukhi is written from right to left while Gurmukhi is written from left to right.

¹⁸Sardesai, R. (1992). *Sunday Times of India*.

10.3 Punjab: Land of Five Rivers and India's Gatekeeper

Punjab (Gurmukhi: ਪੰਜਾਬ; Shahmukhi: پنجاب) is a geopolitical, cultural, and historical region in the northwestern part of the Indian subcontinent, comprising areas of eastern Pakistan and northwestern India (Maps 1 and 2). Although the name Punjab is of Persian origin, its two parts (پنج, *panj*, “five” and آب, *âb*, “water”) are cognates of the Sanskrit words, पञ्च, *pañca*, “five” and अप, *âp*, “water,” of the same meaning. The word *pañjâb* thus means “The Land of Five Waters,” referring to the rivers Jhelum, Chenab, Ravi, Sutlej, and Beas. All are tributaries of the Indus River, the Sutlej being the largest. The ancient Greeks referred to the region as Pentapotamía (Greek: Πενταποταμία), which has the same meaning as the Persian word.


Punjab also happened to be the land of tremendous intellectual ferment. The Vedas, Ashtadhyayi, Guru Granth Sahib, Yoga Sutras, the Bhagavad Gita, Puranas, and many of the Dharm Sutras were composed here. References to a land of five rivers may be found in the Mahabharata (Sanskrit, “Great epic of the Bharata dynasty”). Mahabharata is one of the two major Sanskrit epics of India, valued for its literary merit and its religious inspiration (the other being the Ramayana). It is a text about both *dharma* (Sanskrit, “Hindu moral law”) and *itihasa* (Sanskrit, “that’s what happened”). Contained within the Mahabharata is the Bhagavad Gita (Sanskrit, “The beautiful song by God”), Hinduism’s most important religious book. The sage Vyasa (c. 5 BC) is traditionally named as the Mahabharata’s author and the poem reached its present form around 400 AD. The poem is made up of almost 100,000 couplets—about seven times the length of the *Iliad* and the *Odyssey* combined—divided into 18 *parvans* (Sanskrit, “sections”), plus a supplement titled Harivamsha (Sanskrit, “Genealogy of the God Hari”; i.e., of Vishnu). Its various incidents have been portrayed in stone, notably in sculptured reliefs at Angkor Wat and Angkor Thom in Cambodia and in Indian miniature paintings.

The geography of Punjab has influenced its history. Being the gateway of India, attacks by foreign invaders for thousands of years was borne by Punjab, which suffered heavy human and monetary casualties. In contrast, the rest of the country continued to live a life of splendid isolation. The plains of Punjab were sites of decisive battles, which were fought by Punjabis to check invaders from entering the interior of India. Every invader sought possession of Punjab and a road to fame. Among those who occupied Punjab until the 18th century were the Persians (Cyrus and Darius), Macedonians (Alexander the Great), Scythians, Parthians, Kushans, Huns, Arabs, Turks, Mongols, and British. In fact, Punjab was the last part of India to be annexed by the British. In 1849, Punjab fell to the troops of the British East India Company and subsequently became a province of the British Crown.

Alexander the Great (356 BC–323 BC) (Map 3) was one of the most famous warriors to venture into Punjab (Image 1).¹⁹ There, at the Battle of the Hydaspes

¹⁹The true story of Alexander the Great, History Channel. Available at: <https://www.youtube.com/watch?v=imRNmDnkUcE> (accessed on May 5, 2023).

in 326 BC, he *might* have lost to the Punjabi King Porus, a legendary warrior whose territory spanned the region between the Jhelum River (Hydaspes) and Chenab River (Acesines) in Punjab. A fierce battle in a raging thunderstorm was fought, and, for the first time, the Greeks encountered elephants in war. It was by far the toughest battle of Alexander's entire military campaign. Apparently, the huge beasts and their awful trumpets made the Greek horses tremble. The death of his beloved horse, Bucephalus, is attributed to the battle. In the aftermath of this epic battle, an impressed Alexander not only reinstated Porus as his satrap but also granted him dominion over lands to the south-east extending as far as the Hyphasis (Beas River). Since Porus is only mentioned in Greek sources, which differ considerably among themselves, it is hard to confirm the details of the battle with certainty. Historians have argued that Alexander was, in fact, defeated by Porus and that the two men became friends, and that this explained why Alexander left him enormous territories (*"History is a set of lies agreed upon."*—Napoleon Bonaparte). One thing is undisputed: Alexander's eastward march into India ended in Punjab; unable to wage war, he was forced to return home. Did his army mutiny in Punjab or was he defeated by Porus?



Map 3. Alexander's eastward march into Punjab and his route to the Beas River.



Image 1. An oil-on-canvas painting titled *Alexander and Porus* by Charles Le Brun depicting Alexander and Porus during the Battle of the Hydaspes (Jhelum River). It was painted in 1673 and currently hangs in the Louvre Museum in Paris.

The predominant ethnolinguistic group of the Punjab region is the Punjabi people, who speak the Indo-Aryan Punjabi language. Punjabi Muslims are the majority in West Punjab (now Punjab province of Pakistan), while Punjabi Sikhs and Punjabi Hindus are the majority in East Punjab (now Punjab state of India). Other religious groups include Christians, Jains, Zoroastrians, Buddhists, and Ravidassias. Punjab, which consists of rich and fertile plains, emerged as an important agricultural region, especially following the Green Revolution from the mid-1960s through the mid-1970s. It continues to serve as the breadbasket of both India and Pakistan.

10.4 Lahore

جس نے لاہور نہیں دیکھا وہ پیدا ہی نہیں ہوا // *Jis Lahore Nai Vekhya O Jamyai Nai*

(One who has not seen Lahore has not been born.)

— Anonymous

Lahore in British India—now in Pakistan²⁰—was one of the largest cities and the historic-cultural center of Punjab and the entire northern region of the subcontinent (Photo 7). It was the seat of Urdu poetry, splendid Mughal architecture, Punjabi cuisine, and philosophy. It was one of India’s most sophisticated, socially liberal, progressive, and cosmopolitan cities. Lahore’s origins date from antiquity. The first document that mentions Lahore by name is the *Hudud al-‘Alam* (Urdu, “The Regions of the World”), written in 982 BC.

²⁰Following independence, India has had its share of political turbulence. However, nothing compares to the grim state of politics in Pakistan. Pakistan has struggled with instability and military coups since its founding in 1947. The two established political dynasties clash and take turns falling in and out of favor with the military, with the victors targeting their rivals via the judiciary.




Photo 7. Major architectural attractions of Lahore. Clockwise from the top: Badshahi Mosque, Wazir Khan Mosque, Naulakha Pavilion, Lahore Museum, Shalimar Gardens, Minar-e-Pakistan, Lahore Fort, Greater Iqbal Park.

It describes it as a town that had “impressive temples, large markets and huge orchards.” As previously discussed, Lahore had been controlled by numerous empires throughout the course of its history and reached the height of its splendor under the mighty Mughal Empire between the late 16th and early 18th centuries. During this epoch, Lahore served as its capital city. The Mughals lavished their love and their considerable talents on the city. However, upon its capture by Nader Shah’s forces in 1739, it fell into a period of decay while being contested between Afghans and Sikhs. Lahore eventually became the capital of the Sikh Empire under the great Maharaja Ranjit Singh of Lahore (Image 2) in the early 19th century, regaining much of its lost grandeur. Lahore subsequently was annexed to the British Empire and made the capital of British Punjab. Central to India’s freedom movement, the city served as the site of the declaration of Indian independence in 1929 (Section 10.2).



Image 2. Oil painting of Maharajah Ranjit Singh by the artist Manu Kaur Saluja. The painting depicts Ranjit Singh, who was blind by one eye, sitting on his golden throne within the walls of the Lahore Fort. He is in full dress armor, with the spectacular Koh-i-Noor diamond on his right arm in its original setting. Contrary to whatever story the British government may spin, it was looted by the British East India Company during the annexation of Punjab in 1849, during the reign of the then eleven-year-old Maharaja Duleep Singh. Part of the British Crown Jewels, the 105-carat diamond is currently set in the crown of the late Queen Elizabeth. The British Crown Jewels, stolen from around the world, are housed in the Tower of London and disgracefully displayed to the public as a proud mark of British colonial pride. Image courtesy of Manu Kaur Saluja and the Royal Ontario Museum, Toronto, Canada.

It is no exaggeration that since the early 1900s, including my youth (1930s and 1940s), Lahore was a unique center of intellectual interaction and activity which produced or influenced a long and distinguished line of writers, poets, artists, lawyers, movie stars, and political activists. Without a doubt, Lahore was the most highly cultured city of north India, arguably India. Distinguished intellectual centers like The Oriental College, The Mayo School of Arts, and Government College Lahore were flourishing. The city boasted of the largest number of Urdu literary journals, newspapers, and books, and two of India's best English language dailies. Distinguished journalists hosted literary events. The annual plays staged at Government College Lahore and Dyal Singh College were a treat awaited by the city's elite. The city rang with the echoes of the poetry of Urdu and Persian masters. Legendary movie stars and playback singers of Indian and Punjabi cinema—household names today—originated from Lahore.

The vibrance and pulsating intellectual activity of the Lahore of my youth of the 1930s and 1940s is beautifully captured in a memoir published in Lahore in 2012²¹:

The well-to-do Westernized elite drank and danced and talked in the Gymkhana and Cosmopolitan clubs. The home-grown dazzling lights set off their fireworks at the Arab Hotel, Nagina Bakery, Mukham Din's teashop, Halqa-i Arbab-e Zauq, India Tea House and India Coffee House. The greatest in the land like Tagore, came and spoke at the SPSK Hall. Political debates were held at Bradlaugh Hall. Amrita Sher Gill painted, and B. C. Sanyal sculpted. The best British and American films were screened at Regal and Plaza...The baithaks in the walled city trained young musicians and singers and invited the connoisseurs to come and listen to classical music. The radio came a little later and the literati wallowed in a new channel which immediately enlarged the circulation of what they wrote, said or composed. With Bokhari's genius presiding over the radio network, the first generation of literary broadcasters was in the making...Impressive edifices adorned the landscape: Lawrence Hall, Chiefs' College, Government House, High Court, Masonic Lodge, Legislative Assembly, General Post Office, Museum, Mayo School of Art, the University, Government College, and Central Training College. The queen of all roads, the Mall, was bordered by tall trees and wide footpaths, and boasted a glittering array of expensive shops. The racecourse and the Lawrence Gardens were the lungs of the city. No high-rise buildings existed. With no encroachments the roads looked wider. The bungalows of Davis, Empress, Egerton, Queens and Jail Roads were elegantly built and located in the middle of green lawns. The skyline was soothing. Nature's green was the dominating colour of the city. Breathing was easy, and so was enjoying life...The serene Faletti's was centrally located on Egerton Road, behind the assembly chamber and facing Rai Bahadur Ram Saran Das's mansion. Jinnah, Abul Kamal Azad, and Ava Gardner stayed here...Built in 1940-43 in the Lawrence Gardens, [The Open Air Theater] is a magnificent imitation of a Greek amphitheater.

²¹Aziz, K. K. (2012). *The Coffee House of Lahore, a Memoir 1942-57*. Sang-e-Meel Publications, Lahore, Pakistan.

Theatrical companies of those days, all non-Muslim, staged plays here and young college students or fresh graduates acted in them, like [legendary future movie stars] Kamini Kaushal, Gita Bali and Om Prakash.

Furthermore, growing up in Lahore in the 1930s and 1940s, it was impossible to miss the rich history of the great city as described by esteemed Indian scholar and jurist S. M. Latif at the turn of the 20th century²²:

Although the capital of the Panjáb could never vie with the Imperial city of Delhi, the Rome of Asia, in the variety and profusion of its ancient monumental remains, or with the city of Akbar (Akbarabad, or Agra) in the splendour of its architecture, it, nevertheless, possesses as many and as interesting historical sights and reminiscences as any other famous city in India; while no Indian city can boast of having been the seat of so many Imperial dynasties as Lahore. Its lofty houses, gilded minarets, and bulb-like domes, visible from afar, give it an imposing appearance, while its crowded streets, busy markets, and thriving industries, furnish internal evidence of great prosperity and successful progress. It is situated in a region famous in history as the camping ground of the early Aryan migration and civilisation, as the seat of the holy singers of the Vedic hymns—the fairer race, who, reducing to bondage, or driving back the black-skinned servile races, spread eastwards, and whose records, side by side with the Egyptian records and the Chinese philosophy, go back further than those of any other country. The Panjáb was the home of Northern Buddhism...The region calls attention from the interest attaching to it as the classic ground of Alexander's conquests, which materially influenced Brahmanism in the Panjáb, and gave the first impulse to sculptural art in Northern India...Viewed from a political standpoint, nature has given the Panjáb a crowning position in the great Indian Peninsula. It is aptly termed the steel-head of the spear of this great empire, the guard-room of India on the north. From the earliest times, the Panjáb has served as a bulwark of defence against foreign aggression, the outpost of the line of battle; and it has proved one of the greatest recruiting grounds of armies in the East. It is pre-eminently the soldier's land, "the sword in hand of India," whose warriors have fought bravely...But it is in its position as the chief city of this land of great traditions that its political interest chiefly consists. Lahore claims the attention of both the student of history and the general reader. Here, in his royal palace, did the politic Akbar held his cabinet councils. The place is associated with the loves of Jahángir and Núr Jabán, and is memorable as the birth-place of the magnificent Shah Jahán. When the reflecting mind of the pious Nanak conceived the amelioration of man's social condition and the combination of conflicting creeds into one, enjoining the worship of one invisible God, the political position given to Lahore contributed, in no small a degree, to the development of the religious order [Sikhism] established by him...In more recent times we find it remarkable as the capital of a kingdom founded by Ranjit Singh, the lion of the Panjáb...How many conquerors have fixed their eyes on this glittering prize [Lahore], the very key to India!

²²Latif, S. M. (1892). *Lahore: Its History, Architectural Remains and Antiquities*. New Imperial Press, Lahore, India.

Lahore today is *not* the same.²³ History has dealt the lovers of Lahore more than their share of broken hearts. According to *The New York Times*: “This graceful and cultured city, with a history that stretches by some accounts back into the days of the epic Ramayana, passed through many conquering hands—Hindu, Mogul, Persian, Afghan, Sikh and British—on the way to becoming an intellectual center of the Indian subcontinent, only to be relegated with the partition of British India to the status of a provincial Pakistani capital.”²⁴ Lahore used to be called the City of Gardens. However, due to rapid urbanization, pollution, and poor planning, it has lost its aesthetically important urban vegetation, trees, and greenery. The “urban farm-life” of my childhood is gone. I still mourn the loss of my mother city, which I can visit no longer but never will forget. Lahore is the place to which I always will belong. In this context, I direct the reader to Amrita Pritam’s (1919–2005) (Photo 8) masterpiece titled ਕਿਉਂ ਉਥੇ ਦਿਲ ਛੱਡ ਦਿੱਤਾ?/*Kyun Uthhe Dil Chhod Dita?* (Punjabi, “Why did you leave your heart there?”²⁵) which reads in part



Photo 8. Amrita Pritam at All India Radio Lahore, pre-1947. She was the grande dame of Punjabi letters, who nurtured two generations of Punjabi writers and poets. Her career spanned six decades and produced over 100 books of poetry, fiction, biographies, essays, and Punjabi folk songs that have been translated into several Indian and foreign languages. Pritam was the product of the other side of Punjab (i.e., Western Punjab, now in Pakistan), and she religiously remained so all her life drawing her strength and symbols with all the sublimity embodied in the works of great Sufi poets and saints.

²³Lahore - Before Partition (Technicolor Footage). Available at: <https://www.youtube.com/watch?v=apEk8Yu0KXU> (accessed on April 30, 2023).

²⁴Crossette, B. (1981). *The New York Times*, June 14 Issue, Section 10, p. 1.

²⁵Kyun uthhe dil chhod aaye? (Punjabi, “Why did you leave your heart there?”). Available at: https://www.facebook.com/285689198213/videos/981496262471491?_so_=permalink (accessed on April 30, 2023).

(Translation from Punjabi):

My grandmother used to remember Lahore all her life. She used to narrate the stories of Bano Bazar morning and evening. Wet eyes and a blind throat couldn't stop them...What kind of reality was this, which was now just a dream, what kind of city was this, which belonged to us even after leaving it, once I asked why did you leave the heart, why did you leave your heart?...Every day, we used to listen to the songs of Noor Jahan sitting on the temple and the velvet voice of Surya was spoken in the sweater. Thoughts with threads in the evening. We used to roam around in Fulkari, spreading a machete in every boat, careless...This is a matter of the time when all five rivers of Punjab lived in one country...

10.5 Urdu: The Language of Love

I consider Urdu India's embattled language of love.²⁶ Urdu is a gorgeous language. It is a language of romance—more beautiful than French or Italian. Urdu, a member of the Indo-Aryan group within the Indo-European family of languages, is spoken chiefly in northwestern India (e.g., Punjab) and Pakistan. Urdu was born in north India (around Delhi) in the 12th century. It was heavily influenced by Arabic, Persian, and Turkish. For centuries, it has been the prominent language of culture and poetry in India, often promoted by Mughal rulers. Let us not forget that its literature and journalism have played major roles in India's independence movement. Apart from this, Urdu is central to romantic expression in the songs of Indian cinema that are entrenched in Indian life. Urdu has been my language of angst, heartbreak, and celebration. I grew up humming songs from India cinema that draw heavily on Urdu poetry. If Urdu is lost from India cinema, we will lose the manner with which we communicate our thoughts and feelings, our decorum. At this age, television serves as my great friend and the major source of my daily entertainment. I get a substantial dose of Urdu, Punjabi, Hindi, English, and Persian programming. Almost every night, I watch a combination of old Bollywood movies that are rich in Urdu poetry, American Westerns, old Bollywood film songs, variety programs, cricket games, and talk shows.

Contrary to what many believe, Urdu is not foreign to India or a language of Pakistan, which adopted it as its national language. Urdu is not related to any religion; it is related to culture, especially Punjabi culture on both sides of Punjab (i.e., Indian Punjab state and Pakistan Punjab province). Still, in recent years the language has taken on an Islamic identity in India. I hope this trend can be reversed. In this regard, the Rekhta Foundation, and its poetry festival, Jashn-e-Rekhta (Urdu, "celebration of Rekhta") started by Sanjiv Saraf, offer encouraging signs.²⁷ The foundation is devoted to the preservation and promotion of the Urdu language and culture. I also commend the superb poet Javed Akhtar and his lovely wife, the multi-talented Indian movie star Shabana Azmi for their support of this wonderful foundation and for being a regular at Jashn-e-Rekhta.

²⁶Romancing Urdu. Available at: <https://www.youtube.com/watch?v=mkm-6DN5guQ> (accessed on April 30, 2023).

²⁷Jashn-e-Rekhta 2022: The charm of Urdu is back. Available at: <https://www.youtube.com/watch?v=0UClEfxgE8> (accessed on April 30, 2023).

Much of Urdu poetry is a simple “sher”²⁸—two versed lines in which the first sets up an idea and the second completes it. M. J. Akbar’s 2004 “Byline” column from *The Asian Age* newspaper beautifully sums up how I feel about this lovely, sophisticated language:

With the ebb of Urdu, a civilization has diminished. Urdu is utterly civil, rooted in values and anchored in two words that supersede translation: tehzeeb and akhlaq. A “practical” Urdu-English dictionary defines tehzeeb as civilization, etiquette, manners, politeness, courtesy, polish, refinement, instruction, education, discipline, culture. It is all this and much more, including that very delicate wit that nuances an idea or a sentiment with a sensitivity that becomes a bridge between lovers and a gulf between antagonists. Akhlaq is the practice of tehzeeb.

10.6 India: The Economic Jewel in the Crown

India was governed for the benefit of Britain. Britain’s rise for 200 years was financed by its depredation of India.

—Shashi Tharoor (b. 1956),
Inglorious Empire: What the British Did to India, 2017.

A commercial company [British East India Company] enslaved a nation comprising two hundred million people.

—Leo Tolstoy (1828–1910), Letter dated December 14, 1908.

Indian civilization (i.e., the Indus Valley civilization) began around 5,000 years ago in the northwestern part of the subcontinent because it was watered by the regions’ rivers. It was a highly sophisticated civilization of advanced cities that traded with the civilizations of Mesopotamia (Iraq) and Egypt. It featured an advanced economic system, well-developed agriculture practices, domestication of animals, and production of sharp tools/weapons from copper, bronze, and tin. There is archeological evidence of exceptional urban planning as evidenced by the well-laid streets, drainage systems, and water supply found in the valley’s major cities, namely, Dholavira, Harappa, Lothal, Mohenjo-daro, and Rakhigarhi. After 1500 BC, India faced its first major wave of invaders and migrants from the north. These were the so-called Indo-Aryans, branches of a larger tribe of Indo-Europeans who settled in Persia and throughout Europe, as well as India. Originating probably in southern Russia and Ukraine, the Indo-Europeans were creative agriculturalists who were likely the first people

²⁸A *sher* is a couplet in Urdu poetry; a *ghazal* is a form of poetry which is a collection of various shers. Each sher consists of two lines, and each line is called *misra*. A ghazal commonly consists of five to fifteen couplets, which are independent, but are linked—abstractly, in their theme and more strictly in their poetic form. The first line of a ghazal must include a refrain, which is a word or a phrase that can be easily fitted into the other couplets. The first sher is known as *matla*. The last Sher is called *maqta*, but only if the poet uses his *takhalus*. Note that every sher is a poem in itself; it is the smallest unit of Urdu poetry.

to domesticate horses and use war chariots in battle. India has served as the birthplace of several major religions: Hinduism, Sikhism, Buddhism, and Jainism. North India's major languages (like Punjabi) are related to Latin and Greek and therefore modern English, whereas those of South India are completely different. Also, the subcontinent has attracted visitors and invaders for centuries: Some came in numbers large enough to alter the Indian civilization, while others (merchants or pilgrims) settled there and were absorbed into the diversity of India.

European imperialism and its dehumanizing effects on the colonized are well documented.²⁹ They need no further analysis here; I have experienced it first hand. In the 300 years following the discovery of a maritime route to India by the Portuguese explorer Vasco da Gama, European powers—primarily the British, the French, the Dutch, and the Portuguese—made a beeline for India. Though they ostensibly came for trade and commerce, the lines between exploration and exploitation blurred rapidly. Their focus on the so-called trade devolved into an intense rivalry to loot India's fabled riches, gold, diamonds, art, spices, tea, and cotton. The result was a systematic, almost surgical striping of India's riches. It was theft on a grand scale.³⁰ The Mughals were an exception. The mighty Mughals weaved a fine net of harmony and safeguarded India's culture and integrity.³¹ On the other hand, the British kept Indians at bay in every possible way. The Mughal empire was producing about one fourth of the world's industrial output up until the 18th century when the British showed up. In fact, India's Gross Domestic Product (GDP) had a faster growth rate during the Mughal era than in the 1,500 years prior. While the Mughals served India, the British methodically looted India.

India was the centerpiece of the British colonial empire, its economic crown jewel. India remained essential to Britain's economic well-being, a major market for exports of both goods and capital; it kept its factories humming and bank accounts expanding. All of this helped Britain, but it did not benefit Indians in any way. For example, local textile weavers and manufacturers lost their livelihoods because of cheap cloth imported from Britain. The railroads and telegraph lines in India were useful only for British commerce and administration. Unlike other colonies during the age of British imperialism, India was designed to pay for itself—without direct assistance from the home government or British taxpayers. Under the British rule, India's share of the world economy declined from 24.4% in 1700 down to 4.2% in 1950. During the 1600s, Indian GDP was 60% of British GDP; by the end of the 19th century, it had decreased to less

²⁹Colonialism and imperialism. Available at: <https://www.youtube.com/watch?v=x4DpXd5US9c> (accessed on April 30, 2023).

³⁰Dr. Shashi Tharoor, MP: Britain does owe reparations. Available at: <https://www.youtube.com/watch?v=f7CW7S0zxv4> (accessed on April 30, 2023).

³¹Whenever Indian cinema is discussed, one name always surfaces. It is the 1960 movie, *Mughal-e-Azam* (Urdu, "The Great Mughal"), the gold standard by which all Indian cinema is judged. This magnum opus of cinema remains one of the most impressive works in terms of story, direction, set design, costumes, Urdu and Persian poetry, musical score, songs, and dialogues. In my view, it rivals Hollywood movies like *Gone with the Wind* and *Sound of Music*. *Mughal-e-Azam*. Available at: <https://www.youtube.com/watch?v=e7hP9UNp0Hw&t=1693s> (accessed on May 1, 2023).

than 15%.³² From the 1st century until the start of the British colonization in the 17th century, India's GDP varied between 25% and 35% of the world's total GDP—more than Europe's combined GDP.³³ It dropped to 2% by the time the British hastily departed India in 1947. Few know that a primary cause of India's post-independence poverty is the interest of the loan of INR 1,800 to 2,000 crore for which responsibility of repayment was inherited by the government of independent India, as per the Transfer of Power Agreement.³⁴ These economic examples are merely brushstrokes that paint a picture of how British colonial rule negatively affected India—not only during colonial rule but also after The Partition of India.

The British drained the resources of India, damaged its economy, and financed the British expansion for 200 years.³⁵ In my opinion, nothing good came from the British colonial rule. The British journalist Richard Gott has been unsparing in his denunciation of Britain's imperialism³⁶:

We now know that the British Empire was essentially a Hitlerian project on a grand scale, involving military conquest and dictatorship, extermination and genocide, martial law and "special courts", slavery and forced labour, and, of course, concentration camps and the transoceanic migration of peoples. Whatever way we now look at Empire, this vision must remain dominant.

10.7 India's Independence, Partition of Punjab, and My Exodus from Lahore

There's no place like home.

—*The Wizard of Oz*, 1939.

India is the one land that all men desire to see, and having seen once, by even a glimpse, would not give that glimpse for all the shows of all the rest of the globe combined.

—Mark Twain (1835–1910), American Writer

To other countries, I may go as a tourist, but to India, I come as a pilgrim.

—Martin Luther King, Jr. (1929–1968), American Civil Rights Leader

³²Broadberry, S., J. Custodis, and B. Gupta. (2015). India and the great divergence: An Anglo-Indian comparison of GDP per capita, 1600–1871. *Explorations in Economic History* 55:58–75.

³³Tharoor, S. (2017). *Inglorious Empire: What the British Did to India*. C. Hurst & Co., UK.

³⁴See: Dr. Rajendra Prasad's *India Divided*, originally published in 1946 and reprinted by Penguin Books in 2010 in India, pp. 401–405. This book puts an estimate of public debt at Rs. 2,000 crore (refer to table XLVII on p. 405). To really appreciate the value of 1,800 crore rupees in 1947, one must take into account that the exchange rate of the British pound was 13.50 rupees per pound, the exchange rate for the American dollar was 5.00 rupees per dollar, and pure gold was selling at 88.62 rupees per 10 grams.

³⁵British Imperialism in India. Available at: <https://www.youtube.com/watch?v=6KGdAdX3H8k> (accessed on May 1, 2023).

³⁶Gott, R. (2001). Whitewash. (Book Review). *Ornamentalism: How the British Saw Their Empire* by D. Cannadine, *The Guardian*, May 5th.

After the Second World War, freedom from the British suppression and colonial rule appeared imminent. The Punjabis, who had fought in large numbers for the British in both World Wars, were pressing for freedom. As previously discussed, Punjabis had a military legacy that spanned centuries. Just as they had protected India from earlier invasions, they wanted to defend themselves from British occupation, even if it meant employing brute force. It appeared that the Indian freedom struggle against the British had reached a breaking point (“*If there is no struggle, there is no progress.*”—Frederick Douglass).

But at what cost? As they withdrew, the British proposed carving a new Muslim nation—Pakistan—from India. Lord Mountbatten, the last British Viceroy of India, formally proposed the Partition Plan on June 3, 1947, at a press conference. At that time, he stated that India would become an independent country on August 15, 1947. The two Indian states that would be divided to achieve this would be Punjab in the west and Bengal in the east.³⁷ Pandit Nehru and Mahatma Gandhi (1869–1948) opposed the proposed partition plan of the British colonial government (Photo 9).

Displacement is central to Punjabi identity as it is to Jewish and Armenian identity («...Տնահան արեք ուղարկեք անապատները: Թողեք առանց հացուջրի: Հրդեհեք տներն ու եկեղեցիները: Տեսեք՝ նորից չէ՛ն խնդա, երգի եւ աղոթի: Քանի որ երբ նրանցից երկու հոգի հանդիպեն աշխարհի որեւէ մի վայրում, տեսե՛ք, թե ինչպես են ստեղծելու նոր Հայաստան:» Վիլյամ Սարոյան; translation from Armenian: “*Send them into the desert without bread or water. Burn their homes and churches. Then see if they will not laugh, sing and pray again. For when two of them meet anywhere in the world, see if they will not create a New Armenia...*”—William Saroyan).

Panic crept into the minds of residents in Lahore, Punjab’s ancient capital. I personally recall a pervasive feeling of impending doom. The detailed plans and precise demarcations were kept secret from the public until the very end, which created further confusion and uncertainty. The fate of Lahore hung in the balance. Was Lahore to remain in India or was it to be partitioned into the new nation of Pakistan? With each passing day, it appeared that peaceful coexistence between Muslims and non-Muslims in Punjab was in serious jeopardy. As events unfolded, it became clear that the foolish and hasty decision of the British colonialists to partition Punjab resulted in the mass exodus, ethnic cleansing, and deaths of millions.^{38,39}

³⁷Why was India split into two countries? Available at: <https://www.facebook.com/TEDEducation/videos/why-was-india-split-into-two-countries/2976780925934102/> (accessed on April 30, 2023).

³⁸India and Pakistan: What was partition? Available at: <https://www.youtube.com/watch?v=YkLFGWTKPY4> (accessed on May 1, 2023).

³⁹Pakistan was created through The Partition of India based on religious segregation. This concept of dividing a nation along religious lines resulted in the displacement of fifteen million people, the murder of more than one million, and the rape of 75,000 women. This alone demonstrates that this was a catastrophic error. Opposition to The Partition of India—and its hideous underlying “two-nation theory”—was widespread in British India in the 20th century. It was opposed by most Hindus, Christians, Anglo-Indians, Parsis, and Sikhs, as well as many Muslims.



Photo 9. The land of the sacred Ganges and the towering Himalayas has given the world some personalities whose ideals were as pure as the water of this ancient river and whose aims were as lofty as the mighty Himalayas. This is a classic photo of two such pillars of world history. “Pandit” Jawaharlal Nehru (left) is sharing a joke with “Mahatma” Mohandas K. Gandhi (right) during a meeting of the All India Congress in Bombay on July 6, 1946. The honorific *Pandit* (Sanskrit, “knowledge owner” or “learned man”) has been commonly applied before Nehru’s name while *Mahatma* (Sanskrit, “great-souled”) before Gandhi’s. The mutual respect and admiration of the two remarkable men is apparent. Neither man supported the partition of India. This is one of my favorite photos in the context to Indian independence. The photo was taken by Max Dresier of the Associated Press. Based on this photograph, a commemorative postage stamp was issued by India Posts and Telegraphs Department on August 15, 1973, to mark the 25th anniversary of Indian independence. Then Prime Minister of India, Indira Gandhi (who was Nehru’s daughter), remarked on the stamp’s release, that “in spite of all their external divergence” the two men were “comrades in revolution and the remaking of man.” Few relationships in history have been more emotionally earnest, intellectually intense, and politically productive. In essence, they were master and disciple, spiritual father and son, and fellow pilgrims in search of truth.

By 1946, killings, looting, and destruction of property had started all around us in Lahore. My mother, a devout temple-going person, brought daily news of friends moving from the Krishan Nagar neighborhood in Lahore, where we lived, to the Hindu and Sikh-dominated areas in India. As Secretary of Education with the Lahore Corporation, my father was in a prestigious government position and gauged the situation differently. He told us that we should not give into communal rumors. Nevertheless, the mayor of the Lahore Corporation provided

an armed guard for his protection. Shortly thereafter, the situation quickly worsened in Lahore. Arson and looting commenced in broad daylight, even in our Krishan Nagar neighborhood, which was populated entirely by non-Muslims. We heard news of the impending transfer of power from British to Indian hands. Muslims migrating from eastern Punjab brought tales, often exaggerated, of communal violence. Somehow, I assumed that these things would pass and that life, as I knew it then, would continue as before. However, this dream turned into a nightmare. I realized that the world I had known, and whose continuity I had taken for granted, had ceased to exist. Communities that had peacefully coexisted for a thousand years were caught in the wake of sectarian violence. The mass migration of non-Muslims to the eastern part of the Indian subcontinent had commenced—first as a trickle, later as a wave. This was ethnic cleansing at its worst. Our world was collapsing around us. I recalled my private tutoring at home and newspaper reports, where we learned about the mass-exodus of Jewish communities as Nazism scourged Europe.



By August 13, 1947, Krishan Nagar—my place of birth and my family's residence—had become a ghost town. Although I was not the oldest, my parents often sought my counsel in serious matters. I concluded that we all had to leave. My parents and siblings reluctantly agreed to leave on the evening of August 13th. Once the decision was made, we worked as an efficient team. We managed to grab a few belongings, packed them into cloth bundles, and frantically loaded them onto an abandoned horse cart. Given their youthful ignorance, the younger siblings considered this to be another fun challenge, another bonding opportunity to please the elder siblings. I physically moved everything two miles away to a local high school that served as a temporary, poorly guarded refugee camp. To this day, I do not understand how I found such superhuman strength. It must have been sheer desperation and the will to help the family survive! You can't fight instinct.

Being forced to flee one's home is a life-changing event. It is a terrifying and stunning experience. We reached the crowded and poorly managed refugee camp. Its inhabitants were dazed. Things were in chaos and misery surrounded us. Families literally were pushing against the walls of the camp. (Throughout my life, I have witnessed similar cruel images on TV or in print, the only difference being the geographic location of the traumatized faces.) Once we entered the refugee camp, we claimed a small space of land, spread a few bedsheets, and sat on them in anticipation of assistance. Things had unfolded so quickly. Were we in denial at what had transpired? Were we waiting for a miracle? This was 1947, a mere two years after the Second World War, and the world had no time for "third world" refugees in the Indian subcontinent. Soon the realization set in that we were alone in this mess. Nevertheless, we were overwhelmed by deep anguish to have been driven so mercilessly out the place we fondly called "home."

Amid this backdrop of turbulence, my youngest brother, Devinder Bawa, who was five months old developed a fever of 103°F.⁴⁰ With great difficulty, I managed to locate a cot for him. Sensing his deteriorating condition, the family searched for medical care—a fruitless task in the chaos of a refugee camp. Something needed to be done fast. Then, at grave personal risk, I decided to walk the two miles back to “our” house in Krishan Nagar to fetch medicine and other essentials. The neighborhood was pitch dark on a very warm and sultry August night. Not a soul was around. The sizeable population of stray cats and dogs normally found in the neighborhood had dwindled remarkably. Miraculously, I returned to the refugee camp with the essentials in hand and without incident. This proved to be pivotal in my brother’s recovery. Devinder’s shivers became less intense, and he started to show signs of life again. This settled us down a bit, and we dozed in and out of sleep. Even on the summer night, the temperature had dropped, and we could feel the freezing air against our cheeks. In the moonlight, the faces and eyes of the refugees reflected their helplessness. You could hear sobbing and children crying (“*Not all screams are heard...Not all prayers are answered.*”—Grace Andren). It was a quest for survival. We all were too numb to feel anything, too fatigued to express the palpable grief, too broken to beg, too traumatized to contemplate our future.

Merely one day later (August 14, 1947), as the conditions both inside and outside turned treacherous, we felt the need to depart from the refugee camp. Clearly, the governmental void had resulted in a deterioration of law and order. The meager resources allocated for the refugee camp had diminished. There was no real government. No one could ensure our safety. During the night, we could hear looting taking place in the nearby neighborhoods. Vagabonds roamed the streets with impunity, robbing, molesting, and worse. People wrote their names on houses that had been deserted, claiming them as their own. We were unsure about what to do. We clung together as a group, grasping onto the few bundles that were now our sole possessions (our home had been seized at that point). But family was most important to us; we were all alive and together. We ate some of the dry fruit and stale bread that we had brought with us two days back. Obtaining clean water was virtually impossible. The day blended into the evening. Then, just a few minutes before midnight of August 15, 1947, someone nearby

⁴⁰There is a story tied to Devinder that unfolded three decades later. In an interesting twist of fate, in the late 1970s, Devinder married Sunita Bhatia (now Sunita Bawa), a graduate student in the Microbiology Department at Panjab University. The Microbiology Department was located on the same floor as my Biophysics Department. Devinder, who became an engineer and worked at Ford in the US, was visiting me in my office and saw Sunita. He wanted to see if I could arrange a meeting. I approached my colleague, Dr. D. V. Vadhera, Professor and Head of the Microbiology Department. As they say, the rest is history. I must add that five years earlier, I was on the joint admissions committee, interviewed Sunita, and signed off her admission as an undergraduate to the Microbiology Department. The Basic Medical Sciences building housed four basic medical science departments of the university—Biophysics, Microbiology, Pharmacy, and Biochemistry, and a joint admissions committee interviewed all top applicants.

turned on a radio and a cracking voice came on. It was Pandit Nehru and we were about to hear one of the greatest speeches of the 20th century. It was his iconic speech about the denouement of the British colonial rule in India⁴¹:

Long years ago, we made a tryst with destiny; and now the time comes when we shall redeem our pledge, not wholly or in full measure, but very substantially. At the stroke of the midnight hour, when the world sleeps, India will awake to life and freedom. A moment comes, which comes but rarely in history, when we step out from the old to the new—when an age ends, and when the soul of a nation, long suppressed, finds utterance...

Unsure of our next move and fearing for our safety in the now-muddy refugee camp, we barely slept after Nehru's landmark oration. Later that day, Louis Mountbatten lowered the Union Jack as the last Viceroy of British India and hoisted the Indian tricolor flag as the first Governor-General of free India. The newly composed Indian national anthem, written by Nobel Laureate Rabindranath Tagore, played in the background.⁴² The first stanza of the national anthem referenced "Punjab:" जन-गण-मन अधिनायक जय हे, भारत भाग्य विधाता! पंजाब-सिंध-गुजरात-मराठा... (Hindi, "Thou art the ruler of the minds of all people, dispenser of India's destiny. Thy name rouses the hearts of Punjab, Sindh, Gujarat, and Maratha..."). The British rule in India began in 1757, when the [British] East India Company had commenced with control over the country. The Company ruled India for 100 years until the British Crown replaced it following the Indian Mutiny of 1857–58, which was India's First War of Independence. Although freedom had come to India on August 15, 1947, we in the refugee camp had mixed feelings, for our beloved Punjab state had been partitioned. The butterfly had lost its wings ("*Nations are born in the hearts of poets; they prosper and die in the hands of politicians.*"—Muhammad Iqbal).

At daybreak, fearing for our safety in the refugee camp, we reluctantly decided to depart Lahore, now a part of Pakistan. My father, still believing in the goodness of men and hoping to return to our home in Krishan Nagar two miles away, decided to stay back in the refugee camp. With unimaginable grief and tears, the rest of the family left the refugee camp and Lahore forever on the afternoon of August 15, 1947. India was now independent of the British colonialists, but we were refugees with an uncertain future and an unknown destination. Even today in 2023, more than 75 years later, the memory of this painful exodus is vivid in my mind: It haunts me when I see similar events unfold on TV.

⁴¹"Tryst with Destiny" was an English-language speech delivered by Jawaharlal Nehru, the first Prime Minister of India, to the Indian Constituent Assembly in the Parliament House in Delhi on the eve of India's independence before midnight on August 14, 1947. Available at: <https://www.youtube.com/watch?v=lrEkYscgbqE> (accessed on May 1, 2023).

⁴²Eminent artists, actors, and sportspersons contribute to The Official Anthem of #HarGharTiranga. Available at: <https://www.facebook.com/gkishanreddy/videos/eminant-artists-actors-sportspersons-contribute-to-the-official-anthem-of-hargha/625334715975134/> (accessed on May 1, 2023).

We boarded a military truck, still clinging to our few bundles of belongings. Everyone was packed like sardines. The humidity and the bright August sun were merciless. We were part of a military convoy, supposedly taking us to somewhere in India. Everyone appeared dazed by lack of sleep and from the uncertainty of where we were headed. On our way to the newly established “unofficial” international border, we passed the famous Lahore Canal. On its banks each summer, we used to have picnics and mango parties. We would keep the mangoes in ice water to cool them down. Oh, such sweet memories! As we drove on, I saw refugees travelling in both directions—towards India and Pakistan—on foot and in bullock carts (Photos 10–13). We felt lucky to be in the relative comfort and safety of a military vehicle. I also witnessed scenes that are too difficult to fathom or describe. Suffice it to say that humans had turned barbaric. A scene that haunts me to this day is that of people cooking food on fires lit for burning dead bodies (“*What the eyes had seen could not be erased.*”—Frank Herbert).

How was it possible for people to do this to one another? On both sides of the border, inhuman incidents had taken place—by Hindus, Muslims, and Sikhs. How could it be that this ancient land, which had produced so many sages—Jain Mahavira, Gautama the Buddha, Kabir, and Guru Nanak—had been consumed in an orgy of violence? I wondered if the voice of sanity was silenced forever. Was Gandhi correct in his Kingsley Hall Speech of 1931: “*In the midst of darkness, light exists. In the midst of untruth, truth exists.*”

As we crossed the border, I realized that I had become a refugee in my own homeland. I was heartbroken at having left our lovely home and the luxurious lifestyle that we had known. After a few hours that seemed like years, we reached Khalsa College, Amritsar.⁴³ There, men and women labored in the sweltering August heat to serve us *daal* (Hindi, “lentil soup”), *roti* (Hindi, “Indian bread”), and water. What a paradox! Here was humanity at its best, serving brothers and sisters; and yet, we had left behind humankind at its worst, butchering each other. Everything seemed so senseless: the murders, looting, and burning. For days, we wandered the streets aimlessly. There were no schools or colleges open. We managed to find an abandoned house, but we knew that our life would never be the same again. My poor mother carried water up four flights of steps; the days of butlers and servants were a distant memory. Food was provided by a local temple.

Almost a year after the Partition, during the summer of 1948, we were traveling to Dehradun in the Himalayas. Near Cheru Bridge, I saw hundreds of steel trunks lying abandoned in the now-dry riverbed. You could see bodies scattered everywhere. The stench was intolerable. Apparently, Muslims traveling in a *kafila* (Urdu, “group”) were overcome by the rising river waters and had tried to escape by climbing onto trees. However, poisonous snakes had also climbed up those same trees. It was a quest for survival. Yet, I could see people down in the riverbed removing jewelry from the dead.

⁴³Amritsar lies about 15 miles (25 km) east of the international border with Pakistan and where the Jallianwala Bagh massacre took place in 1919.



Photos 10–13. Photographs depicting one of the biggest mass migrations in history, triggered by Britain's chaotic withdrawal from India in August 1947. People who lived together for centuries were forced out of their homes as one of the largest and most ethnically diverse nations in the world was divided ("The Partition"). Mistrust, large-scale violence, and upheaval ensued as millions were uprooted from their homeland. They were forced to escape on foot, bullock carts, and trains across the newly established international border "to nowhere." The horrific event displaced between 10 and 20 million people along religious lines, creating overwhelming calamity in the newly constituted nations of India and Pakistan. Unquestionably, it is one of the largest refugee crises in history. The violent nature of The Partition created an atmosphere of hostility and suspicion between India and Pakistan that affects their relationship to this day (*continued*).



Photos 10–13. (Continued)

Although the British had just ceded the reins of power to the new Indian Government, their indifference to the violence was appalling. Only a few weeks before The Partition, Viceroy Mountbatten, was confident of a peaceful transfer of power, assuring all that he “*shall see to it that there is no bloodshed and riot... that there are no communal disturbances anywhere in the country...*”⁴⁴ The Partition and subsequent rushed British withdrawal led to exactly the opposite result. Mountbatten was wrong; his vision flawed, his misjudgment fatal. But did he really care? Did he lose sleep over the mess that he and his imperial government had created? The new artificial international borders sparked mass migration and widespread sectarian violence that engulfed village after village, private homes, and even women and children, who were once considered beyond the societally constructed boundaries of communal violence. In fact, the traditional forms of violence gave way to genocidal massacres. After The Partition, the fledgling governments of India and Pakistan were left with all responsibility to implement the border. This was not enough to protect the cities much less the caravans of the hundreds of thousands of refugees who continued to flee their homes for months. Scholars have argued that the unprecedented violence was not a sudden wave of anger and madness but was anticipated by the colonial rulers themselves. In any case, the British are to blame for triggering this genocide. I agree that The Partition meets all the elements of genocide.⁴⁵ The Partition was one of the great tragedies of the 20th century.⁴⁶ By some estimates, it created approximately 15 million refugees; around 2 million people died⁴⁷ (“*Мирно они умрут, мирно иссякнут во имя Твое, и за гробом не найдут ничего, кроме смерти. Но мы сохраним тайну, и за их счастье мы прельстим их наградой небес и вечности*”—Федор Достоевский; translation from Russian: *Peacefully they will die, peacefully they will expire in Thy name, and beyond the grave they will find nothing but death. But we shall keep the secret, and for their happiness we shall allure them with the reward of heaven and eternity.*—Fyodor Dostoyevsky).



⁴⁴Jagmohan (2005). *Soul and Structure of Governance in India*. Allied Publishers Pvt. Ltd., Delhi, India, p. 49: “*At least on this question I shall give you complete assurance. I shall see to it that there is no bloodshed and riot. I am a soldier and not a civilian. Once the partition is accepted in principle, I shall issue orders to see that there are no communal disturbances anywhere in the country. If there should be the slightest agitation, I shall adopt the sternest measures to nip the trouble in the bud.*”

⁴⁵Since the scale and level of brutality during the partition massacres was (a) manifested with genocidal tendencies that included mass killing; and (b) designed to obliterate an existing generation and prevent its future reproduction, I label the British Partition of India a genocide. For example, see, Hansen, A. B. (2002). *Partition and Genocide Manifestation of Violence in PUNJAB: 1937–1947*. India Research Press, New Delhi, pp. 195–197.

⁴⁶Partition: The day India burned. Available at: <https://www.youtube.com/watch?v=jGiTaQ60Je0> (accessed on May 1, 2023).

⁴⁷India-Pakistan partition explained. Available at: <https://www.youtube.com/watch?v=OnTYLyNUPMc> (accessed on May 1, 2023).

Amrita Pritam (Photo 8) was a pioneer of modern Punjabi poetry and literature. Her bold, deeply romantic, and spiritual poems have a universal appeal. They are admired on both sides of the Punjab border. Amid communal rioting in August 1947, she evoked the spirit of the 17th century Punjabi Sufi poet, Waris Shah (1722–1798) of *Heer Ranjha*⁴⁸ fame, with her immortal poem titled *Ajj aakhan Waris Shah nu* (Punjabi, “*Today I call forth Waris Shah*”). In this elegy to Waris Shah, she implores him to rise from his grave and rewrite the devastating narrative that marred Punjab during The Partition in 1947. Penned on a piece of paper during a train journey from Dehradun, she expressed her anguish on the genocide in Punjab.⁴⁹

The following are the three opening verses of the poem⁵⁰ in Punjabi and their translation in English:

ਅੱਜ ਆਖਾਂ ਵਾਰਸ ਸਾਹ ਨੂੰ ਕਿਤੋਂ ਕਬਰਾਂ ਵਿਚੋਂ ਬੋਲਾ
 ਤੇ ਅੱਜ ਕਿਤਾਬੇ ਇਸਕ ਦਾ ਕੋਈ ਅਗਲਾ ਵਰਕਾ ਫੇਲਾ
 ਇਕ ਰੋਈ ਸੀ ਧੀ ਪੰਜਾਬ ਦੀ ਤੂੰ ਲਿਖ ਲਿਖ ਮਾਰੇ ਵੈਣਾ
 ਅਜ ਲੱਖਾਂ ਧੀਆਂ ਰੋਈਆਂ ਤੈਨੂੰ ਵਾਰਸ ਸਾਹ ਨੂੰ ਕਹਿਣਾ
 ਉੱਠ ਦਰਦਮੰਦਾਂ ਦਿਆਂ ਦਰਦੀਆਂ ਉੱਠ ਤੱਕ ਆਪਣਾ ਪੰਜਾਬ।
 ਅਜ ਬੋਲੇ ਲਾਸ਼ਾਂ ਵਿਛੀਆਂ ਤੇ ਲਹੂ ਦੀ ਭਰੀ ਚਨਾਬ।
 ਕਿਸੇ ਨੇ ਪੰਜਾਂ ਪਾਈਆਂ ਵਿੱਚ ਦਿੱਤੀ ਜ਼ਹਿਰ ਰਲੂ
 ਤੇ ਉਹਨਾ ਪਾਈਆਂ ਧਰਤ ਨੂੰ ਦਿੱਤਾ ਪਾਈ ਲਾ

*I say to Waris Shah today, speak out from your tomb,
 and let a fresh page unfurl from the Book of Love's womb.
 Just one daughter [Heer] of Punjab's woes caused your laments to flow,
 today a million daughters weep, and you they do implore.
 Arise you chronicler of pain and witness your Punjab,
 where the fields are lined with corpses and blood flows down the Chenab.*

From August until the autumn of 1947, we took refuge with relatives in various villages and rural towns of Punjab, eventually landing in Amritsar. It was a far cry from the carefree life of Lahore. I think it made us grow up much faster than we wished. We also had lost all contact with our father. We were desperate

⁴⁸Waris Shah is longed for by lovers. *Heer Ranjha* is the immortal love legend of Punjab from 250 years ago. The story of *Heer Ranjha* is sung and found anywhere where there are Punjabis and the Punjabi language. Along with other tragic love tales from Punjab such as *Laila Majnu* and *Sassui Punnhun*, this true story is often compared to Shakespeare's *Romeo and Juliet*. The famous song from Bollywood classic *Heer Ranjha* is available at: <https://www.youtube.com/watch?v=WTjNfr449ac> (accessed on May 1, 2023).

⁴⁹In her autobiography, *The Revenue Stamp*, Amrita Pritam recalls the train journey thus: “*Uprooted from Lahore, I had rehabilitated myself at Dehradun for some time. I went to Delhi looking for work and a place to live. On my return journey in the train, I felt the wind was piercing the dark night and wailing at the sorrows the Partition had brought. I had come away from Lahore with just one red shawl and I had torn it into two to cover both my babies. Everything had been torn apart. The words of Waris Shah about how the dead and parted would meet, echoed in my mind. And my poem took shape.*”

⁵⁰*Aaj aakhan Waris Shah nu* (Amrita Pritam)—narrated by Gulzar. Available at: <https://www.youtube.com/watch?v=rBvFabOMPVs> (accessed on May 1, 2023).

to find him. Uncertainty fuels worry and anxiety. Once again, everyone in the family looked up to me for help and once again, I stepped up to the plate. On Diwali⁵¹ of 1947, I returned to Lahore—now in Pakistan—to locate and persuade my father to join us in India. For my safety, I went in an Indian military convoy which handed me over to a Pakistani soldier at the international border. I learned that the refugee camp had been disbanded a few weeks after we left. So, I requested to go to Krishan Nagar instead in hope that my father had taken refuge in our old home or with some Muslim neighbors. I did not know what else to do. I was shocked to learn that the Pakistani soldier did not know how to get to Krishan Nagar. It was because he was a refugee from a farm on the other side of Punjab (East Punjab) and had been in Lahore for only a few months. Somehow, this was now to be his new homeland and he was expected to adjust to city life. Holding back tears, he recounted his lost world. I could relate to his pain. We strangely bonded in those moments, realizing that both of us were pawns of political and religious upheaval. I directed him to Krishan Nagar. When we reached there, I embraced him and quickly disembarked. I was anxious to locate my father. I was not sure if I would find him or if we had lost him to the madness of The Partition. As soon as I descended from the truck into my old neighborhood, by then pillaged, Muslim youths surrounded me. I realized that I was wearing a *khadi kurta-pyjama* (*kurta*, Hindi, “long shirt;” *pyjama*, Hindi, “baggy pants”), a sure sign of being a Hindu or a Sikh. Clearly my life was in jeopardy. Fortunately for me, the youths were called away to help loot a store on the corner. Upon reaching my old street, I was relieved to find out that my father already had left for Amritsar. Somehow, I managed to make it back to India safely without any further incident. In the end, my family had made it out alive. We had lost all our possessions, but we were all together—this was most important (“*Happiness resides not in possessions, and not in gold, happiness dwells in the soul.*”—Democritus). What a great Diwali it was! Adjusting to our *new* homeland was another matter though.

Eventually my father got an excellent job in Rohtak, Punjab (now in the state of Haryana). He was appointed as Secretary, Municipal Corporation, a position second only to the Deputy Commissioner of Rohtak. This high-ranking governmental position provided him with a massive bungalow and all possible amenities, including a house staff. Amazingly, life became comfortable again. Since then, life has rolled on. Most of my ten siblings and elderly mother migrated to the US. My mother died at 100; my father in his late 80s. My sisters and my eldest brother all have passed away. The remaining brothers all reside in the Midwest; most have retired from productive professional careers. I went to

⁵¹Diwali (also called Divali or Deepavali) is the Indian “festival of lights” that celebrates the triumph of light over dark and good over evil. It symbolizes blessings of victory, freedom, and enlightenment. The name comes from *dipavali* (Sanskrit, “row of light”). On the night of Diwali, which is on the day of the new moon when the sky is at its darkest, celebrants decorate their homes with candles and *diyas* (Hindi, “clay oil lamps”), and *rangolis* (Hindi, “colorful art circle patterns”). As children we looked forward to Diwali celebrations mainly because of the dazzling array of Punjabi sweets served at home and the fireworks celebrations in which we all participated in the wee hours of the night.

Columbia and Cornell on a Fulbright Fellowship in 1958 and never looked back. That said, my large family never lived under one roof again as we all had dreamed of while growing up in Lahore.

Navigating life's most difficult challenges is never easy. However, most of the pain and hardships of life were only minor prickles after 1947. Few tribulations ever fazed me again. The potholes that I encountered in my journey felt like minor bumps, the roadblocks mere temporary bypasses to my ultimate destinations.

10.8 Divide-and-Rule: A British Specialty

Make sure you divide India into three, four, five pieces. Make sure you do that.

—Winston Churchill to the Viceroy of India, 1946

Borders certainly are among the most important factors that have influenced the development of world affairs. European expansion in the 18th and 19th centuries imposed new borders on Africa and Asia. Many native people viewed these boundaries as arbitrary and, after independence, continued to contest their legitimacy. At the end of both World Wars in the 20th century, world leaders (especially European colonial powers) drew artificial and impermanent lines separating assorted people around the globe. This has contributed to ethnic cleansing, refugee crises, famines, military conflicts, ecological damage, unemployment, rise of militancy, and much worse.

Punjab always has been a land of shifting borders, culturally as well as geographically. Punjab of both Pakistan and India have borne the unequal burden of The Partition of 1947. The border between India and Pakistan has been disputed ever since. This classic example of an arbitrary border was especially pronounced because there was no geographic reason for the boundary and no history legitimizing it. It was only done to carve out a Muslim-majority state out of India.⁵² In fact, the well-tried, cruel British tactic of “divide-and-rule” was on full display as they made a hasty exit from the subcontinent. Clearly, such lingering effects of British colonial legacy reverberate even today in conflicts ranging from Palestine to Armenia. Borders can physically separate people but rarely prevent their economic, political, social, and cultural interaction. It is hard to split the Punjabis along religious lines when they share much more culturally: food, music, habits, clothing, and language, just to name a few examples.

As discussed, the British partitioning of Punjab in the north-west and Bengal in the east created the Hindu-dominated secular nation of India and a separate Muslim nation of Pakistan (now Pakistan and Bangladesh). It was a plan formed in haste and disregard for those whose lives were split by a line drawn on a map by a London lawyer, Cyril Radcliffe (1899–1977), and his committee of eight judges (Maps 1 and 2). Shockingly, Radcliffe destroyed all his papers related to

⁵²Divide & rule: Rajmohan Gandhi. Available at: <https://www.youtube.com/watch?v=roISI9RjHJ4> (accessed on May 1, 2023).

his work on The Partition of India before he departed India on Independence Day itself. What was he trying to hide? According to the veteran journalist and author Kuldip Nayar (1923–2018), Radcliffe flew over these parts of northern India only once in a Dakota before demarcating borders.⁵³ He had never even been east of Paris. Remarkably, he admitted that he lacked fitness for the Indian climate, and was eager to depart India. He constantly complained that the time at his disposal was so short that he could not do an adequate job. Although I lived through the horrors of this mess, all of this is incredible to me even in 2023! Why was Radcliffe in India in the first place? Should the demarcation representing 175,000 square miles (450,000 km²) of territory with 88 million people have been handled by such an ill-prepared and incompetent person? Why was he provided outdated maps and inaccurate census figures to do a rush-job of gigantic consequences in a mere 36 days? Apart from Radcliffe, I also place the blame on the British government for their appalling indifference for appointing him and for Mountbatten for pressuring him to conclude his assignment at the earliest (“*To avoid criticism, do nothing, say nothing, be nothing.*”—Elbert Hubbard).

In 1987, forty years after The Partition, I got an opportunity to visit Lahore. It was to attend a scientific conference at the Center for Advanced Molecular Biology of Punjab University arranged by my son’s US college roommate, an exchange student from Lahore. I drove in my car from Chandigarh to Lahore with my colleague, the late Dr. P. L. Wahi, who was Director of the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh. Like me, Dr. Wahi was also a refugee from western Punjab (Sargodha). Upon my arrival, we were treated very well and given a fantastic reception, the famous Punjabi hospitality on full display. Between dinner receptions and social events, there were stories to tell and reminiscences to share of my past life in Lahore. Some of the old-timers lamented the lost beauty of the city, its gardens and architecture neglected by a series of corrupt politicians and military dictatorships. The city was certainly more crowded, much noisier, with more dilapidated buildings. My hosts took me to a few of the same *mohallas* (Urdu/Hindi, “neighborhoods”) that I used to frequent as a youngster to pick up legendary Punjabi snacks and dishes: lassi, phirni, chhole bhature, halwa poori, falooda, makhni doodh, samosas, kebab, karrhi, paneer, kulfi, pinni, rabri, kulchas, dahi vada, khoa, paya, sarson da saag, makki di roti, taftan, roti, kachori, aloo parathas, kheer, chure, panjiri, tandoori chicken, pakoras, aloo chaat, jalebis, and so on (Image 3). I sampled some of the food—it tasted the same, if not better! It was as if nothing had changed. But life in Lahore was so different then. In my mind, I made comparisons of life past and present. I visited my old home, which I was able to locate easily, despite the maze of modern construction and large-scale urbanization. It felt as if I had never left, though. I also visited my old school, Government College Lahore, where a group of enthusiastic students gave me a guided tour of the then-famous institution. They asked me if I studied with famous alumni (called *Ravians*), including novelist Khushwant Singh; Nobelists Dr. Har Gobind Khorana and

⁵³Nayar, K. (2006). *Scoop! Inside Stories from Partition to the Present*. HarperCollins, New York, USA.

Dr. Abdus Salam; and legends of Indian cinema, Balraj Sahni and Dev Anand. When I finally located my old classroom, my mind raced with questions: Was this the price of independence? Was it worth it? Was the partition of Punjab and India necessary? The pictures of those horrific days and months still were vivid in my mind, even after four decades. I was overcome with grief and raw emotion; my hosts and students comforted me. It felt like they were my own students back at Panjab University in Chandigarh.



Image 3. A sampling of Punjabi food.

On our final evening, we dined at Faletti's Hotel, Lahore's grand hotel since 1880, where pre-independence society congregated. As I gazed at its marvelous *mélange* of Victorian, Colonial, and Art Deco interiors, my memory, once again, flashed back to those horrific days of August 1947. It was here then that much of British colonial society in Punjab danced to the music of a genteel orchestra—oblivious or callous to The Partition—while the neighborhoods around them burned.

10.9 The Second Partition of Punjab


इक दिल के टुकड़े हज़ार हुये, कोई यहाँ गिरा कोई वहाँ गिरा / *Ek dil ke tukde hazaar hue, koi yahaan gira, koi wahaan gira.*

(*One heart broke into a thousand pieces; some fell here, some fell there.*)

—Qamar Jalalabadi (1917–2003), Punjabi and Urdu Poet

Punjab was a different country for a large part of its history. It was largely distinct from the rest of the area we know today as India. Punjab was under Islamic rule from the 1100s to the 1700s. The first king to shake off Islamic rule over Punjab was Banda Bahadur. From the 1700s to the 1790s, a large part of the then-Punjab was an independent confederation of Sikh States, extending


from Afghanistan in the west up to Rewari, Haryana, in the east. From 1795 onwards, almost all of Punjab from the banks of the Sutlej to the Khyber Pass (near Peshawar) was Maharaja Ranjit Singh's (Image 2) independent country. Although the British had taken over most of India by 1818 (following the Maratha Wars), Punjab alone stood as an independent country until 1845 before it lost the First Anglo-Sikh War. It was only after the Second Anglo-Sikh War of 1849 that the prized Punjab was merged into British India.



Map 4. The Second Partition of Punjab. Note that both “Punjab” and “Panjab” are correct while referring to the state. Map kindly provided by The Panjabi Centre/Desi Radio, UK.

British rule in India finally came to an end in 1947. On the way out, they portioned the subcontinent (Punjab in the west and Bengal in the east). Punjab that was left in India was referred to as East Punjab, while the part that had been carved out into Pakistan was known as West Punjab (Map 4). After 1947, East Punjab was foolishly further reduced in size by shortsighted politicians and religious fanatics. East Punjab was trifurcated into two additional states (Map 4). These two new states were created on a linguistic basis: The hilly regions of Punjab were carved out as *Himachal Pradesh* (Hindi, “snow-laden mountain province”) and *Haryana* (Hindi, “the abode of God”). The sad reality of the British Partition (i.e., The Partition) was that the once-huge Punjab became devoid of

its five rivers and more than half of its land. The Second Partition resulted in a further loss of substantial territory, pride, and economy. This latter mess was the result of the *Punjabi Suba* (Punjabi, “Punjabi-speaking state”) movement, a long-drawn out political agitation launched mostly by Sikhs and the Akali Dal that demanded the creation of a distinct Punjabi state from the newly portioned East Punjab. In my view, the Sikhs, who were accustomed to a privileged position under British colonial rule, had failed to fully adjust to their diminished political status in East Punjab under a Hindu majority. Basically, this calculated move has resulted in two additional sets of political entities: two legislative assemblies, two chief minister posts, and two governorships. The old British trick of “divide-and-rule” was very much alive and too tempting to resist for self-serving politicians; now everyone had their respect fiefdoms. It is ironic that Punjab bore the brunt of The Partition and was at the forefront of India’s freedom struggle (in real numbers of martyrs), only to ultimately be diminished in size and prestige (Map 5).



Map 5. District map of Punjab state in 2023.

I must add that I strongly believe in the Punjabi ideology that is known as *Punjabi-iat*—a vision of Punjabi-speaking people transcending limitations of geography. Maybe someday the butterfly will reacquire its clipped wings and fly again.

10.10 My Education in Independent India

Be aware of your own worth, use all of your power to achieve it. Create an ocean from a dewdrop. Do not beg for light from the moon, obtain it from the spark within you.

—Muhammad Iqbal (1877–1938), Indian Poet of Urdu and Punjabi

We can't change the direction of the wind, but we can adjust the sails.

—Indian Proverb

Although I was a refugee at a chaotic time, I knew my worth. Clearly education was the way out. As I charted the uncertain voyage of my professional career, education and hard work were themes that resonated with constancy. During grammar school in Lahore, I was taught the fundamental subjects: science, arts, history, philosophy, and multiple languages (including Punjabi, English, and Urdu). Most importantly, my education instilled discipline and the motivation to succeed. At home, there was reading of the classics and holy books at night by the light of a kerosene lamp (the Bhagavad Gita, the Holy Quran, the Guru Granth Sahib, and the Holy Bible). Poetry (Urdu, Persian, and Punjabi) and music (American, British, Indian film, and Punjabi folk) was foundational for us. College education was considered essential ("*Education is the best provision for old age.*"—Aristotle).

I always felt a strong inclination toward literature and history, akin to my feelings towards science. As far back as I can remember, though, I wanted to be either a doctor or a scientist. I was always an excellent student and encouraged by my teachers and family to pursue medicine. Very early in my career, however, I became attracted to exploration rather than to medical practice or patient care. I was feeling restless and remember having serious conversations with my parents about what I should do with my life. Should I study medicine, or go into biomedical research? I felt I was taking the easier pathway if I pursued medicine. If I did research, though, I would always face skepticism and challenges from colleagues, who would demand clarity from my scientific investigations and data. This felt much healthier to me, and so I decided to pursue research with a passion. I could imagine wonderful discoveries in the future ("*You see things and you say 'Why?' But I dream things that never were and I say 'Why not?'*"—George Bernard Shaw). Furthermore, our extensive library at home excited me about science and biomedical research. I entered college at the age of 15. At the time of India's independence, I was in the first year of BSc (Honors School) at the prestigious Government College Lahore (Photo 14). The College (now a university) was established in 1864 by the British India government and produced notable scholars.⁵⁴ I must highlight Dewan

⁵⁴Secrets of Lahore: Government College University. Available at: <https://www.youtube.com/watch?v=ErLAlHjKy4&t=355s> (accessed on May 1, 2023).

Anand Kumar,⁵⁵ a gifted teacher of mine at the College, who later became the first long-term Vice-Chancellor of the newly formed Panjab University at Chandigarh in independent India. He served for eight years beginning 1949. A remarkable personality from a royal family, his engrossing lectures were matched by his exceptional presentation style. He was ambidextrous and drew stunning biological images using both hands with different colored chalks on a slate blackboard. I have never witnessed this unusual ability since.



Photo 14. Shown above is Government College Lahore in the 1880s, with its spectacular Gothic architecture. Photo courtesy of the British Library, London.



When I became a refugee and had to migrate from Lahore to the eastern part of Punjab, I continued my undergraduate studies in zoology at the newly formed East Panjab University, based in Hoshiarpur, Punjab. There, a segment of the teaching faculty had relocated from the parent university in Lahore. I was an interested student, full of questions (*“He who asks a question is a fool for five minutes; he who does not ask a question remains a fool forever.”*—Chinese proverb). My reputation for being an outstanding student was cemented after I stood first-class-first (equivalent to *summa cum laude*) during both my undergraduate education (BSc, Honors School, 1949) and my master’s program (MSc, Honors

⁵⁵Dewan Anand Kumar was educated at Cambridge. He was appointed a Reader in the Zoology Department at Punjab University at Lahore in 1920, and Department Head in 1942. In 1946 he was made the Dean of University Instruction (DUI). A few years later, he became the Vice-Chancellor of Panjab University, a time when the university remained scattered at various cities.

School, 1951). As I look back at my MSc graduating class photograph from 1951 (Photo 15), I recall a memorable time in my life: I was 21 years old and proud to celebrate this milestone. Also, I had earned gold medals from Panjab University. Academically, this set the tone for accolades to come.



Photo 15. Farewell to the third year Zoology Honors School class of East Panjab University. This photography was taken in 1951 when East Panjab University was temporarily based in Hoshiarpur, Punjab. It includes faculty and students of the Zoology Department. (Sitting) S. R. Bawa, Bhupinder Sud, S. D. Malik, Dr. Vishwa Nath (principal), N. K. Gupta, Ramesh Satija, O. P. Dhingra. (First Row) Om Bahadur, Rajinder Rishi, Sudershan, F. C. Vohra, Shayama Vermani, Balbir Dhillon, Devki Jolly, Baldev Singh, Karta Krishan, Mohan Lal Jaiswal, Kulbir Singh. (Second row) Joginder Nath, Joginder Singh, Gian Sood, Sohan Lal, Khushi Ram, Ram Parshad, Manohar Lal, S. D. Sharma, Prem Chand, J. L. Gabba. (Third row) Asket Singh, Sarni, Harish Chopra, Swaran Singh, B. S. Bhimber, Jaggi.

I found it relatively easy to breeze through the curriculum, except for the labs, which always required careful application. Those who knew me were convinced that I was destined to do great things. I was lucky to have magnificent teachers, who made their subjects come alive. This was possible, in part, because some had worked in industry and could relate the classroom to the real world more convincingly than our textbooks could. I genuinely looked forward to going to class. It was wonderful to be guided by superb professors, who conveyed complex scientific concepts with elegant simplicity and infused their lectures with flare (*“It is the supreme art of the teacher to awaken joy in creative expression and knowledge. If you can’t explain it simply, you don’t understand it well enough.”*—Albert

Einstein). One professor from whom I learned a great deal was Dr. Vishwa Nath, the Cambridge-educated Zoology Department head who would later become my master's (Photo 15) and PhD advisor. I am grateful to him for his skillful guidance throughout my research and for his many acts of kindness that sustained me in many a moment of doubt that every graduate student or medical student experiences. He was an internationally renowned cytologist and spermatologist. The Indian National Science Academy has instituted the "Vishwa Nath Memorial Lecture" in his honor.

Dr. Nath's patron was Maharaja Sir Bhupinder Singh (1891–1938), the flamboyant and uber-rich ruler of the princely state of Patiala in Punjab. The *Maharaja* (Sanskrit, "great king"), whose reign was from 1900 to 1938, lived an extravagant life of excess. He was owner of the world-famous "Patiala Necklace" designed by Cartier, one of the most expensive pieces of jewelry ever created (Photo 16). It is often said that besides his passions for beautiful women and sparkling gems, the Maharaja's addiction to Rolls-Royce practically kept the firm in business.⁵⁶ I believe that the Maharaja and Dr. Nath got to know each other while the former was a student at Aitchison Chief's College in Lahore. Dr. Nath told me that the Maharaja financed his trip and PhD studies to Cambridge. The two close friends shared a common passion: cricket. In fact, the Maharaja was the captain of the Indian cricket team that toured England in 1911. Even during my college years, Dr. Nath did not miss an opportunity to watch cricket test matches, partake in the sport, or serve as an umpire.

Dr. Nath was a dedicated scientist, who had an incredible aptitude for discovering the right problem and the most elegant experiment to solve it. I was delighted that one of my early publications was co-authored with Dr. Nath and published in *Nature*. After several more papers, visits to other labs, and presentation at various meetings, I began to get a little recognition in microscopy and cell biology research communities. Working under Dr. Nath's supervision not only was rewarding scientifically but also instilled skills that guided me in later years—as when I directed my own large laboratory and electron microscope facility. Dr. Nath taught me order and precision in the laboratory, which served me well throughout my scientific career. In fact, his pedagogy continued to resonate when I started teaching medical students at Cornell University Medical College and, later, biomedical students at Panjab University in Chandigarh. Exposure to a variety of professors, who talked convincingly about all manner of subjects, made me a better teacher. Dr. Nath was particularly brilliant at explaining histological and zoological concepts, as well as newer topics in molecular biology—like the Central

⁵⁶It has been reported that up to one-fifth the number of Rolls-Royce cars that were manufactured before the First World War had Indian owners. Maharaja Bhupinder Singh toured London incognito and went into a Rolls-Royce showroom; the salesman sneered at him and said that the Maharaja should take his leave because he would not be able to afford anything in there. The salesman's manner infuriated the Maharaja, so he ordered 50 Rolls-Royces to be shipped to India where the cars were then used to collect municipal trash. Until a Rolls-Royce representative came to personally apologize to him in India, the garbage collecting job continued for the expensive cars. Source: Indian Auto. Available at: <https://indianauto.com/> (accessed on May 1, 2023).

Dogma, which just had been formulated a few years earlier. To him, I credit my career in research, although there were many other central influences along the way. When my growing appreciation of life in academia inspired me to become a “super teacher,” Dr. Nath was my role model.



Photo 16. Bhopinder Singh, Maharaja of Patiala (c. 1911).

While at Panjab University under the guidance of Dr. Nath, I employed bright field light microscopy to examine Boudin’s osmium tetroxide-fixed and paraffin-embedded testicular cells from a variety of insects. At that time, microscopic images were reproduced by *camera lucida* (Latin, “light chamber”). Around 1953, with the availability of the phase contrast microscope, I demonstrated the existence of fibers and mid-body granules in live spermatocytes of the grasshopper (*Chrotogonus* sp.) and the house cricket (*Gryllus domesticus*). Until that time, cytologists considered them to be artifacts of fixation. Later, also employing phase contrast microscopy, I obtained photomicrographs of various cytoplasmic organelles during spermatogenesis in the firebrat (*Thermobia domestica*).⁵⁷

⁵⁷*Thermobia domestica* (sometimes called firebrat or *Thermophila furnorum*) is a small hexapod (typically 1–1.5 cm) insect. Firebrats look like silverfish but lack the silvery sheen. The firebrat prefers higher temperatures and requires some humidity, and can be found in bakeries and near boilers or furnaces.

During my undergraduate years at East Panjab University in Hoshiarpur (Photo 15) I resided in a large rented residential building known as Amba Bhawan. Here, a few of my zoology classmates and I tried to focus on our studies, though it was a far cry from what would be perceived as today's typical carefree college life. We all shared a common thread, though: We all had been uprooted from various towns of western Punjab (Lahore, Rawalpindi, Peshawar, Gujranwala); we all were often broke; we all had seen grief in our teen years; we all considered education as our ticket to success. Amba Bhawan was located on Railway Road, a few miles away from the temporary university campus. We all walked to the campus. Finally, there was some degree of stability after the tumultuous few years following The Partition. Another advantage was that we all were zoology students and could exchange class notes and textbooks. Some of the upperclassmen would tutor the lower classmates. During this time, one bizarre episode is worth mentioning. One morning, as I stepped out of the shower and onto the interior courtyard, I came face-to-face with a tiger. I was stunned and froze in terror. Thankfully, it turned out to be an escaped circus tiger, and after a few seconds that felt like minutes, the tiger simply turned away and scaled the six-foot-high wall. I quickly entered my room, dressed, and described the incident to my housemates. They initially joked with me that I must have mistaken a cat for a tiger since I did not have my glasses on.

After obtaining my master's degree, I decided to sit for the prestigious Indian Military Academy (IMA) examination (Photos 17 and 18). Established in 1932 and located in Dehradun, the 1,400-acre IMA trains officers for various branches of the Indian military. The selected cadets undergo rigorous training after which they are permanently commissioned as lieutenants. The IMA's mission is to train future military leaders of the Indian Armed Forces. Specifically, I was interested in joining the Indian Air Force. I prepared for the grueling written examination taken at Ambala Cant. To the surprise of many, I passed it with flying colors. After clearing the written exam, I went to Delhi for further evaluation and physical fitness tests. I passed these successfully as well, thereby followed by a few assessments at the Air Force Selection Board (AFSB). I survived these also. Then, I had to undergo certain medical tests to make it to the merit list to finally join the Armed Forces. It is at this final stage that I failed my eye exam and was not selected. Some of the candidates who cleared this final hurdle eventually rose to the highest ranks in the Indian Air Force.

10.11 My Life with Microscopes: An Ongoing Affair

I have always been impressed with microscopes, stains, microtomes, and micrographs. Early on, I realized that the biochemist's view of the cell was, at best, a blurry one (*"A picture is worth a thousand words."*—Fred R. Barnard). Moreover, my relative lack of fluency in biostatistics and higher mathematics was apparent (*"True knowledge is to be aware of one's ignorance."*—Rudolf Virchow, letter to his father, c. 1830s).⁵⁸ Hence, I decided to focus on microscopy, histology, and cell

⁵⁸This is ironic because my father, Bhagat Ram Bawa, not only was brilliant at mathematics but also had authored a few textbooks on mathematics and physics that were standard reading in high schools in Punjab from the 1940s until the mid-1970s.



Photo 17. Aerial view of the Indian Military Academy (IMA) in 1932, the year it was established by General Sir Philip Chetwode, the Supreme Commander-in-Chief of the British India Army. The IMA was established for the training of Indian gentlemen as officers independent of the Royal Military Academy Sandhurst (RMAS), the British Army's initial officer training center. The photograph is courtesy of the estate of Colonel A. J. G. Bird of the Bengal Sappers and Miners, 1922–1932.



Photo 18. Air Force Candidates' Selection Board in Dehradun, February 6, 1952 (Batch No. FAG/5083). I am seated second from the right.

biology. The study of cells and tissues became a part of my life. My fascination and affair with microscopy and cell biology began in earnest during my graduate school years in India. During my early research years, a lot of these instruments were off-limits in the lab, available only to professors and postdoctoral fellows—and only at the universities with well-funded research facilities.

The light microscope (or optical microscope) can be used to view living and dead specimens (Images 4 and 5). While the transmission electron microscope (TEM) uses an electron beam to visualize the specimen, the light microscope employs a light beam to illuminate it. Also, the magnification is much lower than that of an electron microscope. The electron microscope is useful for viewing intracellular components not visible via light microscopy (Image 6). Electron microscopy commonly magnifies 100X to 300X more than the highest magnification of light microscopy. Typically, the sections must be ultra-thin cut to allow adequate penetration of electrons. The histological stains most useful for electron microscopy are those with heavy metal salts, as they create a phase-contrast needed to visualize structures. TEMs are better for investigating internal structures (Image 7), while scanning electron microscopes (SEMs) are typically the choice for topology or surface structures (Images 8–10). TEMs have accelerating potentials of several thousand volts and produce an electron beam that penetrates tissue and cell slices/sections of ~0.2 nm thicknesses. The development of high-voltage electron microscopes (HVEMs) in the 1970s was a major advance in microscopy. The HVEM was capable of accelerating electrons over a potential of one million volts, making it possible to study the specimens having the thickness of whole cells. Basically, the interior of the cell is revealed in depth. I was lucky to have access to HVEMs soon after the first prototypes were available for biomedical research: first in 1980 at the University of Wisconsin-Madison in the Hans Ris Lab and, later, in the 1990s at Wadsworth Laboratories in Albany, New York. These microscopes are quite spectacular, usually occupying two floors of a laboratory (they are approximately 30 feet tall) and weighing about 20 tons.

The major limitations of biological electron microscopy are due to the damage that high-energy electrons inflict on the specimen and that the liquid water present in the biological sample cannot be retained in the high vacuum of the microscope. Since my Columbia days in the early 1960s, cryo-electron microscopy (cryo-EM) had been considered a potential route to overcoming both of these limitations.⁵⁹ In the early 1980s, while I was at Downstate Medical Center in New York City and at the HVEM Facility of the University of Wisconsin-Madison, it was discovered that biological specimens can be vitrified for cryo-EM whereby water is immobilized in a vitreous state in which biological structures appear perfectly preserved. As a result, I started to employ cryo-EM in my research around the early 1980s. This finding also opened the avenue that led around 2010, through the contribution of researchers like Dr. Richard Henderson and Dr. Joachim Frank (who was at Wadsworth Laboratories in Albany when I worked there), to major advances in molecular structural biology and eventually to the 2017 chemistry Nobel Prize.

⁵⁹Fernandez-Moran, H. (1960). Low-temperature preparation techniques for electron microscopy of biological specimens based on rapid freezing with liquid Helium II. *Annals of The New York Academy of Sciences* **85**:689–713.



Image 4. The hand-crafted, leather, and gold-tooled Hooke microscope, originally manufactured by Christopher White of London. Hooke is believed to have used this microscope for the observations that formed the basis of his book *Micrographia*. Photographed at the National Museum of Health and Medicine, Silver Spring, Maryland.




Image 5. General view of an early light microscope with various attachments.




Image 6. Size does matter. The relative sizes of various microscopic and non-microscopic objects. Note that a typical virus measures about 100 nm, 10 times smaller than a typical bacterium (~1 μm), which is at least 10 times smaller than a typical plant or animal cell (~10–100 μm). Most microbes are unicellular and so small that they require magnification to be seen. However, there are some unicellular microbes that are visible to the naked eye, and some multicellular organisms that are microscopic. An object must measure about 100 μm to be visible without a microscope, but most microorganisms are many times smaller than that. For some perspective, consider that a typical animal cell measures roughly 10 μm across but is still microscopic. Bacterial cells are typically about 1 μm, and viruses can be 10 times smaller than bacteria. Courtesy of OpenStax.



Image 7. This historic 1965 image depicts a transmission electron microscope (TEM). This remarkable instrument uses a beam of electrons that passes through an extremely thin specimen and on to an imaging surface. Rather than having a glass lens focusing the light (as in the case of a light microscope), the TEM employs an electromagnetic lens which focuses the electrons into a very fine beam. Sometimes a fluorescent surface is used, and at other times a sheet of photographic film, or in the case of modern-day technology, a digital camera captures the image. The electron microscope can reveal details that are tens of thousands of times smaller than can be seen by even the highest quality light microscope. TEMs can magnify objects up to 2 million times. Image courtesy of the Centers for Disease Control and Prevention.




Image 8. SEM of *Escherichia coli* (*E. coli*). Low-temperature electron micrograph of a cluster of *E. coli*, magnified 10,000X. *E. coli* is a Gram-negative, facultative anaerobic, rod-shaped, coliform bacterium that is commonly found in the lower intestine of warm-blooded organisms. There are six classic pathotypes of *E. coli*: enteropathogenic *E. coli* (EPEC), Shiga toxin-producing *E. coli* (STEC), enteroaggregative *E. coli* (EAEC), enterotoxigenic *E. coli* (ETEC), enteroinvasive *E. coli* (EIEC), and diffusely adherent *E. coli* (DAEC). Most *E. coli* strains are harmless, but some serotypes (EPEC, ETEC, etc.) can cause serious disease. The harmless strains are part of the normal microbiome of the gut and can benefit their hosts by producing vitamin K2, and preventing colonization of the intestine with pathogenic bacteria, having a mutualistic relationship. *E. coli* is expelled into the environment within fecal matter. Courtesy of the Agricultural Research Service of the US Department of Agriculture and Wikipedia.




Image 9. Scanning electron micrograph of methicillin-resistant *Staphylococcus aureus* (MRSA) and a dead human neutrophil. Courtesy of the National Institute of Allergy and Infectious Diseases.




Image 10. This digitally colorized SEM image depicts a number of corkscrew-shaped, *Leptospira* atop a 0.1 μm polycarbonate filter. Courtesy of Janice Haney Carr, Centers for Disease Control and Prevention.

Histology—sometimes referred to as microscopic anatomy or histochemistry—is the microscopic visualization of tissue structure and the characteristic changes that tissue may have undergone. The tissue sample processing involves sequential steps of fixation, embedding, sectioning, staining, and microscopic examination (and sometimes antigen retrieval). Today, in a modern histology laboratory, most of these steps are automated. However, for a large part of my scientific career, this was not the case.

All chemicals in a laboratory setting should be handled appropriately. Current safety guidelines are a must for success in the laboratory or clinic. I feel a need to add this short note of precaution here as my extensive experience in the lab has shown me that often proper protocols for handling toxic chemicals are not fully followed. Stains, fixatives, and embedding agents employed in microscopy can be toxic. The introduction of the fixation of tissue with osmium tetroxide by Nobelist Dr. George Palade in the 1950s ushered in the modern era of electron microscopy of biological materials (Photo 19). However, a need for greater contrast and greater resolution in visualizing internal membranous and other structures has led to the introduction of methods for staining with heavy metal salts to enhance cell ultrastructure. Glutaraldehyde and osmium tetroxide fix cells by cross-linking their proteins via the amine groups (glutaraldehyde) or their phospholipids (osmium). Fixatives are harmful, volatile agents that can fix any cell they contact, including respiratory epithelium, corneas, and skin epithelial cells. On the other hand, the plastics used to embed tissue are often carcinogenic. During the embedding process, these plastics are dissolved in solvents that can penetrate through any plastic glove and exposure to them often causes permanent damage.




Photo 19. Giants of Electron Microscopy. Photographs of Nobelist Dr. George Palade (1912–2008) (top) and Nobelist Dr. Ernst Ruska (1906–1988) (lower left). Dr. Palade, “the father of modern cell biology,” shared the 1974 Nobel Prize in physiology or medicine with Dr. Albert Claude and Dr. Christian de Duve “for their discoveries concerning the structural and functional organization of the cell.” The first operational electron microscope was constructed by Dr. Ruska and Dr. Max Knoll in 1932 and, six years later, Dr. Ruska had the first version of it on the market. A later generation Ruska high resolution electron microscope from around 1934 is shown above (lower right). In 1986, Ruska received the Nobel Prize in physics for his “fundamental work in electron optics and for the design of the first electron microscope.”

Medical histology—that is, tissue studies in which the samples are obtained from a patient—involves findings that are interpreted by a pathologist. The histochemical analysis of a tissue specimen allows the pathologist not only to diagnose but also to determine the severity of disease. Advanced interpretation in conjunction with a patient’s medical history ultimately dictates the prognosis and treatment course. Obviously, the choice of histological stains for a given specimen depends on the investigational question at hand. Special stains for specific tissues not only aid in distinguishing structural alterations therein but also alert the physician to alterations in cellular physiology, both of which are highly relevant to making a diagnosis. In my view, histological examination and, subsequently, staining are the gold standard for the diagnosis of many pathological diseases. While we may automate the various tissue processing steps, or even incorporate the over-hyped Artificial Intelligence (AI) for data interpretation, I am concerned about over-reliance on technology in medical histology and pathology.

In contrast to AI and high-throughput technologies, I hold high regard for the microtome, which is a sophisticated cutting instrument used for sectioning a block of embedded tissue (i.e., paraffin-embedded, plastic-embedded, or frozen tissues). In a microtome, a sharp knife and the tissue block are held in a fixed orientation relative to each other, and with each pass of the tissue past the knife, the tissue block is advanced by a preset distance—the section thickness. For frozen sections, the section thickness typically ranges 8–15 μm , for wax sections 4–10 μm , and for plastic histological sections 0.5–3 μm . Typically, plastic sections used in TEM are in the range 60–100 nm.

I started my work in microscopy prior to the development of microtomes. It was the era of the “glass cutting edge.” With it, I was able to cut thin sections more consistently, easily, and rapidly than with steel microtome knives. During my graduate school years, I relied on “glass knives” that I had obtained by simply breaking them from a strip of glass.⁶⁰ It was well recognized that fewer grooves or scratches are found on the face of a block of tissue after it has been cut with the glass edge. Glass knives are inexpensive. They are produced by breaking a strip of plate glass, whose subsequent edges will form clearance facets. Fractures generally are smooth and straight. Any competent glass cutter with standard equipment can produce these knives from stock plate glass. When I moved to New York City for my postdoctoral studies, I created my own glass knives for microscopy. Although unsafe, I would often enter demolished buildings to retrieve broken glass, which would then be crafted into glass knives in the lab. Such adventures by graduate students or post-doctoral fellows are no longer tolerated. In fact, they could be the basis of immediate expulsion or termination.

Since I first employed microscopy in 1951, I have witnessed numerous variations and technological advances in microscopy (Images 11–13). Examples include electron and scanning probe microscopes. Those wonderful machines—that allow us to peer at objects on the atomic and nanoscales—traditionally have been large and expensive. Increasingly, microscopic engineers and developers

⁶⁰Latta, H., and J. F. Hartmann. (1950). Use of a glass edge in thin sectioning for electron microscopy. *Experimental Biology and Medicine* 74(2):436–439.




Image 11. Fragile X chromosome made visible by atomic force microscopy (AFM). The arrow indicates the fragile site. Micrograph courtesy of Dr. Ben Oostra.




Image 12. Internal structure of a human immunodeficiency virus (HIV) particle showing the capsid surrounding the RNA-containing core in red and the membrane in blue. The yellow area is electron dense material, including proteases, between the core and the membrane. This false-color micrograph is courtesy of Stephen Fuller.




Image 13. Super-resolution optical micrograph of DNA stain in a human fetal lung fibroblast nucleus acquired with 3D structured illumination microscope (3D SIM). A rare phenomenon has occurred in this image; the majority of the genome has been caught in misreplication. If a single chromosome becomes caught and pulled between the two new cells, it can lead to the presence of small chromatin threads/bridges joining the adjacent nuclei. This leads to clearly demarcated chromatin fiber visible throughout the interior of the nucleus, and as the new cells move apart, the tension distributed by the cable-like chromatin deforms the entire nuclear envelope. The width of the image is 84 μm . Micrograph courtesy of Ezequiel Miron, University of Oxford.




Image 14. An artist's rendition of a coronavirus. Courtesy of Wikimedia.




Image 15. SARS-CoV-2 and the cell. (a) Electron microscopy plays an important confirmatory role in diagnosis and determining subcellular localization. A false-color transmission electron micrograph of SARS-CoV-2 isolated from a patient. Coronaviruses are approximately 80–120 nm in diameter. (b) A false-color scanning electron micrograph of an apoptotic cell (green) infected with SARS-CoV-2 isolated from a patient. The virions can be observed as small yellow spheres. (a) and (b) are courtesy of NIAID. (c) Fluorescence microscopy can show subcellular localization. Co-localization of FLAG-tagged SARS-CoV-2 protein Orf6 with nuclear pore complex protein Nup358 in HEK293T cells as imaged by stimulated emission depletion (STED) super-resolution microscopy. The scale bar in the left-most panel is 5 μm . Scale bar in the magnified panels is 1 μm . This panel is adapted from Miorin, L. et al. (2020). *PNAS* **117**:28344–28354.




Image 16. Digitally colorized transmission electron micrograph of SARS-CoV-2 virions. Virion nanoparticles, isolated from a patient in the US, are shown emerging from the surface of cells cultured in the lab. The coronae (bluish) are visible on the surface of the virus (yellow-red). Courtesy of the National Institutes of Health.

are introducing smaller, less expensive, and sometimes portable versions of these devices. Last year, I read a report from Washington University in St. Louis about the Vortex Microscope, which captures 3D motion of molecules in a liquid. Advances in cryo-EM, driven by single-particle analysis and *in situ* tomography, have been phenomenal since I used them in the late 1990s. For example, cryo-EM has contributed to antibody development against the SARS-CoV-2 spike protein (Images 14–17).⁶¹ I have also recently seen reports that electron microscopy of biological tissue of large tissue blocks (e.g., whole brains) is underway. In my view, this has a long way to go because homogeneous, high-quality electron microscopy staining of large biological samples will be a major challenge. I recently visited the Advanced Imaging Center at the prestigious Howard Hughes Medical Institute (HHMI) Janelia Research Campus close to my home here in Ashburn, Virginia. The HHMI houses a marvelous collection of well-maintained, cutting-edge microscopes. Currently, I am putting the finishing touches on a manuscript for publication pertaining to acrosome formation in spermiogenesis. My affair with microscopy continues...




Image 17. The peplomers of a SARS-CoV-2. This classic illustration reveals the surface morphology/topography of the virus nanoparticle. Note the spikes that adorn the outer surface of the virus impart the look of a corona surrounding it when viewed electron microscopically. A peplomer (Greek, *peplos*, “robe,” “[woman’s] dress” + *meros*, “part”) is one of the knoblike spike structures (red, orange, yellow), generally composed of glycoproteins (spike protein) and projecting from the lipid bilayer of the surface envelope of an enveloped virus. Peplomers play important roles in the infection process. Courtesy of the Centers for Disease Control and Prevention.

10.12 The Passage from India

I arrived in the US in 1958. It was my first trip abroad, and I had been awarded the prestigious Fulbright Fellowship to do postdoctoral work at Columbia University. I traveled by a cargo ship that, in addition to cargo, comprised eight passengers,

⁶¹Bawa, R., Editor. (2022). *Advances in Clinical Immunology, Medical Microbiology, COVID-19, and Big Data*. ISBN. Jenny Stanford Publishing, Singapore.

a few crew members, and the boat captain. We embarked on our voyage from Bombay Harbor, travelled through the Suez Canal, and arrived in New York Harbor after a month's journey. The voyage only could be described as "hell." There were few comforts, and seasickness was the name of the game. Eventually, we were greeted by the bright lights of New York Harbor—a spectacular image that is etched in my mind to this day. I initially stayed with Dr. Roop C. Sawhney in his elegant apartment on the Upper East Side. Dr. Sawhney was a Professor of Mathematics at NYU, and I owe much gratitude to him, as he facilitated a smooth transition to life in the Big Apple. He taught me how to elegantly dress for cold weather, how to properly eat steak, how to open a bank account, and how to safely drive. He was a bachelor and took me everywhere. I observed him closely and absorbed everything like a sponge. Four months later, my wife and young daughter joined me in New York, and we moved into a lovely flat on Riverside Drive (Manhattan) close to the Juilliard School of Music. My wife soon started working as Assistant Teacher at the Nursery-Kindergarten of Riverside School. Life was good (Photo 20).



Photo 20. With Rani in New York City, 1960. In 1947, we were both refugees in our own country, children of colonialism and scarred by the horrific partition of our beloved Punjab state. A decade later in 1958, we were in New York City—a city full of life, hope, vibrance, and diversity. We were excited to make a brand new start. Sampling the city's food, art, music, culture, and neighborhoods was a treat. We were redefining the present and creating our future. A decade later in 1969, at the age of 38, I was a Professor and Department Head. I had fulfilled my dream of being a tenured university professor. Over a period of two decades, I had moved from a refugee camp to the Ivory Tower. It felt that I was the king of the hill and top of the heap. I owe much to the Great City. (*"If I can make it there, I'll make it practically anywhere. It's up to you. New York, New York."*—Frank Sinatra).

New York City was the biomedical mecca in the early 1960s. At that time, numerous pioneers and eminent researchers in biomedicine, anatomy, electron microscopy, and cell biology worked at Columbia, Cornell University Medical College, and Rockefeller University—all outstanding research institutions within

a one-mile radius. At Columbia and Cornell, I had the rare opportunity to work with the eminent minds of cell biology and microscopy.

Electron microscopes were developed in the 1930s, as the collaborative product of innumerable scientists—a truly international endeavor. The first electron micrographs were published in 1940 in Germany, and they were of bacteriophages. Cell biology emerged as a modern field after the electron microscope became more widely available in the 1940s and 1950s. The electron microscope gained prominence in biomedical research when Nobelist Dr. George Palade and Dr. Fritiof S. Sjöstrand independently published the first high-resolution micrographs of mitochondria in *Nature* in 1952 and 1953, respectively. Dr. Fritiof S. Sjöstrand (Photo 21) was a pioneer of electron microscopy and biomedicine. Dr. Sjöstrand, Dr. Keith Porter, and Dr. Palade constituted the “Big Three” in the 1950s for their exploratory use of the electron microscope to describe the details of cellular structure that anchored the burgeoning field of cell biology. Dr. Sjöstrand’s work in the field of biological electron microscopy led to several pioneering developments and discoveries. As indicated above, in addition to producing the first high-resolution electron micrographs of biological tissue, he invented the “Sjöstrand Microtome” for ultra-sectioning biological tissue (Photo 21), was the first to describe the mitochondrial membranes (Image 18), and studied retinal synapses. Dr. Sjöstrand founded the *Journal of Ultrastructure Research* in 1957 (now *Journal of Structural Biology*). I extensively published in *Ultrastructure Research* and served on its editorial board from 1969 to 1985. Dr. Sjöstrand visited me at Panjab University several times, and I was a visiting professor in his lab at UCLA. In recognition of his remarkable contributions to the development of electron microscopy, the *Annual Sjöstrand Lecture* series was set up in 2018 in Sweden.




Photo 21. With my colleague, the distinguished Dr. Fritiof S. Sjöstrand (left) at the 12th International Congress on Electron Microscopy in August 1990 in Seattle. In the early 1950s, Dr. Sjöstrand developed an advanced microtome for thin sectioning, dramatically improving ultrathin sectioning with minimal distortion. He then engineered the next generation of microtomes using electrical heating of the specimen to advance it toward the knife, and the instrument became known as the “Sjöstrand Ultramicrotome” (right).




Image 18. An electron micrograph depicting sperm mitochondria essential for sperm motility. Mitochondria are organelles surrounded by double membranes, distributed in the cytosol of most eukaryotic cells and convert the potential energy of pyruvate molecules into ATP. A sperm cell contains around 50–75 pieces of mitochondria in its midpiece. The structure and function of the sperm mitochondria and mitochondria in somatic cells are basically similar. The sperm mitochondria generate ATP for the movement of the sperm. Mitochondria contain their own DNA (mitochondrial DNA), are semiautonomous, and have the capacity to replicate, divide, and fuse independent of the somatic nuclear division cycle. Further details: Bawa, S. R., and G. Werner. (1988). *Journal of Ultrastructure and Molecular Structure Research* **98(3)**:281–293.



My first encounter with a transmission electron microscope (TEM) happened in 1958, while I was at Columbia's Department of Zoology. This is exactly where I wanted to do my postdoctoral studies. Being a zoologist, I had extensively consulted the 3rd edition of Dr. Edmund B. Wilson's classic text, *The Cell in Development and Inheritance* (1925), one of the most influential textbooks in modern biology.

I cherished Wilson's book and often read it aloud to my microscopic anatomy students. Dr. Wilson⁶² was Professor of Zoology at Columbia in the 1890s, hence my attraction to the department.

My mentor at Columbia was the word-renowned anatomist Dr. Arthur Pollister, Professor and Chair of the Department of Zoology. He correctly predicted that chromosomal DNA carried the genetic information of the cell. Remarkably, this was done via microscopes and chemical dyes alone, in the absence of any X-ray diffraction studies or chemical analyses. In this context, it is worth referring to his obituary in *The New York Times* of October 22, 1994:

Dr. Pollister was among the first scientists to use the electron microscope in biological research. In 1949, he led a team that built an electronic device employing both visible and invisible light to determine the quantities of the constituents of a cell. Named the micro-spectro-photometer, it was sensitive enough to "weigh" quantities of a single cell's components existing in less than one-trillionth of an ounce. That made it possible to determine with unprecedented precision differences in the constituents of normal and diseased cells. Dr. Pollister's device, which took seven years to develop, advanced the studies of cells for research on cancer, anemia, genetics, biology, biophysics and related fields. Within a year, his team located and estimated the amount of DNA, the vital chemical substance that is responsible for hereditary control of life functions. He and his colleagues invented cutting techniques and "glass knives" that cut biological samples thin enough to view with the electron microscope. Using slices of frog's eggs one-millionth of an inch thick, they reported in 1954 the existence of tiny "threads of life" that link the nucleus of a living cell with its outer membrane.

I was fortunate to have worked under Dr. Pollister's supervision and generate a few widely cited publications. Dr. Pollister insisted that I be listed as the sole author of all of these, as he considered the work product to be entirely mine. He felt it would be inappropriate to have him listed as a coauthor. Such was the class and character of the pioneers of cell biology and biomedical research of the 1950s and 1960s. Such episodes had a major impact on my professional life. I humbly carried on this practice whenever possible in my career, as I guided graduate students in their research. Unfortunately, nowadays I see the practice of "honorary authorship" as a norm, rather than the exception that should be shunned ("*The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood...*"—Theodore Roosevelt). Dr. Pollister clearly approved of my research and teaching while at Columbia. A recommendation letter that he provided me dated February 19, 1964, attests to this:

⁶²Dr. Edmund B. Wilson was a pioneering American zoologist and geneticist who wrote the famous textbook: Wilson, E. B. (1925). *The Cell in Development and Heredity*, 3rd ed. (1st ed. 1896; 2nd ed. 1900). Macmillan, New York, USA. He was one of the first researchers to describe the chromosomal basis of sex. Wilson is credited as being America's first cell biologist. In 1898, he used the similarity in embryos to describe phylogenetic relationships. By observing spiral cleavage in mollusks, flatworms, and annelids, he concluded that the same organs came from the same group of cells and concluded that all these organisms must have a common ancestor.

My association with Doctor Bawa was a close one for three years here at Columbia, when he was a laboratory instructor in my undergraduate course and then a post-doctoral fellow. He was one of the most successful of all the teachers during the thirty-two years I have been offering this course. He was always fully prepared, was patient and helpful with each student (whether good or bad) and was invariably cooperative in all the work of the course outside the classroom. Students respected and liked Doctor Bawa; it is no exaggeration to say that the laboratory morale during those two years was at its highest peak. I regard Dr. Bawa as what we often call a "born teacher", meaning that he has the rare combination of intellect and personality that qualify him most admirably for imparting knowledge to those just encountering a new area of knowledge. Dr. Bawa is also notably skilled as a research worker... As a cytologist, he has boldly studied and mastered such difficult techniques as electron and interference microscopy...The future of cytology lies in the hands of such men—and of the younger Indian workers whom I have known, Bawa is especially outstanding. His mastery of these modern ways of working with cells plus his uncommon drive and capacity for hard, persistent effort are likely to place him among the future leaders of the field. He could undoubtedly have a fine career in the United States, but quite properly feels that his service can be of much greater value in his native country.

A decade later in 1969, upon my appointment as a full professor at Panjab University, he shared a copy of a confidential letter he had written on October 28, 1959. It reads, in part:

Our staff was unanimous in praise of Dr. Bawa's service in this post...He is a gifted teacher. In spite of this heavy teaching load, Dr. Bawa managed to carry on considerable research...For this year, Dr. Bawa was awarded one of the four coveted Post-Doctoral Boese Fellowships of Columbia University. This was a merited recognition of his promise as an investigator, which was amply indicated by his published research and studies during 1958–59. We have come to have great respect for Dr. Bawa as a scientist and to like him as a fine person. He is a fully accepted member of our closely knit research group—a status very rarely achieved by a visitor. We shall have genuine regret when he ends his stay with us.



Following my years at Columbia University, I was hired as an instructor at Cornell University Medical College, Department of Anatomy, during Dr. Donald Fawcett's (1917–2009) chairmanship. I was there for three years from 1960 to 1963. In the 1950s and 1960s, great strides in cell biology and biomedicine continued to be made at Cornell. I felt exhilarated to be in the right place at the right time ("*Life is like a game of cards. The hand you are dealt is determinism; the way you play it is free will.*"—Jawaharlal Nehru). For instance, around 1960, the American Society for Cell Biology (ASCB) was founded by premiere names

in biology while I was in the department. These quintessentially descriptive scientists—whose seminal work would be advanced by later generations of cell biologists and biochemists—were Drs. Keith Porter, Montrose Moses, Morgan Harris, Hans Ris, Hewson Swift, and J. Herbert Taylor.

Dr. Fawcett was a master of electron microscopy and one of the greatest cell biologists of his time.⁶³ His greatest achievement was his description of the structure of spermatozoa and the male reproductive system. He used his exceptional skills in the darkroom to produce superb prints of electron micrographs to illustrate the key features of each image. In my opinion, his detailed ultrastructural works on human spermatozoa and the anatomy of male reproductive system are among the finest cellular images ever produced in this field. As a fellow spermatologist and anatomist, I appreciated the research environment and facilities in the department. Later, after I had left Cornell in 1963, I was flattered to note that two of my electron micrograph images of the Sertoli cell of the human testes were included by Dr. Fawcett in his classic textbook of histology.⁶⁴ In my mind, this validated the significance of my research work while at Cornell. It clearly met the high standards of Dr. Fawcett *viz-a-viz* embedding, staining, and sectioning of biological tissue.

The esteemed department faculty also included Dr. George N. Papanicolaou (1883–1962), a pioneer who elucidated the physiology and cytologic characteristics of the female reproductive system (Photo 22). He is best known for creating the Papanicolaou test, more commonly referred to as the Pap smear, a cytological staining technique that revolutionized the early detection of cervical cancer in female patients (Images 19 and 20).⁶⁵ Dr. Papanicolaou was a remarkable human being, a man of compassion and grace. Despite our enormous age difference (I was 29 and he was in his 80s) and academic status (he was an Emeritus Professor, and I was a Lecturer), I often found myself in his modest office. We both were interested in career opportunities in America and arrived as immigrants in New York City with little money in our pockets. Being a zoologist, I was fascinated that he had worked with Dr. Ernst Haeckel (1834–1919) in

⁶³Dr. Fawcett described the early days of electron microscopy as follows: “*For morphologists the decade from 1950 to 1960 held the same anticipation and excitement that attends the opening of a new continent for exploration. The electron microscope revealed marvelous order and functional design in the organization of every tissue and organ that was examined and added significantly to our understanding of our own structure.*”

⁶⁴Fawcett, D. W. (1997). *Bloom and Fawcett: A Textbook of Histology*. 12th Sub-edition. Hodder Arnold, London, UK.

⁶⁵The Pap smear involves (i) sample collection, (ii) staining, and (iii) microscopic analysis. (i) Sample Collection: The cells to be stained are collected from gynecological smears, sputum samples, brushings, fine needle aspiration materials, and/or washings. (ii) Staining: The multichromatic stain involves five dyes: Hematoxylin for the nucleus, Orange G for keratin, Eosin for superficial structures, Light Green SF for cytoplasm, and Bismarck Brown. (iii) Microscopic Examination: In the setting of a cervical cancer screening Pap smear, the resulting stain of the epithelial cells from the transitional zone of the cervix undergoes analysis for precancerous and cancerous processes. Often a second slide is prepared for immunostaining with the biomarker p16INK4a for identifying dysplasia.

Germany, one of the first influential supporters of Darwin.⁶⁶ Dr. Haeckel, the “German Darwin,” was a zoologist, artist, philosopher, and doctor. He discovered and described hundreds of species, coined key terms (ecology and ontogeny/phylogeny), and popularized the “recapitulation theory” during embryonic development of animals. His artwork, comprising more than 100 exquisite illustrations and watercolors, was published in his masterwork, *Kunstformen der Natur* (Image 21). I often would quiz Dr. Papanicolaou on his encounters with other giants of science and medicine. He was most modest in his response, often downplaying his interaction with them. Eventually, I received a rare honor from him: Dr. Papanicolaou allowed me to sit in his desk chair in his office. He also gave me a copy of his 1954 classic, *Atlas of Exfoliative Cytology*.⁶⁷ This book was a milestone in the development of the rapidly expanding field of cytologic diagnosis. It contained detailed instructions on the collection, processing, and staining of a wide variety of biologic materials. In the 1950s and early 1960s, the application of exfoliative cytology to the study of cancer, endocrine, and metabolic disorders was still in its infancy. As the methods for the identification of cancer cells improved over the decades and became less expensive, exfoliative cytology became more feasible. In 1961, after nearly 50 years at Cornell, Dr. Papanicolaou decided to leave Cornell to establish the Cancer Institute of Miami (now Papanicolaou Cancer Research Institute). I was one of the first ones to bid him farewell. Sadly, he passed away a few months after arriving in Miami. Although we were in the same department for less than two years, I owe him much gratitude for his honest advice and for being a guiding star.

Dr. Fawcett left Cornell around 1960 to chair the Anatomy Department at Harvard Medical School in Boston. Our new chairman was Dr. Roy C. Swan, Jr. (1921–1996), noted for his research in kidney and skeletal muscle physiology. He remained my departmental chair until I left Cornell in 1963 (Photo 22). In fact, he was chair for 18 years, and in 1970, he was named the Joseph C. Hinsey Professor of Anatomy. His textbook, titled *Gunshot Wounds: Pathophysiology and Management*, is the gold standard in the field and is used by medical schools, emergency services workers, and medical examiners. Dr. Swan was a wonderful mentor and supported my research activities.

⁶⁶According to Willmann, R., and J. Voss. (2020). *The Art and Science of Ernst Haeckel*. 40th edition. Taschen, New York: “At the heart of Haeckel’s colossal legacy was the motivation not only to discover but also to explain. To do this, he created hundreds of detailed drawings, watercolors, and sketches of his findings which he published in successive volumes, including several marine organism collections and the majestic *Kunstformen der Natur* (Art Forms in Nature), which could serve as the cornerstone of Haeckel’s entire life project. Like a meticulous visual encyclopedia of living things, Haeckel’s work was as remarkable for its graphic precision and meticulous shading as for its understanding of organic evolution.”

⁶⁷See: Papanicolaou, G. N. (1954). *Atlas of Exfoliative Cytology*. Harvard University Press, Cambridge, Massachusetts, USA.




Image 19. Papanicolaou stain showing a low-grade squamous intraepithelial lesion (LSIL) from a Pap test. LSIL is an abnormality found on a pap test that consists of cells that are abnormal and may develop into cervical cancer. Abnormal cells have an enlarged nucleus, irregular chromatin, and relatively abundant cytoplasm. Binucleation and perinuclear glycogen are commonly seen. Courtesy of Wikipedia.




Image 20. Pap stain of adenocarcinoma in peritoneal fluid. Cytopathology of peritoneal fluid in a case of peritoneal carcinomatosis, showing typical features of adenocarcinoma. The Pap stain is one of the most widely used stains in cytology, where it is used to aid pathologists in making a diagnosis. Although most notable for its use in the Pap test or Pap smear as a reliable technique in cervical cancer screening in gynecology, it is also used to stain non-gynecological specimen preparations from a variety of bodily secretions and from small needle biopsies of organs and tissues. Courtesy of Wikimedia.



Image 21. Sea anemones from Dr. Ernst Haeckel's *Kunstformen der Natur* of 1904.

Dr. Leonard L. Ross (1928–2013), Assistant Professor in the department, was a distinguished medical scientist. Prior to his tenure at Cornell, he taught anatomy at the University of Alabama Medical and Dental Colleges in the 1950s, where he established its first electron microscopy facility. Since he was among the first to employ the electron microscope as an investigative tool, I greatly valued his guidance in my research activities. He was warm and generous, freely sharing equipment, chemicals, and technical skills. We developed a close professional and personal relationship. He was a born educator and an exceptional teacher. In the early 1970s, Dr. Ross was appointed Professor of Anatomy at Cornell before moving to Philadelphia in 1973 as Professor and Chairman of the Department of Anatomy at the Medical College of Pennsylvania. He was a terrific administrator and served as the provost of Hahnemann University and Dean of

the Hahnemann University School of Medicine, the only non-physician at that time in the country to hold that title at a medical school. Before his retirement in the late 1990s, he was Dean of the consolidated Medical College of Pennsylvania and Hahnemann University.




Photo 22. Faculty of the Department of Anatomy at Cornell University Medical College in 1960. I am standing, third from left. The legendary Dr. George N. Papanicolaou is seated fourth from the left. The department Chair, Dr. Roy C. Swan, Jr., is seated fifth from the left. Dr. Leonard L. Ross is seated first from the right while Dr. George B. Chapman is seated second from the right.

Dr. George B. Chapman (1925–2016), Associate Professor in the department, was another excellent role model with whom I formed a tight bond. He was a rare individual who made a difference by being on this planet; one of the finest human beings I have ever met. He pioneered several techniques in biological electron microscopy. He epitomized the phrase, “gentleman and a scholar.” We discussed varied topics: my research on the human testes, developing new staining techniques, improving ultra-sectioning of tissues, updating the histology lectures for our medical students, life in Europe during the Second World War (he had been a radioman in the US Navy), his graduate school years under Dr. James Hillier (Hillier constructed the first practical electron microscope in 1938), my life in Lahore under the British colonial rule (1929–1947), and so on. He was a bachelor all his life and lived with his aging mother until her death in 2011. I left for India in 1963, the year he was recruited to head Georgetown University’s Biology Department, where he spent 50 years and retired in 2011. He provided me with an excellent two-page recommendation letter, dated November 11, 1963. It reads, in part:

I was privileged to have Dr. Bawa as a colleague during the three years I served as Associate Professor of Anatomy, in charge of the course of microscopic anatomy at Cornell...Dr. Bawa was one of the few lecturers to be accorded the applause of the

students at the end of a lecture...In this highly competitive field of research [electron microscopy], Dr. Bawa can be rated among the most competent...I can only add that I would, at any time, be pleased to be able to list Dr. Bawa among my colleagues. I trust that these comments have conveyed some impression of the high regard I have for Dr. Bawa as a person, as a teacher and as a scientist.

In addition to providing life-changing connections, my research work at Cornell afforded me the opportunity to work with a Philips TEM at Columbia. I recall a feeling of great excitement and expectation when, in 1960, I finally received training on the Philips TEM at Columbia. Later, I had access to an RCA TEM while at Cornell. The spirit of research permeated these departments and institutions. It was my high privilege to be associated with the scholarly faculty, medical fellows, and students at Columbia and Cornell. Presentations at workshops, symposiums, and international scientific meetings helped me in my professional development. Since my investigations on *Thermobia* spermatozoa at Columbia had been very promising, I naturally extended them while at Cornell by employing a variety of techniques and tools. Many of them were being developed by the pioneers who surrounded me as colleagues or under whom I was training. It was an era of rapid advancements in biological sciences. Electron microscopy enabled me to delineate further the structural details of those developing sperm cells which previously had been beyond the reach of the light microscope. *Thermobia* spermatozoa turned out to be atypical flagellate sperm because their acrosome (an organelle for effecting the fertilization of the ovum) was located toward the tail end of the sperm rather than at the usual apical end. Furthermore, these spermatozoa were highly unusual in another respect: They were joined in pairs and yet exhibited motility (Image 22). In fact, unpaired spermatozoa appeared immotile. I filmed spermatozoa in motion in the laboratory of Dr. Keith Porter at the Rockefeller Institute for Medical Research (now Rockefeller University).⁶⁸ Encouraged by new preparative techniques in fixation, embedding, sectioning, and staining ultrathin sections, I subsequently extended my research to various organelles of developing sperm cells. Tubules, hitherto unreported, were found in the cytoplasm of late spermatids of *Thermobia*. Additionally, electron microscopy enabled me to unravel the complex architecture of the plasma membrane of the paired spermatozoa in the water beetle (*Dytiscus* sp). Over the years, I have also studied the complicated differentiation of the developing spermatids of the Pseudoscorpion (*Diplotemnus* sp.). This process is unique because it is accomplished without the presence of microtubules. Instead, membranous tubes (unlike those reported before) measuring about 50 nm in diameter were found in these spermatids.

⁶⁸This 16 mm film, which I still possess, has been the subject of many a conversation at international conferences, dinner talks, and presentations. I last presented it at a departmental seminar at Rensselaer Polytechnic Institute in Troy, New York, where my son Raj Bawa, PhD, MD, was an Adjunct Professor from 1998 to 2018.




Image 22. A schematic diagram of a mature spermatozoon of *Thermobia*. It has been divided into segments I to VII. Further details: Bawa, S. R. (1964). *Journal of Cell Biology* 23:431-445.

10.13 From Cornell to Panjab University

Upon my return to India, which was meant to be a visit to meet relatives after five long years in New York, I was approached by Dr. A. C. Joshi (1908–1971). He was the first Vice-Chancellor of Panjab University after it had been consolidated in 1958–60 at Chandigarh, a city that did not even exist prior to 1947. Panjab University (note the “a”) traces its origins to the University of the Punjab (note the “u”) at Lahore (now Pakistan), which was founded in 1882. After the partition of Punjab state, East Panjab University was established on October 1, 1947. Initially housed at a cantonment in Solan, it was later relocated to a newly built campus in Chandigarh, during which time it was renamed Panjab University. In fact, until 1956, the teaching departments were scattered across Amritsar, Ludhiana, Jalandhar, Hoshiarpur, and even Delhi, while the library was at Shimla. It was only between 1958 and 1960 that all the departments moved to the new city of Chandigarh under the aegis of Dr. A. C. Joshi. Being a displaced person from Lahore, I fully appreciated the adverse circumstances under which Panjab University had been called into being. The university, which is spread across 550 acres, today has 78 departments and 10 centers/chairs for teaching and research at the main campus in Chandigarh. It has 188 affiliated colleges spread over the eight districts of Punjab and Chandigarh, with regional centers at Muktsar, Ludhiana, and Hoshiarpur.

Dr. Joshi was diligently seeking talent to lead the various departments of Panjab University. As a result, I was heavily recruited by him and after my first interview was given an impressive initial offer to serve as Founding Head and Reader of the Department of Biophysics at the university. As I previously described, I had no intention of staying in India and had accepted a position at Georgetown University. Nevertheless, the exciting prospect of a job at the sprawling campus of beautiful Panjab University, in the stunning city of Chandigarh at the foothills of the majestic Himalayas, was appealing. The university campus was well planned, constructed of beautiful red sandstone (Photos 23–25). After all, the nascent university was to serve as a showcase for the country. Moreover, I believe that its cornerstone had been laid by Nehru.

Many buildings in Chandigarh and at Panjab University were constructed under the direct supervision of the revered Swiss-French architect, Charles-Édouard Jeanneret (1887–1965), known as Le Corbusier⁶⁹ (an altered form of his maternal grandfather’s name, Lecorbésier), and his cousin, Pierre Jeanneret (1896–1967). Le Corbusier was an architect, designer, painter, urban planner, writer, and a pioneer of modern architecture (Photo 26 and Image 23).

⁶⁹ART/ARCHITECTURE – Le Corbusier. Available at: https://www.youtube.com/watch?v=-sT1f1Se_9g (accessed on May 1, 2023).




Photo 23. An aerial view of the Panjab University campus in the early 1960s, when I joined the faculty as a Reader-Head of the Biophysics Department. The Basic Medical Sciences building, under construction, is not visible in this photo.



Photo 24. The Gandhi Bhawan is a major landmark of Chandigarh. It is a Panjab University center dedicated to the study of the words and works of Gandhi. Basically, it is an auditorium hall that sits in the middle of a pond. A mural by the architect greets visitors at the entry. The words “Truth is God” are written at the entrance. It was designed by Pierre Jeanneret, the Chief Architect of Panjab University. Jeanneret used innovative cast concrete to evoke an abstracted floating lotus flower, marrying angular lines with swelling organic forms, all fittingly set into a large reflecting pool.



Photo 25. India’s first prime minister Pandit Jawaharlal Nehru with Vice-Chancellor, Dr. A. C. Joshi at the inauguration ceremony of the Panjab University Library on October 23, 1963. The foundation stone of the new Library building was laid in 1958 by Dr. S. Radhakrishnan, the then Vice-President of India. During the inauguration ceremony, the remote control to lift the curtains malfunctioned and two employees had to manually raise them. Nehru then joked with the Vice-Chancellor: “*Mr. VC mere saath dhoka hua hai*” (“Mr. Vice-Chancellor, I have been ditched”).



Image 23. The 10-Franc Swiss bank note depicting Le Corbusier. Swiss francs, like most world currencies, have long featured notable faces from the past. The Corbusier 10-Franc bill was in circulation since 1995. The Swiss National Bank has now retired it. The reverse side of the note depicts the Palace of Justice at Chandigarh and the facade of the Secretariat at Chandigarh.

Le Corbusier is widely acclaimed as one of the most influential architects of the 20th century whose radical ideas, designs, and writings presented a whole-scale reinvention not only of individual structures but of entire concepts of modern living. Moreover, he gained international recognition as a designer of furniture and as an architect of sacred buildings, for example, the famous pilgrim church of Notre-Dame-du-Haut in Ronchamp. He designed buildings in Europe, Japan, India, and the Americas. He prepared the master plan for Chandigarh and contributed specific designs for several buildings, especially the government buildings. Le Corbusier used skeleton construction and prefabrication techniques in an innovative industrial approach to building. The government complex in Chandigarh was designed in this fashion. Like his contemporaries, Frank Lloyd Wright and Mies van der Rohe, he lacked formal architectural training. In 2016, seventeen of his projects in seven countries were inscribed in the list of UNESCO World Heritage Sites.⁷⁰

⁷⁰UNESCO World Heritage List. Available at: <https://whc.unesco.org/en/list/> (accessed on May 11, 2023).



Photo 26. Le Corbusier in his studio (*“Architecture is the masterly, correct, and magnificent play of masses brought together in light. Our eyes are made to see forms in light: light and shade reveal these forms.”*—Le Corbusier).



The story of Chandigarh is a fascinating chronicle during which India made a bold attempt to make a break with her past. Nehru wanted “[t]hat [Chandigarh] should be a new city, a symbol of India’s freedom, unfettered by the traditions of the past...an expression of the nation’s faith in the future.”⁷¹ Clearly, Chandigarh is the brainchild of Nehru (Photo 27). There are numerous elements embodied in this city that make it interesting and its story one worth telling. At the backdrop was the confusing and compelling circumstances of The Partition whereby the proud Punjabis had suffered more than anyone in India. The contribution of Punjabis to India’s freedom speaks for itself. They had now lost their ancient and beloved capital, Lahore, to Pakistan. The Indian government felt that none of the existing cities of Punjab possessed sufficient stature and magnificence to make up for the psychological loss of Lahore. Rehabilitation of the refugees from West Punjab and administering the strife-stricken state were also urgent necessities. Dr. Ravi Kalia, Professor at

⁷¹India: The influence of the architectural work of Le Corbusier within the states parties of the property. Available at: <https://lecorbusier-worldheritage.org/en/the-influence-of-the-architectural-work/india/> (accessed on April 30, 2023).




Photo 27. Le Corbusier and Jawaharlal Nehru, 1950s (“Many people argue about Chandigarh, some like it, some dislike it. It is totally immaterial, whether you like it or not. It is the biggest thing in India of this kind. That is why I welcome it [...] because it hits you on the head, because it makes you think.”—Jawaharlal Nehru, 1959).


The City College of New York, provides a fascinating history of Chandigarh’s planning and construction in his excellent book⁷²:

The development of Chandigarh represents a fascinating study of practical politics, personal ambitions of politicians and planners, and the high ideals of Prime Minister Jawaharlal Nehru and the planner Le Corbusier. The new capital city of Punjab also represents India’s pride and best urban hopes for the future. Chandigarh was to serve as a training school for Indian planners, who could then duplicate their experience in other cities to improve communication systems, raise economic standards, and permit light and air to penetrate tightly knit unauthorized neighborhoods. It was to rehabilitate refugees and the displaced Punjab government, to restore the dignity of the Indian Punjabi damaged by partition and the loss of Lahore. It was also hoped that Chandigarh would bring law and order to a state torn by communal frenzy, promote economic activities in the region, and improve the lot of those who had suffered losses during the partition of the subcontinent. But above everything else it was to serve as a symbol of India’s break with the past...The American Albert Mayer provided the initial master plan for Chandigarh, which was finally put in place, with modifications, by the Swiss-born French architect Charles-Édouard Jeanneret, popularly known as Le Corbusier, his cousin Pierre Jeanneret, and the English husband-and-wife team of Edwin Maxwell Fry and Jane Beverly Drew...The development of Chandigarh has wider implications for communal relations, the fiscal and social wisdom of building new cities, the urban-political tradition, architectural developments, and the conflict between traditional and colonial influences far beyond a new city environment. Chandigarh

⁷²Kalia, R. (1999). *Chandigarh: The Making of an Indian City*. Oxford University Press, New Delhi, India.



Unique landmarks of Chandigarh. Clockwise from top-left: Rock Garden, Rose Garden, Gandhi Bhawan at Panjab University, Chandigarh High Court, close-up of Chandigarh High Court, Rock Garden, Open Hand Monument, Sukhna Lake.



Unique landmarks of Chandigarh. Clockwise from top: Pinjore Mughal Gardens, Sukhna Lake, Student Centre at Panjab University, Secretariat Building of the Chandigarh Capitol Complex, Rock Garden, Rose Garden.

has shown that new designs and construction do not by themselves make the dream of planning and building a modern urban environment come true. Instead, Chandigarh demonstrates that it is not the personal narrative of a deified ruler nor an exaggerated account of a mythic planner, but rather the individual and collective account of its citizens, striving for self-determination, self-knowledge, and self-actualization.

Dr. A. C. Joshi, a man of exceptional vision and a superb administrator, was the first Vice-Chancellor of Panjab University when it relocated to Chandigarh in 1958–60 (Photos 25 and 28). A man of few words, he was articulate and focused, as if on a mission. The first Chief Commissioner of Chandigarh and my close friend, Dr. M. S. Randhawa (1909–1986), was a classmate of Dr. A. C. Joshi at Government College Lahore. Dr. Randhawa described Dr. Joshi's intimate connection with Panjab University in the *Indian National Science Academy* journal (undated entry): *"In 1957 he got the greatest opportunity of his life when he was appointed as Vice-Chancellor of Panjab University. With single-minded determination and great sense of dedication, he started building up the new campus of the university. Mr. P. Jeanneret was the Chief Architect of the campus and was assisted by B. P. Mathur, Senior Architect. Both these persons worked in close collaboration with Joshi, who examined all the building plans in great detail and gave many helpful suggestions. The result of this collaboration was the beautiful campus of the University at Chandigarh which has won admiration of educationists from all over the world. If any person can validly claim to be the father of this University, it is A. C. Joshi."*



Photo 28. The Panjab University Library (left) and the Student Center (right) reflect unique, bold architectural styles.

Dr. Joshi was impressed by my academic credentials and extensive publication record in distinguished international journals. He had learned of my natural teaching ability. He also knew that I lacked administrative experience but did

not seem to be too concerned. I was less sure of my abilities as an administrator; indeed, I was only 33. During the interview process, Dr. Joshi had assured me that, in due time, I would succeed in building a new department from the ground up. He said time was on my side (*"All great achievements require time."*—Maya Angelou). Many questioned his judgement in providing a high level of autonomy to a relatively young professional with minimal administrative experience. Most vocal among them was Dr. P. S. Gill, the distinguished physicist famous for his work on Cosmic Rays. In the end, my detractors failed to derail my appointment and I officially took charge of the Department of Biophysics in May 1964.

At the university, I found myself in the company of other exceptional department heads: Dr P. N. Mehra (Botany Department Head and "father of angiosperms"), Dr. Mulk Raj Anand (Literature Department Head and internationally renowned writer), Balwant Gargi (Director of Theatre and iconic playwright); Dr. Manmohan Singh (Economics Department Head and future Prime Minister of India); Dr. B. N. Goswami (Fine Arts Department Head and renowned art historian), Dr. R. P. Bambah (Math Department Head and famous for "Number Theory").



Establishing a new department was no small feat. There were many moving parts. In some respects, it was like navigating without a compass. Nevertheless, I was up to the task and knew it. Creating a blueprint for the department from the ground up was a slow process. I had to formulate curricula for undergraduate and graduate classes in the highly interdisciplinary field of biophysics. The concept of a department still existed mostly on paper and architectural maps. I also was asked to provide my input regarding the architecture of the Basic Medical Sciences building and supervise design aspects of the Electron Microscope Laboratories. Creative ways were required to tackle unique and unpredictable challenges, which seemed to sprout from nowhere. After all, we were a young university in a newly independent nation. Gradually, my vision started to take shape. Importantly, my ideas and concepts were blessed by the university's top brass. I could see the building space starting to fill up with people and equipment. I was excited at the prospect of having students and classes soon (*"Do the difficult things while they are easy and do the great things while they are small. A journey of a thousand miles must begin with a single step."*—Lao Tzu). Looking back, I more fully appreciate that it was a daunting task. Maybe at that time, due to my youth and ignorance, I found it exhilarating and challenging.

Being at the helm of the department required long hours, endless devotion, decisive action, and a willingness to take big risks (Photos 29 and 30). Simultaneously, I just had started the construction of a lovely bungalow in one of Chandigarh's posh neighborhoods (Sector 11-A). At that time, my world revolved around building codes, architects, and construction materials. On the one hand, I was working on designs for my new home and, on the other, I was reviewing plans for laboratory facilities of my department. My wife and I also had been blessed with a nine-pound baby boy whom the obstetrician fondly nicknamed



Photo 29. At work in my office at the Biophysics Department in the late 1970s when I was the Department Chair. A large part of my day was spent on administrative duties, teaching, and research. However, I made every effort to drive home for lunch and dinner with the family.



Photo 30. At work in my office in 1988 when I served as Dean of Foreign Students. I was guided by an experienced group of assistants and clerks, whose organizational skills and support was instrumental in the smooth operation of every aspect of my professional life, whether department chair, dean, or coordinator of the Biotechnology Center.

“Pinky” (the editor of this volume) on account of his rosy cheeks and boisterous nature (Photo 31). We were on top of the world. I had made it. Was it luck, timing, talent, or a combination of all? Looking back, it is hard not to appreciate one thing: so much success and only 33 years old!



Photo 31. My young family in Chandigarh, 1964.

I knew that communication is key to building trust, ensuring alignment, enhancing research collaboration, brainstorming, and yielding innovative ideas. I had learnt this on my numerous trips to Japan during the 1960s. Keeping this in mind, I made sure that my entire department was based initially on a single floor. I found that the distance between the adjacent floors in the same building inhibited interaction. Of course, this would be somewhat less possible in later years as the department expanded. Later, in the early 1970s, I had intercom service installed throughout the ever-expanding department to supplement the notoriously unreliable phone service in India at that time. This was a novel idea, which others replicated in their own facilities. Mr. Roshan Lal and the late Mr. Gurbachan Singh were two remarkable and indispensable engineering technicians, who not only installed the intercom system but also maintained it with stellar efficiency. Their service for four decades formed the backbone of the department in some respects. They were called upon to repair or calibrate anything that had moving parts—microscopes, water distillers, Geiger-Müller counters, lathe machines, ultracentrifuges, faulty faucets, and countless other machines, devices, and gadgets. They also fabricated special devices and custom glassware for the department. Looking back, I believe some of their novel devices and fabrication methods should have been the subject of Indian and foreign patent applications.

I always valued merit over a charted agenda; hence, I grew the department faculty meticulously and gradually. I often was criticized for this and even pressured by the university Vice-Chancellor to expand the department at a greater pace. Nonetheless, I stood my ground and hired the best faculty I could find. Almost all faculty were trained either in the US or in Europe. My search for talent was constant. I even hired someone whom I met in a chance encounter at the Geneva Airport passenger lounge in 1965. He was shocked when I gave him a handwritten note hiring him on the spot. He was a brilliant physicist and an equally good human, Mr. P. K. Sharma, who reported for work a month later. He retired following more than three decades of distinguished service to the department.

I was poor at politics but adept at spotting merit (*"Politics is the art of looking for trouble, finding it everywhere, diagnosing it incorrectly and applying the wrong remedies."*—Groucho Marx). Complicating matters, Chandigarh was a political trifecta in some ways: the capital of Punjab state, the capital of Haryana state, and a federally administered Union Territory. This meant constant interference in the affairs of the university from three distinct entities. Department heads were expected to curry favors to bureaucrats and their surrogates. I took great pride in that I did not tow the party line and was an incumbrance to their corrupt agendas. I had nothing to lose because I wished to gain nothing from them. I never hired or employed any family member or relative either. I always shunned politicians and was guarded about my own political thinking. I have always been an independent thinker with a clarity of thought when it comes to right and wrong. I have borne the consequences of standing up to evil and bad people, even in my own family, a price that I will continue to gladly pay for the suppressed voice of the helpless. A positive outcome of all this was that the department flourished on merit, diversity, and talent. Gossip and distractions were kept to a minimum (*"Great minds discuss ideas, medium minds discuss events, and little minds discuss people."*—Hindu Proverb).

The first employee I hired was Mr. Pal Singh as personal assistant, a loyal man of great character, class, and energy. He served the department for more than forty years. Initially, I was given a few rooms in the massive building that housed the Zoology Department while the Basic Medical Sciences was under construction. Mr. Singh used to sit in the hall outside my office on a stool and respond to my buzzer. Our two-man department was up and running. Later, I hired three lecturers and two research scholars. The faculty, staff, and student body were gradually expanding. Teaching and research programs in the Department of Biophysics started in July 1965. In the session between 1965 and 1966, fifteen students (eleven boys and four girls) were admitted to the first-year class of the Honors School. Their graduation in 1968 was an exciting moment for me (Photo 32). During the next session (1967–1968), the number of students in the rolls of the department rose to forty-seven. My vision was taking shape; I had pulled it off! We were still a small, intimate group that had the feel of a close-knit family. The students and the faculty often picnicked and hosted department functions with great enthusiasm, a luxury that was not possible once the department grew larger (Photos 33 and 34). There were frequent get togethers at our home

in Sector 11-A (Photo 35). We also hosted numerous foreign scientists and collaborators (Photo 36).



Photo 32. Graduation day for the first batch of undergraduate students in 1968.



Photo 33. Photograph taken in the mid-1960s of the first batch of students and faculty members in the newly founded department. In my opinion, this batch was one of the finest with respect to their academic capabilities and career performance. They achieved great success in academia and industry around the globe. I am seated third from the right, next to my wife (checkered coat).



Photo 34. Photograph from the late-1960s of students on a Himalayan field trip. I am on the extreme left. Field trips are critical to the academic development of students as they offer students the opportunity to learn about a subject in a more hands-on and immersive way than they can in the classroom and from textbooks. It builds upon classroom instruction (*Tell me and I forget, teach me and I may remember, involve me and I learn.*— Benjamin Franklin).



Photo 35. At my home in Chandigarh with some of my students, 1970s. My students, colleagues, and staff were an extension of my family. While I always cared about the education of my students and obtaining new research results, I cared equally as much for their well-being. Almost every student was invited to my home for dinner, tea, or parties. Occasionally, it was an all-women event (as above). Sometimes it involved celebration of various Indian festivals such as Holi, Lohri, and Diwali. Other times, it was a card game or board game. Such close interactions with each other made my students into a group of lifelong friends and collaborators. However, I always adhered to one important principle: No business or departmental matter would ever be discussed or conducted at my home. It is critically important to maintain a proper work-life balance.



Photo 36. Mr. Suraj Bhan, Vice-Chancellor of Panjab University (extreme right) with some of my foreign colleagues at my home in Chandigarh for dinner.

As my department continued to flourish, I focused on other endeavors to enhance scientific activities for the faculty and students. I founded the Biophysics Society in 1965 to organize lectures of reputed scientists and, also, to provide an opportunity for occasional get-togethers of staff and students within the department. Additionally, I served as Secretary of the Northern India Science Association (NISA) with my department acting as the secretariat. NISA was founded by my close friend, the polymath Dr. M. S. Randhawa (Photo 37). NISA published an attractive monthly journal, *Everyday Science*, until the early 1990s. When I first met Dr. Randhawa in 1964, he was already a distinguished Indian historian, statesman, artist, educator, Indian Civil Service (ICS) member, botanist, and author. We instantly bonded. My association with him grew when in 1966 he was appointed the first Chief Commissioner of Chandigarh. Although Dr. Randhawa was twenty years older, we had similar upbringing: Both of us grew up in Lahore, attended Government College Lahore, and were refugees in 1947. It was an honor to work with Dr. Randhawa, a Renaissance man of India. He was a great man, a rare combination—a gifted administrator and an exceptional scholar-scientist. I often made the delightful car trip from Chandigarh to Kharar to his home, the Garden House, as he called it. We had some memorable discussions, interspersed with work-talk, at his bed-study. In 1947, Dr. Randhawa oversaw the entire function where Jawaharlal Nehru delivered his famous “Tryst with

Destiny” speech on the eve of India’s independence when I was in the refugee camp (Section 10.7).⁷³ He played major roles in the establishment of agricultural research in India, the “Green Revolution” in India, establishing Chandigarh, resettling Punjabis uprooted by The Partition as India’s Director-General of Rehabilitation, and documenting the arts of Punjab. He established the Rose Garden in Chandigarh, the Punjab Agricultural University at Ludhiana, the Government Museum and Art Gallery in Chandigarh, and the Anglo-Sikh War Memorial near Ferozepur. He wrote several books, including *Beautifying India, Beautiful Trees and Gardens, History of Indian Agriculture* (four volumes), compiled nine collections on Kangra, Basoli and Chamba paintings, and four collections of folk songs of Punjab, Kangra, Kullu and Haryana. A biographer gave him the sobriquet *Punjab da Chhewan Dariya* (Punjabi, “the sixth river of Punjab”). John Kenneth Galbraith (1908–2006), the eminent Harvard economist and diplomat, paid tribute to Dr. Randhawa⁷⁴:

[Dr. Randhawa] is, indeed, an extraordinary man. His mind has ranged over nearly the whole sphere of knowledge of science and art, from soil conservation to botany, to city management, history, religion, architecture and art. And in none of these has he been content to be an amateur. In every one he has manifested both the instinct and the diligence of the professional. I continue to be puzzled that one mild man could know accurately so much and to such good purpose.

Dr. Randhawa implemented his vision of Chandigarh with perseverance and left his footprints for future generations. I have seen his remarkable ideas blossom over the years, from 1964 to today⁷⁵:

As the first Commissioner of the Union Territory of Chandigarh, Randhawa played a pivotal role that ensured his place in history. The entire lay out of the landscape and the arboriculture of Chandigarh is his gift to the successive generations. The concept of planting ornamental trees planted in a very systematic manner on both sides of the roads throughout the north of Chandigarh was to provide tree cover and ensure picturesque flowering round the year. If Chandigarh is City Beautiful today, it is solely because Randhawa was so driven by the zeal to plant trees. So much so, he inspected the watering of these plants at 4 am every day. He lived 30 km away from Chandigarh at his farmhouse in Kharar, but reached the city unfailingly at 4 every morning and went from road to road ensuring that all plants were watered and the dead saplings replaced. Today, one has a perfect view of white and golden silver oaks, jacarandas, lagerstormias, mahoganys, amaltas, gulmohars, bauhinias (kachnar), etc. Randhawa gave a green cover of majestic trees like pilkhan and Arjun. It was his vision that enabled a large number of writers, poets, painters and artists to own residential plots in Chandigarh at concessional rates.

⁷³“It was the night of India’s freedom after 200 years of British rule. Jawaharlal Nehru was to unfurl the National Flag from the Red Fort in the morning. A man was unfurling the Flag after every one hour the whole night. He was going through the motions, including wrapping the flowers, hoisting it and then unfurling it at the strategic point again and again. He was none other than M. S. Randhawa, the then Deputy Commissioner, Delhi. A perfectionist, he was afraid that something may go wrong and did not want to take any chance since it was an emotional and historic moment for all. This incident symbolizes the kind of focus that came to be associated with Randhawa.” Source: Sharma, R. (2006). Beautiful mind, dutiful life. *The Tribune*, Chandigarh.

⁷⁴Galbraith, J. K. (1969). Introduction. *Roopa-Lekha* 38(1–2):9.

⁷⁵Sharma, R. (2006). Beautiful mind, dutiful life. *The Tribune*, Chandigarh.




Photo 37. Dr. M. S. Randhawa on the rampart of the Red Fort in Delhi on the eve of India's independence on August 15, 1947. He is flanked by the "Iron Man of India," Sardar Vallabhbhai Patel, the first Home Minister (left) and Dr. Rajendra Prasad, India's first President (right). Both Patel and Prasad were distinguished statesmen and lawyers at the forefront of India's independence struggle from British colonial rule. Patel was instrumental in the peaceful integration of the princely Indian states into the Indian Union and the political unification of India. However, Patel's decisiveness on the partition of Punjab and Bengal was criticized by Gandhi, Nehru, secular Muslims, and socialists for a perceived eagerness to do so.

The 53rd Session of the Indian Science Congress, with the theme "Science in India," was held on the university campus in January 1966. I served as the youngest member of the organizing committee, which was given charge of all festivities, symposia, social events, travel arrangements, lodgings, sightseeing, and programing. It was a marvelous opportunity to showcase the burgeoning university. Inaugurated by the President of India, the Congress was attended by top scholars from India and abroad as well as representatives from foreign societies and academies. My entire departmental staff and students attended; the event afforded them a unique opportunity to be exposed to the latest advances in biomedicine. In January 1973, the Diamond Jubilee Session of the Indian Science Congress was held at Panjab University.

Although I had faculty with diverse experience, I continually updated the program and knew each refinement added value. I recognized that diversity in the subject matter, as well as the personnel themselves, was crucial to an interdisciplinary field like biophysics. By investing in solid faculty, then creating and continually improving upon a cutting-edge curriculum, my new department was a win-win for both students and faculty. Teaching and research were intertwined; developments for each were made in tandem, which proved to be a recipe for success. After all, we were a teaching institution and imparting education

was our prime goal. Our department was one of the first in the country to offer undergraduate courses in biophysics. Today, it is the only department in India, which offers both undergraduate and postgraduate courses in the discipline of biophysics under the framework of the prestigious Honors School System. Based on a competitive national entrance exam, it draws students from both pre-medical and pre-engineering streams, blends them for four years, and ultimately graduates them as energetic biophysicists. I believe I managed to raise the Biophysics Department to an international status, in which research is accomplished on several major projects. I pressed my colleagues and students to publish their research in high-impact⁷⁶ international journals for it is important to measure oneself on a global stage.

I also encouraged a work-life balance. Social gatherings, celebration of various festivals, picnicking, and departmental variety programs were all to be enthusiastically enjoyed. We even participated in students' weddings (Photo 38). I was taught to rejoice in people's happy moments but lend a helping hand or shoulder to ease the burden of those in grief. Every year a new batch of students would graduate...we all would feel their departure. To this day, many of them keep in touch with me. I encouraged feedback, novel ideas, and criticisms in an open forum (Photo 39). This was an efficient way to implement reasonable adjustments and resolve critical issues early on before they spiraled out of hand.

Movies were entertainment that the students, faculty, and staff particularly relished. I tapped into this commonality. Rani and I used to watch every new Indian (Hindustani) movie before we left for New York in 1958. Even as a bachelor during my college years, I made every effort to see each new movie screened. It did not matter to me if it was in Hindi, Punjabi, Urdu, or English. Our favorite Indian movie stars were the super talented and handsome actors of the 1950s, 1960s, 1970s, and 1980s: the Kapoor family (Raj Kapoor, Shammi Kapoor, Prithvi Raj Kapoor, Shashi Kapoor, Randhir Kapoor, Rishi Kapoor), Shabana Azmi, Raj Babbar, Simi Grewal, Dev Anand, Pran, Bindu, Sunil Dutt, Madhu Bala, Meena Kumari, Dharmendra, Suraya, Om Prakash, Rajesh Khanna, Waheeda Rehman, Balraj Sahni, Rajendra Kumar, Raaj Kumar, Mumtaz, Mala Sinha, Prem Chopra, Prem Nath, Zeenat Aman, Guru Dutt, Anupam Kher, Amrish Puri, Nargis, Dilip Kumar, Kulbhushan Kharbanda, Om Puri, Rekha, Rakhi, Manoj Kumar, Bharat Bhushan, Nutan, Vyjayanthimala, and many more. In their energetic screen presence, superb performances, dialogues, and acting, we found the full spectrum of our own emotions—our joys, our sorrows, our prayers, and our love. Newer arrivals like Sanjay Dutt, Shahrukh Khan, Rani Mukerji, Ranbir Kapoor, Salman Khan, Sridevi, Hrithik Roshan, Priyanka Chopra Jonas, Akshay Kumar, Aamir Khan, Deepika Padukone, and others may have a great online presence and following,

⁷⁶Impact factor (IF), or Journal Impact Factor, is a measure of the frequency with which the "average article" published in a given journal has been cited in a particular year or period. IF originally was developed by Eugene Garfield, the founder of the Institute for Scientific Information (ISI), which is now a part of Clarivate Analytics. The calculation is based on a two-year period and involves dividing the number of times articles were cited by the number of articles that are citable. The higher the IF, the more highly ranked the journal. It is one tool used to compare journals in a subject category. In general, the IF of 10 or higher is considered remarkable, while 3 is good. As an example, *Nature* had an impact factor of 69.504 in 2021. CiteScore is similar to IF but is based instead on a 4-year period.



Photo 38. Photograph taken at the wedding of my student, Dr. M. R. Bansal. I am seated second from the left while my wife is seated first on the right. The bride and the groom are seated in between us. My young son is leaning on me. I attended the weddings of many of my students unless it was logistically not possible. It was critical for me to participate in this special day as it was a major milestone in their development. My presence simply validated it. Over the years, I played matchmaker to a few of my students. I relished all my roles, some designated, some adopted—teacher, guide, research mentor, faculty advisor, matchmaker, motivator, leader, organizer, and host.

but they lack that screen presence and talent of the trailblazers of the 1950s–1980s who put their unforgettable mark on the entertainment industry. These new actors clearly have much to learn from the great masters. We rarely missed any English movie while in New York and later in Chandigarh, especially those starring Marilyn Monroe, Katharine Hepburn, Humphrey Bogart, Marlene Dietrich, Clint Eastwood, Judy Garland, Elizabeth Taylor, Bette Davis, Cary Grant, Marx Brothers, Bob Hope, Grace Kelly, Greta Garbo, Audrey Hepburn, Clark Gable, Robert Mitchum, James Stewart, Henry Fonda, Fred Astaire, Ingrid Bergman, Ava Gardner, Rita Hayworth, Burt Lancaster, Gene Kelly, Laurence Olivier, John Wayne, Gary Cooper, Lauren Bacall, Charlie Chaplin, Spencer Tracy, Kirk Douglas, James Cagney, William Holden, Marlon Brando, Sophia Loren, Frank Sinatra, or Gregory Peck. These Bollywood and Hollywood stars of yesteryear left behind an unforgettable legacy of artistry at its finest peak. Nowadays, it is disheartening to see mediocrity at the Oscars and the Indian Filmfare movie awards. Show-business and talent cannot be equated (*“Never confuse the size of your paycheck with the size of your talent.”—Marlon Brando*).



Photo 39. For decades, the “Tea Room” has served as a common meeting place for all faculty members of the department. In the early days, since the staff came from different scientific disciplines of biophysics, these afternoon teas played a critical role in cross-disciplinary exchange of ideas. I am told that this tradition, along with the massive solid Burmese teak table I got constructed in the mid-1960s, survives to this day. The Tea Room continues to be an intellectual meeting ground for the department where free flow of ideas, reflection, criticisms, and discussions is still welcome (“*You can never get a cup of tea large enough or a book long enough to suit me.*”—C. S. Lewis).



In 1969, the department hosted the *1st International Symposium on Electron Microscopy in Biophysics and Molecular Biology*. The three-day symposium was organized to mark the inauguration of the department’s Electron Microscope Facility. It was sponsored by the University Grants Commission, Panjab University, Deutsche Export-und Importgesellschaft Feinmechanik-Optik, the German Democratic Republic, and Mr. K. Lal Bhakri, New Delhi. More than 100 biophysicists, molecular biologists, cell biologists, and biochemists participated. The distinguished speaker list included a galaxy of eminent international stars (Photo 40). The abstracts of the papers presented in the symposium were published in the *Journal of Ultrastructure Research* (1971) **37**:243–257. In 1984, the *Second International Symposium in Biophysics and Electron Microscopy* was held at the department and a proceedings volume was produced. I am proud to note that, since its inception, thousands of high-caliber research papers have emanated from my department—one of the youngest science departments of the university.



Photo 40. Group photo of the international and national speakers at the *1st International Symposium on Electron Microscopy in Biophysics and Molecular Biology* held at the department in 1969. Mr. Suraj Bhan, the Vice-Chancellor of Panjab University, is seated 5th from the left, next to the Governor of Haryana state. I am seated 7th from the left. *First row:* Mr. I. D. Paul, Prof. Jean André (France), Prof. F. S. Sjöstrand (USA), Mrs. Briggita Sjöstrand (USA), Mr. Suraj Bhan (Vice-Chancellor), Mr. B. N. Chakravarty (Governor of Haryana), Prof. S. R. Bawa (Convener), Prof. Noboru Higashi (Japan), Prof. P. N. Mehra, Prof. William Bernhard (France), Prof. G. F. Meyer (West Germany), Dr. Mrs. S. M. Sirsat, Prof. S. K. Malhotra (Canada). *Second row:* Dr. S. K. Sharma, Dr. R. P. Agarwala, Mr. B. K. Puri, Dr. Kanwar Bahadur, Prof. P. N. Srivastava, Dr. S. P. Sharma, Dr. K. G. Srivastava, Dr. Mrs. U. Kanwar, Miss Shimla Goyal, Dr. N. Chatterjee, Miss U. Saha, Miss S. Choudhury, Dr. Asha Khanna, Mrs. P. Bidwai, Miss Jasbir Cheema, Mrs. K. Sundaram, Dr. Kamal Bhasin, Mr. Kuldip Singh Rahil, Mr. P. K. Sharma, Dr. K. C. Kanwar, Dr. D. P. Dubey. *Third row:* Mr. Bhajan Singh, Dr. R. P. Kushwaha, Dr. N. R. Kalla, Dr. A. C. Shipstone, Dr. K. S. Korgaonkar, Dr. M. P. Yadav, Mr. G. S. Gupta, Dr. A. N. Namboodiri, Mr. U. C. Chaudhri, Mr. D. K. Chatteraj, Dr. G. P. Dutta. Dr. Baccio Baccetti (Italy) is not in the photo as he had to return to Siena as he received a telegram that his son was ill.

Since 1951, I have devoted an increasing share of my research efforts to the male reproductive tract in humans and animals, primarily because of the unique challenges it presents to the microscopist. Subsequently, to study the dynamics of the mammalian testis, I directed particular attention to the effects of hyperthermia, electromagnetic radiation (55 MHz), vasectomy, and anti-fertility drugs on testicular cells as well as developing spermatozoa. Light microscopy (bright field, phase contrast, and fluorescent), electron microscopy (transmission, scanning, and high voltage), histochemical techniques, spectroscopy (ESR, NMR), and cryo-techniques (freeze-fracture and fracture label) were also successfully used in these studies. Furthermore, microscopy was used to study (i) catecholamine-induced and Adriamycin-induced cardiomyopathies in rats, (ii) normal and dark-adapted reptilian retina, and (iii) autonomic innervation and hormonal status in the female pregnant rat. I also embarked on various studies involving (i) the biochemical mechanisms involved in cadmium-induced renal

hypertension, (ii) the biophysics of the snake spleen, (iii) the biophysics of hearing, (iv) cerebellar synapses and neurotransmitters during protein-malnutrition, and (v) the mammalian olfactory bulb. Recent years have witnessed the rapid evolution of a host of novel tools and techniques pertaining to biomedical research with respect to microscopy, cell biology, and molecular biology. Most of them involve a great deal of what is conventionally described as biophysics. As a young microscopist (Photo 41), stumbling through chemistry, physics, and math, I failed to appreciate how essential other sciences are for understanding biology. Modern cell biology is inextricably linked to chemistry, physics, and math—almost as if no boundaries between them exist. In fact, as the lines between various areas of biomedical research blurred, I engaged even more in interdisciplinary collaboration, as reflected in my publications from the mid-1980s onwards (list provided at the end of the chapter).



Photo 41. In the Electron Microscope Laboratory on an ultramicrotome, sectioning embedded biological tissue in preparation for microscopic examination.

Over the years, I have extensively studied the ultrastructure of the Sertoli cell⁷⁷ of the human and mammalian testis and the role of microtubules in these cells. Spermatogenesis is supported by intricate crosstalk between Sertoli cells and germ cells, which takes place in the epithelium of seminiferous tubules. Sertoli cells, also known as mother or nurse cells, provide nutrients, paracrine factors, cytokines, and other biomolecules to support germ cell development.

⁷⁷Sertoli cells (SerC) are essential for testicular development, spermatogenesis, and formation of the blood-testis barrier. Named after the Italian physiologist, Enrico Sertoli (1842–1910), SerC limit the passage of substances such as hormones and nutrients to the adluminal compartment of the seminiferous tubules. In addition to forming the blood-testis barrier, SerC also provide the main structural support for the seminiferous tubules and protect the germ cells from the immune system.

When I was a visiting professor in the Anatomy Department at Downstate Medical Center (now SUNY Downstate Health Sciences University) in New York City from 1979 until 1980, my research focused on the fine structure of rat Sertoli cells cultured on monolayers. As a side note, I am proud to point out that the Professor and Chair of the department was Dr. Donald Fishman, a former medical student of mine from the early 1960s while I was an instructor at Cornell University Medical College. I continued this research with Dr. Hans Ris at the High Voltage Electron Microscope (HVEM) Facility at the University of Wisconsin-Madison in 1980 (Photo 42). There, we examined intact, untreated whole-mounts of cultured Sertoli cells to understand the complex three-dimensional configurations of cytoskeletal proteins. We also attempted to study the existence of the “microtrabecular lattice” (MTL), which the distinguished Dr. Keith Porter had described in the 1970s and 1980s. At that time, employing the HVEM, the cytoplasm or ground substance of eukaryotic cells had been shown to be divided into two major phases: the microtrabecular lattice and the intertrabecular spaces. It was believed that the lattice was not apparent in electron-micrographs of conventional thin TEM sections because the sections lacked the depth necessary to reveal the network. In fact, Dr. Porter, whom I had known since the late 1950s when he was at the Rockefeller Institute for Medical Research (now Rockefeller University) and I was at Cornell, considered the microtrabecular lattice seen in electron micrographs to closely represent the non-random structure of the cytoplasmic ground substance of living cultured cells.⁷⁸ However, I was unable to visualize this microtrabecular lattice via HVEM in cultured Sertoli cells.⁷⁹ I considered it to be an artifact of fixation and/or processing. In this regard, I cite an elegant analysis by another luminary of cell biology, Dr. John Heuser.⁸⁰ It is an instructive one for both the budding researcher as well as the seasoned one: Avoid being clouded by the flashy methods and tools of your time (“*Do not judge a book by its cover.*”—Lester Fuller and Edwin Rolfe):

Keith Porter culminated his stellar career as the founding father of biological electron microscopy by acquiring, in the late 1970s, a high-voltage electron microscope (HVEM). With this magnificent instrument he examined whole-mounts of cultured cells, and perceived within them a structured cytoplasmic matrix he named the “microtrabecular lattice”. Over the next decade Porter published a series of studies, together with a team of outstanding young colleagues, which elaborated his broader “microtrabecular concept.” This concept posited that microtrabeculae were real physical entities that represented the fundamental organization of the cytoplasm, and that they were the physical basis of cytoplasmic motility and of cell-shape

⁷⁸Wolosewick, J. J., and K. R. Porter. (1979). Microtrabecular lattice of the cytoplasmic ground substance. Artifact or reality. *Journal of Cell Biology* **82**(1):114–139.

⁷⁹Bawa, S. R., D. Fischman, R. R. Weihing, and H. Ris. (1982). Cultured Sertoli cells examined with TEM/HVEM and fluorescent microscopy. In: *Proceedings of the II European Workshop on the Molecular and Cellular Endocrinology of the Testis*, Boekelo, The Netherlands.

⁸⁰Heuser, J. (2002). Whatever happened to the ‘microtrabecular concept’? *Biology of the Cell* **94**(9): 561–596.

determination. The present review presents Porter's original images of microtrabeculae, after conversion to a more interpretable "digital-anaglyph" form, and discusses the rise and fall of the microtrabecular concept. Further, it explains how the HVEM images of microtrabeculae finally came to be considered as an artifact of the preparative methods Porter used to prepare whole cells for HVEM. Still, Keith's "microtrabecular concept" foretold of our current appreciation of the complexity and pervasiveness of the cytoskeleton, which has now been found by more modern methods of EM to actually be the fundamental organizing principle of the cytoplasmic matrix. During the impending eclipse of Porter's microtrabecular concept in the late 1980s, many of Keith's colleagues fondly described the cell as being filled, not with protoplasm, but with "Porterplasm." Despite the fact that Keith's view was clouded by the methods of his time, it would be fitting and apt to retain this name, still today, for the ordered matrix of cytoskeletal macromolecules that exists in the living cell. In the end, the story of what happened to Porter's microtrabecular concept should be an object lesson in scientific hubris that should humble and inform all of us in cell biology, even today—particularly when we begin to think that our most recent methods and observations are achieving "the last word."




Photo 42. I met Dr. Hans Ris, one of the seminal minds of cell biology, in 1961 at Columbia University. I was a Fulbright Fellow, and he was an Associate Professor in the Zoology Department (now the Department of Biological Sciences). In the mid-1980s, I spent time in his lab at the University of Wisconsin-Madison. The photograph on the right shows Dr. Ris together with a one-million volt electron microscope at the University of Wisconsin-Madison. It was part of the High Voltage Electron Microscope (HVEM) Facility. This NIH-funded facility worked with interpreting the chemistry of chromosomes and later the nuclear pore complex. In his biographical memoir published in 2011 by the National Academies, Drs. Michael Dolan and Lynn Margulis describe his monumental contributions to science and his remarkable career: *Hans Ris occupied a unique historical position: he was a cytologist (student of the cell) at the beginning of the molecular biological revolution and a superb electron microscopist when "biochemical and biophysical cytology" was renamed "cell biology."* ... he influenced the careers of scores of scientists as he generously collaborated to produce a massive collection of remarkably informative micrographs. He was a naturalist on a mission of investigation, an observer-researcher his entire life.

Dr. Porter himself best described the microtrabecular lattice conundrum⁸¹:

In the strictest sense, of course, the content of the images is all artifact where the usual procedures are employed. The question is one of equivalence. To what extent do the images represent what was in the [cytoplasm] when the fixative was applied, and to what extent may these images be used to investigate the form and function of this part of the cell?

Male contraception has been a challenge due to the high rate of sperm production (condoms or vasectomies being the most effective approaches). Nevertheless, attempts have been made to design chemical agents as contraceptives. Sertoli cells present attractive targets for anti-fertility agents. With this background and my extensive experience with Sertoli cells, I was interested in drugs that could have selective yet reversible effects on Sertoli cells, thereby leading to safe and effective male contraceptives. In this context, while I was a Visiting Scientist at the Worcester Foundation for Experimental Biology (WFEB)⁸² in Shrewsbury, Massachusetts, from 1980 until 1981, I studied the relationship of cytoskeletal proteins vis-à-vis shape changes in the cultured Sertoli cells in both treated and untreated environments. Specifically, I studied the microtubule distribution pattern in non-stimulated and FSH-dibutyryl cAMP-stimulated cultured rat Sertoli cells by labeling them via anti-tubulin (see footnote 79). WFEB was best known for the development of the combined oral contraceptive/birth control pill by Gregory Goodwin Pincus (1903–1967) and Min Chueh Chang (1908–1991) and for pioneering research on *in vitro* fertilization (IVF) by Chang.

Today, electron microscopy continues along a rapid trajectory with ancillary techniques like freeze-fracturing and freeze-labeling (Image 24). These methods, to some extent, free the microscopist from limitations of two-dimensional images by revealing cell components in bas-relief. They also provide information that previously has been inaccessible via ultrathin sections. I have used freeze-fracture to supplement ¹³C Nuclear Magnetic Resonance (NMR) and ³¹P Electron Spin Resonance (ESR) data on the plasma membrane of the goat (*Capra indicus*), buffalo bull (*Bubalus bubalis*), and various bird spermatozoa. The distribution of the intramembranous particles (IMPs) in various regions of the spermatozoa also has been investigated; their disposition believed to correlate with sperm motility (Image 25). TEM of freeze-fractured replicas of the sperm-forming cells of the goat, buffalo bull, and dog provided further insight into the organizational variation of the plasma membrane of spermatozoa during their journey into the epididymis. Similarly, by employing numerous microscopic and biochemical techniques, I studied how microtubules function in the morphogenesis and development of the spermatozoon head in a variety of animals, such as the red slender loris (*Lori tardigradus*), palm squirrel (*Funambulus pennantii*), Indian hedgehog (*Paraechinus micropus*), and house crow (*Corvus splendens*).

⁸¹Powell, K. (2005). "Porterplasm" and the microtrabecular lattice. *Journal of Cell Biology* **170**(6): 864–865.

⁸²In 1995, the WFEB's name was changed to the Worcester Foundation for Biomedical Research. In 1997, it was taken over by the University of Massachusetts Medical School (UMMS). Also see: Chang, M. C. (1985). Recollections of 40 years at the Worcester Foundation for Experimental Biology. *Physiologist* **28**(5):400–401.




Image 24. Freeze-fracture electron microscopy is a technique for examining the ultrastructure of rapidly frozen biological samples via transmission electron microscopy. The technique involves breaking a frozen biological specimen to reveal internal structures, such as membrane structure and protein distribution (Image 25). On the other hand, freeze etching is the sublimation of surface ice under vacuum to reveal details of the fractured face that were originally hidden. Freeze replica immunolabelling (FRIL) is another related technique that can provide new insights into the roles of membrane proteins in dynamic cellular processes.























Image 25. The micrograph represents a freeze-fracture replica of water buffalo sperm. Intramembrane particles (IMPs) are present on the major portion of the acrosome (A). The post acrosome (PA) is densely populated with IMPs. "Cords" demarcating the posterior boundary of the sperm head are visible (arrowheads). 31,000X. Further details: Bains, H. K., M. A. Pabst, G. Werner, and S. R. Bawa. (1993). *Journal of Submicroscopic Cytology and Pathology* 25(4):465-470.

After retiring from Panjab University in 1992, I relocated back to the US and joined the David Axelrod Institute of the New York State Department of Health in Albany, New York. I worked in the laboratory of Dr. Kathleen A. McDonough, now Deputy Director of the Division of Infectious Disease Bacterial Pathogenesis and Professor of Public Health at SUNY in Albany, New York. I relished the opportunity to join her team and impressive laboratory. I will always be grateful to her for her kindness, flexibility, and patience with me, given that my best research years were behind me. There, I focused on electron microscopy in conjunction with immuno-cytochemical methods to elucidate the mechanism of infection and pathogenesis of tuberculosis by (a) localizing surface antigens of *Mycobacterium tuberculosis* and (b) studying the mechanism of entry, growth, and elimination of *Mycobacteria* in lung epithelial cultures and macrophage cultures. I also examined the virulence of bacteria from the genus *Ehrlichia* by employing canine macrophage cultures. In a separate collaboration with Dr. M. H. Miller, Professor of Microbiology at Albany Medical College, we studied the effects of β -lactams with affinities for different penicillin-binding proteins on the cell envelope of *P. aeruginosa* as determined by differential contrast microscopy (DIC), TEM, and uptake of ^3H -Gentamicin. Following seven wonderful years in the McDonough lab, I retired from the David Axelrod Institute in 1999. Dr. McDonough's note to me dated July 1999 reflects our mutual respect and relationship:

Dear Dr. Bawa, With deep gratitude for all your years of hard work, boundless good nature, and terrific generosity of spirit, your gentle wisdom has been a daily gift that will always be remembered and treasured. Wishing you the best of luck in your new adventures, and looking forward to continued fruitful collaborations in our common endeavors against infectious disease.

Since 2002, I have been a scientific advisor at my son's firm, Bawa Biotech LLC, in Ashburn, Virginia. Founded in 2002, Bawa Biotech LLC is a medical, biotechnology and pharmaceutical consultancy as well as a patent law firm. As scientific advisor, I have also co-authored several publications pertaining to patent law issues and FDA regulation of nanomedicine.⁸³ Nowadays, if my health permits, I am more involved in scientific/biomedical editing and e-lecturing via Zoom and other platforms. I have also started to dedicate an ever-increasing share of my day to the *Sudesh Bawa Medical Foundation*, a non-profit medical organization formed by my son.

⁸³American Society for Nanomedicine, Resource Center: Available at: <https://www.nanomedus.org/resource-center> (accessed on May 25, 2023).

 <p>Solid NPs</p>	 <p>Polymer-Drug Conjugate</p>	 <p>Polymer-Polypeptide Conjugate</p>	 <p>Functionalized Gold NP</p>	 <p>Biomimetic NP</p>
 <p>Ligand Functionalized Nanoliposomes</p>	 <p>Drug Loaded Nanoliposome</p>	 <p>Nucleic Acid Loaded Nanoliposome</p>	 <p>Pegylated Stealth Nanoliposome</p>	 <p>Peptide-siRNA Nanoliposome</p>
 <p>GRAS Stabilized Nanocrystal</p>	 <p>Silica Encapsulated Gold Nanoshell</p>	 <p>Functionalized Nanodiamonds</p>	 <p>Solid Polymeric NP</p>	 <p>Phospholipid Coated Magnetic NP</p>
 <p>Ultrasmall Silica NP (C Dot)</p>	 <p>Drug Encapsulated Dendrimer</p>	 <p>Drug Loaded NMOFs</p>	 <p>Polymeric Micelle</p>	 <p>DNA Origami</p>





















 Solid Lipid NP	 Nanogel	 Aptamers	 Polymer-Graphene Oxide
 Drug Loaded Chitosan-PEG Coated Nanogel	 Functionalized Drug Magnetic NP	 Surface Functionalized Solid NP	 Hexosome Lipid NPs
 Drug Loaded Bioinspired Bile Micelle	 Silica NP	 Enzyme Nanocarrier	 Cubosome Lipid NPs
 Self-Assembling Peptides	 Viral NP	 C ₆₀ Buckminsterfullerene	 Hafnium Oxide NP
 Dextran Coated USPION	 Nanonized API	 Peptide f-CNTs	 Peptide f-CNTs

Image 26. Nanoscale Drug Delivery Systems (Nanodrugs or Drug Nanoparticles) (Continued).

Image 26. (*Continued*)

Schematic representation of selected engineered nanoparticles (NPs) used in drug delivery that are either approved by global regulatory bodies, are in preclinical development or are in various phases of clinical trials. They are considered as first or second generation, some are multifunctional in their mode of action, most ranging in an average diameter from one nanometer (1 nm) to a micron (1,000 nm). Active bio-targeting of a NP is often achieved via conjugating ligands or functional groups (e.g., antibodies, peptides, aptamers, folate, hyaluronic acid). These molecules are tagged to the NP surface with or without spacers/linkers such as PEG. Many nanodrugs depicted above (e.g., metal-based NPs, functionalized carbon nanotubes [f-CNTs], nanoscale metal organic frameworks [NMOFs]), although extensively advertised for drug delivery, will pose enormous regulatory approval and commercialization challenges. They will not appear in the clinic this century. Non-engineered antibodies, natural biological motors (e.g., sperms), engineered nanomotors, and naturally occurring NPs (e.g., natural protein nanotubes), although potential drug delivery candidates, are specifically excluded here. Note that antibody–drug conjugates (ADCs) are also encompassed by the cartoon labeled “Polymer–Polypeptide Conjugate.” Therapeutic monoclonal antibodies (TMAbs), polymer-polypeptide conjugates, and aptamers shown are classic biologics, but they are also nanodrugs as they fall within the widely accepted standard definition of nanodrugs. The list of NPs depicted here is not exhaustive, the illustrations do not reflect precise three-dimensional shape or configuration and the NPs are not drawn to scale.

Abbreviations: NP, nanoparticle; PEG, polyethylene glycol; GRAS, Generally Recognized As Safe; C dot, Cornell dot; API, active pharmaceutical ingredient; ADCs, antibody–drug conjugates; NMOFs, nanoscale metal organic frameworks; f-CNTs, functionalized carbon nanotubes; siRNA, small interfering ribonucleic acid; USPION, ultrasmall superparamagnetic iron oxide nanoparticle; TMAbs, therapeutic monoclonal antibodies.

10.14 A Glimpse of Home Life at the University

After living in my personal villa (House No. 169, Sector 11-A) from 1964 to 1974, I was offered one of the three largest residences on the 550-acre campus of Panjab University. The residence came with a full-time gardener, servant quarters, massive lawns for afternoon teas, a vegetable garden, and an impressive orchard. The offer was too tempting to refuse. We moved into our charming new home (House No. G-2, Sector 14) in 1974 (Photo 43). It was two doors down from the Vice-Chancellor's official university residence. I was now the fifth most senior person in the university hierarchy, given that my appointment as Reader/Department Head was at the young age of 33. Subsequently, I became Full Professor at 39. It was a remarkable achievement for a refugee! Most proud was my father, by then in his 70s. Although he did not openly express it, his calm demeanor could not hide his apparent joy at my professional accomplishments. We were a humble family that shunned showiness and never bragged about anything. Moreover, all achievements



Photo 43. Our charming home (House No. G-2, Sector 14) on the Panjab University campus. Each summer, we stayed in Chandigarh until June-end prior to the annual monsoon season so that we could relish the summer fruit and the wonderful produce that our massive garden offered. In addition to the vegetables and herbs, the orchard had a variety of fruit trees: mangos (nine varieties), bananas, figs, peaches, grapefruits, pomegranates, and grapes. We even grew sugarcane, peanuts, and corn. Our neighbor, the Dean of Panjab University, had planted wheat. The fertile alluvial soil of Punjab is a gift of nature.⁸⁴

⁸⁴*Aisa des hai mera* song from the Bollywood classic, *Veer-Zaara*: Available at: <https://www.youtube.com/watch?v=wDheWYmNEhQ> (accessed on June 1, 2023).

in life are relative. My father used to bike to campus for visits with my family, or to attend special departmental functions and picnics. I cherished the time spent with my elderly parents. They were my heroes, having endured colonialism and the loss of their way of life. I visited their home every Sunday evening unless I was out of town. I never lost sight of the fact that my parents and family were most important to me in life. Although I was professionally successful at a young age, life had taught me that material wealth and high positions can evaporate in a flash. After all, I was the child of The Partition, having witnessed this firsthand. In addition to my family, I viewed the students and faculty of my biophysics department as my extended family, whose members deserved appreciation and nurturing.

To live and work in Chandigarh was a delight. Summer vacations often were spent in the hill stations of the majestic *Himalayas* (Sanskrit, “abode of the snow”). For centuries, the stark beauty of the Himalayas has been a source of inspiration and awe to poets, travelers, and adventurers.⁸⁵ Our favorite trip to the Himalayas used to be a month-long stay in the Kashmir valley, especially the lush green meadows and pristine waters of *Pahalgom* (Kashmiri, “village of shepherds”). Nature has endowed Kashmir with unfathomable beauty; it is rightly called the “Switzerland of the East” (“*All my life through, the new sights of Nature made me rejoice like a child.*”—Marie Curie). Our summer trips to Kashmir ended when the Himalayas claimed our younger son, Mickey. He was not even four, innocent and helpless. I often think of his gentle and sweet demeanor. Mickey’s days were spent following and playing with his best friend, his older brother Pinky. Life has its natural order and children are supposed to outlive their parents. Rani and I were both still in our 30s and tried our best to comfort each other. But we had a hard time finding strength to go through the dark days up ahead, or to fill the emptiness in our hearts. The sorrow of this loss almost half a century ago has stayed with me to this day (“*Memories saturate my heart and the story of you spills from my eyes.*”—Grace Andren).



Chandigarh was and will always be a paradise in India. In this regard, I refer to the marvelous—though somewhat dated—description of this wonderful city by Barbara Crossette, a *New York Times* Reporter, who spent six months in India teaching at Panjab University on a Fulbright Fellowship⁸⁶:

To see Chandigarh is to see India in a new way...The city of Chandigarh, on the edge of the Punjab plain near the foothills of the Himalayas, was built to replace the

⁸⁵*Deewana hua badal* song from the Bollywood classic, *Kashmir ki Kali*: Available at: <https://www.youtube.com/watch?v=00I61W2pMss> (accessed on June 1, 2023).

⁸⁶Crossette, B. (1982). Le Corbusier’s Chandigarh. *The New York Times*. April 25th Issue, Section 10, p. 21.

Punjabi capital of Lahore, lost to Pakistan in 1947. Today it is an urban showpiece—a clean and open “garden” city with an annual rose festival, a cool lakeside park, a captivating folk-sculpture Rock Garden—and a collection of Le Corbusier buildings that attracts architects from all over the world. Chandigarh is a city, rare in India, where walking—except under the punishing summer sun—is a pleasure. Le Corbusier envisioned a city divided strictly by function. There were to be residential sectors, an industrial area, a sector for colleges—the university is worth a detour; its attractive campus contains Le Corbusier’s Gandhi Bhavan, a center for the study of the works and legacy of Mohandas K. Gandhi—and a research institution, a central commercial and office area, a spacious capitol complex against a mountain backdrop. A lush green valley running through the center of it all, gives the city “lungs.” Each residential area was allotted its own shops, schools and other essential services. Roads were designed to channel traffic away from homes. Sector 16 has the Zakir Hussain Rose Garden, which is at its most colorful in winter months, especially January and February when the whole city, cool at night, is brightened by the “European” flower season. During the annual February Rose Festival, blooms of every color are matched by the bright silk of saris worn by women who come to stroll around the fountains or sit on the grassy lawns. Walking through the “leisure valley” toward the mountains from the Rose Garden, brings a visitor to the Chandigarh Museum and Art Gallery. This small museum contains a good permanent collection of Gandhara sculptural art, which flourished in the Indus River valley, in what is now Pakistan, in the last few centuries B.C. and the early part of the Christian era. Gandhara art is distinguished by its Hellenistic rather than Oriental style, from the drape of the clothing to the Mediterranean faces of the Buddha. Across the park drive from the museum is a meadow where colorful tents called shamianas are erected for concerts from time to time. At the edge of the parkland is a very popular exhibit of another kind: a captured Pakistani [US Patton] tank. The Secretariat is a Le Corbusier building in his European style: massive, 10 stories tall and given to unexpected angles. The High Court building, which can be reached by a walk more or less east along an access road, was designed specifically for the Indian climate: it has Le Corbusier’s “parasol” roof—an overhanging but rolled-up lid of concrete to fend off rain and sun. From the High Court, one can walk across a stretch of scrub land to the Rock Garden. As in all planned cities not inhabited by robots, people have wrought their own modifications, and probably nowhere in India is there anything as happily whimsical as this fantasy created by an untutored sculptor, Nek Chand. Mr. Chand produced a collection of captivating creatures fashioned of discarded construction materials, old pots, and broken crockery. After the Rock Garden, the hardy walker can strike out along Uttar Marg (which translates roughly as Northern Boulevard) to Sukhna Lake, an artificially created body of water that is at almost any time of day arguably the most pleasant place in Chandigarh. On a clear morning one can catch a glimpse of the snowy high Himalayas, and by afternoon, the lakeside park provides a perfect place for reading or just sitting on the retaining wall or along a grassy bank. At night the place has a special magic, with the stars of the immense Punjabi sky vying with the lights of Kasauli, the first of the Himalayan hill stations, sparkling in the distance. A long lakeside walkway seems to disappear into the distant Shivalik Hills.

10.15 International Travel and Research Collaborations

Alone we can do so little; together we can do so much.

—Helen Keller (1880–1968)

I always have believed deeply in the importance of both national and international cooperation for the progress of science. Teamwork is critical to success. It is not the team with the best players that wins but it is the players with the best team that wins (“*[Teamwork] is the fuel that allows common people to attain uncommon results.*”—Andrew Carnegie). Science, like music and food, brings people, cultures, and even enemies together. Biomedical sciences have a rich tradition of collaboration. Today, biomedical research is even more interdisciplinary and technologically based than in years past. In fact, this collaborative spirit is reflected in my own research publications. They were mostly single author in the 1950s and 1960s; however, just three decades later, they involved collaboration with immunologists, chemists, and physicists. In fact, the percentage of the Nobel Prizes in medicine, chemistry, and physics awarded to two or three individuals for one project has increased over the past 30–40 years. This emphasizes the value and frequency of collaborative work in these fields. Furthermore, a look at the recent issues of any major biomedical journal reveals the high frequency of collaborative research today. Scientific collaboration also has economic benefits: When scientists work together, they not only share ideas, lab facilities, and resources but also form innovative and interdisciplinary solutions for existing problems.

Over the decades, I visited many laboratories in multiple countries, made numerous friends, and learned more than I possibly could have imagined (“*There are more things in heaven and earth, Horatio, than are dreamt of in your philosophy.*”—William Shakespeare’s *Hamlet*). A nonagenarian’s life is full of stories and experiences, too numerous to be recited here. As mentioned previously, these will be the subject of my autobiography that currently is under preparation.

I was lucky to travel the world for collaborative research, presentations at international conferences, as a member of governmental advisory boards, and even for vacations. Many of my trips were memorable—some not only for the professional activities but also for the bizarre stories related to them. My short trips generally were made solo. On those occasions, when I was a visiting professor for a longer stay, the entire family would either accompany me or follow me a few months later. Some of these best long stays during the late 1980s and 1990s were in Germany, where I was a Humboldt Fellow on five separate occasions. I spent a few summers in the lab of Dr. Gerhard Werner at Saarland University in Saarbrücken, Germany. It was a long and productive association that resulted in outstanding research work. Each time a manuscript was accepted for publication, it was an excuse to celebrate with a party at his home. He died a few years ago; my last collaborator was gone. His intellect, warmth, and graciousness are dearly missed.

Japan was a particularly favorite country for me to visit—not only for its unique cuisine and culture but also for its well-equipped research facilities. Whenever I was shopping for a transmission electron microscope (TEM) or scanning electron microscope (SEM), Japan was my destination in addition to Germany and the US. I purchased one JEOL TEM and one SEM for the university from Japan in the late 1980s for the newly established, Regional Sophisticated Instrumental Center (RSIC). Two of my favorite scientists whom I visited frequently in Japan were Dr. Noboru Higashi, Professor and Director of the Institute for Virus Research at Kyoto University, and Dr. G. Yasuzumi, Professor of Anatomy at Nara Medical College in Kashiwara, Japan. Dr. Higashi made significant contributions to microbiology. His research on the ultrastructure of rickettsia, chlamydia, poxviruses, and togaviruses as well as their mode of replication is considered world-class. Also, he was one of the first to introduce the well-controlled *in vitro* culture system into electron microscopic studies of viruses and established the foundation of chlamydia organisms as obligate intercellular parasites. On the other hand, Dr. G. Yasuzumi did seminal work elucidating the role of various cellular structural elements in mammalian fertilization. I was in awe of his prowess to work continuously in the lab for 10–12 hours straight. Electron microscopy is a laborious endeavor, requiring hours in the dark with limited breaks. One must have enormous patience, a surgeon's steady hand, and exceptional skills at preparing samples involving multiple processing steps. In short, it requires skill, perseverance, laser concentration, and long hours with a low probability of success. I caution the budding microscopist to be prepared for the usual final result: the developed print or micrograph following immense labor will generally be of limited value, replete with artifacts, and unpublishable. However, it is important not to be frustrated or be overwhelmed by disappointment. Repeated failures and incremental success are part of this area of research. Patience and perseverance will eventually yield a beautiful micrograph that has all the desired structural elements worthy of publication in a respectable journal (*"A bend in the road is not the end of the road...Unless you fail to make the turn."*—Helen Keller).

In the mid-1990s, I had a productive research partnership with Dr. Maria Anna Pabst, Professor at the Medical University of Graz in Austria. I frequented her laboratory for research activities, often working in the Electron Microscope Facility into the wee hours. Our joint publications pertaining to surface mapping of spermatozoa via a variety of cutting-edge tools and techniques, including TEM, lectin binding, and freeze-fracture replica immunolabeling, were very well received. Dr. Pabst, who retired a few years ago, is a multit talented scientist and artist. Her artistic flair involves transforming canvas-printed electron microscopic images by rendering them with colored Indian ink. Previously, her work on a 1,000-year-old mummy from Chiribaya Alta in Southern Peru and a 5,300-year-old Tyrolean Iceman garnered worldwide scientific accolades.

Some of my most memorable trips were to the lab of Dr. Baccio Baccetti (1931–2010), Professor and Director of the Institute of Zoology at the University of Siena, when I was a visiting professor there in the 1970s. His interests were many, but insects were the common denominator of all his research. He collected many insect specimens and put together a large collection that was transferred

to the Museo Civico di Storia Naturale of Genoa. Dr. Baccetti, who was the editor of the *Journal of Submicroscopic Cytology*, set an example as an exceptional scientist, with an enormous capacity for work and limitless erudition. He possessed a rare combination of qualities, being both a deep thinker and virtuoso experimenter. He was an equally good man, displaying inexhaustible optimism, vitality, and love of life. Dr. Baccetti hosted us at Pontignano Monastery outside Siena (Photo 44). These were probably the most memorable summers for my family—we enjoyed the deluxe accommodations, surrounding farms, and stunning vineyards of Lombardy. We had a first-class chef, Beppe, who prepared delicious Italian and European meals for us (Photo 45). A car was provided to me for my daily drive to the university and for weekend sightseeing trips. Since it was summer, we enjoyed *The Palio* horse race, Italy's most famous annual sporting event. Upon our return to Chandigarh, Dr. Baccetti sent a massive container that contained fine Italian China, upon which he served dinners for us at his home (I happened to compliment the exquisite beauty of the dinner set!). On another occasion, he sent us an enormous shipment of the finest Italian mozzarella and tomato sauce by airmail, a real treat for anyone in the mid-1970s. My wife, who was a master in the kitchen, used the mozzarella over a period of months to craft amazing pizzas for the family.



Photo 44. The Certosa di Pontignano (Pontignano Charterhouse), also known as the Certosa di San Pietro, is a magnificent Carthusian monastery and church in the neighborhood of Pontignano, a few kilometers north of Siena, in Tuscany, Italy. It was founded in the 14th century. It retains all the elements of Carthusian architecture with large cloisters, individual monk's cells, each with a small garden, and a large church that still preserves 14th century features. The former monastery of Pontignano (now part of the University of Sienna) is set amongst olive groves and has three cloister gardens. Two are traditional grass rectangles and one is now a renaissance parterre garden.



Photo 45. My son with head cook Beppe and his staff in the kitchen at Pontignano Charterhouse, north of Siena, Italy. Not only were they exceptional chefs who prepared gourmet Italian meals for the family during our stays, but they were patient and generous with their time. Some of our favorite foods included Ribollita, Sardinian stuffed eggplant, Ragù alla bolognese, woven lasagna, Sfogliatella, Crostini Toscani, Panzanella, Bistecca alla Fiorentina, Fagioli con salsiccia, Tagliatelle al tartufo, and Pecorino Toscana—all lovingly served by Beppe and his team.

During one of my trips to East Berlin in the 1960s, an army colonel demanded that he personally review each of my 45 slides used for my scientific talk. He had a perplexed look as he examined each slide by holding it against the sunlight. I do not blame him for his confusion, as they were 35 mm Kodak film slides of various electron micrographs and stained histological tissue. Did he consider me a spy and believe that my slides carried encrypted information? Did he think this information could have been a threat to German democratic socialism? He wanted me to explain what each slide represented, a task that I found both amusing and exhausting. Soon we both moved on: He had fulfilled his bureaucratic duty and I complied with his unreasonable request. Obviously, he never had heard of an electron microscope, although the “magnificent machine” had been invented by the German Nobel Laureate, Dr. Ernst Ruska in the 1930s (Photo 19). Anyway, I finally was allowed to enter East Berlin. During my week-long stay there, my hosts showed me around. One image is still fresh in my mind: people standing in a long queue to purchase bread and bananas at a grocery store. It reminded me of my refugee days when we would eat our meals sitting on the ground. There, small containers would be thrust into our face by those who parsimoniously dispensed lentil soup from ladles. I was told that the

reparations owed by the Germans to the Soviets after the Second World War (*Deutsche Reparationen*) had impoverished the Soviet Zone of Occupation and severely weakened the economy of East Germany. Between 1945 and 1946 alone, the Soviets had confiscated and transported approximately 33% of industrial plant resources to the USSR. By the early 1950s, they had extracted nearly \$10 billion worth of agricultural and industrial products from reparations.⁸⁷

Another visit to an Iron Curtain country is worth mentioning briefly. During a trip to Communist Warsaw in the late 1960s, I faced challenges similar to those encountered in the German Democratic Republic. I was tailed by a secret service police officer for most of my ten-day stay. He even followed me to the Grand Theatre-National Opera. Although nerve-racking, I do not believe that my life was ever in danger. Nevertheless, it was a unique experience.

Some of the conferences and symposia, which I presented or attended, had awkward moments or humorous twists. During a major international conference held in Europe during the late 1960s (the Charles de Gaulle era), a French speaker started his presentation in English only to suddenly switch over to French. The audience was stunned; he refused to switch back to English and eventually was asked to leave. Another similar bizarre incident occurred in 2002 at Rensselaer Polytechnic Institute at a biotechnology symposium chaired by my son. The opening keynote was a 45-minute presentation by the editor of *Nature Biotechnology*. After his presentation ran over by 15 minutes, my son politely asked to him close out. However, he continued for another 30 minutes, yet kept assuring the audience that he was near the end of his talk. This was yet another case of a distinguished speaker who had too much to showcase for the available time allotted (*"The greatest virtue of a speaker is not only to say what is necessary, but also not to say what is not necessary."*—Cicero). Eventually, the Dean of Science, Dr. Joseph Eckert, stood next to him and literally gently nudged him off the podium.

Procuring samples of both human and non-human tissue was critical to my research endeavors. During my Cornell days in the early 1960s, for my research work on the Sertoli cells of the human testes, I flew to Birmingham, Alabama. There I had arranged to obtain testes from a volunteer prisoner on death row. A prison doctor castrated the death-row inmate and provided me with the necessary tissue. It was a strange sight indeed: a surgeon operating on the inmate; I serving as the surgical assistant; and a dozen prisoners surrounding us observing the procedure at close range. There were two guards nearby, certainly not enough in case something went awry. Obviously, it was a different era without informed consent, approval forms, and institutional review boards (IRBs). I was in the segregated South. It was prior to Dr. Martin Luther King, Jr.'s (1929–1968) famous speech or the Civil Rights movement. Birmingham in the early 1960s was the most segregated city in the US where Jim Crow laws separated black and white people in parks, pools, elevators, drinking fountains, and lunch counters. Black Americans even were barred from working at the same downtown businesses where they

⁸⁷Naimark, N. M. (1995). *The Russians in Germany: A History of the Soviet Zone of Occupation, 1945–1949*. Harvard University Press, Cambridge.

shopped. It reminded me of British India and my youth in Lahore only a decade earlier where brutal, racially motivated prejudice, segregation, and violence were the norm. Being in New York City and at the rarefied ivory towers of academia, I was isolated from the news pertaining to the ills perpetrated against Black Americans of the South. I realized that there were two Americas (*“And we must face the hard fact that many Americans would like to have a nation which is a democracy for white Americans but simultaneously a dictatorship over black Americans.”*—Martin Luther King, Jr.). The evils and legacy of slavery persisted. My adopted country—the one that I viewed as the shining star on the hill—was, in fact, rotten at the core.

During my Panjab University days, I would venture on sample expeditions into the Himalayas or to the Indian Ocean. One memorable trip involved being on a day-long trip on a yacht with a crew of fishermen, who helped me procure a variety of sea-animals deep in the Indian Ocean near the Andaman and Nicobar Islands. I later realized that, in my excitement, I had forgotten to wear a lifejacket—an oversight that I did not repeat. Upon my return flight, I went home and temporarily stored the containers with the live sea life in my refrigerator. The neighborhood children visited the house all day to peer into the strange world. In fact, they were always excited to see me following a trip because it involved something unique and exciting for them (chocolates from Switzerland, toys from the US, live sea animals from the Indian ocean, exotic birds from the Himalayas, etc.).

My life in biomedicine often involved traveling with tissue samples (normal or pathological) that had been polymer-embedded and were ready for sectioning, staining, and microscopic examination. These were hard to procure for my collaborators in Europe or the US. It was a wonderful joint endeavor: I provided samples that were then processed in the world-class research facilities of my collaborators. Such efforts resulted in stellar publications. For human pathological or autopsy/biopsy tissue, I had my collaborators worldwide. For non-human tissue, I generally relied upon the excellent animal facility located adjacent to our Basic Medical Sciences building. This facility housed a variety of animals, birds, and fish. Additionally, I had access to numerous research stations throughout India. Over the years, I conducted research on monkey, goat, squirrel, cobra, mouse, rat, rabbit, hedgehog, turtle, rose-ringed parakeet, common hornet, honeybee, lizard, parrot, chicken, Indian crow, sparrow, pigeon, and so on.

Besides procuring samples from the most unusual places, like a US prison in the segregated South or the Indian Ocean, I was frequently forced to navigate complex logistics or devise creative ways to transport them. Carrying biological samples would prove especially arduous when I travelled abroad. It often caused commotion at airports and transit points. If I declared what I was carrying, my “material” would almost always be confiscated or trashed, thereby defeating the purpose of my scientific trip. On the other hand, if I did not disclose the biological samples, they could be considered contraband resulting in a stiff fine or worse. I was stuck between a rock and a hard place. In case the custom officer decided to photograph or X-ray the sample, it caused further confusion. Although the tissue samples were embedded in polymer, I nevertheless was always wary of

X-rays; I wondered if that could somehow introduce artifacts. I started to carry my faculty ID badge, business cards, and invitation letters from my hosts—all in hopes of pleading my innocence, if necessary. I would have to do even more explaining if I carried with me medicinal pills, plant extracts, or protein samples. Once, to my amusement, an airport police officer in Europe smashed open an ampule and tasted its contents; the bitter white powder was lyophilized protein.

10.16 Future of the Research Enterprise

As I have stated, extensive research and pedagogy have been powerful catalysts for my personal and professional development. My professional journey has allowed me to bear witness to incredible intellectual feats. In contrast to the phenomenal advances in biomedicine, I have also observed the evolution of unacceptable trends in the scientific community, including increased plagiarism, fraud, and irreproducibility of preclinical research. Other threats to the future of scientific research include the rise of predatory journals, compromised confidentiality of the peer-review process, and financial influence of large pharmaceutical companies. One trend with unknown consequences is open access research—or, rather, sharing early results of studies and experiments online. This gained momentum during the COVID-19 crisis. Hopefully, this online availability of research outputs incorporates rigorous quality checks, the lifeblood of authentic scientific progress.⁸⁸

(a) Scientific Misconduct

Science depends on complete trust. The vast majority of researchers report the facts as per the results of experiments. Many errors that occur can be attributed to mistakes in preparing figures or interpreting data. Mistakes also can be introduced by being too trusting of commercial reagents and antibodies.⁸⁹ This said, I am most concerned with a minority of studies in which data are fabricated deliberately. This pollutes scientific literature, drains finite resources, and misdirects future research endeavors.

Dr. Vishwa J. Gupta, an internationally renowned paleontologist from my own Panjab University, conducted large-scale scientific fraud. His two decades of scientific research work, during which he generated more than 400 research papers, came under scrutiny. Many had fabricated data and/or images. For example, he purchased fossils from shops, museums, or academic collections and then falsely claimed to have found them in the Himalayas. According to the *New York Times* (1989), it was “the most serious case of its kind since the Piltdown hoax more than half a century ago.” Sadly, as a result, the paleontological literature on the Himalayas has become shot through with disinformation.⁹⁰ I find it equally

⁸⁸I will leave these important issues out of my brief discussion here, as they will be dealt with in an editorial piece that I currently am working on for Volume 5 of this series.

⁸⁹Shortcuts taken by antibody manufacturers and researchers alike have resulted in a crisis of reproducibility in antibody performance. Obviously, this greatly affects the identification of drug targets, thereby contributing to the reproducibility crisis in biomedical research.

⁹⁰Talent, J. (1989). The case of the peripatetic fossils. *Nature* **338**:613–615.

appalling that despite overwhelming published evidence of multiple acts of research misconduct and despite being found guilty of misconduct by our university, Dr. Gupta remained a tenured professor until his retirement in 2002.

Based on my experience reviewing grant applications and serving on journal editorial boards, I believe that the number of fraudulent papers is increasing rapidly. This is due, in part, to authors purchasing papers through “paper mills,” which generate literature by recycling text and figures. This illustrates the need for vigilance against deliberate fraud, which should be arbitrated with the gravity of other criminal investigations. Journals should require contributing authors to provide rigorous data to support their conclusions; standards should be implemented consistently prior to publication. Fraud should be unacceptable now and always. To guard against falsified publications, it is critical to employ a variety of safeguards including anti-plagiarism software, and image integrity analytics.

(b) Irreproducibility of Basic Research

Apart from fraud (i.e., scientific misconduct discussed in (a) above), there is another major issue regarding biomedical research—the elephant in the room. It is the irreproducibility of preclinical research and/or data due to sloppy science. In this regard, I refer to an excellent review⁹¹:

We are in the midst of a widening research crisis. The current pervasive culture of science focuses on rewarding flashy, eye-catching, and positive findings. There is an increased emphasis on making provocative statements rather than presenting technical details or reporting basic elements of experimental design. These are some of the factors that have resulted in irreproducible preclinical research in biomedicine, mainly from academia. There are reports that less than one-third of biomedical papers can be reproduced; this is due to sloppy science blamed in part on scientific culture, training, and incentives. A survey of nearly 900 members by the American Society for Cell Biology in 2015 found that more than two-thirds of respondents had been on at least one occasion unable to reproduce published results. These results are strikingly similar to another online survey of 1,576 researchers by Nature conducted in 2016 that reported that 70% of researchers have tried and failed to reproduce another scientist's experiments, and more than half have failed to reproduce their own experiments. Irreproducible research delays treatments, wastes time, and squanders research dollars. It is clearly widespread. In fact, it is seen in all disciplines of biomedical research, with the area most susceptible being research work that employs animal models. Research institution administrators, faculty members, and trainees all share blame here. They must do far more for reproducibility of biomedical research data. Most institutions will, however, not make the necessary moves unless forced by a regulatory or funding body. However, note that there is no evidence to suggest that irreproducibility is caused by scientific misconduct [...] Obviously, human clinical trials are less at risk from irreproducibility

⁹¹Bawa, R. (2017). A practical guide to translating nanomedical products. In: J. Cornier, et al. (eds.). *Pharmaceutical Nanotechnology: Innovation and Production*. 1st edition. Wiley-VCH Verlag, Chapter 28, pp. 663–695.

because they are already governed by various regulations that stipulate rigorous design and independent oversight [...] the American Statistical Association (ASA) issued principles to guide use of the P-value and warned that P-values cannot be used to determine whether a hypothesis is true or whether the results are important. According to the ASA, misuse of P-values is also contributing to this irreproducibility crisis.

10.17 Concluding Remarks: Moving toward the Future while Reflecting on the Past

Yesterday is but a dream, tomorrow but a vision.

—Indian Proverb

Life is short. Break the rules, forgive quickly, kiss slowly, love truly, laugh uncontrollably, and never regret anything that makes you smile.

—Mark Twain (1835–1910), American Writer

We do not learn from experience... we learn from reflecting on experience.

—John Dewey (1859–1952), American Psychologist

Don't judge your greatness by your shadow at sunset.

—Pythagoras (570 BC–495 BC),
Greek Philosopher and Mathematician

Learn from yesterday, live for today, hope for tomorrow. The important thing is not to stop questioning.

—Albert Einstein (1879–1955),
American Physicist and Nobel Laureate

I have been fortunate enough to be an active participant in the development of the most interesting and exciting areas of cell biology and biomedicine, and in the elucidation of essential concepts for both fields. My career has been a journey, whose destination never was clear along the way. Through my research and during my travels, opportunities continually presented themselves though I had little more than a guess as to where they might lead. In broad brushstrokes, I have made strides in the fields of spermatology, microscopy, reproductive medicine, cardiology, and cell biology. Yet, when I reflect on my publications and curriculum vitae, I realize they are the product of an uncharted walk along the paths of opportunity; they are not the purposeful pursuit of prowess in a specific area. I hope that my ability to navigate uncertain, and sometimes dire circumstances might provide encouragement to students. My personal and professional life proves a simple point: In the face of uncertainty and extreme odds, one can not only survive but thrive. The message is clear: Never give up, look forward, and put your best with honest intentions.

Whatever may have shaped my meandering, the rewards have been many and regrets few (“*Tell me, what is it you plan to do with your one wild and precious life?*”—Mary Oliver). I fan the embers of fading memories to understand how and why such meandering has been so fruitful. One ember, which still is glowing in the ashes of my memories, is a passion for science and biomedical research. It is important to have passion for whichever path one chooses. I chose benchwork over patient care. Money and fame should be secondary considerations. With training and inspirational education that began in my childhood home, my life’s journey led to scientific satisfaction and travels to exotic lands. Following retirement, I have served as both consultant and scientific advisor, which has been stimulating and pleasant. I still am invited to give lectures, participate in workshops, and write articles for journals and books. Obviously, now I cannot undertake or participate in such events, at least not with the same vigor. Age does have its limitations. I look back and feel that I have led a very full and productive life and have created something for future generations. I hope that I have spawned generations of scientific offspring, who continue my scientific legacy and make crucial contributions to the development of basic sciences and applied biomedicine. This would symbolize the continuity of science and the passing of the torch to the next generation.

Over the later years of my academic life, teaching became a passion equal to—if not more important than—research. Initially, my teaching was limited to a few courses: microscopic anatomy and microscopy. Later, I became involved in giving guest lectures in at least seven more courses, including some outside of my department. Over the past 65 years, I have taught more than a dozen different courses, and thousands of students have passed through my classes. Additionally, I have served as thesis advisor to around 37 master’s and PhD students. Both the students who passed through my classrooms and the graduate students in my laboratory have gone on to successful careers in academia, government, and industry around the globe. In short, it has been a tremendous joy and privilege to conduct research and to teach. It has been an exciting experience to observe and participate in the growth of the Department of Biophysics at Panjab University in Chandigarh: from one employee when I took charge in 1964 to approximately 70 when I retired three decades later. The years since have been full, challenging, and gratifying. Several of my students, classmates, collaborators, staff members, and colleagues from around the world have maintained contact with me. I make a point of calling as many of them as I can on New Year—a process that generally takes most of the day.

The educational process of teaching and research is one of teamwork between students and teachers. The student’s qualifications must include the ability and willingness to learn while the teacher’s qualifications must include the ability and passion to teach, provide inspiration, imagination, and impart meaningful knowledge (“*Any man can learn anything he will, but no man can teach except to those who want to learn.*”—Henry Ford). Great teachers are not born; they are

built over time and through education, perseverance, practice, and guidance. In this context, there is one point that I cannot emphasize enough: *What* is taught is important but *how* it is taught is equally significant. The great Indian surgeon Sushruta (“father of plastic surgery”), who probably lived in the 6th century BC, touches on how to be a successful student and emphasizes the importance of good study habits: “*A pupil who is pure, obedient to his preceptor, applies himself steadily to his work, and abandons laziness and excessive sleep, will arrive at the end of the science he has been studying.*”

I hope people realize that my real legacy is not in material things: It is in the intangibles of academic excellence and devotion. Live your life through experiences, not materialism. I value the people whose lives and careers I have directly impacted. I equally value those that I influenced indirectly through those whom I taught and shepherded to success. I believe that there are only three professionals in this world who are entrusted with one’s most intimate details—a physician, a priest, and a teacher. I am fortunate to be on this list.

I must vent about one issue that has damaged the international reputation of Indian universities. I lament the demise of the permanent headship system in Indian universities, including Panjab University. Permanent headship refers to life-long tenure at a university. As a rule, all central universities in India now follow the “headship rotation model.” This ill-conceived injection of democracy into Indian academia involves rotating the department chair from one person to the next, generally after a mere three years—all based solely on seniority and with complete disregard for merit or talent. As a result, a junior lecturer could be the department head when there are numerous tenured full professors. This is exactly the current situation in my former Department of Biophysics. Obviously, this ridiculous set-up has eroded confidence in and quality of Indian universities. Contrary to the assertions of those pushing for the expansion of this outrageous system, it does little to ensure equality, accountability, shared responsibility, and a cooperative work culture. In my academic experience, the permanent headship system, where the appointed person occupied the post until his/her retirement, was always based on merit. It clearly represents a superior alternative to the current headship rotation model. As a compromise, maybe a hybrid rotation approach can be tested. According to this model, the senior-most professor would take over as the department head for a period of time, or upon the retirement of the incumbent; after expiry of the term, the next senior-most professor takes over as department head. In those rare circumstances where the departments have no professor or associate professor, the senior-most lecturer/assistant professor could serve as head. Things are not that rosy at US universities either. From my perspective, there has been a gradual loss of academic freedom, inflation of student grades, unjustified increase in tuition, rise of legacy admissions, financial influence to drive specific agendas, and a curriculum (at least in the sciences) that poorly prepares the student for the global economy. Not to sound cynical, but

maybe this is simply a reflection of our rotten societal forces that persist today, mediocrity at every level in academia, few inspirational educators, and lack of visionary administrators.

I still follow developments of my department from afar, which celebrated its Golden Jubilee in 2014 (Photos 46–48). In commemoration of this occasion, I took my immediate family from the US to Chandigarh to participate in the week-long festivities. My former MSc student, Dr. D. K. Dhawan, Professor and Chair of the department, not only organized a world-class program but ensured that we had a comfortable stay at the university guest house. Celebrations were filled with lectures, seminars, social events, parties, and variety programs. The Vice-Chancellor, Dr. A. K. Grover, inaugurated the opening session and gave a wonderful presentation highlighting noteworthy achievements of the university (Photo 46). He mentioned that he was an undergraduate at the university in 1969 and had attended the international symposium that I had organized then (Photo 40). He also made an interesting observation that I never previously thought of: A founder of an institute or department almost never is present for the Golden Jubilee celebrations. There was a poignancy in this observation because I knew in my heart that it would be the last time our immediate family would be together. I was right.



Photo 46. Inauguration ceremonies of the Golden Jubilee of the Biophysics Department in 2014. The Vice-Chancellor of Panjab University, Dr. A. K. Grover, is on the left, Dr. D. K. Dhawan, Professor and Chair, is in the middle, and I am on the right.

Golden Jubilee Year - Biophysics Alumni Meet - 2014



Photo 47. Group photograph taken at Pinjore Gardens during the Golden Jubilee celebrations of our Biophysics Department in 2014. As can be seen in the background, the Garden complex is beautifully illuminated at night. Pinjore Gardens, a historic 17th century Mughal Garden located in the foothills of the Himalayas, were one of summer retreats of the Mughal Emperor Aurangzeb (1658–1707), who then had his capital at Lahore. Pinjore Gardens have often been used as a setting for filming Bollywood movies.



Photo 48. Pinjore Gardens at night. This exquisite, historical garden is well-known for its fountains, lush greenery, and its various water bodies.

Nowadays, I live in Virginia (Photo 49) with my son and daughter-in-law (Photo 50). My son is my caregiver and I have no words for the daily sacrifices he makes tending to my myriad of ever-increasing needs. His world revolves around me. At times, I feel worthless: almost 94 years old, handicapped, with severe osteoarthritis, limited mobility, poor eyesight, urinary incontinence, and substantial hearing loss. I am more aware than ever that time is finite (*"Time obliterates the fictions of opinion and confirms the decisions of nature."*—Cicero). I feel depressed, only to be quickly reminded that I am still mentally sharp and in a loving home. I do realize that I have never had any surgeries or cognitive issues. I still manage to venture out frequently and maintain a relatively active social network. As I analyze my life and look back, I have a better perspective of things, both good and bad (*"Getting old is like climbing a mountain; you get a little out of breath, but the view is much better!"*—Ingrid Bergman). I do appreciate everything and take things in stride, as I always have.

I lost my gentle Rani on September 21, 2020. I miss her because she was my whole world, my life, and the very reason for my existence. We were married for 66 years but knew each other for more than 80 years. I always could count on her valuable advice, support, and unconditional love. While returning home from a long day's work, I knew that she would be waiting for me with a lovely smile, a warm heart, and an amazing meal. (*"There is no greater happiness for a man than approaching a door at the end of a day knowing someone on the other side of that door is waiting for the sound of his footsteps."*—Ronald Reagan). I miss the way Rani (Photo 51) talked, the way she walked. I miss the way she laughed at my jokes, especially on those occasions when she accompanied me to speaking engagements and had to listen to my old stories again. I miss her warmth, calm demeanor, and the sunshine of her smile. I miss her every second of every minute (*"It has been said, 'time heals all wounds.' I do not agree. The wounds remain. In time, the mind, protecting its sanity, covers them with scar tissue and the pain lessens. But it is never gone."*—Rose Kennedy).



Photo 49. My residence in Ashburn, in picturesque Loudoun County, Virginia. Loudoun is the nation's wealthiest county with the highest median household income. It is also where 70% of the world's internet traffic flows through every second of every day.



Photo 50. Rani and I with our son and lovely daughter-in-law, Sangita, at Rensselaer Polytechnic Institute in Troy, New York, around 2006. The occasion was the annual international biotechnology conference organized and chaired by my son. The beautiful fall foliage of Upstate New York is visible in the background.



Photo 51. At home with Rani in Niskayuna, New York (c. 2002). Happier times!

(रहें ना रहें हम महका करेंगे बनके कली, बनके सबा, बाग-ए-वफ़ा में / *rahe na rahe hum mahakaa karenge, banke kali banke sabaa baagh-e-wafaa mei*; translation from Urdu: *Whether or not I am here, this fragrance will remain, as if a flower, as if a breeze in our devoted garden.*—Majrooh Sultanpuri)

(नाम गुम जाएगा चेहरा ये बदल जाएगा मेरी आवाज़ ही पहचान है गर याद रहे / *naam gum jaayegaa chaharaa yeh badal jaayegaa merii aavaaz hii pahchaan hai gar yaad rahe*; translation from Hindi: *My name will disappear; my face will change with time; only my memory will remain as my identity, just remember this.*—Gulzar and R. D. Burman).

Disclosures and Conflict of Interest

This chapter is based, in part, on my autobiography that is currently under preparation. The stories penned here spun out at speed because at my age there is hardly anything to live on except nostalgia and recreating the past. They have benefited from my conversations with countless individuals over time. I have especially enjoyed summoning my dear friends, siblings, classmates, colleagues, students, employees, and family to sessions of sweet memory. Many of them now sleep their last sleep, I have wept at the separation.

In 2010, I started penning my autobiography. Prior to this, I had collected reference materials, photographs, notes, letters, and my previous short articles—all serving as the basis for a decent start for this chapter. There were days when I would handwrite or type 5–25 pages, spanned by weeks when I was idle, busy with other things, or tending to my ailing wife. All our lives, whether in Europe,

India, or US, Rani and I lived in a single-family home, blessed to have each other's company and support. When Rani was gone, my precious security blanket and pillar of strength were lost; there was little motivation to continue on with my autobiography or this chapter. It is only because of the kind encouragement and support of the publisher and the editors of this volume that I concluded this chapter.

Sometimes my handwriting was legible, while other times, I had a hard time deciphering it. Although I tried to be chronological in my approach, often I could not make sense of the sequence of events that I had recorded. Eventually, I got a large amount of my writings typed. Then, I meticulously edited it, cross-checking for accuracy and timelines. Finally, I was further able to piece together events, travels, visits, lectures, incidents, and conferences. The editors and publisher meticulously read many iterations of the manuscript and insisted on further reflection and clarification. They also made several helpful suggestions and saved me from many errors. My deep gratitude to them.

The views expressed in this chapter are solely mine. No writing assistance was utilized to produce this chapter and no payment was received for its preparation.

Acknowledgements

I would be remiss not to acknowledge my many collaborators, mentors, teachers, students, staff, and colleagues, without whom I never could have accomplished what has been done over the past 75 years. They were some of the smartest people I've had the privilege to work with. My departmental faculty and staff at Panjab University, while I was department head and later dean, provided superb support, advice, and undertook all assignments with honesty and dedication. Many colleagues and, especially, my many teachers have contributed much to my scientific work and personal growth. I truly appreciate the confidence they had in me. They lit up my career path, so I could achieve my goals. Their doors were always open to me, and they were extremely generous with their time and advice. I have tried my best to follow their example and reciprocate the favor. Finally, I also would like to thank the editors for soliciting this chapter and the publishers for their patience in receiving it. Although, they have been subjected to multiple versions of the various parts of this chapter, they have provided outstanding advice and criticism throughout the process.

Included among my collaborators are all the graduate students and postdoctoral fellows, who "worked in the trenches" and made much of the progress possible. Their dedication, fresh perspectives, passion, novel insights, challenging questions, and honest hard work were critical to the research endeavors in my laboratory. It made the discovery process productive and exciting. They ended up teaching me new skills, techniques, and inspired me. They are (in alphabetical order): Avtar K. Attri, P. Bahl, S. Bahl, Harminder K. Bains, Madhu Bhasin, P. P. Bidwai, N. C. Bissonauth, Reena Darbari, Ranjana Deo, D. K. Dhawan, P. Gill, G. S. Gupta, S. Hussanmal, M. S. Jabbar, R. Kachroo, S. C. Kapur, R. Kaul, Rajinder Kaur, Rashwinder Kaur, Neelam Mahajan, Ricky Malhotra, Raj K. Marwaha, Meena Mehra, Balraj Mittal,

Ashok Moza, R. Pannu, P. Prakash, C. M. Pathak, Adarsh Pratibha, C. P. Puri, R. K. Rai, N. K. Relan, Rupinder K. Sandhu, P. Sharma, S. K. Sharma, Ishwar Singh, S. Singh, and Rakesh C. YashRoy.

Since 1951, my research has been funded by fellowships and grants from numerous sources: Fulbright Program, US Department of State; Cornell University Medical College, New York City; Columbia University, New York City; The Population Council, Inc., New York City; University of Wisconsin-Madison, USA; UCLA, USA; University of Manitoba, Canada; Panjab University, India; Alexander von Humboldt Foundation, Germany; University Grants Commission, India; Indian Council of Medical Research; PL 480 Funds, US Department of Agriculture; Bawa Biotech, LLC, USA; Worcester Foundation for Experimental Biology, USA; University of Hamburg, Germany; Downstate Medical Center, New York City; Tata Institute of Fundamental Research, India; Albany Medical Center, USA; New York State Department of Health, USA; Saarland University, Germany; Medical University of Graz, Austria; and University of Siena, Italy.

I fondly acknowledge the faculty, technicians, clerks, and non-teaching staff members of my Biophysics Department at Panjab University from 1964 until my retirement in 1992. These are (in no particular order): Dr. G. S. Gupta, Dr. Ashwani Koul, Dr. K. C. Kanwar, the late Dr. F. S. Nandel, the late Dr. S. N. Sanyal, Dr. M. L. Garg, Dr. M. R. Bansal, Dr. N. R. Kalla, Dr. D. K. Dhawan, Dr. Bimla Nehru, Dr. P. P. Bidwai, Dr. V. K. Shukla, Dr. N. K. Relan, Dr. D. V. Rai, P. K. Sharma, Dr. Rajesh Mehra, the late Dr. Shimla Bansal, the late Dr. P. C. Mangal, Dr. M. P. Bansal, Dharam Singh, Kishori Lal (department photographer), Krishan Lal (department librarian), Pal Singh (first employee in 1964), Kashmiri Lal, Pritam Chand, K. S. Verma, Roshan Lal, the late Gurbachan Singh, Charan Singh, Asutaty Mehta, Kuldeep Singh, Dharma Singh Dogra, the late Ram Avadh, Ram Chander, Neelam Batra, Sham Lal, the late Som Dutt, the late Barsati Ram, Chaman Lal, Balaur Chand, Bharat Bhushan, Karam Singh Thakur, Manohar Lal Chug, Ram Samujh, Amarjit Singh, Yash Pal, Ajmer Singh Kang, Damodar Dass, and Sewai Singh.

Over the years, I have collaborated with numerous investigators and researchers, including the late Dr. Vishwa Nath (Panjab University); the late Dr. Gerhard Werner (Saarland University, Germany); Dr. Toshio Nagano (University of Chiba, Japan); the late Dr. Jean Andre (University of Paris, France); Dr. Marianne A. Pabst (University of Graz, Austria); the late Dr. E. Horstmann (University of Hamburg, Germany); the late Dr. Baccio Baccetti and the late Dr. Romano Dallai (both of the University of Siena, Italy); the late Dr. Pawan K. Singal (University of Manitoba, Canada); the late Dr. Brij L. Gupta (University of Cambridge, UK); the late Dr. F. S. Sjöstrand (UCLA, USA); the late Dr. Hans Ris (University of Wisconsin-Madison, USA); Dr. Raj Bawa (Bawa Biotech LLC, USA, Guanine Inc., USA, and Teva Pharmaceutical Industries Ltd., Israel); Dr. Garish Govil (Tata Institute of Fundamental Research, India); the late Dr. D. V. S. Jain (Chemistry Department, Panjab University); Dr. Donald Fishman, (Anatomy Department, Downstate Medical Center, New York City); Dr. S. P. Anand (National Dairy Research Institute, India); Dr. Kathleen McDonough (New York State Department

of Health, Albany, NY, USA); Dr. G. S. Gupta, Dr. P. P. Bidwai, Dr. N. R. Kalla, Dr. U. Kanwar, Dr. K. C. Kanwar, Dr. N. K. Relan, and Dr. M. R. Bansal (all of the Biophysics Department, Panjab University); Dr. C. P. Puri (Institute of Research in Reproduction, India); and Dr. Shoba Sehgal (Postgraduate Institute of Medical Education and Research, India). Over the years, technical support of Madan Lal Sharma and Kishori Lal (Panjab University); E. Maatz (Saarland University); Betty Wallace and Robert Ward (Columbia University); and Brigitta Sjöstrand (UCLA) is gratefully acknowledged.

I would also like to acknowledge various individuals who have helped me along my journey by offering counsel or providing support: the late Dr. George N. Papanicolaou; the late Dr. Leonard L. Ross, the late Dr. George B. Chapman (all former Professors of Anatomy, Cornell University Medical College, New York City); Dr. Shaker A. Mousa (Endowed Professor, Albany College of Pharmacy, Albany, NY); Dr. S. Sirsat (former Professor, Cancer Research Institute, Bombay, India); the late Des Raj Kapur (Catering Business Owner, Hoshiarpur, India); the late Dr. R. K. Misra (former Professor and Head, All India Institute of Medical Sciences, Delhi, India); Kamal Doshi (Certified Public Accountant, McLean, VA); Dr. P. N. Srivastava (former Vice Chancellor, Allahabad University, India); Dr. Vinod Shah (former Vice Chancellor, Ahmedabad University, India); Dr. Ashok SenGupta (formerly of Harvard Medical School and BU School of Medicine, Boston, MA); Theresa B. Marangas (Attorney, Meier Law Firm PLLC, Latham, NY); Lata Maheshwari (Certified Public Accountant, Herndon, VA); the late Dr. R. E. Beamish and Dr. N. S. Dhalla (both former Professors at the University of Manitoba, Canada), Dr. Charles W. Boylen (Professor Emeritus, Rensselaer Polytechnic Institute, Troy, NY); the late Dr. Shanti Swarup (former Professor and Head, Political Science, Panjab University, Chandigarh, India); Dr. Charles A. Trout (Primary Care Physician, Albany, NY); Bryan M. Clenahan, (Attorney and former Albany County Legislator, Albany, NY); the late Mr. K. S. Bedi (*Everyday Science*, Biophysics Department, Panjab University, Chandigarh, India); the late Dr. Noboru Higashi (former Professor, University of Kyoto, Japan); Stephanie Martino-Kilmartin (Licensed Real Estate Salesperson, Clancy, Albany, NY); the late Dr. G. F. Meyer (former Professor, Germany); Lilit Ghazaryan (Artist and Poet, Rockville, MD); Kishor Doshi and Kalpana Doshi (Richmond, TX); the late Dr. Neuman (former Professor, Saarland University, Germany); Dr. Mabel M. P. Cheng (Eye Surgeon, Niskayuna, NY); the late Dr. H. S. Vashisht, Dr. Ram Parshad, the late Dr. G. L. Arora, Dr. O. P. Dhingra, the late Dr. Romesh Satija, the late Dr. Deshraj Kapoor, Dr. Shakti Kapoor, Dr. B. N. Sud, the late Dr. Usha Kanwar, the late Dr. G. P. Sharma (all former Professors of Zoology, Panjab University, India); the late Dr. Rajender Pal (Director of Fisheries, Himachal Pradesh); the late Dr. Saroj Mehta (Professor of Pediatric Gastroenterology, Postgraduate Institute of Medical Education and Research, India); the late Dr. Rastogi (former Professor of Endocrinology, Post Graduate Institute of Medical Research, India); Dr. Cheema (former Professor of Botany, Panjab University, India); Elizabeth A. Pacheco (Purcellville, VA); the late Dewan Anand Kumar, the late Dr. A. C.

Joshi, the late Lala Suraj Bhan and Dr. A. K. Grover (all former Vice-Chancellors of Panjab University, India); the late Dr. Roop C. Sawhney (former Professor, New York University, New York City); the late Dr. Keith Porter (former Professor, Rockefeller Institute for Medical Research, New York City); the late Dr. Arthur Pollister (former Professor and Chair of Zoology, Columbia University, New York City); the late Dr. Marion Hines (former Professor of Zoology, Columbia University, New York City); the late Dr. Donald Fawcett, (former Professor and Chair of Anatomy, Cornell University Medical College, New York City); the late Dr. Roy C. Swan, Jr. (former Professor and Chair of Anatomy, Cornell University Medical College, New York City); the late Dr. M. S. Randhawa (former first Commissioner of Chandigarh, India); Nilima Mehra (Journalist and TV Producer, MHz Networks, Fairfax Station, VA); Florence Montgomery (Nurse, Schenectady, NY); Jayne Thrane (Caregiver, Melrose, NY); Arvind Kanswal (Associate Publisher, Jenny Stanford Publishing, Singapore); Paula Dalotto-Lippitt (Entrepreneur, Altamont, NY); Maxwell W. Lippitt (Software Engineer, Altamont, NY); Dr. Pathak (Professor of Biophysics, Postgraduate Institute of Medical Education and Research, India), Dr. Rajesh N. Mehra (Primary Care Physician, Fairfax Station, VA); the late Sam Coleman, Jr. (Handman, Albany, NY); Dr. Ajaib Singh (Professor, Panjab University, India); Dr. Ambrish K. Gupta and Dr. Jyotsna Gupta (Primary Care Physicians, McLean, VA); Dr. Ken Belle and Terry Belle (Authors and Poets, Richmond, TX); Michelle C. Rost, Jennifer S. Rudolph and Prem Jaddu (Managers, 1st National Bank of Scotia, Niskayuna, NY); Dr. Albert N. Huho (Dermatologist, Schenectady, NY); Dr. Robert Busch (Endocrinology Department, Albany Medical Center, Albany, NY); Dr. Richard Holub (Physician, Albany, NY); Dr. Jay K. Doshi (Dentist, Spring, TX); Dr. Sulagna Mookherjee (Associate Professor, Cardiology Department, Albany Medical Center, Albany, NY); Dr. Aisha Awais Sarwar (Pharmacist, St. Peter's Hospital, Albany, NY); Dr. Alok Rustogi (Primary Care Physician, Potomac Falls, VA); Dr. Paul J. Davis (Co-Founder, NanoPharmaceuticals LLC, Rensselaer, NY); Tony Rossler (Caregiver, Scotia, NY); and Dr. Darrell Reisner (Ophthalmologist, Reston, VA).

Brief Biography



S. R. Bawa, MSc, PhD, is currently scientific advisor at Bawa Biotech LLC, a biotechnology and patent law firm founded in 2002 and based in Ashburn, Virginia. Previously, he was Founding Chairman and Professor of Biophysics at Panjab University, Chandigarh, India (1964–1992). At Panjab University, he also served as Dean of Foreign Students (1986–1988) and Coordinator of the Biotechnology Center (1986–1988). He was president of the Electron Microscopy Society of India (1986–1992), Secretary of the Indian Biophysical Society (1986–1988), and Founding Secretary of the Northern India Science Association (1966–1992). Dr. Bawa received his BSc (University Gold Medal), MSc (University Gold Medal), and PhD degrees in 1949, 1951, and 1954, respectively, from Panjab University. He was a Fulbright Fellow and Instructor (1958–1960) and a Boese Postdoctoral Research Fellow

(1959–1960), both at Columbia University. He was an Instructor (1961–1963) in the Department of Anatomy at Cornell University Medical College. In 1964, at the age of 34, he assumed the position of Founding Head and Reader of the newly established Biophysics Department at Panjab University, Chandigarh, India. He was promoted to Professor and Head in 1969. After retiring from Panjab University in 1992, Dr. Bawa joined the David Axelrod Institute of the New York State Department of Health in Albany, New York, from where he retired in 1999. Dr. Bawa has published over 150 scientific papers in peer-reviewed journals, books, and conference proceedings. His numerous accolades include Alexander von Humboldt Fellowship, Germany (five times); Fulbright Fellowship, US; US Alumni Research Travel Grant, US; Boese Postdoctoral Fellowship, Columbia University, US; British Council Invitee, UK; Diatome Award of the Electron Microscope Society of America; PL-480 Research Project and Appreciation Award, US Department of Agriculture; Kazato Research Award, Japan; and National Lectureship, India. He is an elected member or life member of various professional societies and organizations. He has served on various international scientific committees, advisory boards, government expert panels, and held visiting professorships in the US, Canada, and Europe. He has been a member of various peer-reviewed international journal editorial boards, including *Ultramicroscopy* (1986–1995, Elsevier), *Andrologia* (1993–1995, Blackwell/Wiley), *Acta Anatomica* (1974–1977, Karger), *Journal of Ultrastructure Research* (1969–1985, Elsevier) and *Journal of Submicroscopic Cytology* (1970–1977, Università di Bologna). Since 2004, the *Dr. S. R. Bawa Merit Scholarship* is awarded by Panjab University to a student standing first in the BSc (Honors School) class in biophysics. In 2022, Panjab University presented Dr. Bawa the *Distinguished Alumnus Award*.

Graduate Students' Thesis Advisor

Below is the list of graduate students for the PhD and MSc (Honors School) degrees whom I supervised at Panjab University, Chandigarh, from 1970 to 1993.

Candidate	Thesis Title	Year Degree Awarded
R. Kaur	Spermiogenesis and molecular characterization of spermatozoon plasma membrane	1993
H. K. Bains	Regional heterogeneity of the sperm plasma membrane—a biophysical study	1992
S. Bahl	Human spermatozoa: Ultrastructural and magnetic resonance studies	1987
R. Kaul	Ultrastructure study of cardiac muscle of lizard, parrot and squirrel	1986
R. Darbari	Adriamycin treated rat myocardium—light and electron microscope study	1985

Candidate	Thesis Title	Year Degree Awarded
R. Kaur	Surface topography of ejaculate spermatozoon of buffalo and maturing spermatozoa of goat—an electron microscope and spin-label study	1984
I. Singh	Autonomic innervation of the female rat genital tract in relation to hormonal status and pregnancy—light and electron microscopic studies	1983
R. Malhotra	Light and electron microscopic studies of gossypol acetic acid treated rat testis and buffalo bull spermatozoa	1983
S. C. Kapur	Physiochemical and biochemical mechanisms involved in cadmium-induced renal hypertension in rats	1982
R. Kachroo	Effect of gossypol on lactic dehydrogenase <i>in vivo</i>	1982
M. S. Jabbal	Effect of electromagnetic radiations (55MHz) on human spermatozoa and seminal variations	1979
N. C. Bissonauth	Pituitary-testicular studies in the Indian palm squirrel, <i>Funambulus pennantii</i> : seasonal plasma	1979
P. P. Bidwai	Light and electron microscopic studies of the testes and associated sex glands of the Indian hedgehog, <i>Paraechinus micropus</i>	1977
P. Prakash	Biochemical and histological studies on developing cerebellum of rat stressed by maternal protein-calorie malnutrition	1977
S. Hussanmal	Changes in the epididymis of rat after vasectomy	1977
Rajinder Kaur	Effect of maternal protein calorie malnutrition of the young rat	1977
D. K. Dhawan	Immunological and biochemical studies on fractionated bull spermatozoa	1977
P. Sharma	Cytomorphological and biochemical studies of the Leydig cells in the seasonally breeding palm squirrel, <i>Funambulus pennantii</i> Wroughton	1976
R. K. Rai	Cerebellar synapses and neurotransmitter in the protein-malnourished rats	1976
S. K. Sharma	Cerebellar cortex myelinogenesis in the malnourished rat	1976
Ranjana Deo	Hyperthermia and impaired male fertility in rats	1975
A. K. Attri	Quantitative enumeration of spermatogenesis in male ground squirrel, <i>Funambulus pennantii</i>	1975
P. Bahl	Seasonal fluctuations in testicular interstitial tissue in the Indian palm squirrel, <i>Funambulus pennantii</i>	1975
G. S. Gupta	Physiochemical studies on normal and irradiated mammalian testes	1974

Candidate	Thesis Title	Year Degree Awarded
P. Gill	Testicular and epididymal study of male ground squirrel <i>Funambulus pennantii</i>	1974
N. K. Relan	Experimental studies on pineal, pituitary, testis and adrenal of the chicken	1974
B. Mittal	Experimental studies on chicken brain with special reference to the optic tectum	1974
Adarsh Pratibha	Biophysical studies on hedgehog and snake spleen	1971
R. Pannu	Visual apparatus of the common hornet, <i>Polistes hebreus Fab</i>	1971
S. Singh	Biophysics of hearing: Architectonics of hedgehog cochlea	1971
R. K. Sandhu	Histophysiology of the ovary and uterus of hedgehog, <i>Hemiechinus auritis collaris</i>	1970
R. C. YashRoy	Visual mechanism, cytochemical architecture and radiation effects of bird retina and pecten	1970
A. Moza	Mammalian olfactory bulb: Experimental studies	1970
C. M. Pathak	Normal and dark adapted reptilian retina—histochemical and biochemical analysis	1970
C. P. Puri	Pituitary-testicular interaction in the rose-ringed parakeet, <i>Psittacula Krameri scopoli</i>	1970
R. K. Marwaha	Studies on the testis and associated glands of the honey bee, <i>Apis indica</i>	1970
Neelam Mahajan	Comparative studies on the mammalian retina	1970

Principal Scientific Publications

- Nath, V., S. R. Bawa, R. K. Bhardwaj, and B. L. Gupta. (1951). Sperm formation in certain Coleoptera with particular reference to chromosome number, acrosome and mitochondrial nebenkern. *Research Bulletin of the East Panjab University* **16**:39–50.
- Bawa, S. R. (1953). Studies on insect spermatogenesis. I. Hemipter-Heteroptera. The sex chromosomes and cytoplasmic inclusions in the male germ cells of *Laccotrephes maculates* Fabr. and *Sphaerodema rusticum* Fabr. *Research Bulletin of the East Panjab University* **39**:181.
- Bawa, S. R. (1954). Studies on insect spermatogenesis. No. II. Lepidoptera. On the formation of the acrosome and mitochondrial nebenkern in *Prodenia litura* Fabr. and *Anaphaeis* sp. *Research Bulletin of the Panjab University* **45**:39.
- Nath, V., S. R. Bawa, and B. S. Bhimber. (1954). Are spindle fibres and mid-body granules artifacts? *Nature (London)* **173**:312.

- Bawa, S. R. (1955). Studies on insect spermatogenesis. No. III. Othoptera. Spermatogenesis of *Chrotogonus trachypterus* (Blanch) with observations under the phase contrast microscope. *Research Bulletin of the Panjab University* **69**:47.
- Bawa, S. R. (1957). Studies on insect spermatogenesis. No. IV. Odonata. Spermatogenesis of *Neurobasis* sp. *Research Bulletin of the Panjab University* **121**:395–399.
- Bawa, S. R. (1959). Studies on insect spermatogenesis. V. Dermaptera. Spermatogenesis of Indian Earwig, *Labidura riparia* with observations under the phase-contrast microscope. *La Cellule* **59**:7–17.
- Bawa, S. R. (1959). Studies on insect spermatogenesis. VI. The cytoplasmic inclusions in the living male germ cells of *Pyrilla* sp. and *Dysdercus cingulatus* as revealed by phase microscopy and by neutral red staining. *Cytologia* **24**:165–180.
- Bawa, S. R. (1960). Some observations on spermatogenesis of a fire-brat *Thermobia domestica*—cytochemical, phase and electron microscope study. *Journal of Applied Physics* **31**:1847.
- Bawa, S. R. (1960). Studies on insect spermatogenesis. VII. Thysanura: A morphological and cytochemical study of spermatogenesis of *Thermobia domestica* pack. *Journal of Morphology* **107**:141–161.
- Bawa, S. R. (1960). Atypical spermatogenesis in *Thermobia domestica*. *Nature (London)* **188(4756)**:1132.
- Bawa, S. R. (1961). Atypical spermatogenesis in *Thermobia domestica*. *Nature (London)* **190(4775)**:743.
- Bawa, S. R. (1962) Atypical spermatozoa of *Thermobia domestica*—an apterous insect. *Anatomical Record* **412(2)**:213–214.
- Bawa, S. R. (1963). Comparative fine structure of animal sperm tail. In: *Proceedings of the Annual Meeting American Society for Cell biology*, San Francisco, USA, p. 12.
- Bawa, S. R. (1963). Fine structure of the Sertoli cell of the human testis. *Journal of Ultrastructure Research* **9**:459–474.
- Bawa, S. R. (1963). Outer coarse fibers of the mammalian sperm tail—an electron microscope study. *Journal of Ultrastructure Research* **9**:475–483.
- Bawa, S. R. (1964). Electron microscopy of double spermatozoa of an insect, *Thermobia domestica* pack. In: M. Titlbach (editor). *Proceedings of the 3rd European Regional Conference on Electron Microscopy*, Prague, Czechoslovakia, Publishing House of the Czechoslovak Academy of Sciences, pp. 445–446.
- Bawa, S. R. (1964). Electron microscope study of spermatogenesis in a fire-brat insect, *Thermobia domestica* pack. Mature spermatozoon. *Journal of Cell Biology* **23**:431–445.
- Bawa, S. R. (1966). Epithelium of the male reproductive duct of an insect, *Thermobia domestica*. In: R. Uyeda (editor). *Proceedings of the Sixth International Congress for Electron Microscopy*, Kyoto, Japan, Maruzen Co., Tokyo, pp. 663–664.
- Bawa, S. R. (1969). Biophysics in India. In: *Proceedings of the Third International Biophysics Congress International Union for Pure and Applied Biophysics*, Boston, USA, Vol. II, pp. 108–109.
- Bidwai, P. P., and S. R. Bawa. (1969). New observations on the hearts of Indian crow, sparrow and pigeon. *Panjab University Research Journal (Science)*. **20(1-2)**:239–248.

- Bawa, S. R., F. S. Sjöstrand, K. C. Kanwar, and U. Kanwar. (1970). Pseudoscorpion spermatozoon: Phase and electron microscopy. In: P. Favard (editor). *Proceedings of the VII International Congress on Electron Microscopy*, Grenoble, France, Societe Francaise de Electronique, Paris, pp. 649–650.
- Gupta, G. S., and S. R. Bawa. (1970). Secretory activities of prostates and seminal vesicles after localized X-irradiation of rat testes. *Journal of Reproduction and Fertility* **21**:329–331.
- Kanwar, K. C., S. R. Bawa, and P. K. Singal. (1971). Mode of formation of giant cells in testicular hyperthermia. *Fertility and Sterility* **22**:778–783.
- Bawa, S. R., N. R. Kalla, S. Bansal, and K. C. Kanwar. (1971). Length of spermatozoon nuclei in normal and sterile *Callosobruchus maculatus* (Coleoptera: Bruchidae). *Annals of the Entomological Society of America* **64**(4):952–953.
- Bawa, S. R., and K. C. Kanwar. (1971). Comparative fine structure of the insect spermatozoa. *Journal of Ultrastructure Research* **37**(1–2):250–251.
- Bawa, S. R., K. C. Kanwar, and P. K. Singal. (1971). Unilateral hyperthermic shocks to rat testis. *Journal of Reproduction and Fertility* **25**(2):271–273.
- Bawa, S. R., and A. Moza. (1971) Studies on gamma irradiated mammalian olfactory bulb. In: *Proceedings of the Symposium of the Basic Mechanisms in Radiation Biology and Medicine*, Department of Atomic Energy, Government of India, pp. 569–576.
- Bawa, S. R., F. S. Sjostrand, U. Kanwar, and K. C. Kanwar. (1971). Electron microscopic studies on the “Flagellate-nonflagellate” pseudoscorpion sperm. *Journal of Ultrastructure Research* **37**(1–2):251.
- Bawa, S. R., R. P. S. Walia, S. Goyal, and K. C. Kanwar. (1971). Fine structure of the venom gland of Indian Krait. *Journal of Ultrastructure Research* **37**(1–2):257.
- Bawa, S. R., and R. C. YashRoy. (1971). Dark and light adaptation studies on chicken retina and pecten. In: E. Broda (editor). *Proc. First Eur. Proceedings of the Third International Biophysics Congress*, Baden, W. Germany, Verlag Wiener Med. Akad., Vienna, Austria, Vol. 5, pp. 123–127.
- Bawa, S. R., and R. C. YashRoy. (1971). Effects of gamma irradiation on the chicken retina. *Radiation Research* **48**(2):303–311.
- Bidwai, P., and Bawa, S. R. (1971). A new paraffin embedding technique for the localization of thiamine-pyrophosphatase and acid and alkaline phosphatases. *Indian Journal of Experimental Biology* **9**(1):107–108.
- Bidwai, P. P., and Bawa, S. R. (1971). Existence of degenerating cells in the seminiferous tubules of the normal adult and retrogressed testis of Indian hedgehog, *Paraechinus micopus*. *Journal of Reproduction and Fertility* **26**(3):359–360.
- Dhopeswarkar, G. A., and Bawa, S. R. (1971). Recent advances towards the understanding of blood-brain barrier systems. *Journal of Scientific and Industrial Research* **30**(1): 22–27.
- Gill, J., K. C. Kanwar, and Bawa, S. R. (1971). Abnormal “sterile” strain in *Callosobruchus maculatus* (Coleoptera: Bruchidae). *Annals of the Entomological Society of America* **64**(5):1186–1188.
- Gupta, G. S., and S. R. Bawa. (1971). Phosphatases in testes and epididymides of albino rats after partial body gamma irradiation. *Journal of Reproduction and Fertility* **27**(3): 451–454.

- Bawa, S. R., K. C. Kanwar, and R. K. Gupta. (1972). Interspecific hybridization and abnormal strain of *Callosobruchus maculatus*. *Annals of Entomological Society of America* **65**(5): 1241–1242.
- Bawa, S. R., and R. C. YashRoy. (1972). Effects of dark adaptation and light adaptation on the retina and pecten of chicken. *Experimental Eye Research* **13**(1):92–97.
- Bawa, S. R., and R. C. YashRoy. (1972) Effect of visible light on phospholipids and cholinesterase of the chicken retina. *Acta Ophthalmologica* **50**(4):583–588.
- Bawa, S. R., and R. C. YashRoy. (1972). Vulture retina enzyme distribution and function. *Neurobiology* **2**(4):162–168.
- Bidwai, P. P., and S. R. Bawa. (1972). Histochemical study of the seminal vesicle secretion of the Indian hedgehog with particular reference to the crystalloid bodies. *Journal of Reproduction and Fertility* **30**(2):219–223.
- Kanwar, K. C., S. R. Bawa, and P. K. Singal. (1972). Chromatographic analysis of protein hydrolysates of rat testis after heat shocks. *Fertility and Sterility* **23**(3):182–185.
- Bidwai, P. P., and S. R. Bawa. (1973). Effect of seasonal changes, testosterone and pituitary extract on the prostate of Indian hedgehog. *Indian Journal of Experimental Biology* **11**(3):175–179.
- Bidwai, P. P., and S. R. Bawa. (1973). Spermatogonial study of the Indian hedgehog, *Paraechinus micropus* in the breeding and non-breeding seasons. *Acta Anatomica* **86**(2):222–227.
- Bawa, S. R., and G. S. Gupta. (1974). Glycogen in nongerminal cells of rat testis following gamma irradiation. *Journal of Reproduction and Fertility* **41**(1):185–188.
- Bawa, S. R., and R. C. YashRoy. (1974). Structure and function of vulture pecten. *Acta Anatomica* **89**(3):473–480.
- Bawa, S. R., K. C. Kanwar, and R. K. Marwaha. (1974). Studies on sperm survival in fertile and sterile strains of *Callosobruchus maculatus* (Coleoptera: Bruchidae). *Annals of the Entomological Society of America* **67**(3):519–520.
- Bawa, S. R., K. C. Kanwar, and R. K. Marwaha. (1974). Paper chromatographic analysis of free amino acids in sterile and fertile strains of *Callosobruchus maculatus*. *Annals of the Entomological Society of America* **67**(6):997–999.
- Bawa, S. R. (1974). Epithelium of the male reproductive duct of *Thermobia domestica* (*Thysanura Lepismatidae*). *International Journal of Insect Morphology and Embryology* **3**(1):87–100.
- Gupta, G. S., and S. R. Bawa. (1974). Citric acid and phosphorous-32 activity in alcohol soluble fraction of rat prostate and seminal vesicles after localized p³² irradiation of testes. *Strahlentherapie* **148**(4):420–423.
- Gupta, G. S., and S. R. Bawa. (1974). Testicular nucleic acids and testes pituitary axis following the local body gamma irradiation. In: G. K. Rastogi (editor). *Proceedings of the Fifth Asia and Oceania Congress of Endocrinology*, Endocrine Society of India, Vol. I, pp. 228–237.
- Kanwar, K. C., S. R. Bawa, and P. K. Singal. (1974). Testicular hyperthermic shocks and the boundary tissue of the seminiferous tubules in rats. *Journal of Reproduction and Fertility* **41**(1):201–204.

- Bawa, S. R. (1975). Joined spermatozoa. In: B. Afzelius (editor). *The Functional Anatomy of the Spermatozoon*, Pergamon Press, Oxford, UK, and New York, USA, pp. 259–266.
- Bawa, S. R. (1975). Comparative studies on the origin of the chromatoid body. In: J. G. Duckett and P. A. Racey (editors). *The Biology of the Male Gamete*, Academic Press, London, UK, and New York, USA, pp. 275–278.
- Bawa, S. R., and R. K. Marwaha. (1975). Apical cells in testis of the honey bee, *Apis indica*. *Indian Journal of Entomology* **37(2)**:211–212.
- Bawa, S. R., and R. K. Marwaha. (1975). Cytochemical studies of the secretion of accessory gland and seminal vesicles of the honey bee, *Apis cerana indica* Fabr. *Journal of Apicultural Research* **14(1)**:15.
- Bawa, S. R., and R. K. Marwaha. (1975). The sperm bundles of honeybee, *Apis cerana indica*. *Experientia (Basel)* **31(6)**:684–686.
- Bawa, S. R., and K. C. Kanwar. (1975). Fine structure of *Callosobruchus maculatus* spermatozoon. *Journal of Submicroscopic Cytology* **71(1)**:71–80.
- Gupta, G. S., and S. R. Bawa. (1975). Radiation effects on testes. II. Incorporation of ⁶⁵Zn after partial body gamma irradiation of rats. *Journal of Reproduction and Fertility* **42(1)**:29–34.
- Gupta, G. S., and S. R. Bawa. (1975). Radiation effects on testes. IV. Studies on succinic dehydrogenase, cytochrome oxidase, adenosine triphosphate, and physical behavior of mitochondria following localized gamma irradiation. *Strahlentherapie* **148(6)**:633–642.
- Gupta, G. S., and S. R. Bawa. (1975). Radiation effects on rat testes. V. Studies on lysosomal enzymes (acid phosphatase and acid DNase) and their physiological significance following partial body gamma irradiation. *Journal of Reproduction and Fertility* **44(2)**:223–233.
- Gupta, G. S., and S. R. Bawa. (1975). Radiation effects on testes. VI. 5' nucleotidase and adenosine triphosphatase following partial body gamma irradiation. *Radiobiologia Radiotherapia* **16(2)**:221–234.
- Gupta, G. S., and S. R. Bawa. (1975). Radiation effects on rat testes. VII. Alterations in nucleic acids and p³² incorporation after partial body gamma irradiation. *Strahlentherapie* **149(3)**:324–332.
- Gupta, G. S., and S. R. Bawa. (1975). Radiation effects on testes. VIII. Kinetic properties of hydrolases following partial body gamma irradiation of rats. *Strahlentherapie* **149(5)**:528–534.
- Gupta, G. S., and S. R. Bawa. (1975). Radiation effects on rat testes. IX. Studies on oxidative enzymes after partial body gamma irradiation. *Strahlentherapie* **150(2)**:158–161.
- Gupta, P. K., U. Dhar, and S. R. Bawa. (1975). Effect of malathion and radiation separately and jointly upon rat enzymes *in vivo*. *Environmental Physiology and Biochemistry* **5(1)**:49–53.
- Bawa, S. R., and B. Mittal. (1976). Effect of gamma-irradiation on cholesterol of chicken brain. *Strahlentherapie* **151(2)**:162–164.
- Bidwai, P., and S. R. Bawa. (1976). Effect of testosterone and pituitary extract on the retrogressed testes and seminal vesicles of Indian hedgehog, *Paraechinus micropus*. *Indian Journal of Experimental Biology* **14**:268–271.

- Gupta, P. K., U. Dhar, V. Kapoor, and S. R. Bawa. (1976). Effect of cholinesterase inhibitor malathion on whole body irradiated rats. *Bulletin of Environmental Contamination and Toxicology* **16(2)**:219-224.
- Bidwai, P., and S. R. Bawa. (1977). Phase microscope study of the giant cells from the normal testes of the Indian hedgehog, *Paraechinus micropus*. *Acta Anatomica* **98(1)**: 101-105.
- Gupta, G. S., and S. R. Bawa. (1977). Radiation effects on testes. X. Studies on inorganic pyrophosphatase and pyrophosphate following gamma irradiation of rats. *Radiation Research* **71(1)**:83-96.
- Gupta, G. S., and S. R. Bawa. (1977). Radiation effects on testes. XI. Studies on glycogen and its metabolizing enzymes following radiation-induced atrophy. *Radiation Research* **71(1)**:97-108.
- Gupta, G. S., and S. R. Bawa. (1977). Radiation effects on testes. XII. Monovalent electrolytes in relation to radiation injury of germinal epithelium. *Radiation Research* **72(2)**: 226-237.
- Gupta, G. S., and S. R. Bawa. (1978). Radiation effects on testes. XIII. Studies on isocitrate dehydrogenase following partial-body gamma irradiation. *Radiation Research* **73(3)**: 476-489.
- Gupta, G. S., and S. R. Bawa. (1978). Radiation effects on Testes. XIV. Studies on glucose 6-phosphate dehydrogenase following partial-body gamma irradiation. *Radiation Research* **73(3)**:490-501.
- Meena, K., P. K. Gupta, and S. R. Bawa. (1978). Endrin-induced toxicity in normal and irradiated rats. *Environmental Research* **16(1-3)**:373-382.
- Bhasin, M., S. R. Bawa, and D. V. S. Jain. (1979). Resistance to hypotonic shock by sheep erythrocytes on their incubation with isotonic disaccharides. *Indian Journal of Biochemistry and Biophysics* **16(4)**:246-248.
- Gupta, G. S., and S. R. Bawa. (1979). Radiation effects on testes. XV. Role of NAD and NADP linked dehydrogenases in radiation-induced atrophy. *Strahlentherapie* **155(4)**: 287-292.
- Kumar, R., and S. R. Bawa. (1979). Hepatic silver binding protein from sparrow, *Passer domesticus*. *Experientia (Basel)* **35(12)**:1621-1623.
- Mehra R. K., S. R. Bawa, and K. C. Kanwar. (1980). ²⁰³Hg binding in the liver and kidney of frog, *Rana tigrina*. *Toxicology Letters* **61(1)**:37-42.
- Bidwai, P. P., and S. R. Bawa. (1981). A correlative study of the restorative effects of endogenous and exogenous hormones on the Leydig cells, the testis and the epididymis of the regressed hedgehog. *International Journal of Andrology* **4(5)**:590-605.
- Bidwai, P. P., and S. R. Bawa. (1981). Correlative study of the ultrastructure and the physiology of the seasonal regression of the epididymal epithelium in the hedgehog, *Paraechinus micropus*. *Andrologia* **13(1)**:20-32.
- Bawa, S. R., D. Fischman, R. R. Weihing, and H. Ris. (1982). Cultured Sertoli cells examined with TEM/HVEM and fluorescent microscopy. In: *Proceedings of the II European Workshop on Molecular and Cellular Endocrinology of the Testis*, Boekelo, The Netherlands.

- Bawa, S. R., and G. Werner. (1983). Are microtubules indispensable for sperm morphogenesis? A comparative fine structure study. In: J. Andre (editor). *The Sperm Cell*, Martinus Nijhoff Publishers, The Hague, Boston and London, pp. 245–248.
- Bawa, S. R. (1984). Microtubules in the developing spermatids of house crow, *Corvus splendens*. In: *Proceedings of the 10th International Congress on Animal Reproduction and Artificial Insemination*, Urbana, Champagne, USA, Vol. I, p. 35.
- Bawa, S. R. (1984). Electron microscopy of normal and gossypol acetic acid treated spermatozoa of Indian buffalo bull, *Bubalus bubalis*. In: *Proceedings of the 3rd Asia-Pacific Conference on Electron Microscopy*, Singapore.
- Bawa, S. R., P. K. Singal, N. K. Relan, and R. Kaur. (1985). A histochemical study of long term changes in myocardial lipid distribution induced by isoproterenol. In: R. E. Beamish, V. Panagia, and N. S. Dhalla (editors). *Pathogenesis of Stress-Induced Heart Disease*, Martinus Nijhoff Publishing, Boston, Massachusetts, USA, pp. 380–387.
- Singh, I., A. Shankaranarayanan, and S. R. Bawa. (1985). Autonomic innervation of pregnant and non-pregnant rat uterus. *IRCS Medical Science* **13(4)**:324–325.
- Bawa, S. R. (1986). Buffalo bull (*Bubalus Bubalis*) spermatozoon-TEM and SEM study. In: T. Imura et al. (editors). *Proceedings of the XIth International Congress on Electron Microscopy*, Kyoto, Japan, *Journal of Microscopy* **25(Sup.)**:2971–2972.
- Bawa, S. R., and R. Kaur. (1986). TEM and spin label study of goat spermatozoa. In: *Proceedings of the 5th International Symposium on Spermatology*, Fujiyoshida, Japan. *Development, Growth and Differentiation* **28(Sup.)**:65.
- Bawa, S. R., P. K. Singal, R. Darbari, R. Kaur, and R. Bawa. (1986). Adriamycin treated cardiac muscle—An electron microscope study. In: *Proceedings of the XIth International Congress on Electron Microscopy*, Kyoto, Japan, pp. 3525–3526.
- Bawa, S. R., and R. Kaur. (1987). Does Gossypol—a potent male contraceptive—alter sperm plasma membrane? In: *Proceedings of the ESCO-ESHRE Joint Congress*, Budapest, Hungary.
- Ishwar, S., A. Shankaranarayanan, and S. R. Bawa. (1987). Neurogenic involvement in follicular development and ovulation—a probability. *International Journal of Fertility* **32(5)**:275–282.
- Singal, P. K., S. R. Bawa, R. Darbari, R. Kaur, C. M. R. Deally, and R. Bawa. (1987). Effect of chronic Adriamycin treatment of rats on myocardium lipid histochemistry. In: N. S. Dhalla et al. (editors). *Pathophysiology of Heart Disease*, Martinus Nijhoff Publishing, Boston, pp. 297–309.
- Bahl, S., S. R. Bawa, S. Srivastava, R. S. Phadke, and G. Govil. (1988). Magnetic resonance studies of intact human spermatozoa. *Physiological Chemistry and Physics and Medical NMR* **20(3)**:183–188.
- Bawa, S. R. (1988). *Biophysics and Electron Microscopy*. Panjab University Press, India, 338 p.
- Bawa, S. R., and R. Kaur. (1988). TEM and SEM of sperm forming cells of Buffalo bull (*Bubalus bubalis*). In: S. R. Bawa (editor). *Biophysics and Electron Microscopy*, Panjab University Press, India, pp. 319–330.
- Bawa, S. R., and R. Kaur. (1988). Ultrastructure study of goat spermatozoon. In: S. R. Bawa (editor). *Biophysics and Electron Microscopy*, Panjab University Press, India, pp. 305–318.

- Bawa, S. R., P. K. Singal, R. Darbari, and R. Kaur. (1988) Ultrastructure study of rat myocardium following chronic Adriamycin treatment. In: S. R. Bawa (editor). *Biophysics and Electron Microscopy*, Panjab University Press, India, pp. 157–161.
- Bawa, S. R., and G. Werner. (1988). Cyst and flagellar sheath formation in *Diplotemnus* sp. spermiogenesis. *Journal of Ultrastructure and Molecular Structure Research* **101**:51–61.
- Bawa, S. R., and G. Werner. (1988). Mitochondrial changes in spermatogenesis of the pseudoscorpion, *Diplotemnus* sp. *Journal of Ultrastructure and Molecular Structure Research* **98(3)**:281–293.
- Ishwar, S., A. Shankaranarayanan, and S. R. Bawa. (1988). Gonadal hormones and the innervation of the utero-vaginal segment. *Asia Pacific Journal of Pharmacology* **3(1)**: 11–18.
- Werner, G., and S. R. Bawa. (1988) Acrosome formation in the pseudoscorpion *Diplotemnus* sp. *Journal of Ultrastructure and Molecular Structure Research* **98(2)**:105–118.
- Werner, G., and S. R. Bawa. (1988) Spermatogenesis in the pseudoscorpion *Diplotemnus* sp. with special reference to nuclear changes. *Journal of Ultrastructure and Molecular Structure Research* **98(2)**:119–136.
- Werner, G., and S. R. Bawa. (1989). Membranous tubes in pseudoscorpion spermiogenesis. *Tissue and Cell* **21(1)**:153–156.
- Werner, G., and S. R. Bawa. (1989). Nuclear cytoplasmic exchange during spermatogenesis. In: P. M. Motta (editor). *Progress in Clinical and Biological Research*, Vol. 296, *Developments in Ultrastructure of Reproduction*, Alan R. Liss, Inc., New York, pp. 171–176.
- Ishwar, S., A. Shankaranarayanan, and S. R. Bawa. (1989). Catecholaminergic neurons of the oviduct under different hormonal milieu. *Asia Pacific Journal of Pharmacology* **4(2)**:113–120.
- Bawa, S. R. (1990). Electron microscopy in India. *Bulletin of the Electron Microscopy Society of America* **20(1)**:47–49.
- Bawa, S. R., R. Kaur, G. Govil, and R. Phadke. (1990). ESR, NMR spectroscopy of goat (*Capra indicus*) spermatozoa. In: *Proceedings of the 10th International Biophysics Congress*, Vancouver, Canada.
- Bawa, S. R., R. Kaur, T. Nagano, S. Sehgal, and G. Govil. (1990). Biophysical view of goat (*Capra indicus*) spermatozoa. In: *Proceedings of the VIth International Congress on Spermatology*, Siena, Italy.
- Bawa, S. R., R. Kaur, and M. Pabst. (1990) Microtubules in crow (*Corvus splendens*) spermiogenesis—TEM and SEM study. In: L. D. Peachey and D. B. Williams (editors). *Proceedings of the XIIth International Congress on Electron Microscopy*. Seattle, USA, San Francisco Press, Inc., Vol. 3, pp. 52–53.
- Bains, H. K., K. C. Kanwar, and S. R. Bawa. (1991). Sertoli-germ interactions in iron administered rats—an ultrastructural study. In: G. W. Bailey (editor). *Proceedings of the 49th Annual Meeting of the Electron Microscopy Society of America*, San Francisco Press, Inc., USA, pp. 314–315.
- Bawa, S. R. (1992). Sperm-sperm associations. In: *Proceedings of the Vth Asia-Pacific Electron Microscopy Conference*, Beijing, China.
- Bawa, S. R., and H. K. Bains. (1992). Electron microscopy of associated spermatozoa of squirrel (*Funambulus pennantii*). In: G. W. Bailey et al. (editors). *Proceedings of the 50th*

- Annual Meeting of the Electron Microscopy Society of America*, San Francisco Press, Inc., pp. 624–625.
- Bawa, S. R., and H. K. Bains. (1992). Epididymal epithelial sperm interactions in Loris—a primate. In: *Proceedings of the 7th European Workshop on Molecular and Cellular Endocrinology of the Testis*, Elmau, Germany, p. 121.
- Bawa, S. R., S. Sehgal, and H. K. Bains. (1992). Sugar domains of the human spermatozoa. In: *5th International Congress on Cell Biology*, Madrid, Spain, p. 47.
- Bains, H. K., and S. R. Bawa. (1992). Changing pattern of concanavalin A receptor sites on the sperm surface of epididymal and ejaculate spermatozoa of buffalo-bull, goat and dog. In: *Proceedings of the 7th European Workshop on Molecular and Cellular Endocrinology of the Testis*, Elmau, Germany, p. 124.
- Bawa, S. R., R. Bawa, and H. K. Bains. (1993). Peanut agglutinin receptors in the epididymal spermatozoa of the palm squirrel (*Funambulus pennantii*). In: G. W. Bailey et al. (editors). *Proceedings of the 51st Annual Meeting of the Microscopy Society of America*, San Francisco Press, Inc., pp. 324–325.
- Bawa, S. R., R. Bawa, and H. K. Bains. (1993). Electron microscopy of the changes in the sperm head curvature of the palm squirrel (*Funambulus pennantii*). In: G. W. Bailey et al. (editors). *Proceedings of the 51st Annual Meeting of the Microscopy Society of America*, San Francisco Press, Inc., USA, pp. 334–335.
- Bains, H. K., S. Sehgal, and S. R. Bawa. (1993). Human sperm surface mapping with lectins. *Acta Anatomica* **145(3)**:207–211.
- Bains, H. K., M. A. Pabst, and S. R. Bawa. (1993). Changes in the lectin binding sites on the testicular, epididymal, vas and ejaculated spermatozoon surface of dog. *Andrologia* **25(1)**:19–24.
- Bains, H. K., S. R. Bawa, M. A. Pabst, and S. Sehgal. (1993). Plasma membrane alterations of the maturing goat (*Capra indicus*) spermatozoa—lectin binding and freeze fracture study. *Cell and Tissue Research* **271(1)**:159–168.
- Bains, H. K., M. A. Pabst, G. Werner, and S. R. Bawa. (1993). Ultrastructural localization of wheat germ agglutinin binding sites on the sperm surface of water buffalo (*Bubalus bubalis*): A fracture label study. *Journal of Submicroscopic Cytology and Pathology* **25(4)**:465–470.
- Bawa, S. R., G. Govil, M. S. Dhingra, G. Werner, and H. K. Bains (1993). Spectroscopic and microscopic studies of buffalo bull (*Bubalus bubalis*) spermatozoa. *Journal of Submicroscopic Cytology and Pathology* **25(1)**:37–46.
- Bawa, S. R., M. A. Pabst, G. Werner, and H. K. Bains. (1993). Capacitated and acrosome reacted spermatozoa of goat (*Capra indicus*)—A fluorescence and electron microscopic study. *Andrologia* **25(3)**:123–135.
- Srivastava, S., R. Kaur, S. R. Bawa, R. S. Phadke, H. K. Bains, S. Sehgal, and G. Govil. (1993). Maturation, capacitation and metabolism of goat spermatozoa using magnetic resonance methods. *Andrologia* **25(4)**:223–227. Germany.
- Bawa, S. R., and K. McDonough (1996). Sperm plasma membrane. In: *Proceedings of the Second Asian Oceanic Congress on Andrology*, Chandigarh, India.
- Duncan, L., S. R. Bawa, W. Liu, A. Louie, P. Kaw, J. Avino, N. L. Jumbe, G. Drusano, K. McDonough, and M. H. Miller. (1998). Effects of β -lactams with affinities for different penicillin

binding proteins (PBP) on the cell envelope of *P. aeruginosa* (Pa) as determined by differential contrast microscopy (DIC), transmission electron microscopy (TEM) and the uptake of ^3H -Gentamicin. *Interscience Conference on Antimicrobial Agents and Chemotherapy*, San Diego, California, USA.

- Bawa, R., S. R. Bawa, S. B. Maebius, T. Flynn, and C. Wei. (2005). Protecting new ideas and inventions in nanomedicine via patents. *Nanomedicine* **1(2)**:150–158.
- Bawa, R., S. R. Bawa, and S. Maebius. (2005). The nanotechnology patent 'gold rush.' *Journal of Intellectual Property Rights* **10**:426–433.
- Bawa, R., and S. R. Bawa. (2005). Protecting new inventions in nanomedicine. In: C. G. Wagner (editor). *Foresight, Innovation, and Strategy: Towards a Wiser Future*. World Future Society, Bethesda, Maryland, USA, pp. 31–44.
- Bawa, R., S. R. Bawa, S. B. Maebius, and C. Iyer. (2006). Bionanotechnology patents: Challenges and opportunities. In: J. D. Bronzino (editor). *The Biomedical Engineering Handbook. 3rd edition, Tissue Engineering and Artificial Organs*, CRC Press, Boca Raton, Florida, USA, pp. 29–1 to 29–16.
- Bawa, R., S. R. Bawa, and R. Mehra. (2016). The translational challenge in medicine at the nanoscale. In: R. Bawa (editor); G. F. Audette and B. E. Reese (assistant editors). *Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk*, Jenny Stanford Publishing, Singapore, Chapter 58, pp. 1291–1346.
- Bawa, R., G. F. Audette, S. R. Bawa, B. Patel, B. D. Johnson, and R. Khanna (editors). (2023). *Advances in Medical Imaging, Detection, and Diagnosis*. Jenny Stanford Publishing, Singapore, 1392 p.
- Bawa, S. R. (2023). My personal and professional journey: Reflections, memories and confessions. In: Bawa, R., G. F. Audette, S. R. Bawa, B. Patel, B. D. Johnson, and R. Khanna (editors). *Advances in Medical Imaging, Detection, and Diagnosis*. Jenny Stanford Publishing, Singapore, chapter 10, pp. 331–472.
- Bawa, R., and S. R. Bawa. (2023). During spermiogenesis in the hedgehog, *Paraechinus micropus*, ribosomes directly take part in the formation of the acrosome. (*In preparation*).

Chapter 11

Quantitative Polymerase Chain Reaction and Precision Medicine

Joel L. Ramirez, MD, and Johannes R. Kratz, MD

Division of Cardiothoracic Surgery, University of California, San Francisco, California, USA

johannes.kratz@ucsf.edu

Keywords: densitometry, drug resistance, electrophoresis, *Escherichia coli*, gene expression, genomics, human immunodeficiency virus (HIV), metastasis, microRNA (miRNA), minimal residual disease (MRD), molecular biology, *Neisseria meningitidis*, non-small cell lung cancer (NSCLC), Northern Blot, nucleotide extraction, polymerase chain reaction (PCR), precision medicine, proteomics, quantitative polymerase chain reaction (qPCR), sentinel lymph nodes (SLN), sequence variations, Southern Blot, standardization, *Staphylococcus aureus*, thermal cycler, tumor-node metastasis (TNM)

In this chapter, we describe what quantitative polymerase chain reaction (qPCR) is as well as provide a brief history of its development. We then focus on how it is being used in precision medicine and as a companion diagnostic. Although there is broad utility of qPCR, we utilize examples in oncology and infectious disease to exemplify how qPCR has been successfully utilized in the past. We provide evidence for the robustness of qPCR as a companion diagnostic and for its potential to become a precision medicine standard. We also address how qPCR can be used in the future, some of the limitations associated with qPCR, and how some of these limitations can be addressed.

11.1 A Brief History of qPCR

Standard polymerase chain reaction (PCR) was originally described and introduced in the 1980s by Mullis et al. [1]. Since then PCR has been utilized to clone genes, map genes, sequence deoxyribonucleic acid (DNA), and detect gene expression.

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

When it was first introduced, there was hope that it would be able to be utilized to quantify amounts of DNA originally present in samples. However, quantification of products of PCR has been challenging. In fact, when PCR was originally discovered there was a lot of controversy on whether PCR would ever be able to be quantify DNA sufficiently or accurately [2]. Soon after initial development, PCR was demonstrated to be capable of both relative and absolute quantitation under strict and ideal research laboratory conditions, which made initially made practice applications challenging [3]. Indeed, transformation of PCR to a rapid, robust, and reproducible quantitative technique took many years. In 1993, Higuchi et al. utilized a video recorder to monitor real-time detection of fluorescence emitted from ethidium bromide binding to double stranded DNA [4], allowing for real-time quantification of DNA being replicated. Since then, developments in molecular biology, chemistry, and computer science have allowed for the evolution of qPCR as an accepted mechanism for quantification of DNA.

11.2 What Is qPCR?

qPCR, also known as real-time PCR or rtPCR, is a molecular biology laboratory technique based on PCR that allows for the experimenter to identify quantities of DNA in a sample. Where traditional PCR allowed for qualitative assessment of the presence of genetic material, qPCR can give a quantitative assessment of the amount of genetic material present. This can allow for the detection of quantities of specific genes, or genetic sequences, present. qPCR is carried out similarly to traditional PCR and extraction of genetic material from samples prior to analysis is required. Depending on the sample of interest, this step varies in method and in difficulty; however, several commercially available kits are available to complete this step (Qiagen, BioRad, and Life Technologies, for example, all produce commonly used nucleotide extraction kits).

After extraction of DNA, samples containing DNA are put into a thermal cycler along with primers, deoxyribonucleotides, buffer solution, and a heat-resistant DNA polymerase. By selecting the primers, the experimenter can effectively choose the genetic sequence of interest to be replicated. The thermal cycler allows for rapid cycling between hot and cold temperatures, which allows for repeated cycles of DNA replication. These cycles typically have three distinct stages. The first stage occurs at ~95 degrees Celsius and heating to this temperature causes separation of DNA's double chain structure into two single strands of complimentary DNA. The second stage is characterized by decreasing the temperature to ~50 degrees Celsius, which allows for the binding of the DNA primers to the single strands of DNA. In the third stage, the temperature is increased to ~70 degrees Celsius, which allows for DNA polymerase to bind to the primer and single strands of DNA and undergo polymerization, creating two new pairs of double stranded DNA, identical to the original. This three-stage cycle gets repeated for 30–50 times.

Unique to qPCR is the addition of a substance marked with a fluorophore that fluoresces when excited by a specific wavelength. This fluorophore can be non-specific and have the capability to bind to any dsDNA present, giving an estimation of the amount of DNA being replicated. Fluorophore markers can also be specific and contain a DNA sequence that is complimentary to the gene of interest (TaqMan technology; Roche), although this method is more expensive and more difficult to prepare than utilization of non-specific fluorophores. Fluorescently labeled nucleotides can be used as well (SYBR technology; Life Technologies). qPCR has a fourth stage that is characterized by excitation of the fluorophore and measurement of fluorescence. Computer software can then detect the amount of fluorescence and account for the current PCR cycle to estimate the amount of DNA from the gene of interest. This allows for direct quantification of products generated with each cycle of PCR in real-time, whereas conventional PCR would have to be preceded by other separate techniques to quantify DNA.

qPCR does not rely on any additional downstream laboratory techniques or measurements (i.e., electrophoresis, densitometry, Northern Blot, or Southern Blot) to quantify the production of DNA. As such, this makes it a fairly easy test to run, decreases variability in results, and improves the reliability of it as a diagnostic test. There are several articles describing the techniques of qPCR, instrument selection, primer selection, marker selection, and software analysis of results in more depth [5].

11.3 Current Uses of qPCR in Precision Medicine

qPCR allows for a quick and accurate quantification of genetic material. This includes both DNA and RNA. However, in order to utilize qPCR to quantify RNA, the RNA must first be converted to DNA, commonly via reverse transcription. The ability to convert RNA to DNA and then quantify that amount of DNA has allowed qPCR to play a role in measuring gene expression and gene transcription. This ability has led to qPCR playing a very important role in basic and translational research. In addition to playing a role in research, qPCR has developed into having numerous clinical and diagnostic uses. The ability to quantify gene expression has positioned qPCR as a tool useful in diagnosing disease, identification of subclinical relapse of disease, monitoring treatment response, and in identification of drug targets. qPCR is a robust tool that is easily reproducible in a research laboratory or clinical laboratory. Although qPCR is currently being utilized as a companion diagnostic in several fields of medicine, we will focus on examples in oncology and infectious disease.

11.4 qPCR in Oncology

As our knowledge of cancer grows, the medical and scientific community has been able to identify several genomic and proteomic markers of disease that have

improved the ability to diagnose and treat several cancers. Additionally, genomics and proteomics has allowed for improved stratification of disease, allowing for the identification of genetic high-risk and low-risk cancers, which has improved surveillance and has helped dictate treatment modalities. qPCR has been utilized as a modality for detecting DNA and gene expression in oncologic diagnosis and treatment. Furthermore, the ability to quantify the amount of genes of interests can then be utilized to stratify total burden of disease or concern for recurrence. Although not complete nor exhaustive, we cover several examples of how qPCR is being used in precision oncologic medicine below.

11.4.1 Lung Cancer

The clinical standard for classifying lung cancer is based upon the tumor-node-metastasis (TNM) staging [6]. However, even in patients with early-stage lung cancer (Stage I and II) as determined by TNM staging, differences in outcomes have been reported. The treatment of early-stage lung cancer is typically limited surgical resection (segment or wedge) or lobectomy. Despite the greater morbidity associated with surgical lobectomy, lobectomy has been demonstrated to have superior mortality outcomes in the treatment of non-small cell lung cancer (NSCLC) [7]. The decision of whether to perform a sub-lobar resection or to remove the entire lung lobe has largely been based upon the surgeon's clinical judgment of how well a patient would tolerate a full lobectomy. It has additionally been unclear who would benefit from adjuvant chemotherapy in addition to surgical resection of the tumor in early-stage disease. In an attempt to further refine staging and the management of lung cancer on the basis of molecular differences, qPCR has been utilized to identify molecular signatures that can help aid the surgeon in determining an individual's prognosis and treatment.

In 2004, Endoh et al. reported using qPCR to determine the expression patterns of all stages of adenocarcinoma of the lung [8]. In the same study, several genes were identified and implicated in helping to determine clinical prognosis and outcomes [8]. Since then several other investigators have reported success in using qPCR to identify molecular patterns that have prognostic significance in early-stage adenocarcinoma [9–11]. In 2007, Chen et al. and Lau et al. utilized qPCR to create a molecular signature that they proved was prognostic for Stage I NSCLC [12, 13]. In 2012, Kratz et al. reported used qPCR to create an assay that identified a 14-gene molecular signature that had prognostic significance in Stage I, II, and III NSCLC [14]. The qPCR based assay developed by Kratz et al. is currently being assessed in an international clinical trial to measure the effects of adjuvant therapy in early-stage patients identified as “high risk” by this assay [15]. A follow-up study in 2019 further confirmed that addition of molecular characterization was associated with improved estimation of disease-free survival compared with conventional TNM staging in patients with NSCLC [16]. The authors concluded that incorporation of a molecular prognostic classifier into staging may lead to better identification of high-risk patients and proposed

that “biology” be added to TNM staging, which would yield a TNMB system. Similar assays utilizing qPCR have been created to help determine prognosis in squamous cell carcinoma as well [17].

In all of these cases, qPCR was used to identify tumor gene expression patterns associated with worse outcomes. There is the potential for these qPCR-based gene signatures to improve traditional TNM staging, and assessment of their use in directing surgery as well as adjuvant therapy after surgery is currently underway [15]. In addition to using qPCR to identify genes in tumor tissue, qPCR has been utilized to quantify tumor derived cell-free DNA in the serum of patients with lung cancer [18].

11.4.2 Leukemia

Leukemia is a malignant disease of the bone marrow. There are several forms of disease, each with differing prognoses. Prognosis of disease is commonly dependent on response to treatment and time-to-relapse. Relapse is believed to be due to residual disease that remains in the patient even after treatment, this is commonly referred to as minimal residual disease (MRD). Efforts have been made to measure MRD in patients during or after treatment in order to provide clinicians with prognostic information. It is believed that early identification of MRD may direct earlier treatment and improve outcomes of relapse. However, predicting or identifying subclinical disease using a minimally invasive approach poses many challenges, which makes it an elusive goal for the majority of diagnostics.

qPCR has been utilized to detect MRD in patients with several different forms of leukemia. For example, qPCR has been used to identify and quantify commonly mutated genes in the bone marrow and serum of patients with acute myelogenous leukemia (AML) [19]. Several of these genes have been reported to have prognostic significance and qPCR is highly sensitive for detecting MRD in patients with AML containing these mutated genes [19, 20].

Similarly, qPCR has been reported to play a role in assessing MRD in chronic myeloid leukemia (CML) [21]. CML is characterized by a chromosomal translocation, resulting in the creation of a fusion gene, *BCR-ABL1*, which results in a constitutively active tyrosine receptor kinase. Utilizing qPCR to quantify *BCR-ABL1* transcript levels has become the standard of care in molecular monitoring of CML [22]. These assessments are done at time of diagnosis and at 3, 6, and 12 months after beginning therapy. By quantifying *BCR-ABL1* transcript levels, qPCR is capable of measuring response to therapy. Guidelines have been written describing acceptable *BCR-ABL1* transcript levels at different stages of treatment [22]. If patients fail to meet these levels, treatments can be changed, and patients could be selected for prolonged follow-up or increased surveillance. In addition to playing a role in the assessment of AML and CML, qPCR has also been reported to play a role in assessing MRD in acute lymphoblastic leukemia [23].

11.4.3 Breast Cancer

In patients diagnosed with breast cancer, biopsy of sentinel lymph nodes (SLN) is commonly performed in order to rule out lymphatic spread of cancer cells. Determination of lymph node invasion by cancer cells has previously been done using pathology slides and stains, however, recent evidence has suggested that this underestimates the presence of disease [24]. Underestimating the spread of cancer cells into the lymphatics could mean that this subgroup of patients is receiving inadequate treatment, which could lead to higher rates of relapse and higher mortality.

Recently, qPCR has been utilized in the assessment for breast cancer cells in SLN biopsies. Utilizing qPCR to assess SLNs has increased the sensitivity of cancer cell detection and has allowed for the detection of micrometastases and individual tumor cells [25]. qPCR has been used to identify single genes in SLN as well as an array of genes associated with breast cancer. Multigene qPCR assays have been shown to have superb accuracy for detection of cancer in addition to being quick, easy, and objective when compared to histopathologic examination [26, 27]. In addition to the advantages mentioned above, utilizing qPCR to analyze SLNs improves the detectability of cancer. The use of qPCR has been reported in prospective studies to improve outcomes when compared with traditional histopathological examination [28].

In addition to assessment of SLNs, qPCR has more recently been used to detect circulating microRNAs (miRNA) associated with breast cancer. MiRNAs are a class of small noncoding RNA molecules that regulate gene expression and can be found in tissue in plasma. Certain miRNAs have been associated with tumors and are expressed irregularly when compared to patients without cancer. MiRNAs have been identified as potentially playing a role in early cancer diagnosis, staging, and prognosis. Several miRNAs have been identified in patients with breast cancer [29]. Quantifying these miRNAs, or ratios of miRNAs, could improve breast cancer diagnosis, treatment, and surveillance.

As we learn more about breast cancer, there have also been movements to begin classifying breast cancers based upon their molecular profile, similar to the TNMB staging mentioned previously [30]. As this becomes more accepted, qPCR is positioned to continue playing an important role in breast cancer diagnosis, monitoring, and precision medicine.

11.4.4 Colorectal Cancer

A large percentage of patients with local colorectal cancer, as deemed by TNM staging, eventually go on to develop metastases even after surgical resection of the tumor. Metastasis is characterized by spread of the tumor cells from the primary tumor into the lymphatics or bloodstream where they can spread to other organs in the body. Identification of tumor cells circulating in the plasma can be done via cytology, immunocytochemistry, or flow cytometry. However, all of these methods are slow, inefficient, and lack sensitivity. qPCR has recently been used to identify tumor cell genes and RNA circulating in the plasma.

qPCR has been used to identify single genes and multiple genes extracted from circulating tumor cells [31] in the plasma. Although there is currently limited data on the use of these techniques in colorectal cancer, the existing data suggests that quantification of genetic products from circulating tumor cells may play a role in prognosis, surveillance, and treatment of colorectal disease [31]. In addition to assessing for circulating tumor cells, qPCR has also been utilized as a screening tool to measure miRNAs associated with colorectal cancer [32]. Although results vary depending on selection of miRNAs to assay, using qPCR to measure these miRNAs has resulted in high sensitivity and high specificity diagnostic assays [33].

11.4.5 Gastric Cancer

Gastric cancer is another form of cancer that benefits from accurate diagnosis, staging, and treatment, all of which are challenged by imperfect methods of disease detection. Peritoneal dissemination of cancer cells has been associated with poor outcomes including metastases and relapse of disease [34]. There have been several attempts to use cytology and immunocytochemistry to identify the presence of intraperitoneal tumor cells using peritoneal lavage. Although conventional peritoneal lavage cytology is highly specific, it lacks sensitivity.

Similar to colorectal cancer, qPCR can be utilized to identify genetic contents of gastric tumor cells. However, in contrast to colorectal cancer and in the context of gastric cancer, we are interested in assessing for the presence of tumor cells within the peritoneal cavity. qPCR can be utilized to detect genes associated with gastric cancer cells extracted from peritoneal lavage samples. When compared to conventional methods of intraperitoneal cancer cell detection, qPCR has been reported to be superior to cytology with a higher sensitivity [35], making qPCR the best tool to detect the presence of intraperitoneal tumor cells in gastric cancer. The presence of intraperitoneal tumor cells, as detected by qPCR, has also had prognostic significance and has been reported to be associated with an increased risk of death and intraperitoneal metastases [36]. Furthermore, early detection of intraperitoneal tumor cells may allow for additional treatment focused to the peritoneal cavity.

In addition to playing a role in identifying the presence of intraperitoneal tumor cells, qPCR has been used to assess for lymph node invasion [37] and the presence of plasma miRNAs related to gastric cancer [38]. Additionally, the use of qPCR has also been reported to be superior to traditional histopathological examination in assessing for lymph node invasion [39] in gastric cancer.

11.5 qPCR in Infectious Disease

Several infectious diseases have similar presentations with overlapping signs and symptoms, making it difficult to correctly differentiate them. However, treatments for these diseases differ and if the correct treatment is not prescribed then patients are at risk for developing worse infection that can lead to increased

morbidity and mortality. It is therefore critical to be able to quickly and accurately diagnose infectious diseases with high sensitivity and specificity. In addition to providing diagnoses, qPCR can be utilized to quickly assay for the presence or absence of mutated genes, which can help assess for drug resistance and can direct treatment. Advantages of utilizing qPCR versus standard PCR in the diagnosis of infectious diseases includes increased sensitivity, improved reliability, low contamination risk, and the benefits of an automated process [5]. qPCR has been used to complement the management of bacterial, viral, fungal, and parasitic infections but we will focus on examples of the management of bacterial and viral infections as these forms of infection are generally more common.

11.5.1 Bacteria

qPCR has been utilized to identify several forms of bacteria including *Staphylococcus aureus*, *Neisseria meningitidis*, *Escherichia coli*, several groups of *Streptococcus*, and *Clostridium difficile*, among many others [40]. There are several advantages of utilizing qPCR rather than cultures to diagnose bacterial infections. Culturing bacteria is a time- and resource-intensive process which requires microbiology laboratory staff to regularly check the cultures and follow-up with clinicians. It commonly can take days-to-weeks for growth of bacteria to occur in cultures, sometimes even months. Several bacterial are unable to be cultured, require weeks-to-months to culture, and/or require special culture medium. Additionally, it requires the proper collection and transportation of samples from the bedside to the microbiology laboratory without contamination. Utilization of qPCR reduces the steps required to make an accurate bacterial diagnosis and reduces the role of human error.

In addition to identifying bacterial organisms in a rapid and efficient manner, qPCR can allow for the detection and quantification of genes that code for virulence factors [41]. Identification of virulence factors could help direct antibiotic selection and improve the speed at which the patient receives the appropriate antibiotic. This not only would reduce the risk of the infection progressing but utilizing narrow and specific antibiotics rather than broad-spectrum antibiotics could reduce the development of antibiotic resistance and reduce the incidence of adverse outcomes associated with broad-spectrum antibiotic use (gastrointestinal upset, hospital-acquired infection, disruption of microbiome, etc.).

Diagnosing infections by mycobacteria using conventional techniques has been difficult. These conventional techniques include acid-fast staining and complex medium cultures, which are both time-intensive and have poor sensitivity. Additionally, these conventional techniques do not help differentiate species of mycobacterium. However, recent utilization of qPCR to detect mycobacteria has led to an improvement of sensitivity and a reduction of diagnosis time from weeks to hours [5]. Additionally, qPCR can be utilized to differentiate families of mycobacteria and identify the presence of genes that can confer resistance to commonly used antitubercular drugs [5]. Examples of these genes include the *rpoB*

and *katG* genes, which are both genes that when mutated can confer resistance to rifampin and isoniazid, respectively [5]. Improved detection of infection by mycobacteria and accurate identification of the presence of drug resistance allows for earlier and more accurate diagnoses as well as improved treatment selection. Proper management and treatment of mycobacteria infections has significance worldwide.

11.5.2 Viruses

qPCR has also recently begun to play a role in the management of viral infections. Viruses can be more difficult to identify than bacteria. Culturing viruses is a difficult and long process, compared to culturing bacteria. Given these challenges, diagnosing viral infections has largely been accomplished using conventional PCR. Although conventional PCR has been utilized to diagnose several viral infections, qPCR has an additional benefit of being able to quantify the amount of virus present. This is commonly referred to as the viral load and it plays a crucial role in surveillance of infection with human immunodeficiency virus (HIV). Being able to quantify the amount of virus present is also useful in serial monitoring of transplant patients who are being assessed for evolving infections or response to treatment. Lastly, quantification of viral loads can help differentiate patients who are carriers of virus or who have been previously infected from patients who may be actively infected. This may help direct clinical decision-making and selection of interventions.

In addition to utilizing qPCR to manage infections with HIV, qPCR has been used to diagnose herpes simplex virus, varicella zoster virus, influenza virus, coronavirus, cytomegalovirus, and Epstein–Barr virus among many others [5]. During the COVID-19 pandemic, qPCR played an integral role in testing for the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was responsible for the devastating disease [42]. In addition to being quicker and easier to perform, qPCR has been shown to have improved sensitivity in identifying these viruses when compared to conventional PCR. qPCR techniques have the added benefit of being able to quantify the amount of virus, which has many applications and uses specific to several viruses.

11.6 Limitations of qPCR

As with any laboratory technique, there are some limitations to qPCR. Since qPCR is a molecular assay, selection of the appropriate gene or genes of interest is required for analysis. This can be difficult when assessing for genes that are unknown, polymorphic, or have sequence variation. If the gene overlaps between cells or organisms then there is a risk of having false positives results. Genes of interest may also change over time. For example, as cancers, infectious diseases, and genes associated with medication resistance adapt over time, genes that are of interest now may no longer be in the future or might have mutated genetic sequences.

A method to address these issues is to develop multiple-gene assays, which can assess for the presence of several genes. Multiple-gene assays also allow for the assessment of several cell types or organisms at the same time, which positions qPCR as a superb screening test.

Another limitation to the widespread use of qPCR is the lack of commercial standardization of assays between laboratories. It is particularly difficult to compare results of scientific studies of assays when their methods differ slightly. However, this is becoming less and less of a problem as the use of qPCR grows and commercialization of assays becomes more common. For example, this issue has already been addressed by the creation of quality control programs in utilizing qPCR for diagnosing influenza in avian samples [5]. Similar programs could be created to ensure the ability to compare across assays.

Lastly, qPCR is slightly more expensive than conventional PCR. Although the cost difference between individual assays is small, equipment utilized to run qPCR is more expensive than conventional PCR. Additionally, it requires time and financial resources to adequately construct assay protocols and train staff, both of which are key to developing reproducible and reliable results [5]. This leads to fairly large start-up costs for laboratories interested in utilizing qPCR. However, many hospital and clinics are able to send samples out to commercial laboratories to have qPCR analyses run.

11.7 Future Use of qPCR in Precision Medicine

qPCR is a robust and reliable laboratory technique that has been demonstrated to have excellent sensitivity and specificity for identifying genes of interest. With proper standardization and laboratory technique, qPCR is easily reproducible within and between institutions. qPCR has already been demonstrated to be an excellent companion diagnostic and has a significant role in precision medicine. Its use is continuing to grow as limitations are addressed.

Abbreviations

AML:	acute myelogenous leukemia
CML:	chronic myeloid leukemia
DNA:	deoxyribonucleic acid
HIV:	human immunodeficiency virus
miRNA:	microRNAs
MRD:	minimal residual disease
NSCLC:	non-small cell lung cancer
PCR:	polymerase chain reaction
qPCR:	quantitative polymerase chain reaction
SARS-CoV-2:	severe acute respiratory syndrome coronavirus 2
SLN:	sentinel lymph nodes
TNM:	tumor-node-metastasis

Disclosures and Conflict of Interest

This chapter was originally published as: Ramirez, J. L., Kratz, J. R. (2019). Quantitative polymerase chain reaction for companion diagnostics and precision medicine application. In: Kim, I.-J., ed. *Companion Diagnostics (CDx) in Precision Medicine*, Jenny Stanford Publishing, Singapore, chapter 3, pp. 55–72, and appears here, with edits and updates, by kind permission of the publisher.

References

1. Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. *Cold Spring Harb Symp Quant Biol* 1986; 51 Pt 1: 263–273.
2. Ferre F. Quantitative or semi-quantitative PCR: reality versus myth. *PCR Methods Appl* 1992; 2: 1–9.
3. Wang AM, Doyle MV and Mark DF. Quantitation of mRNA by the polymerase chain reaction. *Proc Natl Acad Sci U S A* 1989; 86: 9717–9721.
4. Higuchi R, Fockler C, Dollinger G, et al. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. *Biotechnology (N Y)* 1993; 11: 1026–1030.
5. Espy MJ, Uhl JR, Sloan LM, et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. *Clin Microbiol Rev* 2006; 19: 165–256.
6. Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2017; 12: 1109–1121.
7. Ginsberg RJ and Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. *Ann Thorac Surg* 1995; 60: 615–622; discussion 622–613.
8. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. *J Clin Oncol* 2004; 22: 811–819.
9. Bianchi F, Nuciforo P, Vecchi M, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. *J Clin Invest* 2007; 117: 3436–3444.
10. Reed CE, Graham A, Hoda RS, et al. A simple two-gene prognostic model for adenocarcinoma of the lung. *J Thorac Cardiovasc Surg* 2008; 135: 627–634.
11. Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. *Clin Cancer Res* 2008; 14: 5565–5570.
12. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. *N Engl J Med* 2007; 356: 11–20.
13. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. *J Clin Oncol* 2007; 25: 5562–5569.
14. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. *Lancet* 2012; 379: 823–832.

15. Kratz JR, Mann MJ and Jablons DM. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature. *Transl Lung Cancer Res* 2013; 2: 222–225.
16. Haro GJ, Sheu B, Cook NR, et al. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer. *JAMA Netw Open* 2019; 2: e1917062.
17. Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. *Clin Cancer Res* 2008; 14: 4794–4799.
18. Jiang T, Zhai C, Su C, et al. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis. *Lung Cancer* 2016; 100: 63–70.
19. Cruz NM, Mencia-Trinchant N, Hassane DC, et al. Minimal residual disease in acute myelogenous leukemia. *Int J Lab Hematol* 2017; 39 Suppl 1: 53–60.
20. Tomlinson B and Lazarus HM. Enhancing acute myeloid leukemia therapy-monitoring response using residual disease testing as a guide to therapeutic decision-making. *Expert Rev Hematol* 2017; 10: 563–574.
21. Cross NC, Hochhaus A and Muller MC. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. *Ann Hematol* 2015; 94 Suppl 2: S219–225.
22. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood* 2013; 122: 872–884.
23. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. *Leukemia* 2010; 24: 521–535.
24. Dowlatshahi K, Fan M, Anderson JM, et al. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. *Ann Surg Oncol* 2001; 8: 675–681.
25. Wallwiener CW, Wallwiener M, Kurth RR, et al. Molecular detection of breast cancer metastasis in sentinel lymph nodes by reverse transcriptase polymerase chain reaction (RT-PCR): identifying, evaluating and establishing multi-marker panels. *Breast Cancer Res Treat* 2011; 130: 833–844.
26. Veys I, Durbecq V, Majaj S, et al. Eighteen months clinical experience with the GeneSearch breast lymph node assay. *Am J Surg* 2009; 198: 203–209.
27. Sai-Giridhar P, Al-Ramadhani S, George D, et al. A multicentre validation of Metasin: a molecular assay for the intraoperative assessment of sentinel lymph nodes from breast cancer patients. *Histopathology* 2016; 68: 875–887.
28. Verbanac KM, Min CJ, Mannie AE, et al. Long-term follow-up study of a prospective multicenter sentinel node trial: molecular detection of breast cancer sentinel node metastases. *Ann Surg Oncol* 2010; 17 Suppl 3: 368–377.
29. Pimentel F, Bonilla P, Ravishankar YG, et al. Technology in MicroRNA Profiling: Circulating MicroRNAs as Noninvasive Cancer Biomarkers in Breast Cancer. *J Lab Autom* 2015; 20: 574–588.
30. Wesolowski R and Ramaswamy B. Gene expression profiling: changing face of breast cancer classification and management. *Gene Expr* 2011; 15: 105–115.
31. Sergeant G, Penninckx F and Topal B. Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood--a systematic review. *J Surg Res* 2008; 150: 144–152.

32. Ahmed FE. miRNA as markers for the diagnostic screening of colon cancer. *Expert Rev Anticancer Ther* 2014; 14: 463–485.
33. Ganepola GA, Nizin J, Rutledge JR, et al. Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. *World J Gastrointest Oncol* 2014; 6: 83–97.
34. Pecqueux M, Fritzmann J, Adamu M, et al. Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis. *Oncotarget* 2015; 6: 35564–35578.
35. Kodera Y, Nakanishi H, Ito S, et al. Quantitative detection of disseminated cancer cells in the greater omentum of gastric carcinoma patients with real-time RT-PCR: a comparison with peritoneal lavage cytology. *Gastric Cancer* 2002; 5: 69–76.
36. Kodera Y, Nakanishi H, Ito S, et al. Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of followup. *J Am Coll Surg* 2006; 202: 231–236.
37. Yanagita S, Uenosono Y, Arigami T, et al. The clinical usefulness of the intraoperative detection of sentinel lymph node metastases by a rapid RT-PCR system in patients with gastric cancer. *Cancer* 2016; 122: 386–392.
38. Wang QX, Zhu YQ, Zhang H, et al. Altered MiRNA expression in gastric cancer: a systematic review and meta-analysis. *Cell Physiol Biochem* 2015; 35: 933–944.
39. Yoon H and Lee DH. New approaches to gastric cancer staging: beyond endoscopic ultrasound, computed tomography and positron emission tomography. *World J Gastroenterol* 2014; 20: 13783–13790.
40. Mothershed EA and Whitney AM. Nucleic acid-based methods for the detection of bacterial pathogens: present and future considerations for the clinical laboratory. *Clin Chim Acta* 2006; 363: 206–220.
41. Procop GW. Molecular diagnostics for the detection and characterization of microbial pathogens. *Clin Infect Dis* 2007; 45 Suppl 2: S99–S111.
42. Team C-I. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nat Med* 2020; 26: 861–868.

Chapter 12

Protein Biomarker Signatures in Precision Diagnostics of Cancer

Henrik Winther, PhD,^a and Carl Borrebaeck, PhD^b

^aImmunovia AB, Medicon Village, Lund, Sweden

^bCREATE Health Cancer Center, Department of Immunotechnology, Lund University, Lund, Sweden

henrik.winther@immunovia.com

Keywords: area under the curve (AUC), assay workflow, bioinformatics, biomarker, biopsies, cancer, China Food and Drug Administration (CFDA), circulating tumor DNA (ctDNA), clinical accuracy, cross-validation, diagnostic, enzyme-linked immunosorbent assay (ELISA), European Medicines Agency (EMA), genomics, hands-on-time (HOT), high-density antibody microarrays, immunohistochemistry, *in vitro* diagnostic (IVD), limit of detection, limit of quantification, mass spectrometry (MS), medical device, microarray, multiple reaction monitoring (MRM), multiplexing, next-generation sequencing (NGS), premarket approval, profiling, protein, proteomics, reaction monitoring, receiver operating characteristic, regulatory considerations, responsiveness, selected reaction monitoring (SRM), serum, specificity, turnaround time, US Food and Drug Administration (FDA)

12.1 Early Diagnosis and Biomarker Profiling within Cancer

Early diagnosing and patient individualized biomarker profiling are two key elements for curative interventions within cancer [1, 2]. Detecting cancer, when the tumor is still localized, allows for a more efficient treatment—either through surgery alone or with systemic therapies, treating a naïve and less heterogeneous tumor cell population. If the tumor development progresses unidentified and moves into later stages, individualized tumor biomarker profiling becomes essential for an effective treatment. Developing tumors consist of complex and stage-dependent genetic heterogenous cell-populations. Each cell clone can have different mutation profiles and various protein pathways activated, which often hinders

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

single targeted therapies to embrace all the heterogenous clonalities and therefore leads to drug inefficiency, resistance, and disease relapse. Biomarker profiling of an evolving tumor draws a picture of those driver genes and proteins activated for that specific patient with a certain tumor type and at a specific tumor stage, and hence defines a more precise (molecular) diagnosis that should be used in a personalized targeted treatment approach.

Proteomics and genomics technologies have been used intensively over the last two decades in the revealing of ever more clinical relevant proteins and genetic mutations and alterations [3–5], which might serve as feasible therapeutic targets, but are also applied in the development of specific biomarker signatures capable of either detecting a cancer in its very early stage or in dichotomizing patients into drug responders and non-responders [6–8]. During the last 5–7 years, the trend and focus have been on genome-wide sequencing of tumors, where different genomics technologies (e.g., next-generation sequencing [NGS]) are applied in the identification of genetic mutations and alterations coding for tumor driver genes [9].

Even if the proteomics technologies have not recently had the same scientific and public attention as their genomics counterpart, it is obvious that proteomics analyses (including posttranslational modifications), measuring those genes and epigenetic changes that have actually been translated into proteins and that are now dictating the current state of the disease, are extremely important for diagnostic, prognostic, predictive, and treatment purposes.

Proteomics tools have evolved during the last decade. Several new techniques, including mass spectrometry (MS), selected reaction monitoring (SRM)/multiple reaction monitoring (MRM), multiplexed enzyme-linked immunosorbent assay (ELISA), and high-density antibody microarrays, have emerged that can allow separation and relative quantification of many proteins (depth of proteome coverage) in a short period of time and at a low cost [10–12]. However, several limitations prevent them from reaching the bedside [13]. Independent of the platform chosen, the premises for the successful development of a medical device applicable for diagnostic and predictive testing purposes include several basic requirements. Let us take a closer look at these key prerequisites below.

12.2 Technology Requirements for Precision Diagnostic Medical Devices





Technology-wise, the medical device platform must assure a sufficient analytical sensitivity (limit of detection [LOD]/limit of quantification [LOQ]) and specificity as well as a robust and reliable (also known as “safe and effective” in FDA terms) precision performance—i.e., the closeness of agreement between a series of measurements obtained for the same sample under a specified set of conditions [14]. A very strong technical (analytical) performance is hence a key request, but not sufficient for the successful clinical deployment of the medical device. The

clinical (diagnostic) sensitivity and specificity, typically defined by the content of biomarkers and their algorithmic interrelationships when running on the platform, are obviously extremely important for the ability of the medical test to identify those patients with (clinical sensitivity) and without (clinical specificity) the disease of interest. An ideal assay demonstrates clinical sensitivity and specificity of 100%, but this is never achieved in practice because an increase in sensitivity is only gained at the expense of specificity, and vice versa [15, 16]. Often the combined relationship between clinical sensitivity and specificity—known as medical device accuracy—is illustrated through ROC (receiver operating characteristic) curves, where the area under the curve (AUC) represents the accuracy of the test [6, 17]. A perfect test would have an AUC at 1, but as mentioned above, this is never achieved. Usually for diagnostic tests, an AUC at 0.6–0.7 is considered poor, AUC at 0.7–0.8 is fair, AUC at 0.8–0.9 is good, and AUC 0.9–1.0 is excellent [6]. In a recently developed proteomics microarray assay for detection of early (stage I & II) pancreatic cancer, the AUC value (clinical accuracy) reached an impressive 0.98 on combining the IMMray™ platform with a protein signature (algorithm) of 25 biomarkers [18, 19]. Detecting pancreatic cancer in its early stages and with that high accuracy will have the potential to significantly improve the future survival rates of pancreatic cancer patients. With a test accuracy of AUC 0.98, assays like the IMMray™ qualify to become a monitoring tool in high-risk populations, because it is generally believed that if the risk in a given population increases 8- to 10-fold over average risk, there is a cost-benefit advantage to screening [20].

From the point of view of a technology development design, securing an *easy* market access should also be taken into consideration. Developing a diagnostic test for a technology platform already present in the routine laboratories will secure both a comprehensive footprint of the diagnostic test (easy access for patients) and an easy adaption of the test into a fully integrated system solution with an efficient laboratory workflow. Newer technologies have a longer transfer time into the routine setting, and if unintentionally designed, with an obstructive workflow, it will even further delay the uptake of the medical device [21, 22]. Taking a closer look at the current (November 2018) US food and drug administration (FDA) list of cleared or approved companion diagnostic (CDx) devices within cancer, Table 12.1 confirms a strategy of developing this kind of medical devices—i.e., predictive for drug eligibility—by applying older single-plexing technologies (IHC, ISH, PCR) using traditional test materials.

Immunohistochemistry (IHC) is such a single-plexing protein biomarker detection technology which has been around for almost 90 years [23]. The CDx IHC medical devices developed by several diagnostic companies and registered by FDA, for use within oncology, are only detecting single biomarkers (proteins) and typically performing the analysis on routine formalin fixed tissues. Such a simple assay design is in sharp contrast to those highly innovative drugs whose prescriptions to patients are subject to the test results of the IHC assays.

Table 12.1 CDx technology evolution, based on the November 2018 FDA list of cleared or approved CDx devices within cancer

Year of FDA approval → CDx technology ↓	1998–2002	2003–2007	2008–2012	2013	2014	2015	2016	2017	2018
IHC 	2	4	3	1	2	2	1	2	3
ISH 	2	1	5	1			2		
PCR 			2	3	2	3	2	4	7
NGS 								4	
Total CDx approvals	4	5	10	5	2	5	5	10	10
CDx approvals/year	0.8	1.0	2.0	5	4	5	5	10	10
#Bio-markers [^]	1	1	1	1*	1-2*	1	1-2*	1-8*	1-2*
Test Materials	FFPE	FFPE	FFPE	FFPE	FFPE:1 LiqB:1	FFPE	FFPE:2 BM: 2 LiqB:1	FFPE:6 LiqB:4	FFPE:4 LiqB:6

Abbreviations: IHC, immunohistochemistry; ISH, *in situ* hybridization; PCR, polymerase chain reaction; NGS, next generation sequencing; FFPE, formalin fixed paraffin embedded; LiqB, liquid biopsy; BM, bone marrow.

[^]Biomarkers = proteins or genes—not variants (e.g., mutations) of a specific protein or gene.

*Several mutations under each biomarker.

Note: Addition of new indications or new drugs to an already existing device—through the FDA PMA Supplement Procedure—is counted as separate entities in the table (e.g., in 2015 the PD-L1 IHC 22C3 pharmDx device was FDA approved for pembrolizumab in lung cancer and then later in 2017 and 2018 data were established to have the same kit approved as CDx's for pembrolizumab in gastric-, cervix-, and urothelial cancers, respectively—i.e., a total of 4 CDx's for the PD-L1 IHC 22C3 pharmDx device).

It is well known that the pre-analytical parameters (time to tissue fixation, actual fixation time, fixative-sample size ratio, fixative type, etc.) vary significantly within IHC and hence can lead to suboptimal test results [24, 25]. Similarly, the dynamic range of the IHC analytical sensitivity is limited and the quantitative properties of IHC barely exist [26]. Adding to this, the IHC single biomarker analysis approach, when trying to predict drug responsiveness, in a super-complex setting, staged by several pathways and multiple proteins active during a tumor development, it is surprising that the new innovative immune-oncology drugs like pembrolizumab and nivolumab are still using IHC as their preferred CDx test tool [27, 28]. IHC is, however, a technology present in every laboratory—either as a manual test procedure or as a fully integrated automated solution—which guarantees immediate access to testing for relevant patients [29].

To achieve the point where a protein biomarker signature test runs as an easy accessible routine assay procedure for precision diagnostics, and with a high analytical and clinical performance (as outlined above), this requires a full technology-system integration approach by the supplier, where all the individual steps of the system solution are optimized: sampling, technical array design, controls, and bioinformatics. It is not for this chapter to discuss the optimization of the single elements of the test system, but just to emphasize—to the developer—the importance of (and later product owner) being in “control” of all reagents, equipment, and processes, as well as their interlinkage, when applied in the diagnostic test.

12.3 Biomarker Multiplexing Provides Higher Diagnostic Accuracies

When a technology like the IMMray™, mentioned above, achieves clinical accuracies above AUC 0.9, it is tempting to assume that the driver of the high accuracy is defined by the proteomics multiplexing approach, where protein biomarker signatures, as opposed to individual biomarkers, can provide a more broad-sighted view of the pathway activities on-going during a tumor development. Expanding the number of relevant surveilled biomarkers in a diagnostic test will increase the likelihood of this test to better detect distinctively diseased patients in a global heterogeneous population [6, 30], but it is a matter of bioinformatics expertise to decide on the right biomarkers and the optimal number of biomarkers in the signature to achieve acceptable and approvable test accuracies. Different bioinformatics principles such as “Leave-one-out cross-validation,” “Backward elimination,” and “Support vector machine” are often used when deciding on which biomarkers to include—and exclude—in the final signature [31]. In the bioinformatics analysis on omics experimental data, it is important to understand that the clinical relevant diagnostic biomarker signature created is specifically designed to work within a carefully defined technical solution, and hence the individual biomarker components of the signature may not necessarily be relevant

in diagnosing the same disease, but in using a different technology. The starting point for any proteomics multiplexing assay development, before applying technology platforms and bioinformatics tools, is the biomarker depth of analysis—i.e., the content and range of proteins surveilled. Depending on the clinical question raised and the sample material type, the list of biomarkers used in the discovery phase can be chosen based on different strategies, such as specific pathway focus, pathway activated proteins, disease biology, biomarkers well established in the literature, etc. For genomics profiling technologies, the depth of analysis includes discussions around genomes, exosomes, genes, epigenetic changes, DNA versus RNA, etc. For tumor profiling, circulating tumor DNA (ctDNA) in the cell-free DNA (cfDNA) component of blood plasma and serum has become an attractive testing material (easy accessible/minimally invasive, less labor than tissue biopsies, and highly standardized collection methods) for genomics analyses [32, 33]. The leading applications for genomics liquid biopsies are projected to be the therapy monitoring and diagnosis of disease recurrence [34], even if the highly promoted Grail project will focus on developing a blood test to identify all types of cancers, particularly “the early detection of cancer in asymptomatic individuals” [35]. However, previous studies have demonstrated that the amount of ctDNA released from early-stage tumors is hardly detectable, even when extremely sensitive technologies are used for detection [36], and as a consequence, early detection of cancer using ctDNA has been challenged [35, 37].

Routine screening by ctDNA mutation detection is not practically feasible, because the achievement of a sufficient test sensitivity will require excessively high blood volumes (150–300 mL) [37]. Such high volumes will negatively impact the economic screening cost. By use of proteomics technologies analyzing blood plasma or serum samples for the expression of circulating immune-regulatory proteins, inflammatory cytokines, and certain tumor markers, it has been demonstrated that even precancerous cellular changes as well as later tumor stages can be detected with the help of signatures encompassing these biomarkers [18, 19]. Not having to wait for an actual tumor to be well established and secreting ctDNA into the blood circulation is clearly a major advantage of the above-mentioned proteomics techniques, because they will be able to identify a tumor in its very early development (Fig. 12.1). The IMMrayTM microarray proteomics platform is such a proteomics technology, and apart from its diagnostic capabilities of very early stage pancreatic cancer patients, the platform only requires 10 μ L serum per sample to run a test, which all together makes the assay attractive as a screening tool [38, 39]. The consensus today is that the information content is too limited in single-biomarker tests and that multiplexing is an absolute requirement to achieve high enough clinical accuracy, in particular for early diagnosis [6].

Biomarker multiplexing and establishment of diagnostic signatures obviously do not have to be confined to either a proteomics, a genomics, or other omics technologies. In the lately reported CancerSeek blood test the levels of eight

proteins are evaluated in combination with the screening for mutations in 2,001 genomic positions. The presence of a mutation in a gene or an elevation of the level of any of these proteins will classify a patient as positive. Currently, the CancerSeek test is pursued within eight cancer types [40], although early detection of these cancers will be much hampered because of the rather limited sensitivities.




Figure 12.1 Cancer diagnostic time slots pending the technology applied.




Figure 12.2 The biological information flow clearly illustrates proteins as key biomarkers both enabling the actual cell functions and regulating gene expression.

Combining genomics and proteomics information into a diagnostic, prognostic, or predictive biomarker signature captures the central dogma of biological information flow: DNA encodes the RNA messenger. RNA builds the proteins. Proteins ultimately enable structure and function, bringing genes, including the oncogenes, to life. Proteins further regulate the genes through a selectively controlled turning on and off of certain genes in certain cells, at certain times. Conceptually, the complex nature of biological information flow is illustrated in Fig. 12.2.

12.4 Regulatory Considerations

Protein-based profiling assays used for diagnostic, prognostic, predictive, and monitoring purposes are obligated to follow the country-by-country regulatory standards required by authorities with regard to medical devices. Depending on the markets pursued by the single assay provider, the regulatory requirements can be very different [41]. When relevant markets have been chosen as “go-to-markets,” and the intended use of the assay has been locked, the individual country regulatory requirements will naturally define the assay development design requirements and clinical data that have to be established for this specific device to satisfy the authorities. The intended use of an assay should typically include clear definitions on specimen type, testing methodology, disease condition(s), and the clinical question answered by the test [42, 43]. Currently, the attractive markets for precision diagnostics typically include the US, Europe, Japan, and China. Below, we discuss the regulatory guiding principles in the US and Europe while only touching upon some high-level considerations for other countries.

12.4.1 United States

In the US, *in vitro* diagnostic (IVD) medical devices are divided by FDA into three different classes, depending on the intended use of the device and the risks to the patients that could occur if the test fails [16, 44]. A protein biomarker signature-test used to provide information that is essential for the safe and effective use of a corresponding therapeutic product will be classified as a class III device, posing a significant risk to the patient, because the test alone decides the patient treatment regimen. When such a predictive biomarker assay is linked to the indication of a specific drug, it is called a CDx [45, 46]. Another type of class III IVD devices—complementary diagnostics—has quite recently (autumn 2015) been introduced by the FDA, but without any official definition or guideline issued on the subject. Unlike companion diagnostics, complementary diagnostics aid the therapeutic decision process, but are not required when prescribing the corresponding drug. The impact of complementary diagnostics, and how the two types of class III tests come to share the stage, remains to be seen [47].

Class III devices undergo the highest regulatory scrutiny where the test provider must demonstrate, through intensive analytical and clinical validation

studies, that the device is robust and reliable in patient care. All data have to be submitted to and approved by the FDA before the IVD test can be marketed—also known as premarket approval (PMA) [44, 45]. For a protein biomarker-signature test used as a stand-alone device for early detection of a certain cancer type, the FDA would typically review and “clear” the IVD assay through the premarket notification pathway, categorizing the device as a moderate-risk, class II (otherwise known as 510(k)) product. The regulatory standard for 510(k) review is that the assay provider must demonstrate that the safety and effectiveness of the new device is “substantially equivalent” to a predicate device, which is obviously a lower burden of proof than demonstrating for the first time (class III products) that the device is robust and reliable. If no predicate device exists, the FDA permits clearance through the 510(k) De Novo pathway, where assay providers are required to demonstrate the safety and effectiveness of the device, but unlike class III devices, a premarket inspection of the manufacturing site is not required [44].

The lowest risk device, class I, is an IVD test typically used in combination with several other tests to confirm a diagnosis. Class I devices do not require premarket FDA approval or clearance, but are still to be registered and listed with the FDA [44].

12.4.2 European Union

In the EU and other regions like Japan, Australia, and Canada, changes in the medical IVD regulations are currently under way and especially devices used as companion diagnostics experience stronger and updated requirements [45]. Since April 2017, the new EU medical device regulations (MDR) and IVD regulations (IVDR) have been in effect, but the transition period is 5 years, and hence it is not until May 2022 that all medical devices used in the EU will have to comply with the requirements of the new IVDR [48, 49].

There are two major changes in the EU regulations. Today, the European Medicines Agency (EMA) does not regulate or approve the diagnostic test; rather, marketing of test requires that the assay provider obtains a CE marking. CE marking (Conformite Europeene) indicates that the product has been assessed and meets the EU safety, health, and environmental protection requirements. Therefore, it is the assay providers themselves who perform a product conformity assessment and who self-certify the product. In the new MDR system, the product conformity assessment must be performed by an independent notified body, which also has to consult the EMA or one of the medical product national competent authorities. The second major change includes the introduction of a risk-based classification system that takes patient impact into consideration. Today, in the EU, companion diagnostic products are classified as “general IVDs,” which means low-risk devices—even if these CDx’s are used as stand-alone decision tools for the treatment of patients. With the new IVDR, CDx’s are no longer considered “low-risk” devices; they are referred to as class C products,

indicating high individual risk or moderate public health risk. The higher risk classification of CDx's, naturally increases the analytical and clinical performance requirements, as well as strengthens the conformity assessment, as mentioned above, before the products achieve the CE marking and are released into the EU market. Likewise, the postmarket surveillance activities for class C products have also been updated with more stringent requirements [48, 50].

12.4.3 China

Protein multiplexing IVD assays for precision diagnostics in China is likely to be classified as class III products in a classification system using principles similar to the ones applied on IVDs under the FDA in the US. In China, the China Food and Drug Administration (CFDA) is the main agency that oversees drugs and medical devices, including IVDs, and it is mandatory that medical device manufacturers register their devices prior to any commercialization in China [51]. Class III medical devices require full registration, including in-country testing, formal technical review, and possible clinical trials prior to approval. For devices manufactured outside China, the CFDA registration also requires proof of marketing approval from the country of origin. The in-country testing is performed according to Chinese national and industrial standards (stability, accuracy, repeatability, etc.) and has to take place at a CFDA authorized test center (currently, there are 22 such centers), who will issue the outcome test report, ideally confirming the analytical robustness and reliability of the assay [52]. The CFDA will naturally also require clinical evaluation of class II and class III devices. For a new protein multiplexing IVD precision diagnostics, the clinical evaluation data will most likely be generated through a clinical study conducted in China. A common procedure would include testing of at least a thousand Chinese specimens in three different hospitals. There are two alternatives to the local Chinese clinical study when establishing the clinical evaluation data. One is reusing the clinical data used for approval/certification in the manufacturer's home country, but this requires strong data on the patient ethnical distribution. Alternatively, a manufacturer can provide a report leveraging clinical data/literature of a predicate device already on the Chinese market. However, authorization from the predicate device's manufacturer needs to be obtained for any unpublished data, and hence the competitive barrier may block this route [53].

12.5 Other Prerequisites to the Successful Release of Protein Biomarker Signatures for Precision Diagnostics

Even if the newer diagnostic technologies like the IMMray™ demonstrate innovative and compelling clinical performance through their biomarker multiplexing approach on liquid patient samples combined with bioinformatics-generated treatment decision-making algorithms, and all according to the relevant regulatory

requirements, successful market introduction of an assay still depend on a couple of important customer requirements.

12.5.1 Assay Workflow, Turnaround Time, and Hands-On Time

To become a routinely applied test, the assay will need to easily adapt into the workflow of traditional diagnostic laboratories. Parameters like turnaround-time (TAT), hands-on-time (HOT), testing capacity, and maintenance are essential in this respect. Laboratory TAT is measured from the time the sample arrives at the molecular pathology laboratory until the result is reported, while total TAT is measured from the time the sample is taken from the patient until the diagnostic result is reported. The length of both types of TAT may vary according not only to the complexity of the assay but to the logistics involved, including regional differences due to infrastructure issues and the logistics of transporting samples in some areas. NGS is perhaps the most complex testing methodology and takes longer to perform. It is not available in all laboratories and is more likely to be undertaken in academic institutions or commercial laboratories. It has been observed that in the US, KRAS testing in non-small-cell lung cancer using NGS has an average laboratory turnaround time of 13 days compared with Sanger sequencing with an average of 9 days [54, 55]. Lately, it has been reported that up to 50% of patients could be missing out on the right targeted therapy due to insufficient TATs [56]. Figure 12.3 illustrates, as an example, the IMMray™ proteomics laboratory TAT, which is significantly better than the abovementioned NGS TAT's.



Figure 12.3 The IMMray™ proteomics laboratory turnaround time starts after the patient sample has been received (day 1). The initial steps include the actual microarray testing (day 2), followed by a microarray scanning (day 2). The scanned color-intensities, representing different protein biomarkers, are interpreted through a cloud-based algorithm (day 2), which will then provide the final test result reported to the physician (day 3).

Minimizing the hands-on-time during patient sample handling and assay processing has two important purposes. Minimal operator interaction will limit the manual labor required to run a test and hence provide an opportunity for

maximizing the resource efficiency, which in the end will lower the operating laboratory costs. In addition, a low HOT is typically achieved through a higher degree of automation of the assay procedure, whereby fewer errors from “human hands” are tied into a distorted testing result. Turning complex multiplexing proteomics profiling assays into fully automated platforms, displaying robust and reliable test results, is therefore a task that has to be considered during the assay design phase. The Idylla™ platform from the company Biocartis is a school example of a fully automated assay platform designed and developed to achieve an optimal TAT and HOT in the laboratory workflow while still keeping high diagnostic accuracies. The Idylla™ instrument is a real-time PCR platform. It can do simultaneous detection of up to 30 molecular targets in one of its cartridges, and it covers the entire process from sample to result within 150 minutes with less than 2 minutes of hands-on time [57].

12.5.2 Assay Reimbursement and Inclusion in National Guidelines

A recent commentary [58] suggested that after two decades or more of technology and method development, proteomic technologies have in recent years advanced to where they can be routinely applied to clinical questions. That said, the authors of the commentary acknowledged that even as the technical challenges of proteomic test development have become more manageable, questions of regulatory approval, reimbursement, and clinical adoption remain significant hurdles to successful commercialization. The regulatory challenges were addressed in Section 12.4. When it comes to reimbursement of a proteomic diagnostic test, the approach is very similar to the regulatory strategy: depending on the commercialization markets pursued by the test-provider, each country has its own separate system for covering medical devices. It is therefore important to develop a reimbursement strategy in parallel with the development of the regulatory and clinical strategy for new proteomic diagnostic devices. In the ideal world, the new diagnostic device would be covered universally by insurance companies in all patient care settings. The ideal coverage would also happen through existing codes, meaning those codes already established as an “insurer language” representing the specific services provided to patients. The codes are used on claim forms submitted to insurers to enable payers to process and pay claims efficiently [59]. Establishing a new code—i.e., the new proteomics diagnostic device cannot be described by existing codes—is a much more cumbersome process requiring a good body of clinical data. Finally, the ideal coverage would lead to a product payment sufficient and adequate for providers (e.g., hospitals and physicians) in each setting where the product will be used. Even if the medical device coverage systems are country based, they are typically defined through the three “reimbursement pillars,” coverage, coding, and payment, as described in the text above. Different countries have different ways/institutions (including clinical policy units) of assessing whether a medical technology warrants clinical coverage. However, as a guiding principle the medical diagnostic

device should fulfill the following criteria: (i) The diagnostic test must have final approval from appropriate governmental regulatory bodies, where required. (ii) Scientific evidence must permit conclusions about the effect of the test on medical outcomes. (iii) The proteomics diagnostic test must improve net health outcomes (iv) The diagnostic test must provide as much health benefit as established alternatives. (v) The improvements in health must be attainable outside investigational settings [60]. In some countries it is required by law also to consider public comments during the coverage determination process, before the final judgement is made [61].

Having obtained an adequate reimbursement for the new proteomics cancer diagnostic test is certainly quite an accomplishment and a big step towards acceptance within the medical community. Getting the test into national cancer diagnostic guidelines determines the next stage of product success. The national cancer guidelines are, as the word *national* implies, country specific (some countries with several guidance providers, e.g., the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) in the US), with different procedures for evaluating and approving the new technologies. In general, a new diagnostic test is likely to be selected, and hence become a new national diagnostic guideline, if the test meets the country specific eligibility criteria (i.e., it is considered innovative from a technology point of view, has been regulatory approved/cleared, and its price is reasonable, etc.), and if the test offers substantial benefits to patients or the health and care system compared with current practice. These benefits need to be supported by strong evidence, including advices from experts, patients, and caretakers. It should also be demonstrated that the development of a national guidance will mean a faster and more consistent adoption of the new technology into the routine diagnostic setting.

12.6 Future Perspectives

A great deal of progress has been made in the field of precision diagnostics of cancer in the recent years. The complex nature of a developing cancer has made it clear that diagnostic medical devices need to be founded on technologies capable of performing multiplexed biomarker analysis and thereby achieve clinical sensitivities that are much improved compared to the current single-plexing tests. From Table 12.1, it can actually be observed that we are slowly moving away from the earlier days' single-plexing biomarker strategy into today's multiplexing approach, allowing for more precise and more effective intended uses of our cancer diagnostic devices. Biomarker multiplexing comes hand in hand with a much stronger focus on bioinformatics, combining the multiple biomarker expression data (from different omics technologies) with other relevant patient demographics/clinical data and converting these into signatures and algorithms that constitute the basis for molecular diagnostic, prognostic, and predictive clinical claims. The recently announced CancerSeek Test—testing

for 16 genes as well as 8 serum protein biomarkers—is a good example of a multiplexing test, where two omics (proteomics and genomics) observations are combined into an algorithm (machine-based learning) dichotomizing patients into healthy and diseased sub-cohorts.

The CancerSeek Test is certainly not complete in many ways, yet forward-looking in some perspectives. First is the test's use of patient non-invasive liquid biopsies—in this case, circulating tumor DNA (ctDNA) from the blood—versus today's routine use of surgical biopsies like formalin-fixed and paraffin-embedded (FFPE) tissues, for analysis. From a patient-, workflow-, standardization-, and cost perspective, the use of liquid biopsies for biomarker analysis is certainly preferable. Liquid biopsies have the potential to revolutionize cancer care. However, there are challenges to the widespread use of this new approach and there is still a place for tissue biopsies. For liquid biopsies, it is still relatively early and some questions still need to be answered. For example, to what extent does test accuracy vary among tumor types and stages of disease? Does the liquid biopsy provide a representative sampling of all the genetic clones in a tumor or is there a bias to specific subregions? Researchers are currently working to answer these questions.

A second forward-looking perspective of the CancerSeek Test is tightly connected to the above-mentioned use of liquid biopsies. The biggest benefit lies in the potential of liquid biopsies to detect disease progression or treatment resistance long before it would trigger clinical symptoms or appear on imaging scans. Deciphering blood with the help of a proteomics technology, like the IMMray™, allows for a multiplexed biomarker surveillance of the body's immune response and thereby very early detection of changes in the biomarker profiling as a consequence of different cellular activities in the tumor establishment process. This will lead to a much earlier detection of a developing cancer and hence the possibility of an earlier curative intervention. The immune system is by far the most sensitive biosensor, and basing a diagnostic test on changes in this systemic response to disease will outperform all other tests based on the *in situ* presence of an established tumor, including technologies utilizing ctDNA, IHC, MS, circulating tumors/exosomes, etc., simply by the fact that even the initial changes in the host immune responses are captured. Diagnosing cancer earlier by using minimal invasive sampling, and with significantly higher sensitivities, certainly promises a bright future, which, naturally, will also make an important difference to the way we understand and treat cancer in the future.

Abbreviations

- ASCO: American Society of Clinical Oncology
- AUC: area under the curve
- BM: bone marrow
- CDx: companion diagnostic
- CFDA: China Food and Drug Administration

cfDNA: cell-free DNA
 ctDNA: circulating tumor DNA
 ELISA: enzyme-linked immunosorbent assay
 EMA: European Medicines Agency
 FDA: US Food and Drug Administration
 FFPE: formalin fixed paraffin embedded
 HOT: hands-on-time
 IHC: immunohistochemistry
 ISH: *in situ* hybridization
 IVD: *in vitro* diagnostic
 IVDR: *in vitro* diagnostic regulations
 LiqB: liquid biopsy
 LOD: limit of detection
 LOQ: limit of quantification
 MDR: medical device regulations
 MRM: multiple reaction monitoring
 MS: mass spectrometry
 NCCN: National Comprehensive Cancer Network
 NGS: next-generation sequencing
 PCR: polymerase chain reaction
 PMA: premarket approval
 SRM: selected reaction monitoring
 TAT: turnaround-time

Disclosures and Conflict of Interest

This chapter was originally published as: Winther, H., Borrebaeck, C. (2019). Quantitative polymerase chain reaction for companion diagnostics and precision medicine application. In: Kim, I.-J., ed. *Companion Diagnostics (CDx) in Precision Medicine*, Jenny Stanford Publishing, Singapore, chapter 4, pp. 73–96, and appears here, with edits and updates, by kind permission of the publisher.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. *CA Cancer J Clin.* 2017; 67:7–30.
2. Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, et al. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPACT) trial. *Clin Cancer Res.* 2015; 21(9):2029–2037.
3. Riley CP, Adamec J. Discovery of new biomarkers of cancer using proteomics technology. *Curr Cancer Ther Rev.* 2011; 7(2):91–103.
4. Sallam RM. Proteomics in cancer biomarkers discovery: challenges and applications. *Dis Markers.* 2015; 2015:321370.
5. Boutros PC. The path to routine use of genomic biomarkers in the cancer clinic. *Genome Res.* 2015; 25(10):1508–1513.

6. Borrebaeck CAK. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. *Nat Rev Cancer*. 2017; 17(3):199–204.
7. Neagu M, Constantin C, Tanase C, Boda D. Patented biomarker panels in early detection of cancer. *Recent Pat Biomark*. 2011; 1:10–24.
8. Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. *Clin Transl Med*. 2014; 3(7):1–36.
9. Tokheim CJ, Papadopoulos N, Kinzler KW, Vogelstein B, Karchin R. Evaluating the evaluation of cancer driver genes. *Proc Natl Acad Sci USA*. 2016; 113(50):14330–14335.
10. Ahmad Y, Arya A, Gangwar A, Paul S, Bhargava K. Proteomics in diagnosis: past, present and future. *J Proteom Genom Res*. 2014; 1(1):1–10.
11. Yu X, Schneiderhan-Marra N, Joos TO. Protein microarrays for personalized medicine. *Clin Chem*. 2010; 56(3):376–387.
12. Abbatiello SE, Schilling B, Mani DR, Zimmerman LJ, Hall SC, et al. Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. *Mol Cell Proteomics*. 2015; 14(9):2357–2374.
13. Breker M, Schuldiner M. The emergence of proteome-wide technologies: systematic analysis of proteins comes of age. *Nat Rev Mol Cell Biol*. 2014; 15:453–464.
14. Clinical and Laboratory Standards Institute. *EPO5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline*. 2nd ed. Wayne, PA: NCCLS; 2004.
15. Lalkhen AG, McCluskey A. Clinical tests: sensitivity and specificity. *Cont Ed Anaesth Crit Care Pain*. 2008; 8:221–223.
16. Füzery AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. *Clin Proteomics*. 2013; 10(13): 1–14.
17. Hajian-Tilaki K. Receiver operating characteristics (ROC) curve analysis for medical diagnostic test evaluation. *Caspian J Intern Med*. 2013; 4(2):672–635.
18. Melby LD, Holmer A, Wingren C, Johansen J, Bojesen SE, et al. Early-stage diagnosis of pancreatic cancer offers opportunity to improve overall patient survival. *Ann Oncol*. 2016; 27(6):vi15–vi42.
19. Melby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, et al. Serum biomarker signature-based liquid biopsy for diagnosis of early stage pancreatic cancer. *J Clin Oncol*. 2018; 36(28):2887–2894.
20. Andersen DK, Andren-Sandberg A°, Duell EJ, Goggins M, Murray K, et al. Pancreatis-diabetes-pancreatic cancer. *Pancreas*. 2013; 42(8):1227–1237.
21. Zineh I, Huang S-M. Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. *Biomark Med*. 2011; 5(6):705–713.
22. McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. *Sci Transl Med*. 2013; 5(189):189sr4.
23. Duraiyan J, Govindarajan R, Kaliyappan K, Palanisamy M. Applications of immunohistochemistry. *J Pharm Bioallied Sci*. 2012; 4(2):307–309.

24. Atkins D, Reiffen K-A, Tegtmeier CL, Winther H, Bonato MS, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. *J Histochem Cytochem.* 2004; 52(7):893–901.
25. Engel K, Moore H. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. *Arch Pathol Lab Med.* 2011; 135(5):537–543.
26. Rudbeck L. Adding quality to your qualitative IHC. *Med Lab Obs.* 2015; 47(12):18–21.
27. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. *J Thorac Oncol.* 2017; 12(2):208–222.
28. Phillips T, Millett MM, Zhang X, Jansson M, Cleveland R, et al. Development of a diagnostic programmed cell death 1-ligand 1 immunohistochemistry assay for nivolumab therapy in melanoma. *Appl Immunohistochem Mol Morphol.* 2018; 26(1):6–12.
29. Grand View Research. Immunohistochemistry (IHC) market analysis by product (antibodies, reagents, equipment, kits), by application (diagnostics, drug testing), by end-use (hospitals, diagnostic laboratories), & segment forecasts, 2014–2025. Report ID: GVR-1-68038-718-6, 2017.
30. Shenglin M, Wenzhe W, Bing X, Shirong Z, Haining Y, et al. Multiplexed serum biomarkers for the detection of lung cancer. *EBioMedicine.* 2016; 11:210–218.
31. Harishchander A. A review on application of biomarkers in the field of bioinformatics & nanotechnology for individualized cancer treatment. *J Proteomics Bioinform.* 2017; 5(6):1–6.
32. Bettgowda C, Sausen M, Leary RJ, Kinde I, Wang Y, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med.* 2014; 6(224):224ra24.
33. Haber DA, Velculesc VE. Circulating tumor cells and circulating tumor DNA. *Cancer Discov.* 2014; 4:650–661.
34. Belcher K. Therapy monitoring emerges as a promising application for liquid biopsy. *Frost and Sullivan Press Release.* 2016. Available at: <https://www.frost.com/news/press-releases/majority-users-identify-therapy-monitoring-promising-liquid-biopsy-application/> (accessed on November 20, 2022).
35. Aravanis AA, Lee M, Klausner RD. Next-generation sequencing of circulating tumor DNA for early cancer detection. *Cell.* 2017; 168(4):571–574.
36. Phallen J, Sausen M, Adleff V, Leal A, Hruban C. Direct detection of early-stage cancers using circulating tumor DNA. *Sci Transl Med.* 2017; 9(403):eaan2415.
37. Haque IS, Elemento O. Challenges in using ctDNA to achieve early detection of cancer. *bioRxiv* 2017, 237578. Available at doi: <http://doi.org/10.1101/237578> (accessed November 20, 2022).
38. Delfani P, Melby LD, Nordström M, Holmer A, Ohlsson M, et al. Technical advances of the recombinant antibody microarray technology platform for clinical immunoproteomics. *PLoS One*, 2016; 11(7):e0159138.
39. Wingren C, Sandström A, Segersvärd R, Carlsson A, Andersson R, et al. Identification of serum biomarker signatures associated with pancreatic cancer. *Cancer Res.* 2012; 72(10):2481–2490.

40. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, et al. Detection and localization of surgically respectable cancers with a multi-analyte blood test. *Science*. 2018; 359(6378):926–930.
41. World Health Organization. WHO global model regulatory framework for medical devices including IVDS, draft for comment. Available at: https://www.who.int/medicines/areas/quality_safety/quality_assurance/2016-07-27ModelregulatoryFramework_MedDev_QAS16-664Rev1.pdf (accessed on November 20, 2022).
42. US Food & Drug Administration. Guidance for industry: general/specific-intended-use. 2017. Available at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/generalspecific-intended-use-guidance-industry> (accessed on November 20, 2022).
43. French-Mowat E, Burnett J. How are medical devices regulated in the European Union? *JR Soc Med*. 2012; 105(1):S22–S28.
44. US Food & Drug Administration. Overview of medical device classification and reclassification. 2017. Available at: <https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHTransparency/ucm378714.htm> (accessed on November 20, 2022).
45. Jørgensen JT, Hersom M. Clinical and regulatory aspects of companion diagnostic development in oncology. *Clin Pharmacol Ther*. 2018; 103(6):999–1008.
46. Roscoe DM, Hu Y-F, Philip R. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. *Expert Rev Mol Diagn*. 2015; 15(7):869–880.
47. Scheerens H, Malong A, Bassett K, Boyd Z, Gupta V, et al. Current status of companion and complementary diagnostics. *Clin Trans Sci*. 2017; 10:84–92.
48. Regulation (EU) 2017/746 of the European Parliament and of the council of 5 April 2017 on *in vitro* diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU. Available at: <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0746> (accessed on November 20, 2022).
49. Rose P, Weirsoe J, Wolf M. The new EU medical device regulation (MDR): practical implications for manufacturers. 2017. Available at: <https://maetrics.com/wp-content/uploads/2017/05/Maetrics-MDR-White-Paper-May-2017.pdf> (accessed on November 20, 2022).
50. Jørgensen JT, Nielsen KB. Companion diagnostics: from biomarkers to diagnostics. *Comprehensive Medicinal Chemistry III*, 2017; 2:530–545.
51. Decree of the State Council of the People's Republic of China, No. 650. Regulations on supervisory management of medical devices. Available at: <http://www.nmpa-classification.com/articles/%E3%80%90nmpa-regulations%E3%80%91decree-of-the-state-council-of-the-peoples-republic-of-china-no-650/> (accessed November 20, 2022).
52. Order of China Food and Drug Administration No. 4. Provisions for medical device registration. 2014. Available at: <https://www.emergogroup.com/sites/default/files/china-order-no-4-provisions-for-medical-device-registration.pdf> (accessed on November 20, 2022).
53. Regulation on the Supervision and Administration of Medical Devices (Decree of the State Council No. 650). Technical guidance on clinical evaluation of medical devices,

- annex 2. 2014. Available at: <https://www.emergogroup.com/sites/default/files/china-cfda-cer-guidance-english-translation.pdf> (accessed on November 20, 2022).
54. Sherwood JL, Brown H, Rettino A, Schrieck A, Clark G, et al. Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice. *ESMO Open*. 2017; 2:e000235.
 55. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. *Cancer*. 2015; 121(4):631–639.
 56. Diaceutics. How turnaround time can become an issue in laboratory diagnostic testing. 2017. Available at: <https://www.diaceutics.com/articles/turnaround-time-can-become-issue-laboratory-diagnostic-testing> (accessed on November 20, 2022).
 57. Solassol J, Vendrell J, Haas C, Bellosillo B, Montagut C, et al. Multi-center evaluation of the fully automated PCR-based Idylla™ KRAS mutation assay for rapid KRAS mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal cancer. *PLoS One*. 2016; 11(9):e0163444.
 58. Kearney P, Boniface JJ, Price ND, Hood L. The building blocks of successful translation of proteomics to the clinic. *Curr Opin Biotechnol*. 2018; 51:123–129.
 59. Roundtable of Translating Genomic-Based Research for Health; Board on Health Sciences Policy; Institute of Medicine. Assessing genomic sequencing information for health care decision workshop summary. National Academy of Sciences. How insurers decide whether to pay for testing. 2014. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK241339/> (accessed on November 20, 2022).
 60. Diage T. Planning for successful medical device reimbursement: so your device is cleared, now what? NAMS, 2013. Available at: <https://www.gaits.org/documents/20151/228856/NAMSA-Planning-for-Successful-Medical-Device-Reimbursement.pdf/cd489d6c-1c59-45ef-6363-ab290371de2c> (accessed on November 20, 2022).
 61. Ciani O, Wilcher B, van Giessen A, Taylor RS. Linking the regulatory and reimbursement processes for medical devices: the need for integrated assessments. *Health Econ*. 2017; 26(S1):13–29.

Chapter 13

Next-Generation Sequencing for Companion Diagnostics and Precision Medicine

Il-Jin Kim, PhD,^{a,b} Pedro Mendez, PhD,^b and David Jablons, MD^b

^aGuardant Health, Redwood City, California, USA

^bThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA

ijkimsf@gmail.com

Keywords: Cetuximab, chromogenic *in situ* hybridization (CISH), Clinical Laboratory Improvement Amendments, colorectal cancer, combinatorial probe-anchor ligation, companion diagnostics (CDx), cyclic reversible termination, cyclic reversible termination (CRT), Erlotinib, fluorescence *in situ* hybridization (FISH), immunohistochemistry (IHC), limit of detection, nanopore sequencing, next-generation sequencing (NGS), non-small-cell lung cancer, Osimertinib, premarket approval, quantitative polymerase chain reaction (qPCR), rolling circle amplification (RCA), sequencing by ligation (SBL), sequencing by synthesis, single-nucleotide addition (SNA), single-nucleotide variants, total internal reflection fluorescence, turnaround time (TAT), US Food and Drug Administration (FDA), variants with unknown significance, whole-genome sequencing (WGS), zero-mode waveguides

13.1 Introduction

The tremendous recent advances in genetic studies owe a great deal to the completion of human genome project in 2003 [1, 2] and the availability of next-generation sequencing (NGS) [3, 4]. Previously, Sanger sequencing using fluorescently labeled dideoxy chain-terminating nucleotide [5, 6] was widely used for many genetic analyses. Although Sanger sequencing is highly accurate and data analysis is easy, the time required and the high cost limit the ability to cover large scale genetic or genome analyses like the whole-exome (collection of the whole coding regions of genes) or whole-genome sequencing (WGS). In contrast, NGS can handle large-scale genome sequences within multiple days to weeks at a reasonable cost. Since its first appearance on the market in 2004 [3, 7, 8],

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

NGS became a gold standard for large-scale sequencing analyses in many areas of research and applications like exome or WGS analyses using cancer samples [9–15]. NGS has also become more popular in clinical applications such as smaller or targeted panel analysis in cancer patients for identifying driver mutations or drug target mutations for companion diagnostics (CDx) [9, 16–18]. Unlike quantitative polymerase chain reaction (qPCR) or Sanger sequencing, NGS can easily cover a few dozens to a few thousands of genes in a selected panel. Many Clinical Laboratory Improvement Amendments (CLIA) laboratories now provide mutation, copy number, or fusion data using different types of NGS for precision medicine purposes [16].

Before 2016, only a few NGS-based assays were FDA-approved. Two were for cystic fibrosis mutation carrier screening and the Illumina MiSeqDx Universal kit was approved for non-CDx purposes [19]. By December 2017, four NGS tests were FDA-approved for oncology CDx testing (www.fda.gov). The first of these was the FoundationFocus CDxBRCA test (Foundation Medicine) for *BRCA1* and *BRCA2* mutation detection in ovarian cancer patients for PARP inhibitor treatment in December 2016 (PMA: P160018). The second NGS test was OncoPrint Dx (ThermoFisher Scientific), a CDx assay for selecting inhibitors for *EGFR*, *ALK*, *ROS1*, *MEK*, and *RAF*, approved in June 2017. This assay can detect genetic alterations in 23 genes and provides additional genetic variations beyond the designated and approved mutations and fusions (PMA: P160045). The third NGS test is Illumina's *RAS* extended panel analyzing 56 variants from *KRAS* and *NRAS* genes, which was approved by the FDA for Amgen's Vectibix (panitumumab) treatment in metastatic colorectal cancer patients with wild-type *RAS* (PMA: P160038). The last NGS test is the FoundationOne CDx (Foundation Medicine Inc.). This assay detects mutations (substitutions, insertions, or deletions) and copy number alterations in 324 genes including *EGFR*, *BRAF*, *HER2*, *KRAS*, *NRAS*, and *BRCA1/2*. Fusions in selected genes, microsatellite instability, and tumor mutational burden can also be detected in this assay.

All previous FDA-approved genetic assays were basically for a “one-drug/one-gene” model [20] until the multi-gene NGS assay, OncoPrint Dx, was approved for CDx. The best examples of the FDA-approved single-gene CDx assays are the Cobas *KRAS* qPCR assay for Cetuximab (colorectal cancer) and the *EGFR* qPCR mutation assay for Erlotinib or Osimertinib (non-small-cell lung cancer) [21].

Cancer, which is well known for its complexity [22, 23], is characterized by a collection of many genetic events rather than single gene mutation. Because the biggest strength of NGS is to cover more than a few dozen genes or even the whole genome in a single assay [9, 17, 18], it is logical to expect to see more and more FDA-approved NGS-based assays for CDx used for precision medicine. In this chapter, we describe different NGS platforms and their potential applications for CDx and clinical analyses.

13.2 Platforms of Next-Generation Sequencing

There are four different NGS platforms [7, 18]: (i) Sequencing by synthesis (SBS)-cyclic reversible termination (CRT), (ii) sequencing by synthesis (SBS) single-

nucleotide addition (SNA), (iii) sequencing by ligation (SBL), and (iv) single-molecule real-time (SMRT) long read sequencing (or third-generation sequencing).

Major commercially available NGS platforms and assays are described below according to these four categories. The focus of this chapter is on providing an overview of the commercially available NGS systems, rather a detailed discussion of their technical aspects. For those details, we refer readers to review papers of NGS [7, 18–20, 24–26].

13.2.1 Sequencing by Synthesis: Cyclic Reversible Termination

13.2.1.1 Illumina system

Illumina has the biggest NGS market share (more than 70% [27]) worldwide. Since Illumina acquired Solexa in 2007, Illumina has led NGS research and applications. Illumina has released many different types of platforms, from a small scale sequencer (MiniSeq) to a highest throughput sequencer (HiSeqX and NovaSeq 6000) [18]. Illumina MiSeqDx received CE marking from the EU in June 2013 [20] and was cleared by FDA as a class II device [510(K)] in November 2013 [20]. The FDA also cleared Illumina's cystic fibrosis mutation assays for selecting carrier identification by covering 139 variants of the *CFTR* gene [20]. In June 2017, Illumina's extended *RAS* panel was FDA-approved for CDx: panitumumab treatment in metastatic colorectal cancer patients (www.fda.gov).

Illumina systems use the sequencing by synthesis method of CRT (Fig. 13.1) [7]. Fragmented DNA with an adaptor is hybridized to an immobilized probe on a solid surface or flow cell. Double-strand DNAs are synthesized by polymerase and then denatured. The remaining single-strand DNA attached to the surface flips over to another adjacent probe fixed on the surface, forming a bridge (Fig. 13.1). This is repeated until clusters with around 100–200 million copies are generated [7]. This is a clonal amplification step used by Illumina. In each cycle, four fluorophore-labeled nucleotides compete for the matched hybridization to the stranded DNA (Fig. 13.1) [7]. After a matched nucleotide is added, it is recognized and imaged by total internal reflection fluorescence (TIRF) microscopy (Fig. 13.1) [7, 25]. After imaging, the fluorophores are cleaved and removed from the flow cell. The nucleotide is then chemically blocked by adding 3'-OH to prevent further polymerization [7, 18]. This "(1) nucleotide addition, (2) imaging, and (3) 3'-OH generation by fluorophore cleavage" is repeated until the whole sequencing is completed (Fig. 13.1). Most Illumina systems use four fluorophore lasers, except for NextSeq and MiniSeq, which use only two [18]. It is advantageous to use only two lasers because it can save time from the time-consuming imaging step, which makes the whole sequencing process simple and short. Compared to other benchtop sequencers (i.e., Ion PGM) mainly designed for small to medium scale clinical sequencing, the sequencing time is longer for Illumina systems. Thus, two-laser sequencers can be advantageous for shortening the sequencing time. However, the two-laser system has lower accuracy than the four-laser system [18, 28], although this seems controversial [26].




Figure 13.1 Illumina sequencing system: sequencing by synthesis (cyclic reversible termination). The Illumina technology allows the library preparation by different methods, including (a) DNA fragmentation and universal adaptors ligation for *de novo* whole-genome sequencing, (b) DNA tagmentation using Tn5 transposase, or (c) using capturing probes, followed by PCR. The libraries are quantified, and equimolar concentration of each library is pooled (if more than one sample are analyzed in the same experiment), denatured, and attached to the sequencing flow cell, followed by bridge amplification and sequencing cluster formation. The nucleic acid sequence of the template is obtained by detecting the incorporated reversible-terminator, fluorophore-labeled dNTPs. During each sequencing flow, images of the entire flow cell are acquired and processed to identify the nucleotides incorporated into each cluster.

Strength: As discussed above, different Illumina systems have more than 70% of market share combined [27]. Accordingly, many data analysis tools, sequencing protocols, reference samples, and data formats could therefore be developed that reference Illumina systems. Because many NGS commercial panels are created based on or compatible with Illumina systems, it is much easier to find a solution for any known technical problem.

One of the biggest issues in using NGS is low accuracy compared to other technologies like Sanger sequencing. The error rate of NGS is 1% to 30% depending on the platform [18, 29]. The main problem is an inaccuracy in a homopolymer region containing a repeat of the same nucleotides (i.e., AAAAAA or TTTTTTTTTT) [18]. Unlike other NGS technologies, Illumina uses the SBS method and shows relatively higher accuracy in a homopolymer region. According to the 2013 FDA 510(K) decision summary [20], Illumina specifies its detection capability as single-nucleotide variants (SNVs) and deletions up to three bases and one base pair (BP) insertion in a non-homopolymer region [20]. Although even Illumina systems are not free from the homopolymer issue, it is widely accepted that Illumina has fewer false-positive and -negative data in insertion or deletion calls compared to other NGS systems [18, 24, 25]. Instead, substitutions were reported as the most common error type in Illumina [7].

Weakness: Since the focus of this chapter is on NGS CDx for precision medicine, it is important to present the pros and cons of Illumina systems for clinical application. Most clinical NGS is currently being analyzed in a CLIA laboratory. Small targeted gene panels (i.e., 25–500 genes) are popular for NGS CLIA lab analysis for precision medicine. Formalin-fixed paraffin-embedded (FFPE), liquid biopsy or blood samples are or will be the main sample types for NGS CDx or clinical application. Consequently, DNA from clinical samples will easily be limited in terms of quality and quantity, which will directly affect the sequencing results. Illumina requires a 250 ng of FFPE DNA for its TruSeq cancer panel (www.illumina.com), whereas its major competitor, Ion PGM or PGM Dx, requires only 10 ng. The higher amount of DNA required can significantly increase the quantity not sufficient (QNS) rate in a clinical laboratory [16, 30]. In a recent report in an NGS CLIA laboratory analyzing 1528 cancer specimens, 22.5% of samples failed mainly because of insufficient tissue or DNA [30]. Thus, the relatively higher amount of DNA required for the Illumina system can be a potential weakness for the NGS CDx analysis using challenging clinical specimens.

Another potential weakness of Illumina systems for NGS CDx analysis is the longer sequencing time and a lack of flexibility for the sequencing run. Unlike the Ion PGM system that provides three different chips (314, 316, and 318 V2 chips) with different capacities (www.thermofisher.com), the only option for Illumina MiSeqDx is one type of flow cell. When many samples are analyzed at one time, this would not be an issue. However, it could be an issue when sequencing a small number of samples requiring a fast turnaround time, especially for patients with late stage or recurrent cancer. When sequencing a small number of samples

and a small NGS panel size (i.e., less than 50 genes), it would be wise to select a small chip size for quick and cost-efficient sequencing. Another potential weakness for CDx and clinical sequencing is that Illumina systems have no selection option for a different size of sequencing flow cell.

13.2.1.2 GeneReader (Qiagen)

Qiagen acquired Intelligent BioSystems in 2012 and re-launched its system, GeneReader, in 2015 [18]. GeneReader was developed mainly for cancer-targeted panel sequencing [18]. Like Illumina systems, GeneReader uses the SBS method [18], in a bead-based environment. But it does not maximize the use of fluorophore-labeled nucleotides for synthesis, whereas Illumina uses all fluorophore-labeled nucleotides [18]. Fluorophore-labeled nucleotides compete with unlabeled nucleotides for hybridization [18]. The strength of this system may be the leverage of Qiagen's existing DNA/RNA extraction system, QIAcube, and an NGS data analysis tool, Ingenuity. By combining these components, it can be a potentially "all-in-one" NGS system [18, 25]. As this system is still new compared to other NGS platforms, more feedback and evaluation will be required to determine GeneReader's pros and cons more precisely.

13.2.2 Sequencing by Synthesis: Single-Nucleotide Addition

13.2.2.1 454 pyrosequencing (Roche)

The first commercialized NGS system shown on the market was 454 pyrosequencing in 2005 [3, 24]. For this system, deoxynucleoside triphosphate (dNTPs) are added to the template-bound bead in a PicoTiterPlate [3]. When each dNTP is incorporated into a newly synthesized DNA strand, a pyrophosphate molecule is produced and reacted with ATP sulfurylase, leading to a change of adenosine 5' phosphosulfate (APS) into ATP [3]. The covered ATP with luciferase changes luciferin into light and oxyluciferin. The generated light is detected by a charge-coupled device camera [3, 18].

Whereas 454 sequencing provides longer read lengths (i.e., 400–700 bp) than short read-length sequencing [18], higher error rates of indels in homopolymer regions are a main problem [18]. Roche discontinued this system in 2016.

13.2.2.2 Ion Torrent (ThermoFisher Scientific)

Ion Torrent is a semiconductor sequencing system with several different platforms such as Proton, PGM, PGM Dx, and S5. Ion Torrent is the major competitor with Illumina and has the second biggest market share [27]. Ion Torrent is the first NGS system to not use optical sensing [18, 25]. This made Ion PGM or PGM Dx one of the fastest NGS systems available on the market, since imaging is a time-consuming step and one of the major reasons for a long sequencing running time. The Ion PGM Dx system was registered as a class II (special controls; exempt from the premarket notification procedures) device in June 2017 (510(k) Number: K170299 from www.fda.gov).

With Ion Torrent, sample library preparation is PCR-based, followed by ligation of universal adaptors and barcodes. Each library molecule along with one sequencing bead and PCR reagents are emulsified into a droplet (also known as sequencing microreactor). Each microreactor is used as template of emulsion PCR to attach and amplify the library molecule to the sequencing bead. The isolation of one library molecule and sequencing bead allows the monoclonal amplification of the library template (Fig. 13.2) [24]. Unlike SBS-CRT methods, the Ion Torrent system detects unlabeled dNTP and releases H⁺ ions detected by pH meter [31]. Each dNTP causes a very subtle change of pH (0.02 unit) [18], which can be used for the sequencing base calling (Fig. 13.2). The change of pH is detected by a complementary metal-oxide semiconductor and an ion-sensitive field-effect transistor [18].

Strength: First, the Ion Torrent semiconductor sequencing system provides different sizes of chips that provide flexibility for sequencing. For Ion PGM or PGM Dx, three sequencing chips, 314TM (30–100 MB), 316TM (300 MB–1 GB), and 318TM (600 MB–2 GB), can be selected for sequencing, depending on the number of samples or size of sequencing panels (www.thermofisher.com).

Selecting the most appropriate sequencing chip significantly helps save the running cost and time required for many clinical laboratories and CDx applications.

Second, Ion Torrent is faster than other NGS systems because the expensive and time-consuming optical sensing is removed, which also makes the equipment cheaper than other competitors. After sample library preparation, PGM 314 chip sequencing takes less than 3 h to complete the sequencing run (www.thermofisher.com). This can be a huge advantage for precision medicine and CDx applications where patients with emergent conditions are waiting for results for drug selection.

Third, Ion Torrent requires only a minimum amount of DNA for sequencing. Ten ng of DNA is enough for most clinical sequencing using Ion PGM or PGM Dx. One of the most important factors for the CDx assay is to overcome the problem of patient samples with poor quality and quantity. Patient samples (i.e., cancer biopsy specimens) for sequencing often consist of only small left-over specimens (i.e., tissue block) after pathological diagnostic analysis. Thus, the ability to use a small amount of DNA for CDx assay is critical to increase the success rate [30]. The Ion Torrent system using PCR-based amplification with specifically designed primers can be advantageous for a low amount of input DNA, although the PCR approach can also be a disadvantageous because of the higher error rate caused by PCR amplification.

The last potential advantage of the Ion Torrent system is a built-in bioinformatics program, Torrent Suite. Bioinformatics analysis is still a big bottleneck of routine NGS analysis in a small laboratory or hospital. A plug-in system of the NGS data analysis program can be a big advantage for researchers and CLIA laboratories as long as it is robust. However, this built-in program cannot perfectly fix the high error rate, and it is still highly recommended to confirm and validate the results obtained from the built-in data analysis program, especially for indels.




Figure 13.2 Ion Torrent sequencing: sequencing by synthesis (single-nucleotide addition). The Ion Torrent technology is based on the preparation of PCR-based sequencing libraries using High-Fidelity DNA polymerase. A microfluidics system is used to generate droplets (also known as microreactors), ideally containing a sequencing-bead, PCR reagents and a single DNA molecule. The sequencing-bead of each microreactor is templated and monoclonally amplified by emulsion PCR. *Then, the droplets are disrupted, and the templated sequencing beads are positively selected using magnetic beads. Next, each templated sequencing bead is loaded into a different pH microsensor well of the sequencing chip. The nucleic acid sequence of the template DNA is obtained during the sequencing flows. During each sequencing flow, only one dNTP type is used. The concentration of H⁺ released during a given sequencing flow should be proportional to the number of nucleotide units incorporated during the sequencing reaction. **When more than one biological sample are sequenced in one experiment, the sequencing libraries from each sample must be ligated using universal adaptors and different barcodes. In addition, equimolar concentration of each library must be loaded in the emulsion PCR.

Weakness: The Ion Torrent system is well known for inaccurate indel calls in homopolymer regions. Although Illumina reportedly has the same issue, it is much worse in the Ion Torrent system [7, 18, 24].

When the same dNTPs are incorporated and recorded, pH change signals are not perfectly linear with the number of nucleotides, causing inaccurate base calling and high error rates. There are reports that a homopolymer with more than seven bases is hard to sequence correctly with Ion Torrent or pyrosequencing technologies [24, 31]. However, in our own experience with Ion Torrent system, even 2–3 bp repeats of the same nucleotides (i.e., AA, CC, or TTT) are very challenging to call correctly, leading to false-positive variants. Notwithstanding several advantages (low equipment cost, low input DNA, faster sequencing time, and flexibility for sequencing chips) over other NGS systems, very high error rates caused by the homopolymer issue, especially for deletions and insertions, is the biggest hurdle for this system to be a leading one for clinical sequencing and CDx application. If the Ion Torrent system is used, it is ideal to check all identified insertion or deletion mutations by using the raw sequencing read view (i.e., Integrative Genomics Viewer) and confirm any suspicious variant or mutation by another sequencing method like Sanger sequencing.

Another potential caveat for amplicon-based multiplex PCR methods is a complicating multiplex PCR design. Compared to a bait-based hybridization capturing method, GC or AT contents of the primer-binding or amplification regions significantly affect efficient amplification. Germline polymorphisms or mutations at the primer binding sites can cause a failure of amplification or a strand bias.

13.2.3 Sequencing by Ligation

13.2.3.1 SOLiD (ThermoFisher Scientific)

SOLiD was on the market in 2008 [24] and is characterized by two-base encoded probes [18]. Unlike other sequencing system with one fluorescent signal detection from one nucleotide incorporation, SOLiD generates one fluorescent signal from a combination of two nucleotides [25, 32]. Thus, a fluorescent signal cannot be directly interpreted into a nucleotide calling. It needs a “color-space” coding [7, 18, 25]. SOLiD is the only commercially available NGS system that uses a multi-base probe and color-space technique. Sixteen possible combinations from four fluorophores are possible, and this should be interpreted into a correct single base by repeat of ligation and sequencing steps [32].

Like the Ion Torrent system, in the SOLiD system, DNA is amplified in an emulsion PCR. The constructed DNA library is enriched and then attached to a glass flowchip. A universal primer is attached and ligated into the library adaptors and fluorescent signal is emitted after three-base cleavage from the octamer containing di-base probes [25]. With multiple “ligation-detection-cleavage” steps, the whole sequencing process is completed.

This system can increase the sequencing accuracy up to 99.99% by repeat of sequencing cycles [24]. However, many repeats of reactions take a much longer

sequencing time (7–14 days) [24]. A short read-length less than 75 bp in a paired sequencing read can be another shortfall [18, 24].

13.2.3.2 Complete Genomics (Beijing Genome Institute)

Complete Genomics technology is known as DNA nanoball sequencing and designed for WGS [33]. By using the combinatorial probe-anchor ligation (cPAL) or combinatorial probe-anchor synthesis [34], an anchor and a probe hybridize to a self-assembling DNA nanoball. The DNA nanoball is generated in a solution [18]. DNA is fragmented and ligated to one of four adaptors. The circular DNA-adaptor complex is then amplified, circularized, and cleaved with a restriction enzyme [18]. This step is repeated until all four adaptors are ligated to DNA, making a circular complex. The circular templates are amplified to make a DNA nanoball through rolling circle amplification (RCA) [18, 33]. DNA nanoballs are immobilized in a flow cell and imaged. The advantage of this system is to use high-density DNA nanoball sequencing, leading to repetitive sequencing and high accuracy (gap-free pattern) [24, 25, 33]. A short read length, longer sequencing time, multiple PCRs, and complicating bioinformatics analyses are drawbacks for this system [24, 25].

13.2.4 Real-Time Long-Read Sequencing (or Third-Generation Sequencing)

All the sequencing systems mentioned above produce short sequence reads ranging from 25–1000 bp [18]. Compared to the first version of an NGS system about 10 years ago, the read length has been improved in general. However, it is still not enough to detect complex structural variants with such short reads. If multiple nucleotide variants at consecutive sequences (i.e., CT variants in one allele vs. C variant in one allele and T variant in another allele) are shown in one sample, it is hard to call correct genotypes or variants in regular short-read NGS without phasing [35].

A long-read sequencing can provide correct genotypes because it facilitates *de novo assembly* with phasing information [35, 36]. Thus, it is a major goal to make long reads when developing new NGS or third-generation sequencing systems. Moreover, long-read or third-generation sequencing removes clonal amplification and can thereby avoid the PCR-related bias [24]. It can also detect native DNA directly rather than secondary signals from DNA incorporation [24, 37].

The following two systems are leading sequencing technologies for long-read or third-generation sequencing.

13.2.4.1 Pacific Bioscience (PacBio)

PacBio system (developed by Nanofluidics) uses SMRT long-read sequencing. The average read length is above 1 kB and up to 10–40 kB [24, 26], which makes *de novo assembly*, structural variant detection, and mRNA transcriptome analysis much easier [1, 26, 38, 39]. SMRT sequencing fixes a single DNA polymerase

in the bottom of a nanophotonic chamber called zero-mode waveguides (ZMWs) [26, 40, 41]. Unlike other sequencing systems (i.e., SBS methods) where DNA is fixed, DNA has mobility and can access to the immobilized DNA polymerase in the ZMWs chamber, where the sequencing takes place [25]. Fluorescence-labeled dNTPs are incorporated, visualized, and recorded by a laser and camera in a real-time way [18]. This system is known to have high error rates (up to 11%), especially for detecting indels [26]. To overcome the high error rate, multiple sequencings at the same site forming circular consensus sequences are required [42–44]. SMRT sequencing is less sensitive to GC contents compared to other sequencing platforms [45] and would be ideal for detecting structural variants or *de novo* assembly [1, 39].

13.2.4.2 MinION (Oxford Nanopore)

MinION is a small USB-based portable sequencing system. It was first on the market in 2014 [25] and performed sensationally for its small size, with huge potential for clinical sequencing and CDx application. Unlike other sequencing platforms that detect indirect signals like light, fluorescence, or pH, MinION detects intact single-strand DNA [18]. MinION requires a minimum amount of equipment and thus, can be run in a non-classical laboratory-based system [46].

The sample preparation for MinION is inexpensive because of removal of fluorophores, polymerases, and ligases [24]. DNA is initially fragmented and then ligated to two adaptors, making a leader-hairpin complex (Fig. 13.3) [18]. Then 1D and 2D reads are sequentially passed through the nanopore, where current is passing through [18]. When DNA moves into the pore, with the help of motor protein, voltage shift happens and is recorded as a k-mer sequence (Fig. 13.3) [25]. As no library amplification is required and 2–4 TB sequencing per two-day run is expected, very high throughput and quick sequencing is available with MinION [18].

The whole system can be packed in a regular travel luggage [46] making it a very portable and ubiquitous sequencing application. It requires minimum laboratory equipment (thermocycler, dry bath, fluorometer, and microfuge) [46]. MinION was used recently to detect Ebola virus in West Africa, where resources were limited for laboratory work [46]. Sequencing took only 15–60 min, and results were generated within 24 h for certain cases [46]. Detecting life-threatening pathogens like Ebola may be the best example of how to use a small and portable sequencing system for clinical application, even in harsh conditions with limited resources [46, 47]. Researchers who used MinION to detect Ebola virus suggested that this system can be widely used if it does not depend on the internet use for data analyses [46]. Although MinION is a USB-based small sequencing system, it still requires an internet connection to the main data analysis server remotely [46]. If it had a built-in data analysis tool and did not depend on the internet connection, it would have greater potential for quick and simple analyses related to virus or bacteria detection in underdeveloped countries or military camps.




Figure 13.3 Nanopore sequencing. The Oxford Nanopore technology allows the sequencing of long reads. The libraries can be prepared using either by DNA fragmentation and universal adaptors ligation, for *de novo* whole-genome sequencing or by DNA tagmentation using Tn5 transposase. During the library preparation, two different sequencing adaptors are ligated to both ends of each DNA fragment. (a) The “Y (leader)” adaptor contains a motor protein that unwinds the dsDNA into ssDNA as it passes through the nanopore, until the sequencing of the forward strand of the DNA template is completed. The “hairpin” adaptor contains another protein (called “hairpin protein”) that functions as linker of the forward and reverse strand of the DNA template, allowing the reverse strand of the DNA template pass through the nanopore, thus being sequenced. (b, c) The nucleotide composition of the DNA fragment, located in the nanopore at a given time point, has a characteristic voltage profile that allows the identification of the DNA sequence of the molecule as it passes through the pore.

Table 13.1 Summary of next-generation sequencing (NGS) or third-generation sequencing [7, 8, 18, 20, 24–26]

Category	Platform	Read length*	FDA-approved NGS CDx assays ⁺	Pros	Cons
Sequencing by synthesis (CRT)	Illumina	36–300	Praxis Extended RAS panel (PMA: P160038)	<ul style="list-style-type: none"> • Market leader • Less homopolymer issue • Various platforms 	<ul style="list-style-type: none"> • Less flexibility for flow cell selection • Higher DNA input
	Qiagen	107	NA	All-in-one system	Not much user data
Sequencing by synthesis (SNA)	454	400–700	NA	Relatively longer read length	High error rate in homopolymer regions
	Ion Torrent	200–400	Oncomine Dx (PMA: P160045)	<ul style="list-style-type: none"> • Low cost, fast TAT • High flexibility • Lower DNA input 	High error rate in homopolymer regions
Sequencing by ligation	SOLiD	50–100	NA	<ul style="list-style-type: none"> • Two-base encoding • High accuracy 	Long sequencing running time
	Complete Genomics	28–100	NA	High accuracy	<ul style="list-style-type: none"> • Short read length • Only service-based system for WGS
Real-Time long-read (third-generation sequencing)	PacBio	Up to 40 kB	NA	<ul style="list-style-type: none"> • Long sequencing read length • Single molecule sequencing 	<ul style="list-style-type: none"> • Limited throughput • High error rate • High cost
	MinION	Up to 200 kB	NA	<ul style="list-style-type: none"> • High throughput • Portable and short sequencing time • Long sequencing read length 	High error rates in homopolymer regions (indel)

Abbreviations: CRT, cyclic reversible termination; SNA, single-nucleotide addition; TAT, turnaround time; NA, not available; PMA, premarket approval; WGS, whole-genome sequencing.

*Base pair (bp).

⁺Another NGS CDx panel, FoundationFocus CDxBRCA test (Foundation Medicine), was FDA-approved for *BRCA1* and *BRCA2* mutation detection (PMA: P160018, www.fda.gov). Four NGS CDx panels have been FDA-approved as of December 2017.

Although the advantages of MinION sound very promising compared to other sequencing systems, there remains an important issue to overcome. It has a large error rate of up to 30% [18], making this system impossible to use for most clinical applications that require very high accuracy. It is important to detect even one bp change in cancer-related or driver genes (i.e., *EGFR* L858R, *BRAF* V600E, *KRAS* codon 12 and 13 mutations) for selecting targeted therapy. Moreover, MinION is not free from the homopolymer issue and would need to overcome this challenge to be used as a robust CDx. It looks more promising to use MinION for virus or bacteria detection [47], that is, it may be enough to detect the existence of bacteria or a virus, rather than single bp level nucleotide change. However, even in pathogen detection, it is possible that variant or resistant new species

could require a single bp-level resolution. To be used as a robust CDx assay, high accuracy is the first thing to obtain regardless of application types.

Each of the NGS platforms described above is summarized in Table 13.1.

13.3 Bioinformatics

Bioinformatics data analysis is a big hurdle and bottleneck not only for CDx or clinical sequencing, but probably all large-scale genome analyses. Clinical NGS CDx analysis is not significantly different from regular NGS analysis. The following is a general process for bioinformatics analysis in clinical NGS analysis (also see Fig. 13.4) [20, 48].

- (1) **Raw sequencing data:** Raw sequencing reads are initially generated. DAT files are the initial sequencing files from the imaging (Illumina) or pH change (Ion Torrent) [20]. Basecall (BCL) files are data with nucleotides converted from original imaging or pH data [20]. One of the advantages of NGS is the ability to pool different samples using barcodes (multiplexing) and run them in one sequencing run. Once raw sequencing data is obtained, each sequence should be matched into the original sample. This is called demultiplexing [49].
- (2) **FASTQ:** After demultiplexing, FASTQ files containing sequencing read data and base quality score (Phred quality score or Q score) [50, 51] are generated. Phred or Q score is defined as $Q_{\text{Phred}} = -10\log_{10} P(\text{error})$ [35, 52]. Q20 is the most commonly used cut off for NGS and means 1% error or 99% accuracy in base calling [52].
- (3) **BAM:** Sequencing reads are then aligned to the reference sequences, which generate BAM files. In the Ion Torrent system, unlike in the Illumina platform, the first file that users get is the aligned BAM file. For a customized alignment, several alignment tools are available such as Burrows-Wheeler Aligner [53], Novoalign (<http://www.novocraft.com>), or Bowtie 2 [54].
- (4) **Pre-processing:** After the BAM file is generated, sequences need to be filtered [48]. “Duplicate read removal” is the process of removing duplicates introduced by PCR during library preparation [55]. When insertions or deletions are shown in the reads, it can cause false variant calling by misaligning with reference genome. To reduce this artifact, “read realignment” near insertion or deletion mutations is also required. This indel realignment may not be necessary in a newly released NGS analysis program [56].
- (5) **Variant calling (VCF file):** After the sequencing reads are filtered, if the sequence(s) is different from the reference sequences, it is called a variant or mutation and generates a VCF file. The called variants are then filtered to reduce false-positive and false-negative results [20].
- (6) **Annotation:** The filtered variants are annotated for mutation and clinical information. Annotations using four different categories—population frequency-, structural-, prediction-, or evidence-based approaches—have

been described [48]. There are several commonly used tools for annotation. GATK is one commonly used germline calling program [57]. SAMtools for multiple post-processing or annotating was used for 1,000 genome projects [58]. For somatic mutation detection, VarScan 2 [59] and Mutect [60] are widely used. For copy number variation analysis, ExomeCNV [61] and CNVkit [62] can be used. Ion Torrent Suite, which is a built-in data analysis program in the Ion Torrent system, provides various applications from somatic mutation calling, copy number variants, to fusion detection.

- (7) **Clinical reporting:** Unlike research-based NGS analysis, which would need only annotated sequencing data, CDx and clinical sequencing need other clinical information, including the FDA-approved drug list targeting identified mutations or copy number variations or fusion proteins. Ongoing clinical trial information may also be needed, especially when there is no FDA-approved drug targeting the identified genetic variants or no mutation is identified.




Figure 13.4 A workflow of NGS bioinformatics analyses.

13.4 NGS Applications for CDx and Clinical Laboratory Analysis

13.4.1 Mutation

DNA mutation analysis is one of the key oncology CDx genetic assays approved by the FDA. There are three major genetic assay types for oncology CDx: (i) DNA mutation analysis, (ii) immunohistochemistry (IHC) of single protein for overexpression, and (iii) fluorescence *in situ* hybridization (FISH) or chromogenic *in situ* hybridization (CISH) for amplification or fusion detection [19–21, 63, 64].

DNA mutation analysis is usually done by qPCR or Sanger sequencing, which is good for detecting mutations in a single gene. *BRCA1* and *BRCA2* are analyzed by Sanger sequencing for mutation detection for Olaparib treatment in ovarian cancer patients [65]. CDx mutational analysis of *BRAF*, *KRAS*, *EGFR*, and *KIT* are FDA-approved for qPCR or PCR-based methods [21]. The commonality of these assays is the single-gene analysis. PCR-based assay and Sanger sequencing are good for analyzing one gene or few mutation hot spot sites (i.e., *BRAF* V600E, *KIT* D816V, *EGFR* L858R, and *KRAS* codon 12 and 13 mutations). This “single-gene for one drug” concept was valid until the very recent approval of Oncomine Dx, which contains 23 genes in one NGS panel for oncology CDx (www.fda.gov). We are still in an early stage of CDx and targeted therapy development. The high

complexity of cancer [22, 23] means that higher throughput multi-gene assays would be needed for new anti-cancer drugs as CDx assays. NGS or third-generation sequencing may be the best choice for analyzing many genes at one time and will be approved for more CDx purposes.

13.4.1.1 Targeted sequencing panel

When NGS is used for CDx applications, it is very likely to make a targeted small panel to reduce the cost, time, and bioinformatics burden. Most clinical NGS sequencing done in CLIA-certified laboratories is targeted sequencing analysis rather than exome sequencing or WGS [16]. There are two major methods for analyzing a small targeted panel.

- (1) **Amplicon method:** This is a PCR-based amplification method that uses a specifically designed primer set [9, 17]. Two good examples of amplicon-based targeted NGS panels are AmpliSeq panels (i.e., Cancer Hotspot Panel with 50 genes and 207 amplicons) from ThermoFisher Scientific, and the TruSeq cancer panel (48 genes with 212 amplicons) from Illumina. Another fast, non-restriction-enzyme-based amplification method (NextDay Seq, CureSeq Inc.) reportedly enables the whole targeted sequencing process, from patient samples to the final clinical report, to be completed within 48 h [16, 66, 67].
- (2) **Hybridization-based capture method:** Most Illumina systems except the TruSeq amplicon panel use the hybridization capturing method using probes called 'BAIT' [7]. Exome sequencing with predesigned probes is a good example for the hybridization capturing library preparation [7].

13.4.2 Fusion

Fusion protein detection is also one of the major CDx applications to corresponding anti-cancer targeted therapies [68, 69]. Either IHC or ISH-based methods are FDA-approved assays for oncology CDx purposes. ALK fusion detection (i.e., EML4-ALK in non-small cell lung cancer) was approved for crizotinib treatment either by IHC or FISH [21]. Although IHC or ISH-based methods are gold standards for fusion detection, NGS can also be used for the fusion detection. The recently approved OncoPrint Dx (ThermoFisher Scientific) detects *ROS1* fusions for crizotinib treatment in non-small-cell lung cancer patients. The FoundationOne CDx (Foundation Medicine Inc.) FDA-approved in November 2017 detects *ALK* fusions for crizotinib, alectinib, or ceritinib treatment in non-small cell lung cancer patients.

Fusion detection can easily be done by combining DNA mutation analysis in one sequencing run, which can be more efficient and cost-efficient than separated DNA mutation analysis and ISH or IHC analysis. There is potential for NGS to be used for fusion detection as a CDx assay. The caveat is that there is a chance of missing a novel fusion type if predesigned PCR primers are used in a targeted NGS panel using RNA or cDNA. There is no concern for the presence of novel fusion type with IHC or ISH probes.

13.4.3 Copy Number Variation and Expression

DNA mutation and fusion detection are more qualitative types of analysis. Although the cut-off level should still be set up for calling the positive results, it is basically a yes or no question for detecting mutations or fusions. In contrast, copy number and expression analysis are more quantitative. Measurement of HER2 overexpression and amplification (HercepTest) was the first approved CDx for Herceptin treatment in 1998 [70]. There are many different types of FDA-approved HER2 CDx assays [21]. All were based on either IHC or ISH-based methods until FoundationOne CDx (Foundation Medicine Inc.) was FDA-approved in November 2017. The FoundationOne CDx (Foundation Medicine Inc.) NGS assay detects *ERBB2* (HER2) amplification in breast cancer patients for trastuzumab or ado-trastuzumab emtansine or pertuzumab treatment [21]. NGS can also provide quantitative data using RNA samples. Transcriptome analysis is NGS analysis using RNA samples. However, transcriptome analysis is less common than DNA mutation or fusion analysis for the following reasons. First, like in microarray gene expression analysis, a normalization algorithm should be considered for evaluating expression level by transcriptome analysis [71], which is not always robust for judging the difference in RNA expression. Second, clinical samples are easily degraded and show poor DNA and RNA quality. It is not easy to get high quality and enough RNA from FFPE biopsy clinical specimens. Old and poorly preserved clinical samples are prone to provide incorrect expression data when transcriptome analysis is used. Third, IHC and ISH methods are pretty simple for their protocols and much cheaper than complicated NGS methods.

13.4.3.1 FDA-approved NGS CDx assays

There were four FDA-approved oncology NGS CDx assays as of December 2017 (www.fda.gov) (Table 13.1). In 2016, the CDxBRCA test (Foundation Medicine) analyzing *BRCA1* and *BRCA2* was FDA approved for Parp inhibitor treatment in ovarian cancer patients. In 2017, *RAS* panel (Illumina) and Oncomine Dx (ThermoFisher Scientific) were FDA approved for mutation and/or fusion detection in metastatic colorectal cancer and non-small cell lung cancer, respectively. For Oncomine Dx, it is notable that the FDA first approved the genetic assay covering different types of genetic variants, mutations, and fusion detection. Until Oncomine DX was approved, mutation was approved by PCR-based or Sanger sequencing methods [21]. Fusion was approved by IHC or FISH analyses [21]. Oncomine Dx detects both mutations (single-nucleotide variants and deletions) and fusions (*ROS1*) from 23 genes. This approval suggests that a multivariate assay covering multiple genes and different types of genetic variants can be a dominant assay type for clinical and CDx application in the future. The FoundationOne CDx (Foundation Medicine Inc.) is the most recently FDA-approved CDx NGS assay covering multiple variants (mutations, copy number changes, fusions, microsatellite instability, and tumor mutational burden) from 324 genes.

Although the FDA has approved only four NGS-based CDx assays, demand is increasing for approval of a multivariate panel. For example, overall nonsynonymous tumor mutation burden or neoantigen burden are important for predicting

responses to immune checkpoint inhibitors and are associated with clinical benefit [72–74]. This can be a potential CDx application before immunotherapy is used in cancer patients. To know the mutation burdens in neoantigens, it is inevitable to sequence many genes, not a single or small number. In this case, NGS or third-generation sequencing can be the best option. FoundationOne CDx (Foundation Medicine Inc.) is the first FDA-approved CDx assay measuring tumor mutational burden.

13.5 Potential Issues and Future Directions

13.5.1 Cost

The cost of NGS has significantly decreased over the last decade [19, 75]. The trend of cost reduction outpaced the trend of Moore's law, which describes a general rule for the doubling of computer power every two years [19, 75]. The NGS cost decreased significantly relative to computer processing cost [75]. It is still expensive compared to single gene analysis assays like qPCR and Sanger sequencing. However, if multiple genes are analyzed or multiple genetic variant types (i.e., mutation plus fusion) need to be analyzed at one time, NGS would be much faster and cheaper than Sanger sequencing or PCR-based methods. Now, \$1000 whole genome sequencing is available [19]. The development of new and improved NGS or third-generation sequencing will reduce the cost even further.

13.5.2 Clinical Interpretation of NGS Data

If a multi-gene panel is used for NGS analysis as a CDx assay, it is possible to see genetic variants in unexpected sites or genes. Most targeted cancer panels used in CLIA laboratories are NGS panels with 25–500 genes [16]. By covering a broad range of genetic pathways and many cancer-related genes, it is inevitable to see many genetic variants with unknown significance. This may be an important issue to address correctly in order to obtain FDA approval. There should be a general consensus how to address variants with unknown significance (VUS). In a large-scale NGS analyses like exome or WGS, how to interpret the clinical and biological meaning of many genetic VUS is already an issue. For CDx application, the interpretation can directly affect the clinical decision. Thus, all the efforts should be made to resolve these issues and reach a consensus among government agencies, pharmaceutical companies, diagnostic biotech companies, and academia. The coverage of sequencing (sequencing depth) and a cut-off level (i.e., 2% or 5% or 10%) for detecting variants with different minor allele frequencies are also important issues for NGS CDx.

13.5.3 Security of Personal Genome Information

Personal genome information is no less important than other private information, and the need for secured storage of personal information is evident in the era of

internet, mobile, and social networks. NGS analyzes many genes at one time and can identify many genetic variants and mutations that are directly or indirectly related to many diseases. The bigger the NGS panel size, the greater the chance of getting more information about genetic variation. Sharing of genome data is encouraged among hospitals, academic institutes, and commercial companies in order to increase the chance of developing new therapeutic targets and diagnostic markers by maximizing the resources [35, 76]. Although this would be a good direction for precision medicine to take, personal genome information must be securely stored before any sharing or pooling of data takes place.

13.5.4 Standardization of Protocols and Quality Controls

This chapter has reviewed several different NGS or third-generation sequencing platforms and sample preparation methods. Most FDA-approved assays such as IHC, FISH, or qPCR use similar protocols, although their detailed technological specifications differ. For NGS, it is much more complicated. Some NGS assays detect only DNA mutation, whereas others detect both DNA mutations and RNA fusion. Some assays cover even copy-number changes. Thus, it is not easy to have general standardized protocols and controls for evaluating each system. For general controls, both experimental and interpretational controls should be considered. For experimental controls, it may be required to generate cell-line-originated or chemically synthesized controls for general use. Those artificially generated controls are not the same with patient samples of course. However, it is realistic to make general controls to be used for every platform. For bioinformatics and interpretation controls, raw sequencing data previously sequenced but fully unidentified for personal information can be used for controls. The FDA can make guidelines for analyzing data (both variant detection and clinical interpretation) and evaluates the performance and results of each platform. NGS provides too much information at one time, especially for exome sequencing or WGS. It is therefore critical to make a general, but strict and robust standard for downstream data analysis and interpretation to avoid any undesirable clinical decisions.

Abbreviations

APS:	adenosine 5' phosphosulfate
BP:	base pair
CDx:	companion Diagnostics
CISH:	chromogenic <i>in situ</i> hybridization
CLIA:	Clinical Laboratory Improvement Amendments
cPAL:	combinatorial probe-anchor ligation
CRT:	cyclic reversible termination
dNTPs:	deoxynucleoside triphosphate
FDA:	US Food and Drug Administration

FFPE:	formalin-fixed paraffin-embedded
FISH:	fluorescence <i>in situ</i> hybridization
IHC:	immunohistochemistry
NGS:	next-generation sequencing
PCR:	polymerase chain reaction
PMA:	premarket approval
QNS:	quantity not sufficient
qPCR:	quantitative polymerase chain reaction
RCA:	rolling circle amplification
SBL:	sequencing by ligation
SBS:	sequencing by synthesis
SMRT:	single-molecule real-time
SNA:	single-nucleotide addition
SNVs:	single-nucleotide variants
TAT:	turnaround time
TIRF:	total internal reflection fluorescence
VUS:	variants with unknown significance
WGS:	whole-genome sequencing
ZMWs:	zero-mode waveguides

Disclosures and Conflict of Interest

This chapter was originally published as: Kim, I.-J., Mendez, P., Jablons, D. (2019), Next-generation sequencing (NGS) for companion diagnostics (CDx) and precision medicine. In: Il-Jin Kim, ed. *Companion Diagnostics (CDx) in Precision Medicine*, Jenny Stanford Publishing, Singapore, chapter 5, pp. 97–128, and appears here, with edits and updates, by kind permission of the publisher.

References

1. Chaisson MJP, Huddleston J, Dennis MY, et al. Resolving the complexity of the human genome using single-molecule sequencing. *Nature*. 2015; 517(7536):608–611.
2. Human Genome Sequencing Consortium I. Finishing the euchromatic sequence of the human genome. *Nature*. 2004; 431(7011):931–945.
3. Margulies M, Egholm M, Altman W, Attiya S, Bader J. Genome sequencing in microfabricated high-density picolitre reactors. *Nature*. 2005; 437:376–380.
4. Bentley DR, Balasubramanian S, Swerdlow HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. *Nature*. 2008; 456(7218):53–59.
5. Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. *J Mol Biol*. 1975; 94(3).
6. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci*. 1977; 74(12):5463–5467.
7. Metzker ML. Sequencing technologies—the next generation. *Nat Rev Genet*. 2010; 11(1):31–46.

8. Mardis ER. DNA sequencing technologies: 2006–2016. *Nat Protoc.* 2017; 12(2):213–218.
9. Kang HC, Kim HK, Lee S, et al. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. *Oncotarget.* 2016; 7(7):11–14.
10. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. *Nat Genet.* 2011; 43(5):442–446.
11. Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science.* 2010; 330(6009):1410–1413.
12. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. *Science.* 2011; 333(6046):1157–1160.
13. Kandath C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. *Nature.* 2013; 502(7471):333–339.
14. Cancer T, Atlas G. Integrated genomic analyses of ovarian carcinoma. *Nature.* 2011; 474(7353):609–615.
15. Cancer Genom Atlas. Comprehensive molecular characterization of human colon and rectal cancer. *Nature.* 2012; 487(7407):330–337.
16. Mendez P, Dang J, Kim JW, et al. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. *Int J Oncol.* 2016; 49(1):235–242.
17. Fang LT, Lee S, Choi H, et al. Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis. *Int J Oncol.* 2014; 44(1):211–221.
18. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. *Nat Rev Genet.* 2016; 17(6):333–351.
19. Lin E, Chien J, Ong FS, Fan J-B. Challenges and opportunities for next-generation sequencing in companion diagnostics. *Expert Rev Mol Diagn Early online.* 2014:1–17.
20. Pant S, Weiner R, Marton MJ. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. *Front Oncol.* 2014; 4.
21. Dracopoli NC, Boguski MS. The evolution of oncology companion diagnostics from signal transduction to immuno-oncology. *Trends Pharmacol Sci.* 2017; 38(1):41–54.
22. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000; 100(1):57–70.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011; 144(5):646–674.
24. Morey M, Fernández-Marmiesse A, Castiñeiras D, Fraga JM, Couce ML, Cocho JA. A glimpse into past, present, and future DNA sequencing. *Mol Genet Metab.* 2013; 110(1–2):3–24.
25. Garrido-Cardenas JA, Garcia-Maroto F, Alvarez-Bermejo JA, Manzano-Agugliaro F. DNA sequencing sensors: an overview. *Sensors (Switzerland).* 2017; 17(3).
26. Reuter JA, Spacek D V, Snyder MP. High-throughput sequencing technologies. *Mol Cell.* 2015; 58(4):586–597.
27. Thayer AM. Next-gen sequencing is a numbers game. *Chem Eng News.* 2014; 92(33):11–15.

28. Wang X, Yu X, Zhu W, et al. A trimming-and-retrieving alignment scheme for reduced representation bisulfite sequencing. *Bioinformatics*. 2015; 31(12):2040–2042.
29. Escalona M, Rocha S, Posada D. A comparison of tools for the simulation of genomic next-generation sequencing data Europe PMC Funders Group. *Nat Rev Genet*. 2016; 17(8):459–469.
30. Al-Kateb H, Nguyen TDT, Steger-May K, Pfeifer JD. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). *Mol Oncol*. 2015; 9(9):1737–1743.
31. Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. *Nature*. 2011; 475(7356):348–352.
32. Valouev A, Ichikawa J, Tonthat T, et al. A high-resolution, nucleosome position map of *C. elegans* reveals a lack of universal sequence-dictated positioning. *Genome Res*. 2008; 18(7):1051–1063.
33. Drmanac R, Sparks AB, Callow MJ, et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. *Science*. 2010; 327(5961):78–81.
34. Fehlmann T, Reinheimer S, Geng C, et al. cPAS-based sequencing on the BGISEQ-500 to explore small non-coding RNAs. *Clin Epigenetics*. 2016; 8(1):123.
35. Ashley EA. Towards precision medicine. *Nat Rev Genet*. 2016; 17(9):507–522.
36. Chaisson MJP, Wilson RK, Eichler EE. Genetic variation and the *de novo* assembly of human genomes. *Nat Rev Genet*. 2015; 16(11):627–640.
37. Pettersson E, Lundberg J, Ahmadian A. Generations of sequencing technologies. *Genomics*. 2009; 93(2):105–111.
38. English AC, Richards S, Han Y, et al. Mind the gap: upgrading genomes with pacific biosciences RS long-read sequencing technology. *PLoS One*. 2012; 7(11).
39. Sharon D, Tilgner H, Grubert F, Snyder M. A single-molecule long-read survey of the human transcriptome. *Nat Biotechnol*. 2013; 31(11):1009–1014.
40. Levene MJ. Zero-mode waveguides for single-molecule analysis at high concentrations. *Science*. 2003; 299(5607):682–686.
41. Foquet M, Samiee KT, Kong X, et al. Improved fabrication of zero-mode waveguides for single-molecule detection. *J Appl Phys*. 2008; 103(3).
42. Koren S, Schatz MC, Walenz BP, et al. Hybrid error correction and *de novo* assembly of single-molecule sequencing reads. *Nat Biotechnol*. 2012; 30(7):693–700.
43. Carneiro MO, Russ C, Ross MG, Gabriel SB, Nusbaum C, DePristo MA. Pacific biosciences sequencing technology for genotyping and variation discovery in human data. *BMC Genomics*. 2012; 13(1):375.
44. Roberts RJ, Carneiro MO, Schatz MC. The advantages of SMRT sequencing. *Genome Biol*. 2013; 14(6):405.
45. Loomis EW, Eid JS, Peluso P, et al. Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X gene. *Genome Res*. 2013; 23(1):121–128.
46. Quick J, Loman NJ, Duraffour S, et al. Real-time, portable genome sequencing for Ebola surveillance. *Nature*. 2016; 530(7589):228–232.
47. Quick J, Ashton P, Calus S, et al. Rapid draft sequencing and real-time nanopore sequencing in a hospital outbreak of Salmonella. *Genome Biol*. 2015; 16(1):114.

48. Oliver GR, Hart SN, Klee EW. Bioinformatics for clinical next generation sequencing. *Clin Chem*. 2015; 61(1):124–135.
49. Brouwer RWW, van den Hout MCGN, Grosveld FG, van Ijcken WFJ. NARWHAL, a primary analysis pipeline for NGS data. *Bioinformatics*. 2012; 28(2):284–285.
50. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer tracer using Phred. I. Accuracy assessment. *Genome Res*. 1998; 8(3):175–185.
51. Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. *Genome Res*. 1998; 8(3):186–194.
52. Nielsen R, Paul JS, Albrechtsen A, Song YS. Genotype and SNP calling from next-generation sequencing data. *Nat Rev Genet*. 2011; 12(6):443–451.
53. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009; 25(14):1754–1760.
54. Langmead B. Aligning short sequencing reads with Bowtie. *Curr Protoc Bioinforma*. 2010; (SUPP.32), Chapter 11:Unit 11.7.
55. Xu H, Luo X, Qian J, et al. FastUniq: a fast *de novo* duplicates removal tool for paired short reads. *PLoS One*. 2012; 7(12):e52249.
56. Broad Institute. GATK |GATK |Tool Documentation Index. *FastaAlternateReferenceMaker*. 2017. Available at: <https://gatk.broadinstitute.org/hc/en-us/articles/360050815912-FastaAlternateReferenceMaker> (accessed on September 30, 2022).
57. McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*. 2010; 20(9):1297–1303.
58. Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. *Bioinformatics*. 2009; 25(16):2078–2079.
59. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res*. 2012; 22(3):568–576.
60. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol*. 2013; 31(3):213–219.
61. Sathirapongsasuti JF, Lee H, Horst BAJ, et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: exomeCNV. *Bioinformatics*. 2011; 27(19):2648–2654.
62. Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing. *PLoS Comput Biol*. 2016; 12(4):e1004873.
63. Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists. *J Mol Diagnostics*. 2017; 19(3):341–365.
64. Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. *Genome Med*. 2015; 7(1):80.
65. Kim G, Ison G, McKee AE, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. *Clin Cancer Res*. 2015; 21(19):4257–4261.

66. Mendez P, Fang LT, Jablons DM, Kim I-J. Systematic comparison of two whole-genome amplification methods for targeted next-generation sequencing using frozen and FFPE normal and cancer tissues. *Sci Rep.* 2017; 7(1):4055.
67. Yoon JH, Kim TW, Mendez P, Jablons DM, Kim IJ. Mobile Genome Express (MGE): a comprehensive automatic genetic analyses pipeline with a mobile device. *PLoS One.* 2017; 12(4).
68. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature.* 2007; 448(7153):561–566.
69. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nat Med.* 2012; 18(3):378–381.
70. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol.* 1999; 17(9):2639–2648.
71. Rapaport F, Khanin R, Liang Y, et al. Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. *Genome Biol.* 2013; 14(9):R95.
72. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science.* 2015; 348(6230):124–128.
73. McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science.* 2016; 351(6280):1463–1469.
74. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science.* 2015; 350(6257):207–211.
75. Muir P, Li S, Lou S, et al. The real cost of sequencing: scaling computation to keep pace with data generation. *Genome Biol.* 2016; 17(1):53.
76. Rehm HL, Berg JS, Brooks LD, et al. ClinGen: the clinical genome resource. *N Engl J Med.* 2015; 372(23):2235–2242.

Chapter 14

Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based *In Vitro* Diagnostics

*Center for Biologics Evaluation and Research,
U.S. Food and Drug Administration, Center for Drug Evaluation and Research,
Silver Spring, Maryland, USA*

Keywords: clinical validity, data administrator, data preservation, *de novo* classification, Federal Food Drug & Cosmetic Act (FD&C Act), Federal Policy for the Protection of Human Subjects, Genetic Information Non-discrimination Act, genetic variants, genotype, genotype-phenotype associations, Health Insurance Portability and Accountability Act (HIPAA), *in vitro* diagnostics (IVDs), metadata, next generation sequencing, phenotype, precision medicine, premarket clearance, premarket submission, Privacy Act, professional training, risk prediction, standard operating procedures (SOPs), U.S. Food and Drug Administration (FDA), validated protocols, variant evaluation

14.1 Introduction

This guidance document describes one part of FDA's efforts to create a flexible and adaptive regulatory approach to the oversight of next generation sequencing (NGS)-based tests. The goal of this effort is to help ensure patients receive accurate, reliable, and clinically meaningful test results, while promoting innovation in test development. This guidance document describes how publicly accessible databases of human genetic variants can serve as sources of valid scientific evidence to support the clinical validity of genotype-phenotype relationships in FDA's regulatory review of both NGS-based tests and genetic and genomic tests based on other technologies. Publicly accessible genetic databases may be useful to support the clinical validity of NGS tests as well as single gene or panel tests that use other technology.

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

FDA's guidance documents, including this guidance document, do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidance means that something is suggested or recommended, but not required.

14.2 Background

Advances in genetic testing, such as NGS, can enable rapid, broad, and deep sequencing of a portion of a gene, an entire exome(s), or a whole genome and may be used clinically for a variety of diagnostic purposes, including risk prediction, diagnosis, and treatment selection for a disease or condition. The rapid adoption of NGS-based tests in both research and clinical practice is leading to identification of an increasing number of genetic variants, including rare variants that may be unique to a single individual or family. Understanding the clinical significance of these genetic variants holds great promise for the future of personalized medicine.

Although the importance of genetic variant data aggregation is widely recognized, today much of the data that would be useful to support clinical validity of genetic and genomic-based tests is generally stored in a manner in which it is not publicly accessible. Aggregation of clinical genotype-phenotype associations and evaluation of the evidence underlying these associations under a well-defined process will continue to promote more rapid translation of genetic information into useful clinical evidence.

For the purposes of this guidance document, a "genetic variant database" is a publicly accessible database of human genetic variants that aggregates and curates reports of human genotype-phenotype relationships to a disease or condition with publicly available documentation of evidence supporting those linkages. Genetic variant databases also include assertions about specific genotype-phenotype correlations. As a best practice, these databases should follow an open-access model (e.g., information about an assertion and the evidence underlying it is publicly accessible to anyone at no charge), to foster greater accuracy, understanding, and use. However, databases that use licensing models and charge fees for commercial use may also fall within the scope of this guidance. While out of the scope of this guidance document, proprietary databases or ones that charge fees for public access may also be sources of valid scientific evidence that could be used to support the clinical validity of genetic or genomic-based tests. Test developers who rely upon these databases may find the recommendations within this guidance useful in preparing premarket submissions for those IVDs. Any database administrator who has questions about whether or not data from their database could be relied on as valid scientific evidence should contact the FDA using the contact information referenced above.

FDA believes that the aggregation, curation, and evaluation of clinical genotype-phenotype associations in genetic variant databases could support

the clinical validity of assertions made about a variant detected by a genetic or genomic-based test and a disease or condition. In relying on assertions in genetic variant databases that follow the recommendations in this guidance, FDA hopes to encourage the deposition of genetic variant information in such publicly accessible databases, reduce regulatory burden on test developers, and spur advancements in the evaluation and implementation of precision medicine.

14.2.1 Publicly Accessible Databases of Human Genetic Variants as Sources of Valid Scientific Evidence Supporting Clinical Validity

To determine whether a genetic or genomic-based test has a reasonable assurance of safety and effectiveness, which, for IVDs, generally means a reasonable assurance of analytical and clinical validity, the Agency relies upon the review of valid scientific evidence to support the analytical and clinical performance of the test. Valid scientific evidence¹ could be evidence from well-controlled investigations, partially controlled studies, studies and objective trials without matched controls, which includes the testing of banked human specimens, well-documented case histories conducted by qualified experts, and reports of significant human experience with a marketed device, such as in certain clinical practice guidelines, from which it can fairly and responsibly be concluded by qualified experts that there is [a] reasonable assurance of safety and effectiveness. In determining whether a particular genetic and genomic-based test has a reasonable assurance of safety and effectiveness, FDA must determine, based on valid scientific evidence, that “in a significant portion of the target population, the use of the device for its intended uses and conditions of use, when accompanied by adequate directions for use and warnings against unsafe use, will provide clinically significant results.”²

The evidence residing in many genetic variant databases has been collected from multiple sources that can meet the valid scientific evidence definition, such as evidence from well-controlled clinical investigations, clinical evidence generated in CLIA (Clinical Laboratory Improvement Amendments of 1988)-certified laboratories, published peer-reviewed literature, and certain case study reports. Some organizations that are developing genetic variant databases have adopted protocols and methodologies and/or external guidelines (e.g., from professional societies or standards development organizations) for evidence aggregation, curation, and evaluation practices. While evaluation processes may vary across databases and organizations, they typically involve the use of qualified experts who make informed conclusions about the presence or absence of a genetic variant and its meaning for a particular disease or clinical decision.

Further, there are several parallels between the processes set forth by well-recognized professional guidelines for variant evaluation and FDA review of clinical validity. Individuals evaluating variants use a range of evidence, including the types and positions of variants, inheritance, prevalence, well-established

¹21 CFR 860.7.

²21 CFR 860.7(e)(1).

functional studies, and prior knowledge of gene-disease relationships. Generally, the standards for use of evidence appear to parallel the types of evidence appropriate to support an FDA premarket submission. Under 21 CFR 860.7(c) (2), “isolated case reports, random experience, reports lacking sufficient details to permit scientific evaluation, and unsubstantiated opinions are not regarded as valid scientific evidence.” FDA assesses clinical validity based on the totality of available evidence provided in a given submission. Similarly, well-recognized professional guidelines recommend that individuals evaluating variants integrate multiple lines of evidence to make an assertion of clinical validity. As such, case series that consist of two or more similar observational studies are more highly regarded as evidence to support a genotype-phenotype association.

The Agency believes such practices for evaluation of genetic variants help assure the quality of data and assertions within genetic variant databases and has built upon these approaches in developing the recommendations in this guidance.

FDA has long believed that public access to supporting data is important so that all interested persons (e.g., healthcare providers and patients) can make the most informed medical treatment decisions possible. To that end, for all IVDs that have received premarket clearance or *de novo* classification from FDA since November 2003, FDA has published a Decision Summary that includes a review of the analytical and clinical validity data submitted by the applicant to support the submission and FDA’s justification in clearing or classifying the IVD; FDA is also required to publish Summaries of Safety and Effectiveness Data for approved PMAs under Section 520(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). FDA believes that similar public availability and access to data contained in genetic variant databases is important to patients and healthcare providers in order to make fully informed medical decisions.

FDA believes that if genetic variant databases follow the recommendations in this document, the data and assertions within would generally constitute valid scientific evidence that can be used to support clinical validity for purposes of FDA approval.

14.3 Scope

This guidance document describes FDA’s considerations in determining whether a genetic variant database is a source of valid scientific evidence that could support the clinical validity of genetic and genomic-based tests in a premarket submission, regardless of the type of technology for the test (e.g., NGS, Sanger sequencing, PCR). This guidance further outlines the process by which administrators of publicly accessible genetic variant databases could voluntarily apply to FDA for recognition, and how FDA would assess such applications and periodically reevaluate recognized databases.

The genetic variant databases discussed in this guidance only include those that make assertions about human genetic variants, and do not include databases

that direct therapies and databases used for microbial genome identification and detection of antimicrobial resistance and virulence markers. This guidance does not apply to software used to classify and interpret genetic variants, but instead, only regards use of curated databases using expert human evaluation.

14.4 Definitions

The following definitions are supplied to provide the reader with an understanding of the specific terms used in this guidance. These definitions should not be construed to be new interpretations or clarification of similar words or phrases in the FD&C Act, FDA regulations, other laws, or other guidance documents.

- **Aggregation:** the process by which variant data are systematically collected, input, and maintained in a genetic variant database. This process may require that data conform to specified formats.
- **Assertion:** the informed assessment of a genotype-phenotype correlation (or lack thereof) given the current state of knowledge for a particular variant. An assertion is generally noted in the genetic variant database entry for a particular variant (e.g., benign, drug resistant, etc.).
- **Curation:** the process by which data regarding a specific variant are selected from various sources and annotated over time.
- **Data Administrator:** FDA acknowledges that many databases may not use the term “administrator” or may have a committee of individuals that oversee the database. Therefore, for the purpose of this guidance, a genetic variant database administrator is the entity or entities that oversee database operations.
- **Evaluation:** the process by which individuals associated with a genetic variant database assess the evidence regarding a linkage between a genetic variant and a disease or condition and make an assertion about that linkage (or lack thereof).
- **Protocol:** an evidence-based tool (e.g., decision matrix, scoring system, algorithm, etc.) used to guide the evaluation of the genotype-phenotype relationship between variants and diseases or conditions.

14.5 Recommendations to Support Recognition of Publicly Accessible Genetic Variant Databases of Human Genetic Variants as Sources of Valid Scientific Evidence Supporting Clinical Validity of Genetic and Genomic-Based Tests

FDA believes that the evidence and assertions contained in a genetic variant database that conforms to the recommendations described below would generally constitute valid scientific evidence that can be used to support the clinical

validity of a genetic and genomic-based test in a premarket submission, and therefore such database could be recognized by FDA for such use.

FDA believes that such a genetic variant database would: (1) operate in a manner that provides sufficient information and assurances regarding the quality of source data and its evidence review and variant assertions; (2) provide transparency regarding its data sources and its operations, particularly around how variant evidence is evaluated; (3) collect, store, and report data and conclusions in compliance with all applicable requirements regarding protected health information, patient privacy, research subject protections, and data security; and (4) house genetic variant information generated by validated methods.

In the subsections below, FDA discusses recommendations for the operation of a genetic variant database, and the aggregation, curation, and evaluation of data therein, so that such data would generally constitute valid scientific evidence supportive of clinical validity. FDA acknowledges that individual genetic variant databases may have different, but equally scientifically valid, approaches to assuring data quality, clinical relevance, data security, patient privacy, and transparency. Additionally, FDA recognizes that several professional societies have developed or are developing guidelines for genetic variant curation and evaluation that may differ depending upon discipline, but may each be appropriate in the context of their purpose. Genetic variant database administrators should focus on ensuring that their procedures and quality requirements are sufficiently robust to provide a high degree of confidence in their assertions regarding genotype-phenotype associations.

14.5.1 Database Procedures and Operations

Transparency and Public Accessibility: FDA recommends that genetic variant database administrators make publicly available sufficient information regarding data sources and standard operating procedures (SOPs) for evaluation of evidence to allow FDA and the public to understand the criteria and processes used to collect and evaluate evidence about variants and enable patients and healthcare providers to make fully informed medical decisions.

SOP Version Control: SOPs should define how variant information is aggregated, curated, and evaluated. These SOPs should be documented and versioned. Changes to SOPs should be clearly documented with sufficiently detailed information regarding the change accompanied by any necessary explanation to ensure all stakeholders understand any limitations created by or implications of the change in procedure. To maintain quality variant assertions and ensure that genetic variant database operations keep pace with advances in technology and scientific knowledge, operations and SOPs should be reviewed at least annually.

Data Preservation: FDA recommends that genetic variant database administrators have processes in place for assessing overall database stability and architecture and for ensuring that data linkages are properly maintained. When a genetic variant database contains linkages to secondary databases, the

genetic variant database administrator should have predefined processes in place to recognize changes to the secondary databases and account for them in version control of the primary database. FDA recommends genetic variant database administrators back-up the database on a regular basis so that it can be reinstated as necessary.

Genetic variant database administrators should have a plan in place to ensure database content and processes are preserved in the event a genetic variant database ceases operations permanently or temporarily (e.g., a database loses funding, infrastructure upgrades). A location to deposit data, including versioning information and supporting SOPs and documentation, in the event that the genetic variant database ceases operation should be identified.

Security and Privacy: Genetic variant database operations must be in compliance with all applicable federal laws and regulations (e.g., the Health Insurance Portability and Accountability Act or HIPAA, the Genetic Information Nondiscrimination Act, the Privacy Act, the Federal Policy for the Protection of Human Subjects (“Common Rule”), etc.) regarding protected health information, patient privacy, research involving human subjects, and data security, as applicable. The genetic database administrator should identify the applicable laws and regulations to assure that any requirements are addressed and transparently documented. Genetic variant database administrators should also put in place adequate security measures to ensure the protection and privacy of personally identifiable information and protected health information and provide training for database staff on security and privacy protection.

Data formats and nomenclature: To facilitate genetic variant database use for regulatory purposes and to help assure the accuracy and quality of variant assertions, genetic variant database administrators should employ commonly accepted data formats and identify which format is used by the genetic database. Furthermore, genetic variant databases should use consistent nomenclature that is widely accepted by the genomics community for gene names and/or symbols, genomic coordinates, variants, described clinical and functional characteristics, and classifications. The genetic variant database administrator should also make available a description of which nomenclature is used to allow FDA and external users to accurately understand the information presented. This standardization will help minimize ambiguity regarding variants and better enable comparisons of variant assertions between different databases or other entities.

14.5.2 Data Quality

It is essential that the data regarding genotypes and phenotypes or clinical information placed into the genetic variant database are of sufficient quality and based on current scientific knowledge in order for there to be a reasonable assurance that the assertions made linking specific genetic variants to diseases or conditions are accurate.

Metadata: Variant data in the genetic variant database should be accompanied by metadata appropriate to the type of variant. To the extent possible or applicable,

this metadata should include information about the analytical performance of the test used to detect the variant, including the number of independent laboratories and/or studies reporting the variant, name of the laboratory(ies) that reported the variant, the name of the test used to detect the variant, and details of the technical characteristics of the test that was used (e.g., reference sequence version or build, instrument, software, bioinformatics tools, etc.). For germline variants, metadata should also include, to the extent possible, variant characteristics (which could include but is not limited to, patient ethnicity, zygosity, phasing, and segregation). For somatic variants, metadata should include, to the extent possible, additional information about the context in which the variant was detected (which could include but is not limited to, variant allele frequency, tumor only versus tumor-normal matched sequencing, cellularity). For cases in which multiple genetic variants factor into determining the overall risk of developing a disease or condition, database administrators should include any multivariant or polygenic scoring methods used in the metadata. As applicable, database administrators should also include as much information as is available regarding the contribution of environmental exposures to the development of a genotype-associated disease or condition.

Genetic variant databases should clearly and transparently document evidence source(s) used to support variant assertions (e.g., literature, well-documented case histories). As discussed in Section IV.A., database administrators should take into consideration applicable security and privacy requirements when collecting and reporting this metadata.

Data Uniqueness: Genetic variant database operations should also include methods to ensure that individual data points (e.g., a variant from one individual for a particular phenotype) are not represented more than once in the database.

14.5.3 Variant Evaluation and Assertions

Variant Evaluation: Written SOPs for variant evaluation, including evaluation of data from clinical practice guidelines, peer-reviewed literature, and pre-curated knowledge bases, should be available to the public for review. SOPs should generally include validated protocols for evaluation. All genetic variant database evaluation rules, and future modifications of those rules, should be explained and made available to the public. Furthermore, if variant assertions from other sources are to be integrated into the genetic variant database, then the evaluation processes and data quality of those outside sources should be clearly identified and audited by the database administrator on a regular basis.

FDA believes that each variant evaluation should be performed by at least two qualified and trained professionals to lessen the risk that any single assertion could be incorrectly made. In cases where it is not feasible for a database administrator to have two independent professionals evaluating the same variant, there should be other ways to mitigate the risk of an incorrect assertion (e.g., multiple levels of review, use of curator training modules). Furthermore, genetic variant databases should have SOPs for resolving internal differences

in evaluation. Providing SOPs publicly for each of these activities will facilitate outside users review of the evidence used in variant evaluation.

FDA believes that use of publicly available and validated protocols for variant evaluation is important to assuring that assertions from genetic variant databases constitute valid scientific evidence supporting the clinical validity of a test. FDA reviewers evaluate evidence in the context of a test's intended use and conditions of use,³ including specific facts about genes or diseases under consideration (e.g., population incidence of a disease, variant incidence, relationship of a variant with respect to ethnicity or haplotype) in their review. Similarly, such factors should be incorporated into a finalized protocol.

Assertions: The types of evidence used for evaluating variants, and their corresponding strengths, should be defined and combined in a protocol. Generally, these protocols should meet the following recommendations:

- Protocols should incorporate multiple lines of scientific evidence, where available, and appropriately weigh each line of evidence.
- Protocols should use a tiered system of assertions (e.g., pathogenic, likely pathogenic) and adequately describe the meanings of each tier.
- Protocols should incorporate unique details of the gene/disease or condition being evaluated, where available or applicable.
- Protocols should be validated.
- All protocols and details supporting each variant assertion should be made available to the public.

Assertions within a genetic variant database should be appropriate to the level of certainty and the nature of the genotype-phenotype relationship, as well as be adequately supported. Assertions should report known variant associations with respect to ethnicity or haplotype, when relevant. Assertions should be versioned, such that changes in assertions over time are identified and maintained. Genetic variant databases should also have mechanisms in place to receive feedback about individual variant assertions (e.g., ability for users to report that there is new or contradictory evidence available regarding a variant assertion) and processes to document, evaluate, and resolve, if necessary, such discordances.

Assertions and the evidence underlying them should be truthful and not misleading and be made in language that is clear and understandable. In order to be FDA-recognized, a genetic variant database should not include any recommendations regarding clinical treatment or diagnosis. However, an assertion that states that a variant is clinically significant as an actionable mutation may be found within an FDA-recognized genetic variant database.

FDA recommends that assertions include descriptive language about a variant such as clinically significant, pathogenic, benign, likely pathogenic, likely benign, variant of unknown significance, etc. as long as such language is truthful, not misleading, and supported by adequate evidence detailed within the genetic variant database.

³Section 513(a)(2) of the FD&C Act; 21 CFR 860.7(e)(1).

FDA believes that it is generally not scientifically appropriate to make a definitive assertion (e.g., pathogenic) about the clinical validity of a variant based on a single piece of evidence, or only on weak evidence. Assertions that a particular genotype-phenotype association is clinically valid should generally involve multiple lines of evidence and, at a minimum, should identify a primary source of scientific evidence and other supporting evidence. Further, wherever appropriate to avoid any potential misunderstanding regarding the strength of the evidence supporting an assertion, the assertion should include a clear description of the evidence associated with it.

14.5.4 Professional Training and Conflicts of Interest

Professional Training: FDA recognizes that many different types of genetics professionals may be involved in the curation and processes for evaluation as part of a team (e.g., genetic counselors, Ph.D.-level scientists, physicians). Adequate training and expertise of individuals evaluating variants plays an important role in the quality of variant review and evaluation. Individuals evaluating variants should have received adequate training and there should be methodologies in place to ensure that such individuals meet and maintain high quality standards over time.

Conflicts of Interest: Conflicts of interest, especially financial ones, could introduce bias and undermine the quality of variant assertions in genetic variant databases, as well as the confidence in such assertions, if not adequately mitigated. To be considered for recognition by FDA, efforts should be made to minimize, and make transparent, any potential conflicts of interest.

14.6 FDA's Genetic Variant Database Recognition Process

FDA believes that data and assertions from genetic variant databases that follow the recommendations discussed in this document would generally constitute valid scientific evidence supportive of clinical validity in a premarket submission. Therefore, FDA intends to implement a recognition process for publicly accessible genetic variant databases and their assertions to streamline premarket review of genetic and genomic-based tests. The genetic variant database recognition process discussed in this document is similar to the standards recognition process under section 514 of the FD&C Act, but would not be conducted under this provision. Specific variant assertions and underlying data from a recognized genetic variant database could generally be submitted by genetic and genomic-based test developers as part of their premarket review submission, if applicable, in some cases without submission of additional clinical data regarding that variant.

Participation in the FDA database recognition process is voluntary and participation would not subject the database to FDA oversight, beyond that needed to retain the recognition. For genetic variant database administrators

who wish to undergo voluntary recognition, this section describes FDA's recommended process for genetic variant database recognition. When evidence from proprietary sources or genetic variant databases that have not been recognized by FDA are used to support the clinical performance of genetic and genomic-based tests, detailed information regarding such sources of evidence should be included in the premarket submission for that test.

FDA intends for its process for recognition of genetic variant databases to involve three steps: (1) voluntary submission of detailed information about the database; (2) FDA review of genetic variant database policies and procedures for obtaining and maintaining data and making variant assertions; and (3) maintenance of FDA recognition of a database. These steps are discussed in detail below.

14.6.1 Recognition Process for Genetic Variant Databases

14.6.1.1 Submission for recognition

Administrators of genetic variant databases seeking to have their assertions be considered by FDA as valid scientific evidence that could provide support for the clinical validity of genetic and genomic-based tests should make a voluntary submission to FDA for genetic variant database recognition. FDA notes that such a request could be for the totality of a genetic variant database, or, at the database administrator's discretion, a subset of the database as defined by the database administrator. Such a submission should demonstrate that the recommendations in this document have been followed or explain why an alternative approach was taken. FDA encourages genetic variant database administrators seeking recognition of their genetic variant database to contact FDA through the Q-Submission Program.⁴ More information on the Database Recognition Program and instructions for recognition requests are available on the FDA Recognition of Public Human Genetic Variant Databases webpage.⁵

14.6.1.2 FDA review of genetic variant database policies and procedures

The intent of this section is to provide additional information to genetic variant database administrators regarding the type of documentation that should be provided to FDA staff for the purpose of voluntary genetic variant database recognition. Complete documentation should address all of the recommendations in this guidance.

⁴Further information about the Q-Submission Program can be found in the FDA guidance document entitled "Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff—Guidance for Industry and Food Administration Staff" (<https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm311176.pdf>).

⁵<https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/PrecisionMedicine-MedicalDevices/ucm603675.htm>.

The following types of documents, which show that the recommendations in this guidance have been met, should be submitted in an application for recognition:

- SOPs, policies or other documents related to the recommendations in this guidance, such as:
 - o General operation of the genetic variant database
 - o Personally identifiable information and protected health information confidentiality and privacy
 - o Data integrity and security
 - o Curation, variant evaluation, and reevaluation
 - o Training for curation, evaluation, privacy and security, and other relevant activities
- Validation studies for evaluation SOPs
- Documentation of the qualifications of the individuals evaluating variants and policies for approving those individuals
- Data preservation plan
- Conflict of interest policies and disclosures of conflicts of interest
- A commitment to make all recommended documents publicly accessible via weblinks

Applications should be accompanied by a cover letter, which should detail the following information:

- Statement of the types of variants the genetic variant database assertions address (e.g., germline)
- Scope or portion of the database for which recognition is being sought
- Point of contact
- Entity name
- Statement that the submitter believes, to the best of his or her knowledge, that all information submitted are truthful and accurate and that no material fact has been omitted

As part of its recognition process, FDA may verify a subset of variant assertions, as appropriate, to assure they are supported and that the genetic variant database is following its SOPs.

Prior to recognition, FDA generally intends to treat this information confidentially and not publicly disclose it except as required by law.⁶ At the time of recognition, the database administrator should make this information publicly available and accessible on the genetic variant database's website. FDA also intends to make available on its own website a list of all FDA-recognized genetic variant databases and other relevant, public information about those databases, such as a summary of the recognition decision.

⁶See, e.g., the FD&C Act sections 301(j) and 520(c), the Trade Secrets Act, 18 U.S.C. 1905, the Freedom of Information Act, 5 U.S.C. 552, and FDA's regulations covering information disclosure at 21 CFR part 20.

14.6.1.3 Maintenance of FDA recognition

FDA intends to review FDA-recognized databases annually but may review more or less frequently as appropriate to verify they continue to follow their SOPs and the recommendations in this guidance.

Continued transparency about policies, procedures, and assertions will play a critical role in maintaining confidence in a genetic variant database and thus, to maintaining recognition. FDA believes that it is important that users and the public have access to information about the capabilities and limitations of a genetic variant database so that patients and healthcare providers can make fully informed medical decisions. Genetic variant database administrators should document and make publicly accessible any changes or updates to the database SOPs on its website. FDA plans to periodically review its recognition of a genetic variant database based upon this transparently documented and publicly available information. As part of this process, FDA will verify that updates to SOPs, as described in Section IV, have been posted. FDA may also “spot-check” assertions about genetic variants to assure they continue to be supported and that the genetic variant database continues to follow its SOPs for evaluation. If the genetic variant database is not maintained according to the specifications under which it was recognized, FDA may withdraw recognition. If recognition is withdrawn, it would be unlikely that FDA would consider assertions from such a genetic variant database to constitute valid scientific evidence supportive of the clinical validity of a test, and FDA would assess what regulatory actions may be appropriate with respect to IVDs supported by such assertions.

14.6.2 Use of Third Parties

FDA has an established third party 510(k) review program for eligible medical devices.⁷ For genetic variant databases, FDA may consider utilizing third parties to assist with genetic variant database recognition in the future. FDA seeks to work with interested parties that have experience with genetic variant databases and genetic and genomic-based tests and can comply with FDA policies, including those regarding screening for conflicts of interest.

14.6.3 Use of Data and Assertions from FDA-Recognized Genetic Variant Databases

Data from FDA-recognized genetic variant databases would generally constitute valid scientific evidence that can be used to support the clinical validity of the genotype-phenotype relationships embodied in the assertions from such databases provided in a premarket submission. Under this policy, FDA expects that test

⁷For additional information, including guidance documents on the topic, please see FDA's website for the Third Party Review Program (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ThirdPartyReview/default.htm>).

developers will be able to use FDA-recognized genetic variant databases to establish, at least in part, the clinical validity of their test. For premarket submissions that rely upon genetic variant databases recognized by FDA, the Agency may determine that submission of any additional valid scientific evidence for certain variant assertions found in these genetic variant databases is not necessary, depending on the sufficiency of the evidence for these assertions.

Disclosures and Conflict of Interest

This chapter was organized by the Series Editor, Raj Bawa, PhD, MD, based on content and figures provided by the FDA. The information presented herein is freely available in the public domain. This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page. This is the final document issued by FDA on April 13, 2018, based on the draft document that was issued on July 8, 2016.

Chapter 15

Innovating the Concept and Practice of Two-Dimensional Gel Electrophoresis in the Analysis of Proteomes at the Proteoform Level

Xianquan Zhan, MD, PhD,^{a,b,c,d} Biao Li,^{a,b,c} Xiaohan Zhan,^{a,b,c} Hartmut Schlüter, PhD,^e Peter R. Jungblut, MD,^f and Jens R. Coorsen, PhD^g

^aUniversity Creative Research Initiatives Center, Shandong First Medical University, Jinan, China

^bKey Laboratory of Cancer Proteomics of Chinese Ministry of Health Central South University, Changsha, China

^cState Local Joint Engineering Laboratory for Anticancer Drugs, Central South University, Changsha, China

^dNational Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China

^eInstitute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

^fMax Planck Unit for the Science of Pathogens, Berlin, Germany

^gDepartments of Health Sciences and Biological Sciences, Brock University, St. Catharines, Ontario, Canada

yjzhan2011@gmail.com

Keywords: bottom-up proteomics, human growth hormone (hGH), human prolactin (hPRL), immobilized pH gradient gel (IPG), isoelectric focusing (IEF), isoelectric point (pI), liquid chromatography (LC), mass spectrometry (MS), optical density (OD), peptide mass fingerprint (PMF), post-translational modification (PTM), protein speciation, protein species, proteoform, splicing, tandem mass spectrometry (MS/MS), tandem mass tags (TMT), top-down proteomics, two-dimensional gel electrophoresis (2DE)

15.1 Introduction

After several attempts to improve protein resolution by combining different electrophoretic methods [1–7], in 1975, O'Farrell published the combination of isoelectric focusing using sodium dodecyl sulfate-polyacrylamide gel electrophoresis

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 S. R. Bawa

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

(SDS-PAGE) [8]. This combination resulted in a breakthrough in resolution where about 1000 spots could be resolved in one gel. This combination was named two-dimensional gel electrophoresis (2DE). Until quite recently, 2DE has largely been used to resolve and array proteins according to their isoelectric points (pI) and relative masses (M_r). The separated proteins, visualized as 2DE “spots” via the use of different staining reagents, thus form a two-dimensional protein map. The difference in spot volumes of matched gel-spots between two different given conditions, such as disease versus normal controls, is used to identify total alterations in protein abundance or changes in the abundance of certain post-translational modifications (PTM) with selective stains; this was primarily based on the conventional concept that 2DE is a high-resolution analytical tool yielding only one or two proteins per spot. Thus, the spot volume represented the combined abundance of each protein species. The difference in spot volumes between matched spots was said to indicate the protein abundance alterations between two different biological situations [9, 10]. Excised protein spots of interest could then be subjected to in-gel digestion with trypsin (or other proteases) and identified using analyses coupling peptide mass fingerprint (PMF) or tandem mass spectrometry (MS/MS) and available databases. This has thus been one of the main analytical strategies to address the complexity of proteomes even before the concept of the proteome appeared in 1995 [11]. With continuous improvements to the overall methodology from a number of groups over the last 40 years, 2DE is the current gold standard for the optimal resolution of proteoforms that underlie proteome complexity; 2DE is thus a critical technical platform—indeed, the most well-established approach—for detailed top-down proteomic analyses. Methodological optimization began with improvements of reproducibility and resolution, reaching 10,000 spots in controlled running conditions and with very large gels (30 cm × 40 cm) [12, 13]. The development and commercialization of immobilized pH gradient (IPG) strips [14], such as Bio-Rad and GE Healthcare products, significantly improved the ease and reproducibility of the isoelectric focusing (IEF) step, helping to establish the 2DE methodology in many laboratories all over the world. The multi-gel SDS-PAGE system was introduced to significantly improve reproducibility in the second dimension of resolution [15, 16]; it was also established that non-linear (NL) pH 3–10 IPG strips were generally superior to the linear gradients and that a constant gel porosity in the second dimension was better than a gradient one with respect to the separation of proteoforms in the analysis of pituitary samples [15, 16]. Meanwhile, some studies demonstrated that more spots were resolved with linear gradient IPG strip in the first dimension and there was a much better resolution with a gradient gel in the second dimension in analysis of serum samples [17, 18]. 2DE protocols are also being continuously and rigorously refined [19–23] to improve the resolution and subsequent MS-identification, including the use of prefractionation [24] and third electrophoretic separations as a post-fractionation strategy [19], optimization of detergent composition in the solubilization buffer [20, 25–31], pre-extraction of sample handling using automated frozen disruption [21], sampling of tissue

with a picosecond-infrared laser (PIRL) technology for getting a better access to the original composition of proteoforms in a tissue [32], a routine “deep imaging” approach to resolve and detect even low-abundance species with 2DE [22], and the newer Coomassie formulation stain/wash protocol and UV-detection as the highest sensitivity protocol for in-gel protein detection, providing detection of intact proteoforms in the low-to-sub-femtomole range (i.e., comparable to the detection of peptides in routine MS analyses) [23]. Indeed, these improved 2DE methods have enabled a newfound respect for the true complexity of proteomes and for the depth of analysis necessary to genuinely understand molecular mechanisms and identify the best possible biomarkers. However, such analyses must go well beyond the still widely held conventional concept that there are only one to two proteins in each 2DE spot in the analysis of the complex proteome [33–35]. It is time for the field of proteomics to recognize the critical complementarity of different available approaches, as already emphasized in 2004 [36]. The pros and cons of each method must be fully understood and respected.

The term protein species [37–39], now often also referred to as a proteoform [40], introduced the view that protein species/proteoforms rather than proteins (i.e., the canonical amino acid sequence alone) are the basic units of a proteome. Protein species is a historically grown and chemically defined term [38, 39]. Proteoform is a one-word and gene-centric term, which is currently widely accepted and already often used. Despite subtle original differences in the interpretations that led to the use of the terms “protein species” and proteoform, they are now most widely accepted as essentially conceptually identical [34, 35, 41], or proteoform is nearly identical with protein species. The products of a single gene actually represent a set of proteoforms, each of which has a specific pI and M_r , and can thus be resolved using 2DE [34, 35]. Here, the term protein species/proteoform is further clearly defined as a primary amino acid sequence + PTMs + spatial conformation + cofactors + binding partners + localization + a clearly defined function (Fig. 15.1). Furthermore, multiple variable transcripts (e.g., splicing variants) correspond to a single gene, and each transcript can be translated into a primary amino acid sequence, each of which may then also consist of multiple proteoforms. Overall, then, proteoforms derived from the same gene can be distributed within different 2DE spots according to variations in pI and M_r , and a given spot may be expected to contain multiple proteoforms derived from different genes. A visible given spot might thus consist of many tiny spots barely resolved from each other, and certainly not visually distinguishable with current technology. Furthermore, while there have been different processes used to estimate the size of the human proteome [42, 43] with values ranging from at least one million proteoforms in a given cell type [44], up to even ≈ 1 billion proteoforms [45], it should come as no surprise that each gel spot may contain many proteoforms with the same or very similar pI and M_r . While there has been some early evidence consistent with this state of complexity [19, 44, 46–48], a recent study has unequivocally confirmed this phenomenon [33, 34], finding that every spot in a 2DE map of a complex native

human proteome contains on average fifty to several hundred proteoforms. Many if not all proteins derived from the same gene are distributed within different 2DE spots, and most species in each gel spot are of low-abundance [34]. Some studies also used a cutting 2D gel pixel (10 mm × 6.66 mm × 1 mm) strategy and identified an average of five proteoforms corresponding to each gene in HePG2 cells [49] and an average of four proteoforms corresponding to each gene in glioblastoma cells [50]. These findings, made possible with high sensitivity mass spectrometers, have now completely broken through the conventional concept of only one to two proteins in each 2DE spot in the analysis of complex proteomes [35]. If stable isotope labeling, such as isobaric tags for relative and absolute quantification (iTRAQ), tandem mass tags (TMT), and stable isotope labeling of amino acids in cell culture (SILAC), are incorporated into the 2DE-LC-MS methodology, then stable isotope-labeling 2DE-LC-MS/MS is expected to be an extremely powerful approach for the large-scale detection, identification, and quantification of proteoforms [35]. An alternative approach might be 2DE-LC-MS/MS using label-free quantification; although this would require a much larger number of LC-MS/MS runs, it is devoid of the issues associated with some of the pre-labelling techniques and would be immediately implementable for any sample type.




Figure 15.1 Relationship of proteoform, protein, and proteome. PTM: Post-translational modifications. Modified from Zhan et al. [35], with permission from Hapres open access publication, copyright 2018; and reproduced from Zhan et al. [95], with permission from MDPI publisher open access publication, copyright 2019.

In summary 2DE-LC-MS/MS provides the most in-depth analysis of proteomes currently available. Further optimization is still possible and reasonably straightforward to achieve. Therefore, innovation in the conception and practice of 2DE, as well as in high-throughput/high-resolution LC-MSMS, will be essential to effectively address the real complexity of proteomes.

15.2 Definition of Spots and Pixels

Generally, a 2DE spot is a visible dot in a 2DE map, which is generated by 2DE-resolved proteoforms at a certain location (i.e., grid reference of pI and M_r). A spot is most generally visualized using stains, such as Coomassie [33] or silver [51], or using fluorescent stains, such as Sypro Ruby and Flamingo [52–54] (Fig. 15.2A). Since a resolving gel has a certain thickness (commonly 1 mm), a given spot has a volume described by a Gaussian distribution, with spot height $\times \pi\delta_x\delta_y$ ($OD \cdot IU^2$) [16]. Spot height is the peak value of the Gaussian spot, and its unit is optical density (OD). δ_x is the standard deviation of the Gaussian distribution of the spot in the x -axis direction in image units (IU). δ_y is the standard deviation of the Gaussian distribution in the y -axis direction (also in IU). One IU = 100 micrometers ($100 \mu\text{m}$) = 0.1 mm (0.1 mm). The units of the spot volume are $OD \times IU^2$. One must note that a specific proteoform will resolve to a single very tiny spot that is resolved from others. However, any proteoforms with very similar pI and M_r will migrate to the identical position in the gel. A given visible spot on a 2DE gel can thus be understood as a tight and overlapping group of very tiny spots [35].




Figure 15.2 The model of gel spots and gel pixels in a 2DE map. (A) The model of a 2D gel spot; (B) The model of a 2D gel pixel. Reproduced from Zhan et al. [95], with permission from MDPI publisher open access publication, copyright 2019.

Every protein staining method has its own sensitivity (i.e., limit of detection) [23, 42, 55–57]. Spot detection thus correlates directly with the total amount of proteoforms present and the optical density of a spot does not give any information about the amount of any of the single components. In reality, the dynamic abundance range of proteoforms is very large, ≈ 12 orders of magnitude [58, 59]. Considering the inherent complexity of proteomes, detection sensitivity, as well as the theoretical plates of separation for a given gel, it can be expected that spot-free regions of the gel contain rare proteoforms because many low-abundance proteoforms do not reach the detection limit of the protein-staining methods used. Therefore, one might cut the 2DE gel into multiple different pixel-sized pieces using a grid (e.g., 3 mm \times 3 mm) for subsequent MS analysis [60] (Fig. 15.2B). A gel pixel has a volume, with length (e.g., 3 mm) \times width (e.g., 3 mm) \times thickness (commonly 1 mm). Of course, the pixel size should be optimized according to the workload and detection sensitivity of the available 2DE-LC-MS/MS platform. Here, we initially assume a pixel size of 3 mm \times 3 mm \times 1 mm; it also might be 1 mm \times 1 mm \times 1 mm, 2 mm \times 2 mm \times 1 mm, 3 mm \times 5 mm \times 1 mm, or other sizes. For example, a big pixel size 10 mm \times 6.66 mm \times 1 mm (a total of 96 sections from a 2D gel 8 cm \times 8 cm \times 1 mm) was used to analyze HePG2 cells with the achievement of 20,462 proteoforms encoded by 3774 genes [49], and glioblastoma cells with the achievement of 16,012 proteoforms encoded by 4050 genes [50]. A pixel contains all proteoforms with a very similar pI and M_r in a given grid area [61, 62]. Such a vision of a molecular scanner [60] was not realized until now because even with the available LC-MS techniques, this would be a very complex, time-consuming, and expensive cataloging exercise, but is ultimately necessary if we are aiming to decipher the proteome at the level of proteoforms.

15.3 Relationship between Proteoform, Protein, and Proteome

The apparent completion of the analysis of the human genome [63] has resulted in the identification of about 20,300 genes (although there are caveats to this estimate [64–66]), and has driven researchers into the era of transcriptomics and proteomics to study phenotypes and their potential linkage back to the genome. Due to RNA splicing and other factors, many transcripts are often derived from a single gene [67–69]; thus, at least 100,000 transcripts are contained in the human transcriptome [44, 70]. Many of the newly synthesized proteins, after leaving the ribosome, are then processed, e.g., by proteolytic cleavage of a signal peptide and modified by one or more post-translational modifications (PTMs); at this point there are more than 400 known PTMs [70]. After being modified, the proteoform reaches its specific subcellular location and selectively interacts with surrounding molecules, sometimes engaging in a complex formation, to carry out its specific biological function. This often transient final structural and functional form of a protein is a protein species/proteoform [38–40]. Thus, a protein is in reality a set of proteoforms [35]. Each proteoform is the specific


and ultimate form of a protein. Proteoforms, but not proteins, are the basic units of any proteome, and are the long-range final functional effectors of a gene (Fig. 15.1). Given sufficient abundance, each proteoform, with its specific pI and M_r , can be resolved and detected using 2DE, and identified with coupled MS/MS.

15.4 A 2DE Spot Contains Many Proteoforms Derived from Different Genes

Many proteoforms with very similar pI and M_r exist in proteomes and can comigrate into a 2DE pixel. Different proteoforms in a single 2DE pixel usually have significant abundance differences. With the use of high sensitivity mass spectrometers, these low-abundance proteoforms can be detected, identified, and quantified. A recent study experimentally confirmed this principle, where every 2DE spot contained about 50 proteoforms on average, sometimes several hundred of them at maximum [33, 34] (Fig. 15.3). This completely breaks through the conventional concept of assuming only one to two proteins (which in reality are different proteoforms) in each gel spot in a 2DE map, although, in some gel spots of a 2DE map, several proteins had already been found [19, 46, 48, 50, 61]. In 2013, Thiede et al. [47] reported that 50% of the spots contained more than one protein (most spots: 2–3 proteins/spot, and only one spot: 22 proteins/spot). In 2015, the Zhan research group first reported that every identified spot contained over fifty proteoforms [33], and then in 2018, confirmed that every 2DE spot analyzed contained over fifty and even up to several hundred proteoforms [34]. Together, these results completely changed the traditional concept of 2DE for proteome analysis, which was addressed in detail in 2018 [35].

15.5 Proteoforms from One Gene Are Distributed within Different 2DE Spots

Many proteoforms arising from the same gene, but each with a specific pI and M_r , are expected to be resolved into different 2DE spots [71–74]. For example, (i) 24 human growth hormone (hGH) proteoforms (each GH proteoform identified with more than 3 peptides) derived from the same GH gene are present in 24 different spots in the 2DE map of the normal human pituitary proteome (Fig. 15.4) [71]; (ii) 6 human prolactin (hPRL) proteoforms derived from the same hPRL gene are present in 6 different spots in the pituitary proteome 2DE map [72]; (iii) 59 HSP27 proteoforms derived from the same HSP27 gene are present in 59 different gel spots in the 2DE map of the human myocardium proteome [73]; (iv) 52 HSP70 proteoforms derived from the same HSP70 gene, 24 gamma-enolase-2 proteoforms derived from the same gamma enolase-2 gene, and 17 lactate dehydrogenase 2B proteoforms derived from the lactate dehydrogenase 2B gene are all present in different gel spots in the 2DE maps of the mouse brain proteome [74]; and (v) 28 and 29 proteoforms of lamin A/C and vimentin, respectively, have been identified in a 2DE map of HeLa cells [47].



Spot no.	Number of proteins identified (single gel spot)	Spot no.	Number of proteins identified (A pool of 3 matched gel spots)		
			Uni_pep2≥1	Uni_pep2≥2	Uni_pep2≥3
L1	25	3	424	289	231
L2	23	7	356	254	182
L3	59	8	408	280	205
L4	52	16	329	226	175
L5	51	22	352	234	162
		31	410	294	222
		46	296	192	136
		48	328	230	166
		49	392	267	171
		50	365	252	187
		52	273	184	126
		53	199	120	80
		58	368	237	169
		60	225	134	85
		61	372	287	234
		63	251	177	137
		64	326	242	186
		65	347	255	200
Total	210	Total	6021	4154	3054
Average	42 (210/5)	Average	334 (6021/18)	230 (4154/18)	169 (3054/18)

Figure 15.3 An average of over 50 to several hundred protein species were identified in every two-dimensional gel electrophoresis (2DE) spot of the human glioblastoma proteome. The glioblastoma proteome was resolved using 18 cm pH 3–10 non-linear immobilized pH gradient gel (NL IPG) strips and 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the second dimension, and stained with Coomassie Blue. Spots L1–L5 came from one gel for tandem mass spectrometry (MS/MS) analysis. Each spot labeled with a red or green number was combined from three matched spots from parallel gels for MS/MS analysis. Modified from Zhan X. et al. [34] with permission from Wiley-VCH.




Figure 15.4 A total of 24 hGH proteoforms are found in the 2DE map of the human pituitary proteome. The human pituitary proteome was resolved as described in Fig. 15.3 and silver stained. IEF: isoelectric focusing. Modified from Zhan X. et al. [71] with permission from Wiley-VCH; and reproduced from Zhan et al. [95], with permission from MDPI publisher open access publication, copyright 2019.

15.6 Most Proteoforms in a 2DE Spot Are of Low-Abundance

With an upper estimate of over 1 million proteoforms in a given cell type of the human organism [44], the dynamic range of these proteoforms is estimated to be up to 10^{12} [58, 59]. The deep-dive study confirmed that most proteoforms are of low-abundance among the about fifty-to-several hundred protein species found in a single given 2DE spot (Table 15.1) [34]. The important correlate of this is that that species most easily identified (i.e., having the best sequence coverage) is also the most abundant in any given spot and thus also most likely to be the species changing in abundance when differences in spot density are assessed (i.e., between experimental conditions) [47, 74]. Overall, the results thus clearly demonstrate that 2DE in combination with LC-MS/MS is a robust, state-of-the-art, top-down approach to resolve and detect low-abundance proteoforms in complex proteomes, but also to carry out routine comparative proteomic analyses.

Table 15.1 Most of proteoforms in a 2D gel spot have a low abundance or extremely low abundance in the analysis of the human glioblastoma proteome

Spot no.	Total (n)	The number of proteins by emPAI range				
		>100 (n)	100–10 (n)	10–1 (n)	1–0.1 (n)	0.1–0.01 (n)
3	289	7	3	28	105	146
7	254	2	6	19	105	122
8	280	2	2	22	130	124
16	226	—	8	32	89	97
22	234	1	3	27	122	81
31	294	—	4	36	125	129
46	192	1	4	19	106	62
48	230	—	1	29	132	68
49	267	3	2	29	139	94
50	252	—	1	40	126	85
52	184	1	—	33	99	51
53	120	—	—	12	61	47
58	237	2	4	31	129	71
60	134	2	4	6	60	62
61	287	1	6	28	116	136
63	177	1	2	24	53	97
64	242	—	1	18	93	130
65	255	—	1	19	85	150

Note: The number of proteins in each emPAI range, which is the estimation of the ratio of each protein with at least two unique peptides identified in the analyzed glioblastoma 2DE spot with OrbiTrap Velos MS/MS. Each spot was analyzed with a combined three matched gel spots. Each identified protein had at least two unique peptides identified. The emPAI is the exponentially modified protein abundance index (emPAI), which was calculated for each protein in an analyzed spot to estimate the amount of each protein in a 2DE spot. emPAI is equal to 10^{PAI} minus one. The protein abundance index (PAI) is the number of identified tryptic peptides divided by the number of theoretically observable tryptic peptides.

Modified from Zhan X et al. [34] with permission from Wiley-VCH, copyright 2018; and reproduced from Zhan et al. [95], with permission from MDPI publisher open access publication, copyright 2019.

15.7 Stable Isotope-Labeled 2DE-LC-MS/MS for the Large-Scale Analysis of Proteoforms

Having established that 2DE-LC-MS/MS is the most effective available method to address the sheer complexity of proteomes via the large-scale resolution, detection, and identification of intact proteoforms in the analysis of the complex proteome [34], what are the current limits of the approach without additional

refinements? Approximately 10,000 2DE spots can be resolved using a 40 cm tube gel in the first dimension of IEF separation and a 40 cm × 30 cm gel in the second dimension of separation [12], or 13,333 gel pixels can be obtained using a 3 mm × 3 mm grid for such a gel. Even for an 18 cm × 20 cm 2DE gel with an 18 cm pH 3–10 nonlinear (NL) IPG strip, commonly 1500–2000 2DE spots or 4000 gel pixels (3 mm × 3 mm grid) are routinely achievable (Fig. 15.2). Similarly, capitalizing on more recent refinements to a 2DE protocol, including separate resolutions for the soluble and membrane sub-proteomes, high-sensitivity near-IR detection of proteoforms, 3D separations of *pI* extremes and regions of protein hyper-abundance, and deep imaging, a total of 2500–3000 spots were detected using a mini-gel format (i.e., 7 cm IPG strips and 82 mm × 58 mm × 1 mm SDS-PAGE); using a conservative estimate of 50 intact proteoforms per spot [34], this indicates a total proteoform resolution of ≈125,000–150,000 species, which is many times the resolution of any other currently available analytical approach. Estimates of proteoform resolution using large format 2DE thus extend from approximately 500,000 to a million or more proteoforms, values that are unlikely to be achieved by approaches using bottom-up only (which nonetheless do not routinely identify proteoforms) or alternate “in-line MS” top-down analyses that still require front-end separations, deal poorly with hydrophobic proteins, and do not permit any large-scale analysis of proteoforms larger than ≈40 kDa [75–80]. The best published detection using capillary zone electrophoresis and in-line top-down MS is 5700 proteoforms from 860 proteins [81, 82]. Nonetheless, both the refinements to the 2DE protocol (i.e., 3D separations and deep imaging) in combination with subsequent high-sensitivity bottom-up MS/MS (LC-MS/MS) (i.e., Orbitrap mass spectrometers) provide for the routine identification of a much larger number of proteoforms at very different levels of abundance (Fig. 15.5). Thus, even considering the important technical advancements contributed by bottom-up approaches over the last decade, 2DE-LC-MS/MS is opening a new horizon that is central to the necessary deep analysis of proteomes at the level of proteoforms.

To ensure the best possible quantitative proteome coverage and the fullest possible sequence and PTM coverage of any given proteoforms, in order to link specific proteoforms to specific biological roles in different physiological or pathological states, further refinements are necessary. The most immediately obvious again capitalize on the complementarity of available methods. The first, quantitative approach would be to quantify each proteoform using stable isotope-labeling of native proteomes before 2DE-LC-MS/MS analysis [35]. For example, SILAC reagents can be used to label all the proteoforms in cultured cells under different conditions, followed by 2DE-LC-MS/MS analysis (Fig. 15.5) [47]. An alternative method, more broadly applicable to the range of sample types encountered in proteomic analyses (i.e., tissues, body fluids), might be stable isotope-labeling of the extracted proteoforms [83–86], again followed by 2DE-LC-MS/MS analysis (Fig. 15.5 and see below).




Figure 15.5 Comparison of methods to study proteoforms. 2DE is a top-down analysis. MS/MS analysis after enzymatic digestion is a “selective” bottom-up analysis. 2DE—two-dimensional gel electrophoresis, MDLC—multiple dimensional liquid chromatography, MS—mass spectrometry, MS/MS—tandem mass spectrometry, PTM—post-translational modification, LC—liquid chromatography, PMF—peptide mass fingerprint. Modified from Zhan X. et al. [70] with permission from Elsevier publisher open access publication, copyright 2018; and reproduced from Zhan et al. [95], with permission from MDPI publisher open access publication, copyright 2019.

One must, however, realize that while SILAC-2DE-LC-MS/MS works well in cell culture [47], it is not applicable to tissue extracts or biological fluids. Alternatively, commercially available isobaric tags (iTRAQ or TMT) [83–86] or isotope-coded affinity tags (ICAT) can be used to label protein amine groups (i.e., the N-terminus and lysine side-chains) or cysteines, respectively, followed by 2DE-LC-MS/MS analysis [83–87]. However, currently, caveats regarding labeling conditions and the potential for non-quantitative labeling of species must be taken into account; in this regard, such deep proteome analyses may be the most effective test of how such reactive labeling approaches actually quantitatively represent the full dynamic range of native proteomes (i.e., are very low abundance species represented as effectively as high abundance species or is such labeling dominated by the law of mass action?). Isotope-free methods are another choice to quantify proteins with 2DE-LC-MS/MS, including label-free methods [75, 88], selected reaction monitoring (SRM) [89], and sequential window acquisition of all theoretical mass spectra (SWATH) [90]. Label-free quantitative mass spectrometry (LFQ-MS) may be a good option with data-dependent acquisition (DDA) [91, 92] to compare changes in the abundance of a specific proteoform between two different treatments or physiological conditions; this is perhaps the most straightforward of approaches considering the prior resolution of proteoforms by 2DE. However, for such an approach to be fully effective, new very complex algorithms will be needed considering the multiple dimensions of resolution (i.e., 2DE dimension, LC-MS dimension, and MS/MS dimension). Nevertheless, such an approach would best capitalize on the complementarity of available analytical methods, such as data-independent acquisition (DIA)-based SWATH methods [90].

15.8 Conclusions

Proteoforms are the basic units of the proteome, the critical players defining molecular mechanisms, and the best possible biomarkers; they are thus of central importance across the spectrum of biological, biomedical, agricultural, and environmental research [35, 41, 44, 76, 93]. 2DE has undergone significant innovations, both in practice and concept, and its recent further state-of-the-art combination with LC-MS/MS analyses of the highest available sensitivity has firmly established 2DE-LC-MS/MS as the most rigorous approach to deep, quantitative proteome analysis at the proteoform level. The applicability of SILAC-2DE-LC/MS has already been shown in the search for proteoforms changing in abundance during apoptosis [47]. In the future, such routine quantitative analyses will be further complemented using established labelled and label-free approaches. 2DE-based Western blot with a given protein antibody coupled with LC-MS/MS can also effectively reduce the number of 2DE-derived gel samples to be analyzed with LC-MS/MS as it can detect proteoforms of a given protein in a 2DE matrix [33, 72, 94]. Overall, the beauty and power of this coupled 2DE-LC-MS/MS methodology is its inherent capacity to capitalize on the combination of refined

top-down and bottom-up analytical approaches. The capacity for genuine deep proteome analysis at the critical proteoform level is now a definite reality.

Abbreviations

2DE:	two-dimensional gel electrophoresis
DDA:	data-dependent acquisition
DIA:	data-independent acquisition
hGH:	human growth hormone
hPRL:	human prolactin
IEF:	isoelectric focusing
IPG:	immobilized pH gradient gel
ICAT:	isotope-coded affinity tags
iTRAQ:	isobaric tags for relative and absolute quantification
IU:	image unit
LC:	liquid chromatography
M_r :	relative molecular mass
MS:	mass spectrometry
MS/MS:	tandem mass spectrometry
OD:	optical density
pI:	isoelectric point
PTM:	post-translational modification
SDS-PAGE:	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SILAC:	stable isotope labeling of amino acids in cell culture
SRM:	selected reaction monitoring
SWATH:	sequential window acquisition of all theoretical mass spectra
TMT:	tandem mass tags

Disclosures and Conflict of Interest

This chapter was originally published as: Zhan, X., Li, B., Zhan, X., Schlüter, H., Jungblut, P. R., Coorsen, J. R. (2019) Innovating the concept and practice of two-dimensional gel electrophoresis in the analysis of proteomes at the proteoform level. *Proteomes*, 7, 36, <https://doi.org/10.3390/proteomes7040036>, and appears here, with edits and updates, by kind permission of the copyright holders.

Author Contributions: X.Z. (Xianquan Zhan) conceived the concept, collected and analyzed references, designed and made the figures and tables, wrote and critically revised the chapter, and was responsible for the financial support and corresponding works. B.L. participated in the collection of references and preparation of figures. X.Z. (Xiaohan Zhan) participated in the collection and

analysis of references, and assisted in the editing of the English language. J.R.C., H.S., and P.R.J. assisted in the further development of the ideas, integration of critical research literature, and chapter editing. All authors approved the final chapter.

Funding: X.Z. (Xianquan Zhan) was supported by the Hunan Provincial Hundred Talent Plan (to X.Z.), the Xiangya Hospital Funds for Talent Introduction (to X.Z.), the China “863” Plan Project (Grant No. 2014AA020610-1 to X.Z.), the National Natural Science Foundation of China (Grant No. 81272798 and 81572278 to X.Z.), and the Hunan Provincial Natural Science Foundation of China (Grant No. 14JJ7008 to X.Z.). J.R.C. acknowledges the support of the Natural Sciences and Engineering Research Council of Canada (NSERC; RGPIN-2019-04324).

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Smithies, O., Poulik, M.D. Two-dimensional electrophoresis of serum proteins. *Nature* **1956**, *177*, 1033.
2. Raymond, S. Acrylamide gel electrophoresis. *Ann. N. Y. Acad. Sci.* **1964**, *121*, 350–365.
3. Kaltschmidt, E., Wittmann, H.G. Ribosomal proteins. VII. Two-dimensional polyacrylamide gel electrophoresis for fingerprinting of ribosomal proteins. *Anal. Biochem.* **1970**, *36*, 401–412.
4. MacGillivray, A.J., Rickwood, D. The heterogeneity of mouse-chromatin nonhistone proteins as evidenced by two-dimensional polyacrylamide-gel electrophoresis and ion-exchange chromatography. *Eur. J. Biochem.* **1974**, *41*, 181–190.
5. Klose, J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. *Humangenetik* **1975**, *26*, 231–243.
6. Scheele, G.A. Two-dimensional gel analysis of soluble proteins. Characterization of guinea pig exocrine pancreatic proteins. *J. Biol. Chem.* **1975**, *250*, 5375–5385.
7. Iborra, F., Buhler, J.M. Protein subunit mapping. A sensitive high resolution method. *Anal. Biochem.* **1976**, *74*, 503–511.
8. O’Farrell, P.H. High resolution two-dimensional electrophoresis of proteins. *J. Biol. Chem.* **1975**, *250*, 4007–4021.
9. Zhan, X., Desiderio, D.M. Heterogeneity analysis of the human pituitary proteome. *Clin. Chem.* **2003**, *49*, 1740–1751.
10. Zhan, X., Desiderio, D.M., Wang, X., Zhan, X., Guo, T., Li, M., Peng, F., Chen, X., Yang, H., Zhang, P., et al. Identification of the proteomic variations of invasive relative to non-invasive non-functional pituitary adenomas. *Electrophoresis* **2014**, *35*, 2184–2194.
11. Wasinger, V.C., Cordwell, S.J., Cerpa-Poljak, A., Yan, J.X., Gooley, A.A., Wilkins, M.R., Duncan, M.W., Harris, R., Williams, K.L., Humphery-Smith, I. Progress with gene-product mapping of the Mollicutes: *Mycoplasma genitalium*. *Electrophoresis* **1995**, *16*, 1090–1094.

12. Klose, J., Kobalz, U. Two-dimensional electrophoresis of proteins: An updated protocol and implications for a functional analysis of the genome. *Electrophoresis* **1995**, *16*, 1034–1059.
13. Zimny-Arndt, U., Schmid, M., Ackermann, R., Jungblut, P.R. Classical proteomics: Two-dimensional electrophoresis/MALDI mass spectrometry. *Methods Mol. Biol.* **2009**, *492*, 65–91.
14. Görg, A., Obermaier, C., Boguth, G., Harder, A., Scheibe, B. The current state of two-dimensional electrophoresis with immobilized pH gradients. *Electrophoresis* **2000**, *21*, 1037–1053.
15. Zhan, X., Desiderio, D.M. Differences in the spatial and quantitative reproducibility between two second-dimensional gel electrophoresis systems. *Electrophoresis* **2003**, *24*, 1834–1846.
16. Zhan, X., Desiderio, D.M. Spot volume vs. amount of protein loaded onto a gel: A detailed, statistical comparison of two gel electrophoresis systems. *Electrophoresis* **2003**, *24*, 1818–1833.
17. D'Silva, A.M., Hyett, J.A., Coorssen, J.R. A routine 'top-down' approach to analysis of the human serum proteome. *Proteomes* **2017**, *5*, 13.
18. D'Silva, A.M., Hyett, J.A., Coorssen, J.R. Proteomic analysis of first trimester maternal serum to identify candidate biomarkers potentially predictive of spontaneous preterm birth. *J. Proteom.* **2018**, *178*, 31–42.
19. Butt, R.H., Coorssen, J.R. Postfractionation for enhanced proteomic analyses: Routine electrophoretic methods increase the resolution of standard 2D-PAGE. *J. Proteome Res.* **2005**, *4*, 982–991.
20. Churchward, M.A., Butt, R.H., Lang, J.C., Hsu, K.K., Coorssen, J.R. Enhanced detergent extraction for analysis of membrane proteomes by two-dimensional gel electrophoresis. *Proteome Sci.* **2005**, *3*, 5.
21. Butt, R.H., Coorssen, J.R. Pre-extraction sample handling by automated frozen disruption significantly improves subsequent proteomic analyses. *J. Proteome Res.* **2006**, *5*, 437–448.
22. Wright, E.P., Prasad, K.A., Padula, M.P., Coorssen, J.R. Deep imaging: How much of the proteome does current top-down technology already resolve? *PLoS ONE* **2014**, *9*, e86058.
23. Noaman, N., Abbineni, P.S., Withers, M., Coorssen, J.R. Coomassie staining provides routine (sub)femtomole in-gel detection of intact proteoforms: Expanding opportunities for genuine top-down proteomics. *Electrophoresis* **2017**, *38*, 3086–3099.
24. Jungblut, P., Klose, J. Composition and genetic variability of Heparin-Sepharose CL-6B protein fractions obtained from the solubilized proteins of mouse organs. *Biochem. Genet.* **1986**, *24*, 925–939.
25. Santos, F.M., Albuquerque, T., Gaspar, L.M., Dias, J.M.L., Castro, E., Sousa, J.P., Paradela, A., Tomaz, C.T., Passarinha, L.A. Refinement of two-dimensional electrophoresis for vitreous proteome profiling using an artificial neural network. *Anal. Bioanal. Chem.* **2019**, *411*, 5115–5126.
26. Posch, A. Sample preparation guidelines for two-dimensional electrophoresis. *Arch. Physiol. Biochem.* **2014**, *120*, 192–197.

27. Kočevár, N., Grazio, S.F., Komel, R. Two-dimensional gel electrophoresis of gastric tissue in an alkaline pH range. *Proteomics*. **2014**, *14*, 311–321.
28. Moche, M., Albrecht, D., Maaß, S., Hecker, M., Westermeier, R., Büttner, K. The new horizon in 2D electrophoresis: New technology to increase resolution and sensitivity. *Electrophoresis* **2013**, *34*, 1510–1518.
29. Zabel, C., Klose, J. High-resolution large-gel 2DE. *Methods Mol. Biol.* **2009**, *519*, 311–338.
30. Afjehi-Sadat, L., Lubec, G. Identification of enzymes and activity from two-dimensional gel electrophoresis. *Nat. Protoc.* **2007**, *2*, 2318–2324.
31. Khoudoli, G.A., Porter, I.M., Blow, J.J., Swedlow, J.R. Optimisation of the two-dimensional gel electrophoresis protocol using the Taguchi approach. *Proteome Sci.* **2004**, *2*, 6.
32. Kwiatkowski, M., Wurlitzer, M., Krutilin, A., Kiani, P., Nimer, R., Omid, M., Manna, A., Bussmann, T., Bartkowiak, K., Kruber, S., et al. Homogenization of tissues via picosecond-infrared laser (PIRL) ablation: Giving a closer view on the in-vivo composition of protein species as compared to mechanical homogenization. *J. Proteom.* **2016**, *134*, 193–202.
33. Peng, F., Li, J., Guo, T., Yang, H., Li, M., Sang, S., Li, X., Desiderio, D.M., Zhan, X. Nitroproteins in human astrocytomas discovered by gel electrophoresis and tandem mass spectrometry. *J. Am. Soc. Mass Spectrom.* **2015**, *26*, 2062–2076.
34. Zhan, X., Yang, H., Peng, F., Li, J., Mu, Y., Long, Y., Cheng, T., Huang, Y., Li, Z., Lu, M., et al. How many proteins can be identified in a 2-DE gel spot within an analysis of a complex human cancer tissue proteome? *Electrophoresis* **2018**, *39*, 965–980.
35. Zhan, X., Li, N., Zhan, X., Qian, S. Revival of 2DE-LC/MS in proteomics and its potential for large-scale study of human proteoforms. *Med One* **2018**, *3*, e180008.
36. Schmidt, F., Donahoe, S., Hagens, K., Mattow, J., Schaible, U.E., Kaufmann, S.H.E., Aebersold, R., Jungblut, P.R. Complementary analysis of the Mycobacterium tuberculosis proteome by two-dimensional electrophoresis and isotope coded affinity tag technology. *Mol. Cell. Proteom.* **2004**, *3*, 24–42.
37. Jungblut, P., Thiede, B., Zimny-Arndt, U., Müller, E.C., Scheler, C., Wittmann-Liebold, B., Otto, A. Resolution power of two-dimensional electrophoresis and identification of proteins from gels. *Electrophoresis* **1996**, *17*, 839–847.
38. Jungblut, P.R., Holzhütter, H.G., Apweiler, R., Schlüter, H. The speciation of the proteome. *Chem. Cent. J.* **2008**, *2*, 16.
39. Schlüter, H., Apweiler, R., Holzhütter, H.G., Jungblut, P.R. Finding one's way in proteomics: A protein species nomenclature. *Chem. Cent. J.* **2009**, *3*, 11.
40. Smith, L.M., Kelleher, N.L. Consortium for Top Down Proteomics. Proteoform: A single term describing protein complexity. *Nat. Methods* **2013**, *10*, 186–187.
41. Coorssen, J.R., Yergey, A.L. Proteomics is analytical chemistry: Fitness-for-purpose in the application of top-down and bottom-up analyses. *Proteomes* **2015**, *3*, 440–453.
42. Naryzhny, S.N., Lisitsa, A.V., Zgoda, V.G., Ponomarenko, E.A., Archakov, A.I. 2DE-based approach for estimation of number of protein species in a cell. *Electrophoresis* **2014**, *35*, 895–900.
43. Ponomarenko, E.A., Poverennaya, E.V., Ilgisonis, E.V., Pyatnitskiy, M.A., Kopylov, A.T., Zgoda, V.G., Lisitsa, A.V., Archakov, A.I. The size of the human proteome: The width and depth. *Int. J. Anal. Chem.* **2016**, *2016*, 7436849.

44. Aebersold, R., Agar, J.N., Amster, I.J., Baker, M.S., Bertozzi, C.R., Boja, E.S., Costello, C.E., Cravatt, B.F., Fenselau, C., Garcia, B.A., et al. How many human proteoforms are there? *Nat. Chem. Biol.* **2018**, *14*, 206–214.
45. Kelleher, N.L. A cell-based approach to the human proteome project. *J. Am. Soc. Mass Spectrom.* **2012**, *23*, 1617–1624.
46. Camprostrini, N., Areces, L.B., Rappsilber, J., Pietrogrande, M.C., Dondi, F., Pastorino, F., Ponzoni, M., Righetti, P.G. Spot overlapping in two-dimensional maps: A serious problem ignored for much too long. *Proteomics* **2005**, *5*, 2385–2395.
47. Thiede, B., Koehler, C.J., Strozynski, M., Treumann, A., Stein, R., Zimny-Arndt, U., Schmid, M., Jungblut, P.R. High resolution quantitative proteomics of HeLa cells protein species using stable isotope labeling with amino acids in cell culture (SILAC), two-dimensional gel electrophoresis (2DE) and nano-liquid chromatography coupled to an LTQ-OrbitrapMass spectrometer. *Mol. Cell. Proteom.* **2013**, *12*, 529–538.
48. Lim, H., Eng, J., Yates, J.R., 3rd, Tollaksen, S.L., Giometti, C.S., Holden, J.F., Adams, M.W., Reich, C.I., Olsen, G.J., Hays, L.G. Identification of 2D-gel proteins: A comparison of MALDI/TOF peptide mass mapping to mu LC-ESI tandem mass spectrometry. *J. Am. Soc. Mass Spectrom.* **2003**, *14*, 957–970.
49. Naryzhny, S.N., Maynskova, M.A., Zgoda, V.G., Ronzhina, N.L., Kleyst, O.A., Vakhrushev, I.V., Archakov, A.I. Virtual-experimental 2DE approach in chromosome-centric human proteome project. *J. Proteome Res.* **2016**, *15*, 525–530.
50. Naryzhny, S.N., Maynskova, M.A., Zgoda, V.G., Ronzhina, N.L., Novikova, S.E., Belyakova, N.V., Kleyst, O.A., Legina, O.K., Pantina, R.A. Proteomic profiling of highgrade glioblastoma using virtual-experimental 2DE. *J. Proteom. Bioinform.* **2016**, *9*, 158–165.
51. Zhan, X., Desiderio, D.M. A reference map of a human pituitary adenoma proteome. *Proteomics* **2003**, *3*, 699–713.
52. Liu, J., Zhan, X., Li, M., Li, G., Zhang, P., Xiao, Z., Shao, M., Peng, F., Hu, R., Chen, Z. Mitochondrial proteomics of nasopharyngeal carcinoma metastasis. *BMC Med. Genom.* **2012**, *5*, 62.
53. Arentz, G., Weiland, F., Oehler, M.K., Hoffmann, P. State of the art of 2D DIGE. *Proteom. Clin. Appl.* **2015**, *9*, 277–288.
54. Chevalier, F., Centeno, D., Rofidal, V., Tauzin, M., Martin, O., Sonamerer, N., Rossignol, M. Different impact of staining procedures using visible stains and fluorescent dyes for large-scale investigation of proteomes by MALDI-TOF mass spectrometry. *J. Proteome Res.* **2006**, *5*, 512–520.
55. Gauci, V.J., Padula, M.P., Coorssen, J.R. Coomassie blue staining for high sensitivity gel-based proteomics. *J. Proteom.* **2013**, *90*, 96–106.
56. Liew, Y.K., Neela, V., Hamat, R.A., Nordin, S.A., Chong, P.P. Modified silver staining in 2DE improves protein detection even at extremely low sample concentration. *Electrophoresis* **2013**, *34*, 397–400.
57. Gauci, V.J., Wright, E.P., Coorssen, J.R. Quantitative proteomics: Assessing the spectrum of in-gel protein detection methods. *J. Chem. Biol.* **2011**, *4*, 3–29.
58. Swindell, W.R., Remmer, H.A., Sarkar, M.K., Xing, X., Barnes, D.H., Wolterink, L., Voorhees, J.J., Nair, R.P., Johnston, A., Elder, J.T., et al. Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance. *Genome Med.* **2015**, *7*, 86.

59. Mehdi, A.M., Patrick, R., Bailey, T.L., Bod'en, M. Predicting the dynamics of protein abundance. *Mol. Cell. Proteom.* **2014**, *13*, 1330–1340.
60. Bienvenut, W.V., Sanchez, J.C., Karmime, A., Rouge, V., Rose, K., Binz, P.A., Hochstrasser, D.F. Toward a clinical molecular scanner for proteome research: Parallel protein chemical processing before and during western blot. *Anal. Chem.* **1999**, *71*, 4800–4807.
61. Naryzhny, S. Inventory of proteoforms as a current challenge of proteomics: Some technical aspects. *J. Proteom.* **2019**.
62. Naryzhny, S.N. Towards the Full Realization of 2DE Power. *Proteomes* **2016**, *4*, 33.
63. Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. *Nature* **2001**, *409*, 860–921.
64. Roest Crollius, H., Jaillon, O., Bernot, A., Dasilva, C., Bouneau, L., Fischer, C., Fizames, C., Wincker, P., Brottier, P., Quétier, F., et al. Estimate of human gene number provided by genome-wide analysis using Tetraodon nigroviridis DNA sequence. *Nat. Genet.* **2000**, *25*, 235–238.
65. Ewing, B., Green, P. Analysis of expressed sequence tags indicates 35,000 human genes. *Nat. Genet.* **2000**, *25*, 232–234.
66. Abascal, F., Juan, D., Jungreis, I., Kellis, M., Martinez, L., Rigau, M., Rodriguez, J.M., Vazquez, J., Tress, M.L. Loose ends: Almost one in five human genes still have unresolved coding status. *Nucleic Acids Res.* **2018**, *46*, 7070–7084.
67. Anderson, L., Seilhamer, J. A comparison of selected mRNA and protein abundances in human liver. *Electrophoresis* **1997**, *18*, 533–537.
68. Gygi, S.P., Rochon, Y., Franza, B.R., Aebersold, R. Correlation between protein and mRNA abundance in yeast. *Mol. Cell. Biol.* **1999**, *19*, 1720–1730.
69. Zhan, X., Long, Y., Zhan, X., Mu, Y. Consideration of statistical vs. biological significances for omics data-based pathway network analysis. *Med One* **2017**, *1*, e170002.
70. Zhan, X., Long, Y., Lu, M. Exploration of variations in proteome and metabolome for predictive diagnostics and personalized treatment algorithms: Innovative approach and examples for potential clinical application. *J. Proteom.* **2018**, *188*, 30–40.
71. Zhan, X., Giorgianni, F., Desiderio, D.M. Proteomics analysis of growth hormone isoforms in the human pituitary. *Proteomics* **2005**, *5*, 1228–1241.
72. Qian, S., Yang, Y., Li, N., Cheng, T., Wang, X., Liu, J., Li, X., Desiderio, D.M., Zhan, X. Prolactin variants in human pituitaries and pituitary adenomas identified with two-dimensional gel electrophoresis and mass spectrometry. *Front. Endocrinol.* **2018**, *9*, 468.
73. Scheler, C., Müller, E.C., Stahl, J., Müller-Werdan, U., Salnikow, J., Jungblut, P.R. Identification and characterization of heat shock protein 27 protein species in human myocardial two-dimensional electrophoresis patterns. *Electrophoresis* **1997**, *18*, 2823–2831.
74. Klose, J., Nock, C., Herrmann, M., Stühler, K., Marcus, K., Blüggel, M., Krause, E., Schalkwyk, L.C., Rastan, S., Brown, S.D., et al. Genetic analysis of the mouse brain proteome. *Nat. Genet.* **2002**, *30*, 385–393.
75. Szabo, Z., Szomor, J.S., Foeldi, I., Janaky, T. Mass spectrometry-based label free quantification of gel separated proteins. *J. Proteom.* **2012**, *75*, 5544–5553.

76. Schaffer, L.V., Millikin, R.J., Miller, R.M., Anderson, L.C., Fellers, R.T., Ge, Y., Kelleher, N.L., LeDuc, R.D., Liu, X., Payne, S.H., et al. Identification and quantification of proteoforms by mass spectrometry. *Proteomics* **2019**, *19*, e1800361.
77. Li, H., Wongkongkathep, P., Van Orden, S.L., Ogorzalek Loo, R.R., Loo, J.A. Revealing ligand binding sites and quantifying subunit variants of noncovalent protein complexes in a single native top-down FTICR MS experiment. *J. Am. Soc. Mass Spectrom.* **2014**, *25*, 2060–2068.
78. Anderson, L.C., DeHart, C.J., Kaiser, N.K., Fellers, R.T., Smith, D.F., Greer, J.B., LeDuc, R.D., Blakney, G.T., Thomas, P.M., Kelleher, N.L., et al. Identification and characterization of human proteoforms by top-down LC-21 Tesla FT-ICR mass spectrometry. *J. Proteome Res.* **2017**, *16*, 1087–1096.
79. Fornelli, L., Durbin, K.R., Fellers, R.T., Early, B.P., Greer, J.B., LeDuc, R.D., Compton, P.D., Kelleher, N.L. Advancing top-down analysis of the human proteome using a benchtop quadrupole-Orbitrap mass spectrometer. *J. Proteome Res.* **2017**, *16*, 609–618.
80. Fornelli, L., Srzentić, K., Huguët, R., Mullen, C., Sharma, S., Zabrouskov, V., Fellers, R.T., Durbin, K.R., Compton, P.D., Kelleher, N.L. Accurate sequence analysis of a monoclonal antibody by top-down and middle-down Orbitrap mass spectrometry applying multiple ion activation techniques. *Anal. Chem.* **2018**, *90*, 8421–8429.
81. McCool, E.N., Lubeckyj, R.A., Shen, A., Chen, D., Kou, Q., Liu, X., Sun, L. Deep top-down proteomics using capillary zone electrophoresis-tandem mass spectrometry: Identification of 5700 proteoforms from the *Escherichia coli* proteome. *Anal. Chem.* **2018**, *90*, 5529–5533.
82. McCool, E.N., Lubeckyj, R., Shen, X., Kou, Q., Liu, X., Sun, L. Large-scale top-down proteomics using capillary zone electrophoresis tandem mass spectrometry. *J. Vis. Exp.* **2018**, *140*, e58644.
83. Wiese, S., Reidegeld, K.A., Meyer, H.E., Warscheid, B. Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research. *Proteomics* **2007**, *7*, 340–350.
84. Prudova, A., auf dem Keller, U., Butler, G.S., Overall, C.M. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. *Mol. Cell. Proteom.* **2010**, *9*, 894–911.
85. Sinclair, J., Timms, J.F. Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS. *Methods* **2011**, *54*, 361–369.
86. Hung, C.W., Tholey, A. Tandem mass tag protein labeling for top-down identification and quantification. *Anal. Chem.* **2012**, *84*, 161–170.
87. Gygi, S.P., Rist, B., Gerber, S.A., Turecek, F., Gelb, M.H., Aebersold, R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. *Nat. Biotechnol.* **1999**, *17*, 994–999.
88. Blein-Nicolas, M., Zivy, M. Thousand and one ways to quantify and compare protein abundances in label-free bottom-up proteomics. *Biochim. Biophys. Acta Proteins Proteom.* **2015**, *1864*, 883–895.
89. Lange, V., Picotti, P., Domon, B., Aebersold, R. Selected reaction monitoring for quantitative proteomics: A tutorial. *Mol. Syst. Biol.* **2008**, *4*, 222.

90. Aebersold, R., Bensimon, A., Collins, B.C., Ludwig, C., Sabido, E. Applications and developments in targeted proteomics: From SRM to DIA/SWATH. *Proteomics* **2016**, *16*, 2065–2067.
91. Autelitano, F., Loyaux, D., Roudières, S., Déon, C., Guette, F., Fabre, P., Ping, Q., Wang, S., Auvergne, R., Badarinarayana, V., et al. Identification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomics. *PLoS ONE* **2014**, *9*, e110316.
92. Schelleter, L., Albaum, S., Walter, S., Noll, T., Hoffrogge, R. Clonal variations in CHO IGF signaling investigated by SILAC-based phosphoproteomics and LFQ-MS. *Appl. Microbiol. Biotechnol.* **2019**.
93. Smith, L.M., Kelleher, N.L. Proteoforms as the next proteomics currency. *Science* **2018**, *359*, 1106–1107.
94. Kusch, K., Uecker, M., Liepold, T., Möbius, W., Hoffmann, C., Neumann, H., Werner, H.B., Jahn, O. Partial immunoblotting of 2D-Gels: A novel method to identify post-translationally modified proteins exemplified for the myelin acetylome. *Proteomes* **2017**, *5*, 3.
95. Zhan, X., Li, B., Zhan, X., Schlüter, H., Jungblut, P.R., Coorsen, J.R. Innovating the concept and practice of two-dimensional gel electrophoresis in the analysis of proteomes at the proteoform level. *Proteomes* **2019**, *7(4)*, 36.

Supplemental Readings

1. Zhan, X. (ed.). *Proteoforms: Concept and Applications in Medical Sciences*. InTech-Open Science Publisher, London, United Kingdom, 2020.
2. Takemori, A., Butcher, D. S., Harman, V. M., Brownridge, P., Shima, K., Higo, D., Ishizaki, J., Hasegawa, H., Suzuki, J., Yamashita, M., Loo, J. A., Loo, R.R.O., Beynon, R.J., Anderson, L.C., Takemori, N. PEPPI-MS: Polyacrylamide-gel-based prefractionation for analysis of intact proteoforms and protein complexes by mass spectrometry. *J. Proteome. Res.* **2020**, *19(9)*, 3779–3791.
3. Herzog, R., Wagner, A., Wrettos, G., Stampf, K., Bromberger, S., Sperl, E., Kratochwill, K. Improved alignment and quantification of protein signals in two-dimensional western blotting. *J. Proteome. Res.* **2020**, *19(6)*, 2379–2390.
4. Marcus, K., Lelong, C., Rabilloud, T. What room for two-dimensional gel-based proteomics in a shotgun proteomics world? *Proteomes.* **2020**, *8(3)*, 17.
5. Marcus, K., Rabilloud, T. How do the different proteomic strategies cope with the complexity of biological regulations in a multi-omic world? Critical appraisal and suggestions for improvements. *Proteomes.* **2020**, *8(3)*, 23.

Chapter 16

Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer

Siew-Wai Pang,^a Noel Jacques Awi,^a Subasri Armon, MD,^b Wendy Wan-Dee Lim, MD,^c John Seng-Hooi Low, MD,^c Kaik-Boo Peh, MD,^d Suat-Cheng Peh, MD, PhD,^{a,c} and Sin-Yeang Teow, PhD^a

^aDepartment of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Jalan University, Subang Jaya, Malaysia

^bPathology Department, Hospital Kuala Lumpur, Jalan Pahang, Kuala Lumpur, Malaysia

^cSunway Medical Centre, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Malaysia

^dMahkota Medical Centre, Mahkota Melaka, Jalan Merdeka, Melaka, Malaysia

15035363@imail.sunway.edu.my, ronaldt@sunway.edu.my

Keywords: amplification refractory mutation system (ARMS), anti-programmed cell death 1 (PD-1), biomarker, checkpoint inhibitors, chemotherapy, circulating free DNA (cfDNA), circulating tumor cells (CTCs), colorectal cancer (CRC), Consensus Molecular Subtypes (CMS), Food and Drug Administration (FDA), gold nanoparticles, Human Epidermal Growth Factor Receptor 2 (HER2), immunohistochemistry (IHC), immunotherapy (IMT), insulin-like growth factor-1, *Kirsten rat sarcoma viral oncogene homolog* (KRAS), methylated Septin9 (mSEPT9), micro-RNA (miRNA), microsatellite instability (MSI), mismatch repair (MMR), monoclonal antibodies (mAbs), negative predictive value (NPV), next-generation sequencing (NGS), non-neoplastic factors, nucleic acid hybridization assay, palliative chemotherapies, Pembrolizumab, personalized medicine, phosphatase and tensin homolog (PTEN), point-of-care test, positive predictive value (PPV), Programmed Death-Ligand 1 (PD-L1), progression-free survival (PFS), prospective study, quantitative PCR (qPCR), quantitative reverse transcription PCR, reverse transcription PCR (RT-qPCR), septin 9, turn-around-time (TAT), tyrosine kinase inhibitor (TKI) therapy, *v-raf murine sarcoma viral oncogene homolog B1* (*BRAF*)

16.1 Colorectal Cancer (CRC) and Its Treatment

Colorectal cancer (CRC) is one of the most common cancers worldwide, ranking third and second for men and women, respectively. In 2018, Global

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

Cancer Observatory (GLOBOCAN) estimated more than 1.8 million new CRC cases worldwide [1]. There are various therapeutic modalities for CRC depending on the pathological characteristics of the tumor. Laparoscopic surgery is normally carried out for early-stage primary disease, open surgery tumor resection for cases with metastases, and adjuvant radiotherapy for nonresectable cases. Other CRC therapies are neoadjuvant and palliative chemotherapies [2, 3], immunotherapy [4], and tyrosine kinase inhibitor (TKI) therapy [5]. The advent of checkpoint inhibitors made of monoclonal antibodies (mAbs) have been a breakthrough for the treatment of several cancers including CRC [6]. The safety profile and its efficacy in treating certain CRC patient populations have led to multiple clinical trials. Figure 16.1 summarizes the list of CRC treatments reviewed according to their date of application or approval by the Food and Drug Administration (FDA) [7–17]. Despite advances in medical and surgical treatment, the long-term survival rates have not improved much [18]. One of the ways in which CRC can be treated optimally is through the elucidation of individual genetic profiles for personalized therapies or precision medicine. Since CRC has several tumor subtypes with complex mutations and genetic variations, treatment decision supported by molecular testing results can dramatically improve the survival rate [19]. The details and specifications of the genes will be discussed in the next section. With advancement of DNA sequencing technologies such as next-generation sequencing (NGS), it is optimistic that precision medicine may be more accessible and affordable, thereby improving clinical outcomes. The subsections below will discuss the current treatment methods for CRC.




Figure 16.1 Simplified timeline of colorectal cancer (CRC) treatment options reviewed. The timeline is not constructed according to scale. The red boxes on the right represent the type of treatment, where CT = chemotherapy, SUR = surgery, IMT = immunotherapy, TKI = tyrosine kinase inhibitor.

16.2 Molecular Biomarkers

Molecular biomarker is an umbrella term for all biomarkers that can be measured based on the biomarker's molecular characteristic. The detection of biomarkers has been the backbone for screening and diagnostic aid in medical laboratories. They are routinely carried out using patient samples such as tissue biopsy, blood, urine, and other biological samples. One of the most common detection methods used in clinical laboratories is immunohistochemistry (IHC), which detects cellular markers and phenotypes specific to certain diseases through staining with highly specific antibodies [20]. Since IHC can be done on both fresh and formalin-fixed tissues, it serves as a convenient, simple, and cost-effective platform for clinical diagnostics [21]. However, there are several limitations. Although it is not difficult to obtain commercially produced antibodies, there are no standard guidelines for the validation of these antibodies. The interpretation of the slides by pathologists can vary considerably and is affected by how the tissue was processed, stored, and handled. This is exacerbated by the presence of intratumoral biomarker heterogeneity that can cause discordance in the classification of cancer [22]. Furthermore, the lack of standardized guidelines for quantitative and semiquantitative scoring raises concern, especially when it involves clinical decisions. While the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) issued guidelines for the handling of biopsy tissues of breast cancer patients, guidelines for other specimens were not available [23]. At present, most of the emerging biomarkers for CRC are more sensitive and specific as they interrogate the disease down to the DNA and RNA level [24]. The sub-sections below will discuss examples of common and potential biomarkers in CRC.

16.2.1 Methylated Septin9 (mSEPT9)

Screening programs for CRC are highly effective [25] as most CRCs develop from premalignant lesions such as adenomas [26]. Traditional screening methods such as fecal occult blood test (FOBT) and fecal immunochemical test (FIT) are routinely used to screen CRC, but are generally low in sensitivity and specificity [27]. Currently, the screening of CRC-related biomarkers such as carcinoembryonic antigen [28] and insulin-like growth factor-1 [29] through liquid biopsy is made more convenient, but still lacks specificity. Thus, efforts were made to detect tumor-specific DNA in the form of circulating free DNA (cfDNA). cfDNA is continuously shed by healthy and tumor cells into the bloodstream and can reflect the entire tumor genome. Methylated Septin 9 (mSEPT9) DNA is the only FDA-approved methylated biomarker for the screening of CRC through the detection of cfDNA in the serum of CRC patients [30, 31]. Warren et al. evaluated the FDA-approved mSEPT9 kit (Epigenomics AG, Germany) and reported an overall

sensitivity and specificity in all CRC stages at 90% and 88%, respectively. In early stages of cancer (I and II), the test was 87% sensitive. False-positive rate was reported at 12%. mSEPT9 can be detected in precancerous lesions such as colorectal adenomas [18], but may not be reliably sensitive [32]. In a small prospective study, mSEPT9 was detected in 12% of adenomas with a false-positive rate of 3% [18]. From the year 2012 onwards, more studies were pointing toward the reliability of detecting mSEPT9 for CRC screening, with sensitivities ranging from 73% to 95.6% [33–37]. The heterogeneity of the sensitivities is likely affected by non-neoplastic factors including, but not limited to, demographics, methodology, lifestyle, and sex [37]. Besides from CRC, SEPT9 may also be involved in the tumor progression of leukemia [38], breast [39], ovarian [40], urologic [41], and brain cancers [42]. Nevertheless, the detection of mSEPT9 as cfDNA for CRC has been proven to be effective and should be considered to be included as a routine screening test for CRC.

The role of mSEPT9 in the screening of CRC is well established, but its prognostic role remains unclear. A recent study by Ma and co-workers linked higher levels of mSEPT9 in post-surgery CRC patients to higher cancer recurrence [43]. If validated by future studies, the same FDA-approved kit can be conveniently used in both screening and prognostic tests without extensive optimizations. Similar to mSEPT9, hypermethylations of other DNA biomarkers are also being investigated for their potential role in CRC screening [44]. Methylated DNA are ideal biomarkers for screening as epigenetic alterations occur very early in polyp-to-cancer progression [45]. In addition, there is a plethora of other potential CRC biomarkers in the form of cfDNA that are being studied [46], but will not be reviewed due to space constraints.

16.2.2 Microsatellite Instability (MSI)

Microsatellite instability (MSI) is described as having genes with altered lengths due to small insertions and deletions of short, repetitive DNA sequences throughout the genome [47, 48]. These mutations are normally found in the coding single nucleotide repeats of tumor suppressor genes such as activin receptor type 2 and transforming growth factor β R2 [49]. Approximately 15% of all CRC cases are MSI, and patients with MSI-high (MSI-H) have a better prognosis in terms of longer overall survival (OS) and lower metastatic rate, but the tumors are more resistant to adjuvant chemotherapy such as 5-fluorouracil (5-FU) [50]. While MSI-H patients have been shown to be unresponsive to 5-FU, a meta-analysis by Jover et al. found that DNA mismatch repair (MMR) mutational status should not be indicative of chemotherapy efficacy [51]. MSI status by itself is also predictive for treatment response to the anti-programmed cell death 1 (PD-1) checkpoint inhibitor pembrolizumab in metastatic CRC (mCRC) patients. Pembrolizumab is only effective in mCRC patients with MSI-H status [52, 53]. The exact interactions and mechanisms between checkpoint inhibitors and MSI status are currently unknown, but its approval by the FDA for the treatment of MSI-H solid tumors is

based on several successes in clinical trials, as summarized by Marcus et al. The approval of pembrolizumab marks the first time in history a drug was approved solely based on a common molecular marker instead of the primary site of origin [7]. Recently, however, tumor mutational burden (TMB) is seen as a superior predictive marker over MSI status. TMB is measured in number of mutations/megabase (mut/MB). This was shown in a study by which anti-PD-1 immunotherapy was effective in microsatellite stable (MSS) CRC tumors with high TMB (≥ 10 mut/MB) [54]. Contrary to other studies demonstrating the lack of efficacy of anti-PD-1 therapy in MSS patients, the importance of TMB over MSI status needs to be investigated further.

16.2.3 KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog)

The significance of (*KRAS*) *Kirsten rat sarcoma viral oncogene homolog* mutational profile as a negative predictive biomarker in the treatment response of mCRC using monoclonal antibody (mAb) against epidermal growth factor receptor (EGFR) is well established [55–57]. Clinical trials such as PRIME (panitumumab) and CRYSTAL (cetuximab) demonstrated positive response towards anti-EGFR mAb therapies only in wild-type (WT) *KRAS* mCRC patients. This is because *KRAS* activation in *KRAS*-mutated mCRC patients is independent of upstream EGFR activation [58, 59]. A subsequent retrospective study by the FDA on seven randomized trials resulted in the approval of cetuximab and panitumumab only in WT *KRAS* mCRC patients [3, 10]. Previously, *KRAS* mutation was identified only by mutations in Codon 12 and 13 of Exon 2, which was subsequently found to be insufficient for an accurate prediction of treatment response [60]. Thus, the CRC clinical guideline urges for extended *RAS* mutation testing including *KRAS* and (*NRAS*) *neuroblastoma RAS viral oncogene homolog* in exon 2 (codons 12 and 13), exon 3 (codon 59 and 61), and exon 4 (codon 117 and 146) [19].

16.2.4 BRAF (v-raf Murine Sarcoma Viral Oncogene Homolog B1)

BRAF (*v-raf murine sarcoma viral oncogene homolog B1*) mutation occurs in 10% of CRC cases, with most of the mutations being presented in Codon 600 [61]. Recent evidences suggest that *BRAF* mutation is a better predictor for the determination of anti-EGFR therapy responses than *RAS* status. This is exemplified by the lower overall response rate (ORR) of anti-EGFR mAb in mutant *BRAF* compared with mutant Exon 2 *KRAS* [62]. Additionally, *BRAF* mutation is associated with the promoter methylation of an MMR gene, *MLH1* (human mutL homolog 1), where a positive *BRAF* mutation is normally accompanied with negative MMR mutation status. The negative mutation status of MMR is important for the prediction of MSI status [63, 64]. In essence, patients with *BRAF* mutations are normally MSS, and are thus less likely to benefit from pembrolizumab treatment. *BRAF* mutation may also indicate poor prognosis in CRC patients [65], but is only demonstrated in *BRAF*-mutated patients with MSS status, as reported by Roth et al. The study showed that *BRAF* mutations hold no prognostic significance in patients with

MSI-H [66]. In contrast, a recent meta-analysis of 1164 nonmetastatic CRC patients with MSI-H showed that *BRAFV600E* mutation does indicate poor prognosis in terms of OS [67]. Whilst the mutational testing of *BRAF* is recommended in the CRC clinical guidelines for prognostic stratification, and MMR status identification, findings suggest that *BRAF* mutation alone is insufficient for a full diagnosis of CRC [19].

16.2.5 Other Potential Biomarkers

The complex genetic nature and heterogeneity of CRC necessitate the detection of a combination of biomarkers for a more accurate diagnosis. Thus, efforts are continuously made to validate additional CRC biomarkers. The sub-sections below will review CRC biomarkers that may potentially be incorporated into routine clinical diagnostics.

16.2.5.1 Programmed death-ligand 1 (PD-L1)

Programmed Death-Ligand 1 (PD-L1) expression is potentially predictive for the treatment response of pembrolizumab since high PD-L1 expression has been associated with MSI-H status [68, 69]. The association between high PD-L1 expression and MSI-H status has, however, been contrasted in another study involving a larger cohort of almost 1,500 samples [70]. It is speculated that these large variations could be attributed to the difference in immunohistochemistry staining methods and scoring criteria due to the spatial and temporal heterogeneity of PD-L1 expression in mCRC patients [71]. Another study concluded that the effectiveness of the checkpoint inhibitor appears to be independent of PD-L1 expression level by tumor cells [72]. Collectively, it is evident that these limitations will need to be addressed before any clinical applications involving PD-L1 expression can be applied on CRC patients.

16.2.5.2 Phosphatidylinositol-4,5-bisphosphate 3-kinase, Catalytic Subunit Alpha (PIK3CA)

PIK3CA mutation has been studied for CRC treatment [73]. It is indicated that the *PIK3CA* exon 20 mutation confers resistance against anti-EGFR mAb therapy in CRC patients. The response rate (RR) was reported to be as low as 0%, together with shorter progression-free survival (PFS) [74]. Conversely, another study demonstrated that *PIK3CA* did not significantly affect resistance against cetuximab [75]. An independent lab-developed test detecting *H1047R* and *E545K* mutations showed sensitivities of 5% and 10% mutant allele fractions, respectively [76].

16.2.5.3 Phosphatase and tensin homolog (PTEN)

Another biomarker proposed to have predictive and prognostic potential in CRC treatment is *Phosphatase and Tensin Homolog (PTEN)* [77]. A study with 67 CRC patients demonstrated that 100% of the patients with negative expression

of PTEN exhibited disease progression following treatment with cetuximab, whereas 30% of the PTEN expression patients showed reduced disease progression [78]. Nevertheless, a study of a larger cohort found that it was not associated to the RR [79]. Another study showed that the negative expression of PTEN only negatively correlates to cetuximab response in tumor metastases but not primary tumor of CRC [80]. Interestingly, some studies showed promising results where PTEN gene alterations resulted in largely poor OS [81, 82], while other findings showed no correlation between patients' survival with changes in PTEN expression [83, 84]. Together, the credibility of PTEN as a potential predictive and prognostic marker cannot be determined as of current, and further investigations need to be carried out.

16.2.5.4 Human epidermal growth factor receptor 2 (HER2)

Human Epidermal Growth Factor Receptor 2 (HER2) is a proto-oncogene in the EGFR family that is mostly known for its oncogenic role in breast cancer [85]. In rare cases, HER2 is amplified in approximately 5% of mCRC patients with WT *KRAS* exon 2. This gene exhibits a high concordance rate in both primary and metastatic tumors of CRC [86] and is mutually exclusive with mutations to *NRAS*, *KRAS*, and *BRAF* [87]. The amplification of HER2 in relation to anti-HER2 treatment response in mCRC patients was evaluated by the phase II HERACLES trial combining two anti-HER2 drugs, trastuzumab and lapatinib. The results of the trial suggested that HER2 amplification may have a potential role as a clinical predictive marker for CRC, but the extreme rarity of this genetic alteration proves challenging for the validation of these results in a phase III clinical trial [88].

16.2.5.5 Micro-RNA (miRNA)

MiRNAs as biomarkers have received increasing attention recently for their predictive, diagnostic, and prognostic roles in CRC [89]. There are several miRNAs that are of importance to CRC. MiR-135a and miR-135b, for example, contribute to the regulation of the Wnt/Wingless pathway through the downregulation of APC (Adenomatous polyposis coli) gene [90] and can potentially act as prognostic markers [91, 92]. Additionally, miR-17-3p and miR-92a (pooled sensitivity, 76%, specificity, 64%) can upregulate the cell proliferation of colon cancer cells and have been found to be elevated in the plasma and CRC tissues [93–95]. MiR-211, on the other hand, can act as a marker for both the diagnosis and prognosis of CRC [96], while miR-133a can be potentially used in predicting response to EGFR inhibitors [97].

16.2.5.6 Consensus Molecular Subtypes (CMS)

Recently, the possibility for the consensus molecular subtypes (CMS) of CRC to be used as biomarkers was explored. The subtypes are grouped into four based on the tumor gene expression pattern and are described as: (1) CMS1—strong immune activation, hypermutated, and MSI-H; (2) CMS2—epithelial and canonical with marked WNT and MYC signaling; (3) CMS3—epithelial with evident metabolic




Figure 16.2 Simplified summary of CRC biomarkers that have more than one role. Biomarkers colored in red are potential CRC biomarkers that require additional validations. Abbreviations: BRAF, *v-raf murine sarcoma viral oncogene homolog B1*; FIT, fecal immunochemical test; CMS, consensus molecular subtypes; EGFR, epidermal growth factor receptor; FOBT, fecal occult blood test; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene homolog; miR, microRNA; MLH1, human mutL homolog 1; mSEPT9, methylated Septin 9; MSH2, human mutS homolog 2; MSI, microsatellite instability; PD-L1, programmed death-ligand 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PMS2, PMS1 homolog 2, mismatch repair system component; PTEN, Phosphatase and tensin homolog; TMB, tumor mutational burden.

dysregulation; and (4) CMS4—mesenchymal with stromal invasion, angiogenesis and prominent transforming growth factor- β activation [98, 99]. Prognostic and predictive values of CMS in mCRC patients independent of cancer staging were evaluated in multiple retrospective analysis. Collectively, CMS was shown to be significantly associated to lower OS and PFS. In terms of OS, CMS1 was associated to worst outcome in contrast to CMS2. Notably, positive drug response to bevacizumab and cetuximab was demonstrated specifically in CMS1 and CMS4, respectively [100–103]. Significant correlations with known CRC biomarkers such as MSI-H, *KRAS*, and *BRAF* mutations were also reported [100]. A simplified summary of the biomarkers reviewed in Sections 16.2.1, 16.2.2, 16.2.3 and 16.2.4 is presented in Fig. 16.2 [18, 19, 43, 54, 56, 57, 70, 74, 78, 79, 88, 91–94, 96, 97, 100–105].

16.3 Current Molecular Diagnostic Technologies

With advancements in technology, major progress has been made in understanding how variations in the genetic alterations of CRC can contribute toward clinical management. These advances have led to the development of precision medicine, which offers individualized medical care based on the patient's personal information and unique genetic profile. This concept has been proven to be successful in improving clinical outcomes compared with the relatively conventional method of indiscriminate radio/chemotherapy [106]. In fact, the list of drugs targeting specific genetic alterations approved by the FDA is rapidly growing for the treatment of advanced-stage solid tumors. Hence, it is important to understand and appreciate current and developing molecular methods available to diagnose CRC and the variety of molecular technologies available to map out the individual's unique molecular profile for efficient treatment strategies.

Before polymerase chain reaction (PCR) was invented, the detection of nucleic acid biomarkers was challenging due to scarcity of nucleic acid and tissue heterogeneity in samples. Now, tumor-specific DNA can be amplified to detectable levels through the more sensitive quantitative PCR (qPCR) [107], while RNA-based biomarkers such as miRNA can be detected using quantitative reverse transcription PCR (RT-qPCR) [94]. As technology improves, extremely scarce biomarkers such as tumor-specific cfDNA can be detected using qPCR, digital PCR, and NGS. Digital PCR is the latest variation of PCR that has since entered the diagnostic market recently, when detection of very rare events or gene variants in patient sample is challenging using qPCR. NGS, on the other hand, refers to high-throughput nucleic acid sequencing platforms using fragmented and PCR-amplified DNA, with performance comparable to digital PCR in terms of rare event detection [108]. The sub-sections below will discuss updates on the use of current molecular diagnostic technologies to detect major CRC-related biomarkers such as *KRAS*, *BRAF*, *MSI*, and so on.

16.3.1 Detection of *KRAS* and *BRAF* mutations

For CRC, the mutational status of the genes *KRAS* and *BRAF* receives additional attention as they can negatively affect the patient's response towards anti-EGFR therapies, with the prevalence of somatic *KRAS* mutations being 40% [109]. A myriad of molecular assays can detect these mutations with limit of detections ranging from 10%–20% mutant allele for Sanger sequencing [110], around 5% for pyrosequencing [110, 111] and high-resolution melt (HRM) curve analysis [110, 112], to 1–5% for qPCR assays [113, 114]. While direct sequencing remains the gold standard for *KRAS* and *BRAF* mutations detection, the method is not popular as it is laborious and lacks sensitivity [106, 115].

16.3.1.1 PCR-based detection

Currently, there are several FDA-approved assays for the detection of *KRAS* and *BRAF* mutations, including cobas 4800 *BRAF* V600 mutation assay [116], cobas 4800 *KRAS* mutation assay, and theascreen *KRAS* assay [117, 118]. These assays are FDA-approved for specific samples, but they are not suitable for use in specimens containing limited tissue such as fine needle aspiration and core biopsy [106]. A study by Nordgård et al. compared the performance and cost-effectiveness of two relatively new sensitive molecular methods for the detection of *KRAS* mutations called amplification refractory mutation system (ARMS) PCR assay and peptic nucleic acid (PNA) clamp PCR [119]. The ARMS PCR assay is an allele-specific PCR that detects a specific known mutated form of a gene [47], while the PNA clamp PCR is capable of selective amplification of nucleic acid sequences that differ by a single base [120]. In comparison, the PNA clamping assay was in favor as it is approximately 20 times cheaper than ARMS and demonstrated higher sensitivity levels [119]. Another method that utilizes a modified PCR protocol termed as coamplification at lower denaturation temperature PCR (COLD-PCR) was designed to detect *KRAS* and *BRAF* V600E mutations in combination with HRM. Compared with traditional PCR and direct sequencing that picked up 57 *KRAS/BRAF* mutations out of 117 CRC samples, this method detected 72 *KRAS/BRAF* mutations, which translates to a 26.3% increase in detection. In addition, this method does not require time-consuming procedures and expensive equipment. Thus, it can be considered for diagnostic uses [121].

In respect of technology, many of the available routine molecular tests are heading toward automation, including EGFR mutation detection. The Idylla (Biocartis, Belgium) is a CE-IVD (CE Marking *In Vitro* Diagnostic for Medical Devices) marked fully-automated qPCR diagnostic platform for EGFR mutations that is simple to perform (hands-on time of less than 2 min), does not require molecular expertise to run, is reliable, rapid, and has a small footprint [122]. Its *KRAS* mutation test allows the simultaneous detection of 21 mutations in clinically relevant codons (12, 13, 59, 61, 117, and 146) from FFPE (formalin-fixed paraffin-embedded) tissue samples, while its *NRAS–BRAF* mutation test can detect codons 12, 13, 59, 61, and 117 for *NRAS* and V600 mutations for *BRAF* [123]. Its ease of use, lack of expertise required to operate the system, and rapid turn-around time allows for the system to be placed in most clinical settings.

16.3.1.2 Nucleic acid hybridization assay

There are cost-effective alternatives for the detection of *KRAS* and *BRAF* other than qPCR. This includes single nucleotide primer extension (SNaPshot) assay and reverse hybridization StripAssay. The SNaPshot is a flexible lab-developed test, while the StripAssay is a commercially available test [115, 124, 125]. For *KRAS*, the detection limits when compared with direct sequencing are 10% and 1%, respectively [115]. In terms of sensitivity and turn-around time, the *KRAS* StripAssay is more favorable as it is a rapid and sensitive test that can be utilized when few tumor cells are present. For *BRAF*, Magnin et al. demonstrated similar results among SNaPshot, direct sequencing, and HRM [125]. Evaluation data on the performance of *BRAF* using the StripAssay is, however, lacking and warrants further investigation. In short, SNaPshot and the *KRAS* StripAssay are suitable for laboratories lacking dedicated equipment, but Sarasqueta et al. has warned for *KRAS*-mutant to be confirmed to reduce the risk of false positives [115].

16.3.1.3 Pre-PCR isolation of circulating tumor cells (CTCs)

Since it is difficult to obtain sufficient or appropriate tumor samples for *KRAS* genotyping, an alternative method is required. Thus, circulating tumor cells (CTCs) have garnered a strong reaction from researchers and clinicians as they are thought to represent the tumor in real-time. The extremely low levels of DNA in CTCs can be detected through qPCR with HRM or droplet digital PCR (ddPCR). When compared, ddPCR was able to detect less than one *KRAS* mutant cell per mL of neat blood (0.05% mutant ratio) while qPCR (TaqMeltPCR) and HRM could only detect up to 0.5% mutant ratio. In addition to its high sensitivity, the noninvasive nature of this procedure also allows for future opportunities to screen, diagnose, and monitor treatment or relapse in real-time without much discomfort to the patients [126]. One of the biggest hurdles to downstream analysis of CTCs is the effective and reliable method of isolating CTCs. There are several commercially available equipment for the isolation of CTCs through physical and biochemical properties such as size exclusion, deformability, and surface marker expression, but they are not without challenges. The size, rigidity, and surface marker expression pattern of CTCs are known to be highly variable. Furthermore, marker-based isolation of CTCs is only possible on the availability of the particular antibody [127].

16.3.1.4 Circulating free DNA (cfDNA) detection

Moving forward, *RAS* mutations can now be detected as cfDNA without the need to isolate CTCs. In a study published in 2018, researchers compared three diagnostic platforms for *RAS* mutations detection through cfDNA: ddPCR (Bio-Rad), NGS (Illumina), and BEAMing/OncoBEAM-RAS-CRC (BEAM, Sysmex Inostics). Tissue biopsies and time-matched blood samples were collected for the simultaneous comparison of mutation profiles between cfDNA and FFPE. The digital PCR-based BEAM reached a detection threshold of 0.03%, significantly lower than the detection thresholds of the two compared platforms at 0.5–1%. The superior

sensitivity of the BEAM allowed the detection of *KRAS* mutations in 5/19 FFPE profiles shown to be negative. Based on the comparison of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) among the three platforms (Table 16.1) [108], the BEAM is superior in most aspects, except for the specificity, which is slightly lower than that of the other two platforms. While the NGS is more suitable for the detection of a large coverage of mutations, the results are oftentimes confirmed with ddPCR [108]. In clinical settings where there is a need to balance the coverage of large mutation profiles with specificity of a particular mutation, it will be useful to have the BEAM together with the NGS as a complementary platform. As shown in Table 16.1, NGS may be a better choice, but the decision on which platform to select will require the consideration of footprint, cost, and turn-around-time (TAT). Furthermore, the clinical relevance of detecting mutations at very low allelic frequency was not assessed. While the results of ddPCR are less informative, it has the shortest TAT of only 8 h for the complete mutational analysis of *KRAS* exon 2. The more extensive mutational analysis of *KRAS* from BEAM and NGS will require around 2 days and 7 days, respectively. In terms of costing, NGS and the BEAM are comparable but cost twice as much compared with the ddPCR [108].

Table 16.1 Comparison of the sensitivity, specificity, PPV (positive predictive value), and NPV (negative predictive value) of ddPCR, BEAM, and NGS for *KRAS* detection [108]

Platform	Sensitivity (%)	Specificity	PPV (%)	NPV (%)
ddPCR	47	77	70	55
BEAM	93	69	78	90
NGS	73	77	79	71

16.3.2 Detection of Microsatellite Instability (MSI)/Microsatellite Stable (MSS) Status

Similar to the detection of other biomarkers, MSI can be detected through PCR-based methods and NGS. The versatility of NGS allows for the simultaneous detection of thousands of different microsatellite loci with a limit of detection of 1% MSI in MSS background. However, the use of NGS for MSI detection is uncommon, as data interpretation requires specific algorithms and computational methods [128]. Notably, MSI can also be detected indirectly through the detection of miRNA biomarkers.

There are several methods in which MSI can be detected. Capillary electrophoresis fragment analysis is one of the earliest molecular method using PCR-amplified samples, but presents with a low limit of detection of 1% to 10% [128]. This method usually interrogates epiphenomenon related to MSI, such as MMR gene loci [129]. The 1997 National Cancer Institute-sponsored MSI workshop recommends the interrogation of five microsatellite loci; three dinucleotide (D2S123, D5S346, and D17S250) and two mononucleotide repeats (BAT-25,

BAT-26), which led to the development of the Bethesda panel. This assay amplifies the repeats through a single multiplex PCR reaction, followed by analysis using capillary electrophoresis. MSI-H is reported when two or more loci are unstable, while instability at a single locus or no instability will be reported as MSI-low and MSS, respectively. Commercially, Promega Corp developed the MSI Analysis System version 1.1 that detects five mononucleotide (BAT-25, BAT-26, NR-21, NR-24, and MONO-27) and two pentanucleotide repeats (PentaC and PentaD). Like the previous assay, capillary electrophoresis is subsequently used for analysis. MSI-H is reported when two or more mononucleotide loci are unstable, while instability at a single mononucleotide locus represents MSI-low, and no instability represents MSS. Murphy et al. compared the two assays with 34 CRC patient samples and found that the concordance rate was at 85%. MSI-H and MSS cases were fully concordant on both assays. While both assays performed adequately in detecting MSI cases, the authors concluded that the MSI Analysis System was superior and will be a better option to resolve cases of MSI-low into either MSS or MSI-H [130]. In another study, the Promega MSI Analysis System version 1.2 was compared to a new “one mononucleotide” MSI marker test, which detects T25 mononucleotide repeat of the caspase 2 gene (*CAT25*). The CAT25 MSI test claims to be a simplified assay with reduced cost and may improve efficiency. Based on the results, the authors concluded that the CAT25 assay performed equally well to the commercial kit and should be considered as a replacement to a five markers test, or at least, be included in the MSI detection panel [131]. Additionally, an MSI gene expression assay with 64 genes has been made available as a diagnostic assay, which helps to accurately identify MSI-positive and MSI-like patients that are not easily recognized by IHC or PCR. Furthermore, this assay does not require a reference paracancerous tissue from the patient for comparison [65].

16.3.3 miRNA Detection

MSI status can also be tested through the detection of miRNA biomarkers in the plasma as cell-free form. One of the methods is through RT-qPCR, which measures the quantity of miRNA indirectly in real-time [132]. Microarray, which utilizes *in situ* hybridization of predesigned probes to the target miRNA is also a reliable method to quantify the amount of miRNA in the sample [133]. An MSI oligonucleotide microarray diagnostic assay based on spotted locked nucleic acid (LNA) can be used to profile the expression of up to 315 miRNAs [89]. While RT-PCR and microarray are highly sensitive and specific, the operational cost is expensive. Dedicated equipment, facilities, and trained personnel are also required to run these tests [134, 135]. Thus, these methods may not be suitable for clinics or settings with poor resources.

Alternatively, resource-lacking clinical settings may opt for lateral flow nucleic acid strip assay using gold nanoparticles [135]. This assay has been demonstrated

to be more apt as a point-of-care test as it is sensitive, inexpensive, rapid, and simple to use [135, 136]. Similar to the microarray system, this assay utilizes predesigned probes conjugated to gold nanoparticles targeting specific miRNAs, leading to the formation of visible bands on the strip [47]. The results are semiquantitative as the intensity of the band increases with the quantity of the miRNA, but can be made more quantitative with the use of a quantitative detection platform [135, 136]. It was shown that miRNAs can be quantified to as low as 1 fmol, and with the use of silver enhancement, it can be as low as 5 amol [134].

16.3.4 Detection of Other Biomarkers

In theory, most of the molecular biomarkers discussed other than *KRAS*, *BRAF*, and MSI can be detected using similar diagnostic platforms such as qPCR and NGS. This is shown in several studies attempting to validate the use of additional biomarkers for CRC diagnostics. A brief summary of CRC biomarkers and their respective diagnostic platforms from Sections 16.2 and 16.3 is tabulated in Table 16.2.

Table 16.2 Summary of CRC biomarkers and their respective diagnostic platforms reviewed

Biomarker	Diagnostic platform	References
mSEPT9	• Methylation-specific real-time PCR	[18]
MSI	• Immunohistochemistry	[64]
	• Next-generation sequencing (NGS)	[89]
	• Fragment analysis	[128]
	• Gene expression assay	[130]
	• miRNA microarray	[89]
TMB	• Whole exome sequencing	[54]
<i>KRAS</i>	• qPCR (Roche Cobas 4800 <i>KRAS</i> mutation, Qiagen theascreen <i>KRAS</i> , Biocartis <i>KRAS</i> mutation assay)	[117, 122]
	• Direct sequencing	[106]
	• Pyrosequencing	[111]
	• Next-generation sequencing (NGS)	[108]
	• High-resolution melt curve (HRM)	[110]
	• Amplification refractory mutation system (ARMS) PCR	[119]
	• Peptic nucleic acid (PNA) clamp PCR	[119]
	• COLD-PCR	[121]
	• Single nucleotide primer extension (SNaPshot)	[115]
	• Reverse hybridization <i>KRAS</i> StripAssay	[115]
• Digital PCR (Bio-Rad droplet digital PCR, Sysmex BEAMing)	[108]	

Biomarker	Diagnostic platform	References
<i>BRAF</i>	• qPCR (Roche Cobas 4800 <i>BRAF</i> V600, Biocartis Idylla <i>NRAS-BRAF</i> mutation assay)	[117, 122]
	• Direct sequencing	[106]
	• Pyrosequencing	[111]
	• Next-generation sequencing (NGS)	[108]
	• High-resolution melt curve (HRM)	[110]
	• COLD-PCR	[121]
	• Immunohistochemistry	[106]
	• Single nucleotide primer extension (SNaPshot)	[125]
miRNA	• Reverse hybridization <i>BRAF</i> StripAssay	[124]
	• Microarray—spotted locked nucleic acid (LNA)	[89]
	• RT-qPCR	[132]
PD-L1	• Lateral flow nucleic acid strip assay using gold nanoparticles	[47]
	• Immunohistochemistry	[68]
PIK3CA	• Real-time PCR	[76]
	• Immunohistochemistry	[73]
	• Gene sequencing	[73]
HER2	• Immunohistochemistry	[86]
	• Quantitative reverse transcription PCR (RT-qPCR)	[85]
PTEN	• Indirect immunofluorescence	[78]
	• Immunohistochemistry	[77]
CMS	• Gene expression microarray	[99]

16.4 Challenges and Limitations

16.4.1 Choice of Molecular Platform

For cancer diagnosis and screening, accuracy, specificity, and fast TAT should be given critical attention [137]. qPCR is currently the choice of molecular method for biomarker detection as many tests are validated and it is more readily available than digital PCR and NGS. In addition, test results can be available within a day. However, the throughput is limited to several targets, and prior knowledge of the target DNA is required. Conversely, a single run of NGS is capable of providing invaluable information including mutations, chromosomal rearrangements, and copy number alterations without any prior knowledge of the targets [138], although it may take up to 7 days for results to be available [108]. Superior sensitivity, specificity, and throughput must not be the sole reason for the molecular platform chosen. Instead, consideration must be given to the type of clinical application, cost effectiveness, and the necessity for superior performance, as it is not possible for

all medical settings to incorporate advanced molecular laboratories. A centralized and highly specialized cancer diagnostic lab will need to be established in major cities or states to process samples from surrounding clinical settings, but may have several drawbacks. The need to handle sensitive clinical samples during transportation and process samples in batches will lead to a longer TAT. Consequently, some critically ill patients may have to wait for several days or up to weeks before receiving appropriate treatment [19, 139].

16.4.2 Laboratory Operations

Guidelines for CRC molecular testing have been established in a joint effort by the American Society for Clinical Pathology (ASCP), American Society of Clinical Oncology (ASCO), Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP). For clinical sample management and laboratory operations, the recommendations by the guidelines will be summarized and discussed here. Firstly, policies should be established in all laboratories to ensure efficient allocation of tissue for molecular tests, especially in scarce specimens. Pathologists can contribute to this by evaluating tissue quantity, quality, and malignant tumor cell fraction. Another way is to limit the number of tissue fragments per individual cassette. Prior assessment of the patients' previous CRC status will contribute to unnecessary repeat tests. The usage of appropriate tissue type may also aid in limiting the wastage of precious tissue; the guidelines recommend using recurrent or mCRC tissues for predictive biomarker testing involved in cancer treatment given that samples are available and adequate, followed by primary tumor tissue. For molecular biomarker mutational testing, FFPE tissue samples are considered acceptable. However, an alteration to the tissue processing protocols or the use of other specimens (including samples of cytologic origins) necessitates additional validation [19].

Another recommended practice to consider is to provide clinically appropriate turn-around time (TAT), which will contribute to the alleviation of patient anxiety and the execution of timely patient management decisions. This can be achieved through the optimal utilization of relevant molecular and IHC tests, possibly through multiplexed assays. In general, nonacute biomarker test results should be available within 10 days of test ordering [19, 140]. The 10 day timeframe should include the time taken for test orders to reach the laboratory, tissue block retrieval, and shipment of said blocks to the performing laboratory. Every effort should be taken by the laboratory to minimize delays in tissue block retrieval, processing time, and the availability of results [19].

16.5 Conclusions and Future Perspectives

It is important to understand the epidemiology, etiology, mechanisms, and how to improve diagnostics and treatment in CRC. Owing to the continuous research of CRC by dedicated researchers, the mechanisms underlying CRC are now more

understood, resulting in extensive diagnostic and treatment options. Detection of circulating free DNA from liquid biopsy is currently in trend as it is less invasive and extremely sensitive. Notably, the detection of methylated SEPT9 in the plasma of CRC patients has been shown to be a reliable screening tool and has been FDA-approved as the first liquid biopsy screening tool for CRC. These sensitive diagnostic tools will shape how and what treatments are prescribed, as certain targeted treatments are only effective in certain genotypes of CRC. Evidently, there will be limitations to the implementation of such tests and treatments in all healthcare settings. Furthermore, as with all new technology, validation studies and standardization of operations and methodologies remain a challenge. In essence, CRC continues to be one of the most prevalent cancers in the world and is mostly detected in advanced stages. Thus, current and future research should strongly emphasize on early screening of CRC as it is one of the most effective way to prevent CRC. The future of CRC prevention, diagnostic, and treatment lies in the decentralization of molecular tests. Currently, extremely sensitive molecular methods for biomarker detection require sophisticated equipment, facilities, and trained personnel, resulting in the need for centralization and longer TAT. This necessitates the development of simple, automated, and robust biomarker detection platforms with smaller footprints.

Abbreviations

APC:	adenomatous polyposis coli
ARMS:	amplification refractory mutation system
<i>BRAF</i> :	B-Raf protein
cfDNA:	circulating free DNA
CMS:	consensus molecular subtypes
COLD-PCR:	coamplification at lower denaturation temperature PCR
CRC:	colorectal cancer
CTC:	circulating tumor cells
ddPCR:	droplet digital PCR
DNA:	deoxyribonucleic acid
EGFR:	epidermal growth factor receptor
FDA:	US Food and Drug Administration
FFPE:	formalin-fixed paraffin embedded
FIT:	fecal immunochemical test
FOBT:	fecal occult blood test
HER2:	human epidermal growth factor 2
IHC:	immunohistochemistry
<i>KRAS</i> :	Kirten rat sarcoma viral oncogene homolog
LNA:	locked nucleic acid
mAb:	monoclonal antibody

mCRC:	metastatic colorectal cancer
miRNA:	microRNA
MLH1:	human mutL homolog 1
MMR:	mismatch repair
mSEPT9:	methylated Septin 9
MSH2:	human mutS homolog 2
MSI:	microsatellite instability
NGS:	next-generation sequencing
NRAS:	neuroblastoma RAS viral oncogene homolog
ORR:	overall response rate
OS:	overall survival
PD-L1:	programmed death-ligand 1
PFS:	progression-free survival
PIK3CA:	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
PMS2:	PMS1 homolog 2, mismatch repair system component
PNA:	peptide nucleic acid
PTEN:	phosphatase and tensin homolog
RR:	response rate
RT-qPCR:	quantitative reverse transcription PCR
SEPT9:	septin 9
TKI:	tyrosine kinase inhibitor
TMB:	tumor mutational burden
WT:	wild-type
5-FU:	5-fluorouracil

Disclosures and Conflict of Interest

This chapter was originally published as: Pang, S.-W., Awi, N.J., Armon, S., Lim, W.-D., Low, J.-H., Peh, K.-B., Peh, S.-C., Teow, S.-Y. (2020). Current update of laboratory molecular diagnostics advancement in management of colorectal cancer (CRC). *Diagnostics*, **10**, 9, <https://doi.org/10.3390/diagnostics10010009>, under the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates, by kind permission of the copyright holders.

Author Contributions: Conceptualization, S.-W.P. and S.-Y.T.; resources, S.A., W.W.-D.L., J.S.-H.L. and K.-B.P.; writing—original draft preparation, S.-W.P., S.-Y.T. and N.J.A.; writing—review and editing, S.-C.P. and S.-Y.T.; supervision, S.-Y.T.; funding acquisition, S.-Y.T., S.-C.P. and J.S.-H.L. All authors have read and agreed to the published version of the chapter.

Funding: This research was partly funded by Sunway Internal Research Grant 2019 (grant number INT-2019-SHMS-DMS-01) and Sunway Medical Centre Research Funds (SRC/002/2017/FR and SRC/003/2017/FR).

Acknowledgments: Siew-Wai Pang and Noel Jacques Awi are recipients of Sunway University Postgraduate's Degree by Research Studentship.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2018**, *68*, 394–424.
2. Heemskerck-Gerritsen, B.A.M., Rookus, M.A., Aalfs, C.M., Ausems, M.G.E.M., Collée, J.M., Jansen, L., Kets, C.M., Keymeulen, K.B.M.I., Koppert, L.B., Meijers-Heijboer, H.E.J., et al. Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. *Int. J. Cancer* **2015**, *136*, 668–677.
3. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. *N. Engl. J. Med.* **2004**, *350*, 2335–2342.
4. Kalyan, A., Kircher, S., Shah, H., Mulcahy, M., Benson, A. Updates on immunotherapy for colorectal cancer. *J. Gastrointest. Oncol.* **2018**, *9*, 160–169.
5. Kircher, S.M., Nimeiri, H.S., Benson, A.B. Targeting angiogenesis in colorectal cancer tyrosine kinase inhibitors. *Cancer J.* **2016**, *22*, 182–189.
6. O'Neil, B.H., Wallmark, J.M., Lorente, D., Elez, E., Raimbourg, J., Gomez-Roca, C., Ejadi, S., Piha-Paul, S.A., Stein, M.N., Abdul Razak, A.R., et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. *PLoS ONE* **2017**, *12*, e0189848.
7. Marcus, L., Lemery, S.J., Keegan, P., Pazdur, R. FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin. Cancer Res.* **2019**, *25*, 3753–3758.
8. Lee, J.J., Chu, E. The adjuvant treatment of stage III colon cancer: Might less be more? *Oncology* **2018**, *32*, 437–442.
9. FDA Approves Nivolumab Plus Ipilimumab Combination for Intermediate or Poor-Risk Advanced Renal Cell Carcinoma. Available at: <https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm> (accessed on October 15, 2022).
10. Rogers, J.E. Patient considerations in metastatic colorectal cancer—role of panitumumab. *Onco Targets Ther.* **2017**, *10*, 2033–2044.
11. Jitawatanarat, P., Ma, W.W. Update on antiangiogenic therapy in colorectal cancer: Aflibercept and regorafenib. *J. Gastrointest. Oncol.* **2013**, *4*, 231–238.
12. Kurkjian, C., Kummar, S. Advances in the treatment of metastatic colorectal cancer. *Disease-a-Month* **2010**, *56*, 187–203.
13. Rothenberg, M.L. Irinotecan (CPT-11): Recent developments and future directions—colorectal cancer and beyond. *Oncologist* **2004**, *6*, 66–80.
14. Ibrahim, A. FDA drug approval summaries: Oxaliplatin. *Oncologist* **2004**, *9*, 8–12.

15. Bertino, J.R. Chemotherapy of colorectal cancer: History and new themes. *Semin. Oncol.* **1997**, *24*, S18-3–S18-7.
16. Milsom, J.W., Hammerhofer, K.A. Role of laparoscopic techniques in colorectal cancer surgery. *Oncology* **1995**, *9*, 393–398.
17. Heald, R.J., Husband, E.M., Ryall, R.D.H. The mesorectum in rectal cancer surgery—The clue to pelvic recurrence? *Br. J. Surg.* **1982**, *69*, 613–616.
18. Warren, J.D., Xiong, W., Bunker, A.M., Vaughn, C.P., Furtado, L.V., Roberts, W.L., Fang, J.C., Samowitz, W.S., Heichman, K.A. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. *BMC Med.* **2011**, *9*, 133.
19. Sepulveda, A.R., Hamilton, S.R., Allegra, C.J., Grody, W., Cushman-Vokoun, A.M., Funkhouser, W.K., Kopetz, S.E., Lieu, C., Lindor, N.M., Minsky, B.D., et al. Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Arch. Pathol. Lab. Med.* **2017**, *35*, 1453–1486.
20. Bordeaux, J., Welsh, A.W., Agarwal, S., Killiam, E., Baquero, M.T., Hanna, J.A., Anagnostou, V.K., Rimm, D.L. Antibody validation. *Biotechniques* **2010**, *48*, 197–209.
21. O’Hurley, G., Sjöstedt, E., Rahman, A., Li, B., Kampf, C., Pontén, F., Gallagher, W.M., Lindskog, C. Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers. *Mol. Oncol.* **2014**, *8*, 783–798.
22. Allott, E.H., Geradts, J., Sun, X., Cohen, S.M., Zirpoli, G.R., Khoury, T., Bshara, W., Chen, M., Sherman, M.E., Palmer, J.R., et al. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. *Breast Cancer Res.* **2016**, *18*, 68.
23. Comănescu, M., Arsene, D., Ardeleanu, C., Bussolati, G. The mandate for a proper preservation in histopathological tissues. *Rom. J. Morphol. Embryol.* **2012**, *53*, 233–242.
24. Laterza, O.F., Hendrickson, R.C., Wagner, J.A. Molecular biomarkers. *Drug Inf. J.* **2007**, *41*, 573–585.
25. Pignone, M., Saha, S., Hoerger, T., Mandelblatt, J. Cost-effectiveness analyses of colorectal cancer screening: A systematic review for the U.S. Preventive Services Task Force. *Ann. Intern. Med.* **2002**, *137*, 96–104.
26. Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., Smits, A.M.M., Bos, J.L. Genetic alterations during colorectal-tumor development. *N. Engl. J. Med.* **1988**, *319*, 525–532.
27. Lieberman, D.A. Clinical practice. Screening for colorectal cancer. *N. Engl. J. Med.* **2009**, *361*, 1179–1187.
28. Gao, Y., Wang, J., Zhou, Y., Sheng, S., Qian, S.Y., Huo, X. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and Ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. *Sci. Rep.* **2018**, *8*, 2732.
29. Shiratsuchi, I., Akagi, Y., Kawahara, A., Kinugasa, T., Romeo, K., Yoshida, T., Ryu, Y., Gotanda, Y., Kage, M., Shirouzu, K. Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. *Anticancer Res.* **2011**, *31*, 2541–2545.
30. Tóth, K., Wasserkort, R., Sipos, F., Kalmár, A., Wichmann, B., Leiszter, K., Valcz, G., Juhász, M., Miheller, P., Patai, Á.V., et al. Detection of methylated Septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. *PLoS One* **2014**, *9*, e115415.

31. Wang, J.Y., Hsieh, J.S., Chang, M.Y., Huang, T.J., Chen, F.M., Cheng, T.L., Alexandersen, K., Huang, Y.S., Tzou, W.S., Lin, S.R. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. *World J. Surg.* **2004**, *28*, 721–726.
32. Church, T.R., Wandell, M., Lofton-Day, C., Mongin, S.J., Burger, M., Payne, S.R., Castañós-Vélez, E., Blumenstein, B.A., Rösch, T., Osborn, N., et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. *Gut* **2014**, *63*, 317–325.
33. Wu, D., Zhou, G., Jin, P., Zhu, J., Li, S., Wu, Q., Wang, G., Sheng, J., Wang, J., Song, L., et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. *J. Mol. Diagn.* **2016**, *18*, 535–545.
34. Jin, P., Kang, Q., Wang, X., Yang, L., Yu, Y., Li, N., He, Y.Q., Han, X., Hang, J., Zhang, J., et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. *J. Gastroenterol. Hepatol.* **2015**, *30*, 830–833.
35. Su, X.L., Wang, Y.F., Li, S.J., Zhang, F., Cui, H.W. High methylation of the SEPT9 gene in Chinese colorectal cancer patients. *Genet. Mol. Res.* **2014**, *13*, 2513–2520.
36. Tóth, K., Sipos, F., Kalmár, A., Patai, Á.V., Wichmann, B., Stoehr, R., Golcher, H., Schellerer, V., Tulassay, Z., Molnár, B. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. *PLoS One* **2012**, *7*, e46000.
37. Wang, Y., Chen, P.-M., Liu, R.-B. Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection. *World J. Gastrointest. Oncol.* **2018**, *10*, 15–22.
38. Kojima, K., Sakai, I., Hasegawa, A., Niiya, H., Azuma, T., Matsuo, Y., Fujii, N., Tanimoto, M., Fujita, S. FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4,11) (q21,q23). *Leukemia* **2004**, *18*, 998–1005.
39. Montagna, C., Lyu, M.S., Hunter, K., Lukes, L., Lowther, W., Reppert, T., Hissong, B., Weaver, Z., Ried, T. The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. *Cancer Res.* **2003**, *63*, 2179–2187.
40. Burrows, J.F., Chanduloy, S., McIlhatton, M.A., Nagar, H., Yeates, K., Donaghy, P., Price, J., Godwin, A.K., Johnston, P.G., Russell, S.E.H. Altered expression of the septin gene, SEPT9, in ovarian neoplasia. *J. Pathol.* **2003**, *201*, 581–588.
41. Amir, S., Golan, M., Mabweesh, N.J. Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. *Mol. Cancer Res.* **2010**, *8*, 643–652.
42. Kim, D.-S., Hubbard, S.-L., Peraud, A., Sahlia, B., Sakai, K., Rutka, J.T. Analysis of mammalian Septin expression in human malignant brain tumors. *Neoplasia* **2004**, *6*, 168–178.
43. Ma, Z.Y., Law, W.L., Ng, E.K.O., Chan, C.S.Y., Lau, K.S., Cheng, Y.Y., Shin, V.Y., Kwong, A., Leung, W.K. Methylated Septin 9 and carcinoembryonic antigen for serological diagnosis and monitoring of patients with colorectal cancer after surgery. *Sci. Rep.* **2019**, *9*, 10326.

44. Ma, Z., Williams, M., Cheng, Y.Y., Leung, W.K. Roles of methylated DNA biomarkers in patients with colorectal cancer. *Dis. Mark.* **2019**, *2019*, 2673543.
45. Nguyen, M.T., Weinberg, D.S. Biomarkers in colorectal cancer screening. *JNCCN J. Natl. Compr. Cancer Netw.* **2016**, *14*, 1033–1040.
46. Vymetalkova, V., Cervena, K., Bartu, L., Vodicka, P. Circulating cell-free DNA and colorectal cancer: A systematic review. *Int. J. Mol. Sci.* **2018**, *19*, 3356.
47. Tsang, A.H.F., Cheng, K.H., Wong, A.S.P., Ng, S.S.M., Ma, B.B.Y., Chan, C.M.L., Tsui, N.B.Y., Chan, L.W.C., Yung, B.Y.M., Wong, S.C.C. Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. *World J. Gastroenterol.* **2014**, *20*, 3847–3857.
48. Vilar, E., Gruber, S.B. Microsatellite instability in colorectal cancer—the stable evidence. *Nat. Rev. Clin. Oncol.* **2010**, *7*, 153–162.
49. Legolvan, M.P., Taliano, R.J., Resnick, M.B. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: A practical approach. *Hum. Pathol.* **2012**, *43*, 1157–1168.
50. Huth, L., Jäkel, J., Dahl, E. Molecular diagnostic applications in colorectal cancer. *Microarrays* **2014**, *3*, 168–179.
51. Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M., Cubiella, J., Balaguer, F., Sempere, L., Xicola, R.M., Bujanda, L., et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. *Eur. J. Cancer* **2009**, *45*, 365–373.
52. Overman, M.J., Lonardi, S., Wong, K.Y.M., Lenz, H.J., Gelsomino, F., Aglietta, M., Morse, M.A., Van Cutsem, E., McDermott, R., Hill, A., et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *J. Clin. Oncol.* **2018**, *36*, 773–779.
53. Overman, M.J., McDermott, R., Leach, J.L., Lonardi, S., Lenz, H.J., Morse, M.A., Desai, J., Hill, A., Axelson, M., Moss, R.A., et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. *Lancet Oncol.* **2017**, *18*, 1182–1191.
54. Gong, J., Wang, C., Lee, P.P., Chu, P., Fakih, M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. *JNCCN J. Natl. Compr. Cancer Netw.* **2017**, *15*, 142–147.
55. Sorich, M.J., Wiese, M.D., Rowland, A., Kichenadasse, G., McKinnon, R.A., Karapetis, C.S. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. *Ann. Oncol.* **2015**, *26*, 13–21.
56. Van Cutsem, E., Lenz, H.J., Köhne, C.H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., Han Van Krieken, J., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *J. Clin. Oncol.* **2015**, *33*, 692–700.
57. Rodrigues, D., Longatto-Filho, A., Martins, S.F. Predictive biomarkers in colorectal cancer: From the single therapeutic target to a plethora of options. *Biomed Res. Int.* **2016**, *2016*, 1–12.
58. Douillard, J.Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. Randomized, Phase III trial of panitumumab

- with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. *J. Clin. Oncol.* **2010**, *28*, 4697–4705.
59. Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N. Engl. J. Med.* **2009**, *360*, 1408–1417.
 60. Douillard, J.-Y., Oliner, K.S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. *N. Engl. J. Med.* **2013**, *369*, 1023–1034.
 61. Ursem, C., Atreya, C.E., Van Loon, K. Emerging treatment options for *BRAF*-mutant colorectal cancer. *Gastrointest. Cancer Targets Ther.* **2018**, *8*, 13–23.
 62. Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. Wild-type *BRAF* is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J. Clin. Oncol.* **2008**, *26*, 5705–5712.
 63. Capper, D., Voigt, A., Bozukova, G., Ahadova, A., Kickingereider, P., Von Deimling, A., Von Knebel Doeberitz, M., Kloor, M. *BRAF* V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. *Int. J. Cancer* **2013**, *133*, 1624–1630.
 64. Chen, W., Swanson, B.J., Frankel, W.L. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. *Diagn. Pathol.* **2017**, *12*, 24.
 65. Tian, S., Roepman, P., Popovici, V., Michaut, M., Majewski, I., Salazar, R., Santos, C., Rosenberg, R., Nitsche, U., Mesker, W.E., et al. A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. *J. Pathol.* **2012**, *228*, 586–595.
 66. Roth, A.D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. Prognostic role of *KRAS* and *BRAF* in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J. Clin. Oncol.* **2010**, *28*, 466–474.
 67. Manthravadi, S., Sun, W., Saeed, A. Prognostic impact of *BRAF* V600E mutation in patients with non-metastatic colorectal cancer with microsatellite instability: A systematic review and meta-analysis. *J. Clin. Oncol.* **2018**, *15*, 3597.
 68. Rosenbaum, M.W., Bledsoe, J.R., Morales-Oyarvide, V., Huynh, T.G., Mino-Kenudson, M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, *BRAF* mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. *Proc. Mod. Pathol.* **2016**, *29*, 1104–1112.
 69. Lee, L.H., Cavalcanti, M.S., Segal, N.H., Hechtman, J.F., Weiser, M.R., Smith, J.J., Garcia-Aguilar, J., Sadot, E., Ntiamoah, P., Markowitz, A.J., et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. *Mod. Pathol.* **2016**, *29*, 1433–1442.
 70. Droeser, R.A., Hirt, C., Viehl, C.T., Frey, D.M., Nebiker, C., Huber, X., Zlobec, I., Eppenberger-Castori, S., Tzankov, A., Rosso, R., et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. *Eur. J. Cancer* **2013**, *49*, 2233–2242.
 71. Wang, H.B., Yao, H., Li, C.S., Liang, L.X., Zhang, Y., Chen, Y.X., Fang, J.Y., Xu, J. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. *J. Dig. Dis.* **2017**, *18*, 574–581.

72. Llosa, N.J., Cruise, M., Tam, A., Wicks, E.C., Hechenbleikner, E.M., Taube, J.M., Blosser, R.L., Fan, H., Wang, H., Luber, B.S., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov.* **2015**, *5*, 43–51.
73. Zhu, Y.F., Yu, B.H., Li, D.L., Ke, H.L., Guo, X.Z., Xiao, X.Y. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. *World J. Gastroenterol.* **2012**, *18*, 3745–3751.
74. Mao, C., Yang, Z.Y., Hu, X.F., Chen, Q., Tang, J.L. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. *Ann. Oncol.* **2012**, *23*, 1518–1525.
75. Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., Tejpar, S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. *Clin. Cancer Res.* **2009**, *15*, 3184–3188.
76. Alvarez-Garcia, V., Bartos, C., Keraite, I., Trivedi, U., Brennan, P.M., Kersaudy-Kerhoas, M., Gharbi, K., Oikonomidou, O., Leslie, N.R. A simple and robust real-time qPCR method for the detection of PIK3CA mutations. *Sci. Rep.* **2018**, *8*, 4290.
77. Yazdani, Y., Farazmandfar, T., Azadeh, H., Zekavatian, Z. The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: MiR-21 and promoter methylation. *J. Biomed. Sci.* **2016**, *23*, 9.
78. Negri, F.V., Bozzetti, C., Lagrasta, C.A., Crafa, P., Bonasoni, M.P., Camisa, R., Pedrazzi, G., Ardizzoni, A. PTEN status in advanced colorectal cancer treated with cetuximab. *Br. J. Cancer* **2010**, *102*, 162–164.
79. Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J. Clin. Oncol.* **2009**, *27*, 5924–5930.
80. Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *J. Clin. Oncol.* **2009**, *27*, 2622–2629.
81. Bohn, B.A., Mina, S., Krohn, A., Simon, R., Kluth, M., Harasimowicz, S., Quaas, A., Bockhorn, M., Izbicki, J.R., Sauter, G., et al. Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. *Hum. Pathol.* **2013**, *44*, 1524–1533.
82. Atreya, C.E., Sangale, Z., Xu, N., Matli, M.R., Tikishvili, E., Welbourn, W., Stone, S., Shokat, K.M., Warren, R.S. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. *Cancer Med.* **2013**, *2*, 496–506.
83. Eklöf, V., Wikberg, M.L., Edin, S., Dahlin, A.M., Jonsson, B.A., Öberg, Å., Rutegård, J., Palmqvist, R. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. *Br. J. Cancer* **2013**, *108*, 2153–2163.
84. Day, F.L., Jorissen, R.N., Lipton, L., Mouradov, D., Sakthianandeswaren, A., Christie, M., Li, S., Tsui, C., Tie, J., Desai, J., et al. PIK3CA and PTEN gene and exon mutation-specific

- clinicopathologic and molecular associations in colorectal cancer. *Clin. Cancer Res.* **2013**, *19*, 3285–3296.
85. Pazhoomand, R., Keyhani, E., Banan, M., Najmabadi, H., Khodadadi, F., Iraniparast, A., Feiz, F., Majidzadeh, K., Bahman, I., Moghadam, F.A., et al. Detection of HER2 status in breast cancer: Comparison of current methods with MLPA and real-time RT-PCR. *Asian Pac. J. Cancer Prev.* **2013**, *14*, 7621–7628.
 86. Valtorta, E., Martino, C., Sartore-Bianchi, A., Penault-Llorca, F., Viale, G., Risio, M., Rugge, M., Grigioni, W., Bencardino, K., Lonardi, S., et al. Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study. *Mod. Pathol.* **2015**, *28*, 1481–1491.
 87. Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., et al. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* **2012**, *487*, 330–337.
 88. Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncol.* **2016**, *17*, 738–746.
 89. Schepeler, T., Reinert, J.T., Ostenfeld, M.S., Christensen, L.L., Silahatoglu, A.N., Dyrskjøt, L., Wiuf, C., Sørensen, F.J., Kruhøffer, M., Laurberg, S., et al. Diagnostic and prognostic microRNAs in stage II colon cancer. *Cancer Res.* **2008**, *68*, 6416–6424.
 90. Nagel, R., Le Sage, C., Diosdado, B., Van Der Waal, M., Oude Vrielink, J.A.F., Bolijn, A., Meijer, G.A., Agami, R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. *Cancer Res.* **2008**, *68*, 5795–5802.
 91. Kan, S.F., Yang, J.S., Sun, G.X., Sun, J.J. MicroRNA-135b is associated with tumor progression in colorectal cancer. *Int. J. Clin. Exp. Med.* **2016**, *9*, 6533–6538.
 92. Zhou, W., Li, X., Liu, F., Xiao, Z., He, M., Shen, S., Liu, S. MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. *Acta Biochim. Biophys. Sin.* **2012**, *44*, 838–846.
 93. Lu, D., Tang, L., Zhuang, Y., Zhao, P. MiR-17-3P regulates the proliferation and survival of colon cancer cells by targeting Par4. *Mol. Med. Rep.* **2018**, *17*, 618–623.
 94. Chen, E., Li, Q., Wang, H., Yang, F., Min, L., Yang, J. MiR-92a promotes tumorigenesis of colorectal cancer, a transcriptomic and functional based study. *Biomed. Pharmacother.* **2018**, *106*, 1370–1377.
 95. Yang, X., Zeng, Z., Hou, Y., Yuan, T., Gao, C., Jia, W., Yi, X., Liu, M. MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: A systematic review and meta-analysis. *PLoS One* **2014**, *9*, e88745.
 96. Pu, X.X., Huang, G.L., Guo, H.Q., Guo, C.C., Li, H., Ye, S., Ling, S., Jiang, L., Tian, Y., Lin, T.Y. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. *J. Gastroenterol. Hepatol.* **2010**, *25*, 1674–1680.
 97. Dong, Y., Zhao, J., Wu, C.-W., Zhang, L., Liu, X., Kang, W., Leung, W.-W., Zhang, N., Chan, F.K.L., Sung, J.J.Y., et al. Tumor suppressor functions of miR-133a in colorectal cancer. *Mol. Cancer Res.* **2013**, *11*, 1051–1060.

98. Guinney, J., Dienstmann, R., Wang, X., De Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. The consensus molecular subtypes of colorectal cancer. *Nat. Med.* **2015**, *21*, 1350–1356.
99. Williams, D.S., Mouradov, D., Jorissen, R.N., Newman, M.R., Amini, E., Nickless, D.K., Teague, J.A., Fang, C.G., Palmieri, M., Parsons, M.J., et al. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. *Gut* **2019**, *68*, 465–474.
100. Marisa, L., Ayadi, M., Balogoun, R., Pilati, C., Le Malicot, K., Lepage, C., Emile, J.-F., Salazar, R., Aust, D.E., Duval, A., et al. Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort. *J. Clin. Oncol.* **2017**, *15*, 3509.
101. Mooi, J.K., Wirapati, P., Asher, R., Lee, C.K., Savas, P., Price, T.J., Townsend, A., Hardingham, J., Buchanan, D., Williams, D., et al. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: Molecular analysis of the AGITG MAX clinical trial. *Ann. Oncol.* **2018**, *29*, 2240–2246.
102. Lenz, H.-J., Ou, F.-S., Venook, A.P., Hochster, H.S., Niedzwiecki, D., Goldberg, R.M., Mayer, R.J., Bertagnoli, M.M., Blanke, C.D., Zemla, T., et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance). *J. Clin. Oncol.* **2019**, *37*, 1876–1885.
103. Okita, A., Takahashi, S., Ouchi, K., Inoue, M., Watanabe, M., Endo, M., Honda, H., Yamada, Y., Ishioka, C. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. *Oncotarget* **2018**, *9*, 18698–18711.
104. Smith, R.A., Andrews, K.S., Brooks, D., Fedewa, S.A., Manassaram-Baptiste, D., Saslow, D., Brawley, O.W., Wender, R.C. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J. Clin.* **2018**, *68*, 297–316.
105. Sargent, D.J., Marsoni, S., Monges, G., Thibodeau, S.N., Labianca, R., Hamilton, S.R., French, A.J., Kabat, B., Foster, N.R., Torri, V., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J. Clin. Oncol.* **2010**, *28*, 3219–3226.
106. Chen, G., Yang, Z., Eshleman, J.R., Netto, G.J., Lin, M.T. Molecular diagnostics for precision medicine in colorectal cancer: Current status and future perspective. *BioMed Res. Int.* **2016**, *2016*, 9850690.
107. Cree, I.A. Diagnostic RAS mutation analysis by polymerase chain reaction (PCR). *Biomol. Detect. Quantif.* **2016**, *8*, 29–32.
108. Garcia, J., Forestier, J., Dusserre, E., Wozny, A.-S., Geiguer, F., Merle, P., Tissot, C., Ferraro-Peyret, C., Jones, F.S., Edelstein, D.L., et al. Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy). *Oncotarget* **2018**, *9*, 21122–21131.
109. Neumann, J., Zeindl-Eberhart, E., Kirchner, T., Jung, A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. *Pathol. Res. Pract.* **2009**, *205*, 858–862.

110. Tsiatis, A.C., Norris-Kirby, A., Rich, R.G., Hafez, M.J., Gocke, C.D., Eshleman, J.R., Murphy, K.M. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: Diagnostic and clinical implications. *J. Mol. Diagn.* **2010**, *12*, 425–432.
111. Szankasi, P., Reading, N.S., Vaughn, C.P., Prchal, J.T., Bahler, D.W., Kelley, T.W. A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: A model for qPCR testing without standard curves. *J. Mol. Diagn.* **2013**, *15*, 248–254.
112. Do, H., Krypuy, M., Mitchell, P.L., Fox, S.B., Dobrovic, A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. *BMC Cancer* **2008**, *8*, 142.
113. Oliner, K., Juan, T., Suggs, S., Wolf, M., Sarosi, I., Freeman, D.J., Gyuris, T., Baron, W., Bakker, A., Parker, A., et al. A comparability study of 5 commercial KRAS tests. *Diagn. Pathol.* **2010**, *5*, 23.
114. Kobunai, T., Watanabe, T., Yamamoto, Y., Eshima, K. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: A comparison between direct sequencing and real-time PCR. *Biochem. Biophys. Res. Commun.* **2010**, *395*, 158–162.
115. Sarasqueta, A.F., Moerland, E., De Bruyne, H., De Graaf, H., Vrancken, T., Van Lijnschoten, G., Van Den Brule, A.J.C. SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. *J. Mol. Diagn.* **2011**, *13*, 199–205.
116. Halait, H., Demartin, K., Shah, S., Soviero, S., Langland, R., Cheng, S., Hillman, G., Wu, L., Lawrence, H.J. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. *Diagn. Mol. Pathol.* **2012**, *21*, 1–8.
117. Harbison, C.T., Horak, C.E., Ledeine, J.M., Mukhopadhyay, P., Malone, D.P., O'Callaghan, C., Jonker, D.J., Karapetis, C.S., Khambata-Ford, S., Gustafson, N., et al. Validation of companion diagnostic for detection of mutations in Codons 12 and 13 of the KRAS gene in patients with metastatic colorectal Cancer: Analysis of the NCIC CTG CO.17 trial. *Arch. Pathol. Lab. Med.* **2013**, *137*, 820–827.
118. Harlé, A., Busser, B., Rouyer, M., Harter, V., Genin, P., Leroux, A., Merlin, J.L. Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. *Virchows Arch.* **2013**, *462*, 329–335.
119. Nordgård, O., Oltedal, S., Janssen, E.A.M., Gilje, B., Kørner, H., Tjensvoll, K., Smaaland, R. Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. *Diagn. Mol. Pathol.* **2012**, *21*, 9–13.
120. Orum, H. PCR clamping. *Curr. Issues Mol. Biol.* **2000**, *2*, 27–30.
121. Mancini, I., Santucci, C., Sestini, R., Simi, L., Pratesi, N., Cianchi, F., Valanzano, R., Pinzani, P., Orlando, C. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. *J. Mol. Diagnostics* **2010**, *12*, 705–711.

122. Solassol, J., Vendrell, J., Märkl, B., Haas, C., Bellosillo, B., Montagut, C., Smith, M., O'Sullivan, B., D'Haene, N., Le Mercier, M., et al. Multi-center evaluation of the fully automated PCR-based Idylla™ KRAS mutation assay for rapid KRAS mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal cancer. *PLoS One* **2016**, *11*, e0163444.
123. Johnston, L., Power, M., Sloan, P., Long, A., Silmon, A., Chaffey, B., Lisgo, A.J., Little, L., Vercauteren, E., Steiniche, T., et al. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. *J. Clin. Pathol.* **2018**, *71*, 336–343.
124. Lewandowska, M.A., Jóźwicki, W., Żurawski, B. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. *Mol. Diagn. Ther.* **2013**, *17*, 193–203.
125. Magnin, S., Viel, E., Baraquin, A., Valmary-Degano, S., Kantelip, B., Pretet, J.L., Mougín, C., Bigand, M., Girardo, B., Borg, C., et al. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. *J. Mol. Diagn.* **2011**, *13*, 485–492.
126. Denis, J.A., Patroni, A., Guillermin, E., Pépin, D., Benali-Furet, N., Wechsler, J., Manceau, G., Bernard, M., Coulet, F., Larsen, A.K., et al. Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. *Mol. Oncol.* **2016**, *10*, 1221–1231.
127. Neumann, M.H.D., Bender, S., Krahn, T., Schlange, T. ctDNA and CTCs in liquid biopsy—Current status and where we need to progress. *Comput. Struct. Biotechnol. J.* **2018**, *16*, 190–195.
128. Baudrin, L.G., Deleuze, J.F., How-Kit, A. Molecular and computational methods for the detection of microsatellite instability in cancer. *Front. Oncol.* **2018**, *8*, 621.
129. Redford, L., Alhilal, G., Needham, S., O'Brien, O., Coaker, J., Tyson, J., Amorim, L.M., Middleton, I., Izuogu, O., Arends, M., et al. A novel panel of short mononucleotide repeats linked to informative polymorphisms enabling effective high volume low cost discrimination between mismatch repair deficient and proficient tumours. *PLoS One* **2018**, *13*, e0203052.
130. Murphy, K.M., Zhang, S., Geiger, T., Hafez, M.J., Bacher, J., Berg, K.D., Eshleman, J.R. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. *J. Mol. Diagn.* **2006**, *8*, 305–311.
131. Babaei, H., Zeinalian, M., Emami, M.H., Hashemzadeh, M., Farahani, N., Salehi, R. Simplified microsatellite instability detection protocol provides equivalent sensitivity to robust detection strategies in Lynch syndrome patients. *Cancer Biol. Med.* **2017**, *14*, 142–150.
132. Chen, C., Ridzon, D.A., Broomer, A.J., Zhou, Z., Lee, D.H., Nguyen, J.T., Barbisin, M., Xu, N.L., Mahuvakar, V.R., Andersen, M.R., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Res.* **2005**, *33*, e179.
133. Li, W., Ruan, K. MicroRNA detection by microarray. *Anal. Bioanal. Chem.* **2009**, *394*, 1117–1124.
134. Hou, S.Y., Hsiao, Y.L., Lin, M.S., Yen, C.C., Chang, C.S. MicroRNA detection using lateral flow nucleic acid strips with gold nanoparticles. *Talanta* **2012**, *99*, 375–379.

135. Mao, X., Xu, H., Zeng, Q., Zeng, L., Liu, G. Molecular beacon-functionalized gold nanoparticles as probes in dry-reagent strip biosensor for DNA analysis. *Chem. Commun.* **2009**, *21*, 3065–3067.
136. He, Y., Zhang, S., Zhang, X., Baloda, M., Gurung, A.S., Xu, H., Zhang, X., Liu, G. Ultrasensitive nucleic acid biosensor based on enzyme-gold nanoparticle dual label and lateral flow strip biosensor. *Biosens. Bioelectron.* **2011**, *26*, 2018–2024.
137. Aravanis, A.M., Lee, M., Klausner, R.D. Next-generation sequencing of circulating tumor DNA for early cancer detection. *Cell* **2017**, *168*, 571–574.
138. Marcuello, M., Vymetalkova, V., Neves, R.P.L., Duran-Sanchon, S., Vedeld, H.M., Tham, E., van Dalum, G., Flügen, G., Garcia-Barberan, V., Fijneman, R.J., et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. *Mol. Asp. Med.* **2019**, *69*, 107–122.
139. Andrews, D., Chetty, Y., Cooper, B.S., Virk, M., Glass, S.K., Letters, A., Kelly, P.A., Sudhanva, M., Jeyaratnam, D. Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: A quasi-randomised study assessing impact on length of stay and antimicrobial use. *BMC Infect. Dis.* **2017**, *17*, 671.
140. Lindeman, N.I., Cagle, P.T., Beasley, M.B., Chitale, D.A., Dacic, S., Giaccone, G., Jenkins, R.B., Kwiatkowski, D.J., Saldivar, J.S., Squire, J., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho. *J. Thorac. Oncol.* **2013**, *8*, 823–859.

Chapter 17

Fully Electronic Urine Dipstick Probe for Combinatorial Detection of Inflammatory Biomarkers

Vikramshankar Kamakoti, PhD, David Kinnamon, MS, Kang Hyeok Choi, Badrinath Jagannath, MS, Mohanraj Ramasamy, MS, and Shalini Prasad, PhD

Department of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA

shalini.prasad@utdallas.edu

Keywords: 8-hydroxy-2'-deoxyguanosine, 8-hydroxyguanine, annexin A3, antigen-antibody binding, apolipoprotein A1 (Apo-A1), atomic force microscopy (AFM), attenuated total reflectance Fourier transform infrared spectroscopy, Coronavirus Disease 2019 (COVID-19), C-reactive protein (CRP), dielectric constant (ϵ), disease diagnostics, electrochemical biosensor, electrochemical impedance spectroscopy (EIS), electrochemical sensors, electrophoretic mobility, energy dispersive x-ray spectroscopy (EDAX), engrailed-2 (EN2) protein, hydrogen peroxide (H₂O₂), interleukin-6 (IL-6), inflammatory biomarkers, Internet of Things (IoT), limit of detection (LOD), next-generation sensor, nuclear mitotic apparatus protein 1 (NUMA1), complement factor H-related 1 (CFHR1), point-of-care diagnostics (POCD), rapid detection, scanning electron microscopy (SEM), specific signal threshold (SST), uric acid, urinary lactoferrin, urinary tract infections (UTIs), urine creatinine, urine dipstick probe, urine-noninvasive body fluid, ζ -potential

17.1 Introduction

Urine is a non-invasive, abundantly available complex bodily fluid with a number of biomarkers for a wide variety of diseases. Hence, a urine chemistry panel will enable the determination of a person's health/physiological status in an easily accessible and noninvasive manner. More recently with the emphasis on identifying rapid test for COVID-19, urine has been considered to be a noninvasive body fluid towards enabling rapid point-of-care tests. There have been a number of strategies in development of biosensor platforms for assessing urinary biomarkers

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

to investigate the chronic health conditions and infectious diseases from the urine [1–4]. The currently available reference gold standard diagnostic techniques for urine analysis like urine microscopy, microbiological culture analysis and, other calorimetric techniques are laboratory intensive, technician-intensive (trained medical professionals required to analyze and interpret the results), resulting in a 24–72 h delay in diagnosis and treatment protocols [5]. Also, the complexity of using antibody-derived techniques in urine samples is prone to inaccuracies in results. For this reason, there has been growing interest in developing new and efficient technology, which can outweigh all these drawbacks. Emerging point-of-care urine diagnostic (POCD) tools are a multitude of rapid medical tests that can be performed at or near the site of patient care [6], which facilitate early disease diagnosis, continuous health monitoring, and management. Recent technological advancements in POCD which include rapid response to critical results, and integration with performance maps, machine learning algorithms, and care paths have significantly reduced the dwelling time in the physician hospital visit, and tedious lab reports. The electrochemical detection format is ideal as it is faster, highly sensitive and specific for diagnostics from multiple bodily fluids. Our research group previously demonstrated various electrochemical-based biosensor devices for detecting intricate infectious disease biomarkers from the sweat [7–12], saliva and blood serum with high sensitivity and specificity. Amalgamation of electrochemical biosensing with Internet of Things (IoT) technology for the development of point-of-care diagnostics can have a significant impact on human health both regionally and globally.

Human urine contains numerous biomarkers that are associated with both chronic and acute diseases. A multitude of clinical studies have shown myriad inflammatory biomarkers [13] that can be detected from urine. Table 17.1 delineates the biomarkers which have been detected in the urine through electrochemical sensing platform in the literature.

The key advantage of using urinary biomarkers over the traditional measurements of inflammatory biomarkers in blood is that urine is quiescent and that molecular activity of a given biomarker does not change much after sampling. Unlike blood, urine proteins do not clot or coagulate, and therefore the need for anticoagulation treatment after collection is eliminated. The severity of disease transmission is less in urine as compared to that through contact or needle-stick injury in blood. There are fewer interference proteins allowing for lucid identification of target proteins. Lastly, urine samples have an ease of collection, handling, and storage.

Human urine contains several carcinogenic biomarkers such as tumor suppressor genes that are also correlated with clinicopathological variables and diagnosis of diseases. The adequate amount of the methylated tumor suppressor genes CCND2, SCGB3A1, BNIP3, ID4, and RUNX3 in the urine of bladder cancer patients provides the key information of not only using urine as the diagnostic tool but also as independent bladder cancer prognosticator [24–26]. In prostate cancer patients, urinary F2-isoprostane is used as a biomarker for gauging levels of oxidative stress in prostate carcinogenesis [27]. Thus, F2-isoprostanes may be deployed to target oxidative stress mechanisms in prostate cancer prevention or

treatment [28]. Additionally, antioxidant status such as glutathione S-transferase, urine pH, and other biomarkers can play a role in preventing diseases including some types of cancer [28]. The detection of inflammatory biomarkers such as interleukin-6 (IL-6) and C-reactive protein (CRP) in urine is critical because these biomarkers provide significant opportunity for detecting bacterial infections and urinary tract infections (UTIs). The increase in levels of IL-6 in urine holds critical significance in the diagnosis of UTI. IL-6 is synthesized by T cells, endothelial cells, macrophages, B cells, and fibroblasts after trauma and infection, resulting in inflammation. The local response of IL-6 occurs at the bladder mucosal surface as a response to bacterial infections [29, 30].

Table 17.1 The biomarkers which have been detected in the urine through electrochemical sensing platform in the literature

S. No.	Target biomarker	Disease associated with the biomarker	Physiological relevance range	Detection limit	Refs
1	Urinary lactoferrin	Urinary tract infection diagnosis	<30.4 ng/ml	145 pg/ml	[14]
2	Engrailed-2 (EN2) protein	Prostate cancer	61.03 to 98.84 nM	5.62 fM	[15]
3	Hydrogen peroxide (H ₂ O ₂)	Oxidative stress		7.5×10 ⁻⁸ M	[16]
4	Apolipoprotein A1 (Apo-A1)	bladder cancer		1 pM	[17]
5	Nuclear mitotic apparatus protein 1 (NUMA1) and complement factor H-related 1 (CFHR1)	bladder cancer		1.58 ng/ml and 1.29 ng/ml	[18]
6	Urine creatinine	Performance index for the renal function	71–265 μmole d ⁻¹ kg ⁻¹	20 ng/ml	[19]
7	Annexin A3	prostate cancer		0.095 ng/mL	[20]
8	8-hydroxy-2'-deoxyguanosine	DNA damage		36.67 nM	[21]
9	Uric acid	multiple sclerosis, diabetes mellitus whereas higher levels of UA result in diseases such as gout, arthritis, obesity, heavy hepatitis, neurological, cardiovascular and kidney diseases	Varies depends on age and gender	1.169 μM	[22]
10	8-hydroxyguanine	diabetes mellitus		5 pM	[23]
11	IL-6 and CRP	Infectious disease and sepsis		1 pg/ml	This work

The physiologically relevant, healthy range of IL-6 is 3 pg/ml, and patients with the elevated level IL-6 above 25 pg/ml are prescribed urological treatments with antibiotics [31–34]. Thus, IL-6 is a significant disease biomarker of interest for UTI and detecting IL-6 provides an early diagnostic hint for UTI [35]. The release of IL-6 triggers the liver to produce proteins such as CRP and fibrin [36, 37]. CRP is another key biomarker for the diagnosis of inflammatory responses. It is one of the important means of differentiating between bacterial and viral infections. The mean concentration of urine CRP was established to be less than 150 pg/ml in healthy patients [37, 38]. Both IL-6 and hs-CRP have been shown to have clinical utility as biomarkers for diagnosing UTI [39]. Hence, there may be an advantage in combinatorial detection of IL-6 and CRP levels, as it would enable the development of rapid point-of-care tests with a higher negative predictive value.

In this work, we present the development of a novel urinary diagnostic “dipstick probe” biosensor, for combinatorial detection of inflammatory biomarkers: CRP and IL-6 through nonfaradaic electrochemical impedance spectroscopy (EIS). We have leveraged the surface of molybdenum (Mo) electrode on a flexible nanoporous polyamide substrate to develop an affinity assay for CRP and IL-6 detection using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride–N-hydroxy succinimide (EDC–NHS) crosslinking chemistry. We have previously demonstrated the feasibility of Mo as a reliable electrode material for designing electrochemical biosensors [40]. The nanoscale network of intercalated pores of the polyamide membrane substrate allows for nanoconfinement of the target analyte enhancing the electrochemical response resulting from capacitive double-layer modulation [7]. The nanoporous structures also mitigate the charge screening effect caused by the nonspecific biomolecules [8]. The binding interactions of Mo with EDC–NHS crosslinker and antibodies were established using Fourier transform infrared spectroscopy (FTIR) and ζ -potential characterization techniques. In this work, we propose a direct measure of the specific urinary analyte through a fully electronic transduction method. We have established the detection capability of our biosensor in physiologically normal and elevated levels of IL-6 and CRP in synthetic and human urine. At last, a proof-of-feasibility of a portable urinary dipstick probe electronic interface has been demonstrated. Our work aims to demonstrate the detection of inflammatory biomarkers in human urine for early disease detection.

17.2 Materials and Methods

17.2.1 Materials and Reagents

NHS, EDC, 2-(N-morpholino)ethane sulfonic acid (MES; pH 3) and phosphate-buffered saline (PBS; 0.1 M, pH7) were obtained from Sigma-Aldrich (MO, USA). Anti-CRP antibody, anti-IL-6 antibody and CRP antigen were procured from Abcam (MA, USA). IL-6 protein was procured from Thermo Fisher Scientific, Inc. (MA, USA). Pooled human urine samples were purchased from Lee BioSolutions, Inc.

(MO, USA). Acrylic cellulose acetate sheets were obtained from Staples (TX, USA). Kapton backing support material was obtained from McMaster Carr (TX, USA). Polyamide membranes of 200 nm pore size were obtained from GE Healthcare (NJ, USA). All solvents and reagents were of analytical grade and used as received.

17.2.2 Fabrication and Surface Characterization of Mo Electrode

The electrode pattern was deposited onto the base polyamide substrate using a shadow mask thin-film electron-beam deposition process. The shadow mask stencils were made from acrylic cellulose acetate polymer sheets. A thin base layer of gold was deposited below the Mo to improve electrode adhesion. A secondary acrylic adhesive glue was patterned to prevent fluid wicking on to contact pads of the electrodes. The deposition profile of the deposited Mo was evaluated using scanning electron microscopy (SEM), energy dispersive x-ray spectroscopy (EDAX) and atomic force microscopy (AFM).

17.3 FTIR Characterization of Surface Chemistry

Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectrograms were performed to establish the binding of the EDC-NHS crosslinker to the Mo surface, and subsequent binding of IL-6 and CRP antibody to the EDC-NHS crosslinker. The tool was equipped with a deuterated triglycine sulfate detector and KBr window. A Harrick VariGATR sampling stage with a 65° germanium ATR crystal was used in this study. Measurements were taken as an average of 512 scans in the range of 4000–600 cm^{-1} with 4 cm^{-1} resolution. ATR-FTIR slides were prepared on cleaned glass slides with analogous metal deposition to the electrode fabrication process. The slides were incubated with 100 μl of the EDC-NHS mixture for 1 h. A 3 \times PBS wash was performed to remove any unbound crosslinker. After washing and completely drying with nitrogen, the Mo EDC-NHS measurement was taken. After EDC-NHS functionalization, 100 μl of 10 $\mu\text{g}/\text{ml}$ target antibody was incubated on the slide surface for an additional 30 min (one slide for IL-6 antibody and one slide for CRP). A 3 \times PBS wash was performed to remove unbound antibodies and the slides were dried with nitrogen and silica desiccant beads before the measurements were taken. All measurements represent individual slide preparations, with none being used more than once.

17.4 Surface Charge Characterization with ζ -Potential

ζ -potential measurements were performed to validate the construction of the immunoassay onto the Mo surface using Malvern Instrument's Zetasizer Nano ZS (MA, USA). Electrophoretic mobility technique was used for ζ -potential measurements. First, ζ -potential of Mo (VI) oxide nanoparticles (Sigma-Aldrich) was measured followed by EDC-NHS bound to the Mo nanoparticles. Further, ζ -potential of anti-IL-6 and anti-CRP antibodies bound to Mo EDC-NHS complex

was measured. 1 ml of sample volume was used for each measurement. ζ -potential for IL-6 and CRP dose concentrations was performed in triplicate to validate the binding of immunoassay in synthetic urine at pH 6.45 between 10 pg/ml and 100 ng/ml using the assay developed on Mo surface. Smoluchowski approximation was used to compute the ζ -potential as follows:

$$\mu = (\varepsilon \cdot \zeta) / \eta \rightarrow 1,$$

where μ is electrophoretic mobility, ε the dielectric constant, ζ the ζ -potential and η the viscosity of the solution.

17.5 Experimental Protocol for Biosensing Experiments

A solution of 100 mM NHS and 400 mM EDC was dissolved in MES (pH 3) buffer just prior to incubation on the sensor. The resulting EDC-NHS complex was then incubated on the sensor surface for 1 h. Post-EDC-NHS functionalization, 8 μ l of PBS was added to the sensing region to remove any unbound crosslinker. 8 μ l of 10 μ g/ml of monoclonal antibody (IL-6 or CRP) in 0.1 M PBS was incubated for 15 min. To emulate a true testing environment, test samples were prepared in spectrometer cuvettes containing 300 μ l of sample, which is sufficient to fully cover the sensor when they are dipped in the cuvette. After approximately 15 s of being continuously dipped in the sample, the sensor was removed from the cuvette and allowed to incubate for 5 min. Studies were conducted in both synthetic urine and pooled human urine. The stability of Mo electrode to function efficiently in varying pH of urine was evaluated by performing electrochemical characterization studies in synthetic urine formulated with at pH 5.5, 6.5 and 7.5. A zero-dose measurement in the absence of target molecule was performed before introducing any samples. All dose concentrations of one target protein (either IL-6 or CRP) were tested on a sensor. IL-6 was tested in the range of 1 pg/ml–10 ng/ml, while CRP was tested in the range of 1 pg/ml–100 ng/ml mapping to their physiologically relevant ranges. EIS measurements were performed at each assay step on Gamry Reference 3000 potentiostat (PA, USA) and developed portable electronic reader in parallel. An AC voltage of 10 mVRMS was applied with a frequency sweep of 1 Hz–1 MHz.

17.6 Portable Electronic Dipstick Interface

The developed electronic reader represented in Fig. 17.5C,D demonstrated the translatability of the biosensor to a portable form factor. The device was constructed in its entirety from off-shelf components, and was programmed using open-source code libraries on Arduino Uno R3 microcontroller. The sinusoidal excitation waveform was generated using an MCP4725 digital-to-analog converter. The current response at the working electrode was captured using a current-to-voltage amplification circuit (INA 121) and read back into the microcontroller using an ADS1015 analog-to-digital converter. The sensor consumes no more

than 5 μA of current in a given measurement, and only takes 8–10 s to complete a measurement, making it an ideal transduction method for ultralow power biosensing.

17.7 Results

17.7.1 Surface Characterization of Mo Biosensor

A two-electrode electrochemical sensor was developed on porous polyamide (PA) substrate. The two-electrode system consists of a reference electrode which is curved around a circular working electrode at the center of the sensing region. The total area of the electrode was 0.7 cm^2 . The two electrodes were interfaced with test equipment using thin traces so that the sensing region of the electrode geometry dominates the impedance response. A COMSOL model of this electrode design included in Supplementary Fig. S17.1, shows maximum distribution of current density and electric displacement field near the working electrode which is favorable for evaluating the current response from electrochemical characterization experiments [40].




Figure 17.1 Surface characterization of molybdenum biosensor. (A) Two-electrode Mo biosensor with polyimide backing; (B) atomic force microscopy image indicating uniform deposition profile of molybdenum; (C) scanning electron microscopy image indicating conformal deposition of molybdenum on polyamide substrate; (D) energy dispersive x-ray spectroscopy characterization of scanning electron microscopy region in (C). *Abbreviation:* Mo, molybdenum.

Further, surface characterization of the Mo-deposited electrodes was performed using SEM and AFM techniques to establish the uniformity of the metal deposition. Figure 17.1C shows the SEM micrograph of the Mo-deposited PA substrate, while Fig. 17.1D shows the EDAX characterization of the represented micrograph. The results depict a strong presence of Mo as evidenced by peaks at 2.29 keV. The resistivity of the deposited Mo electrode measured with four-point probe source meter was 332×10^{-3} K m. To establish the uniformity of the deposition, AFM characterization (Fig. 17.1B) was used. A low root mean square (Rq) roughness of 2.36 nm was measured, with Rq value being an indicator of surface smoothness. With an Rq value of blank glass substrate being measured as 1.08 nm, change in the surface roughness after Mo deposition can be considered negligible. The baseline electrochemical characterization of Mo electrode was performed through open-circuit potential experiments in synthetic urine buffer. Mo electrode demonstrated a stable open-circuit potential for 10 min (data not shown) of measurement indicating the stability of the electrode in the absence of any applied input voltage.

17.7.2 ATR-FTIR Surface Characterization Analysis

ATR-FTIR was used to evaluate the nature of the chemical bonds present at the surface of the Mo electrode to validate the binding of both the EDC-NHS complex to the Mo surface as well as the subsequent binding of antibodies. Figure 17.2A shows a visualization of the three measurements taken to characterize the functionalization steps for each antibody. Figure 17.2B shows the resulting spectra. Table 17.2 outlines the associated wave number location for the relevant peaks in the figure. First, a measurement on blank Mo was done to characterize the presence of the Mo-native oxide, and to have a point of comparison for subsequent binding to the oxide surface. Next, the spectra post functionalization with the EDC-NHS crosslinker complex was taken, followed by measurements after the subsequent binding of IL-6 or CRP antibody. The spectra of the post crosslinker and post antibody presented in Fig. 17.2A,C are the result of subtraction from the Mo baseline to better visualize the peaks. The bare Mo sample shows an absence of discernible peaks with the exception of a broad peak manifesting from 900 to 1100 cm^{-1} . This broad peak is characteristic of the Mo oxide layer that is leveraged for EDC-NHS binding. The FTIR spectra of the crosslinker and the antibody (Ab)-functionalized surfaces demonstrated signature peaks corresponding to the organic functional groups present in the respective molecules.

Table 17.2 Fourier transform infrared spectroscopy characterization study of molybdenum and signature peak analysis

Assignments	Mo	Mo+EDC+NHS	Mo+EDC+NHS+a.IL6	Mo+EDC+NHS+a.CRP
Moly oxide	900–1100	N/A	N/A	N/A
v (C=O)	N/A	1650	1647	1656
vas (N–O)	N/A	1566	N/A	N/A
vas (C–N, C–C)	N/A	N/A	1082	1047

Abbreviations: CRP, C-reactive protein; EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; Mo, molybdenum; NHS, *N*-hydroxysuccinimide.




Figure 17.2 Surface characterization of functionalized molybdenum sample. (A) Fourier transform infrared spectroscopy (FTIR) spectra for functionalization of CRP; (B) Schematic representation of presented FTIR spectra; (C) FTIR spectra for functionalization of IL-6; (D) ζ -potential measurements for CRP and IL-6 antibodies; (E) ζ -potential characterization of CRP and IL-6 antigen concentrations. *Abbreviations:* Ab, antibody; CRP, C-reactive protein; EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; Mo, molybdenum; NHS, N-hydroxysuccinimide.

17.7.3 Surface Charge Characterization Using ζ -Potential

ζ -potential measurements can be used to quantify the modulation of surface charge due to the conjugation of charged species. Figure 17.2D shows that the ζ -potential of Mo nanoparticles in deionized water is -9.28 mV. The ζ -potential decreases to -5.01 mV due to the binding of EDC-NHS to Mo nanoparticles resulting in a change in surface charge. The surface charge modulation due to the binding of antibody-antigen results in the modulation of electrical double layer (EDL) [41]. For the CRP affinity assay, the ζ -potential after antibody conjugation is -3.73 mV as seen in Fig. 17.2D. Figure 17.2E shows that the ζ -potential for three dose concentrations of CRP increases in magnitude from -1.24 to -3.35 mV for dose concentration of 10 pg/ml and 1 ng/ml, respectively. The slight drop in ζ -potential to -3.17 mV at 100 ng/ml of CRP may be attributed to the saturation of CRP. For the IL-6 affinity assay, the ζ -potential after antibody conjugation is -2.76 mV as seen in Fig. 17.2D. Figure 17.2E shows that the ζ -potential for three dose concentrations of IL-6 decreases in magnitude from -2.6 to -1.5 mV with respect to increasing dose. This opposite behavior of CRP and IL-6 due to the varied modulation of EDL with varying dose concentrations is also seen in EIS measurements (discussed in Section 17.7.4, “EIS characterization of CRP and IL-6”).

17.7.4 EIS Characterization of CRP and IL-6

EIS measurements were performed to electrochemically characterize the biosensing performance of the developed urine dipstick biosensor developed to detect CRP and IL-6 in urine.

17.7.5 EIS Characterization of CRP and IL-6 in Synthetic Urine

When testing physiological buffers such as urine, it is important to first characterize the impact performance of the sensor under various physiological conditions such as pH variation. Urine is of variable pH across patients and hence, any affinity biosensor that is sampling for biomarkers in urine must be robust for biosensing over physiological range of urine. EIS biosensing experiments were performed on the developed Mo electrodes for CRP and IL-6 spiked in synthetic urine formulated according to the procedure described by Xu et al. [41] for pH 5.5, 6.45, and 7.5. Figure 17.3A represents the percentage change in impedance at 1 Hz frequency for low (1 pg/ml) and high (100 ng/ml) CRP concentrations spiked in synthetic urine of pH 5.5, 6.5 and 7.5. A decreasing trend in impedance change was observed for increasing dose concentrations of CRP, approximately -20% and approximately -60% for 1 pg/ml and 100 ng/ml, respectively, across the pH ranges tested. The percentage change in impedance for low and the high CRP dose concentrations demonstrated statistical significance of $p < 0.05$ at 95% confidence interval using t -test for all three pH buffers of the synthetic urine, thereby indicating the sensitivity of Mo electrode to detect CRP in varying ionic conditions of urine. Figure 17.3B shows the calibration dose response for CRP using synthetic urine at pH buffer 6.45. The change in impedance ranged from approximately -22% for 1 pg/ml CRP concentration to approximately -61% for 100 ng/ml CRP concentration, and was governed by the equation: $|Z| = -3.451 \cdot \ln[\text{CRP in ng/ml}] - 48.82$ demonstrating an R value of 0.932. A specific signal threshold (SST) of 13% was computed using the following formula. A limit of detection (LOD) of 1 pg/ml was obtained which is the smallest concentration above SST. Figure 17.3C shows the percent change in impedance at low (1 pg/ml) and high (10 ng/ml) concentrations of IL-6 across varying pH. The percentage change in impedance for 1 pg/ml of IL-6 antigen was calculated to be approximately 20% and approximately 50% for 10 ng/ml at all three pH ranges. This presents an opposing trend to the impedance response observed in Fig. 17.3A,B for CRP, which is in agreement with the ζ -potential data presented in Fig. 17.2. Figure 17.3D shows the calibration dosing response for 1 pg/ml to 10 ng/ml IL-6 in pH 6.45 synthetic urine, and was governed by the equation: $|Z| = 2.405 \cdot \ln[\text{IL-6 in ng/ml}] + 36.20$ demonstrating an R² value of 0.995. All dose responses were above the measured SST of 11% with LOD of 1 pg/ml. These results help to establish that the sensor is robust to varying pH and is suitable for testing in physiological buffer. The stability of the antibody functionalization on sensor surface was established through multiple buffer wash steps post Ab functionalization. The impedance values of the subsequent buffer wash steps

were statistically insignificant ($p > 0.05$). The plot has been shown in Supplementary Fig. S17.2A. The specificity of the assay was demonstrated with the addition of creatinine on an IL-6 antibody-functionalized sensor and the results are included in the supplementary information (Supplementary Fig. S17.2B). The absence of correlation between the changes in the impedance with increasing creatinine concentrations spanning its physiologically expressed range established the specificity of the developed assay.




Figure 17.3 Electrochemical impedance spectroscopy characterization of CRP and IL-6 in synthetic urine. (A) Change in impedance analysis for low and high CRP antigen concentrations in three pH ranges of synthetic urine. Dotted lines indicate SST; (B) Impedance analysis for pH 6.45 synthetic urine; (C) Change in impedance analysis for low and high IL-6 antigen concentrations in three pH buffer ranges of synthetic urine. The dotted lines indicate SST; (D) Change in impedance analysis for four IL-6 antigen concentrations in pH 6.45 buffer of synthetic urine. *Abbreviations:* CRP, C-reactive protein; SST, specific signal threshold.

17.7.6 EIS Characterization of CRP and IL-6 in Human Urine

After establishing the sensor's performance in synthetic urine, the sensor was tested using spiked samples of IL-6 and CRP in pooled human urine to evaluate the electrochemical response of the biosensor, and to demonstrate translatability of the technology to complex human samples.

Figure 17.4A indicates the percentage change in impedance for CRP antigen concentrations from 1 pg/ml to 100 ng/ml. An SST of 21% was calculated for the CRP detection assay. The LOD was therefore determined to be at 1 pg/ml, as it is still detected over the established SST. The LOD is within the normal levels of CRP observed in urine. The change in impedance ranges from -34% to -65% increasing as a function of Cdl modulation with increasing CRP concentrations. Figure 17.4B shows the change in impedance for the IL-6 antigen concentrations from 1 pg/ml to 10 ng/ml. The LOD for the IL-6 detection was also determined to be 1 pg/ml, which is in the normal physiological range of IL-6 in urine. The change in impedance ranged from 10% to 51% and is above the 5% SST established for this study. The governing equation for the linear dynamic range from 1 pg/ml to 10 ng/ml is: $|Z| = 3.970 \cdot (\text{IL-6 in ng/ml}) + 34.95$ demonstrating an R^2 value of 0.844.




Figure 17.4 Electrochemical impedance spectroscopy characterization of CRP and IL-6 in human urine. (A) Change in impedance analysis for CRP antigen concentrations; (B) Change in impedance analysis for IL-6 antigen concentrations. Dotted lines indicate SST. *Abbreviations:* CRP, C-reactive protein; SST, specific signal threshold.

17.8 Comparison of Impedance Response with Portable Electronic Hardware Prototype

To demonstrate the translatability of the developed dipstick probe assay into a true portable point-of-care device, a portable reader was developed. The device was designed to perform single frequency EIS measurements at the established

1 Hz analysis point used for detection of the target proteins on the benchtop instrument. The device was designed to capture the changes in impedance response of the sensor from the post functionalization baseline to the selected dose regimes of either CRP or IL-6 to the same level of sensitivity as can be attained by the benchtop instrument.

To quantifiably establish comparability of the device's measurements to the benchtop instrument, the raw impedance values of the device were plotted against the corresponding impedance values of the benchtop instrument for the detection of both molecules. This correlation is plotted for CRP in Fig. 17.5A, showing a linear response with an R^2 value of 0.98 with a slope near 1.0. The governing equation can be defined as $y = 1.043x - 53.26$. Figure 17.5B shows the same correlation when detecting IL-6, showing a linear response with an R^2 value of 0.99 with a slope near 1.0. The governing equation can be defined as $y = 1.062x - 160.2$. These results show that the device is sensitive to the range of impedances produced by the sensor showing comparable performance to the benchtop instrument. Figure 17.5C shows the physical device and demonstrates an example of reporting elevated levels of IL-6 (1–100 pg/ml), while Fig. 17.5D shows the envisioned commercial implementation of this device.




Figure 17.5 Performance of portable electronic device. (A) Impedance correlation between lab instrument and portable instrument for CRP; (B) Impedance correlation between lab instrument and portable instrument for IL-6; (C) Visual demonstration of test results using electronic interface; (D) 3D model representation of portable urine dipstick probe interface. *Abbreviation:* CRP, C-reactive protein.

17.9 Discussion

The surface characterization experimental results established that there is a uniform and smooth deposition of Mo on the nanoporous polyamide substrate. The FTIR analysis of the blank Mo substrate indicated the presence of a passive oxide layer which is leveraged for binding of EDC-NHS crosslinker molecules to the electrode surface. After EDC-NHS binding, the peak seen at 1650 cm^{-1} is indicative of the ν (C=O) carbonyl stretching of the EDC-NHS. The carbonyl stretching is expected post antibody conjugation and is observed in both antibody measurements (1647 and 1656 cm^{-1} for IL-6 and CRP antibody, respectively). The peak at 1566 cm^{-1} observed in the EDC-NHS measurement is from ν (N-O) nitro stretching of the crosslinker, which disappears in the antibody measurements after the aminolysis of the NHS after binding. Once the antibody binds, a new bond ν (N-C, C-C) can be seen at 1082 and 1047 cm^{-1} for IL-6 and CRP antibody, respectively. This evidence suggests that EDC-NHS has strongly bound to the Mo oxide layer, and is stable through the functionalization steps associated with the assay. The results also indicate that both the IL-6 and CRP antibodies are binding to the EDC-NHS crosslinker at the surface of the Mo as opposed to other mechanisms such as physical absorption.

The ζ -potential measurements indicate the surface charge changes and hence we leveraged this property toward characterizing the modulation of the EDL due to antibody-antigen binding of IL-6 and CRP on the Mo nanoparticle surface. ζ -potential is also a measure of repulsion behavior of identical charged species. As a larger molecule (105 kDa), the number of identically charged species is greater at higher dose concentrations of CRP, thus, the ζ -potential increases with increasing dose concentrations. Since, IL-6 is relatively small based on the molecular weight (26 kDa), the number of IL-6 molecules docking on to individual Mo surface would be higher at higher concentration. This results in a lower surface charge, thus, reducing the ζ -potential at higher concentrations. The opposing trends in ζ -potential with respect to concentrations of IL-6 and CRP are due to the difference in the binding mechanism of both the biomolecules on the Mo surface, thus, modulating the EDL differently. EDL consists of two layers, in other words, stern layer and diffuse layer. There exists a "slipping plane" within the diffuse layer where the potential drops linearly from the stern plane. Beyond the slipping plane, the potential drops exponentially. The potential at the slipping plane is the ζ -potential. Higher molecular weight of the macromolecular species results in the slipping plane at a larger distance from the stern plane [43]. The higher ζ -potential of CRP as compared with IL-6 can thus be attributed to the higher molecular weight of CRP. As ζ -potential is a measure of EDL, it can be used to correlate with techniques that modulate the EDL with small voltage perturbations [41].

The changes in impedance due to biomolecular binding of CRP and IL-6 to the corresponding capture probes at the electrode/solution interface were analyzed through EIS. The primary objective was to evaluate the electrochemical response of the developed biosensor across varying pH of urine. Nonfaradaic

EIS primarily captures the EDL dynamics at the electrode–solution interface due to small voltage perturbations. The effect of solution resistance is a surface phenomenon and is typically dominated at higher frequencies of the impedance spectrum [44]. The change in impedance within the EDL is mainly due to modulation of the Cdl resulting from the binding between specific antibody and antigen interaction. The impedance responses with varying concentrations of the target analyte were analyzed at 1 Hz frequency due to the dominance of Cdl at low frequencies [44, 45]. Also, maximum change in impedance response for multiple antigen concentrations was observed at 1 Hz frequency and hence it was chosen as the frequency of analysis of impedance spectra. The negative change in impedance for the CRP dose concentrations indicates that the impedance of dose concentration increases from the baseline impedance. This phenomenon can be attributed to the charge state of CRP in the urine buffer. The dipstick probe biosensor exhibits a wide dynamic range that spans over normal and elevated levels for both CRP and IL-6 in human urine samples, thereby establishing its usefulness to be used as an electronic dipstick probe biosensor.

The goal of the portable electronic reader was to establish that the device was sensitive to the range of impedances exhibited by the sensor, and that the device reports those impedance values with the same accuracy as the benchtop instrument. The main source of error in the correlation of the two tools came from fluctuations in solution resistance as function of time when reconfiguring the sensor from one tool to another, which is not a factor of the device itself. Overall, the device demonstrates translatability of the urinary dipstick for inflammatory biomarkers toward a true point-of-care diagnostic form factor.

17.10 Conclusions

An affinity-based electrochemical biosensor for the detection of two critical inflammatory biomarkers, namely CRP and IL-6, was developed using Mo electrode on a nanoporous flexible substrate. The surface characterization performed through SEM analysis demonstrated a uniform deposition of Mo on the polyamide substrate. The presence of peaks, in FTIR spectra, correlated with the EDC–NHS crosslinker molecules, thereby establishing the surface functionalization of Mo electrode with crosslinker monolayer. Binding of CRP and IL-6 antibody with EDC–NHS-functionalized Mo surface was confirmed using FTIR characterization. The change in the surface charge, calculated through ζ -potential measurements, correlated to the antigen concentrations, thereby validating antigen binding to crosslinker–antibody conjugate. The affinity-based antigen–antibody binding was characterized through nonfaradaic EIS. The dipstick probe biosensor demonstrated ability to detect CRP and IL-6 antigen concentration as low as 1 pg/ml in both pooled human urine and synthetic urine samples. The detection concentration range correlated with threshold cut-off concentrations of diseases associated with these biomarkers. The sensor's performance was preserved in multiple pH

range of synthetic urine. This work is the first demonstration of combinatorial detection of CRP and IL-6 in urine using an electrochemical dipstick probe with Mo electrode. The portable research interface established a close correlation with benchtop measurements thereby supporting its development as a semiquantitative point-of-care biosensor for near-patient testing for detecting inflammatory biomarkers.

17.11 Future Perspectives

The current Mo electrode nanoporous dipstick probe biosensor has the capability to be developed as a quantitative error-free reporting platform for biomarker analysis in human urine. The biosensor holds potential for detecting multiple biomarkers from a single sample. The portable electronic hardware is envisioned as a point-of-care diagnostics tool to be used in clinics and in a home environment. The stability of the electrode enables dynamic monitoring of urinary biomarkers over multiple time intervals thereby benefiting patients with chronic health conditions.

17.12 Summary Points

1. Label-free electrochemical urine dipstick probe with molybdenum electrode has been developed for combinatorial detection of IL-6 and C-reactive protein in urine.
2. The performance of the electrode to detect the target biomarkers has been evaluated in synthetic urine with multiple pH buffers and in human urine.
3. The feasibility to perform point-of-care detection in urine has been demonstrated with portable electronic research hardware.
4. Distinguishability between normal and elevated levels of C-reactive protein and IL-6 in urine has been demonstrated.

Abbreviations

AFM:	atomic force microscopy
ATR-FTIR:	attenuated total reflectance Fourier transform infrared
Apo-A1:	apolipoprotein A1
CFHR1:	complement factor H-related 1
CRP:	C-reactive protein
EDAX:	energy dispersive x-ray spectroscopy
EDL:	electrical double layer
EIS:	electrochemical impedance spectroscopy
EN2:	Engrailed-2
FTIR:	Fourier transform infrared spectroscopy
LOD:	limit of detection

MES:	2-(N-morpholino)ethane sulfonic acid
NHS:	N-hydroxysuccinimide
NUMA1:	nuclear mitotic apparatus protein 1
POCD:	point-of-care diagnostics
SEM:	scanning electron microscopy
SST:	specific signal threshold
UTIs:	urinary tract infections

Disclosures and Conflict of Interest

This chapter was originally published as: Kamakoti, V., Kinnamon, D., Choi, K. H., Jagannath, B., Ramasamy, M., and Prasad, S. (2018). Fully electronic urine dipstick probe for combinatorial detection of inflammatory biomarkers. *Future Sci. OA*, 4(5), <https://doi.org/10.4155/fsoa-2017-0142>, under the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates, by kind permission of the copyright holders.

Author contributions: V Kamakoti, K Hyeok Choi, B Jagannath and D Kinnamon performed the experiments. V Kamakoti, B Jagannath, D Kinnamon, M Ramasamy and S Prasad wrote the chapter.

Disclosure of financial and competing interests: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this chapter. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Acknowledgements: The authors thank KC Lin for helping with atomic force microscopy characterization experiments, J Craven for helping with scanning electron microscope characterization and NR Shanmugam for helping with energy dispersive x-ray spectroscopy characterization experiments.

Ethical conduct of research: The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

References

1. Kumar V, Hebbar S, Kalam R, et al. Creatinine-iron complex and its use in electrochemical measurement of urine creatinine. *IEEE Sensors Journal*. 18(2), 830–836 (2018).
2. Selvakumar LS, Thakur MS. Dipstick based immunochemiluminescence biosensor for the analysis of vitamin B 12 in energy drinks: A novel approach. *Analytica Chimica Acta*. 722, 107–113 (2012).

3. Prasad S, Tyagi AK, Aggarwal BB. Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases. *Experimental Biology and Medicine*. 241(8), 783–799 (2016).
4. Radha Shanmugam N, Muthukumar S, Chaudhry S, Anguiano J, Prasad S. Ultrasensitive nanostructure sensor arrays on flexible substrates for multiplexed and simultaneous electrochemical detection of a panel of cardiac biomarkers. *Biosensors and Bioelectronics*. 89, 764–772 (2017).
5. Zhao C, Thuo MM, Liu X. A microfluidic paper-based electrochemical biosensor array for multiplexed detection of metabolic biomarkers. *Science and Technology of Advanced Materials*. 14(5), 054402 (2013).
6. Kamakoti V, Selvam AP, Shanmugam NR, Muthukumar S, Prasad S. Flexible molybdenum electrodes towards designing affinity based protein biosensors. *Biosensors*. 6(3), 36 (2016).
7. Selvam AP, Prasad S, Barrett TW, Kazmierczak SC. Electrical nanowell diagnostics sensors for rapid and ultrasensitive detection of prostate-specific antigen. *Nanomedicine*. 10(16), 2527–2536 (2015).
8. Munje RD, Muthukumar S, Panneer Selvam A, Prasad S. Flexible nanoporous tunable electrical double layer biosensors for sweat diagnostics. *Scientific Reports*. 5, 14586 (2015).
9. Munje RD, Muthukumar S, Prasad S. Lancet-free and label-free diagnostics of glucose in sweat using Zinc Oxide based flexible bioelectronics. *Sensors and Actuators, B: Chemical*. 238, 482–490 (2017).
10. Selvam AP, Prasad S, Barrett TW, Kazmierczak SC. Electrical nanowell diagnostics sensors for rapid and ultrasensitive detection of prostate-specific antigen. *Nanomedicine*. 10(16), 2527–2536 (2015).
11. Panneer Selvam A, Muthukumar S, Kamakoti V, Prasad S. A wearable biochemical sensor for monitoring alcohol consumption lifestyle through Ethyl glucuronide (EtG) detection in human sweat. *Scientific Reports*. 6, 23111 (2016).
12. Ganguly A, Rice P, Lin KC, Muthukumar S, Prasad S. A combinatorial electrochemical biosensor for sweat biomarker benchmarking. *SLAS Technology*. 25(1), 25–32 (2020).
13. Prasad S, Tyagi AK, Aggarwal BB. Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases. *Experimental Biology and Medicine*. 241(8), 783–799 (2016).
14. Pan Y, Sonn GA, Sin MLY, et al. Electrochemical immunosensor detection of urinary lactoferrin in clinical samples for urinary tract infection diagnosis. *Biosensors and Bioelectronics*. 26(2), 649–654 (2010).
15. Lee S, Jo H, Her J, Lee HY, Ban C. Ultrasensitive electrochemical detection of engrailed-2 based on homeodomain-specific DNA probe recognition for the diagnosis of prostate cancer. *Biosensors and Bioelectronics*. 66, 32–38 (2015).
16. Chatterjee S, Chen A. Functionalization of carbon buckypaper for the sensitive determination of hydrogen peroxide in human urine. *Biosensors and Bioelectronics*. 35(1), 302–307 (2012).
17. Kim SE, Kim YJ, Song S, Lee KN, Seong WK. A simple electrochemical immunosensor platform for detection of Apolipoprotein A1 (Apo-A1) as a bladder cancer biomarker in urine. *Sensors and Actuators, B: Chemical*. 278, 103–109 (2019).

18. Arya SK, Estrela P. Electrochemical ELISA-based platform for bladder cancer protein biomarker detection in urine. *Biosensors and Bioelectronics*. 117, 620–627 (2018).
19. Reddy KK, Gobi KV. Artificial molecular recognition material based biosensor for creatinine by electrochemical impedance analysis. *Sensors and Actuators B: Chemical*. 183, 356–363 (2013).
20. Rebelo TSCR, Pereira CM, Sales MGF, Noronha JP, Silva F. Protein imprinted material electrochemical sensor for determination of Annexin A3 in biological samples. *Electrochimica Acta*. 190, 887–893 (2016).
21. Govindasamy M, Wang SF, Subramanian B, Ramalingam RJ, Al-lohedan H, Sathiyam A. A novel electrochemical sensor for determination of DNA damage biomarker (8-hydroxy-2'-deoxyguanosine) in urine using sonochemically derived graphene oxide sheets covered zinc oxide flower modified electrode. *Ultrasonics Sonochemistry*. 58, 104622 (2019).
22. Sha R, Vishnu N, Badhulika S. MoS₂ based ultra-low-cost, flexible, non-enzymatic and non-invasive electrochemical sensor for highly selective detection of Uric acid in human urine samples. *Sensors and Actuators, B: Chemical*. 279, 53–60 (2019).
23. Bishnoi S, Goyal RN, Shim YB. A novel nanogold-single wall carbon nanotube modified sensor for the electrochemical determination of 8-hydroxyguanine, a diabetes risk biomarker. *Bioelectrochemistry*. 99, 24–29 (2014).
24. Bracha S, McNamara M, Hilgart I, et al. A multiplex biomarker approach for the diagnosis of transitional cell carcinoma from canine urine. *Analytical Biochemistry*. 455(1), 41–47 (2014).
25. García-Baquero R, Puerta P, Beltran M, et al. Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: A 2-center prospective study. *Journal of Urology*. 190(2), 723–730 (2013).
26. Cheng D, Liang B, Li Y. Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer. *Tumori*. 98(6), 762–767 (2012).
27. da Pieve C, Sahgal N, Moore SA, Velasco-Garcia MN. Development of a liquid chromatography/tandem mass spectrometry method to investigate the presence of biomarkers of DNA damage in urine related to red meat consumption and risk of colorectal cancer. *Rapid Communications in Mass Spectrometry*. 27(21), 2493–2503 (2013).
28. Barocas DA, Motley S, Cookson MS, et al. Oxidative stress measured by urine F₂-isoprostane level is associated with prostate cancer. *Journal of Urology*. 185(6), 2102–2107 (2011).
29. Park YJ, Yoo SA, Kim GR, Cho CS, Kim WU. Urinary interleukin-6 as a predictor of radiographic progression in rheumatoid arthritis: A 3-year evaluation. *Scientific Reports*. 6, 35242 (2016).
30. Gürgöze MK, Akarsu S, Yilmaz E, et al. Proinflammatory cytokines and procalcitonin in children with acute pyelonephritis. *Pediatric Nephrology*. 20(10), 1445–1448 (2005).
31. Krzemień G, Roszkowska-Blaim M, Kostro I, et al. Urinary levels of interleukin-6 and interleukin-8 in children with urinary tract infections to age 2. *Medical Science Monitor*. 10(11), CR593-7 (2004).

32. Griebbling TL. Urologic diseases in America project: Trends in resource use for urinary tract infections in women. *Journal of Urology*. 173(4), 1281–1287 (2005).
33. Krzemień G, Szmigielska A, Turczyn A, Pańczyk-Tomaszewska M. Urine interleukin-6, interleukin-8 and transforming growth factor β 1 in infants with urinary tract infection and asymptomatic bacteriuria. *Central European Journal of Immunology*. 41(3), 260–267 (2016).
34. Sundvall PD, Elm M, Ulleryd P, et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: A cross sectional study of 421 nursing home residents. *BMC Geriatrics*. 14(1), 88 (2014).
35. Sundén F, Wullt B. Predictive value of urinary interleukin-6 for symptomatic urinary tract infections in a nursing home population. *International Journal of Urology*. 23(2), 168–174 (2016).
36. Tejani NR, Chonmaitree T, Rassin DK, Howie VM, Owen MJ, Goldman AS. Use of C-reactive protein in differentiation between acute bacterial and viral otitis media. *Pediatrics*. 95(5), 664–669 (1995).
37. Meyer MHF, Hartmann M, Krause HJ, et al. CRP determination based on a novel magnetic biosensor. *Biosensors and Bioelectronics*. 22(6), 973–979 (2007).
38. Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P. Urine and serum C-Reactive protein levels as potential biomarkers of lower urinary tract symptoms. *Urological Science*. 21(3), 132–136 (2010).
39. Nanda N, Juthani-Mehta M. Novel biomarkers for the diagnosis of urinary tract infection: A systematic review. Available at: <https://journals.sagepub.com/doi/10.4137/BMI.S3155> (accessed on October 15, 2022).
40. Kamakoti V, Selvam AP, Shanmugam NR, Muthukumar S, Prasad S. Flexible molybdenum electrodes towards designing affinity based protein biosensors. *Biosensors*. 6(3) (2016).
41. Xu K, Wang C, Liu H, Qian Y. Simultaneous removal of phosphorus and potassium from synthetic urine through the precipitation of magnesium potassium phosphate hexahydrate. *Chemosphere*. 84(2), 207–212 (2011).

Supplementary Information

COMSOL simulation of current density and electric displacement field distribution

The electric displacement field and current density distribution of the applied voltage was simulated using the in-built electrostatics and electric current physics equations. The current density plot indicated a maximum current density distribution near the working electrode. The electric displacement field also demonstrated a maximum distribution near the working electrode thereby indicating that the response from the EIS is from the working electrode.

Assay stability study with buffer wash steps

The stability of the assay was evaluated by performing multiple buffer washes post IL-6 Antibody functionalization step. The impedance of buffer wash steps were studied at 1 Hz. The changes in impedance of the sensor for the buffer wash steps were statistically insignificant ($p > 0.05$) even after five washes thereby indicating the stability of the antibody functionalized on the sensor surface (Figure S17.1A).

Non-specific interaction study

The specificity of the assay was evaluated by performing non-specific interaction study with Creatinine which is a major interfering agent in urine. The valid concentrations of Creatinine as recommended by WHO is from 30 mg/dL to 300 mg/dL [1]. The urinary concentrations ranging from 0.5 mg/ml to 4 mg/ml were tested on IL-6 functionalized sensor. The sensor demonstrated a negligible change in impedance with respect to baseline impedance value. The absence of correlation between creatinine concentrations with change in impedance values establish the absence of binding between non-specific creatinine molecules with IL-6 antibody functionalized sensor surface. Thus, the response of the sensor to non-specific molecules in urine was established.




Figure S17.1 COMSOL simulation of current density and electric field displacement field distribution between working and reference electrode geometries.




Figure 17.S2 (A) Assay stability study with multiple blank buffer washes post Ab functionalization. (B) Non-specific interferant study with creatinine on IL-6 Antibody functionalized sensor.

Supplementary Reference

1. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the US population: implications for urinary biologic monitoring measurements. *Environmental Health Perspectives* 113(2), 192 (2005).

Chapter 18

Nanosensor Diagnostics

Sourav Bhattacharjee, PhD

University College Dublin, Dublin, Ireland

sourav.bhattacharjee@ucd.ie

Keywords: adenosine triphosphate (ATP), carbon nanotubes, cardiac troponin T (cTnT), diagnostic magnetic resonance (DMR), flavin adenine dinucleotide (FAD), Förster/fluorescence resonance energy transfer (FRET), glucose oxidase (GOx), gold nanoparticles (AuNPs), graphene, high-throughput screening (HTS), human chorionic gonadotrophin (HCG), human epidermal growth factor 2 (HER2), human immunodeficiency virus (HIV), interleukin-6 (IL-6), magnetic nanoparticles (MNPs), nanoparticles (NPs), nanorods, para-benzoquinone (p-BQ), photothermal therapy (PTT), point-of-care (POC), prostate-specific antigen (PSA), quantum dots (QDs), surface plasmon resonance (SPR), surface-enhanced Raman scattering (SERS), transmission electron microscopy (TEM)

18.1 Introduction

The unprecedented materialistic and optoelectronic properties of various nanomaterials, including nanoparticles (NPs), render them suitable for further exploration as label-free sensing tools with improved sensitivity or specificity and vast applications in medicine, including point-of-care (POC) diagnostics [1–3]. Availability of more surface area for functionalization in NPs provides adequate scope for designing efficient sensing platforms. However, such conjugation/immobilization of biomolecules onto nanoscale materials can be challenging and is usually done by one of the following routes [4]:

- **Noncovalent techniques**, which maintain the physicochemical properties of both NPs and biomolecules, for example, π - π stacking, van der Waals forces, and electrostatic interactions.
- **Covalent techniques**, which produce stable and reproducible sensing platforms, for example, coupling reactions, such as amide coupling and click chemistry.

- **Supramolecular/coordinative techniques** in order to produce recyclable sensors with a reproducible transducer component, for example, biotin-stratavidin bonding [5] and complex of nitrilotriacetic acid (NTA)/Cu²⁺/histidine [6] or adamantane/ β -cyclodextrin [7].

Most NPs can be synthesized with the precise physicochemical characteristics required for sensing. However, in certain cases, additional maneuvers, like coating with polymers, are required to facilitate immobilization [8] or confer biocompatibility.

18.2 AuNPs

Gold NPs (AuNPs) have emerged as the foremost candidate of the family of NPs from noble metals (Au, Ag, Pt, etc.) for biosensing purposes. Some advantages of AuNPs are biocompatibility, tunability and known optoelectronic behavior, relative ease of production, presence of efficient functionalization techniques, and availability in different sizes or shapes [9]. Both AuNPs and gold surfaces are used for sensing, which relies on the presence of surface plasmons at the air/metal interfaces [10]. A detailed discussion of the physics of surface plasmons unfortunately falls beyond the scope of this book. However, some fundamental principles are discussed below.

Surface plasmons are delocalized conductive electrons that exist at the interface of two materials where the real part of the dielectric constant changes sign across the interface [11, 12]. Such interfaces are present between metal and air or metal and water and are known to exist in AuNPs as well as in other metallic NPs, like silver [13] and copper [14]. When an electromagnetic wave (e.g., light) interacts with surface plasmons on AuNPs of sizes much less than the wavelength of the incident light, the oscillating surface plasmons absorb light at a specific wavelength and resonate with the particular frequency by creating an oscillating dipole moment as described in Mie theory—a phenomenon known as localized surface plasmon resonance (LSPR) (Fig. 18.1) [15–17]. LSPR is dependent on the size and shape of the NPs plus the dielectric constant of the environment [18]. For AuNPs <20 nm in size, the surface plasmon resonance (SPR) is quantitatively denoted by the following equation [19]:

$$C_{\text{ext}} = \frac{24\pi^2 R^3 \epsilon_m^{\frac{3}{2}} N}{\lambda \ln(10)} \cdot \frac{\epsilon_i}{(\epsilon_r + \chi \epsilon_m)^2 + \epsilon_i^2},$$

where C_{ext} is the extinction cross section and denoted as $\epsilon(M^{-1}\text{cm}^{-1}) = \frac{10^{-3} N C_{\text{ext}}(\text{cm})^2}{2.303}$; ϵ is the complex dielectric constant/permittivity of the metal and denoted as a combination of real and imaginary components $\epsilon = \epsilon_r(\omega) + i\epsilon_i(\omega)$, where the real component determines the position of LSPR whereas the imaginary one gives the bandwidth; ϵ_m is the dielectric constant of the environment and $\epsilon_m = n_m^2$, where

n_m is the refractive index of the surrounding environment; λ is the wavelength of incident light; N is the electron density; χ is the shape factor $\chi = \frac{a}{b}$, where a and b are the minor and major axes of the ellipsoid describing the shape of the NP.

The shift of the LSPR band ($\Delta\lambda$) upon development of the adsorbate layer is given by the following equation:

$$\Delta\lambda = m(\Delta n) \left[1 - e^{-2d/l_d} \right],$$

where m is the sensitivity of the refractive index, Δn is the change in the refractive index induced by the adsorbed layer, d is the effective thickness of the adsorbed layer, and l_d is the electromagnetic exponential decay length of the electromagnetic wave.




Figure 18.1 Illustration of LSPR as the surface plasmons on the air/metal interface oscillate and resonate upon interaction with incident electromagnetic light waves. Unlike the gold surface, surface plasmons cannot propagate along the surface in AuNPs and exhibit polarization of the surface plasmons on one side of the AuNPs. Reproduced from Ref. [23] under a Creative Commons agreement (CC BY-SA).

The sensitivity of refractive index (m) is measured from the slope of the LSPR frequency plot against the refractive index. Usually, it is linear within a relatively small range of refractive indices, as predicted by the Drude model of the electronic configuration in metals [20, 21]. The l_d (electromagnetic field decay length) is dependent on the shape of the NPs. The value of the l_d for most of the metallic NPs, including AuNPs, is comparable to the size of common protein molecules, that is, 5–10 nm [22]. This enables high sensitivity for metallic NPs, including AuNPs, in sensing any binding between the analyte and bioreceptor units.

The extinction of the incident light occurs due to energy dissipation by both absorption and scattering. In absorption, energy is dissipated due to inelastic processes, whereas in scattering, the energy of incident light causes oscillations of

electrons in the materials and a photon is emitted—either of the same frequency as that of the incident light (Rayleigh scattering) or of a different one (Raman scattering) [24]. Existence of LSPR increases both the absorption and scattering fivefold to sixfold compared to even the most popular dye molecules. With increasing size of AuNPs, both the scattering cross section and the albedo, that is, the ratio of scattering to cumulative extinction, increase [25]. Hence, while smaller AuNPs (~20 nm) exhibit mostly absorption, the scattering keeps increasing with size and in AuNPs of 100 nm, the extinction is mostly due to scattering. This is important while selecting AuNPs for applied reasons. For example, larger (100 nm) AuNPs are preferred for imaging due to higher light scattering whereas smaller (~20 nm) ones are preferred in photothermal therapy (PTT), where significant energy of the incident light is absorbed to generate heat in order to kill target cells (e.g., in cancer) [26].

Typically, smaller (~20 nm) AuNPs exhibit an LSPR absorption peak of around 520 nm [27], although a peak shift can occur because of multiple factors, as follows:

18.2.1 Particle Size

The bigger AuNPs scatter more due to a larger scattering cross section. As a result, there is considerable broadening and flattening of the absorbance peak with increasing size of the particles. Cumulatively, this causes a red-shift and flattening of the absorbance peak with increasing size. Hence, dispersion of 20 nm AuNPs is bright red in color as most of the light in the blue-green zone (450–550 nm) of the spectrum is absorbed while the red part (~700 nm) is emitted. Conversely, for bigger (~100 nm) AuNPs, a wide area of the spectrum, particularly the red part, is absorbed and as a result, a bluish light is emitted, which makes the dispersions of larger (~100 nm) AuNPs pale blue to purplish in color [28, 29].

18.2.2 Aggregation State

Aggregation of AuNPs causes a red-shift of the LSPR spectrum due to the fact that with aggregation, more delocalized surface plasmons are shared between neighboring particles, which decreases the energy required for LSPR (Fig. 18.2) [30, 31]. Therefore, aggregation of AuNPs causes a change of color in the dispersion and this is used as an effective and simple colorimetric sensing platform for various molecules, such as protamine [32], heparin [33], and α -thrombin [34].

18.2.3 Refractive Index of the Surrounding Medium

Red-shift of the LSPR in AuNPs occurs as the refractive index of the surrounding medium increases, and vice versa [35, 36]. Hence, the LSPR absorbance peak will exhibit a blue-shift as the surrounding medium changes from water ($n = 1.33$) to air ($n = 1$), while a red-shift will be observed if the medium changes to oil ($n = 1.5$).

This technique is thus often utilized in order to tune the LSPR of AuNPs by coating the materials with nonconductive materials, such as silica ($n = 1.5$) [37], polymers ($n = 1.4$ – 1.45) [38], or aluminum oxide ($n = 1.58$ – 1.68) [39](Fig. 18.3).




Figure 18.2 Color of AuNP dispersions due to various degrees of aggregation in serial dilutions of glutathione. The least aggregated dispersion is red (right), while the highest one is pale blue (left) in color. Reproduced from Ref. [23] under a Creative Commons agreement (CC BY-SA).




Figure 18.3 (a) The SPR measurement setup on a gold-coated glass slide placed between a prism and a flow-cell. The setup usually consists of an incident p-polarized light that strikes the conducting sensor slide at the interface between high and low refractive indices, for example, an external medium, like liquid. The angle of incidence (θ) is changed in order to determine the optimal angle to induce resonance of surface plasmons, causing SPR. The point of lowest intensities in the curves, visible as dips, shows the value of θ where SPR occurred, (b) the SPR plot shows the characteristic shift due to the formation of a layer at the surface due to binding. Reproduced from Ref. [50] under a Creative Commons agreement (CC BY).

18.2.4 Shape of AuNPs

The shape of AuNPs is an important attribute in determining the LSPR [40, 41]. The example of gold nanorods (AuNRs) can be given, which, unlike AuNPs, exhibit varied aspect ratios. Typically, for AuNRs, the LSPR band is split into two distinct bands—a stronger, longitudinal band in the near-infrared (NIR) region due to oscillation of surface plasmons along the long axis, and the other, weaker, transverse band in the visible region similar to that of spherical AuNPs due to transverse oscillations. While the stronger, longitudinal band shows significant dependence on the aspect ratio of the AuNRs with a red-shift with an increasing ratio, the transverse band is independent of it. With an advanced synthetic strategy, AuNRs with precise aspect ratios can be prepared for further uses in sensing [42, 43]. The theoretical framework for understanding the LSPR in AuNRs is given on the basis of Gans theory (1915) [44] or discrete dipole approximation [45], albeit a detailed discussion is beyond the scope of this chapter. There are some excellent research articles for consultation [46–48]. In AuNRs the relation of the red-shift of the longitudinal band to the aspect ratio is linear and clearly visible, unlike the rather subtle shift seen for AuNPs on the basis of particle size, and is as follows [49]:

$$\lambda_{\max}(\text{nm}) = 95R + 420,$$

where λ_{\max} is the wavelength of the maximal absorption in the longitudinal band and R is the aspect ratio of AuNRs visible as the dip, or the point of lowest intensity, in the LSPR spectra (Fig. 18.4).




Figure 18.4 Effect of size and aspect ratio of AuNPs on LSPR. Reproduced from Ref. [23] under a Creative Commons agreement (CC BY).

AuNPs can also facilitate in amplifying the signal and, thus, enhance the sensitivity of the diagnostic platform when used in sandwich setups with gold surfaces, due to strong plasmonic field coupling between the AuNPs and gold surfaces [50–53]. In one such study [54], the maximal enhancement of the SPR signal was observed in 40 nm AuNPs conjugated with secondary antibodies or DNA strands and positioned at a distance of 5 nm from the gold surface, separated by a dithiothreitol spacer. The signal amplification was significant, and such techniques are certainly worth exploring in the future. AuNPs are also known to both enhance and quench the emission from fluorophores [55, 56]. Usually, AuNPs >80 nm cause enhancement, while the <80 nm ones cause quenching due to Förster/fluorescence resonance energy transfer (FRET) and/or NP surface energy transfer [57, 58]. The quenching effect can be felt even up to a distance of 40 nm [59], depending on the size of the AuNPs, whereas it is hardly 10 nm for popular organic quencher molecules. Hence, AuNPs have emerged as popular tools in FRET-based sensors, particularly useful in the detection of biomacromolecules like proteins. Additionally, AuNPs are excellent enhancers of the surface-enhanced Raman scattering (SERS) signal [60, 61] and are being used in SERS-based single-cell/molecule assays [62–65].

The LSPR effect of AuNPs can also be coupled with ELISA assays in order to generate highly sensitive sensing platforms, often capable of detecting even single molecules (Fig. 18.5). Typically, in such setups, the horseradish peroxidase (HRP) enzyme is conjugated with AuNPs (~60 nm), frequently via a biotin-streptavidin linkage [66, 67]. The HRP can then convert soluble noncolored compounds into insoluble colored compounds (e.g., 3,3'-diaminobenzidine into polybenzimidazole [68]), which aggregates around the AuNPs, causing a shift in the LSPR, and enables the detection of even up to single molecules of analyte on AuNPs. Alternatively, HRP can be adsorbed on a deposited layer of AuNPs (HRP@AuNPs) over electrodes, providing a higher surface area for adsorption and enabling the detection of reduction in presence of hydrogen peroxide [69].




Figure 18.5 Perturbation of propagating surface plasmons on gold surfaces due to AuNPs (40 nm) at a 5 nm distance, causing change in the evanescent field and amplification of the SPR signal. Reproduced from Ref. [78] under a Creative Commons agreement (CC BY).

Such HRP@AuNP setups are reported to be stable over a longer time span and reproducible [70]. Similarly, a recent study [71] was able to detect prostate-specific antigen (PSA) at attomolar (10^{-18}) levels in mouse serum through LSPR done with gold nanostars—coated with or without poly(*N*-vinyl pyrrolidone)—functionalized with rabbit polyclonal antibody of PSA (Fig. 18.6). Antibody-coated AuNPs were also used successfully as a highly sensitive LSPR detection platform capable of distinguishing various subtypes (A–G) of human immunodeficiency virus (HIV) with a very high accuracy (e.g., 98 ± 39 copies/mL for HIV subtype D), sensitivity, specificity, and reproducibility in human blood samples (Fig. 18.7) [72]. Such platforms have also been used as highly sensitive detection platforms for other viruses, for example, influenza [73], hepatitis B [74], and various cancers (including renal and oral ones) [75–77].




Figure 18.6 Highly sensitive SPR-based detection platform for PSA in mouse serum using antibody-coated gold nanostars. (a) Transmission electron microscopy (TEM) images to confirm increasing aggregation of the gold nanostars functionalized with antibodies to PSA with growing concentrations of PSA, resulting in a shift within the LSPR spectra. (b) The binding curve of the PSA-induced aggregation of PSA antibody-coated nanostars. (c) Plot showing the plasmon shift against the PSA concentration. The pink region is due to nonspecific binding from mixing various concentrations of PSA with gold nanostars not coated with any antibody. The binding of antibody-coated gold nanostar with PSA was significant, enabling attomolar (10^{-18})-level detection. Reproduced from Ref. [79] under a Creative Commons agreement (CC BY).




Figure 18.7 (a) The structure of antibody-coated AuNPs as an LSPR-based platform for the detection of HIV on the basis of the carbodiimide chemistry in order to cover the surface with antibodies specific to various HIV subtypes (A–G). (b) The detection platform was able to detect and distinguish between various HIV subtypes (A–G) in blood samples collected from HIV patients. Reproduced from Ref. [79] under a Creative Commons agreement (CC BY).

AuNPs are known to enhance electrochemical sensitivity in glassy carbon electrodes (GCEs) during electrochemical analysis [80, 81], used widely in biosensing tools for a range of molecules, for example, human chorionic gonadotrophin (hCG) in urine or blood samples [82]. In the case of hCG, AuNPs and methylene blue were included in the GCE layer by layer, which increased the surface area available for adsorption significantly, resulting in higher binding and thus improved sensitivity. In another interesting application, hybrid nanostructures of AuNPs/multiwalled carbon nanotubes (MWCNTs) were used to coat the surfaces of GCEs using thionine cross-linkages to facilitate the immobilization of antibodies in order to develop a highly sensitive detection platform for nicotinamide adenine dinucleotide (NADH) and glucose with detection limits of $0.05 \mu\text{M}$ and $0.7 \mu\text{M}$, respectively [83]. A similar setup using hybrid nanostructures consisting of HRP-functionalized AuNPs and CNTs was used to coat GCEs in order to immobilize

secondary antibodies (Ab_2) for the detection of human IgG. The platform showed a linear response within 0.125–80 ng/mL with a detection limit of 40 pg/mL [84].

AuNPs are also efficient in transferring electrons from electrodes to various charged biomolecules and vice versa. Such transfer of electrons is of paramount importance, particularly in redox enzyme-based sensing platforms, for example, HRP [85]. In reality, the electron transfer between enzyme and electrode is unfortunately often slow due to either improper orientation of the enzyme molecule or denaturation of the enzyme due to impurities. Commonly used soluble mediator molecules of a lower molecular weight to address the problem often exhibit leaching from the electrode and, hence, an appreciable amount is lost into the solution during the process. AuNPs are promising candidates for shuttling electrons in such a process, with or without being part of a composite structure, such as a polymer AuNP (e.g., a chitosan AuNP) [86, 87], and thus increase the signal. The enzyme glucose oxidase (GOx) is particularly important for glucose sensing. However, wiring it successfully to the electrode to enable adequate electron transfer remains a challenge as its active site is embedded deep inside the molecule, with no metal atom in the vicinity to perform the electron transfer [88–90]. Usually, GOx releases two electrons by oxidation of glucose, which under normal circumstances is transferred by flavin adenine dinucleotide (FAD); FAD is reduced to $FADH_2$ in the process. Hence, it is essential to provide a mechanism to regenerate FAD from $FADH_2$ and ensure the continuity of oxidation. AuNPs, as an efficient transporter of electrons, serve the purpose, and a hybrid apo-GOx@AuNP construct was reported [91], which demonstrated a sevenfold higher electron transfer compared to natural processes, resulting in significant amplification of the signal (Fig. 18.8).




Figure 18.8 Illustration of the apo-GOx@AuNP hybrid structure ensuring the transfer of electrons generated by oxidation of glucose to the electric circuit wired to an electrode in order to amplify the signal. Reproduced from Ref. [78] under a Creative Commons agreement (CC BY).

Interestingly, AuNRs are often a better and more suitable material to modify electrodes because of being simple, label-free, reusable, and compatible with microfluidic devices [92]. Moreover, AuNRs show a linear shift of the LSPR signal, with a minute change in the surrounding environment. AuNRs functionalized with target antibodies have already shown promise in the detection of sheep, human, and rabbit IgG1 while offering plenty of scope for multiplexing [93]. Such AuNR-based sensing platforms are reported to detect analytes at femtomolar levels of various molecules, including single-molecule detection in the case of DNA [94], with ample scope for miniaturization, automation, and high-throughput screening (HTS).

In summary, AuNPs, including AuNRs, present an exciting set of nanomaterials that offer novel opportunities for further exploration in biosensing, with wider anticipated applications in medical diagnostics in the form of POC devices. Not only gold but other metallic nanomaterials (silver and copper) also harbor similar properties, although gold enjoys an edge over others due to biocompatibility, well-known chemistry, and opportunities for functionalization. However, for successful translation of such sensing platforms, an essential criterion will be its effectiveness in dealing with real pathological samples, such as blood and urine. Unfortunately, that has remained a challenge so far. However, with the arrival of further knowledge and improvement in functionalization techniques, such challenges are expected to be addressed adequately in the future.

18.3 CNTs

With extraordinary optoelectronic properties, CNTs are exciting materials for biosensing [95, 96]. CNTs, including their structure, have been already discussed in great detail in Chapter 6. This section will focus solely on their sensing applications.

18.3.1 Interesting Physicochemical Properties of CNTs

CNTs can be assumed to be rolled-up graphene sheets, and depending on the number of sheets, can be single or multiple walled (i.e., SWCNTs or MWCNTs), where the walls consist of hexagonal lattices of C-atoms, typical of graphene. With better synthetic techniques, CNTs up to 20 cm in length can be synthesized now, and such cylindrical CNTs, with exceptionally small internal diameters (a few nanometers), present with materials of very high aspect ratios [97]. Most of the SWCNTs are chiral, while some of their configurations (e.g., armchair and zigzag) are not [98]. The external diameters of MWCNTs can be up to 100 nm, while the spacing between two opposing walls is like that in graphite, that is, 3.5 Å [99]. The double-walled CNTs (DWCNTS) represent a transformation from SWCNTs to MWCNTs and, hence, possess properties of both SWCNTs (e.g., ability to form bundles) and MWCNTs (e.g., higher mechanical stability and better options to functionalize) [100, 101] (Fig. 18.9). Overall, CNTs demonstrate a very high

surface area and are excellent materials for functionalization to make them conducive for sensing applications. Depending on their internal diameters and chirality, SWCNTs can behave both as semiconductor/quasi-metallic (e.g., zigzag) and semimetallic (e.g., armchair) materials. The presence of little structural defects and excellent stability at high temperatures (e.g., 300°C in air and 1500°C in vacuum) further contributes to the electrical conductivity of SWCNTs [102–105]. The tensile strength and Young’s modulus of SWCNTs are many times higher than those of steel [106]. The magnetoresistance of SWCNTs depends on multiple factors, including temperature and direction of the field [107].




Figure 18.9 Structure of CNTs as per the number of walls. (A) Structure of SWCNTs as a function of chirality (zigzag, armchair, and chiral). Similar models of (B) DWCNTs and (C) MWCNTs made up of several concentric graphene shells are shown. Reproduced from Ref. [114] under a Creative Commons agreement (CC BY).

Additionally, SWCNTs exhibit strong Raman scattering and absorbance at the NIR region of the spectrum, which makes them suitable for biological imaging and PTT, where internalized CNTs in target tissues (e.g., cancer) are excited by NIR irradiation to generate heat and kill the cells [108–110]. The high absorption of light demonstrated by the CNTs provides opportunities for photoacoustic imaging, which offers better resolution and deeper tissue penetration than conventional ultrasonogram [111]. Such CNT-based contrast agents (e.g., SWCNTs attached to indocyanine green) have already shown promising results during initial experiments [112].

18.3.2 Functionalization of CNTs

One of the major challenges in working with CNTs is their tendency to aggregate. To address this issue, a promising approach is to functionalize surfaces of CNTs (exohedral functionalization [Fig. 18.10]) in order to create a charged surface or exert steric hindrance that enables the CNTs to resist aggregation [113, 114]. Another way to functionalize CNTs is to fill up the interior of the cylindrical CNTs—also known as endohedral functionalization (Fig. 18.10)—with various materials, such as contrast agents, sensors, or magnets, in order to improve their utility in sensing and therapeutics.

- **Exohedral functionalization:** Exohedral functionalization is done by both noncovalent and covalent methods.

Noncovalent functionalization approaches provide advantages like preservation of the electrical and structural properties of CNTs and methodological simplicity. Surfactant molecules are often used to reduce surface tension and prevent aggregation of CNTs. While the charged surfactants prevent aggregation by electrostatic repulsion of the micelles, the neutral ones create a cloak around the CNTs due to the hydrophilic moieties. However, use of surfactants can compromise biocompatibility by inducing cytotoxicity. π - π stacking has been used to functionalize the surfaces of CNTs noncovalently with a triple layer of pyrene [115] or single-stranded DNA (ssDNA) [116] to increase solubility. However, these constructs, especially with the ssDNA, suffer from a lack of stability over a longer period of time [117]. Functionalization of SWCNTs through surface adsorption was found to provide advantages like increased solubility, improved biocompatibility, and opportunities for further conjugation with ligands, for example, polyethyleneimine, to facilitate binding with DNA [118]. Similarly, adsorption of RNA on CNTs is a feasible way of functionalization, although it confers negative charge on the surface and, thus, makes it unsuitable for binding with DNA [119].

Covalent exohedral functionalization techniques have already been discussed in Chapter 6. In brief, oxidation of CNTs with the help of strong oxidizing agents, such as nitric acid, is the most used method, where the terminal

acid ($-\text{COOH}$) groups offer scope for further functionalization [120]. However, a major downfall of such techniques is that many of the interesting materialistic properties of CNTs (e.g., Raman scattering and photoluminescence) are significantly reduced by such harsh reactive conditions [121]. Use of milder oxidizing agents (e.g., K_2FeO_4) is a better option to preserve such properties and provide adequate $-\text{COOH}$ groups for conjugation [122]. Functionalized and charged CNTs show aggregation in biological fluids due to the presence of salts and shielding effect of the ions. PEGylation can be an option to develop CNT conjugates that are stable in such biological media rich in salts [123, 124]. The 1,3-dipolar cycloaddition reaction is perhaps the most widely used technique to functionalize the surfaces of CNTs with single or even multiple molecules via a variety of conjugation techniques (e.g., amidation and arylation) [125]. Interestingly, it was noted that bioavailability, tissue distribution, and pharmacokinetic profiles of CNTs in vivo depend highly on the surface functionalization and thus provide opportunity for developing engineered CNTs with the desired biocompatibility and sensing capability [126].




Figure 18.10 Exohedral and endohedral functionalization of CNTs. (A) Noncovalent functionalization of CNTs with micellar or (B) shell-like surfactants wrapping the CNTs. Hydrophobic and hydrophilic groups are denoted by blue lines and yellow stars, respectively. (C) A model of CNTs filled with C_{60} buckyballs (peapods). (D) DWCNTs filled with molten FeI_2 forming FeI_2 @DWCNTs. Reproduced from Ref. [114] under a Creative Commons agreement (CC BY).

- **Endohedral functionalization:** Manipulation of CNTs is a splendid example of engineering materials at the nanoscale. Here, the internal diameter of

the CNTs is filled with various molecules and the obtained nanoconstructs are often denoted as X@CNTs [127], where X stands for the filling material, like metals and C₆₀ buckyballs (C₆₀@CNTs, also termed as *peapods*) [128]. The process of filling up the CNTs can be done *in situ*, that is, while the CNTs are being synthesized through an electric arc [129] or catalytic chemical vapor deposition [130] techniques, although a step separate from synthesis, that is, *ex situ* filling, is more popular now.

CNTs were successfully filled with various molecules, including anticancer [131, 132] or antimalarial drugs [133], from aqueous solutions. In this process of filling, the precursor molecule to be filled is brought into contact with open-ended CNTs. MWCNTs have been filled with metallic precursors through such a process [134]. Labile biological molecules, including thermolabile drugs, can be filled into the internal hollow space of CNTs, which makes them conducive for drug delivery purposes. However, the loading is typically low (<20%) for most drugs, and unfortunately, falls to even lower levels as the diameter of CNTs decreases. Hence, the process is not suitable for SWCNTs or DWCNTs. Additionally, due to the harsh chemical conditions required to open up the closed ends of the CNTs, the surfaces of the CNTs can be damaged and become unsuitable for functionalization.

In another method, melted materials are used to fill up the CNTs, for example, metals [135], semiconductors [136], magnetic resonance imaging contrast agents [137], or materials for PTT in cancer therapy [138]. The loading is usually better than that in the solution method, although standardized methods to measure loading are yet to be established. However, only molecules that can withstand high temperatures and resist thermal degradation are suitable for such processes.

18.3.3 CNT-Based Biosensors

- **Electrochemical sensors:** Electrochemical biosensors are widely used now due to affordability, fast and reproducible output, portability, and user-friendliness. Most of these sensors rely on enzymatic degradation of analytes in the working electrode to release electrons, which are then transferred to generate a current or voltage signal. CNTs, due to their high conductivity and efficiency in transferring electrons, apart from nanoscale dimensions, a high surface area, and chemical stability, have emerged as a suitable material to be designed as electrochemical biosensing platforms [139–144]. Most CNT-based electrochemical biosensors perform measurements on the basis of amperometric (e.g., detection of formaldehyde released from prodrugs used in the treatment of U251 human glioblastoma tumor cells) [145], impedimetric (e.g., detection of SW48 cells from advanced human colon cancer by CNT-based nanosensor fabricated on a Ni/SiO₂/Si surface) [146, 147], or field-effect transistor (e.g., detection of osteopontin—a biomarker for prostate cancer) [148] platforms. A significant

collection of such CNT-based electrochemical biosensors was reported in recent years as sensitive detection platforms for various ions, metabolites, and proteins [149], such as cancer biomarkers (e.g., α -fetoprotein and carcinoembryonic antigen), DNA, and μ RNA [150] (Fig. 18.11). In a similar setup, the enzyme GOx was conjugated onto SWCNTs [151], similar to the AuNPs as described in the previous section of this chapter, to develop a sensing platform for glucose where the SWCNTs, like AuNPs, transferred the electrons and thus augmented the sensitivity of the sensor. Similar CNT-based electrochemical sensing platforms were also developed for cholesterol [152], nitric oxide [153], adrenaline [154], dopamine [155], and glycoprotein biomarkers [156] by functionalizing SWCNTs with specific RNA aptamers or cancer biomarkers, such as PSA [157] and hCG [158].




Figure 18.11 General designs of (A) an enzyme-based electrochemical biosensor, (B) an electrode wired to glucose oxidase by SWCNTs, (C) a label-free amperometric biosensor for PSA detection, and (D) the design of a microfluidic chip based on CNT electrodes. Reproduced from Ref. [114] under a Creative Commons agreement (CC BY).

A significant fraction of such CNT-based electrochemical biosensing platforms was developed for cancer biomarkers or oncotherapeutics. For example, functionalized MWCNTs were used to develop highly sensitive sensors for microsomal cytochrome P450 enzymes and drugs used to treat breast cancer [159]. Electrodepositions of CNT-based hybrid materials

(e.g., chitosan-MWCNTs) enabled the detection of metabolites (e.g., glucose and lactate), drugs (etoposide, mitoxantrone, etc.) or biomarker proteins (e.g., PSA) in biological samples (e.g., serum) [160]. Similarly, tricosane ($C_{23}H_{48}$) and D-(+)-galactose-functionalized SWCNTs were used in sensing of volatile organic compounds in patients screened for pulmonary cancer [161] and cancer biomarker galectin-3 [162], respectively. In another study, polydopamine-coated MWCNTs functionalized with folic acid were used for the detection of overexpressed folate receptors in various *in vitro* cancer cell lines (Fig. 18.12), for example, HeLa and HL60 [163]. MWCNTs fabricated with electrochemically grown AuNPs were used in early clinical detection of TP53 mutation in DNA samples [164] while MWCNTs coated with a gold-silver alloy were used to detect volatile markers in gastric cancer-derived MGC-803 cells [165].




Figure 18.12 The designs of (A) a folic acid-targeted sensing strategy for an electrochemical detection platform in cancer cells based on polydopamine-coated CNTs, (B) an electrochemical DNA-based biosensor for cancer detection, designed by deposited AuNPs on aligned MWCNTs. Reproduced from Ref. [114] under a Creative Commons agreement (CC BY).

- **Immunosensors:** The CNT-based immunosensors typically consist of CNTs functionalized with specific antibodies (bioreceptor component) in order to capture the analyte in a sandwich-type immunoassay where binding of the analyte to the receptor component causes increase of the electric current and, hence, the signal (Fig. 18.13). Such a setup with SWCNTs functionalized with arg-gly-asp-ser (RGDS) peptide has already been used to detect integrin receptors on cellular surfaces. Such sensors based on functionalized SWCNTs were able to detect trace amounts (<30 pg/mL) of interleukin-6 (IL-6) biomarker *in vitro* in head and neck squamous cell carcinoma cells. An impedimetric immunosensor based on MWCNT-ionic liquid electrode functionalized with AuNPs was used to detect low amounts (10–110 ng/mL) of biomarker human epidermal growth factor 2 (HER2) molecules in serum samples from breast cancer patients.




Figure 18.13 The designs of (A) an electrochemical CNT-based immunosensor with a sensing surface for target detection within a sandwich-type immunoassay, causing amplification of the signal and (B) an immunosensor developed by functionalizing SWCNTs with RGDS peptide to recognize integrin receptors on cell surfaces. Reproduced from Ref. [114] under a Creative Commons agreement (CC BY).

- Optical sensors:** SWCNTs have an inherent photoluminescence resistant to bleaching (650–1400 nm) that enable high-resolution imaging with adequate penetration in tissues and organs [172, 173]. Any change, due to either functionalization or chemical changes in the environment, causes alterations in wavelength and/or intensity of emission from SWCNTs (Fig. 18.14), making them suitable for highly sensitive optical detection platforms [174, 175]. Conjugates of SWCNTs and luciferase enzyme were used for NIR detection of adenosine triphosphate (ATP) in viable cells [176]. SWCNTs stabilized by functionalization with genetically modified M13 phage were used *in vivo* for imaging of deep tissues after intravenous administration [177]. Recently, SWCNTs were used in the detection of trace amounts (100 ng/mL) of cardiac troponin T (cTnT)—the biomarker of acute myocardial infarction—by NIR fluorescence [178]. In short, SWCNTs, coated with chitosan, were used to form a gel-like substance to be further functionalized with NTA and then utilized to immobilize cTnT antibodies in order to bind cTnT in human serum. In another study, conjugates of SWCNTs and indocyanine green dye were covalently linked to the RGD peptide to bind $\alpha_v\beta_3$ integrins associated with angiogenesis in tumors and served as a highly efficient contrast agent in photoacoustic imaging, with ~ 300 times better signal than previous reports on SWCNTs administered intravenously in tumor-bearing mice [112]. Optical sensors based on SWCNTs have also been used to detect the cyclin A molecule—often used as a prognostic marker in the early stages of various cancers—at nanomolar quantities [179].




Figure 18.14 The designs of (A) a genetically modified FRET kinase biosensor where the donor (GFP) and acceptor (RFP) proteins were brought into the vicinity of each other, enabling FRET following a molecular conformational change due to phosphorylation, (B) a nongenetic, peptide-based biosensor sensitive to environmental changes, for example, phosphorylation, (C) a CNT biosensor with a shift of the emission wavelength upon binding of the analyte to receptors conjugated with SWCNTs, (D) an optical biosensor for the detection of ssDNA via quenching of the fluorescence of a dye-labeled oligonucleotide upon noncovalent conjugation with SWCNTs, and (E) photoacoustic detection of integrins by an indocyanine green-labeled SWCNT-based biosensor conjugated with RGD peptides. Reproduced from Ref. [114] under a Creative Commons agreement (CC BY).

18.4 QDs

The unique optical properties of luminescent semiconducting quantum dots (QDs) are widely described. QDs (ZnS@CdSe) were used to detect trace amounts of CA-125—the biomarker of ovarian cancer [180]. An impedimetric biosensor for the detection (0.0016 U/mL) of CA125 was also developed with mercaptopropionic acid-coated gold electrodes containing QDs and silica-coated AuNPs. A combination of magnetic beads and QDs was used in order to design a sensing platform for DNA from *Leishmania* sp. with absolute specificity and very low detection limits (3125 ng/ μ L) [181], helpful in the diagnosis of Leishmaniasis. In another application, CdZnSeS/ZnS core-shell QDs functionalized with a polymer containing dihydrolipoic acid and human serum albumin labeled with cyanine-3 dye were used as FRET donor to investigate the interactions of clofazimine, a drug used in multidrug-resistant cases of TB and breast cancer, with proteins like human serum albumin [182]. AuNPs make an exciting FRET pair with QDs

due to their efficiency as acceptors and quench the QDs and have been used in the detection of DNA and oligonucleotides (Fig. 18.15). CdTe QDs coated with L-cysteine and modulated with Zn^{2+} cations were used to detect ATP in human serum samples [183] while CdSe@ZnS QDs conjugated with hemin were used to sense absorption of iron from heme [184]. Carboxylated QDs functionalized with antithrombin III were used to detect heparin by triggering aggregation with a very low detection limit (9.3×10^{-5} U/mL) and a linear response within 4.65×10^{-4} U/mL to 0.023 U/mL [185]. Similarly, the detection of transferrin, the 77 kDa glycoprotein that participates in the transport of iron in body, at very low amounts (5.69×10^{-9} M) in fetal bovine serum samples was possible with Mn-doped ZnS QDs capped with mercaptophenylboronic acid [186]. Graphene QDs (GQDs) present exciting and emerging opportunity for sensing. For example, the fluorescence of GQDs is quenched by para-benzoquinone (p-BQ) but recovers when vitamin C (L-ascorbic acid) reduces the p-BQ molecules that were used to detect vitamin C [187]. A similar methodology was used for the detection of alkaline phosphatase, which hydrolyzes L-ascorbic acid-2-phosphate molecule in order to release L-ascorbic acid and thus enhances the fluorescence of GQDs.




Figure 18.15 Illustration of the principle behind FRET between QDs and AuNPs while the fluorescence is re-established after the recognition. The target DNA can hybridize either with the receptor DNA or with the short sequence of the AuNP label or with both. Reproduced from Ref. [78] under a Creative Commons agreement (CC BY).

18.5 MNPs

Magnetic NPs (MNPs), for example, iron oxide NPs, are being increasingly used as a sensing platform, although their wider uses still continue to be in medical imaging (Chapter 16). Especially iron oxide NPs are used extensively for the detection and quantification of biomolecules (Fig. 18.16) [188]. Typically, the bioreceptor units consisting of conjugated MNPs are mixed with the analyte to facilitate binding and/or agglomeration, which thereafter can be precipitated by an external magnetic field. This strategy has already been used successfully in the detection of DNA in a complex medium with the use of silica-/gold-coated iron oxide NPs

[189, 190]. Additionally, MNPs provide possibilities of detection on the basis of their magnetic properties (e.g., magnetic resonance and resistance) [191, 192]; biological materials, including tissues and micro-organisms, do not exhibit any such properties. For example, sensing platforms based on magnetoresistant properties of MNPs were developed for the detection of *Escherichia coli* O157:H7 [193] and *Salmonella typhimurium* [194] up to a single colony forming unit/mL. MNPs also offer opportunities for multiplexing in microfluidic devices along with opportunities for designing complicated and miniaturized sensing platforms [195].




Figure 18.16 The mechanism of detection of analytes by MNP-based bioreceptor units. Upon recognition, the captured analytes are isolated by precipitation triggered by the application of an external magnetic field. With the removal of the magnetic field, the MNPs can be redispersed again for further capture. To facilitate high sensitivity, the analyte-bound MNPs may be immobilized on surfaces modified with a secondary antibody and further quantified using diagnostic magnetic resonance (DMR) transduction. Reproduced from Ref. [78] under a Creative Commons agreement (CC BY).

18.6 Summary and Outlook

Nanomaterials, including various NPs, offer exciting opportunities for developing biosensors that are fast, robust, and highly efficient. The capabilities of these sensors are predicted to keep increasing with further advancements in conjugation and better designed platforms. Microfluidic devices will integrate well with this emerging paradigm of nanobiosensors due to their advantages, including multiplexing, portability, and possibility for HTS. However, the ability of these

sensing platforms needs to improve in terms of real-life samples, for example, sputum, whole blood, urine, and cerebrospinal fluid.

Abbreviations

ATP:	adenosine triphosphate
AuNPs:	gold NPs
AuNRs:	gold nanorods
cTnT:	cardian troponin T
DMR:	diagnostic magnetic resonance
DWCNTs:	double-walled CNTs
FAD:	flavin adenine dinucleotide
FRET:	Förster/fluorescence resonance energy transfer
GOx:	glucose oxidase
GQDs:	graphene QDs
hCG:	human chorionic gonadotrophin
HER2:	human epidermal growth factor 2
HIV:	human immunodeficiency virus
HRP:	horseradish peroxidase
HTS:	high-throughput screening
IL-6:	interleukin-6
MNPs:	magnetic NPs
MWCNTs:	multiwalled carbon nanotubes
NADH:	nicotinamide adenine dinucleotide
NIR:	near-infrared
NPs:	nanoparticles
NTA:	nitrioltriacetic acid
p-BQ:	para-benzoquinone
POC:	point-of-care
PSA:	prostate-specific antigen
PTT:	photothermal therapy
QDs:	quantum dots
SERS:	surface- enhanced Raman scattering
SPR:	surface plasmon resonance
ssDNA:	single-stranded DNA
TEM:	transmission electron microscopy

Disclosures and Conflict of Interest

This chapter was originally published as: Bhattacharjee, S. (2020). *Principles of Nanomedicine*. Jenny Stanford Publishing, Singapore, “Nanosensors in Diagnostics,” pp. 419–464, and appears here, with edits and updates, by kind permission of the publisher.

References

1. Y. Wang, L. Yu, X. Kong, L. Sun, Application of nanodiagnostics in point-of-care tests for infectious diseases, *Int. J. Nanomed.* **12** (2017) 4789–4803.
2. V. Gubala, L.F. Harris, A.J. Ricco, M.X. Tan, D.E. Williams, Point of care diagnostics: status and future, *Anal. Chem.* **84**(2) (2012) 487–515.
3. J. Sun, Y. Xianyu, X. Jiang, Point-of-care biochemical assays using gold nanoparticle-implemented microfluidics, *Chem. Soc. Rev.* **43**(17) (2014) 6239–6253.
4. W. Putzbach, N.J. Ronkainen, Immobilization techniques in the fabrication of nanomaterial-based electrochemical biosensors: a review, *Sensors* **13**(4) (2013) 4811–4840.
5. M. Wilchek, E.A. Bayer, The avidin biotin complex in bioanalytical applications, *Anal. Biochem.* **171**(1) (1988) 1–32.
6. N. Haddour, S. Cosnier, C. Gondran, Electrogeneration of a poly(pyrrole)-NTA chelator film for a reversible oriented immobilization of histidine-tagged proteins, *J. Am. Chem. Soc.* **127**(16) (2005) 5752–5753.
7. M. Holzinger, L. Bouffier, R. Villalonga, S. Cosnier, Adamantane/ β -cyclodextrin affinity biosensors based on single-walled carbon nanotubes, *Biosens. Bioelectron.* **24**(5) (2009) 1128–1134.
8. V. Biju, Chemical modifications and bioconjugate reactions of nanomaterials for sensing, imaging, drug delivery and therapy, *Chem. Soc. Rev.* **43**(3) (2014) 744–764.
9. V. Amendola, R. Pilot, M. Frascioni, O.M. Marago, M.A. Iati, Surface plasmon resonance in gold nanoparticles: a review, *J. Phys. Condens. Mat.* **29**(20) (2017) 203002.
10. H.F. Ghaemi, T. Thio, D.E. Grupp, T.W. Ebbesen, H.J. Lezec, Surface plasmons enhance optical transmission through subwavelength holes, *Phys. Rev. B* **58**(11) (1998) 6779–6782.
11. A. Baron, T.B. Hoang, C. Fang, M.H. Mikkelsen, D.R. Smith, Ultrafast self-action of surface-plasmon polaritons at an air/metal interface, *Phys. Rev. B* **91**(19) (2015) 195412.
12. M.A. Garcia, Surface plasmons in metallic nanoparticles: fundamentals and applications, *J. Phys. D Appl. Phys.* **44**(28) (2011) 283001.
13. K.B. Mogensen, K. Kneipp, Size-dependent shifts of plasmon resonance in silver nanoparticle films using controlled dissolution: monitoring the onset of surface screening effects, *J. Phys. Chem. C* **118**(48) (2014) 28075–28083.
14. G.H. Chan, J. Zhao, E.M. Hicks, G.C. Schatz, R.P. Van Duyne, Plasmonic properties of copper nanoparticles fabricated by nanosphere lithography, *Nano Lett.* **7**(7) (2007) 1947–1952.
15. G. Raschke, S. Kowarik, T. Franzl, C. Sonnichsen, T.A. Klar, J. Feldmann, A. Nichtl, K. Kurzinger, Biomolecular recognition based on single gold nanoparticle light scattering, *Nano Lett.* **3**(7) (2003) 935–938.
16. T. Chung, S.-Y. Lee, E.Y. Song, H. Chun, B. Lee, Plasmonic nanostructures for nano-scale bio-sensing, *Sensors* **11**(11) (2011) 10907–10929.

17. T. Sannomiya, J. Vörös, Single plasmonic nanoparticles for biosensing, *Trends Biotechnol.* **29**(7) (2011) 343–351.
18. H. Chen, X. Kou, Z. Yang, W. Ni, J. Wang, Shape- and size-dependent refractive index sensitivity of gold nanoparticles, *Langmuir* **24**(10) (2008) 5233–5237.
19. W.H. Yang, G.C. Schatz, R.P. Van Duyne, Discrete dipole approximation for calculating extinction and Raman intensities for small particles with arbitrary shapes, *J. Chem. Phys.* **103**(3) (1995) 869–875.
20. K.M. Mayer, J.H. Hafner, Localized surface plasmon resonance sensors, *Chem. Rev.* **111**(6) (2011) 3828–3857.
21. A. Derkachova, K. Kolwas, I. Demchenko, Dielectric function for gold in plasmonics applications: size dependence of plasmon resonance frequencies and damping rates for nanospheres, *Plasmonics* **11** (2016) 941–951.
22. A.J. Haes, S. Zou, G.C. Schatz, R.P. Van Duyne, A nanoscale optical biosensor: the long range distance dependence of the localized surface plasmon resonance of noble metal nanoparticles, *J. Phys. Chem. B* **108**(1) (2004) 109–116.
23. Gold nanoparticles. Available at: https://commons.wikimedia.org/wiki/Category:Gold_nanoparticles (accessed on October 15, 2022).
24. P.K. Jain, K.S. Lee, I.H. El-Sayed, M.A. El-Sayed, Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine, *J. Phys. Chem. B* **110**(14) (2006) 7238–7248.
25. K.S. Lee, M.A. El-Sayed, Dependence of the enhanced optical scattering efficiency relative to that of absorption for gold metal nanorods on aspect ratio, size, end-cap shape, and medium refractive index, *J. Phys. Chem. B* **109**(43) (2005) 20331–20338.
26. X. Huang, M.A. El-Sayed, Gold nanoparticles: optical properties and implementations in cancer diagnosis and photothermal therapy, *J. Adv. Res.* **1**(1) (2010) 13–28.
27. S. Link, M.A. El-Sayed, Size and temperature dependence of the plasmon absorption of colloidal gold nanoparticles, *J. Phys. Chem. B* **103**(21) (1999) 4212–4217.
28. V. Juvé, M.F. Cardinal, A. Lombardi, A. Crut, P. Maioli, J. Pérez-Juste, L.M. Liz-Marzán, N. Del Fatti, F. Vallée, Size-dependent surface plasmon resonance broadening in nonspherical nanoparticles: single gold nanorods, *Nano Lett.* **13**(5) (2013) 2234–2240.
29. B.G. Ershov, E.V. Abkhalimov, R.D. Solovov, V.I. Roldughin, Gold nanoparticles in aqueous solutions: influence of size and pH on hydrogen dissociative adsorption and Au(III) ion reduction, *Phys. Chem. Chem. Phys.* **18**(19) (2016) 13459–13466.
30. S.K. Ghosh, T. Pal, Interparticle coupling effect on the surface plasmon resonance of gold nanoparticles: from theory to applications, *Chem. Rev.* **107**(11) (2007) 4797–4862.
31. I. Blakey, Z. Merican, K.J. Thurecht, A method for controlling the aggregation of gold nanoparticles: tuning of optical and spectroscopic properties, *Langmuir* **29**(26) (2013) 8266–8274.
32. N. Vasimalai, S.A. John, Aggregation and de-aggregation of gold nanoparticles induced by polyionic drugs: spectrofluorimetric determination of picogram amounts of protamine and heparin drugs in the presence of 1000-fold concentration of major interferences, *J. Mater. Chem. B* **1**(41) (2013) 5620–5627.

33. X.L. Fu, L.X. Chen, J.H. Li, Ultrasensitive colorimetric detection of heparin based on self-assembly of gold nanoparticles on graphene oxide, *Analyst* **137**(16) (2012) 3653–3658.
34. H. Wei, B. Li, J. Li, E. Wang, S. Dong, Simple and sensitive aptamer-based colorimetric sensing of protein using unmodified gold nanoparticle probes, *Chem. Commun.* **36** (2007) 3735–3737.
35. M.M. Miller, A.A. Lazarides, Sensitivity of metal nanoparticle surface plasmon resonance to the dielectric environment, *J. Phys. Chem. B* **109**(46) (2005) 21556–21565.
36. L. Guo, J.A. Jackman, H.-H. Yang, P. Chen, N.-J. Cho, D.-H. Kim, Strategies for enhancing the sensitivity of plasmonic nanosensors, *Nano Today* **10**(2) (2015) 213–239.
37. Z. Wu, Q. Zeng, H. Wang, Structural controls of AuNR@mSiO₂: tuning of the SPR, and manipulation of the silica shell thickness and structure, *J. Mater. Chem. C* **4**(13) (2016) 2614–2620.
38. J. Matsui, K. Akamatsu, N. Hara, D. Miyoshi, H. Nawafune, K. Tamaki, N. Sugimoto, SPR sensor chip for detection of small molecules using molecularly imprinted polymer with embedded gold nanoparticles, *Anal. Chem.* **77**(13) (2005) 4282–4285.
39. T. Kumeria, A. Santos, D. Losic, Nanoporous anodic alumina platforms: engineered surface chemistry and structure for optical sensing applications, *Sensors* **14**(7) (2014) 11878–11918.
40. H.M. Shen, G.W. Lu, T.Y. Zhang, J. Liu, Y. Gu, P. Perriat, M. Martini, O. Tillement, Q.H. Gong, Shape effect on a single-nanoparticle-based plasmonic nanosensor, *Nanotechnology* **24**(28) (2013).
41. H. Yockell-Lelièvre, F. Lussier, J.F. Masson, Influence of the particle shape and density of self-assembled gold nanoparticle sensors on LSPR and SERS, *J. Phys. Chem. C* **119**(51) (2015) 28577–28585.
42. B. Nikoobakht, M.A. El-Sayed, Preparation and growth mechanism of gold nanorods (NRs) using seed-mediated growth method, *Chem. Mater.* **15**(10) (2003) 1957–1962.
43. C.J. Murphy, T.K. San, A.M. Gole, C.J. Orendorff, J.X. Gao, L. Gou, S.E. Hunyadi, T. Li, Anisotropic metal nanoparticles: synthesis, assembly, and optical applications, *J. Phys. Chem. B* **109**(29) (2005) 13857–13870.
44. R. Gans, Über die form ultramikroskopischer silberteilchen, *Ann. Phys.* **352**(10) (1915) 270–284.
45. X.-B. Xu, Z. Yi, X.-B. Li, Y.-Y. Wang, X. Geng, J.-S. Luo, B.-C. Luo, Y.-G. Yi, Y.-J. Tang, Discrete dipole approximation simulation of the surface plasmon resonance of core/shell nanostructure and the study of resonance cavity effect, *J. Phys. Chem. C* **116**(45) (2012) 24046–24053.
46. X. Fan, W. Zheng, D.J. Singh, Light scattering and surface plasmons on small spherical particles, *Light Sci. Appl.* **3** (2014) e179.
47. V. Amendola, M. Meneghetti, Size evaluation of gold nanoparticles by UV-vis spectroscopy, *J. Phys. Chem. C* **113**(11) (2009) 4277–4285.
48. V. Amendola, Surface plasmon resonance of silver and gold nanoparticles in the proximity of graphene studied using the discrete dipole approximation method, *Phys. Chem. Chem. Phys.* **18**(3) (2016) 2230–2241.

49. S. Link, M.B. Mohamed, M.A. El-Sayed, Simulation of the optical absorption spectra of gold nanorods as a function of their aspect ratio and the effect of the medium dielectric constant, *J. Phys. Chem. B* **103**(16) (1999) 3073–3077.
50. A.M. Vilardell, N. Cinca, A. Jokinen, N. Garcia-Giralt, S. Dosta, I.G. Cano, J.M. Guilemany, Real-time protein and cell binding measurements on hydroxyapatite coatings, *J. Funct. Biomater.* **7**(3) (2016) 23.
51. E. Wijaya, C. Lenaerts, S. Maricot, J. Hastanin, S. Habraken, J.P. Vilcot, R. Boukherroub, S. Szunerits, Surface plasmon resonance-based biosensors: from the development of different SPR structures to novel surface functionalization strategies, *Curr. Opin. Solid State Mater. Sci.* **15**(5) (2011) 208–224.
52. X.W. Guo, Surface plasmon resonance based biosensor technique: a review, *J. Biophotonics* **5**(7) (2012) 483–501.
53. E. Hutter, J.H. Fendler, D. Roy, Surface plasmon resonance studies of gold and silver nanoparticles linked to gold and silver substrates by 2-aminoethanethiol and 1,6-hexanedithiol, *J. Phys. Chem. B* **105**(45) (2001) 11159–11168.
54. S.W. Zeng, X. Yu, W.C. Law, Y.T. Zhang, R. Hu, X.Q. Dinh, H.P. Ho, K.T. Yong, Size dependence of Au NP-enhanced surface plasmon resonance based on differential phase measurement, *Sens. Actuators B Chem.* **176** (2013) 1128–1133.
55. J.R. Lakowicz, Radiative decay engineering 5: metal-enhanced fluorescence and plasmon emission, *Anal. Biochem.* **337**(2) (2005) 171–194.
56. J.R. Lakowicz, K. Ray, M. Chowdhury, H. Szmazinski, Y. Fu, J. Zhang, K. Nowaczyk, Plasmon-controlled fluorescence: a new paradigm in fluorescence spectroscopy, *Analyst* **133**(10) (2008) 1308–1346.
57. K.E. Sapsford, L. Berti, I.L. Medintz, Materials for fluorescence resonance energy transfer analysis: beyond traditional donor-acceptor combinations, *Angew. Chem. Int. Ed.* **45**(28) (2006) 4562–4588.
58. L. Sutarlie, K.M.M. Aung, M.G.L. Lim, S. Lukman, E. Cheung, X. Su, Studying protein–DNA complexes using gold nanoparticles by exploiting particle aggregation, refractive index change, and fluorescence quenching and enhancement principles, *Plasmonics* **9**(4) (2014) 753–763.
59. J. Griffin, A.K. Singh, D. Senapati, P. Rhodes, K. Mitchell, B. Robinson, E. Yu, P.C. Ray, Size- and distance-dependent nanoparticle surface-energy transfer (NSET) method for selective sensing of hepatitis C virus RNA, *Chem. Eur. J.* **15**(2) (2009) 342–351.
60. S. Schlucker, SERS microscopy: nanoparticle probes and biomedical applications, *ChemPhysChem* **10**(9-10) (2009) 1344–1354.
61. X.M. Qian, S.M. Nie, Single-molecule and single-nanoparticle SERS: from fundamental mechanisms to biomedical applications, *Chem. Soc. Rev.* **37**(5) (2008) 912–920.
62. S.M. Nie, S.R. Emery, Probing single molecules and single nanoparticles by surface-enhanced Raman scattering, *Science* **275**(5303) (1997) 1102–1106.
63. M.K. Hossain, G.G. Huang, T. Kaneko, Y. Ozaki, Characteristics of surface-enhanced Raman scattering and surface-enhanced fluorescence using a single and a double layer gold nanostructure, *Phys. Chem. Chem. Phys.* **11**(34) (2009) 7484–7490.
64. D.K. Lim, K.S. Jeon, J.H. Hwang, H. Kim, S. Kwon, Y.D. Suh, J.M. Nam, Highly uniform and reproducible surface-enhanced Raman scattering from DNA-tailorable nanoparticles with 1-nm interior gap, *Nat. Nanotech.* **6**(7) (2011) 452–460.

65. K. Saha, S.S. Agasti, C. Kim, X.N. Li, V.M. Rotello, Gold nanoparticles in chemical and biological sensing, *Chem. Rev.* **112**(5) (2012) 2739–2779.
66. P. Ciaurriz, F. Fernández, E. Tellechea, J.F. Moran, A.C. Asensio, Comparison of four functionalization methods of gold nanoparticles for enhancing the enzyme-linked immunosorbent assay (ELISA), *Beilstein J. Nanotechnol.* **8** (2017) 244–253.
67. Y.-K. Wang, Y.-X. Yan, W.-H. Ji, H.-a. Wang, Q. Zou, J.-H. Sun, Novel chemiluminescence immunoassay for the determination of zearalenone in food samples using gold nanoparticles labeled with streptavidin–horseradish peroxidase, *J. Agric. Food Chem.* **61**(18) (2013) 4250–4256.
68. S. Chen, M. Svedendahl, R.P. Van Duyne, M. Kall, Plasmon-enhanced colorimetric ELISA with single molecule sensitivity, *Nano Lett.* **11**(4) (2011) 1826–1830.
69. F. Gao, R. Yuan, Y. Chai, S. Chen, S. Cao, M. Tang, Amperometric hydrogen peroxide biosensor based on the immobilization of HRP on nano-Au/Thi/poly (*p*-aminobenzene sulfonic acid)-modified glassy carbon electrode, *J. Biochem Biophys. Methods* **70**(3) (2007) 407–413.
70. A.W. Shi, F.L. Qu, M.H. Yang, G.L. Shen, R.Q. Yu, Amperometric H₂O₂ biosensor based on poly-thionine nanowire/HRP/nano-Au-modified glassy carbon electrode, *Sens. Actuators B Chem.* **129**(2) (2008) 779–783.
71. D. Jana, C. Matti, J. He, L. Sagle, Capping agent-free gold nanostars show greatly increased versatility and sensitivity for biosensing, *Anal. Chem.* **87**(7) (2015) 3964–3972.
72. F. Inci, O. Tokel, S. Wang, U.A. Gurkan, S. Tasoglu, D.R. Kuritzkes, U. Demirci, Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood, *ACS Nano* **7**(6) (2013) 4733–4745.
73. Y.-F. Chang, S.-F. Wang, J.C. Huang, L.-C. Su, L. Yao, Y.-C. Li, S.-C. Wu, Y.-M.A. Chen, J.-P. Hsieh, C. Chou, Detection of swine-origin influenza A (H1N1) viruses using a localized surface plasmon coupled fluorescence fiber-optic biosensor, *Biosens. Bioelectron.* **26**(3) (2010) 1068–1073.
74. M.S. Draz, B.A. Fang, L. Li, Z. Chen, Y. Wang, Y. Xu, J. Yang, K. Killeen, F.F. Chen, Hybrid nanocluster plasmonic resonator for immunological detection of hepatitis B virus, *ACS Nano* **6**(9) (2012) 7634–7643.
75. L. Tian, J.J. Morrissey, R. Kattumenu, N. Gandra, E.D. Kharasch, S. Singamaneni, Bioplasmonic paper as a platform for detection of kidney cancer biomarkers, *Anal. Chem.* **84**(22) (2012) 9928–9934.
76. S. Chen, M. Svedendahl, M. Kall, L. Gunnarsson, A. Dmitriev, Ultrahigh sensitivity made simple: nanoplasmonic label-free biosensing with an extremely low limit-of-detection for bacterial and cancer diagnostics, *Nanotechnology* **20**(43) (2009) 434015.
77. I.H. El-Sayed, X. Huang, M.A. El-Sayed, Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer, *Nano Lett.* **5**(5) (2005) 829–834.
78. M. Holzinger, A. Le Goff, S. Cosnier, Nanomaterials for biosensing applications: a review, *Front. Chem.* **2** (2014) 63.
79. S. Unser, I. Bruzas, J. He, L. Sagle, Localized surface plasmon resonance biosensing: current challenges and approaches, *Sensors* **15**(7) (2015) 15684–15716.

80. K.Z. Liang, J.S. Qi, W.J. Mu, Z.G. Chen, Biomolecules/gold nanowires-doped sol-gel film for label-free electrochemical immunoassay of testosterone, *J. Biochem. Biophys. Methods* **70**(6) (2008) 1156–1162.
81. X.L. He, R. Yuan, Y.Q. Chai, Y.T. Shi, A sensitive amperometric immunosensor for carcinoembryonic antigen detection with porous nanogold film and nano-Au/chitosan composite as immobilization matrix, *J. Biochem. Biophys. Methods* **70**(6) (2008) 823–829.
82. R. Chai, R. Yuan, Y.Q. Chai, C.F. Ou, S.R. Cao, X.L. Li, Amperometric immunosensors based on layer-by-layer assembly of gold nanoparticles and methylene blue on thiourea modified glassy carbon electrode for determination of human chorionic gonadotrophin, *Talanta* **74**(5) (2008) 1330–1336.
83. L. Deng, Y.Z. Wang, L. Shang, D. Wen, F.A. Wang, S.J. Dong, A sensitive NADH and glucose biosensor tuned by visible light based on thionine bridged carbon nanotubes and gold nanoparticles multilayer, *Biosens. Bioelectron.* **24**(4) (2008) 951–957.
84. R.J. Cui, H.P. Huang, Z.Z. Yin, D. Gao, J.J. Zhu, Horseradish peroxidase-functionalized gold nanoparticle label for amplified immunoanalysis based on gold nanoparticles/carbon nanotubes hybrids modified biosensor, *Biosens. Bioelectron.* **23**(11) (2008) 1666–1673.
85. Q. Xu, C. Mao, N.-N. Liu, J.-J. Zhu, J. Sheng, Direct electrochemistry of horseradish peroxidase based on biocompatible carboxymethyl chitosan-gold nanoparticle nanocomposite, *Biosens. Bioelectron.* **22**(5) (2006) 768–773.
86. F. Li, Y. Mo, D. Xiao, H. Yuan, Y. Guo, Electroanalytical properties of cytochrome c with direct electron transfer on graphene/gold nanoparticles chitosan modified glass carbon electrode, *Anal. Methods* **4**(11) (2012) 3779–3784.
87. Y. Liu, L. Shi, J. Gong, Y.-T. Fang, N. Bao, H.-Y. Gu, J. Zeng, Glassy carbon electrode modified with gold nanoparticles and hemoglobin in a chitosan matrix for improved pH-switchable sensing of hydrogen peroxide, *Microchim. Acta* **182**(15) (2015) 2461–2468.
88. M.L. Mena, P. Yanez-Sedeno, J.M. Pingarron, A comparison of different strategies for the construction of amperometric enzyme biosensors using gold nanoparticle-modified electrodes, *Anal. Biochem.* **336**(1) (2005) 20–27.
89. B. Willner, E. Katz, I. Willner, Electrical contacting of redox proteins by nanotechnological means, *Curr. Opin. Biotechnol.* **17**(6) (2006) 589–596.
90. J.M. Pingarron, P. Yanez-Sedeno, A. Gonzalez-Cortes, Gold nanoparticle-based electrochemical biosensors, *Electrochim. Acta* **53**(19) (2008) 5848–5866.
91. Y. Xiao, F. Patolsky, E. Katz, J.F. Hainfeld, I. Willner, “Plugging into enzymes”: nanowiring of redox enzymes by a gold nanoparticle, *Science* **299**(5614) (2003) 1877–1881.
92. M. Wasowicz, S. Viswanathan, A. Dvornyk, K. Grzelak, B. Kludkiewicz, H. Radecka, Comparison of electrochemical immunosensors based on gold nano materials and immunoblot techniques for detection of histidine-tagged proteins in culture medium, *Biosens. Bioelectron.* **24**(2) (2008) 284–289.
93. C. Yu, J. Irudayaraj, Quantitative evaluation of sensitivity and selectivity of multiplex nanoSPR biosensor assays, *Biophys. J.* **93**(10) (2007) 3684–3692.

94. G.J. Nusz, S.M. Marinakos, A.C. Curry, A. Dahlin, F. Hook, A. Wax, A. Chilkoti, Label-free plasmonic detection of biomolecular binding by a single gold nanorod, *Anal. Chem.* **80**(4) (2008) 984–989.
95. R.H. Baughman, A.A. Zakhidov, W.A. de Heer, Carbon nanotubes--the route toward applications, *Science* **297**(5582) (2002) 787–792.
96. J. Kong, N.R. Franklin, C. Zhou, M.G. Chapline, S. Peng, K. Cho, H. Dai, Nanotube molecular wires as chemical sensors, *Science* **287**(5453) (2000) 622–625.
97. D.-H. Xu, Z.-G. Wang, J.F. Douglas, Influence of carbon nanotube aspect ratio on normal stress differences in isotactic polypropylene nanocomposite melts, *Macromolecules* **41**(3) (2008) 815–825.
98. H. He, L.A. Pham-Huy, P. Dramou, D.L. Xiao, P.L. Zuo, C. Pham-Huy, Carbon nanotubes: applications in pharmacy and medicine, *Biomed Res. Int.* **2013** (2013) 578290.
99. K. Balasubramanian, M. Burghard, Biosensors based on carbon nanotubes, *Anal. Bioanal. Chem.* **385**(3) (2006) 452–468.
100. S.B. Yang, B.-S. Kong, D.-W. Kim, H.-T. Jung, Comparison of the stability of surface-modified SWNTs and DWNTs network films, *J. Phys. Chem. C* **114**(10) (2010) 4394–4398.
101. M. Pumera, Electrochemical properties of double wall carbon nanotube electrodes, *Nanoscale Res. Lett.* **2** (2007) 87–93.
102. S. Frank, P. Poncharal, Z.L. Wang, W.A.d. Heer, Carbon nanotube quantum resistors, *Science* **280**(5370) (1998) 1744–1746.
103. J.W. Mintmire, C.T. White, Electronic and structural properties of carbon nanotubes, *Carbon* **33**(7) (1995) 893–902.
104. N. Hamada, S.-i. Sawada, A. Oshiyama, New one-dimensional conductors: graphitic microtubules, *Phys. Rev. Lett.* **68**(10) (1992) 1579–1581.
105. Y. Saito, T. Yoshikawa, Bamboo-shaped carbon tube filled partially with nickel, *J. Cryst. Growth* **134**(1-2) (1993) 154–156.
106. M.-F. Yu, O. Lourie, M.J. Dyer, K. Moloni, T.F. Kelly, R.S. Ruoff, Strength and breaking mechanism of multiwalled carbon nanotubes under tensile load, *Science* **287**(5453) (2000) 637–640.
107. J.P. Lu, Novel magnetic properties of carbon nanotubes, *Phys. Rev. Lett.* **74**(7) (1995) 1123–1126.
108. F.F. Zhou, D. Xing, Z.M. Ou, B.Y. Wu, D.E. Resasco, W.R. Chen, Cancer photothermal therapy in the near-infrared region by using single-walled carbon nanotubes, *J. Biomed. Opt.* **14**(2) (2009) 021009.
109. N.W.S. Kam, M. O'Connell, J.A. Wisdom, H.J. Dai, Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction, *Proc. Natl. Acad. Sci.* **102** (2005) 11600–11605.
110. P. Chakravarty, R. Marches, N.S. Zimmerman, A.D.E. Swafford, P. Bajaj, I.H. Musselman, P. Pantano, R.K. Draper, E.S. Vitetta, Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes, *Proc. Natl. Acad. Sci.* **105** (2008) 8697–8702.

111. M.H. Xu, L.H.V. Wang, Photoacoustic imaging in biomedicine, *Rev. Sci. Instrum.* **77** (2006) 041101.
112. A.d.l. Zerda, Z. Liu, S. Bodapati, R. Teed, S. Vaithilingam, B.T. Khuri-Yakub, X. Chen, H. Dai, S.S. Gambhir, Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice, *Nano Lett.* **10** (2010) 2168–2172.
113. D. Tasis, N. Tagmatarchis, V. Georgakilas, M. Prato, Soluble carbon nanotubes, *Chem. Eur. J.* **9** (2003) 4000–4008.
114. C.-M. Tilmaciu, M.C. Morris, Carbon nanotube biosensors, *Front. Chem.* **3** (2015) 59.
115. M. Holzinger, J. Baur, R. Haddad, X. Wang, S. Cosnier, Multiple functionalization of single-walled carbon nanotubes by dip coating, *Chem. Commun.* **47**(8) (2011) 2450–2452.
116. X. Tu, M. Zheng, A DNA-based approach to the carbon nanotube sorting problem, *Nano Res.* **1**(3) (2008) 185–194.
117. K. Kostarelos, L. Lacerda, G. Pastorin, W. Wu, S. Wieckowski, J. Luangsivilay, S. Godefroy, D. Pantarotto, J.-P. Briand, S. Muller, M. Prato, A. Bianco, Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type, *Nat. Nanotech.* **2** (2007) 108–113.
118. Y. Liu, D.C. Wu, W.D. Zhang, X. Jiang, C.B. He, S. Chung Tai, H. Goh Suat, W. Leong Kam, Polyethylenimine-grafted multiwalled carbon nanotubes for secure noncovalent immobilization and efficient delivery of DNA, *Angew. Chem. Int. Ed.* **44** (2005) 4782–4785.
119. V. Sanz, E. Borowiak, P. Lukanov, A.M. Galibert, E. Flahaut, H.M. Coley, S.R.P. Silva, J. McFadden, Optimising DNA binding to carbon nanotubes by non-covalent methods, *Carbon* **49** (2011) 1775–1781.
120. I.D. Rosca, F. Watari, M. Uo, T. Akasaka, Oxidation of multiwalled carbon nanotubes by nitric acid, *Carbon* **43** (2005) 3124–3131.
121. Z. Liu, S. Tabakman, K. Welscher, H. Dai, Carbon nanotubes in biology and medicine: *in vitro* and *in vivo* detection, imaging and drug delivery, *Nano Res.* **2** (2009) 85–120.
122. Z.-y. Zhang, X.-c. Xu, Nondestructive covalent functionalization of carbon nanotubes by selective oxidation of the original defects with K_2FeO_4 , *Appl. Surf. Sci.* **346** (2015) 520–527.
123. Z. Liu, X. Sun, N. Nakayama-Ratchford, H. Dai, Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery, *ACS Nano* **1**(1) (2007) 50–56.
124. Z. Liu, J.T. Robinson, X. Sun, H. Dai, PEGylated nanographene oxide for delivery of water-insoluble cancer drugs, *J. Am. Chem. Soc.* **130** (2008) 10876–10877.
125. D. Pantarotto, R. Singh, D. McCarthy, M. Erhardt, J.P. Briand, M. Prato, K. Kostarelos, A. Bianco, Functionalized carbon nanotubes for plasmid DNA gene delivery, *Angew. Chem. Int. Ed.* **43** (2004) 5242–5246.
126. K.T. Al-Jamal, A. Nunes, L. Methven, H. Ali-Boucetta, S.P. Li, F.M. Toma, M.A. Herrero, W.T. Al-Jamal, H.M.M. ten Eikelder, J. Foster, S. Mather, M. Prato, A. Bianco, K. Kostarelos, Degree of chemical functionalization of carbon nanotubes determines tissue distribution and excretion profile, *Angew. Chem. Int. Ed.* **51** (2012) 6389–6393.
127. M. Monthieux, E. Flahaut, J.P. Cleuziou, Hybrid carbon nanotubes: strategy, progress, and perspectives, *J. Mater. Res.* **21** (2006) 2774–2793.

128. B.W. Smith, M. Monthieux, D.E. Luzzi, Encapsulated C₆₀ in carbon nanotubes, *Nature* **396** (1998) 323–324.
129. P.M. Ajayan, S. Iijima, Capillarity-induced filling of carbon nanotubes, *Nature* **361** (1993) 333–334.
130. S. Hampel, A. Leonhardt, D. Selbmann, K. Biedermann, D. Elefant, C. Müller, T. Gemming, B. Büchner, Growth and characterization of filled carbon nanotubes with ferromagnetic properties, *Carbon* **44** (2006) 2316–2322.
131. S. Hampel, D. Kunze, D. Haase, K. Kramer, M. Rauschenbach, M. Ritschel, A. Leonhardt, J. Thomas, S. Oswald, V. Hoffmann, B. Buechner, Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth, *Nanomedicine UK* **3** (2008) 175–182.
132. C. Tripisciano, K. Kraemer, A. Taylor, E. Borowiak-Palen, Single-wall carbon nanotubes based anticancer drug delivery system, *Chem. Phys. Lett.* **478** (2009) 200–205.
133. V. Sanz, C. Tilmacıu, B. Soula, E. Flahaut, H.M. Coley, S.R.P. Silva, J. McFadden, Chloroquine-enhanced gene delivery mediated by carbon nanotubes, *Carbon* **49** (2011) 5348–5358.
134. S.C. Tsang, Y.K. Chen, P.J.F. Harris, M.L.H. Green, A simple chemical method of opening and filling carbon nanotubes, *Nature* **372** (1994) 159–162.
135. R.D. Gately, M.I.H. Panhuis, Filling of carbon nanotubes and nanofibres, *Beilstein J. Nanotechnol.* **6** (2015) 508–516.
136. G. Chimowa, M. Sendova, E. Flahaut, D. Churochkin, S. Bhattacharyya, Tuning the electrical transport properties of double-walled carbon nanotubes by semiconductor and semi-metal filling, *J. Appl. Phys.* **110**(12) (2011) 123708.
137. J.J. Law, A. Guven, L.J. Wilson, Relaxivity enhancement of aquated Tris (β -diketonate) gadolinium(III) chelates by confinement within ultrashort single-walled carbon nanotubes, *Contrast Media Mol. Imaging* **9** (2014) 409–412.
138. C.M. Tilmacıu, B. Soula, A.M. Galibert, P. Lukanov, L. Datas, J. Gonzalez, L.F. Barquin, J.R. Fernandez, F. Gonzalez-Jimenez, J. Jorge, E. Flahaut, Synthesis of superparamagnetic iron(III) oxide nanowires in double-walled carbon nanotubes, *Chem. Commun.* **43** (2009) 6664–6666.
139. I.E. Tothill, Biosensors for cancer markers diagnosis, *Semin. Cell Dev. Biol.* **20** (2009) 55–62.
140. S. Kumar, W. Ahlawat, R. Kumar, N. Dilbaghi, Graphene, carbon nanotubes, zinc oxide and gold as elite nanomaterials for fabrication of biosensors for healthcare, *Biosens. Bioelectron.* **70** (2015) 498–503.
141. Z.Y. Wang, Z.H. Dai, Carbon nanomaterial-based electrochemical biosensors: an overview, *Nanoscale* **7** (2015) 6420–6431.
142. Q. Zhao, Z. Gan, Q. Zhuang, Electrochemical sensors based on carbon nanotubes, *Electroanalysis* **14** (2002) 1609–1613.
143. Y.H. Lin, F. Lu, Y. Tu, Z.F. Ren, Glucose biosensors based on carbon nanotube nanoelectrode ensembles, *Nano Lett.* **4** (2004) 191–195.
144. C.B. Jacobs, M.J. Peairs, B.J. Venton, Review: carbon nanotube based electrochemical sensors for biomolecules, *Anal. Chim. Acta* **662** (2010) 105–127.

145. L. Bareket, A. Rephaeli, G. Berkovitch, A. Nudelman, J. Rishpon, Carbon nanotubes based electrochemical biosensor for detection of formaldehyde released from a cancer cell line treated with formaldehyde-releasing anticancer prodrugs, *Bioelectrochemistry* **77** (2010) 94–99.
146. M. Abdolahad, M. Janmaleki, M. Taghinejad, H. Taghnejad, F. Salehi, S. Mohajerzadeh, Single-cell resolution diagnosis of cancer cells by carbon nanotube electrical spectroscopy, *Nanoscale* **5** (2013) 3421–3427.
147. M. Abdolahad, M. Taghinejad, H. Taghinejad, M. Janmaleki, S. Mohajerzadeh, A vertically aligned carbon nanotube-based impedance sensing biosensor for rapid and high sensitive detection of cancer cells, *Lab Chip* **12** (2012) 1183–1190.
148. M.B. Lerner, J. D'Souza, T. Pazina, J. Dailey, B.R. Goldsmith, M.K. Robinson, A.T.C. Johnson, Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers, *ACS Nano* **6** (2012) 5143–5149.
149. N.P. Sardesai, J.C. Barron, J.F. Rusling, Carbon nanotube microwell array for sensitive electrochemiluminescent detection of cancer biomarker proteins, *Anal. Chem.* **83** (2011) 6698–6703.
150. R.S. Dey, R.K. Bera, C.R. Raj, Nanomaterial-based functional scaffolds for amperometric sensing of bioanalytes, *Anal. Bioanal. Chem.* **405** (2013) 3431–3448.
151. F. Patolsky, Y. Weizmann, I. Willner, Long-range electrical contacting of redox enzymes by SWCNT connectors, *Angew. Chem. Int. Ed.* **43** (2004) 2113–2117.
152. G. Li, J.M. Liao, G.Q. Hu, N.Z. Ma, P.J. Wu, Study of carbon nanotube modified biosensor for monitoring total cholesterol in blood, *Biosens. Bioelectron.* **20** (2005) 2140–2144.
153. R.M. Santos, M.S. Rodrigues, J. Laranjinha, R.M. Barbosa, Biomimetic sensor based on hemin/carbon nanotubes/chitosan modified microelectrode for nitric oxide measurement in the brain, *Biosens. Bioelectron.* **44** (2013) 152–159.
154. B.B. Prasad, A. Prasad, M.P. Tiwari, R. Madhuri, Multiwalled carbon nanotubes bearing 'terminal monomeric unit' for the fabrication of epinephrine imprinted polymer-based electrochemical sensor, *Biosens. Bioelectron.* **45** (2013) 114–122.
155. G.J. Kress, H.J. Shu, A. Yu, A. Taylor, A. Benz, S. Harmon, S. Mennerick, Fast phasic release properties of dopamine studied with a channel biosensor, *J. Neurosci.* **34** (2014) 11792–11802.
156. G.A. Zelada-Guillen, A. Tweed-Kent, M. Niemann, H.U. Goring, J. Riu, F.X. Rius, Ultrasensitive and real-time detection of proteins in blood using a potentiometric carbon-nanotube aptasensor, *Biosens. Bioelectron.* **41** (2013) 366–371.
157. J. Okuno, K. Maehashi, K. Matsumoto, K. Kerman, Y. Takamura, E. Tamiya, Single-walled carbon nanotube-arrayed microelectrode chip for electrochemical analysis, *Electrochem. Commun.* **9** (2007) 13–18.
158. Y. Tsujita, K. Maehashi, K. Matsumoto, M. Chikae, Y. Takamura, E. Tamiya, Microfluidic and label-free multi-immunosensors based on carbon nanotube microelectrodes, *Jpn. J. Appl. Phys.* **48** (2009) 06FJ02.
159. C. Baj-Rossi, G. De Micheli, S. Carrara, Electrochemical detection of anti-breast-cancer agents in human serum by cytochrome P450-coated carbon nanotubes, *Sensors* **12** (2012) 6520–6537.

160. C. Baj-Rossi, G. De Micheli, S. Carrara, Electrochemical biochip for applications to wireless and batteryless monitoring of free-moving mice, *IEEE Eng. Med. Biol. Soc.* (2014) 2020–2023.
161. F.L. Liu, P. Xiao, H.L. Fang, H.F. Dai, L. Qiao, Y.H. Zhang, Single-walled carbon nanotube-based biosensors for the detection of volatile organic compounds of lung cancer, *Phys. E Low Dimens. Syst. Nanostruct.* **44** (2011) 367–372.
162. Y.K. Park, B. Bold, W.K. Lee, M.H. Jeon, K.H. An, S.Y. Jeong, Y.K. Shim, D-(+)-galactose-conjugated single-walled carbon nanotubes as new chemical probes for electrochemical biosensors for the cancer marker galectin-3, *Int. J. Mol. Sci.* **12** (2011) 2946–2957.
163. T.T. Zheng, R. Zhang, L.F. Zou, J.J. Zhu, A label-free cytosensor for the enhanced electrochemical detection of cancer cells using polydopamine-coated carbon nanotubes, *Analyst* **137** (2012) 1316–1318.
164. H. Fayazfar, A. Afshar, M. Dolati, A. Dolati, DNA impedance biosensor for detection of cancer, TP53 gene mutation, based on gold nanoparticles/aligned carbon nanotubes modified electrode, *Anal. Chim. Acta* **836** (2014) 34–44.
165. Y.X. Zhang, G. Gao, H.J. Liu, H.L. Fu, J. Fan, K. Wang, Y.S. Chen, B.J. Li, C.L. Zhang, X. Zhi, L. He, D.X. Cui, Identification of volatile biomarkers of gastric cancer cells and ultrasensitive electrochemical detection based on sensing interface of Au-Ag alloy coated MWCNTs, *Theranostics* **4** (2014) 154–162.
166. J.V. Veetil, K.M. Ye, Development of immunosensors using carbon nanotubes, *Biotechnol. Prog.* **23** (2007) 517–531.
167. M.R. Kierny, T.D. Cunningham, B.K. Kay, Detection of biomarkers using recombinant antibodies coupled to nanostructured platforms, *Nano Rev.* **3** (2012) 17240.
168. J.F. Rusling, G. Sotzing, F. Papadimitrakopoulou, Designing nanomaterial-enhanced electrochemical immunosensors for cancer biomarker proteins, *Bioelectrochemistry* **76** (2009) 189–194.
169. E. Polo, T.T. Nitka, E. Neubert, L. Erpenbeck, L. Vuković, S. Kruss, Control of integrin affinity by confining RGD peptides on fluorescent carbon nanotubes, *ACS Appl. Mater. Interfaces* **10** (2018) 17693–17703.
170. R. Malhotra, V. Patel, J.P. Vaque, J.S. Gutkind, J.F. Rusling, Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification, *Anal. Chem.* **82** (2010) 3118–3123.
171. E. Arkan, R. Saber, Z. Karimi, M. Shamsipur, A novel antibody-antigen based impedimetric immunosensor for low level detection of HER2 in serum samples of breast cancer patients via modification of a gold nanoparticles decorated multiwall carbon nanotube-ionic liquid electrode, *Anal. Chim. Acta* **874** (2015) 66–74.
172. A.M. Smith, M.C. Mancini, S.M. Nie, Bioimaging: second window for *in vivo* imaging, *Nat. Nanotech.* **4** (2009) 710–711.
173. P.W. Barone, S. Baik, D.A. Heller, M.S. Strano, Near-infrared optical sensors based on single-walled carbon nanotubes, *Nat. Mater.* **4** (2005) 86–92.
174. J. Chen, M.A. Hamon, H. Hu, Y. Chen, A.M. Rao, P.C. Eklund, R.C. Haddon, Solution properties of single-walled carbon nanotubes, *Science* **282** (1998) 95–98.
175. V.C. Moore, M.S. Strano, E.H. Haroz, R.H. Hauge, R.E. Smalley, J. Schmidt, Y. Talmon, Individually suspended single-walled carbon nanotubes in various surfactants, *Nano Lett.* **3** (2003) 1379–1382.

176. J.H. Kim, J.H. Ahn, P.W. Barone, H. Jin, J.Q. Zhang, D.A. Heller, M.S. Strano, A luciferase/single-walled carbon nanotube conjugate for near-infrared fluorescent detection of cellular ATP, *Angew. Chem. Int. Ed.* **49** (2010) 1456–1459.
177. H.J. Yi, D. Ghosh, M.H. Ham, J.F. Qi, P.W. Barone, M.S. Strano, A.M. Belcher, M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors, *Nano Lett.* **12** (2012) 1176–1183.
178. J.Q. Zhang, S. Kruss, A.J. Hilmer, S. Shimizu, Z. Schmois, F. De La Cruz, P.W. Barone, N.F. Reuel, D.A. Heller, M.S. Strano, A rapid, direct, quantitative, and label-free detector of cardiac biomarker troponin T using near-infrared fluorescent single-walled carbon nanotube sensors, *Adv. Healthc. Mater.* **3** (2014) 412–423.
179. X.H. Wang, C.Y. Wang, K.G. Qu, Y.J. Song, J.S. Ren, D. Miyoshi, N. Sugimoto, X.G. Qu, Ultrasensitive and selective detection of a prognostic indicator in early-stage cancer using graphene oxide and carbon nanotubes, *Adv. Funct. Mater.* **20** (2010) 3967–3971.
180. M. Johari-Ahar, M.R. Rashidi, J. Barar, M. Aghaie, D. Mohammadnejad, A. Ramazani, P. Karami, G. Coukos, Y. Omid, An ultra-sensitive impedimetric immunosensor for detection of the serum oncomarker CA-125 in ovarian cancer patients, *Nanoscale* **7** (2015) 3768–3779.
181. M. Andreadou, E. Liandris, M. Gazouli, A. Mataragka, I. Tachtsidis, N. Goutas, D. Vlachodimitropoulos, J. Ikonopoulou, Detection of *Leishmania*-specific DNA and surface antigens using a combination of functionalized magnetic beads and cadmium selenite quantum dots, *J. Microbiol. Methods* **123** (2016) 62–67.
182. H.Y. Yang, Y. Fu, M.S. Jang, Y. Li, J.H. Lee, H. Chae, D.S. Lee, Multifunctional polymer ligand interface CdZnSeS/ZnS quantum dot/Cy3-labeled protein pairs as sensitive FRET sensors, *ACS Appl. Mater. Interfaces* **8** (2016) 35021–35032.
183. F.P. Shi, Y. Li, Z.H. Lin, D.X. Ma, X.G. Su, A novel fluorescent probe for adenosine 5'-triphosphate detection based on Zn²⁺-modulated L-cysteine capped CdTe quantum dots, *Sens. Actuators B Chem.* **220** (2015) 433–440.
184. L.N. Geng, X.L. Duan, Y. Wang, Y.S. Zhao, G.F. Gao, D.L. Liu, Y.Z. Chang, P. Yu, Quantum dots-hemin: preparation and application in the absorption of heme iron, *Nanomedicine NBM* **12** (2016) 1747–1755.
185. S.L. Dong, X.J. Liu, Q.Q. Zhang, W.F. Zhao, C.H. Zong, A.Y. Liang, H.W. Gai, Sensing active heparin by counting aggregated quantum dots at single-particle level, *ACS Sensors* **2** (2017) 80–86.
186. L. Chang, X. He, L. Chen, Y. Zhang, Mercaptophenylboronic acid-capped Mn-doped ZnS quantum dots for highly selective and sensitive fluorescence detection of glycoproteins, *Sens. Actuators B Chem.* **243** (2017) 72–77.
187. H. Huang, B.D. Wang, M. Chen, M.X. Liu, Y. Leng, X.Y. Liu, Y.X. Li, Z.N. Liu, Fluorescence turn-on sensing of ascorbic acid and alkaline phosphatase activity based on graphene quantum dots, *Sens. Actuators B Chem.* **235** (2016) 356–361.
188. B. Haun Jered, T.J. Yoon, H. Lee, R. Weissleder, Magnetic nanoparticle biosensors, *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* **2** (2010) 291–304.
189. X.X. He, H.L. Huo, K.M. Wang, W.H. Tan, P. Gong, J. Ge, Plasmid DNA isolation using amino-silica coated magnetic nanoparticles (ASMNPs), *Talanta* **73** (2007) 764–769.

190. J.H. Min, M.K. Woo, H.Y. Yoon, J.W. Jang, J.H. Wu, C.S. Lim, Y.K. Kim, Isolation of DNA using magnetic nanoparticles coated with dimercaptosuccinic acid, *Anal. Biochem.* **447** (2014) 114–118.
191. S.X. Wang, G. Li, Advances in giant magnetoresistance biosensors with magnetic nanoparticle tags: review and outlook, *IEEE Trans. Magn.* **44** (2008) 1687–1702.
192. T. Konry, S.S. Bale, A. Bhushan, K. Shen, E. Seker, B. Polyak, M. Yarmush, Particles and microfluidics merged: perspectives of highly sensitive diagnostic detection, *Microchim. Acta* **176** (2012) 251–269.
193. M. Mujika, S. Arana, E. Castano, M. Tijero, R. Vilares, J.M. Ruano-Lopez, A. Cruz, L. Sainz, J. Berganza, Magnetoresistive immunosensor for the detection of *Escherichia coli* O157:H7 including a microfluidic network, *Biosens. Bioelectron.* **24** (2009) 1253–1258.
194. S. Liebana, A. Lermo, S. Campoy, J. Barbe, S. Alegret, M.I. Pividori, Magneto immunoseparation of pathogenic bacteria and electrochemical magneto genosensing of the double-tagged amplicon, *Anal. Chem.* **81** (2009) 5812–5820.
195. C. Sun, J.S.H. Lee, M.Q. Zhang, Magnetic nanoparticles in MR imaging and drug delivery, *Adv. Drug Deliv. Rev.* **60** (2008) 1252–1265.

Chapter 19

Measuring Microbiome Effectiveness: A Role for Ingestible Sensors

David Smith and Sohan Jheeta, PhD

NoR CEL, Leeds, UK

dave.smithathome@gmail.com, sohan@sohanjheeta.com

Keywords: atopic disease, autoimmune diseases, b-type cytochromes, *Clostridium difficile*, colonoscopy, computer tomography colonography, digital medicine, dopamine, dysbiosis, faecal microbiota transplantation (FMT), germ-free mice, gut microbial community, holobiont, horizontal gene transfer (HGT), ingestible sensors, microbial diversity, microbial-animal interaction, microbiome, mobile genetic elements (MGEs), noncommunicable disease, polymerase chain reaction (PCR), probiotics, semiochemical, sentinel cells, serotonin, surrogate marker, Tsimane, type 1 diabetes, yogurt-derived microbes

19.1 Introduction: The Microbiome in Health and Disease

There is an increasing incidence of noncommunicable diseases such as obesity [1], mental health problems [2], and atopic disease [3] which are all diseases that are associated with immune system defects stemming from a disturbance of the microbiome [4–6]. Similar to autoimmune diseases that either affect the intestine itself [7] or sites remote from the intestine [8], type 1 diabetes [9] and cancer have also been associated with immune system defects stemming from disturbance of the microbiome [10]. It seems that an effective microbiome is critical during early life, especially in the calibration of the developing immune system [11]. The purpose of this chapter is to briefly consider the possibility of detecting suitable microbial metabolites with the goal of assessing the effectiveness of the human intestinal microbiome.

As previously described [12], the term microbiota is used to indicate actual microbial species, whereas microbiome refers to the sum total of microbes

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

expressing genes that are mainly beneficial to the host; this is because humans evolved within the world of microbes and viruses. Therefore, the microbiome is considered to be more important than individual microbes because useful genes or their phenotypic products can be shared between widely different species [13]. The word dysbiosis [14] is used to describe the partial failure of the microbiome.

19.2 Horizontal Gene Transfer

The overall interaction and control between the constituent organisms in microbiomes relies on the process of horizontal gene transfer (HGT). To wholly understand how living organisms, especially microbial ones, obtain physiological properties and metabolic characteristics which they did not previously have, means having to invoke and understand mechanisms of mobile genetic elements (MGEs), i.e., the exchange or transfer of only a few genes. This process is generally referred to as HGT, as opposed to the process of vertical gene transfer which occurs during sexual reproduction when the entire genome is transferred to the progeny. There are three such mechanisms, namely bacterial transformation [15], bacterial conjugation [16], and transduction [17, 18]. All three HGTs are operational in the human gut, probably simultaneously, transferring genes across species, genera, and even phyla. In short, bacterial transformation occurs when MGEs from lysed microbial cell contents are taken up by other living cells; bacterial conjugation takes place between two living microbial cells, i.e., between the host and competent recipient cells via sex tubes, namely pili. In this respect, the process is an active one and is imitated by the host cell, meanwhile the recipient cells remain passive during conjugation. Finally, transduction happens when phage-infected microbial cells, upon their demise (lysis), release phages that are packed with host cell MGEs and infect other microbial cells, thereby transferring the traits of the host cells to the recipient cells. In all three cases, the recipient cell is transformed due to integration and subsequent recombination of the incoming MGEs with its chromosome. In the context of the human microbiome, HGT, the shedding of genes and the theft of metabolic products is becoming an important factor in health and disease. Koumandou and co-workers mapped the distribution of nine bioenergetic modes using 16S rRNA (more later) sequences from 272 species of fully sequenced prokaryotes, which represented the full diversity of prokaryotic ancestries. They reported that there was an irregular distribution of metabolic pathways among different lineages due to gene transfer events and an ancient origin and diversification of b-type cytochromes, which means that bioenergetic pathways were dynamic amid the human gut microbial community [19–21].

19.3 Microbiome Diversity: Probiotics and Sentinel Cells

Previous research has focused mostly on individual microbial species and their variation in different disease states. However, it is now clear that individual

species vary widely in response to many different conditions, even in the absence of overt disease. Microbiome function, in which valuable genes are expressed by several different species, is likely to be more important than actual microbial entities [22]. In this way, the diversity of the microbiome insures it against the suppression of individual microbes, for example, if there is a significant change in the diet [23]. An individual with low diversity of gut microbiota is vulnerable to diseases if events (or lifestyle choices) mean that there is insufficient residual microbial activity to supply the necessary semiochemicals. Effectively, these noncommunicable diseases are considered to be deficiency diseases, and therefore, in principle, they can be treated by the addition of probiotics to the diet [24].

Commercial probiotics can reduce the risk of antibiotic-induced diarrhoea and necrotising enterocolitis in premature babies [25], especially alongside prebiotic treatment [26]. An effective treatment for *Clostridium difficile* overgrowth is provided by the ultimate probiotic, faecal microbiota transplantation (FMT), in which the whole microbiome is replaced in one go [27, 28]. If the microbiome is not too severely affected, for example, in the attempted treatment of ulcerative colitis, FMT requires several treatments or is not effective at all [29].

It has been found that the presence of yogurt-derived microbes in the diet of mice was enough to evoke an immune response without changing the apparent nature of their microbiome [30]. This dietary microbe immune-stimulating effect was absent in germ-free mice, suggesting that the intestinal microbiome acts as an intermediary between external microbes and the immune system [30]. It seems that the interrogation of external microbes by the *in situ* microbiome can pass information back to indirectly activate the host immune system, rather than direct action between external microbes and the host immune system itself. In an earlier paper, we termed such interrogating species “microbial sentinel cells” [12] and suggested that they are the same as the “old friends” of Rook and co-workers [6]. The implication is that added probiotics could have the same effect as lightly processed foods in which environmental microbes are retained. It is important to note that external microbes damaged by heating could still elicit a positive response if sufficient antigens are present to activate these sentinel cells, reminiscent of Griffith’s transforming factor experiments [15]. In the same manner, enough plasmid particles can survive excessive heat during cooking to be recognized and included within the genome of appropriate microbiota.

The HGT’s processes explain the mechanisms by which exogenous genes become incorporated. For example, consider transformation during the lysis of bacteriophages, MGEs which contain resistance gene elements are released and, then, taken up by surrounding microbes, and therefore confer antibiotic resistance [31]. Such widespread HGT [32, 33] is expected to result in the spread of genes between different genera and even phyla of microbes within the diverse microbiome [1]. Bacteria and archaea [35] contribute the greater amount during gene transfer, whereas microeukaryotes, including amoebae and even some fungal species [36], also play a part, but much less is known about the role of these groups of organisms.

Because microbial communities are composed of hundreds of different species containing members of all three microbial domains of life, namely archaea,

bacteria, and eukarya, we consider it unlikely that we would be able to gain much understanding from the resultant multitude of individual interactions. Accordingly, the microbiome is best considered as a whole; it is this collective interaction between various organisms that is important, including the host, in this respect humans [12]. Interestingly, Margulis first raised the concept of an intact microbiome acting in concert with the host as a single evolutionary unit as far back as 1991 [37]. The term used was “holobiont” [38]. Although it is still under active discussion, the holobiont concept could be applied to both our body and our mutualistic microbiome. This term could also be applied to other animals and could be common to all vertebrate species to a greater or lesser extent.

19.4 Detecting Diversity and Overall Composition of the Microbiome

In general, the challenge with the microbiome is that we are only able to grow less than 5% of the microbial species in a laboratory, the rest are simply too fastidious. However, studies involving techniques such as polymerase chain reaction (PCR) do at least tentatively identify the ribosomal RNA (rRNA) of the known microorganisms; rRNAs, in particular 16S rRNA or 18S rRNA, that are found in all cellular life forms, are ideal for such investigations as they are highly conserved. 16S rRNA is the preserver of all prokaryotes [39] and 18S rRNA is part and parcel of all eukaryotes [40], whereas “S” in 16S/18S is a Svedberg unit of sedimentation, noting that the ribosomes of the former are smaller and lighter (70S and 2700 kDa) in weight than the latter (80S and 4200 kDa). This technique is a process whereby ribosomal genes (strictly speaking ribosomal transcripts), i.e., the DNA segments which code for 16S/18S rRNAs, are highly conserved, and therefore unique to each separate species. In order to make rRNA identification possible, the following three aspects of the conserved regions are necessary: Initially, the conserved genes to be studied need to be universally distributed in all cellular species. Secondly, to identify highly conserved homologous segments of such genes, the conserved regions must, first, be isolated and, then, placed side by side for comparing and contrasting differences in sequences within them. These differences give new genotypic attributes to the newly emerging species. Finally, the rate of point mutations within the conserved region needs to be at acceptable levels and must be due to natural causes, normally taking millions of years rather than a rapid change as experienced by the genome in general. After confirmation of these three requirements, amplification of the conserved segments can be brought about by using polymerase enzymes so as to make it possible to detect microbes within microbiomes.

19.5 The Mutualistic Microbiome: Dysbiosis

Our previous publication [12] followed up the observations of Burkitt during his travels in Africa after the Second World War. Burkitt noted that rural Africans ate

large amounts of fibre and passed stools three to five times more massive than that of typical inhabitants of developed countries. He also noted the absence of what he termed “characteristic modern Western diseases” in his subjects [41]. We developed this observation in light of the current understanding of the microbiome and suggested that various substances released by the microbiota behave as semiochemicals [42], representing the mutualistic interaction of human organs with various microbial metabolites (not exclusively the intestine [7, 8]). In particular, we considered that substances such as dopamine and serotonin act to improve gut motility, i.e., the coordination of nerves and muscles allow the smooth transit of the gut contents [43–45]. In this way, the microbiome receives adequate nutrition to perform its role which is to calibrate the immune system [12]. This mechanism would explain the high faecal volumes noted by Burkitt [41]. By contrast, the failure of these semiochemical systems leads to a fall in faecal volume and a corresponding increase in the likelihood of disease (Fig. 19.1). Note the use of an ingestible sensor to estimate the overall effectiveness of the microbiome (to be described later).




Figure 19.1 Illustrates the consequences of altered microbiome function and variable semiochemical production.

This concept of a single mutualistic microbiome, which has a semiochemical mode of action, albeit with variable interacting microbial species, offers valuable new insight into the development of microbiome-function deficiency diseases. It is important to realize that, to the best of our knowledge, there is no competing

theory that brings the three modern plagues of obesity, altered immune function, and poor mental health under one single rationale. Equally, there are no quantitative data to support or refute our argument [12]. It is the purpose of this chapter to suggest a way to obtain such data.

19.6 Ingestible Sensing Capsules in the Context of Microbiome Studies

Ingestible sensors consist of a miniaturized detector and transmitter packed into a capsule that can be swallowed and tracked through the intestine. They have the capacity to revolutionize the study of the gut with a vast array of potential targets both for direct practical application and for research purposes. Some are commercially available, such as pH, temperature, and pressure sensors, recently reviewed in [46]. A remote sensing procedure called colon capsule endoscopy has been developed to look at the inside of the gut wall using visible light and two video cameras transmitting pictures affording nearly 360 degree coverage to an external monitor. Its effectiveness has been reviewed relative to both conventional colonoscopy and computer tomography colonography [47]. For a slightly different purpose, a single-use remote sensing system has recently been developed to monitor compliance among people suffering from severe mental illness while taking a “digital pill” containing the atypical antipsychotic aripiprazole [48], an example of the expanding field of digital medicine [49]. Any sensing system capable of being miniaturized can be used. One recent example used bacteria that were themselves engineered to produce a luminescent signal on exposure to a specific agent. This signal was converted to a radio transmission for external monitoring. Their proof-of-concept studies used heme protein to detect bleeding in swine intestine. The authors reported that their technology could be applied to the detection of many different substances [50].

The sensing of gas generation by microbial fermentation in the gut has been taken to the point of clinical trials [51]. The gases, hydrogen, carbon dioxide, and oxygen, are the first examples of real-time *in situ* measurement of the chemical components of the gut. They represent the beginning of the process of unravelling the complex chemistry of the microbiome, potentially allowing researchers to follow its function in health and in disease [52, 53].

Many of the semiochemicals released by the microbial contents of the gut are chemically identical to the messenger substances known to be present in the brain, leading to the conclusion that their significance could be due to the timing of their appearance relative to bodily events such as eating or sleeping, for example. The possession of an ingestible sensor calibrated to detect these semiochemicals would be an invaluable aid for understanding the progress of the noncommunicable conditions described by Burkitt as the Western disease [41]. In particular, the successful application of the scientific method requires the possession of reproducible, ideally quantitative, data. The simple measurement of faecal volume does not provide adequate data and has not been used since his studies. An ingestible sensor could be used as a quantitative surrogate marker for

a deeper understanding of these conditions. Until the scientific method is established, it is likely that the microbiome field will remain beset by unsubstantiated claims related to health benefits.

It should be possible to obtain much valuable data from animal experiments, as it is unlikely that microbial–animal interaction is specific to humans. As an example, we hypothesized that the use of antibiotics to enhance the growth of farm animals such as swine [54] is probably due to the degradation of their microbiome [12]. It is interesting to note that both poultry and fish farming also benefit from antibiotic growth promotion [55, 56] suggesting, if it is the same mechanism as growth promotion in mammals, that it stretches back at least to their very earliest forebears.

19.7 Target Metabolites: A Surrogate Marker for Microbiome Effectiveness

The target metabolite chosen depends on technical considerations including chemical selectivity, ease of measurement, and stability to the corrosive conditions of the gut [46]. Another key consideration must be the relevance of the target to the functions of the microbiome itself. Although many compounds are produced within the gut lumen, it is hard to know which behave as specific signalling molecules between the gut and human organs, namely semiochemicals. The short chain fatty acid salts, including acetate, propionate, and butyrate seem to be the end products of fibre metabolism working in an anoxic environment. As such, they represent a marker for an effective working microbiome, however, although they have profound effects on the immune system and the cells of the gut wall, in our opinion they are unlikely to be specific semiochemicals [57, 58].

Serotonin has multiple functions throughout the body [59] and is produced within the gut lumen in the presence of the appropriate microbes [45]. However, there is also production and storage of serotonin within the adjacent enterochromaffin cells under the influence of short chain fatty acids, and therefore it could prove not to be a clear-cut target for an ingestible analytical system [60]. By contrast, dopamine production is known but is less well characterized within the gut lumen [43]. It is known to stimulate the immune system [44] and, although dopamine does not pass the blood-brain barrier, it may yet contribute to strengthening the microbiome-gut-brain axis [5]. An accidental observation made while studying obsessive-compulsive disorder led to the conclusion that dopamine generation in the brain affected insulin sensitivity in peripheral tissues [61]. At the moment, there is no way of estimating the flux of dopamine formation in the gut, and therefore any contribution to diabetes and related conditions. An ingestible sensor calibrated to the determination of dopamine would allow researchers to study this potentially significant connection.

Interestingly, it has been shown that the mechanism of production of messenger chemicals (i.e., neurotransmitters) has been transferred from bacteria to animal cells via horizontal gene transfer. Such neurotransmitters include the catecholamine dopamine and the indole serotonin, along with histamine,

acetylcholine, and even nitric oxide. The suggestion is that these transfers of genes took place separately, both before and after the divergence of animals from fungi [62].

19.8 What Is the Story So Far...?

We have developed the concept of the microbiome as a single “mutualistic microbial community” with variable members, but which interacts with the host by one semiochemical allomone-kairomone mechanism of action [12]. It is believed that there is a limited number of critical metabolites that define an efficient microbiome and that measurement of these would provide an opportunity to quantify their effectiveness. This concept is under active consideration.

The causes of these modern noncommunicable diseases are bound to be complex and difficult to unravel. However, there are still some isolated people leading a mode of life widely removed from the Western lifestyle, similar to those originally studied by Denis Burkitt [41], that exhibit low levels of obesity and heart disease. Such people include the Tsimane, a mixed hunter-gatherer and farming community living in the Bolivian Amazon, under medical care since 2012. Although some of their medical data was reported in 2017, there was no mention of their microbiome status [63]. One problem is that there is no current way to measure the actual effectiveness of the microbiome as a whole, although microbial species may be tabulated.

In conclusion, identification of these critical metabolites and development of an *in situ* method of measurement could offer an unparalleled opportunity to study microbiome effectiveness, as well as the progression and eventual cure of microbiome-function deficiency diseases.

Disclosures and Conflict of Interest

This chapter was originally published as: Smith, D., Jheeta, S. (2020) Measuring microbiome effectiveness: A role for ingestible sensors. *Gastrointest. Disord.* **2**, 3–11, <https://doi.org/10.3390/gidisord2010002>, under the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates, by kind permission of the copyright holders. The authors declare no conflict of interest.

References

1. Reilly, J.J., El-Hamdouchi, A., Diouf, A., Monyeki, A., Somda, S.A. Determining the world-wide prevalence of obesity. *Lancet* **2018**, *39*, 1773–1774.
2. Steel, Z., Mamane, C., Iranpour, C., Chey, T., Jackson, J.W., Patel, V., Silove, D. The global prevalence of common mental disorders: A systematic review and meta-analysis 1980–2013. *Int. J. Epidemiol.* **2014**, *43*, 476–493.

3. Hill, D.A., Spergel, J.M. The atopic march: Critical evidence and clinical relevance. *Ann. Allergy Asthma Immunol.* **2018**, *120*, 131–137.
4. Clemente, J.C., Ursell, L.K., Parfrey, L.W., Knight, R. The impact of the gut microbiota on human health: An integrative view. *Cell* **2012**, *148*, 1258–1270.
5. Torres-Fuentes, C., Schellenkens, H., Dinan, T.G., Cryan, J.F. The microbiota-gut-brain-axis in obesity. *Lancet Gastroenterol. Hepatol.* **2017**, *2*, 747–756.
6. Lowry, C.A., Smith, D.G., Sielber, P.H., Schmidt, D., Stamper, C.E., Hassell, J.E., Yamashita, P.S., Fox, J.H., Reber, S.O., Brenner, L.A., et al. The microbiota, immunoregulation, and mental health: Implications for human health. *Curr. Environ. Health Rep.* **2016**, *3*, 270–286.
7. De Palma, G., Collins, S.M., Bercik, P. The microbiota-gut-brain axis in functional gastrointestinal disorders. *Gut Microbes* **2014**, *5*, 419–429.
8. Opazo, M.C., Ortega-Rocha, E.M., Coronado-Arazola, I., Bonifaz, L.C., Boudin, H., Neunlist, M., Bueno, S.M., Kalgeris, A.M., Riedel, C.A. Intestinal microbiota influences non-intestinal related autoimmune diseases. *Front. Microbiol.* **2018**, *9*, 432.
9. Vaarala, O., Atkinson, M.A., Neu, J. The “perfect storm” for type 1 diabetes—the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. *Diabetes* **2008**, *57*, 2555–2562.
10. Greer, J.B., O’Keefe, S.J. Microbial induction of immunity, inflammation, and cancer. *Front. Physiol.* **2011**, *1*, 168.
11. Zhao, Q., Elson, C.A. Adaptive immune education by gut microbiota antigens. *Immunology* **2018**, *154*, 28–37.
12. Jheeta, S., Smith, D. Seeing the wood for the trees: A new way to view the human intestinal microbiome and its connection with non-communicable disease. *Med. Hypoth.* **2019**, *125*, 70–74.
13. Lozupone, C.A., Hamady, M., Cantarel, B.L., Coutinho, P.M., Henrissat, B., Gordon, J.I., Knight, R. The convergence of carbohydrate active gene repertoires in human gut microbes. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 15076–15081.
14. Hooks, K.B., O’Malley, M.A. Dysbiosis and its discontents. *mBio* **2017**, *8*, e01492–17.
15. Griffith, F. The significance of pneumococcal types. *J. Hyg.* **1928**, *XXVII*, 113–159.
16. Lederberg, J., Tatum, E.L. Gene recombination in *E. coli*. *Nature* **1946**, *158*, 558.
17. Stanier, R.Y., Doudoroff, M., Adelberg, E.A. *General Microbiology*, The MacMillan Press Ltd.: Basingstoke, UK, 1973, Chapter 14.
18. Kellenberger, E. The genetic control of the shape of a virus. *Sci. Am.* **1966**, *215*, 32–39.
19. Koumandou, V.L., Kossida, S. Evolution of the F0F1 ATP synthase complex in light of the patchy distribution of different bioenergetic pathways across prokaryotes. *PLOS Comput. Biol.* **2014**, *10*, e1003821.
20. Agioutantis, P., Koumandou, V.L. Bioenergetic diversity of the human gut microbiome. *Meta Gene* **2018**, *16*, 10–14.
21. Koumandou, V.L., Kossida, S. Evolution of b-type cytochromes in prokaryotes. *Peer J. PrePrints* **2015**, *3*, e1564v1.

22. Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., Knight, R. Diversity, stability and resilience of the human gut microbiota. *Nature* **2012**, *489*, 220–230.
23. Sonnenburg, E.D., Smits, S.A., Tikhonov, M., Higginbottom, S.A., Wingreen, N.S., Sonnenburg, J.L. Diet-induced extinctions in the gut microbiota compound over generations. *Nature* **2016**, *529*, 212–215.
24. Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* **2014**, *11*, 506–514.
25. AlFaleh, K., Anabrees, J. Probiotics for the prevention of necrotising enterocolitis in preterm infants. *Cochrane Database Syst. Rev.* **2014**, *4*, CD005496.
26. Underwood, M.A., Salzman, N.H., Bennett, S.H., Barman, M., Mills, D.A., Marcobal, A., Tancredi, D.J., Bevins, C.L., Sherman, M.P. A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: Impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids. *J. Paediatr. Gastroenterol. Nutr.* **2009**, *48*, 216–225.
27. Petrof, E.O., Khoruts, A. From stool transplants to next-generation microbiota therapeutics. *Gastroenterology* **2014**, *146*, 1573–1582.
28. Hamilton, M.J., Weingarden, A.R., Unno, T., Koruts, A., Sadowsky, M.J. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. *Gut Microbes* **2013**, *4*, 125–135.
29. Borody, T.J., Campbell, J. Fecal microbiota transplantation: Current status and future directions. *Expert Rev. Gastroenterol. Hepatol.* **2011**, *5*, 653–655.
30. Poutahidis, T., Kleinewietfeld, M., Smillie, C., Levkovich, T., Perrota, A., Bhela, S., Varian, B.J., Ibrahim, Y.M., Lakritz, J.R., Kearney, S.M., et al. Microbial reprogramming inhibits Western diet-associated obesity. *PLoS ONE* **2013**, *8*, e68596.
31. Lekunberri, I., Subirats, J., Borrego, C.M., Balcazar, J.L. Exploring the contribution of bacteriophage to antibiotic resistance. *Envir. Pollut.* **2017**, *220*, 981–984.
32. Jheeta, S. The routes of emergence of life from LUCA during the RNA and viral world: A conspectus. *Life* **2015**, *5*, 1445–1453.
33. Jheeta, S. The Landscape of the Emergence of Life. *Life* **2017**, *7*, 27.
34. Keen, E.C., Bliskovsky, V.V., Malagon, F., Baker, J.D., Prince, J.S., Klaus, J.S., Adhya, S.L., Groisman, E.A. Novel “superspreader” bacteriophages promote horizontal gene transfer by transformation. *mBio* **2017**, *8*, e02115-16.
35. Pietilä, M.K., Demina, T.A., Atanasova, N.S., Oksanen, H.M., Bamford, D.H. Archaeal viruses and bacteriophages: Comparisons and contrasts. *Trends Microbiol.* **2014**, *22*, 334–344.
36. Laforest-Lapointe, I., Arrieta, M.-C. Microbial eukaryotes: A missing link in gut microbiome studies. *mSystems* **2018**, *3*, e00201–17.
37. Margulis, L. Symbiogenesis and symbiogenesis. In *Symbiosis as a Source of Evolutionary Innovation: Speciation and Morphogenesis*, Margulis, L., Fester, R., Eds., MIT Press: Cambridge, MA, USA, 1991, pp. 49–92.

38. Guerrero, R., Margulis, L., Berlanga, M. Symbiogenesis: The holobiont as a unit of evolution. *Int. Microbiol.* **2013**, *16*, 133–143.
39. Woese, C.R., Fox, G.E. Phylogenetic structure of the prokaryotic domain: The primary kingdoms. *Proc. Natl. Acad. Sci. USA* **1974**, *74*, 5088–5090.
40. Yarus, M. *Life from an RNA World*, Harvard University Press: Cambridge, MA, USA, 2010, Chapter 3.
41. Burkitt, D.P. Some diseases characteristic of modern western civilization. *BMJ* **1973**, *1*, 274–278.
42. Semiochemicals of forest and shade tree insects in North America and management applications. Available at: <https://iucat.iu.edu/iupui/5439806> (accessed on October 15, 2022).
43. Asano, Y., Hiramoto, T., Nishino, R., Aiba, Y., Kimura, T., Yoshihara, K., Koga, Y., Sudo, N. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. *AJP Gastrointest. Liver Physiol.* **2012**, *303*, G1288–G1295.
44. Xue, R., Zhang, H., Pan, J., Du, Z., Zhou, W., Zhang, Z., Tian, Z., Zhou, R., Bai, L. Peripheral dopamine controlled by gut microbes inhibits invariant natural killer T cell-mediated hepatitis. *Front. Immunol.* **2018**, *9*, 2398.
45. Hata, T., Asano, Y., Yoshihara, K., Kimura-Todani, T., Miyata, N., Zhang, X.-T., Takakura, S., Aiba, Y., Koga, Y., Sudo, N. Regulation of gut luminal serotonin by commensal microbiota in mice. *PLoS ONE* **2017**, *12*, e0180745.
46. Kalantar-Zadeh, K., Ha, N., Ou, J.Z., Berean, K.J. Ingestible sensors. *ACS Sens.* **2017**, *2*, 468–483.
47. Yung, D.E., Rondonotti, E., Koulaouzidis, A. Review: Capsule colonoscopy—a concise clinical overview of current status. *Ann. Transl. Med.* **2016**, *4*, 398.
48. Peters-Strickland, T., Pestreich, L., Hatch, A., Rohatagi, S., Baker, R.A., Docherty, J.P., Markovtsova, L., Raja, P., Weiden, P.J., Walling, D.P. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. *Neuropsychiatr. Dis. Treat.* **2016**, *12*, 2587–2594.
49. Batra, S., Baker, R.A., Wang, T., Forma, F., DiBiasi, F., Peters-Strickland, T. Digital health technology for use in patients with serious mental illness: A systematic review of the literature. *Med. Devices (Auckl)* **2017**, *10*, 237–251.
50. Mimee, M., Nadeau, P., Hayward, A., Carim, S., Flanagan, S., Jerger, L., Collins, J., McDonnell, S., Swartwout, R., Citorik, R.J., et al. An ingestible bacterial-electronic system to monitor gastrointestinal health. *Science* **2018**, *360*, 915–918.
51. Kalantar-Zadeh, K., Berean, K.J., Ha, N., Chrimes, A.F., Xu, K., Grando, D., Ou, J.Z., Pillai, N., Campbell, J.L., Brkljača, R., et al. A human pilot trial of ingestible electronic capsules capable of sensing different gases in the gut. *Nat. Electron.* **2018**, *1*, 79–87.
52. Kalantar-Zadeh, K., Yao, C.K., Berean, K.J., Ha, N., Ou, J.Z., Ward, S.A., Pillai, N., Hill, J., Cottrell, J.J., Dunshea, F.R., et al. Intestinal gas capsules: A proof-of-concept demonstration. *Gastroenterology* **2016**, *150*, 37–39.
53. Ou, J.Z., Cottrell, J.J., Ha, N., Pillai, N., Yao, C.K., Berean, K.J., Ward, S.A., Grando, D., Muir, J., Harrison, C.J., et al. Potential of *in vivo* real-time gastric gas profiling: A pilot evaluation

- of heat-stress and modulating dietary cinnamon effect in an animal model. *Sci. Rep.* **2016**, *6*, 33387.
54. Cromwell, G.L. Why and how antibiotics are used in swine production. *Anim. Biotechn.* **2002**, *13*, 7–27.
 55. Davison, T.F., Freeman, B.M. Physiological aspects of growth promotion in poultry. *Vet. Res. Commun.* **1983**, *7*, 59–68.
 56. Reda, R.M., Ibrahim, R.E., Ahmed, E.-N.G., El-Bouhy, Z.M. Effect of oxytetracycline and florfenicol as growth promoters on the health status of cultured *Oreochromis niloticus*. *Egyptian J. Aquatic Res.* **2013**, *39*, 241–248.
 57. Smith, P.M., Howitt, M.R., Panikov, N., Michaud, M., Gallini, C.A., Bohlooly-Y, M., Glickman, J.N., Garrett, W.S. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* **2013**, *341*, 569–573.
 58. De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchamp, A., Bäckhed, F., Mithieux, G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. *Cell* **2014**, *156*, 84–96.
 59. Berger, M., Gray, J.A., Roth, R.L. The expanded biology of serotonin. *Annu. Rev. Med.* **2009**, *60*, 355–366.
 60. Reigstad, C.S., Salmonson, C.E., Rainey III, J.F., Szurszewski, J.H., Linden, D.R., Sonnenburg, J.L., Farrugia, G., Kashyap, P.C. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. *FASEB J.* **2015**, *29*, 1395–1403.
 61. Ter Horst, K.W., Lammers, N.M., Trinko, R., Opland, D.M., Figeo, M., Ackermans, M.T., Booij, J., van den Munckhof, P., Schuurman, P.R., Fliers, E., et al. Striatal dopamine regulates systemic glucose metabolism in humans and mice. *Sci. Transl. Med.* **2018**, *10*, eaar3752.
 62. Iyer, L.M., Aravind, L., Coon, S.L., Klein, D.C., Koonin, E.V. Evolution of cell-cell signaling in animals: Did late horizontal gene transfer from bacteria have a role? *Trends Genet.* **2004**, *20*, 292–299.
 63. Kaplan, H., Thompson, R.C., Trumble, B.C., Wann, L.S., Allam, A.H., Beheim, B., Frohlich, B., Sutherland, M.L., Sutherland, J.D., Stieglitz, J., et al. Coronary atherosclerosis in indigenous South American Tsimane: A cross sectional cohort study. *Lancet* **2017**, *389*, 1730–1739.

Chapter 20

In-Ear Blood Oxygen Saturation: A Tool for Wearable, Unobtrusive Monitoring of Core Blood Oxygen Saturation

Harry J. Davies, MSc,^{a,b} Ian Williams, PhD,^{a,b} Nicholas S. Peters, PhD,^{b,c} and Danilo P. Mandic, PhD^{a,b}

^aDepartment of Electrical and Electronic Engineering, Imperial College London, London, UK

^bImperial Centre for Cardiac Engineering, Imperial College London, London, UK

^cNational Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK

harry.davies14@imperial.ac.uk

Keywords: alternating current (AC), arterial blood oxygen saturation, blood oxygen delay, blood oxygen saturation (SpO₂), Coronavirus Disease 2019 (COVID-19), direct current (DC), electroencephalography (EEG), Faraday cage, hypoxia, hypoxic SpO₂ levels, photoplethysmogram, photoplethysmography (PPG), pulse oximetry, respiration rate, sleep apnea

20.1 Introduction

One of the major roles of blood is to supply oxygen to tissues throughout the body. This is achieved through the protein haemoglobin within red blood cells, which has a high affinity to oxygen. Thus, as blood passes through capillaries in the lungs, the haemoglobin in red blood cells binds to oxygen which is subsequently pumped through arteries via the heart and transported to various tissues. The maintenance of a high arterial blood oxygen saturation is therefore extremely important, as otherwise tissues cease to be adequately supplied. The term blood oxygen saturation specifically refers to the proportion of haemoglobin in the blood that is carrying oxygen [1], and is given by

$$\text{Oxygen Saturation} = \frac{\text{HbO}_2}{\text{HbO}_2 + \text{Hb}}, \quad (20.1)$$

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

where Hb refers to haemoglobin not bound with oxygen and HbO₂ refers to haemoglobin bound to oxygen.

Arterial blood oxygen saturation is typically measured using pulse oximetry which gives a percentage estimate (SpO₂). It has been established that those with a healthy respiratory system typically exhibit SpO₂ values of 96–98% at sea level [2]. According to the World Health Organization, hypoxia is defined as a blood oxygen saturation level of less than 94%, while a blood oxygen level of less than 90% may indicate the need for clinical action [3]. Hypoxic SpO₂ readings are a sign of hypoxia without breathlessness in Coronavirus Disease 2019 (COVID-19) patients [4, 5] where the major respiratory failure peaks 10 days after initial infection [6]. Indeed, in the case of COVID-19 it is strongly recommended that patients receive supplemental oxygen if their SpO₂ reading falls below 90% [7]. Hypoxic SpO₂ levels may also occur in other examples of respiratory failure [8] and during breathing obstruction which is common in sleep apnea [9].

In practice, the SpO₂ levels are calculated indirectly, through photoplethysmography (PPG), the non-invasive measurement of light absorption (usually red and infrared) through the blood. In short, when more blood is present, less light is reflected, so given a pulsatile increase in blood volume with each heart beat, PPG effectively measures the pulse. Depending on the level of blood oxygen saturation, the PPG measurements also experience a change in the ratio of light absorbance between the red and infrared light. Namely, the extinction coefficient of oxygenated haemoglobin with red light (≈ 660 nm) is lower than it is for deoxygenated haemoglobin, and the reverse is true for infrared light (≈ 880 – 940 nm) [10]. Thus, a simultaneous measurement of the absorbance of both infrared and red light allows for an estimation of blood oxygen saturation. Calculation of blood oxygen saturation, referred to as the ‘ratio of ratios’ method, will be fully explained in the Methods section.

Reflective PPG can be measured from any site with skin that has vasculature [11], but is, for convenience, commonly measured from the fingers (usually the index finger), wrist and earlobe. This convenience comes with some disadvantages pertaining to 24/7 continuous measurements, which include the intrusive nature of measurements given that living life with a finger or earlobe clip is problematic, and also poor sensor skin contact and motion artefacts in the case of the wrist.

Other devices such as wearing a helmet for behind the ear [12] or a headband for the forehead [13], whilst providing good quality signal, giving a proxy for core blood oxygen rather than peripheral and being less obstructive to daily life, are less suitable for 24/7 use as they can be perceived as stigmatising which decreases adherence to wearing the device in the patient and consumer populations.

On the other hand, the recent interest in the development of Hearables [14], has promoted the ear canal as a preferred site for the measurement of vital signs in eHealth technology. Indeed, the ear canal represents a unique opportunity for physiological measurements, due to its proximity to the brain (ear-electroencephalogram (EEG) [15]), the property of the ear canal to act as a shield

from external electrical noise (nature-built Faraday cage [14]), and the general fixed position of the head with respect to vital signs and neural function, as the head does not move much in daily life unlike sites such as the wrist. Owing to these desirable properties, the ear-canal has been established as a feasible wearable site by ear-EEG [15, 16] and ear-ECG [14].

When it comes to ear-PPG, unlike the finger PPG signal and the earlobe signal, it has been shown that the ear canal offers a photoplethysmogram which is stable and resistant to changes in blood volume which occur during hypothermia [17]. This is because peripheral areas of the body experience restricted blood flow during the cold, whereas the ear canal, being a narrow cavity surrounded by skin, maintains internal blood flow levels. Additionally, this makes the ear canal a preferred site for accurate core body temperature measurement. The PPG from the ear canal has also been shown to be far more sensitive than earlobe and finger PPG to amplitude variations that arise from respiration, thus allowing for a better measurement of respiration rate [18]. Furthermore, a significant delay has been observed between earlobe/behind-the-ear pulse oximetry, and pulse oximetry on the hand or the foot for detection of hypoxemia (low levels of blood oxygen) [12, 19], which is primarily caused by the distance from the core blood supply. Although never previously shown, a similar fast response time was hypothesised from the ear canal given that its vasculature is supplied by the carotid artery, as is the brain. The robustness of the PPG signal from the ear canal, the faster expected SpO₂ response time to changes in blood oxygen levels, the opportunity for a proxy to brain oxygen saturation levels and the potential for relatively non-intrusive 24/7 ambulatory monitoring of patients with breathing disorders form the motivation for our research into ear canal pulse oximetry. The aim of this study is therefore to investigate the feasibility, establish technical characteristics, and identify advantages in the recording of SpO₂ from the ear canal, compared with the most commonly used site, the right index finger.

20.2 Materials and Methods

20.2.1 Hardware

The photoplethysmography sensor used was the MAX30101 digital PPG chip by Maxim Integrated (San Jose, CA, USA), consisting of green (537 nm), red (660 nm) and infrared (880 nm) light emitting diodes as well as a photo-diode to measure the reflected light. In our study, the PPG sensor was embedded in a cut out rectangular section of a viscoelastic foam earbud [20], allowing for comfortable insertion. The three light wavelengths (at 537 nm, 660 nm, 880 nm) gave three measures of pulse, and also the signals required to estimate blood oxygen saturation and respiration rate. The PPG circuitry, including the MAX30101 chip, decoupling capacitors and level shifting circuitry that enable digital communication between 1.8 V and 3 V domains, was packaged in a small 3D printed case which was positioned just outside the ear canal, as shown in Fig. 20.1. This same sensor was secured to the right index finger with medical tape for the

simultaneous finger PPG measurement. The PPG chip has dimensions of 5.6 mm × 3.3 mm × 1.55 mm, with the entire in-ear “Hearables” sensor having dimensions of 19 mm × 10 mm × 7 mm. The width and depth of 10 mm × 7 mm correspond to the viscoelastic foam earbud, which is capable of compressing to fit the ear canal.




Figure 20.1 The in-ear photoplethysmography sensor used in our study. (a) Wearable in-ear photoplethysmography sensor for pulse oximetry, with a trimmed memory foam earbud and a 3D printed case to house the circuitry. (b) The sensor placed within the ear canal.

20.2.2 Experimental Protocol

The participants in the recordings were 14 healthy subjects (7 males, 7 females) aged 19–38 years. Two PPG sensors were used per subject, one secured within the right ear canal and the other to the right index finger; both sensors recorded simultaneously. The subjects were seated in front of a monitor during the recording where a video guided them on when to breathe normally, as well as when to exhale and hold their breath. The position of the sensors, monitor and recording device relative to the subject is shown in Fig. 20.2. This video included a built in countdown, so that at every stage of the protocol, depicted in Fig. 20.3, the subject knew the amount of time left. The experiment lasted for 435 s, consisting of 120 s of normal breathing, 3 repeats of 5 s of exhaling and 20 s of breath holding with 60 s of normal breathing between, and a final 120 s of normal breathing, as depicted in Fig. 20.3. The exhale before the breath hold was included because if the oxygen from the lungs is expelled before holding one’s breath, there is a sharper desaturation in blood oxygen than if a subject did not exhale first, thus allowing for clearer comparisons of sensitivity between the different measurement sites. Furthermore, in a real world scenario, such as obstructive sleep apnea, the lungs would not be filled with oxygen before the obstruction to inspiration occurred, making the conventional breath hold, where a subject inhales before holding their breath, less realistic. Subjects were also told to hold down a button, connected to the circuit board, from the moment they started exhaling until they stopped the breath hold. This was necessary, in order to know precisely when the




Figure 20.2 Simultaneous photoplethysmography (PPG) recording from the ear canal and finger. One PPG sensor is placed in the right ear canal, and another is attached to the right index finger. The simultaneous recordings are linked via a circuit board which logs the respective data streams on SD cards. The subjects are instructed on when to breathe normally, exhale and hold their breath via a video played on a monitor (see Fig. 20.3 for the protocol), with a built in countdown to reflect the elapsed time in each phase.




Figure 20.3 Flow diagram of the experiment, outlining the sequence of participants' breathing. The duration of each stage is provided beneath in seconds. The exhale and breath holding stages are repeated three times, the 60 s normal breathing is repeated twice, and 120 s of normal breathing occurs both at the start and at the end of the experiment.

subject was holding their breath, as reaction times would add uncertainty if the instructional display was used as the ground truth. The recordings were performed under the 881/MODREC/18 ethics approval, and all subjects gave full informed consent.

20.2.3 Extraction of the SpO₂ Signal

The ratio of absorbance of infra-red to red light within the PPG sensor changes depending on the proportion of haemoglobin that is oxygenated in the blood. This change can be quantified through the so called ratio of ratios metric [21], given by

$$R = \frac{\frac{AC_{red}}{DC_{red}}}{\frac{AC_{infrared}}{DC_{infrared}}} \quad (20.2)$$

An empirically derived linear approximation can then be used to calculate an SpO₂ value as a proxy to oxygen saturation. Using the manufacturer's suggested calibration [22], the SpO₂ value was calculated as

$$SpO_2 = 104 - 17R. \quad (20.3)$$




Figure 20.4 Examples of the alternating current (AC) and direct current (DC) waveforms within a PPG measurement, from both the right ear canal and the right index finger. The amplitude is lower in the right ear canal for both the red and infrared signals, but the signal is clear and usable. The maximum to minimum amplitude was designated as the AC signal amplitude, which is divided by the DC signal in the ratio of ratios metric to calculate SpO₂.

To obtain the alternating current (AC) components within the PPG measurements, the raw signals were firstly band-pass filtered between 1 Hz and 30 Hz. Peak detection was then performed on the infrared and red AC filtered signals to find their peaks and troughs; this was achieved using the inbuilt

MATLAB by MathWorks (Natick, MA, USA) function `findpeaks`, with a minimum peak prominence of 150 arbitrary units for the infrared signal and 30 arbitrary units for the red signal. The same procedure repeated on the same signals, but scaled by -1 , to find the troughs. Next, the peak values and trough values were separated and interpolated, before their absolute values were added together to give a constant estimate of the AC amplitude. The direct current (DC) components were obtained by low-pass filtering the raw signals at 0.01 Hz. These waveforms are shown in Fig. 20.4.

20.2.4 Data Analysis

20.4.4.1 Resting SpO₂ comparison

The resting SpO₂ was calculated over the 60 s section of normal breathing before the first exhale began. This time was ascertained from the timing of the first button press, explained in the Experimental Protocol subsection. The SpO₂ signal from the finger and ear were averaged individually over this 60 s window to give a resting blood oxygen comparison for each of the measuring sites for every subject. The root mean square difference in average resting SpO₂ was then calculated across all subjects, as well as the mean difference across all subjects.

20.4.4.2 SpO₂ delay

The blood oxygen estimation delay was calculated using the button release point as the marker for minimal blood oxygen, corresponding to the point at which the breath hold ends. The time between this point of minimal blood oxygen and the first trough of the SpO₂ waveform for the ear and the finger was then used to calculate the SpO₂ delay for the ear, the finger and then the relative delay between the ear and the finger. Three measurements for delay were taken for each measuring site, one for every consecutive breath hold as shown in Fig. 20.5.




Figure 20.5 Exemplar SpO₂ recording following the breath hold protocol (see Fig. 20.3). The breath holds (starting with the exhale and finishing at the end of the breath hold) are designated with the shaded regions. The SpO₂ recorded from the right index finger is denoted by the solid blue line, and the SpO₂ recorded from the right ear canal by the solid red line. The three significant drops in SpO₂ levels correspond to the three breath holds. The breath holds also vary slightly in length as they adhere to when the subject holds down a button rather than the set time of the instructional display, thus mirroring the true breath hold duration more accurately.

The mean of these three recorded delays was taken to give an average delay for each measurement site for each subject. The range, on a per subject basis, was taken as a measure of variability within the recordings for each subject. The distribution of mean delays was analysed against age and sex, whereby a paired sample *t*-test was employed to compare male and female delays while Pearson's correlation coefficient was utilised to determine if subject age was correlated to delay.

20.3 Results

For rigour, and to demonstrate non-inferiority of in-ear pulse oximetry to finger pulse oximetry, the experimental results span three major aspects related to the feasibility of in-ear PPG; these are the comparison of resting oxygen levels against standard finger PPG, the respective delays in detection of hypoxic events and the corresponding PPG signal amplitudes.

20.3.1 Resting Oxygen Comparison

The difference in resting SpO₂ between the right ear canal and the right index finger across all subjects had a root mean square value of 1.47% with a mean difference of 0.23% higher saturation in the ear. The distribution of resting values across subjects is provided in Fig. 20.6, and shows that all resting SpO₂ values were within the physiologically healthy range of 94–100%, and therefore there was a complete agreement between the ear canal and finger as measuring sites on whether or not a subject had 'healthy' blood oxygen levels.




Figure 20.6 Mean resting SpO₂ levels taken for each individual subject for the right ear canal (red circles) and the right index finger (blue crosses). The mean was taken across the 60 s of SpO₂ data before the first breath hold sequence. The area within the two green dotted lines represents the healthy blood oxygen range of 94–100%.

20.3.2 Blood Oxygen Delay

The mean relative time delay per subject between the ear and finger pulse oximetry, in other words the time it took from detecting minimal blood oxygen

in the ear to detecting minimal blood oxygen in the finger, ranged from 4.18 s to 24.2 s. The mean relative delay across all 14 subjects was 12.4 s, with a mean relative delay of 9.67 s for the female subjects and a mean relative delay of 15.13 s for the male subjects. The mean female relative delay was significantly lower than the mean male relative delay ($P = 0.03$). The SpO₂ delay values for all subjects are shown in Fig. 20.7, highlighting the large inter-subject variability in SpO₂ delay and moreover the large inter-trial variability in the ear canal vs finger delay for many individual subjects.




Figure 20.7 The absolute blood oxygen delay from the button press to the finger (blue), to the ear (red) and the relative delay between the ear and the finger (purple), shown for every subject. Male subjects are designated with [M] and female subjects with [F]. The delay is calculated from the time that the breath hold stops (true minimum blood oxygen) to the time at which the measuring site detects a minimum in SpO₂. Error bars are included to show the range of the three delay measurements for individual subjects.

Across our 14 subjects there was no overlap between the absolute SpO₂ delay from the right ear canal and the right index finger, as shown in Fig. 20.8. The absolute delay from the right ear canal had a mean of 4.35 s, with a range of 0.97–7.31 s. The absolute delay from the right index finger had a mean of 16.75 s, with a range of 8.52–28.14 s. When separated by sex, the mean absolute delay from the finger was 14.0 s for the female subjects and 19.5 s for the male subjects ($P = 0.03$). The mean absolute delay from the ear canal was 4.3 s for females and 4.4 s for males, as summarised in Table 20.1. Furthermore, there was no correlation found between age and oxygen delay across the participants.

For rigour, the SpO₂ delay between the left and right ear canal was also examined for a single subject, giving a mean delay of 0.46 s from the left ear canal to the right ear canal across the three breath holds, suggesting that measuring SpO₂ from the left ear would yield a similar response time to the right ear, if not slightly faster.

Table 20.1 Summary of mean (\pm standard deviation) SpO₂ delay values (seconds)

	Relative	Finger	Ear canal
Female	9.70 \pm 4.07	14.00 \pm 4.25	4.33 \pm 2.37
Male	15.13 \pm 6.76	19.49 \pm 6.28	4.36 \pm 1.42
Total	12.40 \pm 6.06	16.75 \pm 5.88	4.35 \pm 1.88




Figure 20.8 Boxplots of the mean absolute delays, for all subjects, between the right ear canal and the right index finger. The top and bottom of each coloured box represent respectively the upper and lower quartiles, the dotted lines represent the median, and the whisker lines extending out of the box represent the range. In our data, there is no overlap between the range of absolute delay from the ear canal and the absolute delay from the right index finger.

20.3.3 Photoplethysmogram Amplitude

It was observed that 13 out of 14 subjects had a higher AC PPG amplitude from the right index finger than the right ear canal with the mean finger PPG amplitude 2.35 times higher than for the ear canal. Figure 20.9 presents the individual normalised resting infrared PPG amplitude for the finger and ear canal results for all 14 subjects. In the case of finger amplitude, males had a mean finger amplitude of 1.28×10^3 with a standard deviation of 0.76×10^3 , compared with females who had a mean finger amplitude of 0.90×10^3 and a standard deviation of 0.49×10^3 .




Figure 20.9 The mean resting maximum to minimum AC amplitude of the photoplethysmography signal for all subjects. These values were measured from the 60 s of filtered PPG data before the first breath hold and were normalised to the maximum mean AC amplitude across all subjects.

In the case of ear amplitude, males had a mean ear amplitude of 0.59×10^3 with a standard deviation of 0.40×10^3 , compared with females that had a mean finger amplitude of 0.33×10^3 and a standard deviation of 0.12×10^3 . Neither sex difference between finger amplitudes and ear amplitudes was statistically significant, with $P = 0.14$ and $P = 0.05$ respectively. Importantly, even in the lowest amplitude cases, the in-ear PPG signals were effective for peak detection and thus usable for the calculation of SpO_2 .

20.4 Discussion

20.4.1 Resting SpO_2

Blood oxygen saturation measurements from the right ear canal and the right index finger were comparable at rest, with a minimal systematic offset between the two, indicated by the mean difference of 0.23% higher resting SpO_2 in the right ear canal, as shown in Fig. 20.6. The variability between the two measurement sites, indicated by the root mean square difference of 1.47%, is to be expected, given that mean SpO_2 values were shown to vary as much as 0.9% even across fingers on the same hand [23]. The blood oxygen saturation delay between the ear and the finger may also be a source of error when using the same absolute 60 s time window for comparison, although given that the window was long in comparison with the SpO_2 delay and the fact that resting values stay fairly constant, this source of error should be minimal. Both sensor positions were in 100% agreement concerning the patients having healthy SpO_2 levels of 94 to 100%. The established similarity in the resting oxygen saturation values with the commonly used right index finger location are a first step towards validating the ear canal as an alternative measurement site for pulse oximetry.

20.4.2 SpO_2 Delay

Our results indicate a mean oxygen saturation delay between the right ear canal and the right index finger of 12.4 s. In other words, a steep drop in SpO_2 is detected on average 12.4 s faster from the right ear canal than it is from the right index finger, with two subjects exhibiting over 20 s faster detection from the right ear canal. The faster response from the ear-canal strongly recommends the incorporation of in-ear SpO_2 measurements into so-called Hearables, as there are many situations where fast SpO_2 response time is critical, such as improving outcomes during neonatal resuscitation [24] and closed loop automatic oxygen therapy [25]. Moreover, this opens the avenue to aid comparison of sleep stage scoring and sleep apnea events by aligning changes in SpO_2 to the correct 30 s sleep epoch [26].

We found a large inter-subject variability in both the absolute oxygen delay to the right ear canal and the absolute oxygen delay to the right index finger. On average, the female subjects had lower relative oxygen delay between the

ear and the finger, caused by the much smaller absolute delay to the right index finger in combination with an almost identical absolute delay to the right ear canal. We hypothesise that this could be related to males being taller on average and therefore having longer arms, which would give oxygenated blood further to travel from the heart to the fingers. Variations in height and arm length may also explain some of the large inter-subject variability in absolute SpO₂ delays. With a taller subject we would expect on average a longer distance for blood to travel to both the ear canal and the fingers, but we found no correlation between the absolute delay to the ear and absolute delay to the finger. One relevant factor was average heart rate across the trials, which we found to have a significant moderate positive correlation with absolute delay to the ear ($R = 0.56, P = 0.03$), but was not correlated with absolute delay to the finger. Importantly, age was not found to be a correlating factor to oxygen delay in our subjects. Future work must consist of investigating the efficacy of in-ear SpO₂ as well as the SpO₂ delay in older cohorts that may have underlying respiratory conditions, and not just young healthy subjects. The natural question arises, could SpO₂ delay be an indicator of the health of a patient's circulatory system?

Whilst not as precise as arterial blood gas analysis, this is the first attempt to measure the blood oxygen delay to the ear itself. Importantly it should be noted that although the ear canal responds faster to changes in blood oxygen and much more closely resembles core blood oxygen than peripheral sites such as the finger, it is still not instantaneous, with our results showing a mean blood oxygen delay to the ear of 4.35 s.

20.4.3 Photoplethysmogram Amplitude

The in-ear PPG in this study was found to have consistently smaller amplitudes from the ear canal when compared with the finger. The three reasons for a lower PPG amplitude are: (1) less vascular density of the tissue (2) poorer sensor contact with the skin and (3) arterial pulse pressure amplitude. Considering that the ear and fingers are both common PPG placement sites, given the high density of arterioles and capillaries [27, 28], the most likely explanations for a lower PPG amplitude are therefore sensor placement issues within the ear canal and a lower carotid arterial pulse amplitude compared to the radial artery in the arm.

The large variability in ear canal sizes was somewhat mitigated by different available earbud sizes, but even with the smallest earbud some subjects found it difficult to insert the sensor fully into the ear canal. Some subjects with wider ear canals also noted that the sensor became looser during the trial. These issues did not affect the conclusive nature of this feasibility study and will be addressed in future with an improved sensor design, such as by employing ear-hooks, commonly used with sports headphones, to stabilise the position of sensor within the ear.

Even disregarding placement issues, a lower PPG pulse magnitude may be expected from the ear canal given a higher pressure wave amplitude in the radial

artery of the wrist leading to the fingers, compared to the carotid artery leading to the ear canal [29]. This is also evidenced by the broader peak from the ear canal, shown in Fig. 20.4, which is a characteristic of the pressure wave found in the carotid artery.

Importantly, despite a lower signal amplitude, all data recorded from the ear canal was functional for peak detection of the AC PPG signal and therefore the SpO₂ calculation.

20.5 Conclusions

There is a growing need for improved non-intrusive wearable SpO₂ recording across many different scenarios, from the monitoring of sleep apnea to the tracking of vital signs of outpatients with a threat of respiratory deterioration, such as those with general breathing disorders or those recovering from COVID-19. To this end, we have investigated the possibility of estimating blood oxygen saturation from the ear canal in healthy subjects and have comprehensively demonstrated its non-inferiority compared with conventionally used finger pulse oximetry, with a significantly faster response time averaging 12.4 s. The results have indicated that the favourable speed of in-ear pulse oximetry, in conjunction with the previously documented advantage of resilience to changes in circulation associated with environmental temperature changes (summarised in Table 20.2), may offer significant clinical advantages and a proxy to brain oxygen levels. Given its privileged position on the human body and a fixed distance to vital signs during most daily activities and while sleeping, the ear canal may even be a superior site for measurement of SpO₂ in the scenario of 24/7 continuous monitoring. In an era of urgency for enhanced tracking of hypoxia and increasing use of smart devices for health monitoring, this proof of concept study provides a compelling argument for the integration of ear canal pulse oximetry into current state-of-the-art Hearables [14].

Table 20.2 Summary of different SpO₂ sensor positions

Placement	Fast response	Robust to temperature
Finger	No	No
Earlobe	Yes [19]	No
Ear canal	Yes	Yes [17]

Disclosures and Conflict of Interest

This chapter was originally published as: Davies, H. J., Williams, I., Peters, N. S., Mandic, D. P. (2020). In-ear SpO₂: A tool for wearable, unobtrusive monitoring of core blood oxygen saturation. *Sensors*, **20**, 4879, <https://doi.org/10.3390/s20174879>, under the Creative Commons Attribution (CC BY) license (<http://creativecommons>).

org/licenses/by/4.0/), and appears here, with edits and updates, by kind permission of the copyright holders.

Author Contributions: Conceptualization, H.J.D. and D.P.M.; methodology, H.J.D.; software, H.J.D. and I.W.; validation, H.J.D., D.P.M. and N.S.P.; formal analysis, H.J.D.; investigation, H.J.D.; resources, I.W., H.J.D. and D.P.M.; data curation, H.J.D.; writing—original draft preparation, H.J.D., D.P.M., N.S.P. and I.W.; writing—review and editing, H.J.D., D.P.M. and N.S.P.; visualization, H.J.D.; supervision, D.P.M. and N.S.P.; project administration, D.P.M.; funding acquisition, D.P.M. and N.S.P. All authors have read and agreed to the published version of the chapter.

Funding: This work was supported by the Racing Foundation grant 285/2018, MURI/EPSRC grant EP/P008461, the Dementia Research Institute at Imperial College London, the BHF Centre of Research Excellence, the Imperial Centre for Cardiac Engineering, the Imperial Health Charity and the NIHR Biomedical Research Centre.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Jubran, A. Pulse oximetry. *Crit. Care* **1999**, *3*, R11.
2. Smith, G.B., Prytherch, D.R., Watson, D., Forde, V., Windsor, A., Schmidt, P.E., Featherstone, P.I., Higgins, B., Meredith, P. SpO₂ values in acute medical admissions breathing air—Implications for the British Thoracic Society guideline for emergency oxygen use in adult patients? *Resuscitation* **2012**, *83*, 1201–1205.
3. World Health Organization. *Pulse Oximetry Training Manual*, World Health Organization: Geneva, Switzerland, **2011**.
4. Gattinoni, L., Chiumello, D., Caironi, P., Busana, M., Romitti, F., Brazzi, L., Camporota, L. COVID-19 pneumonia: Different respiratory treatments for different phenotypes? *Intensive Care Med.* **2020**, *46*(6), 1099–1102.
5. Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C., Di Napoli, R. *Features, Evaluation, and Treatment of Coronavirus (COVID-19)*. StatPearls Publishing: Treasure Island, FL, USA, **2022**.
6. Pan, F., Ye, T., Sun, P., Gui, S., Liang, B., Li, L., Zheng, D., Wang, J., Hesketh, R.L., Yang, L., et al. Time course of lung changes on chest CT during recovery from 2019 Novel Coronavirus (COVID-19) pneumonia. *Radiology* **2020**, 200370.
7. Alhazzani, W., Møller, M.H., Arabi, Y.M., Loeb, M., Gong, M.N., Fan, E., Oczkowski, S., Levy, M.M., Derde, L., Dzierba, A., et al. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med.* **2020**, 1–34.
8. Khemani, R.G., Thomas, N.J., Venkatachalam, V., Scimeme, J.P., Berutti, T., Schneider, J.B., Ross, P.A., Willson, D.F., Hall, M.W., Newth, C.J.L. Comparison of SpO₂ to PaO₂ based markers of lung disease severity for children with acute lung injury. *Critical Care Med.* **2012**, *40*, 1309–1316.

9. Oksenberg, A., Arons, E., Nasser, K., Vander, T., Radwan, H. REM-related Obstructive Sleep Apnea: The Effect of Body Position. *J. Clin. Sleep Med.* **2010**, *6*, 343–348.
10. Nitzan, M., Romem, A., Koppel, R. Pulse oximetry: Fundamentals and technology update. *Med. Devices (Auckl. NZ)* **2014**, *7*, 231.
11. Nilsson, L., Goscinski, T., Kalman, S., Lindberg, L.G., Johansson, A. Combined photoplethysmographic monitoring of respiration rate and pulse: A comparison between different measurement sites in spontaneously breathing subjects. *Acta Anaesthesiol. Scand.* **2007**, *51*, 1250–1257.
12. Bradke, B., Everman, B. Investigation of photoplethysmography behind the ear for pulse oximetry in hypoxic conditions with a novel device (SPYDR). *Biosensors* **2020**, *10*, 34.
13. Dresher, R. Wearable forehead pulse oximetry: Minimization of motion and pressure artifacts. Master's Thesis, Worcester Polytechnic Institute, Worcester, MA, USA, **2006**.
14. Goverdovsky, V., Von Rosenberg, W., Nakamura, T., Looney, D., Sharp, D.J., Papavassiliou, C., Morrell, M.J., Mandic, D.P. Hearables: Multimodal physiological in-ear sensing. *Sci. Rep.* **2017**, *7*, 1–10.
15. Looney, D., Kidmose, P., Park, C., Ungstrup, M., Rank, M., Rosenkranz, K., Mandic, D. The in-the-ear recording concept: User-centered and wearable brain monitoring. *IEEE Pulse* **2012**, *3*, 32–42.
16. Nakamura, T., Alqurashi, Y.D., Morrell, M.J., Mandic, D.P. Hearables: Automatic overnight sleep monitoring with standardized in-ear EEG sensor. *IEEE Trans. Biomed. Eng.* **2020**, *67*, 203–212.
17. Budidha, K., Kyriacou, P.A. Investigation of photoplethysmography and arterial blood oxygen saturation from the ear-canal and the finger under conditions of artificially induced hypothermia. In *Proceedings of the IEEE Annual International Conference of the Engineering in Medicine and Biology Society*, EMBS, Milan, Italy, **2015**, pp. 7954–7957.
18. Budidha, K., Kyriacou, P.A. In vivo investigation of ear canal pulse oximetry during hypothermia. *J. Clin. Monit. Comput.* **2018**, *32*, 97–107.
19. Hamber, E.A., Bailey, P.L., James, S.W., Wells, D.T., Lu, J.K., Pace, N.L. Delays in the detection of hypoxemia due to site of pulse oximetry probe placement. *J. Clin. Anesth.* **1999**, *11*, 113–118.
20. Goverdovsky, V., Looney, D., Kidmose, P., Mandic, D.P. In-Ear EEG from viscoelastic generic earpieces: Robust and unobtrusive 24/7 monitoring. *IEEE Sens. J.* **2016**, *16*, 271–277.
21. Rusch, T.L., Sankar, R., Scharf, J.E. Signal processing methods for pulse oximetry. *Comput. Biol. Med.* **1996**, *26*, 143–159.
22. MaximIntegrated. *Recommended Configurations and Operating Profiles for MAX30101/MAX30102 EV Kits*, Technical Report, MaximIntegrated: San Jose, CA, USA, **2018**.
23. Basaranoglu, G., Bakan, M., Umutoglu, T., Zengin, S.U., Idin, K., Salihoglu, Z. Comparison of SpO₂ values from different fingers of the hands. *SpringerPlus* **2015**, *4*, 561.
24. Baquero, H., Alviz, R., Castillo, A., Neira, F., Sola, A. Avoiding hyperoxemia during neonatal resuscitation: Time to response of different SpO₂ monitors. *Acta Paediatr.* **2011**, *100*, 515–518.

25. Morozoff, E.P., Smyth, J.A. Evaluation of three automatic oxygen therapy control algorithms on ventilated low birth weight neonates. In *Proceedings of the 31st IEEE Annual International Conference of the Engineering in Medicine and Biology Society*, Minneapolis, MI, USA, **2009**, pp. 3079–3082.
26. Berry, R.B., Brooks, R., Gamaldo, C.E., Harding, S.M., Lloyd, R.M., Quan, S.F., Troester, M.M., Vaughn, B.V. *AASM/Scoring Manual Version 2.4 The AASM Manual for the Scoring of Sleep and Associated Events*, American Academy of Sleep Medicine: Darien, IL, USA, **2017**.
27. Mannheim, P.D. The light–tissue interaction of pulse oximetry. *Anesth. Analg.* **2007**, *105*, S10–S17.
28. Alvord, L.S., Farmer, B.L. Anatomy and orientation of the human external ear. *J. Am. Acad. Audiol.* **1997**, *8*, 383–390.
29. Kelly, R., Hayward, C., Avolio, A., O'Rourke, M. Noninvasive determination of age-related changes in the human arterial pulse. *Circulation* **1989**, *80*, 1652–1659.

Chapter 21

Nanomaterials in Imaging

Sourav Bhattacharjee, PhD

University College Dublin, Dublin, Ireland

sourav.bhattacharjee@ucd.ie

Keywords: active targeting, angiotensin converting enzyme (ACE), apolipoprotein E, aptamer, asialoglycoprotein, Beer-Lambert law, blood pool agents (BPAs), carbon nanotubes (CNTs), computed tomography, enhanced permeation and retention (EPR) effect, epidermal growth factor, epidermal growth factor receptors (EGFRs), folic acid, gadolinium-diethylenetriaminepentaacetic acid, glycolic chitosan, gold nanoparticles (AuNPs), graphene, hepatocellular carcinoma, magnetic nanoparticles (MNPs), magnetic resonance imaging (MRI), Omnipaque®, PAMAM dendrimers, PEGylated AuNPs, PEGylated perfluorooctyl bromide, photoacoustic imaging, polyelectrolyte complex (PEC), polyelectrolyte complex nanoparticles (PEC NPs), positron emission tomography (PET), quantum dots (QDs), reticuloendothelial system (RES), silicon nanoparticles (SiNPs), single photon emission computed tomography (SPECT), superparamagnetic iron oxide NPs (SPIONs), surface-enhanced Raman scattering, ultrasonogram (USG), $\alpha 5\beta 3$ integrin receptors

21.1 Introduction

With unprecedented optoelectronic properties, nanomaterials present exciting opportunities for medical imaging with high resolution, better contrast, and deeper penetration into the tissues [1, 2]. Various nanomaterials, mostly nanoparticles (NPs), have shown promise in such applications and are currently being investigated [3]. This chapter will build upon the knowledge of the physicochemical properties of materials at the nanoscale and how they behave at the nano/bio

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

interfaces (e.g., enhanced permeation and retention effect (EPR) in tumor sites [4, 5]). A quick revisit of the principles and theory surrounding various NPs, for example, gold NPs (AuNPs), carbon nanotubes (CNTs), magnetic NPs (MNPs), and quantum dots (QDs), that are frequently used for imaging will be helpful in grasping this chapter.

21.2 Gold Nanoparticles

AuNPs are getting increasingly popular in medical imaging, particularly in X-ray computed tomography (CT) scans, which offer scope for affordable multimodal imaging and provide in-depth 3D information on internal organs and structures [6–8]. Typically X-ray CT delivers an image based on contrast resulting from the relative electron densities of various tissues—from low (e.g., soft tissue) [9] to high (e.g., bone) [10]. While passing through internal body structures, the X-ray decreases in intensity as per the Beer–Lambert law [11]:

$$I = I_0 e^{-\mu x},$$

where I_0 = initial intensity of the beam, μ = absorption/attenuation coefficient of the material, and x = thickness of the material pierced by the beam.

The absorption/attenuation coefficient μ (measured in Hounsfield units [HU]) is further represented by the following equation:

$$\mu = \frac{\rho Z^4}{AE^3},$$

where ρ = density, Z = atomic number of the element, A = atomic mass, and E = energy of the X-ray.

Diseased tissues (e.g., tumor) have a disparate electron density compared to the surroundings and, hence, produce identifiable contrast. To increase sensitivity, positive contrast agents (e.g., an aqueous solution of iodinated organic molecules, like iopromide), which accumulate in the target sites, are often used [12, 13]. However, the window of time available for imaging in such iodine-bearing molecules is quite narrow as these molecules are rapidly eliminated by fast renal filtration and extravasation from vasculature [14]. Additionally, iodinated compounds are known to cause renal failure, myocardial infarction, and anaphylactic shock [15]. AuNPs have emerged as a potent, cheap, and safe alternative contrast agent that can be conjugated to various ligands due to their well-known chemistry. Additionally, gold has a high atomic number (79 compared to 53 in the case of iodine) and X-ray absorption coefficient (5.16 cm²/g at 100 keV compared to 1.94 cm²/g in the case of iodine) [16], enabling AuNP-based imaging tools offering an approximately 2.7-fold higher contrast than iodine [17].

21.2.1 AuNPs in Cancer Imaging

21.2.1.1 Active targeting strategies

The higher metabolism and raised demand for carbohydrates in cancerous tissues were utilized to increase contrast about fourfold during *in vitro* (human alveolar epithelial cancer A549 cells) [18] and *in vivo* (tumor-bearing mouse model) [19] imaging by using AuNPs functionalized with 2-deoxy-D-glucose. AuNPs, grafted with specific antibodies, provided a fertile ground for further development of targeted imaging agents. One such study on AuNPs grafted with UM-49 antibodies reported fourfold higher contrast *in vitro* in squamous cell carcinoma cells [20]. PEGylated AuNPs (~38 nm) functionalized with CD4 antibodies were used successfully to target and provide twofold improved contrast in imaging of the lymph nodes in mice after intravenous administration [21]. Similar PEGylated AuNPs functionalized with anti-human epidermal growth factor receptor 2 antibodies were observed to accumulate at the periphery of tumors after intravenous administration [22]. Epidermal growth factor receptors (EGFRs) have been targeted with PEGylated AuNPs for better contrast while imaging, both *in vitro* and *in vivo*, up to at least 4 h from injection, where the NPs were functionalized with cetuximab (monoclonal antibody against EGFR) [23] and anti-EGFR antibody [24], respectively.

Tumor-targeting peptides and proteins have also been grafted onto AuNPs for targeting purposes. AuNPs (16–18 nm) functionalized with bombesin were used to target peptide receptors responsible for gastrin secretion in various cancers, for example, prostate [25]. These AuNP nanoconstructs showed a fourfold higher accumulation in a xenografted tumor model up to 6 h from intraperitoneal injection. In a similar study, AuNPs functionalized with antitumor peptide angioprep-2 were grafted onto core-shell NPs (~200 nm) where a discontinuous 20 nm gold coating was deposited over the docetaxel-loaded PLGA, that is, poly (lactide-co-glycolide) NPs [26]. These AuNP nanoconstructs showed attenuation (slope 0.1 mf gold/mL/HU) in a mouse tumor model compared to control nonfunctionalized AuNP variants due to the EPR effect. The arg-gly-aspartic acid (RGD) peptide-targeting $\alpha_5\beta_3$ integrin receptors, overexpressed on the walls of blood vessels in tumor sites, were also used to functionalize AuNPs [27]. Such RGD-functionalized gold nanospheres (~40 nm) enabled approximately twofold attenuation in a CT scan within an hour after intravenous administration when administered with lipoidal A in rabbits with a xenografted VX2 hepatic tumor.

Aptamers, that is, short strands of oligonucleotide or peptide molecules comprising 15–60 amino acids [28], were also used to functionalize AuNPs for targeting. A threefold attenuation of the CT signal was noted *in vitro* in androgen-sensitive human prostate adenocarcinoma-derived LNCaP cells exposed to AuNPs (12.7 ± 3.3 nm) functionalized with prostate-specific membrane antigen-binding 21-base long A9 RNA aptamer in comparison to the control nontargeted PC3 cells [29]. Similarly, AuNPs (2.4 ± 0.4 nm) conjugated with AS1411 aptamers

showed linear attenuation (slope 0.027 mM gold/HU) in CL1-5 tumor-bearing mice models at different time points ($t = 0, 0.5, 2, 4,$ and 24 h) [30]. CT attenuation due to active targeting in the case of an *in vivo* squamous cell carcinoma mice model was achieved by intravenous administration of AuNPs (59.6 ± 1.9 nm) functionalized with a 22-base anti-EGFR aptamer [31].

Targeting cell membrane-bound receptors appears to be an attractive strategy for delivering AuNPs conjugated with various ligands for enhancing contrast. Receptors for folic acid (FA), suitable for targeting, are overexpressed in various cancer cells [32, 33]. AuNPs entrapped within G5 polyamidoamine (PAMAM) dendrimers and conjugated with FA showed fourfold X-ray attenuation even 6 h after administration, both *in vitro* (human lung adenocarcinoma SPC-A1 cells) and *in vivo* (xenografted tumor mouse model) [34]. Comparable nanoconstructs of AuNP entrapped within amine-terminated cationic G5 PAMAM dendrimers ($G5-NH_2$) conjugated with FA demonstrated at least twofold linear attenuation (slope 0.2 mM gold/HU)—both *in vitro* (human epithelial carcinoma KB cells) [35] and *in vivo* (xenograft tumor model in Balb/c mice) [36] for 24 h after injection. However, this finding was negated in another *in vitro* study, where no edge was offered by the targeted dendrimeric AuNPs over nontargeted ones [37]. Similar dendrimeric AuNP-based nanoconstructs from poly- γ -glutamic acid also showed CT attenuation in both *in vitro* and *in vivo* setups. $G5-NH_2$ -derived AuNPs conjugated with lactobionic acid (LBA) in order to target asialoglycoprotein (ASGP) receptors overexpressed in hepatocellular carcinoma (HCC) showed 1.5-fold higher attenuation after 2 h of intravenous injection in a mouse tumor model [38]. LBA-functionalized AuNPs (14 nm) exhibited higher internalization and attenuation (slope 0.00016 mM gold/HU) in the HCC-derived HepG2 cell line overexpressing ASGP receptors compared to control HeLa cells [39]. Dendrimeric and AuNP-based platforms functionalized with the RGD peptide instead of FA—to target the $\alpha_5\beta_3$ integrin receptors—showed considerable cellular uptake *in vitro* as well as 1.5-fold attenuation for 20 h after injection in a mouse tumor model [40]. Gold nanoclusters wrapped in a silica shell and conjugated with FA were used to target a gastric cancer-derived MGC803 xenograft mouse tumor model, exhibited linear attenuation (slope 0.74 mM gold/HU), and offered high contrast at the tumor site for up to 6 h following injection [41].

AuNPs (24.0 ± 6.2 nm) coated with glycolic chitosan (GC) were used to target tumors and exhibited attenuation comparable to that of commercially available CT contrast agent eXIA 160 *in vitro*. The GC-coated AuNPs produced twice the amount of contrast that nontargeted AuNPs coated with heparin generated *in vivo* for 2 h after administration [42]. Gold-coated iron oxide core@shell, that is, $Fe_2O_3@AuNPs$ (22.1 ± 1.9 nm) functionalized with various lectins, including Ricinus communis agglutinin I and wheat germ agglutinin, enabled dual-mode CT/magnetic resonance imaging (MRI) *in vivo* for 24 h after injection [43]. Similar core@shell $Fe_3O_4@AuNPs$ (5.3 nm) coated with polyethyleneimine (PEI) to facilitate binding with hyaluronic acid and target tumors overexpressing

CD44 receptors showed enhanced internalization and CT attenuation *in vivo* with significant contrast at the tumor site for up to 10 minutes from injection [44]. AuNPs conjugated with bisphosphonates, molecules with binding affinity toward hydroxyapatite (major mineral component in calcified plaques within mammary tissue in breast cancers), showed promising results *in vivo* for up to 48 h after injection via imaging of minute calcified plaques, often missed during conventional mammograms, and provided enhanced CT contrast facilitating early detection [45]. In another study, AuNPs (20 nm) with an adsorbed layer of T-cells overexpressing specific receptors for malignant melanoma showed higher CT contrast in a xenograft mouse melanoma model [46].

21.2.1.2 Passive targeting strategies

Passive targeting strategies are primarily based on principles like EPR [47, 48] and techniques such as PEGylation to avoid filtration by the activated reticuloendothelial system [49, 50], typically noticed after parenteral administration. The core principles are discussed in detail in Chapter 3. This chapter will mostly deal with various examples of such applications.

Extremely small (1.9 ± 0.1 nm) AuNPs were used as an X-ray CT scan contrast agent in tumor-bearing Balb/c mice [51]. Although no AuNPs could be detected in blood after 24 h, significant accumulation of the injected dose (270 mg gold/cm³ suspended in phosphate buffered saline) was noticed in the kidneys (10.62%), tumor (4.2%), liver (3.6%), and muscle (1.2%)—as measured by atomic absorption spectrometry—within 15 minutes of intravenous administration. However, the AuNPs did not show any sequestration in liver and spleen due to very small sizes. Interestingly, these AuNPs enabled visualization of blood vessels as narrow as 100 μ m, which are characteristic of tumors due to rapid angiogenesis. AuNPs stabilized with gum Arabic, resistant toward surface adsorption of serum proteins, were also shown to be effective as an *in vivo* X-ray CT scan contrast agent [52]. Stealth PEGylated AuNPs (30 ± 7.5 nm)—prepared by reacting thiolated PEG (PEG-SH) with citrate-capped AuNPs—exhibited augmented contrast (twofold) and longer circulation in blood (>4 h) compared to iopromide (circulation time in blood <10 minutes) upon intravenous injection in hepatoma-bearing rats [53]. PEGylated gold nanorods (AuNRs) showed higher attenuation of CT compared to the commercially available iodine-containing CT contrast agent iopamidol, with a longer half-life ($t_{1/2}$) of 17 h after intravenous administration [54]. PEGylated gold-silver alloy NPs, 3.6–7.6 nm in size with restricted leaching of Ag⁺ cations, enabled high-resolution mammogram CT scanning to facilitate an early clinical diagnosis *in vivo* for 2 h after intravenous injection [55].

G5-NH₂ PAMAM dendrimers with entrapped AuNPs and masked cationic surface charge through acetylation showed considerable CT attenuation *in vivo* due to the EPR effect after intratumoral and intraperitoneal administrations [56]. Similar G5-NH₂ PAMAM dendrimers carrying chelating agent DOTA-NHS

(tetraazacyclododecane tetraacetic acid), enabling conjugation with gadolinium (Gd), showed a significant increase of intratumoral CT attenuation *in vivo* within 100 minutes of injection [57]. Equivalent G5-NH₂ PAMAM dendrimers containing AuNPs and PEG were used successfully to image the blood pool in a xenograft mice tumor model [58]. Lower generation (G2) PEGylated dendrimers carrying AuNPs have shown better CT attenuation capability *in vivo* compared to Omnipaque® (iohexol) after both intravenous and intraperitoneal administrations, where the NPs were found to localize more in the tumor and urinary bladder (bladder > tumor) with enhanced contrast [59].

Various polymers were used extensively to conjugate different molecules with the AuNP-based contrast agents. PEGylated and branched PEI was used as a scaffold for the synthesis of AuNPs of different sizes (1.9–4.6 nm) while the prepared nanoconstructs showed excellent efficacy as a contrast agent for the blood pool (subcutaneous route) and high intratumoral accumulation (intravenous route) *in vivo* [60]. Adequately high contrast was achieved in the CT scan from the tumor site in a CT26 tumor mice model after intravenous injection of AuNPs functionalized with 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-(methoxy[polyethylene glycol]-2000) (DSPE-PEG₂₀₀₀) [61]. Intravenous administration of a liposomal (208.3 ± 1.3 nm) preparation composed of dipalmitoylphosphatidylcholine, cholesterol, and DSPE-PEG₂₀₀₀ (molar ratio 80:20:5) with encapsulated Fe₃O₄ NPs (15 nm) offered enhanced contrast in tumor models *in vivo* despite being mostly localized in various organs (e.g., liver, spleen, and lungs) [62]. Gold nanoclusters of varied sizes (105–240 nm) encapsulated within a polyacrylic acid (PAA) coating and calcium phosphate exhibited high CT contrast from the tumor site, as determined by inductively coupled plasma-atomic emission spectrometry, when injected intravenously in a tumor-bearing mice model [63]. A PEG₅₀₀₀ylated fullerene-based hybrid nanoconstruct C₆₀@AuNPs (~112 nm), where the PEG was attached to the core with a pH-sensitive hydrazine bond, not only showed improved CT signal from the tumor in a xenograft tumor mouse model, but also demonstrated higher tumor uptake due to the cleaved PEG₅₀₀₀ in the intratumoral acidic environment, as confirmed by histological staining of tumor tissue slides [64].

Other molecules were used as a replacement for PEG to increase the circulation time of the nanomedicines in blood and promote tumor uptake. One such study used AuNPs coated with cinnamon phytochemicals (155 nm), which exhibited excellent uptake *in vitro* in cancerous MCF-7 and PC-3 cells and demonstrated a linear attenuation curve (slope 54.1 μM gold/HU) *in vivo* [65]. Almost fivefold CT attenuation after 24 h of injection was achieved in a mouse tumor model in AuNPs carrying indocyanine green (ICG) dye and coated with mesoporous silica [66]. Similarly, AuNPs carrying Prussian blue (17.8 ± 2.3 nm) showed time-dependent increase of CT attenuation up to 24 h from intravenous administration in a tumor-bearing mouse model while a major fraction of the administered AuNPs accumulated in the spleen [67].

AuNPs (115 ± 5 nm) wrapped in human serum albumin were able to cross the blood-brain barrier and got localized mostly in the thalamus and hypothalamus of the brain, providing opportunities for high-resolution imaging with therapeutic benefits in conditions like transmissible spongiform encephalopathies and *prion disease* [68].

Commercially available AuroVist™ AuNPs (15 nm, blood $t_{1/2}$ 15 h) were used in conjunction with liposomal iodine (~130 nm, blood $t_{1/2}$ ~40 h) to develop a novel protocol for micro-CT to image and quantify tumor blood volume and vascular permeability in a tumor [69]. The AuNPs were injected intravenously 4 days before liposomal iodine, and the micro-CT scans were conducted daily for 6 days after injection. The small AuNPs were extravasated in the tumor tissue within 45 minutes from injection due to the EPR effect. The difference between attenuation of the liposomal iodine and AuNPs was used to image the tumor vasculature and measure the extravasated gold as well as intravascular iodine. In short, initially the AuNPs caused attenuation of ~800 HU in the vasculature, which gradually lessened to 10 HU due to extravasation. However, the attenuation within vasculature increased to 25 HU after administration of iodine, which enabled the imaging of the intratumoral vasculature.

21.2.1.3 AuNPs in the imaging of renal system

Small AuNPs (<2 nm) coated with bovine serum albumin demonstrated contrast and CT attenuation comparable to iopromide at lower doses—both *in vitro* and *in vivo*—for 2 h after injection, enabling high-resolution renal imaging helping in the early detection of pathology [70].

21.2.1.4 AuNPs in the imaging of bones

While bones provide excellent contrast, emerging AuNP-based contrast agents are pushing the boundaries further by enabling the detection of even minute structural defects. AuNPs (15 and 40 nm) conjugated with glutamic acid were used to identify microscale damages at the surfaces of resected bovine bones with the help of scanning electron microscopy. They enabled this by binding with calcium ions in the crystals of bone [71]. In a separate study, a combination of superparamagnetic iron oxide NPs (SPIONs) composed of Fe_3O_4 (200 nm) and AuNPs (4 nm) were coated in silica before being included in a calcium phosphate cement tested *in vitro* and *in vivo* (mouse femoral condyle), enabling visualization for 8 weeks after implantation [72].

21.2.1.5 AuNPs as blood pool imaging agents

The blood pool agents (BPAs), also known as intravascular contrast agents (polymeric Gd-chelates, albumin-binding Gd complexes, etc.), are typically of very high molecular weights [73], which, unlike most other contrast agents, prevents their leakage through vascular walls into interstitial spaces. In addition, these

molecules typically demonstrate higher relaxivity compared to conventional contrast agents [74]. Hence, these molecules remain longer within vascular compartments and enable the imaging of vasculature with higher resolution.

AuNPs stabilized by nontoxic phytochemical gum Arabic showed linear attenuation of the CT signal at both 80 and 140 kVp in a swine model, with liver and spleen being the most prevalent deposition sites, as demonstrated by increased HU for the intravenously administered AuNPs, [75]. Stealth PEGylated AuNPs (~38 nm) showed promise as BPA in Balb/c mice, especially in liver, spleen, kidneys, inferior vena cava, and the right ventricle of the heart, for up to 24 h after intravenous injection [76]. Similar PEG₅₀₀₀ylated AuNPs (14, 18, and 21 nm) provided higher contrast and longer intravascular retention time (~24 h) compared to iodine injection (~6 h) at 60 kVp *in vivo* [77]. AuNP-loaded G5-NH₂ dendrimers, modified with the iodinated CT contrast agent diatrizoic acid (DA) showed 2-fold and 10-fold higher contrast compared to similar AuNP nanoconstructs without DA and without Omnipaque[®], respectively, *in vivo* [78]. In another *in vivo* study, PEGylated G4 PAMAM dendrimers carrying AuNPs performed better than iopamidol as BPA and demonstrated a longer $t_{1/2}$ in blood [79]. Silica-coated gold nanoclusters (98 nm) showed higher CT attenuation, with longer (~18 h) visualization *in vivo*, compared to Iopamiron[®]—a commercially available iodinated contrast agent [80].

21.2.1.6 AuNPs in the imaging of thrombosis

GC-coated AuNPs (~20 nm) were used successfully to image thrombotic plaques at various time points ($t = \frac{1}{2}$ h to 3 weeks) after artificial induction in C57BL/6 mice [81]. Dissolution of the plaques with tissue plasminogen activator gradually decreased the CT attenuation, further elucidating the suitability of such AuNPs in the detection of thrombotic plaques. Further modification of these GC-coated AuNPs with fibrin enhanced the targeting capability, giving superior results *in vitro* (HeLa cells) and *in vivo* (cerebral embolism induced artificially by injection of thrombotic material labeled with fluorescent dye) [82]. AuNPs (~16.7 nm) coated with lisinopril—an ACE (angiotensin converting enzyme) inhibitor used often in congestive cardiac failure and hypertension—stabilized with thioctic acid were used to target the heart and lungs in mice and provided adequate contrast while imaging [83].

21.2.1.7 AuNPs in targeting of macrophages and imaging

Imaging of macrophages provides important information in conditions such as cancer and cardiac diseases. AuNPs (3.1 ± 0.5 nm) encapsulated within high-density lipopolysaccharide capsules (7.2 ± 0.7 nm) exhibited adequate attenuation of the CT signal in spectral CT scans to image artificially induced atherosclerotic plaques, especially in commonly encountered sites like the aortic arch and its bifurcation, in apolipoprotein E knockout (apoE-KO) mice for 24 h after exposure through the intravenous route (tail vein) [84]. Low-density-lipoprotein-encapsulated AuNPs (2–3 nm) exhibited linear CT attenuation (slope 0.25 mM gold/HU) and adequate signals from tumors artificially induced in mice by




Figure 21.1 *In vivo* planar projections after intravenous administration of 2.1 ± 0.4 nm dendrimer-entrapped AuNPs (Au DENPs) in G5 acetamide-terminated polyamidoamine (PAMAM) dendrimers (molar ratio of Au to dendrimer 51.2:1) or iohexol—a commercially available iodine containing a contrast agent (Omnipaque®). Rows I–III display images after intravenous administration of Au DENP, iohexol, and PBS, respectively. In each row (a) denotes the precontrast image, while the other panels show acquisition at $t = 5$ (b), 20 (c), and 60 (d) minutes from injection. In the case of Au DENPs, the following structures could be observed: (I-b) at $t = 5$ minutes, the heart (arrow), the renal vein (oval arrow), and the portal vein (arrow head), with its branches (diamond arrow), were visible, (I-c) at $t = 20$ minutes, the renal vein (oval arrow) and the portal vein (arrow head), with its branches (diamond arrow) remained visible, (I-d) at $t = 60$ minutes, the vascular system went invisible, although the urinary system, including the ureter (open arrow) and the urinary bladder (open arrow head), stayed visible. In the case of iohexol (II), the vascular system could not be imaged initially, although the urinary system could be imaged at $t = 5$ minutes (II-b) while only the urinary bladder could be imaged at $t = 60$ minutes (II-c). Reproduced from Ref. [89] under a Creative Commons agreement (CC BY).

injecting B16-F10 cells [85]. PEG₂₀₀₀ylated core@shell AuNP@silica particles (88 ± 9 nm) demonstrated increased hepatic accumulation *in vivo* and enabled imaging of liver for up to 24 h after intravenous exposure [86]. AuroVist™ AuNPs

(15 nm), phagocytosed by macrophages, were used to track macrophages and quantify the accumulation of macrophages in induced arterial plaques *in vivo* [87]. Significantly higher CT signals were recorded in apoE-KO mice from induced atherosclerotic plaques for 6 h after the intravenous injection of AuNPs encapsulated within G5-NH₂ dendrimers conjugated with methyl-terminated PEG and fluorescein isothiocyanate (Fig. 21.1) [88].

AuNPs coated with heparin (54.6 ± 19.6 nm in aqueous dispersion) were used *in vivo* to target the Kupffer cells of liver and facilitate hepatic imaging. Compared to the commercially available contrast agent eXIA160, these AuNPs showed a higher CT signal from the liver [90]. Strawberry-like AuNPs entrapped within Fe₃O₄ NPs accumulated within hepatic Kupffer cells *in vivo* and enabled imaging of the liver in HCC [91].

21.2.1.8 AuNPs in multimodal imaging

The ability to image physical structures and organs with various modalities (e.g., MRI, CT, ultrasonogram (USG), photoacoustic imaging, and fluorescence) provides the clinician with valuable knowledge in making diagnosis and chalking out the treatment plan (Fig. 21.2). AuNPs present ample opportunities for the development of such multimodal imaging tools as explained below.

- AuNPs in MRI:** Gd-based formulations are standard for MRI applications, although may cause toxicity [92, 93]. SPIONs have also been tried as a replacement for Gd-based products. Unfortunately, SPIONs were found to cause hepatic toxicity due to oxidative stress caused by the generation of reactive oxygen species [94, 95]. AuNRs coated with polypyrrole have shown promise both as CT contrast and MRI agents *in vitro* where the T2 relaxation (128.57/mM/s) was higher than T1 (7.99/mM/s) [96]. PEGylated gold and Fe₃O₄ alloy NPs showed satisfactory results as a multimodal MRI-CT-surface-enhanced Raman scattering (SERS) imaging agent *in vivo* [97]. Fe₃O₄/gold heteronanoconstructs (30.4 ± 8 nm) coated with a poly(DMA-*r*-mPEGMA-*r*-MA) polymer showed higher magnetic resonance (MR) and a 1.5 times higher CT signal compared to the commercially available MR contrast agent Resovist® [98]. AuNPs encapsulated within thiolated and PEGylated Fe₃O₄/silica particles (101.3 nm) were used successfully as both CT and MRI agents in the imaging of mouse tumors [99]. An Au/Fe₃O₄ (3:1) heteroparticle encapsulated within PEG/poly- ϵ -caprolactone polymers showed excellent MR contrast in a mouse tumor model (glioblastoma multiforme), although with negligible CT contrast [100]. AuNPs attached to a Gd-organometallic matrix (4 ± 2 nm) encapsulated within PAA shell showed higher contrast than Magnevist® but CT attenuation comparable to that of Omnipaque® [101]. PEGylated G5 PAMAM dendrimers with encapsulated AuNPs and Gd ions showed excellent contrast in both CT and MRI (1.5-fold increase in kidney/liver and 2-fold in urinary bladder) after 45 minutes of intravenous administration [102].




Figure 21.2 3D volume rendering from CT data in conjunction with smoothed X-ray fluorescence computed tomography images (bicubic interpolation) and corresponding axial CT images of kidney and tumor slices, enabling multimodal quantitative imaging in order to assess *in vivo* (a Swiss nude mouse with a xenografted prostate tumor in the right thigh) biodistribution of AuNPs (1.9 nm AuroVist™) at $t = 5, 45,$ and 140 minutes after intravenous injection. Reproduced from Ref. [113] under a Creative Commons agreement (CC BY).

AuNPs and Fe_3O_4 NPs encapsulated within biocompatible materials like graphene showed linear CT attenuation dependent on the concentration of gold [103]. Similarly, AuNPs and Fe_3O_4 NPs encapsulated within PEGylated graphene oxide (GO) showed a time-dependent increase of contrast in the tumor *in vivo* for 5 minutes after administration [104]. Gd and AuNPs encapsulated within silica (80 nm) demonstrated ninefold higher contrast compared to the control preinjection contrast *in vivo* [105]. Larger AuNPs (~400 nm) with a coating of silica impregnated with manganese oxide and smaller AuNPs showed 1.5 times higher contrast than the commercially available MRI agent Magnevist® [106]. A linear relation between particle concentration and contrast in CT/MRI could also be observed in gold nanostars (60 nm) with a 20 nm thick silica core *in vitro* in BT549 breast carcinoma cells [107]. PEGylated silica NPs (~120 nm) coated with gold

(~16 nm thick) exhibited augmented intratumoral contrast in tumors induced by the injection of B16-F10 cells in nude mice [108]. AuNPs (1.9 and 31 nm) attached to Gd particles showed the maximum accumulation in the renal system in CT imaging and urinary bladder in MRI after 10 and 30 minutes of injection in mice [109].

- **AuNPs as USG contrast agents:** PEGylated perfluorooctyl bromide (PFOB) NPs (~325.6 nm) encapsulated within gold shells were used successfully for *in vivo* renal and hepatic imaging due to the higher acoustic impedance offered by PFOB compared to air [110]. AuNPs encapsulated within polylactic acid with GO layered on top of the particulate constructs showed excellent MRI and CT contrast, both *in vitro* and *in vivo* [111]. Interestingly, these particles, apart from imaging, could also be used as drug delivery agents for pancreatic islet cells, enabling maintenance of blood glucose levels in diabetic mice for up to 6–7 weeks from intraperitoneal administration [112].
- **AuNPs in photoacoustic imaging:** Photoacoustic imaging is an upcoming imaging modality where, like fluorescence, irradiation of visible or near-infrared (NIR) light is used to trigger adiabatic expansion of the tissues, which generates pressure waves. As different tissues produce different waves due to the inherently varied optical and thermal characteristics, these emitted pressure waves can be used to develop images of the tissue/organ under investigation. Contrast agents are used where there is inadequate penetration or contrast within tissues [114–116].

Cinnamon-coated AuNPs have shown promise as photoacoustic contrast agents *in vitro* [65]. Coating the AuNPs with the dye Prussian blue increased their utility in photoacoustic imaging [67]. AuNPs encapsulated within poly-di(carboxylatophenoxyphenoxy)phosphazene of a mean size ~200 nm showed excellent potential as a contrast agent in CT and photoacoustic imaging, both *in vitro* and *in vivo* [117].

21.2.1.9 AuNPs in SPECT and PET imaging

Radiotracers can be conjugated to AuNPs for nuclear imaging purposes, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). Multimodal PET/CT scans were performed successfully *in vivo* by conjugating ^{64}Cu with AuNPs [27]. AuNPs (25 nm) covalently linked to radiotracers ^{111}In or ^{64}Cu were used successfully for SPECT/PET/CT scanning both *in vitro* (T-cells) and *in vivo* (lungs of nude Balb/c mice) [118]. Targeted AuNPs with ^{111}In were also used to image oral tumors *in vivo* [34].

21.2.1.10 AuNPs in fluorescence-based imaging

Apart from self-emission, AuNPs are excellent vectors for delivering fluorescent probes. Multimodal (CT/fluorescence) mesoporous silica-coated AuNPs labeled with ICG delivered a positive outcome *in vivo* [66]. An adequate emission signal was detectable in a mouse model for up to 24 h from the administration of

PEGylated micelles containing AuNPs and *bis*(4-(*N*-(2-naphthyl)phenylamino)phenyl)-fumaronitrile [61], which also enabled tracking of the particles *in vivo* [63]. Multiple other studies [41, 104, 119] have further highlighted the potential of AuNPs as multimodal imaging agents, with fluorescence as one of the ways for imaging.

21.3 Quantum Dots

The QDs, typically nanocrystals (2–10 nm) of semiconductors comprising elements (Cd, Pb, etc.) from groups II–VI, III–IV, and IV–VI in the periodic table [120], offer exciting opportunities for biological imaging due to their resistance to photobleaching, tunability, and high quantum yield [121–123]. Moreover, unlike commonly used organic dyes, QDs can be used for imaging in the NIR region of the spectrum, which is highly desirable in biomedical imaging because there is very little or no interference from the tissues [124, 125]. Synthesis of ternary QDs with elements from three groups I, III, and VI (I→Cu/Ag, III→Ga/In, and VI→S/Se) has broadened the possibilities of integrating multiple assays in a singular platform [126]. Unfortunately, safety issues continue to undermine the feasibility of QDs as effective imaging agents [127, 128]. However, with gain in mastery over synthesis and surface passivation techniques, more biocompatible and promising variants of QDs are emerging. The physics behind the characteristic optoelectronic properties, including the quantum confinement effect, have been discussed in Chapter 2, and the readers are highly encouraged to revisit those sections.

Core@shell CdSe@ZnS QDs conjugated with single-stranded DNA (ssDNA) and tagged with a fluorescent dye FRET probe were used successfully to quantify the extracellular nuclease of *Staphylococcus aureus* [129]. Quantitative multiphoton imaging of tumor biomarkers was enabled by CdSe@ZnS QDs (11.9 nm) conjugated with single-domain antibodies [130]. Cu-doped CdSe@ZnS QDs (~4 nm) presented an excellent tool for bioimaging, with tunable photoluminescence showing a red-shift on increasing the percentage of Cd and Cu [131]. PAA-coated Cu₂(OH)PO₄ QDs (~10.5 nm) presented a multimodal theranostic platform in a HeLa tumor-bearing mice model, enabling PDT/PTT along with NIR and photoacoustic imaging [132]. Iodine-doped carbon dots (~2.7 nm) showed promising results as a biocompatible CT contrast agent and enabled photoluminescence-based imaging in rats [133]. Functionalized QDs, for example, polydentate phosphine-coated 10 nm CdTe@CdSe [134] or capped InP@ZnS [135], were used to map lymph nodes *in vivo* and provide imagery guidance during the resection of lymph nodes in metastatic cancer.

Biocompatible indium-based QDs (12.2 ± 0.29 nm) enabled imaging of the lymph nodes and assessment of biodistribution *in vivo* and *ex vivo* (Fig. 21.3) [136]. Gd-doped carbon QDs (~5.5 nm) provided both high MRI contrast and fluorescence-based imaging *in vitro* [137]. Similar nitrogen- or sulfur-doped

biocompatible carbon QDs (~1.7 nm) with a high quantum yield (39.7%) showed promising results *in vitro* in HeLa cells [138]. In another study, glycine-coated Gd-doped carbon QDs (~1.8 nm) acted as excellent MRI contrast agents and radiosensitizer *in vivo* [139]. Compact bioconjugated CdSe core QDs (~15 nm) conjugated with antibodies overcame the challenges related to labeled antibodies (inadequate photostability, asymmetric emission, etc.) and diffused inside the bone marrow to image rare progenitor and hematopoietic cells [140]. Glutathione-capped FePt-CdS QDs (9–11 nm) displayed efficiency as a bimodal (fluorescence and MRI) imaging agent *in vitro* [141]. Furthermore, synthesis of hybrid QDs (e.g., phthalocyanine with QDs) was shown to enhance the quantum yield of emission by about threefold [142].




Figure 21.3 Color (A) and photoluminescence (B) images of the ex vivo armpit region from exposed rats following subcutaneous administration of QDs. Tissues were illuminated with a light-emitting diode lamp ($\lambda_{em} = 455 \text{ nm}$) while the photoluminescence from the QDs was recorded. The green zones in (B) are due to tissue autofluorescence, while the red ones are due to photoluminescence from QDs accumulated in axillary and thoracic lymph nodes. Reproduced from Ref. [136] under a Creative Commons agreement (CC BY).

21.4 Carbon Nanotubes

Since the discovery, CNTs have attracted plenty of attention due to their unique materialistic and optoelectronic properties, with sundry projected applications, including medicine [143–146]. A significant discussion on such properties exhibited by the CNTs, particularly single-walled carbon nanotubes (SWCNTs), has been included already in Chapter 6 of this book. This section will focus exclusively on the uses of CNTs in the field of biomedical imaging.

21.4.1 CNTs in Fluorescence-Based Imaging

With a quasi-1D structure and narrow bandgap energy (1 eV) [147], CNTs are known to emit at NIR regions—the classical NIR-I region (700–900 nm) and the recently described NIR-II region (1100–1400 nm) [148–150]. These NIR regions present with vast opportunities in biomedical imaging due to satisfactory tissue penetration and minimal interference from the tissue materials (e.g., hemoglobin

and water) due to lack of absorbance and scattering [151]. The NIR-II region is particularly interesting because there is almost no noise in that region [152]. Furthermore, CNTs demonstrate high Stoke's shift, conducive for fluorescence-based imaging [153]. However, a major disadvantage of the CNTs is low quantum yield [154]. Additionally, CNTs lack solubility and pose significant safety concerns [155, 156]. A series of surface conjugation techniques have emerged in recent years to address these issues, although such techniques often compromise the emission properties. Fortunately, the modern techniques to functionalize CNTs have enabled milder reaction conditions that help sustain the integrity of CNTs and even enhance the quantum yield [157]. Surface coating with hydrophilic polymers, like PEG, has further improved its biocompatibility [158].

High-resolution intravital fluorescence microscopy, including imaging of subcutaneous vasculature, in the NIR-II region was successfully conducted in mice with PEGylated and modified SWCNTs [159]. Similar SWCNTs were also tracked to understand the dynamics of nanotubes *in vivo* [160]. Imaging at the NIR-II region and the use of analytical tools, such as principal component analysis, enabled improvement of resolution in acquired imagery data, including those from spleen, liver, and pancreas. SWCNTs functionalized with the PEGylated polymer C₁₈PMH-PEG (poly(maleic anhydride-alt-1-octadecene)-polyethylene glycol) enabled prolonged blood circulation ($t_{1/2} \sim 30$ h) and high (30% of injected dose) intratumoral accumulation in 4T1 breast cancer cell tumors in Balb/c mice [161]. The tumoral fluorescence signal could be detected within 20 s of injection and sustained for 72 h. 3D reconstruction of imagery data confirmed the colocalization of the injected SWCNTs with intratumoral vasculature, further confirming the EPR effect. NIR-II imaging with SWCNTs has recently enabled high-resolution imaging of the vasculature, including differentiation between arteries or veins and assessment of the hemodynamics within the blood vessels in normally perfused and ischemic limbs [162]—which otherwise is difficult to achieve with conventional imaging tools, like micro-CT or USG. An interesting fact in CNT-based NIR-II imaging is the mix of various chiralities in the injected CNT samples, which deteriorates the signal as only a small fraction of the injected SWCNTs is excited by the incident laser. Hence, administration of chirally pure samples not only improves the signal but also helps in lowering the dose, which will be an advantage given the safety concerns with the CNTs. Fortunately, there is a wide range of techniques (e.g., dielectrophoresis, gel filtration, and density gradient centrifugation) capable of preparing chirally pure CNTs [163–166]. In an *in vivo* study with a chirally pure sample of SWCNTs ($\lambda_{\text{ex}} = 808$ nm, $\lambda_{\text{em}} = 1200$ nm) prepared by gel separation, a fivefold higher signal was obtained in comparison to the non-purified samples at a sixfold lower dose [167].

21.4.2 CNTs in Raman Scattering–Based Imaging

SWCNTs are effective Raman scatterers with an exceptionally high scattering cross section, making them suitable for high-resolution imaging of biological materials,

including tissues [168, 169]. The SWCNTs typically demonstrate multiple peaks at the Raman spectrum in the radical breathing mode, which are 100–300/cm, and a tangential G-band (~1580/cm) [170].

SWCNTs wrapped in oligonucleotides were used successfully as a label-free probe to track live 3T3 cells *in vitro* and perform long-term tracking of the conjugated CNTs *in vivo* [171]. The tangential G-band exhibited by the CNTs was used to map and track the intracellular distribution of SWCNTs in carcinoma cells. SWCNTs were used for molecular imaging in murine macrophage RAW 264.7 cells with high-speed confocal Raman imaging [172]. SWCNTs conjugated with RGD peptides enabled imaging of tumors *in vivo* [173].

The precise Raman peaks for every molecule (molecular fingerprint) provide excellent opportunity for developing multiplexed imaging platforms [174–176]. An interesting finding is that the frequency of vibration in the G-band from C–C bonds in SWCNTs depends on the mass of C-atoms [177]. This property was exploited to develop a multiplexed Raman imaging tool based on SWCNTs by varying the ¹³C atoms in SWCNTs and, thus, develop a five color-coded imaging platform for cancer cells *in vitro* (LS174T colon cancer cells) and LS174T cell tumors in athymic nude mice *in vivo* [178].

A practical challenge in CNT-based Raman imaging is the slow acquisition rate, for example, it takes a few h to acquire an image of 100 × 100 pixel size. A way to shorten this acquisition time is to increase the Raman scattering signal by SERS [179, 180]. Coating the SWCNTs with NPs of noble metals (e.g., gold and silver) is an option [181–183]. SWCNTs coated with cationic polyallylamine hydrochloride were used to attach anionic gold nanoseeds as a shell-like structure before functionalization with ssDNA [184]. These ssDNA-conjugated SWCNT constructs were used successfully to image KB and HeLa cells *in vitro*.

In summary, the SWCNTs present the following advantages over conventional Raman tags: (i) narrow (~2 nm width at half-maximal intensity) and intense Raman peaks, enabling a high signal to noise ratio (SNR); (ii) acquisition of Raman signals resistant toward quenching or bleaching, enabling long-term imaging; (iii) scope for multiplexing in order to develop color-coded imaging platform; and (iv) combination with SERS probes to increase SNR and sensitivity.

21.4.3 CNTs in Photoacoustic Imaging

In photoacoustic imaging, the incident laser is absorbed by photoacoustic molecules, like contrast agents, and various tissue materials, which convert the absorbed energy into heat and thus expand thermoelastically [185–187]. Afterward, the energy is released as ultrasonic sound waves, similar to the emission in fluorescence, which is detected and used to generate an image of the samples (Fig. 21.4). Compared to the traditional imaging by optical means, photoacoustic imaging provides higher tissue penetration, with little background noise, due to less scattering or absorbance and increased contrast, with the ability to provide

both 2D and 3D information. Nanomaterials like CNTs (both SWCNTs and MWCNTs) with absorbance in NIR regions are excellent contrast agents for photoacoustic imaging [188–193].




Figure 21.4 The structures of CNT; PMB, or amphiphilic and biocompatible polymer poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate); and PMB-coated CNT. (a) PL spectra of an aqueous dispersion of PMB-CNTs, (b) the black box shows the wavelength of excitation and PL emission used while imaging. (c–e) The NIR-PL images in the mouse at 5 h from the intravenous injection of PMB-CNTs, (f–h) are from the control mouse without injection. The intensity range of PL imaging is given at the bottom left of each image. Abbreviations: Ax, axillar; Bo, bowels; In, inguinal; Is, interscapular; Li, liver; Pe, pelvic; PL, photoluminescence; Pv, paravertebral; and Rp, retroperitoneal. Reproduced from Ref. [199] under a Creative Commons agreement (CC BY).

Photoacoustic imaging was used to detect and quantify SWCNTs in histological samples in picogram quantities [194]. Targeted SWCNTs functionalized with RGD peptides enabled photoacoustic imaging of tumors *in vivo* [195]. The photoacoustic signals can be further enhanced by coating the CNTs with a thin layer of gold or organic materials with NIR absorbance. Such gold-coated CNTs with conjugated antibodies for targeting were used successfully to detect and map endothelial receptors in lymphatic vessels [196] and circulating cancer cells [197] *in vivo* under an external magnetic field. PEGylated SWCNTs conjugated with ICG through π - π stacking achieved subnanometer sensitivity *in vivo* by photoacoustic imaging [198].

21.4.4 CNTs in MRI

CNTs are increasingly being used as MRI agents, as both T1- and T2-contrast agents [200–203]. SWCNTs conjugated with Gd^{3+} ions by both covalent [204] and noncovalent [205] ways were useful T1-contrast agents *in vivo*. SWCNTs with attached iron oxide NPs were used as *in vitro* T2-contrast agents in macrophage cells [206]. MWCNTs loaded with cobalt ferrite NPs enabled significant T2 negative contrast in HeLa and L929 cells *in vitro* [207]. The trace amount of iron impurity in SWCNT samples has been used to develop T2-contrast in MRI, both *in vitro* [208] and *in vivo* [209]. Tracking of stem cells *in vivo* has become quite important, given the increasing use of stem cell-based technologies [210, 211] where CNTs can be an interesting tool. Mesenchymal stem cells (MSCs), including human MSCs, labeled with MWCNTs, could be successfully tracked *in vivo* with T2-weighted MRI [212, 213].

In summary, CNTs are providing novel opportunities in MRI, especially as T2-contrast agents, as they require minimal functionalization due to the proposed uses based on metallic impurities (e.g., iron and cobalt) present in the CNT samples. With improved penetration within tissue and possibilities for designing multimodal imaging platforms, the use of CNTs in developing such MRI platforms are anticipated to expand rapidly in the future.

21.4.5 CNTs in Nuclear Imaging

Various radioisotopes, for example, ^{125}I [214], ^{14}C [215], and ^{111}In [216], can be conjugated to the CNTs in order to develop multimodal imaging platforms *in vivo*. PET could be done *in vivo* by labeling SWCNTs with ^{86}Y [217], with more of similar studies reported on tumor imaging [218, 219]. PEGylated SWCNTs bearing ^{64}Cu and conjugated with RGD peptides were used to target and image U87MG cell tumors with the intratumoral vasculature *in vivo* [220]. Similarly, SWCNTs functionalized with anti-CD20 antibodies and RGD peptides containing ^{111}In were used to target and image human Burkitt lymphoma *in vivo* [221]. SWCNTs were filled with $Na^{125}I$ (endohedral functionalization) to prepare ^{125}I -labeled NTs enabling SPECT/CT scanning *in vivo* [222].

21.5 Magnetic Nanoparticles

Magnetic nanoparticles (MNPs), especially SPIONs and ultrasmall superparamagnetic iron oxide NPs (USPIONs), are excellent MRI contrast agents. Significant details about iron oxide NPs, along with their physicochemical properties, surface passivation techniques, and targeting strategies, are discussed in Chapter 11. A thorough revision of these topics will be useful before progressing through this section.

- **MNPs in cancer imaging:** SPIONs are used as MRI platforms in hepatic cancers with metastatic lesions (2–3 mm) [223] and lymph node metastasis

(5–10 mm) [224]. The acquired data provide valuable help in staging the cancers, along with determining the treatment strategy, for example, in cancers of prostate, breast, and colon [225]. USPIOs are being used to estimate the volume and boundary in the case of brain tumors [226, 227], which remains a challenge with Gd-based contrast agents. Contrary to Gd-chelates, USPIOs exhibit higher cellular uptake and slower clearance from tumors [228], enabling demarcation of the tumor from the necrosed areas [229]. Targeted MNPs are offering further possibilities to enhance their potential in cancer imaging [230], and SPIONs conjugated with chlorotoxin showed excellent targeting and imaging capability in a 9L glioma xenograft tumor model *in vivo* [231].

- **MNPs in molecular imaging:** Molecular imaging enables visualization, characterization, and quantification of various cellular and molecular processes, with a significant impact on clinical detection, drug designing, and choice of therapeutics [232, 233]. MNPs are excellent molecular imaging tools and are being used to image/detect apoptosis [234] (e.g., by conjugation of MNPs with annexin V protein with affinity toward phosphatidylserine moieties in the cell membrane), enzymatic activities [235–237], and cellular migration/trafficking [238]. MNPs engineered to target macrophages were able to spot metastatic lesions at the millimeter scale within nonenlarged lymph nodes, which is almost impossible to achieve by the conventional imaging tools [224].
- **MNPs in imaging of cardiovascular pathology:** MNPs are considered as an effective MRI contrast agent in cardiovascular diseases, including myocardial infarction, atherosclerosis, and vascular diseases [239, 240]. MNPs targeting macrophages were used to image atheromatous plaques [241], while USPIOs were found useful in risk estimation in acute ischemia [242, 243]. MNPs conjugated with peptides to bind vascular cell adhesion protein—the target protein for the macrophages causing atherosclerosis [244]—were used successfully to image induced plaques at the early stages in mice and resected carotid arteries [245].

21.6 Dendrimers

Dendrimers are highly branched and overall monodisperse molecules that are excellent vehicles for delivery due to the void space inside and the presence of many reactive sites conducive for functionalization to facilitate targeting [246–250]. The gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) complex, often used as an MRI contrast agent, can be conjugated to the PAMAM dendrimers. The resulting hybrid nanoconstruct exhibited a longer $t_{1/2}$ in the body compared to the parent Gd-chelate compounds (e.g., 40 ± 10 and 200 ± 100 minutes for dendrimeric formulations with molecular weights of 8508 and 139,000 Da, respectively, compared to 24 ± 4 minutes for Gd-DTPA) [251, 252]. The efficacy of

such dendrimeric MRI contrast agents depended largely on the particle size, and formulations of varied sizes differ vastly in their pharmacokinetic profiles, clearance rates, and activation of the reticuloendothelial system (RES) [253]. For example, smaller G0 and G1 Gd-DTPA-terminated poly(propylene imine) dendrimers demonstrated faster clearance compared to the larger G3 and G5 ones and accumulated mostly in the urinary bladder *in vivo*. However, hepatic sequestration (up to 40% of the administered dose) of the dendrimers remains a significant challenge in translation [249, 250].

Dendrimers functionalized with FA [254–256], antibodies [257], and peptides [258] provide ample opportunities for targeting. G4 Gd-DTPA-PAMAM dendrimers functionalized with FA showed a significant improvement in tumor targeting and increase of the MRI signal in ovarian tumor models overexpressing folate receptors [259]. Similar efficacy was reported for G5 Gd-DTPA-PAMAM dendrimers in a xenograft tumor model *in vivo* [260].

21.7 Polyelectrolyte Complex Nanoparticles

Polyelectrolyte complex (PEC) NPs formed due to supramolecular assembly catalyzed by electrostatic attraction between two oppositely charged polymers [261–263] were used sparsely to facilitate imaging despite being biocompatible and relatively stable [264, 265]. Fluorescent probes (e.g., AlexaFluor 750) were encapsulated within poly(methylene-*co*-guanidine) hydrochloride PEC NPs for *in vivo* imaging [262]. Gd was incorporated in chitosan PEC NPs by grafting and trapping of Gd³⁺ ions. The resulting hybrid nanoparticulate formulation showed efficiency as an MRI contrast agent *in vivo* while the PEC NPs accumulated mostly in the kidneys and liver [265].

21.8 Silicon Nanoparticles

Silicon NPs (SiNPs) are biocompatible imaging agents with plenty of scope for bioconjugation [266, 267]. Contrary to the conventional semiconductor II-VI QDs, silicon is safe and its degraded end product in the body, orthosilicic acid/Si(OH)₄, is excreted through urine [268, 269]. Moreover, silicon is the second-most-abundant element [270], and it is known that porous silicon is biodegradable [271, 272]. SiNPs conjugated with hydrophilic molecules (e.g., allylamine and acrylic acid) enabled water-soluble dispersions suitable for biological applications [273, 274], such as imaging of the HeLa cells, where the SiNPs accumulated mostly in the cellular cytoplasm after internalization [275]. SiNPs encapsulated within water-soluble phospholipid micelles were used in bioimaging, both *in vitro* [276] and *in vivo* [277]. A library of larger (≥50 nm), photostable SiNPs conjugated to a series of hydrophilic molecules, including polymers and micelle-encapsulated nanoconstructs, were subsequently developed, the aim being biological applications [278, 279], although it is known that smaller SiNPs (<10 nm) are more apt for

such uses [280, 281]. A facile, microwave-assisted technique was developed to synthesize SiNPs (3.11 ± 0.65 nm) with a high quantum yield, stability against denaturation caused by fluctuating pH, and resistance to photobleaching for further use in imaging *in vitro* with the help of immunolabeling [282] or functionalization with proteins [283].

21.9 Summary and Outlook

Nanoparticulate imaging agents are providing fresh solutions to the lingering challenges in clinical imaging by providing opportunities like multimodal imaging. However, our knowledge on how NPs interact with biological systems still remains far from satisfactory. Lack of *in vitro*–*in vivo* correlation is also an obstacle in the successful translation of such agents. Biocompatibility will be another important challenge to address. Unfortunately, a lot of these engineered NPs with splendid engineering and competency to achieve various goals, including targeting, also present more complexities, such as biopersistence and toxicity. Therefore, striking the right balance between the degree of chemical modification and acceptable toxicity will be a vital determinant in translation.

It is important for nanomedicines to evade the intrinsic RES-based mechanisms to counter exposure scenarios. An overall observation is that while the larger NPs (roughly 20–100 nm) are filtered by the RES (liver, spleen, and lungs), smaller NPs (<20 nm) undergo quick renal filtration and thus their $t_{1/2}$ in blood is reduced. Techniques like PEGylation offer ways to skip such filtration by intrinsic mechanisms, although more control is required over the synthetic protocols. Moreover, engineered formulations risk losing the commercial edge due to higher production costs, which will be a challenge in commercializing such preparations. In addition, it is imperative that these nanoformulations demonstrate considerable improvement over conventional formulations in phase III trials, which overall has not been the case so far. Hence, in spite of the undeniable potential of these nanoformulations as imaging tools, doubts remain about whether they will succeed in replacing the existing state-of-the-art technologies in the near future. Still, the trajectory analysis of how the field has developed so far does give enough reasons to remain hopeful.

Abbreviations

ACE:	angiotensin converting enzyme
apoE-KO:	apolipoprotein E knockout
ASGP:	asialoglycoprotein
AuNPs:	gold NPs
BPAs:	blood pool agents
CNTs:	carbon nanotubes
CT:	computed tomography
EGFRs:	epidermal growth factor receptors
EPR:	enhanced permeation and retention effect

FA:	folic acid
GC:	glycolic chitosan
Gd-DTPA:	gadolinium-diethylenetriaminepentaacetic acid
GO:	graphene oxide
HCC:	hepatocellular carcinoma
HU:	Hounsfield units
ICG:	indocyanine green
LBA:	lactobionic acid
MNPs:	magnetic NPs
MRI:	magnetic resonance imaging
NIR:	near-infrared
NPs:	nanoparticles
PAA:	polyacrylic acid
PAMAM:	polyamidoamine
PEC:	polyelectrolyte complex
PEI:	polyethyleneimine
PET:	positron emission tomography
PFOB:	PEGylated perfluorooctyl bromide
QDs:	quantum dots
RES:	reticuloendothelial system
SERS:	surface-enhanced Raman scattering
SiNPs:	silicon NPs
SNR:	signal to noise ratio
SPECT:	single photon emission computed tomography
SPIONs:	superparamagnetic iron oxide NPs
ssDNA:	single-stranded DNA
SWCNTs:	single-walled carbon nanotubes
USG:	ultrasonogram
USPIONs:	ultrasmall superparamagnetic iron oxide NPs

Disclosures and Conflict of Interest

This chapter was originally published as: Bhattacharjee, S. (2020). *Principles of Nanomedicine*. Jenny Stanford Publishing, Singapore, chapter 16 “Nanomaterials in imaging,” pp. 465–518, and appears here, with edits and updates, by kind permission of the publisher.

References

1. M. Zhou, R. Zhang, M. Huang, W. Lu, S. Song, M.P. Melancon, M. Tian, D. Liang, C. Li, A chelator-free multifunctional [⁶⁴Cu]-CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy, *J. Am. Chem. Soc.* **132** (2010) 15351–15358.
2. C. Fang, M. Zhang, Multifunctional magnetic nanoparticles for medical imaging applications, *J. Mater. Chem.* **19** (2009) 6258–6266.

3. H.K. Sajja, M.P. East, H. Mao, A.Y. Wang, S. Nie, L. Yang, Development of multifunctional nanoparticles for targeted drug delivery and non-invasive imaging of therapeutic effect, *Curr. Drug Discov. Technol.* **6** (2009) 43–51.
4. K. Greish, Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting, *Methods Mol. Bio.* **624** (2010) 25–37.
5. J. Fang, H. Nakamura, H. Maeda, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, *Adv. Drug Deliv. Rev.* **63** (2011) 136–151.
6. C. Alric, J. Taleb, G.L. Duc, C. Mandon, C. Billotey, A.L. Meur-Herland, T. Brochard, F. Vocanson, M. Janier, P. Perriat, S. Roux, O. Tillement, Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging, *J. Am. Chem. Soc.* **130** (2008) 5908–5915.
7. S. Ahn, S.Y. Jung, S.J. Lee, Gold nanoparticle contrast agents in advanced X-ray imaging technologies, *Molecules* **18** (2013) 5858–5890.
8. D.P. Cormode, P.C. Naha, Z.A. Fayad, Nanoparticle contrast agents for computed tomography: a focus on micelles, *Contrast Media Mol. Imaging* **9** (2014) 37–52.
9. R. Mahmoudi, N. Jabbari, M. aghdasi, H.R. Khalkhali, Energy dependence of measured CT numbers on substituted materials used for CT number calibration of radiotherapy treatment planning systems, *PLoS One* **11** (2016) e0158828.
10. E. Pauwels, D. Van Loo, P. Cornillie, L. Brabant, L. Van Hoorebeke, An exploratory study of contrast agents for soft tissue visualization by means of high resolution X-ray computed tomography imaging, *J. Microsc.* **250** (2013) 21–31.
11. D.F. Swinehart, The Beer-Lambert law, *J. Chem. Educ.* **39** (1962) 333–335.
12. H. Lusic, M.W. Grinstaff, X-Ray computed tomography contrast agents, *Chem. Rev.* **113** (2013) 1641–1666.
13. E.Y. Kim, D.W. Yeh, Y.H. Choe, W.J. Lee, H.K. Lim, Image quality and attenuation values of multi detector CT coronary angiography using high iodine-concentration contrast material: A comparison of the use of iopromide 370 and iomeprol 400, *Acta Radiol.* **51** (2010) 982–989.
14. M. Longmire, P.L. Choyke, H. Kobayashi, Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats, *Nanomedicine UK* **3** (2008) 703–717.
15. J.A.W. Webb, F. Stacul, H.S. Thomsen, S.K. Morcos, C.M.S.C. ESUR, Late adverse reactions to intravascular iodinated contrast media, *Eur. Radiol.* **13** (2003) 181–184.
16. S. Khademi, S. Sarkar, S. Kharrazi, S.M. Amini, A. Shakeri-Zadeh, M.R. Ay, H. Ghadiri, Evaluation of size, morphology, concentration, and surface effect of gold nanoparticles on X-ray attenuation in computed tomography, *Phys. Med.* **45** (2018) 127–133.
17. N. Anton, T.F. Vandamme, Nanotechnology for computed tomography: a real potential recently disclosed, *Pharm. Res.* **31** (2014) 20–34.
18. B. Aydogan, J. Li, T. Rajh, A. Chaudhary, S.J. Chmura, C. Pelizzari, C. Wietholt, M. Kurtoglu, P. Redmond, AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging, *Mol. Imaging Biol.* **12** (2010) 463–467.
19. G. Feng, B. Kong, J. Xing, J. Chen, Enhancing multimodality functional and molecular imaging using glucose-coated gold nanoparticles, *Clin. Radiol.* **69** (2014) 1105–1111.

20. R. Popovtzer, A. Agrawal, N.A. Kotov, A. Popovtzer, J. Balter, T.E. Carey, R. Kopelman, Targeted gold nanoparticles enable molecular CT imaging of cancer, *Nano Lett.* **8** (2008) 4593–4596.
21. W. Eck, A.I. Nicholson, H. Zentgraf, W. Semmler, S. Bartling, Anti-CD4-targeted gold nanoparticles induce specific contrast enhancement of peripheral lymph nodes in X-ray computed tomography of live mice, *Nano Lett.* **10** (2010) 2318–2322.
22. J.F. Hainfeld, M.J. O'Connor, F.A. Dilmanian, D.N. Slatkin, D.J. Adams, H.M. Smilowitz, Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions, *Br. J. Radiol.* **84** (2011) 526–533.
23. H.W. Kao, Y.Y. Lin, C.C. Chen, K.H. Chi, D.C. Tien, C.C. Hsia, M.H. Lin, H.E. Wang, Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model, *Bioorg. Med. Chem. Lett.* **23** (2013) 3180–3185.
24. T. Reuveni, M. Motiei, Z. Romman, A. Popovtzer, R. Popovtzer, Targeted gold nanoparticles enable molecular CT imaging of cancer: an *in vivo* study, *Int. J. Nanomed.* **6** (2011) 2859–2864.
25. N. Chanda, V. Kattumuri, R. Shukla, A. Zambre, K. Katti, A. Upendran, R.R. Kulkarni, P. Kan, G.M. Fent, S.W. Casteel, C.J. Smith, E. Boote, J.D. Robertson, C. Cutler, J.R. Lever, K.V. Katti, R. Kannan, Bombesin functionalized gold nanoparticles show *in vitro* and *in vivo* cancer receptor specificity, *Proc. Natl. Acad. Sci.* **107** (2010) 8760–8765.
26. Y.W. Hao, B.X. Zhang, C.X. Zheng, R. Ji, X.Y. Ren, F.F. Guo, S.L. Sun, J.J. Shi, H.L. Zhang, Z.Z. Zhang, L. Wang, Y. Zhang, The tumor-targeting core-shell structured DTX-loaded PLGA@Au nanoparticles for chemo-photothermal therapy and X-ray imaging, *J. Control. Rel.* **220** (2015) 545–555.
27. M. Tian, W. Lu, R. Zhang, C.Y. Xiong, J. Ensor, J. Nazario, J. Jackson, C. Shaw, K.A. Dixon, J. Miller, K. Wright, C. Li, S. Gupta, Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET/CT study in a rabbit VX2 liver cancer model, *Mol. Imaging Biol.* **15** (2013) 614–624.
28. B.N. Gawande, J.C. Rohloff, J.D. Carter, I. von Carlowitz, C. Zhang, D.J. Schneider, N. Janjic, Selection of DNA aptamers with two modified bases, *Proc. Natl. Acad. Sci.* **114** (2017) 2898–2903.
29. D. Kim, Y.Y. Jeong, S. Jon, A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer, *ACS Nano* **4** (2010) 3689–3696.
30. C.H. Li, T.R. Kuo, H.J. Su, W.Y. Lai, P.C. Yang, J.S. Chen, D.Y. Wang, Y.C. Wu, C.C. Chen, Fluorescence-guided probes of aptamer-targeted gold nanoparticles with computed tomography imaging accesses for *in vivo* tumor resection, *Sci. Rep.* **5** (2015) 15675.
31. M.P. Melancon, M. Zhou, R. Zhang, C.Y. Xiong, P. Allen, X.X. Wen, Q. Huang, M. Wallace, J.N. Myers, R.J. Stafford, D. Liang, A.D. Ellington, C. Li, Selective uptake and imaging of aptamer- and antibody-conjugated hollow nanospheres targeted to epidermal growth factor receptors overexpressed in head and neck cancer, *ACS Nano* **8** (2014) 4530–4538.
32. N. Parker, M.J. Turk, E. Westrick, J.D. Lewis, P.S. Low, C.P. Leamon, Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay, *Anal. Biochem.* **338** (2005) 284–293.

33. A. Cheung, H.J. Bax, D.H. Josephs, K.M. Ilieva, G. Pellizzari, J. Opzoomer, J. Bloomfield, M. Fittall, A. Grigoriadis, M. Figini, S. Canevari, J.F. Spicer, A.N. Tutt, S.N. Karagiannis, Targeting folate receptor alpha for cancer treatment, *Oncotarget* **7** (2016) 52553–52574.
34. H. Wang, L.F. Zheng, C. Peng, M.W. Shen, X.Y. Shi, G.X. Zhang, Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adenocarcinoma, *Biomaterials* **34** (2013) 470–480.
35. H.D. Cai, K.G. Li, J.C. Li, S.H. Wen, Q. Chen, M.W. Shen, L.F. Zheng, G.X. Zhang, X.Y. Shi, Dendrimer-assisted formation of Fe₃O₄/Au nanocomposite particles for targeted dual mode CT/MR imaging of tumors, *Small* **11** (2015) 4584–4593.
36. Q. Chen, K.A. Li, S.H. Wen, H. Liu, C. Peng, H.D. Cai, M.W. Shen, G.X. Zhang, X.Y. Shi, Targeted CT/MR dual mode imaging of tumors using multifunctional dendrimer-entrapped gold nanoparticles, *Biomaterials* **34** (2013) 5200–5209.
37. H. Liu, M.W. Shen, J.L. Zhao, J.Y. Zhu, T.T. Xiao, X.Y. Cao, G.X. Zhang, X.Y. Shi, Facile formation of folic acid-modified dendrimer-stabilized gold-silver alloy nanoparticles for potential cellular computed tomography imaging applications, *Analyst* **138** (2013) 1979–1987.
38. H. Liu, H. Wang, Y.H. Xu, R. Guo, S.H. Wen, Y.P. Huang, W.N. Liu, M.W. Shen, J.L. Zhao, G.X. Zhang, X.Y. Shi, Lactobionic acid-modified dendrimer-entrapped gold nanoparticles for targeted computed tomography imaging of human hepatocellular carcinoma, *ACS Appl. Mater. Interfaces* **6** (2014) 6944–6953.
39. Y.Y. Zeng, D. Zhang, M. Wu, Y. Liu, X. Zhang, L. Li, Z. Li, X. Han, X.Y. Wei, X.L. Liu, Lipid-AuNPs@PDA nanohybrid for MRI/CT imaging and photothermal therapy of hepatocellular carcinoma, *ACS Appl. Mater. Interfaces* **6** (2014) 14266–14277.
40. Q. Chen, H. Wang, H. Liu, S. Wen, C. Peng, M. Shen, G. Zhang, X. Shi, Multifunctional dendrimer-entrapped gold nanoparticles modified with RGD peptide for targeted computed tomography/magnetic resonance dual-modal imaging of tumors, *Anal. Chem.* **87** (2015) 3949–3956.
41. Z.J. Zhou, C.L. Zhang, Q.R. Qian, J.B. Ma, P. Huang, X. Zhang, L.Y. Pan, G. Gao, H.L. Fu, S. Fu, H. Song, X. Zhi, J. Ni, D.X. Cui, Folic acid-conjugated silica capped gold nanoclusters for targeted fluorescence/X-ray computed tomography imaging, *J. Nanobiotechnol.* **11** (2013) 17.
42. I.C. Sun, J.H. Na, S.Y. Jeong, D.E. Kim, I.C. Kwon, K. Choi, C.H. Ahn, K. Kim, Biocompatible glycol chitosan-coated gold nanoparticles for tumor-targeting CT imaging, *Pharm. Res.* **31** (2014) 1418–1425.
43. X.X. He, F.Y. Liu, L. Liu, T.C. Duan, H.M. Zhang, Z.X. Wang, Lectin-conjugated Fe₂O₃@Au core@shell nanoparticles as dual mode contrast agents for *in vivo* detection of tumor, *Mol. Pharm.* **11** (2014) 738–745.
44. J. Li, Y. Hu, J. Yang, P. Wei, W. Sun, M. Shen, G. Zhang, X. Shi, Hyaluronic acid-modified Fe₃O₄@Au core/shell nanostars for multimodal imaging and photothermal therapy of tumors, *Biomaterials* **38** (2015) 10–21.
45. L.E. Cole, T. Vargo-Gogola, R.K. Roeder, Contrast-enhanced X-ray detection of microcalcifications in radiographically dense mammary tissue using targeted gold nanoparticles, *ACS Nano* **9** (2015) 8923–8932.

46. R. Meir, K. Shamalov, O. Betzer, M. Motiei, M. Horovitz-Fried, R. Yehuda, A. Popovtzer, R. Popovtzer, C.J. Cohen, Nanomedicine for cancer immunotherapy: tracking cancer-specific T-cells *in vivo* with gold nanoparticles and CT imaging, *ACS Nano* **9** (2015) 6363–6372.
47. H. Maeda, H. Nakamura, J. Fang, The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging *in vivo*, *Adv. Drug Deliv. Rev.* **65** (2013) 71–79.
48. H. Kobayashi, R. Watanabe, P.L. Choyke, Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?, *Theranostics* **4** (2014) 81–89.
49. S.M. Moghimi, J. Szebeni, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, *Prog. Lipid Res.* **42** (2003) 463–478.
50. A. Sharma, S.V. Madhunapantula, G.P. Robertson, Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems, *Expert Opin. Drug Metab. Toxicol.* **8** (2012) 47–69.
51. J.F. Hainfeld, D.N. Slatkin, T.M. Focella, H.M. Smilowitz, Gold nanoparticles: a new X-ray contrast agent, *Brit. J. Radiol.* **79** (2006) 248–253.
52. V. Kattumuri, K. Katti, S. Bhaskaran, E.J. Boote, S.W. Casteel, G.M. Fent, D.J. Robertson, M. Chandrasekhar, R. Kannan, K.V. Katti, Gum arabic as a phytochemical construct for the stabilization of gold nanoparticles: *in vivo* pharmacokinetics and X-ray-contrast-imaging studies, *Small* **3** (2007) 333–341.
53. D. Kim, S. Park, J.H. Lee, Y.Y. Jeong, S. Jon, Antibiofouling polymer-coated gold nanoparticles as a contrast agent for *in vivo* X-ray computed tomography imaging, *J. Am. Chem. Soc.* **129** (2007) 7661–7665.
54. G. von Maltzahn, J.H. Park, A. Agrawal, N.K. Bandaru, S.K. Das, M.J. Sailor, S.N. Bhatia, Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas, *Cancer Res.* **69** (2009) 3892–3900.
55. P.C. Naha, K.C. Lau, J.C. Hsu, M. Hajfathalian, S. Mian, P. Chhour, L. Uppuluri, E.S. McDonald, A.D.A. Maidment, D.P. Cormode, Gold silver alloy nanoparticles (GSAN): an imaging probe for breast cancer screening with dual-energy mammography or computed tomography, *Nanoscale* **8** (2016) 13740–13754.
56. H. Wang, L.F. Zheng, C. Peng, R. Guo, M.W. Shen, X.Y. Shi, G.X. Zhang, Computed tomography imaging of cancer cells using acetylated dendrimer-entrapped gold nanoparticles, *Biomaterials* **32** (2011) 2979–2988.
57. K.A. Li, S.H. Wen, A.C. Larson, M.W. Shen, Z.L. Zhang, Q. Chen, X.Y. Shi, G.X. Zhang, Multifunctional dendrimer-based nanoparticles for *in vivo* MR/CT dual-modal molecular imaging of breast cancer, *Int. J. Nanomed.* **8** (2013) 2589–2600.
58. C. Peng, L.F. Zheng, Q. Chen, M.W. Shen, R. Guo, H. Wang, X.Y. Cao, G.X. Zhang, X.Y. Shi, PEGylated dendrimer-entrapped gold nanoparticles for *in vivo* blood pool and tumor imaging by computed tomography, *Biomaterials* **33** (2012) 1107–1119.
59. H. Liu, H. Wang, Y.H. Xu, M.W. Shen, J.L. Zhao, G.X. Zhang, X.Y. Shi, Synthesis of PEGylated low generation dendrimer-entrapped gold nanoparticles for CT imaging applications, *Nanoscale* **6** (2014) 4521–4526.

60. B.Q. Zhou, L.F. Zheng, C. Peng, D. Lo, J.C. Li, S.H. Wen, M.W. Shen, G.X. Zhang, X.Y. Shi, Synthesis and characterization of PEGylated polyethylenimine-entrapped gold nanoparticles for blood pool and tumor CT imaging, *ACS Appl. Mater. Interfaces* **6** (2014) 17190–17199.
61. J.M. Zhang, C. Li, X. Zhang, S.D. Huo, S.B. Jin, F.F. An, X.D. Wang, X. Xue, C.I. Okeke, G.Y. Duan, F.G. Guo, X.H. Zhang, J.F. Hao, P.C. Wang, J.C. Zhang, X.J. Liang, *in vivo* tumor-targeted dual-modal fluorescence/CT imaging using a nanoprobe co-loaded with an aggregation-induced emission dye and gold nanoparticles, *Biomaterials* **42** (2015) 103–111.
62. L. Wang, P.P. Zhang, J.J. Shi, Y.W. Hao, D.H. Meng, Y.L. Zhao, Y.Y. Yin, D. Li, J.B. Chang, Z.Z. Zhang, Radiofrequency-triggered tumor-targeting delivery system for theranostics application, *ACS Appl. Mater. Interfaces* **7** (2015) 5736–5747.
63. L. Li, L.Y. Zhang, T.T. Wang, X.T. Wu, H. Ren, C.G. Wang, Z.M. Su, Facile and scalable synthesis of novel spherical Au nanocluster assemblies@polyacrylic acid/calcium phosphate nanoparticles for dual-modal imaging-guided cancer chemotherapy, *Small* **11** (2015) 3162–3173.
64. J.J. Shi, Z.Y. Chen, L. Wang, B.H. Wang, L.H. Xu, L. Hou, Z.Z. Zhang, A tumor-specific cleavable nanosystem of PEG-modified C60@Au hybrid aggregates for radio frequency-controlled release, hyperthermia, photodynamic therapy and X-ray imaging, *Acta Biomater.* **29** (2016) 282–297.
65. N. Chanda, R. Shukla, A. Zambre, S. Mekapothula, R.R. Kulkarni, K. Katti, K. Bhattacharyya, G.M. Fent, S.W. Casteel, E.J. Boote, J.A. Viator, A. Upendran, R. Kannan, K.V. Katti, An effective strategy for the synthesis of biocompatible gold nanoparticles using cinnamon phytochemicals for phantom CT imaging and photoacoustic detection of cancerous cells, *Pharm. Res.* **28** (2011) 279–291.
66. T. Luo, P. Huang, G. Gao, G.X. Shen, S. Fu, D.X. Cui, C.Q. Zhou, Q.S. Ren, Mesoporous silica-coated gold nanorods with embedded indocyanine green for dual mode X-ray CT and NIR fluorescence imaging, *Opt. Express* **19** (2011) 17030–17039.
67. L.J. Jing, X.L. Liang, Z.J. Deng, S.S. Feng, X.D. Li, M.M. Huang, C.H. Li, Z.F. Dai, Prussian blue coated gold nanoparticles for simultaneous photoacoustic/CT bimodal imaging and photothermal ablation of cancer, *Biomaterials* **35** (2014) 5814–5821.
68. F. Sousa, S. Mandal, C. Garrovo, A. Astolfo, A. Bonifacio, D. Latawiec, R.H. Menk, F. Arfelli, S. Huewel, G. Legname, H.J. Galla, S. Krol, Functionalized gold nanoparticles: a detailed *in vivo* multimodal microscopic brain distribution study, *Nanoscale* **2** (2010) 2826–2834.
69. D.P. Clark, K. Ghaghada, E.J. Moding, D.G. Kirsch, C.T. Badea, *in vivo* characterization of tumor vasculature using iodine and gold nanoparticles and dual energy micro-CT, *Phys. Med. Biol.* **58** (2013) 1683–1704.
70. Y.L. Wang, C. Xu, J. Zhai, F.P. Gao, R. Liu, L. Gao, Y.L. Zhao, Z.F. Chai, X.Y. Gao, Label-free Au cluster used for *in vivo* 2D and 3D computed tomography of murine Kidneys, *Anal. Chem.* **87** (2015) 343–345.
71. Z.Y. Zhang, R.D. Ross, R.K. Roeder, Preparation of functionalized gold nanoparticles as a targeted X-ray contrast agent for damaged bone tissue, *Nanoscale* **2** (2010) 582–586.

72. M. Ventura, Y. Sun, V. Rusu, P. Laverman, P. Borm, A. Heerschap, E. Oosterwijk, O.C. Boerman, J.A. Jansen, X.F. Walboomers, Dual contrast agent for computed tomography and magnetic resonance hard tissue imaging, *Tissue Eng. Part C Methods* **19** (2013) 405–416.
73. W. Zhu, D. Artemov, Biocompatible blood pool MRI contrast agents based on hyaluronan, *Contrast Media Mol. Imaging* **6** (2011) 61–68.
74. C.F.G.C. Geraldes, S. Laurent, Classification and basic properties of contrast agents for magnetic resonance imaging, *Contrast Media Mol. Imaging* **4** (2009) 1–23.
75. E. Boote, G. Fent, V. Kattumuri, S. Casteel, K. Katti, N. Chanda, R. Kannan, K. Katti, R. Churchill, Gold nanoparticle contrast in a phantom and juvenile swine: models for molecular imaging of human organs using X-ray computed tomography, *Acad. Radiol.* **17** (2010) 410–417.
76. Q.Y. Cai, S.H. Kim, K.S. Choi, S.Y. Kim, S.J. Byun, K.W. Kim, S.H. Park, S.K. Juhng, K.H. Yoon, Colloidal gold nanoparticles as a blood-pool contrast agent for x-ray computed tomography in mice, *Invest. Radiol.* **42** (2007) 797–806.
77. J.T. Au, G. Craig, V. Longo, P. Zanzonico, M. Mason, Y. Fong, P.J. Allen, Gold nanoparticles provide bright long-lasting vascular contrast for CT imaging, *Am. J. Roentgenol.* **200** (2013) 1347–1351.
78. C. Peng, K.G. Li, X.Y. Cao, T.T. Xiao, W.X. Hon, L.F. Zheng, R. Guo, M.W. Shen, G.X. Zhang, X.Y. Shi, Facile formation of dendrimer-stabilized gold nanoparticles modified with diatrizoic acid for enhanced computed tomography imaging applications, *Nanoscale* **4** (2012) 6768–6778.
79. C. Kojima, Y. Umeda, M. Ogawa, A. Harada, Y. Magata, K. Kono, X-ray computed tomography contrast agents prepared by seeded growth of gold nanoparticles in PEGylated dendrimer, *Nanotechnology* **21** (2010) 245104.
80. K. Hayashi, M. Nakamura, K. Ishimura, Near-infrared fluorescent silica-coated gold nanoparticle clusters for X-ray computed tomography/optical dual modal imaging of the lymphatic system, *Adv. Healthc. Mater.* **2** (2013) 756–763.
81. D.E. Kim, J.Y. Kim, I.C. Sun, D. Schellingerhout, S.K. Lee, C.H. Ahn, I.C. Kwon, K. Kim, Hyperacute direct thrombus imaging using computed tomography and gold nanoparticles, *Ann. Neurol.* **73** (2013) 617–625.
82. J.Y. Kim, J.H. Ryu, D. Schellingerhout, I.C. Sun, S.K. Lee, S. Jeon, J. Kim, I.C. Kwon, M. Nahrendorf, C.H. Ahn, K. Kim, D.E. Kim, Direct imaging of cerebral thromboemboli using computed tomography and fibrin-targeted gold nanoparticles, *Theranostics* **5** (2015) 1098–1114.
83. W.E. Ghann, O. Aras, T. Fleiter, M.C. Daniel, Syntheses and characterization of lisinopril-coated gold nanoparticles as highly stable targeted CT contrast agents in cardiovascular diseases, *Langmuir* **28** (2012) 10398–10408.
84. D.P. Cormode, E. Roessler, A. Thran, T. Skajaa, R.E. Gordon, J.P. Schlomka, V. Fuster, E.A. Fisher, W.J.M. Mulder, R. Proksa, Z.A. Fayad, Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles, *Radiology* **256** (2010) 774–782.
85. I.E. Allijn, W. Leong, J. Tang, A. Gianella, A.J. Mieszawska, F. Fay, G. Ma, S. Russell, C.B. Callo, R.E. Gordon, E. Korkmaz, J.A. Post, Y.M. Zhao, H.C. Gerritsen, A. Thran, R. Proksa, H. Daerr, G. Storm, V. Fuster, E.A. Fisher, Z.A. Fayad, W.J.M. Mulder, D.P. Cormode, Gold

- nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level, *ACS Nano* **7** (2013) 9761–9770.
86. M.M. van Schooneveld, D.P. Cormode, R. Koole, J.T. van Wijngaarden, C. Calcagno, T. Skajaa, J. Hilhorst, D.C. 't Hart, Z.A. Fayad, W.J.M. Mulder, A. Meijerink, A fluorescent, paramagnetic and PEGylated gold/silica nanoparticle for MRI, CT and fluorescence imaging, *Contrast Media Mol. Imaging* **5** (2010) 231–236.
 87. D. De Wilde, B. Trachet, C. Van der Donckt, B. Vandeghinste, B. Descamps, C. Vanhove, G.R.Y. De Meyer, P. Segers, Vulnerable plaque detection and quantification with gold particle-enhanced computed tomography in atherosclerotic mouse models, *Mol. Imaging* **14** (2015) 6.
 88. J.B. Qin, C. Peng, B.H. Zhao, K.C. Ye, F.K. Yuan, Z.Y. Peng, X.R. Yang, L.J. Huang, M. Jiang, Q.H. Zhao, G.Y. Tang, X.W. Lu, Noninvasive detection of macrophages in atherosclerotic lesions by computed tomography enhanced with PEGylated gold nanoparticles, *Int. J. Nanomed.* **9** (2014) 5575–5590.
 89. H. Wang, L. Zheng, R. Guo, C. Peng, M. Shen, X. Shi, G. Zhang, Dendrimer-entrapped gold nanoparticles as potential CT contrast agents for blood pool imaging, *Nanoscale Res. Lett.* **7** (2012) 190.
 90. I.C. Sun, D.K. Eun, J.H. Na, S. Lee, I.J. Kim, I.C. Youn, C.Y. Ko, H.S. Kim, D. Lim, K. Choi, B. Messersmith Phillip, T.G. Park, S.Y. Kim, I.C. Kwon, K. Kim, C.H. Ahn, Heparin-coated gold nanoparticles for liver-specific CT imaging, *Chem. Eur. J.* **15** (2009) 13341–13347.
 91. H.Y. Zhao, L. Liu, J. He, C.C. Pan, H. Li, Z.Y. Zhou, Y. Ding, D. Huo, Y. Hu, Synthesis and application of strawberry-like Fe₃O₄-Au nanoparticles as CT-MR dual-modality contrast agents in accurate detection of the progressive liver disease, *Biomaterials* **51** (2015) 194–207.
 92. M. Rogosnitzky, S. Branch, Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms, *Biometals* **29** (2016) 365–376.
 93. J. Ramalho, R.C. Semelka, M. Ramalho, R.H. Nunes, M. AlObaidy, M. Castillo, Gadolinium-based contrast agent accumulation and toxicity: an update, *Am. J. Neuroradiol.* **37** (2016) 1192–1198.
 94. Q. Feng, Y. Liu, J. Huang, K. Chen, J. Huang, K. Xiao, Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings, *Sci. Rep.* **8** (2018) 2082.
 95. Y. Wei, M. Zhao, F. Yang, Y. Mao, H. Xie, Q. Zhou, Iron overload by superparamagnetic iron oxide nanoparticles is a high risk factor in cirrhosis by a systems toxicology assessment, *Sci. Rep.* **6** (2016) 29110.
 96. W. Feng, X. Zhou, W. Nie, L. Chen, K. Qiu, Y. Zhang, C. He, Au/polypyrrole@Fe₃O₄ nanocomposites for MR/CT dual-modal imaging guided-photothermal therapy: an *in vitro* study, *ACS Appl. Mater. Interfaces* **7** (2015) 4354–4367.
 97. V. Amendola, S. Scaramuzza, L. Litti, M. Meneghetti, G. Zuccolotto, A. Rosato, E. Nicolato, P. Marzola, G. Fracasso, C. Anselmi, M. Pinto, M. Colombatti, Magneto-plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging, *Small* **10** (2014) 2476–2486.
 98. D. Kim, M.K. Yu, T.S. Lee, J.J. Park, Y.Y. Jeong, S. Jon, Amphiphilic polymer-coated hybrid nanoparticles as CT/MRI dual contrast agents, *Nanotechnology* **22** (2011) 155101.

99. W.J. Dong, Y.S. Li, D.C. Niu, Z. Ma, X.H. Liu, J.L. Gu, W.R. Zhao, Y.Y. Zheng, J.L. Shi, A simple route to prepare monodisperse Au NP-decorated, dye-doped, superparamagnetic nanocomposites for optical, MR, and CT trimodal imaging, *Small* **9** (2013) 2500–2508.
100. L. Sun, D.Y. Joh, A. Al-Zaki, M. Stangl, S. Murty, J.J. Davis, B.C. Baumann, M. Alonso-Basanta, G.D. Kao, A. Tsourkas, J.F. Dorsey, Theranostic application of mixed gold and superparamagnetic iron oxide nanoparticle micelles in glioblastoma multiforme, *J. Biomed. Nanotechnol.* **12** (2016) 347–356.
101. C.X. Tian, L.P. Zhu, F. Lin, S.G. Boyes, Poly(acrylic acid) bridged gadolinium metal-organic framework-gold nanoparticle composites as contrast agents for computed tomography and magnetic resonance bimodal imaging, *ACS Appl. Mater. Interfaces* **7** (2015) 17765–17775.
102. S.H. Wen, K.G. Li, H.D. Cai, Q. Chen, M.W. Shen, Y.P. Huang, C. Peng, W.X. Hou, M.F. Zhu, G.X. Zhang, X.Y. Shi, Multifunctional dendrimer-entrapped gold nanoparticles for dual mode CT/MR imaging applications, *Biomaterials* **34** (2013) 1570–1580.
103. Y.T. Chen, F. Guo, Y. Qiu, H.R. Hu, I. Kulaots, E. Walsh, R.H. Hurt, Encapsulation of particle ensembles in graphene nanosacks as a new route to multifunctional materials, *ACS Nano* **7** (2013) 3744–3753.
104. X.Z. Shi, H. Gong, Y.J. Li, C. Wang, L. Cheng, Z. Liu, Graphene-based magnetic plasmonic nanocomposite for dual bioimaging and photothermal therapy, *Biomaterials* **34** (2013) 4786–4793.
105. X.T. Wu, C.X. Li, S.C. Liao, L. Li, T.T. Wang, Z.M. Su, C.G. Wang, J.H. Zhao, C.P. Sui, J. Lin, Silica-encapsulated Gd³⁺-aggregated gold nanoclusters for *in vitro* and *in vivo* multimodal cancer imaging, *Chem. Eur. J.* **20** (2014) 8876–8882.
106. K. Zhang, H.R. Chen, P. Li, X.W. Bo, X.L. Li, Z. Zeng, H.X. Xu, Marriage strategy of structure and composition designs for intensifying ultrasound & MR & CT trimodal contrast imaging, *ACS Appl. Mater. Interfaces* **7** (2015) 18590–18599.
107. Y. Liu, Z. Chang, H.K. Yuan, A.M. Fales, T. Vo-Dinh, Quintuple-modality (SERS-MRI-CT-TPL-PTT) plasmonic nanoprobe for theranostics, *Nanoscale* **5** (2013) 12126–12131.
108. A.J. Coughlin, J.S. Ananta, N.F. Deng, I.V. Larina, P. Decuzzi, J.L. West, Gadolinium-conjugated gold nanoshells for multimodal diagnostic imaging and photothermal cancer therapy, *Small* **10** (2014) 556–565.
109. C. Alric, J. Taleb, G. Le Duc, C. Mandon, C. Billotey, A. Le Meur-Herland, T. Brochard, F. Vocanson, M. Janier, P. Perriat, S. Roux, O. Tillement, Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging, *J. Am. Chem. Soc.* **130** (2008) 5908–5915.
110. H. Ke, X. Yue, J. Wang, S. Xing, Q. Zhang, Z. Dai, J. Tian, S. Wang, Y. Jin, Gold nanoshelled liquid perfluorocarbon nanocapsules for combined dual modal ultrasound/CT imaging and photothermal therapy of cancer, *Small* **10** (2014) 1220–1227.
111. Y.S. Jin, J.R. Wang, H.T. Ke, S.M. Wang, Z.F. Dai, Graphene oxide modified PLA microcapsules containing gold nanoparticles for ultrasonic/CT bimodal imaging guided photothermal tumor therapy, *Biomaterials* **34** (2013) 4794–4802.
112. D.R. Arifin, C.M. Long, A.A. Gilad, C.E. Alric, S. Roux, O. Tillement, T.W. Link, A. Arepally, J.W.M. Bulte, Trimodal gadolinium-gold microcapsules containing pancreatic islet cells restore normoglycemia in diabetic mice and can be tracked by using US, CT, and positive-contrast MR imaging, *Radiology* **260** (2011) 790–798.

113. N. Manohar, F.J. Reynoso, P. Diagaradjane, S. Krishnan, S.H. Cho, Quantitative imaging of gold nanoparticle distribution in a tumor-bearing mouse using benchtop x-ray fluorescence computed tomography, *Sci. Rep.* **6** (2016) 22079.
114. S. Mallidi, G.P. Luke, S. Emelianov, Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance, *Trends Biotechnol.* **29** (2011) 213–221.
115. D. Wu, L. Huang, M.S. Jiang, H.B. Jiang, Contrast agents for photoacoustic and thermoacoustic imaging: a review, *Int. J. Mol. Sci.* **15** (2014) 23616–23639.
116. J. Weber, P.C. Beard, S.E. Bohndiek, Contrast agents for molecular photoacoustic imaging, *Nat. Methods* **13** (2016) 639–650.
117. R. Cheheltani, R.M. Ezzibdeh, P. Chhour, K. Pulaparathi, J. Kim, M. Jurcova, J.C. Hsu, C. Blundell, H.I. Litt, V.A. Ferrari, H.R. Allcock, C.M. Sehgal, D.P. Cormode, Tunable, biodegradable gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging, *Biomaterials* **102** (2016) 87–97.
118. H. Li, L. Diaz, D. Lee, L. Cui, X. Liang, Y.S. Cheng, *in vivo* imaging of T cells loaded with gold nanoparticles: a pilot study, *Radiol. Med.* **119** (2014) 269–276.
119. K. Hayashi, M. Nakamura, H. Miki, S. Ozaki, M. Abe, T. Matsumoto, K. Ishimura, Gold nanoparticle cluster-plasmon-enhanced fluorescent silica core-shell nanoparticles for X-ray computed tomography-fluorescence dual-mode imaging of tumors, *Chem. Commun.* **49** (2013) 5334–5336.
120. Q. Liu, X. Zhang, L.B. Abdalla, A. Zunger, Transforming common III–V and II–VI semiconductor compounds into topological heterostructures: the case of CdTe/InSb superlattices, *Adv. Funct. Mater.* **26** (2016) 3259–3267.
121. M.M. Barroso, Quantum dots in cell biology, *J. Histochem. Cytochem.* **59** (2011) 237–251.
122. M.A. Walling, J.A. Novak, J.R.E. Shepard, Quantum dots for live cell and *in vivo* imaging, *Int. J. Mol. Sci.* **10** (2009) 441–491.
123. J. Li, J.-J. Zhu, Quantum dots for fluorescent biosensing and bio-imaging applications, *Analyst* **138** (2013) 2506–2515.
124. J.S. Kim, K.J. Cho, T.H. Tran, M. Nurunnabi, T.H. Moon, S.M. Hong, Y.-k. Lee, *in vivo* NIR imaging with CdTe/CdSe quantum dots entrapped in PLGA nanospheres, *J. Colloid Interface Sci.* **353** (2011) 363–371.
125. J. Gao, K. Chen, R. Xie, J. Xie, Y. Yan, Z. Cheng, X. Peng, X. Chen, *in vivo* tumor-targeted fluorescence imaging using near-infrared non-cadmium quantum dots, *Bioconjugate Chem.* **21** (2010) 604–609.
126. X.Y. Ji, F. Peng, Y.L. Zhong, Y.Y. Su, Y. He, Fluorescent quantum dots: synthesis, biomedical optical imaging, and biosafety assessment, *Colloids Surf. B Biointerfaces* **124** (2014) 132–139.
127. E. Oh, R. Liu, A. Nel, K.B. Gemill, M. Bilal, Y. Cohen, I.L. Medintz, Meta-analysis of cellular toxicity for cadmium-containing quantum dots, *Nat. Nanotech.* **11** (2016) 479–486.
128. K.-T. Yong, W.-C. Law, R. Hu, L. Ye, L. Liu, M.T. Swihart, P.N. Prasad, Nanotoxicity assessment of quantum dots: from cellular to primate studies, *Chem. Soc. Rev.* **42** (2013) 1236–1250.
129. S. Huang, Q. Xiao, Z.K. He, Y. Liu, P. Tinnefeld, X.R. Su, X.N. Peng, A high sensitive and specific QDs FRET bioprobe for MNase, *Chem. Commun.* (2008) 5990–5992.

130. H. Hafian, A. Sukhanova, M. Turini, P. Chames, D. Baty, M. Pluot, J.H.M. Cohen, I. Nabiev, J.M. Millot, Multiphoton imaging of tumor biomarkers with conjugates of single-domain antibodies and quantum dots, *Nanomedicine NBM* **10** (2014) 1701–1709.
131. A. Yakoubi, T. Ben Chaabane, A. Aboulaich, R. Mahiou, L. Balan, G. Medjahdi, R. Schneider, Aqueous synthesis of Cu-doped CdZnS quantum dots with controlled and efficient photoluminescence, *J. Lumin.* **175** (2016) 193–202.
132. W. Guo, Z. Qiu, C. Guo, D. Ding, T. Li, F. Wang, J. Sun, N. Zheng, S. Liu, Multifunctional theranostic agent of $\text{Cu}_2(\text{OH})\text{PO}_4$ quantum dots for photoacoustic image-guided photothermal/photodynamic combination cancer therapy, *ACS Appl. Mater. Interfaces* **9** (2017) 9348–9358.
133. M.M. Zhang, H.X. Ju, L. Zhang, M.Z. Sun, Z.W. Zhou, Z.Y. Dai, L.R. Zhang, A.H. Gong, C.Y. Wu, F.Y. Du, Engineering iodine-doped carbon dots as dual-modal probes for fluorescence and X-ray CT imaging, *Int. J. Nanomed.* **10** (2015) 6943–6953.
134. S. Kim, Y.T. Lim, E.G. Soltész, A.M. De Grand, J. Lee, A. Nakayama, J.A. Parker, T. Mihaljevic, R.G. Laurence, D.M. Dor, L.H. Cohn, M.G. Bawendi, J.V. Frangioni, Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping, *Nat. Biotechnol.* **22** (2004) 93–97.
135. H. Kobayashi, Y. Hama, Y. Koyama, T. Barrett, C.A.S. Regino, Y. Urano, P.L. Choyke, Simultaneous multicolor imaging of five different lymphatic basins using quantum dots, *Nano Lett.* **7** (2007) 1711–1716.
136. E. Yaghini, H.D. Turner, A.M. Le Marois, K. Suhling, I. Naasani, A.J. MacRobert, *in vivo* biodistribution studies and *ex vivo* lymph node imaging using heavy metal-free quantum dots, *Biomaterials* **104** (2016) 182–191.
137. C.Y. Yu, T.T. Xuan, Y.W. Chen, Z.J. Zhao, X.X. Liu, G.H. Lian, H.L. Li, Gadolinium-doped carbon dots with high quantum yield as an effective fluorescence and magnetic resonance bimodal imaging probe, *J Alloys Compd.* **688** (2016) 611–619.
138. J.C. Chen, J.H. Liu, J.Z. Li, L.Q. Xu, Y.J. Qiao, One-pot synthesis of nitrogen and sulfur co-doped carbon dots and its application for sensor and multicolor cellular imaging, *J. Colloid Interface Sci.* **485** (2017) 167–174.
139. F.Y. Du, L.R. Zhang, L. Zhang, M.M. Zhang, A.H. Gong, Y.W. Tan, J.W. Miao, Y.H. Gong, M.Z. Sun, H.X. Ju, C.Y. Wu, S.Q. Zou, Engineered gadolinium-doped carbon dots for magnetic resonance imaging-guided radiotherapy of tumors, *Biomaterials* **121** (2017) 109–120.
140. H.S. Han, E. Niemeyer, Y.H. Huang, W.S. Kamoun, J.D. Martin, J. Bhaumik, Y.C. Chen, S. Roberge, J. Cui, M.R. Martin, D. Fukumura, R.K. Jain, M.G. Bawendi, D.G. Duda, Quantum dot/antibody conjugates for *in vivo* cytometric imaging in mice, *Proc. Natl. Acad. Sci.* **112** (2015) 1350–1355.
141. D.K. Jha, K. Saikia, S. Chakrabarti, K. Bhattacharya, K.S. Varadarajan, A.B. Patel, D. Goyary, P. Chattopadhyay, P. Deb, Direct one-pot synthesis of glutathione capped hydrophilic FePt-CdS nanoprobe for efficient bimodal imaging application, *Mater. Sci. Eng. C* **72** (2017) 415–424.
142. O. Osifeko, T. Nyokong, Synthesis and physicochemical properties of zinc and indium phthalocyanines conjugated to quantum dots, gold and magnetic nanoparticles, *Dyes Pigm.* **131** (2016) 186–200.
143. S. Iijima, Helical microtubules of graphitic carbon, *Nature* **354** (1991) 56–58.

144. H.J. Dai, Carbon nanotubes: synthesis, integration, and properties, *Acc. Chem. Res.* **35** (2002) 1035–1044.
145. M.S. Dresselhaus, H. Dai, Carbon nanotubes: continued innovations and challenges, *MRS Bull.* **29** (2004) 237–239.
146. R. Alshehri, A.M. Ilyas, A. Hasan, A. Arnaout, F. Ahmed, A. Memic, Carbon nanotubes in biomedical applications: factors, mechanisms, and remedies of toxicity, *J. Med. Chem.* **59** (2016) 8149–8167.
147. J.W.G. Wildoer, L.C. Venema, A.G. Rinzler, R.E. Smalley, C. Dekker, Electronic structure of atomically resolved carbon nanotubes, *Nature* **391** (1998) 59–62.
148. K. Welscher, S.P. Sherlock, H.J. Dai, Deep-tissue anatomical imaging of mice using carbon nanotube fluorophores in the second near-infrared window, *Proc. Natl. Acad. Sci.* **108** (2011) 8943–8948.
149. D.A. Heller, S. Baik, T.E. Eurell, M.S. Strano, Single-walled carbon nanotube spectroscopy in live cells: towards long-term labels and optical sensors, *Adv. Mater.* **17** (2005) 2793–2799.
150. G.S. Hong, H.J. Dai, *in vivo* fluorescence imaging in the second near-infrared window using carbon nanotubes, *Methods Mol. Biol.* **1444** (2016) 167–181.
151. N.M. Bardhan, D. Ghosh, A.M. Belcher, Carbon nanotubes as *in vivo* bacterial probes, *Nat. Commun.* **5** (2014) 4918.
152. A.M. Smith, M.C. Mancini, S. Nie, Second window for *in vivo* imaging, *Nat. Nanotech.* **4** (2009) 710–711.
153. B.J. Gifford, S. Kilina, H. Htoon, S.K. Doorn, S. Tretiak, Exciton localization and optical emission in aryl-functionalized carbon nanotubes, *J. Phys. Chem. C* **122** (2018) 1828–1838.
154. Y. Luo, E.D. Ahmadi, K. Shayan, Y. Ma, K.S. Mistry, C. Zhang, J. Hone, J.L. Blackburn, S. Strauf, Purcell-enhanced quantum yield from carbon nanotube excitons coupled to plasmonic nanocavities, *Nat. Commun.* **8** (2017) 1413.
155. M. Holzinger, O. Vostrowsky, A. Hirsch, F. Hennrich, M. Kappes, R. Weiss, F. Jellen, Sidewall functionalization of carbon nanotubes, *Angew. Chem. Int. Ed.* **40** (2001) 4002–4005.
156. Y. Liu, Y. Zhao, B. Sun, C. Chen, Understanding the toxicity of carbon nanotubes, *Acc. Chem. Res.* **46** (2013) 702–713.
157. T. Shiraki, T. Shiraishi, G. Juhász, N. Nakashima, Emergence of new red-shifted carbon nanotube photoluminescence based on proximal doped-site design, *Sci. Rep.* **6** (2016) 28393.
158. N. Hadidi, F. Kobarfard, N. Nafissi-Varcheh, R. Aboofazeli, PEGylated single-walled carbon nanotubes as nanocarriers for cyclosporin A delivery, *AAPS PharmSciTech* **14** (2013) 593–600.
159. K. Welscher, Z. Liu, S.P. Sherlock, J.T. Robinson, Z. Chen, D. Daranciang, H. Dai, A route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice, *Nat. Nanotech.* **4** (2009) 773–780.
160. K. Welscher, S.P. Sherlock, H.J. Dai, Deep-tissue anatomical imaging of mice using carbon nanotube fluorophores in the second near-infrared window, *Proc. Natl. Acad. Sci.* **108** (2011) 8943–8948.

161. J.T. Robinson, G.S. Hong, Y.Y. Liang, B. Zhang, O.K. Yaghi, H.J. Dai, *in vivo* fluorescence imaging in the second near-infrared window with long circulating carbon nanotubes capable of ultrahigh tumor uptake, *J. Am. Chem. Soc.* **134** (2012) 10664–10669.
162. G.S. Hong, J.C. Lee, J.T. Robinson, U. Raaz, L.M. Xie, N.F. Huang, J.P. Cooke, H.J. Dai, Multifunctional *in vivo* vascular imaging using near-infrared II fluorescence, *Nat. Med.* **18** (2012) 1841–1846.
163. S. Ghosh, S.M. Bachilo, R.B. Weisman, Advanced sorting of single-walled carbon nanotubes by nonlinear density-gradient ultracentrifugation, *Nat. Nanotech.* **5** (2010) 443–450.
164. X.M. Tu, S. Manohar, A. Jagota, M. Zheng, DNA sequence motifs for structure-specific recognition and separation of carbon nanotubes, *Nature* **460** (2009) 250–253.
165. H.P. Liu, D. Nishide, T. Tanaka, H. Kataura, Large-scale single-chirality separation of single-wall carbon nanotubes by simple gel chromatography, *Nat. Commun.* **2** (2011) 309.
166. Y. Miyata, K. Shiozawa, Y. Asada, Y. Ohno, R. Kitaura, T. Mizutani, H. Shinohara, Length-sorted semiconducting carbon nanotubes for high-mobility thin film transistors, *Nano Res.* **4** (2011) 963–970.
167. S. Diao, G.S. Hong, J.T. Robinson, L.Y. Jiao, A.L. Antaris, J.Z. Wu, C.L. Choi, H.J. Dai, Chirality enriched (12,1) and (11,3) single-walled carbon nanotubes for biological imaging, *J. Am. Chem. Soc.* **134** (2012) 16971–16974.
168. Z.A. Liu, X.L. Li, S.M. Tabakman, K.L. Jiang, S.S. Fan, H.J. Dai, Multiplexed multicolor Raman imaging of live cells with isotopically modified single walled carbon nanotubes, *J. Am. Chem. Soc.* **130** (2008) 13540–13541.
169. C.L. Zavaleta, B.R. Smith, I. Walton, W. Doering, G. Davis, B. Shojaei, M.J. Natan, S.S. Gambhir, Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopy, *Proc. Natl. Acad. Sci.* **106** (2009) 13511–13516.
170. A.M. Rao, E. Richter, S. Bandow, B. Chase, P.C. Eklund, K.A. Williams, S. Fang, K.R. Subbaswamy, M. Menon, A. Thess, R.E. Smalley, G. Dresselhaus, M.S. Dresselhaus, Diameter-selective Raman scattering from vibrational modes in carbon nanotubes, *Science* **275** (1997) 187–191.
171. D.A. Heller, S. Baik, T.E. Eurell, M.S. Strano, Single-walled carbon nanotube spectroscopy in live cells: towards long-term labels and optical sensors, *Adv. Mater.* **17** (2005) 2793–2799.
172. C. Lamprecht, N. Gierlinger, E. Heister, B. Unterauer, B. Plochberger, M. Brameshuber, P. Hinterdorfer, S. Hild, A. Ebner, Mapping the intracellular distribution of carbon nanotubes after targeted delivery to carcinoma cells using confocal Raman imaging as a label-free technique, *J. Phys. Condens. Matter* **24** (2012) 164206.
173. J.W. Kang, F.T. Nguyen, N. Lue, R.R. Dasari, D.A. Heller, Measuring uptake dynamics of multiple identifiable carbon nanotube species via high-speed confocal Raman imaging of live cells, *Nano Lett.* **12** (2012) 6170–6174.
174. G.A. Wagnieres, W.M. Star, B.C. Wilson, *in vivo* fluorescence spectroscopy and imaging for oncological applications, *Photochem. Photobiol.* **68** (1998) 603–632.
175. Y.W.C. Cao, R.C. Jin, C.A. Mirkin, Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection, *Science* **297** (2002) 1536–1540.

176. S. Keren, C. Zavaleta, Z. Cheng, A. de la Zerda, O. Gheysens, S.S. Gambhir, Noninvasive molecular imaging of small living subjects using Raman spectroscopy, *Proc. Natl. Acad. Sci.* **105** (2008) 5844–5849.
177. X.L. Li, X.M. Tu, S. Zaric, K. Welsher, W.S. Seo, W. Zhao, H.J. Dai, Selective synthesis combined with chemical separation of single-walled carbon nanotubes for chirality selection, *J. Am. Chem. Soc.* **129** (2007) 15770–15771.
178. Z. Liu, S. Tabakman, S. Sherlock, X.L. Li, Z. Chen, K.L. Jiang, S.S. Fan, H.J. Dai, Multiplexed five-color molecular imaging of cancer cells and tumor tissues with carbon nanotube Raman tags in the near-infrared, *Nano Res.* **3** (2010) 222–233.
179. M. Navas-Moreno, M. Mehrpouyan, T. Chernenko, D. Candas, M. Fan, J.J. Li, M. Yan, J.W. Chan, Nanoparticles for live cell microscopy: a surface-enhanced Raman scattering perspective, *Sci. Rep.* **7** (2017) 4471.
180. C.L. Sun, M.X. Gao, X.M. Zhang, Surface-enhanced Raman scattering (SERS) imaging-guided real-time photothermal ablation of target cancer cells using polydopamine-encapsulated gold nanorods as multifunctional agents, *Anal. Bioanal. Chem.* **409** (2017) 4915–4926.
181. D. Takagi, Y. Homma, H. Hibino, S. Suzuki, Y. Kobayashi, Single-walled carbon nanotube growth from highly activated metal nanoparticles, *Nano Lett.* **6** (2006) 2642–2645.
182. D. Wang, Z.C. Li, L.W. Chen, Templated synthesis of single-walled carbon nanotube and metal nanoparticle assemblies in solution, *J. Am. Chem. Soc.* **128** (2006) 15078–15079.
183. Y.C. Chen, J. Young Robert, V. Macpherson Julie, R. Wilson Neil, Silver-decorated carbon nanotube networks as SERS substrates, *J. Raman Spectrosc.* **42** (2011) 1255–1262.
184. X.J. Wang, C. Wang, L. Cheng, S.T. Lee, Z. Liu, Noble metal coated single-walled carbon nanotubes for applications in surface enhanced Raman scattering imaging and photothermal therapy, *J. Am. Chem. Soc.* **134** (2012) 7414–7422.
185. X.D. Wang, Y.J. Pang, G. Ku, X.Y. Xie, G. Stoica, L.H.V. Wang, Noninvasive laser-induced photoacoustic tomography for structural and functional *in vivo* imaging of the brain, *Nat. Biotechnol.* **21** (2003) 803–806.
186. G. Ku, L.H.V. Wang, Deeply penetrating photoacoustic tomography in biological tissues enhanced with an optical contrast agent, *Opt. Lett.* **30** (2005) 507–509.
187. C.G.A. Hoelen, F.F.M. de Mul, R. Pongers, A. Dekker, Three-dimensional photoacoustic imaging of blood vessels in tissue, *Opt. Lett.* **23** (1998) 648–650.
188. K. Yang, L.L. Hu, X.X. Ma, S.Q. Ye, L. Cheng, X.Z. Shi, C.H. Li, Y.G. Li, Z. Liu, Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles, *Adv. Mater.* **24** (2012) 1868–1872.
189. G. Ku, M. Zhou, S.L. Song, Q. Huang, J. Hazle, C. Li, Copper sulfide nanoparticles as a new class of photoacoustic contrast agent for deep tissue imaging at 1064 nm, *ACS Nano* **6** (2012) 7489–7496.
190. A. Agarwal, S.W. Huang, M. O'Donnell, K.C. Day, M. Day, N. Kotov, S. Ashkenazi, Targeted gold nanorod contrast agent for prostate cancer detection by photoacoustic imaging, *J. Appl. Phys.* **102** (2007) 064701–064704.
191. J.T. Robinson, K. Welsher, S.M. Tabakman, S.P. Sherlock, H. Wang, R. Luong, H. Dai, High performance *in vivo* near-IR (>1 μm) imaging and photothermal cancer therapy with carbon nanotubes, *Nano Res.* **3** (2010) 779–793.

192. X.W. Liu, H.Q. Tao, K. Yang, S.A. Zhang, S.T. Lee, Z.A. Liu, Optimization of surface chemistry on single-walled carbon nanotubes for *in vivo* photothermal ablation of tumors, *Biomaterials* **32** (2011) 144–151.
193. H.K. Moon, S.H. Lee, H.C. Choi, *in vivo* near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes, *ACS Nano* **3** (2009) 3707–3713.
194. P.K. Avti, S. Hu, C. Favazza, A.G. Mikos, J.A. Jansen, K.R. Shroyer, L.H.V. Wang, B. Sitharaman, Detection, mapping, and quantification of single walled carbon nanotubes in histological specimens with photoacoustic microscopy, *PLoS One* **7** (2012) e35064.
195. L.N. Wu, X. Cai, K. Nelson, W.X. Xing, J. Xia, R.Y. Zhang, A.J. Stacy, M. Luderer, G.M. Lanza, L.V. Wang, B.Z. Shen, D.P.J. Pan, A green synthesis of carbon nanoparticles from honey and their use in real-time photoacoustic imaging, *Nano Res.* **6** (2013) 312–325.
196. J.W. Kim, E.I. Galanzha, E.V. Shashkov, H.M. Moon, V.P. Zharov, Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents, *Nat. Nanotech.* **4** (2009) 688–694.
197. E.I. Galanzha, E.V. Shashkov, T. Kelly, J.W. Kim, L.L. Yang, V.P. Zharov, *in vivo* magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells, *Nat. Nanotech.* **4** (2009) 855–860.
198. A. de la Zerda, Z.A. Liu, S. Bodapati, R. Teed, S. Vaithilingam, B.T. Khuri-Yakub, X.Y. Chen, H.J. Dai, S.S. Gambhir, Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice, *Nano Lett.* **10** (2010) 2168–2172.
199. M. Yudasaka, Y. Yomogida, M. Zhang, T. Tanaka, M. Nakahara, N. Kobayashi, Y. Okamoto-Ogura, K. Machida, K. Ishihara, K. Saeki, H. Kataura, Near-infrared photoluminescent carbon nanotubes for imaging of brown fat, *Sci. Rep.* **7** (2017) 44760.
200. B.T. Doan, J. Seguin, M. Breton, R. Le Beherec, M. Bessodes, J.A. Rodriguez-Manzo, F. Banhart, J.C. Beloeil, D. Scherman, C. Richard, Functionalized single-walled carbon nanotubes containing traces of iron as new negative MRI contrast agents for *in vivo* imaging, *Contrast Media Mol. Imaging* **7** (2012) 153–159.
201. A. Al Faraj, F. Fauvelle, N. Luciani, G. Lacroix, M. Levy, Y. Cremillieux, E. Canet-Soulas, *in vivo* biodistribution and biological impact of injected carbon nanotubes using magnetic resonance techniques, *Int. J. Nanomed.* **6** (2011) 351–361.
202. A. Cerpa, M. Kober, D. Calle, V. Negri, J.M. Gavira, A. Hernanz, F. Briones, S. Cerdan, P. Ballesteros, Single-walled carbon nanotubes as anisotropic relaxation probes for magnetic resonance imaging, *MedChemComm.* **4** (2013) 669–672.
203. J. Rivera Eladio, R. Sethi, F. Qu, R. Krishnamurthy, R. Muthupillai, M. Alford, A. Swanson Michael, S. Eaton Sandra, R. Eaton Gareth, J. Wilson Lon, Nitroxide radicals@US-tubes: new spin labels for biomedical applications, *Adv. Funct. Mater.* **22** (2012) 3691–3698.
204. J. Miyawaki, M. Yudasaka, H. Imai, H. Yorimitsu, H. Isobe, E. Nakamura, S. Iijima, Synthesis of ultrafine Gd₂O₃ nanoparticles inside single-wall carbon nanohorns, *J. Phys. Chem. B* **110** (2006) 5179–5181.
205. C. Richard, B.-T. Doan, J.-C. Beloeil, M. Bessodes, É. Tóth, D. Scherman, Noncovalent functionalization of carbon nanotubes with amphiphilic Gd³⁺ chelates: toward powerful T1 and T2 MRI contrast agents, *Nano Lett.* **8** (2008) 232–236.
206. J.H. Choi, F.T. Nguyen, P.W. Barone, D.A. Heller, A.E. Moll, D. Patel, S.A. Boppart, M.S. Strano, Multimodal biomedical imaging with asymmetric single-walled carbon nanotube/iron oxide nanoparticle complexes, *Nano Lett.* **7** (2007) 861–867.

207. H.X. Wu, G. Liu, X. Wang, J.M. Zhang, Y. Chen, J.L. Shi, H. Yang, H. Hu, S.P. Yang, Solvothermal synthesis of cobalt ferrite nanoparticles loaded on multiwalled carbon nanotubes for magnetic resonance imaging and drug delivery, *Acta Biomater.* **7** (2011) 3496–3504.
208. J.S. Ananta, M.L. Matson, A.M. Tang, T. Mandal, S. Lin, K. Wong, S.T. Wong, L.J. Wilson, Single-walled carbon nanotube materials as T₂-weighted MRI contrast agents, *J. Phys. Chem. C* **113** (2009) 19369–19372.
209. A. Al Faraj, K. Cieslar, G. Lacroix, S. Gaillard, E. Canot-Soulas, Y. Cremillieux, *in vivo* imaging of carbon nanotube biodistribution using magnetic resonance imaging, *Nano Lett.* **9** (2009) 1023–1027.
210. J.M. Gimble, A.J. Katz, B.A. Bunnell, Adipose-derived stem cells for regenerative medicine, *Circ. Res.* **100** (2007) 1249–1260.
211. A.I. Caplan, Adult mesenchymal stem cells for tissue engineering versus regenerative medicine, *J. Cell Physiol.* **213** (2007) 341–347.
212. O. Vittorio, S.L. Duce, A. Pietrabissa, A. Cuschieri, Multiwall carbon nanotubes as MRI contrast agents for tracking stem cells, *Nanotechnology* **22** (2011) 095706.
213. C. Wang, X.X. Ma, S.Q. Ye, L. Cheng, K. Yang, L. Guo, C.H. Li, Y.G. Li, Z. Liu, Protamine functionalized single-walled carbon nanotubes for stem cell labeling and *in vivo* Raman/magnetic resonance/photoacoustic triple-modal imaging, *Adv. Funct. Mater.* **22** (2012) 2363–2375.
214. H.F. Wang, J. Wang, X.Y. Deng, H.F. Sun, Z.J. Shi, Z.N. Gu, Y.F. Liu, Y.L. Zhao, Biodistribution of carbon single-wall carbon nanotubes in mice, *J. Nanosci. Nanotechnol.* **4** (2004) 1019–1024.
215. X.Y. Deng, S.T. Yang, H.Y. Nie, H.F. Wang, Y.F. Liu, A generally adoptable radiotracing method for tracking carbon nanotubes in animals, *Nanotechnology* **19** (2008) 075101.
216. L. Lacerda, A. Soundararajan, R. Singh, G. Pastorin, K.T. Al-Jamal, J. Turton, P. Frederik, M.A. Herrero, S. Li, A. Bao, D. Emfietzoglou, S. Mather, W.T. Phillips, M. Prato, A. Bianco, B. Goins, K. Kostarelos, Dynamic imaging of functionalized multi-walled carbon nanotube systemic circulation and urinary excretion, *Adv. Mater.* **20** (2007) 225–230.
217. M.R. McDevitt, D. Chattopadhyay, J.S. Jaggi, R.D. Finn, P.B. Zanzonico, C. Villa, D. Rey, J. Mendenhall, C.A. Batt, J.T. Njardarson, D.A. Scheinberg, PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice, *PLoS One* **2** (2007) e907.
218. A. Sanginario, B. Miccoli, D. Demarchi, Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment, *Biosensors* **7** (2017) 9.
219. H. Hong, T. Gao, W. Cai, Molecular imaging with single-walled carbon nanotubes, *Nano Today* **4** (2009) 252–261.
220. Z. Liu, W.B. Cai, L.N. He, N. Nakayama, K. Chen, X.M. Sun, X.Y. Chen, H.J. Dai, *in vivo* biodistribution and highly efficient tumour targeting of carbon nanotubes in mice, *Nat. Nanotech.* **2** (2007) 47–52.
221. M.R. McDevitt, D. Chattopadhyay, B.J. Kappel, J.S. Jaggi, S.R. Schiffman, C. Antczak, J.T. Njardarson, R. Brentjens, D.A. Scheinberg, Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes, *J. Nucl. Med.* **48** (2007) 1180–1189.
222. S.Y. Hong, G. Tobias, K.T. Al-Jamal, B. Ballesteros, H. Ali-Boucetta, S. Lozano-Perez, P.D. Nellist, R.B. Sim, C. Finucane, S.J. Mather, M.L.H. Green, K. Kostarelos, B.G. Davis, Filled and glycosylated carbon nanotubes for *in vivo* radioemitter localization and imaging, *Nat. Mater.* **9** (2010) 485–490.

223. C. Corot, P. Robert, J.M. Idee, M. Port, Recent advances in iron oxide nanocrystal technology for medical imaging, *Adv. Drug Deliv. Rev.* **58** (2006) 1471–1504.
224. M.G. Harisinghani, J. Barentsz, P.F. Hahn, W.M. Deserno, S. Tabatabaei, C.H. van de Kaa, J. de la Rosette, R. Weissleder, Noninvasive detection of clinically occult lymph-node metastases in prostate cancer, *New Engl. J. Med.* **348** (2003) 2491–U2495.
225. M.G. Harisinghani, R. Weissleder, Sensitive, noninvasive detection of lymph node metastases, *PLoS Med.* **1** (2004) 202–209.
226. W.S. Enochs, G. Harsh, F. Hochberg, R. Weissleder, Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent, *J. Magn. Reson. Imaging* **9** (1999) 228–232.
227. E.A. Neuwelt, P. Varallyay, A.G. Bago, L.L. Muldoon, G. Nesbit, R. Nixon, Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours, *Neuropath. Appl. Neuro.* **30** (2004) 456–471.
228. P. Varallyay, G. Nesbit, L.L. Muldoon, R.R. Nixon, J. Delashaw, J.I. Cohen, A. Petrillo, D. Rink, E.A. Neuwelt, Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors, *Am. J. Neuroradiol.* **23** (2002) 510–519.
229. C.A. Taschner, S.G. Wetzell, M. Tolnay, J. Froehlich, A. Merlo, E.W. Radue, Characteristics of ultrasmall superparamagnetic iron oxides in patients with brain tumors, *Am. J. Roentgenol.* **185** (2005) 1477–1486.
230. Y.E.L. Koo, G.R. Reddy, M. Bhojani, R. Schneider, M.A. Philbert, A. Rehemtulla, B.D. Ross, R. Kopelman, Brain cancer diagnosis and therapy with nanoplatforms, *Adv. Drug Deliv. Rev.* **58** (2006) 1556–1577.
231. C. Sun, O. Veisoh, J. Gunn, C. Fang, S. Hansen, D. Lee, R. Sze, R.G. Ellenbogen, J. Olson, M. Zhang, *in vivo* MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprob, *Small* **4** (2008) 372–379.
232. R. Weissleder, U. Mahmood, Molecular imaging, *Radiology* **219** (2001) 316–333.
233. R. Weissleder, Molecular imaging in cancer, *Science* **312** (2006) 1168–1171.
234. E.A. Schellenberger, D. Sosnovik, R. Weissleder, L. Josephson, Magneto/optical annexin V, a multimodal protein, *Bioconjugate Chem.* **15** (2004) 1062–1067.
235. D.E. Sosnovik, R. Weissleder, Emerging concepts in molecular MRI, *Curr. Opin. Biotechnol.* **18** (2007) 4–10.
236. C.H. Tung, U. Mahmood, S. Bredow, R. Weissleder, *in vivo* imaging of proteolytic enzyme activity using a novel molecular reporter, *Cancer Res.* **60** (2000) 4953–4958.
237. R. Weissleder, C.H. Tung, U. Mahmood, A. Bogdanov, *in vivo* imaging of tumors with protease-activated near-infrared fluorescent probes, *Nat. Biotechnol.* **17** (1999) 375–378.
238. J.W.M. Bulte, D.L. Kraitchman, Iron oxide MR contrast agents for molecular and cellular imaging, *NMR Biomed.* **17** (2004) 484–499.
239. D.E. Sosnovik, M. Nahrendorf, R. Weissleder, Molecular magnetic resonance imaging in cardiovascular medicine, *Circulation* **115** (2007) 2076–2086.
240. S.A. Wickline, A.M. Neubauer, P.M. Winter, S.D. Caruthers, G.M. Lanza, Molecular imaging and therapy of atherosclerosis with targeted nanoparticles, *J. Magn. Reson. Imaging* **25** (2007) 667–680.

241. C. Corot, K.G. Petry, R. Trivedi, A. Saleh, C. Jonkmanns, J.F. Le Bas, E. Blezer, M. Rausch, B. Brochet, P. Foster-Gareau, D. Baleriaux, S. Gaillard, V. Dousset, Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging, *Invest. Radiol.* **39** (2004) 619–625.
242. M.E. Kooi, V.C. Cappendijk, K.B.J.M. Cleutjens, A.G.H. Kessels, P.J.E.H.M. Kitslaar, M. Borgers, P.M. Frederik, M.J.A.P. Daemen, J.M.A. van Engelshoven, Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by *in vivo* magnetic resonance imaging, *Circulation* **107** (2003) 2453–2458.
243. R.A. Trivedi, J.M. U-King-Im, M.J. Graves, J.J. Cross, J. Horsley, M.J. Goddard, J.N. Skepper, G. Quartey, E. Warburton, I. Joubert, L.Q. Wang, P.J. Kirkpatrick, J. Brown, J.H. Gillard, *in vivo* detection of macrophages in human carotid atheroma—temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI, *Stroke* **35** (2004) 1631–1635.
244. K.A. Kelly, M. Nahrendorf, A.M. Yu, F. Reynolds, R. Weissleder, *in vivo* phage display selection yields atherosclerotic plaque targeted peptides for imaging, *Mol. Imaging Biol.* **8** (2006) 201–207.
245. M. Nahrendorf, F.A. Jaffer, K.A. Kelly, D.E. Sosnovik, E. Aikawa, P. Libby, R. Weissleder, Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis, *Circulation* **114** (2006) 1504–1511.
246. S. Svenson, D.A. Tomalia, Dendrimers in biomedical applications—reflections on the field, *Adv. Drug Deliv. Rev.* **57** (2005) 2106–2129.
247. H. Kobayashi, M.W. Brechbiel, Nano-sized MRI contrast agents with dendrimer cores, *Adv. Drug Deliv. Rev.* **57** (2005) 2271–2286.
248. D.A. Tomalia, L.A. Reyna, S. Svenson, Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging, *Biochem. Soc. Trans.* **35** (2007) 61–67.
249. S. Langereis, A. Dirksen, T.M. Hackeng, M.H.P. van Genderen, E.W. Meijer, Dendrimers and magnetic resonance imaging, *New J. Chem.* **31** (2007) 1152–1160.
250. S. Langereis, G. de Lussanet Quido, H.P. van Genderen Marcel, E.W. Meijer, G.H. Beets-Tan Regina, W. Griffioen Arjan, M.A. van Engelshoven Jos, H. Backes Walter, Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging, *NMR Biomed.* **19** (2006) 133–141.
251. E. Wiener, M.W. Brechbiel, H. Brothers, R.L. Magin, O.A. Gansow, D.A. Tomalia, P.C. Lauterbur, Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents, *Magn. Reson. Med.* **31** (1994) 1–8.
252. L.H. Bryant, W. Brechbiel Martin, C. Wu, W.M. Bulte Jeff, V. Herynek, A. Frank Joseph, Synthesis and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates, *J. Magn. Reson. Imaging* **9** (1999) 348–352.
253. H. Kobayashi, S. Kawamoto, S.-K. Jo, H.L. Bryant, M.W. Brechbiel, R.A. Star, Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores, *Bioconjugate Chem.* **14** (2003) 388–394.
254. S.D. Konda, M. Aref, M. Brechbiel, E.C. Wiener, Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor - work in progress, *Invest. Radiol.* **35** (2000) 50–57.

255. S.D. Konda, S. Wang, M. Brechbiel, E.C. Wiener, Biodistribution of a ^{153}Gd -folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts, *Invest. Radiol.* **37** (2002) 199–204.
256. E.C. Wiener, S.D. Konda, S. Wang, M. Brechbiel, Imaging folate binding protein expression with MRI, *Acad. Radiol.* **9** (2002) S316–S319.
257. C. Wu, M.W. Brechbiel, R.W. Kozak, O.A. Gansow, Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging, *Bioorg. Med. Chem. Lett.* **4** (1994) 449–454.
258. I. van Baal, H. Malda, S.A. Synowsky, J.L.J. van Dongen, T.M. Hackeng, M. Merckx, E.W. Meijer, Multivalent peptide and protein dendrimers using native chemical ligation, *Angew. Chem. Int. Ed.* **44** (2005) 5052–5057.
259. S.D. Konda, M. Aref, S. Wang, M. Brechbiel, E.C. Wiener, Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts, *Magn. Reson. Mater. Phy.* **12** (2001) 104–113.
260. S.D. Swanson, J.F. Kukowska-Latallo, A.K. Patri, C.Y. Chen, S. Ge, Z.Y. Cao, A. Kotlyar, A.T. East, J.R. Baker, Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement, *Int. J. Nanomed.* **3** (2008) 201–210.
261. B.G. De Geest, N.N. Sanders, G.B. Sukhorukov, J. Demeester, S.C. De Smedt, Release mechanisms for polyelectrolyte capsules, *Chem. Soc. Rev.* **36** (2007) 636–649.
262. S.M. Hartig, R.R. Greene, M.M. Dikov, A. Prokop, J.M. Davidson, Multifunctional nanoparticulate polyelectrolyte complexes, *Pharm. Res.* **24** (2007) 2353–2369.
263. Z.H. Liu, Y.P. Jiao, Y.F. Wang, C.R. Zhou, Z.Y. Zhang, Polysaccharides-based nanoparticles as drug delivery systems, *Adv. Drug Deliv. Rev.* **60** (2008) 1650–1662.
264. M.M. Bailey, C.J. Berkland, Nanoparticle formulations in pulmonary drug delivery, *Med. Res. Rev.* **29** (2009) 196–212.
265. M. Huang, Z.X.L. Huang, M. Bilgen, C. Berkland, Magnetic resonance imaging of contrast-enhanced polyelectrolyte complexes, *Nanomedicine NBM* **4** (2008) 30–40.
266. S.P. Song, Y. Qin, Y. He, Q. Huang, C.H. Fan, H.Y. Chen, Functional nanoprobe for ultrasensitive detection of biomolecules, *Chem. Soc. Rev.* **39** (2010) 4234–4243.
267. F. Peng, Y.Y. Su, Y.L. Zhong, C.H. Fan, S.T. Lee, Y. He, Silicon nanomaterials platform for bioimaging, biosensing, and cancer therapy, *Acc. Chem. Res.* **47** (2014) 612–623.
268. Y. He, C.H. Fan, S.T. Lee, Silicon nanostructures for bioapplications, *Nano Today* **5** (2010) 282–295.
269. J.H. Park, L. Gu, G. von Maltzahn, E. Ruoslahti, S.N. Bhatia, M.J. Sailor, Biodegradable luminescent porous silicon nanoparticles for *in vivo* applications, *Nat. Mater.* **8** (2009) 331–336.
270. M.H. Mobarok, T.K. Purkait, M.A. Islam, M. Miskolzie, J.G.C. Veinot, Instantaneous functionalization of chemically etched silicon nanocrystal surfaces, *Angew. Chem. Int. Ed.* **56** (2017) 6073–6077.
271. C. Chiappini, X. Liu, J.R. Fakhoury, M. Ferrari, Biodegradable porous silicon barcode nanowires with defined geometry, *Adv. Funct. Mater.* **20** (2010) 2231–2239.
272. L. Gu, D.J. Hall, Z.T. Qin, E. Anglin, J. Joo, D.J. Mooney, S.B. Howell, M.J. Sailor, *in vivo* time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles, *Nat. Commun.* **4** (2013) 2326.

273. Z.F. Li, E. Ruckenstein, Water-soluble poly(acrylic acid) grafted luminescent silicon nanoparticles and their use as fluorescent biological staining labels, *Nano Lett.* **4** (2004) 1463–1467.
274. J.H. Warner, A. Hoshino, K. Yamamoto, R.D. Tilley, Water-soluble photoluminescent silicon quantum dots, *Angew. Chem. Int. Ed.* **44** (2005) 4550–4554.
275. A. Shiohara, S. Hanada, S. Prabakar, K. Fujioka, T.H. Lim, K. Yamamoto, P.T. Northcote, R.D. Tilley, Chemical reactions on surface molecules attached to silicon quantum dots, *J. Am. Chem. Soc.* **132** (2010) 248–253.
276. F. Erogbogbo, K.T. Yong, I. Roy, G.X. Xu, P.N. Prasad, M.T. Swihart, Biocompatible luminescent silicon quantum dots for imaging of cancer cells, *ACS Nano* **2** (2008) 873–878.
277. F. Erogbogbo, K.T. Yong, I. Roy, R. Hu, W.C. Law, W.W. Zhao, H. Ding, F. Wu, R. Kumar, M.T. Swihart, P.N. Prasad, *in vivo* targeted cancer imaging, sentinel lymph node mapping and multi-channel imaging with biocompatible silicon nanocrystals, *ACS Nano* **5** (2011) 413–423.
278. Y. He, Y.Y. Su, X.B. Yang, Z.H. Kang, T.T. Xu, R.Q. Zhang, C.H. Fan, S.T. Lee, Photo and pH stable, highly-luminescent silicon nanospheres and their bioconjugates for immunofluorescent cell imaging, *J. Am. Chem. Soc.* **131** (2009) 4434–4438.
279. Y. He, Z.H. Kang, Q.S. Li, C.H.A. Tsang, C.H. Fan, S.T. Lee, Ultrastable, highly fluorescent, and water-dispersed silicon-based nanospheres as cellular probes, *Angew. Chem. Int. Ed.* **48** (2009) 128–132.
280. H.S. Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B.I. Ipe, M.G. Bawendi, J.V. Frangioni, Renal clearance of quantum dots, *Nat. Biotechnol.* **25** (2007) 1165–1170.
281. Y.Y. Su, F. Peng, Z.Y. Jiang, Y.L. Zhong, Y.M. Lu, X.X. Jiang, Q. Huang, C.H. Fan, S.T. Lee, Y. He, *in vivo* distribution, pharmacokinetics, and toxicity of aqueous synthesized cadmium-containing quantum dots, *Biomaterials* **32** (2011) 5855–5862.
282. Y. He, Y.L. Zhong, F. Peng, X.P. Wei, Y.Y. Su, Y.M. Lu, S. Su, W. Gu, L.S. Liao, S.T. Lee, One-pot microwave synthesis of water-dispersible, ultraphoto- and pH-stable, and highly fluorescent silicon quantum dots, *J. Am. Chem. Soc.* **133** (2011) 14192–14195.
283. Y.L. Zhong, F. Peng, X.P. Wei, Y.F. Zhou, J. Wang, X.X. Jiang, Y.Y. Su, S. Su, S.T. Lee, Y. He, Microwave-assisted synthesis of biofunctional and fluorescent silicon nanoparticles using proteins as hydrophilic ligands, *Angew. Chem. Int. Ed.* **51** (2012) 8485–8489.

Chapter 22

In vivo Imaging as a Tool to Noninvasively Study Nanosystems

George Loudos, PhD, and Maria Tina Rouchota, PhD

Technological Educational Institute of Athens, Attiki, Athens, Greece

gloudos@teiath.gr, m.rouchota@upatras.gr

Keywords: bioluminescence imaging (BLI), charge-coupled device (CCD), color Doppler sonography, computed tomography (CT), dendritic cell, enhanced permeability and retention (EPR), fluorescence imaging (FLI), gas-filled microbubbles (MBs), gold nanoparticles (GNPs), graphene oxide, human epidermal growth factor receptor, iron oxide nanoparticles (IONPs), magnetic nanoparticles (MNPs), magnetic resonance imaging (MRI), nanobubbles, nanoparticles (NPs), near-infrared, osteoclasts, photoacoustic imaging (PAI), photomultiplier tube, poly(lactic-co-glycolic acid), positron emission tomography (PET), signal-to-noise ratio, silicon photomultipliers, single-photon emission computed tomography (SPECT), superparamagnetic iron oxide NPs ultrasound, type 2, X-ray imaging

22.1 Introduction

In vivo imaging is continuously gaining interest as an efficient noninvasive technique of testing new biomolecules, drugs, and nanoparticles (NPs) *in vivo*. Over the past 30 years, various physical principles describing interaction between radiation and matter have been explored, leading to a number of exciting methodologies that provide anatomic, functional, metabolic, and molecular information. Several techniques have been translated clinically, while all of them keep evolving in terms of improving performance and extending applications.

Nanotechnology is obviously a field that has benefitted a lot from *in vivo* imaging, although its use as a standard part of nanosystems evaluation is not established. One can argue that this delay is mainly due to the multidisciplinary nature of nanomedicine; NPs are usually synthesized by chemists; *in vivo* applications are studied by biologists, and imaging is still led by groups of either

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

medical physicists or engineers. However, over the past decade there have been various examples of using different imaging technologies for studying all types of NPs in different *in vivo* applications. As for other biomolecules, different imaging techniques aim to provide noninvasively answers to several questions that are raised when studying a new tracer. Some questions are:

- Do NPs reach the target for which they are designed?
- When are NPs in the highest concentration on the target?
- How long do they stay in blood circulation?
- Are they also concentrated in organs/tissues that are not targeted?
- Are they stable postinjection; do they form aggregates?
- What happens in the first few minutes postinjection?
- What is the optimal administration route?
- What is the optimal injected concentration?
- How shall we prepare the animals to maximize targeting?
- When is the best time for obtaining biodistribution points?

Definitely, the power of imaging modalities increases when NPs have physical properties that can enhance the imaging signals of one or more imaging modality. In this chapter, the major *in vivo* imaging modalities, with emphasis on preclinical imaging, will be reviewed. Representative examples of performed studies will be given to demonstrate the added value of *in vivo* imaging in nanomedicine research.

Although part of the scientific community debates which modality is the best, the authors believe that each modality has its own advantages and disadvantages. Some of them are technical and some are related to cost and the availability of technology, and of course one should take into account that different modalities provide different nuggets of information. Thus, it is important that an end user be aware of all available technologies, understand the biological problem that needs to be solved, and decide on the proper technology or technologies to be used. Some basic characteristics of existing imaging modalities are given in Fig. 22.1.

22.2 X-Ray Imaging

22.2.1 Basic Principles of X-ray and CT Imaging and Instrumentation

X-rays have been used in medicine as the basis of the first anatomical imaging technique, which continues to evolve up to now. It is based on the simple transmission of X-rays, which are emitted from a source (usually an X-ray tube) and are recorded from an analog or digital detector. As a result, an attenuation map of the object to be imaged is provided, which results in an image of gray values. In the simple X-ray imaging the resulting 2D image has no depth information and overlapping structures are projected in one plane. However, this technique provides a simple image of an animal or human interior and is considered as a trivial exam in many clinical applications. By rotating the object or the detector




Figure 22.1 Pros and cons of main imaging technologies used in nanomedicine.

and applying reconstruction algorithms, one obtains tomographic images of high anatomical information, leading to computed tomography (CT) [1]. CT was invented by Hounsfield and today is a standard clinical tool in all hospitals worldwide. The power of CT imaging has been widely exploited in preclinical research. Downscaling of all necessary components and electronics has led to the development of micro-CT, which has superior performance compared to clinical systems and is now commercially available and optimized for small-animal imaging in preclinical research [2].

Modern micro-CT scanners offer superb cross-sectional images of soft-tissue and skeletal structures with submillimeter spatial resolution, subsecond temporal resolution, and good contrast. The spatial resolution and signal-to-noise ratio (SNR) of micro-CT depend on the operating characteristics of the X-ray tube, the pixel size of the detector, the distance of the examined object from the radiation source, the type of detector, and the focal spot size. Most micro-CT scanners use transmission targets with a focal spot size ranging from 1 to 10 μm , which is far smaller compared to clinical ones, allowing the reconstruction of images with a voxel size of 50 μm . The emitted fan beam or cone beam and the continuous spiral rotation of the X-ray source allow scanning of small objects in a single rotation, which is rather fast and eliminates motion artifacts [3].

22.2.2 Imaging of Gold Nanoparticles

Today CT imaging is usually a stand-alone anatomical technique or is combined with other molecular imaging techniques to provide the anatomical map of an animal or a human. However, the introduction of nanosystems, and mainly gold nanoparticles (GNPs), opened new prospects in its application in molecular imaging. GNPs have been actively studied over the past years as contrast agents in X-ray and CT imaging. GNPs are of particular interest in medical applications, mainly due to their unique optical and electronic properties, as well as their biological compatibility. The physicochemical properties of GNPs can be tuned by selecting their size and shape, as well as their surface functionalization. Details about their preparation and targeting can be found in several references [4]. Today a variety of different GNPs have been produced, including rods, wires, belts and combs, plates and prisms, polyhedra, cages and frames, caps, stars and flowers, and dendrites [5].

The solutions of GNPs show very intense absorption and different colors depending upon the size and shape of the NPs. Over the last decade GNPs have gained attention as an X-ray contrast agent since they exhibit a high X-ray attenuation coefficient compared with standard clinical contrast agents (barium sulfate and iodine), especially at the energy levels of clinical CT [6]. Moreover, they have a longer vascular retention time compared with iodine, due to their higher molecular weight, which increases the available imaging window. Since they are already tested at the clinical level, it is important for them to be designed so they

meet the necessary requirements: delivery, nontoxicity, targeting, and contrast enhancement. Key properties include X-ray attenuation coefficient, colloidal stability in physiological media and during storage, vascular retention time, biodistribution, and cytotoxicity. Phantom studies have shown that the X-ray attenuation of GNPs increases linearly with mass concentration, indicating that the delivery of a high concentration of GNPs on the target will result in a high contrast [7].

Several applications of imaging GNPs have been reported, mostly focused on oncology, and some indicatives are given here. Nakagawa et al. [8] used NPs as a CT contrast agent to image tumors using an enhanced permeability and retention (EPR) effect. They showed that the localization of the GNPs in the tumor is affected by differences in particle size and was enhanced by the conjugation of a specific antibody against the tumor. Wang et al. [9] reported the use of folic acid–modified dendrimer-entrapped GNPs as nanoprobe for *in vivo* targeted CT imaging of human lung adenocarcinoma and successfully explored intravenous, intratumoral, and intraperitoneal administration of the particles. Kim et al. [10] labeled human mesenchymal stem cells with 40 nm citrate-stabilized GNPs and used CT imaging for different cell concentrations, showing that the number of labeled cells can be quantified in a way that is similar when radioactive or fluorine tracers are used. Chhour et al. [11] used GNPs to label monocytes located within plaques, allowing noninvasive CT imaging to be used as a tool to assess monocyte accumulation within plaques. In a very interesting study, Xu et al. [12] studied the interaction between renal clearable GNPs and the kidneys with normal function and unilateral ureteral obstruction. Their results show that the accumulation and clearance of renal clearable GNPs in normal and obstructed kidneys could be quantitatively and noninvasively evaluated with planar X-ray imaging at a contrast six times higher than that provided by iodine agents.

A typical image of commercially available GNPs is shown in Fig. 22.2.

22.3 Magnetic Resonance Imaging

22.3.1 Basic Principles and Instrumentation

Magnetic resonance imaging (MRI) is a very powerful and versatile imaging modality with various clinical applications, ranging from anatomical to functional and molecular imaging. It exploits the magnetic properties of water hydrogen atoms, which are present in living organisms, when a strong static magnetic field, on the order of 0.5 to 9.4 tesla, is applied [13]. A series of repetitive radio frequency pulses and gradients excite the spins of hydrogen atoms, followed by Fourier space sampling to reconstruct multiplanar images of the organ(s) of interest. Different sophisticated MRI sequences have been developed, which extract rich information about anatomy, morphology, function, and metabolism.



Figure 22.2 *In vivo* micro-CT of a mouse after injection with a commercial 15 nm X-ray contrast agent. Courtesy of BIOEMTECH, GR.

Functional MRI allows imaging and anatomic identification of areas of the brain while the subject performs a specific task. Today dedicated micro-MRI systems provide noninvasive *in vivo* whole-body small-animal imaging with a high spatial resolution, around 100 μm for rodent studies, and excellent contrast for soft tissue differentiation [14]. Such systems are commercially available from various manufacturers and are a powerful tool in preclinical research, including the study of NPs, covering a wide range of applications, from oncology and brain research to cardiology and tissue engineering. Besides standard imaging, the principles of magnetic resonance are explored in other applications. The most common is magnetic resonance spectroscopy, which involves identification of the atomic spectra of regions of interest [14]. Finally, hyperpolarized MRI is a rapidly evolving technique that can dramatically increase the SNR in magnetic resonance [15] and will definitely have a strong impact on its applications, including nanomedicine.

22.3.2 Imaging of Magnetic Nanoparticles

Magnetic nanoparticles (MNPs) have attracted a lot of attention as MRI contrast agents. Iron oxide NPs (IONPs) and ferrite NPs shorten $T2^*$ relaxation times and have been successfully employed as $T2$ MRI contrast agents with improved properties. Extensive research has resulted in the development of $T1$ contrast agents, which bypass the drawbacks of iron oxide–negative $T2$ contrast agents. The use of MNPs as MRI contrast agents is an active but already mature field, which includes several applications at different and exciting domains besides oncology. While the recent trend is toward the use of MNPs for multimodal imaging, in this section examples of using only MRI are given. The recent literature is rich and some indicative examples are reported.

Schleich et al. used alternative strategies for targeting tumors: via the EPR effect and passive targeting, active targeting of $\alpha_v\beta_3$ integrin via arginine-glycine-aspartic (RGD) grafting, use of an external magnetic field a combination of the magnetic field and active targeting [16]. MRI successfully quantified and visualized the concentration of NPs in the tumors and the advantages of combining active and magnetic targeting. Yilmaz et al. [17] used IONPs and T2-/T2*-weighted MRI for noninvasive myocardial macrophage imaging. Although they did not observe significant enhancement of the myocardial (peri-)infarct zone using this imaging compared to conventional gadolinium-based necrosis/fibrosis imaging, the study was performed clinically, showing the potential of this approach. Cheng et al. [18] combined superparamagnetic iron oxide NPs (SPIONs) with curcumin, a natural compound that specifically binds to amyloid plaques, and used T2* MRI on mice to visualize amyloid plaques. Immunohistochemical examination of the mouse brains revealed that curcumin MNPs were colocalized with amyloid plaques, showing the potential of noninvasive diagnosis of Alzheimer's disease with MRI. Kim et al. [19] used MNPs to label bone-marrow-derived mesenchymal stromal cells and neural stem cells and then used a 3T MRI for imaging *in vivo* a cancer mouse model. The study showed that this approach should facilitate the translation of this agent to clinical trials for evaluation of trafficking of cells by MRI. Lee et al. [20] investigated the potential of limiting the aggravation of osteoporosis by reducing the activity of osteoclasts (OCs) through thermolysis, by culturing osteoblasts and OCs with IONPs. MRI was successfully used to visualize the accumulation of NPs in osteoporosis applications.

22.4 Ultrasound

22.4.1 Basic Principles and Instrumentation

Ultrasonography, or ultrasound (US), provides anatomical information about soft tissue structures by taking advantage of the differential transmission and reflection of US waves in the range of 5–20 MHz between adjacent tissue layers. The higher the delivered US frequency, the higher the tissue spatial resolution achieved, at the expense of higher attenuation by tissue, resulting in more superficial penetration [21].

Depending on probe wavelength and depth of the target organ, an US provides a fast, portable, and cost-efficient diagnostic image with a high frame rate, high resolution, high sensitivity, and sufficient contrast. Today, US imaging is a highly versatile real-time technique that can be useful in various applications, offering anatomical screening of organ disease and pathology on multiple anatomical planes.

On a preclinical level, high-frequency linear or curvilinear broadband transducers operating around 12–15 MHz are employed for solid organ and soft tissue imaging of small animals, like mice. US employs several real-time techniques, including M-Mode, which refers to 1D imaging of space over time; B-Mode,

which is 2D imaging over time; 3D static or dynamic imaging; and color Doppler sonography, which provides hemodynamic information about heart and vessel blood flow on the basis of the Doppler frequency-shift phenomenon [22].

22.4.2 Imaging Nanobubbles

US contrast agents are gas-filled microbubbles (MBs) with diameters between 1 and 5 μm . Due to their size, MBs have optimal acoustic responses in the MHz range used for US imaging. In principle, multimodal US contrast agents entrap, attach, or adsorb other imaging agents, including NPs, in or on the shell of the MB in order to allow the exploitation of USs for NP imaging. In recent years, nanobubbles (NBs) with shells composed of polymers or phospholipids and gas, liquid, or solid cores have been applied in extravascular US imaging. A small particle size is a basic requirement for US contrast-enhanced agents that penetrate tumor blood vessel pores to allow for targeted imaging and therapy. However, compared to MBs, the nanoscale size of the particles used has the disadvantage of weakening the imaging ability of clinical diagnostic US.

Most reported applications of NBs focus on tumor imaging. Yin et al. [23] showed that lipid NBs with a size of ~ 435 nm were suitable for passive tumor targeting US imaging and suggested that the ultrasonic imaging ability was comparable to that of MBs. Yang et al. [24] developed uniform nanosized NBs of ~ 480 nm, which were conjugated antibody molecules with specific affinity to human epidermal growth factor receptor type 2 (HER2)-overexpressing tumors. These NBs presented good US enhancement, being a promising agent for efficient molecular imaging with potential application in early cancer quantitative diagnosis. Long et al. [25] have used oxygen NBs < 100 nm as a vehicle for site-specific oxygen delivery and simultaneously as a US contrast agent. *In vivo* studies showed that NBs can be used as a means for epigenetic regulation, US imaging, and cancer therapeutics, thus having a significant impact on new-age cancer treatment methods in oncology. Foroutan et al. [26] assessed the use of biodegradable P_2O_5 -CaO- Na_2O phosphate-based glass nanospheres for labeling mesenchymal stem cells. Then US imaging was used and confirmed their promising use as contrast agents for this modality.

22.5 Scintigraphic and SPECT Imaging

22.5.1 Basic Principles and Instrumentation

Single-photon emission computed tomography (SPECT) imaging is based on the detection of gamma photons, emitted from radiotracers and injected in an animal or a human. The basic detector of a SPECT system is the Anger gamma camera [27], which includes all detector modules required to convert emitted photons to images. A collimator made by lead or tungsten is a grid of parallel holes (hexagonal or square), allows the detection of photons traveling parallel to

its holes, and is the main limiting factor of a SPECT system's resolution and sensitivity. A scintillator converts all accepted photons to optical photons with energies of a few electron volts. The scintillator is coupled to a photomultiplier tube (PMT) by using an optical light guide and when optical photons strike the PMT's photocathode a number of photoelectrons are emitted. Inside the PMT those electrons are multiplied by a factor of 10^6 and an electron cloud hits the PMT's anode. This signal is collected, amplified, and processed to calculate the energy and position of each incident photon. Thus, a gamma camera works in a photon counting mode and provides planar images that have no depth information, similar to X-ray imaging. When the gamma camera is rotated around the object to be imaged, projection data are obtained and by using a proper reconstruction algorithm tomographic SPECT images are reconstructed [28].

The increased need for dedicated animal studies has pushed SPECT technology over the past 15 years. New collimator designs have drastically improved resolution and sensitivity, leading to systems with a submillimeter resolution. Significant advances have occurred in scintillator research, and several new materials can be used on a small scale, offering a high light output and a very good energy resolution. Position-sensitive PMT tubes were introduced by the end of the 1990s and are the detector of choice in most dedicated SPECT systems, since they offer a very high intrinsic resolution. Recent improvements in readout electronics have increased systems' sensitivity and mainly decreased their overall size and cost. Cadmium zinc telluride systems are an alternative to the combination of the scintillator-PMT modules, allowing direct photon detection with a significantly higher energy resolution. Over the past five years, the introduction of silicon photomultipliers (SiPMs), as a prominent alternative to PMTs, is being rapidly adopted in SPECT [29]. Today, micro-SPECT systems are available from several manufacturers and are usually combined with CT and/or positron emission tomography (PET).

22.5.2 Imaging Nanoparticles Labeled with Gamma Emitters

The use of gamma-emitting isotopes allows imaging NPs with high sensitivity compared to the previously mentioned techniques. Depending on the imaging system a spatial resolution of ~ 1 mm can provide accurate quantitative information of an NP's spatiotemporal biodistribution. By selecting isotopes of relatively long half-lives, it is possible to image various NPs for a period of 24 h (for ^{99m}Tc), up to several days when long-lived isotopes are used (i.e., ^{111}In). Furthermore, use of more than one radioisotope, emitting at different energies, is an advantage of SPECT, which allows simultaneous imaging of more than one NP at the same time or a combination of imaging an NP in parallel with a molecular mechanism of interest. While SPECT cannot provide fast 3D images, due to the need of multiple projections, scintigraphic imaging is a very efficient tool for fast screening of various NPs and can easily provide valuable information, especially during their synthesis and optimization steps.

An important consideration is that the labeling of NPs using radioisotopes needs special processing of the NPs and is not straightforward, as is the case for GNPs (with X-rays), MNPs (with MRI), and NBs (with US). Thus, it is important to perform all required stability and radiochemical quality control tests to ensure that labeling is stable and NPs maintain the same characteristics postlabeling; however, such procedures are in place for different biomolecules and can be tuned for application in nanomedicine. However, numerous publications have shown the advantages of this approach in different NP structures.

Although nuclear imaging of NPs is given in another chapter of this book, some indicative and challenging studies are reported here. This author group has used ^{99m}Tc labeling to image various types of nanosystems, including MNPs, liposomes, silver NPs, and polymer NPs. Recently, Fazaeli et al. [30] used graphene oxide (GO) sheets functionalized by aminopropylsilyl groups, labeled by $^{198,199}\text{Au}$ NP radioisotopes for fast *in vivo* targeting and SPECT imaging. Results showed that $^{198,199}\text{Au}@AF\text{-GO}$ provide excellent tumor targeting/imaging and are quickly washed out from the body, being potentially effective and promising nanomaterials in nanotechnology-based cancer diagnosis and therapy. GNPs were functionalized by Black et al. [31] with an MMP9-cleavable peptide and then radiolabeled with both ^{125}I and ^{111}In . The two isotopes allowed the formulation of two separate images during a single scan, enabling *in vivo* differentiation of tumors with differing MMP9 expression. Tseng et al. [32] used lipid calcium-phosphate NPs, labeled with ^{111}In and suitable for small interfering RNA delivery. Imaging studies showed preferential accumulation in the lymph nodes, which was significantly higher than liver and spleen accumulation in a 4T1 breast cancer lymph node metastasis model. Currently, SPECT is considered as a standard technology for studying NPs and more exciting applications include the combination of the technology with other imaging modalities, which take advantage of the unique NP properties and will be explained later in this chapter.

22.6 Coincidence and PET Imaging

22.6.1 Basic Principles and Instrumentation

PET imaging has several similarities with SPECT, since it includes radiotracer injection and photon detection. However, differences in the main physical principles affect detector design and potential applications. PET radiopharmaceuticals emit positrons instead of photons, which have variable kinetic energy [33]. Depending on this energy, a positron travels a short distance (up to a few millimeters) and when it hits an electron, both are annihilated, producing two antiparallel photons with energy equal to 511 keV. A PET detector should have at least two opposite detectors, while a full ring system maximizes the sensitivity of the technique. In conventional systems, these photons are detected by using the same concept as that in the Anger camera, but a major difference is the absence of a collimator. The trajectory of the annihilation point is determined by the line

that connects two photons, detected in a short time window (usually 4 to 20 ns). Then a reconstruction algorithm is applied to calculate the position of the annihilation point. PET performance is limited by the positron range, the photons' noncolinearity, scattering, attenuation, and random events, although advanced software tools compensate for them.

Evolution in PET usually starts from the preclinical level, and there are several examples of technological achievements that have been transferred to clinical application. Like SPECT, the combination of position-sensitive PMT tubes and pixelated scintillators leads to a significant improvement in resolution and sensitivity. Rapid evolution in electronics has allowed a significant improvement of temporal resolution on the order of a few picoseconds. This makes possible the calculation of the difference in the time of flight of detected photons. Like SPECT, several commercial micro-PET systems are available; in most cases they are coupled to CT, but the recent trend is their combination with MRI [34].

22.6.2 Imaging Nanoparticles Labeled with Positron Emitters

There are several advantages of using PET isotopes to radiolabel and image NPs. On the preclinical level, the spatial resolution in PET is slightly lower than that in SPECT, but still on the order of 1 mm, while PET sensitivity can be 100 times higher. Current PET systems have ring detectors, which in many cases can cover the entire body of a mouse in a single shot. In this way tomographic imaging is possible immediately after injection, allowing the performance of fast 3D dynamic studies and the use of novel tools, such as kinetic modeling and parametric imaging. Although on a clinical level ^{18}F -FDG and ^{18}F based tracers are used in the majority of applications, new isotopes gain interest. ^{66}Ga and ^{68}Ga , which can be made available by $^{68}\text{Ge}/^{68}\text{Ga}$ generators, can be easily coupled to many NPs and do not require a cyclotron. ^{64}Cu , ^{124}I , ^{81}Rb , and ^{89}Zr are being assessed by several research groups since they have long half-lives and they offer the possibility of studying NPs for a long period. Although several studies use PET for imaging various types of NPs, most of them use only PET as an imaging modality for obtaining images of NP biodistribution at different time points [35]. There is still a long way to fully exploiting the power of this technology, including the analysis of collected data and the use of new radioisotopes.

Some interesting examples are the work of Pérez-Medina et al. [36], who radiolabeled high-density lipid NPs with ^{89}Zr for PET imaging of tumor-associated macrophages. They showed that these ^{89}Zr -labeled NPs are specific for macrophages and can provide noninvasive quantitative information for macrophage PET imaging. Yang et al. [37] synthesized ^{64}Cu -doped Au nanocages as tracers for PET imaging. Results showed efficient passive accumulation in both 4T1 and patient-derived xenograft tumor models due to the EPR effect. Lee et al. [38] developed ^{124}I -labeled tannic acid GNPs for dendritic cell (DC) labeling and *in vivo* tracking of their migration with PET. This tracer was able to track the migration of DCs to lymphoid organs even in extremely low concentrations. Stockhofe et al. [39]

radiolabeled cross-linked micelles with ^{68}Ga as promising new PET imaging tracers. Sirianni et al. [40] used ^{18}F -4-fluorobenzylamine and a commercially available biotin derivate to label poly(lactic-*co*-glycolic acid) (PLGA) NPs. Then by applying PET imaging they measured the kinetics of delivering NPs of varying sizes to the rat brain, obtaining accurate information about NP distribution as a function of time, both during and after the infusion. Definitely, current research trend is a combination of PET with other anatomical or functional techniques for imaging NPs and benefit from their properties. The emphasis is on PET/MRI, as described later, although other interesting combinations are under active investigation.

22.7 Optical Imaging

22.7.1 Basic Principles and Instrumentation

Optical imaging methods use tracers that emit optical photons to image specific targets, without using radiation. Optical imaging can be divided into fluorescence imaging (FLI) and bioluminescence imaging (BLI) [41]. Bioluminescence is a normal process in animals like firefly that express an enzyme called luciferase, as a result of photochemical reactions. In BLI cells of interest have to be engineered first in order to express luciferase and then induced in the small animal. Injection of luciferine results in its oxidization by luciferase, and light is produced 10–12 min. after luciferin injection. This light signal is detected by a charge-coupled device (CCD) camera, and planar intensity images are produced. BLI is a highly sensitive technique, and only a few cells can provide sufficient signal. On the other hand in FLI the optical signal comes from a fluorescent molecule that can be either endogenous (collagen, hemoglobin, etc.) or injected (green fluorescent protein and other optical contrast agents). An external light source is used to excite the fluorophore, and a CCD detects the lower-energy emission light. Additional imaging components are filters that select excitation and emission wavelengths.

The main drawback of optical imaging is the strong absorption and scattering of optical photons, which travel only a few millimeters, thus limiting its application mostly to small animals [42]. However, near-infrared (NIR) fluorescence with emission wavelengths between 650 and 900 nm allows imaging at greater depths. Another challenge in optical imaging is tomographic imaging (fluorescence tomography), since scattering and attenuation vary according to the photons' wavelength and tissues through which they penetrate. In fluorescence tomography light coupling is performed using fibers in contact with the imaged object, or contact-free detection. The first mode limits flexibility. In the second mode model-based reconstruction methods have to be used, whose optimization is an open issue. Several commercial systems are available in the market that coupled with CT have good penetration as high-throughput preclinical screening tools.

22.7.2 Optical Imaging of Nanoparticles

The main benefit of using optical imaging in studying NPs is the lack of radiation and the relatively low cost of the technique. While it is possible to obtain very fast images, with increased throughput, a drawback is the low spatial resolution and absence of quantitative information. In addition, it is not possible to transfer this methodology to a clinical level in most cases due to the depth of absorption. However, this technology offers a robust screening tool, enabling repeated scanning of the same animal over a long period, and has been selected as a first *in vivo* step by many researchers. Although labeling NPs with fluorescent dyes is a standard way for their *in vivo* assessment [43] the recent challenge is the exploitation of novel NPs and materials that have interesting optical properties and can be used in *in vivo* imaging with no or minimum modification.

Quantum dots are among the first NPs whose optical properties attracted interest in *in vivo* imaging, with several reported examples [44]. Rampazzo et al. [45] studied luminescent silica NPs as contrast agents in optical imaging and optical sensing and for other high-sensitivity applications. Maldiney et al. [46] used NIR persistent luminescence NPs that are excited *in vivo* using highly penetrating low-energy red photons. Following their intravenous injection, it was possible to follow their biodistribution by simple whole-animal optical imaging, which opens new prospects for a variety of diagnosis applications. A very interesting application was the use of NaGdF₄:Eu³⁺ NPs that are excited with X-rays and produce NIR light at 692 nm [47]. Gnach et al. [48] compared lanthanide-doped up-converting NaYF₄ and organic fluorophores for application in deep-tissue imaging, showing that NIR photoexcitation was favorable over conventional ultraviolet photoexcitation.

22.8 Multimodal Imaging

Each imaging modality has its own advantages and limitations, and the acquired information is actually complementary in between them. The rationale behind multimodality imaging is to combine a low-sensitivity modality with high spatial resolution and tissue contrast (CT or MRI) with another low-resolution but high-sensitivity one. Commercially available systems for clinical practice and appropriately modified for preclinical small-animal research include PET-CT, SPECT-CT, PET-MRI, and even PET-CT-MRI. Recently new promising combinations of complementary modalities have entered the field.

22.8.1 PET/CT and SPECT/CT

The obvious combination of merging detailed X-ray anatomical imaging with the functional information of PET or SPECT was proposed in the late 1990s [49]. Sequential systems facilitating hardware fusion of scintigraphic and X-ray images provided accurate localization of the tracer's concentration in planar and

tomographic mode. Using this concept, clinical PET/CT made a breakthrough in nuclear medicine market and almost eliminated standard PET scanners. SPECT/CT followed PET/CT and has now gained acceptance in medical community, and the same concept was transferred to small-animal imaging. There are two main advantages of merging anatomical with functional information. The first is the accurate localization of hot spots, which may be useful for inexperienced end users, and the second has to do with the use of anatomical information for attenuation correction [50], mostly in PET and then in SPECT. The true integration of these modalities in a single detector and the simultaneous acquisition of multimodal data remain a challenge.

Today almost all groups studying NPs with radioisotope techniques use combined SPECT/CT or PET/CT. Still, in this case we should not refer to multimodal NP imaging, since the CT information is used as an anatomic map and not to specifically image NPs, as in the case of Fig. 11.3, where calcium phosphate (CaP) nanoparticles are distributed into a normal mouse through the trachea and are located in the lungs.

However, in the case of radiolabeled GNPs there are nice prospects of imaging the same tracer with both modalities and benefit from their complementarity. In this way CT can be used to image GNPs with a high resolution while PET or SPECT can add the quantitative information. The work of Li et al. [51] that combines SPECT and CT for targeting vulnerable atherosclerosis plaques supports this hypothesis. Furthermore, Xu et al. [52] used dendrimer-entrapped GNPs functionalized with an RGD peptide and labeled with ^{99m}Tc , delivering a promising nanoprobe for targeted SPECT/CT imaging of $\alpha_v\beta_3$ integrin-expressing tumors.




Figure 22.3 *In vivo* combined micro-SPECT/CT imaging of a mouse after injection of CaP nanoparticles radiolabeled with $\text{Tc}99\text{m}$ through the trachea. Clear accumulation in the lungs is observed. Courtesy of BIOEMTECH, GR.

22.8.2 PET/MRI and SPECT/MRI

PET/MRI started as an engineering challenge, initially motivated by the success of PET/CT and the possible advantages that the replacement of CT with MRI would have [53]. PET/MRI is something more than replacing CT with MRI. Even if this was the only change, one can identify some important advantages; since MRI does not add an extra dose for the patient, it is possible to extend the PET applications in diagnostic cases where CT dosage seems useless and becomes the major preventing parameter, such as pediatric scans, brain imaging, and cardiac imaging. The second benefit is without a doubt the high soft tissue contrast, which is provided by MRI and besides tumor location can be valuable in both brain and cardiac imaging, where the soft tissue anatomy can be combined with PET functional information. Thirdly, PET requires data acquisition of a few minutes per bed position and this time can be exploited by the acquisition of different MRI sequences, thus resulting in a series of different images that will be diagnostically interpreted.

PET/MRI systems are needed to address several technical challenges. By the proper choice of avalanche photodiode detectors and other components and shielding of the associated electronics, it was possible to place a PET insert inside the MRI scanner and obtain simultaneously PET/MRI images during the early 2000s. However, the interest in PET/MRI technology increased exponentially following the introduction of SiPMs. Having the same advantages as PMTs (a supply voltage requirement of ~ 50 V, a very compact size, timing resolution down to 100 ps, and magnetic compatibility), it appears that SiPMs can be an ideal detector for whole-body PET/MRI. Slower but significant progress has been made toward SPECT/MRI, and current research is focused on smart geometries and collimator materials, aiming to provide simultaneous prototypes [54].

In terms of applications the real power of using PET/MRI for imaging NPs is in the fact that either PET tracers are used to label magnetic NPs or a combination of radioisotopes and MRI contrast agents are used simultaneously. The current status has been summarized in two very nice reviews, one from Tang et al. [55] and one from Lahooti et al. [56]. In most cases ^{68}Ga is used to label IONPs. Bouziotis et al. [57] used AGuIX NPs, which are ultrasmall NPs made of polysiloxane and surrounded by gadolinium chelates. Other examples are the use of ^{69}Ge -labeled IONPs [58], ^{64}Cu -labeled IONPs [59], and ^{89}Zr hyaluronan NPs [60].

22.8.3 Photoacoustic Imaging

Photoacoustic imaging (PAI) is a new modality that converts incident photons into US waves ultrasonically and overcomes the optical diffusion limit [61]. Thus, PAI combines the rich contrast of optical imaging with the high resolution and deep penetration of US imaging. With the rapid development of laser technology and US detection, PAI has enabled scalable visualization at levels from organelles

to organs and has attracted tremendous attention over the past decade [62]. This new emerging, noninvasive, and nonionizing imaging technique can unveil different physiopathological processes and disease states in a wide range of biomedical applications. Photoacoustic molecular imaging is a promising technique for multiscalable biomedical applications and has tremendous potential in the emerging field of theranostics [61].

At the macroscopic level, photoacoustic computed tomography allows brain, organ, and whole-body imaging of creatures ranging from small animals to primates. Recently, PAI has received immense attention as a promising means of diagnostic and therapeutic monitoring. Although this technology is rather new, it has been rapidly adopted by nanomedicine community and different NP types have been studied *in vivo*. Xie et al. [63] studied the use of self-quenched semiconducting polymer NPs for amplified *in vivo* PAI. Sun et al. [64] developed PEGylated phosphorus NPs for combined PAI and photothermal cancer therapy. In a very promising study Miao et al. [65] used PA for semiconducting oligomer NPs for the *in vivo* imaging of pH in cancer mice models. Efforts to combine PAI with other modalities include combination with MRI, as reported by Sano et al. [66], or PAI with CT [67].

Abbreviations

BLI:	bioluminescence imaging
CaP:	calcium phosphate
CCD:	charge-coupled device
CT:	computed tomography
DC:	dendritic cell
EPR:	enhanced permeability and retention
FLI:	fluorescence imaging
GNPs:	gold nanoparticles
GO:	graphene oxide
HER2:	human epidermal growth factor receptor type 2
IONPs:	iron oxide nanoparticles
MBs:	microbubbles
MNPs:	magnetic nanoparticles
MRI:	magnetic resonance imaging
NBs]:	nanobubbles
NIR:	near-infrared
NPs:	nanoparticles
OCs:	osteoclasts
PAI:	photoacoustic imaging
PET:	positron emission tomography
PLGA:	poly(lactic-co-glycolic acid)
PMT:	photomultiplier tube
SiPMs:	silicon photomultipliers

SNR: signal-to-noise ratio
 SPECT: single-photon emission computed tomography
 SPIONs: superparamagnetic iron oxide nanoparticles
 US: ultrasound

Disclosures and Conflict of Interest

This chapter was originally published as: Loudos, G. and Rouchota, M. T. (2019). In: Demetzos, C., Pispas, S., Pippa, N., eds. *Drug Delivery Nanosystems: From Bioinspiration and Biomimetics to Clinical Applications*, Jenny Stanford Publishing, Singapore, chapter 11, pp. 339–364, and appears here, with edits and updates, by kind permission of the publisher.

References

1. Hsieh, J. (2015). *Computed Tomography: Principles, Design, Artifacts, and Recent Advances*, 3rd ed., SPIE Press Book, Bellingham, Washington, USA.
2. Badea, C. T., Drangova, M., Holdsworth, D. W. and Johnson, G. A. (2008). *In vivo* small-animal imaging using micro-CT and digital subtraction angiography, *Phys. Med. Biol.*, **53**, pp. 319–350.
3. Schambach, S. J., Bag, S., Schilling, L., et al. (2010). Application of micro-CT in small animal imaging, *Methods*, **50**, pp. 2–13.
4. Zeng, S., Yong, K. T., Roy, I., et al. (2011). A review on functionalized gold nanoparticles for biosensing applications, *Plasmonics*, **6**, p. 491.
5. Alex, S. and Tiwari, A. (2015). Functionalized gold nanoparticles: synthesis, properties and applications: a review, *J. Nanosc. Nanotech.*, **15**, pp. 1869–1894.
6. Hainfeld, J. F., Slatkin, D. N., Focella, T. M., et al. (2006). Gold nanoparticles: a new x-ray contrast agent, *Br. J. Radiol.*, **79**(939), pp. 248–253.
7. Galper, M. W., Saung, M. T., Fuster, V., et al. (2012). Effect of computed tomography scanning parameters on gold nanoparticle and iodine contrast, *Invest. Radiol.*, **47**(8), pp. 475–481.
8. Nakagawa, T., Gonda, K., Kamei, T., et al. (2016). X-ray computed tomography imaging of a tumor with high sensitivity using gold nanoparticles conjugated to a cancer-specific antibody via polyethylene glycol chains on their surface, *Sci. Technol. Adv. Mater.*, **17**, pp. 387–397.
9. Wang, H., Zheng, L., Peng, C., et al. (2013). Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobe for targeted CT imaging of human lung adenocarcinoma, *Biomaterials*, **34**(2), pp. 470–480.
10. Kim, T., Lee, N. D., Arifin, R., et al. (2017). *In vivo* micro-CT imaging of human mesenchymal stem cells labeled with gold-poly-l-lysine nanocomplexes, *Adv. Funct. Mater.*, **27**, p. 1604213.
11. Pratap, P., Sean, C. N. (2016). Labeling monocytes with gold nanoparticles to track their recruitment in atherosclerosis with computed tomography, *Biomaterials*, **87**, pp. 93–103.

12. Xu, J., Yu, M., Carter, P., et al. (2017). *In vivo* x-ray imaging of transport of renal clearable gold nanoparticles in the kidneys, *Ang. Chem. Int.*, **56**(43), pp. 13356–13360.
13. Miraux, S., Massot, P., Ribot, E. J., et al. (2008). 3D TrueFISP imaging of mouse brain at 4.7T and 9.4T, *J. Magn. Reson. Imaging*, **28**, pp. 497–503.
14. Beckmann, N., Kneuer, R., Gremlich, H.-U., et al. (2007). *In vivo* mouse imaging and spectroscopy in drug discovery, *NMR Biomed.*, **20**, pp. 154–185.
15. Miloushev, V. Z., Keshari, K. R. and Holodny, A. I. (2016). Hyperpolarization MRI: preclinical models and potential applications in neuroradiology, *Top. Magn. Reson. Imaging*, **25**(1), pp. 31–37.
16. Schleich, N., Po, C., Jacobs, D., et al. (2014). Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy, *J. Control. Release*, **194**, pp. 82–91.
17. Yilmaz, A., Rösch, S., Klingel, K., et al. (2013). Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction—preliminary results, *Int. J. Cardiol.*, **163**(2), pp. 175–182.
18. Cheng, K. K., Chan, P. S., Fan, S., et al. (2015). Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer's disease mice using magnetic resonance imaging (MRI), *Biomaterials*, **44**, pp. 155–172.
19. Kim, S. J., Lewis, B., Steiner, M. S., et al. (2016). Superparamagnetic iron oxide nanoparticles for direct labeling of stem cells and *in vivo* MRI tracking, *Contr. Med. Mol. Imaging*, **11**(1), pp. 55–64.
20. Lee, M. S., Su, C. M., Yeh, J. C., et al. (2016). Synthesis of composite magnetic nanoparticles Fe₃O₄ with alendronate for osteoporosis treatment, *Int. J. Nanomed.*, **11**, pp. 4583–4594.
21. Voigt, J. U. (2009). Ultrasound molecular imaging, *Methods*, **48**, pp. 92–97.
22. Cheung, A. M., Brown, A. S., Hastie, L. A., et al. (2005). Three-dimensional ultrasound biomicroscopy for xenograft growth analysis, *Ultrasound Med. Biol.*, **31**, pp. 865–870.
23. Yin, T., Wang, P., Zheng, R., et al. (2012). Nanobubbles for enhanced ultrasound imaging of tumors, *Int. J. Nanomed.*, **7**, pp. 895–904.
24. Yang, H., Cai, W., Xu, L, et al. (2015). Nanobubble-affibody: novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor, *Biomaterials*, **37**, pp. 279–288.
25. Long, C. M., Bhandari, P. N. and Irudayaraj, J., (2016). Nanobubbles provide theranostic relief to cancer hypoxia, *The Summer Undergraduate Research Fellowship (SURF) Symposium*, Purdue University, Indiana, Paper 76.
26. Foroutan, F., Jokerst, J. V., Gambhir, S. S., et al. (2015). Sol-Gel synthesis and electrospraying of biodegradable (P2O₅)₅₅–(CaO)₃₀–(Na₂O)₁₅ glass nanospheres as a transient contrast agent for ultrasound stem cell imaging, *ACS Nano*, **9**(2), pp. 1868–1877.
27. Anger, H. O., Powell, M. R., van Dyke, D. C., et al. (1967). Recent applications of the scintillation camera, *Strahlentherapie Sonderb.*, **65**, pp. 70–93.
28. O'Connor, M. K. and Kemp, B. J. (2006). Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations, *Semin. Nucl. Med.*, **36**, pp. 258–266.

29. Kagadis, G., Loudos, G. and Katsanos, K. (2010). *In vivo* small animal imaging: current status and future prospects, *Med. Phys.*, **37**(12), pp. 6421–6441.
30. Fazaeli, Y., Akhavan, O., Rahighi, R., et al. (2014). *In vivo* SPECT imaging of tumors by 198,199Au-labeled graphene oxide nanostructures, *Mater. Sci. Eng. C*, **45**, pp. 196–204.
31. Black, K., Akers, W. J., Sudlow, G., et al. (2015). Dual-radiolabeled nanoparticle SPECT probes for bioimaging, *Nanoscale*, **7**, pp. 440–444.
32. Tseng, Y. C., Xu, Z., Guley, K., et al. (2014). Lipid–calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases, *Biomaterials*, **35**(16), pp. 4688–4698.
33. Larobina, M., Brunetti, A. and Salvatore, M. (2006). Small animal PET: a review of commercially available imaging systems, *Curr. Med. Imaging Rev.*, **2**, pp. 187–192.
34. Catana, C., Wu, Y., Judenhofer, M. S., et al. (2006). Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner, *J. Nucl. Med.*, **47**, pp. 1968–1976.
35. Xing, Y., Zhao, J., Shi, X., et al. (2014). Recent development of radiolabeled nanoparticles for PET imaging, *Austin J. Nanomed. Nanotechnol.*, **2**(2), p. 1016.
36. Pérez-Medina, C., Tang, J., Abdel-Atti, D., et al. (2015). PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein nanoparticles, *J. Nucl. Med.*, **56**(8), pp. 1272–1277.
37. Yang, M., Huo, D., Gilroy, K. D., et al. (2017). Facile synthesis of 64Cu-doped Au nanocages for positron emission tomography imaging, *ChemNanoMat*, **3**, pp. 44–50.
38. Lee, S. B., Lee, S. W., Jeong, S. Y., et al. (2017). Engineering of radioiodine-labeled gold core–shell nanoparticles as efficient nuclear medicine imaging agents for trafficking of dendritic cells, *ACS Appl. Mater. Interfaces*, **9**(10), pp. 8480–8489.
39. Stockhofe, K., Gimnich, M., Klinker, K., et al. (2016). Radiolabeling of cross-linked polymer micelles with 68Ga for PET-imaging, *J. Nucl. Med.*, **57**, p. 1082.
40. Sirianni, R. W., Zheng, M., Patel, T., et al. (2014). Radiolabeling of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with biotinylated F-18 prosthetic groups and imaging of their delivery to the brain with positron emission tomography, *Bioconjugate Chem.*, **25**(12), pp. 2157–2165.
41. Sadikot, R. T. and Blackwell, T. S. (2005). Bioluminescence imaging, *Proc. Am. Thorac. Soc.*, **2**, pp. 537–540.
42. Ntziachristos, V. (2006). Fluorescence molecular imaging, *Annu. Rev. Biomed. Eng.*, **8**, pp. 1–33.
43. Wolfbeis, O. S. (2015). An overview of nanoparticles commonly used in fluorescent bioimaging, *Chem. Soc. Rev.*, **44**, pp. 4743–4768.
44. Liab, J. and Zhu, J. J. (2013). Quantum dots for fluorescent biosensing and bio-imaging applications, *Analyst*, **138**, pp. 2506–2515.
45. Rampazzo, E., Prodi, L., Petrizza, L. and Zaccheroni, N. (2016). Luminescent silica nanoparticles featuring collective processes for optical imaging, *Top. Curr. Chem.*, **370**, pp. 1–28.
46. Maldiney, T., Bessière, A. and Seguin, J. (2014). The *in vivo* activation of persistent nanophosphors for optical imaging of vascularization, tumours and grafted cells, *Nat. Mater.*, **13**, pp. 418–426.

47. Sudheendra, L., Das, G. K., Li, C., et al. (2014). NaGdF₄:Eu³⁺ nanoparticles for enhanced X-ray excited optical imaging, *Chem. Mater.*, **26** (5), pp. 1881–1888.
48. Gnach, A., Prorok, K., Misiak, M., et al. (2014). Up-converting NaYF₄:0.1%Tm³⁺, 20%Yb³⁺ nanoparticles as luminescent labels for deep-tissue optical imaging, *J. Rare Earths*, **32**(3), pp. 207–212.
49. Even-Sapir, E., Keidar, Z. and Bar-Shalom, R. (2009). Hybrid imaging SPECT/CT and PET/CT—improving the diagnostic accuracy of functional/metabolic and anatomic imaging, *Semin. Nucl. Med.*, **39**, pp. 264–275.
50. Zaidi, H. and Hasegawa, B. (2003). Determination of the attenuation map in emission tomography, *J. Nucl. Med.*, **44**, pp. 291–315.
51. Li, X., Wang, C., Tan, H., et al. (2016). Gold nanoparticles-based SPECT/CT imaging probe targeting for vulnerable atherosclerosis plaques, *Biomaterials*, **108**, pp. 71–80.
52. Xiaoying Xu, X., Zhao, L. and Li, X. (2017). Targeted tumor SPECT/CT dual mode imaging using multifunctional RGD-modified low generation dendrimer-entrapped gold nanoparticles, *Biomater. Sci.*, **5**, pp. 2393–2397.
53. Wehrl, H. F., Judenhofer, M. S., Wiehr, S. and Pichler, B. J. (2009). Pre-clinical PET/MR: technological advances and new perspectives in biomedical research, *Eur. J. Nucl. Med. Mol. Imaging*, **36**, pp. 56–68.
54. Hutton, B. F., Occhipinti, M., Kuehne, A., et al. (2018). Development of clinical simultaneous SPECT/MRI, *Br. J. Radiol.*, **91**(1081), p. 20160690.
55. Tang, T., Garcia, J. and Louie, A. Y. (2017). PET/SPECT/MRI multimodal nanoparticles, *Des. Appl. Nanopart. Biomed. Imaging*, pp. 205–228.
56. Lahooti, A., Sarkar, S., Laurent, S. and Shanehsazzadeh, S. (2016). Dual nano-sized contrast agents in PET/MRI: a systematic review, *Contr. Med. Mol. Imaging*, **11**, pp. 428–447.
57. Bouziotis, P., Stellas, D. and Thomas, E., (2017). ⁶⁸Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy, *Nanomedicine*, **12**(13), pp. 1561–1574.
58. Chakravarty, R., Valdovinos, H. F., Chen, F., et al. (2014). Intrinsically germanium-69-labeled iron oxide nanoparticles: synthesis and in-vivo dual-modality PET/MR imaging, *Adv. Mater.*, **26**(30), pp. 5119–5123.
59. Tu, C., Ng, T. S. C., Jacobs, R. E., et al. (2014). Multimodality PET/MRI agents targeted to activated macrophages, *J. Biol. Inorg. Chem.*, **19**, pp. 247–258.
60. Beldman, T. J., Senders, M. L., Alaarg, A., et al. (2017). Hyaluronan nanoparticles selectively target plaque-associated macrophages and improve plaque stability in atherosclerosis, *ACS Nano*, **11**(6), pp. 5785–5799.
61. Liu, Y., Nie, L. and Chen, X. (2016). Photoacoustic molecular imaging: from multiscale biomedical applications towards early-stage theranostics, *Trends in Biotechnol.*, **34**(5), pp. 420–433.
62. Wang, L. V. and Hu, S. (2012). Photoacoustic tomography: *in vivo* imaging from organelles to organs, *Science*, **335**, pp. 1458–1462.
63. Xie, C., Upputuri, P. K. and Zhen, X. (2017). Self-quenched semiconducting polymer nanoparticles for amplified *in vivo* photoacoustic imaging, *Biomaterials*, **119**, pp. 1–8.

64. Sun, C., Wen, L. and Zeng, J. (2016). One-pot solventless preparation of PEGylated black phosphorus nanoparticles for photoacoustic imaging and photothermal therapy of cancer, *Biomaterials*, **91**, pp. 81–89.
65. Miao, Q., Lyu, Y., Ding, D. and Pu, K. (2016). Photoacoustic imaging: semiconducting oligomer nanoparticles as an activatable photoacoustic probe with amplified brightness for *in vivo* imaging of pH, *Adv. Mater.*, **28**(19), pp. 3662–3668.
66. Sano, K. (2017). Development of molecular probes based on iron oxide nanoparticles for *in vivo* magnetic resonance/photoacoustic dual imaging of target molecules in tumors, *Yakugaku Zasshi*, **137**(1), pp. 55–60.
67. Cheheltani, R., Ezzibdeh, R. M., Chhour, P., et al. (2016). Tunable, biodegradable gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging, *Biomaterials*, **102**, pp. 87–97.

Chapter 23

Assessment and Quantification of the Core Muscles in Individuals with and without Achilles Tendon Pathology by Ultrasound Imaging

Carlos Romero-Morales, MSc, PT, PhD,^a César Calvo-Lobo, MSc, PT, PhD,^b
Marta San-Antolín, PhD, PHYSC,^c Pedro Martín-Llantino, MSc, PT, PhD,^a
David Rodríguez-Sanz, MSc, DP, PT, PhD,^b María Bravo-Aguilar, MSc, PT, PhD,^a
and Daniel López-López, MSc, DP, MPH, PhD^d

^a*Faculty of Sport Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain*

^b*Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, Madrid, Spain*

^c*Department of Psychology, Universidad Europea de Madrid, Villaviciosa de Odón, Spain*

^d*Research, Health and Podiatry Group, Department of Health Sciences, Faculty of Nursing and Podiatry, Universidade da Coruña, Industrial Campus of Ferrol, Spain*

cescalvo@ucm.es

Keywords: Achilles' tendinopathy (AT), cross-sectional area (CSA), external oblique (EO), internal oblique (IO), inter-recti distance (IRD), low back pain (LBP), multifidus muscles, musculoskeletal disorders, rectus abdominis (RA), transversus abdominis (TrAb), ultrasonography, ultrasound imaging (USI)

23.1 Background

The core complex is composed of the rectus abdominis (RA), external oblique (EO), internal oblique (IO), transversus abdominis (TrAb), and multifidus muscles [1]. The current research indicates that these muscles work in a coordinated manner with the pelvic floor muscles and diaphragm. Moreover, the proper functioning of this complex involves the pressure stabilization of the abdominal cavity and a

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

proper load transfer through the lower limbs, pelvic floor system and trunk. A deficit of the core muscle function has been reported result in structural architecture differences in individuals with chronic low back pain (LBP) [2]. Research has determined the importance of a quantitative and defined evaluation of the paraspinal muscles by ultrasound imaging (USI); e.g., the study of the multifidus muscles for the evaluation of the size and behavior during contraction and at rest in individuals with lumbopelvic disorders [3, 4].

The Achilles tendon is the strongest and largest tendon in the body. This structure is composed of the confluence of the soleus and gastrocnemius muscles. However, the Achilles tendon is frequently injured despite it being a strong structure that can bear loads of 3500 N. (Fig. 23.1) [5].




Figure 23.1 Anatomy and structure of the Achilles tendon.

Achilles tendinopathy (AT) has been described as a very common overuse pathology and one of the most prevalent diseases in the general population [6]. The AT incidence rate is reported from 1.16 to 2.35 per 1000 individuals per year [7]. AT injuries are reported in both sexes but have a higher incidence in middle-aged men [8]. Individuals who develop AT present a combination of pain, morning stiffness, swelling, and inability to perform sports activities [9]. Li and Hua [10] reported three categories of AT: non-insertional AT (located from 4 to 6 cm proximal to the Achilles insertion at the calcaneus); insertional AT (at the Achilles tendon insertion at the calcaneus) and other disorders (e.g., bursitis). Load training programs play an important role in the management of this condition [11]. These programs are oriented to work isotonic and eccentrically the lower limb muscles, abdominal wall and paraspinal muscles are involved working in a coordinated manner to provide body stability and balance. In addition,

lower limb disorders could be related to the alterations in the load transfer mechanisms through the body, in both directions [12].

Current literature shows evidence of the use of USI to assess the muscle thickness and cross-sectional area (CSA) as a complement of a physical therapy examination [13, 14]. For example, USI has been performed in static and dynamic B-mode for the intrinsic and extrinsic muscles, plantar fascia, individuals who suffered an ankle sprain and AT [15–17]. Considering the trunk region, Whittaker et al. [18] described the relationship between individuals with LPP and changes in abdominal wall muscles. In sports populations, USI examination of the abdominal wall muscles and the connective tissues in elite basketball players compared with amateur basketball players [19, 20]. Multifidus muscles were studied in healthy populations [21, 22] and subjects with low back pain, reporting a decrease in the CSA [3]. Several authors suggest that USI, as a valid, non-invasive, and reliable tool, provides a complete and a real-time evaluation of the muscle, fascia and connective tissues [23, 24].

Previous studies about AT have been evaluated detailing structures surrounding the Achilles tendon complex. However, research on muscles and connective tissues involved in the load transfer and biomechanics in subjects with lower limb pathology is still needed. The aim of this research was to observe the differences in the thickness of core muscles in patients with and without AT.

23.2 Material and Methods

23.2.1 Achilles Tendinopathy

Individuals with AT were considered if they presented the following features: tendon pain, irritation or soreness at 2 to 6 cm from the calcaneal entheses, symptoms for at least 3 months, morning stiffness or an improvement of the symptoms throughout the day or after warm-up.

23.2.2 Ultrasound Imaging Evaluation

The current research on the USI of the core muscles was based on the supine position. The images of the EO, IO, and TrAb muscles were performed by placing the transducer in the mid-axillary line, between the subcostal line and the iliac crest [18] following Whittaker et al.'s guidelines [25] (Fig. 23.1A). For the RA muscle assessment, the transducer was aligned with the umbilicus, and just under the umbilicus for the inter-recti distance (IRD) evaluation (Fig. 23.1B). Several authors have described the muscle thickness as the distance between the edges of each muscle, and IRD is considered as the distance between the both RA muscles [18]. For the assessment of the multifidus muscles, individuals lied in the prone position. According to Wallwork et al.'s [26] guidelines, the thickness of the multifidus muscles was described inside edge of the superior margin of the multifidus muscle [26] (Fig. 23.2A).




Figure 23.2 Ultrasound imaging thickness for the EO, IO, TrAb (A), RA thickness muscles and IRD (B) and multifidus thickness (C). *Abbreviations:* EO, external oblique; IO, internal oblique; TrAb, transversus abdominis; RA, rectus abdominis; IRD, inter-recti distance.

23.3 Results

There was a decrease in the thickness of the EO, IO, TrAb, and RA muscles for the individuals with tendinopathy. However, an increase was reported in the IRD and multifidus thickness in the tendinopathy group compared with the healthy individuals (Fig. 23.3).




Figure 23.3 Bar graph for the IRD, RA, EO, IO, TrAb and multifidus thickness mean values.

23.4 Discussion

The present findings are in line with the previous studies that show a relationship between Achilles tendinopathy and morphological muscle changes [15–16], reporting a difference in the core muscles between populations [19]. Wallwork et al. [26] showed good reliability of the USI evaluation of the voluntary contraction of the multifidus muscles. Moreover, Hides et al. [27] argued that dynamic studies of paraspinal muscles by USI may be useful in providing a visual feedback in populations with lumbar disorders. Based on the authors' findings, the results of the present study showed significant differences in individuals with pathology—chronic mid-portion AT—compared with the healthy subjects. However, Hides et al. [27] reported differences in multifidus muscles in individuals with subacute LBP showing a decrease in the CSA in favor to the pathology group. Several authors argued that core load management programs increased the multifidus CSA [28], in order to improve the core protection, stabilization in a coordinated manner with the anterior wall muscles. Prior USI research on abdominal wall muscles has focused on the IO and TrAb muscles [29–31]. In addition, Jansen et al. [30] did not find differences in the thickness of the IO and TrAb muscles in LBP compared with healthy individuals. However, our research showed a decrease in the RA thickness and an increased IRD for the tendinopathy group. Coldron et al. [32] also found in postpartum women a significantly thinner RA and a wider IRD. On the same lines, Romero et al. [19] compared by USI the abdominal wall muscles of elite basketball players and amateurs, showing a significantly increase in the IRD in the former. These results could be related to the high musculoskeletal system demand in the elite basketball players due to the multiple training sessions per week. The RA muscle has the greatest thickness of the abdominal wall muscles [33], playing an important role in transferring loads in a coordinated manner with the EO, OI, and TrAb muscles. Mota et al. [34] argued that the exploration by palpation of the IRD is sufficient for clinical practice. However, USI is a more accurate method to recommend in clinical practice and research on IRD. In addition, the work developed by Rankin et al. [33] supports the reliability and validity of the RA muscle examination by USI.

Regarding the anterolateral abdominal muscles, several authors have examined and compared by USI different populations with respect to healthy groups. For example, Jansen et al. [30] showed a smaller TrAb thickness in subjects with longstanding adduction-related groin pain compared with healthy athletes. Rostami et al. [35] compared the thickness of the anterolateral muscles of competitive off-road cyclists with and without LBP showing a lower thickness of the TrAb for the LBP group. On these lines, the results of the present investigation presented a decrease in the TrAb, IO, and EO thickness for the tendinopathy group. The important role of the TrAb muscle in the control of the spine was widely evidenced, with the deep trunk abdominal muscles considered as main outcomes

to assess and manage specific populations with different musculoskeletal disorders such as LPP, LBP, or AT individuals [36, 37].

23.5 Conclusions

The thickness of the core muscles was found to be reduced in the patients with AT compared with the healthy subjects. However, further research is still needed to improve the knowledge and the relationship between the lower limb and the core complex in patients with and without pathology.

Disclosures and Conflict of Interest

This chapter was originally published as: Romero-Morales, C., Martín-Llantino, P., Calvo-Lobo, C., San-Antolín, M., López-López, D., Blanco-Morales, M., Rodríguez-Sanz, D. (2020). Ultrasound imaging of the abdominal wall and trunk muscles in patients with Achilles tendinopathy versus healthy participants. *Diagnostics*, **10**, 17, <https://doi.org/10.3390/diagnostics10010017>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here with permission from and with updates by the authors.

References

1. Brown SHM, Ward SR, Cook MS, Lieber RL. Architectural analysis of human abdominal wall muscles: implications for mechanical function. *Spine* (Phila Pa 1976). 2011 Mar; 36(5): 355–62.
2. Radebold A, Cholewicki J, Panjabi MM, Patel TC. Muscle response pattern to sudden trunk loading in healthy individuals and in patients with chronic low back pain. *Spine* (Phila Pa 1976). 2000 Apr 15; 25(8): 947–54. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10767807> (accessed on October 15, 2022).
3. Hides J, Gilmore C, Stanton W, Bohlscheid E. Multifidus size and symmetry among chronic LBP and healthy asymptomatic subjects. *Man Ther*. 2008 Feb; 13(1): 43–9.
4. Stokes M, Hides J, Elliott J, Kiesel K, Hodges P. Rehabilitative ultrasound imaging of the posterior paraspinal muscles. *J Orthop Sports Phys Ther*. 2007 Oct; 37(10): 581–95.
5. Freedman BR, Gordon JA, Soslowsky LJ. The Achilles tendon: fundamental properties and mechanisms governing healing. *Muscles Ligaments Tendons J*. 2014 Jul 14; 4(2): 245–55. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25332943> (accessed on October 15, 2022).
6. Alfredson H. Chronic midportion Achilles tendinopathy: an update on research and treatment. *Clin Sports Med*. 2003 Oct; 22(4): 727–41.
7. Albers IS, Zwerver J, Diercks RL, Dekker JH, Van den Akker-Scheek I. Incidence and prevalence of lower extremity tendinopathy in a Dutch general practice population: a cross sectional study. *BMC Musculoskelet Disord*. 2016 Jan; 17: 16.
8. Alfredson H, Lorentzon R. Chronic Achilles tendinosis: recommendations for treatment and prevention. *Sports Med*. 2000 Feb; 29(2): 135–46.

9. Cook JL, Khan KM, Purdam C. Achilles tendinopathy. *Man Ther.* 2002 Aug; 7(3): 121–30.
10. Li H-Y, Hua Y-H. Achilles tendinopathy: current concepts about the basic science and clinical treatments. *Biomed Res Int.* 2016; 2016: 6492597.
11. Boesen AP, Boesen MI, Koenig MJ, Bliddal H, Torp-Pedersen S, Langberg H. Evidence of accumulated stress in Achilles and anterior knee tendons in elite badminton players. *Knee Surg Sports Traumatol Arthrosc [Internet].* 2010/07/22. 2011 Jan; 19(1): 30–7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20652535> (accessed on October 15, 2022).
12. Richardson CA, Snijders CJ, Hides JA, Damen L, Pas MS, Storm J. The relation between the transversus abdominis muscles, sacroiliac joint mechanics, and low back pain. *Spine (Phila Pa 1976).* 2002 Feb; 27(4): 399–405.
13. Chang K-V, Yang K-C, Wu W-T, Huang K-C, Han D-S. Association between metabolic syndrome and limb muscle quantity and quality in older adults: a pilot ultrasound study. *Diabetes Metab Syndr Obes.* 2019 Sep 11; 12: 1821–30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31571957> (accessed on October 15, 2022).
14. Chang K-V, Wu W-T, Huang K-C, Jan WH, Han D-S. Limb muscle quality and quantity in elderly adults with dynapenia but not sarcopenia: An ultrasound imaging study. *Exp Gerontol.* 2018 Jul; 108: 54–61.
15. Romero-Morales C, Martín-Llantino PJ, Calvo-Lobo C, Sanchez-Gomez R, Lopez-Lopez D, Pareja-Galeano H, et al. Ultrasound evaluation of extrinsic foot muscles in patients with chronic non-insertional Achilles tendinopathy: A case-control study. *Phys Ther Sport.* 2019 Feb; 37: 44–8.
16. Romero-Morales C, Martín-Llantino PJ, Calvo-Lobo C, López-López D, Sánchez-Gómez R, De-La-Cruz-Torres B, et al. Ultrasonography features of the plantar fascia complex in patients with chronic non-insertional Achilles tendinopathy: A case-control study. *Sensors (Basel).* 2019 May; 19(9): 2052.
17. Lobo CC, Morales CR, Sanz DR, Corbalan IS, Marin AG, Lopez DL. Ultrasonography comparison of peroneus muscle cross-sectional area in subjects with or without lateral ankle sprains. *J Manipulative Physiol Ther.* 2016 Nov; 39(9): 635–44.
18. Whittaker JL, Warner MB, Stokes M. Comparison of the sonographic features of the abdominal wall muscles and connective tissues in individuals with and without lumbopelvic pain. *J Orthop Sport Phys Ther.* 2013 Jan; 43(1): 11–9.
19. Romero-Morales C, Almazán-Polo J, Rodríguez-Sanz D, Palomo-López P, López-López D, Vázquez-González S, et al. Rehabilitative ultrasound imaging features of the abdominal wall muscles in elite and amateur basketball players. *Appl Sci.* 2018; 8(5). Available at: <http://www.mdpi.com/2076-3417/8/5/809> (accessed on October 15, 2022).
20. Morales CR, Polo JA, Sanz DR, Lopez DL, Gonzalez SV, Buria JLA, et al. Ultrasonography features of abdominal perimuscular connective tissue in elite and amateur basketball players: an observational study. *Rev Assoc Med Bras.* 2018 Oct; 64(10): 936–41.
21. Shi J, Zheng YP, Chen X, Huang QH. Assessment of muscle fatigue using sonomyography: muscle thickness change detected from ultrasound images. *Med Eng Phys.* 2007 May; 29(4): 472–9.
22. Chang K-V, Kara M, Su DC-J, Gurcay E, Kaymak B, Wu W-T, et al. Sonoanatomy of the spine: a comprehensive scanning protocol from cervical to sacral region. *Med Ultrason.* 2019 Nov; 21(4): 474–82.

23. Teyhen DS, Gill NW, Whittaker JL, Henry SM, Hides JA, Hodges P. Rehabilitative ultrasound imaging of the abdominal muscles. *J Orthop Sports Phys Ther.* 2007 Aug; 37(8): 450–66.
24. Romero-Morales C, Martin-Llantino PJ, Calvo-Lobo C, Palomo-Lopez P, Lopez-Lopez D, Pareja-Galeano H, et al. Comparison of the sonographic features of the Achilles Tendon complex in patients with and without achilles tendinopathy: A case-control study. *Phys Ther Sport.* 2019 Jan; 35: 122–6.
25. Whittaker JL, Stokes M. Ultrasound imaging and muscle function. *J Orthop Sport Phys Ther.* 2011 Aug; 41(8): 572–80.
26. Wallwork TL, Hides JA, Stanton WR. Intrarater and interrater reliability of assessment of lumbar multifidus muscle thickness using rehabilitative ultrasound imaging. *J Orthop Sports Phys Ther.* 2007 Oct; 37(10): 608–12.
27. Hides JA, Saide M, Stokes MJ, Jull GA, Cooper DH. Evidence of lumbar multifidus muscle wasting ipsilateral to symptoms in patients with acute/subacute low back pain. *Spine (Phila Pa 1976).* 1994; 19(2): 165–72.
28. Kliziene I, Sipaviciene S, Klizas S, Imbrasiene D. Effects of core stability exercises on multifidus muscles in healthy women and women with chronic low-back pain. *J Back Musculoskelet Rehabil.* 2015; 28(4): 841–7.
29. Hides JA, Belavy DL, Stanton W, Wilson SJ, Rittweger J, Felsenberg D, et al. Magnetic resonance imaging assessment of trunk muscles during prolonged bed rest. *Spine (Phila Pa 1976).* 2007 Jul; 32(15): 1687–92.
30. Jansen J, Weir A, Denis R, Mens J, Backx F, Stam H. Resting thickness of transversus abdominis is decreased in athletes with longstanding adduction-related groin pain. *Man Ther.* 2010 Apr; 15(2): 200–5.
31. Stuge B, Morkved S, Dahl HH, Vollestad N. Abdominal and pelvic floor muscle function in women with and without long lasting pelvic girdle pain. *Man Ther.* 2006 Nov; 11(4): 287–96.
32. Coldron Y, Stokes MJ, Newham DJ, Cook K. Postpartum characteristics of rectus abdominis on ultrasound imaging. *Man Ther.* 2008 May; 13(2): 112–21.
33. Rankin G, Stokes M, Newham DJ. Abdominal muscle size and symmetry in normal subjects. *Muscle Nerve.* 2006 Sep; 34(3): 320–6.
34. Mota P, Pascoal AG, Sancho F, Carita AI, Bo K. Reliability of the inter-rectus distance measured by palpation. Comparison of palpation and ultrasound measurements. *Man Ther.* 2013 Aug; 18(4): 294–8.
35. Rostami M, Ansari M, Noormohammadpour P, Mansournia MA, Kordi R. Ultrasound assessment of trunk muscles and back flexibility, strength and endurance in off-road cyclists with and without low back pain. *J Back Musculoskelet Rehabil.* 2015; 28(4): 635–44.
36. Sutherland MA, Gage M, Mangum LC, Hertel J, Russell S, Saliba SA, et al. Changes in muscle thickness across positions on ultrasound imaging in participants with or without a history of low back pain. *J Athl Train.* 2018 Jun; 53(6): 553–9.
37. Whittaker JL. Ultrasound imaging of the lateral abdominal wall muscles in individuals with lumbopelvic pain and signs of concurrent hypocapnia. *Man Ther.* 2008 Oct; 13(5): 404–10.

Chapter 24

Loop-Mediated Isothermal Amplification (LAMP): An Advanced Molecular Point-of-Care Technique for the Detection of *Leishmania* Infection

Chukwunonso O. Nzelu, PhD,^a Hirotomo Kato, DVM, PhD,^b and
Nathan C. Peters, PhD^a

^aSnyder Institute for Chronic Diseases,

Departments of Microbiology, Immunology, and Infectious Diseases,
Cumming School of Medicine and Comparative Biology and Experimental Medicine,
Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada

^bDivision of Medical Zoology, Department of Infection and Immunity,
Jichi Medical University, Tochigi, Japan

chukwunonso.nzelu@ucalgary.ca, ncpeters@ucalgary.ca

Keywords: canine leishmaniasis (CanL), cutaneous leishmaniasis (CL), direct agglutination test (DAT), enzyme-linked immunosorbent assay (ELISA), Flinders Technology Associates (FTA), fluorescent detection reagents (FDR), Foundation for Innovative New Diagnostics (FIND), immunofluorescence antibody test (IFAT), kinetoplast DNA (kDNA), *Leishmania*, leishmaniasis, loop-mediated isothermal amplification (LAMP), molecular diagnostics, molecular xenomonitoring (MX), mucocutaneous leishmaniasis (MCL), nucleic acid amplification test (NAAT), nucleic acid sequence-based amplification (NASBA), PCR-restriction fragment length polymorphism (PCR-RFLP), point-of-care (POC), polymerase chain reaction (PCR), post kala-azar dermal leishmaniasis (PKDL), protozoa, quantitative polymerase chain reaction (qPCR), recombinase polymerase amplification (RPA), ribosomal RNA (rRNA), serological test, visceral leishmaniasis (VL), World Health Organization (WHO)

24.1 Introduction

Leishmaniasis is a diverse spectrum of clinical syndromes caused by more than 20 species of the obligate intracellular protozoa parasites of the genus *Leishmania*

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

and is transmitted by the bite of an infected female sand fly. Leishmaniasis is one of the most neglected and poverty-related tropical diseases in the world [1]. The disease is endemic in 98 countries, affecting 12 million people worldwide, with an estimated 350 million people at risk of infection [2]. Unfortunately, in most countries, the incidence of disease is often underestimated largely due to unrecognized cases, lack of access to healthcare, or under-reporting [3]. Different species of *Leishmania* cause disease in both humans and animals, and *Leishmania* is often referred to as a zoonosis. After deposition into the skin, *Leishmania* can give rise to mild and atypical types of cutaneous leishmaniasis (CL), a destructive mucocutaneous leishmaniasis (MCL), and deadly systemic visceral leishmaniasis (VL). The clinical manifestations of disease are largely associated with the infecting strain of the parasite. Considering leishmaniasis is an emerging and uncontrolled disease in some regions and is increasing in some endemic areas, timely diagnosis and treatment of patients is of paramount importance to contain the disease.

Currently available diagnostic tools for leishmaniasis can be divided into three groups: parasitological, serological, and molecular diagnostics, each of them coming with advantages and disadvantages. The traditional parasitological methods, which include microscopy and parasite culturing, remain the diagnostic gold standard. Though technically specific, it suffers from low sensitivity, and only a handful of health centers in the field are able to culture parasites. Serological methods with comparable sensitivity to parasitological methods are available in the form of enzyme-linked immunosorbent assay (ELISA) and rapid diagnostic tests (RDTs) based on rK39 [4, 5], immunofluorescence antibody test (IFAT), western blotting, and direct agglutination test (DAT) [6, 7]. However, serology-based diagnostic techniques also have some disadvantages, such as cross-reactivity and false-positive results [4, 6, 7]. Molecular methods provide an effective alternative to the aforementioned methods and are of greater sensitivity and specificity [6, 7]. The presence of *Leishmania* DNA as a molecular biomarker for infection can be effectively employed in both human and other mammalian hosts. Human clinical samples, such as whole blood, urine, bone marrow, lymph nodes, serum, buffy coat [6], and cutaneous lesion aspirates or scrapings [8, 9], have reliably been used to detect the presence of parasitic DNA. Despite the apparent availability of effective diagnostics tests, resource limitations in endemic countries or a lack of experience among physicians and laboratory technicians in nonendemic countries leads to either no diagnosis or delays and inaccurate diagnosis. Consequently, a sensitive and specific molecular diagnostic method is required in both endemic and nonendemic regions. One of the most basic and widely used molecular diagnostic techniques is polymerase chain reaction (PCR) detection of *Leishmania* DNA [6, 7]. Detection of pathogen DNA directly from clinical samples has permitted more analytically sensitive diagnosis of infection. However, the technique requires expensive equipment, DNA purification, a long time to diagnosis, and a lack of field applicability, thereby preventing the use of PCR-based diagnostics in resource-limited, disease-endemic settings. To overcome PCR limitations, in the year 2000,

a novel molecular technique, the loop-mediated isothermal amplification (LAMP), was developed as a field-friendly and cost-effective diagnostic tool [10], and it appears to be a feasible molecular diagnostic tool for both endemic and nonendemic regions. LAMP has the advantage of no major capital equipment requirement, simplified DNA extraction methods like boil and spin, naked eye detection of amplification, and the use of dry reagents, including the polymerase enzyme.

Several studies have shown the utility of the LAMP technique as a useful tool for rapid detection of pathogenic agents (bacteria, parasites, and viruses) of infectious diseases [9, 11–15]. LAMP diagnostic kits have also been developed by the Eiken Chemical Co. (Japan) for human African trypanosomiasis (HAT) [16], tuberculosis [17], malaria [18, 19], and leishmaniasis [20, 21]; and recently the LAMP diagnostic kit for tuberculosis has been endorsed by the World Health Organization [22]. Meridian Biosciences (Cincinnati, OH) has also developed a centrifugation-free assay called *illumigene* for malaria genus-level detection [23]. Since the advent of LAMP as a simple and robust nucleic acid amplification test (NAAT), different studies have shown a number of prototype LAMP assays in the field of leishmaniasis. Here we present a review, current status, diagnostic performance, and perspectives of molecular-based LAMP technique for leishmaniasis, as well as its prospects as a xenomonitoring/surveillance tool in endemic areas. Box 1 shows the search strategy and selection criteria used in this review. The flow of included studies is graphically presented in Fig. 24.1.

Box 24.1 Information sources, search strategies, and study selection

The authors searched for articles in PubMed, Embase, Web of Science, Google Scholar, and Scopus, with the following keywords: *Leishmania* LAMP assay; cutaneous leishmaniasis; molecular diagnosis; PCR and LAMP; *Leishmania* diagnosis; colorimetric dye; parasitic DNA; leishmaniasis; mucocutaneous leishmaniasis; visceral leishmaniasis; post kala-azar dermal leishmaniasis; canine leishmaniasis; and sand fly, surveillance, xenomonitoring, and other related words.

The eligibility criteria included the following: original studies evaluating LAMP test; clinical cutaneous leishmaniasis, visceral leishmaniasis, post kala-azar dermal leishmaniasis in human, canine leishmaniasis, and *Leishmania* detection in sand flies as respective target conditions; adequate reference classification; and absolute numbers of true-positive, true-negative, false-positive, and false-negative observations derivable from the data presented in the diagnosis of human leishmaniasis. Commercial and laboratory developed tests were eligible. LAMP test accuracy were summarized as sensitivity and specificity with 95% confidence intervals. Analysis was performed using *Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.*




Figure 24.1 Flowchart of the studies identified, screened, and included in this review.

24.2 LAMP Technique: Its Developments and Features

A recent advance in molecular (nucleic acid-based) diagnostics has been the development of LAMP [10], among others like nucleic acid sequence-based amplification (NASBA) and recombinase polymerase amplification (RPA) [24, 25]. The LAMP technique employs a *Bacillus stearothermophilus* (*Bst*) DNA polymerase—which has both polymerase and reverse transcriptase activity—and a set of four primers (two inner primers, with typical length of approximately 40–42 bp and two outer primers, with typical length approximately 17–20 bp) that recognize six distinct sequences of the target DNA, which makes them highly specific to the target. Occasionally, the addition of two extra primers (loop forward primer and loop backward primer, with a typical length of approximately 20 bp) referred to as loop primers accelerates the amplification




Figure 24.2 Schematic representation of molecular mechanism of LAMP (three major steps in the LAMP reaction) and localization of the LAMP primers on target DNA sequence.

reaction, thereby decreasing the reaction time required [26]. The design of the LAMP primers is easy and can readily be done through a user-friendly online platform: Primer Explorer V4 software (<http://primerexplorer.jp/e>) running in java Runtime environment, a product of Eiken Chemical Co. LAMP has the capacity to amplify a few copies of DNA to 10^9 in <60 min with high efficiency [10]. The mechanism behind the LAMP reaction involves three major steps: initiation, cycling amplification, and elongation (Fig. 24.2). Typically, the reaction begins with the binding of the inner primers containing sequences of the sense and antisense strands of the target DNA, and this is followed by strand displacement DNA synthesis by the outer primers (initial step). Subsequently, the cyclical amplification step and elongation occur [10]. One good feature of LAMP is the auto strand displacement properties of *Bst* polymerase, which enables amplification reaction using heating block or normal water bath maintained at a specific temperature without the use of expensive thermal cyclers. The appearance of magnesium pyrophosphate precipitate (a by-product of DNA amplification) provides a positive indicator of the target DNA amplification. Real-time turbidimetry facilitates the quantification of the template DNA in the reaction and allows the analysis of minute quantities of DNA. Furthermore, LAMP amplicon can be analyzed using agarose gel electrophoresis and/or simple colorimetric naked eye visualization closed detection systems [27] and real-time fluorimetry [21, 28]. Therefore, the major advantage of LAMP is its application in a field or resource-limited setting.

24.3 Application of LAMP Technique to Leishmaniasis

24.3.1 CL

CL is the most prevalent clinical form of leishmaniasis worldwide, characterized by the presence of ulcerative lesions leading to disfiguring and/or incapacitating scars [2]. CL is endemic in the tropics and neotropics and in more than 70 countries worldwide, and 90% of cases occur in seven countries: Afghanistan, Algeria, Brazil, Iran, Peru, Saudi Arabia, and Syria [29]. CL is most commonly associated with *Leishmania (Leishmania) major*, *L. (L.) tropica*, and *L. (L.) aethiopica* species in the Old World and multiple species of *Leishmania*—*L. (L.) mexicana*, *L. (L.) amazonensis*, *L. (Viannia) braziliensis*, *L. (V.) guyanensis*, *L. (V.) panamensis*, and *L. (V.) peruviana*—in the New World [30]. In some regions, two or more species are often sympatric [31]. Species prevalent in the Old World in most cases cause self-limiting ulcers, while the New World species are known to cause a syndrome called American tegumentary leishmaniasis—comprised of CL and a variety of other manifestations, like MCL—and a diffuse and disseminated cutaneous leishmaniasis (DCL or diffuse-CL) [32].

Because the clinical spectrum of CL is broad and can be misdiagnosed as other skin conditions such as cutaneous mycoses, leprosy, keloid, lupus vulgaris, or sarcoidosis [33], a differential diagnosis can be very important for treatment.

While microscopy and culture remain the gold standard for CL diagnosis, the sensitivity is variable and time consuming, demanding technical expertise and significant infrastructure. Serology-based method is not very useful in CL diagnosis because of undetectable or low antibodies titers. Many molecular diagnostic methods that allow the use of less invasive sampling with better sensitivity and specificity have been developed extensively for CL diagnosis. Particularly, PCR-technique targeting different gene sequences have been employed over the last decades for CL diagnosis [34, 35]. PCR platforms for CL show specificity (84–100%) and sensitivity (90–98%) [34, 36].

The first LAMP test for CL on skin biopsy was a generic, reverse transcriptase (RT-LAMP), targeting the conserved region of the *Leishmania* 18S ribosomal RNA (rRNA) gene with infection detection limit of 10 and 100 parasites/ml [37]. Different studies have recently developed this technique for various applications, especially those based on the *Leishmania* 18S rRNA and minicircle kinetoplast DNA (kDNA) genes in CL endemic countries (Table 24.1). The choice of 18S rRNA gene in most pan-*Leishmania* LAMP assays was due to its high conservation across *Leishmania* species, while the kDNA gene has been proven to yield high sensitivity against other genes in comparative studies due to its high copy number [38, 39]. More recently, a LAMP assay targeting the cysteine protease B (cpb) gene has also been used for diagnosis of CL cases in Tunisia [40]. A comparative study of pan-*Leishmania* LAMP assays employing primers targeting *Leishmania* 18S rRNA and histone genes, respectively, using purified DNAs of CL-causing species—*L. (L.) major*, *L. (L.) tropica*, *L. (L.) mexicana*, *L. (V.) braziliensis*, *L. (V.) guyanensis*, *L. (V.) panamensis*—revealed a similar limit of detection at 0.01 parasite/ μ l for both genes, but the histone primer was found to be incapable of amplifying all *L. (V.) guyanensis* and *L. (V.) braziliensis* strains tested, indicating low sequence homology to some strains [39]. Studies have shown the usefulness of patient saliva [41] and a direct boil-LAMP method [42] in the diagnosis of CL. The boil method was found not to compromise *Leishmania* detection sensitivity of the LAMP assays [42, 43]. Furthermore, a Flinders Technology Associates (FTA)-LAMP for CL with detection sensitivity as low as 0.01 parasites/ μ l was demonstrated with clinical tissue spotted on FTA cards obtained from patients in Peru [9]. The established LAMP assay showed the usefulness of FTA cards as a direct sampling tool for diagnosis of CL and was comparable to using purified DNA as a template. The reported FTA-LAMP is a further improvement in the application of LAMP in that it circumvents the need for liquid handling during sample collection and transportation, as well as refrigerant/cold storage. In spite of the fact that only a few human CL-LAMP studies were identified in our review of available literature, the diagnostic accuracy of LAMP testing for CL revealed sensitivity of 80%–92% and specificity of 94%–100% on tissue biopsies in three studies [44–46] (Fig. 24.3A). Overall, these reports support a potential role of LAMP as a reliable point-of-care (POC) diagnostic test for CL, which will be widely applicable in both endemic and nonendemic regions.


Table 24.1 Overview of LAMP assays for diagnosis of human and canine leishmaniases reported in previous studies

Subject	LAMP target	Sample (n)	DNA extraction	Sensitivity (%)	Specificity (%)	Reference test	Dis.	Country	Ref.
Human	kDNA	Blood (10)	Qiagen Mini prep	80.0	100	Microscopy	VL	Bangladesh	Takagi and colleagues, 2009 [14]
Human	18S rRNA	Blood (30) Skin biopsy (43)	Organic solvent	83.0 98.0	98.0 N/A	Microscopy qRT-PCR	VL CL	Sudan Suriname	Adams and colleagues, 2010 [37]
Human	kDNA	Buffy-coat (75)	Qiagen Mini prep	90.7	100	Microscopy	VL	Bangladesh	Khan and colleagues, 2012 [56]
Human	kDNA	Blood (55) BMA (15) Tissue biopsy (62)	Qiagen Mini prep	96.4 100 96.8	98.5 98.5 100	Microscopy qPCR	VL VL PKDL	India	Verma and colleagues, 2013 [57]
Dog	cpb	Blood (75)	Wizard DNA kit	54.2	80.0	Microscopy	CanL	Tunisia	Chaouch and colleagues, 2013 [72]
Human	kDNA	Blood (47)	Qiagen Mini prep	93.6	100	DAT	VL	Iran	Ghasemian and colleagues, 2014 [59]
Human	18S rRNA	Blood (2) Saliva (2) Tissue biopsy (1) BMA (1)	Direct-Boil Qiagen Mini prep	N/A	N/A	Microscopy	VL CL CL VL	Thailand	Sirworarat and colleagues, 2015 [41]
Dog	kDNA	Conjunctiva l swab (111)	Boil-Spin	61.3	97.0	Microscopy	CanL	China	Gao and colleagues, 2015 [73]
Human	kDNA	Tissue biopsies (31)	Qiagen Mini prep	82.6	100	Microscopy	CL	Sri Lanka	Kathalawala and Karunaweera, 2015 [45]
Human	18S rRNA	Tissue biopsy-FTA-card (122)	FTA purification reagent (Whatman)	N/A	N/A	Nested-PCR	CL	Peru	Nzulu and colleagues, 2016 [9]


Subject	LAMP target	Sample (n)	DNA extraction	Sensitivity (%)	Specificity (%)	Reference test	Dis.	Country	Ref.
Human	kDNA	Blood (66)	Qiagen Mini	96.9	100	qPCR	VL	India	Verma and colleagues, 2017 [44]
		BMA (15)	prep	100	100		VL		
		Tissue biopsy (67)		97.0	100		PKDL		
		Tissue biopsy (10)		80.0	100		CL		
Human	18S rRNA and kDNA	Whole blood and Buffy-coat (185)	Boil-Spin and Qiagen Mini prep	97.6 100	99.0 99.0	Microscopy	VL	Sudan	Mukhtar and colleagues, 2018 [20]
Human	18S rRNA	Tissue biopsy (2)	Direct-Boil	N/A	N/A	PCR	CL	Japan (Imported cases)	Imai and colleagues, 2018 [42]
Human	18S rRNA and kDNA	Tissue biopsies (105) Whole blood PBMC Buffy-coat (50)	Qiagen Mini prep	95.0	86.0	Microscopy	CL	Colombia	Adams and colleagues, 2018 [39]
				92.3	100		VL	Ethiopia	
				88.5	95.8		VL		
				92.3	95.8		VL		
Human	18S rRNA and kDNA	Tissue biopsy (274)	Qiagen Mini prep	92.2	94.1	Microscopy PCR	CL	Afghanistan	Vink et al., 2018 [46]
Human	kDNA	Blood (179) Blood (72)	Qiagen Mini prep Direct-blood-lysis	98.3	96.6	Microscopy	VL	India	Dixit and colleagues, 2018 [58]
				93.1	100	rK39 qPCR	VL		

Abbreviations: BMA, bone marrow aspirates; CanL, canine leishmaniasis; CL, cutaneous leishmaniasis; cpb, cysteine protease B; DAT, direct agglutination test; Dis, disease; FTA, Filders Technology Associates; kDNA, kinetoplast DNA; LAMP, loop-mediated isothermal amplification; n, number of samples; N/A, not applicable; PBMC, peripheral blood mononuclear cells; PKDL, post kala-azar dermal leishmaniasis; qPCR, quantitative PCR; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; Ref, references; rK39, recombinant antigen-based immunochromatography test; VL, visceral leishmaniasis.

A. CL-LAMP (Tissue biopsy)



B. VL-LAMP (Whole blood)



C. VL-LAMP (Buffy coat)



D. HIV-VL-LAMP (Whole blood)



E. PKDL-LAMP (Tissue biopsy)




Figure 24.3 Reported LAMP diagnostic accuracy by study and test with forest plots. (A) CL-LAMP on tissue biopsy (B) VL-LAMP on whole blood. (C) VL-LAMP on buffy coat. (D) HIV-VL co-infection-LAMP on whole blood. (E) PKDL-LAMP on tissue biopsy. *Abbreviations:* CL, cutaneous leishmaniasis; FN, False-negative; FP, False-positive; PKDL, post kala-azar dermal leishmaniasis; TN: True-negative; TP, True-positive; VL, visceral leishmaniasis.

24.3.2 VL and PKDL

VL is characterized by fever, weight loss, wasting, and splenomegaly and is fatal if left untreated. VL is caused by *L. (L.) infantum* (both in the New and Old World) or *L. (L.) donovani* (only in the Old World). The disease is prevalent in tropical regions, with more than 90% of total cases reported from India, Bangladesh, Sudan, Brazil, Ethiopia, and South Sudan [47]. Post kala-azar dermal leishmaniasis (PKDL) is a complication of VL, characterized by macular, maculopapular, and nodular lesions in a patient who has recovered from VL. Significantly, during interepidemic periods of VL, patients who developed PKDL are considered as

potential reservoir hosts for the parasite [48]. Therefore, detection and identification of both VL and PKDL patients in endemic areas are of paramount importance to combat leishmaniasis.

Diagnosis of both VL and PKDL relies on microscopic examination of tissue smears; however, this method suffers from low sensitivity. For VL, microscopy has a sensitivity of 93%–99% for spleen aspirate, 53%–86% for bone marrow, and 53%–65% for lymph node aspirates [49], while for PKDL it has a sensitivity of 67%–100% for nodular lesions, 36%–69% for popular lesions, and 7%–33% for macular lesions [50]. Serological methods such as DAT, ELISA, and the rK39 strip test have high sensitivity but come with their own challenges—like an inability to discriminate between symptomatic and asymptomatic cases, cross-reactivity with other diseases, and inconsistent performance in HIV-VL co-infection cases—and are particularly not conclusive for PKDL diagnosis [51–52]. Like in the case of CL diagnosis, several PCR molecular-based tools have been successfully shown to have increased sensitivity and accuracy in VL and PKDL diagnosis using various templates [6, 35, 53]. Molecular tests are potentially important in the case of HIV-VL co-infection because of low antibody response in HIV-infected patients, which lowers the sensitivity of serological tests [54]. Among the three forms of leishmaniasis, the development of diagnostics for VL based on LAMP has gained more focus, and the Foundation for Innovative New Diagnostics (FIND) has also devoted its efforts towards reducing the burden of VL through innovative LAMP technique (<http://www.finddiagnostics.org>). Such interest on VL is not surprising because recent VL diagnostics modelling data indicate that early diagnosis and treatment of patients have the potential to immensely reduce the transmission of the disease in endemic areas [55]. Therefore, early detection of the infectious agent will require a simple and rapid specific test, which consequently makes LAMP an ideal test for VL.

Species-specific LAMP assays based on the kDNA gene have been largely established for VL and PKDL diagnosis in endemic areas (Table 24.1), as well as genus-specific LAMP for VL either based on the *Leishmania* 18S rRNA or ITS1 genes [28, 41], which were in-house assays. Loopamp *Leishmania* Detection kit (Eiken Chemical, Japan), a first *Leishmania* LAMP kit, which comes in a ready-to-use format with primers targeting both 18S rRNA and kDNA minicircles, specific to the *Leishmania* genus has also been evaluated for the diagnosis of VL [20]. There were no significant differences between the sensitivities or specificities of the LAMP kit test on whole blood and buffy-coat samples processed either by the simple boil and spin method or commercial QIAgen kits for VL in Sudan [20]. A similar study has shown that LAMP performed on DNA extracted from whole blood had good sensitivity compared to microscopy of highly invasive biopsy samples [39]. The diagnostic accuracy of LAMP testing for VL was reported as high (sensitivity 80%–100% and specificity 96%–100%) in all studies irrespective of the sample tested (whole blood, buffy coat) [14, 20, 37, 39, 44, 56–59] (Fig. 24.3B and 24.3C). The amplification efficiency of LAMP in detection of *Leishmania* infection in multiple less or noninvasive DNA sources, such as saliva

and peripheral blood [41], is valuable in reducing the probability of a false negative. In addition, LAMP may particularly be important for patients who are co-infected with human immunodeficiency virus (HIV). In patients suffering from both HIV and VL, LAMP was proven to have a good diagnostic efficacy with 100% (95% CI, 59%–100%) sensitivity and 100% (95% CI, 86%–100%) specificity [39, 41] (Fig. 24.3D). Two studies provided diagnostic accuracy on LAMP testing for PKDL on tissue biopsies [44, 57]. The sensitivity and specificity were reported as high (97% and 100%, respectively) in both studies (Fig. 24.3E). Furthermore, at VL and PKDL posttreatment stages, LAMP can potentially be utilized in the assessment of cure [44]; however, a study had previously revealed the inability of LAMP to amplify posttreatment patients when the number of parasites fell to extremely low levels, approximately 10 parasites/ml [37]. Variation in the LAMP detection limit or sensitivity may be related to the primers and the target region selected, the *Leishmania* species involved, and the DNA extraction methods employed. Taken collectively, LAMP has shown very good diagnostic performance for VL and PKDL—with high sensitivity and specificity similar to PCR methods—and has emerged as a promising POC test for screening at-risk populations, and HIV-VL diagnosis, as well as assessment of cure for VL and PKDL in endemic areas.

24.3.3 Canine Leishmaniasis (CanL)

Canine leishmaniasis (CanL) is an important zoonotic disease mainly caused by *L. (L.) infantum*, which is associated with the long history of companionship between dogs and humans, as well as with sand fly vectors. The disease exists in about 50 countries among the 98 countries where human leishmaniasis are endemic, affecting mainly three foci: China, the Mediterranean basin, and Brazil [60]. Although *L. (L.) infantum* has been identified as the main aetiologic agent of CanL in the Old World [61], in the New World other species such as *L. (L.) chagasi (infantum)*, *L. (L.) mexicana*, *L. (L.) amazonensis*, and *L. (V.) braziliensis* may be included as potential aetiologic agents [60, 62]. Canine infection with *Leishmania* has two effects: as a reservoir for human leishmaniasis and as a cause of a severe disease in dogs, which is usually fatal when left untreated [63]. Infected dogs play an important role in the transmission of leishmaniasis and as such represent a real threat to uninfected dogs and humans in endemic areas where sand fly vectors are present. Symptomatic dogs present clinical signs such as peripheral lymphadenopathy, weight loss, papular, nodular dermatitis, decreased appetite, lethargy, and splenomegaly [60, 64]. The diagnosis of CanL is complex due to its variable clinical manifestations and lack of symptoms during the early stage of the infection. Therefore, a reliable, accurate, and rapid diagnostic test is essential in early management of infected dogs and to prevent zoonotic transmission of the *Leishmania* parasite to humans in endemic areas. CanL diagnosis does not differ substantially from that in humans; several direct methods (culture of parasites and microscopy) and indirect methods (serological and molecular tests) are readily available for the diagnosis of CanL.

Parasitological and serological tests have limitations in the diagnosis of CanL, especially in asymptomatic dogs or during early infection [65]. Although parasitological diagnosis is the definitive methodology of detection and splenic aspirates are considered as the method of choice among lymph node and bone marrow for CanL diagnosis [66], CanL is frequently diagnosed through the detection of specific antibodies against *Leishmania* parasites, using serological techniques. However, serological tests (DAT, IFAT, ELISA) present some drawbacks, such as cross-reaction with *Trypanosoma* parasites, species causing CL, and other hemoparasites; and false results in low titers or cases of immunological anergy [67]. Nevertheless, PCR with all its variants has had the greatest success due to its high sensitivity (89% to 100%) and specificity (95% to 100%) in the diagnosis of CanL [68–71].

Few studies have shown the utility of LAMP in the diagnosis of CanL (Table 24.1). A *L. (L.) infantum*-specific LAMP assay was developed successfully, targeting the *cpb* multicopy gene to detect parasites in the blood of 75 dogs using purified DNA [72]. The LAMP delivered 54.2% sensitivity and 80% specificity, and the results were comparable with nested-PCR but had lower sensitivity to IFAT (88.5%), which showed in contrast lower specificity (45%) [72]. A further study compared the performance of kDNA-based *L. (L.) infantum*-specific LAMP assay on conjunctival swab samples with conventional PCR, ELISA (serum), and microscopy (bone marrow) and found that LAMP detected 61.3% of infected dogs, which was similar to PCR (58.6%) and significantly higher than ELISA (40.5%) and microscopy (10.8%) [73]. However, the kDNA LAMP primer sets designed from a *L. (L.) infantum* strain isolated in China did not amplify strains from other countries and as such are not suitable for use in other endemic areas. Additionally, the study highlighted that the noninvasive sample collection resulted in a high uptake among dog owners, which is commendable for the control of CanL. These studies provide examples of how LAMP can be implemented in field detection and early management of CanL.

24.4 Molecular Xenomonitoring/Surveillance Potentials of LAMP for Leishmaniasis

Molecular xenomonitoring (MX) is the screening of haematophagous insects for the presence of a pathogen's genetic material (DNA/RNA) using molecular-based assays. Phlebotomine sand flies are the putative vectors of leishmaniasis, and approximately 800 species have been recorded in five major genera: *Phlebotomus* and *Sergentomyia* in the Old World and *Lutzomyia*, *Brumptomyia*, and *Warileya* in the New World [74]. However, only species belonging to the genera *Phlebotomus* and *Lutzomyia* are the putative vectors of *Leishmania* [74, 75]. The spread of leishmaniasis largely depends on the distribution of sand fly vectors. Therefore, entomological monitoring of *Leishmania* infection in leishmaniasis endemic areas provides epidemiologic advantages for predicting

the risk and expansion of the diseases, the estimation of which depends on the reliable identification of infected sand flies [27]. Additionally, estimation of infection rates in the vector could serve as an indicator of a change in transmission intensity and assessment of control programs [27].

Hitherto, detection of *Leishmania* parasites within individual sand flies relied largely on dissection and microscopic examination of individual flies, which is technically demanding, laborious, and time consuming—especially when large numbers of specimens must be examined due to the low *Leishmania* infection rate in sand flies (0.01–1%), even in endemic areas [76]. To overcome these technical limitations, in the last three decades molecular approaches (PCR formats) have been increasingly employed in the detection of *Leishmania* DNA in individual or pooled sand flies [76, 77]. Of interest, LAMP has also been shown to be a good MX tool for generation of information on the distribution or expansion of leishmaniasis. In addition, from cost-effectiveness and field perspectives, LAMP offers some advantages over PCR as a usefulness method for surveillance and epidemiological studies of leishmaniasis in endemic areas. The first established LAMP for rapid mass-screening of individual sand flies for *Leishmania* infection was a generic-*Leishmania* 18S rRNA-based LAMP with preaddition of malachite green (MG) detection closed system, which can detect 0.01 parasites [27]. The field-based-MG-LAMP results using a crude sand fly template without DNA purification for *Leishmania* DNA detection (Fig. 24.4) were comparable to classical microscopy and PCR. The LAMP was found to be a high-throughput screening tool for the detection of *Leishmania*-infected *Lutzomyia* sand fly species (8 out of 397 field-caught flies) in the endemic areas of Ecuador [27]. Another study validated the established LAMP for individual screening of 150 wild-caught sand flies from endemic areas of Iran and revealed that the 18S rRNA-based-LAMP detected 10 *Leishmania* DNA positive sand flies (*Sergentomyia baghdadis*, *S. sintoni*, and *Phlebotomus papatasi*) [78]. A similar study also experimentally validated the potential field applicability of the MG-LAMP for detection of *L. martiniquensis* DNA in sand flies in Thailand; however, no *Leishmania* DNA was detected by LAMP and PCR when applied to 380 field-caught flies, probably due to low infection rate in the study area [79]. Additionally, the performance of the MG-LAMP was further validated using purified DNA from sand fly pools and was found to be of potential use for the entomological surveillance of CL in Colombia with 100% sensitivity and 96.8% specificity [80]. Indeed, these reported studies have shown the potential usefulness of LAMP for mass-screening of sand flies in the Old and New World. Importantly, LAMP allows for an immediate real-time assessment of the presence of *Leishmania* parasites in endemic foci, which demonstrates the possibility of its integration as a simple and cost-effective molecular tool for monitoring or surveillance of infections and identification of the vector species.




Figure 24.4 Graphic demonstration of colorimetric-MG-based LAMP assay for rapid mass-screening of individual sand flies for *Leishmania* infection.

24.5 LAMP Amplicon End-Point Closed Detection System

A wide range of approaches are available for the qualitative detection of LAMP amplicons. The amplified products can be detected visually using multiple parameters, including turbidity, fluorescence, and color with the naked eyes and/or UV light (Table 24.2). Following agarose gel electrophoresis, an open detection system is usually used as a confirmatory analysis of the LAMP products that appear as cauliflower-like structures with multiple loops. The presence of turbidity (white color precipitate) in sample from byproducts of amplification has been used as the indicator of a positive *Leishmania* DNA LAMP reaction, while absence of turbidity indicated a negative LAMP reaction [43, 56]. However, turbidity is challenging to discern and is unstable over time. As an alternative to turbidity, intercalating fluorescent dyes were used for direct detection of the *Leishmania* DNA LAMP positive samples such as calcein [73], SYBR Green I [57, 78], fluorescent detection reagents (FDR) (Eiken) [37, 43], which are technically inconvenient due to its requirement for a UV illuminator for test result discrimination, and can bind nonspecifically to any dsDNA, even to the primer-dimers leading to an incorrect interpretation of results [81]. In addition, fluorescence-based assays require specialized equipment such as the LED illuminators [21] to enable the readout of the fluorescence dyes or the use of real-time fluorimetry [21, 28]. The use of specialized equipment for the visualization of the LAMP results reduces the versatility of the LAMP and tends to increase the overall cost of the LAMP assay, which might hinder its use in resource-limited countries. On the other hand, despite the reported good sensitivity,

Table 24.2 Summary of methods used in LAMP amplicon end-point detection in previous studies

Detection parameter	Open/closed system	Evaluation of results	Equipment for endpoint detection	Remarks	References
Turbidity	Closed	Turbid—positive Clear—negative	Turbidimeter or none	Not always easy to interpret	Khan and colleagues, 2012 [56]; Mikita and colleagues, 2014 [43]
Gel-electrophoresis	Open	Ladder-like bands—positive No band—negative	UV transilluminator	Prone to contamination	Nzelu and colleagues, 2014 [27]; Gao and colleagues, 2015 [73]
Calcein	Closed	Green—positive Orange—negative	UV lamp	Inconvenient due to dangerous UV illuminator	Gao and colleagues, 2015 [73]
SYBR Green I	Open or closed	Green—positive Orange—negative	UV light or none	Inhibits LAMP reaction and prone to contamination when added postreaction	Verma and colleagues, 2013, 2017 [44, 57]; Ghodrati and colleagues, 2017 [78]; Dixit and colleagues, 2018 [58]
FDR (Eiken)	Closed	Fluorescent green—positive Pale brown—negative	UV light	Expensive	Adams and colleagues, 2010 [37]; Mikita and colleagues, 2014 [43]
Hydroxy naphthol blue	Closed	Sky blue—positive Violet—negative	Light box (optional) or none	Ambiguous to discern, requires operator to distinguish results	Goto and colleagues, 2009 [82]
Malachite green	Closed	Light blue—positive Colorless—negative	None	Easy to discern results by the naked eye; stable and can be kept for record purposes	Nzelu and colleagues, 2014 [27], 2016 [9]; Sriworarat and colleagues, 2015 [41]; León and colleagues, 2018 [80]

Abbreviations: FDR, Fluorescent detection reagent; LAMP, loop-mediated isothermal amplification; UV, ultra-violet.

SYBR Green I could inhibit the LAMP reaction if added before isothermal incubation. Therefore, the dye must be introduced post-LAMP reaction, requiring the LAMP tube to be opened or postamplification handling (open detection system), which is a contamination risk and usually leads to false-positive results. Recently, studies have shown the use of SYBR Green I placed on the inner side of the cap of reaction tube in a closed-LAMP assay; however, the assay requires an additional step of brief spin after LAMP reaction for amplicon discrimination [44, 58]. The detection of amplicon with preaddition of FDR eliminates the openings of tubes and reduces contamination problems; however, FDR has low detection sensitivity [82] and is costly [37]. Colorimetric-LAMP detection dyes, like hydroxy naphthol blue (HNB) and MG, have also been utilized for the naked eye visualization of positive LAMP products in closed systems. The addition of HNB and MG dyes in the LAMP reaction tube prior amplification eliminates the opening of tubes and completely avoids contamination problems [9, 27]. HNB dye changes from violet to a sky blue color [82] and requires the operator to distinguish between positive and negative color results, which can be ambiguous. In contrast, MG signal recognition is highly sensitive, the system gives a clear-cut difference between positives (light blue color) and negatives (colorless) based on naked eye visualization, and interpretation by an independent observer is not required [9, 27, 41, 80]. MG-LAMP products are stable and thus can be kept for record purposes. Several studies have shown the reliability, robust sensitivity, and wide applicability of MG-based-LAMP closed detection system for *Leishmania* and other purposes. MG has been used for detection of *Leishmania* DNA in crude *Lutzomyia* sand fly extract in Ecuador [27]; patient's tissue spotted on FTA-card in Peru [9]; blood, saliva, and tissue biopsies in Thailand [41]; and direct smears and sand flies in Colombia [80]. Taken together, the incorporation of a closed-LAMP assay offer new prospects for improved detection of infections, as well as positioning LAMP as a quick, one-step, POC molecular diagnostic and xenomonitoring tool for leishmaniasis and other diseases.

24.6 Cost and Hands-On Time of the *Leishmania* LAMP Test

Besides technical feasibility and performance, the major issue related to the large-scale and routine implementation of molecular diagnostics is its cost-effectiveness. LAMP has proven to be applicable to field detection, potentially eliminating the need for expensive DNA purification kits, thermal cyclers, and gel electrophoresis. The reported costs of *Leishmania* LAMP range from less than US\$1–\$3.50 per test [37, 43], compared to US\$12 for qPCR, US\$2.50 for PCR-restriction fragment length polymorphism (PCR-RFLP) [34, 37], US\$1.5–2.5 for DAT, around US\$1 for rk39-based immunochromatographic-RDT [83], and less than US\$1 for microscopy per test. Some studies have suggested that the use of a very cheap colorimetric dye like MG [9, 80] for LAMP amplicon visualization, instead of Eiken fluorescent detection reagent [37], and heat treated samples as a template DNA source [41–43, 58] may further reduce the cost per test. A

study indicated that a malaria LAMP assay using heat treated blood cost between US\$0.40 and US\$0.70, which is lower than currently available RDT's [13]. Although *Leishmania*-RDT has a cost similar to microscopy when used at reference centers/clinics, LAMP appears to be more appropriate and cost effective during CL seasons or outbreaks, when its capacity to process several tests at a time can be maximized [84]. Moreover, lowering the cost of LAMP will broaden its application, especially in resources-limited countries where leishmaniasis is endemic.

Rapid turnaround time is equally an important aspect of any test, and patients and clinicians require a test that can produce a result rapidly for prompt treatment. The hands-on time to result for closed-LAMP is 30–60 mins [9, 20, 44], compared to 3–6 h for most PCR assays and 10–20 mins for rK39-RDT [83]. LAMP, being much faster than PCR assays, falls in the category of a high performance result oriented NAAT, which will support leishmaniasis elimination initiatives.

24.7 Concluding Remarks and Future Directions

The development and application of LAMP technique in the diagnosis of leishmaniasis cases in endemic areas is in line with the recent global trend in seeking rapid, POC tests for the control of infectious diseases. LAMP appears to be an ideal diagnostic test suitable for neglected and forgotten tropical diseases in the world, including leishmaniasis. Furthermore, it meets the guidelines laid down by the World Health Organization (WHO) that diagnostics for developing countries should be ASSURED: Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, and Deliverable to end users [85]. In this review, we compiled the diagnostic performance and recent advances employing the LAMP assay to detect *Leishmania* in human CL, VL, PKDL, CanL, and sand flies. Based on the current review and discussion, the following points should be considered. 1) Making diagnostic techniques patient-centric (in-clinic and in the field) was the main aim behind the advent of LAMP as a POC test; therefore, LAMP quantitative diagnostic methods that were developed are not applicable as POC tests because they require relatively costly equipment and personnel. Quantitative assays are good for special purposes, such as research. 2) The sensitivity and specificity of LAMP largely depends on the primer sets employed; hence, care must be taken when designing primers. Although it is challenging to choose a correct and proper target for amplification (either a highly conserved region or a target site that is species-specific), it is imperative to ensure that the assay amplifies the predicted target and is specific, which may require some preliminary experimental optimization before final primer selection. While the Primer Explorer software can be employed to design primer sets, successful primers can be manually designed even when preferred target sites are not selected by the software. 3) One of the most attractive features of LAMP is the ability to overcome potential inhibitors

in unpurified templates. The use of boiled clinical samples [41–43], direct-blood lysis [58], and crude sand fly extract [27] reduces time, cost, and the requirement for extensive laboratory infrastructure. The stability of the target DNA in crude sand fly extract stored at -20°C for months/years has been reported [27] but has not been reported for boiled supernatant (boil and spin or Direct Boil-LAMP). Hence, it is important to develop buffers that can stabilize DNA in the supernatant in order to ensure subsequent amplification consistency before it can be relied upon as template. 4) High risk of carry-over contamination, which often leads to false-positive results in supposedly negative controls, is a major challenge of LAMP. Amplicons are usually stable, and as such, unintended carry-over contamination may occur. It is recommended to adopt a closed end-point detection system in order to avoid postamplification contamination. 5) The Loopamp *Leishmania* Detection Kit—which is in a ready-to-use format, has an additional advantage of dried reagents including *Leishmania* genus-specific primers, and has shelf life of one year if stored between 1 and 30°C (Eiken)—is a further advancement of LAMP. Additionally, an electricity-free stable heat block based on exothermic chemical reactions and phase-change material has been demonstrated for amplification reaction [86], and the use of rechargeable solar batteries as alternative energy-source has also been proposed [81]. However, the development of a consensus standardized integrated system from simple sample collection and preservation, template preparation, and amplification platform to closed detection unit for end-point use will be essential for field and in-clinic testing even in the most remote rural endemic areas. 6) It is important to highlight that LAMP positivity should always be interpreted in combination with clinic pathological evaluations. Focusing on the aforementioned points will undoubtedly improve the application of LAMP in the diagnosis of leishmaniasis. Importantly, LAMP has come to stay as a potential rapid POC test for diagnosis and entomological monitoring of *Leishmania* infection in endemic areas.

Key Learning Points

- Leishmaniasis remains one of the world's most neglected and poverty-related tropical diseases, and early detection of *Leishmania* will require a simple and rapid diagnostic test for timely treatment of patients.
- A closed LAMP diagnostic tool with high specificity, sensitivity, rapidity, and simplicity provides an effective point-of-care test applicable in *Leishmania* endemic and nonendemic areas.
- LAMP tests are potentially important in the diagnosis of HIV-VL co-infection cases because of low antibody response in HIV-infected patients, which lowers the sensitivity of serological tests.
- A rapid and reliable diagnostic test is important for the management of *Leishmania*-infected dogs to prevent zoonotic transmission of the parasite in endemic areas.
- LAMP allows for an immediate real-time assessment of the presence of *Leishmania* parasites in endemic foci, and monitoring of *Leishmania* infection in sand flies can provide epidemiologic data for predicting the risk and expansion of the disease.

Top Five Papers

1. Adams ER, Schoone G, Versteeg I, Gomes MA, Diro E, Mori Y, et al. Development and evaluation of a novel loop mediated isothermal amplification assay for the diagnosis of cutaneous and visceral leishmaniasis. *J Clin Microbiol.* 2018; 56 (7): e00386–18.
2. Gao C, Ding D, Wang J, Steverding D, Wang X, Yang Y, et al. Development of a LAMP assay for detection of *Leishmania infantum* infection in dogs using conjunctival swab samples. *Parasit Vectors.* 2015; 8: 370.
3. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* 2000; 28 (12): E63.
4. Nzelu CO, Gomez EA, Caceres AG, Sakurai T, Martini-Robles L, Uezato H, et al. Development of a loop-mediated isothermal amplification method for rapid mass-screening of sand flies for *Leishmania* infection. *Acta Trop.* 2014; 132: 1–6.
5. Verma S, Singh R, Sharma V, Bumb RA, Negi NS, Ramesh V, et al. Development of a rapid loop-mediated isothermal amplification assay for diagnosis and assessment of cure of *Leishmania* infection. *BMC Infect Dis.* 2017; 17 (1), 223.

Abbreviations

BMA:	bone marrow aspirates
<i>Bst</i> :	<i>Bacillus stearothermophilus</i>
CanL:	canine Leishmaniasis
CL:	cutaneous leishmaniasis
cpb:	cysteine protease B
DAT:	direct agglutination test
DCL:	disseminated cutaneous leishmaniasis
ELISA:	enzyme-linked immunosorbent assay
FDR:	fluorescent detection reagents
FIND:	Foundation for Innovative New Diagnostics
FN:	false-negative
FP:	false-positive
FTA:	Flinders Technology Associates
HAT:	human African trypanosomiasis
HIV:	human immunodeficiency virus
HNB:	hydroxy naphthol blue
IFAT:	immunofluorescence antibody test
kDNA:	minicircle kinetoplast DNA
LAMP:	loop-mediated isothermal amplification
MCL:	mucocutaneous leishmaniasis
MG:	malachite green
MX:	molecular xenomonitoring

NAAT:	nucleic acid amplification test
NASBA:	nucleic acid sequence-based amplification
PBMC:	peripheral blood mononuclear cells
PCR:	polymerase chain reaction
PCR-RFLP:	PCR-restriction fragment length polymorphism
PKDL:	post kala-azar dermal leishmaniasis
POC:	point-of-care
qPCR:	quantitative polymerase chain reaction
qRT-PCR:	quantitative reverse-transcriptase polymerase chain reaction
RDTs:	rapid diagnostic tests
rK39:	recombinant antigen-based immunochromatography test
RPA:	recombinase polymerase amplification
rRNA:	ribosomal RNA
RT:	reverse transcriptase
TN:	true-negative
UV:	ultra-violet
VL:	visceral leishmaniasis

Disclosures and Conflict of Interest

This chapter was originally published as: Nzelu, C. O., Kato, H., Peters, N. C. (2019). Loop-mediated isothermal amplification (LAMP): An advanced molecular point-of-care technique for the detection of *Leishmania* infection. *PLoS Negl. Trop. Dis.*, **13**(11), e0007698, <https://doi.org/10.1371/journal.pntd.0007698>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Funding: This work was supported by funding from the Infections, Inflammation and Chronic Diseases Research Strategy, Vice-President of Research Office, University of Calgary (<https://ucalgary.ca/iicd/>) and the Canadian Institutes of Health Research (<http://www.cihr-irsc.gc.ca/e/193.html>), grant MPO 142302, to NCP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

References

1. Hotez PJ, Pecoul B, Rajjai S, Boehme C, Aksoy S, Malecela M, et al. Eliminating the neglected tropical diseases: translational science and new technologies. *PLoS Negl Trop Dis.* 2016; 10(3): e0003895.
2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. *PLoS ONE.* 2012; 7(5): e35671.
3. McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. *Q J Med.* 2014; 107: 7–14.

4. Boelaert M, Verdonck K, Menten J, Sunyoto T, van Griensven J, Chappuis F, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. *Cochrane Database Syst Rev.* 2014; 6: CD009135.
5. Cunningham J, Hasker E, Das P, El Safi S, Goto H, Mondal D, et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. *Clin Infect Dis.* 2012; 55(10): 1312–1319.
6. de Ruiter CM, van der Veer C, Leeftang MM, Deborggraeve S, Lucas C, Adams ER. Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy. *J Clin Microbiol.* 2014; 52(9): 3147–3155.
7. de Vries HJC, Reedijk SH, Schallig HDFH. Cutaneous leishmaniasis: recent developments in diagnosis and management. *Am J Clin Dermatol.* 2015; 16(2): 99–109.
8. Kato H, Caceres AG, Mimori T, Ishimaru Y, Sayed ASM, Fujita M, et al. Use of FTA cards for direct sampling of patients' lesions in the ecological study of cutaneous leishmaniasis. *J Clin Microbiol.* 2010; 48(10): 3661–3665.
9. Nzelu CO, Caceres AG, Guerrero-Quincho S, Tineo-Villafuerte E, Rodriguez-Delfin L, Mimori T, et al. A rapid molecular diagnosis of cutaneous leishmaniasis by colorimetric malachite green-loop-mediated isothermal amplification (LAMP) combined with an FTA card as a direct sampling tool. *Acta Trop.* 2016; 153: 116–119.
10. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* 2000; 28(12): E63.
11. Notomi T, Mori Y, Tomita N, Kanda H. Loop-mediated isothermal amplification (LAMP): principle, features, and future prospects. *J Microbiol.* 2015; 53(1): 1–5.
12. Iwamoto T, Sonobe T, Hayashi K. Loop-mediated isothermal amplification for direct detection of mycobacterium tuberculosis complex *M. avium* and *M. intracellulare* in sputum samples. *J Clin Microbiol.* 2003; 41(6): 2616–2622.
13. Poon LL, Wong BW, Ma EH, Chan KH, Chow LM, Abeyewickreme W, et al. Sensitive and inexpensive molecular test for falciparum malaria: detecting *Plasmodium falciparum* DNA directly from heat-treated blood by loop-mediated isothermal amplification. *Clin Chem.* 2006; 52(2), 303–306.
14. Takagi H, Itoh M, Islam MZ, Razzaque A, Ekram ARM, Hashiguchi Y, et al. Sensitive, specific and rapid detection of *Leishmania donovani* DNA by loop-mediated isothermal amplification. *Am J Trop Med Hyg.* 2009; 81(4): 578–582.
15. Bao H, Zhao Y, Wang Y, Xu X, Shi J, Zeng X, et al. Development of a reverse transcription loop-mediated isothermal amplification method for the rapid detection of subtype H7N9 avian influenza virus. *Biomed Res Int.* 2014; 2014: 525064.
16. Njiru ZK, Mikosza AS, Armstrong T, Enyaru JC, Ndung'u JM, Thompson AR. Loop-mediated isothermal amplification (LAMP) method for rapid detection of *Trypanosoma brucei rhodesiense*. *PLoS Negl Trop Dis.* 2008; 2(1): e147.
17. Mitarai S, Okumura M, Toyota E, Yoshiyama T, Aono A, Sejimo A, et al. Evaluation of a simple loop-mediated isothermal amplification test kit for the diagnosis of tuberculosis. *Int J Tuberc Lung Dis.* 2011; 15(9): 1211–1217.
18. Hopkins H, González IJ, Polley SD, Angutoko P, Ategeka J, Asilmwe C, et al. Highly sensitive detection of malaria parasitemia in a malaria-endemic setting: performance

- of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda. *J Infect Dis.* 2013; 208(4): 645–652.
19. Polley SD, González IJ, Mohamed D, Daly R, Bowers K, Watson J, et al. Clinical evaluation of a loop-mediated amplification kit for diagnosis of imported malaria. *J Infect Dis.* 2013; 208(4): 637–644.
 20. Mukhtar M, Ali SS, Boshara SA, Albertini A, Monnerat S, Bessell P, et al. Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). *PLoS Negl Trop Dis.* 2018; 12(2): e0006264.
 21. Ibarra-Meneses A, Cruz I, Chicharri C, Sánchez C, Biéler S, Broger T, et al. Evaluation of fluorimetry and direct visualization to interpret results of a loop-mediated isothermal amplification kit to detect *Leishmania* DNA. *Parasit Vectors.* 2018; 17: 11(1): 250.
 22. WHO. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance. 2016. WHO/HTM/TB/2016.07. Available at: <http://apps.who.int/iris/bitstream/10665/249154/1/9789241511186-eng.pdf> (accessed on October 15, 2022).
 23. Rypien C, Chow B, Chan WW, Church DL, Pillai DR. Detection of *Plasmodium* infection by the illumigene malaria assay compared to reference microscopy and real-time PCR. *J Clin Microbiol.* 2017; 55(10): 3037–3045.
 24. Piepenburg O, Williams CH, Stemle DL, Armes NA. DNA detection using recombination proteins. *PLoS Biol.* 2006; 4: e204.
 25. Gill P, Ghaemi A. Nucleic acid isothermal amplification technologies: a review. *Nucleosides Nucleotides Nucleic Acids.* 2008; 27(3): 224–243.
 26. Nagamine K, Hase T, Notomi T. Accelerated reaction by loop-mediated isothermal amplification using loop primers. *Mol Cell Probes.* 2002; 16(3): 223–229.
 27. Nzulu CO, Gomez EA, Caceres AG, Sakurai T, Martini-Robles L, Uezato H, et al. Development of a loop-mediated isothermal amplification method for rapid mass-screening of sand flies for *Leishmania* infection. *Acta Trop.* 2014; 132: 1–6.
 28. Abbasi I, Kirstein OD, Hailu A, Warburg A. Optimization of loop-mediated isothermal amplification (LAMP) assays for the detection of *Leishmania* DNA in human blood samples. *Acta Trop.* 2016; 162: 20–26.
 29. Desjeux P. Leishmaniasis: current situation and new perspectives. *Comp Immunol Microbiol Infect Dis.* 2004; 27(5): 305–318.
 30. WHO. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the control of leishmaniasis. *World Health Organ Tech Rep Ser.* 949, Geneva. 2010.
 31. Hashiguchi Y, Velez LN, Villegas NV, Mimori T, Gomes EAL, Kato H. Leishmaniasis in Ecuador: comprehensive review and current status. *Acta Trop.* 2017; 166: 299–315.
 32. Hashiguchi Y, Gomes EL, Kato H, Martini LR, Velez LN, Uezato H. Diffuse and disseminated cutaneous leishmaniasis: cases experienced in Ecuador and a brief review. *Trop Med Health.* 2016; 44: 2.
 33. Gradoni L. *Conn's Current Therapy, Infectious Diseases.* Elsevier, Philadelphia, PA, 2016; pp. 134–136.

34. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. *J Clin Microbiol.* 2007; 45(1): 21–25.
35. Akhoundi M, Downing T, Votýpka J, Kuhls K, Lukeš J, Cannet A, et al. *Leishmania* infections: molecular targets and diagnosis. *Mol Aspects Med.* 2017; 57: 1–29.
36. Adams ER, Gomes MA, Scheske L, Rios R, Marquez R, Cossio A, et al. Sensitive diagnosis of cutaneous leishmaniasis by lesion swab sampling coupled to qPCR. *Parasitology.* 2014; 141(14): 1891–1897.
37. Adams ER, Schoone GJ, Ageed AF, Safi SE, Schallig HD. Development of a reverse transcriptase loop-mediated isothermal amplification (LAMP) assay for the sensitive detection of *Leishmania* parasites in clinical samples. *Am J Trop Med Hyg.* 2010; 82(4): 591–596.
38. Yurchenko VY, Merzlyak EM, Kolesnikov AA, Martinkina LP, Vengerov YY. Structure of *Leishmania* minicircle kinetoplast DNA classes. *J Clin Microbiol.* 1999; 37(5), 1656–1657.
39. Adams ER, Schoone G, Versteeg I, Gomes MA, Diro E, Mori Y, et al. Development and evaluation of a novel loop mediated isothermal amplification assay for the diagnosis of cutaneous and visceral leishmaniasis. *J Clin Microbiol.* 2018; 56(7): e00386–18.
40. Chaouch M, Aoun K, Ben Othman S, Ben Abid M, Ben Sghaier I, Bouratbine A, et al. Development and assessment of *Leishmania major*- and *Leishmania tropica*-specific loop-mediated isothermal amplification assays for the diagnosis of cutaneous leishmaniasis in Tunisia. *Am J Trop Med Hyg.* 2019; 19–0097.
41. Sriworarat C, Phumee A, Mungthin M, Leelayoova S, Siriyasatien P. Development of loop-mediated isothermal amplification (LAMP) for simple detection of *Leishmania* infection. *Parasit Vectors.* 2015; 8: 591.
42. Imai K, Tarumoto N, Amo K, Takahashi M, Sakamoto N, Kosaka A, et al. Non-invasive diagnosis of cutaneous leishmaniasis by the direct boil loop-mediated isothermal amplification method and MinION™ nanopore sequencing. *Parasitol Int.* 2018; 67(1): 34–37.
43. Mikita K, Maeda T, Yoshikawa S, Ono T, Miyahira Y, Kawana A. The direct boil-LAMP method: a simple and rapid diagnostic method for cutaneous leishmaniasis. *Parasitol. Int.* 2014; 63(6), 785–789.
44. Verma S, Singh R, Sharma V, Bumb RA, Negi NS, Ramesh V, et al. Development of a rapid loop-mediated isothermal amplification assay for diagnosis and assessment of cure of *Leishmania* infection. *BMC Infect Dis.* 2017; 17(1), 223.
45. Kothalawala HS, Karunaweera ND. Loop-mediated isothermal amplification assay as a sensitive diagnostic tool for *Leishmania donovani* infections in Sri Lanka. *Ceylon Med J.* 2016; 61(2): 68–70.
46. Vink MMT, Nahzat SM, Rahimi H, Buhler C, Ahmadi BA, Nader M, et al. Evaluation of point-of-care tests for cutaneous leishmaniasis diagnosis in Kabul Afghanistan. *EBioMedicine.* 2018; 37: 453–460.
47. WHO. Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014. *Wkly Epidemiol Rec.* 2016; 91(22): 285–296.
48. Desjeux P, Ghosh RS, Dhalaria P, Strub-Wourgaft N, Zijlstra EE. Report of the post kala-azar dermal leishmaniasis (PKDL) consortium meeting, New Delhi India, 27–29. *Parasit Vectors.* 2013; 6: 196.

49. Siddig M, Ghalib H, Shillington DC, Petersen EA. Visceral leishmaniasis in the Sudan: comparative parasitological methods of diagnosis. *Trans R Soc Trop Med Hyg.* 1988; 82(1): 66–68.
50. Salotra P, Singh R. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. *Indian J Med Res.* 2006; 123(3): 295–310.
51. Singh R, Raju BVS, Jain RK, Salotra P. Potential of direct agglutination test based on promastigote and amastigote antigens for serodiagnosis of post-kala-azar dermal leishmaniasis. *Clin Diagn Lab Immunol.* 2005; 12(10): 1191–1194.
52. Srivastava P, Dayama A, Mehrotra S, Sundar S. Diagnosis of visceral leishmaniasis. *Trans R Soc Med Hyg.* 2011; 105(1): 1–6.
53. Sreenivas G, Anasari NA, Kataria J, Salotra P. Nested PCR assay for detection of *Leishmania donovani* in slit aspirates from post-kala-azar dermal leishmaniasis lesion. *J Clin Microbiol.* 2004; 42(4): 1777–1778.
54. Cota GF, de sousa MR, Demarqui FN, Rabello A. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. *PLoS Negl Trop Dis.* 2012; 5(5): e1665.
55. Medley GF, Hollingsworth TD, Olliaro PL, Adams ER. Health-seeking behavior, diagnostics and transmission dynamics in the control of visceral leishmaniasis in the Indian subcontinent. *Nature.* 2015; 528(7580): S102–S108.
56. Khan MG, Bhaskar KR, Salam MA, Akther T, Pluschke G, Mondai D. Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for detection of *Leishmania* DNA in buffy coat from visceral leishmaniasis patients. *Parasit Vectors.* 2012; 5: 280.
57. Verma S, Avishek K, Sharma V, Negi NS, Ramesh V, Salotra P. Application of loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis. *Diagn Microbiol Infect Dis.* 2013; 75(4): 390–395.
58. Dixit KK, Verma S, Singh OP, Singh D, Singh AP, Guota R, et al. Validation of SYBR Green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL). *PLoS Negl Trop Dis.* 2018; 12(11): e0006922.
59. Ghasemian M, Gharavi MJ, Akhlaghi L, Mohebbali M, Meamar AR, Aryan E, et al. Development and assessment of loop-mediated isothermal amplification (LAMP) assay for the diagnosis of human visceral leishmaniasis in Iran. *Iranian J Parasitol.* 2014; 9(1): 50–59.
60. Alvar J, Cañavate C, Molina R, Moreno J, Nieto J. Canine leishmaniasis. *Adv Parasitol.* 2004; 57: 1–88.
61. Gramiccia M, Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. *Int J Parasitol.* 2005; 35(11–12): 1169–1180.
62. Lainson R, Shaw JJ. Leishmaniasis in the new world. In: Collier L, Balows A., Sussman M. eds., *Topley & Wilson's Microbiology and Microbial Infections: Parasitology*, vol. 5, 10th ed., Arnold, London. 2005; pp. 313–349.
63. Reguera RM, Moran M, Perez-Pertejo Y, Garcia-Estrada C, Balana-Fouce R. Current status on prevention and treatment of canine leishmaniasis. *Vet Parasitol.* 2016; 227: 98–114.

64. Noli C, Saridomichelakis MN. An update on the diagnosis and treatment of canine leishmaniasis caused by *Leishmania infantum* (syn. *L. chagasi*). *Vet J*. 2014; 202(3): 425–435.
65. Ferreira ED, de Lana M, Carneiro M, Reis AB, Paes DV, da Silva ES, et al. Comparison of serological assays for the diagnosis of canine visceral leishmaniasis in animals presenting different clinical manifestations. *Vet Parasitol*. 2007; 146(3–4): 235–241.
66. Barrouin-Melo SM, Larangeira DF, Trigo J, Aguiar PH, dos-Santos WL, Pontes-de-Carvalho L. Comparison between splenic and lymph node aspirations as sampling methods for the parasitological detection of *Leishmania chagasi* infection in dogs. *Mem Inst Oswaldo Cruz*. 2004; 99(2): 195–197.
67. Lopes EG, Seva AP, Ferreira F, Nunes CM, Keid LB, Hiramoto RM, et al. Serological and molecular diagnostic tests for canine leishmaniasis in Brazilian endemic area: one out of five seronegative dogs are infected. *Epidemiol Infect*. 2017; 145(12): 2436–2444.
68. Lachaud L, Chabbert E, Dubessay P, Dereure J, Lamothe J, Dedet JP, et al. Value of two PCR methods for the diagnosis of canine visceral leishmaniasis and the detection of asymptomatic carriers. *Parasitology*. 2002; 125(3): 197–207.
69. Moreira M, Luvizotto MCR, Garcia JF, Corbett C, Laurenti M. Comparison of parasitological, immunological and molecular methods for the diagnosis of leishmaniasis in dogs with different clinical signs. *Vet Parasitol*. 2007; 145(3–4): 245–252.
70. Carson C, Quinnell RJ, Holden J, Garcez LM, Deborggraeve S, Courtenay O. Comparison of *Leishmania* OligoC-Test PCR with conventional and real-time PCR for diagnosis of canine *Leishmania* infection. *J Clin Microbiol*. 2010; 48(9): 3325–3330.
71. Mohammadiha A, Mohebbali M, Haghghi A, Mahdian R, Abadi AR, Zarei Z, et al. Comparison of real-time PCR and conventional PCR with two DNA targets for detection of *Leishmania (Leishmania) infantum* infection in human and dog blood sample. *Exp Parasitol*. 2013; 133(1): 89–94.
72. Chaouch M, Mhadhbi M, Adams ER, Schoone GJ, Limam S, Gharbi Z, et al. Development and evaluation of a loop-mediated isothermal amplification (LAMP) assay for rapid detection of *Leishmania infantum* in canine leishmaniasis based on cysteine protease b gene. *Vet Parasitol*. 2013; 198(1–2): 78–84.
73. Gao C, Ding D, Wang J, Steverding D, Wang X, Yang Y, et al. Development of a LAMP assay for detection of *Leishmania infantum* infection in dogs using conjunctival swab samples. *Parasit Vectors*. 2015; 8: 370.
74. Munstermann LE. Phlebotomine sand flies, the Psychodidae. In: Marquardt WC, Black WC, Freier JE, Hagedorn HH, Hemingway J, et al., editor. *Biology of Disease Vectors*, 2nd ed., Elsevier, San Diego, CA. 2004: pp. 141–151.
75. Kato H, Gomez EA, Cáceres AG, Uezato H, Mimori T, Hashiguchi Y. Molecular epidemiology for vector research on leishmaniasis. *Int J Environ Res Public Health*. 2010; 7(3): 814–826.
76. Kato H, Uezato H, Katakura K, Calvopiña M, Marco JD, Barroso PA, et al. Detection and identification of *Leishmania* species within naturally infected sand flies in the Andean areas of Ecuador by a polymerase chain reaction. *Am J Trop Med Hyg*. 2005; 72(1): 87–93.
77. Nzelu CO, Kato H, Pupilampu N, Desewu K, Odoom S, Wilsom MD, et al. First detection of *Leishmania tropica* DNA and *Trypanosoma* species in *Sergentomyia* sand flies

- (Diptera: Psychodidae) from an outbreak area of cutaneous leishmaniasis in Ghana. *PLoS Negl Trop Dis*. 2014; 8: e2630.
78. Ghodrati M, Spotin A, Hazratian T, Mahami-Oskouei M, Bordbar A, Ebrahimi S, et al. Diagnosis accuracy of loop-mediated isothermal amplification assay as a field molecular tool for rapid mass screening of old world *Leishmania* infections in sand flies and *in vitro* culture. *Iran J Parasitol*. 2017; 12(4): 506–515.
 79. Tiwanathagorn S, Kato H, Yeewa R, Muengpan A, Polseela R, Leelayoova S. Comparison of LAMP and PCR for molecular mass screening of sand flies for *Leishmania martiniquensis* infection. *Mem Inst Oswaldo Cruz*. 2017; 112(2), 100–107.
 80. León CM, Muñoz M, Tabares JH, Hernandez C, Florez C, Ayala MS, et al. Analytical performance of a loop-mediated isothermal amplification assay for *Leishmania* DNA detection in sand flies and direct smears of patients with cutaneous leishmaniasis. *Am J Trop Med Hyg*. 2018; 98(5): 1325–1331.
 81. Njiru ZK. Loop-mediated isothermal amplification technology: towards point of care diagnostics. *PLoS Negl Trop Dis*. 2012; 6(6): e1572.
 82. Goto M, Honda E, Ogura A, Nomoto A, Hanaki K. Colorimetric detection of loop-mediated isothermal amplification reaction by using hydroxyl naphthol blue. *Biotechniques*. 2009; 46(3): 167–172.
 83. Singh OP, Sundar S. Developments in diagnosis of visceral leishmaniasis in the elimination era. *J Parasitol Res*. 2015: 239469.
 84. Aerts C, Vink M, Pashtoon SJ, Nahzat S, Picado A, Cruz I, et al. Cost effectiveness of new diagnostic tools for cutaneous leishmaniasis in Afghanistan. *Appl Health Econ Health Policy*. 2019; 17(2): 213–230.
 85. Mabey D, Peeling RW, Ustianowski A, Perkins MD. Diagnostics for the developing world. *Nat Rev Microbiol*. 2004; 2: 231–240.
 86. LaBarre P, Hawkins KR, Gerlach J, Wilmoth J, Beddoe A, Singleton J, et al. A simple, inexpensive device for nucleic acid amplification without electricity—towards instrument-free molecular diagnostics in low-resource settings. *PLoS ONE*. 2011; 6(5): e19738.

Chapter 25

Are Nanobiosensors an Improved Solution for Diagnosis of *Leishmania*?

Sona Jain, PhD,^a Wanessa Santana,^a Silvio S. Dolabella, PhD,^b André L. S. Santos, PhD,^c Eliana B. Souto, PhD,^{d,e} and Patrícia Severino, PhD^a

^aPostgraduate Program in Industrial Biotechnology, Universidade Tiradentes, Aracaju, Brazil

^bDepartment of Morphology, Federal University of Sergipe, São Cristóvão, Brazil

^cPaulo de Góes Microbiology Institute, Department of General Microbiology,

Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

^dCEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar, Braga, Portugal

^eDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, Coimbra, Portugal

sona.arun@souunit.com.br, eliana.souto@ceb.uminho.pt

Keywords: antibodies, aptamers, complement fixation reaction (CFR), complementary DNA (cDNA), cutaneous leishmaniasis (CL), canine visceral leishmaniasis (CVL), diagnostics, direct agglutination test (DAT), differential pulse voltammetry (DPV), enzyme-linked immunoenzymatic assay (ELISA), 6-carboxyfluorescein-labeled single stranded DNA (FAM-ssDNA), fast agglutination screening test (FAST), genosensors, immunochromatographic test (IC), immunosensors, intrinsically conducting polymers (ICP), immunofluorescence assay (IFA), kinetoplastid membrane protein-11 KMP-11), lateral flow biosensors (LFBs), lateral flow immunoassay (LFIA), mucocutaneous leishmaniasis (ML), nanomaterials, neglected tropical diseases (NTDs), non-spherical gold nanoparticles (nsAuNPs), parasitic diseases, point-of-care (POC), poly A binding protein (PABP), polyamidoamine dendrimers (PAMAM), polyethylene terephthalate (PET), polyaniline (PANI), poly(3,4-ethylenedioxythiophene) (PEDOT), polymerase chain reaction (PCR), polypyrrole (PPY), proteoliposomes, quantum dots (QDs), recombinant chimeric antigen (rCag), real-time quantitative PCR (qPCR), self-assembled layers (SAM), screen-printed carbon electrodes (SPCEs), surface plasmon resonance (SPR), systematic evolution of ligands by exponential enrichment (SELEX), single stranded DNA (ssDNA), visceral leishmaniasis (VL), Western Blot (WB)

25.1 Introduction

Leishmaniasis is one of the seven most important tropical diseases in the world. It is caused by the obligate intracellular parasitic protozoa belonging to the genus *Leishmania* and affects millions of people in the world. In 2018,

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

leishmaniasis was reported in 98 countries and territories across four continents. With approximately 1–2 million new cases and 70,000 deaths every year, it is among the deadliest of the neglected tropical diseases (NTDs) [1, 2]

Leishmaniasis usually affects underdeveloped countries in Africa, Asia, and Latin America (Fig. 25.1A), and is related to malnutrition, population migration, poor living conditions, fragile immune system, and lack of resources [3]. Recent surveys indicate that approximately 350 million people live in a vulnerable situation with the risk of contracting leishmaniasis. From a global perspective, the disease currently affects approximately 12–15 million people worldwide [4].




Figure 25.1 Geographical distribution of leishmaniasis in the world (A). Life cycle of *Leishmania* in sand fly and mammalian host (B). The two main evolutionary forms during their life cycle: the promastigote (in the invertebrate host) and the amastigote (present in the vertebrate host) are shown.

There are more than 20 *Leishmania* species distributed worldwide that are transmitted by over 90 phlebotomine sandfly species [5]. Leishmaniasis is usually transmitted by the bite of an infected female sandfly to mammalian host, such as rodents, marsupials, edentates, monkeys, and wild or domestic canines (Fig. 25.1B). Humans are accidentally infected in endemic areas [6]. Distinct species of *Leishmania* can cause different clinical manifestations, and the disease can be grouped into three main clinical forms: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (ML), and visceral leishmaniasis (VL), also known as kala-azar [3]. Each form varies in the degree of severity, where VL is the most severe form presenting the highest mortality.

CL is the most prevalent form caused by leishmanial species, such as *L. tropica*, *L. amazonensis*, *L. aethiopica*, and *L. major*, and it is generally painless and chronic, resulting in constant scar and critical stigma or disability [7]. ML is most frequently found in Americas and is caused by species such as *L. braziliensis* and *L. mexicana*. ML is characterized by the appearance of lesions that may

partially or completely destroy the mucous membranes of the cavities of the nose, mouth, and throat, leading to disfigurement of the patient with consequent social exclusion [8]. As mentioned before, VL is the most severe form of the disease caused by *L. donovani* and *L. infantum*, and it is characterized by fever, weight loss, enlargement of liver and spleen, pancytopenia, and hypergammaglobulinemia and may be fatal if left untreated [9].

Early treatment as well as rapid and accurate diagnosis of the disease are important for its control [10, 11]. Parasitological, serological, and molecular methods currently in use for diagnosis still have limitations that make the confirmation of the disease difficult [12]. The parasitological diagnosis, in addition to being invasive, shows low sensitivity. Serological tests work well in people who have a good immune response, but immuno-depressed patients, for example, do not respond well due to deficiencies in antibody production. Molecular tests, although of high precision, generally depend on equipment that is not always available [13]. The current diagnostic methods are thus often not sufficient, being presumptive, and diagnosis in most cases usually involves the identification of the *Leishmania* species mainly based on local epidemiology and clinical aspects [14]. This generates an urgent need to develop more sensitive, specific, and accessible tests, with easy application in the field, especially in poorly or modestly equipped laboratories.

Recent years have seen a great advancement in the development of nanomaterials and bioanalytical chemistry. Many emerging methods have been described based on nanomaterials such as optical labels (Hu et al. 2017), use of new signal transduction mechanisms [15], and use of aptamers over antibodies [16, 17]. In this review, we discuss the state-of-the-art on the use of nanomaterials for the detection of leishmanial parasites and the role of surface-tailored aptamers for the improved diagnosis of the disease.

25.2 Current Diagnostic Methods and Limitations

The control of leishmaniasis requires a combined set of intervention strategies, among which early diagnosis and treatment are important aspects. Current diagnosis is mostly based on the use of immunological and parasitological tests combined with clinical symptoms. However, in the case of CL and ML, serological tests have limited value.

25.2.1 Parasitological Tests

Parasitological tests are still considered the gold standard for the diagnosis of leishmaniasis. In this direct identification method, diagnosis is made microscopically by identifying amastigotes in affected tissues (CL/ML injury site) or in sample aspirated from the spleen, bone marrow, or lymph nodes in case of VL patients [10, 11, 14]. The inoculation of samples in experimental animals

(xenodiagnoses), as well as the *in vitro* culture of *Leishmania* promastigotes in culture medium, are also used in the routine diagnosis of leishmaniasis. A combination of microscopy and culture methods enhances the diagnostic sensitivity by more than 85% [14, 18]. However, all these methods are expensive and time-consuming, require skilled labor, and do not discriminate between *Leishmania* species [10, 11].

25.2.2 Immunological Tests

The leishmania skin test or Montenegro test is used to measure the delayed-type hypersensitivity reaction to an intradermal injection of a suspension of killed *Leishmania* promastigotes [10, 11]. It is a simple, sensitive, and specific method for CL; however, it does not allow the identification of species and does not differentiate past infections from present infections [10]. In addition, the test gives negative results during the disease period in VL [11].

Serological tests like indirect immunofluorescence assay (IFA), immunoenzymatic assay (ELISA), and the immunochromatographic test (IC) are also frequently utilized for the diagnosis of leishmaniasis. Other less employed serological tests include direct agglutination test (DAT), fast agglutination screening test (FAST), the complement fixation reaction (CFR), and Western blot (WB). The sensitivity and specificity of these methods are directly related to the technique used and the manifestation of the disease [11, 19]. Moreover, these antibody detection tests do not differentiate between recent and past infections, as the antibodies remain positive months after curing the patient [14]. The IFA test shows acceptable sensitivity (87–100%) and specificity (77–100%) [8, 20, 21]. However, the need for a fluorescence microscope limits the use of the IFA test to reference laboratories [14]. ELISA is the preferred laboratory test for serodiagnosis of VL. The technique is highly sensitive, but its specificity depends upon the antigens used. Variations in sensitivity (80–100%) and specificity (71–100%) are reported in ELISA tests using crude *Leishmania* spp. antigens [22–24]. The use of recombinant or purified antigens, such as membrane glycoproteins gp63, gp72, gp70, and rK39 specific to the *Leishmania* genus, improve the sensitivity and specificity of the technique. However, cross-reactions with diseases caused by other trypanosomatids can still occur [23]. In view of the need to achieve high precision, several new serological methodologies have been developed in recent years, and research using rapid immunochromatographic tests has been explored. Among these, the point-of-care (POC) tests using different antigens are popular, however they show varying sensitivity and specificity among different populations [14]. With respect to cytometry, although the technique has also shown high sensitivity and specificity, and presents advantages over other immunoassays, it is costly and requires specialized technicians to manipulate the equipment. Thus, its use in diagnostic routine is limited and is usually intended for large research centers [25–27].

25.2.3 Molecular Tests

Polymerase chain reaction (PCR) is a highly sensitive and important method used for the diagnosis of leishmaniasis, mainly in immunosuppressed patients. PCR can be performed using a wide variety of samples, such as blood, spleen, and lymph node [10, 14]. One of its main advantages is the possibility of quantifying the parasitic load in the samples (qPCR), allowing the progression of the disease to be monitored and, consequently, the effectiveness of the anti-*Leishmania* therapy used [10, 14]. Molecular techniques, although not used in the routine diagnosis, are highly sensitive. PCR has a reported specificity of 100% (for CL) with an improved sensitivity of 20 to 30% when compared with conventional parasitology diagnosis, and thus its inclusion as one of the routinely diagnostic methods could be highly beneficial. Real-time quantitative PCR (qPCR) has been shown to have high analytical sensitivity (0.0125 parasites per mL of blood) and excellent linearity [28]. PCR allows identification of the species of *Leishmania* that is causing the infection [10, 29]. However, the lack of standardization in the protocols for the different reaction steps (obtaining the samples, extracting the DNA, and selecting the primers) makes it difficult to implement the technique on a large scale [11, 30]. Furthermore, these tests remain limited to reference hospitals and research centers because of high costs and the requirement for special equipment and skilled personnel. Efforts are needed to make PCR more economical and easier to use, especially in endemic areas [11, 14]. Despite the great progress, there is still no standard test for the diagnosis of leishmaniasis. An effective diagnostic method, needs to be sensitive, specific, fast, accessible, and easy to use, among other factors. Together, these factors will result in early efficient disease identification.

25.3 Emerging Nanomaterial-Based Detection Technologies

The limitations encountered in the methods currently in use for the diagnosis of *Leishmania* demand development of new, efficient, rapid, and innovative POC approaches. Over the years, biosensors and nano-based technologies have proven to be promising options to meet this ever-increasing demand. Biosensors consist of a biomolecule (antigen, antibody, oligonucleotide, or enzyme) as recognition element coupled to a signal transducer. Binding of the recognition element to the target generates a signal by the transducer [31]. Based on the recognition element, biosensors can be categorized as immunosensors, genosensors, and aptamer-based sensors [32]. Immunosensors use antibodies as the recognition element. The transducer in this case converts the antibody–antigen interaction into a measurable physical signal. Genosensors, on the other hand, are DNA biosensors involving a hybridization reaction between two complementary oligonucleotides [33]. In this case, the use of nucleic acids eliminates the need for

expensive antibodies, resulting in higher stability and discarding the need for special storage. Aptamer-based sensors make use of aptamers (single-stranded DNA oligonucleotides that can specifically bind target analytes) also known as chemical antibodies [34].

Nanomaterials are known for their excellent optical, catalytic, electrical, and magnetic properties [35–39]. Many published reports describe the use of these special physical and chemical characteristics of nanomaterials for the development of biosensors and other nano-based tools for the detection of *Leishmania* which will be described in this section (Table 25.1).

Table 25.1 Nano-based biosensors described for the detection of *Leishmania*

Type of biosensor	Nanomaterial used	Type of pathogen	Target biomolecule	Limit of detection	Refs
Genosensor/optical	PPY PANI	<i>L. infantum</i>	FAM-ssDNA	1.1 nM [†] 1.3 nM	[23]
Genosensor/optical Immunosensor/ optical	cadmium selenite QD	<i>Leishmania</i> spp.	Conserved specific genomic DNA LPG and gp36 antigens	3.125 ng/μL [‡] 10 ³ cells/mL [¥]	[40]
Genosensor/optical	AuNP	<i>L. infantum</i>	KinetoplastDNA	100 fmol	[41]
Genosensor/optical	AuNP	<i>L. major</i>	KinetoplastDNA	7.0 pg/μL	[42]
Genosensor/optical	AuNP	<i>Leishmania</i> spp.	KinetoplastDNA	11.5 ng/μL	[43]
Immunosensor/ optical	AuNP	<i>L. infantum</i>	Chimeric recombinant antigens (K9, K39, and K26)	—	[44]
Immunosensor/ impedimetric	PAMAM	<i>L. amazonensis</i>	membrane proteins	10 ⁻⁵ mg/mL	[45]
Immunosensor/ SPR	PAMAM	<i>L. infantum</i>	hypothetical C1protein	7.83 nmol/L	[46]
Genosensor/ electrochemical	cobalt-zinc ferrite QD	<i>L. major</i>	KinetoplastDNA	1.8 × 10 ⁻¹⁴ ng/μL	[47]
Genosensor/ electrochemical	AuNP	<i>L. major</i>	<i>L. major</i> specific DNA	1.8 × 10 ⁻²⁰ mol/L 0.7 ng/μL	[48]
Genosensor/ electrochemical	AuNP	<i>L. infantum</i>	KinetoplastDNA	2 × 10 ⁻¹⁹ mol/L	[49]
Genosensor/ electrochemical	AuNP	<i>Leishmania</i> spp.	Leishmania specific DNA	1ZM	[50]

Type of biosensor	Nanomaterial used	Type of pathogen	Target biomolecule	Limit of detection	Refs
Casein-gp63 interaction/ electrochemical	AuNP	<i>L. infantum</i>	gp63 surface protein	0.55 parasite/mL	[51]
Genosensor/ electrochemical	AuNP	<i>Leishmania</i> spp.	KinetoplastDNA	0.8 parasite/mL	[52]
Aptasensor/ electrochemical	AuNP	<i>L. infantum</i>	Kinetoplastid membrane protein-11	2.27 mM	[53]

Abbreviations: PPY, polypyrrole; PAN, polyaniline; QD, quantum dot; PAMAM, polyamidoamine dendrimer; AuNP, gold nanoparticle; FAM-ssDNA, 6-carboxyfluorescein-labeled single stranded DNA.

[†]In this case, the value represents the concentration of DNA as the target molecule is ssDNA from *L. infantum*.

[‡]In this case, the value represents the concentration of DNA as target molecule is genomic DNA.

[§]In this case, the value represents the number of parasites.

25.3.1 Nanomaterials as Fluorescence Quenchers

Various types of nanostructures such carbon nanotubes; graphene oxide [54, 55]; Au [56]; Ag [57, 58] and ceria [59] nanoparticles; quantum dots [60]; metal-organic structures [61, 62]; transition metal nanosheets [63, 64]; and conductive polymers—such as poly(3,4-ethylenedioxythiophene) (PEDOT) nanoparticles [65], polypyrrole (PPY) nanospheres [66], and polyaniline (PANI) nanofibers, have been reported as effective fluorescence quenchers. Immobilizing these nanostructures on flexible substrates and their further integration in portable devices have been explored in many different applications. Functionalized nanostructures (with the probe of interest) have been used as fluorescence test strips, reducing the time required to carry out a diagnostic assay.

Pedro et al. (2019) [67] described the use of nanomaterials as nanoquenchers for fluorescent DNA assays. The nanostructure developed interacted with the fluorophore of a labeled DNA probe (*L. infantum* specific) through electron transfer processes which resulted in quenching of the fluorescence emission. Restoration of the fluorescence could only be achieved in the presence of complementary DNA to the original DNA probe. Subsequently, the probe-target hybridization resulted in desorption of the labeled probe into the supernatant. In their work, the authors used nanostructured ICP/PET (intrinsically conducting polymers/polyethylene terephthalate) films for the detection of *L. infantum* specific DNA sequences (Fig. 25.2). The DNA detection system utilized PPY and PANI films immobilized with 6-carboxyfluorescein-labeled single stranded DNA (FAM-ssDNA), resulting in the quenching of the luminescence signal. Later, when the FAM-ssDNA/ICP film system was put in contact with the target ssDNA, the hybridization of the probe with its complementary target caused the formation of double-stranded DNA, release of the FAM-ssDNA from the surface of the films,

and fluorescence recovery. Both types of polymeric films utilized in the study showed high sensitivity, with respective detection limits of 1.1 nM (PPY) and 1.3 nM (PANI) against the target ssDNA. Furthermore, the authors reported a linear response for the fluorescence intensity in a large concentration range of the target DNA (1–300 nM and 1–500 nM, for PPY and PANI, respectively). The FAM-ssDNA/ICP sensors showed high selectivity and could differentiate between full complementary sequences and those with just a single mismatch. They could also function in spiked complex medium, such as human blood serum, and exhibited good shelf stability. The functionalized ICP films also exhibited good shelf stability (PPY/PANI films were functional up to 180 days and probe immobilized films were functional for several days). The nanostructured ICP films described in this study show potential practical applications as strip tests for fast and sensitive fluorescent DNA detection in point-of-care clinical diagnosis protocols. This study thus describes the development of an inexpensive and simple molecular test that would not necessarily replace PCR analyses, but would rather complement them as efficient pre-screening methods. In this method, although PCR amplification is not required, both DNA extraction from a biological sample and the conversion of double-stranded DNA (dsDNA) to ssDNA are still necessary.




Figure 25.2 Nanostructured films as quenchers for fluorescent detection. Mechanism of fluorescence detection (of nucleic acids) using nanostructured ICP/PET films as sensing platform is demonstrated.

25.3.2 Nanomaterial as Fluorophore

Quantum dots (QDs) are nanosized semiconducting materials that have proven to be 20 times brighter and 100 times more stable compared to conventional fluorescent probes. Andreadou et al. (2016) [40] showed the use of cadmium selenite (CdSe) QDs as signal detector for the detection of *Leishmania*.




Figure 25.3 (A) Detection of *Leishmania*-specific target DNA using quantum dots. Target DNA was first denatured, followed by the hybridization of the functionalized magnetic beads to quantum dots via complimentary sequences. A magnetic device was then used to separate the conjugates from the solution and the positive result was detected by fluorescence. (B) Use of quantum dots for detecting *Leishmania*-specific proteins. Leishmanial cells were first conjugated with a monoclonal anti-*Leishmania* LPG antibody which initially bound to a biotin-labeled polyclonal anti-mouse IgM and later to streptavidin-coated magnetic beads. After separation using a magnet, the second monoclonal antibody (anti-*Leishmania* gp63) first bound to the protozoan cells and then to the biotin labeled polyclonal anti-mouse IgG. The complexes were separated again using a magnet and finally detected by streptavidin-coated quantum dots.

Two different systems were described by this group: one for detection of *Leishmania*-specific DNA, and another for the detection of *Leishmania*-specific surface proteins (LPG and gp63). In both, the system's magnetic beads were used to separate the analytes from the solution, whereas the presence of the targeted molecules was demonstrated by using QDs. The aim here was to develop a methodology that would be technically easy to perform, not require a specific equipment, and at the same time detect all the main pathogens of *Leishmania* spp. For the DNA-based biosensor, two highly specific DNA oligonucleotides (probe 1 and probe 2) conserved among the main leishmanial pathogens were utilized as DNA probes [68]. These DNA probes (probes 1 and 2) were biotinylated at their 5' end and detected with streptavidin-bound QDs (15–20 nm in size). Denatured single-stranded target DNA was first put in contact with biotinylated probe 1 and was separated using the magnetic beads conjugated with streptavidin.

The separated mixture was incubated with biotinylated probe 2 and finally detected with QDs bound to streptavidin (Fig. 25.3A). A similar methodology was used for the detection of the two different leishmanial surface antigens (LPG and gp63), using monoclonal antibodies, biotinylated IgG/IgM, and streptavidin-bound QDs. Magnetic beads conjugated with streptavidin were used as separation probe (Fig. 25.3B). The fluorescent signal generated in both the systems was detected visually or by optical analysis (605 nm). Positive results were obtained in all the positive samples analyzed, and no fluorescent signal was obtained in the negative control samples, thus generating a sensitivity and specificity of 100%. The limit of detection was calculated to be 3.125 ng/ μ L and 10^3 cells/mL for the DNA and protein methods, respectively.

25.3.3 Use of Dendrimers

Perinoto et al. (2010) [45] developed a nanostructured biosensor system to detect specific anti-*Leishmania* antibodies using capacitance measurements. In this system, phospholipid liposomes incorporating *L. amazonensis*-specific membrane antigenic proteins (proteoliposomes) together with dendrimers attached to the surface of interdigitated gold electrodes were used as the immobilized phase. The electrodes containing antigenic proteins were then used to detect antibodies. Binding of the antibodies to the electrode resulted in variations in the measured electrical response. Freshly prepared proteoliposomes were immobilized on interdigitated electrodes using the layer-by-layer technique in conjunction with polyamidoamine dendrimers 4 (PAMAM). Dendrimers, due to their branched, porous structure, are utilized for immobilizing proteins in biosensors, as they increase sensitivity and response times due to diffusion of analytes through the multilayer structure. Furthermore, the porous architecture of the film is important for confining electrical charges within its structure, which are responsible for the detectable changes in the electrical response. The PAMAM/proteoliposome electrode developed in this study could differentiate the capacitance signal between the positive and negative serum samples without

showing any cross-reactivity with anti-*T. cruzi* IgGs, which are responsible for significant false positive in the current diagnostic methodologies. The capacitance-based system developed here can be extended for the diagnosis of other bacterial, protozoan, and helminth infectious diseases.

Souto et al. (2015) [46] also made use of PAMAM for detection of anti-*L. infantum* antibodies using a surface plasmon resonance (SPR)-based immunosensor. The authors used recombinant protein from *L. infantum* with unknown function (hypothetical C1 protein or C1 antigen) as a recognition element for the development of SPR immunosensor. SPR-based sensors are widely recognized as a potential analytical tool due to their extreme sensitivity to small changes in the refractive index near to the sensor surface caused by the variation of the mass on the transducer surface. SPR requires neither label nor tracer, thus reducing the number of steps for the analysis of biomolecular interactions in real time. In the current study, the immunosensor was developed by depositing self-assembled layers (SAM) of cysteamine on gold surface followed by the addition of a fourth-generation poly (amidoamine) dendrimer (PAMAM (G4)) onto which the C1 antigen was immobilized. Binding of antibody to the immobilized antigen resulted in the variation of the angle of resonance which was recorded. The authors in this work confirmed the specific binding of CVL (canine visceral leishmania) antibodies to the immobilized recombinant C1 antigen showing a limit of detection of 7.83 nmol/L. No signal was obtained for negative canine sera. A similar result was also shown by this group using different *L. infantum* antigens immobilized on SAM of 11-MUA on gold substrate for the development of a SPR immunosensor in canine serum [69].

25.3.4 Surface Plasmon Coupling

Detection of the amplification products (e.g., gel electrophoresis) after PCR amplification requires time-consuming protocols performed by trained personnel, with high cost. The aim of the study conducted by Toubanaki et al. (2016) [41] was simplification of PCR product detection, using a nucleic acid lateral flow, combined with functionalized gold nanoparticles. Gold nanoparticles, besides providing high specific surface (thus enabling the immobilization of an increased amount of bioreceptor units), were also used for visualization based on their interparticle surface plasmon coupling [70, 71]. Lateral flow biosensors (LFBs) are diagnostic devices based on one time use of paper as a carrier material, where dry reagents are activated by applying a fluid sample. LFBs are important for diagnostic purposes as they are affordable, sensitive, specific, user-friendly, rapid, robust, and equipment-free [71, 72]. They are an ideal platform for single use at point of care, where only a positive/negative signal is desired, with fast result time (approximately 20 min) [73, 74]. In the current study [41], amplification reactions targeting kinetoplast DNA of *Leishmania* spp. Were performed on canine blood samples, and a positive signal was obtained as a red test zone on LFB. LFB consisted of an immersion pad (17 mm), a glass-fiber conjugate pad (8 mm), nitrocellulose diagnostic membrane (25 mm in length), and an absorbent pad (same

as immersion pad) assembled on a plastic adhesive backing. The genomic DNA extracted from the canine sample was subjected to PCR for kinetoplast DNA amplification using biotinylated primers. Amplified product was mixed with dATP-tailed *Leishmania*-specific probe, and the mixture was applied to the conjugation pad next to the poly (dT) conjugated gold. Gold nanoparticles functionalized with oligo (dT) segments interacted with the hybridized complex of target DNA–poly (dA) probe and then were captured by immobilized streptavidin in the test zone of the LFB, indicating a positive signal (characteristic red line due to gold nanoparticle accumulation). The visual detection was completed in 20 min. Extensive optimization enabled the detection of 100 mol of target DNA. The biosensor was evaluated with actual clinical samples of infected dog blood and successfully confirmed the presence of *Leishmania*, while no product was detected for negative samples. Overall, the proposed lateral flow biosensor described by the authors is an appealing alternative platform for the detection of *Leishmania*-specific amplification products with low cost and attractive simplicity. Detection of the PCR products via LFB provides sequence confirmation by target–probe hybridization compared to size-based recognition of the amplified fragments in case of electrophoresis. The pre-hybridized sample can be applied directly on the biosensor, and only a small amount of developing solution and gold nanoparticles is required for visualization, eliminating the need of gel electrophoresis. The cost of the assay in terms of reagents and the biosensor was described to be about three euro. Furthermore, the biosensor allowed visual detection of *Leishmania*-specific amplification products within minutes without the need of any instruments. Overall, the proposed lateral flow biosensor can be considered an appealing alternative platform for *Leishmania*-specific amplification products detection with low cost and attractive simplicity.

Sattarahmady et al. (2016) [42] reported a gold nanoparticle-based genosensor for the visual and spectrophotometric detection of non-protein-coding region of the kDNA minicircle genome from *L. major*. The mechanism was based on hybridization of AuNPs-probeDNA with a target complementary DNA sequence. Changes in the plasmonic property of AuNPs, which depends on size, surface function, and interval distance between the particles, were used to induce a color change which was used for sensing. AuNPs (16 nm) used in this study had a stable red color which turned to purple on the addition of HCl due to aggregation by acid. However, no color change was observed in the presence of complimentary sequences, probably due to the formation of double-stranded DNA, which increases the stability of the AuNP probe toward aggregation. The method described by the authors showed specificity for detection of *L. major* with a detection limit of 7.0 pg/ μ L. The method was evaluated with success for the detection of *L. major* genomic DNA (DNA extracts of standard cultures of *L. major*) as well as its detection in clinical samples (DNA extracted from clinical samples). Based on the same principles (AuNP and aggregation by HCl), Andreadou et al. (2014) [43] designed a genosensor using four single-stranded oligonucleotides based on conserved regions of *Leishmania* genome as probe and confirmed the specificity and sensitivity of the sensor using positive and negative control samples

and the whole blood collected from dogs with suspected canine leishmaniasis. The minimum detection limit was defined to 11.5 ng/ μ L of target DNA sample with 100% repeatability and reproducibility.

Anfossi et al. (2018) [44] also described a lateral flow immunoassay (LFIA) for quick diagnosis of canine leishmaniasis which can also be extended to other animals (Fig. 25.4). The device used highly specific chimeric recombinant antigens (K9, K39, and K26) from the amastigote form of *L. infantum* and measured anti-leishmanial antibodies present in the serum. Protein A (from *Staphylococcus* known to bind to immunoglobulins from various animals) labeled with gold nanoparticles (30 nm mean diameter and a SPR band at 525 nm) was used as the signal reporter, and the visual results after 15 min were comparable to that generated by ELISA and IFAT. The developed LFIA showed high diagnostic sensitivity (98.4%) and specificity (98.9%), in agreement with serological reference methods for diagnosing canine visceral leishmaniasis. Furthermore, the authors confirmed long thermal stability (six months of storage at room temperature or 4 °C).




Figure 25.4 Representation of the lateral flow immunoassay (LFIA) device used for the diagnosis of visceral leishmaniasis. The strip composed of an analytical membrane contained a recombinant chimeric antigen (rCAG) and protein A (pA) which formed the test and control lines, respectively. The signal reporter included pA labeled with gold nanoparticles which are red in color due to a surface resonance band at 525 nm. AuNP-pA included in the device in dried form was pre-impregnated to the probe pad. The device also included a sample pad to adsorb the sample and distribute it uniformly to the membrane. An adsorbent pad was included to decrease the background color by increasing the volume of the sample flow. A single visible line (control) was generated for a canine serum which had no anti-leishmanial antibodies (negative sample). The presence of specific anti-leishmanial antibodies was shown by the specific binding of these antibodies to the rCAG, which produced a second red line (Test zone).

25.3.5 Nanomaterials as Reducing Agents

Heli et al. (2016) [47] reported the use of a cobalt-zinc ferrite ($\text{Co}_{0.5}\text{Zn}_{0.5}\text{Fe}_2\text{O}_4$) magnetic QD-modified carbon electrode for the detection of a 24-mer *L. major* DNA. Methylene blue (MB) was used as an electrochemical indicator. Cobalt ferrite has been reported to interact with DNA and stabilize its structure. The cobalt-zinc ferrite quantum dots used in this study, apart from providing a high surface area for the immobilization of the ssDNA probe, also had an electrocatalytic effect toward the electroreduction of methylene blue, resulting in a higher peak current and sensitivity. Cyclic voltammograms of methylene blue were measured before and after hybridization. MB bound with both single-stranded DNA (ssDNA) and dsDNA but showed higher affinity for dsDNA. A limit of detection as low as 2×10^{-19} mol/L was observed for the complementary 24-mer target ssDNA. Similar results were also observed for *L. major* genomic DNA with limit of detection equal to 1.8×10^{-14} ng/ μL . This electrochemical genosensor was also tested with genomic DNA extracted from *L. infantum* and *L. tropica*, and DNA extracted from positive clinical samples (biopsy specimens of human samples with cutaneous leishmaniasis). The fabricated label-free, PCR-free genosensor designed in this study showed selectivity towards detection of *L. major* in both cultivated and clinical samples.

Moradi et al. (2016) [75], using a similar methodology, also designed a PCR and label-free DNA sensor using *L. major*-specific DNA (pDNA) conjugated to gold nanoleaves, electrodeposited on gold electrodes using spermidine as shape directing agent. The methylene blue reduction peak was measured before and after hybridization of the complementary DNA. The biosensor could distinguish *L. major* from a non-complementary sequence oligonucleotide as well as the *L. tropica* genomic DNA. *L. major* in patient samples was also detected with a high selectivity. A limit of detection as low as 1.8×10^{-20} mol/L for the synthetic DNA and 0.07 ng/ μL for the genomic DNA was recorded.

Similarly, Nazari-Vanini et al. (2018) [49] reported the use of an electrochemical DNA sensor for detection of the *L. infantum* genome using toluidine blue as a reduction signal (Fig. 25.5). Non-spherical gold nanoparticles (nsAuNPs) functionalized with probe DNA (a thiolated 26-base oligonucleotide of *L. infantum* minicircle kDNA) were deposited on a gold electrode, which was tested with complementary DNA (cDNA). For this, different concentrations of cDNA were incubated with a biofunctionalized electrode for 40 min at 37 °C to conduct the hybridization. Differential pulse voltammetry (DPV) measurements were recorded before and after hybridization, and change in toluidine blue reduction signal (related to the reduction of toluidine blue bound to single stranded or double stranded DNA) was recorded. The sensor showed a linear relation with the concentration of cDNA in the range of 1×10^{-18} to 1×10^{-10} mol/L with the limit of detection of 2×10^{-19} mol/L. Higher selectivity for cDNA compared to sequences generated with 1, 2, and 3 mismatches was also recorded. The electrochemical response of the DNA sensor for extracted genomic DNA from

L. infantum was also investigated. *L. infantum* genomic DNA showed good selectivity, and no response was observed for genomic DNA from *L. tropica* and *L. major*. In order to apply the DNA sensor for detection of the pathogen in real samples, genomic DNA from clinical samples was collected, and the resulting samples were directly analyzed by the DNA sensor without any pretreatment (e.g., PCR amplification). The developed DNA sensor in this study successfully recognized the positive samples, indicating the applicability of the DNA sensor for clinical analysis of real samples. The analytical response of the DNA sensor was observed for consecutive days to examine the stability of the sensor. The DNA sensor maintained a relatively constant response for up to 60 days with minor random fluctuations. Accordingly, the storage period of the DNA sensor was reported to be 2 months. The authors reported higher sensitivity, improved selectivity, shorter analysis time, and greater ease of fabrication and application of the developed sensor compared with the other available techniques.




Figure 25.5 Design and functioning of an electrochemical genosensor using nsAuNP.

Similarly, a AuNP-toluidine-based electrochemical genosensor was also recently reported by Mobed et al. (2020) [50] using *Leishmania*-specific genomic DNA. The researchers also reported very low detection limit (1ZM) and a good linear range (10^{-6} to 10^{-21} M) for cDNA detection, which is one of the striking features of this biosensor. The biosensor developed using an AuNP-modified electrode also showed selectivity (using one, two, and three mismatched nucleotides). The authors confirmed the functionality of the biosensor in human plasma samples and showed the regenerative properties of the biosensor. AuNPs played a double role in this biosensor. The terminal sulfur atoms of thiolated DNA bound to the AuNPs as a result of a stable interaction between S and Au. Furthermore, AuNPs resulted in signal amplification resulting in a good genosensor sensitivity.

Surface protein gp63, expressed by both promastigote and amastigote forms of the *Leishmania*, shows the ability to degrade various substrates, such as casein, hemoglobin, gelatin, fibrinogen, and albumin [76, 77]. Diouani et al. (2019) [51] described the use of AuNP-casein conjugates for the detection of *Leishmania*

(Fig. 25.6). AuNPs in this system acted both as nanocarriers and electrocatalytic labels (for catalytic reduction of hydrogen). On the other hand, conjugation of caseins with AuNPs, in addition to providing high stability to the system (ability of casein to form stable micelles), also provided these nanoparticles with biocompatible functionalities (casein-gp63 interaction). Thus, the AuNP-casein conjugate (~18 nm) was incubated with different concentrations (2×10^{-2} and 2×10^{-6} parasites/mL) of promastigotes. The formed complexes were collected by centrifugation, treated with acidic solution, and then the collected AuNPs were placed on the working electrode surface of screen-printed carbon electrodes (SPCEs) and chronoamperometric measurements were carried out. Cathodic current associated with the reduction of protons (H^+) to hydrogen, in acidic medium, amplified by the catalytic effect of AuNPs was recorded and correlated to the concentration of AuNPs and in turn to the leishmanial parasites present in the sample. The authors describe a linear relationship between 2×10^{-2} and 2×10^5 parasites/mL with a limit of detection of about 0.55 parasite/mL.




Figure 25.6 Schematic illustration of the chronoamperometric detection principle of *Leishmania infantum* parasites through hydrogen evolution reaction catalyzed by gold nanoparticles.

De la Escosura-Muñiz et al. (2016) [52] utilized isothermal amplification of kinetoplast minicircle DNA using primers labeled with AuNP and magnetic beads. The electrocatalytic activity of the AuNP (hydrogen evolution reaction) allowed rapid detection of DNA, captured using a magnet placed on the reverse side of

the screen-printed carbon electrodes. PCR amplified DNA from positive sample (canine *Leishmania*) could be easily discriminated from those of healthy dogs using this methodology. Less than one parasite per milliliter of blood could be detected. This approach is thus more sensitive than traditional methods based on real-time PCR and is also more rapid, cheap, and user-friendly.

25.3.6 Aptamers over Antibodies

Aptamers are short single-stranded RNA or DNA oligonucleotides capable of binding various biological targets with high affinity and specificity. They are isolated from randomized oligonucleotide libraries using a molecular process named SELEX (Systematic Evolution of Ligands by Exponential enrichment). Aptamers are chemically synthesized and show several advantages over antibodies such as increased stability, easy low-cost synthesis, and easy regeneration and structural modifications. Moreover, the dissociation equilibrium constants (K_d) of aptamers are in the range of nM to pM, indicating that aptamers have a similar or greater affinity for their target than antibodies. Like antibodies, their properties are defined by the ionic conditions and pH in which they are placed. However, being shorter polymers (diameter: ~2 nm), aptamers are generally more sensitive than antibodies (diameter: ~15 nm) to their physical and chemical environment [34, 78]. These properties make aptamers excellent candidates for biomedical diagnosis [71].

Despite increased advances in our understanding of the parasite biology and host-parasite interactions, protozoan parasites still affect millions of people around the world, and there is an urgent need for novel therapeutics and diagnostics options. Recent studies have generated a huge interest in aptamers as promising diagnostic tools and shown their superiority for diagnostics in comparison with other tools, essentially monoclonal antibodies that are widely used for detection of target molecules in the biomedical field [79–82]. This section will describe the aptamers selected against *Leishmania*-specific proteins which can be used instead of antibodies in diagnostic tools. One of the proposed aptasensor using the selected aptamers is also described.

A research group lead by Professor Gonzalez has used SELEX to select and characterize various aptamers targeting *L. infantum*-specific proteins such as *L. infantum*-specific histone, kinetoplast membrane protein, and Poly A Binding Protein (PAPB). All these aptamers were first isolated using respective recombinant proteins, and later their binding affinities were tested using ELONA, slot blot, and Western blot with both recombinant and endogenous proteins [83–87].

25.3.6.1 *L. infantum* histone-specific aptamers

Leishmanial parasites (together with *Trypanosoma* species) belong to the group of kinetoplastids due to the presence of a DNA-containing kinetoplast, located in the single mitochondrion at the base of the cell's flagellum. Although histones

are extremely conserved proteins, kinetoplastid core histone show sequence divergences in the amino and in the carboxy-terminal domains that can be used as potential diagnostic and/or therapeutics targets.

So far, two aptamers (AptLiH2A#2, AptLiH2A#1) against *L. infantum*-specific H2A (LiH2A) and two aptamers (AptLiH3#4 and AptLiH3#10) against *L. infantum*-specific H3 (LiH3) have been reported by this group [84–87]. These aptamers were cloned and sequenced using previously selected aptamer populations (derived from ssDNA enriched population) after 3 rounds of SELEX targeting LiH2A and LiH3 recombinant proteins. Binding assays and protein interaction studies (ELONA, slot blot, and Western blot) conformed the high affinity of these selected aptamers with respective recombinant histones. At the same time, almost no binding to BSA or other leishmanial proteins was observed. Sensitivity of the aptamers to recognize LiH2A and LiH3A from *L. infantum* promastigotes was also confirmed in the cell lysates. Binding was confirmed in case of total proteins and nuclear fractions with no reactivity against cytoplasmic fractions. Their binding efficiencies and limit of detection are shown in Table 25.2. Structural analysis of the aptamer sequences using the program mFold and QGRS-mapper showed typical stem and loop motifs with higher probability of a G-quadruplex structure for the aptamers AptLiH2A#1LiH2A and AptLiH3#10. Their sequences, secondary structures, and lowest free energies are shown in Fig. 25.7. In the two aptamers (AptLiH2A#1 and AptLiH2A#2) targeting LiH2A, high affinity binding was shown only with peptides 5 and 8 of LiH2A protein. ($p < 0.01$; ANOVA followed by Dunnett's test). Similar studies with LiH3 showed that aptamers AptLiH3#4 and AptLiH3#10 recognize the region between the amino acids 21 to 60, corresponding to peptides 3, 4, and 5, with high affinity ($p < 0.001$; ANOVA followed by Dunnett's test), which correspond to the amino terminal domain with the highest sequence variability and presence of antigenic determinants of the protein.




Figure 25.7 Sequence (A) and secondary structures of aptamers selected against *L. infantum*-specific proteins B: LiH2, C: LiH3 D: PABP. The boxed G-doublets are those with the highest probability (G-Score) of participating to the G-quadruplex formation (A,B). The nucleotides labeled in red are those conserved in the sequence of the three aptamers (C,D).

Table 25.2 Aptamers selected against *Leishmania*-specific proteins

Aptamer	Target protein	Organism	Affinity (K_d)	Minimum number of detectable promastigotes	Refs
AptLiH2A#2, AptLiH2A#1	H2A	<i>L. infantum</i>	0.96 ± 0.17 nM 1.16 ± 0.28 nM	7500 7500	[85]
AptLiH3#4 AptLiH3#10	H3	<i>L. infantum</i>	0.52 ± 0.05 nM 0.37 ± 0.05 nM	6000 9000	[87]
ApPABP#3 ApPABP#7 ApPABP#11	PAPB	<i>L. infantum</i>	5.4 ± 1.1 nM 6.0 ± 2.6 nM 10.8 ± 2.7 nM	2500	[86]
Aptamer population	KMP-11	<i>L. infantum</i>	—	—	[83]

25.3.6.2 Aptamer targeting poly-A binding protein

The poly-A binding protein (PABP) is a conserved eukaryotic polypeptide involved in many cellular functions linked with the metabolism of messenger RNAs. Different PABPs have been described in *T. cruzi*, *T. brucei*, *L. major*, and *L. amazonensis*. The PABP homolog from *L. infantum*, called LiPABP, shows conserved domains present in other PABPs and maintains poly (A) binding properties. Three aptamers—ApPABP#3, ApPABP#7, and ApPABP#11—were selected after four rounds of SELEX against rLiPABP protein [86]. The aptamers were able to recognize the recombinant protein with affinity in the low nanomolar range (5–10 nM). No binding to BSA was observed during similar conditions. Slot blot assays showed that only 50 nM of each of the three aptamers could detect as low as 6.25 ng of LiPABP. The secondary structure of the aptamers was analyzed by using the Rapidshape program as shown in Fig. 25.7. Based on their free energy value, ApPABP#7 appears to be the more stable aptamer ($\Delta G = -14.00$ kcal/mol), followed by ApPABP#11 ($\Delta G = -9.30$ kcal/mol) and ApPABP#3 ($\Delta G = -7.40$ kcal/mol).

25.3.6.3 Aptamer against kinetoplast surface protein

Kinetoplastid membrane protein-11 (KMP-11) is a major component of the cell membrane of kinetoplastid parasites. Moreno et al. (2003) [83] described a pool of ssDNA aptamers against *L. infantum* gold-labeled recombinant KMP-11 (LiKPM-11). Using dot blot ELISA and Western blot assays, the authors showed that the aptamer population obtained after ten rounds of SELEX showed selective binding to the rKMP-11 and total proteins from *L. infantum*. No binding to BSA and total proteins from *Escherichia coli* were observed. The same authors further checked the functionality of this interaction using an electrochemical biosensor (Fig. 25.8) [53]. LiKMP-11-functionalized gold nanoparticles were electrodeposited on arrayed gold microelectrode. The previously selected aptamer population

was digoxigenin-labeled, and electrochemical measurements were recorded using an anti-digoxigenin antibody labeled with horseradish peroxidase. BSA-gold nanoparticles electrodes were used as negative control. The response of the biosensor to different LiKMP-11 concentration was measured using a displacement assay, where the electroporated microelectrodes were first incubated with a digoxigenin-labeled aptamer population and later put in contact with different concentrations of LiKMP-11 (0, 0.05, 0.25, and 0.5 mg/mL) for 1 h. After two washes with SELEX buffer, the electrodes were incubated with anti-digoxigenin antibody labeled with horseradish peroxidase in SELEX buffer, and the H_2O_2 electroreduction currents were measured. The authors obtained a linear relationship between free LiKMP-11 concentration and the intensity of the electrochemical reduction current. A limit of detection of 25 mg/mL (2.27 mM) of LiKMP-11 was achieved, which, although being very high, demonstrates the functionality of the current approach towards the development of an aptasensor for the diagnosis of leishmanial parasites.




Figure 25.8 Scheme of the proposed KMP-11 aptasensor.

25.4 Conclusions

Rapid and accurate diagnosis is of extreme importance for the control of leishmaniasis. Different species of *Leishmania* present variable aspects of virulence and pathogenicity. This, together with the host genetics, result in the wide clinical diversity of leishmaniasis, which makes the diagnosis of the disease more complex. Moreover, the clinical symptoms observed in VL are similar to that of different diseases common in areas where leishmaniasis is endemic, so that a specific diagnostic method is required to avoid cross-reactivity with other diseases. The most specific methods for the diagnosis of *Leishmania* spp. are currently available in reference hospitals or research centers, so that the most used field assays detect only a few species of *Leishmania*, not being suitable for regions with several endemic species. Therefore, there is a need to develop more accurate and accessible tests, as well as sensitive tests for patients co-infected with HIV and for asymptomatic infections, besides effective biomarkers for monitoring patients who have undergone different treatment regimens or who have had recurrences. Many new techniques are being studied, with the aim to promote improved diagnosis. Several cost-effective, convenient biosensors have been described over the years for the rapid and accurate diagnosis of Leishmania.

These also show high sensitivity and longer durability. A number of engineered biosensors making use of excellent conduction, catalytic, optical, and structural properties of nanomaterials are already in use for diagnosis and imaging in health sector for diagnosis of diseases like cancer. Nevertheless, there are still doubts and opportunities for improving these methods. More research aiming to improve the efficiency of these methods and the standardization of steps are necessary. Besides, costs must be evaluated carefully as leishmaniasis is basically a disease of poor countries. Published research describes the use of many inorganic materials like carbon nanotubes, graphene oxide, gold, silver, quantum dots, and conductive polymers for the design of diagnostic tools. These materials can link specific antigens, thus improving probe–target interaction. The use of the nanomaterial for signal amplification has also been well explored. However, further improvements are required with respect to the specificity of the transduced signal evicting cross-reactions. The use of conducting, catalytic, optical, and structural properties of nanomaterials are promising; however, the question is: Is this technique viable to be used at large scale with an effective cost–benefit ratio? Most of the recognition elements in biosensors described in this review showed the use of antibodies with only one study making use of aptamers. Aptamers are highly promising with superior properties compared to antibodies. Selection of new, more sensitive aptamers with better and more systematic characterization is definitely desired. Moreover, most of the aptamer-based biosensors rely on simple binding and are prone to nonspecific binding, especially in a complex sample matrix. An electrochemical DNA (E-DNA) sensor platform could be a good alternative, where signaling does not rely on simple absorption of the target on the sensor, thus the system performs well even in a complex medium. Sensors based on aptamer conformational change or catalysis could thus be more accurate.

Abbreviations

AuNP:	gold nanoparticle
cDNA:	complementary DNA
CdSe:	cadmium selenite
CFR:	complement fixation reaction
CL:	cutaneous leishmaniasis
CVL:	canine visceral leishmania
DAT:	direct agglutination test
DPV:	differential pulse voltammetry
dsDNA:	double-stranded DNA
E-DNA:	electrochemical DNA
ELISA:	enzyme-linked immunoenzymatic assay
FAM-ssDNA:	6-carboxyfluorescein-labeled single stranded DNA
FAST:	fast agglutination screening test
IC:	immunochromatographic

ICP:	intrinsically conducting polymers
IFA:	immunofluorescence assay
KMP-11:	kinetoplastid membrane protein-11
LFBS:	lateral flow biosensors
LFIA:	lateral flow immunoassay
LiH2A:	<i>L. infantum</i> -specific H2A
LiH3:	<i>L. infantum</i> -specific H3
LiKPM-11:	<i>L. infantum</i> gold-labeled recombinant KMP-11
MB:	Methylene blue
ML:	mucocutaneous leishmaniasis
NTDs:	neglected tropical diseases
nsAuNPs:	non-spherical gold nanoparticles
PABP:	poly A binding protein
PAMAM:	polyamidoamine dendrimers
PANI:	polyaniline
PCR:	polymerase chain reaction
pDNA:	<i>L. maior</i> -specific DNA
PEDOT:	poly(3,4-ethylenedioxythiophene)
PET:	polyethylene terephthalate
POC:	point-of-care
PPY:	polypyrrole
QD:	quantum dot
rCag:	recombinant chimeric antigen
qPCR:	real-time quantitative PCR
SAM:	self-assembled layers
SELEX:	systematic evolution of ligands by exponential enrichment
SPCEs:	screen-printed carbon electrodes
SPR:	surface plasmon resonance
ssDNA:	single-stranded DNA
VL:	visceral leishmaniasis
WB:	Western blot

Disclosures and Conflict of Interest

This chapter was originally published as: Jain, S., Santana, W., Dolabella, S. S., Santos, A. L. S., Souto, E. B., Severino, P. (2021). Are nanobiosensors an improved solution for diagnosis of *Leishmania*? *Pharmaceutics*, **13**, 491, <https://doi.org/10.3390/pharmaceutics13040491>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates, by kind permission of the copyright holders.

Author Contributions: All authors have substantially contributed to the conceptualization, methodology, formal analysis of collected data, building up of figures and tables, investigation, resources, and data analysis. S.J., W.S., S.S.D., and A.L.S.S. have contributed to the writing—original draft, data search, and

literature research. S.J., E.B.S., and P.S. have contributed for the writing—review, validation, and editing. S.J., W.S., S.S.D., A.L.S.S., E.B.S., and P.S. have contributed to the project administration, supervision, and funding acquisition. All authors have read and agreed to the published version of the chapter.

Funding: This research was funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico for the scientific grants (CNPq 301964/2019-0 Chamada 06/2019, Chamada CNPq nº 01/2019) and Portuguese Science and Technology Foundation, Ministry of Science and Education (FCT/MEC) through the sponsorship of the projects M-ERA-NET-0004/2015-PAIRED and UIDB/04469/2020 (strategic fund), co-financed by FEDER, under the Partnership Agreement PT2020.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Torres-Guerrero, E., Quintanilla-Cedillo, M.R., Ruiz-Esmenjaud, J., Arenas, R. Leishmaniasis: A review. *F1000Research* **2017**, *6*, 750.
2. De las Heras, F.G. Overview of neglected tropical diseases. In *Third World Diseases*, Elliott, R., Ed., Springer: Berlin/Heidelberg, Germany, 2011, pp. 1–46.
3. Burza, S., Croft, S.L., Boelaert, M. Leishmaniasis. *Lancet* **2018**, *392*, 951–970.
4. Herrera, G., Barragán, N., Luna, N., Martínez, D., De Martino, F., Medina, J., Niño, S., Páez, L., Ramírez, A., Vega, L., et al. An interactive database of *Leishmania* species distribution in the Americas. *Sci. Data* **2020**, *7*, 110.
5. Alvar, J., Vélez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., Den Boer, M. Leishmaniasis worldwide and global estimates of its incidence. *PLoS ONE* **2012**, *7*, e035671.
6. Quinell, R.J., Courtenay, O. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. *Parasitology* **2009**, *136*, 1915–1934.
7. Aronson, N., Herwaldt, B.L., Libman, M., Pearson, R., Lopez-Velez, R., Weina, P., Carvalho, E., Ephros, M., Jeronimo, S., Magill, A. Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). *Am. J. Trop. Med. Hyg.* **2017**, *96*, 24–45.
8. McGwire, B.S., Satoskar, A.R. Leishmaniasis: Clinical syndromes and treatment. *QJM Int. J. Med.* **2013**, *107*, 7–14.
9. Varma, N., Naseem, S. Hematologic changes in visceral leishmaniasis/kala azar. *Indian J. Hematol. Blood Transfus.* **2010**, *26*, 78–82.
10. Akhoundi, M., Downing, T., Votýpka, J., Kuhls, K., Lukeš, J., Cannet, A., Ravel, C., Marty, P., Delaunay, P., Kasbari, M., et al. Leishmania infections: Molecular targets and diagnosis. *Mol. Asp. Med.* **2017**, *57*, 1–29.
11. Roatt, B.M., De Oliveira Cardoso, J.M., De Brito, R.C.F., Coura-Vital, W., De Oliveira Aguiar-Soares, R.D., Reis, A.B. Recent advances and new strategies on leishmaniasis treatment. *Appl. Microbiol. Biotechnol.* **2020**, *104*, 8965–8977.
12. Goto, H., Lindoso, J.A. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. *Expert Rev. Anti-Infect. Ther.* **2010**, *8*, 419–433.

13. Georgiadou, S.P., Makaritsis, K.P., Dalekos, G.N. Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. *J. Transl. Int. Med.* **2015**, *3*, 43–50.
14. Kotb, E.E., Antonio Sampedro, M., Javier, R.-G., Yannick, H.-M., Ahamd, A., Jose Mari Navarro, M., Jose Gutierrez, F. Diagnosis of leishmaniasis. *J. Infect. Dev. Ctries.* **2014**, *8*.
15. Liu, J., Cao, Z., Lu, Y. Functional nucleic acid sensors. *Chem. Rev.* **2009**, *109*, 1948–1998.
16. Alizadeh, N., Memar, M.Y., Moaddab, S.R., Kafil, H.S. Aptamer-assisted novel technologies for detecting bacterial pathogens. *Biomed. Pharmacother.* **2017**, *93*, 737–745.
17. Majdinasab, M., Hayat, A., Marty, J.L. Aptamer-based assays and aptasensors for detection of pathogenic bacteria in food samples. *TrAC Trends Anal. Chem.* **2018**, *107*, 60–77.
18. Blum, J., Desjeux, P., Schwartz, E., Beck, B., Hatz, C. Treatment of cutaneous leishmaniasis among travellers. *J. Antimicrob. Chemother.* **2004**, *53*, 158–166.
19. Molina, I., Fisa, R., Riera, C., Falcó, V., Elizalde, A., Salvador, F., Crespo, M., Curran, A., López-Chejade, P., Tebar, S., et al. Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients. *Am. J. Trop. Med. Hyg.* **2013**, *89*, 105–110.
20. Iqbal, J., Hira, P.R., Saroj, G., Philip, R., Al-Ali, F., Madda, P.J., Sher, A. Imported visceral leishmaniasis: Diagnostic dilemmas and comparative analysis of three assays. *J. Clin. Microbiol.* **2002**, *40*, 475–479.
21. Boelaert, M., Rijal, S., Regmi, S., Singh, R., Karki, B., Jacquet, D., Chappuis, F., Campino, L., Desjeux, P., Le Ray, D., et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. *Am. J. Trop. Med. Hyg.* **2004**, *70*, 72–77.
22. Sundar, S., Rai, M. Laboratory diagnosis of visceral leishmaniasis. *Clin. Diagn. Lab. Immunol.* **2002**, *9*, 951–958.
23. Pedras, M.J., De Gouvêa Viana, L., De Oliveira, E.J., Rabello, A. Comparative evaluation of direct agglutination test, rK39 and soluble antigen ELISA and IFAT for the diagnosis of visceral leishmaniasis. *Trans. R. Soc. Trop. Med. Hyg.* **2008**, *102*, 172–178.
24. De Assis, T.S.M., Caligiorne, R.B., Romero, G.A.S., Rabello, A. Detection of Leishmania kDNA in human serum samples for the diagnosis of visceral leishmaniasis. *Trans. R. Soc. Trop. Med. Hyg.* **2009**, *103*, 1269–1272.
25. Fagundes, A., Schubach, A., Paula, C.C.d., Bogio, A., Antonio, L.d.F., Schiavoni, P.B., Monteiro, V.d.S., Madeira, M.d.F., Quintella, L.P., Valette-Rosalino, C.M., et al. Evaluation of polymerase chain reaction in the routine diagnosis for tegumentary leishmaniasis in a referral centre. *J. Memórias Inst. Oswaldo Cruz.* **2010**, *105*, 109–112.
26. De Castro Zacche-Tonini, A., Fonseca, G.S.F., De Jesus, L., Barros, G.B., Coelho-Dos-Reis, J.G.A., Béla, S.R., Machado, A.S., Carneiro, A., Andrade, G.M.Q., Vasconcelos-Santos, D.V., et al. Establishing tools for early diagnosis of congenital toxoplasmosis: Flow cytometric IgG avidity assay as a confirmatory test for neonatal screening. *J. Immunol. Methods* **2017**, *451*, 37–47.
27. Alessio, G.D., De Araújo, F.F., Sales Júnior, P.A., Gomes, M.S., Amaral, L.R.D., Pascoal Xavier, M.A., Teixeira-Carvalho, A., De Lana, M., Martins-Filho, O.A. Accomplishing the genotype-specific serodiagnosis of single and dual *Trypanosoma cruzi* infections by flow cytometry Chagas-Flow ATE-IgG2a. *PLoS Negl. Trop. Dis.* **2018**, *12*, e0006140.

28. Mary, C., Faraut, F., Lascombe, L., Dumon, H. Quantification of *Leishmania infantum* DNA by a real-time PCR assay with high sensitivity. *J. Clin. Microbiol.* **2004**, *42*, 5249–5255.
29. Schönián, G., Kuhls, K., Mauricio, I.L. Molecular approaches for a better understanding of the epidemiology and population genetics of Leishmania. *Parasitology* **2011**, *138*, 405–425.
30. Hossain, F., Ghosh, P., Khan, M.A.A., Duthie, M.S., Vallur, A.C., Picone, A., Howard, R.F., Reed, S.G., Mondal, D. Real-time PCR in detection and quantitation of *Leishmania donovani* for the diagnosis of Visceral Leishmaniasis patients and the monitoring of their response to treatment. *PLoS ONE* **2017**, *12*, e0185606.
31. Bhalla, N., Jolly, P., Formisano, N., Estrela, P. Introduction to biosensors. *Essays Biochem.* **2016**, *60*, 1–8.
32. Zhang, Z., Cong, Y., Huang, Y., Du, X. Nanomaterials-based electrochemical immunosensors. *Micromachines* **2019**, *10*, 397.
33. Kaushik, M., Khurana, S., Mehra, K., Yadav, N., Mishra, S., Kukreti, S. Emerging trends in advanced nanomaterials based electrochemical genosensors. *Curr. Pharm. Des.* **2018**, *24*, 3697–3709.
34. Yu, X., Yang, Y.-P., Dikici, E., Deo, S.K., Daunert, S. Beyond antibodies as binding partners: The role of antibody mimetics in bioanalysis. *Annu. Rev. Anal. Chem.* **2017**, *10*, 293–320.
35. Kumar, S., Ahlawat, W., Kumar, R., Dilbaghi, N. Graphene, carbon nanotubes, zinc oxide and gold as elite nanomaterials for fabrication of biosensors for healthcare. *Biosens. Bioelectron.* **2015**, *70*, 498–503.
36. Shavanova, K., Bakakina, Y., Burkova, I., Shtepliuk, I., Viter, R., Ubelis, A., Beni, V., Starodub, N., Yakimova, R., Khranovskyy, V. Application of 2D non-graphene materials and 2D oxide nanostructures for biosensing technology. *Sensors* **2016**, *16*, 223.
37. Hu, Y., Cheng, H., Zhao, X., Wu, J., Muhammad, F., Lin, S., He, J., Zhou, L., Zhang, C., Deng, Y., et al. Surface-enhanced Raman scattering active gold nanoparticles with enzyme-mimicking activities for measuring glucose and lactate in living tissues. *ACS Nano* **2017**, *11*, 5558–5566.
38. Jain, S., Huang, Z., Dixon, B.R., Sattar, S., Liu, J. *Cryptosporidium parvum* oocyst directed assembly of gold nanoparticles and graphene oxide. *Front. Chem. Sci. Eng.* **2019**, *13*, 608–615.
39. Jain, S., Costa Melo, T.G., Dolabella, S.S., Liu, J. Current and emerging tools for detecting protozoan cysts and oocysts in water. *TrAC Trends Anal. Chem.* **2019**, *121*, 115695.
40. Andreadou, M., Liandris, E., Gazouli, M., Mataragka, A., Tachtsidis, I., Goutas, N., Vlachodimitropoulos, D., Ikononopoulos, J. Detection of Leishmania-specific DNA and surface antigens using a combination of functionalized magnetic beads and cadmium selenite quantum dots. *J. Microbiol. Methods* **2016**, *123*, 62–67.
41. Toubanaki, D.K., Athanasiou, E., Karagouni, E. Gold nanoparticle-based lateral flow biosensor for rapid visual detection of Leishmania-specific DNA amplification products. *J. Microbiol. Methods* **2016**, *127*, 51–58.
42. Sattarahmady, N., Movahedpour, A., Heli, H., Hatam, G.R. Gold nanoparticles-based biosensing of Leishmania major kDNA genome: Visual and spectrophotometric detections. *Sens. Actuators B Chem.* **2016**, *235*, 723–731.

43. Andreadou, M., Liandris, E., Gazouli, M., Taka, S., Antoniou, M., Theodoropoulos, G., Tachtsidis, I., Goutas, N., Vlachodimitropoulos, D., Kasampalidis, I., et al. A novel non-amplification assay for the detection of *Leishmania* spp. in clinical samples using gold nanoparticles. *J. Microbiol. Methods* **2014**, *96*, 56–61.
44. Anfossi, L., Di Nardo, F., Profiti, M., Nogarol, C., Cavalera, S., Baggiani, C., Giovannoli, C., Spano, G., Ferroglio, E., Mignone, W., et al. A versatile and sensitive lateral flow immunoassay for the rapid diagnosis of visceral leishmaniasis. *Anal. Bioanal. Chem.* **2018**, *410*, 4123–4134.
45. Perinoto, Â.C., Maki, R.M., Colhone, M.C., Santos, F.R., Migliaccio, V., Daghestanli, K.R., Stabeli, R.G., Ciancaglini, P., Paulovich, F.V., De Oliveira, M.C., et al. Biosensors for efficient diagnosis of leishmaniasis: Innovations in bioanalytics for a neglected disease. *Anal. Chem.* **2010**, *82*, 9763–9768.
46. Souto, D.E., Fonseca, A.M., Barragan, J.T., Luz Rde, C., Andrade, H.M., Damos, F.S., Kubota, L.T. SPR analysis of the interaction between a recombinant protein of unknown function in *Leishmania infantum* immobilised on dendrimers and antibodies of the visceral leishmaniasis: A potential use in immunodiagnosis. *Biosens. Bioelectron.* **2015**, *70*, 275–281.
47. Heli, H., Sattarahmady, N., Hatam, G.R., Reisi, F., Vais, R.D. An electrochemical genosensor for Leishmania major detection based on dual effect of immobilization and electrocatalysis of cobalt-zinc ferrite quantum dots. *Talanta* **2016**, *156–157*, 172–179.
48. Moradi, M., Sattarahmady, N., Hatam, G., Heli, H. Electrochemical Genosensing of Leishmania major using Gold Hierarchical Nanoleaflets. *J. Biol. Today's World* **2016**, *5*, 128–136.
49. Nazari-Vanani, R., Sattarahmady, N., Yadegari, H., Delshadi, N., Hatam, G.R., Heli, H. Electrochemical quantitation of *Leishmania infantum* based on detection of its kDNA genome and transduction of non-spherical gold nanoparticles. *Anal. Chim. Acta* **2018**, *1041*, 40–49.
50. Mobed, A., Mehri, P., Hasanzadeh, M., Mokhtarzadeh, A. Binding of Leishmania spp with gold nanoparticles supported polyethylene glycol and its application for the sensitive detection of infectious photogenes in human plasma samples: A novel biosensor. *J. Mol. Recognit.* **2020**, *33*, e2839.
51. Diouani, M.F., Ouerghi, O., Belgacem, K., Sayhi, M., Ionescu, R., Laouini, D. Casein-conjugated gold nanoparticles for amperometric detection of *Leishmania infantum*. *Biosensors* **2019**, *9*, 68.
52. De la Escosura-Muñiz, A., Baptista-Pires, L., Serrano, L., Altet, L., Francino, O., Sánchez, A., Merkoçi, A. Magnetic bead/gold nanoparticle double-labeled primers for electrochemical detection of isothermal amplified Leishmania DNA. *Small* **2016**, *12*, 205–213.
53. Moreno, M., González, V.M., Rincón, E., Domingo, A., Domínguez, E. Aptasensor based on the selective electrodeposition of protein-linked gold nanoparticles on screen-printed electrodes. *Analyst* **2011**, *136*, 1810–1815.
54. He, S., Song, B., Li, D., Zhu, C., Qi, W., Wen, Y., Wang, L., Song, S., Fang, H., Fan, C. A graphene nanoprobe for rapid, sensitive, and multicolor fluorescent DNA analysis. *Adv. Funct. Mater.* **2010**, *20*, 453–459.

55. Liu, Z., Su, X. A novel fluorescent DNA sensor for ultrasensitive detection of *Helicobacter pylori*. *Biosens. Bioelectron.* **2017**, *87*, 66–72.
56. Dubertret, B., Calame, M., Libchaber, A.J. Single-mismatch detection using gold-quenched fluorescent oligonucleotides. *Nat. Biotechnol.* **2001**, *19*, 365–370.
57. Li, H., Zhang, Y., Wang, L., Tian, J., Sun, X. Nucleic acid detection using carbon nanoparticles as a fluorescent sensing platform. *Chem. Commun.* **2011**, *47*, 961–963.
58. Yan, J.-K., Ma, H.-L., Cai, P.-F., Wu, J.-Y. Highly selective and sensitive nucleic acid detection based on polysaccharide-functionalized silver nanoparticles. *Spectrochim. Acta Part A Mol. Biomol. Spectrosc.* **2015**, *134*, 17–21.
59. Bülbül, G., Hayat, A., Mustafa, F., Andreescu, S. DNA assay based on nanoceria as fluorescence quenchers (NanoCeracQ DNA assay). *Sci. Rep.* **2018**, *8*, 2426.
60. Loo, A.H., Sofer, Z., Bouša, D., Ulbrich, P., Bonanni, A., Pumera, M. Carboxylic carbon quantum dots as a fluorescent sensing platform for DNA detection. *ACS Appl. Mater. Interfaces* **2016**, *8*, 1951–1957.
61. Zhao, H.-Q., Qiu, G.-H., Liang, Z., Li, M.-M., Sun, B., Qin, L., Yang, S.-P., Chen, W.-H., Chen, J.-X. A zinc(II)-based two-dimensional MOF for sensitive and selective sensing of HIV-1 ds-DNA sequences. *Anal. Chim. Acta* **2016**, *922*, 55–63.
62. Tang, G., Gao, J., Wang, C., Tan, H. Luminescent lanthanide coordination polymer as a platform for DNA colorimetric detection. *Sens. Actuators B Chem.* **2017**, *244*, 571–576.
63. Zhu, C., Zeng, Z., Li, H., Li, F., Fan, C., Zhang, H. Single-layer MoS₂-based nanoprobe for homogeneous detection of biomolecules. *J. Am. Chem. Soc.* **2013**, *135*, 5998–6001.
64. Mo, L., Li, J., Liu, Q., Qiu, L., Tan, W. Nucleic acid-functionalized transition metal nanosheets for biosensing applications. *Biosens. Bioelectron.* **2017**, *89*, 201–211.
65. Zhang, Y., Liu, S., Wang, L., Luo, Y., Tian, J., Asiri, A.M., Al-Youbi, A.O., Sun, X. Novel use of poly(3,4-ethylenedioxythiophene) nanoparticles for fluorescent nucleic acid detection. *ACS Comb. Sci.* **2012**, *14*, 191–196.
66. Lu, W., Qin, X., Chang, G., Sun, X. 2,4,6-Tris (2-pyridyl)-1,3,5-triazine nanobelts as an effective fluorescent sensing platform for DNA detection. *J. Nanosci. Nanotechnol.* **2012**, *12*, 2089–2093.
67. Pedro, G.C., Gorza, F.D.S., Da Silva, R.J., Do Nascimento, K.T.O., Medina-Llamas, J.C., Chávez-Guajardo, A.E., Alcaraz-Espinoza, J.J., De Melo, C.P. A novel nucleic acid fluorescent sensing platform based on nanostructured films of intrinsically conducting polymers. *Anal. Chim. Acta* **2019**, *1047*, 214–224.
68. Andreadou, M., Liandris, E., Kasampalidis, I.N., Taka, S., Antoniou, M., Ntais, P., Vaiopoulou, A., Theodoropoulos, G., Gazouli, M., Ikonopoulou, J. Evaluation of the performance of selected in-house and commercially available PCR and real-time PCR assays for the detection of *Leishmania* DNA in canine clinical samples. *Exp. Parasitol.* **2012**, *131*, 419–424.
69. Souto, D.E.P., Silva, J.V., Martins, H.R., Reis, A.B., Luz, R.C.S., Kubota, L.T., Damos, F.S. Development of a label-free immunosensor based on surface plasmon resonance technique for the detection of anti-*Leishmania infantum* antibodies in canine serum. *Biosens. Bioelectron.* **2013**, *46*, 22–29.
70. Aldewachi, H., Chalati, T., Woodroffe, M.N., Bricklebank, N., Sharrack, B., Gardiner, P. Gold nanoparticle-based colorimetric biosensors. *Nanoscale* **2018**, *10*, 18–33.

71. Zhou, W., Jimmy Huang, P.-J., Ding, J., Liu, J. Aptamer-based biosensors for biomedical diagnostics. *Analyst* **2014**, *139*, 2627–2640.
72. Wang, Y., Yan, W., Fu, S., Hu, S., Wang, Y., Xu, J., Ye, C. Multiple cross displacement amplification coupled with nanoparticles-based lateral flow biosensor for detection of *Staphylococcus aureus* and identification of methicillin-resistant *S. aureus*. *Front. Microbiol.* **2018**, *9*, 907.
73. Posthuma-Trumpie, G.A., Korf, J., Van Amerongen, A. Lateral flow (immuno)assay: Its strengths, weaknesses, opportunities and threats. A literature survey. *Anal. Bioanal. Chem.* **2009**, *393*, 569–582.
74. Rivas, L., Reuterswård, P., Rasti, R., Herrmann, B., Mårtensson, A., Alfvén, T., Gantelius, J., Andersson-Svahn, H. A vertical flow paper-microarray assay with isothermal DNA amplification for detection of *Neisseria meningitidis*. *Talanta* **2018**, *183*, 192–200.
75. Moradi, M., Sattarahmady, N., Rahi, A., Hatam, G.R., Sorkhabadi, S.M.R., Heli, H. A label-free, PCR-free and signal-on electrochemical DNA biosensor for Leishmania major based on gold nanoleaves. *Talanta* **2016**, *161*, 48–53.
76. Bouvier, J., Schneider, P., Etges, R., Bordier, C. Peptide substrate specificity of the membrane-bound metalloprotease of Leishmania. *Biochemistry* **1990**, *29*, 10113–10119.
77. Yao, C., Donelson, J.E., Wilson, M.E. The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. *Mol. Biochem. Parasitol.* **2003**, *132*, 1–16.
78. Bayat, P., Nosrati, R., Alibolandi, M., Rafatpanah, H., Abnous, K., Khedri, M., Ramezani, M. SELEX methods on the road to protein targeting with nucleic acid aptamers. *Biochimie* **2018**, *154*, 132–155.
79. Ospina-Villa, J.D., Zamorano-Carrillo, A., Castañón-Sánchez, C.A., Ramírez-Moreno, E., Marchat, L.A. Aptamers as a promising approach for the control of parasitic diseases. *Braz. J. Infect. Dis.* **2016**, *20*, 610–618.
80. Wolter, O., Mayer, G. Aptamers as valuable molecular tools in neurosciences. *J. Neurosci.* **2017**, *37*, 2517–2523.
81. Pan, Q., Luo, F., Liu, M., Zhang, X.-L. Oligonucleotide aptamers: Promising and powerful diagnostic and therapeutic tools for infectious diseases. *J. Infect.* **2018**, *77*, 83–98.
82. Ruiz Ciancio, D., Vargas, M.R., Thiel, W.H., Bruno, M.A., Giangrande, P.H., Mestre, M.B. Aptamers as diagnostic tools in cancer. *Pharmaceuticals* **2018**, *11*, 86.
83. Moreno, M., Rincón, E., Piñeiro, D., Fernández, G., Domingo, A., Jiménez-Ruíz, A., Salinas, M., González, V.C.M. Selection of aptamers against KMP-11 using colloidal gold during the SELEX process. *Biochem. Biophys. Res. Commun.* **2003**, *308*, 214–218.
84. Ramos, E., Piñeiro, D., Soto, M., Abanades, D.R., Martín, M.E., Salinas, M., González, V.M. A DNA aptamer population specifically detects *Leishmania infantum* H2A antigen. *Lab. Investig. J. Tech. Methods Pathol.* **2007**, *87*, 409–416.
85. Martín, M.E., García-Hernández, M., García-Recio, E.M., Gómez-Chacón, G.F., Sánchez-López, M., González, V.M. DNA aptamers selectively target *Leishmania infantum* H2A protein. *PLoS ONE* **2013**, *8*, e078886.
86. Guerra-Pérez, N., Ramos, E., García-Hernández, M., Pinto, C., Soto, M., Martín, M.E., González, V.M. Molecular and functional characterization of ssDNA aptamers that specifically bind *Leishmania infantum* PABP. *PLoS ONE* **2015**, *10*, e0140048.

87. Frezza, V., Pinto-Díez, C., Fernández, G., Soto, M., Martín, M.E., García-Sacristán, A., González, V.M. DNA aptamers targeting *Leishmania infantum* H3 protein as potential diagnostic tools. *Anal. Chim. Acta* **2020**, *1107*, 155–163.

Chapter 26

Carbapenem-Resistant *Enterobacteriaceae* Testing in 45 Minutes Using Oligonucleotide Detection Tags

Neil Gordon, BEng, MBA,^a Raj Bawa, PhD, MD,^{a,b,c} Garry Palmateer, MSc,^a Mehdi Rajabi, PhD,^{a,d} Jesse B. Gordon, PhD,^e Noor M. Kotb, BS,^f Rakshika Balasubramaniam,^g and Benjamin R. Gordon, BSc^h

^aGuanine, Inc., Rensselaer, New York, USA

^bPatent Law Department, Bawa Biotech LLC, Ashburn, Virginia, USA

^cThe Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, New York, USA

^dPolysciences, Inc., Warrington, Pennsylvania, USA

^eDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

^fRangan Lab, Icahn School of Medicine at Mount Sinai, New York, NY, USA

^gTScan Therapeutics, Boston, Massachusetts, USA

^hDepartment of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, Quebec, Canada

neil.gordon@guanineinc.com, bawa@bawabiotech.com

Keywords: 8-oxoguanine, β -lactam antibiotics, amperometry, antibiotic resistance, carbapenemase-producing carbapenem-resistant *Enterobacteriaceae* (CP-CRE), DNA biosensor, electrochemical detection, electrochemistry, guanine, imipenemase (IMP), isolation culture, *Klebsiella pneumoniae* carbapenemase (KPC), New Delhi metallo- β -lactamase (NDM), oligonucleotide detection tags, oxacillinase-48 (OXA-48), point of care (POC), quadruplex, Verona integron-encoded metallo- β -lactamase (VIM)

26.1 Introduction

Antibiotic-resistant bacterial infections are becoming a public health crisis in the United States and worldwide. In the United States alone, antibiotic-resistant bacteria are responsible for at least 2.8 million infections and 35,000 deaths annually [1]. The Centers for Disease Control and Prevention (CDC) has led a series

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

of actions involving education, surveillance, and antibiotic stewardship that have reduced antibiotic-resistant infections and deaths by 18% in communities and 28% in hospitals. The breakdown of infections and deaths is supplied in the CDC report for seven antibiotic-resistant bacteria for 2012 and 2017 and is summarized in Table 26.1. The data show that the CDC actions succeeded in reducing illnesses and deaths across all antibiotic-resistant bacteria, except for *Enterobacteriaceae* such as *Klebsiella pneumoniae* and *Escherichia coli*. Of particular concern are infections caused by carbapenem-resistant *Enterobacteriaceae* (CRE) since carbapenems are considered the drug of last resort with limited new treatments on the horizon [2].

Table 26.1 Changes in infections and deaths from antibiotic resistant bacteria in 2012 and 2017

Antibiotic-resistant bacteria	2012 infections	2017 infections	% Variance	2012 deaths	2017 deaths	% Variance
<i>Enterobacteriaceae</i> increases in infections and deaths						
ESBL-producing <i>Enterobacteriaceae</i>	131,900	197,000	49%	6,300	9,100	44%
Carbapenem-resistant <i>Enterobacteriaceae</i>	11,800	13,100	11%	1,000	1,100	10%
<i>Non-Enterobacteriaceae</i> decreases in infections and deaths						
Methicillin-resistant <i>Staphylococcus aureus</i>	401,000	323,700	-19%	13,600	10,600	-22%
Drug-resistant <i>Candida</i>	44,800	34,800	-22%	2,200	1,700	-23%
Carbapenem-resistant <i>Acinetobacter</i>	11,700	8,500	-27%	1,000	700	-30%
Drug-resistant <i>Neisseria gonorrhoeae</i>	46,000	32,600	-29%	3,900	2,700	-31%
Vancomycin-resistant <i>Enterococcus</i>	84,800	54,500	-36%	8,500	5,400	-36%

Note: Data based on the CDC Report [1].

Abbreviation: ESBL, extended-spectrum beta-lactamases.

Carbapenems are highly effective and are often the only treatment option for severe bacterial infections. Some CREs possess genes that produce carbapenemase enzymes including KPC, New Delhi metallo- β -lactamase (NDM), oxacillinase-48 (OXA-48), Verona integron-encoded metallo- β -lactamase (VIM), and imipenemase (IMP) [3]. These carbapenemase enzymes allow CREs to survive carbapenem treatments by hydrolyzing the carbapenem's β -lactam ring thus deactivating the molecule's antibacterial properties. Some CREs have developed additional resistance mechanisms including redundant β -lactamases, genes conferring resistance to other antimicrobial classes, chromosomal porin mutations that prevent accumulation of β -lactam agents, and over-expression of efflux pumps that

extrude β -lactam agents [4–6]. Carbapenemases are commonly expressed from mobile genetic elements such as plasmids or transposons, which can be acquired and passed on through horizontal gene transfer, making CP-CREs extremely virulent and highly resistant to any therapy.

Timely treatment of CP-CRE infections is critical and is most successful when administered at the early stage of the infection when the bacteria are at a low concentration. A study of over 50,000 patients hospitalized with complicated urinary tract infections, complicated intra-abdominal infection, hospital-associated pneumonias, or bloodstream infections determined that CRE patients whose treatment is delayed by 2 or more days have double the hospital costs and a fourfold increased risk of mortality compared with timely treatment (Table 26.2) [7–9].

Table 26.2 Impact of delayed therapy on CRE infection

Infection	Timely appropriate therapy	Delayed appropriate therapy by 2+ days
Hospital cost/patient		
CRE infection	\$9,875	\$25,506
Non-CRE infection	\$11,539	\$21,828
Risk of mortality or discharge to hospice		
CRE infection	0.9%	3.7%
Hospital stay		
CRE infection	5.1 days	8.5 days

Note: Data based on [7, 8].

Abbreviation: CRE, carbapenem-resistant *Enterobacteriaceae*.

Despite the need for timely treatment of CP-CRE infections, the current turnaround time for detecting CP-CRE, including all approved antimicrobial susceptibility testing (AST) assays for CRE, is 2 to 4 days as noted on Table 26.3. These include broth microdilution, matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry, real-time polymerase chain reaction (RT-PCR), microarray, multidisc mechanism testing, gradient minimum inhibitory concentration (MIC) strip (Etest), and Carba NP. Virtually all CP-CRE detection methods require a time-intensive bacteria culture to isolate and produce a measurable quantity of bacteria for testing as the minimum threshold of detection is well above concentrations found in human samples. CP-CRE detection tests also vary by their availability in clinical labs, accuracy, ease of use, cost, and need for specialized equipment [10–12]. Based on the increasing prevalence of antibiotic-resistant CRE infections [1], the rise of new resistance strains and the lack of new antimicrobials planned for the market, the best defense against antibiotic-resistant CRE would be a rapid, simple, inexpensive, and accurate test that could be used in essentially any healthcare setting.

Table 26.3 Antimicrobial susceptibility testing methods for detecting CP-CRE

CP-CRE detection method	Time from sample to result		
	Isolation culture	Test process	Total
Quadruplex hybridization assay	None	45 min	45 min
Broth microdilution	1–2 days	1–2 days	2–4 days
MALDI-TOF	1–2 days	< 1 day	2–3 days
Real-time PCR	1–2 days	hours	2–3 days
Microarray	1–2 days	< 1 day	2–3 days
Multidisc mechanism testing	1–2 days	2 days	3–4 days
Gradient MIC strip (E-test)	1–2 days	1–2 days	2–4 days
Carba NP	1–2 days	<2 h	2–3 days

Note: Data based on [10–12].

Abbreviations: CP-CRE, carbapenemase-producing carbapenem-resistant *Enterobacteriaceae*; MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight; MIC, minimum inhibitory concentration; PCR, polymerase chain reaction.

26.1.1 Approach

CP-CRE detection was performed using a sandwich hybridization assay. Nucleic acid targets were captured using a magnetic microparticle containing oligonucleotides with guanine detection tags and capture probes complementary to a segment of the target. A second portion of the target hybridizes to a recognition layer of oligonucleotides on a biosensor electrode (Fig. 26.1). A voltammetry technique produces an electrical signal from the redox properties of the detection tags bound to the particle. In order to overcome the poor detection limits currently encountered with nucleic acid biosensors, guanine nucleotides are employed as 20-mer polyguanine oligonucleotide detection tags and millions of detection tags are conjugated to the microparticle to amplify the detection signal. The 20-mer polyguanine oligonucleotides are pre-fabricated into guanine-quadruplexes which generate 8-oxoguanine oxidization signals at ~ 0.47 V for improved signal-to-noise resolution over guanine oxidation signals. The microparticle has a magnetic core which allows the nucleic acid targets and detection tags to be magnetically separated from nonspecific materials that cause false detection signals and degrade the signal-to-noise resolution.

The detection method used in the experiments provides a new paradigm for electrochemical detection of nucleic acids [13–17]. Electrochemical detection is an appealing technique because of its rapid, simple, and inexpensive applications in measuring redox chemicals such as glucose. Electrochemical biosensors for detecting redox nucleotides such as guanine have not attained widespread appeal because of their inability to achieve low detection limits necessary for clinical applications.




Figure 26.1 Quadruplex sandwich hybridization assay components [13, 14] with KPC 16S rRNA sequence used in hybridization assay.

26.2 Materials and Methods

26.2.1 Isolates

Study isolates included three quality control (QC) strains of CP-CRE that are available to clinical laboratories: *Klebsiella pneumoniae* ATCC BAA 1705 (KPC-2), *Klebsiella pneumoniae* ATCC BAA-2814 (KPC-3), and *E. coli* ATCC BAA 2340. Non-carbapenemase-producing *Klebsiella pneumoniae* ATCC 13883 was also evaluated. The study tested 28 samples comprising 22 carbapenemase-producing sample, 4 non-carbapenemase-producing samples, and 2 samples with no bacteria.

Table 26.4 Identification of CP-CRE carbapenemase tested

Bacteria	Carbapenemase	Identification
<i>K. pneumoniae</i>	KPC-2	ATCC BAA-1705
<i>K. pneumoniae</i>	KPC-3	ATCC BAA-2814
<i>E. Coli</i>	KPC	ATCC BAA-2340
<i>K. pneumoniae</i>	None	ATCC 13883

Abbreviations: CP-CRE, carbapenemase-producing carbapenem-resistant *Enterobacteriaceae*; KPC, *Klebsiella pneumoniae* carbapenemase; KPC-2 *Klebsiella pneumoniae* ATCC BAA 1705; KPC-3, *Klebsiella pneumoniae* ATCC BAA-2814.

26.2.2 Probe Design

Detection probes were designed to hybridize with targets associated with the *bla*_{KPC} gene. Suitable targets were identified as the 16S rRNA gene (GenBank: X87276.1) associated with strain ATCC BAA-1705 and corresponding to *bla*_{KPC-2} and with strain ATCC BAA-2814 corresponding to *bla*_{KPC-3} (ATCC, Manassas, VA). As illustrated in Fig. 26.2, nucleotide sequences of ~70 bases were used for capture and recognition. The recognition sequence was selected at the 3' end and the capture sequence was selected a few hundred bases from the 3' end. This configuration produced a larger oxidation signal peak than binding at the 5' end because the quadruplexes were closer to the biosensor. The capture probe also contained a 20-mer polyguanine sequence on the same oligonucleotide (Table 26.5). Polyguanine was transformed into guanine-quadruplexes by heating the oligonucleotides in a sodium acetate-formamide solution.




Figure 26.2 A *K. pneumoniae* 16S rRNA associated with *bla*_{KPC-2} forms a sandwich hybridization assay with a magnetic particle conjugated with a polyguanine capture probes and a biosensor conjugated with a recognition probe.

Table 26.5 Sequences for detecting *bla*_{KPC-2} gene from *K. pneumoniae* 16S rRNA

Target	Sequence ID.	RNA sequence	ssOligo Probe	
KPC-2 16s rRNA (ATCC BAA 1705)	GenBank: X87276.1	GCCGGAACT CAAAGGAGAC TGCCAGTGAT AACTGGAGG AAGGTGGGGA TGACGTCAAG TCATCATGGC	5' Biotin-TTA GGGGGGGGGGGGGGGGGGGG TTATTTTT CGGCCCTGA GTTCCTCTG ACGGTCACTA TTTGACCTCC TTCCACCCT ACTGCAGTTC AGTAGTACCG 3'	Capture
		GGGAGG GCGTTACCA CTTTGTGATT CATGACTGGG GTGAAGTCGT AACAAGGTAA CCGTAGGGGA ACCTGCGGTT GGATCACCTC CTTT	5' Biotin-TT TTT TTT TT AAAG GAGGTGATCC AACCGCAGGT TCCCCTACGG TTACCTTGTT ACGACTTCAC CCCAGTCATG AATCACAAAG TGTAAGCGC CCTCCC 3'	Recognition

Abbreviation: KPC-2 *Klebsiella pneumoniae* ATCC BAA 1705.

The recognition and capture probes are biotinylated. The capture probes were conjugated to streptavidin-coated magnetic microparticles (Bangs Laboratories, Fishers, IN) and the recognition probes were conjugated to unique working electrodes on a 96-well streptavidin-coated carbon biosensor microtiter (DropSens, Llanera, Spain) using streptavidin–biotin interactions.

26.2.3 Filter Concentration and Lysis

Bacteria were prepared in tryptic soy agar medium (Becton, Dickinson (BD), Franklin Lakes, NJ) and serially diluted in broth medium and commercial urine (Sigma-Aldrich, St. Louis, MO) to 10^4 cfu/mL. Samples were concentrated with a 0.45 μm filter (Pall, Port Washington, NY) and re-suspended in biology-grade water and incubated at room temperature for 15 min. The β -lactam antibiotic meropenem was added to the resuspension to assess if meropenem caused a signal increase from the KPC-producing bacteria. Meropenem doses ranged from 0 $\mu\text{g}/\text{mL}$ to 2048 $\mu\text{g}/\text{mL}$. Bacteria were then lysed in 200 μL lysis buffer consisting of 2 M guanidinium thiocyanate (GTC), 80 mM beta-mercaptoethanol (BME), 25 mM sodium citrate, 20 $\mu\text{g}/\text{ml}$ of glycogen (pH 6) with 5 μL dimethyl sulfoxide (1%) then incubated at room temperature (RT) for 5 min.

26.2.4 Magnetic Separation

The solution was mixed for 5 min with 7 μL of 1.5 μm streptavidin-coated magnetic particles conjugated with quadruplex tags and DNA detection probes (Integrated DNA Technologies (IDT), San Jose, CA), then incubated at RT for 10 min. Samples were placed in a magnetic separation microtiter (Epigentek, Farmingdale, NY) and a magnet was applied for 2 min, then the supernatant was discarded. The magnet was removed and the magnetic particle complexes were washed with 100 μL 80 mM sodium acetate (pH 9). The magnetic particle complexes were then re-suspended in sodium acetate and allowed to hybridize for 10 min at RT on a streptavidin-coated carbon working electrode conjugated with capture probes and enable sandwich structures to form as illustrated in Fig. 26.1.

Prior to the experiments, different sized particles were evaluated for their corresponding 8-oxoguanine signals. The 100 nm and 350 nm magnetic particles (Micromod, Rostock, Germany) did not provide measurable 8-oxoguanine oxidation signals and the particles appeared to have decomposed during the test process. The 500 nm, 750 nm and 1.5 μm streptavidin-coated magnetic microparticles (Bangs Laboratories, Fishers, IN) were all successfully able to measure 8-oxoguanine oxidation signals. The 1.5 μm particles generated the strongest signals and were thus used in the experiments.

26.2.5 Amperometric Voltammetry

The biosensor microtiter was connected to a potentiostat (PalmSens). A square wave voltammetry scan produces a peak electrical current at ~ 0.47 V from

8-oxoguanine oxidation in sodium acetate (pH 9) (Fig. 26.3A). A voltammetry scan was made with sodium acetate (pH 9) before the magnetic particle-RNA-biosensor sandwiches were formed to provide a baseline signal. The net 8-oxoguanine oxidation signal was determined to be the difference between the 8-oxoguanine oxidation signal in sodium acetate and sodium acetate signal (Fig. 26.3B).




Figure 26.3 (A) Voltammetry scan of quadruplex 8-oxoguanine oxidation current peak in sodium acetate (pH 9) with a peak current signal at ~ 0.47 V and the background signal from sodium acetate (pH 9) on the same sensor before the sandwiches were formed, and (B) the net signal calculated from the difference of the two scans in A.

The assay was initially developed with the 96-well carbon microtiter sensors and was coated in the lab with streptavidin. Each sensor was evaluated for a baseline signal with 80 mM sodium acetate (pH 9) to ensure proper sensor functionality. The 8-oxoguanine oxidation signal generated for the same sample varied by 2–10% between sensors. When the development work switched to

microtiter sensors pre-coated with streptavidin, the variability increased by up to 40%. Variability was reduced by subtracting the baseline sodium acetate buffer signal measured prior to hybridization, from the 8-oxoguanine oxidation signal measured on the same sensor. This reduced the same sample variation to 3–16% between sensors. The pre-coated microtiter sensor displayed a new peak at 0.15 V, which did not occur when streptavidin was coated in the lab. This new peak was likely due to oxidation from residual chemicals from the streptavidin coating process employed by DropSens. It was observed that the 0.15 V peak varied in amplitude on different sensors and in some cases 10 or more baseline scans were needed to remove the 0.15 V peak before the sensor could be used for hybridization.

Square wave voltammetry (SWV) scan parameters were optimized for 8-oxoguanine in advance of the KPC experiments by adsorbing quadruplex oligonucleotides on the sensor surface and applying SWV scans. Variations of SWV settings were evaluated to find the setting that produced the greatest 8-oxoguanine oxidation signal peak. This setting was then used for KPC assay development.

26.3 Results

Twenty-eight samples were tested for the presence of KPC enzymes from CP-CRE and non-CP-CRE. The results are summarized in Table 26.6. All 22 samples containing CP-CRE generated a positive signal which was greater than the 0.2 μA background baseline. Of the 6 samples containing the susceptible *K. pneumoniae* or no bacteria, 5 reported true negative with the signal below the threshold. The normalized 8-oxoguanine oxidation signal peak at ~ 0.47 V was used to detect the presence of carbapenemase KPC enzymes as illustrated in Fig. 26.4. One false positive occurred with a non-KPC-producing *K. pneumoniae* and was likely caused by poor sensor calibration.

The magnitude of the KPC signal was measured for each CP-CRE species. As shown in Table 26.7, all three species reported an average signal greater than the threshold but with different average signal magnitudes: 1.2 μA for the KPC-2 species, 1.1 μA for the KPC-3 species, and 0.4 μA for the *E. coli* KPC species. The strain that did not produce KPC had an average signal of 0.1 μA , which was below the threshold detection value. The magnitude of the KPC signal was also measured for samples resuspended in meropenem for the ATCC BAA 1705 (KPC-2) and ATCC BAA-2814 (KPC-3) species. High dose exposure between 512 $\mu\text{g/mL}$ and 2048 $\mu\text{g/mL}$ meropenem produced an average signal of 1.2 μA , while low dose exposure between 0 $\mu\text{g/mL}$ and 128 $\mu\text{g/mL}$ (Table 26.8) meropenem produced an average signal of 1.1 μA . Based on the test results, there appeared to be no relationship between meropenem exposure and the KPC signal. Testing with bacteria samples in broth and urine provided near identical results suggesting that filtered urine followed by magnetic separation had no impact on hybridization or 8-oxoguanine oxidation signal generation.




Figure 26.4 Voltammetry scan of quadruplex 8-oxoguanine oxidation signal from KPC-producing and non-KPC-producing *K. pneumoniae* after baseline scan subtraction.

Table 26.6 Summary of samples tested for KPC

	True outcome	False outcome	
Positive test prediction	22	1	PPV = 22/23
Negative test prediction	0	5	NPV = 5/5
	Sen. = 22/22	Spec. = 5/6	

Abbreviation: KPC, *Klebsiella pneumoniae* carbapenemase.

Table 26.7 KPC signal amplitude by CP-CRE species

CP-CRE species	Average signal
ATCC BAA 1705 (KPC-2) (8)	1.2 µA
ATCC BAA-2814 (KPC-3) (12)	1.1 µA
ATCC BAA-2340 (<i>E. coli</i> KPC) (2)	0.4 µA
ATCC 13883 (Non-KPC) (4)	0.1 µA
No Bacteria (2)	0.1 µA

Abbreviations: CP-CRE, carbapenemase-producing carbapenem-resistant *Enterobacteriaceae*; KPC, *Klebsiella pneumoniae* carbapenemase.

Table 26.8 KPC signal amplitude by meropenem dose

Meropenem dose	Average signal
512–2048 µg/mL Meropenem (13)	1.2 µA
0–128 µg/mL Meropenem (7)	1.1 µA

Abbreviation: KPC, *Klebsiella pneumoniae* carbapenemase.

26.4 Discussion

The 2014 US National Strategy for Combating Antibiotic-Resistant Bacteria [18] identified a critical goal for improved diagnostics to detect antibiotic resistance profiles in 30 min or less for 18 bacteria of highest concern. This was intended to allow physicians to make optimal treatment decisions, and help public health officials prevent the transmission of disease and slow the development of resistance. Despite this goal most effective antibiotic-resistant diagnostic tests still take several days from specimen collection to results and can be extended by days or weeks if cultures are required. As a consequence treatment decisions are typically made before laboratory results are available. Patients may be initially treated with antibiotics when none are needed, prescribed an inappropriate antibiotic, or treated with multiple antibiotics when a single antibiotic would have been effective [18].

The objective of this study was to detect carbapenem-resistant *Enterobacteriaceae* directly from a sample without using a culture. The approach employed a modified lateral flow test protocol that captured nucleic acid targets from a KPC RNA sequence and formed a hybridization sandwich structure on a biosensor electrode. The novelty of the approach was to replace optical labels with a microparticle conjugated with millions of electrical quadruplex tags. The study investigated if rapid direct detection of KPC using quadruplex tags was able to produce sufficient sensitivity and specificity and avoid the need for a time-intensive culture.

The study demonstrated that three different CP-CRE bacteria tested positive in all 22 samples, and non CP-CRE samples tested negative in 5 of 6 samples. This study was the first use of quadruplex tags in a hybridization assay and as a consequence significant effort was spent optimizing the assay which prevented more samples from being tested.

Hybridization time and additional process steps for filtration, meropenem incubation, lysing and magnetic separation extended the test time to 45 min. Meropenem incubation was found to have no impact on carbapenemase production and could be removed from the protocol. The assay did not employ PCR so hybridization components were not limited in length to 20 mer sequences. It was found that probes with 70 mer sequences substantially reduced hybridization time and improved detection accuracy over shorter sequences.

The study employed bacteria concentrations of 10^4 cfu/mL. A further reduction in detection limit would be needed for clinical use. Lower concentration

samples containing 100 cfu/mL were successfully detected but not included in the study results. Further work will increase the magnetic particle size beyond 1.5 μm diameter. A larger microparticle will deliver more quadruplex tags per KPC RNA complex and provide a measurable signal at lower concentrations. Further work will also employ a sample volume greater than 1 mL. Filter concentrating a larger sample volume will capture more bacteria for detection and achieve lower detection limits.

The study was limited to KPC and did not evaluate other carbapenemase enzymes. One of the advantages of electrochemical detection is the ability to detect a number of unique analytes from the same sample using multiple working electrodes. A commercial example is the Abbott i-STAT. Future work will detect KPC, NDM, OXA-48, VIM and IMP separately on individual electrodes to indicate which carbapenemase is present.

The quadruplex CP-CRE assay is intended to be used in a point-of-care cartridge without requiring the sample to be prepared with a culture. A culture-free CP-CRE test will allow appropriate treatment to be provided days earlier than with current tests. Not only will this improve patient outcomes, but the associated healthcare costs can be reduced. A POC test will provide the opportunity to fast track testing for CP-CREs by identifying patients who are at high risk of encountering a CP-CRE infection. A POC test can also be administered at a physician's office.

Another unmet need is rapid culture-free testing of extended-spectrum beta-lactamases (ESBL)-producing *Enterobacteriaceae*. ESBL-producing *Enterobacteriaceae* have over 10 times higher incidences than carbapenemase-producing *Enterobacteriaceae*, and incurred a 49% increase in infections and 44% increase in deaths *between 2012 and 2017*. A culture-free ESBL-producing *Enterobacteriaceae* test can complement the CP-CRE test to determine if carbapenem or ESBL treatment is more appropriate.

The study encountered some limitations which will be addressed in further development activities. The assay was tested with spiked broth and urine samples instead of patient specimens. Future work will test a wider range of KPC strains and CP-CRE organisms from actual patient specimens.

26.5 Conclusion

The study demonstrated that KPC from CP-CRE is accurately detected using quadruplex tags in 45 min without bacteria isolation, culture, or PCR. While the experiments were done with 10^4 cfu/mL spikes, high sensitivity and specificity will be required at lower detection limits for clinical use. All process steps are conducted at room temperature which will enable the test to be conducted in a point-of-care cartridge with a portable potentiostat.

The study also demonstrated that signal amplification using quadruplex tags could be an alternative to PCR and cultures for detecting bacteria and viruses since it is faster, easier, and less expensive to attach millions of tags than to replicate millions of copies.

The core components of the quadruplex detection approach are mostly generic. A new assay can be rapidly adapted to detect a nucleic acid target from a genome sequence of a RNA, DNA, or gene. Sensor electrodes and magnetic microparticle conjugates can be customized for new targets by conjugating the required probes. This allows a baseline assay to be rapidly developed and subsequently optimized for the required sample type and assay performance. Protein targets can use aptamers or antibodies in a sandwich immunoassay along with the quadruplex tags on the magnetic particle conjugates.

Many applications can benefit by detecting nucleic acid targets with quadruplex hybridization assays at the POC or in a resource-limited setting where PCR equipment, laboratory, and skilled operators are not available. Quadruplex hybridization assays conducted at the POC can avoid false-negative test outcomes caused by nucleic acid degradation from transporting samples to a laboratory, and from freezing and thawing processes when temporarily stored before sample preparation. Quadruplex tags with magnetic separation can also reduce the incidence of false-positive test outcomes by avoiding complex sample process steps and removing materials that interfere with detection.

Another limitation of nucleic acid amplification tests, including PCR, is the inability for the test to distinguish viable organisms from dead organisms. Pathogenic nucleic acids can remain in the body for weeks after the organisms are dead and produce a positive test outcome. This can incorrectly indicate that the patient requires treatment, can infect others or needs to be quarantined. In many cases a culture is the recommended test to determine if microorganisms are viable. However cultures can take several days or weeks for microorganisms to be isolated and cultured to produce a measurable optical signal or color change. The quadruplex test is quantitative and generates an electrical signal that is proportional to the number of analytes in the sample. A portion of the sample can undergo a rapid test to determine if the target microorganism is present. A new sample can be measured at a later time or a second portion of the original sample can be incubated at an elevated temperature with nutrients to allow a few reproduction cycles to produce a higher signal than the initial test if the target microorganisms are viable. Because of the sensitivity of the tags, as few as 4–6 reproduction cycles could be needed which is a fraction of the time of a traditional culture using insensitive dye or optical labels.

Abbreviations

AST:	antimicrobial susceptibility testing
BME:	beta-mercaptoethanol
BSL3:	Biosafety Level 3
CDC:	Centers for Disease Control and Prevention
CLIA:	Clinical Laboratory Improvement Amendments
COVID-19:	Coronavirus disease 2019
CP-CRE:	carbapenemase-producing carbapenem-resistant <i>Enterobacteriaceae</i>
CRE:	Carbapenem-resistant <i>Enterobacteriaceae</i>

ESBL:	extended-spectrum beta-lactamases
GTC:	guanidinium thiocyanate
IMP:	imipenemase
KPC:	<i>Klebsiella pneumoniae</i> carbapenemase
KPC-2:	<i>Klebsiella pneumoniae</i> ATCC BAA 1705
KPC-3:	<i>Klebsiella pneumoniae</i> ATCC BAA-2814
MALDI-TOF:	matrix-assisted laser desorption/ionization-time of flight mass spectrometry
MIC:	minimum inhibitory concentration
NDM:	New Delhi metallo- β -lactamase
OXA-48:	oxacillinase-48
PCR:	polymerase chain reaction
POC:	point of care
QC:	quality control
RT:	room temperature
RT-PCR:	real-time polymerase chain reaction
SWV:	square wave voltammetry
VIM:	Verona integron-encoded metallo- β -lactamase

Disclosures and Conflict of Interest

Funding for this research was provided by the Centers for Disease Control and Prevention as SBIR 1R43CK000522-01. Neil Gordon is the founder and president of Guanine, Inc., and has a financial interest in the company. Raj Bawa, PhD, MD, is vice president and chief IP officer of Guanine, Inc., and also serves as scientific advisor to Teva Pharmaceutical Industries, Ltd., Israel. No writing assistance was utilized in the production of this chapter.

References

1. Centers for Disease Control and Prevention (2019). Antibiotic resistance threats in the United States. Available at: <https://www.cdc.gov/drugresistance/biggest-threats.html> (accessed on November 13, 2022).
2. Nordmann, P., Girlich, D., Poirel, L. (2012). Detection of carbapenemase producers in *Enterobacteriaceae* by use of a novel screening medium. *J. Clin. Microbiol.*, **50**, 2761–2766.
3. Bush, K., Jacoby, G.A. (2010). Updated functional classification of β -lactamases. *Antimicrob. Agents Chemother.*, **54**, 969–976.
4. Santajit, S., Indrawattana, N. (2016). Mechanisms of antimicrobial resistance in ESKAPE pathogens. *BioMed. Res. Intl.*, **2016**, art. 2475067.
5. Munita, J.M., Arias, C.A. (2016). Mechanisms of antibiotic resistance. *Microbiol Spectr.*, **4**(2), doi:10.1128/microbiolspec.VMBF-0016-2015.
6. Paczoca, M., Mecsas, J. (2016). *Klebsiella pneumoniae*: Going on the offense with a strong defense. *Microbiol. Mol. Biol. Rev.*, **80**, 629–661.

7. Infectious Disease News October 06, 2017, ID Week (2017). Delayed appropriate therapy more harmful than CRE diagnosis. Available at: <https://www.healio.com/news/infectious-disease/20171006/delayed-appropriate-therapy-more-harmful-than-cre-diagnosis> (accessed on November 13, 2022).
8. Lodise, T.P., Zhao, Q., Fahrbach, K., Gillard, P.J., Martin, A. (2018). A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to *Klebsiella pneumoniae* or *Escherichia coli*: How long is too long?. *BMC Infect. Dis.*, **18**, 625. <https://doi.org/10.1186/s12879-018-3524-8>.
9. Buehler, S.S., Madison, B., Snyder, S.R., Derzon, J.H., Cornish, N.E., Saubolle, M.A., Weissfeld, A.S., Weinstein, M.P., Liebow, E.B., Wolk, D.M. (2016). Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: A laboratory medicine best practices systematic review and meta-analysis. *Clin. Microbiol. Rev.*, **29**, 59–103.
10. Lutgring, J., Limbago, B. (2016). The problem of carbapenemase-producing-carbapenem-resistant-*Enterobacteriaceae* Detection. *J. Clin. Microbiol.*, **54**, 529–534.
11. AbdelGhani, S., Thomson, G.K., Snyder, J.W., Thomson, K.S. (2015). Comparison of the Carba NP, modified Carba NP, and updated Rosco Neo-Rapid Carb kit tests for carbapenemase detection. *J. Clin. Microbiol.*, **53**, 3539–3542.
12. Croxatto, A., Coste, A.T., Pillonel, T., Bertelli, C., Greub, G., Prod'hom, G. (2019). Evaluation of the BD Phoenix™ CPO Detect Test for the detection of carbapenemase producers. *Clin. Microbiol. Infect.*, **26**, 644.e9–644.e15.
13. Gordon, N. (2021). Bioanalyte signal amplification and detection with artificial intelligence diagnosis. United States Patent and Trademark Office, US 11,105,801 B2 (patent issued on August 31, 2022).
14. Gordon, N. (2018). Ultra-sensitive bioanalyte quantification from self-assembled quadruplex tags. United States Patent & Trademark Office, US 2018/0106791 A1 (patent application published on April 19, 2018).
15. Gordon, N. (2017). Ultra-sensitive detection of extremely low level biological analytes using electrochemical signal amplification and biosensor. United States Patent and Trademark Office, US 9,624,532 B2 (patent issued on April 18, 2017).
16. Jayamohan, H. Gale, B.K., Minson, B.J., Lambert, C.J., Gordon, N., Sant, H.J. (2015). Highly sensitive bacteria quantification using immunomagnetic separation and electrochemical detection of guanine-labeled secondary beads. *Sensors*, **15**, 12034–12052.
17. Drummond, T.G., Hill, M.G., Barton, J.K. (2003). Electrochemical DNA sensors. *Nature Biotech.*, **21**, 1192–1199.
18. The White House (2014). National strategy for combating antibiotic resistant bacteria. Available at: https://obamawhitehouse.archives.gov/sites/default/files/docs/carb_national_strategy.pdf (accessed on November 13, 2022).
19. Kitchel, B., Rasheed, J.K., Patel, J.B., et al. (2009). Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: Clonal expansion of multilocus sequence type 258. *Antimicrob. Agents Chemother.*, **53**, 3365–3370.
20. Mulroney, K.T., et al. (2017). Rapid susceptibility profiling of carbapenem-resistant *Klebsiella pneumoniae*. *Sci. Rep.*, **7**(1), 1903.

21. National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion (2015). Facility guidance for control of carbapenem-resistant *Enterobacteriaceae* (CRE) November 2015 update—CRE Toolkit, CS261687-A.
22. Victoria, A., Parker, V.A., Logan, C.K., Currie, B. (2014). Carbapenem-Resistant *Enterobacteriaceae* (CRE) Control and Prevention Toolkit, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, AHRQ Publication No. 14-0028-EF.
23. Centers for Disease Control and Prevention (CDC) (2009). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing *Enterobacteriaceae* in acute care facilities. *Morb. Mortal. Wkly. Rep.*, **58**, 256–260.
24. Lee, J., Patel, G., Huprikar, S., et al. (2009). Decreased susceptibility to polymyxin B during treatment of carbapenem-resistant *Klebsiella pneumoniae* infection. *J. Clin. Microbiol.*, **47**, 1611–1612.
25. Gupta, N., Limbago, B.M., Patel, J.B., et al. (2011). Carbapenem-resistant *Enterobacteriaceae*: Epidemiology and prevention. *Clin. Infect. Dis.*, **53**, 60–67.
26. Bratu, S., Mooty, M., Nichani, S., et al. (2005). Emergence of KPC-possessing *Klebsiella pneumoniae* in Brooklyn, New York: Epidemiology and recommendations for detection. *Antimicrob. Agents Chemother.*, **49**, 3018–3020.
27. Morrill, H.J., Pogue, J.M., Kaye, K.S., LaPlante, K.L. (2015). Treatment options for carbapenem-resistant Enterobacteriaceae infections. *Open Forum Infect. Dis.*, **2**(2), ofv050.
28. Won, S.Y., Munoz-Price, L.S., Lolans, K., et al. (2011). Emergence and rapid regional spread of *Klebsiella pneumoniae* carbapenemase-producing Enterobacteriaceae. *Clin. Infect. Dis.*, **53**, 532–540.
29. Arnold, R.S., Thom, K.A., Sharma, S., Phillips, M., (2012). Emergence of *Klebsiella pneumoniae* carbapenemase (KPC)-producing bacteria. *South Med. J.*, **104**, 40–45.
30. Yigit, H., Queenan, A.M., Anderson, G.J., et al. (2001). Novel carbapenem-hydrolyzing beta-lactamase KPC-1 from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.*, **45**, 1151–1161.

Chapter 27

Ultrasonography of the Kidney: A Pictorial Review

**Kristoffer Linkdskov Hansen, MD, PhD, Michael Bachmann Nielsen, MD, PhD,
and Caroline Ewertsen, MD, PhD**

Department of Radiology, Copenhagen University Hospital, Copenhagen, Denmark

lindskov@gmail.com

Keywords: acceleration time (AoAT), acute renal injury, adenocarcinoma, advanced polycystic kidney disease, angiomyofibroma, Bosniak classification, chronic kidney disease (CKD), contrast-enhanced computed tomography (CECT), contrast-enhanced ultrasound (CEUS), cortical thickness, cysts, diastolic velocity (Vd), Doppler examination, Doppler US, echogenic, elastography, glomerular sclerosis, heteroechoic, hydronephrosis, hyperechoic, hypoechoic, interstitial fibrosis, kidney disease, lymphoma, magnetic resonance imaging (MRI), oncocytoma, parenchymal thickness, pyonephrosis, renal anatomy, renal calculi, renal cell carcinoma (RCC), resistive index (RI), squamous cell carcinoma, systolic acceleration (Ao Accel), systolic velocity (Vs), transitional cell carcinoma, tuberous sclerosis, tubular atrophy, ultrasonography, ultrasound (US), ultrasound-guided interventions, urinary obstruction, urolithiasis, ultrasound-guided biopsy, vesicoureteric reflux, von Hippel-Lindau disease

27.1 Introduction

Renal ultrasound (US) is a common examination, which has been performed for decades [1]. Using B-mode imaging, assessment of renal anatomy is easily performed, and US is often used as image guidance for renal interventions. Furthermore, novel applications in renal US have been introduced with contrast-enhanced ultrasound (CEUS), elastography and fusion imaging. In this pictorial review, we will highlight the most common findings in renal US.

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

27.2 Examination Technique

The ultrasonic renal exam does not require any preparation of the patient and is usually performed with the patient in the supine position. The kidneys are examined in longitudinal and transverse scan planes with the transducer placed in the flanks. When insonation of the kidney is obscured by intestinal air, the supine scan position is combined with the lateral decubitus position with the transducer moved dorsally. Preferably, the exam is initiated in the longitudinal scan plane, parallel to the long diameter of the kidney, as the kidney is easier to distinguish [2].

In the adult patient, a curved array transducer with center frequencies of 3–6 MHz is used, while the pediatric patient should be examined with a linear array transducer with higher center frequencies. Artifacts of the lowest ribs always shadow the upper poles of the kidneys. However, the whole kidney can be examined during either normal respiration or breath hold, as the kidney will follow the diaphragm and change position accordingly [2].

27.3 Findings in the Normal Kidney

In the longitudinal scan plane, the kidney has the characteristic oval bean-shape. The right kidney is often found more caudally and is slimmer than the left kidney, which may have a so-called dromedary hump due to its proximity to the spleen [3]. The kidney is surrounded by a capsule separating the kidney from the echogenic perirenal fat, which is seen as a thin linear structure [3].

The kidney is divided into parenchyma and renal sinus. The renal sinus is hyperechoic and is composed of calyces, the renal pelvis, fat and the major intrarenal vessels. In the normal kidney, the urinary collecting system in the renal sinus is not visible, but it creates a heteroechoic appearance with the interposed fat and vessels. The parenchyma is more hypoechoic and homogenous and is divided into the outermost cortex and the innermost and slightly less echogenic medullary pyramids [3]. Between the pyramids are the cortical infoldings, called columns of Bertin (Fig. 27.1). In the pediatric patient, it is easier to differentiate the hypoechoic medullary pyramids from the more echogenic peripheral zone of the cortex in the parenchyma rim, as well as the columns of Bertin (Fig. 27.2) [2, 4].

The length of the adult kidney is normally 10–12 cm, and the right kidney is often slightly longer than the left kidney [3, 5]. The adult kidney size is variable due to the correlation with body height and age [3–7]; however, normograms for pediatric kidney size are available [7–9].

Cortical thickness should be estimated from the base of the pyramid and is generally 7–10 mm. If the pyramids are difficult to differentiate, the parenchymal thickness can be measured instead and should be 15–20 mm (Fig. 27.3) [6]. The echogenicity of the cortex decreases with age and is less echogenic than or equal to the liver and spleen at the same depth in individuals older than six months [3]. In neonates and children up to six months of age, the cortex is more echogenic than the liver and spleen when compared at the same depth [10].



Figure 27.1 Normal adult kidney. Measurement of kidney length on the US image is illustrated by '+' and a dashed line. * Column of Bertin; ** pyramid; *** cortex; **** sinus.




Figure 27.2 Normal pediatric kidney. * Column of Bertin; ** pyramid; *** cortex; **** sinus.

Doppler examination of the kidney is widely used, and the vessels are easily depicted by the color Doppler technique in order to evaluate perfusion. Applying spectral Doppler to the renal artery and selected interlobular arteries, peak systolic velocities, resistive index and acceleration curves can be estimated (Fig. 27.4) [11], e.g., peak systolic velocity of the renal artery above 180 cm/s is a predictor of renal artery stenosis of more than 60%, and the resistive index, which is a calculated from peak systolic and end systolic velocity, above 0.70 is indicative of abnormal renovascular resistance [7].




Figure 27.3 Measures of the kidney. L = length. P = parenchymal thickness. C = cortical thickness.




Figure 27.4 Doppler ultrasound (US) of a normal adult kidney with the estimation of the systolic velocity (Vs), the diastolic velocity (Vd), acceleration time (AoAT), systolic acceleration (Ao Accel) and resistive index (RI). Red and blue colors in the color box represent flow towards and away from the transducer, respectively. The spectrogram below the B-mode image shows flow velocity (m/s) against time (s) obtained within the range gate. The small flash icons on the spectrogram represent initiation of the flow measurement.

27.4 Cystic Renal Masses

Masses are seen as a distortion of the normal renal architecture. Most renal masses are simple cortical cysts with a round appearance and a smooth thin capsule encompassing anechoic fluid. The incidence increases with age, as at least 50% of people above the age of 50 have a simple cyst in one of the kidneys [12]. Cysts cause posterior enhancement as a consequence of reduced attenuation of the ultrasound within the cyst fluid (Fig. 27.5). The simple cyst is a benign lesion, which does not require further evaluation [13].



Figure 27.5 Simple cyst with posterior enhancement in an adult kidney. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.

Complex cysts can have membranes dividing the fluid-filled center with internal echoes, calcifications or irregular thickened walls. The complex cyst can be further evaluated with Doppler US, and for Bosniak classification and follow-up of complex cysts, either contrast-enhanced ultrasound (CEUS) or contrast-enhanced computed tomography (CECT) are used (Fig. 27.6) [14, 15]. The Bosniak classification is divided into four groups going from I, corresponding to a simple cyst, to IV, corresponding to a cyst with solid parts and an 85–100% risk of malignancy [13, 16].

In polycystic kidney disease, multiple cysts of varying size in close contact with each other are seen filling virtually the entire renal region. In advanced stages of this disease, the kidneys are enlarged with a lack of corticomedullary differentiation (Fig. 27.7) [17].




Figure 27.6 Complex cyst with thickened walls and membranes in the lower pole of an adult kidney. Measurements of kidney length and the complex cyst on the US image are illustrated by '+' and dashed lines.



Figure 27.7 Advanced polycystic kidney disease with multiple cysts.

27.5 Solid Renal Masses

A solid renal mass appears in the US exam with internal echoes, without the well-defined, smooth walls seen in cysts, often with Doppler signal, and is frequently malignant or has a high malignant potential [4]. The most common malignant renal parenchymal tumor is renal cell carcinoma (RCC), which accounts for 86% of the malignancies in the kidney [2]. RCCs are typically isoechoic and peripherally located in the parenchyma but can be both hypo- and hyper-echoic and are found centrally in medulla or sinus. The lesions can be multifocal and have cystic elements due to necrosis, calcifications and be multifocal (Fig. 27.8 and Fig. 27.9) [2]. RCC is associated with von Hippel–Lindau disease, and with tuberous sclerosis, and US has been recommended as a tool for assessment and follow-up of renal masses in these patients [18].



Figure 27.8 Cortical solid mass, which later was shown to be renal cell carcinoma. Measurement of the solid mass on the US image is illustrated by '+' and a dashed line.

However, US is not the primary modality for the evaluation of solid tumors in the kidney, and CT is the first choice modality [19]. Nevertheless, hemorrhagic cysts can resemble RCC on CT, but they are easily distinguished with US using Doppler [19]. In RCCs, Doppler US often shows vessels with high velocities caused by neovascularization and arteriovenous shunting.

Some RCCs are hypovascular and not distinguishable with Doppler US. Therefore, renal tumors without a Doppler signal, which are not obvious simple cysts on US and CT, should be further investigated with CEUS, as CEUS is more sensitive than both Doppler US and CT for the detection of hypovascular tumors [20].



Figure 27.9 Renal cell carcinoma with both cystic and solid components located in the cortex. Measurement of tumor on the US image is illustrated by '+' and a dashed line.




Figure 27.10 Solid tumor in the renal sinus seen as a hypoechoic mass, later found to be lymphoma. The '1' and '2' on the US image are reference points used for CT fusion (not shown).

Other malignant tumors in the kidney are transitional cell carcinoma and squamous cell carcinoma, which arise from the urothelium and are found the

renal sinus, as well as adenocarcinoma, lymphoma and metastases, which can be found anywhere in the kidney (Fig. 27.10) [2, 4].

Benign solid tumors of the kidney are oncocytoma and angiomyofibroma. Oncocytoma has a varying ultrasonic appearance but may have a central scar or calcification as a hallmark [21]. Angiomyofibroma are often found in patients with tuberous sclerosis. They are composed of fat, smooth muscle tissue and vascular elements. The echogenicity is governed by the composition of these elements, but the lesion is often hyperechoic (Fig. 27.11 and Fig. 27.12) [22].



Figure 27.11 Angiomyolipoma seen as a hyperechoic mass in the upper pole of an adult kidney.



Figure 27.12 Patient with tuberous sclerosis and multiple angiomyolipomas in the kidney. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.

Benign tumors are difficult to separate from malignant tumors using US. Thus, solid renal masses found on US are difficult to classify and should be further evaluated with CT. In special cases of cystic or solid renal masses, additional ultrasound-guided biopsy or drainage is performed to identify the histologic tumor type before a decision on surgery is made [23].

27.6 Hydronephrosis

One of the primary indications for referral to US evaluation of the kidneys is evaluation of the urinary collecting system [4]. Enlargement of the urinary collecting system is usually related to urinary obstruction and can include the pelvis, the calyces and the ureter. Hydronephrosis is seen as an anechoic fluid-filled interconnected space with enhancement within the renal sinus, and normally, the dilated pelvis can be differentiated from the dilated calyces.

Several conditions can result in urinary obstruction. In both adults and children, masses, such as abscesses and tumors, can compress the ureter. In children, hydronephrosis can be caused by ureteropelvic junction obstruction, ectopic inserted ureter, primary megaureter and posterior urethral valve (Fig. 27.13). In the latter, both kidneys will be affected. In adults, hydronephrosis can be caused by urolithiasis, obstructing the outlet of the renal pelvis or the ureter, and compression of the ureter from, e.g., pregnancy and retroperitoneal fibrosis [24]. Urolithiasis is the most common cause of hydronephrosis in the adult patient and has a prevalence of 10–15% [25].



Figure 27.13 Hydronephrosis due to ureteropelvic junction obstruction in a pediatric patient.

Under normal conditions, the ureter is not seen with US. However, in, e.g., urinary obstruction and vesicoureteric reflux with dilation of the ureter, the proximal part in continuation with the renal pelvis, as well as the distal part near the ostium can be evaluated (Fig. 27.14).



Figure 27.14 Bilateral dilatation of the ureters due to vesicoureteric reflux in a pediatric patient.

The hydronephrosis is typically graded visually and can be divided into five categories going from a slight expansion of the renal pelvis to end-stage hydronephrosis with cortical thinning (Fig. 27.15) [16]. The evaluation of hydronephrosis can also include measures of calyces at the level of the neck in the longitudinal scan plane, of the dilated renal pelvis in the transverse scan plane and the cortical thickness, as explained previously (Fig. 27.16 and Fig. 27.17) [4].




Figure 27.15 End-stage hydronephrosis with cortical thinning. Measurement of pelvic dilatation on the US image is illustrated by '+' and a dashed line.



Figure 27.16 Hydronephrosis with dilated anechoic pelvis and calyces, along with cortical atrophy. The width of a calyx is measured on the US image in the longitudinal scan plane and illustrated by '+' and a dashed line.



Figure 27.17 Same patient as in Fig. 27.16 with measurement of the pelvis dilation in the transverse scan plane illustrated on the US image with '+' and a dashed line.

If the fluid in the dilated collecting system has echoes, pyonephrosis should be excluded by clinical exam, blood analysis and, in special cases, puncture or drainage. Hydronephrosis can also be caused by non-obstructive conditions,

such as brisk diuresis in patients treated with diuretics, in pregnant women and in children with vesicoureteral reflux [24].

27.7 Renal Calculi

Even though US has a lower sensitivity and specificity than CT for the detection of urolithiasis, US, if available, is recommended as the initial imaging modality in patients with renal colic and suspected urolithiasis [26, 27]. US has no risk of radiation, is reproducible and inexpensive, and the outcome is not significantly different for patients with suspected urolithiasis undergoing initial US exam compared to patients undergoing initial CT exam [26, 28].

With US, larger stones (>5–7 mm) within the kidney, i.e., in the calyces, the pelvis and the pyeloureteric junction, can be differentiated, especially in the cases with accompanying hydronephrosis (Fig. 27.18 and Fig. 27.19) [26, 29]. Hyperechoic stones are seen with accompanying posterior shadowing. Additional twinkling artifacts below the stone can often be seen using Doppler US [30]. Large stones filling the entire collecting system are called coral stones or staghorn calculi and are easily visualized with US (Fig. 27.20). Stones in the ureters are usually not visualized with US due to the air-filled intestines obscuring the insonation window. However, ureteral stones near the ostium can be visualized with a scan position over the bladder. An exam of the ureteric orifices and the excretion of urine to the bladder can be performed by inspecting the ureteric jets in the bladder with color Doppler US (Fig. 27.21) [4, 24].



Figure 27.18 Renal stone located at the pyeloureteric junction with accompanying hydronephrosis.




Figure 27.19 Centrally located stone with posterior shadowing. No hydronephrosis is present. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.



Figure 27.20 Staghorn calculi filling the entire collecting system and creating pronounced shadowing.




Figure 27.21 Left hydronephrotic ureter with ureteric jet. No stone is visible. The red color in the color box represents motion towards the transducer as defined by the color bar.

27.8 Chronic Kidney Disease (CKD)

US is useful for diagnostic and prognostic purposes in chronic kidney disease. Whether the underlying pathologic change is glomerular sclerosis, tubular atrophy, interstitial fibrosis or inflammation, the result is often increased echogenicity of the cortex. The echogenicity of the kidney should be related to the echogenicity of either the liver or the spleen (Fig. 27.22 and Fig. 27.23) [2].



Figure 27.22 Chronic renal disease caused by glomerulonephritis with increased echogenicity and reduced cortical thickness. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.

Moreover, decreased renal size and cortical thinning are also often seen and especially when disease progresses (Fig. 27.24 and Fig. 27.25). However, kidney size correlates to height, and short persons tend to have small kidneys; thus, kidney size as the only parameter is not reliable [2].



Figure 27.23 Nephrotic syndrome. Hyperechoic kidney without demarcation of cortex and medulla.




Figure 27.24 Chronic pyelonephritis with reduced kidney size and focal cortical thinning. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.




Figure 27.25 End-stage chronic kidney disease with increased echogenicity, homogenous architecture without visible differentiation between parenchyma and renal sinus and reduced kidney size. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.

27.9 Acute Renal Injury

The acute changes in the kidney are often examined with US as the first-line modality, where CT and magnetic resonance imaging (MRI) are used for the follow-up examinations and when US fails to demonstrate abnormalities [31].




Figure 27.26 Acute pyelonephritis with increased cortical echogenicity and blurred delineation of the upper pole.



Figure 27.27 Postoperative renal failure with increased cortical echogenicity and kidney size. Biopsy showed acute tubular necrosis.



Figure 27.28 Renal trauma with laceration of the lower pole and subcapsular fluid collection below the kidney.

27.10 US-Guided Intervention

Sonography is the modality of choice for guidance when performing intervention in the kidney, whether it is kidney biopsy, percutaneous nephrostomy or abscess drainage. Historically, thermal ablation of renal tumors is performed under CT guidance, as the risk of injuring neighboring intestines during the US-guided procedure was considered too high due to poor identification of the moving

bowels [4, 23]. However, recent guidelines for renal interventional US include radiofrequency, microwave and cryoablation with US as the ideal imaging guide [33, 34].

For percutaneous nephrostomy and abscess drainage, either the one-step or the Seldinger technique is used. Using the Seldinger technique, the cavity is punctured with a sharp hollow needle, called a trocar. A round-tipped guidewire is then advanced through the lumen of the trocar, and after withdrawal of the trocar, a catheter or nephrostomy can be inserted over the guidewire to ensure correct placement. The one-step technique is when insertion of the drain or nephrostomy is done without the aid of a guidewire [4]. The interventions are performed under local anesthesia and in a sterile setup. The procedures can be carried out with or without needle guidance according to preference, experience and setup (Fig. 27.29) [33, 34].




Figure 27.29 (A) Percutaneous nephrostomy tube placed through a calyx in the lower pole of a kidney with hydronephrosis. (B) The pigtail catheter is placed in the dilated calyx. The tube in (A) and the pigtail in (B) are marked with white arrows.

27.11 CEUS, Image Fusion and Elastography

CEUS can evaluate microvasculature, which color Doppler US is unable to detect. In renal US examination, CEUS can be used to differentiate tumor and pseudotumor, such as prominent columns of Bertin. Pseudotumors enhance as adjacent renal tissue. The use of CEUS is recommended in special cases to distinguish between cystic and hypovascularized solid lesions, to characterize complex cysts, abscesses, traumatic lesions and ischemic lesions [35, 36]. Solid malignant tumors in the kidney do not exhibit specific enhancement patterns like some liver lesions, and no valid enhancement criteria between benign and malignant renal lesions have been proposed [37, 38]. However, CEUS is used in some patients after ablation of renal cell carcinoma to evaluate contrast uptake in the treated area (Fig. 27.30).



Figure 27.30 Renal cell carcinoma successfully treated with thermal ablation, as no contrast enhancement is seen.

Image fusion of ultrasound with a previously recorded dataset of CT or other modalities is rarely used in renal US. Reports on image fusion using CEUS or US combined with CT or MRI in the examination of renal lesions and in difficult US-guided renal interventions have been published (Fig. 27.31) [39]. However, no recommendations have been published so far.




Figure 27.31 Unspecific cortical lesion on CT is confirmed cystic and benign with contrast-enhanced ultrasound (CEUS) using image fusion.

Elastography is a US method to visualize the elasticity of tissue. Preliminary reports on US elastography used on transplanted kidneys to evaluate cortical fibrosis have been published showing promising results (Fig. 27.32) [40].




Figure 27.32 Strain elastography of a normal kidney. Red depicts soft areas, and blue depicts hard areas relative to the entire elastography image. Note that the medulla is softer than the cortex. A color bar is shown to the left of the image, where 'S' and 'H' denote soft and hard tissue, respectively.

27.12 Conclusions

Renal US is a versatile and useful examination. US is an accessible, inexpensive and fast aid for decision-making in patients with renal symptoms and for guidance in renal intervention. However, renal US has certain limitations, and other modalities, such as CT and MRI, should always be considered as supplementary imaging modalities in the assessment of renal disease.

Disclosures and Conflict of Interest

This chapter was originally published as: Hansen, K. L., Nielsen, M. B., Ewertsen, C. (2016). Ultrasonography of the kidney: A pictorial review. *Diagnostics*, **6**, 2, <https://doi.org/10.3390/diagnostics6010002>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates, by kind permission of the copyright holders.

Author Contributions: Kristoffer Lindskov Hansen and Caroline Ewertsen contributed equally to this chapter. Kristoffer Lindskov Hansen and Caroline Ewertsen conducted the data collection and Kristoffer Lindskov Hansen wrote the chapter. Michael Bachmann Nielsen and Caroline Ewertsen edited and proofread the chapter.

Conflicts of Interest: The authors declare no conflict of interest.

Acknowledgments: The authors thank Kim Krarup for providing images of a nephrostomy.

References

1. Wilson, D. A. Ultrasonic scanning of the kidneys. *Ann. Clin. Lab. Sci.*, 1981, 11, 367–376.
2. Rumack, C. M., Wilson, S. R., Charboneau, J. W. *Diagnostic Ultrasound*, 3rd ed., Elsevier Health Sciences: St. Louis, MO, USA, 2005.
3. Emamian, S. A., Nielsen, M. B., Pedersen, J. F., Ytte, L. Sonographic evaluation of renal appearance in 665 adult volunteers. Correlation with age and obesity. *Acta Radiol.*, 1993, 34, 482–485.
4. Pedersen, M. H., Nielsen, M. B., Skjoldbye, B. *Basics of Clinical Ultrasound*, Ultra Pocket Books: Copenhagen, Denmark, 2006.
5. Emamian, S. A., Nielsen, M. B., Pedersen, J. F. Tenth percentiles of kidney length in adult volunteers. *Am. J. Roentgenol.*, 1994, 163, 748.
6. O'Neill, W. C. Renal relevant radiology: Use of ultrasound in kidney disease and nephrology procedures. *Clin. J. Am. Soc. Nephrol.*, 2014, 9, 373–381.
7. Sidhu, P. S., Wui, K. C. *Measurement in Ultrasound*, Oxford University Press Inc.: New York, NY, USA, 2004.
8. Dinkel, E., Ertel, M., Dittrich, M., Peters, H., Berres, M., Schulte-Wissermann, H. Kidney size in childhood. Sonographical growth charts for kidney length and volume. *Pediatr. Radiol.*, 1985, 15, 38–43.
9. Kadioglu, A. Renal measurements, including length, parenchymal thickness, and medullary pyramid thickness, in healthy children: What are the normative ultrasound values? *Am. J. Roentgenol.*, 2010, 194, 509–515.
10. Haller, J. O., Berdon, W. E., Friedman, A. P. Increased renal cortical echogenicity: A normal finding in neonates and infants. *Radiology*, 1982, 142, 173–174.
11. Tublin, M. E., Bude, R. O., Platt, J. F. The resistive index in renal doppler sonography: Where do we stand? *Am. J. Roentgenol.*, 2003, 180, 885–892.
12. Pedersen, J. F., Emamian, S. A., Nielsen, M. B. Simple renal cyst: Relations to age and arterial blood pressure. *Br. J. Radiol.*, 1993, 66, 581–584.
13. Bosniak, M. A. Diagnosis and management of patients with complicated cystic lesions of the kidney. *Am. J. Roentgenol.*, 1997, 169, 819–821.
14. McGuire, B. B., Fitzpatrick, J. M. The diagnosis and management of complex renal cysts. *Curr. Opin. Urol.*, 2010, 20, 349–354.
15. Ignee, A., Straub, B., Brix, D., Schuessler, G., Ott, M., Dietrich, C. F. The value of contrast enhanced ultrasound (CEUS) in the characterisation of patients with renal masses. *Clin. Hemorheol. Microcirc.*, 2010, 46, 275–290.
16. Dietrich, C. F. *Efsumb Course Book on Ultrasound*, EFSUMB: London, UK, 2012.
17. O'Neill, W. C., Robbin, M. L., Bae, K. T., Grantham, J. J., Chapman, A. B., Guay-Woodford, L. M., Torres, V. E., King, B. F., Wetzell, L. H., Thompson, P. A., et al. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: The consortium of renal imaging studies in polycystic kidney disease (CRISP). *Am. J. Kidney Dis.*, 2005, 46, 1058–1064.
18. Meister, M., Choyke, P., Anderson, C., Patel, U. Radiological evaluation, management, and surveillance of renal masses in von hippel-lindau disease. *Clin. Radiol.*, 2009, 64, 589–600.

19. Leveridge, M. J., Bostrom, P. J., Koulouris, G., Finelli, A., Lawrentschuk, N. Imaging renal cell carcinoma with ultrasonography, CT and MRI. *Nat. Rev. Urol.*, 2010, 7, 311–325.
20. Tamai, H., Takiguchi, Y., Oka, M., Shingaki, N., Enomoto, S., Shiraki, T., Furuta, M., Inoue, I., Iguchi, M., Yanaoka, K., et al. Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors. *J. Ultrasound Med.*, 2005, 24, 1635–1640.
21. Lou, L., Teng, J., Lin, X., Zhang, H. Ultrasonographic features of renal oncocytoma with histopathologic correlation. *J. Clin. Ultrasound*, 2014, 42, 129–133.
22. Yamashita, Y., Ueno, S., Makita, O., Ogata, I., Hatanaka, Y., Watanabe, O., Takahashi, M. Hyperechoic renal tumors: Anechoic rim and intratumoral cysts in us differentiation of renal cell carcinoma from angiomyolipoma. *Radiology*, 1993, 188, 179–182.
23. Clark, T. W., Millward, S. F., Gervais, D. A., Goldberg, S. N., Grassi, C. J., Kinney, T. B., Phillips, D. A., Sacks, D., Cardella, J. F. Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for percutaneous thermal ablation of renal cell carcinoma. *J. Vasc. Interv. Radiol.*, 2009, 20, S409–S416.
24. Mostbeck, G. H., Zontsich, T., Turetschek, K. Ultrasound of the kidney: Obstruction and medical diseases. *Eur. Radiol.*, 2001, 11, 1878–1889.
25. Chi, A. C., Flury, S. C. Urology patients in the nephrology practice. *Adv. Chronic Kidney Dis.*, 2013, 20, 441–448.
26. Turk, C., Petrik, A., Sarica, K., Seitz, C., Skolarikos, A., Straub, M., Knoll, T. Eau guidelines on diagnosis and conservative management of urolithiasis. *Eur. Urol.*, 2015.
27. Nicolau, C., Claudon, M., Derchi, L. E., Adam, E. J., Nielsen, M. B., Mostbeck, G., Owens, C. M., Nyhsen, C., Yarmenitis, S. Imaging patients with renal colic—consider ultrasound first. *Insights Imaging*, 2015, 6, 441–447.
28. Smith-Bindman, R., Aubin, C., Bailitz, J., Bengiamin, R. N., Camargo, C. A., Jr., Corbo, J., Dean, A. J., Goldstein, R. B., Griffey, R. T., Jay, G. D., et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. *N. Engl. J. Med.*, 2014, 371, 1100–1110.
29. Noble, V. E., Brown, D. F. Renal ultrasound. *Emerg. Med. Clin. N. Am.*, 2004, 22, 641–659.
30. Winkel, R. R., Kalhauge, A., Fredfeldt, K. E. The usefulness of ultrasound colour-doppler twinkling artefact for detecting urolithiasis compared with low dose nonenhanced computerized tomography. *Ultrasound Med. Biol.*, 2012, 38, 1180–1187.
31. Craig, W. D., Wagner, B. J., Travis, M. D. Pyelonephritis: Radiologic-pathologic review. *Radiographics*, 2008, 28, 255–277.
32. Dayal, M., Gamanagatti, S., Kumar, A. Imaging in renal trauma. *World J. Radiol.*, 2013, 5, 275–284.
33. Lorentzen, T., Nolsoe, C. P., Ewertsen, C., Nielsen, M. B., Leen, E., Havre, R. F., Gritzmann, N., Brkljacic, B., Nurnberg, D., Kabaalioglu, A., et al. EfsUMB guidelines on interventional ultrasound (INVUS), part I—General aspects (long version). *Ultraschall Med.*, 2015, 36, E1–E14.
34. Dietrich, C. F., Lorentzen, T., Appelbaum, L., Buscarini, E., Cantisani, V., Correas, J. M., Culi, X. W., Onofrio, M. D., Hocke, M., Ignee, A., et al. EfsUMB guidelines on interventional ultrasound (INVUS), part III, abdominal treatment procedures (long version). *Ultraschall Med.*, 2015, 36, 1–32.

35. Dietrich, C. F., Averkiou, M. A., Correas, J. M., Lassau, N., Leen, E., Piscaglia, F. An EFSUMB introduction into dynamic contrast-enhanced ultrasound (DCE-US) for quantification of tumour perfusion. *Ultraschall Med.*, 2012, 33, 344–351.
36. Bertolotto, M., Cicero, C., Perrone, R., Degrassi, F., Cacciato, F., Cova, M. A. Renal masses with equivocal enhancement at CT: Characterization with contrast-enhanced ultrasound. *Am. J. Roentgenol.*, 2015, 204, W557–W565.
37. Cokkinos, D. D., Antypa, E. G., Skilakaki, M., Kriketou, D., Tavernaraki, E., Piperopoulos, P. N. Contrast enhanced ultrasound of the kidneys: What is it capable of? *Biomed. Res. Int.*, 2013, 2013.
38. King, K. G., Gulati, M., Malhi, H., Hwang, D., Gill, I. S., Cheng, P. M., Grant, E. G., Duddalwar, V. A. Quantitative assessment of solid renal masses by contrast-enhanced ultrasound with time-intensity curves: How we do it. *Abdom. Imaging*, 2015, 40, 2461–2471.
39. Ewertsen, C., Saftoiu, A., Gruionu, L. G., Karstrup, S., Nielsen, M. B. Real-time image fusion involving diagnostic ultrasound. *Am. J. Roentgenol.*, 2012, 200, W249–W255.
40. Grenier, N., Gennisson, J. L., Cornelis, F., le Bras, Y., Couzi, L. Renal ultrasound elastography. *Diagn. Interv. Imaging*, 2013, 94, 545–550.

Chapter 28

The Accuracy of Lung Auscultation in the Practice of Physicians and Medical Students

Honorata Hafke-Dys, PhD,^{a,b} Anna Bręborowicz, PhD,^c Paweł Kleka, PhD,^d
Jędrzej Kociński, PhD,^{a,b} and Adam Biniakowski, PhD^b

^a*Institute of Acoustics, Faculty of Physics, Adam Mickiewicz University in Poznań,
Uniwersytetu Poznańskiego, Poland*

^b*StethoMe, Winogrady, Poland*

^c*Department of Pediatric Pneumonology,
Allergology and Clinical Immunology, K. Jonscher Clinical Hospital in Poznań,
Poznań University of Medical Sciences, Szpitalna, Poland*

^d*Institute of Psychology, Adam Mickiewicz University, Wieniawskiego, Poland*

h.hafke@amu.edu.pl, hafke@stethome.com

Keywords: abnormal bronchial sound, acousticians, American Thoracic Society (ATS), auscultation, coarse crackles, crepitus, diminished breath sound, European Respiratory Society (ERS), expiratory wheezes, fine crackles, general practitioner (GP), inspiratory wheezes, International Lung Sounds Association (ILSA), louder breath sound, medium crackles, nomenclature, normal bronchial sound, pleural rub, prolonged expiratory phase, pulmonary, pulmonologists, respiratory sounds, rhonchi, sound classes, squawk, stethoscope, stridor, vesicular breath sound

28.1 Introduction

Auscultation is a very common examination carried out by every general practitioner (GP) or family doctor. It is fast, easy and does not require advanced technology. Regardless of the type of stethoscope used (essentially a low cost device) the most important features of auscultation are non-invasiveness, simplicity and portability. However, the results of this kind of examination are subjective in nature, strongly dependent as they are on the experience and perceptual abilities of doctors and are hence prone to large errors. Indeed, physicians often differ in their assessments. Mangione and Nieman [1] examined the pulmonary auscultatory

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

skills of medical students, pulmonologists and interns in internal medicine and family practice. They found that internal medicine and family practice doctors are not statistically superior to medical students. Only pulmonologists achieved statistically better results than others (e.g., for a diagnostic score: Cohen's $d = 1.16$, $p < .001$; [1]).

Furthermore, discrepancies also arise from the differing nomenclature and formal distinctions between sound classes used in the existing medical literature. This is a wide ranging problem of international magnitude, as has been shown by numerous authors [2–5]. Pasterkamp et al. [6], proposed a unified nomenclature for six languages and suggested a standardized terminology. However, there is still no uniformly standardized classification of the types of phenomena characteristic of the human respiratory system that is used by the medical community as a whole. Physicians often use words to describe perceived pathologies in the respiratory system that are associated with distinct semantic meanings in different handbooks or universities. This leads to problems in preliminary auscultation courses, and more importantly during later professional work, when doctors exchange or consult diagnoses. They use different descriptions of the same sounds or semantically similar and sometimes even identical terms to describe distinct phenomena. This results in descriptions that are ambiguous at the very least or in extreme cases even incomprehensible to other doctors, which in turn may require repetition of examinations to resolve. A further technical point is that the sounds are not stored and there is no possibility to go back to the recordings or compare them to other sounds, so there is also no possibility to verify the description, which increases the ambiguity even further.

28.2 Study Objectives

The main goal of this chapter is to answer the following question: How correctly and consistently do physicians and medical students evaluate respiratory sounds, and do they categorize them identically? In this context, other aspects of the problem have also been analyzed in detail: Do pulmonologists perform better than other groups of physicians? How does the group of students fit into this community? These questions stem from the hypothesis that the reduction of pathological classes as proposed by Pasterkamp et al. [6], European Respiratory Society (ERS), International Lung Sounds Association (ILSA) or American Thoracic Society (ATS) may lead to an increase in efficiency of auscultation by medical staff. Particularly it means that even though physicians use the class of crepitus and medium crackles (see Table 28.1 for details) they cannot distinguished those classes from other crackles while listening and thus these terms should not be used. Moreover, we test the hypothesis that due to expert and daily practice, pulmonologists are likely to perform better than non-pulmonology medical providers and trainees.

Table 28.1 The sound classes presented in the test

Sound class described by the team of medical specialists (the "standard")	Sound number in presentation
Vesicular breath sound	1, 9, 21
Normal bronchial sound	3, 16
Abnormal bronchial sound	8
Louder breath sound, prolonged expiratory phase and rhonchi	14, 24
Fine crackles	4, 23
Fine crackles and crepitus	13
Fine crackles and abnormal bronchial sound	18
Medium crackles	19
Coarse crackles	5, 12
Crepitus	22
Rhonchi and expiratory wheezes	6
Rhonchi	7
Stridor	10
Expiratory wheezes	11, 15, 20
Inspiratory wheezes and rhonchi	17
Inspiratory and expiratory wheezes	2

The investigated problem is especially crucial because most unwell patients, undergo examination by GPs and family doctors whose auscultation results are taken into account in more detailed diagnosis and further treatment [7].

28.3 Materials and Methods

The study was approved by the Bioethical Commission of the Poznań University of Medical Science.

Our test was anonymous and conducted online via the Internet using Questionpro Professional. This software was chosen because it enables the presentation of uncompressed and high quality audio to users. Moreover, before the experiment was made available to the participants, the quality of the signals in this software was subjectively verified by two experienced acousticians (sound engineers) independently (without hearing loss) for distortions and possible artifacts. No difference was found between direct and online listening. In addition, to minimize the possibility of a layperson completing the survey, the survey was distributed among the academic medical community and in hospitals. It was also passed on to interested people by both lecturers at medical universities and by practicing doctors.

The experiment consisted of two parts.

In the first part, a survey was used. Each participant responded to a number of questions regarding: (a) education, the specialization started or held, (b) the assessment of their own skills in adult and child auscultation, (c) the type of stethoscope (electronic/analog) used and the frequency of auscultation performed in their medical practice, (d) their opinions on a 5-grade scale on: the number of hours devoted to studying auscultation during their study and specialization, the need for additional training, and the scale of the problem of ambiguity in the nomenclature used in the classification of auscultation sounds.

The second part focused on the classification of auscultation sounds presented to each participant. This part consisted of 24 sounds (see Table 28.1 for details) that the test participant listened to, evaluated and assigned to specific classes (details below). Nine sounds were selected from the demonstration recordings included on the CD companion to *Fundamentals of Lung and Heart Sounds* [8]. The remaining sounds were recorded with a Littmann 3200 electronic stethoscope and consisted of the respiratory sounds of children aged 5 months to 14 years (average 7.6 years).

The choice of sounds for the test was conducted in two steps. First, sounds from a database of over 2000 sounds were selected by acousticians. The chosen sounds contained the least number of distortions and artifacts caused by the transducer of the stethoscope. The second equally important step was the choice of sound classes so as to have a pool of as diverse and unambiguous sounds as possible. In this way 50 different sound examples were selected. The final selection of sounds for the tests was made by a specialist team of eight experienced pediatricians and pulmonologists working at the Karol Jonscher Clinical Hospital in Poznań, Karol Marcinkowski Poznań University of Medical Sciences. At the meeting of these physicians, a Fostex PH-50 headset coupled with high quality professional headphones (Sennheiser HD600) enabled all the physicians to listen simultaneously to sound samples. Upon listening to each signal, they classified the sound. A common position was then reached after a discussion. The final set of sounds chosen for the test consisted of sounds that did not lead to any cause of doubt among the physicians. This set of signals along with their descriptions is called the "standard" here.

The sounds represented certain classes (Table 28.1) and were presented to the participants as a collection of signals from 24 different patients. An exemplary answer sheet illustrating the scope of data presented to the participants is presented in Fig. 28.1.

The terms used in the classes were chosen to include the entire spectrum of nomenclature that is used in contemporary medical literature [1, 4, 6, 8–11]. Some of the descriptions (e.g., squawk, diminished breath sound, pleural rub) did not correspond to any signals present in the recordings. During the experiment more than one class could be assigned to each sound by a listener. Each sound signal was supplemented with the following additional graphical and textual information:

position where the stethoscope chestpiece was placed on the chest during the recording, and the age, height and weight of the patient (Fig. 28.1). Each participant was informed of the need to use high quality headphones during the experiment. The participants were allowed to rerun each sound as many times as they needed and return to and modify previous descriptions. No feedback was used, *i.e.* the participants were not informed about the correctness of their response during the test. Moreover, the order of the presentation of the data was random (though identical for all participants). This was done to inhibit the possibility of systematic learning of patterns and hence correct answers by the participants during the listening task.




Figure 28.1 An example of the answer sheet used in the experiment and possible answers. During the experiment more than one class could be marked and each sound could be played as many times as needed.

Due to the exploratory nature of the research, we assumed a type 1 error level of $\alpha = 0.10$ for statistical hypothesis testing.

The survey was anonymous and voluntary. The participants were informed in the survey that their results would be analyzed and published. All the participants were over the age of 18 years. The recordings were collected in the Karol Jonscher Clinical Hospital in Poznań, Poznań University of Medical Sciences by physicians from the Department of Pediatric Pneumonology, Allergology and Clinical Immunology, with the consent of the Bioethical Commission of the Poznań University of Medical Sciences. Also, the legal guardians of children taking part were required to sign written permission for the recordings to be made.

Both parts of the experiment (survey and descriptions) were completed by 205 participants. Firstly, the results from the questionnaires were analyzed for their quality. The average time taken to complete the questionnaires was 25 min. The total duration of the signals, excluding the survey part, was about 4 min. Therefore, the responses of the participants who completed the entire experiment in less than 5 min were rejected as unreliable, and the remaining 185 questionnaires were approved for further analysis. Among these, there were: 16 pulmonologists, 22 pediatricians, 29 doctors of other specializations, 50 doctors during their internship and 68 medical students.

28.4 Results

Among the respondents, the majority (67%) auscultate patients at least once a week, while 14% do it at least once a month. The remaining group auscultate their patients less than once a month (19%). Only 4.9% of the surveyed physicians use an electronic stethoscope in their daily practice. Figure 28.2 shows how the physicians rated their skills in the auscultation of children and adults.




Figure 28.2 The percentage distribution of responses to the question of assessing one's own skills (on a scale of 0 = "very poorly" to 5 = "very well") for the auscultation of adult and child respiratory systems.

The results of the auscultation experiment were divided according to the correspondence of sound classification carried out by the participants with the “standard” developed by the team of medical specialists (Table 28.1). For each sound presented to the participants, the responses were categorized as in Table 28.2 and the percentage distribution of each such category is shown in Fig. 28.3.

Table 28.2 Assumptions used to evaluate the responses of participants and the abbreviation used

Abbreviation	Response category	Description of category
ZW	The answer was in agreement with the standard	Full agreement with the “standard” and no incorrect answers
CW	The answer was partially in agreement with the standard	At least one correct answer marked; additional phenomena that were not included in the “standard” were marked
N	Incorrect answer	Among the marked phenomena, the response from the “standard” was not marked




Figure 28.3 The distribution of answers that are in: full agreement with the “standard” (ZW), partial agreement with the “standard” (CW) and incorrect (N).

Analyzing all the data presented up to now, one may infer that doctors classify sounds with varying accuracy (Fig. 28.3). In general, after averaging the responses for all the sounds we find that there are 14.6% of ZW answers (full agreement with the “standard”), 26.2% of CW answers (partial agreement with the “standard”, see Table 28.2), while most answers are of type N (incorrect answers)—59.3% ($\chi^2(2) = 59.8, p < 0.001$). Furthermore, it can be seen by conducting the Kruskal-Wallis test that there are statistical differences between

the groups of physicians of different specializations in the category of correct answers ZW ($\chi^2(4) = 16.0, p < 0.003$). Pair analysis of the differences in answers between groups of physicians of different specializations using post hoc tests with a Holm correction show that pulmonologists have statistically higher scores (15.9%) than students (14.4%, $p = 0.023$) and interns (13.8%, $p = 0.060$). This analysis also shows that students had significantly lower scores in CW's (24.1%) than pulmonologists (36.4%, $p = 0.022$), pediatricians (26.7%, $p = 0.022$) and other specializations (24.6%, $p = 0.073$). With regard to incorrect answers (N), students obtained the most (61.5%), while pulmonologists obtained the least (47.7%) ($\chi^2(4) = 69.9, p < 0.001$). Next, the differences for individual sound classes (Fig. 28.4) are analyzed on the basis of a Kruskal-Wallis test and post hoc tests with a Holm correction for statistically significant differences. According to the analysis, pulmonologists distinguish the sound classes better than other groups—as many as three classes are significantly recognized differently by the group of pulmonologists relative to other specializations: fine crackles ($\chi^2(4) = 11.9, p = 0.018$), stridor ($\chi^2 = 14.4, p = 0.006$) and rhonchi ($\chi^2(4) = 11.1, p = 0.026$).




Figure 28.4 The juxtaposition of correct ($P = ZW \cup CW$) answers for each sound class for doctors of different specializations and medical students.

For further analysis, the sounds were grouped according to their class and the percentage of correct responses (P), and considered for each medical specialization separately (Fig. 28.4). To give a general view, we assumed the correct answer

category (P) to contain both the responses in full (ZW) and partial (CW) agreement with the “standard”.

Next, we grouped the responses using the main classes proposed by ERS [6], ILSA or ATS. In practice, this means that if the participant had indicated any of the subgroups shown in Table 28.3 and any of them were marked as correct in the “standard”, the answer was treated as a correct one. The cases of the vesicular breath and bronchial sounds, are each treated as standalone sounds. In this way, five main classes of sounds were created (Table 28.3).

Table 28.3 The main classes of respiratory sounds and the subclasses that are part of them

Main class	Subclasses included in the main class
Normal lung sound	Vesicular breath sound Diminished breath sound Louder breath sound Normal bronchial sound
Abnormal bronchial sound	No subclasses
Crackles	Fine crackles Medium crackles Coarse crackles Crepitus
Wheezes	Inspiratory wheezes Expiratory wheezes Stridor
Rhonchi	No subclasses

After grouping the responses as in Table 28.3, for all the classes associated with pathological signals, the pulmonologist group is still seen to be the most effective one (Fig. 28.5). However, statistically significant differences based on the Kruskal-Wallis test and a comparison of the groups of participants in pairs are obtained only for the rhonchi class between the group of pulmonologists who scored higher than the pediatricians ($p = 0.085$), interns ($p = 0.085$), other specializations ($p = 0.046$) and medical students ($p = 0.015$). For wheezes, pulmonologists had statistically significantly higher scores than other specializations ($p = 0.008$). Also interns had better scores than physicians of other specializations ($p = 0.026$). Generally, we find that that this grouping highlights the advantage of pulmonologists over the rest of the groups in the correct recognition of phenomena related to respiratory sounds.

The lowest value of false interpretation appears for the wheezes class. This suggests that this class is the easiest to recognize because the acoustically distinctive features contained in the signal are easy to detect and interpret. There was no difference in the results for the different groups of physicians: normal lung sound ($\chi^2(4) = 2.4, p = 0.671$); abnormal bronchial sound ($\chi^2(4) = 4.5,$

$p = 0.348$); rhonchi ($\chi^2(4) = 2.1, p = 0.722$); crackles ($\chi^2(4) = 1.0, p = 0.908$); wheezes ($\chi^2(4) = 7.0, p = 0.135$).




Figure 28.5 The percentage of correct detection of the grouped sound classes (main classes, Table 28.3) by physicians of various specializations. To emphasize the differences, the points for individual groups are connected by lines.

A graph of the correlation between the correct answers for each main class is presented using the the described grouping (Fig. 28.5). For each group of participants the percentage of false positives is about 50% and decreases to 30% for wheezes only.

Furthermore, we analyzed what phenomena other than corresponding to the “standard” were marked by the participants. It should be emphasized that the purpose of this analysis was primarily to investigate inter-relations between groups of classes which is important in the context of further future unification of the existing nomenclature. We assumed that phenomena that are most similar would also most often be confused with each other and hence should be grouped together giving rise to the the following coarse-grained classes: the crackles class (Fig. 28.6), breath sounds (vesicular and louder) and bronchial sounds (Fig. 28.7), wheezes and rhonchi class (Fig. 28.8). Each plot shows all responses, where specifically the correct answer is depicted in gray. In this way, one can analyze which classes were chosen by the respondents and the kind and frequency of the mistakes made.




Figure 28.6 The percentage distribution of responses marked for the classes (a) crepitus (b) fine crackles (c) medium crackles (d) coarse crackles. The light gray bar depicts the correct answer.




Figure 28.7 The percentage distribution of responses marked for the classes (a) vesicular breath sound; (b) normal bronchial sound; (c) louder breath sound. The light gray bar depicts the correct answer.




Figure 28.8 The percentage distribution of responses marked for (a) inspiratory wheezes, (b) expiratory wheezes, (c) rhonchi class. The light gray bar depicts the correct answer.

Finally, in the test, both the reference sounds included on the CD of the physician handbook [8] and real-life sounds recorded using the Littmann 3200 stethoscope were used. The effect of the type of sound recording on the results was analyzed, taking into account the specialization of the participants. On the basis of the results of the Wilcoxon test, no significant difference in the percentage of any type of diagnoses between the two kinds of recording (CD and Littmann 3200) was observed in any of the participants ($p > 0.10$).

28.5 Discussion

It should be emphasized that the medical community recognizes the problem of the ambiguous nomenclature used in the classification of respiratory sounds. In our test, more than 65% of respondents strongly agree or agree, and only 14.2% disagree or strongly disagree with the statement that the classification of respiratory sounds requires coherence and uniformity.

Analyzing different sources of recordings one may state that the type of recording did not affect the results of participants and that they performed at a similar level at the task of classification of sounds irrespective of different origins (from a book or from a hospital). It means that the results can be generalized and are not affected by the user or device. Therefore they can be analyzed together.

Analyzing the results corresponding to the juxtaposition of coarse, medium, fine crackles and crepitus (Fig. 28.6), it can be seen that these are the classes that are confused with each other. Coarse crackles are most often confused with other types of crackles and crepitus, and even rhonchi. In the medium crackle class the results are similar to those for coarse crackles, but the most noticeable additional class marked for this phenomenon was crepitus.

In turn, fine crackles are not confused so often with rhonchi and medium and coarse crackles, but are often confused with the crepitus category, which is a class that is marked much more often than in the standard (fine crackles). This state of affairs seems natural, because in many medical communities crepitus is equivalent to fine crackles, or is a subgroup of this class [11]. This findings lead to the conclusion that only two classes for these phenomena should be distinguished, namely fine and coarse classes. Nevertheless, in the case of crepitus, the most common category marked was vesicular breath sound, which may mean that the respondents did not notice the sound class and treated the extra sound as an artifact occurring during the recording. This is confirmed by Fig. 28.7A, in which the answers differing from the correct ones (vesicular breath sound) are shown. Note that the respondents, in addition to the correct answer, most often chose a louder breath sound and crepitus. In the case of normal bronchial sound (Fig. 28.7B), the louder breath sound was more frequent than the correct answer. In addition, the respondents also often noted a prolonged expiration phase.

In samples consisting of the louder breath sound (Fig. 28.7C), the subjects often recognized the three respiratory pathology classes—inspiratory and

expiratory wheezes or rhonchi. In the case of normal sounds, these classes were never selected.

In the case of the juxtaposition of inspiratory and expiratory wheezes (Fig. 28.8), notice that they are generally recognized correctly, as witnessed by the highest percentage of correct answers provided. These two classes were also confused most frequently, i.e. inspiratory wheezes were confused with expiratory wheezes and vice versa. In addition, only in the case of inspiratory wheezes was rhonchi marked as an additional class. This means that distinguishing the inspiratory and expiratory phases poses significant difficulty to physicians.

In the case of rhonchi (Fig. 28.8C), notice that this is the class closest to wheezes and is most often confused with them. The class of inspiratory and expiratory wheezes is marked almost as often as the rhonchi class, which was the correct answer here. Additionally, for the rhonchi class a louder breath sound and prolonged expiration phase were also often marked.

In general, comparing the results in Figs. 28.8A and 28.8C, we find that the wheezes and rhonchi group are subjectively close to each other and are often confused due to similar acoustic features. Figure 28.8C shows that in sound samples which contained rhonchi, according to the “standard”, the respondents mainly mistook them for the class of wheezes. Moreover, the class of rhonchi was also often chosen (Fig. 28.6) when the standard response was medium or coarse crackles. We infer that the rhonchi class possesses the acoustic features characteristic for the crackles class, causing confusion among the participants. Rhonchi, like wheezes, are continuous and periodic sounds. However, their fundamental frequency is lower than that of wheezes. They are often mistaken for them. This is consistent with the results obtained by Willkins et al. [4], who also showed that rhonchi are an ambiguous class that are very often incorrectly identified. In conclusion, these results point towards the fact that the class of rhonchi is quite ambiguous and is differently classified by the respondents due to the fact that it has the features of both wheezes and crackles.

The comparison of the results of correct answers for the detailed classification and the classification with the grouped (main) classes shows that grouping according to ERS, ILSA and ATS nomenclature significantly increases the percentage of correct responses. This is also consistent with the research by Malbye et.al. [12] and emphasized in handbooks [13].

The comparison of the efficiency of different groups of medical staff shown in Fig. 28.5 reveals that pulmonologists perform better than other groups- this is also consistent with the results of Mangione and Nieman [1]. Their advantage is the greatest for the rhonchi class. Interns and pediatricians perform next best followed by medical students and other specializations. We note here, that the former two classes of physicians use stethoscopes in their everyday practice similarly to pulmonologists. Furthermore physicians (except for pulmonologists), in general, are not better than medical students. It must be emphasized that some authors (e.g., [14]) do not find pulmonologists to have an advantage.

28.6 Conclusions

The main findings of this study are collected below:

- The average number of correct detections of auscultation phenomena in our test using the wide detailed nomenclature used in the medical community ranges from only 24.1% for students to 36.5% for pulmonologists.
- The highest number of correct answers was obtained for the wheeze classes. This is not surprising, since they are the most characteristic sounds: continuous, tonal, periodic and relatively loud. For coarse and fine crackle classes, the number of correct detections was lower.
- The most ambiguous is the class of rhonchi, which is at the boundary between the class of wheezes and the class of coarse crackles.
- Our results lend support to the use of the classification of ERS [6], ILSA or ATS which is simple, short, well defined acoustically, and do not imply any wrong mechanism of production. On this basis one can distinguish two main categories of sounds: discontinuous sounds (which are divided into classes of fine and coarse crackles), and continuous sounds (wheezes and rhonchi). These four classes seem to be enough since more detailed ones cannot be correctly distinguished by physicians.
- For all classes of sounds, the advantage of the group of pulmonologists in terms of their correct answers is evident in our results. The effectiveness of physicians in the clear classification of auscultation sounds with the use of detailed sound classes is very heterogeneous and does not bring any advantage over general classes.
- Due to the ever-growing market of electronic stethoscopes, it is possible to record normal and pathological respiratory sounds. It is therefore possible to create large sound databases that can be subsequently described by experts in the field of pulmonology. Such databases, consisting of sound examples with descriptions and attributed sound classes, can be used to train medical students and improve the competence of medical practitioners of various specialities.

Supporting Information

S1 Table. Raw data table. According to Table 28.1 in the chapter. <https://doi.org/10.1371/journal.pone.0220606.s001>.

S1 File. Survey template in Polish. <https://doi.org/10.1371/journal.pone.0220606.s002>.

S2 File. Survey template in English. <https://doi.org/10.1371/journal.pone.0220606.s003>.

Disclosures and Conflict of Interest

This chapter was originally published as: Hafke-Dys, H., Bręborowicz, A., Kleka, P., Kociński, J., Biniakowski, A. (2019). The accuracy of lung auscultation in the practice of physicians and medical students. *PLoS ONE*, **14**(8), e0220606, <https://doi.org/10.1371/journal.pone.0220606>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: All relevant data are within the chapter and its Supporting Information files.

Funding: This work was supported by a grant from The National Centre of Research and Development (NCRD) in Poland and the European Union under Sub-Measure 1.1.1 of the Operational Programme Smart Growth (PO IR) “Industrial R&D carried out by enterprises” (Fast Track), agreement no. POIR.01.01.01-00- 0528/16-00. All authors were paid for their work by StethoMe, which is the grantee. The funder provided support in the form of salaries for authors HH-D, ABr, PK, JK, ABi, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the chapter. The specific roles of these authors are articulated in the ‘author contributions’ section. The commercial affiliation of HH-D, JK, ABi did not play a role in this study.

Competing interests: Honorata Hafke-Dys and Jędrzej Kociński are employed by both Adam Mickiewicz University in Poznań and the company StethoMe, and are shareholders of StethoMe. Adam Biniakowski is employed by StethoMe. Anna Bręborowicz is the StethoMe content consultant and coordinated the recordings at the hospital. All the authors were paid for their work. This does not alter the authors’ adherence to the PLOS ONE policies on sharing data and materials, and the results were obtained with all the required ethical standards and objectivity. It must be emphasized that StethoMe was established because the authors obtained the results presented in the chapter and sought to change the status quo in this area of examination. This research was first inspired by the everyday situation in a GP’s office encountered by Honorata Hafke-Dys, Kociński and their children, and then by literature research and cooperation with: prof. Anna Bręborowicz from the Karol Jonscher Clinical Hospital in Poznań; Poznań University of Medical Sciences; and physicians from the Department of Pediatric Pneumonology, Allergology and Clinical Immunology.

Acknowledgments: The Authors would like to thank the Management of the Karol Jonscher Clinical Hospital in Poznań, Poznań University of Medical Sciences and the physicians from the Department of Pediatric Pneumonology, Allergology and Clinical Immunology of this hospital for their help in recording and description of the acoustic signals. The authors also thank Angelika Podoła for her help in survey collection.

Author Contributions

Conceptualization: Honorata Hafke-Dys, Anna Bręborowicz; Formal analysis: Paweł Kleka; Investigation: Adam Biniakowski; Methodology: Honorata Hafke-Dys; Software: Adam Biniakowski; Supervision: Anna Bręborowicz; Validation: Jędrzej Kociński; Visualization: Paweł Kleka, Adam Biniakowski; Writing – original draft: Honorata Hafke-Dys, Jędrzej Kociński; Writing – review & editing: Honorata Hafke-Dys, Jędrzej Kociński.

References

1. Mangione S, Nieman LZ. Pulmonary Auscultatory skills during training in internal medicine and family practice. *American Journal of Respiratory and Critical Care Medicine*. 1999;159(4):1119–1124.
2. Bunin NJ, Loudon RG. Lung sound terminology in case reports. *Chest*. 1979;76(6):690–692.
3. Cugell DW. Lung sound nomenclature. *American Review of Respiratory Disease*. 1987;136(4):1016.
4. Wilkins RL, Dexter JR, Murphy RLJ, DelBono EA. Lung sound nomenclature survey. *Chest*. 1990;98(4):886–889.
5. Francis NA, Melbye H, Kelly MJ, Cals JW, Hopstaken RM, Coenen S, et al. Variation in family physicians' recording of auscultation abnormalities in patients with acute cough is not explained by case mix. A study from 12 European networks. *European Journal of General Practice*. 2013;19(2):77–84.
6. Pasterkamp H, Brand PLP, Everard M, Garcia-Marcos L, Melbye H, Priftis KN. Towards the standardisation of lung sound nomenclature. *European Respiratory Journal*. 2016;47(3):724–732.
7. Turnbull S, Lucas PJ, Redmond NM, Christensen H, Thornton H, Cabral C, Blair PS, Delaney BC, Thompson M, Little P, Peters TJ, Hay AD. What gives rise to clinician gut feeling, its influence on management decisions and its prognostic value for children with RTI in primary care: a prospective cohort study. *BMC Family Practice*. 2018; 19, 25.
8. Wilkins R, Hodgkin J, Lopez B. *Fundamentals of Lung and Heart Sounds*, 3rd ed., St Louis, United States: Mosby; 2004.
9. Pasterkamp H, Montgomery M, Wiebicke W. Nomenclature used by health care professionals to describe breath sounds in asthma. *Chest*. 1987;92(2):346–352.
10. Rowińska-Zakrzewska E, Kus J. In Polish: *Respiratory System Diseases* (Choroby układu oddechowego). Warszawa: Państwowy Zakład Wydawnictw Lekarskich; 2004.
11. Szczeklik E, Szczeklik A.: In Polish: *General Diagnostics of Internal Diseases* (Diagnostyka ogólna chorób wewnętrznych). Warszawa: Państwowy Zakład Wydawnictw Lekarskich; 1979.
12. Melbye H, Garcia-Marcos L, Brand P, The ERS Task Force for Lung Sounds. Wheezes, crackles and rhonchi: simplifying description of lung sounds increases the agreement on their classification: a study of 12 physicians' classification of lung sounds from video recordings. *BMJ Open Respiratory Research* 2016;3(1): e000136.

13. Priftis KN, Hadjileontiadis LJ, Everard ML, *Breath Sounds. From Basic Science to Clinical Practice*. 1st ed., Cham: Springer; 2018.
14. Aviles-Solis JC, Vanbelle S, Halvorsen PA, Francis N, Cals JWL, et al. International perception of lung sounds: a comparison of classification across some European borders. *BMJ Open Respiratory Research*. 2017; Dec 18;4(1):e000250.

Chapter 29

PCR for the Detection of Pathogens in Neonatal Early Onset Sepsis

Clarissa Oeser, MSc,^{a,b} Marcus Pond, PhD,^c Philip Butcher, PhD,^c Alison Bedford Russell, MD,^d Philipp Henneke, MD, PhD,^e Ken Laing, PhD,^c Timothy Planche, MD, PhD,^c Paul T. Heath, MD, PhD,^a and Kathryn Harris, PhD^f

^a*Paediatric Infectious Diseases, Institute of Infection and Immunity, St George's, University of London, London, UK*

^b*Current address: Clarissa Oeser, National Infection Service, Public Health England, London, UK*

^c*Molecular Microbiology, Institute of Infection and Immunity, St George's, University of London, London, UK*

^d*Neonatology, Birmingham Women's NHS Foundation Trust, Birmingham, UK*

^e*Pediatric Infectious Disease and Rheumatology, University Medical Center Freiburg, Freiburg, Germany*

^f*Microbiology, Virology and Infection Control, Great Ormond Street Hospital, NHS Foundation Trust, London, UK*

clarissa_oeser@yahoo.com

Keywords: 16S rRNA, antibiotics, bacteraemia, bacterial pathogens, base excess (BE), biomarkers, *Candida* spp., clinical diagnosis, C-reactive protein (CRP), diagnostic reliability, early onset sepsis (EOS), Group A *Streptococcus* (GAS), Group B *Streptococcus* (GBS), multiplex PCR, neonatal, polymerase chain reaction (PCR), quantitative polymerase chain reaction (qPCR), real-time PCR, white cell count (WCC)

29.1 Introduction

Treatment for presumed sepsis is common in the neonatal period. Early onset sepsis (EOS) is defined as infection occurring within the first 48–72 h of life, most often acquired shortly before or during delivery. The most common causal pathogen in the UK is *Streptococcus agalactiae* (GBS), followed by *Escherichia coli* [1].

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

Blood cultures remain the gold standard for diagnosing neonatal sepsis, in spite of being positive in a minority of cases with suspected sepsis, especially EOS [2, 3]. False negative blood cultures may occur as a result of small volumes of blood obtained, low levels of bacteraemia, use of prior (intrapartum) antibiotics or fastidious bacteria, fungi or viruses. Because a negative blood culture cannot exclude infection, antibiotic therapy is often continued beyond 48 h despite negative blood cultures, especially, but not always, when there are clinical signs and laboratory markers consistent with infection [4]. This increases antibiotic usage, which in turn increases the risk of development of antibiotic resistant pathogens [5–8], as well as potential immune dysregulation in childhood, as a result of disruptions in nascent gut microbiome [9]. Moreover, prolonged empirical antibiotic therapy (>5 days) among neonates <1000g birth weight has been associated with an increased risk of death and necrotizing enterocolitis [10].

In an era of increasing antibiotic stewardship, improved diagnostic reliability is essential for limiting antibiotic usage. PCR-based techniques have the potential to improve diagnostic reliability.

In this study, whole blood samples of neonates with suspected EOS on the basis of risk and/or clinical indicators were processed by PCR methods including multiplexed, real-time PCR assays targeting a panel of bacterial pathogens, broad range bacterial 16S rRNA gene PCR and a multiplexed real-time PCR assay targeting *Candida* spp, in order to identify pathogens not detected by routine culture methods.

29.2 Materials and Methods

29.2.1 Subjects

Neonates less than 72 h of age undergoing investigation for presumed sepsis were recruited in three tertiary centres, following written parental consent. All neonates were inborn, evaluated either in the neonatal or maternity ward. The first-choice antibiotic regimen for empirical treatment of suspected EOS recommended by the National Institute for Health and Care Excellence is benzylpenicillin with gentamicin. Investigations for sepsis could occur as a result of compatible clinical or laboratory signs or because of perceived risk factors in an otherwise asymptomatic neonate.

29.2.2 Sample Collection

Whole blood (0.5–1 ml) was collected in an EDTA bottle at the time of venipuncture when performing the initial sepsis screen or within 24 h of initial evaluation. Confirmed infection was defined as a positive bacterial blood culture in the presence of clinical signs and symptoms of infection.

29.3 Culture Methods

Whole blood was collected using aseptic technique and cultured in BacT Alert Pediatric culture bottles for five days. As this was part of routine medical care of the patients and not the study procedure, blood volume collected was not recorded.

29.3.1 DNA Extraction

Total DNA was extracted from 100 μ l of whole blood using the Roche MagNA PURE automated extraction instrument (Roche Diagnostics, West Sussex, UK). DNA extracts were stored at -70°C .

29.3.2 Bacterial Multiplex PCR

Targets were bacteria known to account for the majority of EOS in developed countries [1, 11]. All extracts were processed by a panel of six bacterial multiplexed real-time PCR assays targeting *S. pneumoniae*, *S. agalactiae* (GBS), *S. aureus*, *S. pyogenes* (GAS)/*Streptococcus pyogenes*, *Enterobacteriaceae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Ureaplasma parvum*, *Ureaplasma urealyticum*, *Mycoplasma hominis* and *Mycoplasma genitalium* (see Table 29.1). The individual pathogen specific PCRs had been developed and evaluated previously [12–20]. For the purpose of this study, the efficiency of the reaction when a primer is combined with others was compared to the efficiency of the primer functioning on its own. Serial ten-fold dilutions of a known concentration of target DNA were amplified as monoplex and to test for inhibition, the resulting Ct values were compared to those required for detection of the same amount of target DNA in a triplex PCR. The reaction contained 13 μ l of QuantiFast Multiplex mastermix (Qiagen, Crawley, United Kingdom) and 7 μ l of DNA extract. Primer and probes used for each reaction and their concentrations are shown in Table 29.1.

A positive internal control was added to every sample prior to extraction to control for extraction efficiency and PCR inhibition. Every batch of samples tested included a negative and positive control. Thermocycling was performed on the BioRad CFX 96 Real Time PCR detection system (BioRad, Hertfordshire, UK) as follows: 5 min at 95°C followed by 45 cycles of 15 s at 95°C and 30 s at 60°C .

A positive PCR signal was defined as quantification cycle (Cq) ≤ 40 . Amplicons of samples testing positive for *Enterobacteriaceae* were sequenced. Only samples yielding sequences that could be identified to at least genus level using BLAST analysis against the Genbank database were considered true positives.

Table 29.1 Primers and probes used in this study

Organism	Oligo Name	Sequence 5' to 3'	Target gene	Conc (µM)	Reference
<i>Streptococcus pneumoniae</i>	LytA-F	ACG CAA TCT AGC AGA TGA AGC	LytA	0.2	Harris 2008 [12]
	LytA-R	TGT TTG GTT GGT TAT TCG TGC		0.2	
	LytA-Probe	FAM-TTT GCC GAA AAC GCT TGA TAC AGG G- BHQ1		0.2	
<i>Streptococcus agalactiae</i> (GBS)	GBS-F	ATC CTG AGA CAA CAC TGA CA	Sip	0.2	Berseng 2007 [13]
	GBS-R	TTG CTG GTG TTT CTA TTT TCA		0.2	
	GBS-Probe	JOE-ATC AGA AGA GTC ATA CTG CYA CTT C-BHQ1		0.2	Tann 2014 [14]
<i>Staphylococcus aureus</i>	SA_Forward	GTA GAT TGG GCA ATT ACA TTT TGG AGG	Coa	0.15	Sabet 2006 [15]
	SA_Reverse	GGC ATC TGC TTT GTT ATC CCA TGT A		0.15	
	SA_Probe	FAM- TAG GCG CAT TAG CAG TTG CAT C-BHQ1		0.15	
<i>Streptococcus pyogenes</i>	GAS_Forward	TGG ATG TGG TTG CAG GTT TAG AC	csrR	0.3	Tann 2014 [14]
	GAS_Reverse	CGG GCA AGT AGT TCT TCA ATG G		0.3	
	GAS_Probe	JOE-CGG TGC AGA CGA CTA TAT TGT TAA ACC-BHQ1		0.2	
<i>Enterobacteriaceae</i> family	Ent_Forward	ACCTGGGTACWACCAACTCTTCTGT	dnaK	0.3	Tann 2014 [14]
	Ent_Reverse	GTCACCTGCCTGACGTTTAGC		0.3	
	Ent_Probe	JOE-AGGATGGTGAACACTGGTGGTCAGCC-BHQ1		0.3	
<i>Enterococcus faecium</i>	Fium_Forward	TTC TTT GCT TTA TCC GAT GT	ddlfm	0.2	Mohn 2004 [16]
	Fium_Reverse	CGG TTT TCT GCT TTT GTA AT		0.2	
	Fium_Probe	FAM- ACT AGA ACC CAT ATT CGC C-BHQ1		0.15	
<i>Enterococcus faecalis</i>	Falis_Forward	CGCTTCTTTCTCCCGAGT	16S	0.24	Santo Domingo 2003 [17]
	Falis_Reverse	GCCATGGGCATAAACTG		0.24	
	Falis_Probe	Hex-GAGGAGTGGGGAGC-BHQ1		0.15	
<i>Ureaplasma parvum</i>	UPure F	CAT TGA TGT TGC ACA AGG AGA AA	ure	0.24	Cao 2009 [18]
	UPure R	TTA GCA CCA ACA TAA GGA GCT AAA TC		0.24	
	UPure Probe	FAM-TTG ACC ACC CTT ACG AG-BHQ1		0.15	

Organism	Oligo Name	Sequence 5' to 3'	Target gene	Conc (µM)	Reference
<i>Ureaplasma urealyticum</i>	Uure_F	ATC GAC GTT GCC CAA GGG GA	ure	0.24	Cao 2009 [18]
	Uure_R	TTA GCA CCA ACA TAA GGA GCT AAA TC		0.24	
	Uure Probe	HEX-TTG TCC GCC TTT ACG AG-BHQ1		0.15	
<i>Mycoplasma genitalium</i>	MgPa-355F	GAGAAATACCTTGATGGTCAGCAA	G-37T	0.25	Jensen 2004 [19]
	MgPa-432R	GTTAATATCATATAAAGCTTACCGTTGTTATC		0.25	
	MgPa-380	FAM-ACTTTCCAATCAGAAAGTT-MGB		0.15	
<i>Mycoplasma hominis</i>	MHydCfwd	TCA CTA AAC CCG GTA TTT TCT AAC AA	yidC	0.25	Ferandon 2010 [20]
	MHydCrev	TTG GCA TAT ATT GCG ATA GTG CTT		0.25	
	MHydC	HEX- CTA CCA ATA ATT TTA ATA TCT GTC GGT ATG-BHQ1		0.15	
Internal positive control (added in A, B, C, D, E and F)	IPC_F	GGA CAC TAT GCC CCT CCT TAG A	mus	0.1	Tann 2014 [14]
	IPC_R	AGC TCCAAA CTC CGT CTC TGT AA		0.1	
	IPC_Probe	CY5-TTG GGA ACA AAA CAC CCA TGG AAG GA-BHQ3		0.1	
<i>Candida</i> spp.	cand-CR1 (forward)	CGGGTGGGAAATTCGGT	RPR1	0.1	Innings 2007 [22]
	cand-CR5 (reverse)	CAATGATCGGTATCGGGT		0.1	
	cand-ROX (reverse)	ROX- TTTCGCATATTgCACTAAaYaGa-BHQ2		0.1	
<i>C. glabrata</i>	gla-CR3 (forward)	RGCAACGGCTGGGAAT		0.1	
	cand-CR5 (reverse)	CAATGATCGGTATCGGGT		0.1	
	gla-JOE (reverse)	JOE-TAAAGCCTCACACGATTTTGACAC- BHQ1		0.1	
<i>C. krusei</i>	cand-CR1 (forward)	CGGGTGGGAAATTCGGT		0.1	
	krus-CR5 (reverse)	TAGTGATCGGTATCGAGTT		0.1	
	krus-Cy5 (reverse)	Cy5- CCAAACTTGTACAAGCAAGTACCA- BHQ3		0.1	
<i>C. albicans</i>	cand-CR1 (forward)	CGGGTGGGAAATTCGGT		0.1	
	cand-CR5 (reverse)	CAATGATCGGTATCGGGT		0.1	
	alb-FAM (reverse)	Fam-CAGCTTTGTAGTAAAGAATTACTCAC-BHQ1		0.1	

29.3.3 16S rRNA gene PCR

Samples testing negative by bacterial multiplex PCR were processed by 16S rRNA gene PCR using Power SYBR® Green PCR Master Mix (Life Technologies, Paisley, UK). 5 µl extracted DNA was added to 12.5 µl Master mix, 0.1 µM of forward primer 16SFa (GCTCAGATTGAACGCTGG), 0.05 µM each of forward primer 16SFb1 and 16SFb2 (GCTCAGGACGAACGCTGG and GCTCAGGATGAACGCTGG), 0.1 µM of reverse primer 16SR (ACTGCTGCCTCCCGTA) [21] and 6.5 µl molecular grade nuclease free water (Qiagen). This primer pair covers the highly variable region V1-V2, amplifying a PCR product of approximately 320 base pairs. This primer pair had been developed for routine use in Great Ormond Street Children Hospital clinical microbiology laboratory for diagnosis of culture negative samples and identification of unknown isolates [21].

29.3.4 *Candida* Multiplex PCR

Samples from which no bacterial pathogen was identified were further processed by a multiplexed real-time PCR targeting *C. albicans*, *C. glabrata*, *C. krusei*, *C. dubliniensis*, *C. famata*, *C. guilliermondii*, *C. parapsilosis* and *C. tropicalis* [22]. The reaction contained 13 µl of QuantiFast Multiplex mastermix (Qiagen), 7 µl of extracted DNA, and 0.1 each of primers (cand-CR1; cand-CR5) and 0.1 µM probe (cand-rox) (Table 29.1).

29.3.5 Sequencing

For positive *Enterobacteriaceae* and 16S rRNA gene PCR assays the resulting amplicon was sequenced using Big-dye 3.1 sequencing kit (Thermo Fisher, Paisley, UK) and run on a 3130 Genetic analyser (ThermoFisher).

29.3.6 Clinical Observations

Clinical signs to be recorded at enrolment were specified in the study proforma and included fever, hypothermia, respiratory distress, grunting, nasal flare, tachypnoea, recession/retraction, hypoxia, tachycardia, bradycardia, poor perfusion, hypotension, poor feeding, irritability, hypotonia, convulsions, apnoea, lethargy, metabolic acidosis, glucose imbalance, high white cell count (WCC), neutrophil count and raised C-reactive protein (CRP).

Fever was defined as axillary/central temperature of $\geq 38^{\circ}\text{C}$ on one occasion or $\geq 37.5^{\circ}\text{C}$ on two occasions separated by at least 1 h. A raised CRP was defined as >10 mg/L, a raised WCC as $(>20\,000 \times 10^9$ cells/L), glucose imbalance as $\leq 2.2/\geq 10$ mmol/l for 4 h in spite of corrective measures and metabolic acidosis as base excess (BE) ≥ -8 mmol/L over 4 h in spite of corrective measures.

To correlate the number of clinical signs and laboratory markers with bacterial load samples detected by qPCR, samples were grouped by their PCR signal into strongly positive (<35 Cq), positive (35–38 Cq), weakly positive (38–40 Cq)

and negative (>40 Cq or no signal) as is routine in clinical practice. In samples positive for multiple bacteria only the strongest signal was taken into account. The groups were compared using a two-tailed Fisher's exact test (GraphPad Software, La Jolla California, USA).

29.4 Results

29.4.1 Clinical Observations

Blood samples from 208 neonates were analyzed. Fifty-nine (28%) were preterm (<37 weeks gestational age), with 12 (6%) very preterm (28 to <32 weeks) and 11 (5%) extremely preterm (<28 weeks). Sixty mothers had received intrapartum antibiotics. One or more clinical signs were observed in 147 (71%) of all neonates: 17 (6 signs), 15 (5 signs), 19 (4 signs), 30 (3 signs), 36 (2 signs) and 30 (1 sign). The most commonly occurring signs were respiratory: tachypnoea, respiratory distress, grunting or recession. Sixty-five (31%) neonates had an elevated CRP. Of those, 27 neonates had an elevated CRP on initial screen and also on the following day, whilst 26 neonates had an elevated CRP only on the second day. A repeat CRP was not performed in all neonates; in 107 (51%) CRP results were only available from the day of the initial screen. An elevated white cell count was reported in 46 neonates (22%). All neonates survived to hospital discharge.

29.4.2 Culture Positivity

Samples from 5 neonates were culture positive and all were also positive by PCR for the same organism (four GBS and one *E. faecalis*). The remaining 203 samples were culture negative after five days of incubation and PCR detected an organism in 91 (45%) of these. The five infants ranged in gestation from 39 to 42 weeks. One baby had six clinical signs, two five and the remaining two had four clinical signs, ranging from fever, grunting, tachypnoea, recession, hypoxia, irritability, hypotonia and convulsions to glucose imbalance. In one of the five babies, the mother had received antenatal antibiotics.

29.4.3 Bacterial PCR

Samples from 208 neonates were tested by the bacterial real-time PCR panel and samples from 96 neonates tested positive for at least one bacterial species. Of those neonates with a positive bacterial PCR, 22 of 96 (23%) were born prematurely and 25 of their mothers (26%) had received intrapartum antibiotics. Clinical signs and/or laboratory results indicative of sepsis were present in 80 (83%); 69 (72%) had clinical signs; 34 (35%) had an elevated CRP and 23 (24%) had an abnormal white cell count. 18 samples tested positive for more than one bacterium. Seven of the 29 with no recorded clinical signs had

an elevated CRP (one of them also had an elevated WCC), a further six had an elevated WCC.

Of those neonates with a negative culture and a negative bacterial PCR ($n = 112$), 87 (77%) had clinical signs consistent with sepsis. Of the 32 with no clinical signs, seven had an elevated CRP and/or WCC.

Newborns with a positive PCR result did not differ significantly from those with a negative PCR result in term of clinical signs, laboratory markers prematurity or maternal antibiotic with the exception of hypothermia, which was significantly more common amongst infants with a positive PCR result (see Table 29.2).

Table 29.2 Most common signs and clinical features of newborns testing PCR positive vs negative

	PCR +ve % (N)	PCR -ve % (N)	p-value
Prematurity	23 (22)	32 (36)	0.25
Maternal antibiotics	26 (25)	33 (37)	0.47
Total symptomatic	83 (80)	77 (87)	0.48
Tachypnoea	43 (41)	40 (44)	0.67
Hypothermia	31 (30)	2 (2)	0.00026
Recession/retraction	25 (24)	28 (31)	0.74
Grunting	22 (21)	29 (33)	0.94
Fever	17 (16)	17 (19)	0.97
Nasal flare	11 (11)	13 (14)	0.90




Figure 29.1 Distribution of bacteria detected by specific bacterial PCR in 96 samples of neonates with suspected EOS.

The distribution of bacterial species detected by multiplex PCR is described in Fig. 29.1 and Table 29.3. The most frequently detected organisms were *S. aureus* in 28 samples (24%), *Enterobacteriaceae* in 23 samples (20%), *S. pneumoniae* in 21 samples (18%) and GBS in 17 samples (15%).

Table 29.3 Distribution of bacteria detected by multiplex PCR by Cq range

Pathogen	<35 Cq (strongly positive)	35–38 Cq (positive)	38–40 Cq (weakly positive)	% (N)
<i>S. aureus</i>	4	17	7	24 (28)
<i>Enterobacteriaceae</i>	5	18	0	20 (23)
<i>S. pneumoniae</i>	1	16	4	18 (21)
<i>Streptococcus agalactiae</i>	10	5	2	15 (17)
<i>Enterococcus</i> spp. ¹	4	7	2	11 (13)
GAS	2	4	2	7 (8)
<i>Ureaplasma</i> spp. ²	1	3	1	4 (5)
<i>M. hominis</i>	1	1	0	2 (2)
Total [% (n)]	24 (28)	60 (71)	15 (18)	100 (117)

Note: The total number of bacteria (117) is higher than the number of samples positive for multiplex PCR (96) as 18 samples contained multiple bacteria.

¹10 *E. faecalis*, 3 *E. faecium*.

²4 *U. parvum*, 1 *U. urealyticum*.

Table 29.4 Correlation between clinical signs/laboratory markers and PCR results

	<35 vs 35–38 Cq <35% (N)	<i>p</i> -value	35–38 vs Cq = 35–38% (N)	<i>p</i> -value	Cq = 38–40% (N)	38–40 vs >40 <i>p</i> -value
Laboratory markers						
CRP	50 (12)	0.08	29 (17)	0.74	36 (5)	0.34
WCC	25 (6)	1.00	27 (16)	0.16	7 (1)	0.30
Clinical signs						
≥1 sign	88 (21)	0.005	54 (32)	0.37	71 (10)	1
≥2 signs	75 (18)	0.02	46 (27)	1.00	43 (6)	0.27
≥3 signs	60 (14)	0.05	32(19)	1.00	29 (4)	0.56
≥ 4 signs	42 (10)	0.19	25 (15)	1.00	21 (3)	1.00
≥ 5 signs	38 (9)	0.009	10 (6)	0.64	14 (2)	1.00
≥ 6 signs	13 (3)	0.35	5 (3)	0.24	14 (2)	0.35

Note: This table shows the percentage (number) of infants with samples in each Cq range and number of clinical signs (1 to 6) as well as percentage (number) of infants with abnormal laboratory markers and the *p*-values as calculated by two-tailed Fisher's exact test.

Correlation between clinical signs/laboratory markers and PCR results.

Table 29.4 describes the association between clinical and laboratory features of infants with presumed sepsis and their PCR results. Neonates with strongly positive signals (<35 Cq) were likely to have more clinical signs than those with positive, weak or no signals. This was particularly so for strongly positive vs. positive signals for those with ≥ 1 sign ($p = 0.005$) and ≥ 5 signs ($p = 0.009$). Associations between abnormal CRP and WCC values with PCR results were less apparent.

Twenty-seven samples tested positive for *Enterobacteriaceae* by PCR and the resulting amplicons were sequenced. In 23 of these a single organism was identified by BLAST analysis to at least genus level whilst in the remaining four, sequence data appeared mixed or no data was produced. *E. coli* and *Enterobacter* spp. were detected most frequently (see Table 29.5).

Table 29.5 Enterobacteriaceae identified by Sanger sequencing of the Enterobacteriaceae dnaK PCR product from 23 samples

Amplicon sequencing results for pan- <i>Enterobacteriaceae</i> PCR positive samples	N
<i>E.coli</i>	7
<i>Enterobacter</i> spp.	5
<i>Enterobacter</i> spp./ <i>Citrobacter</i> spp.	3
<i>Klebsiella</i> spp.	2
<i>Klebsiella</i> spp./ <i>E. coli</i>	1
<i>Klebsiella</i> spp./ <i>Enterobacter</i>	1
<i>Citrobacter</i> spp.	1
<i>Citrobacter</i> spp./ <i>Pantoea</i> spp.	2
<i>Serratia</i> spp.	1
Total	23

In 18/117 (15%) of positive samples more than one pathogen was detected; 15 samples tested positive for 2 bacterial species and 1 sample each tested positive for 3 and 4 bacterial species. Table 29.6 shows the combinations of bacteria found together.

29.4.4 16S rRNA Gene PCR

In total 108 samples were processed by 16S rRNA gene PCR; these included samples positive for *Enterobacteriaceae* for which sequence-based identification could not be achieved.

Table 29.6 Combinations of bacteria found in 18 samples positive for more than one organism and their numbers

Polymicrobial infection	No.
<i>S. pneumoniae</i> + <i>S. aureus</i>	5
<i>S. pneumoniae</i> + GBS	2
<i>S. aureus</i> + <i>Enterobacteriaceae</i>	2
<i>S. aureus</i> + <i>Enterococcus</i> spp.	2
<i>S. pneumoniae</i> + <i>S. pyogenes</i>	1
<i>S. pneumoniae</i> + <i>Enterobacteriaceae</i>	1
GBS + <i>Enterobacteriaceae</i>	1
<i>U. parvum</i> + <i>S. aureus</i>	1
GBS + GAS	1
<i>S. pneumoniae</i> + <i>S. agalactiae</i> + <i>E. faecalis</i>	1
<i>S. pneumoniae</i> + <i>S. aureus</i> + <i>Enterococcus</i> spp. + <i>S. agalactiae</i>	1
Total	18

Of these, 13 were 16S rRNA gene PCR positive and sequencing of the PCR product identified *Streptococcus* spp. (mitis group) in two cases and *Propionibacterium* spp. in three cases. In four cases, waterborne organisms (*Pseudomonas* spp./*P. fluorescens*), likely to be contaminants, were identified; the remaining four cases showed a mixed or no sequence data.

29.4.5 *Candida* Multiplex PCR

Of the 60 samples that were negative by every other test, 36 had sufficient residual extract for testing with the *Candida* multiplexed PCR. All tested negative.

29.5 Discussion

A large number of neonates are treated with antibiotics for presumed infection despite having no organism detected in their blood cultures.

A recent meta-analysis on molecular assays for the diagnosis of sepsis in neonates reports a mean sensitivity of 0.90 and specificity of 0.93. The authors conclude that molecular assays are feasible in neonates and due to their rapid detection times compared to blood cultures may impact on early diagnosis and treatment [23].

This study investigated blood samples of neonates with suspected EOS and demonstrated that a panel of multiplexed real-time PCR assays could identify pathogens in 45% of cases where blood cultures were negative as well as correctly

identifying a pathogen in 100% of cases where blood cultures were positive. Furthermore, we have shown that higher bacterial load appears to correlate with the number of clinical signs at presentation. No significant association was detected between an abnormal CRP and PCR results, however this study was conducted before current NICE guidelines were implemented, which recommend to perform a repeat CRP at 18–24 h [24]. A CRP value from a sample obtained too early in life could represent a false negative. Only half of all neonates had results of a second CRP available, therefore a complete evaluation of this association was not possible.

The samples of this study were subject to some limitations. Extraction was performed on a robotic platform, a technique shown to be inferior to manual extraction in terms of DNA yield and purity [25]. Extracts were stored at -70° Celsius until final processing. Storage conditions can have significant impact on DNA integrity [26] and extracts are especially vulnerable to repeated freeze/thaw cycles [27]. A number of samples were subjected to repetitions of the different processing steps; potentially increased contamination and/or degradation could have occurred each time.

Some members of the *Enterobacteriaceae* family are ubiquitous skin and bowel commensals and environmental contaminants. The high number of these bacteria detected raises suspicion of contamination and amongst samples positive for *Enterobacteriaceae* only those yielding a sequence identifiable to genus level by BLAST analysis were therefore reported. This was based on the previous observation that contamination usually occurs with multiple species from this family (K. Harris–unpublished data).

Overall, *S. aureus* was the most frequently detected organism (23%) and even though generally considered as representing true infection [28], early infant colonization is not uncommon [29] and thus skin contamination may also have contributed to the high number found in this study.

Nonetheless, with cautious interpretation of these data, this study has notable findings. Most significantly, a large proportion of samples (45%) tested positive by bacterial multiplex PCR. In contrast, a pathogen was identified by routine culture methods in only 2.4%.

S. pneumoniae was present in 18% of all positive samples, more frequent than GBS (15%). *S. pneumoniae* is a relatively rare pathogen in neonatal sepsis (1–11%) [30], and a rare cause of neonatal skin colonization, yet when it occurs, the course of the disease has been reported to be more severe, particularly in EOS [31]. Early onset *S. pneumoniae* infection is often associated with maternal vaginal colonization or disease [32–34]. The bacterium can be difficult to culture, particularly following administration of intrapartum antibiotics [12, 35], which could lead to under diagnosis based on blood culture data. Thus this study might reflect a more accurate representation of its prevalence in newborn sepsis.

Enterococcus spp. were detected in 11% of all PCR positive cases. Of concern is that only in one case was it isolated by blood culture, despite there being no general awareness of difficulties in culturing these bacteria. An increase

of *Enterococcus* spp. in neonatal units has been reported [36] and concerns regarding the spread of vancomycin-resistant strains has prompted many units to adopt surveillance and control measures [37, 38].

GAS is considered a neonatal pathogen of the past [39]. However, PCR methods detected GAS in eight samples (7%). Similarly, *Ureaplasma* spp. and *Mycoplasma* spp., which have been associated with premature birth and infection [40], are rarely detected in cultures due to their fastidious growth requirements. PCR was able to identify these organisms in seven cases. Increased detection of these pathogens, together with further evidence of their significance, could have implications for treatment regimens.

A large number of samples (15%) tested positive for multiple bacteria. The proportion of mixed infections reported by culture based studies range from 1–19% [1, 41–45]. These results, to some extent, may represent contamination, as discussed above. However, polymicrobial bloodstream infections are important, as they are associated with a more than 3-fold increase in mortality, increase in duration of infection and greater severity of illness [45, 46].

The correlation between the number of clinical signs and PCR positivity is a novel finding and provides some confidence in the relevance of these tests. Clinical signs and laboratory markers are known to be subjective and non-specific in the context of neonatal sepsis [47] but have not been validated using PCR as gold standard. The only individual sign to show significance between PCR positive and negative cases was hypothermia, strengthening its value as a marker of sepsis. Clinical signs of sepsis to evaluate sepsis in this study are therefore also nonspecific and included signs of respiratory distress which may reflect different pathologies particularly in the premature infant. Our data suggests that use of PCR could provide insight into the value of different (and the number of) clinical signs and biomarkers in diagnosing neonatal sepsis.

29.6 Conclusions

Molecular diagnostic methods are capable of detecting a large number of pathogens in samples from neonates with suspected sepsis. False positive results can have significant implications for clinical practice as well as research. Therefore strict procedures for sample collection and processing to avoid contamination need to be applied, as well as cautious interpretation of results particularly when organisms associated with skin or environmental contamination are detected. In this study, in contrast to many studies based on culture, GBS was not the most commonly detected pathogen in early onset sepsis. Indeed, *S. pneumoniae* may be a more important pathogen in EOS than the existing literature indicates. Polymicrobial sepsis might also occur more often than currently estimated. As an additional diagnostic tool, PCR methods have the potential to increase diagnostic reliability of causal pathogens for neonatal sepsis. This could facilitate a reduction in unnecessary broad spectrum antibiotic

usage, and target treatment to improve outcomes, as well as limit the development of antibiotic resistance. Future studies could also explore associations of clinical signs and PCR positivity from different organisms.

Abbreviations

BE:	base excess
CRP:	C-reactive protein
EOS:	early onset sepsis
GAS:	group A Streptococcus
GBS:	group B Streptococcus
PCR:	polymerase chain reaction
qPCR:	quantitative PCR
WCC:	white cell count

Disclosures and Conflict of Interest

This chapter was originally published as Oeser, C., Pond, M., Butcher, P., Bedford Russell, A., Henneke, P., Laing, K., et al. (2020). PCR for the detection of pathogens in neonatal early onset sepsis. *PLoS ONE*, **15**(1), e0226817, <https://doi.org/10.1371/journal.pone.0226817>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

The authors received not specific funding for this work. The authors have declared that no competing interests exist. Data are available from NCBI (accession numbers MN865675-MN865689).

Author Contributions

Conceptualization: Clarissa Oeser, Marcus Pond, Philip Butcher, Paul T. Heath, Kathryn Harris; Data curation: Clarissa Oeser; Formal analysis: Clarissa Oeser; Investigation: Clarissa Oeser; Methodology: Clarissa Oeser, Marcus Pond, Philip Butcher, Alison Bedford Russell, Ken Laing, Timothy Planche, Kathryn Harris; Project administration: Clarissa Oeser; Resources: Philipp Henneke; Supervision: Philip Butcher; Writing – original draft: Clarissa Oeser; Writing – review & editing: Marcus Pond, Philip Butcher, Alison Bedford Russell, Philipp Henneke, Ken Laing, Timothy Planche, Paul T. Heath, Kathryn Harris.

References

1. Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al. Neonatal infections in England: the NeonIN surveillance network. *Arch Dis Child Fetal Neonatal Ed.* 2011; 96(1): F9–F14.

2. Stocker M, Fontana M, El Helou S, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. *Neonatology*. 2010; 97(2): 165–74.
3. Blackburn RM, Muller-Pebody B, Planche T, Johnson A, Hopkins S, Sharland M, et al. Neonatal sepsis—many blood samples, few positive cultures: implications for improving antibiotic prescribing. *Arch Dis Child Fetal Neonatal Ed*. 2012; 97(6): F487–8.
4. Wirtschafter DD, Padilla G, Suh O, Wan K, Trupp D, Fayard EE. Antibiotic use for presumed neonatally acquired infections far exceeds that for central line-associated blood stream infections: an exploratory critique. *J Perinatol*. 2011; 31(8): 514–8.
5. Patel SJ, Saiman L. Principles and strategies of antimicrobial stewardship in the neonatal intensive care unit. *Semin Perinatol*. 2012; 36(6): 431–6.
6. Patel SJ, Saiman L. Antibiotic resistance in neonatal intensive care unit pathogens: mechanisms, clinical impact, and prevention including antibiotic stewardship. *Clin Perinatol*. 2010; 37(3): 547–63.
7. Macharashvili N, Kourbatova E, Butsashvili M, Tsertsvadze T, McNutt LA, Leonard MK. Etiology of neonatal blood stream infections in Tbilisi, Republic of Georgia. *Int J Infect Dis*. 2009; 13(4): 499–505.
8. Yilmaz NO, Agus N, Helvacı M, Kose S, Ozer E, Sahbudak Z. Change in pathogens causing late-onset sepsis in neonatal intensive care unit in Izmir, Turkey. *Iran J Pediatr*. 2010; 20(4): 451–8.
9. Meropol SB, Edwards A. Development of the infant intestinal microbiome: a bird's eye view of a complex process. *Birth Defects Res Part C Embryo Today Rev*. 2015; 105(4): 228–39.
10. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sánchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. *Pediatrics*. 2009; 123(1): 58–66.
11. Muller-Pebody B, Johnson AP, Heath PT, Gilbert RE, Henderson KL, Sharland M; iCAP Group. Empirical treatment of neonatal sepsis: are the current guidelines adequate? *Arch Dis Child Fetal Neonatal Ed*. 2011; 96(1): F4–8.
12. Harris KA, Turner P, Green EA, Hartley JC. Duplex real-time PCR assay for detection of *Streptococcus pneumoniae* in clinical samples and determination of penicillin susceptibility. *J Clin Microbiol*. 2008; 46(8): 2751–8.
13. Berseng H, Bevanger L, Rygg M, Bergh K. Real-time PCR targeting the sip gene for detection of group B Streptococcus colonization in pregnant women at delivery. *J Med Microbiol*. 2007; 56(Pt 2): 223–8.
14. Tann C, Nkurunziza P, Nakakeeto M, Oweka J, Kurinczuk JJ, Were J et al. Prevalence of bloodstream pathogens is higher in neonatal encephalopathy cases vs. controls using a novel panel of real-time PCR assays. *PLoS One*. 2014; 9(5): e97259.
15. Sabet NS, Subramaniam G, Navaratnam P, Sekaran SD. Simultaneous species identification and detection of methicillin resistance in staphylococci using triplex real-time PCR assay. *Diagn Microbiol Infect Dis*. 2006; 56(1): 13–8.

16. Mohn SC, Ulvik A, Jureen R, Willems RJ, Top J, Leavis H et al. Duplex real-time PCR assay for rapid detection of ampicillin-resistant *Enterococcus faecium*. *Antimicrob Agents Chemother*. 2004; 48(2): 556–60.
17. Santo Domingo JW, Siefring SC, Haugland RA. Real-time PCR method to detect *Enterococcus faecalis* in water. *Biotechnol Lett*. 2003; 25(3): 261–5.
18. Cao X, et al., Real-time TaqMan polymerase chain reaction assays for quantitative detection and differentiation of *Ureaplasma urealyticum* and *Ureaplasma parvum*. *Diagn Microbiol Infect Dis*. 2007; 57(4): 373–8.
19. Jensen JS, Björnelius E, Dohn B, Lidbrink Use of TaqMan 5' nuclease real-time PCR for quantitative detection of *Mycoplasma genitalium* DNA in males with and without urethritis who were attendees at a sexually transmitted disease clinic. *J Clin Microbiol*, 2004; 42(2): 683–92.
20. Ferandon C, Peuchant O, Janis C, Benard A, Renaudin H, Pereyre S, et al., Development of a real-time PCR targeting the *yidC* gene for the detection of *Mycoplasma hominis* and comparison with quantitative culture. *Clin Microbiol Infect*. 2011; 17(2): 155–9.
21. Harris KA, Hartley JC. Development of broad-range 16S rDNA PCR for use in the routine diagnostic clinical microbiology service. *J Med Microbiol*. 2003; 52(Pt 8): 685–91.
22. Innings A, Ullberg M, Johansson A, Rubin CJ, Noreus N, Isaksson M, et al. Multiplex real-time PCR targeting the RNase P RNA gene for detection and identification of *Candida* species in blood. *J Clin Microbiol*. 2007; 45(3): 874–80.
23. Pammi M, Flores A, Versalovic J, Leeflang MMG. Molecular assays for the diagnosis of sepsis in neonates. *Cochrane Database of Sys Rev*. 2017; 2. CD011926.
24. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. *Clin Microbiol Rev*. 2014; 27(1): 21–47.
25. Riemann K, Adamizik M, Frauenrath S, Egensperger R, Schmid KW, Brockenmeyer NH, et al. Comparison of manual and automated nucleic acid extraction from whole-blood samples. *J Clin Lab Anal*. 2007; 21(4): 244–8.
26. Roder B, Fruhwirt K, Vogl C, Wagner M, Rossmanith P. Impact of long-term storage on stability of standard DNA for nucleic acid-based methods. *J Clin Microbiol*. 2010; 48(11): 4260–2.
27. Ross KS, Haites NE, Kelly KF. Repeated freezing and thawing of peripheral blood and DNA in suspension: effects on DNA yield and integrity. *J Med Genet*. 1990; 27(9): 569–70.
28. Hall KK, Lyman JA. Updated review of blood culture contamination. *Clin Microbiol Rev*. 2006; 19(4): 788–802.
29. Jimenez-Truque N, Tedeschi S, Saye EJ, McKenna BD, Langdon W, Wright JP, et al. Relationship between maternal and neonatal *Staphylococcus aureus* colonization. *Pediatrics*. 2012; 129(5): e1252–9.
30. Hoffman JA, Mason EO, Schutze GE, Tan TQ, Barson WJ, Givner LB, et al. *Streptococcus pneumoniae* infections in the neonate. *Pediatrics*. 2003; 112(5): 1095–102.
31. Gomez M, Alter S, Kumar ML, Murphy S, Rathore MH. Neonatal *Streptococcus pneumoniae* infection: case reports and review of the literature. *Pediatr Infect Dis J*. 1999; 18(11): 1014–8.

32. Simpson JM, Patel JS, Ispahani P. *Streptococcus pneumoniae* invasive disease in the neonatal period: an increasing problem? *Eur J Pediatr.* 1995; 154(7): 563–6.
33. Rhodes PG, Burry VF, Hall RT, Cox R. Pneumococcal septicemia and meningitis in the neonate. *J Pediatr.* 1975; 86(4): 593–5.
34. Sallam A, Paes B. *Streptococcus pneumoniae*: an old bug with significant maternal-newborn implications. *Am J Perinatol.* 2004; 21(8): 491–5.
35. Petti CA, Woods CW, Reller LB. *Streptococcus pneumoniae* antigen test using positive blood culture bottles as an alternative method to diagnose pneumococcal bacteremia. *J Clin Microbiol.* 2005; 43(5): 2510–2.
36. McNeeley DF, Saint-Louis F, Noel GJ. Neonatal enterococcal bacteremia: an increasingly frequent event with potentially untreatable pathogens. *Pediatr Infect Dis J.* 1996; 15(9): 800–5.
37. Sherer CR, Sprague BM, Campos JM, Nambiar S, Temple R, Short B, et al. Characterizing vancomycin-resistant enterococci in neonatal intensive care. *Emerg Infect Dis.* 2005; 11(9): 1470–2.
38. Singh N, Léger MM, Campbell J, Short B, Campos JM. Control of vancomycin-resistant enterococci in the neonatal intensive care unit. *Infect Control Hosp Epidemiol.* 2005; 26(7): 646–9.
39. Greenberg D, Leibovitz E, Shinnwell ES, Yagupsky P, Dagan R. Neonatal sepsis caused by *Streptococcus pyogenes*: resurgence of an old etiology? *Pediatr Infect Dis J.* 1999; 18(5): 479–81.
40. Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. *Clin Microbiol Rev.* 2005; 18(4): 757–89.
41. Yapicioglu H, Ozcan K, Sertdemir Y, Mutlu B, Satar M, Narli N, et al. Healthcare-associated infections in a neonatal intensive care unit in Turkey in 2008: incidence and risk factors, a prospective study. *J Trop Pediatr.* 2011; 57(3): 157–64.
42. Ronnestad A, Abrahamsen TG, Medbø S, Reigstad H, Lossius K, Kaaresen PI, et al. Septicemia in the first week of life in a Norwegian national cohort of extremely premature infants. *Pediatrics.* 2005; 115(3): e262–8.
43. Olsen AL, Reinholdt J, Jensen AM, Andersen LP, Jensen ET. Nosocomial infection in a Danish neonatal intensive care unit: a prospective study. *Acta Paediatr.* 2009; 98(8): 1294–9.
44. Wojkowska-Mach J, Borszewska-Kornacka M, Domańska J, Gadzinowski J, Gulczyńska E, Helwich E, et al. Early-onset infections of very-low-birth-weight infants in Polish neonatal intensive care units. *Pediatr Infect Dis J.* 2012; 31(7): 691–5.
45. Pammi M, Zhong D, Johnson Y, Revell P, Versalovic J. Polymicrobial bloodstream infections in the neonatal intensive care unit are associated with increased mortality: a case-control study. *BMC Infect Dis.* 2014; 14: 390.
46. Tsai MH, Chu SM, Hsu JF, Lien R, Huang HR, Chiang MC, et al. Polymicrobial bloodstream infection in neonates: microbiology, clinical characteristics, and risk factors. *PLoS One.* 2014; 9(1): e83082.
47. Chiesa C, Panero A, Osborn JF, Simonetti AF, Pacifico L. Diagnosis of neonatal sepsis: a clinical and laboratory challenge. *Clin Chem.* 2004; 50(2): 279–87.

Chapter 30

Multiplex qPCR Discriminates Variants of Concern to Enhance Global Surveillance of SARS-CoV-2

Chantal B. F. Vogels, PhD,^a Mallery I. Breban,^a Isabel M. Ott,^a Tara Alpert, PhD,^a Mary E. Petrone, MSc,^a Anne E. Watkins, MPH,^a Chaney C. Kalinich, MPH,^a Rebecca Earnest, MPH,^a Jessica E. Rothman, MSc,^a Jaqueline Goes de Jesus, PhD,^b Ingra Morales Claro,^b Giulia Magalhães Ferreira,^{b,c} Myuki A. E. Crispim,^d Brazil-UK CADDE Genomic Network,^e Lavanya Singh, PhD,^f Houriiyah Tegally,^f Ugochukwu J. Anyaneji,^f Network for Genomic Surveillance in South Africa,^e Emma B. Hodcroft, PhD,^g Christopher E. Mason, PhD,^h Gaurav Khullar, MD,^h Jessica Metti,^h Joel T. Dudley, PhD,^h Matthew J. MacKay,^h Megan Nash,^h Jianhui Wang, PhD,ⁱ Chen Liu, MD, PhD,ⁱ Pei Hui, MD, PhD,ⁱ Steven Murphy, MD,^j Caleb Neal, MPH,^j Eva Laszlo,^j Marie L. Landry, MD,^k Anthony Muyombwe, PhD,^l Randy Downing,^l Jafar Razeq, PhD,^l Tulio de Oliveira, PhD,^f Nuno R. Faria, PhD,^{b,m,n} Ester C. Sabino, PhD,^b Richard A. Neher, PhD,^{o,p} Joseph R. Fauver, PhD,^a and Nathan D. Grubaugh, PhD^{a,q}

^aDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA

^bDepartamento de Molestias Infecciosas e Parasitárias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

^cLaboratório de Virologia, Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil

^dFundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil

^eMembership of the Brazil-UK CADDE Genomic Network and the Network for Genomic Surveillance in South Africa (NGS-SA) is provided in the Acknowledgments

^fKwaZulu-Natal Research Innovation and Sequencing Platform, School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa

^gInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

^hTempus Labs, Chicago, Illinois, USA

ⁱDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA

^jMurphy Medical Associates, Greenwich, Connecticut, USA

^kDepartments of Laboratory Medicine and Medicine, Yale School of Medicine, New Haven, Connecticut, USA

^lConnecticut State Department of Public Health, Rocky Hill, Connecticut, USA

^mMRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College London, London, UK

ⁿDepartment of Zoology, University of Oxford, Oxford, UK

^oBiozentrum, University of Basel, Basel, Switzerland

^pSwiss Institute of Bioinformatics, Lausanne, Switzerland

^qDepartment of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut, USA

chantal.vogels@yale.edu, joseph.fauver@yale.edu, nathan.grubaugh@yale.edu

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

Keywords: complementary DNA (cDNA), Coronavirus Disease 2019 (COVID-19), cycle threshold (Ct), global initiative on sharing avian influenza data (GISAID), Institutional Review Board (IRB), open reading frame (ORF), reverse transcriptase quantitative PCR (RT-qPCR), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), spike gene target failure (SGTF), variants of concern (VOC), variants of interest (VOI)

30.1 Introduction

Broadly accessible and inexpensive surveillance methods are needed to track Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants of concern (VOC) around the world. While sequencing is the gold standard to identify circulating SARS-CoV-2 variants, routine genomic surveillance is not available in many locations primarily due to a lack of resources and expertise. In the current situation, with the identification of the VOC B.1.1.7, B.1.351, and P.1 [1–3] and with the likelihood that more will emerge, a lack of genomic surveillance leaves public health authorities with a patchy and skewed picture to inform decision-making. The discovery of B.1.1.7 variants causing spike gene target failure (SGTF) results when tested using the TaqPath PCR assay provided labs in the United Kingdom and throughout Europe with a ready-made, simple tool for tracking the frequencies of this variant [4–7]. As B.1.1.7 spread to other countries, TaqPath SGTF results were used as a frontline screening tool for sequencing and an approximation for B.1.1.7 population frequency [8]. These findings highlight the usefulness of a PCR assay that produces distinctive results when targeting variants in virus genomes for both tracking and sequencing prioritization.

The TaqPath assay was not specifically designed for SARS-CoV-2 variant surveillance, and it has several limitations. The 6-nucleotide deletion in the spike gene at amino acid positions 69 and 70 (spike $\Delta 69-70$) that causes the TaqPath SGTF is also present in other SARS-CoV-2 lineages (Fig. 30.1, Table S1), most notably in Pango lineages B.1.258 detected throughout Europe and in B.1.375 detected primarily in the United States [9, 10], meaning that SGTF results are not definitive for B.1.1.7. Furthermore, too much focus on TaqPath SGTF results will leave blind spots for other emerging SARS-CoV-2 VOC that do not have spike $\Delta 69-70$. In particular, B.1.351 and P.1, which were recently discovered in South Africa and Brazil [11, 12], respectively, may also be more transmissible and contain mutations that could help to evade immune responses [11–13]. For all of these reasons, a PCR assay specifically designed for variant surveillance would help to fill in many of the gaps about their distribution and frequency.




Figure 30.1 Identification of genome targets to differentiate B.1.1.7, B.1.351, P.1, and other SARS-CoV-2 lineages. (A) Location on the SARS-CoV-2 genome where the targeted deletions in the ORF1a gene at amino acid positions 3675–3677 (Δ3675–3677) and the spike gene at amino acid positions 69–70 (Δ69–70) occur. (B) The Nextstrain “global build” (nextstrain.org/ncov/global) accessed on January 22, 2021 showing the phylogenetic representation of 4,046 SARS-CoV-2 genomes colored by the presence of deletions at amino acid positions ORF1a 3575–3677 and spike 69–70. (C–F) Zooms of large SARS-CoV-2 clades, which include the VOC B.1.1.7, B.1.351, and P.1, containing 1 or both deletions. A list of SARS-CoV-2 genomes used in the analysis is available in S1 Data. *Abbreviations:* SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SGTF, spike gene target failure; VOC, variants of concern.

30.2 Results

We analyzed over 400,000 SARS-CoV-2 genomes on GISAID and used custom Nextstrain builds [14] to identify that a 9-nucleotide deletion in the ORF1a gene at amino acid positions 3675–3677 (ORF1a Δ 3675–3677) occurs in the B.1.1.7, B.1.351, and P.1 variants, but is only found in 0.03% (103/377,011) of all other genomes (Fig. 30.1, Table S1). Within the B.1.351 lineage, however, 18.4% of the sequences do not have ORF1a Δ 3675–3677 (Table S1). By designing a PCR assay that targets both ORF1a Δ 3675–3677 and spike Δ 69–70 (Fig. 30.1A), we can detect most viruses from all 3 current VOC (ORF1a results, Fig. 30.1B–E), differentiate B.1.1.7 (ORF1a and spike results, Fig. 30.1D–F), and provide results similar to TaqPath SGTF to compare datasets (spike results).

To create a multiplexed reverse transcription quantitative PCR (RT-qPCR) screening assay for the B.1.1.7, B.1.351, and P.1 variants, we designed 2 sets of primers that flank each of ORF1a Δ 3675–3677 and spike Δ 69–70 and probes specific to the undeleted “wild-type” sequences. As a control, we included the CDC N1 (nucleocapsid) primer and probe set that will detect both the wild-type and variant viruses [15]. As designed, testing SARS-CoV-2 RNA that contains ORF1a Δ 3675–3677 and/or spike Δ 69–70 will generate undetected cycle threshold (Ct) values with the specific PCR target sets as the probes cannot anneal to the deleted sequences, but will have “positive” N1 Ct values. This configuration ensures that target failures are likely due to the presence of deletions and that there is sufficient virus RNA for sequencing confirmation. Our RT-qPCR conditions are highly similar to our previously published SARS-CoV-2 multiplex assay [16], and a detailed protocol is openly available [17].

We evaluated the analytical sensitivity of our multiplexed RT-qPCR assay using synthetic RNA designed based on the original Wuhan-Hu-1 sequence and a B.1.1.7 sequence (England/205041766/2020). As the B.1.1.7 sequence contains both ORF1a Δ 3675–3677 and spike Δ 69–70 and the Wuhan-Hu-1 sequence contains neither deletion, using these RNAs allows us to fully evaluate the designed primer and probe sets. We tested a 2-fold dilution series from 100 copies/ μ L to 1 copy/ μ L for both RNA controls in triplicate (Table 30.1). Using the Wuhan-Hu-1 RNA, we found similar detection (within 1 Ct) across all 3 N1, ORF1a, and spike targets, and all 3 could detect virus RNA at our lowest concentration of 1 copy/ μ L, indicating that our primer and probes sets were efficiently designed. Using the B.1.1.7 RNA, we again could detect the RNA down to 1 copy/ μ L with the N1 set, but did not detect any concentration of the virus RNA with the ORF1a and spike sets, confirming the expected “target failure” signature when testing viruses containing both ORF1a Δ 3675–3677 and spike Δ 69–70. Overall, our PCR screening assay could easily differentiate between SARS-CoV-2 RNA with and without the ORF1a and spike deletions by comparing the Ct values to the N1 control.

Table 30.1 Analytical sensitivity of the multiplexed RT-qPCR assay to screen for VOC using primer/probe sets targeting key deletions

RNA	Concentration	N1-FAM			ORF1a-Cy5			Spike-HEX		
Wuhan-Hu-1	100 copies/ μ L	30.4	30.5	30.4	31.1	31.2	31.1	30.8	30.8	30.9
	50 copies/ μ L	31.5	31.5	31.4	32.1	32.1	32.0	31.9	31.6	31.7
	25 copies/ μ L	32.3	32.7	32.7	33.0	33.1	33.2	32.8	32.8	33.0
	12 copies/ μ L	33.3	33.7	33.3	34.1	34.2	34.2	34.0	33.6	34.1
	6 copies/ μ L	34.5	34.3	34.9	35.1	35.2	35.4	35.1	34.3	35.6
	3 copies/ μ L	35.0	37.0	36.1	35.6	36.6	36.8	35.4	36.1	35.8
	1 copy/ μ L	37.0	37.0	35.7	37.2	36.7	37.0	36.4	36.4	36.3
B.1.1.7	100 copies/ μ L	29.1	29.2	29.2	ND	ND	ND	ND	ND	ND
	50 copies/ μ L	30.1	30.2	30.2	ND	ND	ND	ND	ND	ND
	25 copies/ μ L	31.1	31.2	31.2	ND	ND	ND	ND	ND	ND
	12 copies/ μ L	32.5	32.2	32.1	ND	ND	ND	ND	ND	ND
	6 copies/ μ L	33.0	33.2	33.1	ND	ND	ND	ND	ND	ND
	3 copies/ μ L	33.7	34.6	34.0	ND	ND	ND	ND	ND	ND
	1 copy/ μ L	35.0	35.2	35.3	ND	ND	ND	ND	ND	ND

Note: Listed are Ct values for the 3 primer–probe sets targeting the SARS-CoV-2 nucleocapsid (N1-FAM), ORF1a 3675–3766 deletion (ORF1a-Cy5), and spike 69–70 deletion (Spike-HEX). Two-fold dilutions of synthetic control RNA (Wuhan-Hu-1 and B.1.1.7) were tested in triplicate.

Wuhan-Hu-1 = Twist synthetic RNA control 2; B.1.1.7 = Twist synthetic RNA control 14; N1-FAM = CDC N1 primer–probe set targeting the nucleocapsid with FAM fluorophore [15]; ORF1a-Cy5 = Yale primer–probe set targeting the ORF1a gene 3675–3677 deletion with Cy5 fluorophore [17]; Spike-HEX = Yale primer–probe set targeting the spike gene 69–70 deletion with HEX fluorophore [17].

Abbreviations: CT, cycle threshold; RT-qPCR, reverse transcription quantitative PCR; VOC, variants of concern.

Next, we validated our multiplex RT-qPCR variant screening assay using 1,361 known Coronavirus Disease 2019 (COVID-19) clinical samples that we have previously sequenced in our laboratories in the US, Brazil, and South Africa (Fig. 30.2, S2 Data). We tested 481 samples from SARS-CoV-2 lineages without either ORF1a Δ 3675–3677 and spike Δ 69–70 (classified as “other” lineage), 606 samples with both ORF1a Δ 3675–3677 and spike Δ 69–70 deletions, 227 samples with only the ORF1a Δ 3675–3677 deletion, and 47 samples with only the spike Δ 69–70 deletion. Of the samples without both deletions (expected outcome = detection with all 3 primer/probe sets), 1.2% (6/481) were P.2 (variants of interest [VOI]), 2.1% (10/481) were B.1.427 (VOC), 4.2% (20/481) were B.1.429 (VOC), and 92.5% (445/481) were other lineages not of current interest (Fig. 30.2A). Of the samples with both ORF1a Δ 3675–3677 and spike Δ 69–70 deletions (expected outcome = target failure with both the ORF1a and spike sets), 98.2% (595/606) were B.1.1.7 (VOC), 1.3% (8/606) were B.1.525 (VOI), and 0.5% (3/606)

were other lineages not of current interest (Fig. 30.2B). Of the samples with ORF1a $\Delta 3675\text{--}3677$, 11.5% (26/227) were B.1.351 (VOC), 9.3% (21/227) were P.1 (VOC), 70.9% (161/227) were B.1.526 (VOI; includes B.1.526.1 and B.1.526.2), and 8.4% (19/227) were other lineages not of current interest (Fig. 30.2C). Of the samples with only the spike $\Delta 69\text{--}70$ deletion, 87.2% (41/47) were B.1.375, and 12.8% (6/47) were other lineages not of current interest (Fig. 30.2D). Importantly, unlike the TaqPath assay SGTF results, we could differentiate between B.1.1.7 and other variants that only have the spike deletion, such as B.1.375 that is not currently a VOC/VOI.




Figure 30.2 ORF1a and spike target failure used to differentiate between SARS-CoV-2 VOC B.1.1.7, B.1.351, P.1, and other lineages currently not of concern. (A) Lineages (including B.1.427 and B.1.429) without target failure are detected by all 3 targets of the multiplex RT-qPCR assay. (B) Double target failure indicates the presence of the ORF1a $\Delta 3675\text{--}3677$ and spike $\Delta 69\text{--}70$ deletions and can be used to identify potential B.1.1.7 variants. (C) ORF1a target failure indicates the presence of the ORF1a $\Delta 3675\text{--}3677$ deletion, present in B.1.351 and P.1 VOC. (D) Spike target failure indicates presence of the spike $\Delta 69\text{--}70$ deletion, which is present in various lineages, including B.1.375. Shown are the Ct values for the N1, ORF1a, and spike primer-probe sets, with lines connecting Ct values obtained with the 3 sets for the same specimen. The dotted line indicates the limit of detection. Data used to make this figure can be found in S2 Data. Ct, cycle threshold; RT-qPCR, reverse transcription quantitative PCR; *Abbreviations*: SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; VOC, variants of concern; VOI, variants of interest.

When splitting up our findings by country, we tested a total of 1,290 samples from the US, 23 from Brazil, and 48 from South Africa. Within the US, the majority of samples were from Connecticut, Illinois, New Jersey, and New York. Of the samples without target failure, 2.2% (10/451) were B.1.427 (VOC), 4.4% (20/451) were B.1.429 (VOC), and 93.3% (421/451) were other lineages not of current interest. Of the samples with double target failure, 98.2% (595/606) were B.1.1.7 (VOC), 1.3% (8/606) were B.1.525 (VOI), and 0.5% (3/606) were other lineages not of current interest. Of the samples with ORF1a target failure, 1.1% (2/186) were B.1.351 (VOC), 2.7% (5/186) were P.1 (VOC), 86.6% (161/186) were B.1.526 (VOI; includes B.1.526.1 and B.1.526.2), and 9.7% (18/186) were other lineages. Of the samples with spike target failure, 87.2% (41/47) were B.1.375, and 12.8% (6/47) were other lineages. Thus, if we used ORF1a target failure (with or without spike target failure) to identify high priority samples for sequencing, we would have confirmed 100% of the B.1.1.7, B.1.351, and P.1 samples in the US. In addition, we would have detected 2 new VOI (B.1.525 and B.1.526, both containing the E484K mutation) [18] while triaging 34.9% (451/1,290) of the samples.

In Brazil, we tested samples from the cities of São Paulo and Manaus. Of the samples without target failure, 85.7% (6/7) were P.2 (VOI), and 14.3% (1/7) were other lineages. Of the samples with ORF1a target failure, 100% (16/16) were P.1 (VOC). Within South Africa, samples were tested from the KwaZulu-Natal Province. Of the samples without target failure, 100% (23/23) samples belonged to other lineages. Of the samples with ORF1a target failure, 96% (24/25) were B.1.351 (VOC), and 4% (1/25) belonged to other lineages. Thus, our clinical results demonstrate how our multiplex RT-qPCR assay can detect potential SARS-CoV-2 VOC and/or VOI from a variety of settings to prioritize samples for sequencing.

30.3 Discussion

The rapid emergence of the SARS-CoV-2 VOC necessitates an immediate roll out of surveillance tools. Although whole genome sequencing is required to definitively identify specific variants, resource and capacity constraints can limit the number of samples that can be sequenced. The Thermo Fisher TaqPath assay has demonstrated the value of PCR for variant surveillance, but it is limited to B.1.1.7 and cannot differentiate between other viruses containing spike $\Delta 69-70$. By targeting 2 different large nucleotide deletions, ORF1a $\Delta 3675-3677$ and spike $\Delta 69-70$, we demonstrate that our multiplex PCR can rapidly screen for B.1.1.7, B.1.351, and P.1 variants, detect other VOI, and differentiate between most non-VOC. Thus, our multiplex RT-qPCR variant screening assay can be used to prioritize samples for sequencing and as a surveillance tool to help monitor the distribution and population frequency of suspected variants.

There are some limitations to our study as presented here. First, we initially observed autofluorescence of the N1 primer-probe set when testing negative template controls. By lowering the N1 primers and probe concentrations to 200 nM and 100 nM per reaction, respectively, we have reduced autofluorescence

to levels above our threshold of Ct 35 (autofluorescence detected in 3/48 reactions with average Ct 39.6). Importantly, this PCR assay should only be used to screen known SARS-CoV-2 positive clinical samples for the presence of key deletions found in VOC (where autofluorescence will not be a factor), and it should not be used as a primary clinical diagnostic. We also suggest using a N1 threshold Ct of 30 to 35 for calling target failures in the ORF1a and spike sets and performing whole genome sequencing to confirm the identity of variants. For instance, the threshold for the system used in Brazil was lowered to Ct 30 as there did not seem to be consistent detection of all 3 sets above that threshold. Thus, the threshold may differ between used RT-qPCR kits and instruments and needs to be determined by individual laboratories.

Second, our assay will not be 100% sensitive and/or specific to all VOC or VOI, especially given the rapid emergence of new mutations and variants. For instance, we detected other recently emerged virus lineages with double target failure (notably B.1.525) and ORF1a target failure (notably B.1.526), which are not currently VOC. B.1.525 and B.1.526, however, are recognized as VOI as some contain the E484K and other key spike mutations that require further evaluation of their implications for transmissibility and immune escape [18]. Moreover, B.1.427 and B.1.429 (no gene target failure) have been recognized as VOC since the initial development of our assay [19], but neither cause ORF1a or spike target failures. Lastly, there is a monophyletic clade within the B.1.351 lineage that has ORF1a Δ 3675–3677 filled back in, perhaps due to recombination with viruses that did not have the deletion. Depending on changing scenarios, presence as well as absence of the ORF1a and spike deletions can both be used to target for potential VOC or VOI, or to estimate their frequencies over time. Thus, these examples demonstrate that continuous monitoring of the lineages that contain the ORF1a Δ 3675–3677 and spike Δ 69–70 deletions will be necessary to direct the local uses of our assay.

30.4 Materials and Methods

30.4.1 Ethics

United States. The Institutional Review Board (IRB) from the Yale University Human Research Protection Program determined that the RT-qPCR testing and sequencing of de-identified remnant COVID-19 clinical samples conducted in this study is not research involving human patients (IRB Protocol ID: 2000028599).

Brazil. Sample collection and genetic characterization were approved under the Brazilian National IRB (CONEP) CAAE 30101720.1.0000.0068.

South Africa. We used de-identified remnant nasopharyngeal and oropharyngeal swab samples from patients testing positive for SARS-CoV-2 by RT-qPCR from public health and private medical diagnostics laboratories in South Africa. The project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee (protocol reference no. BREC/00001195/2020;

project title: COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: epidemiological investigation to guide prevention and clinical care). Individual participant consent was not required for the genomic surveillance. This requirement was waived by the research ethics committees.

The sample IDs displayed in S2 Data are not known outside the research groups and cannot be used to reidentify any subject.

30.4.2 Analysis of Public SARS-CoV-2 Genomes

All available SARS-CoV-2 data (402,899 genomes) were downloaded on January 22, 2021 from GISAID and evaluated for the presence of ORF1a Δ 3675–3677 and spike Δ 69–70. Phylogenetic analysis of a subset of 4,046 SARS-CoV-2 genomes was performed using Nextstrain [14], downsampled as shown using the “global build” on January 22, 2021 (<https://nextstrain.org/ncov/global>). A list of SARS-CoV-2 genomes used in the analysis is available in S1 Data.

30.4.3 Multiplex RT-qPCR with Probes

A detailed protocol of our multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 VOC can be found on protocols.io [17]. In brief, our multiplex RT-qPCR assay consists of the CDC N1 [15] and the newly designed ORF1a Δ 3675–3677 and spike Δ 69–70 primer–probe sets (Table S2). We used the NEB Luna universal probe 1-Step RT-qPCR kit with 200 nM of N1 primers, 100 nM of N1 probe, 400 nM of the ORF1a and spike primers, 200 nM of ORF1a and spike probes, and 5 μ L of nucleic acid in a total reaction volume of 20 μ L. Thermocycler conditions were reverse transcription for 10 min at 55°C, initial denaturation for 1 min at 95°C, followed by 40 cycles of 10 s at 95°C and 30 s at 55°C. During initial validation, we ran the PCR for 45 cycles. Differentiation between VOC is based on target failure of the ORF1a and/or spike primer–probe sets (Table S3).

30.4.4 Limit of Detection

We used Twist synthetic SARS-CoV-2 RNA controls 2 (GenBank ID: MN908947.3; GISAID ID: Wuhan-Hu-1) and control 14 (GenBank ID: EPI_ISL_710528; GISAID ID: England/205041766/2020) to determine the limit of detection of the screening RT-qPCR assay. We tested a 2-fold dilution series from 100 copies/ μ L to 1 copy/ μ L for both RNA controls in triplicate and confirmed that the lowest concentration that was detected in all 3 replicates by 20 additional replicates.

30.4.5 Validation and Sequence Confirmation

United States. We validated our approach using known SARS-CoV-2 positive clinical samples. Briefly, we extracted nucleic acid from 300 μ L viral transport medium from nasopharyngeal swabs and eluted in 75 μ L using the MagMAX viral/pathogen nucleic acid isolation kit (Thermo Fisher Scientific, Waltham, MA,

United States). Extracted nucleic acid was tested by our multiplexed RT-qPCR assay and then sequenced using the Illumina COVIDSeq Test RUO version for the NovaSeq (paired-end 150), or using a slightly modified ARTIC Network nCoV-2019 sequencing protocol for the Oxford Nanopore MinION [20, 21]. These modifications include extending incubation periods of ligation reactions and including a bead-based clean-up step following dA-tailing. MinION sequencing runs were monitored using RAMPART [22]. Consensus sequences were generated using the ARTIC Network bioinformatics pipeline and lineages were assigned using Pangolin v.2.0 [23, 24]. GISAID accession numbers for all SARS-CoV-2 genomes used to validate our approach are listed in S2 Data.

Brazil. To validate the detection of the P.1 lineage, we selected 23 samples (16 P.1 and 7 others) that had been sequenced using the ARTIC protocol on the MinION sequencing platform, as previously described [12, 25]. In brief, viral RNA was isolated from RT-PCR positive samples using QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany), following the manufacturer's instructions. cDNA was synthesized with random hexamers and the Protoscript II First Strand cDNA synthesis Kit (New England Biolabs, Ipswich, MA, United States). Whole genome multiplex-PCR amplification was then conducted using the ARTIC network SARS-CoV-2 V3 primer scheme with the Q5 High-Fidelity DNA polymerase (New England Biolabs). Multiplex-PCR products were purified by using AmpureXP beads (Beckman Coulter, Brea, CA, United States), and quantification was carried out using the Qubit dsDNA High Sensitivity assay on the Qubit 3.0 (Life Technologies, Carlsbad, CA, United States). Samples were then normalized in an equimolar proportion of 10 ng per sample. After end repair and dA tailing, DNA fragments were barcoded using the EXP-NBD104 (1–12) and EXP-NBD114 (13–24) Native Barcoding Kits (Oxford Nanopore Technologies, Oxford, United Kingdom). Barcoded samples were pooled together and sequencing adapter ligation was performed using the SQK-LSK 109 Kit (Oxford Nanopore Technologies). Sequencing libraries were loaded onto an R9.4.1 flow-cell (Oxford Nanopore Technologies) and sequenced using MinKNOW version 20.10.3 (Oxford Nanopore Technologies). We tested RNA from sequenced samples with the multiplex RT-qPCR as described above using the Applied Biosystems 7500 real-time PCR machine (Thermo Fisher Scientific) and a lowered threshold of Ct 30.

South Africa. We extracted nucleic acid using the Chemagic 360 (PerkinElmer, Waltham, MA, United States). Briefly, 200 μ l of viral transport medium from each swab sample was extracted and eluted in 100 μ l using the Viral NA/gDNA kit. Complementary DNA (cDNA) synthesis, PCR, whole genome sequencing, and genome assembly was done as previously described in detail using the ARCTIC protocol [11, 20]. Out of the sequenced samples, we selected 24 B.1.351 samples and 24 samples belonging to other lineages to validate the RT-qPCR assay. We adapted the protocol by using the TaqPath 1-Step multiplex master mix (Thermo Fisher Scientific) with 5 μ l of extracted nucleic acid in a total reaction volume of 20 μ l. Samples were amplified using the QuantStudio 7 Flex Real-Time PCR System using the following PCR conditions: Uracil-N-glycosylase (UNG)

incubation for 2 min at 25°C, reverse transcription for 15 min at 50°C, polymerase activation for 2 min at 95°C, followed by 40 cycles of amplification at 95°C for 3 s and 55°C for 30 s.

30.5 Supporting Information

Table S1. Summary of SARS-CoV-2 genomes with the ORF1a 3675–3677 and/or Spike 69–70 deletions (GISAID on January 21, 2020). SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2. <https://doi.org/10.1371/journal.pbio.3001236.s001>.

Table S2. Primers and probes used in the multiplexed RT-qPCR variant screening assay. RT-qPCR, reverse transcription quantitative PCR. <https://doi.org/10.1371/journal.pbio.3001236.s002>.

Table S3. Interpretation of results from the multiplexed RT-qPCR variant screening assay. RT-qPCR, reverse transcription quantitative PCR. <https://doi.org/10.1371/journal.pbio.3001236.s003>.

S1 Data. Underlying data for Fig. 30.1. <https://doi.org/10.1371/journal.pbio.3001236.s004>.

S2 Data. Underlying data for Fig. 30.2. <https://doi.org/10.1371/journal.pbio.3001236.s005>.

Abbreviations

cDNA:	complementary DNA
COVID-19:	Coronavirus Disease 2019
Ct:	cycle threshold
IRB:	Institutional Review Board
NGS-SA:	network for Genomic Surveillance in South Africa
RT-qPCR:	reverse transcription quantitative PCR
SARS-CoV-2:	Severe Acute Respiratory Syndrome Coronavirus 2
SGTF:	spike gene target failure
UNG:	uracil-N-glycosylase
VOC:	variants of concern
VOI:	variants of interest

Disclosures and Conflict of Interest

This chapter was originally published as: Vogels, C. B. F., Breban, M. I., Ott, I. M., Alpert, T., Petrone, M. E., Watkins, A. E., et al. (2021). Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. *PLoS Biol.*, **19**(5), e3001236, <https://doi.org/10.1371/journal.pbio.3001236>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Genomic data are available on GISAID (see S2 Data for accession numbers). All RT-qPCR data are included in this article and the supporting information.

Funding: This work was funded by CTSA Grant Number TL1 TR001864 (TA and MEP), Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z; NRF), a Medical Research Council-São Paulo Research Foundation CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0; NRF), Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (NDG), and CDC Contract # 75D30120C09570 (NDG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

Members of Brazil-UK CADDE Genomic Network: Flavia Cristina da Silva Sales, Mariana Severo Ramundo, Darlan S. Candido, Camila Alves Maia Silva, Mariana Cardoso de Pinho, Thais de Moura Coletti, Pâmela dos Santos Andrade, Leandro Menezes de Souza, Esmênia Coelho Rocha, Ana Carolina Gomes Jardim, Erika Manuli, Nelson Gaburo Jr, Celso Granato, José Eduardo Levi, Silvia Costa, William Marciel de Souza, Maria Anice Salum, Rafael Pereira, Andreza de Souza, Lucy E. Matkin, Mauricio L. Nogueira, Anna Sara Levin, Philippe Mayaud, Neal Alexander, Renato Souza, Andre Luis Acosta, Carlos Prete, Joshua Quick, Oliver Brady, Janey Messina, Moritz Kraemer, Nelson da Cruz Gouveia, Izabel Oliva, Marcilio de Souza, Carolina Lazari, Cecilia Salete Alencar, Julien Thézé, Lewis Buss, Leonardo Araujo, Mariana S. Cunha, Nicholas J Loman, Oliver G. Pybus, and Renato S. Aguiar.

Members of Network for Genomic Surveillance in South Africa (NGS-SA): Eduan Wilkinson, Nokukhanya Msomi, Arash Iranzadeh, Vagner Fonseca, Deelan Doolabh, Emmanuel James San, Koleka Mlisana, Anne von Gottberg, Sibongile Walaza, Mushal Allam, Arshad Ismail, Thabo Mohale, Allison J. Glass, Susan Engelbrecht, Gert Van Zyl, Wolfgang Preiser, Francesco Petruccione, Alex Sigal, Diana Hardie, Gert Marais, Marvin Hsiao, Stephen Korsman, Mary-Ann Davies, Lynn Tyers, Innocent Mudau, Denis York, Caroline Maslo, Dominique Goedhals, Shareef Abrahams, Oluwakemi Laguda-Akingba, Arghavan Alisoltani-Dehkordi, Adam Godzik, Constantinos Kurt Wibmer, Bryan Trevor Sewell, José Lourenço, Sergei L. Kosakovsky Pond, Steven Weaver, Marta Giovanetti, Luiz Carlos Junior Alcantara, Darren Martin, Jinal N. Bhiman, and Carolyn Williamson.

Joseph R. Fauver and Nathan D. Grubaugh are joint senior authors on this work. Chantal B. F. Vogels and Mallery I. Breban contributed equally to this work. Membership of the Brazil-UK CADDE Genomic Network and the Network for Genomic Surveillance in South Africa (NGS-SA) is provided in the Acknowledgments.

Author Contributions

Conceptualization: Chantal B. F. Vogels, Richard A. Neher, Joseph R. Fauver, Nathan D. Grubaugh; **Data curation:** Chantal B. F. Vogels; **Formal analysis:** Chantal B. F. Vogels, Mallery I. Breban, Isabel M. Ott, Tara Alpert, Mary E. Petrone, Anne E. Watkins, Chaney C. Kalinich, Rebecca Earnest, Jessica E. Rothman, Jaqueline Goes de Jesus, Ingra Morales Claro, Giulia Magalhães Ferreira, Myuki A. E. Crispim, Lavanya Singh, Houriiyah Tegally, Ugochukwu J. Anyaneji, Tulio de Oliveira, Nuno R. Faria, Ester C. Sabino, Richard A. Neher, Joseph R. Fauver, Nathan D. Grubaugh; **Funding acquisition:** Nathan D. Grubaugh; **Investigation:** Chantal B. F. Vogels, Mallery I. Breban, Isabel M.

Ott, Tara Alpert, Mary E. Petrone, Anne E. Watkins, Chaney C. Kalinich, Rebecca Earnest, Jessica E. Rothman, Jaqueline Goes de Jesus, Ingra Morales Claro, Giulia Magalhães Ferreira, Myuki A. E. Crispim, Lavanya Singh, Houriiyah Tegally, Ugochukwu J. Anyaneji, Emma B. Hodcroft, Christopher E. Mason, Gaurav Khullar, Jessica Metti, Joel T. Dudley, Matthew J. MacKay, Megan Nash, Jianhui Wang, Chen Liu, Pei Hui, Steven Murphy, Caleb Neal, Eva Laszlo, Marie L. Landry, Anthony Muyombwe, Randy Downing, Jafar Razeq, Tulio de Oliveira, Nuno R. Faria, Ester C. Sabino, Richard A. Neher, Joseph R. Fauver, Nathan D. Grubaugh; Methodology: Chantal B. F. Vogels, Joseph R. Fauver, Nathan D. Grubaugh; Resources: Jaqueline Goes de Jesus, Ingra Morales Claro, Giulia Magalhães Ferreira, Myuki A. E. Crispim, Lavanya Singh, Houriiyah Tegally, Ugochukwu J. Anyaneji, Christopher E. Mason, Gaurav Khullar, Jessica Metti, Joel T. Dudley, Matthew J. MacKay, Megan Nash, Jianhui Wang, Chen Liu, Pei Hui, Steven Murphy, Caleb Neal, Eva Laszlo, Marie L. Landry, Anthony Muyombwe, Randy Downing, Jafar Razeq, Tulio de Oliveira, Nuno R. Faria, Ester C. Sabino, Nathan D. Grubaugh; Supervision: Joseph R. Fauver, Nathan D. Grubaugh; Validation: Chantal B. F. Vogels, Mallery I. Breban, Jaqueline Goes de Jesus, Ingra Morales Claro, Giulia Magalhães Ferreira, Myuki A. E. Crispim, Lavanya Singh, Houriiyah Tegally, Ugochukwu J. Anyaneji, Tulio de Oliveira, Nuno R. Faria, Ester C. Sabino, Joseph R. Fauver, Nathan D. Grubaugh; Visualization: Chantal B. F. Vogels, Emma B. Hodcroft, Nathan D. Grubaugh; Writing – original draft: Chantal B. F. Vogels, Nathan D. Grubaugh; Writing – review & editing: Chantal B. F. Vogels, Mallery I. Breban, Isabel M. Ott, Tara Alpert, Mary E. Petrone, Anne E. Watkins, Chaney C. Kalinich, Rebecca Earnest, Jessica E. Rothman, Jaqueline Goes de Jesus, Ingra Morales Claro, Giulia Magalhães Ferreira, Myuki A. E. Crispim, Lavanya Singh, Houriiyah Tegally, Ugochukwu J. Anyaneji, Emma B. Hodcroft, Christopher E. Mason, Gaurav Khullar, Jessica Metti, Joel T. Dudley, Matthew J. MacKay, Megan Nash, Jianhui Wang, Chen Liu, Pei Hui, Steven Murphy, Caleb Neal, Eva Laszlo, Marie L. Landry, Anthony Muyombwe, Randy Downing, Jafar Razeq, Tulio de Oliveira, Nuno R. Faria, Ester C. Sabino, Richard A. Neher, Joseph R. Fauver, Nathan D. Grubaugh.

Acknowledgments: The authors thank A. Brito, C. Chiu, A. Luring, A. Altajar, D. Comstock, P. Jack, S. Taylor, and V. Parsons for diagnostic samples, clinical support, and/or discussion. A list of acknowledgements for the SARS-CoV-2 data used in Fig. 30.1 can be found in the S1 Data.

References

1. Davies NG, Barnard RC, Jarvis CI, Kucharski AJ, Munday J, Pearson CAB, et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. medRxiv 2020.12.24.20248822; doi: <https://doi.org/10.1101/2020.12.24.20248822>.
2. Rambaut A, Loman N, Pybus O BW, Barrett J, Carabelli A, Connor T, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. 2020. Available at: <https://virological.org/t/preliminary->

- genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (accessed on November 20, 2022).
3. Luring AS, Hodcroft EB. Genetic variants of SARS-CoV-2—What do they mean? *JAMA*. 2021;325(6):529–531.
 4. Borges V, Sousa C, Menezes L, A MG, Picão M, Almeida JP, et al. Tracking SARS-CoV-2 VOC 202012/01 (lineage B.1.1.7) dissemination in Portugal: insights from nationwide RT-PCR Spike gene drop out data. 2021. Available at: <https://virological.org/t/tracking-sars-cov-2-voc-202012-01-lineage-b-1-1-7-dissemination-in-portugal-insights-from-nationwide-rt-pcr-spike-gene-drop-out-data/600> (accessed on November 20, 2022).
 5. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. *medRxiv*. 2021.
 6. Thermo Fisher Scientific. Solutions for surveillance of the S gene mutation in the B.1.1.7 (501Y.V1) SARS-CoV-2 strain lineage. 2020. Available at: <https://www.thermofisher.com/blog/behindthebench/solutions-for-surveillance-of-the-s-gene-mutation-in-the-b117-501yv1-sars-cov-2-strain-lineage/> (accessed on November 20, 2022).
 7. Kidd M, Richter A, Best A, Mirza J, Percival B, Mayhew M, et al. S-variant SARS-CoV-2 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-QPCR. *medRxiv*. 2020.
 8. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, et al. Emergence of SARS-CoV-2 B.1.1.7 lineage—United States, December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep*. 2021; 70: 95–99.
 9. Moreno G, Braun K, Larsen BB, Alpert T, Worobey M, Grubaugh N, et al. Detection of non-B.1.1.7 spike $\Delta 69/70$ sequences (B.1.375) in the United States. 2021. Available at: <https://virological.org/t/detection-of-non-b-1-1-7-spike-69-70-sequences-b-1-375-in-the-united-states/587/2> (accessed on November 20, 2022).
 10. Larsen BB, Worobey M. Identification of a novel SARS-CoV-2 Spike 69–70 deletion lineage circulating in the United States. 2020. Available at: <https://virological.org/t/identification-of-a-novel-sars-cov-2-spike-69-70-deletion-lineage-circulating-in-the-united-states/577> (accessed on November 20, 2022).
 11. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*. 2020.
 12. Faria NR, I MC, Candido D, La MF, Andrade PS, Coletti TM, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. 2021. Available at: <https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586> (accessed on November 20, 2022).
 13. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. *Cell Host Microbe*. 2021; 29(3): 463–476.e6.
 14. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*. 2018; 34: 4121–4123.
 15. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, et al. US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome

- coronavirus 2. *Emerg Infect Dis.* 2020; 26(8). Available at: https://wwwnc.cdc.gov/eid/article/26/8/20-1246_article (accessed on November 20, 2022).
16. Kudo E, Israelow B, Vogels CBF, Lu P, Wyllie AL, Tokuyama M, et al. Detection of SARS-CoV-2 RNA by multiplex RT-qPCR. *bioRxiv.* 2020.
 17. Vogels C, Fauver J, Grubaugh N. Multiplexed RT-qPCR to screen for SARS-CoV-2 B.1.1.7, B.1.351, and P.1 variants of concern v3. protocols.io. ZappyLab, Inc.; 2021. Available at: <https://www.protocols.io/view/multiplexed-rt-qpcr-to-screen-for-sars-cov-2-b-1-1-br9vm966> (accessed on November 20, 2022).
 18. Lasek-Nesselquist E, Lapierre P, Schneider E, St. George K, Pata J. The localized rise of a B.1.526 variant containing an E484K mutation in New York State. medRxiv. 2021.
 19. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv 2021.03.07.21252647; doi: <https://doi.org/10.1101/2021.03.07.21252647>.
 20. Quick J. nCoV-2019 sequencing protocol v3. 2020. Available at: <https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye> (accessed on November 20, 2022).
 21. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. *Nat Protoc.* 2017; 12: 1261–176.
 22. Artic Network. 2020 [cited 25 Jan 2021]. Available at: <https://artic.network/ncov-2019/ncov2019-using-rampart.html> (accessed on November 20, 2022).
 23. Artic Network. 2020 [cited 25 Jan 2021]. Available at: <https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html> (accessed on November 20, 2022).
 24. Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol.* 2020; 5:1403–1407.
 25. Tyson JR, Phillip J, Stoddart D, Sparks N, Wickenhagen A, Hall G, et al. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. *bioRxiv.* 2020.

Chapter 31

Diagnosing Point-of-Care Diagnostics for Neglected Tropical Diseases

**Mitasha Bharadwaj, PhD, Michel Bengtson, PhD, Mirte Golverdingen, MSc,
Loulotte Waling, MSc, and Cees Dekker, PhD**

*Department of Bionanoscience, Kavli Institute of Nanoscience Delft,
Delft University of Technology, Delft, The Netherlands*

c.dekker@tudelft.nl

Keywords: ancillary testing, aptamer-linked immunosorbent assays, bedside testing, biomarker-based PoC tests, clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), community healthcare worker (CHW), cross-reactivity, customized PoC diagnostics, diagnostics, disability-adjusted life year (DALY), Dual Path Platform (DPP), enzyme-linked aptamer assays, enzyme-linked oligonucleotide assays, immunological PoC tests, lab-on-a-chip, loop-mediated isothermal amplification (LAMP), medical Subject Headings (MeSH), molecular PoC tests, multiplexed testing, near-patient laboratory testing, neglected tropical diseases (NTDs), next generation sequencing (NGS), nucleic acid amplification tests (NAATs), nucleic-acid-based PoC tests, point-of-care (PoC), point-of-care circulating cathodic antigen (POC-CCA), polymerase chain reaction (PCR), post-kala-azar dermal leishmaniasis (PKDL), recombinase polymerase amplification (RPA), remote rapid testing, Sexually Transmitted Diseases Diagnostics Initiative (SDI), tuberculosis (TB), turnaround time (TAT), up-converting phosphor lateral flow circulating anodic antigen (UCP-LF CAA), visceral leishmaniasis-lateral flow device (VL-LFD), World Health Organization (WHO)

31.1 Point-of-Care Diagnostics

The International Organization for Standardization defines point-of-care (PoC) diagnostic testing as “testing that is performed near or at the site of a patient with the result leading to a possible change in the care of the patient” [1]. In practical implementations, a PoC test is a specific and sensitive assessment wherein a user

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

needs to administer a minimum number of steps to obtain an easy-to-interpret, rapid (within a short turnaround time (TAT)), and robust result. PoC tests are used everywhere within the health chain where there is need for a fast diagnostic outcome that is independent from sophisticated, time-consuming, labor-intensive, and expensive laboratory procedures. PoC tests are usually designed to function equipment free as portable units with stable reagents that function efficiently within a broad range of environmental settings. Because of these favorable characteristics, PoC diagnostics is also known as “bedside testing,” “remote rapid testing,” “near-patient laboratory testing,” “ancillary testing,” and “decentralized testing” [2–4].

The ease of use of PoC diagnostics clearly exhibits potential to serve as an early diagnostic tool in resource-limited settings. Especially with recent advances in PoC diagnostics based on “lab-on-a-chip” technology, PoC tests can be applied for triage, test of cure, and/or confirmatory diagnostics [5, 6]. While a confirmatory test, by definition, verifies a diseased state, a test of cure is used to validate the efficacy of the administered treatment and to distinguish relapse of a disease and reinfections. PoC diagnostics can circumvent issues such as shortage of healthcare staff and underequipped laboratories, thereby improving clinical interventions, which is especially advantageous in resource-limited settings. PoC tests can be field deployable, i.e., they have the ability to be administered in the field within resource-limited settings without the need for a laboratory, which are equipped with sophisticated equipment such as microscopes. Furthermore, PoC diagnostics can also be multiplexed, i.e., simultaneously diagnose more than 1 pathogen from a single sample. Thus, PoC diagnostics, especially when multiplexed, can reduce treatment costs, support disease surveillance, and minimize the unnecessary use of antimicrobials, thereby preventing the emergence of resistant strains [5]. In a nutshell, simple, rapid, reproducible, and robust PoC diagnostic tests are a preferred choice for the diagnosis of neglected tropical diseases (NTDs) that are endemic in resource-limited settings.

NTDs are diseases of poverty that affect more than a billion people worldwide. These communicable diseases are endemic to regions that have limited access to healthcare, and, hence, despite available treatments, they can be fatal. These diseases are referred to as “neglected” as they receive inadequate attention, e.g., in terms of research funding, when compared to other diseases such as malaria, human immunodeficiency virus, and tuberculosis (TB) [7]. NTDs represent a disease burden of at least 22 million disability-adjusted life years (DALYs) lost, roughly half the burden of TB or malaria [7]. The World Health Organization (WHO) has identified 24 NTDs, for control and elimination in the 2021–2030 roadmap [8]. Although tremendous progress has been made in combatting NTDs over the past decade, they still prevail in high incidence numbers, significantly contributing to numerous DALYs of afflicted populations (Fig. 31.1). In effect, NTDs pose the biggest disease burden to developing tropical economies [9–13].




Figure 31.1 Spread of NTDs. Cumulative DALYs lost of afflicted populations due to the NTDs human African trypanosomiasis, chagas disease, schistosomiasis, leishmaniasis, lymphatic filariasis, onchocerciasis, taeniasis cysticercosis, echinococcosis, dengue, trachoma, rabies, leprosy, and soil-transmitted helminthiases. World map adapted from WHO [8].

Abbreviations: DALY, disability-adjusted life year; NTD, neglected tropical disease; WHO, World Health Organization.

WHO's Sexually Transmitted Diseases Diagnostics Initiative (SDI) developed the ASSURED criteria as a benchmark for diagnosis, which stands for affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and deliverable to end users [14]. Recent advances in the PoC diagnostics highlighted the issues with data and sample collection; therefore, new term "REASSURED" was coined comprising of real-time connectivity and ease of specimen collection and environmental friendliness to existing ASSURED [15]. Furthermore, disease-specific guidelines called "target product profiles" have been developed for certain NTDs. Unfortunately, despite multiple guidelines such as these for NTDs, there is a lack of commercially viable diagnostic tests, i.e., certified by regulatory commissions for medical use. Thus, while scientific research has been conducted for recognizing new targets and novel approaches for NTDs diagnoses, the tests based on such research are typically not developed further for their commercial use [16–20]. The need of the hour is commercially available, field-deployable PoC tests to facilitate early disease diagnosis, which is crucial for NTDs control and treatment, and for designing strategies for the gradual elimination of these endemic diseases.

In this review, we first discuss different technical approaches for PoC diagnostic tests, i.e., their basic working principle, advantages, and limitations.

Next, in the core of this review, we outline the status quo of PoC NTD diagnostics, highlighting the implementation need for various PoC NTD diagnostics. We end with a discussion and recommendations for future developments to further accelerate the goal of achieving efficient NTD diagnostics.

31.2 Three Different Approaches for PoC Diagnostics

At the heart, PoC diagnostics is an approach to identify and possibly quantify a specific analyte. Based on the variety of biomolecular ways for detection of specific analytes, PoC tests can be classified into immunological tests, nucleic acid-based tests, and other biomarker-based tests (Fig. 31.2)—which we describe below.




Figure 31.2 Three types of PoC diagnostic tests. A biological sample (such as blood, urine, saliva, sweat, etc.) can be utilized for various types of PoC diagnosis. **Left:** immunological PoC test. A biological sample is dropped onto the sample pad of a lateral flow assay, which acts as a filtering unit to sieve out unnecessary constituents. Upon administration of a reaction buffer (or its automated release), the analyte flows through the reagent pad, wherein an antigen–antibody complex is formed. Driven by capillary action, this complex migrates to the next zone with control and test lines. While the appearance of a visible color at the test line confirms the infection, the control line signal ensures the test functionality. **Middle:** nucleic acid–based PoC test. Here, genetic material of a pathogen serves as the analyte. DNA/RNA from the pathogen is extracted from infected host cells or circulating cell free within the clinical sample (body fluids). While extracted RNA is first reverse transcribed to obtain cDNA, extracted DNA can be directly amplified using PCR or using isothermal amplification (e.g., RPA or LAMP), typically in a fully automated portable unit. In some systems, the amplified DNA is then used for CRISPR/Cas recognition or other downstream processing to yield a diagnostic result within a lateral flow assay or a microfluidic lab-on-a-chip device. NGS can also be utilized to identify specific diseases using a portable sequencer. **Right:** biomarker-based PoC test (other than antigen biomarkers). A biological sample is administered onto the test pad that in this case has specific surface-bound molecules such as aptamers that target the analyte. Upon successful interactions, a visible color readout is obtained. The test can be in the form of separate wells. *Abbreviations:* LAMP, loop-mediated isothermal amplification; NGS, next-generation sequencing; PCR, polymerase chain reaction; PoC, point-of-care; RPA, recombinase polymerase amplification.

31.2.1 Immunological PoC Tests

Immunological PoC tests detect the presence of an antigen (or its molecular counterpart) or an antibody that is generated as an immune response to an infection. In these PoC tests, an antibody/antigen immobilized on a solid substrate binds to the specific analyte, forming an immune complex that subsequently generates a signal that is visible to a naked eye (Fig. 31.2). The specific antigen–antibody interactions that are at the core of these immunosensors allow for both qualitative detection and quantitative assessment.

Immunological PoC tests have numerous advantages and hence are among the most commonly used tests. In addition to a quick TAT of approximately 15 min, these PoC tests do not require sample preparation, and, thus, a clinical sample can be administered onto the test pad directly. Immunological PoC tests can be field deployable as they are simple, rapid, easy to use, equipment free, and robust, thus allowing administering at decentralized locations in an NTD-endemic region. Moreover, immunological PoC tests are cost effective compared to the other PoC approaches [21] discussed below.

Immunological PoC tests also have limitations [22]. Due to cross-reactivity, autoantibodies and rheumatoid factors can reduce the efficacy of antigen-based immunological PoC tests, as these molecules can specifically bind to free antigens in the sample and thereby block them from interacting with the specific antibody immobilized on the immunosensor. Antigen quantity also critically influences early disease diagnosis. While low antigen levels might result in false negatives, high levels of the antigen can cause “prozone” wherein excess antigen occupies most of the antibody-binding sites and interferes with the downstream steps, thus resulting in false negative test results (hook effect). Antigen denaturation is another major factor affecting the lifetime and functionality of antigen-based PoC tests. Furthermore, antibody-based tests in general cannot be used as a confirmatory test or as a test of cure because they can provide false positive results due to the presence of antibodies that persist postinfection in the body. Furthermore, the growth cycle of a pathogen can influence the immune response. While fast-growing pathogens could elicit an immune response within a few days of infection, slow-growing pathogens could take weeks before a detectable amount of antibody can appear in the bodily fluid, resulting in false negative results. In many cases, pathogens can evade the immune system and reside in the body for weeks to months before a detectable immune response is generated (asymptomatic carriers). Likewise, the overall efficiency of an immunological PoC test may be influenced by the varying immune responses of individuals within a population, especially when afflicted populations are malnourished or have compromised immune systems due to comorbidities. Finally, multiplexing immunological PoC tests is challenging as the test can favor one analyte over another, affecting the analytical efficiency. Immunological PoC tests are also not ideal to diagnose species specificity and to prescribe optimal treatment choices, for example, in antibiotic therapy. Therefore, immunological PoC tests are mostly

used as screening tests to select patients for subsequent confirmatory diagnosis [2, 23].

31.2.2 Nucleic Acid–Based PoC Tests (Molecular PoC Tests)

Nucleic acid–based PoC tests probe for the presence of genetic material of the pathogen (DNA or RNA) to diagnose specific diseases. While specific amplification of the pathogen's genetic material for disease diagnosis can be performed using nucleic acid amplification tests (NAATs), mapping of the pathogen sequence for diagnosis is commonly done by next-generation sequencing (NGS) of the DNA/RNA (Fig. 31.2). Commercially available PoC NAATs are based on the polymerase chain reaction (PCR) that occurs in a closed automated device that utilizes prepackaged single-use integrated cartridges filled with reagents for the nucleic acid amplification [2]. The user simply needs to load the sample fluid and start the reaction by pressing a button. The entire PCR reaction then proceeds inside the device, and the result is displayed within a TAT of 20 to 60 min on a screen. Such small, portable, and battery/power-operated PCR units can be used for the detection of a range of pathogens by simply adapting the cartridges [24, 25].

With the increasing demand for field-deployable PoC molecular diagnostic tests, new isothermal NAATs are being designed that, unlike PCR, do not require a thermocycler but instead function at a constant temperature, for example, at 37°C or even at room temperature [26, 27]. Examples of commonly used isothermal NAATs are strand displacement amplification, loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA), techniques that allow the amplification and detection within a TAT of 20 min. As these methods may suffer from relatively low specificity, novel Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based systems are being developed to function downstream of isothermal NAATs to enhance the specificity [17]. Capable of multiplexing, such detection systems could potentially become the best PoC molecular diagnostic toolbox. Owing to advancements in in-silico approaches, unique DNA targets can be identified for every pathogen. Thus, nucleic acid–based PoC tests can be multiplexed and have the potential to detect many diseases simultaneously ($n \geq 100$ with microarrays) [28]. However, so far, they have been restricted to laboratory diagnostics, and further development is needed to adapt them into field-deployable PoC tests [29–33]. Portable NGS devices are one of the most promising candidates for efficient PoC diagnostics in the near future. Similar to NAATs, innovative Next Generation Sequencing (NGS) technologies have been developed for nontrained personnel with simplified handling, fast and accurate results, and reduced sample volumes [34].

Nucleic acid–based PoC tests provide a range of advantages. Given their very high sensitivity and specificity, they can detect even a single pathogen in a biological sample. Furthermore, they lend themselves well for multiplexing. These PoC tests can serve as confirmatory diagnostics as they can identify the infection etiology, microbial resistance, and the extent of an infection

(virulence)—thereby accelerating the choice of treatment [35]. Limitations of nucleic acid-based PoC tests are mostly found in the pretreatment of the samples. Owing to the extreme sensitivity of nucleic acid-based tests, uncontaminated input samples need to be administered in a closed automated unit to avoid false positive results [36]. A further challenge can be to ensure accurate detection of traces of microbial nucleic acids within the pool of other components in the biological sample, say, the human genome, to avoid false negative results. A related challenge is to ensure specificity by identifying a unique target for the pathogen's DNA that does not exhibit any homology with other genomes in the sample. At this point in time, nucleic acid-based PoC tests are too costly for resource-limited settings [37]. On top of that, additional costs due to hardware infrastructure for data handling may be a concern in such settings [34].

31.2.3 Biomarker-Based PoC Tests

Biomarkers are biological molecules (other than antigens) that occur naturally in living beings and can be used to indicate a diseased state when deviations occur in their concentrations from the physiologically normal value. In this review, we refer to biomarkers as any molecule other than the antigen itself or the antibody that is elicited in response to the infection (cf. Section 31.2.1) or the pathogen's nucleic acid material (cf. Section 31.2.2). While a plethora of biomarkers has been identified for infectious disease diagnosis [38, 39], C-reactive protein is so far the only biomarker that is available as a commercial PoC test for infectious diseases, and it is used for selecting effective antimicrobial treatment in acute respiratory tract infections [2].

New opportunities for biomarker-based PoC tests are emerging with aptamers-specific oligonucleotide sequences that bind a biomarker with high affinity. Since aptamers are synthetically produced, unlike antibodies, they are highly reproducible, cost effective, and easy to modify. Aptamers are thermostable and can be reversibly denatured, making them a potent biosensor for PoC tests (Fig. 31.2). These “aptasors” have, for example, been developed for aptamer-linked immunosorbent assays or enzyme-linked oligonucleotide assays also known as enzyme-linked aptamer assays [40–42].

The main advantages of biomarker-based PoC tests are that they can provide fast and accurate results [38, 42]. Quite some research is ongoing to develop biomarker-based PoC tests for confirmatory diagnosis. A major disadvantage is the higher costs in the development and commercial applicability of biomarker-based PoC tests compared to immunological PoC tests [2].

31.3 PoC Tests for Neglected Tropical Diseases

Owing to the advantages of PoC tests, they are highly preferred for diagnosing NTDs in resource-limited settings. NTD diagnostics is challenging since these diseases often strongly relate to the context, which includes the needs and capabilities of

the end users, available resources and infrastructure, extent of disease endemicity, and treatment options [20]. Successful implementation of NTD PoC diagnostics must therefore consider, in addition to the technical efficiency, the context-specific requirements.

In this chapter, we comprehensively summarize the available literature for each of the 24 NTDs that were identified in the 2021–2030 roadmap of WHO [8], focusing on their current diagnostics, specifically on PoC tests if available, and the implementation need for future PoC diagnostics. An extensive overview is provided in the Supporting information. A detailed evaluation of the status quo of PoC diagnostics for all 24 NTDs facilitated us to formulate prerequisites of a PoC test that would fit the disease-specific context. Next to recognizing the required technical improvements, complimentary needs were identified based on the treatment and follow-up routines for the NTDs. A summary of the resulting information on the current PoC tests (both commercially available tests as well as tests in the pilot phase) and implementation needs for future PoC tests is presented in Table 31.1.

We found that 6 NTDs do not have any commercially available PoC tests, 16 NTDs are currently diagnosed with immunological PoC tests, and 7 NTDs are currently diagnosed with nucleic acid–based tests. The 6 NTDs for which no commercially available PoC diagnostic test is available are taeniasis, rhodesiense human African trypanosomiasis, dracunculiasis, and the skin NTDs leprosy, mycetoma, and chromoblastomycosis. For taeniasis, a new analyte for a PoC test must be identified that can serve as a biomarker for the presence of tapeworms and their larval forms, not only in humans but also in pork meat and water, to prevent ingestion of contaminated food and water. Likewise, for dracunculiasis, testing of water bodies for disease surveillance necessitates a field-deployable nucleic acid–based test. For chromoblastomycosis and mycetoma, novel PoC tests, ideally nucleic acid–based, are required that can recognize causal species efficient treatment. Although immunological-based PoC tests are available for the diagnosis of rabies, schistosomiasis, chagas disease, lymphatic filariasis, chikungunya, snake bite envenoming, dengue, trachoma, and yaws, these are found to be suboptimal (see Supporting information), and further development of more reliable tests for the diagnosis of these NTDs is needed. The most common need among these NTDs is found to be the field deployability, followed by confirmatory diagnosis and test of cure. Notably, field deployability includes requirements such as reliability (stable storage at room temperature), reproducibility (batch-to-batch variation), costs, and accessibility to the test. Both immunological-based and nucleic acid–based PoC tests are available for foodborne trematodiasis, echinococcosis, buruli ulcer, leishmaniasis (both visceral and cutaneous), onchocerciasis, and gambiense human African trypanosomiasis. Interestingly, despite the availability of a PoC test, these tests need to be further optimized for use in the field, preferably for applications as simple as “under a tree.” Dedicated field studies (quality assessment and field validation) must be conducted to evaluate the performance of such PoC tests.

Table 31.1 NTD-specific status quo of existing PoC test and future implementation needs for PoC tests

Disease name	Current PoC tests	Implementation needs	Refs.
Foodborne trematodiasis	<ul style="list-style-type: none"> ✓ 2 antigen-based tests and 1 nucleic acid–based test for <i>Fasciola gigantica</i> ✓ 3 nucleic acid–based tests for <i>Opisthorchis viverrini</i> ✓ 1 antigen-based test for <i>Paragonimus</i> spp. ✓ 1 antigen-based and 1 nucleic acid–based test for <i>Clonorchis sinensis</i> 	<ul style="list-style-type: none"> ✓ Effective field-deployable sample preparation as DNA extraction is limited to a laboratory ✓ Quality assessment and field validation for all the current PoC tests 	[52–54]
Taeniasis cysticercosis	None reported	<ul style="list-style-type: none"> ✓ Quality assessment and field validation of the antigen-based proof-of-principle test (see Supporting information at the end of the chapter) ✓ Novel biomarker identification ✓ Reliable field-deployable PoC test 	[55, 56]
Echinococcosis	<ul style="list-style-type: none"> ✓ Several commercial antibody tests for cystic and alveolar echinococcosis (e.g., VIRAPID HYDRATIDOSIS, ADAMUCE, RIDASCREEN <i>Echinococcus</i> IgG test) ✓ 1 nucleic acid–based LAMP test for cystic echinococcosis 	<ul style="list-style-type: none"> ✓ More reliable PoC tests as current tests have low sensitivity and cannot detect inactive cysts ✓ Confirmatory diagnostic tests for humans (test of cure) ✓ Field-deployable screening tests for dogs 	[52, 57]
Rabies	<ul style="list-style-type: none"> ✓ Several commercial immunological tests (e.g., Vet-o-test Rabies Ag and Antigen Rapid Rabies Ag test kit) 	<ul style="list-style-type: none"> ✓ Novel circulating biomarker identification for dogs and humans to mitigate invasive sampling (brain tissue) ✓ Field-deployable PoC test for humans ✓ Quality assessment and field validation for all current PoC tests 	[58–60]
Chromoblastomycosis	None reported	<ul style="list-style-type: none"> ✓ Field-deployable nucleic acid–based test as species specificity will aid effective treatment 	[61]
Leishmaniasis (cutaneous)	<ul style="list-style-type: none"> ✓ CL Detect Rapid Test (antibody-based test) ✓ Loopamp Leishmania detection kit (nucleic acid–based) ✓ palmPCR (handheld battery-operated device) (nucleic acid–based) 	<ul style="list-style-type: none"> ✓ Field-deployable sample preparation is required for the Loopamp Leishmania Detection Kit and palmPCR ✓ Quality assessment and field validation for all current PoC tests 	[62–65]

(Continued)

Table 31.1 (Continued)

Disease name	Current PoC tests	Implementation needs	Refs.
Mycetoma	None reported	<ul style="list-style-type: none"> ✓ Field-deployable nucleic acid-based test as species specificity will aid effective treatment (bacterial treatment is more effective than fungal treatment) 	[66]
Human African trypanosomiases (<i>rhodesiense</i>)	None reported	<ul style="list-style-type: none"> ✓ Novel circulating biomarker identification ✓ Field-deployable nucleic acid-based species-specific tests will aid effective treatment 	[67–69]
Buruli ulcer	<ul style="list-style-type: none"> ✓ Pilot immunological tests and molecular tests (LAMP and RPA) 	<ul style="list-style-type: none"> ✓ Quality assessment and field validation of the pilot tests ✓ Field-deployable sample preparation ✓ Confirmatory test (test of cure) is critical in cases of coinfections 	[70–72]
Schistosomiasis	<ul style="list-style-type: none"> ✓ Schisto POC-CCA for <i>Schistosoma japonicum</i> and <i>Schistosoma mansoni</i> ✓ UCP-LF CAA assay ✓ Schistosoma ICT IgG-IgM rapid test 	<ul style="list-style-type: none"> ✓ Field-deployable nucleic acid-based test to enable the detection of low parasitaemia ✓ Field-deployable antigen-based test to detect <i>Schistosoma haematobium</i>. ✓ Ultrasensitive field-deployable antigen-based test to detect low intensity <i>Schistosoma</i> 	[73–76]
Chagas disease	<ul style="list-style-type: none"> ✓ Several commercial immunological tests (e.g., Chagas STAT-PAK assay, Chagas Detect Rapid Plus test (antigen-based), Trypanasoma Detect) 	<ul style="list-style-type: none"> ✓ Field-deployable nucleic acid-based test to detect congenital chagas disease 	[13, 77, 78]
Leishmaniasis (visceral)	<ul style="list-style-type: none"> ✓ IT-LEISH Kit ✓ Kalazar Detect ✓ <i>Onsite Leishmania AB</i> Rapid Test ✓ VL-LFD device 	<ul style="list-style-type: none"> ✓ A robust test for use in East Africa, where the IT-LEISH Kit is not effective ✓ Quality assessment and field validation of the VL-LFD device ✓ Field-deployable nucleic acid-based test (test of cure), which is crucial for the diagnosis of post-kala-azar (PKDL) 	[79–81]
Lymphatic filariasis	<ul style="list-style-type: none"> ✓ Alere Filariasis Test Strip (antibody-based) ✓ SD BIOLINE Lymphatic Filariasis IgG4 (antigen-based) ✓ Brugia Rapid (antigen-based) 	<ul style="list-style-type: none"> ✓ Field-deployable PoC test without cross-reactivity with <i>Loa loa</i> ✓ Multiplexed test with <i>Loa loa</i> ✓ Novel circulating biomarker identification 	[82, 83]

Disease name	Current PoC tests	Implementation needs	Refs.
Chikungunya	<ul style="list-style-type: none"> ✓ SD BIOLINE Chikungunya (antigen-based) ✓ Chikungunya IgM Combo Rapid Test CE (antigen- based) 	<ul style="list-style-type: none"> ✓ Quality assessment and field validation ✓ Field-deployable PoC test without cross-reactivity with dengue ✓ Multiplexed test with dengue ✓ Novel circulating biomarker identification 	[84, 85]
Scabies	<ul style="list-style-type: none"> ✓ Burrow ink test ✓ Handheld dermatoscopy test 	<ul style="list-style-type: none"> ✓ A standardized diagnostic procedure will prevent misdiagnoses and delayed treatment 	[86–88]
Onchocerciasis	<ul style="list-style-type: none"> ✓ SD BIOLINE <i>Onchocerciasis</i> IgG4 (antigen-based) ✓ SD BIOLOINE <i>Onchocerciasis</i>/LF biplex test with <i>Onchocerca volvulus</i> and <i>Wuchereria bancrofti</i> (antigen-based) 	<ul style="list-style-type: none"> ✓ Field-deployable PoC test without cross-reactivity with <i>Loa loa</i> as this coinfection affects the treatment regimen ✓ Novel circulating biomarker identification ✓ Confirmatory test (test of cure) to aid surveillance in the current eradication era 	[89]
Human African trypanosomiases (<i>gambiense</i>)	<ul style="list-style-type: none"> ✓ SD BIOLINE HAT and SD BIOLINE HAT 2.0 (antigen- based) ✓ HAT Sero K-Set (antigen-based) 	<ul style="list-style-type: none"> ✓ Quality assessment and field validation ✓ Field-deployable nucleic acid–based species-specific tests will aid effective treatment ✓ Confirmatory test (test of cure) 	[90–92]
Snake bite envenoming	<ul style="list-style-type: none"> ✓ 1 test for 5 Australian species (antibody-based) 	<ul style="list-style-type: none"> ✓ PoC test that is multiplexed for species that are geographically distinct ✓ A reliable PoC coagulation analyzer to diagnose coagulopathy 	[13, 93–95]
Dengue	<ul style="list-style-type: none"> ✓ Multiple commercial antigen and antibody-based tests (e.g., SD BIOLINE Dengue Duo Rapid Test Kit and ASSURE Dengue IgA Rapid test (antigen-based)) 	<ul style="list-style-type: none"> ✓ Field-deployable PoC test without cross-reactivity with the Zika virus ✓ Novel circulating biomarker identification ✓ Multiplexed test with the Zika virus 	[13, 96–98]
Dracunculiasis	None reported	<ul style="list-style-type: none"> ✓ Field-deployable nucleic acid–based test for humans, for canines, and for copepods (crustaceans) to test bodies of water for surveillance purposes during the current eradication era 	[8, 99]

(Continued)

Table 31.1 (Continued)

Disease name	Current PoC tests	Implementation needs	Refs.
Leprosy	None reported	<ul style="list-style-type: none"> ✓ Quality assessment and field validation of the biomarker-based proof-of-principle test (see Supporting information) 	[39]
Soil-transmitted helminthiases	<ul style="list-style-type: none"> ✓ Kankanet (smart microscopy tool) 	<ul style="list-style-type: none"> ✓ Improved algorithms for other infectious species as Kankanet can only detect <i>Ascaris lumbricoides</i> ✓ Field-deployable test to detect resistance to treatment and test of cure ✓ Multiplexed tests for other helminth infections 	
Trachoma	<ul style="list-style-type: none"> ✓ 1 lateral flow test (antigen-based) ✓ Grading tool 	<ul style="list-style-type: none"> ✓ Quality assessment and field validation ✓ PoC test with enhanced sensitivity to detect acute infections ✓ Confirmatory test (test of cure) 	[101–103]
Yaws	<ul style="list-style-type: none"> ✓ DPP 	<ul style="list-style-type: none"> ✓ Quality assessment and field-deployable nucleic acid-based test to distinguish between yaws and syphilis ✓ Multiplexed test with syphilis 	[104–107]

Note: For each NTD, an overview is given of current PoC tests and the most urgent implementation needs. Current PoC tests are either listed according to their commercial product names or as tests in the pilot phase. NTDs that have several commercial PoC tests, such as echinococcosis, have been described in detail in the Supporting information.

Abbreviations: DPP, Dual Path D Platform; LAMP, loop-mediated isothermal amplification; NTD, neglected tropical disease; PKDL, post-kala-azar dermal leishmaniasis; PoC, point-of-care; POC-CCA, point-of-care circulating cathodic antigen; RPA, recombinase polymerase amplification; UCP-LF CAA, up-converting phosphor lateral flow circulating anodic antigen; VL-LFD, visceral leishmaniasis–lateral flow device.

We grouped these 24 NTDs based on our observations on common technical requirements for developing novel PoC tests for efficient diagnosis (see Fig. 31.3). The demand for confirmatory diagnosis and a test of cure was one of the most common implementation needs as can be deduced from the requirement for robust PoC tests utilizing nucleic acid-based detection (red ellipse) or recognizing novel biomarkers (green ellipse). Along with field validation of existing PoC tests (purple), robust confirmatory species-specific tests are required for efficient and effective diagnosis of visceral leishmaniasis and gambiense human African trypanosomiasis. Likewise, new sensitive and specific tests such as nucleic acid-based/biomarker PoC tests are required for the diagnosis of schistosomiasis particularly in case of low parasitemia. Nucleic acid-based PoC tests would also be the ideal solution for diagnosing congenital and asymptomatic chagas disease. For taeniasis and rhodesiense human African trypanosomiasis, PoC tests with novel biomarker detection are required since there are currently no PoC tests available for these NTDs. For lymphatic filariasis, dengue, and chikungunya, existing PoC tests are inefficient as they are cross-reactive with other infectious diseases (Table 31.1). Febrile illnesses dengue and chikungunya are often misdiagnosed as they occur as a seasonal outbreak within Zika-endemic regions, and, hence, novel PoC tests should be capable of multiplexing to distinguish between these viral illnesses and thereby accelerate the diagnoses and minimize treatment delays.




Figure 31.3 Venn diagram depicting the PoC implementation needs for various NTDs. After reviewing the 24 NTDs (see Supporting information and Table 31.1), NTDs were placed in the colored circles based on their PoC implementation need. The legends indicate the particular diagnostic need of the NTD. NTDs in bold depict priority for PoC diagnoses as set in WHO's 2021–2030 roadmap [8].

Abbreviations: NTD, neglected tropical disease; PoC, point-of-care; WHO, World Health Organization.

Similarly, onchocerciasis diagnosis would benefit from a confirmatory test and a test of cure. For the skin NTDs cutaneous leishmaniasis and buruli ulcer, sample preparation is a major concern as skin samples must be obtained in a sterile environment. Thus, novel PoC tests that could function with (noninvasive) surface scrapings of the skin tissue are required for efficient diagnosis here.

Analysis of the status quo of NTDs diagnostics practices highlighted that, although technically adequate PoC tests might exist for certain NTDs, it is the disease unawareness and test unavailability in the endemic regions that often delimit the effective use of PoC tests. Henceforth, based on WHO's 2021–2030 roadmap [8] and diagnostic technical advisory group for NTDs [20], and our comprehensive literature survey (Supporting information), we further analyzed the NTDs for disease awareness, tests availability, and diagnostic technology insufficiencies (Fig. 31.4). To rank the diagnostic insufficiencies of the 24 NTDs, we identified 3 parameters: awareness, availability, and diagnostic technology, and scored the needs for each NTD from “in control” to “action critically needed.” For many of the NTDs, we found that the major diagnostic insufficiency was contributed by test unavailability and lack of disease awareness, as seen for the 8 NTDs in the far left of Fig. 31.4. For example, diagnosis of snake bite envenoming and rabies is delayed due to preference to traditional healing practices because there is lack of awareness and existing tests are not readily available. Similarly, for skin NTDs including chromoblastomycosis, mycetoma, and cutaneous leishmaniasis, misdiagnosis due to lack of awareness results in delayed diagnosis and treatment. Likewise, diagnostic insufficiencies for foodborne trematodiasis, echinococcosis, scabies, and other ectoparasites could be addressed by ensuring disease awareness and existing test availability, and novel PoC diagnostics should be developed only if efficient diagnosis is still not achieved. Summing up, it is pivotal to urgently address the issues of disease awareness and test availability because they act as the main obstacles in the introduction of novel PoC tests in endemic settings.

In addition to disease unawareness and tests unavailability, other limitations and barriers can hinder successful implementation of PoC tests for NTDs [17, 43]. PoC tests can potentially yield inaccurate test results due to poor analytical quality or improper sample handling—indicating a need for staff training for proper test protocols, result documentation, and device maintenance. Furthermore, the clinical relevance of a PoC test over conventional reference diagnostic standards has been a persistent concern among medical practitioners. Since “first-generation” lateral flow rapid immunochromatographic tests for infectious diseases were often questioned for their analytical quality over laboratory counterparts, new sophisticated PoC tests are often subjected to some mistrust by medical practitioners in remote regions [44]. Surprisingly, rapid on-the-spot self-testing or testing by health workers who cannot provide the adequate posttest counseling can in practice also have unexpected effects. For certain diseases, a positive result of a PoC test can significantly affect the mental and social well-being of the patient. NTDs with a high psychosocial burden includes human

African trypanosomiasis, chagas disease, skin NTDs (leprosy and cutaneous leishmaniasis), or diseases that may cause lifelong physical disabilities such as an amputation of affected body part in case of buruli ulcer or mycetoma. Therefore, in addition to providing a PoC test, an effective diagnostic protocol for adequate awareness and counseling is needed among the health workers in the local communities to provide psychosocial support. Moreover, since diagnosis of NTDs is currently often based on physical examination and suspicion due to disease endemicity in the region, a negative PoC test result can challenge and jeopardize the relationship between the patient and the healthcare worker or the medical practitioner [45], possibly even yielding more general mistrust toward western medicine and a shift of healthcare-seeking behavior toward traditional healers.




Figure 31.4 Diagnostic insufficiencies for NTDs. NTDs were ranked in the order of diagnostic insufficiencies (black bars) as deduced from 3 parameters: diagnostics technology (purple), availability (blue), and awareness (red), and scored for “action critically needed” to “in control.” Information was obtained from a literature survey, including comprehensive recent reports from WHO, particularly WHO 2021–2030 roadmap [8] and the diagnostic technical advisory group for NTDs report [20]. Data were critically analyzed to gather diagnostic insufficiencies for individual diseases.

Abbreviations: NTD, neglected tropical disease; WHO, World Health Organization.

Finally, there are issues of cost and political context. The implementation of PoC tests for NTDs should follow standardized clinical pathways to ensure the judicious use of the PoC test [1]. Lack of technical support and maintenance is often an issue, especially in remote settings. Since sophisticated research is

needed for the development of PoC diagnostic tests, many tests are far from cost effective, especially for NTDs wherein all interventions are donor dependent and generally administered free of charge. A lack of incentive and low return on investments are common reasons for neglect relating to NTDs diagnoses in comparison to other infectious diseases. Costs due to supply chain, transport, and storage also hinder the sustainable use of a PoC test for NTDs [46]. Moreover, clinical trials (validation) of PoC diagnoses for NTDs are difficult to conduct for various reasons, including persistent migration and poor healthcare-seeking behaviors among marginalized populations. Besides, adoption of new technologies in endemic regions often faces long delays in obtaining regulatory approval and in subsequent implementation in healthcare systems [47]. Health services in endemic regions are often insufficiently equipped for the management of NTDs and a lack of governmental support to implement innovative PoC tests for NTDs can be challenging, especially when new PoC tests do not confer a direct economic advantage over existing laboratory-based diagnostic test in the region [48]. Summing, implementation of PoC diagnostics for NTDs presents significant challenges.

31.4 Discussion and Conclusions

From our review of the status quo of PoC diagnostic tests and practices for all of the 24 NTDs mentioned in WHO's 2021–2030 roadmap, we determined the diagnostic needs and formulated prerequisites of the relevant PoC tests. We identified that confirmatory diagnosis and a test of cure are the most common implementation needs for all NTDs. A paradigm shift is needed toward developing fully automated robust PoC tests for confirmatory NTDs diagnostics and possibly test of cure. Additionally, due to a vicious circle of disease endemicity, i.e., poor healthcare-seeking behavior due to extreme poverty, lack of awareness, persistent migration, and poor livelihood of marginalized populations, NTD diagnostic tests must be brought to the doorsteps of remote communities. Field-deployable PoC tests at the local community level for NTD screening would benefit treatment and aid in reaching the desired goal of NTD elimination. Multiplexed PoC diagnostics for related illnesses would not only ensure correct diagnosis, identifying comorbidities and benefitting timely treatment, but also eliminate problems due to misdiagnoses and reduce financial burdens upon seeking healthcare. For multiplexing PoC devices, the disease combination could result from various considerations. For example, multiplexed tests can be made for diseases that are geographically overlapping, especially when treatments differ in case of comorbidities, or for diseases that present overlapping clinical presentations such as febrile illnesses. However, the research and development involved in such multiplexed tests are challenging as unique and non-cross-interfering targets must be identified for every pathogen, and, therefore, the cost of a multiplexed test can be larger. Yet, in the bigger picture, multiplexing is a cost-beneficial practice in

the long run, as diagnosing multiple infections using a single sample reduces costs incurred due to multiple independent tests and corresponding treatment delays.

Developing technically advanced PoC diagnostic tests does not automatically ensure that they will be routinely used in endemic regions. Therefore, in addition to technically improving PoC diagnostic tests, it is vital that future interventions focus on creating awareness programs and developing appropriate logistics to ensure that the necessary PoC tests are available within endemic regions for those NTDs where the major diagnostic need lies in a lack of awareness and test unavailability. In other words, it is important to determine if an NTD requires a novel PoC test or if efforts should enhance awareness or increase availability of existing PoC tests. Research should thus only focus on developing novel PoC tests for those NTDs where the technical inefficiencies of existing diagnostic tests present the main barrier, but local awareness of the NTD must be enhanced with progressive knowledge transfer and capacity building initiatives to engage and empower the local communities. Lessons learned from successful diagnostic strategies should be customized and applied to NTDs. For example, the success stories from malaria control programs can be adapted to related febrile illnesses such as dengue and chikungunya.

Since multiple NTDs are often prevalent in endemic regions, common solutions can be combined and integrated. In almost every individual NTD study, we observed that complex multiparametric factors are present that involve challenges and potential strategies to combat them. For example, skin NTDs such as buruli ulcer, cutaneous leishmaniasis, leprosy, mycetoma, yaws, and onchocerciasis all require common diagnostics practices and case management strategies [49] and thus can be integrated for disease awareness, disease mapping, and training of the healthcare workers. Likewise, linking logistics to ensure availability of the diagnostics tests in remote regions presents opportunities for integration, i.e., the supply chain for multiple tests can be combined so that the tests can be delivered together from national hospitals to the peripheral health facilities in the endemic regions.

In general, a comprehensive approach with a 360° view of the NTDs (and other diseases) spread within a region, and their context is needed to devise a reliable, sustainable, robust solution for combating NTDs. NTD-afflicted communities have inadequate basic amenities such as water, food, housing, etc., which cause further spread of diseases in endemic regions. For example, water often plays a critical and common role in the spread of NTDs. Schistosomiasis is a waterborne disease, wherein parasites multiply in water snails, and, hence, water acts as a reservoir of this disease vector. Likewise, trachoma is a water-scarce disease, wherein person-to-person transmission is due to a lack of water for basic hygiene. Thus, for combating schistosomiasis and trachoma, a common solution could be to ensure the availability of quality water along with basic sanitation and hygiene practices (WASH) [50]. Similarly, insect-transmitted diseases such as dengue, chikungunya, trypanosomiasis, and leishmaniasis can be combatted together

by integrating vector control programs like insecticide-treated nets, indoor insecticide spraying, treatment of water reservoirs, and awareness programs. Hence, multiple NTDs that have direct correlation with the basic needs such as clean water, sanitation, nutrition, vector management activities, veterinary public health activities, etc. can be combated together by providing common solutions. In essence, instead of vertical interventions that target one disease at a time, multiple NTDs can be tackled simultaneously by horizontally integrating related interventions to achieve common objectives and thereby aid the prevention and control of NTDs.



Figure 31.5 The healthcare paradox for NTDs in endemic regions. At the lowest level, the healthcare system in the NTD endemic region has minimally trained CHWs capable of providing referrals to a level up such as local dispensaries with limited resources including technicians and/or midwives, followed by health centers with trained medical professionals, laboratory space, equipment, and/or inpatient wards. These CHWs at the base of the pyramid also play a vital role in facilitating mobile health outreach services, thereby bridging the gap between patients and medical facilities. One level further up is adequately equipped provisional hospitals followed by fully functional national hospitals at the top of the pyramid. Notably, the burden of NTDs is highest at the lowest healthcare level. This indicates the healthcare paradox, i.e., the highest NTD needs occur at the base of the pyramid where resources are inadequate, and, thus, the disease spreads further due to unmet healthcare needs. To interrupt this vicious cycle of disease endemicity, easy-to-use NTD diagnostics should be introduced to the CHWs at the lowest level. Bringing NTD diagnostics at the doorstep of the endemic populations will ensure efficient disease diagnosis and treatment, reduce costs, and thereby alleviate the healthcare burden.

Abbreviations: CHW, community healthcare worker; NTD, neglected tropical disease.

Finally, for the successful control and desired eradication of an NTD, customized PoC diagnostic solutions need to be devised. The healthcare paradox in NTD-endemic regions is that the highest need for healthcare occurs in areas with minimum resources, i.e., at the lowest level of healthcare system, thus posing significant challenges for patients that seek adequate healthcare (Fig. 31.5).

Thus, diagnostic solutions should not only be patient centric and abide to context-specific requirements as highlighted above but they should also be in line with subsequent treatment approaches and healthcare system in general. For example, if treatment requires hospitalization, a robust PoC diagnostic test for screening of the disease would suffice in the field, and follow-up tests can be performed at the hospital. However, for NTDs wherein treatment can be limited to medication that can be administered at home or at local minimally equipped healthcare center, a robust confirmatory PoC diagnostic test would be needed. In a nutshell, a context-specific holistic approach is necessitated that combines early disease diagnosis, effective treatment interventions, and control strategies for multiple diseases at the same time [12, 45, 46, 48, 49].

Summing up, to accelerate the global efforts for management of NTDs, crosscutting strategies spanning across all NTDs interventions from the development of new PoC diagnostic tests to treatment and control, to improvements such as WASH, nutrition, and living standards, to issues of cost and political context need to work hand in hand. Especially now that emerging diseases cause global pandemics, consolidated initiatives such as the “one health” approach [51] is fitting for the timely management of NTDs to alleviate the global healthcare burden.

31.5 Methods

A literature review was conducted using an exploratory search strategy of electronic databases, including Google Scholar, PubMed, Medline, Google Patents, Google Books, Web of Science, Espacenet, Pubget, Scopus, IEEE Xplore, Open Content, WHO websites, CDC website, and Wikipedia. For the entire chapter, we searched for research articles with the keywords relevant to each section of the review. We used Medical Subject Headings (MeSH) terms for disease names and causal species names, in combination with keywords including “diagnostics,” “rapid diagnostic tests,” “commercial tests,” “point-of-care tests/testing,” “NTD diagnostics,” “bedside testing,” “remote rapid testing,” “near-patient laboratory testing,” “ancillary testing,” and “decentralized testing” in different combinations. We analyzed all articles and reports published and included those relevant to the scope of this review. Additional articles were obtained by citation tracking of review and original articles. For the comprehensive overview provided in the Supporting information, NTDs were equally divided among authors, (i.e., 4 to 5 NTDs per author) to produce an overview of the PoC diagnosis for each NTD (see Supporting information), yielding a brief description of the disease, the current diagnostics, and PoC tests, if available. Thereafter, the overview of PoC diagnosis of the NTDs was reviewed by the first authors, and implementation needs were deduced. Implementation needs refer to specific technical requirements that would support the translation from proof-of-principle tests to field-deployable PoC tests. Any discrepancies were discussed among all authors until a consensus was reached.

Supporting information

Available at: <https://doi.org/10.1371/journal.pntd.0009405.s001>.

This file contains an overview of all 24 NTDs identified by WHO 2021–2030 roadmap (based on diagnostic requirements and is an extension of the well-known list of 20 NTDs). These NTDs are presented in the order of their diagnostic insufficiencies (Fig. 31.4) wherein for each NTD, we provide a brief 1-page overview with a brief introduction with a description of the disease, current diagnostics, and PoC test, if available. Implementation need. In the description, the NTDs appear in the same order as for the figures and the table in the chapter.

<https://doi.org/10.1371/journal.pntd.0009405.s001> (DOCX)

Key Learning Points

- Robust test of cure and confirmatory diagnostics at the point-of-care (PoC) are needed for effective management and surveillance of neglected tropical diseases (NTDs).
- Diagnostic practices for NTDs should be context specific.
- In addition to novel NTDs diagnostics, disease awareness strategies and the availability of PoC diagnostic tests must be ensured for effective use of novel diagnostics.
- Diagnostic solutions should be integrated to address multiple diseases simultaneously.

Top Five Papers

1. World Health Organization. Report of the first meeting of the WHO Diagnostic Technical Advisory Group for Neglected Tropical Diseases. Geneva; October 30–31, 2019. Available at: <https://apps.who.int/iris/bitstream/handle/10665/331954/9789240003590-eng.pdf?sequence=1&isAllowed=y> (accessed on September 15, 2022).
2. Lupp P., Junker R., editors. *Point-of-Care Testing, Principles and Clinical Applications*. Berlin Heidelberg: Springer-Verlag; 2018.
3. Shephard, M., editor. *A Practical Guide on Global Point-of-Care Testing*. CSIRO Publishing; 2016.
4. World Health Organization. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030. Available at: <https://www.who.int/publications/i/item/9789240010352> (accessed on September 15, 2022).
5. Pai, M., Ghiasi, M., Pai, N. P. Point-of-care diagnostic testing in global health: what is the point? *Microbe Magazine*. 2015; 10(3): 103–107.

Abbreviations

CHW:	community healthcare worker
CRISPR:	clustered Regularly Interspaced Short Palindromic Repeats
DALYs:	disability-adjusted life years
DPP:	Dual Path Platform
LAMP:	loop-mediated isothermal amplification
MeSH:	medical Subject Headings
NAATs:	nucleic acid amplification tests
NGS:	next-generation sequencing
NTDs:	neglected tropical diseases
PCR:	polymerase chain reaction
PKDL:	post-kala-azar dermal leishmaniasis
PoC:	point-of-care
POC-CCA:	point-of-care circulating cathodic antigen
RPA:	recombinase polymerase amplification
SDI:	sexually Transmitted Diseases Diagnostics Initiative
TB:	tuberculosis
UCP-LF CAA:	up-converting phosphor lateral flow circulating anodic antigen
VL-LFD:	visceral leishmaniasis–lateral flow device
WASH:	water along with basic sanitation and hygiene practices
WHO:	World Health Organization

Disclosures and Conflict of Interest

This chapter was originally published as: Bharadwaj, M., Bengtson, M., Golverdingen, M., Waling, L., Dekker, C. (2021). Diagnosing point-of-care diagnostics for neglected tropical diseases. *PLoS Negl. Trop. Dis.*, **15**(6), e0009405, <https://doi.org/10.1371/journal.pntd.0009405>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Mitasha Bharadwaj and Michel Bengtson contributed equally to this work.

Funding: This work was supported by Delft Global Initiative (<https://www.tudelft.nl/global>) CD received the grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

Acknowledgments: We thank Oskar Franch, Jaco van der Torre, Astrid ten Bosch, Lisette van Lieshout, and Jan-Carel Diehl for discussions.

References

1. Standardization IO for. Point-of-care Testing (POCT): Requirements for Quality and Competence. 2006. Available at: <https://www.iso.org/standard/71119.html> (accessed on September 16, 2022).

2. Luppá P, Junker R. *Point-of-Care Testing, Principles and Clinical Applications*. Springer. 2018.
3. Bissonnette L, Bergeron MG. Diagnosing infections: current and anticipated technologies for point-of-care diagnostics and home-based testing. *Clin Microbiol Infect*. 2010; 16(8): 1044–53.
4. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Diagnostic point-of-care tests in resource-limited settings. *Lancet Infect Dis*. 2014; 14: 239–49.
5. Dincer C, Bruch R, Kling A, Dittrich PS, Urban GA. Multiplexed point-of-care testing—xPOCT. *Trends Biotechnol*. 2017; 35: 728–42.
6. Yang H, Chen Z, Cao X, Li Z, Stavrakis S, Choo J, et al. A sample-in-digital-answer-out system for rapid detection and quantitation of infectious pathogens in bodily fluids. *Anal Bioanal Chem*. 2018; 366: 1–12.
7. Hotez PJ, Alvarado M, Basáñez M-G, Bolliger I, Bourne R, Boussinesq M, et al. The Global Burden of Disease Study 2010: interpretation and implications for the neglected tropical diseases. *PLoS Negl Trop Dis*. 2014; e2865: 8.
8. WHO. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization. 2020.
9. Mitra AK, Mawson AR. Neglected tropical diseases: epidemiology and global burden. *Trop Med Infect Dis*. 2017; 2: 36.
10. Molyneux DH, Savioli L, Engels D. Neglected tropical diseases: progress towards addressing the chronic pandemic. *Lancet*. 2017; 389: 312–25.
11. Hollingsworth TD. Counting down the 2020 goals for 9 neglected tropical diseases: what have we learned from quantitative analysis and transmission modeling? *Clin Infect Dis*. 2018; 66: S237–44.
12. Kumar A. Picturing health: speak up, do more—the first World NTD Day. *Lancet*. 2020; 395: 551–8.
13. WHO. WHO global consultations for new roadmap on NTDs. 2019. Available at: https://www.who.int/neglected_diseases/news/WHO-global-consultations-for-new-Roadmap-on-NTD/en/ (accessed on September 15, 2022).
14. Peeling RW, Holmes KK, Mabey D, Ronald A. Rapid tests for sexually transmitted infections (STIs): the way forward. *Sex Transm Infect*. 2006; 82: v1.
15. Land KJ, Boeras DI, Chen X-S, Ramsay AR, Peeling RW. REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. *Nat Microbiol*. 2019; 4: 46–54.
16. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. *PLoS Med*. 2012; 9: e1001306–7.
17. Shephard M. *A Practical Guide to Global Point-of-Care Testing*. CSIRO Publishing; 2016.
18. Mabey D, Peeling RW, Ustianowski A, Perkins MD. Diagnostics for the developing world. *Nat Rev Microbiol*. 2004; 2: 231–40.
19. Kost GJ, Tran NK, Louie RF. *Point-of-Care Testing: Principles, Practice, and Critical-Emergency-Disaster Medicine*. 8th ed. American Cancer Society. 2006.

20. WHO. Report of the first meeting of the WHO Diagnostic Technical Advisory Group for Neglected Tropical Diseases. 2020. Available at: <https://apps.who.int/iris/bitstream/handle/10665/331954/9789240003590-eng.pdf?ua=1> (accessed on September 15, 2022).
21. Kozel TR, Burnham-Marusich AR. Point-of-care testing for infectious diseases: past, present, and future. *J Clin Microbiol.* 2017; 55: 2313–20.
22. Campbell S, Landry ML. *Rapid Antigen Tests*. 9th ed. 2014. pp. 31–51.
23. von Lode P. Point-of-care immunotesting: approaching the analytical performance of central laboratory methods. *Clin Biochem.* 2005; 38: 591–606.
24. Carter IWJ, Schuller M, James GS, Sloots TP, Halliday CL. *PCR for Clinical Microbiology*. Springer Science & Business Media. 2010.
25. Butler J. *Advanced Topics in Forensic DNA Typing*. Elsevier Inc. 2012.
26. Ferguson T, Niemz A. Nucleic Acid Isothermal Amplification Technologies and Point-of-Care Diagnostics. In: Marks RS, Lobel L, Sall A (eds). *Viral Diagnostics*, Jenny Stanford Publishing, 2014, pp. 409–26.
27. Craw P, Balachandran W. Isothermal nucleic acid amplification technologies for point-of-care diagnostics: a critical review. *Lab Chip.* 2012; 12: 2469–86.
28. Koehler JW, Douglas CE, Minogue TD. A highly multiplexed broad pathogen detection assay for infectious disease diagnostics. *PLoS Negl Trop Dis.* 2018; 12: e0006889.
29. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. *Nat Protoc.* 2019; 14: 2986–3012.
30. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, et al. Field-deployable viral diagnostics using CRISPR-Cas13. *Science.* 2018; 360: 444–8.
31. Chertow DS. Next-generation diagnostics with CRISPR. *Science.* 2018; 360: 381–2.
32. Li Y, Li S, Wang J, Liu G. CRISPR/cas systems towards next-generation biosensing. *Trends Biotechnol.* 2019; 37: 730–743.
33. Chiu C. Cutting-edge infectious disease diagnostics with CRISPR. *Cell Host Microbe.* 2018; 23: 702–4.
34. Tang YW, Stratton CW (eds). *Advanced Techniques in Diagnostic Microbiology*, Springer International Publishing. 2018.
35. Minh VD, Hanh LQ, Vu M. Clinical use of nucleic-acid-amplification tests. *Chest.* 2000; 118: 574–5.
36. Furrows SJ, Ridgway GL. “Good laboratory practice” in diagnostic laboratories using nucleic acid amplification methods. *Clin Microbiol Infect.* 2001; 7: 227–9.
37. Cantera JL, White H, Diaz MH, Beall SG, Winchell JM, Lillis L, et al. Assessment of eight nucleic acid amplification technologies for potential use to detect infectious agents in low-resource settings. *PLoS ONE.* 2019; 14: e0215756.
38. Aabenhus R, Jensen J-US, Jørgensen KJ, Hróbjartsson A, Bjerrum L. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. *Cochrane Database Syst Rev.* 2014; 15: CD010130.
39. van Hooij A, van den Eeden S, Richardus R, Fat ETK, Wilson L, Franken KLMC, et al. Application of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy diagnosis in the field. *EBioMedicine.* 2019; 47: 301–8.

40. Reali S, Najib EY, Balázs KET, Tan ACH, Váradi L, Hibbs DE, et al. Novel diagnostics for point-of-care bacterial detection and identification. *RSC Adv.* 2019; 9: 21486–97.
41. Yadav GS, Kumar V, Aggarwal NK. *Aptamers*. Springer Nature. 2019.
42. Pan Q, Luo F, Liu M, Zhang XL. Oligonucleotide aptamers: promising and powerful diagnostic and therapeutic tools for infectious diseases. *J Infect.* 2018; 77: 83–98.
43. Shaw JLV. Practical challenges related to point of care testing. *Pract Lab Med.* 2016; 4: 22–9.
44. John AS. The evidence to support point-of-care testing. *Clin Biochem Rev.* 2010; 31: 111–9.
45. Hays JP, Mitsakakis K, Luz S, van Belkum A, Becker K, van den Bruel A, et al. The successful uptake and sustainability of rapid infectious disease and antimicrobial resistance point-of-care testing requires a complex “mix-and-match” implementation package. *Eur J Clin Microbiol Infect Dis.* 2019; 38: 1015–22.
46. Hicks JM, Haeckel R, Price CP, Lewandrowski K, Wu A. Recommendations and opinions for the use of point-of-care testing for hospitals and primary care: summary of a 1999 symposium. *Clin Chim Acta.* 2001; 303: 1–17.
47. Peeling RW. Diagnostics in a digital age: an opportunity to strengthen health systems and improve health outcomes. *Int Health.* 2015; 7: 384–9.
48. Freedman DB. Clinical governance: implications for point-of-care testing. *Ann Clin Biochem.* 2002; 39: 421–3.
49. WHO. Recognizing neglected tropical diseases through changes on the skin. June 1, 2018. Available at: <http://apps.who.int/iris/bitstream/handle/10665/272723/9789241513531-eng.pdf?ua=1> (accessed on September 15, 2022).
50. WHO. Water sanitation & hygiene for accelerating and sustaining progress on neglected tropical diseases: a global strategy—2015–2020. Available at: http://apps.who.int/iris/bitstream/10665/182735/1/WHO_FWC_WSH_15.12_eng.pdf? (accessed on September 15, 2022).
51. WHO. The Control of Neglected Zoonotic Diseases. July 2015 pp. 1–48. Available at: https://www.who.int/neglected_diseases/ISBN9789241508568_ok.pdf?ua=1 (accessed on September 15, 2022).
52. Mubanga C, Mwape KE, Phiri IK, Trevisan C, Zulu G, Chabala C, et al. Progress on the development of rapid diagnostic tests for foodborne neglected zoonotic helminthiasis: a systematic review. *Acta Trop.* 2019; 194: 135–47.
53. Li L, Liu X, Zhou B, Zhang S, Wang G, Ma G, et al. Multiple food-borne trematodiasis with profound systemic involvement: a case report and literature review. *BMC Infect Dis.* 2019; 19: 526.
54. Sadaow L, Sanpool O, Rodpai R, Yamasaki H, Ittiprasert W, Mann VH, et al. Development of an immunochromatographic point-of-care test for serodiagnosis of opisthorchiasis and clonorchiasis. *Am J Trop Med Hyg.* 2019; 101: 1156–60.
55. WHO. Taenia solium taeniasis/cysticercosis diagnostic tools: report of a stakeholder meeting, Geneva, 17–18 December 2015. 2016.
56. Corstjens PLAM, de Dood CJ, Priest JW, Tanke HJ, Handali S, in PCWG. Feasibility of a lateral flow test for neurocysticercosis using novel up-converting nanomaterials and a lightweight strip analyzer. *PLoS Negl Trop Dis.* 2014; 8: e2944.

57. Tamarozzi F, Covini I, Mariconti M, Narra R, Tinelli C, Silvestri AD, et al. Comparison of the diagnostic accuracy of three rapid tests for the serodiagnosis of hepatic cystic echinococcosis in humans. *PLoS Negl Trop Dis*. 2016; 10: e0004444.
58. Certoma A, Lunt RA, Vosloo W, Smith I, Colling A, Williams DT, et al. Assessment of a rabies virus rapid diagnostic test for the detection of Australian bat lyssavirus. *Trop Med Infect Dis*. 2018; 3: 109.
59. Léchenne M, Naïssengar K, Lepelletier A, Alfaroukh IO, Bourhy H, Zinsstag J, et al. Validation of a rapid rabies diagnostic tool for field surveillance in developing countries. *PLoS Negl Trop Dis*. 2016; 10: e0005010.
60. Kang B, Oh J, Lee C, Park B-K, Park Y, Hong K, et al. Evaluation of a rapid immunodiagnostic test kit for rabies virus. *J Virol Methods*. 2007; 145: 30–6.
61. Bienvenu A-L, Picot S. Mycetoma and chromoblastomycosis: perspective for diagnosis improvement using biomarkers. *Molecules*. 2020; 25: 2594.
62. Schallig HDFH, Hu RVP, Kent AD, van Loenen M, Menting S, Picado A, et al. Evaluation of point of care tests for the diagnosis of cutaneous leishmaniasis in Suriname. *BMC Infect Dis*. 2019; 19: 25.
63. Veland N, Espinosa D, Valencia BM, Ramos AP, Calderon F, Arevalo J, et al. Polymerase chain reaction detection of *Leishmania* kDNA from the urine of Peruvian patients with cutaneous and mucocutaneous leishmaniasis. *Am J Trop Med Hyg*. 2011; 84: 556–61.
64. Adams ER, Schoone G, Versteeg I, Gomez MA, Diro E, Mori Y, et al. Development and evaluation of a novel loop-mediated isothermal amplification assay for diagnosis of cutaneous and visceral leishmaniasis. *J Clin Microbiol*. 2018; 56: S102.
65. Mirzaei A. Immunodetection and molecular determination of visceral and cutaneous *Leishmania* infection using patients' urine. *Infect Genet Evol*. 2018; 63: 257–68.
66. DNDi. Mycetoma: New hope for neglected patients—Developing effective treatments for a truly neglected disease. 2019. Available at: https://www.dndi.org/wp-content/uploads/2019/02/DNDi_Mycetoma_2019.pdf (accessed on September 15, 2022).
67. Bonnet J, Boudot C, Courtioux B. Overview of the diagnostic methods used in the field for human African Trypanosomiasis: what could change in the next years? *Biomed Res Int*. 2015; 2015: 583262–10.
68. Biéler S, Waltenberger H, Barrett MP, McCulloch R, Mottram JC, Carrington M, et al. Evaluation of antigens for development of a serological test for human African Trypanosomiasis. *PLoS ONE*. 2016; 11: e0168074.
69. Matovu E, Kazibwe AJ, Mugasa CM, Ndung'u JM, Njiru ZK. Towards point-of-care diagnostic and staging tools for human African Trypanosomiasis. *J Trop Med*. 2012; 2012: 340538–9.
70. Sakyi SA, Aboagye SY, Otchere ID, Yeboah-Manu D. Clinical and laboratory diagnosis of Buruli ulcer disease: a systematic review. *Can J Infect Dis Med Microbiol*. 2016; 2016: 5310718–0.
71. World Health Organization. Integrating neglected tropical diseases in global health and development: fourth WHO report on neglected tropical diseases. 2018. Available at: <https://apps.who.int/iris/handle/10665/255011> (accessed on September 15, 2022).

72. Diesburg SP, Guelig D, Burton R, Singleton J, Labarre P. Development of a single-use, disposable, electricity-free, nucleic acid amplification platform. *2015 IEEE Global Humanitarian Technology Conference (GHTC)*; 2015: 400–6.
73. Utzinger J, Becker SL, Knopp S, Blum J, Neumayr AL, Keiser J, et al. Neglected tropical diseases: diagnosis, clinical management, treatment and control. *Swiss Med Wkly*. 2012; w13727: 142.
74. Legesse M, Erko B. Field-based evaluation of a reagent strip test for diagnosis of *Schistosoma mansoni* by detecting circulating cathodic antigen in urine before and after chemotherapy. *Trans R Soc Trop Med Hyg*. 2007; 101: 668–73.
75. Colley DG, King CH, Kittur N, Ramzy RMR, Secor WE, Fredericks-James M, et al. Evaluation, Validation, and recognition of the point-of-care circulating cathodic antigen, urine-based assay for mapping schistosoma mansoni infections. *Am J Trop Med Hyg*. 2020; 103: 42–9.
76. Beltrame A, Guerriero M, Angheben A, Gobbi F, Requena-Mendez A, Zammarchi L, et al. Accuracy of parasitological and immunological tests for the screening of human schistosomiasis in immigrants and refugees from African countries: an approach with latent class analysis. *PLoS Negl Trop Dis*. 2017; 11: e0005593.
77. Shah V, Ferrufino L, Gilman RH, Ramirez M, Saenza E, Malaga E, et al. Field Evaluation of the InBios chagas detect plus rapid test in serum and whole-blood specimens in Bolivia. *Clin Vaccine Immunol*. 2014; 21: 1645–1649.
78. Ponce C, Ponce E, Vinelli E, Montoya A, de Aguilar V, Gonzalez A, et al. Validation of a rapid and reliable test for diagnosis of Chagas' disease by detection of trypanosoma cruzi-specific antibodies in blood of donors and patients in Central America. *J Clin Microbiol*. 2005; 43: 5065–8.
79. Boelaert M, Verdonck K, Menten J, Sunyoto T, van Griensven J, Chappuis F, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. *Cochrane Database Syst. Rev*. 2014; 2014: CD009135.
80. Singh OP, Sundar S. Developments in diagnosis of visceral leishmaniasis in the elimination era. *J Parasitol Res*. 2015; 2015: 239469.
81. Mondal D, Ghosh P, Khan MAA, Hossain F, Böhlken-Fascher S, Matlashewski G, et al. Mobile suitcase laboratory for rapid detection of *Leishmania donovani* using recombinase polymerase amplification assay. *Parasit Vectors*. 2016; 9: 281–8.
82. Rebollo MP, Bockarie MJ. Can lymphatic filariasis be eliminated by 2020? *Trends Parasitol*. 2017; 33: 83–92.
83. Hertz MI, Nana-Djeunga H, Kamgno J, Njouendou AJ, Chunda VC, Wanji S, et al. Identification and characterization of *Loa loa* antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic filariasis. *PLoS Negl Trop Dis*. 2018; 12: e0006963.
84. Hayashida K, Orba Y, Sequeira PC, Sugimoto C, Hall WW, Eshita Y, et al. Field diagnosis and genotyping of chikungunya virus using a dried reverse transcription loop-mediated isothermal amplification (LAMP) assay and MinION sequencing. *PLoS Negl Trop Dis*. 2019; 13: e0007480.
85. Vongsouvath M, Bharucha T, Seephonelee M, de Lamballerie X, Newton PN, Dubot-Pérès A. Harnessing dengue rapid diagnostic tests for the combined surveillance of dengue, Zika, and chikungunya viruses in Laos. *Am J Trop Med Hyg*. 2020; 102: 1244–1248.

86. Kinyanjui T, Middleton J, Güttel S, Cassell J, Ross J, House T. Scabies in residential care homes: modelling, inference and interventions for well-connected population sub-units. *PLoS Comput Biol.* 2018; 14: e1006046.
87. Leung V, Miller M. Detection of scabies: a systematic review of diagnostic methods. *Can J Infect Dis Med Microbiol.* 2011; 22: 143–6.
88. Park JH, Kim CW, Kim SS. The diagnostic accuracy of dermoscopy for scabies. *Ann Dermatol.* 2012; 24: 194–9.
89. Steel C, Golden A, Stevens E, Yokobe L, Domingo GJ, de los Santos T, et al. Rapid point-of-contact tool for mapping and integrated surveillance of *Wuchereria bancrofti* and *Onchocerca volvulus* infection. *Clin Vaccine Immunol.* 2015; 22: 896–901.
90. Lumbala C, Biéler S, Kayembe S, Makabuza J, Ongarello S, Ndung'u JM. Prospective evaluation of a rapid diagnostic test for *Trypanosoma brucei gambiense* infection developed using recombinant antigens. *PLoS Negl Trop Dis.* 2018; 12: e0006386.
91. Boelaert M, Mukendi D, Bottieau E, Lilo JRK, Verdonck K, Minikulu L, et al. A phase III diagnostic accuracy study of a rapid diagnostic test for diagnosis of second-stage human African trypanosomiasis in the democratic republic of the congo. *EBioMedicine.* 2018; 27: 11–7.
92. Chappuis F, Loutan L, Simarro P, Lejon V, Büscher P. Options for field diagnosis of human African trypanosomiasis. *Clin Microbiol Rev.* 2005; 18: 133–46.
93. Williams HF, Layfield HJ, Vallance T, Patel K, Bicknell AB, Trim SA, et al. The urgent need to develop novel strategies for the diagnosis and treatment of snakebites. *Toxins.* 2019; 11: 363.
94. Laxme RRS, Khochare S, de Souza HF, Ahuja B, Suranse V, Martin G, et al. Beyond the “big four”: Venom profiling of the medically important yet neglected Indian snakes reveals disturbing antivenom deficiencies. *PLoS Negl Trop Dis.* 2019; 13: e0007899.
95. O'Rourke KM, Correlje E, Martin CL, Robertson JD, Isbister GK. Point-of-care derived INR does not reliably detect significant coagulopathy following Australian snakebite. *Thromb Res.* 2013; 132: 610–3.
96. Gan W, Gu Y, Han J, Li CX, Sun J, Liu P. Chitosan-modified filter paper for nucleic acid extraction and “*in situ* PCR” on a thermoplastic microchip. *Anal Chem.* 2017; 89: 3568–75.
97. Wang SM, Sekaran SD. Early diagnosis of dengue infection using a commercial Dengue Duo rapid test kit for the detection of NS1, IGM, and IGG. *Am J Trop Med Hyg.* 2010; 83: 690–5.
98. Blacksell SD, Jarman RG, Bailey MS, Tanganuchitcharnchai A, Jenjaroen K, Gibbons RV, et al. Evaluation of six commercial point-of-care tests for diagnosis of acute dengue infections: the need for combining NS1 antigen and IgM/IgG antibody detection to achieve acceptable levels of accuracy. *Clin Vaccine Immunol.* 2011; 18: 2095–101.
99. Boyce MR, Carlin EP, Schermerhorn J, Standley CJ. A one health approach for guinea worm disease control: scope and opportunities. *Trop Med Infect Dis.* 2020; 5: 159.
100. Yang A, Bakhtari N, Langdon-Embry L, Redwood E, Lapierre SG, Rakotomanga P, et al. Kankanet: an artificial neural network-based object detection smartphone application and mobile microscope as a point-of-care diagnostic aid for soil-transmitted helminthiasis. *PLoS Negl Trop Dis.* 2019; 13: e0007577.

101. Gwyn S, Mitchell A, Dean D, Mkocha H, Handali S, Martin DL. Lateral flow-based antibody testing for *Chlamydia trachomatis*. *J Immunol Methods*. 2016; 435: 27–31.
102. Solomon AW, Mesurier RTL, Williams WJ. A diagnostic instrument to help field graders evaluate active trachoma. *Ophthalmic Epidemiol*. 2018; 25: 399–402.
103. Harding-Esch EM, Holland MJ, Schémann J-F, Molina S, Sarr I, Andreassen AA, et al. Diagnostic accuracy of a prototype point-of-care test for ocular *Chlamydia trachomatis* under field conditions in The Gambia and Senegal. *PLoS Negl Trop Dis*. 2011; e1234: 5.
104. Marks M, Goncalves A, Vahi V, Sokana O, Puiahi E, Zhang Z, et al. Evaluation of a rapid diagnostic test for yaws infection in a community surveillance setting. *PLoS Negl Trop Dis*. 2014; 8: e3156.
105. Chi K-H, Danavall D, Taleo F, Pillay A, Ye T, Nachamkin E, et al. Molecular differentiation of *treponema pallidum* subspecies in skin ulceration clinically suspected as yaws in vanuatu using real-time multiplex PCR and serological methods. *Am J Trop Med Hyg*. 2015; 92: 134–8.
106. Yin Y-P, Chen X-S, Wei W-H, Gong K-L, Cao W-L, Yong G, et al. A dual point-of-care test shows good performance in simultaneously detecting nontreponemal and treponemal antibodies in patients with syphilis: a multisite evaluation study in China. *Clin Infect Dis*. 2013; 56: 659–65.
107. Basing LAW, Simpson SV, Adu-Sarkodie Y, Linnes JC. A Loop-mediated isothermal amplification assay for the detection of *treponema pallidum* subsp. *pertenue*. *Am J Trop Med Hyg*. 2020; 103: 253–59.

Chapter 32

Capture and Visualization of Live *Mycobacterium tuberculosis* Bacilli from Tuberculosis Patient Bioaerosols

Ryan Dinkele,^{a,b} Sophia Gessner, PhD,^{a,b} Andrea McKerry,^c Bryan Leonard, MPH,^c Ronnett Seldon, MSc,^c Anastasia S. Koch, PhD,^{a,b} Carl Morrow, PhD,^{b,c} Melitta Gqada,^c Mireille Kamariza, PhD,^d Carolyn R. Bertozzi, PhD,^{e,f} Brian Smith,^g Courtney McCloud,^g Andrew Kamholz, PhD,^g Wayne Bryden, PhD,^h Charles Call, PhD,^h Gilla Kaplan, PhD,ⁱ Valerie Mizrahi, PhD,^{a,b,j} Robin Wood, PhD,^{b,c} and Digby F. Warner, PhD^{a,b,j}

^aDepartment of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

^bInstitute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

^cDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

^dDepartment of Biology, Stanford University, Stanford, California, USA

^eDepartment of Chemistry, Stanford University, Stanford, California, USA

^fHoward Hughes Medical Institute, Stanford University, Stanford, California, USA

^gEdge Embossing, Boston, Massachusetts, USA

^hZeteo Tech, Sykesville, Maryland, USA

ⁱDepartment of Medicine, University of Cape Town, Cape Town, South Africa

^jWellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa

robin.wood@hiv-research.org.za, digby.warner@uct.ac.za

Keywords: 4-*N,N*-dimethyls-amino-1,8-naphthalimide-trehalose (DMN-trehalose), bioaerosols, chest radiography scores, colony forming unit (CFU), community-based exposure, diagnostic, DMN-trehalose, epifluorescent illumination, fluorescence microscopy, identikit, multi-drug resistant (MDR), *Mycobacterium tuberculosis* (*Mtb*), nanowell array, nanowell-arrayed microscope, paucibacillary, Quencher-Trehalose-Fluorophore (QTF), Respiratory Aerosol Sampling Chamber (RASC), respiratory aerosol sampling chamber (RASC), sub-clinical infections, tuberculosis (TB)

32.1 Introduction

Mycobacterium tuberculosis (*Mtb*), the causative agent of tuberculosis (TB), is the leading infectious killer globally, claiming ~1.4 million lives annually [1]. TB control

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

is heavily predicated on treatment of active disease. However, delayed and missed diagnoses, and the six-month duration of standard chemotherapy, contribute to failure of this approach to control the TB epidemic [2]. The increasing prevalence of drug-resistant TB, compounded by evidence of the transmission of multi-drug resistant (MDR) *Mtb* strains, further undermines this approach [3]. Together, these factors have focused attention on blocking *Mtb* transmission as a critical area for novel interventions [4]. In turn, this has highlighted significant gaps in our knowledge of *Mtb* transmission: fewer than 30% of new *Mtb* infections can be linked to a known TB case, suggesting the existence of unrecognized transmitters in TB endemic communities [5].

Reconstruction of transmission chains has traditionally required genetic fingerprinting of *Mtb* strains isolated from active TB cases and their diseased contacts. Despite advances in molecular epidemiology, this has proven enormously challenging even in low-incidence settings [6]. Consequently, the host and mycobacterial factors which ensure successful transmission remain obscure [7]. Since the interval between the time of infection and diagnosed disease varies, analyses are necessarily retrospective, making intervention impossible [8]. Moreover, targeting surveillance to active disease means that the potential contribution of asymptomatic transmitters is overlooked [9]. The question of whether asymptomatic individuals are able to transmit *Mtb* is especially relevant for TB control: to date, community-based exposure studies have focused predominantly on household contacts which account for fewer than 20% of infections in high TB-burden settings [10].

Direct study of aerosolized *Mtb* is equally complicated: issues such as timing of sampling, the small numbers of bacilli released in exhaled air and sputum, and the presence of environmental and patient-derived contaminating microorganisms and particulate matter impose profound technical and analytical challenges [11, 12]. Enumeration of viable aerosolized *Mtb* via microbiological culture is complicated by the semi-quantitative nature of “time to positivity” in liquid culture and the slow formation of colony forming units (CFU) on solid media (four to eight weeks for colonies to become visible) [13]. Additional complications arise from the presence in clinical *Mtb* samples of “differentially detectable” organisms [12]—which means that microbiological culture often underestimates the true size of the viable bacillary population, and the temporal—and, consequently, genetic [14] and physiological—separation of the (single) transmitted bacillus from the micro-population ($\sim 10^6$ cells) contained in a visible *Mtb* colony on a plate. Decontamination, too, undermines assessments of bacillary load and physiological state. Where excessive, it depletes the number and viability of *Mtb* bacilli in the sample [15]; where inadequate, it risks overgrowth by contaminants, obscuring the signal.

Molecular methods have enabled detection of *Mtb* DNA in bioaerosols [16], however they do not distinguish live from dead organisms, and even protocols which target RNA [17] require extraction of intracellular nucleic acid, obviating the potential to investigate the physiological and metabolic state(s) of aerosolized bacilli. The method of bacillary capture is also important: approaches based on cough assume symptomatic spread, ignoring the possibility of *Mtb* transmission

during normal respiratory activity and, therefore, potentially not capturing other natural transmission events [18], especially those from sub-clinical infections [19]. Face-mask and equivalent sampling methodologies either render live-cell analyses impossible or *in vitro* propagation (via microbiological culture) unavoidable [20]. In addition, many methods are unable to determine whether bacilli derive from small (buoyant) or large aerosol droplets. This is a critical flaw given the likelihood that size determines aerosol longevity and ability to access lung alveoli, key elements of infectiousness [21].

To address these challenges, we sought to develop a method for culture-independent detection, quantification, and visualization of live bacilli in bioaerosols captured using the Respiratory Aerosol Sampling Chamber (RASC), a small personal clean-room enabling capture of particulate material released by an individual patient during normal respiratory activity, including natural (non-induced) cough. In previous work, we demonstrated the potential for liquid capture of aerosolized *Mtb* in the RASC, eliminating the dependency on solid culture-based techniques for bacillary detection [11, 12]. This was a key innovation since it opened the possibility for detection, isolation, and manipulation of live bacilli for downstream phenotypic and genomic studies. Here, we advance this technology in a new cohort of recently diagnosed TB patients, incorporating methodologies for the specific labelling and enumeration of low numbers of live *Mtb* bacilli from aerosol samples in a format which enables detection via live-cell fluorescence microscopy of single bacilli arrayed in a nanowell device. Moreover, by assigning localization co-ordinates to individual fluorescent organisms in the nanowells, we demonstrate the capacity to extend microscopic analyses to live cells for prolonged durations under incubation.

32.2 Results

32.2.1 A Custom-Built Nanowell Device for Microscopic Analyses

The fluorescent trehalose analogue, 4-*N*, *N*-dimethyls-amino-1,8-naphthalimide-trehalose (DMN-trehalose), enables rapid labelling and microscopic detection of *Mtb* in sputum or liquid medium [22]. Since active membrane biosynthesis is necessary for DMN-trehalose incorporation, this probe possesses the advantage of labelling live, metabolically active organisms only. Moreover, the solvatochromic properties of the DMN fluorophore mean that the signal is enhanced following incorporation into the mycobacterial cell envelope, limiting background noise and thus circumventing the need for multiple wash steps—a critical consideration when aiming to detect all *Mtb* in a potentially paucibacillary (<100 bacilli/ml) bioaerosol sample. To enhance our capacity for isolation and DMN-trehalose-enabled microscopic detection of single *Mtb* cells from bioaerosol, we developed a custom-designed device comprising arrays of 50 × 50 μm nanowells (Fig. 32.1A and 32.1B). Physical separation of samples across thousands of individual nanowell compartments was considered beneficial in ensuring that (i) any contaminating particulate matter would be distributed across the nanowells and (ii) all viable organic material would be isolated in discrete nanowell chambers, reducing

the likelihood that faster-growing non-*Mtb* organisms (“contaminants” for TB diagnostic purposes, but natural components of aerosol microbiomes) might overwhelm the device following overnight labelling.




Figure 32.1 Design and fabrication of nanowell-arrayed microscope slides for the compartmentalization and visualization of TB bioaerosols. (A) Photograph and (B) schematic of a nanowell-arrayed microscope slide. (C) 3D scan of a $207.840 \times 277.029 \mu\text{m}$ section of the slide. Each device ($25 \text{ mm} \times 75 \text{ mm}$) consists of two rows of eight round microwells machined from cast acrylic. The microwells are 6 mm in diameter and 2 mm deep. The nanowell film, which is bonded to the superstructure with UV-curing adhesive, is made from embossed COC film. The nanowells have side-wall angles of 35° and are $50 \mu\text{m}$ deep. The distance through the bottom of each well to the back of the film is $\sim 170 \mu\text{m}$, equivalent to a number 1.5 coverslip.

32.2.2 Towards an Identikit of DMN-Trehalose-Positive *Mtb* Bacilli

In developing a framework (or “identikit”) for the assignment of “putative *Mtb* bacillus” to individual fluorescent structures/microparticles detected in the

nanowell device, we processed exponentially growing and aged cultures of the laboratory strain, *Mtb* H37Rv, via the DMN-trehalose labelling protocol to assess the potential for morphological variation as a function of metabolic and replicative status. The median length of *Mtb* H37Rv bacilli (Fig. 32.2A) did not change between exponential growth (2.83 μm , IQR = 0.85 μm) and early stationary phase (2.77 μm , IQR = 1.19 μm). In contrast, there was a small but statistically significant difference in average cell width (Fig. 32.2B), with bacilli entering early stationary phase (0.60 μm , IQR = 0.07 μm) very slightly thinner than exponentially growing organisms (0.63, IQR = 0.04 μm). However, the average differences observed in mycobacterial cell width were unable to differentiate log from stationary phase bacilli owing to the largely overlapping distributions. This observation, plus the knowledge that bacillary length is commonly reported as a feature of morphological heterogeneity of clinical *Mtb* isolates [23], supported the adoption of width (~ 0.47 μm to ~ 0.86 μm) and DMN-trehalose positivity as primary markers for the identification of “putative *Mtb*” in bioaerosol samples.




Figure 32.2 Differentiation of growth states in *Mtb* using DMN-trehalose and cell morphology. Comparisons between log (green) and stationary (blue) phase *Mtb* according to (A) cell length, (B) width, and (C) polarity index. (D) Average DMN-trehalose profile for log and stationary phase bacilli, with single-cell examples in both (E) log and (F) stationary phase. Polarity index for each cell was calculated as the median fluorescence intensity at region (1) divided by the median fluorescence intensity at region (2) in panel (D). Wilcoxon signed-rank test performed, $p < 0.001 = ***$, NS = not significant.

The metabolic state of aerosolized *Mtb* remains unknown. Therefore, we investigated the utility of cytological profiling via DMN-trehalose staining to differentiate bacilli broadly as either slow or fast growers based on their growth phase. Substantial differences in DMN-trehalose uptake and distribution along the

cell length were observed between log and stationary phase bacilli (Fig. 32.2C–F). The polarity index, a simple metric of the relative brightness of the pole compared to the mid cell, was greater in log phase (1.21, IQR = 0.242) compared to stationary phase cells (0.948, IQR = 0.112) (Fig. 32.2C). As such, cells identified as putative *Mtb* based on cell width and DMN-trehalose positivity could be characterized broadly into at least two categories based on DMN-trehalose staining.

DMN-trehalose is not specific for *Mtb*: all bacteria within the Actinomycetales which encode homologs of the mycobacterial antigen 85 complex possess the capacity to incorporate the fluorescent label. Among these, *Corynebacteria* are a common constituent of the oral microbiome and were previously identified in TB sputum samples [22]. Therefore, to expand our database of potential DMN-trehalose-positive (DMN-tre+) organisms, we included the opportunistic pathogen, *Corynebacterium striatum* [24], in the *in vitro* analyses. Following DMN-trehalose labelling, *C. striatum* was readily distinguishable from mycobacteria, yielding a distinct cytological profile characterized by an ovoid cell shape with near-uniform fluorescence signal throughout the cell membrane and septa (Fig. S1A, panel i).

32.2.3 Microscopic Identification and Characterization of DMN-tre+ *Mtb* in TB Bioaerosols

Thirty-one individuals with GeneXpert-positive, drug-susceptible TB were recruited into a pilot study (Table 32.1) for the capture and single-cell detection of live, *Mtb* bacilli in patient bioaerosols (Fig. 32.3). Putative DMN-tre+ *Mtb* was identified based on cell width and DMN-trehalose positivity in 90% (28/31) of the TB patient bioaerosols (Table 32.1).




Figure 32.3 Workflow from participant recruitment to image analysis. (i) Recruitment of TB GeneXpert+ patients. (ii) One hour of bioaerosol production during tidal breathing and non-induced cough within the Respiratory Aerosol Sampling Chamber (RASC). (iii) Liquid capture of patient bioaerosol via Bertin Coriolis μ Biological Air Sampler. (iv) Bioaerosol concentration and staining with 100 μ M DMN-trehalose during overnight (~16 h) incubation at 37°C. (v) Sample arraying within the nanowell device. (vi) Manual sample scanning and bacilli enumeration. (vii) Nanowell imaging (row 2 represents a zoomed in section from row 1). Columns represent 3 different patients. Bacilli not matching inclusion criteria are excluded from subsequent analysis. Scale bar, 5 μ m.

Table 32.1 Summary of samples investigated

		Total	Positive (%)	Median count*
Sample type	TB ⁺ patient	31	28 (90.3)	14.0
	Empty RASC	26	14 (53.8)	1.5
Total		57		

*Median number of putative *Mtb* bacilli detected in the sample.




Figure 32.4 Detection and characterization of putative *Mtb* within bioaerosols of confirmed TB patients. (A) Plot comparing the number of putative *Mtb* detected within TB⁺ participants (red, $n = 31$) and empty RASC controls (orange, $n = 27$). Comparing distributions of (B) cell lengths and (C) cell widths in putative *Mtb* bacilli detected within bioaerosols of TB patients (red) to *Mtb* H37Rv cultured within the lab (green). Representative (D) images and (E) plots of the three distinct, exemplar cytological profiles from three patients in which putative *Mtb* were detected. (F) Average plots and idealised drawings indicating the different staining patterns of all bacilli detected in these three patients. (H) Polarity index and (I) length of the bacilli detected within these patients. (J) Representative images of clumps of putative *Mtb* detected within bioaerosol samples (TRDS182). Scale bar = 5 μm . Wilcoxon Rank-Sum test performed, $p < 0.01 = **$, $p < 0.001 = ***$, $p < 0.0001 = ****$, NS = not significant.

The median count in the captured air from TB-positive patients was 14 (range 0–36) versus 1.5 (range 0–10) in the air analyzed from the empty RASC booths suggesting low-level carry over/contamination of the booth between tested individuals (Fig. 32.4A). When comparing the basic morphological characteristics of aerosolized *Mtb* to those observed in log-phase, it was apparent that they were significantly shorter (Fig. 32.4B) but with the same width on average (Fig. 32.4C). However, a greater degree of width variation was observed in clinical samples (Fig. 32.4C), suggesting that application of the selected width criteria ($\sim 0.47 \mu\text{m}$ to $\sim 0.86 \mu\text{m}$) to patient aerosols might be conservative.

Further investigation into the profiles of DMN-trehalose incorporation led to the observation of three distinct labelling patterns (Fig. 32.4D–F), namely: polar labelling (sample TRDS182, top row), diffuse labelling (sample TRDS174, middle row), and a patchy labelling pattern (sample 180801JM9, bottom row). Both polar and diffuse labelling have been previously observed in log and stationary phase bacilli, respectively (Fig. 32.2D). Interestingly, this patchy labelling pattern wasn't common in our *in vitro* experiments. Like the *in vitro* cultured organisms, no significant differences in cell length were observed for the different labeling patterns in the bioaerosol samples (Fig. 32.4H). However, more prominent differences were seen in labelling pattern of DMN-trehalose (Fig. 32.4I), highlighting the potential utility of the trehalose probe in indicating underlying metabolic states of aerosolized bacilli. Additional surprising results were the observation of clumps and small clusters of organisms; however, these were not common and were observed in only a fraction (2/31) of patients (Fig. 32.4J).

Numerous organisms were detected with features closely matching those observed for laboratory-grown *C. striatum* (Fig. S1A, panel ii). We also observed multiple DMN-tre⁺ organisms of possible bacterial and/ or fungal origin—despite the expectation that the ability to metabolize the fluorescent trehalose analogue should be limited to the Actinomycetales (Fig. S1B). Utilizing the morphologic exclusion criteria developed above, all of these were eliminated from “putative *Mtb*” classification despite showing a DMN-tre⁺ phenotype (Fig. S1B).

32.2.4 Serial Imaging of Captured, DMN-tre⁺ *Mtb* Bacilli in the Arrayed Nanowells

A key motivation informing the development of the RASC platform was the need to capture live, aerosol-derived *Mtb* for analysis and propagation as part of a larger research program in TB transmission and *Mtb* aerobiology. This requires the capacity not only to isolate and detect individual bacilli, but also to maintain the viability of organisms in a format amenable to extended analysis and cultivation. To investigate the suitability of the nanowell array for this purpose, we prepared a small subset of bioaerosol samples for extended incubation *in vitro*. The samples were processed according to the standard DMN-trehalose staining protocol but, after the final wash step, were resuspended in fresh Middlebrook

7H9 culture medium before arraying on the nanowell slide and incubating at 37°C without shaking. Following initial identification of putative DMN-tre⁺ *Mtb* bacilli (Day 0), images were captured every 24 h for the first week (excluding weekends) and again on Day 14 post isolation using the x-y coordinates of the specific nanowell to enable re-location of the same organisms for serial imaging (Fig. 32.5).




Figure 32.5 Serial imaging of organisms captured directly from patient bioaerosol for up to two weeks. Single bacilli identified from 4 separate patients were serially imaged daily for the first 7 days (except weekends) and weekly thereafter. Up to three bacilli were tracked per patient (bacilli number—represented by shape and dashed lines) in four patients (represented by colour) and identified as either “Putative *Mtb*” or “Other”. (A–C) Representative bacilli from two separate patients imaged on days 0, 1, 2, 5, 6, 7, and 14. (A) and (B) represent putative *Mtb*, whereas (C) represents other organisms with a low probability of being *Mtb* based on the applied inclusion criteria. Summary of bacterial changes in (D) length and (E) mean fluorescence intensity minus the average background intensity. Scale bar = 5 μ m.

Over the two-week incubation period, no changes in length were observed for any of the cells, whether classified as “Putative *Mtb*” or “Other”. Similarly, the fluorescence intensities over background for individual cells displayed only minor increases for some of the “Other” organisms. It’s possible that the incubation time was too short to allow for adaptation of the bioaerosol-derived bacilli to the culture medium and/or solid substrate, with any alterations in metabolic or replicative state expected to manifest in altered bacillary morphology and/or DMN-trehalose profile; therefore, ongoing work includes exploring different culture media and extending the analysis from weeks to months. We were nevertheless encouraged by the ability to obtain serial images of the same organisms, supporting the utility of the nanowell array in enabling re-imaging of DMN-tre⁺ bacilli identified immediately post capture and assigned a unique “address” to allow for re-location.

32.3 Discussion

Fluorescence microscopy of bioaerosol samples enabled the detection of putative live *Mtb* in 90% of GeneXpert-confirmed TB patients. While absolute bacillary numbers in exhaled air samples were low (the maximum DMN-tre⁺ count was 36), it must be remembered that these samples were collected from only 60 min in the RASC and without requirement for a specific respiratory maneuver or induced cough. Consequently, simple extrapolation of the 14 bacilli median would suggest the release of around ~336 viable bacilli per day. This number is consistent with recent estimates based on face-mask sampling [7]. However, direct comparison is difficult owing to the use in that study of quantitative PCR targeting of the *IS6110* locus (present in *Mtb* genomes in variable copy number) with an acknowledged detection limit of ~33 CFU from the gelatin filters. Of note, release of several hundred metabolically active bacilli (inferred from DMN-trehalose incorporation) implies significant infection potential; moreover, the observation here of putative *Mtb* “clumps” resonates with *in vitro* evidence demonstrating the enhanced capacity of *Mtb* aggregates to subvert macrophage antimicrobial defenses [25].

The physiological state of aerosolized organisms remains uncertain owing to the previous unavailability of tools to investigate this stage of the TB disease cycle. Although DMN-trehalose positivity alone implies metabolic activity (bacilli must be viable to incorporate the trehalose analog into the mycomembrane), it is not known if these organisms are replicatively active, nor if aerosolized bacilli contain defining alterations in cell envelope [26] or other macromolecular compositions and/or inclusions [27]. We determined the sensitivity of DMN-trehalose labelling to metabolic state as a function of log *versus* stationary phase growth, recording significant differences that could be used to distinguish these states. Similar profiles were observed in organisms from patient bioaerosols, however the implications of these observations remain uncertain and will require further research, potentially involving the incorporation of more than one spectrally compatible fluorescent probe [28]. The potential exists to extend this work

beyond investigating metabolic state, focusing on drug resistance, for example. Previous work has shown differences in probe incorporation profiles in response to antibiotic treatment [29]. At a quantitative level, imaging organisms from diagnosed TB patients before and after treatment initiation, as well as serially over the course of standard chemotherapy, might therefore offer a more rapid indication of drug efficacy, in effect affording the sensitivity of broncho-alveolar lavage without the invasiveness of that procedure.

Considerable effort was made to minimize the acquisition of “contaminating” debris during RASC sampling—for example, by working in a clean-room and requiring that all patients wore disposable biohazard suits to reduce release of non-respiratory particles. This is because the cleanliness of samples is critical for microscopic visualization: auto-fluorescence is a major confounder in environmental samples and debris can obscure *Mtb* bacilli under microscopic investigation (Fig. S2). The nanowell device, too, was designed to maximize *Mtb* detection by increasing the likelihood of separating debris and bacilli through sample dispersal across thousands of nanowell chambers. It is possible that the composition and origin of the particulate matter will prove invaluable in future in determining the anatomical origin of aerosolized bacilli. In this work, though, raising the signal from putative *Mtb* above background noise was our priority. Our “empty booth” controls—in which sampling was performed in the empty RASC in the absence of an incumbent individual and was therefore expected to be *Mtb* free—returned 54% (14/26) positivity; however, the difference in median count compared to the TB-positive patients suggested that these organisms were carried over from the cyclone collection system or RASC (Fig. 32.4A). Moreover, improvements to the collection system subsequent to this study have ensured complete sterilization, eliminating carryover as confounder.

Bioaerosols impose numerous additional complications which are not applicable to the current standard clinical TB specimens, such as sputum. For example, in processing our samples, we deliberately omitted a decontamination step (sample loss is too significant a factor when dealing with tens of organisms), risking the potential for proportionally larger numbers of non-*Mtb* DMN-trehalose-positive organisms to be present in the bioaerosol samples than in decontaminated sputum. The amplification of fluorescence consequent on incorporation into the mycomembrane suggests the possible use of DMN-trehalose in detecting *Mtb* within untreated and decontaminated sputum [22]. However, the fact that Ag85-dependent trehalose mycolylation is not unique to mycobacteria [22] complicates the use of this probe on its own to classify aerosol samples as “*Mtb* positive”. When the present work was initiated, there was a lack of ancillary *Mycobacterium*-specific probes which could be applied to increase the specificity of the microscopic detection while retaining sample viability (thus excluding standard approaches including auramine and acid-fast staining which involve inactivation steps). More recently, other mycobacterial probes have become available, including (i) the CDG-DNB3 dual fluorescence probe which is activated by the mycobacterial BlaC β -lactamase and retained in the cell wall following covalent modification by the decaprenylphosphoryl- β -D-ribose 2'-epimerase,

DprE1 [30]; (ii) the TAMRA-labelled benzothiazinone analogue, JN108, which also targets the mycobacterial membrane protein, DprE1, and according to its developers, is able to differentiate *Corynebacterium* from *Mycobacterium* on the basis of fluorescence localization [31]; and (iii) the Quencher-Trehalose-Fluorophore (QTF) which, like DMN-trehalose is a fluorogenic analogue of the natural substrate of mycobacterial mycolyltransferases [32]. It is too soon to ascertain whether any of these will add value to the analysis; moreover, the overlapping auto-fluorescent signal in many samples urges the development of alternative probes in the red end of the visible spectrum. Current work aims to refine our framework for identification of *Mtb* based on automated detection of fluorophores, utilizing algorithms that capture metabolic and morphological characteristics.

Although we did not detect any clear alterations in morphology or DMN-trehalose incorporation profile, the incubation period was limited to two weeks which might be too short to allow for metabolic and/or replicative adaptation in the captured organisms; ongoing work is extending the duration of incubation, and will also explore the use of other compartmentalized capture devices as alternatives to the COC-embossed nanowell format. At the very least, these results support the ability to capture and maintain single *Mtb* cells in an arrayed format for serial imaging, and hint at the potential to exploit the physical separation of cells into nanowell compartments for clonal propagation of bacilli downstream for genomic and other analyses which require biomass [33].

As for any study describing the development of technologies to investigate a previously occult stage of the infectious disease cycle, the approach detailed here inevitably carries inherent limitations which must be considered when interpreting the data: (i) We have not presented orthogonal data confirming the identity of the “putative *Mtb*” identified microscopically. The presumptive evidence, however, is strong: the bioaerosol samples were obtained from GeneXpert-positive TB patients immediately after diagnosis and before treatment initiation, and our previous work has demonstrated the isolation in the RASC platform of PCR-confirmed *Mtb* colony forming units in bioaerosol samples [11, 12]. Moreover, ongoing work in which two samples collected from the same individual are analysed via DMN-trehalose probing and either auramine staining or RD9 PCR detection have confirmed 100% positivity correlation. (ii) The bacillary counts and morphological phenotypes presented here are not augmented with clinical metadata (chest radiography scores, HIV status, *etc.*). Our intention in this study was to establish the technological platform for bioaerosol sample capture and analysis—as described in our recently published protocol [34], current and planned work involves the application of the RASC to carefully designed clinical cohorts. (iii) The criteria used to classify DMN-tre⁺ organisms as “putative *Mtb*” are potentially restrictive, especially given that prevailing assumptions about the size and shape of clinical *Mtb* isolates are heavily influenced by the commonly applied staining methods (almost never supported by confirmatory molecular or microbiological data) as well as knowledge of *Mtb* morphology from growth *in vitro* in defined culture, in some cases in intracellular infection

models or under applied stress conditions. There is a strong likelihood that we are failing to detect *Mtb* which do not conform to these criteria and, moreover, our use of fluorescence positivity necessarily excludes organism which might be transiently inactive or quiescent [35]. We are exploring the incorporation of automated image detection software to facilitate machine-driven detection of “interesting” structures following capture of microscopy images for all particulate matter (organic and inorganic) arrayed on the nanowell slides. This development is proposed to address a further limitation of our approach, namely that our method relies on detecting then imaging cells (including microscope focusing) based on DMN-trehalose fluorescence. The noise in some samples means finding an optimal focus can be a challenge, which may artifactually increase or decrease the width (and to some degree the length) of the bacilli we measure.

Our priority now is the deployment of the RASC to identify viable *Mtb* in aerosol collected from potentially infectious subclinical cases [19]. The capacity for non-invasive capture and isolation of viable *Mtb* from bioaerosol within 24 h of collection also supports the potential utility of the RASC to measure the impact of TB treatment on the viability of *Mtb* bioaerosol release. Finally, while this technology enables the detection of viable bacilli, like all aerosol capture methods it does not provide a measure of infectiousness. Ascertaining which *Mtb* isolates go on to infect new individuals and cause TB disease will require innovative approaches toward “closing the loop”; that is, demonstrating productive infection of a new host following release. Historically, this has been achieved primarily by demonstrating infection of animals [36] (thus satisfying a key criterion of Koch’s Postulates); the application of genomic epidemiology in combination with RASC-enabled bacillary capture, perhaps in closed community (or even household) settings, offers a modern alternative. For now, the planned modifications to our platform are primarily informed by the need to enable multi-omic analyses of the single-cell organisms isolated from patient aerosols to generate insights that can be pursued in the human host, the natural target of *Mtb*.

32.4 Materials and Methods

32.4.1 Ethics Statement

Ethics approval was obtained from the Human Research Ethics Committee, University of Cape Town (HREC 529/2019). Patients were recruited from primary healthcare facilities in Masiphumelele and Ocean View, peri-urban townships located outside Cape Town, South Africa. Informed consent was obtained from all participants and criteria for inclusion were (i) 18 years or older, (ii) GeneXpert-positive TB, and (iii) no evidence of drug resistant TB. All participants were recruited prior to initiation of standard anti-TB chemotherapy; following routine diagnosis, participants were transferred for RASC sampling, ethical approval having sanctioned a 2 h delay to initiation of standard TB chemotherapy to enable bioaerosol collection.

32.4.2 Sample Collection

Bioaerosol collection was done as previously described [12] with the sampling method improved by using a Coriolis μ Biological Air Sampler (Bertin Technologies SAS, France) possessing the capacity to capture up to 500 L of expired air. This enabled the concentration of <500 L of expired air per subject per hour into ~5–10 mL sterile phosphate-buffered saline (PBS), thus ensuring high sampling volumes while producing a tractable, low-volume liquid output for downstream manipulation and analysis.

32.4.3 Bacterial Culture Conditions and DMN-Trehalose Staining

The laboratory strain, *Mtb* H37RvMA [37], was grown at 37°C in Middlebrook 7H9 (Difco) liquid broth supplemented with 0.2% (v/v) glycerol, 10% (v/v) Middlebrook OADC enrichment and 0.05% (w/v) Tween80 (Sigma-Aldrich). *Corynebacterium striatum* was cultured in LB broth (Sigma-Aldrich) at 37°C.

The solvatochromic probe, 4-*N,N*-dimethylamino-1,8-naphthalimide-trehalose (DMN-trehalose) [22], was used for all staining. Enzymatic incorporation of DMN-trehalose into the hydrophobic mycomembrane by the mycobacterial Antigen-85 complex enhances DMN fluorescence one thousand-fold, limiting background noise attributable to unincorporated probe and circumventing the need for multiple washes. For staining of exponentially replicating and stationary-phase bacilli, *Mtb* H37Rv cultures were grown to an OD_{600} ~0.5 and ~1.2, respectively, before staining with 100 μ M DMN-trehalose for 2 h. Thereafter, cells were harvested by centrifugation at 13000 $\times g$ for 5 min before resuspending in PBS prior to visualization.

32.4.4 Staining of Bioaerosol Samples

The 5–10 mL bioaerosol samples were concentrated by centrifugation at 3000 $\times g$ for 10 min (Allegra X-15R, Beckman Coulter). The pellet was resuspended in 200 μ l fresh Middlebrook 7H9 medium and stained overnight (12–16 h), following which the stained sample was concentrated at 13000 $\times g$ for 5 min and resuspended in 20 μ l sterile filtered PBS.

32.4.5 Nanowell Arraying

Stained bioaerosol samples were arrayed in a custom-designed nanowell device (Edge Embossing), the superstructure of which consisted of two rows of eight wells (16 total) overlaid on an embossed cyclic olefin copolymer (COC) film (Fig. 32.1A and 32.1B). The COC film contained the 50 \times 50 μ m nanowells which were arrayed ~140 μ m apart center-to-center (Fig. 32.1C). Each microwell therefore comprised approximately 1600 nanowells. Prior to inoculation, the device was plasma coated (Novascan) to counteract hydrophobicity. Following DMN-trehalose staining, the concentrated aerosol sample was added to a single

microwell. Samples were loaded and plates sealed using an adhesive film (ThermoFischer Scientific) before centrifuging at $3000 \times g$ for 10 min to disperse the sample for imaging.

32.4.6 Serial Imaging of Putative *Mtb* in Bioaerosols

As described above, the 5–10 mL bioaerosol samples were concentrated by centrifugation at $3000 \times g$ for 10 min (Allegra X-15R, Beckman Coulter). The pellet was resuspended in 200 μ l fresh Middlebrook 7H9 medium and stained overnight (12–16 h), following which the stained sample was concentrated at $13000 \times g$ for 5 min and resuspended in 20 μ l fresh Middlebrook 7H9 medium and incubated at 37°C without shaking. Images were captured as described in fluorescent microscopy every 24 h for the first week (excluding weekends) and again on day 14 post isolation, with incubation at 37°C throughout.

32.4.7 Fluorescence Microscopy

Imaging was done on a Zeiss Axio Observer 7 equipped with a 100 \times plan-apochromatic phase 3 oil immersion objective with a numerical aperture of 1.4. Epifluorescent illumination was provided by a 475 nm LED and non-specific fluorescence was removed with a Zeiss 38 HE filter set. Images were acquired using the Zeiss Zen software, and quantitative data extracted using MicrobeJ [38]. For serial imaging of bioaerosol samples, re-identification of putative bacilli detected at Day 0 was done by determining the x-y coordinates of the specific nanowell relative to the top-most, center nanowell in the macro well.

32.4.8 Statistical Analysis

Data were exported from MicrobeJ and analyses performed using R, version 3.5.1. Data normality was assessed visually and, where applicable, a Wilcoxon Rank-Sum test was performed.

Supporting Information

S1 Fig. Exclusion of non-mycobacterial, DMN-tre⁺ organisms detected in bioaerosol samples based on cell morphology and staining profile. (A) Representative images of (i) *C. striatum* cultured in LB broth during log-phase and stained with 100 μ M DMN-trehalose for 5 min, and (ii) DMN-tre⁺ organisms detected within a bioaerosol sample. (B) A panel of non-*Mtb*, DMN-tre⁺ organisms, as determined by our inclusion criteria, identified in various bioaerosol samples. Scale bar, 5 μ m. <https://doi.org/10.1371/journal.ppat.1009262.s001>.

S2 Fig. Debris commonly found within TB bioaerosols. Representative images of the three major categories of debris found within bioaerosol samples after overnight staining with 100 μ M DMN-trehalose and visualization within a

50 × 50 µm nanowell. (A) Large, crystalline debris, (B) small fluorescent debris, and (C) granular debris. <https://doi.org/10.1371/journal.ppat.1009262.s002>.

Abbreviations

CFU:	colony forming unit
DMN-trehalose:	N-dimethyls-amino-1,8-naphthalimide-trehalose
MDR:	multi-drug resistant
Mtb:	<i>Mycobacterium tuberculosis</i>
PBS:	phosphate-buffered saline
QTF:	quencher-trehalose-fluorophore
RASC:	respiratory aerosol sampling chamber
TB:	tuberculosis

Disclosures and Conflict of Interest

This chapter was originally published as: Dinkele, R., Gessner, S., McKerry, A., Leonard, B., Seldon, R., Koch, A. S., et al. (2021). Capture and visualization of live *Mycobacterium tuberculosis* bacilli from tuberculosis patient bioaerosols. *PLoS Pathog.*, **17**(2), e1009262, <https://doi.org/10.1371/journal.ppat.1009262>.

Funding: The authors acknowledge the financial support of the South African Medical Research Council (www.samrc.ac.za) with funds from National Treasury under its Economic Competitiveness and Support Package (MRC-RFA-UFSP-01-2013/CCAMP, R.W.), for Extramural Unit funding (to V.M.), and via the Strategic Health Innovations Partnerships Unit (www.samrc.ac.za/innovation/strategic-health-innovation-partnerships) (to D.F.W and V.M). The authors are grateful for funding from the Bill and Melinda Gates Foundation (www.gatesfoundation.org; OPP1116641, R.W.), the Research Council of Norway (www.forskningssradet.no; R&D Project 261669 “Reversing antimicrobial resistance”, D.F.W.), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (www.nichd.nih.gov; U01HD085531, D.F.W.), and the US National Institute of Allergy and Infectious Diseases (www.niaid.nih.gov; R01AI147347, R.W.). The authors also acknowledge the Howard Hughes Medical Institute (www.hhmi.org) for a Senior International Research Scholars grant (V.M.), Stanford University’s Diversifying Academia, Recruiting Excellence Fellowship (www.stanford.edu), and the NIH Predoctoral Fellowship F31AI129359 (M.K), the Bill and Melinda Gates Foundation (OPP115061) and NIH (AI051622) grants (to C.R.B.), and the Carnegie Corporation of New York (www.carnegie.org) via sub-award from the University of Cape Town (www.uct.ac.za) (to A.K). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

Ryan Dinkele and Sophia Gessner contributed equally to this work.

Author Contributions

Conceptualization: Ryan Dinkele, Sophia Gessner, Carl Morrow, Gilla Kaplan, Valerie Mizrahi, Robin Wood, Digby F. Warner; Data curation: Ryan Dinkele, Sophia Gessner, Andrea McKerry, Bryan Leonard, Ronnett Seldon, Carl Morrow; Formal analysis: Ryan Dinkele, Sophia Gessner, Anastasia S. Koch, Carl Morrow, Robin Wood, Digby F. Warner; Funding acquisition: Valerie Mizrahi, Robin Wood, Digby F. Warner; Investigation: Ryan Dinkele, Sophia Gessner, Wayne Bryden, Charles Call, Robin Wood, Digby F. Warner; Methodology: Ryan Dinkele, Sophia Gessner, Andrea McKerry, Bryan Leonard, Ronnett Seldon, Anastasia S. Koch, Brian Smith, Courtney McCloud, Andrew Kamholz, Wayne Bryden, Charles Call, Digby F. Warner; Project administration: Ryan Dinkele, Sophia Gessner, Ronnett Seldon, Carl Morrow, Melitta Gqada; Resources: Mireille Kamariza, Carolyn R. Bertozzi, Brian Smith, Courtney McCloud, Andrew Kamholz, Wayne Bryden, Charles Call; Supervision: Valerie Mizrahi, Robin Wood, Digby F. Warner; Visualization: Ryan Dinkele, Andrea McKerry, Bryan Leonard; Writing – original draft: Ryan Dinkele, Sophia Gessner, Anastasia S. Koch, Digby F. Warner; Writing – review & editing: Ryan Dinkele, Sophia Gessner, Anastasia S. Koch, Carl Morrow, Mireille Kamariza, Gilla Kaplan, Valerie Mizrahi, Robin Wood, Digby F. Warner.

References

1. World Health Organization. Global Tuberculosis Report. 2019. Available at: <https://www.who.int/publications/i/item/9789241565714> (accessed on October 15, 2022).
2. Kaplan G. Tuberculosis control in crisis-causes and solutions. *Prog Biophys Mol Biol.* 2019; 152:6–9.
3. Sharma A, Hill A, Kurbatova E, van der Walt M, Kvasnovsky C, Tupasi T, et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. *Lancet Infect Dis.* 2017; 17:707–715.
4. Koch A, Cox H. Preventing drug-resistant tuberculosis transmission. *Lancet Infect Dis.* 2020; 20(2): 157–158.
5. Glynn JR, Guerra-Assunção JA, Houben RMGJ, Sichali L, Mzembe T, Mwaungulu LK, et al. Whole genome sequencing shows a low proportion of tuberculosis disease is attributable to known close contacts in rural Malawi. *PLoS One.* 2015; 10: 1–12.
6. Stucki D, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, et al. Standard genotyping overestimates transmission of *Mycobacterium tuberculosis* among immigrants in a low-incidence country. *J Clin Microbiol.* 2016; 54: 1862–1870.
7. Williams CM, Abdulwhhab M, Birring SS, De Kock E, Garton NJ, Townsend E, et al. Exhaled *Mycobacterium tuberculosis* output and detection of subclinical disease by face-mask sampling: prospective observational studies. *Lancet Infect Dis.* 2020; 3099: 1–11.

8. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. *BMJ*. 2018; 362: 1–10.
9. Xu Y, Cancino-Muñoz I, Torres-Puente M, Villamayor LM, Borrás R, Borrás-Mañez M, et al. High-resolution mapping of tuberculosis transmission: whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain. *PLoS Med*. 2019; 16: e1002961.
10. Martínez L, Shen Y, Mupere E, Kizza A, Hill PC, Whalen CC. Transmission of *Mycobacterium Tuberculosis* in households and the community: a systematic review and meta-analysis. *Am J Epidemiol*. 2017; 185: 1327–1339.
11. Wood R, Morrow C, Barry CE, Bryden WA, Call CJ, Hickey AJ, et al. Real-time investigation of tuberculosis transmission: developing the respiratory aerosol sampling chamber (RASC). *PLoS One*. 2016; 11: 1–16.
12. Patterson B, Morrow C, Singh V, Moosa A, Gqada M, Woodward J, et al. Detection of *Mycobacterium tuberculosis* bacilli in bio-aerosols from untreated TB patients. *Gates Open Res*. 2018; 1: 11.
13. Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, et al. The relationship between *Mycobacterium tuberculosis* MGIT time to positivity and CFU in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. *J Antimicrob Chemother*. 2015; 70: 448–455.
14. Nimmo C, Shaw LP, Doyle R, Williams R, Brien K, Burgess C, et al. Whole genome sequencing *Mycobacterium tuberculosis* directly from sputum identifies more genetic diversity than sequencing from culture. *BMC Genomics*. 2019; 20: 1–9.
15. Kennedy JA, Baron VO, Hammond RJH, Sloan DJ, Gillespie SH. Centrifugation and decontamination procedures selectively impair recovery of important populations in *Mycobacterium smegmatis*. *Tuberculosis* 2018; 112: 79–82.
16. Matuka O, Singh TS, Bryce E, Yassi A, Kgasha O, Zungu M, et al. Pilot study to detect airborne *Mycobacterium tuberculosis* exposure in a South African public healthcare facility outpatient clinic. *J Hosp Infect*. 2015; 89: 192–196.
17. Sabiiti W, Azam K, Farmer CE, Kuchaka D, Mtafya B, Bowness R, et al. Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis molecular bacterial load assay. *Thorax*. 2020; 75: 606–608.
18. Patterson B, Wood R. Is cough really necessary for TB transmission? *Tuberculosis*. 2019; 117: 31–35.
19. Kendall E, Shrestha S, Dowdy DW. The epidemiological importance of subclinical tuberculosis: a critical re-appraisal. *Am J Respir Crit Care Med*. 2020; 203(2): 168–174.
20. Williams CML, Cheah ESG, Malkin J, Patel H, Out J, Mlaga K, et al. Face mask sampling for the detection of *Mycobacterium tuberculosis* in expelled aerosols. *PLoS One*. 2014; 9: 1–7.
21. Fennelly KP, Jones-López EC. Quantity and quality of inhaled dose predicts immunopathology in tuberculosis. *Front Immunol*. 2015; 6: 1–13.
22. Kamariza M, Shieh P, Ealand CS, Peters JS, Chu B, Rodríguez-Rivera FP, et al. Rapid detection of *Mycobacterium tuberculosis* in sputum with a solvatochromic trehalose probe. *Sci Transl Med*. 2018; 10(430): eaam6310.

23. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. *Chest*. 2010; 137: 122–128.
24. Alibi S, Ferjani A, Boukadida J, Cano ME, Fernández- Martínez M, Martínez-Martínez L, Navas J. Occurrence of *Corynebacterium striatum* as an emerging antibiotic-resistant nosocomial pathogen in a Tunisian hospital. *Sci Rep*. 2017; 7: 1–8.
25. Mahamed D, Boulle M, Ganga Y, Mc Arthur C, Skroch S, Oom L, et al. Intracellular growth of *Mycobacterium tuberculosis* after macrophage cell death leads to serial killing of host cells. *eLife*. 2017; 6: 1–27.
26. Michaud JM, Thompson LR, Kaul D, Espinoza JL, Richter RA, Xu ZZ, et al. Taxon-specific aerosolization of bacteria and viruses in an experimental ocean-atmosphere mesocosm. *Nat Commun*. 2018; 9: 1–10.
27. Garton NJ, Barer MR. Mycobacterial lipid bodies and the chemosensitivity and transmission of tuberculosis. In: Goldfine H, editor. *Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids*. Springer International Publishing; 2020. pp. 109–132.
28. Rodriguez-Rivera FP, Zhou X, Theriot JA, Bertozzi CR. Visualization of mycobacterial membrane dynamics in live cells. *J Am Chem Soc*. 2017; 139: 3488–3495.
29. Rodriguez-Rivera FP, Zhou X, Theriot JA, Bertozzi CR. Acute modulation of mycobacterial cell envelope biogenesis by front-line tuberculosis drugs. *Angew Chemie Int Ed*. 2018; 57: 5267–5272.
30. Cheng Y, Xie J, Lee KH, Gaur R, Song A, Dai T, et al. Rapid and specific labeling of single live *Mycobacterium tuberculosis* with a dual-targeting fluorogenic probe. *Sci Transl Med*. 2018; 10: 1–13.
31. Sommer R, Neres J, Piton J, Dhar N, Van Der Sar A, Mukherjee R, et al. Fluorescent benzothiazinone analogues efficiently and selectively label Dpre1 in Mycobacteria and Actinobacteria. *ACS Chem Biol*. 2018; 13: 3184–3192.
32. Hodges HL, Brown RA, Crooks JA, Weibel DB, Kiessling LL. Imaging mycobacterial growth and division with a fluorogenic probe. *Proc Natl Acad Sci*. 2018; 115: 5271–5276.
33. Goig GA, Cancino-Muñoz I, Torres-Puente M, Villamayor LM, Navarro D, Borrás R, et al. Whole-genome sequencing of *Mycobacterium tuberculosis* directly from clinical samples for high-resolution genomic epidemiology and drug resistance surveillance: an observational study. *The Lancet Microbe*. 2020; 1: e175–183.
34. Patterson B, Koch A, Gessner S, Dinkele R, Gqada M, Bryden W, et al. Bioaerosol sampling of patients with suspected pulmonary tuberculosis: a study protocol. *BMC Infect Dis*. 2020; 20: 1–7.
35. Chengalroyen MD, Beukes GM, Gordhan BG, Streicher EM, Churchyard G, Hafner R, et al. Detection and quantification of differentially culturable tubercle bacteria in sputum from patients with tuberculosis. *Am J Respir Crit Care Med*. 2016; 194: 1532–1540.
36. Donald PR, Diacon AH, Lange C, Demers A-M, von Groote-Biddlingmeier F, Nardell E. Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878–1940. *Int J Tuberc Lung Dis*. 2018; 22: 972–982.

37. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, et al. Variation among genome sequences of H37Rv strains of *Mycobacterium tuberculosis* from multiple laboratories. *J Bacteriol.* 2010; 192: 3645–3653.
38. Ducret A, Quardokus E, Brun Y. MicrobeJ, a tool for high throughput bacterial cell detection and quantitative analysis. *Nat Microbiol.* 2016; 1: 1–14.

Chapter 33

Diagnostic Accuracy of a Novel Tuberculosis Point-of-Care Urine Lipoarabinomannan Assay for People Living with HIV: A Meta-Analysis of Individual In- and Outpatient Data

Tobias Broger, MSc,^a Mark P. Nicol, PhD,^{b,c,d} Rita Székely, PhD,^a Stephanie Bjerrum, MD, PhD,^{e,f} Bianca Sossen, MBChB,^{g,h} Charlotte Schutz, MBChB, MPH,^{g,h} Japheth A. Opintan, PhD,ⁱ Isik S. Johansen, DMSc,^{e,f} Satoshi Mitarai, PhD,^j Kinuyo Chikamatsu, PhD,^j Andrew D. Kerkhoff, MD, PhD,^k Aurélien Macé, PhD,^a Stefano Ongarello, PhD,^a Graeme Meintjes, PhD,^{g,h} Claudia M. Denking, MD, PhD,^{a,l} Samuel G. Schumacher, PhD^a

^a*FINN, Geneva, Switzerland*

^b*Division of Infection and Immunity, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia*

^c*Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa*

^d*National Health Laboratory Service, Cape Town, South Africa*

^e*Mycobacterial Research Centre of Southern Denmark, Department of Infectious Diseases, Odense University Hospital, Odense, Denmark*

^f*Department of Clinical Research, Unit of Infectious Diseases, University of Southern Denmark, Odense, Denmark*

^g*Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa*

^h*Wellcome Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa*

ⁱ*Department of Medical Microbiology, School of Biomedical and Allied Sciences, College of Health Sciences, University of Ghana, Accra, Ghana*

^j*Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan*

^k*Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, Department of Medicine, University of California, San Francisco, California, USA*

^l*Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany*

Samuel.Schumacher@finddx.org

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

Keywords: composite reference standard (CRS), cross-reactivity, demographics, Fujifilm SILVAMP TB LAM (SILVAMP-LAM), individual patient data (IPD), lipoarabinomannan (LAM), mycobacteria growth indicator tube (MGIT), microbiological reference standard (MRS), *Mycobacterium tuberculosis* (Mtb), nontuberculous mycobacteria (NTM), people living with HIV (PLHIV), point-of-care (POC), tuberculosis (TB), urinary tract, Xpert MTB/RIF (Xpert)

33.1 Introduction

Tuberculosis (TB) is the most common cause of death in people living with HIV (PLHIV), whose risk of developing active TB is estimated to be approximately 30 times greater than in people without HIV [1]. Evidence from randomized diagnostic studies shows that early diagnosis of TB among PLHIV reduces mortality [2, 3].

Traditional diagnostic methods, such as culture or smear microscopy, are slow or low in sensitivity. More sensitive modern techniques, such as Xpert MTB/RIF (Xpert), require a certain infrastructure, are costly, and are not widely accessible. Moreover, TB is harder to diagnose in PLHIV, since many of the patients have extrapulmonary TB (approximately 25%), produce paucibacillary sputum samples, or cannot reliably produce a sputum specimen [4, 5]. TB in PLHIV is often fatal if undiagnosed or left untreated. New, rapid, non-sputum-based point-of-care (POC) diagnostic solutions to detect TB, especially in vulnerable groups, are urgently needed [6].

The commercially available Alere Determine TB LAM lateral flow assay (LF-LAM; Abbott, Chicago, US; in previous studies also called AlereLAM) is a rapid, inexpensive POC TB test [7]. While its use is associated with a mortality benefit in severely ill and immunocompromised PLHIV [2, 3], it has only moderate sensitivity in patients with a low CD4 count and has had low programmatic uptake [8–10]. We have already reported on the novel Fujifilm SILVAMP TB LAM (SILVAMP-LAM; Fujifilm, Tokyo, Japan; in previous studies also called FujiLAM) assay. SILVAMP-LAM, similarly to LF-LAM, detects the presence of lipoarabinomannan (LAM) in urine using a visually read lateral flow test, but unlike LF-LAM, SILVAMP-LAM utilizes silver amplification. For inpatients with HIV, it offers on average an increase in sensitivity of approximately 25%–30% compared to LF-LAM across CD4 strata, while maintaining a high specificity when a composite reference standard is used [11].

Here, we present all available individual patient data (IPD), both published [11, 12] and unpublished, from SILVAMP-LAM testing (“intervention” per PRISMA guidelines [13]) in adult inpatients and outpatients with HIV (“patients”) in comparison to LF-LAM (“comparator”) across 5 prospective cohorts (“studies”) and analyze its diagnostic accuracy (“outcome”). These data contributed to a guidance development group consultation of the World Health Organization in May 2019.

33.2 Methods

33.2.1 Study Population

Biobanked urine samples from adult PLHIV (≥ 18 years), collected in 5 prospective cohort studies in South Africa, Vietnam, and Ghana, were assessed (Table S1). Study protocols and statistical analysis plans for the different studies are available upon request. A study that combines inpatient cohorts from South Africa (cohorts 1A, 2, and 3) [11] and the study from Ghana (cohort 5) [12] have been published.

For the first cohort from South Africa, adults with TB symptoms able to produce sputum were enrolled consecutively, independently of their HIV status. Inpatients were enrolled on admission to Khayelitsha Hospital (cohort 1A), while outpatients were enrolled at the Town Two and Nolungile primary healthcare facilities in the Khayelitsha township (cohort 1B), between February 2017 and August 2017. Those in whom the disease was thought to be only extrapulmonary were excluded.

The second cohort from South Africa (cohort 2) enrolled adult inpatients with HIV consecutively, independently of their CD4 count, as they were admitted to adult medical wards at GF Jooste Hospital between June 2012 and October 2013, regardless of their ability to produce sputum or whether they reported TB symptoms [14].

The third cohort from South Africa (cohort 3) enrolled inpatient PLHIV at Khayelitsha Hospital with a $CD4 \leq 350$ cells/ μ l in whom TB was considered the most likely diagnosis at presentation between January 2014 and October 2016 [15]. A list of all potentially eligible patients was compiled daily, and a random selection procedure (using a die after all potentially eligible patients had been identified) was followed to enroll 2–4 patients daily.

The fourth cohort (cohort 4), from Vietnam, used samples from consecutively enrolled patients presenting to the outpatient clinics of a public sector district hospital (Pham Ngoc Thach Hospital, Ho Chi Minh City) with symptoms suggestive of TB, independently of HIV status, between September 2016 and July 2017.

For cohort 5, HIV-infected adults eligible for antiretroviral therapy were consecutively enrolled irrespective of whether they reported TB signs and symptoms from an outpatient clinic in the Fevers Unit of Korle-Bu Teaching Hospital, a public referral hospital in Accra, the capital city of Ghana, between January 2013 and March 2014 [12, 16].

All cohorts excluded patients who were already receiving anti-TB therapy. Where patients were enrolled independently of HIV status, the present study included only PLHIV. More details on the individual cohorts can be found in Table S1 and Table S2. Relevant data are available in S1 Data. Study protocols are available upon request.

All study-related activities were approved by the human research ethics committees of the respective sites including City of Cape Town (Ref. 10364a) and the University of Cape Town Human Research Ethics Committee (UCT HREC,

Ref. 250/2018) for cohort 1, UCT HREC (Ref. 001/2012) for cohort 2, UCT HREC (Ref. 057/2013) for cohort 3, Ministry of Health Vietnam (Ref. 2493/QĐ-BYT) for cohort 4, and the Institutional Review Board of University of Ghana Medical School (Ref. MS-Et/M.4-P3.3/2012-13) and the Danish National Committee (Ref. 1302133/Doc No. 1206169) for cohort 5. Written informed consent was obtained from patients, as per the study protocols. Study participation did not affect standard of care. All reporting follows STARD and PRISMA guidelines [17, 18] (S1 STARD Checklist and S1 PRISMA IPD Checklist), and no analysis plan was prespecified.

33.2.2 Laboratory Methods

Samples. Urine specimens were stored at -80°C (cohort 1, cohort 3, cohort 4) and -20°C (cohort 2, cohort 5) (Table S3). Aliquots of frozen, unprocessed urine were thawed to ambient temperature and mixed manually prior to testing with SILVAMP-LAM and LF-LAM. Samples that were not immediately used for testing were stored at 4°C for a maximum of 4 h.

Users and training. SILVAMP-LAM and LF-LAM testing was performed by skilled laboratory technicians in research laboratories at the University of Cape Town and the Research Institute of Tuberculosis of the Japan Anti-Tuberculosis Association. The technicians were newly trained to perform SILVAMP-LAM. Training included review of the English instructions for use, explanation and demonstration of both assays by a trainer, and conductance of up to 3 tests by the users followed by a proficiency test questionnaire. The user's ability to correctly interpret the LF-LAM band intensity was assessed using 20 scanned LF-LAM test strips with different results next to the 4-grade reference scale card. The total training time for both tests was 4–6 h.

Index testing (SILVAMP-LAM). Testing with SILVAMP-LAM was performed according to the manufacturer's instructions using urine from the same aliquot as that used with LF-LAM. The 5-step test procedure is illustrated in an online video [19] and takes 50–60 min from start to end result. In brief, urine is added to the reagent tube up to the indicator line (approximately 200 μl), mixed, and incubated for 40 min at ambient temperature. After mixing again, 2 drops of urine/reagent are added to the test strip at position 1. Following this, button 2 is pressed immediately. After the "go-next" color indicator mark turns orange (within 3–10 min), button 3 is pressed. The result is then read within 10 min. The SILVAMP-LAM assay does not use a reference scale card and any visible test line is considered positive.

Comparator testing (LF-LAM). LF-LAM is a commercially available lateral flow assay that detects LAM with polyclonal antibodies. It is currently recommended by WHO to assist in the diagnosis of active TB in PLHIV [20]. LF-LAM was used according to the test's package insert. To sum up, 60 μl of urine is applied to the sample pad. After 25 min, the test strip is interpreted using the 4-grade reference scale card, with the grade 1 cut-off point as the positivity threshold.

Blinding. SILVAMP-LAM was read independently by 2 readers blinded to the results of one another (blinded double reading). After the initial test interpretation,

the 2 readers compared results and, in the event of discordance, re-inspected the test to establish a final consensus result (by mutual agreement) that was then used for analysis. The same procedure was used for LF-LAM. SILVAMP-LAM and LF-LAM reading occurred blinded to the test results of the other LAM-based test, patient diagnosis, and all other TB test results. SILVAMP-LAM and LF-LAM results were not available to the assessors of the reference standard.

Test failure. In case of SILVAMP-LAM or LF-LAM failure, the test was repeated once. Accuracy calculations were performed from the valid result (first or second attempt).

Reference standard testing. For reference standard testing, the specimens were processed using standardized protocols from centralized accredited laboratories of the different sites. The testing flow for each cohort is shown in Table S2. Sputum, blood, and urine specimens for *Mycobacterium tuberculosis* (MtB) reference standard testing were collected at enrollment, and additional clinical samples were obtained during hospital admission and at follow-up. Sputum collection across cohorts was done by an experienced nurse or trained clinical research worker, and sputum induction was performed (except for cohort 5) when required. Reference standard testing was performed on all available sputum specimens and included Xpert MTB/RIF (Xpert, Cepheid, Sunnyvale, CA, US; testing predated rollout of Xpert Ultra MTB/RIF), sputum smear microscopy (fluorescence microscopy using Auramine O staining and/or Ziehl–Neelsen staining), Mycobacteria Growth Indicator Tube (MGIT) liquid culture (Becton Dickinson, Franklin Lakes, NJ, US), and solid culture on Löwenstein–Jensen medium. The presence of MtB complex in solid or liquid culture was confirmed with MPT64 antigen detection and/or MTBDR*plus*, MTBC, or CM/AS line probe assays (Bruker Hain [formerly Hain Lifesciences], Nehren, Germany). Blood culture from all participants was done in BACTEC Myco/F Lytic culture vials (Becton Dickinson). The exception was that no blood cultures were done for cohorts 4 and 5. WHO-prequalified in vitro diagnostic tests were used for HIV testing (rapid diagnostic tests) and CD4 cell counting (flow cytometry). For urine Xpert testing, 30–40 ml of urine (in cohort 5, only 6 ml) was centrifuged, and, following removal of the supernatant, the pellet was re-suspended in the residual urine volume, then 0.75 ml was tested using Xpert. No urinary Xpert testing was done for cohort 4. For cohorts 2 and 3, additional respiratory and non-respiratory samples such as pleural fluid, cerebrospinal fluid, and tissue fine needle aspirates were obtained, where clinically indicated, and tested using MGIT liquid culture and/or microscopy and/or Xpert. Details of testing according to cohort are reported in Table S2.

33.2.3 Case Definitions

Patients were assigned to 1 of 4 diagnostic categories using a combination of clinical and laboratory findings. Table S4 indicates the categorization per cohort. Briefly, “definite TB” included patients with microbiologically confirmed *M.tb* (any culture or any Xpert positive for *M.tb*). “Not TB” included patients with

all microscopy, culture, and Xpert tests negative for *M.tb* (including at least 1 negative noncontaminated culture result), who were not started on anti-TB treatment and were alive or who improved at 2 to 3 months' follow-up. "Possible TB" was diagnosed in patients who did not satisfy the criteria for "definite TB" but had clinical/radiological features suggestive of TB and were started on TB treatment by non-study clinicians. Patients who did not fall into any of these categories were considered "unclassifiable" and removed from the main analyses but included in a sensitivity analysis. Definition and examples of the "unclassifiable" category can be found in Table S5.

33.2.4 Statistical Methods

Simple descriptive statistics were used to characterize cohorts. Sensitivity and specificity of the index test were estimated against a microbiological reference standard (MRS) or a composite reference standard (CRS). The "definite TB" and "not TB" categories were used to allocate patients into positive and negative, respectively. The "possible TB" group was considered negative by MRS but positive by CRS, as previously proposed in a study guidance publication [21].

Diagnostic accuracy was determined separately for each cohort, and 95% confidence intervals (95% CIs) were computed using Wilson's score method. Sensitivity and specificity of LF-LAM and SILVAMP-LAM for each cohort were compared using the McNemar test. To estimate sensitivity and specificity across cohorts and CD4 strata, we performed a 2-stage IPD meta-analysis; aggregate data (true positives, false negatives, false positives, true negatives) were extracted from the individual studies and combined using a Bayesian bivariate random-effects model using the meta4diag package [22]. Results are presented with 95% CIs. In a sensitivity analysis, we assessed the effect on performance when the "unclassifiable" cases were included (a) as MRS negative or (b) as CRS positive. Cohen's kappa coefficient was used to determine inter-reader agreement for SILVAMP-LAM and LF-LAM. The data analysis was performed with R (version 3.5.1) and STATA 15.

33.3 Results

33.3.1 Study Population

Overall, 3,062 potentially eligible participants were screened across the 5 cohorts, of which 1,132 were ineligible according to exclusion criteria predefined in the cohort protocols (Fig. 33.1). HIV-negative participants were excluded and will be reported separately. As a result, 1,930 patients were considered for urine LAM testing on biobanked samples. For the primary analysis, an additional 335 participants were excluded, either due to unavailability of a urine sample ($n = 129$), failed index test ($n = 6$), or being "unclassifiable" ($n = 200$).




Figure 33.1 Flow diagram showing the study populations and the number of patients included overall, per cohort, per hospitalization status, and per TB case definition. *Abbreviations:* CRS, composite reference standard; LAM, lipoarabinomannan; MRS, microbiological reference standard; TB, tuberculosis; w or w/o, with or without.

Consequently, 1,595 PLHIV across all 5 cohorts were combined for the primary analysis. The majority were inpatients (968; 61%), and 627 (39%) were outpatients. All inpatients came from South African sites, while outpatient data originated primarily from Ghana (63%), with South Africa contributing 28%, and Vietnam the remaining 9%. The characteristics across all PLHIV (and across cohorts) are reported in Table 33.1.

Participants were typically young adults (median age 37 years [IQR 30–43]), and 59% were female. Forty-three percent had a CD4 count below or equal to 100 cells/ μ l and 36% above 200 cells/ μ l. Most participants (94%) had a positive WHO symptom screen for TB upon enrollment. Forty-five percent ($n = 724$) were diagnosed with definite TB, and 119 (7%) died within 2–3 months after enrollment.

Table 33.1 Demographic and clinical characteristics of all PLHIV

Characteristic	All PLHIV (n = 1,595)	Inpatient PLHIV (n = 968)	Outpatient PLHIV (n = 627)
Demographic and clinical characteristics			
Age—years	36.6 (30; 43)	35 (30; 42)	38 (31; 44)
Female sex	939 (59%)	523 (54%)	416 (66%)
Positive WHO TB symptom screen	1,498 (94%)	933 (96%)	565 (90%)
History of TB	536 (34%)	439 (45%)	97 (16%)
Antiretroviral therapy	558 (35%)	394 (41%)	164 (26%)
CD4 count—cells/ μ l	126 (42; 302)	86 (33; 190)	249 (91; 477)
Distribution in diagnostic categories			
Definite TB	724 (45%)	600 (62%)	124 (20%)
Possible TB	110 (7%)	91 (9%)	19 (3%)
Not TB	761 (48%)	277 (29%)	484 (77%)
CD4 count (cells/μl)			
0 to 100	677 (43%)	516 (53%)	161 (26%)
101 to 200	319 (20%)	216 (22%)	103 (16%)
>200	581 (36%)	231 (24%)	350 (56%)
Unknown	18 (1%)	5 (1%)	13 (2%)
Outcome			
Died within 2–3 months	119 (7%)	105 (11%)	14 (2%)
Alive	1,354 (85%)	810 (84%)	544 (87%)
Lost to follow-up	35 (2%)	16 (2%)	19 (3%)
No follow-up done/required*	87 (6%)	37 (4%)	50 (8%)

Note: Data are given as median (interquartile range) or number (percent).

*No follow-up done/required: empty follow-up field in case report form of cohort 4 or no follow-up required at other sites.

Abbreviations: PLHIV, people living with HIV; TB, tuberculosis; WHO, World Health Organization.

33.3.2 Comparison of Diagnostic Sensitivity of SILVAMP-LAM and LF-LAM

The meta-analysis of all PLHIV across cohorts showed an overall sensitivity for active TB detection of 70.7% (95% CI 59.0%–80.8%) for SILVAMP-LAM compared to 34.9% (95% CI 19.5%–50.9%) for LF-LAM against the MRS, with a difference of 35.8 percentage points between the 2 tests (Fig. 33.2A). When using the CRS, the sensitivity difference between the assays was 34.4 percentage points: the

overall SILVAMP-LAM point estimate was 65.8% (95% CI 55.9%–74.6%) and that of LF-LAM, 31.4% (95% CI 19.1%–43.7%). Amongst inpatients, SILVAMP-LAM sensitivity was 28.1 percentage points higher compared to LF-LAM, and confidence intervals did not overlap (Fig. 33.2B). In outpatients, SILVAMP-LAM sensitivity was 42.7 percentage points higher compared to LF-LAM, but confidence intervals overlapped (Fig. 33.2B). An analysis per cohort, and tables comparing LF-LAM to SILVAMP-LAM results, can be found in Fig. S1, Table S6 and Table S7.




Figure 33.2 Accuracy of SILVAMP-LAM and LF-LAM against different reference standards and in in- and outpatients. Forest plots of sensitivity and specificity and differences between SILVAMP-LAM and LF-LAM (A) against the microbiological and composite reference standards for all cohorts combined and (B) against the MRS by in- and outpatients. The axis for sensitivity ranges from 0% to 100%, while the axis for specificity ranges from 50% to 100%. *Abbreviations:* CRS, composite reference standard; FN, false negative; FP, false positive; LF-LAM, Alere Determine TB LAM lateral flow assay; MRS, microbiological reference standard; SILVAMP-LAM, Fujifilm SILVAMP TB LAM; Sn, sensitivity; Sp, specificity; TN, true negative; TP, true positive.

When patients were stratified by CD4 count, we observed an inverse relationship between sensitivity and CD4 count for both assays (Fig. 33.3A): the sensitivity was higher for lower CD4 counts and systematically decreased for higher CD4 counts. In patients with a CD4 count ≤ 100 cells/ μ l, SILVAMP-LAM had a sensitivity of 87.1% (95% CI 79.3%–93.6%), compared to 56.0% (95% CI 43.9%–64.9%) for LF-LAM (Fig. 33.3A). A similar difference in sensitivity was observed in patients with less severe immunosuppression (CD4 > 200 cells/ μ l), but overall sensitivity was lower for both assays in this group: 43.9% (95% CI 34.3%–53.9%) for SILVAMP-LAM and 10.9% (95% CI 5.2%–18.4%) for LF-LAM (Fig. 33.3A). The difference in performance in inpatients versus outpatients was largely explained by the differences in the distribution of the populations across CD4 strata, as outlined in Fig. 33.3B.




Figure 33.3 Accuracy of SILVAMP-LAM and LF-LAM across CD4 strata. Forest plots of sensitivity and specificity of (A) SILVAMP-LAM and LF-LAM in CD4 strata ≤ 100 , 101–200, and >200 cells/ μl against the microbiological reference standard for all cohorts combined and (B) SILVAMP-LAM only against the microbiological reference standard in in- and outpatients in the CD4 strata. The axis for sensitivity ranges from 0% to 100%, while the axis for specificity ranges from 50% to 100%. *Abbreviations:* FN, false negative; FP, false positive; LF-LAM, Alere Determine TB LAM lateral flow assay; SILVAMP-LAM, Fujifilm SILVAMP TB LAM; TN, true negative; TP, true positive.

Additional information on the distribution of patients across cohorts by CD4 group and smear status is provided in Table S8 and Table S9. An analysis of accuracy by smear status is provided in Fig. S2. A sensitivity analysis including those falling in the “unclassifiable” category is reported in Table S10. When the “unclassifiable” cases were included as CRS positive, the sensitivity decreased for both tests, but more for SILVAMP-LAM (12.2%) than for LF-LAM (4.7%).

33.3.3 Comparison of Diagnostic Specificity of SILVAMP-LAM and LF-LAM

The specificity estimates, when using the MRS for the meta-analysis, were 90.9% (95% CI 87.2%–93.7%) and 95.3% (95% CI 92.2%–97.7%) for SILVAMP-LAM and LF-LAM, respectively (Fig. 33.2A); however, the confidence intervals overlapped. When using the CRS, the overall specificity estimates were higher: 93.4% (95% CI 89.3%–96.2%) for SILVAMP-LAM and 97.3% (95% CI 95.1%–98.9%) for LF-LAM (Fig. 33.2A). Here too, the confidence intervals overlapped. The specificity of SILVAMP-LAM was lower amongst those with $\text{CD4} \leq 100$ cells/ μl (80.5% using the MRS and 85.2% using the CRS) compared to those in the higher CD4 count strata (Fig. 33.3A). Of the 47 patients with SILVAMP-LAM false-positive results,

34 (72%) came from patients with CD4 count ≤ 100 cells/ μ l, while overall this CD4 group included 43% of patients. Nontuberculous mycobacteria (NTM) were cultured from sputum (*M. avium/intracellulare* complex) in 2 of the patients classified as “not TB” but positive by SILVAMP-LAM. A more detailed analysis of all false-positive results, with additional information on the clinical and laboratory workup of the individual patients, is provided in Table S11.

When the “unclassifiable” patients were included in a sensitivity analysis as MRS negative, the specificity remained largely the same (with a difference of -0.4 percentage points for SILVAMP-LAM and -0.8 percentage points for LF-LAM).

33.3.4 Invalid Results and Inter-Reader Agreement

Out of 1,801 initial test runs with SILVAMP-LAM, 26 tests (1.4%) failed (by comparison to 6 that failed for LF-LAM; 0.3%). Reasons for failure are reported in Table S12. The most common reason for failure was that no control line was present (12/26). A repeat was possible for 23 out of 26 samples (3 had insufficient sample), and 20 yielded a valid result on repeat. Thus, there was an overall invalid rate of 0.16% (3/1,824 runs). Interrater agreement was very high both for SILVAMP-LAM and LF-LAM (kappa 0.95 and 0.92, respectively; Table S13).

33.4 Discussion

In this assessment of 1,595 hospitalized and non-hospitalized PLHIV from settings with high TB burden, the SILVAMP-LAM assay identified a substantially higher proportion of TB patients than LF-LAM. While the specificity was lower for SILVAMP-LAM than for LF-LAM, the 95% confidence intervals of specificity for these tests overlapped. In all sub-analyses by CD4 count (Fig. 33.3), the sensitivity of SILVAMP-LAM was higher (range 23.8–37.4 percentage points) than that of LF-LAM, with non-overlapping confidence intervals for the inpatient cohort (likely due to the higher case number, which allowed more accurate estimates).

As in previous reports [11, 23], we found an inverse relationship between the sensitivity of LAM tests and CD4 count (Fig. 33.3), and sensitivities of the tests were lowest in cohort 1B, where the majority of patients had CD4 count > 200 cells/ μ l (Fig. S1; Table S9). The sensitivity of SILVAMP-LAM was the highest (87.1%, 95% CI 79.3%–93.6%) in patients with the highest risk of having disseminated TB and of death from TB associated with severe immunosuppression (patients with CD4 ≤ 100 cells/ μ l) [24]. SILVAMP-LAM could have diagnosed TB in up to 89% of patients who died [25], and testing, particularly in immunocompromised patient populations, is expected to have a mortality benefit, as has been shown for LF-LAM [2, 3], although this still needs to be evaluated. The moderate sensitivity that was maintained even in the highest CD4 stratum (44.4%) will result in a higher diagnostic yield for SILVAMP-LAM and will offer an expanded opportunity of rapid diagnosis on presentation in this patient population.

The increase in sensitivity that had been observed in inpatients was confirmed in outpatients, and differences in performance of SILVAMP-LAM between in- and outpatients were explained by differences in CD4 group distributions [11]. For LF-LAM, the CD4 count distribution did not fully explain the sensitivity difference observed between in- and outpatients. This finding is in line with the results published in the updated Cochrane meta-analysis for LF-LAM [23].

The point estimates of specificity for SILVAMP-LAM were lower than those for LF-LAM using both the MRS and the CRS. However, the lower specificity of both LF-LAM and SILVAMP-LAM could be explained in part by an imperfect reference standard that lacks complete sensitivity (i.e., reference-standard-negative, LAM-positive results that represent true TB) [26]. It is possible that an imperfect reference standard could disproportionately affect a more sensitive test. The lower specificity seen with a decreased CD4 count in this study, and the improved specificity seen with the CRS compared to the MRS, further support this explanation. Also, in higher CD4 count strata, the specificities of the 2 tests approximate each other, which provides further supporting evidence. In addition, cohorts with no or with only limited culture or Xpert testing in blood or urine (Table S2 and Fig. S1; cohorts 4 and 5) reported lower specificities, which again might point towards underdiagnosis by the reference standard, as shown in previous studies [26, 27].

An alternative explanation for the reduced specificity of SILVAMP-LAM could be cross-reactivity to other pathogens. This was a problem with LF-LAM, as the polyclonal antibodies used in the test are known to react with urinary tract pathogens and fast-growing NTM [28, 29]. Cross-reactivity to common urinary tract pathogens and fast-growing NTM has been excluded in studies assessing the antibodies used in SILVAMP-LAM, but some cross-reactivity has been observed with slow-growing NTM [28, 30]. Our data suggest that cross-reactivity is a small problem, if at all, as slow-growing NTM were observed in only 2 out of 47 patients with false-positive results on SILVAMP-LAM (Table S11).

This meta-analysis has some limitations, pointing to areas needing further research. SILVAMP-LAM testing was done using biobanked specimens from hospitalized and non-hospitalized patients. However, there is evidence to suggest that data from retrospective LAM testing based on frozen samples are comparable to data from testing on fresh samples [31, 32]. The operators in the current study were highly skilled laboratory personnel in reference centers. SILVAMP-LAM may have the potential to be implemented as a POC assay in primary care clinics, HIV clinics, or TB microscopy centers. The accuracy, feasibility, and acceptability in these settings, with often less-skilled workers, needs to be evaluated in a separate study, particularly considering the slightly higher complexity of SILVAMP-LAM over LF-LAM. The inclusion of different cohorts with different study designs resulted in heterogeneity and different exclusion rates; however, differences in diagnostic sensitivity between SILVAMP-LAM and LF-LAM persisted in a sensitivity analysis including the “unclassifiable” category (Table S10) and in the analyses by CD4 subgroup (Fig. 33.3). Further, antiretroviral treatment may have influenced

patient outcome and thus the reference standard categories “possible TB” and “unclassifiable.”

SILVAMP-LAM has the potential to have similar or improved favorable effects on patient outcomes compared to LF-LAM, although a prospective study in relevant clinical settings is needed to evaluate this.

Neither LF-LAM nor SILVAMP-LAM can differentiate drug-resistant from drug-sensitive TB, and therefore it is important that these rapid diagnostic tools are supplemented with drug susceptibility testing. Evaluation of SILVAMP-LAM in diagnostic algorithms therefore should be considered.

In 2019, over 5 years after the establishment of the WHO policy on LF-LAM, a survey of 31 countries with high TB/HIV burden, with responses obtained from 24, showed that only 11 countries had LF-LAM policies in place, with only 5 countries currently using LF-LAM [10]. Limited budgets, lack of country-specific data, administrative hurdles such as local regulatory approval, lack of coordination between national TB and HIV programs, and small perceived patient population size were the most commonly cited constraints on LF-LAM adoption [10]. There is real potential for a broader and simpler WHO recommendation for SILVAMP-LAM given its higher sensitivity, and this could help to overcome some of these implementation barriers.

Collectively, these results suggest that, if implemented in clinical practice and linked with appropriate treatment, the SILVAMP-LAM assay would allow for earlier diagnosis of HIV-associated TB in a larger proportion of hospitalized and non-hospitalized patients compared to the current LF-LAM test.

Supporting Information

S1 Data. <https://doi.org/10.1371/journal.pmed.1003113.s001>.

S1 Fig. Forest plots of sensitivity and specificity for SILVAMP-LAM and LF-LAM by cohort against the microbiological reference standard (MRS) and the composite reference standard (CRS). <https://doi.org/10.1371/journal.pmed.1003113.s002>.

S2 Fig. Accuracy by smear status. <https://doi.org/10.1371/journal.pmed.1003113.s003>.

S1 PRISMA IPD Checklist. <https://doi.org/10.1371/journal.pmed.1003113.s004>.

S1 STARD Checklist. <https://doi.org/10.1371/journal.pmed.1003113.s005>.

S1 Table. Study population, setting and location, eligibility, and inclusion and exclusion criteria used for the studies. <https://doi.org/10.1371/journal.pmed.1003113.s006>.

S2 Table. Specimen collection and testing flow by cohort. <https://doi.org/10.1371/journal.pmed.1003113.s007>.

S3 Table. Specimen storage. <https://doi.org/10.1371/journal.pmed.1003113.s008>.

S4 Table. Diagnostic categories by cohort. <https://doi.org/10.1371/journal.pmed.1003113.s009>.

S5 Table. Definition and examples of “unclassifiable” category. <https://doi.org/10.1371/journal.pmed.1003113.s010>.

S6 Table. Two-by-two table of SILVAMP-LAM versus LF-LAM among “definite TB” patients. <https://doi.org/10.1371/journal.pmed.1003113.s011>.

S7 Table. Two-by-two table of SILVAMP-LAM versus LF-LAM among “not TB” patients. <https://doi.org/10.1371/journal.pmed.1003113.s012>.

S8 Table. Analysis by cohort, smear status, and CD4 group for all HIV-positive inpatients. <https://doi.org/10.1371/journal.pmed.1003113.s013>.

S9 Table. Analysis by cohort, smear status, and CD4 group for all HIV-positive outpatients. <https://doi.org/10.1371/journal.pmed.1003113.s014>.

S10 Table. Sensitivity analysis of diagnostic accuracy for all PLHIV (including “unclassifiable” patients) by MRS and CRS. <https://doi.org/10.1371/journal.pmed.1003113.s015>.

S11 Table. Further Information on patients categorized as “not TB” with positive SILVAMP-LAM results. <https://doi.org/10.1371/journal.pmed.1003113.s016>.

S12 Table. SILVAMP-LAM failure rates and errors for all samples tested. <https://doi.org/10.1371/journal.pmed.1003113.s017>.

S13 Table. Agreement of 2 independent test readers for all samples tested. <https://doi.org/10.1371/journal.pmed.1003113.s018>.

S1 Translation. Japanese translation of the abstract by Satoshi Mitarai. <https://doi.org/10.1371/journal.pmed.1003113.s019>.

Abbreviations

CRS:	composite reference standard
FN:	false negative
FP:	false positive
IPD:	individual patient data
LAM:	lipoarabinomannan
LF-LAM:	Alere Determine TB LAM lateral flow assay
MtB:	<i>Mycobacterium tuberculosis</i>
MGIT:	mycobacteria growth indicator tube
MRS:	microbiological reference standard
NTM:	nontuberculous mycobacteria
PLHIV:	people living with HIV
POC:	point-of-care
SILVAMP-LAM:	Fujifilm SILVAMP TB LAM
TB:	tuberculosis
TN:	true negative
TP:	true positive
Xpert:	Xpert MTB/RIF

Disclosures and Conflict of Interest

This chapter was originally published as: Broger, T., Nicol, M. P., Székely, R., Bjerrum, S., Sossen, B., Schutz, C., et al. (2020). Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data. *PLoS Med.*, **17**(5), e1003113, <https://doi.org/10.1371/journal.pmed.1003113>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Funding: This work was funded by the Global Health Innovative Technology (GHIT) Fund (grant number G2017-207), the UK Department for International Development (DFID) (grant number 300341-102), the Dutch Ministry of Foreign Affairs (grant number PDP15CH14), the Bill & Melinda Gates Foundation (grant number OPP1105925), the Australian Department of Foreign Affairs and Trade (grant number 70957) and the German Federal Ministry of Education and Research (BMBF; grant number 2020 62 156). The Cohort2 study was funded by the Wellcome Trust (088590 and 085251). GM was supported by Wellcome Trust (098316 and 203135/Z/16/Z), the South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation (NRF) of South Africa (Grant No 64787), NRF incentive funding (UID: 85858) and the South African Medical Research Council through its TB and HIV Collaborating Centres Programme, with funds received from the National Department of Health (RFA#SAMRC-RFA-CC:TB/HIV/AIDS-01-2014). CS received funding from the South African Medical Research Council through the National Health Scholarship Programme. ADK received funding from the National Institute of Allergy and Infectious Diseases (Grant No T32 AI060530). BS received salary support from the Wellcome Trust (grant number 088316). CMD is supported by a fellowship of the Burroughs–Wellcome Fund from the American Society of Tropical Medicine and Hygiene. The opinions, findings and conclusions expressed in this chapter reflect those of the authors alone. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: I have read the journal's policy and the authors of this chapter have the following competing interests: TB, SGS, AM, SO, RS and CMD were previously or are currently employed by FIND. TB reports a patent in the field of lipoarabinomannan detection. CMD is a member of *PLOS Medicine's* Editorial Board. The rest of the authors declare no competing interests associated with this manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Acknowledgments: The authors thank the late Stephen D. Lawn, who designed and led the cohort 2 study.

Tobias Broger and Mark P. Nicol contributed equally to this work.

Claudia M. Denkinger and Samuel G. Schumacher are joint senior authors on this work.

Author Contributions

Conceptualization: Tobias Broger, Claudia M. Denkinge, Samuel G. Schumacher; Data curation: Tobias Broger, Rita Székely, Stephanie Bjerrum, Charlotte Schutz, Japheth A. Opintan, Satoshi Mitarai, Kinuyo Chikamatsu, Andrew D. Kerkhoff, Aurélien Macé; Formal analysis: Tobias Broger, Mark P. Nicol, Rita Székely, Stephanie Bjerrum, Bianca Sossen, Charlotte Schutz, Japheth A. Opintan, Isik S. Johansen, Satoshi Mitarai, Kinuyo Chikamatsu, Andrew D. Kerkhoff, Aurélien Macé, Stefano Ongarello, Graeme Meintjes, Claudia M. Denkinge, Samuel G. Schumacher; Funding acquisition: Tobias Broger, Mark P. Nicol, Stephanie Bjerrum, Graeme Meintjes, Claudia M. Denkinge; Investigation: Bianca Sossen, Satoshi Mitarai; Methodology: Tobias Broger, Mark P. Nicol, Bianca Sossen, Andrew D. Kerkhoff, Aurélien Macé, Graeme Meintjes, Claudia M. Denkinge, Samuel G. Schumacher; Project administration: Tobias Broger, Rita Székely, Bianca Sossen, Kinuyo Chikamatsu; Supervision: Mark P. Nicol, Satoshi Mitarai, Stefano Ongarello, Graeme Meintjes, Claudia M. Denkinge; Validation: Mark P. Nicol, Stephanie Bjerrum, Charlotte Schutz, Japheth A. Opintan, Isik S. Johansen, Satoshi Mitarai, Kinuyo Chikamatsu, Andrew D. Kerkhoff, Aurélien Macé, Graeme Meintjes, Claudia M. Denkinge, Samuel G. Schumacher; Visualization: Tobias Broger, Mark P. Nicol, Stephanie Bjerrum, Bianca Sossen, Aurélien Macé, Stefano Ongarello, Claudia M. Denkinge, Samuel G. Schumacher; Writing–original draft: Tobias Broger, Mark P. Nicol, Rita Székely, Stephanie Bjerrum, Bianca Sossen, Aurélien Macé, Stefano Ongarello, Claudia M. Denkinge, Samuel G. Schumacher; Writing–review & editing: Tobias Broger, Mark P. Nicol, Rita Székely, Stephanie Bjerrum, Bianca Sossen, Charlotte Schutz, Japheth A. Opintan, Isik S. Johansen, Satoshi Mitarai, Kinuyo Chikamatsu, Andrew D. Kerkhoff, Aurélien Macé, Stefano Ongarello, Graeme Meintjes, Claudia M. Denkinge, Samuel G. Schumacher.

References

1. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. *Lancet HIV*. 2018; 5: e515–e523.
2. Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D, Alufandika-Moyo M, et al. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. *Lancet*. 2018; 392: 292–301.
3. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. *Lancet*. 2016; 387: 1187–1197.
4. Huerga H, Ferlazzo G, Bevilacqua P, Kirubi B, Ardizzoni E, Wanjala S, et al. Incremental yield of including Determine-TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV-positive patients in Kenya. *PLoS ONE*. 2017; 12: e0170976.

5. Boyles TH, Griesel R, Stewart A, Mendelson M, Maartens G. Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV. *Int J Infect Dis.* 2018; 75: 67–73.
6. World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: World Health Organization; 2014. Available at: http://apps.who.int/iris/bitstream/10665/135617/1/WHO_HTM_TB_2014.18_eng.pdf (accessed on November 20, 2022).
7. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. *BMC Infect Dis.* 2012; 12: 103.
8. Treatment Action Group. Tuberculosis diagnostics pipeline report 2019. New York: Treatment Action Group; 2019. Available at: <https://www.treatmentactiongroup.org/resources/pipeline-report/2019-pipeline-report/> (accessed on November 20, 2022).
9. Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. *Cochrane Database Syst Rev.* 2016; (5): CD011420.
10. Singhroy DN, MacLean E, Kohli M, Lessem E, Branigan D, England K, et al. Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. *Gates Open Res.* 2020; 4: 24.
11. Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. *Lancet Infect Dis.* 2019; 19: 852–861.
12. Bjerrum S, Broger T, Székely R, Mitarai S, Opintan JA, Kenu E, et al. Diagnostic accuracy of a novel and rapid lipoarabinomannan test for diagnosing tuberculosis among people with human immunodeficiency virus. *Open Forum Infect Dis.* 2020; 7: ofz530.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009; 6: e1000097.
14. Lawn SD, Kerkhoff AD, Burton R, Schutz C, Boulle A, Vogt M, et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort. *BMC Med.* 2017; 15: 67.
15. Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, et al. Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. *PLoS Med.* 2019; 16: e1002840.
16. Bjerrum S, Kenu E, Lartey M, Newman MJ, Addo KK, Andersen AB, et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana—findings from the DETECT HIV-TB study. *BMC Infect Dis.* 2015; 15: 407.
17. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *Clin Chem.* 2015; 61: 1446–1452.
18. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies. *JAMA.* 2018; 319: 388.

19. FIND. Fujifilm SILVAMP TB LAM test procedure. YouTube. April 24, 2019. Available at: <https://youtu.be/aK-QtzkLBUG> (accessed on November 20, 2022).
20. World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV—policy update (2019). Geneva: World Health Organization; 2019. Available at: <https://apps.who.int/iris/handle/10665/329479> (accessed on November 20, 2022).
21. Drain PK, Gardiner JL, Hannah H, Broger T, Dheda K, Fielding K, et al. Guidance for studies evaluating the accuracy of biomarker-based nonsputum tests to diagnose tuberculosis. *J Infect Dis.* 2019; 220: S108–S115.
22. Guo J, Riebler A. meta4diag: Bayesian bivariate meta-analysis of diagnostic test studies for routine practice. *J Stat Softw.* 2018; 83(1): 1–31.
23. Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling AA, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. *Cochrane Database Syst Rev.* 2019; 10: CD011420.
24. Leeds IL, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, Leonard MK, et al. Site of extrapulmonary tuberculosis is associated with HIV infection. *Clin Infect Dis.* 2012; 55: 75–81.
25. Sossen B, Broger T, Kerkhoff AD, Schutz C, Trollip A, Moreau E, et al. 'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in patients hospitalized with human immunodeficiency virus in South Africa. *Clin Infect Dis.* 2020; 71(8): 1973–1976.
26. Lawn SD, Kerkhoff AD, Nicol MP, Meintjes G. Underestimation of the true specificity of the urine lipoarabinomannan point-of-care diagnostic assay for HIV-associated tuberculosis. *J Acquir Immune Defic Syndr.* 2015; 69: e144–e146.
27. Lawn SD, Kerkhoff AD, Burton R, Meintjes G. Underestimation of the incremental diagnostic yield of HIV-associated tuberculosis in studies of the Determine TB-LAM Ag urine assay. *AIDS.* 2014; 28: 1846–1848.
28. Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, et al. A novel sensitive immunoassay targeting the 5-methylthio-d-xylofuranose–lipoarabinomannan epitope meets the WHO's performance target for tuberculosis diagnosis. *J Clin Microbiol.* 2018; 56(12): e01338-18.
29. Kroidl I, Clowes P, Mwakyeu J, Maboko L, Kiangi A, Rachow A, et al. Reasons for false-positive lipoarabinomannan ELISA results in a Tanzanian population. *Scand J Infect Dis.* 2014; 46: 144–148.
30. Kawasaki M, Echiverri C, Raymond L, Cadena E, Reside E, Gler MT, et al. Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: analytic validation and evaluation in two cohorts. *PLOS Med.* 2019; 16: e1002780.
31. Broger T, Muyoyeta M, Kerkhoff AD, Denkinge CM, Moreau E. Tuberculosis test results using fresh versus biobanked urine samples with FujiLAM. *Lancet Infect Dis.* 2020; 20: 22–23.
32. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. *Eur Respir J.* 2011; 38: 1398–1405.

Chapter 34

History of Thermal Imaging from 1960

Kurt Ammer, MD, PhD, and Francis Ring, DSc

*Faculty of Advanced Technology,
University of South Wales, Pontypridd, UK*

Keywords: clinical practice, image generation, image processing, infrared radiation, Leidenfrost transfer system, radiometry, rheumatology, thermal sensors, thermographic index, thermography

The identification of infrared radiation was made in 1800; yet it was 78 years after the detection of “dark heat” that the first trial was conducted to investigate the amount of infrared radiation from the human skin. The first radiometry-based skin temperatures were calculated in 1921 and directly read from the radiometer in 1923 [1, 2]. Subsequently, infrared imaging was developed as a military tool, which was not declassified for civilian use until the late 1950s.

34.1 Development of Imaging Systems

In Germany, Marianus Czerny, the professor of physics at Goethe Institute Frankfurt University, laid foundations for the development of thermal sensors. One of his students in the USA, Bowling Barnes, built the first thermal imager based on thermistors in the 1950s [3]. In the UK, a research physicist Dr Max Cade had built a scanning infrared thermograph using an electronic detector of indium antimonide [4]. The prototype of this scanner was used for clinical research in the UK in 1959. Though the images were primitive, it was evident that they could show variations in skin temperature. Subsequently a more usable, but bulky device was built that produced a better-quality image of the human body. However, a single hand thermogram took 5 minutes to record. Camera systems in the 1950s and 1960s made use of reflective optics with motorized mirrors to perform a scan for image generation. High-speed motors produced high frequency noise and the acoustic shielding of the system was inadequate. A comparison of the systems available at that time is shown in Table 34.1 [5].

Advances in Medical Imaging, Detection and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bruce D. Johnson, and Mandira N. Mehra

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

Table 34.1 Thermographic Systems available in the late 1960s

System	Bofors	Aga	EMI	Rank	Barnes M1B	Barnes T6D	Barnes T4
Detector	Indium-antimonide	Indium-antimonide	Indium-antimonide	Indium-antimonide	Thermistor	Pyroelectric	Thermistor
Cooling	75 cc N ₂	75 cc N ₂	Leidenfrost transfer 1 L N ₂	Leidenfrost transfer 5 L N ₂	Not required	Not required	Not required
Scanning time	0.5 s	Instant	0.5 s 2.0 s	Instant	90 s	30 s	60 s
Field of view	25° × 12.5°	25° × 12.5° or 10° × 10° or 40° × 40°	21° × 8°	28° × 34°	10° × 15° or 10° × 20°	10° × 10°	20° × 10°
Focal length	0.25 m-∞	0.95 m-∞	1 m-∞	0.25 m-∞	3 ft-∞	2.5 ft-∞	60 cm 180 cm
Picture lines	160 lines	210 lines/frame	100 lines	120 lines	90 lines/frame	10,000 elements	60 lines
Elements	40,000 elements		25 lines		250 elements/line		120 elements
Display size	68 × 34 mm or 68 × 68 mm	90 × 90 mm or 67 × 74 mm	100 × 60 mm	145 × 114 mm	Polaroid	95 × 72 mm Polaroid only	Polaroid
Frame rate	2/s	16/s	2/s 0.5/s	46/s	Single frames	Single frames at 30 s	Single frames
Camera	35 mm Polaroid	35 mm Polaroid	35 mm Polaroid	35 mm	Polaroid	Polaroid	Polaroid
Recording	Photographic intensity modulation A-scan	Photographic intensity modulation A-scan	Photographic intensity modulation A-scan	Photographic intensity modulation, separate A-scan	Polaroid film only	Direct to colour Polaroid film	Direct to Polaroid film
Isotherm	Four widths 2.5-20% of range set	Single adjustable				Minimum range 2.5°C integral colour range	Eight step isotherms extra
Line-scan	Output from display unit for oscilloscope	—	Integral with system display	Separate recorder	Analogue signal for recorder Thermoscope	Vertical scan locked for oscilloscope or chart recorder	Photocomparator for thermograms, extra

The first introduction of a commercial camera system with a lens was in the late 1960s [6]. This improvement not only reduced noise but facilitated the clinical camera, but temperature measurement remained difficult. The estimation of temperature became possible using isotherms, and in 1972, the research group in Bath UK, developed a system called the thermographic Index based on measuring the area of isotherms within a specified anatomical region [7]. Some manufacturers introduced a crosswire facility to indicate a spot temperature within the displayed image (circa 1985). At this time, personal computers became more commonly available, and facilities to define regions of interest and employ image processing techniques. Errors introduced by analogue to digital conversion were not recognized at that time before full digital technology became standard.

In the 1960s, indium antimonide was used as a single element detector, cooled by liquid nitrogen, that was added manually to the detector flask at regular intervals. Leidenfrost transfer systems, electronic and gas cooling were developed, which reduced the need for regular topping up of nitrogen. It is now known that some of the variables encountered with the thermal imagers could well have been due to inconsistent levels of the coolant on the detector cell. While cooled detector systems still give high performance thermal imaging, uncooled cameras have now reached a high level of thermal resolution and are more convenient in clinical applications.

34.2 Development of Applications

While the first developments were focused on medical studies, veterinary applications were also conducted, which broadened into wider biological fields.

34.2.1 Medical Applications

The first conference on medical thermography was held in New York in 1963 and another in Strasbourg, France, in 1966. Infrared imaging in medicine was in its infancy, but those early proceedings showed the variety and detail, given the relatively primitive state of the technology. One author concluded, "All that has been revealed by this technique is nothing compared with what is left to be discovered" [8]. More than 60 years have passed since this was written, and certainly more has been revealed, but we may well repeat the optimistic statement from 1963 today!

As the proceedings and publications of the early years (1960–1970s) show the predominant interest was in the possible screening and early diagnosis for breast cancer by thermography [9–11]. This interest gradually reduced with the arrival of alternative breast imaging modalities. Skin malignancies, e.g. melanoma, have been another application of diagnostic thermography from the beginning [12] to the present day [13]. Diagnosis of Raynaud's phenomenon and the response to a cold challenge have been successful applications of thermography. The need for standardization was realized from the outset [14, 15]. Other vascular

conditions included venous disorders [16] and tissue viability [17, 18]. Studies in plastic surgery have recently re-confirmed the value of thermal imaging for tissue viability assessment [19]. Infrared-thermography and other techniques of mapping temperature distribution on surface of the body has been applied in spinal disorders and related neurological syndromes for more than 40 years. However, the validity of thermal imaging for diagnosing back disorders is still an ongoing debate [20]. Some investigators have tried to find a relationship between skin temperature and innervation fields of sensory nerve fibres, but this has not been established.

In recent years following pandemic fever outbreaks, e.g. severe acute respiratory syndrome (SARS) and avian flu, the need for fever screening in international travel led to the employment of thermal imaging. The International Organization for Standardization was required to address the issue of minimum standards needed to detect the presence of fever [21].

Thermal imaging has been first used as an outcome measurement in the field of rheumatology. Different dosage of anti-inflammatory compound drugs was objectively compared in clinical trials. At that time, little attention had been given to standardization of procedures. However, standardized methodology was required to meet the essentials of good clinical practice [22, 23]. In addition to anti-inflammatory drugs, a number of thermographic studies have shown the effect of vasoactive drugs on skin temperature [24–26].

34.2.2 Applications in Biology

Thermography in veterinary medicine was included in the first international symposium in New York 1963 [27]. Other early applications included animal physiology [28, 29], animal models of physiological functions [30] and pharmacology [31]. Further diagnostic thermography was developed for domestic and farm animals [32, 33]. Specialized centres around the world have extended thermal imaging studies in animals, i.e., cattle, horses, pigs, etc.

Historical bibliographies are useful resource to understand the past and extent those results with current technology. The following are two particularly relevant sources:

- *International Bibliography of Medical Thermology*, by Margaret Abernathy and Thomas Bradford Abernathy, *Thermology*, 1987, vol. 2, no. 3, pp. 117–534.
- *Publications on Thermology 1989 to 2012*. An electronic archive DVD. Thermology International, 2014, vol 24, no. 2: 82–83.

Disclosures and Conflict of Interest

This chapter was originally published as: Ammer, K., Ring, F. (2019). *The Thermal Human Body: A Practical Guide to Thermal Imaging*. Jenny Stanford Publishing, Singapore, chapter 1 “History of Thermal Imaging from 1960,” pp. 1–8, and appears here, with edits and updates, by kind permission of the publisher.

References

1. Aldrich LB. The Melikeron: An approximately black-body pyranometer. *Smithsonian Miscellaneous Collections* 1922, 72(13)3–11.
2. Aldrich LB. A study of body radiation. *Smithsonian Miscellaneous Collections* 1928, 81(6), 1–54.
3. Barnes RB. Thermography, Thermography & its clinical applications. *Annals of the New York Academy of Sciences* 1964, 121, 34–48.
4. Cade CM. High-speed thermography. Thermography & its clinical applications. *Annals of the New York Academy of Sciences* 1964, 121, 71–79.
5. Ring EFJ. Equipment for medical thermography. *British Journal of Hospital Medicine* 1971, 5, equipment suppl, 24.
6. Dibley D. Opto-mechanical systems for IR thermography. In: Ammer K, Ring EFJ, eds, *The Thermal Image in Medicine and Biology*. Uhlen Verlag Wien, 1995, pp. 33–39.
7. Winsor T. Bendbezu J. Thermography & the peripheral circulation. Thermography & its clinical applications. *Annals of the New York Academy of Sciences* 1964, 121, 135–156.
8. Collins AJ, Ring EFJ, Cosh JA, Bacon PA. Quantitation of thermography in arthritis using multi isothermal analysis. 1. The thermographic index. *Annals of Rheumatic Diseases* 1974, 33, 113–115.
9. Williams KL, Williams FL, Handley RS. Infra-red thermometry in the diagnosis of breast disease. *The Lancet* 1961, 278(7217), 1378–1381.
10. Melander OLOF. Thermography as the primary step in mass screening for breast cancer. *Bibliotheca Radiologica* 1975, (6), 91–96.
11. Stark AM et al. Malignant diseases section, in Ring EFJ, Phillips B, eds, *Recent Advances in Medical Thermology*, Plenum Press, New York, London, 1984, pp. 549–634.
12. Lintermans J, Maillard GF. Essai d'explication thermochimique de l'hyperthermie. *Archiv für dermatologische Forschung* 1971, 240, 237–244.
13. Di Carlo A, Elia F, Desiderio F, Catricalà C, Solivetti FM, Laino L. Can video thermography improve differential diagnosis and therapy between basal cell carcinoma and actinic keratosis? *Dermatologic Therapy* 2014, 27(5), 290–297.
14. Ring EFJ, Aarts NJM, Black CM, Bösiger P, et al. Raynaud's Phenomenon: Assessment by thermography (EAT-report). *Thermology* 1988, 3, 69–73.
15. Ammer K. Cold challenge to provoke a vasospastic reaction in fingers determined by temperature measurements; a systematic review. *Thermology International* 2009, 19(4), 109–118.
16. Patil KD, Williams JR, Williams, KL. Thermographic localization of incompetent perforating veins in the leg. *BMJ* 1970, 1(5690), 195–197.
17. Henderson HP, Hackett, ME. The value of thermograph in peripheral vascular disease. *Angiology* 1978, 29, 65–75.
18. Spence VA, McCollum PT, Walker WF, Murdoch G. Assessment of tissue viability in relation to the selection of amputation level. *Prosthetics and Orthotics International* 1984, 8(2), 67–75.

19. de Weerd L, Mercer JB, Weum S. Dynamic infrared thermography. *Clinics in Plastic Surgery* 2011, 38(2), 277–292.
20. Ammer K. Thermography in spinal disorders: A narrative review. *Thermology International* 2010, 20(4), 117–125.
21. Ring EFJ, McEvoy H, Jung A, Zuber J, Machin G. New standards for devices used for the measurement of human body temperature. *Journal of Medical Engineering & Technology* 2010, 34(4), 249–253.
22. Bacon PA, Ring EFJ, Collins AJ. Thermography in the assessment of anti-rheumatic agents. In: Gordon JL, Hazleman BL, eds, *Rheumatoid Arthritis*. Amsterdam: Elsevier/ North Holland Biomedical Press, 1977, pp. 105–110.
23. Bird HA, Ring EFJ, Bacon PA. A thermographic and clinical comparison of three intra-articular steroid preparations in rheumatoid arthritis. *Annals of Rheumatic Diseases* 1979, 38, 36–39.
24. Ring EFJ, Owens CWI, Cosh JA; Eghtedari A. Infrared techniques in the assessment of peripheral temperature response to anti-hypertensive drugs. In: Birley DM, ed. *The Clinical Impact of Beta-Adreno-Receptor Blockage*. Horsham, UK, 1980, pp. 267–273.
25. Ring EFJ, Porto LO, Bacon PA. Quantitative thermal imaging to assess inositol-nicotinate treatment for Raynaud's syndrome. *Journal of International Medical Research* 1981, 9, 393–400.
26. Giacobozzo M, Valducci G, Martelletti P, Romiti A, Gallo MF, Valducci M. Telethermographic investigations in migraine patients before and after flunarizine treatment. *Cephalalgia* 1985, 5 (2 suppl), 169–171.
27. Smith WM. Applications of thermography in veterinary medicine. *Annals of the New York Academy of Sciences*, 1964, 121(1), 248–254.
28. Cena K, Clark JA. Thermographic measurements of the surface temperature of animals. *Journal of Mammalogy* 1973, 54, 1003–1007.
29. Szekely M, Kellermayer M, Donhoffer S. Thermoregulatory role of periaortic brown adipose tissue in rats acclimated to different ambient temperatures. *Acta Physiologica Academiae Scientiarum Hungaricae* 1970, 40 (3), 251–260.
30. Collins AJ, Ring EFJ. Measurement of inflammation in man and animals by radiometry. *British Journal of Pharmacology* 1972, 44(1), 145–152.
31. Malm A, Arborelius M, Bornmyr S, Lilja B, Gill RL. Effects of oxygen on acute myocardial infarction: A thermographic study in the dog. *Cardiovascular Research*, 1977, 11(6), 512–518.
32. Stromberg B. Thermography in veterinary medicine. *Bibliotheca Radiologica* 1975, 6, 231–236.
33. Purohit RC. History and research review of thermology in veterinary medicine at Auburn University. *Thermology International* 2007, 17(4) 127–132.

Chapter 35

A Novel Deep Learning-Based Point-of-Care Diagnostic Method for Detecting *Plasmodium falciparum* with Fluorescence Digital Microscopy

Oscar Holmström, MD, PhD,^a Sebastian Stenman, MD,^a Antti Suutala, MScEng,^a Hannu Moilanen,^b Hakan Küçükkel,^a Billy Ngasala, MD, PhD,^{c,d} Andreas Mårtensson, PhD,^c Lwidiko Mhamilawa, PhD,^{c,d} Berit Aydin-Schmidt, PhD,^e Mikael Lundin, MD,^a Vinod Diwan, PhD,^f Nina Linder, MD, PhD,^{a,c} and Johan Lundin, PhD^{a,c}

^a*Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland*

^b*Center of Microscopy and Nanotechnology, University of Oulu, Oulu, Finland*

^c*Department of Women's and Children's Health, International Maternal and Child Health, Uppsala University, Uppsala, Sweden*

^d*Department of Medical Entomology and Parasitology, School of Public Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania*

^e*Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden*

^f*Department of Global Public Health, Karolinska Institute, Stockholm, Sweden*

oscar.holmstrom@helsinki.fi

Keywords: artemisinin-based combination therapy (ACT), circle Hough Transform (CHT), complementary metal oxide semiconductor (CMOS), convolutional neural networks (CNNs), deep learning (DL), deep-learning system (DLS), digitization, field of view (FOV), light-emitting diode (LED), loop-mediated isothermal amplification (LAMP), malaria, matrix laboratory (MATLAB), nucleic acids amplification tests (NAATs), *Plasmodium falciparum*, point-of-care (POC), quantitative polymerase chain reaction (qPCR), rapid diagnostic tests (RDTs), red blood cells (RBCs), Secure Socket Layer (SSL), Structural Similarity Index (SSIM), white blood cells (WBCs)

35.1 Introduction

Malaria remains a global health burden with over 200 million new yearly cases [1]. Although the disease incidence has decreased by approximately 10% during the last decade, data indicates that progress has stalled during recent years [1]. As most malaria cases occur in rural areas [1], the disease burden is

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

caused partly by difficulties in diagnosing the disease. Currently, multiple techniques exist for malaria diagnostics [2]. Light microscopy assessment of blood smears to detect *Plasmodium* parasites remains the diagnostic gold standard [3] and allows detection and quantification of the various *Plasmodium* species while also being more sensitive than rapid diagnostic tests (RDTs) [4]. Disadvantages with microscopy-based testing include a high level of labour intensiveness, subjectivity [5, 6], dependence on the microscopist's skill and experience [7], requirements in terms of sample preparation and varying sensitivity for lower-level and mixed infections [4]. In addition to microscopy, easy-to-use RDTs based on lateral flow immunochromatography to detect *Plasmodium*-specific antigens are being used to an increasing extent [8]. These RDTs enable rapid diagnostics at the point-of-care (POC), but have limited accuracy for non-*falciparum* [2] and low-level infections, do not allow for quantification of parasites when monitoring treatment response, and remain positive after treatment initiation, which means that results should ideally be validated by other methods [4]. Detection of *Plasmodium* spp. nucleic acid with nucleic acid amplification tests (NAATs) has superior analytical sensitivity compared to other methods, especially for mixed infections [9], and allows quantification of parasitaemia (by real-time quantitative polymerase chain reaction; qPCR) but is more technically demanding, expensive and therefore not widely available [4], although certain NAAT-methods, such as loop-mediated isothermal amplification (LAMP) show promise as a field-usable techniques [10]. Consequently, the World Health Organization (WHO) currently recommends microscopy-based methods to confirm diagnosis in suspected cases of malaria [3]. Various staining methods have been proposed for microscopy identification of malaria parasites in blood smears, with Giemsa staining being the standard method [5]. As visual analysis of blood smears is time-consuming and subjective, fluorescent staining methods have been proposed to facilitate the sample analysis process [11]. Cell-permeable fluorescent stains can be used to visualize the intracellular *Plasmodium* parasites more clearly and at lower magnification [12] to reduce the need for high-power microscopy equipment. Fluorescent stainings can also be combined with brightfield staining protocols [11]. As access to microscopy diagnostics is severely limited in many areas, the potential to utilize optical components from widely available consumer electronic products (such as smartphone cameras) to create digital microscopes has been recognized [13–15]. By utilizing miniaturized, low-cost optomechanical components, several devices for POC digitization of microscopy slides have been developed. Compared to larger-sized, laboratory-grade slide scanners, these types of devices can be manufactured significantly cheaper [16] and have other potential advantages, such as a smaller physical size for increased portability, which make them potentially more suitable for POC usage. Although these components are significantly less expensive than those used in high-end alternatives, the imaging performance achievable is sufficient to, e.g., visualize pathogens in common infectious diseases [17] and for analysis of histological samples [18]. Digitization of samples at the POC combined with the

mobile connectivity of the instruments also mean that samples can be uploaded to a cloud server for remote access and analysis using digital methods [19]. Multiple approaches have been studied for automated, computer-assisted diagnosis of malaria using both traditional computer vision methods and more recently machine learning algorithms based on deep convolutional neural networks [20–22]. Several efforts have been made to digitize blood smears for malaria diagnostics with POC slide scanners, but a significant challenge with conventionally stained samples is the need for higher magnifications than what is typically supported by these platforms [21].

In this proof-of-concept study we describe how thin blood smears acquired in field-settings in Tanzania, stained with the 4',6-diamidino-2-phenylindole (DAPI) fluorophore and scanned using a low-cost POC digital microscope scanner prototype enables visualization of *P. falciparum* parasites. *P. falciparum* is both the most prevalent malaria parasite in Africa, and the cause of the vast majority of malaria-related deaths [1]. By digitizing both brightfield and fluorescent image channels from blood smears, and combining them into hybrid images, intracellular malaria parasites can be visualized in the digital samples. Furthermore, we train and apply two separate deep-learning algorithms to automatically detect and quantify *P. falciparum* trophozoites in the digital samples. Results are compared to the visual analysis of the digital samples and to expert microscopy of Giemsa-stained thick smears, using samples collected on the day of initiation of artemisinin-based combination therapy (ACT) and three days after treatment initiation.

35.2 Materials and Methods

35.2.1 Acquisition and Preparation of Samples

We acquired 125 thin blood films for this study, which were collected as part of the trial by Mhamilawa et al. [23]. The samples were pseudonymized with study numbers before being accessed by the researchers. The overall study workflow and sample analysis process is illustrated as a STARD diagram in the supplementary material (Fig. S4). The samples were collected in a region with moderate levels of malaria transmission where *P. falciparum* is the predominant species (Bagamoyo District, Tanzania) during a time-period between July 2017 and March 2018. Samples were collected from volunteering patients who fulfilled the inclusion criteria (age between 1 and 65 years, history of fever in the last 24 hours or axillary temperature $\geq 37.5^{\circ}\text{C}$, microscopy-confirmed uncomplicated *P. falciparum* mono-infection and written informed consent obtained). Microscopy confirmation of malaria positivity was performed on separate Giemsa-stained thick blood smears by certified professional microscopists. The number of asexual parasites and gametocytes was determined by counting the number of visible parasites per 200 white blood cells (WBCs) using a hand tally counter. The parasite

density, measured as the number of asexual parasites per microliter (μl) of blood, was estimated by dividing the number of detected asexual parasites per by the number of WBCs counted (200) and multiplying the value by the assumed WBC count μl of blood (8,000 WBC/ μl). A blood smear was considered negative after examining 100 high-power fields or counting 500 WBC with no parasites seen. Each slide was read by two independent and experienced microscopists, and upon disagreement on presence of parasites or if density differed by more than 25%, the slides were subjected to a third independent and decisive reader (blinded to the results from the previous readers). The mean parasitemia of the two most concordant readings were used as final parasite densities. In total, 125 unstained thin blood films from 100 separate patients were obtained for this study. 100 of these samples were collected before initiation of artemisinin-based combination therapy (ACT) (Day 0), and 25 samples were follow-up thin blood smears collected three days after initiation of ACT (Day 3). The Day 3 samples were also analysed by light microscopy examination, according to the procedure described above. Samples were fixed with methanol (water < 3%) by incubating for approximately 20 minutes at room temperature, and stored in slide boxes following this. For the staining of the samples, the slides were initially rinsed with deionized water, after which staining of the samples was performed using a mounting media solution containing 4',6-Diamidino-2-phenylindole (DAPI) fluorescent stain (Fluoroshield with DAPI, Sigma-Aldrich Finland Oy, Espoo, Finland). DAPI is a primary stain for DNA and RNA which penetrates cellular membranes to stain the DNA (and RNA) of the *Plasmodium* parasites inside intact erythrocytes. The DAPI staining solution was applied to the sample and distributed over the surface of the glass slide. Following this, the sample was let to stand at room temperature for five minutes, after which a cover slip was carefully applied to the sample to avoid air bubbles. After staining, the quality of the sample was examined visually with a fluorescence microscope to confirm that the staining quality was adequate for analysis (i.e., visible fluorescent WBCs to confirm successful staining and low amounts of debris).

35.2.2 Digitization of Slides

For the digitization of the samples we used a prototype of a portable, digital microscope scanner, developed and patented by the University of Helsinki (Helsinki, Finland) for POC scanning of biological samples (Fig. 35.1). The device supports brightfield and fluorescent imaging of glass slides and scanning of sample areas measuring multiple fields of view (FOVs), by capturing and stitching together multiple FOVs in a similar way as conventional whole-slide microscopy scanners. The device is constructed using inexpensive plastic optomechanical components from consumer electronic products. Total material costs for the components are comparable to the price of a mid-range smartphone (approximately 600–1200 USD), and significantly lower than the prices of conventional slide scanners with device costs typically between 50,000 to 300,000 USD [16]. Notably, similarly to other

digital slide scanners, the operation of the device requires a computer (equipped with USB), which price is not included in this approximation.




Figure 35.1 Prototype point-of-care digital slide scanner. (a) The prototype digital slide scanner (1) with slide adjustment motor unit (2) and laptop computer used to control device (3). (b) USAF standardized resolution test chart, digitized with the microscope prototype, showing the smallest set of resolvable bars (corresponding to a spatial resolution of $0.9 \mu\text{m}$).

Digital images are captured using a camera module typically used in smartphone camera systems (See3CAM_130, e-con Systems Inc., St Louis, USA), featuring a 13-megapixel (maximum resolution 4208×3120 pixels) complementary metal oxide semiconductor (CMOS) sensor with a plastic $f/3.2$ lens. A white light-emitting diode (LED) is used as the light source for brightfield imaging and an ultraviolet LED combined with a retractable band pass filter for fluorescent imaging (peak wavelength 365 nm). If the FOV is digitized using both the brightfield and fluorescence modes of the microscope, the resulting image can be rendered into a single merged image (Fig. 35.2).

With the current image sensor and lens, the pixel size was $0.22 \mu\text{m}$ and the spatial resolution $0.9 \mu\text{m}$, as measured using a standardized USAF resolution test chart and white-light LED illumination (Fig. 35.1). One sensor FOV measures 0.22 mm^2 , which is approximately five times larger than the FOV of a typical $100\times$ objective (0.22 mm^2 compared to 0.04 mm^2).

The device is connected to and operated from a computer by universal serial bus (USB), which also provides power for the device. An external motor unit (Fig. 35.2) is used to move the sample holder with the glass slide to scan the sample. Coarse focus can be adjusted with a manual focus lever and fine focus with the built-in autofocus routine of the camera module. The device is controlled with a custom software written in the matrix laboratory (MATLAB, MathWorks Inc, Natick, MA) computing and programming environment, which features a live view from the camera feed, overview of scanned areas and controls for adjusting parameters of slide scanning (e.g., area to be captured, focus and

exposure). Digitization of areas measuring more than one FOV utilizes the motor unit for automatic slide translation while the camera captures multiple images. The individual digitized samples in this study measured 12–20 FOVs per sample, representing a thin smear area (red blood cell [RBC] monolayer) without significant amounts of artefacts or debris when examined visually) of 2.65–4.41 mm². This corresponds to approximately 80–140 optical microscopy FOVs, using a conventional 100× magnification [24]. Image files were saved locally in the Tagged Image File Format (TIFF) and converted to a wavelet file format (Enhanced Compressed Wavelet, ECW, ER Mapper, Intergraph, Atlanta, Georgia) with a compression ratio of 1:9, before uploading to the image management platform (Aiforia Cloud, Aiforia Technologies Oy, Helsinki, Finland). This amount of compression has been shown in earlier studies to preserve sufficient detail to not alter results significantly [25]. Remote access to the image server for sample viewing is established using a web browser, secured with Secure Socket Layer (SSL).




Figure 35.2 Digitized thin blood smear. Microscopic field of view (FOV), showing the corresponding (a) brightfield, (b) fluorescence and (c) merged thin blood smear digital images. Red bounding boxes showing enlarged areas with (1) infected red blood cells (RBCs), (2) normal RBCs, (3) leukocytes and (4) fluorescent debris.

35.2.3 Visual Analysis of Digital Samples and Training of Deep-Learning Systems

Samples were visually evaluated by two researchers (O.H. and S.S.), who independently reviewed the digital samples on an LCD computer monitor and counted all visible *Plasmodium* parasites in the images. Parasites were manually annotated on the slide-management platform and the annotations served as ground truth for the digital image analysis. Sample parasitaemia was calculated as the number of detected parasites divided by the number of red blood cells (RBCs) detected by digital image analysis as described below. Results were recorded in a spreadsheet table (Microsoft Excel, Microsoft, Redmond WA).

For the digital analysis of the samples we trained two separate image analysis algorithms, based on deep learning (DL) with deep convolutional neural networks (CNNs). We utilized manually annotated image regions ($n = 1,176$) from a subset of thin blood smears ($n = 25$) to train the algorithms to detect visible malaria trophozoites and RBCs. A summary with comparison of the main features and differences of the algorithms is available in the supporting information (S1 File).

For the first deep-learning system (DLS 1), the digitized samples were uploaded to a commercially available, cloud-based machine-learning platform (Aiforia Cloud and Create, Aiforia Technologies Oy, Helsinki, Finland). Using this platform, a supervised deep-learning system (DLS) was trained to detect intracellular trophozoites in the digital images. For this method, the corresponding brightfield and fluorescence image channels were merged into hybrid images (Fig. 35.3). The training data was visually reviewed by a researcher (S.S.), and visible trophozoites and RBCs were annotated to constitute the training data. This system consists of two sequential CNN algorithms. The first algorithm detects all RBCs (i.e., infected and non-infected). The corresponding results are then forwarded to a second layer, containing two separate algorithms; one that detects infected RBCs (RBCs with visible fluorescent intracellular trophozoites; i.e., parasite candidates) and one that detects non-infected RBCs (RBCs without visible parasite candidates). The sample parasitaemia is calculated as the number of detected parasites divided by the total number of detected RBCs (Fig. 35.2). To increase the generalizability of the model, digital image augmentations by perturbation of the training data were utilized. In the first CNN layer, augmentations used were rotation (0–360°), variation of scale ($\pm 10\%$), shear distortion ($\pm 10\%$), aspect ratio ($\pm 10\%$), contrast ($\pm 10\%$), white balance ($\pm 10\%$) and luminance ($\pm 10\%$). In the second layer, the training material was augmented by rotation (0–360°), variation of scale ($\pm 5\%$), shear distortion ($\pm 5\%$), aspect ratio ($\pm 5\%$), contrast ($\pm 5\%$), white balance ($\pm 5\%$) and luminance ($\pm 5\%$). Training of the model was performed with 7,584 completed iterations (training epochs) of training and a predetermined feature size for object classification of 7 μm (RBCs) and 3 μm (parasites), using an image analysis window size (FOV) of 15 μm .




Figure 35.3 Training of deep-learning system 1 and analysis of blood smear. Workflow for training of the first deep-learning system (DLS 1) and subsequent analysis of samples using the trained model. (a): Training of the DLS was performed on merged images (brightfield and fluorescent images combined) where regions with visible red blood cells (RBCs) and trophozoites (parasites) were manually annotated and used to train the DLS to detect RBCs and classify them as infected vs. non-infected. (b): Analysis of samples in the validation series was performed on merged images in two steps: 1) Segmentation of all visible RBCs and 2) quantification of infected and non-infected RBCs to determine overall level of parasitaemia.

The second deep-learning system (DLS 2) analysis method also utilizes deep learning with CNNs, and analyses the brightfield and fluorescence images from the sample separately. The workflow of this system is described in Fig. 35.4. First, the RBCs in the brightfield-only image are identified using circle Hough Transform (CHT) to allow the selection of individual, well-preserved RBCs, while avoiding overlapping, clumped or otherwise deformed cells. Subsequently, a normalized cross correlation and peak finding algorithm [26] identifies the locations matching with a parasite template in the corresponding fluorescence-only image where the correlation peaks represent the centroids of the parasite candidates. Selected RBCs are then used to create a quantitation mask, and by combining the data from both images the parasite candidates are then addressed to the selected individual RBCs in the merged image. Notably, only the detected fluorescence signals emitted from locations inside the RBCs are included (with a small margin to cover the applique parasite forms and possible optical misalignment of the image channels). This also enables the detection of multiple objects within a single RBC; such as multiple visible parasites. A threshold was determined for the cross-correlation coefficient and Structural Similarity Index (SSIM) [27] value of the candidates to reduce computation cost by not including




Figure 35.4 Training of deep-learning system 2 and analysis of blood smear. Workflow of training and analysis with the second deep-learning system (DLS 2) using the GoogLeNet model. Panels showing brightfield images with segmented red blood cells (RBCs), the corresponding fluorescence image with detected parasite candidates, classification of parasites and exported analysis results.

the least likely parasite objects, i.e., weak signals emitting from the background fluorescence. The SSIM Index assesses the visual impact of luminance, contrast and structure characteristics of an image.

For the classification part, transfer learning [28] was utilized using a pre-trained GoogLeNet network [29]. The model is a binary-classification CNN which was trained using manually selected image-regions from the training series of samples, representing visible parasites and non-parasite fluorescent objects (i.e., debris and other artefacts). The training data was visually reviewed by a researcher (A.S.), and visible trophozoites ($n = 5059$) and other fluorescence signals ($n = 856$) were annotated from the training samples to constitute the training data for the two classes. As the parasitaemia level was relatively high in a large part of the training samples, the number of true parasites was significantly higher than the number representing other fluorescence signals. To reduce training imbalance and to ensure that high-parasitaemia samples would not dominate the training while preserving a sufficiently diverse distribution of parasites, the number of parasites selected from each training sample was limited based on the SSIM value of the candidate objects. Specifically, in each training sample, only the candidates with a unique SSIM value were included in the training. Rotation ($0-360^\circ$) and variation of scale ($\pm 5\%$) were utilized to augment image data, to prevent overfitting. Training of the model was performed in 30 training epochs with a batch size of 32 using a stochastic gradient descent solver with a momentum of 0.9 and initial learning rate of 0.0003. During the analysis phase the RBC was marked infected if at least one addressed parasite candidate was classified as a trophozoite with a classification score of at least 95/100. The overall parasitaemia was determined by the ratio of infected RBCs to the total number of RBCs (Fig. S1). DLS 2 is run locally and therefore suitable for potential integration directly into the imaging system for rapid analysis.

35.2.4 Statistical Analysis

Statistical analysis of results was performed using a general-purpose statistical software package (Stata 15.1 for Mac, Stata Corp., College Station, TX, USA). We calculated a Pearson's product-moment correlation to determine the relationship between parasitaemia determined by visual examination and analysis with the deep learning models in the digital samples. We utilized a two-sided paired Wilcoxon Signed-Rank test to assess the difference in detected levels of parasitaemia between the Day 0 and Day 3 samples. Power analysis for these calculations were conducted using the G*Power software v3.1.7 (Universität Kiel, Kiel, Germany) to determine a sufficient sample size, using an alpha of 0.05, a power of 0.95 and an effect size of 1.17 (as calculated based on the difference between visually determined levels of parasitaemia in slide pairs from the training data), which yielded a minimum required number of samples of 34 (17 slide pairs) [30].

35.2.5 Ethical Statement

The study was conducted in accordance with the Declaration of Helsinki on Good Clinical Practice. Ethical clearance for the study was issued by the National Institute for Medical Research (NIMR/HQ/R.8a/Vol.IX/2477) and Muhimbili University of Health and Allied Sciences, Tanzania, (MU/DRP/ERP/Vol.IX/174) and the original clinical trial registered on clinicaltrials.gov (Identifier: NCT03241901). Written informed consent was obtained from the study participants prior to enrolment in the study.

35.3 Results

35.3.1 Quantification of Parasites in Digital Samples

Prior to analysis of the main samples used in the study, we tested the image capture and algorithms on a series of test blood thin smears, prepared in laboratory conditions from blood cultures with known levels of *P. falciparum* infection ($n = 7$; approximately 0%, 0.2%, 0.5%, 1% and 2%, respectively). Here, we confirmed that fluorescent parasites and parasitized red blood cells (RBCs) could be visualized at the spatial resolution provided by the instrument. Overall, we observed a high level of similarity and almost perfect correlation between the DLS-based sample analysis and the known infection levels of the samples ($r(7) = 0.99, p < 0.001$) (Fig. S4).

For the samples used in the study, after exclusion of samples used for the training of the deep-learning systems, 97 samples remained in the validation series, of which 77 samples were thin blood smears collected at baseline, prior to initiation of treatment with ACT (Day 0), and 20 samples were follow-up thin blood smears collected on day 3 after treatment initiation (Day 3). All samples collected on day 0 were confirmed as malaria-positive by light-microscopy assessment of thick smears from the same patients, with a mean parasitaemia of 58,711 parasites/ μL (95%CI 44,055–73,368 parasites/ μL) and correspondingly a mean estimated parasitaemia of 1.17% (95% CI 0.88–1.47). The follow-up samples on day 3 after treatment initiation were all confirmed microscopy negative for malaria (no visible parasites in the Giemsa thick smear). The visual analysis of all fluorescently stained digitized day 0 thin smears revealed visible parasites, with an overall mean rate of infected RBCs of 1.79% (CI95% 1.31–2.26%). The visual analysis of the Day 3 digital samples detected a significantly lower rate of infected RBCs (0.014%, 95%CI 0.009–0.009–0.020%, $z = -3.92, p < 0.001$). The DLS analysis of the digitized thin smears returned similar levels of detected infected RBCs as the visual analysis of the digital samples in all analysed microscopy-positive samples (mean 1.70% [95%CI 1.27–2.15%] and 1.76% [95% CI 1.32–2.20%]) (Table 35.1).

Table 35.1 Results from analysis of blood smears with the different methods

Diagnostic comparison	Visual analysis of digitized thin smears	DLS1 analysis of digitized thin smears	DLS2 analysis of digitized thin smears	Microscopy thick-smear analysis (Giemsa)
Day 0				
Number of samples	77	77	77	77
Mean number of parasites detected per analysed area (n, 95% CI)	398 (297–498)	396 (295–496)	348 (261–436)	n/a*
Percentage of infected RBCs (%; 95% CI)	1.79 (1.31–2.26)	1.70 (1.27–2.15)	1.76 (1.32–2.20)	1.17 (0.88–1.47)
Mean estimated parasitemia (trophozoites/ μ L, 95% CI)	89,500 (65,500–113,000)**	85,000 (63,500–107,500)**	88,000 (66,000–110,000)**	58,711 (44,054–73,368)
Day 3				
Number of samples	20	20	20	20
Mean number of parasites detected per analysed area (n, 95% CI)	3 (2–4)	11 (4–17)	9 (2–16)	0
Percentage of infected RBCs (%; 95% CI)	0.01 (0.01–0.02)	0.05 (0.02–0.08)	0.05 (0.01–0.09)	0
Mean estimated parasitemia (trophozoites/ μ L, 95% CI)	500 (500–1,000)**	2,500 (1,000–4,000)**	2,500 (500–4,500)**	0

Note: Results from analysis of blood samples by light microscopy of Giemsa-stained thick smears, visual analysis of digitized DAPI-stained samples and DLS-based analysis of the digitized DAPI-stained samples. Parasitaemia estimated as the rate of infected red blood cells (RBCs), multiplied by the assumed number of RBCs per μ l of blood (5,000,000).

*Not available from thick smear analysis.

**Calculated based on the commonly used approximation of 5,000,000 RBCs per μ L.

The results from the DLS analysis of the Day 3 digitized thin smears also yielded similar values as the visual sample analysis (mean 0.05% [95%CI 0.017–0.083] and 0.05% [95%CI 0.009–0.094]). When assessing correlation between the DLS analysis and the visual analysis of the digital samples, an almost perfect correlation in detected rate of trophozoites was observed, as calculated with the Pearson's product-moment correlation coefficient, for the microscopy-positive samples ($r(77) = 0.9996$ and 0.9986 , $p < 0.01$), by analysis with DLS 1 and DLS 2. Compared to the estimated rate of infected RBCs in the Giemsa thick-smear analysis, the correlation for the DLS 1 and DLS 2 results were strong ($r(77) = 0.740$, $p < 0.01$ and $r(77) = 0.743$, $p < 0.01$, respectively) and for the detected rate of infected RBCs in the microscopy-negative samples, a modest correlation was observed for the DLS-based analysis of samples, compared to the visual sample analysis ($r(20) = 0.61$ and 0.42 , $p < 0.01$) (Fig. 35.5 and Fig. 35.6).

To further evaluate the DLS-based quantification of *P. falciparum* parasitemia in the Day 0 samples, we also compared the results from the digital analyses to the level of infection, as determined by quantitative PCR (qPCR). Here, we also observed a strong correlation between the DLS- and the qPCR-based assessment of infection level ($r(27) = 0.90$). As qPCR results were only available for a subset of patients (27), these are provided in more detail as supplementary material (Fig. S2).




Figure 35.5 Detected level of parasitemia by the different methods. Box plots illustrating the detected levels of *P. falciparum* parasitemia (percentage of infected red blood cells; RBCs) in malaria-positive blood smears collected prior to initiation of treatment (Day 0) by the deep learning systems (DLS) and by visual analysis of the digital, DAPI-stained slides and by conventional light microscopy of Giemsa-stained thick smears.




Figure 35.6 Correlation between detected levels of parasitemia by deep learning-based and visual sample analysis. Correlation between levels of *P. falciparum* parasitemia, as detected with the deep learning systems (DLSs), and by visual analysis of the digital samples, collected on (a) Day 0 and (b) Day 3.

35.2.2 Monitoring of Parasite Clearance in Thin Smears Collected at the Day of ACT Treatment Initiation and Three Days Later

After exclusion of samples used for training of the image-analysis systems, 40 samples, containing a total number of 20 pairs of thin smears (Day 0 and Day 3) remained. By expert light microscopy assessment of the Giemsa-stained thick smears from the same patients, all Day 0 samples ($n = 20$) were classified as positive for *P. falciparum* parasites, and all Day 3 ($n = 20$) samples classified as negative for visible parasites. Overall, assessed rates of infected RBCs in the Day 3 samples were significantly lower with all methods studied, than the rates detected in the pre-treatment (Day 0) samples and the results showed high correlation between the methods studied (Table 35.1). A Wilcoxon signed-rank test revealed that the post-treatment (Day 3) parasitaemia of the digitized DAPI-stained samples was significantly lower than the pre-treatment parasitaemia (Day 0), as determined by visual analysis (mean: 0.01% [95%CI: 0.01–0.02%] vs. 1.76% [CI 95: 1.32–2.20], $z = -3.92$, $p < 0.001$), analysis by DLS 1 (mean: 0.05% [CI 95% 0.02–0.08] vs. 1.70% [CI 95% 1.27–2.15%], $z = -3.92$, $p < 0.001$) and analysis by DLS 2 (mean: 0.05% [CI 95% 0.01–0.09] vs. 1.76% [CI 95: 1.32–2.20], $z = -3.92$, $p < 0.001$) (Fig. 35.7).




Figure 35.7 Detected levels of parasitemia on Day 0 and Day 3, following initiation of treatment. Box plots illustrating the detected levels of *P. falciparum* parasitemia (percentage of infected red blood cells; RBCs) in blood smears collected at baseline, prior to initiation of treatment (Day 0) and three days following initiation of treatment (Day 3). Results shown as detected by analysis with the deep learning systems (DLS) and by visual analysis of the digital slides.

35.4 Discussion

In this study we acquired thin blood smears from patients with light microscopy-determined uncomplicated *P. falciparum* infection, collected at baseline before initiation of artemisinin-based combination therapy (ACT) and three days following treatment initiation. We stained the samples using a simplified fluorescent staining protocol and digitized both the fluorescence and brightfield images into hybrid digital samples, using a small-sized POC digital microscope prototype. The digital samples were uploaded to a cloud-server and analysed with two deep learning-based systems to detect and quantify malaria parasites in the samples. Results were compared to visual assessment of the digitized samples, and to light microscopy examination of Giemsa-stained thick smears. Overall, we observed strong correlations in the numerical results, i.e., values for detected level of parasitaemia with the DLS-based system in malaria-positive samples and visual assessment of the digital samples ($r = 0.98\text{--}0.99$, $p < 0.01$) and ($r = 0.42\text{--}0.61$, $p < 0.01$).

Compared to the light-microscopy assessment of Giemsa-stained thick smears, the correlation in detected number of parasites was strong but lower (0.74, $p < 0.01$), likely as the quantification of parasites is not directly comparable when using different methods of analysis and sample types (thick and thin blood films). Notably, previous studies have shown that the visual approximation of parasite density in especially thick blood films is prone to variations, due to factors such as reader technique, quality of slides and the random distribution of parasites and WBCs [31, 32]. Here, both DLSs performed with high similarity to the manual assessment of the digitized thin smears. When assessing parasite clearance by DLS-based analysis of digital samples collected on Day 3 after initiation of ACT, significantly lower levels of parasite candidates were detected in the samples using the digital methods (0.05% vs. 1.73%, $z = -3.92$). For quantification of *P. falciparum* parasites in malaria-positive samples, both deep learning algorithms performed with high correlation ($r > 0.99$) to the manual, visual quantification of parasites in the digital samples, suggesting that the methods are comparable. Notably, a similarly high level of correlation was also observed when comparing the results from the DLSs to the qPCR-based assessment of infection level ($r = 0.90$), although these results were only available for a subset of patients (Fig. S2). Overall, the number of detected signals (parasite candidates) by analysis with the DLSs was low in microscopy-negative samples, and mainly corresponded to fluorescent artefacts and debris (Fig. S3). The results here suggest that it would be possible to establish an operative threshold for the DLSs to separate positive and negative samples with relatively high sensitivity. Here, by using a threshold for positivity of 0.10% (detected level of parasitemia) for classifying a sample as malaria-positive, the detection of positive samples in the validation series would be possible with approximately 95% sensitivity and specificity. This could initially be useful, e.g., as a triage system to automatically detect the majority of abnormal slides, although the accurate detection of low-level infections would require higher sensitivity.

Our results are in line with findings from earlier studies, where fluorescence malaria field microscopy has shown promise as a field-applicable and inexpensive diagnostic technology [33]. Similarly to our findings, previous work has suggested that high sensitivity (up to 98%) and reasonable sensitivity (89%) can be achieved using visual fluorescence field microscopy, compared to conventional methods, and especially for samples with high levels of parasitaemia [34]. Previous work has also demonstrated how the digital analysis of DAPI-stained blood samples, digitized with a 40× objective digital microscope in laboratory conditions, can be used to quantify levels of parasitaemia and even classify the infection stage of the parasites [35]. Notably, the principal challenges with equivocal fluorescent particles being detected as parasites in samples with low levels of parasitemia encountered here has also been described previously [33]. Although significantly lower amounts of parasite signals were detected in the microscopy-negative samples, the levels were still relatively high compared to, e.g., the detection limits of conventional Giemsa thick smear microscopy. Therefore, to achieve ideal levels of sensitivity for primary malaria diagnostics, methods to improve sensitivity for especially low-level infections are essential. These include steps to minimize sample contaminations to allow the digitization of large, representative sample areas (i.e., uncontaminated monolayers of RBCs). To achieve similar levels of sensitivity as Giemsa thick smear-microscopy and RDTs, increasing the total sample area analysed (currently ~100 high-power FOVs) or utilizing methods to increase the amounts of visible RBCs per image field are crucial.

As this work represents a proof-of-concept study, it has certain limitations that need to be addressed. Firstly, the principal challenge encountered here and the major cause of false-positive signals in the microscopy-negative samples was the presence of artefacts and debris in the blood smears, which resulted in fluorescent signals not originating from parasites. Although the staining process described here is simple to perform, the technique is, similarly to conventional staining methods, prone to contaminations, which was challenging especially in samples with higher levels of contamination and low parasite densities (Fig. S1). This emphasizes the need for robust sample processing to ensure usability in field settings. Therefore, although this technology could potentially facilitate the sample analysis and reduce the need for trained experts to analyse samples, the staining process is a crucial step which still requires trained personnel on site. Secondly, here, we compared the parasite quantification in stained thin blood smears to the microscopy-assessment of thick smears from the patients, and accordingly observed a certain variation in the estimated infection levels. To determine the correlation to Giemsa microscopy, the analysis of Giemsa-stained thin blood smears from the same patients would be the preferred ground truth, which was not available in the current study. Notably, when testing the algorithms on samples prepared in laboratory conditions with known levels of *P. falciparum* infection, a strong correlation ($r > 0.99$, $p < 0.001$) was observed in DLS-detected levels of infection and known parasitaemia (Fig. S4). Lastly, we digitized areas of the thin smears that contained representative monolayers with minimal amounts of

artefacts, but in a clinical setting, larger representative sample areas would be analysed to improve the sensitivity for lower-level infections.

35.5 Conclusion

This proof-of-concept study shows that detection and quantification of *P. falciparum* parasites in thin blood smears is feasible, using a simplified fluorescent staining process, an inexpensive, POC portable slide-scanner and a deep learning-algorithm. As digital microscopy is currently limited mainly to laboratories with access to high-end digitization equipment, this method warrants further investigation as a potential novel platform for AI-based, digital malaria microscopy at the POC. The method can facilitate microscopy diagnostics in field settings and offer the benefits that digital and automated microscopy is associated with, e.g., more objective and reproducible results, potentially reduced time for needed for sample analysis (compared to the manual quantification of parasites), and a method that can be used for monitoring of treatment efficacy through assessment of parasite clearance. Also, the method is likely to be applicable for different *Plasmodium* species and other pathogens, especially those where fluorescence microscopy may offer additional diagnostic advantages.

35.6 Hardware, Software and Data Availability Statement

The data and results underlying the conclusions in the article are included in the chapter and/or the Supplementary Material. Requests for additional, de-identified data are handled by the Data Access Committee at Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland (e-mail: fimm-dac@helsinki.fi). The prototype instrument used for digitization of the samples is developed and patented (patent publication number: US20180246306) by the University of Helsinki (Helsinki, Finland). At the time of writing, the device is still in prototype stage and therefore not commercially available. We are open to collaborations for academic, non-profit purposes; requests for access to the hardware and software used in this study can be directed to the corresponding author, and will be considered from researchers with the aim to generate data for the public good.

Supporting Information

S1 Fig. Deep learning-based analysis of control samples. Results from deep learning-based analysis of control samples, prepared from blood cultures in laboratory-conditions with known levels of *P. falciparum* infections (0% and approximately 0.2%, 0.5%, 1% and 2% levels of parasitemia, respectively). Correlation between results measured with the Pearson's product-moment correlation coefficient and showing an almost perfect level of correlation ($r(7) = 0.99$). <https://doi.org/10.1371/journal.pone.0242355.s001>.

S2 Fig. Deep learning-based determination of parasitemia, compared to assessment by quantitative PCR. Detected level of malaria infection before initiation of treatment, as determined by analysis with the deep learning-systems (DLSs), compared to quantitative PCR-based analysis of samples from a subset of patients. DLS-detected parasitemia calculated based on an assumed amount of 5,000,000 RBCs per μL of blood. Correlation between results measured with the Pearson's product-moment correlation coefficient and showing a high level of correlation ($r(27) = 0.90$). <https://doi.org/10.1371/journal.pone.0242355.s002>.

S3 Fig. Digitized Giemsa-stained thin blood smear. Digitized Giemsa-stained thin blood smear from patient in study cohort. Images showing sample with high amounts of visible artefacts and debris. <https://doi.org/10.1371/journal.pone.0242355.s003>.

S4 Fig. Study workflow. STARD diagram of study workflow and sample processing. <https://doi.org/10.1371/journal.pone.0242355.s004>.

S1 File. Comparison of deep-learning systems and generated raw data for article. <https://doi.org/10.1371/journal.pone.0242355.s005>.

Abbreviations

ACT:	artemisinin-based combination therapy
CHT:	circle Hough Transform
CMOS:	complementary metal oxide semiconductor
CNNs:	convolutional neural networks
DAPI:	diamidino-2-phenylindole
DL:	deep learning
DLS:	deep-learning system
FOV:	field of view
LAMP:	loop-mediated isothermal amplification
LED:	light-emitting diode
MATLAB:	matrix laboratory
NAATs:	nucleic acids amplification tests
POC:	point-of-care
qPCR:	quantitative polymerase chain reaction
RBCs:	red blood cells
RDTs:	rapid diagnostic tests
SSIM:	Structural Similarity Index
SSL:	Secure Socket Layer
TIFF:	Tagged Image File Format
USB:	universal serial bus
WBCs:	white blood cells
WHO:	World Health Organization

Disclosures and Conflict of Interest

This chapter was originally published as: Holmström, O., Stenman, S., Suutala, A., Moilanen, H., Kücükkel, H., Ngasala, B., et al. (2020). A novel deep learning-based point-of-care diagnostic method for detecting *Plasmodium falciparum* with fluorescence digital microscopy. *PLoS ONE*, 15(11), e0242355, <https://doi.org/10.1371/journal.pone.0242355>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: All relevant data are within the chapter and its Supporting Information files.

Funding: This work was funded by the Swedish Research Council, Swedish International Development Agency (SIDA) and Sigrid Jusélius Foundation. In addition, the study has been supported by Finska Läkaresällskapet, Biomedicum Foundation, Medicinska Understödsföreningen Liv och Hälsa rf, the Nvidia Corporation and Wilhelm och Else Stockmanns stiftelse. We furthermore greatly acknowledge the assistance and support from the Helsinki Institute of Life Science (HiLIFE) and the FIMM Digital Microscopy and Molecular Pathology Unit supported by Helsinki University and Biocenter Finland. The funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: Johan Lundin and Mikael Lundin are founders and co-owners of Aiforia Technologies Oy, Helsinki, Finland. The Nvidia Corporation donated a GPU via the Academic Grant Application Program, which was used during this study. The prototype instrument used for digitization of the samples is developed and patented (patent number: US20180246306) by the University of Helsinki (Helsinki, Finland). This does not alter our adherence to *PLOS ONE* policies on sharing data and materials.

Author Contributions

Conceptualization: Oscar Holmström, Antti Suutala, Hannu Moilanen, Billy Ngasala, Andreas Mårtensson, Lwidiko Mhâmilawa, Vinod Diwan, Nina Linder, Johan Lundin; **Formal analysis:** Oscar Holmström, Sebastian Stenman, Antti Suutala, Hannu Moilanen, Hakan Kücükkel, Johan Lundin; **Investigation:** Oscar Holmström, Sebastian Stenman, Hakan Kücükkel, Johan Lundin; **Methodology:** Oscar Holmström, Sebastian Stenman, Antti Suutala, Hannu Moilanen, Billy Ngasala, Andreas Mårtensson, Lwidiko Mhamilawa, Berit Aydin-Schmidt, Mikael Lundin, Vinod Diwan, Nina Linder, Johan Lundin; **Project administration:** Billy Ngasala, Andreas Mårtensson, Johan Lundin; **Resources:** Hannu Moilanen; **Software:** Antti Suutala, Hakan Kücükkel, Mikael Lundin; **Supervision:** Vinod Diwan, Nina Linder, Johan Lundin; **Validation:** Oscar Holmström, Antti Suutala.

References

1. World Health Organization. World Malaria Report 2018. Available at: <http://apps.who.int/iris/bitstream/handle/10665/275867/9789241565653-eng.pdf> (accessed on November 22, 2022).
2. Charpentier E, Benichou E, Pagès A, Chauvin P, Fillaux J, Valentin A, et al. Performance evaluation of different strategies based on microscopy techniques, rapid diagnostic test and molecular loop-mediated isothermal amplification assay for the diagnosis of imported malaria. *Clin Microbiol Infection*, 2020; 26(1): 115–121.
3. World Health Organization. *Guidelines for the Treatment of Malaria*, 3rd ed. 2015.
4. Mathison BA, Pritt BS. Update on malaria diagnostics and test utilization. *J Clin Microbiol*, 2017; 55(7): 2009–2017.
5. World Health Organization. *Malaria Microscopy Quality Assurance Manual—Ver. 2*. January 2016.
6. Frean J, Perovic O, Fensham V, McCarthy K, von Gottberg A, de Gouveia L, et al. External quality assessment of national public health laboratories in Africa, 2002–2009. *Bull World Health Organ*, 2012; 90(3): 191–199A.
7. O’Meara WP, Barcus M, Wongsrichanalai C, Muth S, Maguire JD, Jordan RG, et al. Reader technique as a source of variability in determining malaria parasite density by microscopy. *Malar J*, 2006; 5: 118.
8. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). *Am J Trop Med Hyg*, 2007; 77(6 Suppl): 119–127.
9. Leski TA, Taitt CR, Swaray AG, Bangura U, Reynolds ND, Holtz A, et al. Use of real-time multiplex PCR, malaria rapid diagnostic test and microscopy to investigate the prevalence of *Plasmodium* species among febrile hospital patients in Sierra Leone. *Malar J*, 2020; 19(1): 84.
10. Mhamilawa LE, Aydin-Schmidt B, Mmbando BP, Ngasala B, Morris U. Detection of *plasmodium falciparum* by light microscopy, loop-mediated isothermal amplification, and polymerase chain reaction on day 3 after initiation of artemether–lumefantrine treatment for uncomplicated malaria in bagamoyo district, tanzania: a comparative trial. *Am J Trop Med Hyg*, 2019; 101(5): 1144–1147.
11. Guy R, Liu P, Pennefather P, Crandall I. The use of fluorescence enhancement to improve the microscopic diagnosis of falciparum malaria. *Malar J*, 2007; 6(1): 89.
12. Wongsrichanalai C, Kawamoto F. Fluorescent microscopy and fluorescent labelling for malaria diagnosis. In: Hommel M, Kremsner PG, editors. *Encyclopedia of Malaria New York, NY: Springer New York*; 2021. pp. 1–7.
13. Boppart SA, Richards-Kortum R. Point-of-care and point-of-procedure optical imaging technologies for primary care and global health. *Sci Trans Med*, 2014; 6(253): 253rv2.
14. International Telecommunication Union. ICT facts and figures—the world in 2015. 2015; Available at: <https://www.itu.int/en/ITU-D/Statistics/Documents/facts/ICTFactsFigures2015.pdf> (accessed on November 22, 2022).

15. Contreras-Naranjo JC, Wei Q, Ozcan A. Mobile phone-based microscopy, sensing, and diagnostics. *IEEE J Selected Topics Quantum Electron*, 2016; 22(3): 1–14.
16. Digital Pathology Association, 2020. Digital pathology FAQ. Available at: <https://digitalpathologyassociation.org/faq> (accessed on November 22, 2022).
17. Holmstrom O, Linder N, Ngasala B, Martensson A, Linder E, Lundin M, et al. Point-of-care mobile digital microscopy and deep learning for the detection of soil-transmitted helminths and *Schistosoma haematobium*. *Glob Health Action*, 2017; 10(sup3): 1337325.
18. Holmstrom O, Linder N, Moilanen H, Suutala A, Nordling S, Stahls A, et al. Detection of breast cancer lymph node metastases in frozen sections with a point-of-care low-cost microscope scanner. *PLoS ONE*, 2019; 14(3): e0208366.
19. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology. *Nat Rev Clin Oncol*, 2019; 16(11): 703–715.
20. Moon S, Lee S, Kim H, Freitas-Junior L, Kang M, Ayong L, et al. An image analysis algorithm for malaria parasite stage classification and viability quantification. *PloS ONE*, 2013; 8(4): e61812.
21. Linder N, Turkki R, Walliander M, Martensson A, Diwan V, Rahtu E, et al. A malaria diagnostic tool based on computer vision screening and visualization of *Plasmodium falciparum* candidate areas in digitized blood smears. *PLoS ONE*, 2014; 9(8): e104855.
22. Poostchi M, Silamut K, Maude RJ, Jaeger S, Thoma G. Image analysis and machine learning for detecting malaria. *Trans Res J Lab Clin Med*, 2018; 194: 36–55.
23. Mhamilawa LE, Ngasala B, Morris U, Kitabi EN, Barnes R, Soe AP, et al. Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated *Plasmodium falciparum* malaria in Bagamoyo district, Tanzania: a randomized controlled trial. *Malar J*, 2020; 19(1): 216.
24. World Health Organization. Malaria parasite counting. Malaria microscopy standard operating procedure. 2016; Available at: https://www.who.int/docs/default-source/wpro---documents/toolkit/malaria-sop/gmp-sop-09-revised.pdf?sfvrsn=6587afac_2 (accessed on November 22, 2022).
25. Konsti J, Lundin M, Linder N, Haglund C, Blomqvist C, Nevanlinna H, et al. Effect of image compression and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium. *Diagn Pathol*, 2012; 7: 29.
26. Natan A, Fast 2D peak finder, MATLAB central file exchange, 2013. Available at: <https://www.mathworks.com/matlabcentral/fileexchange/37388-fast-2d-peak-finder> (accessed on November 22, 2022).
27. Wang Z, Bovik AC, Sheikh HR, and Simoncelli EP, Image quality assessment: from error visibility to structural similarity, *IEEE Trans Image Proc*, 2004, 13(4), 600–612.
28. Tajbakhsh N, Shin J, Gurudu S, Hurst RT, Kendall C, Gotway M, et al. Convolutional neural networks for medical image analysis: fine tuning or full training? *IEEE Trans Med Imaging*, 2016; 35: 1.

29. Szegedy C, Liu W, Jia Y, Sermanet P, Reed S, Anguelov D, et al. Going deeper with convolutions. *arXiv*. 2015.
30. Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*, 2007, 39(2): 175–191.
31. Bejon P, Andrews L, Hunt-Cooke A, Sanderson F, Gilbert SC, Hill AVS. Thick blood film examination for *Plasmodium falciparum* malaria has reduced sensitivity and underestimates parasite density. *Malar J*, 2006; 5: 104.
32. O'Meara W, McKenzie F, Magill A, Forney J, Permpanich B, Lucas C, et al. Sources of variability in determining malaria parasite density by microscopy. *Am J Trop Med Hyg*, 2005; 73: 593–598.
33. Sousa-Figueiredo JC, Oguttu D, Adriko M, Besigye F, Nankasi A, Arinaitwe JR, et al. Investigating portable fluorescent microscopy (CyScope) as an alternative rapid diagnostic test for malaria in children and women of child-bearing age. *Malar J*, 2010, 9, 245–245.
34. Hassan S, Haggaz A, Mohammed-Elhassan E, Malik E, Adam I. 2011, Fluorescence microscope (Cyscope®) for malaria diagnosis in pregnant women in Medani Hospital, Sudan, *Diagn Pathol*, 2011, 6, 88.
35. Moon S, Lee S, Kim H, Freitas-Junior L, Kang M, Ayong L, et al. An image analysis algorithm for malaria parasite stage classification and viability quantification. *PLoS ONE*, 2013; 8(4): e61812.

Chapter 36

Positron Emission Tomography and Magnetic Resonance Imaging in Experimental Human Malaria to Identify Organ-Specific Changes in Morphology and Glucose Metabolism: A Prospective Cohort Study

John Woodford, PhD,^{a,b} Ashley Gillman, PhD,^c Peter Jenvey, MBBS,^d Jennie Roberts, MBBS,^d Stephen Woolley, MSc,^{a,c} Bridget E. Barber, PhD,^{a,f} Melissa Fernandez,^a Stephen Rose, MD,^c Paul Thomas, PhD,^g Nicholas M. Anstey, PhD,^f and James S. McCarthy, PhD^{a,b}

^aClinical Tropical Medicine Laboratory,
QIMR-Berghofer Medical Research Institute, Brisbane, Australia

^bUniversity of Queensland, Brisbane, Australia

^cCommonwealth Scientific and Industrial Research Organisation, Brisbane, Australia

^dDepartment of Radiology, Royal Brisbane and Women's Hospital, Brisbane, Australia

^eCentre for Defence Pathology, Royal Centre for Defence Medicine, Birmingham, UK

^fGlobal and Tropical Health Division,

Menzies School of Health Research and Charles Darwin University, Darwin, Australia

^gHerston Imaging Research Facility, Brisbane, Australia

john.woodford@uqconnect.edu.au

Keywords: body mass index (BMI), biomimetic 18-F fluorodeoxyglucose (FDG), confidence interval (CI), functional imaging, hepatic imaging, induced blood-stage malaria (IBSM), infected red blood cells (iRBCs), magnetic resonance imaging (MRI), malaria, nuclear medicine, *Plasmodium falciparum* (Pf), *Plasmodium vivax* (Pv), positron emission tomography (PET), quantitative polymerase chain reaction (qPCR), regions of interest (ROIs), splenic imaging, splenic tropism, standardized uptake values (SUVs), Strengthening The Reporting of Observational Studies in Epidemiology (STROBE), upper limit of normal (ULN), vertebral bone marrow imaging

36.1 Introduction

Plasmodium vivax and *Plasmodium falciparum* have key differences in their biology, pathophysiology, and disease manifestations. These are thought to largely arise

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

from differences in microvascular parasite sequestration [1–3] and host red blood cell tropism, with *P. vivax* having a strict tropism for immature reticulocytes [4, 5]. Differences in organ-specific parasite tropism have also been proposed [3]. Although *P. vivax* is not thought to undergo significant microvascular tissue sequestration, there is emerging evidence that the spleen may harbor a large hidden reservoir of replicating parasites [6, 7]. The evaluation of sequestration and organ-specific parasite tropism has largely relied on biochemical markers, nonhuman primate models, and postmortem studies, which have been critical to progress our understanding of disease pathophysiology but are imperfect tools to study the dynamics of infection in humans.

The tissue distribution of *P. falciparum* on autopsy has been well described. In a seminal publication by Marchiafava and Bignami, the greatest concentration of schizonts was found in the brain, followed by the lungs, spleen, bone marrow, liver, and intestines [1]. Although human autopsy studies of *P. vivax* are comparatively rare, parasite material has been identified in the spleen, liver, and lungs, but not the brain [8]. Studies of *P. vivax* tropism in nonhuman primates have been limited by the need for prior splenectomy [9]. In these studies, few or no parasites were identified in the brain or intestines, whereas the bone marrow and liver sinusoids were major tissue reservoirs for *P. vivax* schizonts and gametocytes [9]. An apparent predilection for the spleen, bone marrow, and liver is consistent with biomarker evidence of a hidden biomass of parasite accumulating in non-endothelial lined spaces [10] and the strict reticulocyte tropism of this species, which may promote concentration in organs in which immature reticulocytes accumulate [4, 11]. Nonetheless, this hypothesis is challenging to confirm in life, where these processes are largely inaccessible to evaluation. In this context, magnetic resonance imaging (MRI) and functional imaging using nuclear medicine such as positron emission tomography (PET) may be useful noninvasive methods to study deep tissue processes and organ-specific tropism, particularly in early and non-severe infection.

As access to clinical imaging infrastructure in malaria endemic areas continues to improve, an increasing number of studies have demonstrated the utility of MRI to evaluate the brain in cerebral [12] and uncomplicated falciparum malaria [13, 14]. In contrast, PET imaging in malaria is limited to a small number of nonhuman primate studies [15, 16] and a single case report of serendipitous imaging in suspected lymphoma [17]. In the nonhuman primate studies, uptake of the glucose biomimetic 18-F fluorodeoxyglucose (FDG) was colocalized with sequestered infected red blood cells (iRBCs) as ascertained on subsequent autopsy [16], suggesting that PET imaging using this widely available radiotracer that targets glucose utilization may be a useful modality to localize organ-specific parasite accumulation and host response in life.

We sought to investigate organ-specific changes in morphology and glucose metabolism in the spleen, vertebral bone marrow, and liver in early *P. vivax* and *P. falciparum* infection using FDG PET/MRI imaging of participants with experimentally induced blood-stage malaria (IBSM). We hypothesized that alterations in glucose metabolism would be present in the regions of interest (ROIs).

Secondly, we hypothesized that the patterns of PET/MRI would differ between participants with *P. vivax* and *P. falciparum* infection.

36.2 Methods

This was a prospective, single-center exploratory study performed between 2016 and 2019 at the Herston Imaging Research Facility, Brisbane, Australia. Participants were recruited to the imaging study after enrolling in IBSM studies. In brief, baseline FDG PET/MRI was performed prior to malaria inoculation. Healthy, malaria-naïve participants were then inoculated with approximately 564 viable *P. vivax* or approximately 2,800 *P. falciparum* (3D7) infected erythrocytes. Peripheral blood parasitemia was monitored at least daily by quantitative polymerase chain reaction (qPCR) from day 4 after inoculation as described previously [18]. A postinoculation FDG PET/MRI was performed near to the peak of parasitemia, in the 24 h prior to administration of antimalarial treatment. Standard safety assessments including clinical review, hematology, and biochemistry parameters were performed at specified times during the IBSM studies including baseline, 1 day following postinoculation imaging (at time of treatment), and in convalescence, 1 to 2 weeks after postinoculation imaging [19, 20]. A total of 8 participants were planned for enrollment, based on the availability of funding, IBSM study cohorts, and imaging facilities.

36.2.1 Imaging Procedures

Baseline and postinoculation FDG PET/MRI were performed on all participants using the 3 Tesla Magnetom Biograph mMR (Siemens, Erlangen, Germany). All participants completed an institutional MRI safety checklist prior to imaging. The female participants underwent qualitative human chorionic gonadotropin testing prior to imaging to exclude pregnancy. Participants were required have a normal fasting glucose at enrolment and to abstain from strenuous exercise and follow a low-carbohydrate diet in the 24 h prior to imaging with a 6 h fasting period immediately prior to help standardize FDG uptake [21, 22]. Diet and activity information sheets were provided to assist participant adherence. Due to the different growth rate of parasites in IBSM, the interval between baseline and postinoculation imaging differed in the *P. vivax* and *P. falciparum* studies.

Nuclear medicine and radiology specialists reporting all imaging were not aware of the inoculum species. Mean standardized uptake values (SUVs) were estimated for the prespecified ROIs including the spleen, vertebral bone marrow, and liver. SUV is the most commonly used measurement of radiotracer activity and represents the ratio of tissue radioactivity related to FDG at a given time and the injected dose of radioactivity per kilogram of participant weight. Organ volumes were calculated for the spleen and liver. As an exploratory analysis, the quantitative rate of irreversible radiotracer uptake was modeled for the ROIs. Detailed methods and imaging protocols are outlined in the S1 Text.

36.2.2 Statistical Analysis

All imaging results are presented descriptively for the *P. vivax* and *P. falciparum* groups. Where relevant, results for each inoculum group are presented as mean (95% confidence interval (CI)) percentage change from baseline for quantitative imaging metrics. A >10% percentage difference in SUV from baseline to postinoculation imaging was considered meaningful based on intraindividual, inter-scan variability reported in stringent FDG PET imaging trials in malignancy and non-malignancy settings [23–25]. Parasitemia at the time of postinoculation imaging was estimated by interpolating the linear rate of change between the nearest log-transformed study parasitemia measurements.

Statistical analysis was performed using Prism 8.4.2 (GraphPad, San Diego, United States of America). In an exploratory analysis, baseline and postinoculation imaging metrics and selected hematology and biochemistry parameters were compared using paired, 2-tailed *t* tests. Differences between the mean percentage change from baseline for quantitative imaging metrics for *P. vivax* and *P. falciparum* groups were compared using unpaired *t* tests. Differences between selected hematology and biochemistry parameters and parasitemia measurements for *P. vivax* and *P. falciparum* groups were compared using unpaired *t* tests of Mann–Whitney U tests. A *p*-value <0.05 was considered significant. No adjustments have been made for multiple comparisons.

36.2.3 Study Approval

Participants were recruited from 3 IBSM studies: 2 published (*P. falciparum*: NCT02867059 [26] and *P. vivax*: ACTRN12616000174482 [27]) and 1 unpublished (*P. falciparum*: ACTRN12619001085167). These studies were approved by the QIMR-Berghofer Medical Research Institute Ethics Committee. The exploratory imaging study was approved by the QIMR-Berghofer Medical Research Institute and Queensland Health Metro North Ethics committees. The exploratory imaging study was prospectively linked to 2 of the IBSM studies (ACTRN12616001458426 linked to IBSM study NCT02867059 and ACTRN12616001238460 linked to IBSM study ACTRN12616000174482 (see S1 Protocol)). The third IBSM study incorporated the exploratory imaging study into the main protocol (ACTRN12619001085167). All participants provided written informed consent for the IBSM studies and the exploratory imaging study. This study has been reported as per the STrengthening the Reporting of OBServational studies in Epidemiology (STROBE) guidelines (S1 Checklist).

36.3 Results

A total of 8 healthy, malaria-naive participants were recruited. All participants underwent baseline imaging within 7 days before inoculation. One participant

was enrolled and underwent baseline imaging, but was excluded from the IBSM study before inoculation due to incidental hypokalemia on baseline biochemistry. This participant did not undergo postinoculation imaging and was excluded from the analysis. Seven participants underwent postinoculation imaging. The study population is described in Table 36.1. Included participants had a median age of 20 years (range 19 to 23), and 6/7 were male. Three were inoculated with *P. vivax* and 4 with *P. falciparum*. All participants developed a measurable parasitemia (Fig. 36.1) and reported symptoms of early malaria infection prior to treatment. Parasitemia at postinoculation imaging was at least as high in the *P. falciparum* group (median 22,326 [range 998 to 99,134 parasites/mL]) as the *P. vivax* group (median 6,042 [range 5,818 to 29,097 parasites/mL, Mann-Whitney U test $p > 0.99$]). Although the day of treatment varied between studies, both groups underwent imaging a median 9 days following inoculation. Imaging results for the ROIs including organ volumes and SUVs are presented in Fig. 36.2 and Table S1. Exploratory calculation of the quantitative rate of radiotracer uptake for the ROIs is presented in the Table S1 and Text S2.

Table 36.1 Study population information.

Participant	Age (years)	Sex	BMI	Trial	Challenge agent	Dose (viable p/mL)	Day of post-inoculation imaging	Parasitemia at imaging (p/mL)
1	20	F	29.5	Collins et al. (2020) [27]	Pv	564	9	29,097
2	23	M	22.9	Collins et al. (2020) [27]	Pv	564	9	5,818
3	20	M	22.0	Collins et al. (2020) [27]	Pv	564	9	6,042
4	19	M	28.5	Gaur et al. (2020) [26]	Pf	2,800	7	1,427
5	22	M	22.0	Gaur et al. (2020) [26]	Pf	2,800	7	998
6	19	M	19.7	ACTRN12619001085167	Pf	2,800	11	43,224
7	19	M	24.2	ACTRN12619001085167	Pf	2,800	10	99,134

Note: Parasitemia at imaging: estimated by interpolating the linear rate of change between the closest log-transformed parasitemia measurements.

Abbreviations: BMI, body mass index; Pf, *P. falciparum*; Pv, *P. vivax*.




Figure 36.1 Parasitemia curves for participants inoculated with (A) *P. vivax* and (B) *P. falciparum*.




Figure 36.2 Imaging indices at baseline and postinoculation. (A) Spleen (volume), (B) Liver (volume), (C) Spleen (SUV), (D) Liver (SUV), and (E) Vertebral Bone Marrow (SUV). *P. vivax* group represented by black lines with unfilled markers. *P. falciparum* group represented by gray lines with filled markers. Asterisk represents $p < 0.05$ in paired t test comparison with baseline measurements (black for *P. vivax*, gray for *P. falciparum*). SUV, standardized uptake value.

36.3.1 Splenic Imaging

In the *P. vivax* group, splenic SUVs increased +15.5% from baseline (CI -0.7% to +31.7%). SUVs on postinoculation imaging were significantly higher on postinoculation imaging compared to baseline imaging (paired *t* test $p = 0.044$). This was visible on qualitative review in some participants (Fig. 36.3). Splenic volume increased a mean +28.8% from baseline imaging but did not reach statistical significance (CI +0.3% to +57.3%, paired *t* test $p = 0.053$).




Figure 36.3 Baseline and postinoculation PET imaging in Participant 1 (*P. vivax* group). Increased radiotracer uptake is evident in the spleen on postinoculation imaging (arrowhead). PET, positron emission tomography.

In the *P. falciparum* group, splenic SUVs increased +5.5% from baseline (CI +1.4% to +9.6%, paired *t* test $p = 0.019$), less than the prespecified 10% threshold. Splenic volume increased +22.9% from baseline but did not reach statistical significance (CI -15.3% to +61.1%, paired *t* test $p = 0.20$.) Participant 4 demonstrated a slight reduction in splenic volume, contrary to all other participants.

Compared to the *P. falciparum* group, the *P. vivax* group demonstrated a greater increase in splenic SUV from baseline to postinoculation imaging (+15.5% [CI -0.7% to +31.7%] versus +5.5% [CI +1.4% to +9.6%], unpaired *t* test $p = 0.036$). The change in splenic volume was larger in the *P. vivax* group compared to the *P. falciparum* group but did not reach statistical significance (+28.8% [CI +0.3% to +57.3%] versus +22.9% [CI -15.3% to +61.1%], unpaired *t* test $p = 0.72$).

36.3.2 Vertebral Bone Marrow Imaging

Vertebral bone marrow SUVs were stable on postinoculation imaging in both the *P. vivax* group (+4.6% [CI -15.9% to +25.0%], paired *t* test $p = 0.44$) and the *P. falciparum* group (+3.2% [CI -3.2% to +9.6%], paired *t* test $p = 0.17$). Participant 2 (*P. vivax* group) was the only individual demonstrating a change in SUV above the prespecified 10% threshold. There was no significant difference in change in percentage change in SUV between the groups (unpaired *t* test $p = 0.77$).

36.3.3 Hepatic Imaging

In both the *P. vivax* and *P. falciparum* groups, hepatic volume and SUVs remained stable on postinoculation imaging (*P. vivax*: hepatic volume: +0.2% [CI -23.6% to +24.0%], paired *t* test $p = 0.84$; SUV: +6.2% [CI -8.7% to +21.1%], paired *t* test $p = 0.18$; *P. falciparum*: hepatic volume: +3.9% [CI -6.2% to 14.0%], paired *t* test $p = 0.32$; SUV: -1.4% [CI -4.6% to +1.8%], paired *t* test $p = 0.25$). Participant 2 (*P. vivax* group) was the only individual demonstrating a change in SUV above the prespecified 10% threshold.

There was no significant difference in hepatic volume change or SUV change between the groups (percentage change in volume unpaired *t* test $p = 0.56$ and SUV unpaired *t* test $p = 0.06$).

36.3.4 Safety, Clinical Review, and Laboratory Parameters

No imaging-related adverse events or incidental radiological findings requiring clinical follow-up were recorded. All participants experienced symptoms of early malaria infection. Non-tender palpable splenomegaly was reported in Participant 3 following *P. vivax* inoculation on routine examination performed on the day of postinoculation imaging. This was present on inspiration, extended 1 cm below the costal margin, and resolved on follow-up examination 3 days following postinoculation imaging. Clinical hepatomegaly or splenomegaly was not reported for the remaining participants in either group.

Routine hematology (hemoglobin, hematocrit, and platelet count) and biochemistry (total bilirubin and alanine transaminase) measurements were collected at baseline, postinoculation (at time of treatment), and in convalescence for all participants. The majority of hematology and biochemistry measurements were within the laboratory reference range (Fig. S1, Table S2). Changes in laboratory parameters in our study population were similar to those observed in the overall contributing IBSM study populations [26, 27].

In the *P. vivax* group, hemoglobin and hematocrit decreased significantly between baseline and postinoculation (mean 148 g/L [CI 103 to 193] versus 137 g/L [CI 94 to 180], paired *t* test $p = 0.045$ and 0.43 L/L [CI 0.33 to 0.53] versus 0.39 L/L [CI 0.28 to 0.50], paired *t* test $p = 0.008$, respectively) and further at convalescence (148 g/L [CI 103 to 193] versus 133 g/L [CI 85 to 182], paired *t* test $p = 0.004$ and 0.43 L/L [CI 0.33 to 0.53] versus 0.38 L/L [CI 0.25 to 0.51], paired *t* test $p = 0.020$). Platelets decreased at postinoculation ($206 \times 10^9/L$ [CI 172 to 241] versus $134 \times 10^9/L$ [CI 109 to 159], paired *t* test $p = 0.034$) and increased slightly compared to baseline at convalescence, but did not reach statistical significance ($206 \times 10^9/L$ [CI 172 to 241] versus $218 \times 10^9/L$ [range 211 to 226], paired *t* test $p = 0.28$). There were no statistically significant changes in biochemistry measurements between baseline and postinoculation or between baseline and convalescence (Table S2), although Participant 1 experienced a clinically relevant elevation in alanine transaminase in convalescence

(Day 17, 86 IU/L, $2.2 \times$ upper limit of normal (ULN)). In the *P. falciparum* group, there were no statistically significant changes in hematology or biochemistry measurements between baseline and postinoculation or between baseline and convalescence (Table S2). Participants 5, 6, and 7 each experienced elevated alanine transaminase measurements in convalescence (85 IU/L, $2.1 \times$ ULN; 73 IU/L, $1.8 \times$ ULN; 128 IU/L, $3.2 \times$ ULN, respectively).

Compared to the *P. falciparum* group, the hemoglobin decrease was greater from baseline to postinoculation in the *P. vivax* group (mean -7.2% [CI -13.4% to -1.1%] versus $+1.2\%$ [CI -1.3% to $+3.8\%$], unpaired *t* test $p = 0.003$). This was similar for hematocrit (-8.7% [CI -13.5% to -3.9%] versus -2.3% [CI -6.4% to $+1.9\%$], unpaired *t* test $p = 0.017$). Conversely, decrease in platelet count was greater from baseline to convalescence in the *P. falciparum* group compared to the *P. vivax* group (-33.5% [CI -69.5% to $+2.5\%$] versus $+5.9\%$ [CI -10.7% to $+22.6\%$], unpaired *t* test $p = 0.035$). There were no other differences between the groups in any other changes in hematology or biochemistry measurements.

36.4 Discussion

We demonstrate that medical imaging using PET and MRI are technically feasible and safe in experimental human *P. vivax* and *P. falciparum* infection and can define organ-specific physiological changes very early in disease. The increase in splenic volume and utilization of glucose on postinoculation imaging was most pronounced in the *P. vivax* group. Although the sample size is small, in the exploratory statistical comparisons, increase in splenic SUV was significantly greater in participants with *P. vivax* compared to those with *P. falciparum*. These findings suggest splenic tropism with both species early in the course of disease, but that it is significantly greater for *P. vivax* compared to *P. falciparum*.

Changes in splenic imaging metrics may be associated with either increased parasite or host activity, or a combination of both. This is consistent with nonhuman primate *Plasmodium coatneyi* infection studies, where increased splenic FDG uptake associated with accumulation of iRBCs in the red pulp and lymphoid hyperplasia have been reported [16]. *In vitro* studies have shown that iRBCs consume up to 100 times the amount of glucose than that consumed by uninfected erythrocytes [28] and that trophozoite uptake is up to 6-fold greater than that of ring stages [29]. While no *Plasmodium* studies have been performed to identify if this *in vitro* glucose consumption is sufficient to be detected by FDG PET, the principle of clinically detectable tracer uptake by pathogens has been demonstrated in bacteria [30]. Taken together, these findings may suggest that splenic FDG signal reflects iRBC accumulation within the spleen.

The spleen has been proposed as a site for accumulation of *P. vivax* infection [3, 6, 10, 31]. The extent to which this occurs in early infection and in clinical disease is not clear. Indirect evidence points to accumulation of non-phagocytosed *P. vivax* iRBCs in the spleen in acute malaria [4, 10], with supporting direct

evidence from case reports [6, 32]. Furthermore, early splenic rupture may occur more frequently in *P. vivax* compared to *P. falciparum* infection [33], which may suggest a greater tropism of this species for the spleen. In an *ex vivo* perfused spleen model, a subpopulation of *P. falciparum* ring stage parasites are retained in the red pulp of the spleen [34], hypothesized as mechanism to reduce acute host morbidity and prolong the duration of transmissible infection [35]. In a nonhuman primate *P. vivax* model, spleen-dependent expression of molecules mediating adhesion to human splenic fibroblasts has been described [36], suggesting the presence of a parasite phenotype that may favor splenic accumulation. Finally, very recent data suggest that immature reticulocytes accumulate in the human spleen providing a favorable niche for *P. vivax* accumulation [11]. We now show evidence supporting splenic tropism and splenic accumulation of *P. vivax* very early in infection.

Both *P. falciparum* [1, 37] and *P. vivax* [9, 38] have also been shown to infect the bone marrow. The lack of signal change in the vertebral bone marrow suggest that this tissue may have a lower parasite biomass in early infection, or alternatively, that parasites located in the bone marrow do not provoke as prominent host metabolic response. This is in keeping with a recent study suggesting that in acute vivax malaria, the parasite concentration in the bone marrow is, on average, no higher than that circulating in peripheral blood [38].

Similarly, while *P. falciparum* [1] and *P. vivax* [8] have been found in liver at autopsy, the absence of volume or tracer signal change in our study suggests that this may not be a site of accumulation early in infection. In our cohort, participants from both the *P. vivax* and *P. falciparum* groups experienced elevated transaminases in convalescence. Elevated transaminases following treatment have been previously described in experimental *P. vivax* [39], *P. falciparum* [40] infections, and in naturally acquired infection in non- or pauci-immune patients [39, 41] and are unlikely to be related to imaging, but rather may be related to inflammation and hemolysis [39].

The *P. vivax* group experienced a greater decrease in hematology indices from baseline to postinoculation compared to the *P. falciparum* group. The greater removal of RBCs from circulation previously described in *P. vivax* infection compared to *P. falciparum* infection is thought to occur in the spleen [42], which may also contribute to the imaging findings. Reduction in platelets in experimental malaria has been previously described and may relate to splenic pooling or more generalized platelet removal from circulation due to endothelial activation or parasite killing [43]. We and others have previously described the association between endothelial activation and thrombocytopenia in experimental malaria [44, 45], and labeled, auto-transfused platelets have been observed to undergo disseminated extra-splenic consumption in uncomplicated *P. falciparum* infection [46].

There were several limitations to this study. The population of the study was small, and statistical comparisons of baseline imaging to postinoculation imaging are necessarily of an exploratory nature, as there is limited power

to discriminate between groups. Secondly, while FDG is a readily available radiotracer, it is relatively nonspecific and is unable to differentiate between host and parasite activity. Advances in radiochemistry may permit the development of a radiotracer with sufficient specificity to selectively image iRBCs. Finally, we were unable to control for other variables that may have influenced the differences observed between the groups such as parasitemia at the time of imaging.

To date, the ability to localize the pathology of malaria in life has been limited, and direct evaluation of sequestration and organ-specific parasite tropism has relied upon animal models and postmortem studies. Using the IBSM model, we have demonstrated that the medical imaging techniques MRI and PET may be used to study human *P. vivax* and *P. falciparum* infection in life and observe early infection in a way not previously possible. The presence of alterations in splenic glucose uptake and volume soon after blood-stage infection compared to baseline suggests that these imaging techniques may be useful to localize disease. The differences observed between species consolidates the concept of species-specific tissue tropism, where *P. vivax* has a greater predilection for the spleen. Our findings suggest that the hypothesized endosplenic life cycle of *P. vivax* may be established soon after blood-stage infection.

Supporting Information

S1 Checklist. STROBE Checklist. <https://doi.org/10.1371/journal.pmed.1003567.s001>.

S1 Text. Methods. <https://doi.org/10.1371/journal.pmed.1003567.s002>.

S2 Text. Results. <https://doi.org/10.1371/journal.pmed.1003567.s003>.

S1 Table. Abdominal quantitative imaging metrics. <https://doi.org/10.1371/journal.pmed.1003567.s004>

S2 Table. Hematology and biochemistry parameters. <https://doi.org/10.1371/journal.pmed.1003567.s005>.

S1 Fig. Hematology and biochemistry parameters at baseline, postinoculation, and convalescence. (A) Hemoglobin (g/L), (B) Hematocrit (L/L), (C) Platelets ($10^9/L$), (D) Total Bilirubin (mmol/L), and (E) ALT (IU/L). <https://doi.org/10.1371/journal.pmed.1003567.s006>.

S1 Protocol. Study protocol. <https://doi.org/10.1371/journal.pmed.1003567.s007>.

Abbreviations

BMI:	body mass index
CI:	confidence interval
FDG:	biomimetic 18-F fluorodeoxyglucose
IBSM:	induced blood-stage malaria
iRBCs:	infected red blood cells
MRI:	magnetic resonance imaging
PET:	positron emission tomography
Pf:	<i>Plasmodium falciparum</i>

Pv: *Plasmodium vivax*
qPCR: quantitative polymerase chain reaction
ROI: region of interest
STROBE: STrengthening the Reporting of OBServational studies in Epidemiology
SUV: standardized uptake values
ULN: upper limit of normal

Disclosures and Conflict of Interest

This chapter was originally published as: Woodford, J., Gillman, A., Jenvey, P., Roberts, J., Woolley, S., Barber, B. E., et al. (2021). Positron emission tomography and magnetic resonance imaging in experimental human malaria to identify organ-specific changes in morphology and glucose metabolism: A prospective cohort study. *PLoS Med.*, **18**(5), e1003567, <https://doi.org/10.1371/journal.pmed.1003567>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: Raw imaging files are electronically tagged with personally identifiable information and cannot be shared publicly to protect the confidentiality of participants. All other data are within the chapter and its Supporting Information files.

Funding: This project was supported by a HIRF Seed Funding Grant, Metro North Hospital and Health Service (J.W) and by the Australian National Health and Medical Research Council (J.S.M #1135955, #1037304, #1132975, and N.M.A #1135820, 1098334). The clinical trials contributing participants were funded by the Australian National Health and Medical Research Council (J.S.M #1132975), the Bill and Melinda Gates Foundation (J.S.M OPP1111147) and the Global Health Innovative Technology Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

Acknowledgments: The authors would like to thank Louise Campbell and Peta Gray from HIRF for their help in coordinating the imaging of participants and Dr. Manoj Bhatt at the Department of Nuclear Medicine, RBWH for serving as the imaging medical monitor; Marita Prior at the Department of Radiology, RBWH for her help in coordinating the reporting of imaging; study staff at Q-Pharm Pty Ltd for their help in coordinating the IBSM participant exploratory study involvement; Medicines for Malaria Venture for encouraging investigator-initiated studies; and all participants for volunteering their time.

Conceptualization: John Woodford, Nicholas M. Anstey, James S. McCarthy; **Data curation:** John Woodford, Ashley Gillman.; **Formal analysis:** John Woodford, Ashley Gillman, Peter Jenvey, Jennie Roberts.; **Funding acquisition:** John Woodford, James S. McCarthy; **Investigation:** John Woodford, Stephen Woolley; **Methodology:** John Woodford, Ashley Gillman, Peter Jenvey; **Project administration:** John Woodford,

Stephen Woolley, Bridget E. Barber, Melissa Fernandez; Resources: Melissa Fernandez; Software: Ashley Gillman; Supervision: Bridget E. Barber, Stephen Rose, Paul Thomas, Nicholas M. Anstey, James S. McCarthy; Writing–original draft: John Woodford; Writing–review & editing: John Woodford, Ashley Gillman, Stephen Woolley, Bridget E. Barber, Melissa Fernandez, Stephen Rose, Paul Thomas, Nicholas M. Anstey, James S. McCarthy.

References

1. Marchiafava E, Bignami A. *On Summer-Autumnal Fever*. London: New Sydenham. Society. 1894.
2. Bass CC. An attempt to explain the greater pathogenicity of *Plasmodium falciparum* as compared with other species. *Am J Trop Med Hyg*. 1921; s1-1(1): 29–33.
3. Baird JK. Evidence and implications of mortality associated with acute *Plasmodium vivax* malaria. *Clin Microbiol Rev*. 2013; 26(1): 36–57.
4. Malleret B, Li A, Zhang R, Tan KSW, Suwanarusk R, Claser C, et al. *Plasmodium vivax*: restricted tropism and rapid remodeling of CD71-positive reticulocytes. *Blood*. 2015; 125(8): 1314–24.
5. Gruszczuk J, Kanjee U, Chan L-J, Menant S, Malleret B, Lim NTY, et al. Transferrin receptor 1 is a reticulocyte-specific receptor for *Plasmodium vivax*. *Science*. 2018; 359(6371): 48–55.
6. Machado Siqueira A, Lopes Magalhaes BM, Cardoso Melo G, Ferrer M, Castillo P, Martin-Jaular L, et al. Spleen rupture in a case of untreated *Plasmodium vivax* infection. *PLoS Negl Trop Dis*. 2012; 6(12): e1934.
7. Kho S, Qotrunnada L, Leonardo L, Andries B, Wardani P, Fricot A, et al. Hidden biomass of intact malaria parasites in the human spleen. *N Engl J Med*. 2021; 384: 2067–9.
8. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, et al. Postmortem characterization of patients with clinical diagnosis of *Plasmodium vivax* malaria: to what extent does this parasite kill? *Clin Infect Dis*. 2012; 55(8): e67–74.
9. Obaldia N 3rd, Meibalan E, Sa JM, Ma S, Clark MA, Mejia P, et al. Bone marrow is a major parasite reservoir in *Plasmodium vivax* infection. *MBio*. 2018; 9(3): e00625–18.
10. Barber BE, William T, Grigg MJ, Parameswaran U, Piers KA, Price RN, et al. Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. *PLoS Pathog*. 2015; 11(1): e1004558.
11. Kho S, Qotrunnada L, Leonardo L, Andries B, Wardani P, Fricot A, et al. Evaluation of splenic accumulation and colocalization of immature reticulocytes and *Plasmodium vivax* in asymptomatic malaria: a prospective human splenectomy study. *PLoS Med*. 2021; 18(5): e1003632.
12. Seydel KB, Kampondeni SD, Valim C, Potchen MJ, Milner DA, Muwalo FW, et al. Brain swelling and death in children with cerebral malaria. *N Engl J Med*. 2015; 372(12): 1126–37.
13. Laothamatas J, Sammet CL, Golay X, Van Cauteren M, Lekprasert V, Tangpukdee N, et al. Transient lesion in the splenium of the corpus callosum in acute uncomplicated falciparum malaria. *Am J Trop Med Hyg*. 2014; 90(6): 1117–23.

14. Frolich AM, Tober-Lau P, Schonfeld M, Brehm TT, Kurth F, Vinnemeier CD, et al. Brain magnetic resonance imaging in imported malaria. *Malar J*. 2019; 18(1): 74.
15. Sugiyama M, Ikeda E, Kawai S, Higuchi T, Zhang H, Khan N, et al. Cerebral metabolic reduction in severe malaria: fluorodeoxyglucose-positron emission tomography imaging in a primate model of severe human malaria with cerebral involvement. *Am J Trop Med Hyg*. 2004; 71(5): 542–5.
16. Kawai S, Ikeda E, Sugiyama M, Matsumoto J, Higuchi T, Zhang H, et al. Enhancement of splenic glucose metabolism during acute malarial infection: correlation of findings of FDG-PET imaging with pathological changes in a primate model of severe human malaria. *Am J Trop Med Hyg*. 2006; 74(3): 353–60.
17. Jeph S, Thakur K, Shamim S, Aggarwal A. Malaria masquerading as relapse of Hodgkin's lymphoma on contrast enhanced 18 F-fluorodeoxyglucose positron emission tomography/computed tomography: a diagnostic dilemma. *Indian J Nucl Med*. 2014; 29: 102–4.
18. Rockett RJ, Tozer SJ, Peatey C, Bialasiewicz S, Whiley DM, Nissen MD, et al. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of *Plasmodium falciparum* load in experimentally infected human volunteers. *Malar J*. 2011; 10: 48.
19. McCarthy JS, Sekuloski S, Griffin PM, Elliott S, Douglas N, Peatey C, et al. A pilot randomised trial of induced blood-stage *Plasmodium falciparum* infections in healthy volunteers for testing efficacy of new antimalarial drugs. *PLoS ONE*. 2011; 6(8): e21914.
20. Griffin P, Pasay C, Elliott S, Sekuloski S, Sikulu M, Hugo L, et al. Safety and reproducibility of a clinical trial system using induced blood stage *Plasmodium vivax* infection and its potential as a model to evaluate malaria transmission. *PLoS Negl Trop Dis*. 2016; 10(12): e0005139.
21. Karunanithi S, Soundararajan R, Sharma P, Naswa N, Bal C, Kumar R. Spectrum of physiologic and pathologic skeletal muscle (18)F-FDG uptake on PET/CT. *AJR Am J Roentgenol*. 2015; 205(2): W141–9.
22. Kumar P, Patel CD, Singla S, Malhotra A. Effect of duration of fasting and diet on the myocardial uptake of F-18-2-fluoro-2-deoxyglucose (F-18 FDG) at rest. *Indian J Nucl Med*. 2014; 29(3): 140–5.
23. Lodge MA. Repeatability of SUV in oncologic (18)F-FDG PET. *J Nucl Med*. 2017; 58(4): 523–32.
24. Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. *J Nucl Med*. 2004; 45(5): 784–8.
25. Gheysens O, Postnov A, Deroose CM, Vandermeulen C, de Hoon J, Declercq R, et al. Quantification, variability, and reproducibility of basal skeletal muscle glucose uptake in healthy humans using 18F-FDG PET/CT. *J Nucl Med*. 2015; 56(10): 1520–6.
26. Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, et al. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel *Plasmodium falciparum* ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. *Lancet Infect Dis*. 2020; 20(8): 964–975.

27. Collins KA, Wang CY, Adams M, Mitchell H, Robinson GJ, Rampton M, et al. A *Plasmodium vivax* experimental human infection model for evaluating efficacy of interventions. *J Clin Invest*. 2020; 130(6): 2920–2927.
28. Roth E Jr., *Plasmodium falciparum* carbohydrate metabolism: a connection between host cell and parasite. *Blood Cells*. 1990; 16(2–3): 453–60; discussion 61–6.
29. Shivapurkar R, Hingamire T, Kulkarni AS, Rajamohanan PR, Reddy DS, Shanmugam D. Evaluating antimalarial efficacy by tracking glycolysis in *Plasmodium falciparum* using NMR spectroscopy. *Sci Rep*. 2018; 8(1): 18076.
30. Heuker M, Sijbesma JWA, Aguilar Suarez R, de Jong JR, Boersma HH, Luurtsema G, et al. *In vitro* imaging of bacteria using (18)F-fluorodeoxyglucose micro positron emission tomography. *Sci Rep*. 2017; 7(1): 4973.
31. Adams WL. The role of the spleen in infectious diseases. *Pac Med J*. 1897; 40(227).
32. Lubitz JM. Pathology of rupture of the spleen in acute vivax malaria. *Am J Pathol*. 1948; 24(3): 724.
33. Imbert P, Rapp C, Buffet PA. Pathological rupture of the spleen in malaria: analysis of 55 cases (1958–2008). *Travel Med Infect Dis*. 2009; 7(3): 147–59.
34. Safeukui I, Correas JM, Brousse V, Hirt D, Deplaine G, Mule S, et al. Retention of *Plasmodium falciparum* ring-infected erythrocytes in the slow, open microcirculation of the human spleen. *Blood*. 2008; 112(6): 2520–8.
35. Buffet PA, Safeukui I, Milon G, Mercereau-Puijalon O, David PH. Retention of erythrocytes in the spleen: a double-edged process in human malaria. *Curr Opin Hematol*. 2009; 16(3): 157–64.
36. Fernandez-Becerra C, Bernabeu M, Castellanos A, Correa BR, Obadia T, Ramirez M, et al. *Plasmodium vivax* spleen-dependent genes encode antigens associated with cytoadhesion and clinical protection. *Proc Natl Acad Sci USA*. 2020; 117(23): 13056–65.
37. Joice R, Nilsson SK, Montgomery J, Dankwa S, Egan E, Morahan B, et al. *Plasmodium falciparum* transmission stages accumulate in the human bone marrow. *Sci Transl Med*. 2014; 6(244): 244re5.
38. Brito MAM, Baro B, Raiol TC, Ayllon-Hermida A, Safe IP, Deroost K, et al. Morphological and transcriptional changes in human bone marrow during natural *Plasmodium vivax* malaria infections. *J Infect Dis*. 2020; June 18: jiaa177. doi: 10.1093/infdis/jiaa177.
39. Odedra A, Webb L, Marquart L, Britton L, Chalon S, Moehrle J, et al. Liver function test abnormalities in experimental and clinical *Plasmodium vivax* infection. *Am J Trop Med Hyg*. 2020; 103(5): 1910–7.
40. Chughlay FM, Akakpo S, Odedra A, Csermak-Renner K, Djeriou E, Winnips C, et al. Liver enzyme elevations in *Plasmodium falciparum* volunteer infection studies: findings and recommendations. *Am J Trop Med Hyg*. 2020; 103(1): 378–93.
41. Woodford J, Shanks GD, Griffin P, Chalon S, McCarthy JS. The dynamics of liver function test abnormalities after malaria infection: a retrospective observational study. *Am J Trop Med Hyg*. 2018; 98(4): 1113–9.
42. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of *Plasmodium vivax* malaria. *Malar J*. 2012; 11: 135.

43. Kho S, Barber BE, Johar E, Andries B, Poespoprodjo JR, Kenangalem E, et al. Platelets kill circulating parasites of all major *Plasmodium* species in human malaria. *Blood*. 2018; 132(12): 1332–44.
44. Woodford J, Yeo TW, Piera KA, Butler K, Weinberg JB, McCarthy JS, et al. Early endothelial activation precedes glycocalyx degradation and microvascular dysfunction in experimentally induced *Plasmodium falciparum* and *Plasmodium vivax* infection. *Infect Immun*. 2020; 88(5): e00895–19.
45. de Mast Q, Groot E, Lenting PJ, de Groot PG, McCall M, Sauerwein RW, et al. Thrombocytopenia and release of activated von Willebrand Factor during early *Plasmodium falciparum* malaria. *J Infect Dis*. 2007; 196(4): 622–8.
46. Karanikas G, Zedwitz-Liebenstein K, Eidherr H, Schuetz M, Sauerman R, Dudczak R, et al. Platelet kinetics and scintigraphic imaging in thrombocytopenic malaria patients. *Thromb Haemost*. 2004; 91(3): 553–7.

Chapter 37

Chemical Tools for Decoding Redox Signaling at the Host–Microbe Interface

Elizabeth M. Gordon, MSc,^{a,b} and Stavroula K. Hatzios, PhD^{a,b,c}

^a*Department of Molecular, Cellular, and Developmental Biology,
Yale University, New Haven, Connecticut, USA*

^b*Microbial Sciences Institute, Yale University, West Haven, Connecticut, USA*

^c*Department of Chemistry, Yale University, New Haven, Connecticut, USA*

stavroula.hatzios@yale.edu

Keywords: cysteine, host-microbe interface, isotopic tandem orthogonal proteolysis-activity-based protein profiling (isoTOP-ABPP), liquid chromatography (LC), mass spectrometry (MS), NADPH oxidases (NOX), oxidation (ox), oxidative posttranslational modifications (OxiPTMs), proteome, reactive nitrogen species (RNS), reactive oxygen species (ROS), redox signaling

37.1 Introduction

Host cells deploy a variety of chemically reactive small molecules, such as reactive oxygen species (ROS) and reactive nitrogen species (RNS), to defend themselves against invading pathogens. These molecules are primarily known for their bactericidal activity; however, oxidants like hydrogen peroxide and nitric oxide can also function as signaling molecules that posttranslationally modify redox-sensitive amino acids under non-pathological conditions [1, 2]. Mounting evidence suggests that these oxidants represent an important line of communication between bacterial and host cells. Although it has historically been difficult to detect such redox-signaling events, recently developed chemical proteomic techniques have made it possible to resolve precise oxidation sites within complex proteomes. Here, we focus specifically on the role of ROS as chemical messengers at the

host–microbe interface and highlight new technologies for decoding ROS-mediated signaling. Given that ROS generation is an important factor in many infection-associated pathologies [3], a deeper understanding of how these molecules influence cell signaling during infection could have important implications for human health and disease.

37.2 How Are ROS Generated at the Host–Microbe Interface?

Redox signaling—the regulation of cell signaling by oxidative posttranslational modifications (OxiPTMs)—modulates diverse cellular processes including cell division, metabolism, and antioxidant defense [2]. In mammalian systems, redox signaling is typically activated by ROS produced in response to external stimuli such as growth factors, cytokines, and microbial contact with epithelial barriers [1, 2]. Hydrogen peroxide and superoxide are considered the primary agents of ROS-mediated signaling. NADPH oxidases (NOX) synthesize hydrogen peroxide and superoxide in response to extracellular signals [2]. NOX2, an isoform expressed by phagocytic cells, catalyzes the oxidative burst that is used to eliminate invading pathogens. Other NOX isoforms are expressed by different cell types and produce non-pathological levels of ROS that also contribute to mucosal defense [2].

As in mammalian cells, numerous biological processes contribute to ROS production in bacteria. The most common sources of bacterial ROS are cellular respiration and the autoxidation of flavoproteins [1, 4]. A recently discovered class of NOX-like enzymes in bacteria may also catalyze ROS formation [5]. In addition, certain commensal and pathogenic bacteria excrete millimolar levels of hydrogen peroxide generated by specialized oxidases [6, 7]. Pathogens can also secrete redox-active metabolites that cause damage to epithelial tissues [8], suggesting that microbe-derived ROS may also regulate redox signaling in the host.

37.3 How Do ROS Modulate Cell Signaling at the Posttranslational Level?

Redox signaling occurs through the posttranslational oxidation of proteins containing redox-sensitive amino acids (Fig. 37.1). OxiPTMs can significantly alter protein structure, function, and/or localization. Cysteine residues are arguably the most common targets of OxiPTMs [1]. At physiological pH, cysteine thiols (R-SH) with particularly low pK_a s exist as nucleophilic thiolate anions (R-S⁻). Thiolates can react with ROS to yield a variety of OxiPTMs, including sulfenic (R-SOH), sulfinic (R-SO₂H), and sulfonic (R-SO₃H) acids, as well as disulfides (RS-SR). Other amino acids, like histidine, methionine, and tyrosine, are also susceptible to oxidation under physiological conditions [1, 9]. Given the variety of amino acids that can

be targeted by ROS, and the chemical diversity of the resulting OxiPTMs, specialized methods are required to detect these modifications. Here, we focus on mass spectrometry (MS)-based proteomic techniques for mapping cysteine OxiPTMs that contribute to redox signaling.




Figure 37.1 Redox signaling at the host-microbe interface. ROS produced by bacteria, host epithelial cells, and migratory immune cells can alter cell signaling via the site-specific Ox of proteins containing redox-sensitive cysteines. *Abbreviations:* Ox, oxidation; ROS, reactive oxygen species.

37.4 Why Are Chemical Approaches Useful for Detecting Redox Signaling?

Historically, transcriptional profiling and targeted biochemical analyses have been used to identify oxidation-inducible genes and redox-sensitive proteins. For example, quantitative thiol-disulfide titrations and targeted mutational analyses revealed that the formation of a disulfide bond in OxyR, a widely conserved bacterial transcription factor, induces the transcription of antioxidant enzymes under conditions of oxidative stress [10]. While similar analyses have been valuable for characterizing specific mechanisms of redox-regulated signaling in bacterial and host cells [9, 11], they are not easily scalable to the entire proteome. In addition, because OxiPTMs occur posttranslationally, and many are short-lived, they cannot be directly detected using conventional profiling

approaches. Recently developed chemical proteomic techniques complement traditional methods for uncovering redox-sensitive proteins by enabling the systematic identification of cysteines that are oxidized by ROS.

37.4.1 Chemical Proteomic Techniques for Identifying Oxidized Cysteines

Chemical proteomic methods rely on small-molecule, activity-based probes to facilitate the detection of reactive amino acids within a whole proteome. Probes that selectively label nucleophilic cysteine thiols can be used to globally profile changes in cysteine reactivity due to OxiPTMs, which inhibit probe labeling. By using liquid chromatography (LC)–MS to quantify the relative abundance of probe-labeled peptides under different sample conditions (e.g., cells grown in the presence or absence of oxidative stress), chemical proteomic techniques like isotopic tandem orthogonal proteolysis–activity-based protein profiling (isoTOP–ABPP) [12] and OxICAT [13] can resolve precise sites of cysteine oxidation. For example, in isoTOP–ABPP, reactive cysteines are labeled with a thiol-reactive iodoacetamide-alkyne probe, which is subsequently coupled to an isotopically labeled biotin-azide tag with a cleavable linker via copper-catalyzed azide–alkyne cycloaddition (CuAAC; AKA click chemistry) (Fig. 37.2). Probe-labeled proteins are enriched using streptavidin beads and digested with trypsin. The remaining probe-labeled peptides are eluted from the beads via linker cleavage and quantified by LC/LC–MS/MS. The use of a unique isotopic tag for each sample enables the relative quantification of peptide abundance. Similarly, OxICAT employs isotope-coded iodoacetamide probes with cleavable linkers to detect cysteine OxiPTMs, but incorporates a reduction step into the sample processing workflow to distinguish reduced versus oxidized cysteines within a single sample [13]. First, the proteome is denatured and treated with an isotopically “light” probe to irreversibly label all reduced protein thiols; the sample is then incubated with a reducing agent to permit labeling of reversibly oxidized cysteines (e.g., disulfides) with an isotopically “heavy” probe. Following digestion and purification of the probe-labeled peptides, LC–MS/MS analysis is used to calculate the relative oxidation of individual cysteines within the proteome.

The indirect detection of oxidized cysteines using isoTOP–ABPP or OxICAT offers an unbiased approach to identifying OxiPTMs. Because these methods quantify proteome-wide changes in cysteine reactivity, they can detect a wide range of thiol-based modifications that inhibit probe labeling, irrespective of the type of modification. Methods for the direct detection of proteins containing specific classes of oxidized cysteines have also been developed [14]. These approaches rely on chemotype-specific probes that selectively label distinct classes of OxiPTMs (e.g., alkyne-functionalized dimedone probes for the detection of sulfenic acids and 2-nitroso benzoic acid derivatives for the detection of sulfinic acids [14, 15]), thereby enabling the direct enrichment and MS-based identification of oxidized proteins. The expanding toolkit for profiling cysteine OxiPTMs, which also

includes cell-permeable, photoactivatable probes for studies of transient oxidative modifications in living cells [16], provides new opportunities to investigate dynamic redox signaling in physiological systems.

+ Oxidative Stress




Figure 37.2 Globally profiling cysteine reactivity at the host–microbe interface using isoTOP–ABPP. Nucleophilic cysteines in each sample (e.g., cells treated with or without oxidative stress) are labeled with a thiol-reactive probe, which is then conjugated to an enrichment tag containing an isotopically labeled linker via click chemistry. Following enrichment and trypsin digestion of probe-labeled proteins, the relative abundance of probe-labeled peptides in each sample is quantified by MS. *Abbreviations:* isoTOP–ABPP, isotopic tandem orthogonal proteolysis–activity-based protein profiling; LC, liquid chromatography; MS, mass spectrometry; Ox, oxidation.

37.4.2 Mapping Oxidized Cysteines in Bacterial and Host Cells

To date, MS-based approaches for identifying oxidized cysteines have primarily been used to study cells exposed to chemical oxidants *in vitro*. For example, both isoTOP–ABPP and OxiCAT have uncovered redox-sensitive cysteines in hundreds of bacterial proteins under conditions of oxidative stress [13, 17]. Several of the identified proteins, such as OxyR, contain redox-sensitive thiols with known roles in antioxidant defense, validating the ability of these approaches to detect functionally significant OxiPTMs within the proteome. Notably, many other proteins that were found to contain oxidized cysteines mediate critical processes beyond the antioxidant response, such as bacterial metabolism and DNA replication, suggesting that ROS may play a much broader role in regulating bacterial physiology than previously appreciated. Chemical proteomic tools have more recently been applied to identify cysteines oxidized by physiological sources of ROS. For example, OxiCAT has been used to detect oxidized thiols in the proteome of phagocytosed *Escherichia coli* [18]. In addition, efforts to profile oxidized cysteines in the mucosa of monocolonized mice promise to expand our understanding of symbiotic interactions mediated by bacterial- and host-derived ROS *in vivo* [19].

37.5 Future Directions

ROS produced at the host–microbe interface are well positioned to modulate signaling pathways that underlie symbiosis or pathogenesis. Prior studies of bacteria exposed to oxidative stress *in vitro* have revealed hundreds of proteins that are specifically targeted by ROS [13, 17]. Dissecting the contributions of protein oxidation to signal transduction in physiologically relevant systems, such as animal models of infection, will be necessary to understand the role of OxiPTMs in health and disease.

Many microbe-associated pathologies, such as gastrointestinal cancers, colitis, and peptic ulcers, have been linked to oxidative stress [3]. Oxidative stress can induce DNA damage and genomic instability, but far less is known about the role of protein oxidation in infection. Thus, many questions regarding how OxiPTMs influence disease progression remain unanswered: Does dysbiosis give rise to OxiPTMs that corrupt host cell signaling? Could novel therapeutics targeting redox-sensitive proteins ameliorate disease? Conversely, can mutualistic bacteria trigger redox-signaling pathways that confer health benefits to the host?

Chemical profiling technologies coupled with chemotype-specific probes should help establish the contribution of specific OxiPTMs to host–microbe interactions. Increasingly sophisticated infection models, such as germ-free animals and 3D organoids, will also facilitate the functional analysis of redox signaling in complex systems. A recent quantitative characterization of the mouse cysteine redox proteome demonstrates the feasibility of mapping tissue-specific oxidation events *in vivo* [20]. Harnessing these technologies to detect oxidative crosstalk at the host–microbe interface could uncover a vast network of ROS-mediated signaling pathways that shape bacterial and host physiology.

Abbreviations

isoTOP-ABPP:	isotopic tandem orthogonal proteolysis-activity based protein profiling
LC:	liquid chromatography
MS:	mass spectrometry
NOX:	NAPDH oxidases
ox:	oxidation
OxiPTMs:	oxidative post-translational modifications
RNS:	reactive nitrogen species
ROS:	reactive oxygen species

Disclosures and Conflict of Interest

This chapter was originally published as: Gordon, E. M., Hatzios, S. K. (2020). Chemical tools for decoding redox signaling at the host–microbe interface. *PLoS Pathog.*, 16(12), e1009070, <https://doi.org/10.1371/journal.ppat.1009070>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Funding: The authors would like to acknowledge support from the following grants: NIH grant R35GM137952 (SKH), an Arnold and Mabel Beckman Young Investigator Award (SKH), American Cancer Society Institutional Research Grant #IRG 17-172-57 (SKH), a Pilot Grant from the Yale Cancer Center (SKH), a Gruber Science Fellowship from Yale University (EMG), and NIH Chemical Biology Training Grant T32 GM067543 (EMG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

Acknowledgments: The authors thank the members of the Hatzios lab for providing feedback on the chapter.

References

1. Paulsen CE, Carroll KS. Cysteine-mediated redox signaling: chemistry, biology, and tools for discovery. *Chem Rev.* 2013; 113(7): 4633–79.
2. Lambeth JD, Neish AS. Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. *Annu Rev Pathol.* 2014; 9(1): 119–45.
3. Pérez S, Taléns-Visconti R, Rius-Pérez S, Finamor I, Sastre J. Redox signaling in the gastrointestinal tract. *Free Radic Biol Med.* 2017; 104: 75–103.
4. Imlay JA. The molecular mechanisms and physiological consequences of oxidative stress: lessons from a model bacterium. *Nat Rev Microbiol.* 2013; 11(7): 443–54.
5. Hajjar C, Cherrier MV, Dias Mirandela G, Petit-Hartlein I, Stasia MJ, Fontecilla-Camps JC, et al. The NOX family of proteins is also present in bacteria. *mBio.* 2017; 8(6): e01487–17.
6. Echlin H, Frank MW, Iverson A, Chang T-C, Johnson MDL, Rock CO, et al. Pyruvate oxidase as a critical link between metabolism and capsule biosynthesis in *Streptococcus pneumoniae*. *PLoS Pathog.* 2016; 12(10): e1005951.
7. Condon S. Responses of lactic acid bacteria to oxygen. *FEMS Microbiol Rev.* 1987; 3(3): 269–80.
8. Rada B, Leto TL. Pyocyanin effects on respiratory epithelium: relevance in *Pseudomonas aeruginosa* airway infections. *Trends Microbiol.* 2013; 21(2): 73–81.
9. Imlay JA. Transcription factors that defend bacteria against reactive oxygen species. *Annu Rev Microbiol.* 2015; 69: 93–108.
10. Zheng M, Åslund F, Storz G. Activation of the OxyR transcription factor by reversible disulfide bond formation. *Science.* 1998; 279(5357): 1718.
11. Jones RM, Neish AS. Redox signaling mediated by the gut microbiota. *Free Radic Biol Med.* 2017; 105: 41–7.
12. Weerapana E, Wang C, Simon GM, Richter F, Khare S, Dillon MBD, et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. *Nature.* 2010; 468(7325): 790–5.
13. Leichert LI, Gehrke F, Gudiseva HV, Blackwell T, Ilbert M, Walker AK, et al. Quantifying changes in the thiol redox proteome upon oxidative stress *in vivo*. *PNAS.* 2008; 105(24): 8197.

14. Abo M, Weerapana E. Chemical probes for redox signaling and oxidative stress. *Antioxid Redox Signal*. 2019; 30(10): 1369–86.
15. Yang J, Gupta V, Carroll KS, Liebler DC. Site-specific mapping and quantification of protein S-sulphenylation in cells. *Nat Commun*. 2014; 5(1): 4776.
16. Abo M, Weerapana E. A caged electrophilic probe for global analysis of cysteine reactivity in living cells. *J Am Chem Soc*. 2015; 137(22): 7087–90.
17. Deng X, Weerapana E, Ulanovskaya O, Sun F, Liang H, Ji Q, et al. Proteome-wide quantification and characterization of oxidation-sensitive cysteines in pathogenic bacteria. *Cell Host Microbe*. 2013; 13: 358–70.
18. Xie K, Bunse C, Marcus K, Leichert LI. Quantifying changes in the bacterial thiol redox proteome during host-pathogen interaction. *Redox Biol*. 2019; 21: 101087.
19. Matthews JD, Reedy AR, Wu H, Hinrichs BH, Darby TM, Addis C, et al. Proteomic analysis of microbial induced redox-dependent intestinal signaling. *Redox Biol*. 2019; 20: 526–32.
20. Xiao H, Jedrychowski MP, Schweppe DK, Huttlin EL, Yu Q, Heppner DE, et al. A quantitative tissue-specific landscape of protein redox regulation during aging. *Cell*. 2020; 180(5): 968–83.e24.

Chapter 38

The CRISPR Toolbox in Medical Mycology: State of the Art and Perspectives

Florent Morio, PhD,^{a,b} Lisa Lombardi, PhD,^a and Geraldine Butler, PhD^a

^a*School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin, Ireland*

^b*Département de Parasitologie et Mycologie Médicale, Université de Nantes, Nantes, France*

geraldine.butler@ucd.ie

Keywords: antimicrobial resistance, *Aspergillus fumigatus* (Af), *Ashbya gossypii* (Ag), *Aspergillus* spp., autonomously replicating sequence (ARS), *Candida albicans* (Ca), *Candida neoformans* (Cn), *Candida parapsilosis* (Cp), *Candida* spp., clustered regularly interspaced short palindromic repeats (CRISPR), CRISPR-mediated marker excision (CRIME), CRISPR-RNA (crRNA), *Cryptococcus neoformans* (Cn), *Cryptococcus* spp., double-stranded break, downstream (DW), episomal plasmids, fungal diseases, finding low abundance sequences by hybridization (FLASH), genome editing, hammerhead (HH), homology-directed repair (HDR), human hepatitis delta virus (HDV), hygromycin marker, loss of heterozygosity (LOH), *Meyerozyma guilliermondii* (Mg), microhomology-mediated end joining (MMEJ), nonhomologous end joining (NHEJ), Nourseothricin resistant (NTC R), Nourseothricin susceptible (NTC S), open reading frame (ORF), protospacer adjacent motif (PAM), pyrithiamine resistance cassette (PTRA), repair template (RT), ribozymes, RNA-Cas9 protein complex (RNP), *Saccharomyces cerevisiae* (Sc), sequencing, single-guide RNA (sgRNA), specific highly sensitive enzymatic reporter UnLOCKing (SHERLOCK), trans-activating RNA (tracrRNA), transient CRISPR-Cas9 coupled with electroporation (TRACE), trans-activating crRNA (tracrRNA), upstream (UP), your favorite gene (*YFG*)

38.1 Introduction

The most common fungal diseases are superficial infections, affecting almost two billion people worldwide [1]. Despite being much less common, invasive fungal infections are nonetheless associated with high mortality rates. Fungal pathogens are therefore increasingly recognized as a major human threat. According to

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

current (likely under-) estimates, 1.6 million people die every year from invasive diseases caused by different fungal species (mainly *Cryptococcus*, *Candida*, *Aspergillus*, and *Pneumocystis*), almost the same as from tuberculosis [2]. We are also currently facing a concerning escalation of antifungal resistance, with reports of azole-resistant *Aspergillus fumigatus* and the spread of multidrug-resistant *Candida auris* [3, 4]. In this context, there is an urgent need for efficient genetic manipulation tools to further our understanding of the biology and pathophysiology of fungal pathogens and to decipher drug resistance mechanisms, which are critical for developing novel therapeutic strategies. However, genetic manipulation has often been time-consuming and cumbersome in fungi, particularly in species with diploid genomes that lack a sexual cycle. A low efficiency of transformation and/or homologous recombination, the absence of natural plasmids, and the lack of cloning vectors or the limited number of dominant markers available for selection are additional factors hampering this process [5, 6].

Over the last decade, the groundbreaking discovery of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 revolutionized genome editing [7]. Normally involved in bacterial adaptive immunity against bacteriophages, the discovery that Cas9 endonuclease could not only target infecting viral DNA but virtually any DNA paved the road for the application of this technique to eukaryotic cells, including mammalian cells, plants, and fungi (including the model yeast *Saccharomyces cerevisiae*) [8]. In this chapter, we describe the state of the art of CRISPR-Cas9 applications in four major human fungal pathogens, *Candida* spp., *Cryptococcus neoformans*, *A. fumigatus*, and Mucorales, dissecting the customized strategies for the delivery of functional CRISPR-Cas9 elements. Moreover, we discuss the most promising future perspectives and their further development that will allow mycologists to face the challenge of fungal pathogenesis.

38.2 The CRISPR-Cas9 Toolbox: How Does It Work?

The potential of CRISPR-associated protein Cas9 for genome editing was first reported in 2012 [7, 9]. Cas9, a type II RNA-guided endonuclease, introduces a double-stranded break (DSB) 3 bp upstream of a protospacer adjacent motif (PAM, NGG for *Streptococcus pyogenes* Cas9). Cas9 is directed to the site by a single-guide RNA (sgRNA), encompassing both target specificity and Cas9 binding activity—mediated in the native bacterial system by the CRISPR-RNA (crRNA) and the *trans*-activating crRNA (tracrRNA), respectively. The DSB can be repaired by nonhomologous end joining (NHEJ), usually resulting in insertions or deletions leading to frame shift of the reading frame and premature stop codons. Microhomology-mediated end joining (MMEJ) is an alternative, also error-prone repair pathway requiring short homology regions (2–40 bp) [10]. If a donor template with appropriate homology regions is available (e.g. the second allele in diploid genomes, or exogenous DNA), repair may occur by homology-directed repair (HDR). Precise editing exploits HDR machinery by providing the cells

with donor DNAs harboring the intended mutation flanked by homology arms. Although conventional methods can also be used to introduce mutations by HDR, DSBs significantly increase the rate of these events by up to 4,000-fold [11–15]. As a result, introducing Cas9-mediated DSBs opens up the possibility to exploit HDR even in species in which this pathway is normally not efficient.

38.3 Tips and Tricks of CRISPR–Cas9 in Fungi

Expression of *CAS9*, codon optimization, and nuclear localization of the protein are crucial for the success of CRISPR–Cas9 gene editing. In addition, the expression of a sgRNA suitable for interaction with Cas9 is pivotal. Not surprisingly, there is no one method for introducing these elements that is suitable for every fungal species. Firstly, whereas the versions of Cas9 with codons optimized for human cells work in *C. neoformans* and *A. fumigatus* [16, 17], further modifications are required in many *Candida* species, in which CTG is translated as serine [18]. The choice of the regulatory elements to drive expression of *CAS9* and sgRNA is another potential concern. Despite some flexibility among closely related species, species-specific promoters are usually more effective [19, 20]. The sgRNA is usually expressed from an RNA pol III promoter because it is a nucleus-localized noncoding RNA molecule. Although RNA pol III promoters of some species have been characterized (e.g., *SNR52* promoter in *C. albicans*), mining a genome to find de novo RNA pol III promoters is a cumbersome process of trial and error, which can only be partially streamlined if transcriptome data are available to guide the search. For this reason, suitable RNA pol II promoters can be used instead, provided that the sgRNA molecule is flanked by RNA elements (typically ribozymes or tRNAs) that will mediate the removal of the 5' cap and the 3' poly(A) tail [21].

An additional level of complexity is introduced by the delivery system chosen. Unlike *S. cerevisiae*, no natural plasmids are found in fungal pathogens, and circular vectors are not always stable (e.g., most vectors need to be linearized before being transformed into *C. albicans* and *C. neoformans*). In *Candida glabrata*, *Candida parapsilosis*, and *A. fumigatus*, the availability of autonomously replicating sequences allows the use of episomal plasmids [22, 23]. In Mucorales, by contrast, plasmids usually do not integrate, and when they do, they may lead to unexpected genomic changes or recircularization [24]. One way to get around these problems is to use *in vitro* assembled ribonucleoprotein complexes (RNP) [25–28]. In this approach, cells are directly transformed with the Cas9–sgRNA complex, thus bypassing the need for any species-specific expression or delivery tailoring. However, the higher cost makes this approach unsuitable for large-scale efforts.

Regardless of the way that the DSB is induced, the outcome depends on the repair strategy. Fungal species differ intrinsically in DNA-repair mechanisms. *C. albicans* and *C. parapsilosis*, like *S. cerevisiae*, rely mostly on HDR, whereas *Candida lusitanae*, *A. fumigatus*, and Mucorales rely mostly

on NHEJ], and *Candida glabrata* and *Candida tropicalis* use both HDR and NHEJ [16, 20, 29–31]. Disrupting NHEJ-related genes increases HDR efficiency in some species (e.g., *Ku70/Lig4* deletion increases efficiency from 25% to 81% in *C. lusitaniae* haploid cells) [20]. However, this strategy is not ideal, because NHEJ-defective strains may display reduced virulence [17]. Even in species with high levels of HDR, CRISPR–Cas9 increases the efficiency of this process so much that shorter sequences can be used to direct homologous recombination. As an example, homology arms as short as 50 bp arms resulted in 61% efficiency for deleting *ADE2* in *C. albicans* [30], and homology arms of 30 bp resulted in almost a 100% gene-editing efficiency in *Candida parapsilosis* [29]. Very often *ADE2*, a gene involved in the adenine biosynthetic pathway, is selected as proof of principle target when implementing CRISPR–Cas9 in a new species. In fact, *ade2* mutants are easy to screen because the interruption of the pathway results in the accumulation of a red to pink pigment that colors the colonies.

Finally, general recommendations for guide design to ensure efficiency and reduce off-target effects also apply to these fungi [32]. Numerous guide-design software programs are now available, some allowing uploading of custom genomes, such as EUPaGDT (<http://grna.ctegd.uga.edu/>) or CHOPCHOP (<http://chopchop.cbu.uib.no/>).

38.4 Current Methods Available for Genome Editing in Fungal Pathogens

Figures 38.1 to 38.3 illustrate representative methods for CRISPR-genome editing developed for the fungal pathogens discussed below.

38.4.1 *Candida* Species

In 2015, Vyas and colleagues reported the first CRISPR–Cas9 method in *C. albicans* [18], which relied on the integration of *CAS9* and sgRNA either as a single cassette at the *ENO1* locus (solo system) or as two separate cassettes at the *ENO1* and *RP10* loci, respectively (duet system). Transformed strains were selected using Nourseothricin, due to the presence of the *NAT* gene in the cassette(s). Expression of a CTG-codon-optimized *CAS9* is driven from the promoter at the integration site, whereas the sgRNA is expressed from the RNA pol III promoter *CaSNR52*. HDR-mediated gene editing was achieved by using a donor DNA with 50 bp homology arms to introduce premature stop codons in the *ADE2* gene, with variable efficiencies (20% to 80%), depending on the vector used (solo or duet) (Fig. 38.1A). The system was also used to simultaneously target members of a gene family with a single sgRNA and disrupt essential genes by generating conditional alleles. However, in the original system, the selection marker could not be recycled, making sequential editing in the same background virtually impossible, and stable *CAS9* integration in the genome raised concerns about potential off-target effects.




Figure 38.1 (Continued)

Figure 38.1 (Continued) CRISPR–Cas9 methods in *Candida albicans*. The vignettes illustrate four representative methods used for CRISPR–Cas9 genetic manipulation of *C. albicans*. The constructs expressing Cas9 and the sgRNA and the RT are depicted. Promoter sequences are in white, unless they constitute part of the upstream homology arm for the integration in the genomic locus, in which case they have the same color as the gene targeted for integration. The transformation method is also indicated. The targeted site on *YFG* is indicated by a dash. The ploidy of the alleles is indicated next to the DNA helix. (A) *CAS9*, the sgRNA, and the *NAT* cassette are stably integrated at the *ENO1* locus, and HDR mediates the introduction of an RT carrying a stop codon following Cas9-induced cleavage [18]. (B) Transformation of linear DNA fragments into the cell results in transient expression of Cas9 and sgRNA, and HDR results in the integration of a *NAT* cassette into the targeted locus [33]. A further modification of this system allows for marker recycling [34]. (C) In the LEUpOUT approach, a split-marker strategy enables the *in vivo* reconstitution of the selectable cassette for the expression of the CRISPR elements. Integration of the reconstituted cassette disrupts the functional *LEU2* locus of a *LEU2/leu2* heterozygous strain. HDR between the targeted locus and the RT following Cas9 cut results in the deletion of the gene. HDR between directed repeats flanking the cassette (depicted as black lines on yellow background) mediates the removal of CRISPR elements and the restoration of the *LEU2* ORF, which can be selected on leucine dropout medium [35]. Note that the *leu2* deleted allele originally present in the *LEU2/leu2* heterozygous strain remains untouched during the entire procedure, and so it is not depicted in the scheme. (D) An improved version of the method depicted in (A) allows for marker recycling. A cassette expressing the CRISPR elements and containing a *FLP* recombinase is flanked by *FRT* sequences (targets of Flp) and homology arms that mediate its integration in the *Neut5L* locus. HDR with an RT results in the target gene deletion. Activation of the inducible promoter driving the expression of Flp is followed by excision of the cassette, leaving only an *FRT* sequence in the *Neut5L* locus [30]. **Abbreviations:** CRISPR, clustered regularly interspaced short palindromic repeats; DW, downstream; HDR, homology-directed repair; NTC R, Nourseothricin resistant; NTC S, Nourseothricin susceptible; ORF, open reading frame; RT, repair template; sgRNA, single-guide RNA; UP, upstream; *YFG*, your favorite gene.

Min and colleagues addressed the problem by transiently expressing *CAS9* and the sgRNA in *C. albicans* [33]. The repair template contained an *NAT* cassette, which was used to replace the target gene (Fig. 38.1B). Deletion of both alleles occurred either by independent recombination at both or by recombination at one allele followed by allelic gene conversion. Though this method avoided integrating *CAS9*, it was not until the following year that serial mutagenesis in the same background could be achieved [34, 35]. Huang and colleagues [34] developed an ingenious marker-recycling model called CRISPR-mediated marker excision (CRIME), in which the selection marker used to delete the gene of interest is flanked by directly repeated sequences. Following the deletion of the target gene, the CRISPR–Cas9 system is used again and induces a DSB into the marker itself, leading to marker excision by recombination between the repeats [34].




Figure 38.2 CRISPR–Cas9 methods in non-*albicans* *Candida* species. The vignettes illustrate representative methods for implementation of CRISPR–Cas9 in non-*albicans* species, including *C. parapsilosis sensu lato*, *C. tropicalis*, *C. glabrata*, *C. lusitaniae*, and *C. auris*. The ploidy of the species is indicated next to the DNA helices. (A) Two different selectable episomal plasmids allow the scarless introduction of premature stop codons by HDR in *C. parapsilosis sensu lato* and *C. tropicalis*. The relevant species-specific promoters and ARSs are depicted on the left side (blue dot: *C. parapsilosis sensu lato*; red dot: *C. tropicalis*). The sgRNA is expressed from an RNA pol II promoter, and the release of the mature molecule is mediated by the cleavage of the upstream tRNA molecule and the downstream HDV ribozyme.

(Continued)

Figure 38.2 (Continued) The plasmids are easily lost in the absence of selection [29]. (B) A similar approach can be used for gene editing and deletion in *C. glabrata*. In this case, the sgRNA is expressed from the *Saccharomyces cerevisiae* RNA pol III *SNR52* promoter [30]. (C) The use of CRISPR RNPs, in which the crRNA and tracrRNA are assembled *in vitro* with Cas9 and then electroporated into the cells, results in the integration of a *NAT* cassette into the targeted gene in *C. glabrata*, *C. lusitaniae*, and *C. auris* [25]. Although this method does not require species-specific adaptation of the regulatory elements necessary for the expression of the CRISPR elements, marker recycling is not possible. *Abbreviations:* Ag, *Ashbya gossypii*; ARS, autonomously replicating sequence; Ca, *Candida albicans*; Cp, *C. parapsilosis*; CRISPR, clustered regularly interspaced short palindromic repeats; crRNA, CRISPR-RNA; DW, downstream; HDR, homology-directed repair; HDV, human hepatitis delta virus; Mg, *Meyerozyma guilliermondii*; RNP, RNA-Cas9 protein complex; Sc, *Saccharomyces cerevisiae*; sgRNA, single-guide RNA; tracrRNA, *trans*-activating RNA; UP, upstream; YFG, your favorite gene.

Nguyen and colleagues [35] developed alternative strategies to allow marker recycling in different *C. albicans* genetic backgrounds, namely the LEUpOUT system—which requires an *LEU2/leu2Δ* parental strain—or the HIS-FLP system, applicable to any strain. In both cases, the transient integration of a cassette containing both a selection marker and *CAS9* and sgRNA at a single locus (either *LEU2* or *HIS*)—allowing the deletion of the gene of interest—is followed by the excision of the cassette by either recombination between direct repeats (LEUpOUT) or activation of an *FLP* recombinase [35] (Fig. 38.1C). Markerless deletion in a single transformation and the absence of a cloning step are the main advantages of this method, as well as the possibility to generate reconstituted strains.

Most *C. albicans* editing strategies used an RNA pol III promoter to express the sgRNA. However, Ng and colleagues [21] showed that efficiency of CRISPR-Cas9 in *C. albicans* could be further improved by up to 10 times when the sgRNA is expressed from the strong RNA pol II (*ADH*) promoter and is flanked by an upstream tRNA sequence and a downstream human hepatitis delta virus (HDV) ribozyme to release any added 5' cap and 3' poly(A) tail.

Vyas and colleagues [30] also developed a method for marker recycling. The *CAS9*, sgRNA, and *NAT* sequences are integrated at the *NEUT5L* locus and subsequently removed due to the activation of a *FLP* recombinase (Fig. 38.1D). Transformation with a donor DNA juxtaposing 50 bp upstream and downstream of a given *ORF* results in an unmarked deletion mutant. Because the marker selecting for the presence of the CRISPR-Cas9 elements is recyclable and no marker integration occurs at target gene, the system allows the construction of multiple deletion mutants in virtually any genetic background.

In 2017, Shapiro and colleagues [36] adapted the gene-drive principle described in *S. cerevisiae* to *C. albicans*, thanks to the discovery of mating-competent, *C. albicans* haploids [37–38]. Firstly, a cassette expressing *CAS9* and two sgRNAs is integrated at the *NEUT5L* locus in a haploid cell. The sgRNAs are flanked by sequences homologous to the target gene. Following mating, an intact copy of the target gene is introduced. The sgRNAs direct Cas9 to the target gene, introducing DSBs that are repaired by HDR using the *CAS9* and sgRNA cassette.




Figure 38.3 (Continued)

Figure 38.1 (Continued) CRISPR–Cas9 methods in *Aspergillus fumigatus*, *Cryptococcus neoformans* and *C. deneoformans*. The vignettes illustrate representative methods for CRISPR–Cas9 genetic manipulation of *A. fumigatus* (A–B), *C. neoformans*, and *C. deneoformans* (C–E). All the species depicted here are haploid. (A) In *A. fumigatus*, the CRISPR elements are integrated randomly in the genome of protoplasts and selected due to the presence of an *HPH* cassette. NHEJ results in indels at the cleavage site [16]. (B) MMEJ can be used to integrate an *HPH* cassette into a desired locus by using short homology arms. The strain is first transformed with a plasmid expressing Cas9 and containing a *PYR4* marker and then with an *in vitro* transcribed sgRNA and the *HPH* cassette [45]. (C) In this “suicide” system, a cassette containing both the CRISPR elements and a *URA5* marker flanked by homology arms to the target site can be transformed into an uracil auxotrophic strain of *C. deneoformans*. The double-strand break induced by the transiently expressed Cas9 is repaired by HDR with the *URA5* cassette, and the crossover results in the release of the DNA of the CRISPR elements that induced the cleavage in the first place, which may be degraded (hence the name “suicide” system) [17]. (D) An RNP method was developed for *C. neoformans* and *C. deneoformans*, similar to the one adapted to *Candida* species. The cells are transformed with a mixture of two RNPs, each targeting a different end of the target gene, thus maximizing the chances of gene deletion [27]. (E) *CAS9* can be integrated in the *Safe Haven* on *C. neoformans* H99 and selected due to the presence of a *HYGB* cassette. This strain is then be transformed with two transient plasmids expressing two sgRNAs flanked by ribozymes from the native *ACT1* promoter, targeting the beginning and the end of the target gene. A *NEO* cassette flanked by homology arms to the target gene is used for HDR [53]. *Abbreviations:* Af, *Aspergillus fumigatus*; Cn, *Cryptococcus neoformans*; CRISPR, clustered regularly interspaced short palindromic repeats; crRNA, CRISPR-RNA; HDR, homology-directed repair; HDV, human hepatitis delta virus; HH, hammerhead; MMEJ, microhomology-mediated end joining; NHEJ, nonhomologous end joining RNP, RNA–Cas9 protein complex; Sc, *Saccharomyces cerevisiae*; sgRNA, single-guide RNA; tracrRNA, trans-activating RNA; YFG, your favorite gene.

This step will occur in any subsequent mating event, acting as a “drive” allele. When haploid cells containing the drive allele are mated to wild-type cells, the incoming wild-type allele is cut by Cas9 and deleted by replacement with the sgRNA module via HDR. Mating of haploid *Candida* cells deleted for specific *ORFs* therefore rapidly leads to homozygous diploid double-deletion mutants. This platform allows the analysis of genetic interaction by combining deletions of two genes in the same background. However, the stable integration of *CAS9* within the genome requires monitoring of possible off-target effects.

CRISPR–Cas9 methods have also been implemented in non-*albicans* *Candida* species. Like *C. albicans*, the *C. parapsilosis sensu lato* complex species, *C. tropicalis*, *C. lusitaniae*, and *C. auris* are members of the CTG clade. Norton and colleagues developed the first transient CRISPR–Cas9 expression system for gene deletion in the genetically intractable *C. lusitaniae* [20]. Editing efficiencies of 36% were achieved using 1 kb homology arms to direct integration of a *NAT* cassette at the target gene, using *C. lusitaniae*-specific promoters to express *CAS9* and sgRNA. Efficiency increased to 81% after deleting the NHEJ-associated genes *KU70* and *LIG4*, suggesting that this DNA-repair pathway plays a major role in *C. lusitaniae*.

In 2017, Lombardi and colleagues [39] implemented a plasmid-based CRISPR–Cas9 technology in *C. parapsilosis*, in which the episomal pRIBO vector harbors the *NAT* marker, *CAS9* expressed from the *C. parapsilosis* *CpTEF1* promoter, and an sgRNA expression cassette. The sgRNA is expressed from the *C. parapsilosis* RNA pol II promoter *GAPDH* and flanked by a hammerhead (HH) and HDV ribozymes. Cotransformation of the replicating plasmid with a short donor DNA containing two in-frame stop codons flanked with 40-bp homology arms allowed for high-efficiency gene disruption. Despite variation in efficiency across strains, this method offers the possibility to edit any genetic background (e.g., clinical isolates). The plasmid is easily lost in the absence of selection, allowing sequential gene editing in the same genetic background. Zoppo and colleagues [40] showed that the system can also be used for gene editing in the sibling species *Candida orthopsilosis*. This system was recently improved by replacing the HH ribozyme with a tRNA molecule, which is recognized and cleaved by the yeast ribonuclease Z [29] (Fig. 38.2A). This streamlined the cloning process, in that only the 20 bp guide region needs to be replaced to target a new gene. The editing system functions in *C. parapsilosis*, *C. orthopsilosis*, and *Candida metapsilosis* [29, 41]. At the same time, a different plasmid was constructed that can be used in gene editing in *C. tropicalis* [29]. Notably, adaptation to *C. tropicalis* required not only changing the regulatory elements driving the expression of *CAS9*, *NAT*, and sgRNA—which were derived from *Candida dubliniensis*, *Ashbya gossypii*, and *Meyerozyma guilliermondii*, respectively—but also using a different autonomously replicating sequence, *ARS2* from *C. albicans* [29, 42] (Fig. 38.2A).

CRISPR–Cas9 can also be used in *C. glabrata*, a species that is not part of the CTG clade and is more closely related to *S. cerevisiae* than to *C. albicans*. Enkler and colleagues [19] transformed a triple auxotrophic strain (*his3*, *trp1* and *leu2*) of *C. glabrata* with a *LEU2* plasmid expressing the sgRNA and a *TRP1* plasmid expressing Cas9. By exploiting NHEJ—the preferential DNA-repair mechanism in this species—this strategy allowed up to 100% efficient *ADE2* gene disruption when using *C. glabrata* *CYC1* and *RNAH1* promoters to express *CAS9* and the sgRNA, respectively. Although 500-bp homology arms are usually recommended for HDR in *C. glabrata*, this method was used successfully to insert either short (57 bp) or large (1,202 bp) cassettes by HDR using only 20-bp or 200-bp homology arms, though 200-bp homology arms performed better for the small insert [43]. Vyas and colleagues [30] also generated an editing system in which *CAS9*, sgRNA, and *NAT* sequences are harbored on an episomal plasmid that can be used also in prototrophic clinical isolates of *C. glabrata* (Fig. 38.2B). Transformation of the cells resulted in *ade2* mutants both with and without a repair template designed to introduce premature stop codons in the gene. Recently, Maroc and colleagues described a CRISPR vector containing the sgRNA cassette and expressing *CAS9* under the control of the *MET3* promoter, which can be used to induce mutations by either NHEJ or HDR in *C. glabrata* [44]. Since Cas9 expression is inducible, the authors foresee that this system may also be used for identifying essential genes in this asexual yeast.

As an alternative to expressing *CAS9* and the sgRNA in the cell, Grahl and colleagues [25] assembled Cas9 and the specific crRNA: tracrRNA duplex RNA *in vitro* to form an RNP (Fig. 38.2C). The RNP was then transformed into *C. lusitaniae*, *C. auris*, and *C. glabrata* to induce gene deletion by homologous recombination of a selection marker flanked by 0.5–1 kb homology arms. Efficiencies ranged from 60% to 70%. However, this strategy does not allow marker recycling.

The implementation of the CRISPR–Cas9 technology in *Candida* species boosted our ability to decipher cellular signaling associated with virulence and the underlying genetic interactions. CRISPR–Cas9 used in combination with *C. albicans* mating-competent haploids allowed the investigation of epistatic relationships between members of gene families involved in fungal virulence (e.g., adhesins and efflux pumps) by generating libraries of homozygous double gene-deletion mutants [36]. This technology also streamlined the process of linking specific genes or SNPs (either heterozygous or homozygous) to relevant phenotypes in *Candida* species (e.g., resistance or sensitivity to drugs or cell-wall stressors [41, 45–47]).

38.4.2 *Aspergillus fumigatus*

Gene manipulation in *A. fumigatus* is hampered by low efficiency of HDR (3%–5%), and NHEJ-impaired strains and 1-kb homology arms are traditionally used for site-specific integration [48]. Moreover, a reliable strategy of sexual reproduction in *A. fumigatus* has not been established, making mutagenesis of multiple genes by sexual crossing a challenging task, especially in clinical isolates. The first CRISPR–Cas9 method developed for *A. fumigatus* exploited NHEJ for gene disruption of the *pks* gene—involved in melanin production—by randomly integrating a cassette containing the hygromycin marker (*HPH*), the sgRNA expressed from the *S. cerevisiae* *SNR52* promoter, and the human optimized *CAS9* gene expressed from a *TEF1* promoter in the genome [16] (Fig. 38.3A). Albino mutants were obtained with a 25%–53% frequency. Interestingly, unintended NHEJ-mediated integration of the transforming DNA to the Cas9 cut site was often observed. Notably, *CAS9* expression in the absence of a sgRNA did not alter growth rate or virulence in a murine model.

The following year, Zhang and colleagues [49] exploited MMEJ to efficiently (95%–100%) integrate desired sequences in-frame into a target gene via very short (approximately 35-bp) homology arms. They used strains constitutively expressing a human optimized *CAS9* gene from the fungal *GPDA* promoter on an autonomously replicating plasmid with a *PYR4* selectable marker. The sgRNA targeting the gene of interest, whose expression is driven by the native *A. fumigatus* RNA pol III *U6* promoter, can either be transformed as a linear cassette or directly provided to the cells as an RNA molecule following *in vitro* transcription. An *HPH* cassette flanked by microhomology regions can then be targeted to the cleavage site (Fig. 38.3B). The same approach can be used to insert a green

fluorescent protein (GFP) tag (although the selection for positive transformants is based on the random integration of the *HPH* cassette) and to create multiple mutants. Notably, this method can be used in clinical isolates [49].

In line with other *Aspergillus* species, Weber and colleagues [50] used the RNA pol II *GPDA* promoter to drive the expression of a HH-HDV ribozyme-flanked sgRNA. The authors adopted an ingenious split-marker approach to induce a single-nucleotide deletion in a NHEJ-defective strain containing an integrated tetracycline-inducible *CAS9*. An integrating plasmid harbors the sgRNA expression cassette along with the two halves of the split marker (the pyrithiamine resistance cassette (*PTRA*) of *A. oryzae*) interrupted by the same guide and PAM sequence that is being targeted in the genome. CRISPR-Cas9 mediated cleavage of the native target occurs in parallel with the cleavage of the “twin site” on the split marker, resulting in the reconstitution of the functional selection marker. The desired mutation can then be introduced by HDR with a donor DNA. Although inducible expression of *CAS9* lowers the risks of off-target mutations, it still remains in the genome.

Al Abdallah and colleagues [26] first used the RNP complex in conjunction with MMEJ for gene deletion in *A. fumigatus*. By using two sgRNAs to target Cas9-induced DSBs upstream and downstream of the *PKSP* gene and an *HPH* marker flanked with 35–50 bp homology arms as donor DNA, gene deletion occurred with an efficiency of >90% in both NHEJ-competent and NHEJ-defective strains. Although applicable to virtually any *A. fumigatus* isolates, this approach does not allow marker recycling, because the target gene is replaced by the *HPH* marker. Umeyema and colleagues [51] used a similar strategy to introduce two single point mutations previously identified in clinical isolates in the *CYP51A* gene to assess their role in azole resistance. In this case, the donor DNA was the full gene sequence containing the desired mutation(s), fused to the *HPH* marker. Therefore, despite several improvements, CRISPR-Cas9 in *A. fumigatus* still suffers from the absence of methods for marker recycling.

Single-base CRISPR-Cas9 editing has been used to gain further insights into the emerging phenomenon of azole resistance in *A. fumigatus*. The association of amino acid substitutions with azole resistance (e.g., Gly138Ser in Cyp51A [51]) also led to the discovery of a non-cyp51A mediated resistance mechanism relying on a mutated version of the *SVF1* gene [52].

38.4.3 *Cryptococcus* species

Site-directed mutagenesis has been challenging in Basidiomycetes such as pathogenic *Cryptococcus* species for a long time. The main target species are *C. neoformans* (formerly known as *C. neoformans* var. *grubii*, serotype A), *C. deneoformans* (formerly known as *Cr. neoformans* var. *neoformans*, serotype D), and *C. gattii* [53]. Chemical transformation is not effective in these yeasts, and exogenous DNA is usually introduced into the cells by either biolistic transformation

or electroporation. However, electroporated cells are unstable, and the efficiency of HDR ranges from 0.00001% to 0.001% [54, 55]. By contrast, HDR following biolistic transformation rises to 1%–10%, and transformed cells are more stable [54], making this technique the gold standard for gene targeting in *Cryptococcus*. Unfortunately, biolistic transformation requires expensive equipment. In addition, although NHEJ-defective mutants have higher frequencies of HDR, their reduced virulence prevents their use in pathogenesis studies [56, 57].

The implementation of CRISPR–Cas9 in *Cryptococcus* had a dramatic effect on increasing the efficiency of HDR, so much so that, in the last two years, electroporation is again being used for genetic manipulation. In the system developed by Wang and colleagues [17] for *C. deneoformans*, the sgRNA is expressed from a native cryptococcal RNA pol III *U6* promoter, and a *C. neoformans* *ACT1* promoter drives the expression of a human codon-optimized *CAS9* gene. Notably, electroporation of linearized *URA5* vectors harboring the cassettes in a *ura*-strain resulted in 82%–88% pink auxotrophic colonies when *ADE2* was targeted by NHEJ (or NHEJ-equivalent) repair. Cotransformation with a 1-kb donor DNA also allowed a single codon change mediated by HDR. The *ADE2* gene was also disrupted by replacing with the hygromycin marker *HYGB* flanked by 1-kb homology arms on each side, although HDR occurred only in 8 out of 20 pink transformants, suggesting that the NHEJ pathway may be prevalent. Although the vectors were not integrated in the genome, the cassettes were stable in *C. deneoformans* even in the absence of selective pressure, increasing the risk of off-target effects and making gene complementation virtually impossible (the newly introduced wild-type (WT) copy of the disrupted gene will be recognized and cleaved).

In order to fix this problem, Wang and colleagues [17] further developed a “suicide” system that allows for the elimination of CRISPR components (Fig. 38.3C). In this design, homology arms flank the *URA5* marker on the vector, driving its integration by HDR into the cleaved target gene. As the CRISPR and sgRNA elements are located on one side of the homology arm, they may be resolved by double crossover in HDR and eventually degraded. When put to the test, the “suicide” system efficiently disrupted the gene of interest and roughly 50% of the mutants lost the CRISPR elements, thus allowing subsequent complementation of the disruption.

Arras and colleagues [58] used biolistic transformation to integrate a *HYGB* cassette containing *S. pyogenes* *CAS9* expressed from a native *TEF1* promoter into the *C. neoformans* H99 Safe Haven region on chromosome 1 (Fig. 38.3E). This strain can be subsequently transformed with a vector containing the G418 resistance marker *NEO* and expressing the sgRNA from the *C. neoformans* RNA pol II *ACT1* promoter, flanked with HH and HDV ribozymes [59].

Cotransformation of the vector transiently expressing the sgRNA and a cassette carrying approximately 1-kb homology arms on both sides led to the HDR-mediated gene disruption with an efficiency of 70%. Despite the concerns about the stable expression of Cas9, this system simplifies genetic manipulation in that it requires only the generation of the sgRNA vector and donor DNA constructs for targeting a gene of interest.

In 2018, Fan and Lin [60] developed TRACE (transient CRISPR–Cas9 coupled with electroporation) for both *C. neoformans* and *C. deneoformans*. Cryptococcal cells are electroporated with two linear cassettes with no selectable markers, in which *CAS9* and the sgRNA are under the control of native *C. neoformans* regulatory elements (*GPD1* promoter for the human optimized *CAS9* gene and *U6* promoter for the sgRNA targeting *ADE2*), together with a *NAT* cassette carrying 1-kb homology arms. Pink transformants were obtained with a 50%–90% efficiency depending on the strain, although further analyses showed that not all of the colonies were consistent with HDR-mediated integration of the cassette into *ADE2*. Moreover, both *CAS9* and the sgRNA were found randomly integrated into the genome in some of the transformants. Lowering the amount of Cas9 and sgRNA provided reduced the frequency of the unwanted integration events. TRACE can also be used to simultaneously target members of a gene family and to ectopically complement a mutated gene by introducing a WT copy into the Cas9-cleaved Safe Haven region (SH2).

Two additional approaches for *C. neoformans* and *C. deneoformans* were published by Wang in 2018 [27] (Fig. 38.3D). Both methods rely on the simultaneous use of two guides, targeting the 5' and the 3' of the gene of interest, in an attempt to facilitate deletion by HDR with a *NAT* cassette carrying 800 to 900 bp homology arms. In the first approach, two plasmid vectors are transformed, each containing a *S. pyogenes CAS9* and one of the two sgRNAs expressed from *C. neoformans TEF1* and *U6* promoters. In the second approach, CRISPR elements are provided to the cells via electroporation as an RNP complex. Although more transformants were obtained using the plasmids, the RNP method remains a valuable approach, as it potentially allows the implementation of CRISPR–Cas9 in species for which expression cassettes are not available yet (e.g., *C. gattii* and *C. deuterogattii*).

38.4.4 Mucorales species

The generation of stable gene replacements by HDR is a challenging process in Mucorales, because plasmids tend to not integrate regardless of the size of the homology arms. The first CRISPR–Cas9 method available uses the RNP approach to generate stable mutants in *Mucor circinelloides* [28]. Different to other RNP methods, assembly of Cas9 with the sgRNA occurs *in vivo*, inside the fungal protoplasts. The Cas9-induced DSB resulted in 100% efficiency for both gene disruption by NHEJ and gene deletion by HDR-mediated integration of a *PYRG* cassette flanked by homology arms. Notably, NHEJ led to an unexpected >2.3kb-long deletion upstream of the PAM in the resulting mutants, possibly causing unwanted effects (i.e., the gene adjacent to the targeted one was also affected by the deletion). The HDR pathway is therefore preferable, despite resulting in the stable integration of the section marker. Despite very low transformation efficiency, this method provides stable mutants, streamlining the genetic manipulation of these genetically intractable fungi. Earlier this year, Wang and colleagues demonstrated that a CRISPR–Cas9 plasmid formerly developed

for *Cryptococcus* species could be used for NHEJ-mediated gene disruption in *Rhizopus delemar* [61]. The implementation of CRISPR–Cas9 technology in Mucorales provides a much needed window into the biology of these emerging opportunistic pathogens for which robust genetic tools are lacking.

38.5 Perspectives and Future Directions

Genetic manipulation of fungal pathogens has been a milestone in deepening our understanding of virulence and host–pathogen interactions. The generation of single-gene mutant libraries (e.g., in *C. neoformans* [62], *C. albicans* [63], and *C. parapsilosis* [64], as well as other approaches like promoter replacement [65], transposon mutagenesis to study gene essentiality [66], and heterozygous libraries generated for haploinsufficiency-based genetic interaction studies in *C. albicans* [67] allowed the dissection of the molecular players of fungal biology and pathogenicity.

CRISPR–Cas9 methods are now available for most of the major fungal species causing infections, facilitating genetic engineering by increasing the rate of homologous recombination as never seen before. Unique guide sequences are available to target >90% of the annotated *ORFs* in both *C. albicans* and *C. glabrata* genomes [18, 30]. Different genetic changes can be introduced (e.g., deletion, single-nucleotide mutation, stop codon insertion, barcoding, fluorescent tagging, etc.) in coding as well as noncoding regions. Ongoing research in model eukaryotic organisms like *S. cerevisiae* keeps expanding the boundaries of potential CRISPR applications [11, 68]. An interesting refinement is the possibility of engineering heterozygous mutations in diploid species, which allows the study of heterozygous variants or essential genes. This was first achieved in mammalian cell lines using mixed repair templates carrying a different set of mutations or, alternatively, by exploiting the cut-to-mutation distance (the efficiency of mutation incorporation rapidly falls with increasing distance from the Cas9 cleavage site) [69]. Recently, heterozygous mutations were introduced in *C. parapsilosis* and *C. orthopsilosis* by applying the same principle [29, 41].

Larger chromosomal deletions (>30 kb) and chromosome fusion have been achieved in *S. cerevisiae* through NHEJ repair between endpoints of the DNA breaks, which can facilitate the study of gene clusters or minimal genome research, as well as the study of replication, recombination, and segregation [70–72]. In principle, this may open up the possibility to generate CRISPR–Cas9-induced genome rearrangements in *C. albicans*, in which specific whole-chromosome aneuploidies have been associated with drug resistance and/or cross-adaptation to different drugs [73]. In *S. cerevisiae*, the introduction of a DSB by Cas9 can result in extensive loss of heterozygosity (LOH) events consistent with HDR [74]. Whereas this needs to be taken into account when manipulating polyploid and highly heterozygous genomes, it could also be exploited to study the

impact of LOH on *C. albicans* virulence. In fact, exposure to the mammalian host increases the frequency of LOH in *C. albicans*, likely selecting for specific mutations. In addition, LOH is associated with reduced drug susceptibility in strains sequentially isolated from the same patient [75].

Although most of our knowledge on microbial pathogenesis was built on extensive analyses of one or few laboratory strains, it is becoming increasingly clear that genotype–phenotype correlation should be validated using multiple isolates. An example is the regulatory network controlling biofilm production and hyphal formation in *C. albicans*; circuit diversification appears to be widespread in different isolates, as attested by the fact that loss of function of the same transcription factor can have a different impact on the network depending on the strain [76]. Many of the CRISPR–Cas9 systems developed for pathogenic fungi are applicable to any genetic background, thus allowing the generation of mutations in different clinical isolates and a more robust validation of gene function.

Targeting gene families is also possible by exploiting the homology within coding regions of paralogs. For example, Wijsman used 11 unique guide sequences to delete 21 hexose transporters in *S. cerevisiae*, in only 3 transformation steps [77]. Multiplexing is time-saving and triggers less chromosomal rearrangements than the *Loxp*/Cre system, ensuring high fidelity when addressing extensive genome editing strategies [77]. CRISPR–Cas9 based gene-drive strategies had been developed in *S. cerevisiae* and *C. albicans* [36–78], in which the selfish element itself is used as donor DNA and replaces the WT allele after Cas9 cleavage. In diploid organisms with sexual reproduction, all progeny cells will inherit the gene-drive, bypassing Mendelian inheritance [37].

CRISPR–Cas9 made the construction of genome-scale mutant libraries easier than ever before, thus streamlining downstream applications such as genome-wide variant engineering [79] or gene interaction screens [80], which are useful in identifying fungal-specific genes involved in essential biological processes that could represent potential new therapeutic targets. Finally, directed evolution studies are another perspective that can be achieved for example by a CRISPR-guided nickase fused to an error-prone DNA polymerase, dramatically increasing the mutation rate [81]. Such strategies favoring directed evolution could facilitate the identification of new variant genotypes with successful virulence or antifungal resistance traits.

Besides Cas9, at least 10 different Cas enzymes have been described, differing in structure, PAM recognition sites, or type of cleavage mechanisms, allowing new targeting options [82]. Examples are eSpCas9, SpCas9-HF1 and HypaCas9 (engineered variants of Cas9 with a higher specificity [83–85]), Cas12a (less off-target effect; PAM = TTN; appropriate for low GC-rich regions) [86], and xCas9 (broadest PAM compatibility; PAM = NG, GAA and GAT)[87]. On the other hand, developing CRISPR base editors paved the way for genome editing without introducing DSB DNA-breaks by inducing gene conversions such as C to T, G to A

[88], or A-T to G-C [89]. Anzalone and colleagues further improved this strategy by combining a catalytically impaired Cas9 (only able to nick one DNA strand) with a reverse transcriptase; the complex is driven to the target site by a prime editing guide RNA (pegRNA) that also encodes the edit [90]. This method enables precise targeted insertions and deletions and all 12 possible classes of point mutations (including transversion mutations) without inducing DSBs, therefore minimizing side effects, and at the same time not relying on HDR with a donor DNA to edit the genome. While this is particularly relevant in mammalian cells, it could also be applied to fungi in which the efficiency of HDR remains low, even following a Cas9-induced DSB.

One more step has also been reached by editing RNAs using Cas13 enzymes, making nonpermanent changes of the genome possible [91].

Nonediting applications using Cas9 have also emerged over the years [92]. Fusion of Cas proteins with reporters allows live-cell imaging of DNA and RNA [93]. A catalytically dead variant with no nuclease activity (dCas9) but retaining its binding activity has been used to regulate gene expression in *S. cerevisiae*, allowing either activation (CRISPRa)—when fused to a transcriptional activator—or interference (CRISPRi), when fused to a repressor [94]. Similar systems have recently been developed for *C. albicans*, in which comprehensive genetic interaction maps could not previously be built using RNAi-based genetic knockdown, because RNAi is not effective in this species. The faster and cheaper genetic manipulation of fungal genome and expression facilitated by CRISPR–Cas9 is likely to have a profound impact on medical mycology. Loss of function, gene activation, and gene inhibition strategies can be scaled up as CRISPR–Cas9 libraries [95–97], and large-scale library screens can facilitate the identification of new targets for antifungal therapy, of which there is a desperate need [98].

The use of RNA–Cas9 complexes is particularly important in species refractory to genetic manipulation, making easier and more timely the study of emergent and multiresistant fungi. Although not yet applied to medical mycology, the diagnostics field already started harnessing the potential of CRISPR–Cas9. Myrhvold and colleagues, developed a Cas13-based nucleic acid detection platform, Specific Highly sensitive Enzymatic Reporter unLOCKing (SHERLOCK), coupled with detection by a lateral flow device as a point-of-care test to diagnose Zika and Dengue virus in clinical samples [99]. The extension of this technique to the high sensitivity and specificity detection of fungal DNA could radically improve the diagnosis of fungal infections, especially in low resource settings [100]. CRISPR–Cas9 and Next Generation Sequencing were combined in Finding Low Abundance Sequences by Hybridization (FLASH), a new method for multiplex detection of antimicrobial resistance in clinical samples of Gram-positive bacteria and *Plasmodium falciparum* [101].

The potential applications of CRISPR-based methods developed in either model fungi (like *S. cerevisiae*) or bacteria, viruses, and mammalian cells to the study of fungal pathogenesis are summarized in Table 38.1.

Table 38.1 Potential translation of CRISPR-based methods developed for model organisms to the study of fungal pathogenesis

Method	Developed in	Potential application to fungal pathogens	Refs.
CRISPR-mediated large chromosomal deletions and fusions	<i>S. cerevisiae</i>	Study of the correlation existing between large chromosomal rearrangements and virulence and drug resistance (e.g., aneuploidy and LOH in <i>C. albicans</i> , aneuploidy in <i>C. neoformans</i>)	[70–72]
Directed evolution through CRISPR-guided DNA polymerase	<i>Escherichia coli</i>	Identification of new variant genotypes with virulence or antifungal resistance traits	[81]
CRISPR prime editing	Human cells	Precise DSB-free editing in species refractory to HDR	[90]
Cas13-based nucleic acid detection platform (e.g., SHERLOCK)	Zika and Dengue viruses	Rapid diagnosis of fungal infections in low resource settings based on the development of highly sensitive (attomolar range) kits for detection of fungal DNA	[99]
CRISPR–Cas9 based enrichment of sequences for NGS (e.g., FLASH)	Gram-positive bacteria, <i>P. falciparum</i>	Enrichment of fungal sequences associated with a trait of interest (e.g., antifungal resistance) prior to NGS, potentially resulting in antimicrobial resistance profiling directly from the patient sample	[101]

Abbreviations: CRISPR, clustered regularly interspaced short palindromic repeats; DSB, double-strand break; FLASH, Finding Low Abundance Sequences by Hybridization; HDR, homology-directed repair; LOH, loss of heterozygosity; NGS, next generation sequencing; SHERLOCK, Specific Highly Sensitive Enzymatic Reporter UnLOCKing.

38.6 Conclusions

This chapter provides an updated overview of the state of the art of CRISPR–Cas9 genome editing in pathogenic fungi to both researchers and medical mycologists interested in using this technology. Though we focused on major fungal pathogens encountered in the clinical setting [102], CRISPR–Cas9 methods have also been developed in other human fungal pathogens not discussed here, such as *Malassezia* [103], *Fusarium* [104], and the dimorphic fungus *Blastomyces dermatitidis* [105]. The effectiveness and flexibility of CRISPR–Cas9 have the potential to have a dramatic impact on the field of medical mycology, both in the lab—by boosting genetic manipulation for studying fungal biology and pathogenesis, dissecting the role of virulence factors, and investigating new potential drug targets and host–pathogen interaction—and at the bedside, by improving the diagnosis of fungal infections and the monitoring of antifungal resistance [4]. Moreover, further applications currently developed in model fungi may be applied to fungal pathogens in the near future for studying host–fungi interactions or tackling antifungal resistance [106].

Abbreviations

Af:	<i>Aspergillus fumigatus</i>
Ag:	<i>Ashbya gossypii</i>
ARS:	autonomously replicating sequence
Ca:	<i>Candida albicans</i>
Cn:	<i>Cryptococcus neoformans</i>
Cp:	<i>Candida parapsilosis</i>
CRIME:	CRISPR-mediated marker excision
CRISPR:	clustered regularly interspaced short palindromic repeats
crRNA:	CRISPR-RNA
DSB:	double-stranded break
DW:	downstream
FLASH:	Finding Low Abundance Sequences by Hybridization
HDR:	homology-directed repair
HDV:	hepatitis delta virus
HH:	hammerhead
LOH:	loss of heterozygosity
Mg:	<i>Meyerozyma guilliermondii</i>
MMEJ:	microhomology-mediated end joining
NGS:	next generation sequencing
NHEJ:	nonhomologous end joining
NTC R:	Nourseothricin resistant
NTC S:	Nourseothricin susceptible
ORF:	open reading frame
PAM:	protospacer adjacent motif
PTRA:	pyrithiamine resistance cassette
RNP:	RNA-Cas9 protein complex
RT:	repair template
Sc:	<i>Saccharomyces cerevisiae</i>
sgRNA:	single-guide RNA
SHERLOCK:	Specific Highly Sensitive Enzymatic Reporter UnLOCKing
TRACE:	transient CRISPR-Cas9 coupled with electroporation
tracrRNA:	trans-activating crRNA
UP:	upstream
YFG:	your favorite gene

Disclosures and Conflict of Interest

This chapter was originally published as: Morio, F., Lombardi, L., Butler, G. (2020). The CRISPR toolbox in medical mycology: State of the art and perspectives. *PLoS Pathog.*, **16**(1), e1008201, <https://doi.org/10.1371/journal.ppat.1008201>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

The authors received no specific funding for this study. The authors have declared that no competing interests exist. Florent Morio and Lisa Lombardi contributed equally to this work.

References

1. Cole DC, Govender NP, Chakrabarti A, Sacarlal J, Denning DW. Improvement of fungal disease identification and management: combined health systems and public health approaches. *Lancet Infect Dis*. 2017; 17(12): e412–e419.
2. Bongomin F, Gago S, Oladele R, Denning D. Global and Multi-national prevalence of fungal diseases—estimate precision. *J Fungi*. 2017; 3(4): 57.
3. Chowdhary A, Sharma C, Meis JF. *Candida auris*: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. *PLoS Pathog*. 2017; 13(5): e1006290.
4. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. *Science*. 2018; 360(6390): 739–742.
5. Samaranyake DP, Hanes SD. Milestones in *Candida albicans* gene manipulation. *Fungal Genet Biol*. 2011; 48(9): 858–865.
6. Defosse TA, Courdavault V, Coste AT, Clastre M, de Bernonville TD, Godon C, et al. A standardized toolkit for genetic engineering of CTG clade yeasts. *J Microbiol Methods*. 2018; 144: 152–156.
7. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012; 337(6096): 816–821.
8. Dicarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. Genome engineering in *Saccharomyces cerevisiae* using CRISPR-Cas systems. *Nucleic Acids Res*. 2013; 41(7): 4336–4343.
9. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc Natl Acad Sci U S A*. 2012; 109(39): E2579–2586.
10. Ceccaldi R, Rondinelli B, D’Andrea AD. Repair pathway choices and consequences at the double-strand break. *Trends Cell Biol*. 2016; 26(1): 52–64.
11. Raschmanová H, Weninger A, Glieder A, Kovar K, Vogl T. Implementing CRISPR-Cas technologies in conventional and non-conventional yeasts: current state and future prospects. *Biotechnol Adv*. 2018; 36(3): 641–665.
12. Caldecott KW. Single-strand break repair and genetic disease. *Nat Rev Genet*. 2008; 9(8): 619–631.
13. Rouet P, Smih F, Jasin M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. *Mol Cell Biol*. 1994; 14(12): 8096–8106.
14. Smih F, Rouet P, Romanienko PJ, Jasin M. Double-strand breaks at the target locus stimulate gene targeting in embryonic stem cells. *Nucleic Acids Res*. 1995; 23(24): 5012–5019.

15. Storici F, Durham CL, Gordenin DA, Resnick MA. Chromosomal site-specific double-strand breaks are efficiently targeted for repair by oligonucleotides in yeast. *Proc Natl Acad Sci U S A*. 2003; 100(25): 14994–14999.
16. Fuller KK, Chen S, Loros JJ, Dunlap JC. Development of the CRISPR/Cas9 system for targeted gene disruption in *Aspergillus fumigatus*. *Eukaryot Cell*. 2015; 14(11): 1073–1080.
17. Wang Y, Wei D, Zhu X, Pan J, Zhang P, Huo L, et al. A “suicide” CRISPR-Cas9 system to promote gene deletion and restoration by electroporation in *Cryptococcus neoformans*. *Sci Rep*. 2016; 6: 31145.
18. Vyas VK, Barrasa MI, Fink GR. A *Candida albicans* CRISPR system permits genetic engineering of essential genes and gene families. *Sci Adv*. 2015; 1(3): e1500248.
19. Enkler L, Richer D, Marchand AL, Ferrandon D, Jossinet F. Genome engineering in the yeast pathogen *Candida glabrata* using the CRISPR-Cas9 system. *Sci Rep*. 2016; 6(1): 35766.
20. Norton EL, Sherwood RK, Bennett RJ. Development of a CRISPR-Cas9 system for efficient genome editing of *Candida lusitanae*. *mSphere*. 2017; 2(3): e00217–17.
21. Ng H, Dean N. Dramatic improvement of CRISPR/Cas9 editing in *Candida albicans* by increased single guide RNA expression. *mSphere*. 2017; 2(2): e00385–16.
22. Nosek J, Adamíková L, Zemanová J, Tomáška L, Zufferey R, Mamoun C Ben. Genetic manipulation of the pathogenic yeast *Candida parapsilosis*. *Curr Genet*. 2002; 42(1): 27–35.
23. Krappmann S. CRISPR-Cas9, the new kid on the block of fungal molecular biology. *Med Mycol*. 2017; 55(1): 16–23.
24. Papp T, Csernetics Á, Nyilasi I, ÁBrók M, VÁgvÓlgyi C. Genetic transformation of Zygomycetes fungi. In: *Progress in Mycology*. Dordrecht: Springer Netherlands; 2010. p. 75–94.
25. Grahl N, Demers EG, Crocker AW, Hogan DA. Use of RNA-protein complexes for genome editing in non-*albicans Candida* species. *mSphere*. 2017; 2(3): e00218–17.
26. Al Abdallah Q, Ge W, Fortwendel JR. A simple and universal system for gene manipulation in *Aspergillus fumigatus*: *in vitro*-assembled Cas9-guide RNA ribonucleoproteins coupled with microhomology repair templates. *mSphere*. 2018; 3(3): e00208–18.
27. Wang P. Two distinct approaches for CRISPR-Cas9-mediated gene editing in *Cryptococcus neoformans* and related species. *mSphere*. 2018; 3(3): 1–9.
28. Nagy G, Szebenyi C, Csernetics Á, Vaz AG, Tóth EJ, VÁgvÓlgyi C, et al. Development of a plasmid free CRISPR-Cas9 system for the genetic modification of *Mucor circinelloides*. *Sci Rep*. 2017; 7(1): 16800.
29. Lombardi L, Oliveira-Pacheco J, Butler G. Plasmid-based CRISPR-Cas9 gene editing in multiple *Candida* species. *mSphere*. 2019; 4(2): 557926.
30. Vyas VK, Bushkin GG, Bernstein DA, Getz MA, Sewastianik M, Barrasa MI, et al. New CRISPR mutagenesis strategies reveal variation in repair mechanisms among fungi. *mSphere*. 2018; 3(2): e00154–18.
31. Meussen BJ, de Graaff LH, Sanders JPM, Weusthuis RA. Metabolic engineering of *Rhizopus oryzae* for the production of platform chemicals. *Appl Microbiol Biotechnol*. 2012; 94(4): 875–886.

32. Mitchell AP. Location, location, location: use of CRISPR-Cas9 for genome editing in human pathogenic fungi. *PLoS Pathog.* 2017; 13(3): e1006209.
33. Min K, Ichikawa Y, Woolford CA, Mitchell AP. *Candida albicans* gene deletion with a transient CRISPR-Cas9 system. *mSphere.* 2017; 2(2): e00050–17.
34. Huang MY, Mitchell AP. Marker recycling in *Candida albicans* through CRISPR-Cas9-induced marker excision. *mSphere.* 2017; 2(2): e00050–17.
35. Nguyen N, Quail MMF, Hernday AD. An efficient, rapid, and recyclable system for CRISPR-mediated genome editing in *Candida albicans*. *mSphere.* 2017; 2(2): e00149–17.
36. Shapiro RS, Chavez A, Porter CBM, Hamblin M, Kaas CS, DiCarlo JE, et al. A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in *Candida albicans*. *Nat Microbiol.* 2018; 3(1): 73–82.
37. DiCarlo JE, Chavez A, Dietz SL, Esvelt KM, Church GM. Safeguarding CRISPR-Cas9 gene drives in yeast. *Nat Biotechnol.* 2015; 33(12): 1250–1255.
38. Hickman MA, Zeng G, Forche A, Hiraoka MP, Abbey D, Harrison BD, et al. The “obligate diploid” *Candida albicans* forms mating-competent haploids. *Nature.* 2013; 494(7435): 55–59.
39. Lombardi L, Turner SA, Zhao F, Butler G. Gene editing in clinical isolates of *Candida parapsilosis* using CRISPR/Cas9. *Sci Rep.* 2017; 7(1): 8051.
40. Zoppo M, Lombardi L, Rizzato C, Lupetti A, Bottai D, Papp C, et al. CORT0C04210 is required for *Candida orthopsilosis* adhesion to human buccal cells. *Fungal Genet Biol.* 2018; 120: 19–29.
41. Morio F, Lombardi L, Binder U, Loge C, Robert E, Graessle D, et al. Precise genome editing using a CRISPR-Cas9 method highlights the role of CoERG11 amino acid substitutions in azole resistance in *Candida orthopsilosis*. *J Antimicrob Chemother.* 2019; 74(8): 2230–2238.
42. Cannon RD, Jenkinson HF, Shepherd MG. Isolation and nucleotide sequence of an autonomously replicating sequence (ARS) element functional in *Candida albicans* and *Saccharomyces cerevisiae*. *Mol Gen Genet.* 1990; 221(2): 210–218.
43. Schwarzmüller T, Ma B, Hiller E, Istel F, Tscherner M, Brunke S, et al. Systematic phenotyping of a large-scale *Candida glabrata* deletion collection reveals novel antifungal tolerance genes. *PLoS Pathog.* 2014; 10(6): e1004211.
44. Maroc L, Fairhead C. A new inducible CRISPR-Cas9 system useful for genome editing and study of double-strand break repair in *Candida glabrata*. *Yeast.* 2019; 36(12): 723–731.
45. de San Vicente KM, Schröder MS, Lombardi L, Iracane E, Butler G. Correlating genotype and phenotype in the asexual yeast *Candida orthopsilosis* implicates ZCF29 in sensitivity to caffeine. *G3 (Bethesda).* 2019; 9(9): 3035–3043.
46. Kapoor M, Moloney M, Soltow QA, Pillar CM, Shaw KJ. Evaluation of resistance development to the Gwt1 inhibitor Manogepix (APX001A) in *Candida* species. *Antimicrob Agents Chemother.* 2019; 64(1): e01387–19.
47. Rybak JM, Doorley LA, Nishimoto AT, Barker KS, Palmer GE, Rogers PD. Abrogation of triazole resistance upon deletion of CDR1 in a clinical isolate of *Candida auris*. *Antimicrob Agents Chemother.* 2019; 63(4): e00057–19.

48. Krappmann S, Sasse C, Braus GH. Gene targeting in *Aspergillus fumigatus* by homologous recombination is facilitated in a nonhomologous end-joining-deficient genetic background. *Eukaryot Cell*. 2006; 5(1): 212–215.
49. Zhang C, Meng X, Wei X, Lu L. Highly efficient CRISPR mutagenesis by microhomology-mediated end joining in *Aspergillus fumigatus*. *Fungal Genet Biol*. 2016; 86: 47–57.
50. Weber J, Valiante V, Nødvig CS, Mattern DJ, Slotkowski RA, Mortensen UH, et al. Functional reconstitution of a fungal natural product gene cluster by advanced genome editing. *ACS Synth Biol*. 2017; 6(1): 62–68.
51. Umeyama T, Hayashi Y, Shimosaka H, Inukai T, Yamagoe S, Takatsuka S, et al. Cas9/CRISPR genome editing to demonstrate the contribution of Cyp51A Gly138Ser to azole resistance in *Aspergillus fumigatus*. *Antimicrob Agents Chemother*. 2018; 62(9): e00894–18.
52. Ballard E, Weber J, Melchers WJG, Tammireddy S, Whitfield PD, Brakhage AA, Brown AJP, Verweij PE, Warris A. Recreation of in-host acquired single nucleotide polymorphisms by CRISPR-Cas9 reveals an uncharacterised gene playing a role in *Aspergillus fumigatus* azole resistance via a non-cyp51A mediated resistance mechanism. *Fungal Genet Biol*. 2019; 130: 98–106.
53. Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, et al. Recognition of seven species in the *Cryptococcus gattii/Cryptococcus neoformans* species complex. *Fungal Genet Biol*. 2015; 78: 16–48.
54. Lin X, Chacko N, Wang L, Pavuluri Y. Generation of stable mutants and targeted gene deletion strains in *Cryptococcus neoformans* through electroporation. *Med Mycol*. 2015; 53(3): 225–234.
55. Davidson RC, Cruz MC, Sia RAL, Allen B, Alspaugh JA, Heitman J. Gene disruption by biolistic transformation in serotype D strains of *Cryptococcus neoformans*. *Fungal Genet Biol*. 2000; 29(1): 38–48.
56. Chen Y, Toffaletti DL, Tenor JL, Litvintseva AP, Fang C, Mitchell TG, et al. The *Cryptococcus neoformans* transcriptome at the site of human meningitis. *MBio*. 2014; 5(1): e01087-13.
57. Goins CL, Gerik KJ, Lodge JK. Improvements to gene deletion in the fungal pathogen *Cryptococcus neoformans*: absence of Ku proteins increases homologous recombination, and co-transformation of independent DNA molecules allows rapid complementation of deletion phenotypes. *Fungal Genet Biol*. 2006; 43(8): 531–544.
58. Arras SDM, Chua SMH, Wizrah MSI, Faint JA, Yap AS, Fraser JA. Targeted genome editing via CRISPR in the pathogen *Cryptococcus neoformans*. *PLoS ONE*. 2016; 11(10): e0164322.
59. Gao Y, Zhao Y. Self-processing of ribozyme-flanked RNAs into guide RNAs *in vitro* and *in vivo* for CRISPR-mediated genome editing. *J Integr Plant Biol*. 2014; 56(4): 343–349.
60. Fan Y, Lin X. Multiple applications of a transient CRISPR-Cas9 coupled with electroporation (TRACE) system in the *cryptococcus neoformans* species complex. *Genetics*. 2018; 208(4): 1357–1372.
61. Bruni GO, Zhong K, Lee SC, Wang P. CRISPR-Cas9 induces point mutation in the mucormycosis fungus *Rhizopus delemar*. *Fungal Genet Biol*. 2019; 124: 1–7.

62. Lee KT, So YS, Yang DH, Jung KW, Choi J, Lee DG, Kwon H, Jang J, Wang LL, Cha S, Meyers GL, Jeong E, Jin JH, Lee Y, Hong J, Bang S, Ji JH, Park G, Byun HJ, Park SW, Park YM, Adedoyin G, Kim T, Averette AF, Choi JS, Heitman J, Cheong E, Lee YH, Bahn YS. Systematic functional analysis of kinases in the fungal pathogen *Cryptococcus neoformans*. *Nat Commun*. 2016; 7: 12766.
63. Noble SM., French S, Kohn LA, Chen V, Johnson AD. Systematic screens of a *Candida albicans* homozygous deletion library decouple morphogenetic switching and pathogenicity. *Nat Genet*. 2010; 42: 590–598.
64. Holland LM, Schröder MS, Turner SA, Taff H, Andes D, Grózer Z, Gácsér A, Ames L, Haynes K, Higgins DG, Butler G. Comparative phenotypic analysis of the major fungal pathogens *Candida parapsilosis* and *Candida albicans*. *PLoS Pathog*. 2014; 10(9): e1004365.
65. Roemer T, Jiang B, Davison J, Ketela T, Veillette K, Breton A, Tandia F, Linteau A, Sillaots S, Marta C, Martel N, Veronneau S, Lemieux S, Kauffman S, Becker J, Storms R, Boone C, Bussey H. Large-scale essential gene identification in *Candida albicans* and applications to antifungal drug discovery. *Mol Microbiol*. 2003; 50: 167–181.
66. Segal ES, Gritsenko V, Levitan A, Yadav B, Dror N, Steenwyk JL, Silberberg Y, Mielich K, Rokas A, Gow NAR, Kunze R, Sharan R, Berman J. Gene essentiality analyzed by *in vivo* transposon mutagenesis and machine learning in a stable haploid isolate of *Candida albicans*. *MBio*. 2018; 9(5): e02048-18.
67. Glazier VE, Murante T, Koselny K, Murante D, Esqueda M, Wall GA, Wellington M, Hung CY, Kumar A, Krysan DJ. Systematic complex haploinsufficiency-based genetic analysis of *Candida albicans* transcription factors: tools and applications to virulence-associated phenotypes. *G3 (Bethesda)*. 2018; 8(4): 1299–1314.
68. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. *Science*. 2018; 361(6405): 866–869.
69. Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature*. 2016; 533(7601): 125–129.
70. Hao H, Wang X, Jia H, Yu M, Zhang X, Tang H, et al. Large fragment deletion using a CRISPR/Cas9 system in *Saccharomyces cerevisiae*. *Anal Biochem*. 2016; 509: 118–123.
71. Li Z-H, Liu M, Lyu X-M, Wang F-Q, Wei D-Z. CRISPR/Cpf1 facilitated large fragment deletion in *Saccharomyces cerevisiae*. *J Basic Microbiol*. 2018; 58(12): 1100–1104.
72. Shao Y, Lu N, Xue X, Qin Z. Creating functional chromosome fusions in yeast with CRISPR-Cas9. *Nat Protoc*. 2019; 14(8): 2521–2545.
73. Yang F, Teoh F, Tan ASM, Cao Y, Pavelka N, Berman J. Aneuploidy enables cross-adaptation to unrelated drugs. *Mol Biol Evol*. 2019; 36(8): 1768–1782.
74. Gorter de Vries AR, Couwenberg LGF, van den Broek M, de la Torre Cortés P, Ter Horst J, Pronk JT, Daran JG. Allele-specific genome editing using CRISPR-Cas9 is associated with loss of heterozygosity in diploid yeast. *Nucleic Acids Res*. 2019; 47(3): 1362–1372.
75. Ford CB, Funt JM, Abbey D, Issi L, Guiducci C, Martinez DA, Delorey T, Li BY, White TC, Cuomo C, Rao RP, Berman J, Thompson DA, Regev A. The evolution of drug resistance in clinical isolates of *Candida albicans*. *Elife*. 2015; 4: e00662.

76. Huang MY, Woolford CA, May G, McManus CJ, Mitchell AP. Circuit diversification in a biofilm regulatory network. *PLoS Pathog.* 2019; 15(5): e1007787.
77. Wijsman M, Swiat MA, Marques WL, Hettinga JK, van den Broek M, de la Torre Cortés P, et al. A toolkit for rapid CRISPR-SpCas9 assisted construction of hexose-transport-deficient *Saccharomyces cerevisiae* strains. *FEMS Yeast Res.* 2019; 19(1): foy107.
78. Burt A. Site-specific selfish genes as tools for the control and genetic engineering of natural populations. *Proc Biol Sci.* 2003; 270(1518): 921–928.
79. Sadhu MJ, Bloom JS, Day L, Siegel JJ, Kosuri S, Kruglyak L. Highly parallel genome variant engineering with CRISPR-Cas9. *Nat Genet.* 2018; 50(4): 510–514.
80. Adames NR, Gallegos JE, Peccoud J. Yeast genetic interaction screens in the age of CRISPR/Cas. *Curr Genet.* 2019; 65(2): 307–327.
81. Halperin SO, Tou CJ, Wong EB, Modavi C, Schaffer D V., Dueber JE. CRISPR-guided DNA polymerases enable diversification of all nucleotides in a tunable window. *Nature.* 2018; 560(7717): 248–252.
82. Adli M. The CRISPR tool kit for genome editing and beyond. *Nat Commun.* 2018; 9(1): 1911.
83. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. *Science.* 2016; 351(6268): 84–88.
84. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. *Nature.* 2016; 529(7587): 490–495.
85. Chen JS, Dagdas YS, Kleinstiver benjamin P, Welch MM, Sousa AA, Harrington LB, et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. *Nature.* 2017; 550(7676): 407–410.
86. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, et al. Cpf1 is a single rna-guided endonuclease of a class 2 CRISPR-Cas system. *Cell.* 2015; 163(3): 759–771.
87. Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. *Nature.* 2018; 556(7699): 57–63.
88. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature.* 2016; 533(7603): 420–424.
89. Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of T to G C in genomic DNA without DNA cleavage. *Nature.* 2017; 551(7681): 464–471.
90. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature.* 2019; 576: 149–157.
91. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, et al. RNA targeting with CRISPR-Cas13. *Nature.* 2017; 550(7675): 280–284.
92. Giersch RM, Finnigan GC. Yeast still a beast: diverse applications of CRISPR/CAS editing technology in *S. cerevisiae*. *Yale J Biol Med.* 2017; 90(4): 643–651.

93. Knight SC, Tjian R, Doudna JA. Genomes in focus: development and applications of CRISPR-Cas9 imaging technologies. *Angew Chem Int Ed Engl*. 2018; 57(16): 4329–4337.
94. Schultz C, Lian J, Zhao H. Metabolic engineering of *Saccharomyces cerevisiae* using a trifunctional CRISPR/Cas system for simultaneous gene activation, interference, and deletion. *Methods Enzymol*. 2018; 608: 265–276.
95. Wensing L, Sharma J, Uthayakumar D, Proteau Y, Chavez A, Shapiro RS. A CRISPR interference platform for efficient genetic repression in *Candida albicans*. *mSphere*. 2019; 4(1): e00002-19.
96. Román E, Coman I, Prieto D, Alonso-Monge R, Pla J. Implementation of a CRISPR-based system for gene regulation in *Candida albicans*. *mSphere*. 2019; 4(1): e00001-19.
97. Halder V, Porter CBM, Chavez A, Shapiro RS. Design, execution, and analysis of CRISPR-Cas9-based deletions and genetic interaction networks in the fungal pathogen *Candida albicans*. *Nat Protoc*. 2019; 14(3): 955–975.
98. Scorzoni L, de Paula E Silva AC, Marcos CM, Assato PA, de Melo WC, de Oliveira HC, Costa-Orlandi CB, Mendes-Giannini MJ, Fusco-Almeida AM. Antifungal therapy: new advances in the understanding and treatment of mycosis. *Front Microbiol*. 2017; 8: 36.
99. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, Kellner MJ, Tan AL, Paul LM, Parham LA, Garcia KF, Barnes KG, Chak B, Mondini A, Nogueira ML, Isern S, Michael SF, Lorenzana I, Yozwiak NL, MacInnis BL, Bosch I, Gehrke L, Zhang F, Sabeti PC. Field-deployable viral diagnostics using CRISPR-Cas13. *Science*. 2018; 360(6387): 444–448.
100. Arastehfar A, Wickes BL, Ilkit M, Pincus DH, Daneshnia F, Pan W, Fang W, Boekhout T. Identification of mycoses in developing countries. *J Fungi (Basel)*. 2019; 5(4): 90.
101. Quan J, Langelier C, Kuchta A, Batson J, Teyssier N, Lyden A, Caldera S, McGeever A, Dimitrov B, King R, Wilhelm J, Murphy M, Ares LP, Travisano KA, Sit R, Amato R, Mumbengegwi DR, Smith JL, Bennett A, Gosling R, Mourani PM, Calfee CS, Neff NF, Chow ED, Kim PS, Greenhouse B, DeRisi JL, Crawford ED. FLASH: a next-generation CRISPR diagnostic for multiplexed detection of antimicrobial resistance sequences. *Nucleic Acids Res*. 2019; 47(14): e83.
102. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. *J Fungi (Basel)*. 2017; 3(4): 57.
103. Ianiri G, Dagotto G, Sun S, Heitman J. Advancing functional genetics through Agrobacterium-mediated insertional mutagenesis and CRISPR/Cas9 in the commensal and pathogenic yeast *Malassezia*. *Genetics*. 2019; 212(4): 1163–1179.
104. Wang Q, Coleman J J. CRISPR/Cas9-mediated endogenous gene tagging in *Fusarium oxysporum*. CRISPR/Cas9-mediated endogenous gene tagging in *Fusarium oxysporum*. *Fungal Genet Biol*. 2019; 126: 17–24.
105. Kujoth GC, Sullivan TD, Merkhofer R, Lee TJ, Wang H, Brandhorst T, Wüthrich M, Klein BS. CRISPR/Cas9-mediated gene disruption reveals the importance of zinc metabolism for fitness of the dimorphic fungal pathogen *Blastomyces dermatitidis*. *MBio*. 2018; 9(2): e00412–18.
106. Sanglard D. Finding the needle in a haystack: mapping antifungal drug resistance in fungal pathogen by genomic approaches. *PLoS Pathog*. 2019; 15(1): e1007478.

Chapter 39

The Potential Impact of Urine-LAM Diagnostics on Tuberculosis Incidence and Mortality: A Modelling Analysis

Saskia Ricks, PhD,^a Claudia M. Denkinger, MD, PhD,^{b,c} Samuel G. Schumacher, PhD,^c Timothy B. Hallett, PhD,^a and Nimalan Arinaminpathy, PhD^a

^aMRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK

^bCenter of Infectious Disease, University of Heidelberg, Heidelberg, Germany

^cFoundation for Innovative New Diagnostics, Geneva, Switzerland

saskia.ricks12@imperial.ac.uk

Keywords: antiretroviral therapy (ART), CD4-dependent hazard rates, credible interval (CrI), epidemiology, GeneXpert MTB/RIF (Xpert), HIV/TB coinfection, lipoarabinomannan (LAM), Markov chain Monte Carlo (MCMC), people living with HIV (PLHIV), tuberculosis (TB), urine-based diagnostic

39.1 Introduction

There is a pressing need for new approaches to diagnose tuberculosis (TB), in order to accelerate current slow declines in TB incidence and mortality [1, 2]. In TB diagnosis, microbiological confirmation is typically conducted on sputum samples, using either traditional tools such as smear microscopy [3] or, more recently, rapid molecular tests such as GeneXpert MTB/RIF (‘Xpert’) [4, 5]. However, sputum-based tests have several limitations: Patients can find it difficult to provide good-quality sputum specimens with the required volume, particularly those living with advanced HIV disease [6]. Additionally, sputum-based tests cannot detect extrapulmonary TB in the absence of pulmonary involvement. For these reasons, there has been increasing interest in new non-sputum-based diagnostic tools [7]. In particular, urine-based tests aim to detect the

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

mycobacterium lipoarabinomannan (LAM) antigen, part of the outer cell wall of mycobacteria [6, 8–10]. It is less invasive to collect urine than sputum samples in clinical settings, with lower infection risk to healthcare workers. Moreover, urine-based tests can detect extrapulmonary TB [11]. The Alere Determine™ TB LAM Ag ('LF-LAM') test is the only commercially available urine-based diagnostic for TB [8], a lateral flow LAM assay that is inexpensive and simple enough to be used as a point-of-care test.

However, LF-LAM performs reasonably well only in patients with advanced HIV disease [12]. Consequently, WHO guidelines have restricted the use of LF-LAM to defined patient subgroups, as listed in Table 39.1 [13]. Clinical trials show that LF-LAM may have a valuable impact in increasing early treatment and averting TB deaths in these populations [10, 12]. The technology continues to improve: A newly developed lateral flow test, Fujifilm SILVAMP TB LAM ('SILVAMP-LAM'), has shown improved sensitivity for TB compared to LF-LAM, with comparable specificity [9]. Further, a recent study in programmatic conditions demonstrated the potential for SILVAMP-LAM to identify TB amongst HIV-negative patients, showing a sensitivity of approximately 50% in this population [14]. In the same study, the additional positivity from a laboratory-based LAM assay demonstrated the potential sensitivity gains for future LAM tests. Other developments, such as new techniques for concentrating the LAM antigen available in a sample [15], also highlight the potential for continued improvements in the performance of LAM tests.

Table 39.1 WHO 2019 guidelines on the use of lateral flow urine lipoarabinomannan assays for the diagnosis of active tuberculosis (TB) in people living with HIV [13].

Setting	Population among HIV-positive adults, adolescents, and children	Strength of recommendation
Inpatients	With signs and symptoms of TB (pulmonary and/or extrapulmonary)	Strong
	With advanced HIV disease, or who are seriously ill (e.g., with respiratory rate of more than 30/min, temperature of more than 39°C)	Strong
	Irrespective of signs and symptoms of TB with a CD4 cell count of less than 200 cells/ μ l	Strong
Outpatients	With signs and symptoms of TB (pulmonary and/or extrapulmonary) or seriously ill	Conditional
	Irrespective of signs and symptoms of TB with a CD4 cell count of less than 100 cells/ μ l	Conditional

In this context, and as LAM tests continue to improve, it is important to anticipate their potential epidemiological impact, if deployed widely in future. Here, we examined this potential impact using mathematical models of TB

transmission, informed by the available evidence for the performance of LF-LAM and SILVAMP-LAM in different healthcare settings. We focused on South Africa, the country with the world's highest population rates of TB incidence, as well as the highest levels of HIV/TB coinfection. We modelled the potential TB incidence and mortality declines that would arise from the use of currently licensed LAM tests (consistent with LF-LAM) amongst those receiving HIV care, as well as a hypothetical scenario involving the use of potential future LAM tests in routine TB care, amongst HIV-negative patients.

39.2 Methods

Here we give an outline of the model structure, inputs, and intervention scenarios, with further technical details given in S1 Text.

39.2.1 Model Structure

We developed a deterministic compartmental model of TB transmission amongst adults (>15 years old) in South Africa, incorporating the role of HIV in driving TB dynamics. The overall model structure is illustrated schematically in Fig 39.1. We did not aim to model the dynamics of HIV separately as we were interested in the effect of LAM tests on the TB epidemic, and not the HIV epidemic; thus, for the purpose of this analysis, we took the incidence of HIV, the proportion of people living with HIV (PLHIV) with and without TB, their CD4 cell counts, and the coverage of antiretroviral therapy (ART) over time as given inputs for the model. Doing so allows us to capture the role of projected future ART coverage, and HIV trends, in the future trajectory of the TB epidemic in South Africa. We also developed a similar model of TB transmission in Kenya, a country with a lower HIV burden.

Patients with extrapulmonary TB are often misdiagnosed if tested with sputum-based diagnostics (Table 39.2). To capture the advantages of LAM testing for diagnosing TB amongst these patients, in the model we distinguished extrapulmonary and pulmonary TB, while assuming that only the latter contribute to transmission. The sensitivity of LAM tests depends on the extent of HIV infection, and in particular the CD4 cell count [12]. Accordingly, amongst those with HIV, we modelled 3 different CD4 cell count strata: those with a CD4 count > 200 cells/ μ l, those with a CD4 count between 100 and 200 cells/ μ l, and those with a CD4 count < 100 cells/ μ l. The model captures the rate at which those with HIV progress through declining CD4 counts, during the course of infection. We also incorporated HIV-associated hospitalisation, assuming CD4-dependent hazard rates of admission into hospital, and further assuming that upon admission, any ART-naïve patients are initiated on ART. We also captured the provision of HIV care in outpatient settings, assuming CD4-dependent rates of ART initiation in these settings. The model does not explicitly capture rifampicin-resistant or multi-drug-resistant TB, as these forms account only for 3%–4% of overall TB burden in South Africa.




Figure 39.1 Schematic illustration of the model structure. (A) represents tuberculosis (TB) transmission dynamics in the general community (centre) and hospitalised patients living with HIV, represented by superscript 'inp' (right). Model compartments are as follows: uninfected with TB (U), latent infection (L), active TB disease (I), presented for care and awaiting diagnosis (Dx), on TB treatment (Tx), temporarily dropped out of the TB care cascade due to missed diagnosis or pre-treatment loss to follow-up (E), recovered from TB (R), and inpatient admissions (A). Each compartment is stratified further by HIV status, h , defined in Table B in S1 Text. (B) illustrates the transitions between the different HIV states, including antiretroviral therapy (ART) state and CD4 count level (cells/ μ l). The following states are also further stratified into pulmonary TB and extrapulmonary TB: I , Dx , Tx , E , R^{TC} , R^{SC} , Dx^{out} , I^{inp} , A^{inp} , Tx^{inp} , E^{inp} , $R^{TC,inp}$, and $R^{SC,inp}$. Arrows represent transitions between states, at the per capita rates listed in Table 39.2. Coloured-dash arrows in (A) illustrate movement of individuals with active TB disease into outpatient status (orange), out of outpatient status (green), and into inpatient status (blue). See S1 Text for further technical details, including model equations and calibration.

Table 39.2 List of model parameters and assumptions

Parameter	Symbol	Value (95% credible interval)	Source/notes	
TB natural history				
Mean rate of transmission per TB case	β	14.9 (11.4–18.6)	Model estimate	
TB infectiousness in HIV+ (not virally suppressed) relative to HIV–	κ_1	0.66 (0.60–0.80)	Bacelar (2008) [16] Cohen (2006) [17]	
	θ_h	HIV– and virally suppressed	0.14 (0.115–0.16)	Vynnycky (1997) [18] Dye (1998) [19]
		HIV+, CD4 > 200	0.40 (0.33–0.51)	Daley (1992) [20]
Proportion of TB infections undergoing rapid progression	ρ_h	HIV+, CD4 100–200	0.80 (0.67–0.82)	
		HIV+, CD4 < 200	0.99 (0.90–1.00)	
		HIV– and virally suppressed	0.001 years ⁻¹ (0.0003–0.0024)	Horsburgh (2010) [21] Dye (1998) [19]
Per capita hazard of reactivation of latent TB infection	r_1	HIV+, CD4 > 200	0.005 years ⁻¹ (0.003–0.006)	Badri (2002) [22]
		HIV+, CD4 100–200	0.10 years ⁻¹ (0.085–0.150)	
		HIV+, CD4 < 200	0.20 years ⁻¹ (0.100–0.300)	
Per capita hazard rate of relapse	r_2	Following self-cure	0.06 years ⁻¹ (0.05–0.08)	Marx (2012) [23] Driver (2001) [24]
		Following treatment cure	0.002 years ⁻¹ (0.001–0.003)	Menzies (2009) [25] Thomas (2005) [26]
Stabilisation of relapse risk following treatment	ζ	0.5 years ⁻¹ (0.4–0.6)	Thomas (2005) [26], and assuming that relapse risk is highest in the first 2 years after recovery	

(Continued)

Table 39.2 (Continued)

Parameter	Symbol	Value (95% credible interval)	Source/notes
Per capita hazard rate of spontaneous cure	φ_h	HIV- and virally suppressed 0.17 years ⁻¹ (0.15–0.25)	Tiemersma (2011) [27]
		HIV+ 0 years ⁻¹	
Per capita hazard rate of TB mortality	μ_2	0.37 years ⁻¹ (0.31–0.59)	Model estimate
	μ_4	Excess: inpatient 1 year ⁻¹ (0.5–2.0)	
Reduction in susceptibility due to previous infection	π	0.79 (0.25–0.85)	Andrews (2012) [28]
Proportion of TB cases with pulmonary TB	α_h	HIV- 0.89 (0.80–0.90)	WHO (2019) [2]
		HIV+ 0.60 (0.50–0.70)	
HIV natural history			
Per capita hazard rate of HIV acquisition	γ	0.016 years ⁻¹ (0.013–0.021)	Model estimate, to match HIV incidence
Per capita hazard rate of CD4 progression, amongst those not virally suppressed	η_1	>200 to 100–200 0.31 years ⁻¹ (0.26–0.37)	Model estimate
	η_2	100–200 to <100 0.89 years ⁻¹ (0.88–0.90)	
	μ_{3k}	HIV+ and virally suppressed 0.17 years ⁻¹ (0.15–0.19)	
Per capita hazard rate of HIV mortality		Excess: HIV+, CD4 > 200 0.04 years ⁻¹ (0.02–0.06)	Model estimate
		Excess: HIV+, CD4 100–200 0.17 years ⁻¹ (0.13–0.21)	
		Excess: HIV+, CD4 < 100 0.60 years ⁻¹ (0.42–0.83)	

Parameter	Symbol	Value (95% credible interval)	Source/notes
Routine TB services			
Per capita rate of initial careseeking for TB symptoms	δ_1	HIV- and virally suppressed 2.5 years ⁻¹ (2.2-2.9)	Model estimate
Per capita rate of repeat careseeking for TB symptoms (following missed diagnosis)	δ_2	HIV- and virally suppressed 12 years ⁻¹ (6-24)	Assumption: corresponds to range of 2 weeks to 2 months
Rate of careseeking amongst HIV+, relative to HIV-	κ_2	1.5 (1.0-2.0)	Model estimate
Proportion of TB cases diagnosed correctly, per careseeking attempt in routine TB services	ϵ_R	HIV- pulmonary TB 0.73 (0.63-0.92)	Model estimate
	κ_3	HIV+, relative to HIV- 0.31 (0.20-0.72)	
	κ_4	Extrapulmonary, relative to pulmonary 0.21 (0.20-0.28)	
TB treatment initiation delay	ϕ_R	52 years ⁻¹ (24-100)	Assumed: corresponds to a mean treatment delay of 1 week in routine TB care
Proportion of diagnosed TB cases successfully initiating treatment	ω_R	0.88 (0.77-0.90)	Naidoo (2017) [32] Maraba (2018) [33]
Rate of first-line treatment completion	τ	2 years ⁻¹	Corresponds to a duration of 6 months
Proportion cured after first-line treatment	χ_h	HIV- 0.82 (0.77-0.87)	WHO (2019) [2]
		HIV+ 0.80 (0.75-0.85)	Naidoo (2017) [32]
Proportion that can provide a sputum sample	$\vartheta_h^{\text{sputum}}$	HIV- 0.90 (0.80-0.95)	Geldenhuys (2004) [34] Lawn (2005) [35]
		HIV+ 0.50 (0.37-0.60)	Boyles (2018) [36] Gupta-Wright (2008) [10]
Proportion that can provide a urine sample	$\vartheta_h^{\text{urine}}$	0.90 (0.97-1.00)	Broger (2019) [9]
	$W_{\text{urine } h}$		
Proportion of Xpert-negative results that are clinically diagnosed	t_h	HIV- 0.20 (0.16-0.24)	Naidoo (2017) [32]
		HIV+ 0.30 (0.24-0.36)	

(Continued)

Table 39.2 (Continued)

Parameter	Symbol	Value (95% credible interval)	Source/notes
HIV services			
Per capita rate of hospitalisation	ν_h	HIV+, CD4 > 200	Model estimate
		HIV+, CD4 100–200	0.046 years ⁻¹ (0.032–0.063)
		HIV+, CD4 < 100	0.12 years ⁻¹ (0.08–0.14)
Per capita rate of ART initiation in outpatient settings amongst PLHIV	ω_h	HIV+, CD4 > 200	Model estimate
		HIV+, CD4 100–200	0.043 years ⁻¹ (0.020–0.085)
		HIV+, CD4 < 100	0.15 years ⁻¹ (0.09–0.27)
Proportion on ART that are virally suppressed	ξ_i	HIV+, CD4 < 100	0.28 years ⁻¹ (0.18–0.43)
	ρ	0.88 (0.85–0.90)	UNAIDS estimates [37]
Inpatients: Amongst admissions with TB, proportion having TB symptoms	s_i	0.95 (0.76–1.00)	Kerkhoff (2017) [38]
Inpatients: Amongst admissions with TB, proportion receiving an Xpert test at baseline	ξ_i	1.00 (0.80–1.00)	Assuming proportion amongst inpatients is higher than amongst outpatients (see outpatient data below)
Inpatients: Proportion of diagnosed TB cases successfully initiating treatment	ω_i	1.00 (0.90–1.00)	Naidoo (2017) [32] Maraba (2018) [33]
	ψ_h	HIV+, CD4 > 200	8 days (5–10)
HIV+, CD4 100–200		9 days (6–11)	
HIV+, CD4 < 100		10 days (7–13)	

Parameter	Symbol	Value (95% credible interval)	Source/notes
Outpatients: Amongst those initiating ART, proportion having TB symptoms	s_0	0.82 (0.66–0.98)	Drain (2015) [40]
Outpatients: Amongst those initiating ART, proportion of symptomatic patients currently receiving an Xpert test	ξ_0	0.80 (0.60–0.90)	Christian (2018) [41]
Outpatients: Proportion of diagnosed TB cases successfully initiating treatment	ω_0	0.86 (0.70–0.92)	Naidoo (2017) [32] Maraba (2018) [33]
TB treatment initiation delay	ϕ	365 years ⁻¹ (52–365)	Corresponds to a mean delay of 1 day
Proportion of diagnosed TB cases successfully initiating treatment	ϵ_0	Outpatients	0.86 (0.70–0.92)
	ϵ_1	Inpatients	1.00 (0.90–1.00)
Per capita hazard rate of background mortality	μ_1	0.0156 years ⁻¹	World Bank estimates: corresponds to an average lifespan of 65 years

Note: CD4 counts are cells/ μ l. For further technical details and model specification, see S1 Text.

Abbreviations: ART, antiretroviral therapy; PLHIV, people living with HIV; TB, tuberculosis.

39.2.2 Data Sources

We drew from WHO data for estimates of TB incidence and mortality in South Africa, along with reported notifications and treatment outcomes [2]. For past HIV trends, we drew estimates from UNAIDS [37] for annual HIV incidence, the proportion of HIV cases being initiated on ART each year, and the proportion of those on ART being virally suppressed. For future projections, we drew from the Thembisa model [42], an HIV modelling framework that is the source of UNAIDS estimates (Figs. S5 and S6). Table 39.3 summarises the data for South Africa from these sources.

Table 39.3 Calibration targets for South Africa used to estimate model parameters

Indicator		Value (95% credible interval)	Source
TB epidemiology			
TB incidence, 2018		520 per 100,000 (373–691)	WHO (2019) [2]
Mortality, 2018	HIV–	37 per 100,000 (35–39)	
	HIV+	73 per 100,000 (51–99)	
Notification rate, 2018		420 per 100,000 (358–438)	
HIV epidemiology and care			
HIV prevalence, 2017		7.5 million (6.9 million–8.0 million)	AIDSinfo [37]
Proportion of TB cases coinfecting with HIV		0.59 (0.55–0.65)	WHO (2019) [2]
Proportion of PLHIV who have suppressed viral load		0.64 (0.58–0.68)	AIDSinfo [37]
Of ART-naïve patients in the community, proportion by CD4 category	CD4 > 200	0.76 (0.61–0.91)	Kharsany (2018) [43], Boyer (2016) [44], Huerga (2018) [45]
	CD4 100–200	0.12 (0.10–0.14)	
	CD4 < 100	0.12 (0.10–0.14)	
Of people initiating ART in outpatient settings, proportion by CD4 category	CD4 > 200	0.42 (0.33–0.49)	d’Elia (2015) [46], Drain (2017) [47], Brennan (2018) [48], Larsen (2019) [49], Bock (2018) [50], Cholera (2017) [51], Budgell (2015) [52]
	CD4 100–200	0.26 (0.20–0.30)	
	CD4 < 100	0.32 (0.24–0.36)	
Of people initiating ART as inpatients, proportion by CD4 category	CD4 > 200	0.34 (0.27–0.41)	Kerkhoff (2017) [38], Long (2016) [53], Broger (2019) [9]
	CD4 100–200	0.25 (0.20–0.28)	
	CD4 < 100	0.41 (0.33–0.45)	
Overall number initiating ART, 2017		660,982	AIDSinfo [37]
Percentage of HIV cases being hospitalised annually		5% (3.5%–6.5%)	Meyer-Rath (2013) [39]

Note: CD4 counts are cells/ μ l.

Abbreviations: ART, antiretroviral therapy; PLHIV, people living with HIV; TB, tuberculosis.

We performed a literature search to identify the proportions of PLHIV in the 3 different CD4 strata described above, stratifying by 3 different population types, in line with WHO recommendations: (i) those initiating ART upon admission to hospital, (ii) those initiating ART as outpatients, and (iii) those who are not on ART. Figure S2 summarises the proportions thus extracted, and the sources of data used. These data inform model estimates for the timeliness of HIV treatment as follows: Early treatment yields a patient population with higher CD4 counts at the point of treatment initiation, and, conversely, late treatment is associated with a patient population having lower CD4 counts (Table 39.3; Fig. S2). Therefore, by fitting the model to simultaneously capture CD4 progression and the distribution of CD4 counts at treatment initiation, we estimated the rate of treatment initiation at different CD4 counts, both in outpatient and inpatient settings (Table 39.3; Fig. S2). We additionally collected data from the literature for other parameters: for example, for the proportion of HIV cases that are hospitalised per year [39] and for the current standard of TB care amongst HIV inpatients (e.g., the proportion of hospital admissions receiving a TB test in routine practice) [10].

Using adaptive Markov chain Monte Carlo (MCMC), in particular the adaptive algorithm first proposed by Haario et al. [54], we incorporated uncertainty in model inputs (Table 39.2), propagating this input uncertainty into uncertainty in model projections. We drew 5,000 samples from the posterior distribution. For any model projections based on these samples, we estimated uncertainty intervals using the 2.5th and 97.5th percentiles, referring to this estimate as the Bayesian credible interval (CrI). Further details on the model structure and calibration are given in S1 Text.

39.2.3 Intervention Scenarios

We distinguished ‘current’ and potential ‘future’ LAM tests. For the performance of the former, we drew from a systematic review of LF-LAM [12]. For the latter, we took SILVAMP-LAM as an illustrative example, drawing from a recent study that estimated the performance of this test in HIV-negative patients [14]. This same study highlighted the potential of future LAM tests to have improved performance compared to SILVAMP-LAM: Our parameters for future LAM tests could therefore be interpreted as a lower bound for their performance [9] (Table 39.4). We assumed that differences in test performance between inpatients and outpatients are driven primarily by variations in CD4 distributions between these populations, variations that are captured by the model. Accordingly, we concentrated on study findings stratified by CD4 status, rather than by inpatient or outpatient setting.

A test’s epidemiological impact (i.e., on incidence and mortality) is driven by its sensitivity, or the proportion of true TB cases it can detect. A test’s specificity, or the proportion of those without TB that it correctly diagnoses as negative, has no direct bearing on its epidemiological impact, and instead is more relevant

for the number of unnecessary TB treatments incurred as a result of false-positive diagnosis [55]. As the focus of the current work is on epidemiological impact, we concentrated on test sensitivity and not specificity. Our model therefore does not address the adverse consequences of false-positive results, including additional costs and adverse treatment side effects.

Table 39.4 Test sensitivities

Test	Symbol	HIV-	HIV+				Source
			CD4 > 200	CD4 100–200	CD4 < 100	Virally suppressed	
Sputum Xpert	X_{sn}	89% (85–92)	79% (70–86)	79% (70–86)	79% (70–86)	79% (70–86)	Steingart (2014) [4]
Currently licensed LAM test	A_{sn}	—	12% (5–24)	26% (15–39)	57% (42–70)	42% ^a (32–52)	Bjerrum (2019) [12] Broger (2019) [9]
Future LAM test (consistent with SILVAMP-LAM as illustrative example)	F_{sn}	30% (20–50)	44% (30–59)	61% (44–73)	84% (71–91)	70%* (53–83)	Broger (2019) [9] Broger (2020) [14]

Note: CD4 counts are cells/ μ l. Values in parentheses are 95% credible intervals. We assumed Xpert sensitivity to be independent of CD4 count amongst those with HIV.

*Sensitivities for patients with virally suppressed HIV infection were estimated by taking the ‘overall’ sensitivities of each test presented in the meta-analysis by Bjerrum et al. [12].

Abbreviation: LAM, lipoarabinomannan.

We modelled the deployment of current and future LAM tests in 2 intervention scenarios reflecting models of use in the updated WHO guidelines [13] (Table 39.1). In ‘PLHIV inpatients only’ (scenario i), LAM testing is conducted in PLHIV inpatients with signs and symptoms of TB and in all PLHIV inpatients with CD4 < 200 cells/ μ l, independent of symptoms. In ‘PLHIV inpatients and outpatients’ (scenario ii), LAM testing is conducted in PLHIV inpatients and outpatients prior to initiating ART treatment and with signs and symptoms of TB, in all PLHIV inpatients with CD4 < 200 cells/ μ l, and in all PLHIV outpatients with CD4 < 100 cells/ μ l, independent of symptoms. Additionally, for future LAM tests alone, we modelled a hypothetical future scenario: ‘universal for all TB presumptive patients’ (scenario iii), in which a future LAM test is deployed as part of routine TB diagnosis in patients presenting with symptoms of TB to a healthcare provider, regardless of HIV status. The impact of this scenario derives from the diagnosis of HIV-negative TB, and from the diagnosis of TB amongst those with undiagnosed HIV (and who may miss the opportunity for urine-based

testing under current LAM testing guidelines). To assess which of these factors are most influential for impact, we additionally simulated scenario iii under a hypothetical condition where SILVAMP-LAM has 0 sensitivity for TB in HIV-negative individuals. This artificial scenario is thus deliberately constructed so that the only incremental cases being diagnosed, relative to scenario ii, are those with HIV and not on ART.

We modelled each of these intervention scenarios, assuming them to be initiated in 2020; we assumed that the proportion of the target population accessing these tests increases linearly, until the whole population in South Africa is covered by 2023. We simulated the model forward to 2035, simulating incidence and mortality over this time.

We considered the impact of LAM testing with respect to 2 comparators: (i) a 'status quo' comparator scenario, where the current standard of TB care continues indefinitely (where a proportion of patients presenting to care with signs and symptoms of TB are offered an Xpert test by a healthcare provider) and (ii) an 'Xpert scale-up' comparator scenario, involving the scale-up of sputum-based Xpert across the country, to diagnose TB both amongst those receiving ART and in routine TB services. We assumed that all patients presumed to have TB based on symptoms receive Xpert testing by 2023 (in inpatient, outpatient, and routine care settings).

Consistent with diagnostic yields reported in the literature (Table 39.2), we assumed that only 50% of patients with HIV (in both inpatient and outpatient settings) are able to provide a sputum sample for Xpert testing, while 99% of patients are able to provide a urine sample for LAM testing. We also considered clinical diagnosis that occurs after a negative Xpert test result. We assumed that 20% and 30% of patients with negative Xpert test results are clinically diagnosed and offered treatment amongst HIV-negative and HIV-positive patients, respectively [32]. Using comparator and intervention scenarios, we projected estimates for the numbers of TB cases and deaths that would be averted under the intervention scenarios described above.

Finally, as a sensitivity analysis to examine the applicability of our results to other countries with a generalised HIV epidemic, we extended our model to capture epidemiological conditions consistent with Kenya, where an estimated 27% of TB is in HIV-coinfected patients, compared with 59% for South Africa [2]. There is insufficient data from Kenya to calibrate all model parameters; we therefore sought only to capture gross epidemiological indicators consistent with Kenya (TB incidence, mortality, proportion of HIV coinfection, *etc.*), while assuming the same values as derived for South Africa for all parameters specific to CD4 counts (rates of ART initiation, hospitalisation, *etc.*; see Table S2 for further details). We then simulated the intervention scenarios described above, in this Kenya-like setting.

39.3 Results

Figure S1 shows results of model calibration, displaying the model fit against each of the calibration targets listed in Table 39.3. Our model projects that, under the status quo comparator between 2020 and 2035, there would be 2,700,000 (95% CrI 2,000,000–3,600,000) cumulative incident cases of TB in South Africa, and 420,000 (95% CrI 350,000–520,000) cumulative TB deaths.




Figure 39.2 Model projections for impact of LAM tests in South Africa on TB incidence, relative to the status quo comparator. Under the status quo comparator, the current standard of TB care in South Africa is assumed to continue indefinitely. Shaded areas show Bayesian 95% credible intervals. Solid lines depict a currently licensed test, while dashed lines depict a future LAM test. Colours represent different implementation scenarios: inpatients only (red, scenario i), plus outpatients (blue, scenario ii) and plus routine TB care (yellow, scenario iii). (A) depicts scenarios i and ii only, while (B) additionally shows scenario iii (shown separately owing to the change in scale). Cumulative impacts over the period 2020–2035 are summarised in Table 39.5. *Abbreviations:* LAM, lipoarabinomannan; TB, tuberculosis.

Figures 39.2 and Fig. 39.3 illustrate the potential impact of LAM tests relative to the status quo comparator, showing the TB cases and deaths averted each year, respectively. Table 39.5 summarises the cumulative impact in South Africa over the period 2020 to 2035, showing estimates for both cases and deaths averted. As context to these results, Table S1 shows additional model outputs for the numbers of patients initiating HIV treatment in both outpatient and inpatient settings. Together these results illustrate that LAM tests could have a meaningful impact in saving lives amongst inpatients (scenario i); current and future LAM tests may avert, respectively, 54 (95% CrI 33–86) and 90 (95% CrI 55–145) TB deaths amongst inpatients, a 5.33% (95% CrI 4.18%–6.29%) and 8.75% (95% CrI 7.05%–11.2%) reduction of overall TB deaths in this population. At a population level, 324 (95% CrI 170–596) and 543 (95% CrI 289–982) TB deaths would be averted with current and future LAM tests, respectively, a limited

impact (<1% of the country-level TB burden) that is clearly because of the small size of the population receiving the intervention.




Figure 39.3 Model projections for impact of LAM test in South Africa on TB deaths, relative to the status quo comparator. Under the status quo comparator, the current standard of TB care in South Africa is assumed to continue indefinitely. Shaded areas show Bayesian 95% credible intervals. Solid lines depict a currently licensed test, while dashed lines depict a future LAM test. Colours represent different implementation scenarios: inpatients only (red, scenario i), plus outpatients (blue, scenario ii) and plus routine TB care (yellow, scenario iii). (A) depicts scenarios i and ii only, while (B) additionally shows scenario iii. Cumulative impacts over the period 2020–2035 are summarised in Table 39.5. *Abbreviations:* LAM, lipoarabinomannan; TB, tuberculosis.

Table 39.5 Projected cumulative impact relative to a status quo comparator, South Africa

Deployment level	LAM test	Cumulative incidence averted, 2020–2035		Cumulative TB deaths averted, 2020–2035		Cumulative TB deaths averted amongst inpatients, 2020–2035	
		Number	Percent	Number	Percent	Number	Percent
Inpatients (scenario i)	Currently licensed LAM	692 (402–1,156)	0.026 (0.014–0.043)	324 (170–596)	0.077 (0.045–0.125)	54 (33–86)	5.33 (4.18–6.29)
	Future LAM	1,181 (698–1,990)	0.045 (0.025–0.074)	543 (289–982)	0.129 (0.076–0.203)	90 (55–145)	8.75 (7.05–11.2)
Inpatients and outpatients (scenario ii)	Currently licensed LAM	1,670 (937–2,837)	0.063 (0.035–0.109)	724 (376–1,415)	0.173 (0.097–0.306)	58 (36–93)	5.73 (4.36–6.90)
	Future LAM	2,665 (1,539–4,631)	0.100 (0.056–0.175)	1,153 (594–2,188)	0.276 (0.156–0.486)	96 (58–155)	9.33 (7.43–12.1)
Inpatients, outpatients, and routine TB care (scenario iii)	Future LAM	470,590 (221,830–871,500)	17.7 (8.62–29.0)	123,520 (69,120–206,270)	29.6 (17.8–43.6)	402 (229–685)	39.7 (29.4–49.1)

Note: Under the status quo comparator, we assume the current standard of TB care in South Africa to continue indefinitely. Values in parentheses are 95% credible intervals.

Abbreviations: LAM, lipoarabinomannan; TB, tuberculosis.

When expanding LAM test deployment to outpatient settings (scenario ii), current and future LAM tests would avert, respectively, 724 (95% CrI 376–1,400) and 1,200 (95% CrI 594–2,200) TB deaths, roughly doubling the total deaths averted under scenario i. Notably, however, even with this widened eligibility, LAM tests continue to exert only a modest impact on the population-level TB epidemic, with <1% reductions in TB incidence and mortality (Figs. 39.2A and 39.3A; Table 39.5). It is only when LAM tests are deployed in routine TB services (scenario iii) that true incidence-reducing impact emerges (Figs. 39.2B and 39.3B), with 470,000 (95% CrI 220,000–870,000) cumulative TB incident cases and 120,000 (95% CrI 69,000–210,000) TB deaths averted, respective reductions of 17.7% (95% CrI 8.62%–29.0%) and 29.6% (95% CrI 17.8%–43.6%). Figure S7 illustrates the reason for the limited population-level impact under scenarios i and ii, even in a high-HIV-burden setting such as South Africa: It is due to the series of criteria that successively narrow the pool of eligible individuals to <5% of annual TB incidence.

Table 39.6 Projected cumulative impact relative to an Xpert scale-up comparator, South Africa

Deployment level	LAM test	Cumulative incidence averted, 2020–2035		Cumulative TB deaths averted, 2020–2035		Cumulative TB deaths averted amongst inpatients, 2020–2035	
		Number	Percent	Number	Percent	Number	Percent
Inpatients (scenario i)	Currently licensed LAM	171 (81–322)	0.0079 (0.0043–0.014)	153 (81–324)	0.050 (0.028–0.088)	34 (20–56)	4.68 (3.68–5.62)
	Future LAM	291 (136–546)	0.014 (0.0074–0.025)	256 (134–523)	0.083 (0.047–0.14)	56 (33–93)	7.69 (6.12–10.2)
Inpatients and outpatients (scenario ii)	Currently licensed LAM	395 (192–798)	0.019 (0.010–0.037)	330 (173–747)	0.108 (0.058–0.210)	36 (22–60)	4.99 (3.81–6.13)
	Future LAM	635 (293–1,327)	0.030 (0.016–0.060)	530 (271–1,143)	0.173 (0.094–0.329)	59 (35–98)	8.15 (6.41–10.8)
Inpatients, outpatients, and routine TB care (scenario iii)	Future LAM	119,670 (68,710–169,030)	5.68 (3.18–7.52)	50,174 (33,617–72,557)	16.4 (10.4–22.2)	204 (122–344)	28.7 (21.6–34.5)

Note: Under the Xpert scale-up comparator, we assume comprehensive expansion of access to sputum Xpert across South Africa, such that all individuals with symptoms suggestive of TB are tested with Xpert on their first presentation for care. Numbers in the table show the model-projected impact of LAM tests when deployed as an adjunct to Xpert, assuming (in all settings shown in the table) a simple diagnostic algorithm where TB is diagnosed if either a LAM test or Xpert is positive for TB. Values in parentheses are 95% credible intervals. As described in the main text, in the model we also allow for clinical diagnosis amongst bacteriologically negative symptomatic patients.

Abbreviations: LAM, lipoarabinomannan; TB, tuberculosis.

Table 39.6 summarises the cumulative impact under the Xpert scale-up comparator. In this case the incremental cases averted by a future LAM test in routine TB care (scenario iii) fall to 120,000 (95% CrI 69,000–170,000), a 5.68% (95% CrI 3.18%–7.52%) reduction from the 17.7% (95% CrI 8.62%–29.0%) achieved with the status quo comparator, owing to the improvements in diagnosis already achieved by Xpert scale-up. Under the same scenario, a future LAM test would avert 50,000 (95% CrI 34,000–73,000) TB deaths, a 16.4% (95% CrI 10.4%–22.2%) reduction. Overall, the effect of Xpert scale-up on the incremental impact of LAM tests is lower for deaths averted than for cases averted: This reflects the value of LAM tests in diagnosing extrapulmonary TB and TB in those with advanced disease, patients who would otherwise contribute more strongly to mortality than to transmission.

As noted above, the impact of scenario iii (Figs. 39.2B and 39.3B) could derive either from diagnosis of TB in HIV-negative individuals or from diagnosis of TB amongst those with HIV who have not yet been linked to care. To examine the roles of these 2 populations, we simulated a hypothetical scenario of a future LAM test being deployed in routine TB services, but with 0 sensitivity for TB in HIV-negative individuals. Under this hypothetical scenario the TB cases and deaths averted are, respectively, 12.1% (95% CrI 8.34%–17.6%) and 21.3% (95% CrI 15.2%–29.7%) in South Africa, hypothetical impacts that represent only marginal reductions of those reported in the bottom row of Table 39.5. Overall, these findings illustrate that—when expanded from outpatients in HIV care to routine TB services—the key value of LAM tests would be in diagnosing TB amongst those with HIV who have not yet been initiated on ART.

Similar results are seen in a Kenya-like setting (Tables S3 and S4; Fig. S9). Relative to a status quo comparator, in scenarios i and ii, where LAM tests are deployed only amongst those receiving HIV care, the percentage decline in mortality amongst eligible groups is roughly half that in South Africa (Table S3), owing to the smaller proportion of HIV cases having TB. As in South Africa, population-level declines in incidence and mortality would be <1% in these scenarios. However, when deployment of a future LAM test is expanded to routine TB services, 290,000 (95% CrI 190,000–470,000) cumulative TB incident cases and 58,000 (95% CrI 39,000–86,000) TB deaths are averted, a 19.8% (95% CrI 18.1%–22.7%) and 27.9% (95% CrI 25.7%–31.4%) reduction, respectively, in a Kenya-like setting (Table S3), impacts that are comparable to those estimated for South Africa (Table 39.5).

39.4 Discussion

39.4.1 Summary

New non-sputum-based diagnostic technologies could raise new opportunities to accelerate current declines in TB incidence [56–58]. In the current work we have

addressed one example of such technologies: lateral flow LAM assays, which offer the potential to diagnose TB through urine. Given that LAM tests perform best in PLHIV [12], it was reasonable to hypothesise that they would have a substantial epidemiological impact in settings such as South Africa, where the majority of TB cases are HIV coinfecting. However, our results suggest a more nuanced message: For future LAM tests to achieve population-level reductions in TB burden, they would need to be offered more widely than amongst those receiving HIV care, and in routine TB care. Under this scenario, the patients who would benefit are not just HIV-negative cases, but also those with HIV who have not yet been engaged in HIV care. The latter population could arise from a variety of factors, including the rate of HIV diagnosis or gaps in linkage to ART initiation after a diagnosis has been made. In practice, the feasibility of such wide deployment of LAM tests will depend critically on the performance characteristics of the tests concerned.

While much of the existing literature on LF-LAM addresses its diagnostic performance and implementation in defined clinical settings [9, 10, 12, 14], our work complements this evidence basis by addressing the population level in countries with a high HIV and TB burden. To our knowledge, this is the first modelling study to examine the potential incidence and mortality impact that LF-LAM tests may offer.

39.4.2 Limitations and Key Areas for Future Work

Although we expect similar results to apply in other settings with a generalised HIV epidemic, our analysis does not address high-TB-burden countries where HIV is not a driving factor, such as India. The potential use of LF-LAM in such settings is an important area for further work. In these settings, we expect that the value of a future LAM test might be driven not by its ability to detect TB amongst those with HIV, but rather by its potential to be used more widely than current diagnostic tools needing laboratory capacity: for example, in primary care and in peripheral healthcare settings.

Our work also does not address cost or cost-effectiveness, another important topic for future work. Recent analysis indicated that LF-LAM and SILVAMP-LAM would be cost-effective when deployed in inpatient settings in both Malawi and South Africa [59]; future work, especially in the context of improved-performance tests, could benefit from incorporating a transmission framework. Relatedly, we have also not addressed the staffing and health system capacity that would be needed to facilitate the expansion of LAM testing in South Africa [60], nor the costs associated with undertaking CD4 cell count measurements. It should be noted that CD4 cell count measurement is increasingly being replaced by viral load monitoring. In addition, we have not addressed potential implementation challenges in the use of future LAM tests. For example, SILVAMP-LAM involves an additional step compared to LF-LAM; findings from ongoing trials will be valuable in determining whether this procedure reduces the performance of this technology to any appreciable extent.

Amongst additional model simplifications, we have not covered paediatric TB, an important and underaddressed part of TB burden. We have also taken a country-level perspective, despite wide subnational variation in TB/HIV burden within South Africa [61, 62]. For simplicity we have ignored drug resistance: Despite the potential benefits of LAM tests, one notable limitation of these tests is that they cannot determine drug sensitivity. In the model calibration, we have captured temporal trends and projections in major features of the HIV epidemic in South Africa, such as HIV incidence and the proportion on ART; however, we have modelled other features as static, for example the percentage of HIV cases that are hospitalised. Further data on how this proportion has changed over time should allow our model to better capture these dynamics, potentially affecting our estimates for deaths averted amongst those being hospitalised. However, we have shown that this impact accounts for only a small proportion of overall TB burden in South Africa; we therefore do not expect these changes to affect our overall qualitative findings on the importance of widened eligibility for epidemiological impact.

Given our focus on epidemiological impact, our analysis of test performance is limited to test sensitivity. However, for any future LAM test that is intended for use in routine TB services, test specificity will be a critical performance characteristic, in order to minimise the number of unnecessary TB treatments incurred [55]. As an illustrative example, a test having 95% specificity and 90% sensitivity would—for the 10% TB prevalence that is typical amongst symptomatic individuals presenting to routine TB services—result in 1 false-positive TB diagnosis for every 2 successful TB diagnoses, an unacceptably high rate. Evidence suggests that both LF-LAM and SILVAMP-LAM may have reduced specificity at lower CD4 counts [9, 13]. Estimating this risk is an important area for future work: however, an important first step in this direction is to address the real uncertainties in quantifying specificity where the accuracy of the reference standard is unclear. An example of when a reference standard may be unclear includes the use of a sputum-based microbiological reference standard amongst patients with solely extrapulmonary TB, and potentially also among patients with HIV, who are more likely to produce paucibacillary sputum [6, 63]. Although a LAM test may correctly diagnose such patients, this diagnosis would be deemed incorrect by a sputum-based microbiological reference standard. For future quantitative analysis, therefore, there is a need for more systematic estimates of specificity that take account of such shortcomings of any given reference standard. Combined use of microbiological and composite reference standards (i.e., including clinical diagnosis) may help in this regard.

39.5 Conclusions

In this study, we observe that even in a setting with high HIV burden, such as South Africa, future LAM tests will need to have sufficient performance to be

offered more widely than HIV care, in order to have incidence-reducing impact. Future LAM tests will also need to have sufficient specificity to achieve this impact without incurring an undue burden of unnecessary TB treatment. Any emerging LAM technology meeting these criteria would be invaluable in accelerating current declines in TB burden.

Supporting Information

S1 Fig. Model fits to data for South Africa. Data points are described in Table 39.3. (A) TB incidence; (B) TB mortality per 100,000; (C) TB notifications per 100,000; (D) proportion of PLHIV with suppressed viral loads; (E) ART initiations per 100,000; (F) proportion of TB cases coinfecting with HIV; (G) percentage of HIV cases being hospitalised annually. <https://doi.org/10.1371/journal.pmed.1003466.s001>.

S2 Fig. CD4 count distributions. Model fits to the data: mean model CD4 count distributions amongst ART-naïve PLHIV (blue), inpatients (red), and outpatients (yellow). Grey lines show the model runs, and black data points show the data, based on a literature search (Table 39.3). <https://doi.org/10.1371/journal.pmed.1003466.s002>.

S3 Fig. Markov chain Monte Carlo diagnostics. (A) shows the posterior density trace. (B) and (C) show autocorrelation function plots for 2 selected parameters (rate of transmission and proportion of fast progressors). <https://doi.org/10.1371/journal.pmed.1003466.s003>.

S4 Fig. Multivariate sensitivity analysis of impact for South Africa. Using scenario iii (future LAM test deployment in routine TB care), we used the partial rank correlation coefficient (PRCC) to examine which parameter listed in Table 39.2 the output cases averted is most sensitive towards. Larger bars represent more sensitive parameters. Shown are the 20 most influential model parameters, in decreasing order of sensitivity from top to bottom. <https://doi.org/10.1371/journal.pmed.1003466.s004>.

S5 Fig. Total new HIV infections in South Africa. Past estimates (in blue shading) and future projections (in green shading). <https://doi.org/10.1371/journal.pmed.1003466.s005>.

S6 Fig. Proportion of PLHIV on ART in South Africa. Past estimates (in blue shading) and future projections (in green shading). <https://doi.org/10.1371/journal.pmed.1003466.s006>.

S7 Fig. Cumulative effect of eligibility criteria. Flow diagram illustrating the effect of the most recent eligibility criteria in WHO recommendations for the use of LF-LAM on the size of the subset of TB incident cases who receive LAM testing. In South Africa, of patients with TB disease, around 59% are coinfecting with HIV; of these, 90% are aware of their HIV status, of which, approximately 18% will

initiate ART per year. Depending on the eligibility criteria, around 10%–30% of individuals who initiate ART will be eligible for LAM testing. For the purpose of this illustration, of the 7,700,000 who are HIV-positive, 2,900,000 were estimated not to be on ART in 2018. Approximately 90% of these (2,610,000) are aware of their HIV status. Model estimates suggest that approximately 480,000 initiated ART in 2018. Thus, we approximate that in 2018, 18% of individuals who were aware of their HIV infection initiated ART (480,000/2,610,000). <https://doi.org/10.1371/journal.pmed.1003466.s007>.

S8 Fig. Model fits to data for Kenya. Data points are described in Table S2. (A) TB incidence; (B) TB mortality per 100,000; (C) TB notifications per 100,000; (D) proportion of PLHIV with suppressed viral loads; (E) ART initiations per 100,000; (F) proportion of TB cases coinfecting with HIV; (G) percentage of HIV cases being hospitalised annually. <https://doi.org/10.1371/journal.pmed.1003466.s008>.

S9 Fig. Model projections for impact of LAM tests in Kenya on TB incidence, relative to the status quo comparator. Under this comparator, the current standard of TB care in Kenya is assumed to continue indefinitely. Shaded areas show Bayesian 95% credible intervals. Solid lines depict a currently licensed test, while dashed lines depict a future LAM test. Colours represent different implementation scenarios: inpatients only (red, scenario i), plus outpatients (blue, scenario ii), and plus routine TB care (yellow, scenario iii). (A) depicts scenarios i and ii only, while (B) additionally shows scenario iii (shown separately owing to the change in scale). Cumulative impacts over the period 2020–2035 are summarised in Table S3. <https://doi.org/10.1371/journal.pmed.1003466.s009>.

S1 Table. TB incidence and mortality, and number of patients initiating ART per year, in inpatient and outpatient settings. <https://doi.org/10.1371/journal.pmed.1003466.s010>.

S2 Table. Calibration targets for Kenya used to estimate model parameters. <https://doi.org/10.1371/journal.pmed.1003466.s011>.

S3 Table. Projected cumulative impact relative to a status quo comparator, Kenya. <https://doi.org/10.1371/journal.pmed.1003466.s012>.

S4 Table. Projected cumulative impact relative to an Xpert scale-up comparator, Kenya. <https://doi.org/10.1371/journal.pmed.1003466.s013>.

S1 Text. Supplementary materials and methods. <https://doi.org/10.1371/journal.pmed.1003466.s014>

Abbreviations

ART:	antiretroviral therapy
CrI:	credible interval
LAM:	lipoarabinomannan
MCMC:	Markov chain Monte Carlo

PLHIV: people living with HIV
PRCC: partial rank correlation coefficient
TB: tuberculosis
WHO: World Health Organization
Xpert: GeneXpert MTB/RIF

Disclosures and Conflict of Interest

This chapter was originally published as: Ricks, S., Denkinger, C. M., Schumacher, S. G., Hallett, T. B., Arinaminpathy, N. (2020). The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis. *PLoS Med.*, **17**(12), e1003466, <https://doi.org/10.1371/journal.pmed.1003466>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: All relevant data are within the chapter and its Supporting Information files. Model code can be accessed from: <https://github.com/saskiaricks/urineLAMdiagnostic>.

Funding: SR was supported by grant number 203839/A/16/Z, funded by the Wellcome Trust. NA and TBH were supported by grant number MR/R015600/1, jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: SR, TBH and NA have declared that no competing interests exist. CMD is on the editorial board of PLOS Medicine. SGS reports working for FIND. FIND is a non-for-profit foundation, whose mission is to find diagnostic solutions to overcome diseases of poverty in LMICs. It works closely with the private and public sectors and receives funding from some of its industry partners. It has organisational firewalls to protect it against any undue influences in its work or the publication of its findings. All industry partnerships are subject to review by an independent Scientific Advisory Committee or another independent review body, based on due diligence, TPPs and public sector requirements. FIND catalyses product development, leads evaluations, takes positions, and accelerates access to tools identified as serving its mission. It provides indirect support to industry (e.g., access to open specimen banks, a clinical trial platform, technical support, expertise, laboratory capacity strengthening in LMICs, etc.) to facilitate the development and use of products in these areas. FIND also supports the evaluation of prioritised assays and the early stages of implementation of WHO-approved (guidance & PQ) assays using donor grants. In order to carry out test validations and evaluations, has product evaluation agreements with several private sector companies for the diseases FIND works in which strictly define its independence and neutrality vis-a-vis the companies whose products get evaluated, and describes roles and responsibilities.

Conceptualization: Nimalan Arinaminpathy; Data curation: Claudia M. Denkinge; Formal analysis: Saskia Ricks; Methodology: Saskia Ricks, Nimalan Arinaminpathy; Supervision: Nimalan Arinaminpathy; Writing – original draft: Saskia Ricks, Nimalan Arinaminpathy; Writing – review & editing: Claudia M. Denkinge, Samuel G. Schumacher, Timothy B. Hallett.

References

1. Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. *Lancet Infect Dis*. 2018; 18: e199–210.
2. World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Available at: <https://www.who.int/publications/i/item/global-tuberculosis-report-2019> (accessed on November 20, 2022).
3. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. *Lancet Infect Dis*. 2006; 6: 664–74.
4. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev*. 2014; 2014: CD009593.
5. Evans CA. GeneXpert—a game-changer for tuberculosis control? *PLoS Med*. 2011; 8: e1001064.
6. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. *J Infect Dis*. 2011; 204: S1159–67.
7. World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: World Health Organization; 2014. Available at: https://apps.who.int/iris/bitstream/handle/10665/135617/WHO_HTM_TB_2014.18_eng.pdf?sequence=1 (accessed on November 20, 2022).
8. Lawn SD, Kerkhoff AD, Burton R, Schutz C, Boule A, Vogt M, et al. Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort. *BMC Med*. 2017; 15: 67.
9. Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Reipold EI, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. *Lancet Infect Dis*. 2019; 19: 852–861.
10. Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D, Alufandika-Moyo M, et al. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. *Lancet*. 2018; 392: 292–301.
11. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. *BMC Infect Dis*. 2012; 12: 103.
12. Bjerrum S, Schiller I, Dendukuri N, Eisenhut M, Kohli M, Nathavitharana R, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in

- people living with HIV: an updated systematic review. *Cochrane Database Syst Rev.* 2019; 10: CD011420.
13. World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV. Geneva: World Health Organization; 2019. Available at: <https://www.who.int/publications/i/item/9789241550604> (accessed on November 20, 2022).
 14. Broger T, Nicol MP, Sigal GB, Gotuzzo E, Zimmer AJ, Surtie S, et al. Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. *J Clin Invest.* 2020; 130: 5756–5764.
 15. Paris L, Magni R, Zaidi F, Araujo R, Saini N, Harpole M, et al. Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity. *Sci Transl Med.* 2017; 9: eaal2807.
 16. Bacaër N, Ouifki R, Pretorius C, Wood R, Williams B. Modeling the joint epidemics of TB and HIV in a South African township. *J Math Biol.* 2008; 57: 557–93.
 17. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfecting populations. *Proc Natl Acad Sci U S A.* 2006; 103: 7042–7.
 18. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. *Epidemiol Infect.* 1997; 119: 183–201.
 19. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. *Lancet.* 1998; 352: 1886–91.
 20. Daley CL, Small PM, Schechter GF, Schoolnik GK, McAdam RA, Jacobs WR, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. *N Engl J Med.* 1992; 326: 231–5.
 21. Horsburgh CR, O'Donnell M, Chamblee S, Moreland JL, Johnson J, Marsh BJ, et al. Revisiting rates of reactivation tuberculosis: a population-based approach. *Am J Respir Crit Care Med.* 2010; 182: 420–5.
 22. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. *Lancet.* 2002; 359: 2059–64.
 23. Marx FM, Dunbar R, Enarson DA, Beyers N. The rate of sputum smear-positive tuberculosis after treatment default in a high-burden setting: a retrospective cohort study. *PLoS ONE.* 2012; 7: e45724.
 24. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. *Clin Infect Dis.* 2001; 33: 1762–9.
 25. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. *PLoS Med.* 2009; 6: e1000146.
 26. Thomas A, Gopi PG, Santha T, Chandrasekaran V, Subramani R, Selvakumar N, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. *Int J Tuberc Lung Dis.* 2005; 9: 556–61.

27. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJD. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. *PLoS ONE*. 2011; 6: e17601.
28. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with *Mycobacterium tuberculosis*. *Clin Infect Dis*. 2012; 54: 784–91.
29. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Côte d'Ivoire. *Clin Infect Dis*. 2012; 54: 714–23.
30. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. *Lancet*. 2006; 368: 1254–59.
31. Mangal TD. Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. *AIDS*. 2017; 31: 1073–82.
32. Naidoo P, Theron G, Rangaka MX, Chihota VN, Vaughan L, Brey ZO, et al. The South African tuberculosis care cascade: estimated losses and methodological challenges. *J Infect Dis*. 2017; 216: S702–13.
33. Maraba N, Chihota V, McCarthy K, Churchyard GJ, Grant AD. Linkage to care among adults being investigated for tuberculosis in South Africa: pilot study of a case manager intervention. *BMJ Open*. 2018; 8: e021111.
34. Geldenhuys HD, Whitelaw A, Tameris MD, Van As D, Luabeya KKA, Mahomed H, et al. A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community. *Eur J Clin Microbiol Infect Dis*. 2014; 33: 2259–66.
35. Lawn SD, Kerkhoff AD, Burton R, Schutz C, van Wyk G, Vogt M, et al. Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa. *BMC Med*. 2015; 13: 192.
36. Boyles TH, Griesel R, Stewart A, Mendelson M, Maartens G. Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV. *Int J Infect Dis*. 2018; 75: 67–73.
37. AIDSinfo. Trend of new HIV infections. Geneva: Joint United Programme on HIV/AIDS; 2019. Available at: <http://aidsinfo.unaids.org> (accessed on November 20, 2022).
38. Kerkhoff AD, Barr DA, Schutz C, Burton R, Nicol MP, Lawn SD, et al. Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays. *Sci Rep*. 2017; 7: 10931.
39. Meyer-Rath G, Brennan AT, Fox MP, Modisenyane T, Tshabangu N, Mohapi L, et al. Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa. *J Acquir Immune Defic Syndr*. 2013; 62: 322–8.
40. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Value of urine lipoarabinomannan grade and second test for optimizing clinic-based screening for HIV-associated pulmonary tuberculosis. *J Acquir Immune Defic Syndr*. 2015; 68: 274–80.

41. Christian CS, Gerdtham U, Hompashe D, Smith A, Burger R. Measuring quality gaps in TB screening in South Africa using standardised patient analysis. *Int J Environ Res Public Health*. 2018; 15: 729.
42. Johnson L, Chiu C, Myer L, Davies M, Dorrington R, Bekker L, et al. Prospects for HIV control in South Africa: a model-based analysis. *Glob Health Action*. 2016; 9: 30314.
43. Kharsany A, Cawood C, Khanyile D, Lewis L, Grobler A, Puren A, et al. Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey. *Lancet HIV*. 2018; 5: e427–37.
44. Boyer S, Iwuji C, Gosset A, Protopopescu C, Okesola N, Plazy M, et al. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. *AIDS Care*. 2016; 28(Suppl 3): 39–51.
45. Huerga H, Van Cutsem G, Ben Farhat J, Puren A, Bouhenia M, Wiesner L, et al. Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey. *BMC Public Health*. 2018; 18: 303.
46. d’Elia A, Evans D, McNamara L, Berhanu R, Sanne I, Lonnermark E. Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa. *Pan Afr Med J*. 2015; 22: 4.
47. Drain P, Losina E, Coleman S, Giddy J, Ross D, Katz J, et al. Clinic-based urinary lipoarabinomannan as a biomarker of clinical disease severity and mortality among antiretroviral therapy-naive human immunodeficiency virus-infected adults in South Africa. *Open Forum Infect Dis*. 2017; 4: ofx167.
48. Brennan AT, Jamieson L, Crowther NJ, Fox MP, George JA, Berry KM, et al. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. *PLoS ONE*. 2018; 13: e0204020.
49. Larsen A, Cheyip M, Tesfay A, Vranken P, Fomundam H, Wutoh A, et al. Timing and predictors of initiation on antiretroviral therapy among newly-diagnosed HIV-infected persons in South Africa. *AIDS Behav*. 2019; 23: 375–85.
50. Bock P, Fatti G, Ford N, Jennings K, Kruger J, Gunst C, et al. Attrition when providing antiretroviral treatment at CD4 counts >500 cells/ μ L at three government clinics included in the HPTN 071 (PopART) trial in South Africa. *PLoS ONE*. 2018; 13: e0195127.
51. Cholera R, Pence B, Gaynes B, Bassett J, Qangule N, Pettifor A, et al. Depression and engagement in care among newly diagnosed HIV-infected adults in Johannesburg, South Africa. *AIDS Behav*. 2017; 21: 1632–40.
52. Budgell E, Maskew M, Long L, Sanne I, Fox M. Brief report: does most mortality in patients on ART occur in care or after lost to follow-up? Evidence from the Themba Lethu Clinic, South Africa. *J Acquir Immune Defic Syndr*. 2015; 70: 323–8.
53. Long LC, Fox MP, Sauls C, Evans D, Sanne I, Rosen SB. The high cost of HIV-positive inpatient care at an urban hospital in Johannesburg, South Africa. *PLoS ONE*. 2016; 11: e0148546.
54. Haario H, Saksman E, Tamminen J. An adaptive metropolis algorithm. *Bernoulli*. 2001; 7: 223–42.

55. Houben RMGJ, Lalli M, Kranzer K, Menzies NA, Schumacher SG, Dowdy DW. What if they don't have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis. *Clin Infect Dis*. 2019; 68: 150–6.
56. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. *Lancet*. 2010; 375: 1920–37.
57. Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. *J Infect Dis*. 2015; 211(Suppl 2): S21–8.
58. Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: the Lancet Commission on tuberculosis. *Lancet*. 2019; 393: 1331–84.
59. Reddy KP, Gupta-Wright A, Fielding KL, Costantini S, Zheng A, Corbett EL, et al. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. *Lancet Glob Health*. 2019; 7: E200–8.
60. Sumner T, Bozzani F, Mudzengi D, Hippner P, Houben RMGJ, Cardenas V, et al. Estimating the impact of tuberculosis case detection in constrained health systems: an example of case-finding in South Africa. *Am J Epidemiol*. 2019; 188: 1155–64.
61. Hippner P, Sumner T, Houben RMGJ, Cardenas V, Vassall A, Bozzani F, et al. Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa. *PLoS ONE*. 2019; 14: e0209320.
62. Nanoo A, Izu A, Ismail NA, Ihekweazu C, Abubakar I, Mametja D, et al. Nationwide and regional incidence of microbiologically confirmed pulmonary tuberculosis in South Africa, 2004–12: a time series analysis. *Lancet Infect Dis*. 2015; 15: 1066–76.
63. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. *Lancet Infect Dis*. 2013; 13: 349–61.

Chapter 40

Development of a Multiplex Loop-Mediated Isothermal Amplification (LAMP) Assay for On-Site Diagnosis of SARS CoV-2

Woong Sik Jang,^a Da Hye Lim,^b Jung Yoon, MD,^b Ahran Kim,^b Minsup Lim,^a Jeonghun Nam, PhD,^a Richard Yanagihara, MD, MPH,^c Sook-Won Ryu, MD,^d Bo Kyeong Jung, PhD,^e Nam-Hee Ryoo, MD, PhD,^f and Chae Seung Lim, MD, PhD^b

^a*Emergency Medicine, College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea*

^b*Departments of Laboratory Medicine, College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea*

^c*Pacific Center for Emerging Infectious Diseases Research, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA*

^d*Department of Laboratory Medicine, Kangwon National University, School of Medicine, Kangwondo, Republic of Korea*

^e*Department of Laboratory Medicine, Dankook University College of Medicine, Cheonan, Korea*

^f*Department of Laboratory Medicine, Dongsan Medical Center, Keimyung University, Daegu, Korea*

nhryoo@dsmc.or.kr, malarim@korea.ac.kr

Keywords: adenovirus (AdV), clinical performance, Coronavirus Disease 2019 (COVID-19), cross-reactivity, human bocavirus (HboV), human enterovirus (HEV), human rhinovirus (HRV), Influenza (Inf), institutional review board (IRB), limits of detection (LOD), loop-mediated isothermal amplification (LAMP), molecular diagnostics, nasopharyngeal (NP), oropharyngeal (OP), parainfluenza virus (PIV), polymerase chain reaction (PCR), point-of-care (POC), quantitative polymerase chain reaction (qPCR), quantitative reverse transcription polymerase chain reaction (RT-qPCR), respiratory syncytial virus (RSV), reverse-transcription loop-mediated isothermal amplification (RT-LAMP), RNA-dependent RNA polymerase (RdRP), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2), World Health Organization (WHO)

40.1 Introduction

In December 2019, an outbreak in Wuhan, China of a severe respiratory illness was caused by a previously unrecognized coronavirus, which has since been named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) (genus Betacoronavirus, subgenus Sarbecoronavirus) [1–5]. Clinical signs of the disease,

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

which was subsequently designated Coronavirus Disease 2019 (COVID-19), included fever, cough and shortness of breath, making it difficult to distinguish from other viral respiratory infections [6, 7].

Despite intense efforts to contain the outbreak at the epicenter, the disease has spread throughout China and beyond. The World Health Organization (WHO) declared COVID-19 as a global pandemic, and as of 24 November 2020, Worldometers, which is a real-time international statistics site, announced that the total number of confirmed SARS CoV-2 patients in 220 countries around the world exceeded 59 million, with 1,402,972 that died of the infection. In particular, the USA and India have respectively accumulated over 12 million (263,687 deaths) and 9 million cases (134,254 deaths) of SARS CoV-2. SARS CoV-2 is still spreading worldwide, and there is an urgent need to conduct rapid diagnosis followed by patient isolation and treatment. Currently, an RT-qPCR-based test distributed by WHO is being deployed in many countries to detect SARS CoV-2 RNA, and several commercial RT-qPCR kits (PowerChek™ 2019-nCoV Real-time PCR kit [Kogenebiotech, Seoul, South Korea], granted EUAL in Korea) are available to diagnose SARS CoV-2 in Korea. However, these RT-qPCR detection methods require nearly 3 h to produce results, and skilled technicians and advanced laboratory infrastructure are necessary. As a result, testing is limited to institutions in which specialized medical services are available and in areas where wide-scale surveillance is required.

Loop-mediated isothermal amplification (LAMP) is a highly sensitive, low-cost, single-tube technology to detect the target nucleic acid sequences [2, 8]. Typically, six primers, including four primers selected by combining parts of the target DNA and two additional loop primers, are used to amplify a specific gene region. Bst DNA polymerase, a strand-displacement DNA polymerase, enables a loop structure formation for the inner primers, producing LAMP's unique rapid self-priming amplification [9, 10]. LAMP has been widely applied to detect various microbial pathogens [11–13]. In particular, reverse-transcription LAMP (RT-LAMP) has been used for point-of-care-testing for RNA virus infections [14].

In this study, we have developed multiplex SARS CoV-2 LAMP primer/probe sets using strand-displaceable probes, based on the region of the RdRP, E and N gene of the aligned sequences of SARS CoV-2 subtypes. Among five combination SARS CoV-2 LAMP primer sets, RdRP/N/internal control (actin beta, IC) multiplex LAMP assay showed the lowest detection limits. The performance of the multiplex SARS CoV-2 RdRP/N/IC LAMP assay was compared with direct RT-qPCR methods using the Seegene Allplex™ 2019-nCoV Assay and Kogenebiotech PowerChek™ 2019-nCoV Real-time PCR kit for SARS CoV-2 clinical samples.

40.2 Materials and Methods

40.2.1 Clinical Samples and RNA Extraction

This study was approved by the Medical Ethics Committee of Korea University's Guro Hospital (2019GR0055). Informed consent was waived by the Institutional

Review Board (IRB) because this study used residual samples. To estimate the number of samples required for clinical test of the multiplex RT-LAMP assay, the following formula was used:

$$n \geq \frac{(1.96)^2 p(1-p)}{x^2}$$

where p is the suspected sensitivity, and x is the desired margin of error [15, 16]. The true-positive rate (sensitivity) was defined as the proportion of SARS-CoV-2 positive which is correctly identified by the multiplex RT-LAMP assay compared to the Allplex™ 2019-nCoV Assay (Seegene, Inc., Seoul, South Korea). We suspected the sensitivity and specificity of the multiplex RT-LAMP assay to be 95% with a desired margin of error of 0.04%. Under these conditions, the number of required samples is 114.0475 (rounded up to 115) per group. In this experiment, we have tested total 292 samples (130 positive and 162 negative). A total of 130 clinical samples, including nasopharyngeal (NP) swabs, oropharyngeal (OP) swabs, sputum, saliva and urine, were collected from 91 patients suspected of being infected with SARS CoV-2 in the Republic of Korea. All clinical samples were confirmed using the Allplex™ 2019-nCoV Assay (Seegene, Inc., Seoul, South Korea) and PowerChek™ 2019-nCoV Real-time PCR kit (Kogenebiotech, Seoul, South Korea). To assess the specificity of the multiplex SARS CoV-2 RT-LAMP assay, 162 NP swab specimens were tested from individuals with (72) and without (90) viral respiratory infections. Respiratory viral infections, as confirmed by PCR using the Anyplex™ II RV16 detection kit, included 39 coronavirus (KHU1, NL63, 229E), 3 influenza virus A/H1N1, 3 influenza virus A/H3N2, 3 influenza virus B, 3 respiratory syncytial virus (RSV) A, 3 RSV B, 3 adenovirus, 3 parainfluenzavirus (PIV) types 1 to 4, 3 human bocavirus (HboV), 3 human enterovirus (HEV), 3 human rhinovirus (HRV) and 3 metapneumovirus (MPV). RNA was extracted from 200 μ L of SARS CoV-2 clinical samples using an InviMag Universal RNA Mini Kit (Stratec Molecular, Berlin, Germany), according to the manufacturer's manual. RNA extraction from the 162 NP swab controls was performed using the QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. RNA was stored at -50°C . The SARS CoV-2 RT-LAMP was performed blindly with the operator unaware of any previous test results.

40.2.2 Primer Design

The RT-LAMP primer sets for SARS CoV-2 were designed from conserved regions of the RdRP, E and N genes (Table 40.1). All LAMP primers including two outer primers (forward primer F3 and backward primer B3), two inner primers (forward inner primer FIP and backward inner primer BIP), and two loop primers (forward loop primer LF and backward loop primer LB) were designed using the Primer Explorer version 4 software (Eiken Chemical Co., Tokyo, Japan).

Table 40.1 The multiplex SARS CoV-2 RT-LAMP primer sets used in this study

Target	Name	Sequence (5'-3')	Length (mer)
SARS CoV-2 (RdRP gene)	RdRP F3	CGA TAA GTA TGT CCG CAA TT	20
	RdRP B3	GCT TCA GAC ATA AAA ACA TTG T	22
	RdRP FIP	ATG CGT AAA ACT CAT TCA CAA AGT CCA ACA CAG ACT TTA TGA GTG TC	47
	RdRP BIP	TGA TAC TCT CTG ACG ATG CTG TTT AAA GTT CTT TAT GCT AGC CAC	45
	RdRP BLP	TCA ATA GCA CTT ATG CAT CTC AAG G	25
	RdRP FLP	TGT GTC AAC ATC TCT ATT TCT ATA G	25
	RdRP BLP probe 1	[FAM] - CGG GCC CGT ACA AAG GGA ACA CCC ACA CTC CGT CAA TAG CAC TTA TGC ATC TCA AGG	57
SARS CoV-2 (E gene)	E F3	TCA TTC GTT TCG GAA GAG A	19
	E B3	AGG AAC TCT AGA AGA ATT CAG AT	23
	E FIP	TGT AAC TAG CAA GAA TAC CAC GAA ACA GGT ACG TTA ATA GTT AAT AGC G	49
	E BIP	GCT TCG ATT GTG TGC GTA CTC GAG AGT AAA CGT AAA AAG AAG G	43
	E BLP	GCT GCA ATA TTG TTA ACG TGA GTC	24
	E BLP probe 1	[Hex] - CGG GCC CGT ACA AAG GGA ACA CCC ACA CTC CGG CTG CAA TAT TGT TAA CGT GAG TC	56
	SARS CoV-2 (N gene)	N F3	TGG ACC CCA AAA TCA GCG
N B3		GCC TTG TCC TCG AGG GAA T	19
N FIP		CCA CTG CGT TCT CCA TTC TGG TAA ATG CAC CCC GCA TTA CG	41
N BIP		CGC GAT CAA AAC AAC GTC GGC CCT TGC CAT GTT GAG TGA GA	41
N BLP		GGT TTA CCC AAT AAT ACT GCG TCT T	25
N FLP		TGA ATC TGA GGG TCC ACC AAA	21
N BLP probe 2		[Cy5] - GTC AGT GCA GGC TCC CGT GTT AGG ACG AGG GTA GGG GTT TAC CCA ATA ATA CTG CGT CTT	60
Human (actin beta gene)	IC F3	AGT ACC CCA TCG AGC ACG	18
	IC B3	AGC CTG GAT AGC AAC GTA CA	20
	IC FIP	GAG CCA CAC GCA GCT CAT TGT ATC ACC AAC TGG GAC GAC A	40
	IC BIP	CTG AAC CCC AAG GCC AAC CGG CTG GGG TGT TGA AGG TC	38
	IC BLP	CGA GAA GAT GAC CCA GAT CAT GT	23
	IC FLP	TGT GGT GCC AGA TTT TCT CCA	21
	IC BLP probe 1	[HEX] - CGG GCC CGT ACA AAG GGA ACA CCC ACA CTC CGC GAG AAG ATG ACC CAG ATC ATG T	55
Quencher probe 1	GAG TGT GGG TGT TCC CTT TGT ACG GGC CCG -BHQ1	30	
Quencher probe 2	CCT ACC CTC GTC CTA ACA CGG GAG CCT GCA CTG AC-BHQ2	35	

A 32-oligomer or 35-oligomer fluorophore strand-displaceable probes was designed at the 5' end of the LB primer, and the 30-oligonucleotide or 35-oligonucleotide quencher was complementary to the probe. Strand-displaceable probes were 5'-labeled with FAM, Hex and Cy5 for RdRP, E and N, respectively. Before use in LAMP, all primers were assessed for specificity by performing a BLAST search. All LAMP primers and probes were synthesized by Macrogen, Inc (Seoul, South Korea).

40.2.3 Real-Time PCR (RT-PCR)

To evaluate the performance of the multiplex SARS CoV-2 RT-LAMP assay, two real-time RT-PCR tests, using the PowerChek™ 2019-nCoV Real-time PCR kit (Kogenebiotech, Seoul, Korea) and Allplex™ 2019-nCoV Assay (Seegene, Inc., Seoul, South Korea), were performed by using CFX96 Touch Real time PCR detection System (Bio-Rad, USA). For the PowerChek™ 2019-nCoV Real-time PCR kit, the thermocycling parameters were used as follows: reverse transcription at 50°C for 30 min, inactivation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s, and annealing with fluorescence detection at 60°C for 1 min. The PCR cycling conditions of the Allplex™ 2019-nCoV Assay were as follows: reverse transcription at 50°C for 20 min, inactivation at 95°C for 15 min, 45 cycles of denaturation at 95°C for 15 s, and annealing with fluorescence detection at 58°C for 30 sec.

40.2.4 Multiplex RT-LAMP

The RT-LAMP assay was performed with the Miso® RNA amplification kit (Mmonitor, Daegu, South Korea). For multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay, the reaction mixture was prepared with 12.5 µL of 2x reaction buffer, 1.2 µL of SARS CoV-2 RdRP gene LAMP primer mix, 0.6 µL of SARS CoV-2 N gene LAMP primer mix, 0.6 µL of internal control LAMP primer mix, 600 nM quencher 1 solution, 240 nM quencher 2 solution, 2 µL of enzyme mix, and 2.5 µL of sample RNA (final reaction volume 25 µL). The compositions of all LAMP primer mix were 4 µM of two outer primers (F3 and B3) and 3.32 µM of two inner primers (FIP and BIP), 10 µM of loop LF primer, 4 µM loop LB primer, and 6 µM loop LB probe primer. The RT-LAMP assay was run on CFX 96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) at 60°C for 40 min. The FAM, Hex and Cy5 fluorescence channels were used for detecting RdRP, E and N gene, respectively.

40.2.5 Limits of Detection

pTOP Blunt V2 plasmids, including partial RdRP, E or N gene sequences of SARS CoV-2, were used to test the limit of detection of the RT-LAMP assay. All plasmids were constructed by Macrogen, Inc. (Seoul, South Korea). The plasmids

were serially diluted 10-fold from 1×10^8 copies/ μL to 1×10^0 copies/ μL to determine the detection limit of the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay. In addition, the detection limit of the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP was tested on 10-fold serially diluted clinical samples from SARS CoV-2 patients.

40.3 Results

40.3.1 Optimization of the Multiplex SARS CoV-2 RT-LAMP Assay

The sensitivity of the SARS CoV-2 RdRP, E and N gene RT-LAMP was evaluated by testing synthetic plasmid standards, including synthetic partial RdRP, E and N genes ranging from 10^8 to 10^0 copies/ μL , respectively (Fig. 40.1). The limits of detection for the RdRP gene E gene and N gene were 1×10^1 copies/ μL , 1×10^1 copies/ μL and 1×10^2 copies/ μL , respectively. For multiplex SARS CoV-2 RT-LAMP in one tube, four combination of RdRP (FAM)/E (Hex), RdRP (FAM)/N (Cy5), E (Hex)/N (Cy5) and RdRP (FAM)/E (Hex)/N (Cy5) were tested using strand-displaceable probes. For optimization of four multiplex SARS CoV-2 RdRP/E, RdRP/N, E/N and RdRP/E/N LAMP assays, different ratios (1:1, 1:0.5, 1:1.5 or 1:1:1, 0.8:1:0.5, 1:1:0.5) of primers for the RdRP/E, RdRP/N, E/N and RdRP/E/N were tested, using synthetic RdRP, E and N gene plasmids (Table 40.2). Among the three ratios of both the RdRP/N primer set and E/N primer set, a ratio of 1:0.5 showed faster Ct values (12.64/12.03 and 14.04/11.6, respectively) and

Table 40.2 Different concentration ratios of the SARS CoV-2 RdRP/E, RdRP/N, E/N and RdRP/E/N primer sets (1:1, 1:0.5 and 1:1.5, respectively) for the synthetic SARS CoV-2 RdRP, E and N gene plasmids

Ratios of primers			1:1 (1:1:1)		1:0.5 (0.8:1:0.5)		1:1.5 (1:1:0.5)	
Primer set	Plasmid (10^7)	CT	RFU	CT	RFU	CT	RFU	
Monoplex RT-LAMP	RdRP (FAM)	RdRP	10.73	31987				
	E (Hex)	E	11.11	10860				
	N (Cy5)	N	7.51	10689				
Multiplex RT-LAMP	RdRP (FAM) + E (Hex)	RdRP	13.41	9145	24.16	9333	27.09	603
		E	11.07	3950	28.06	888	21.96	2547
	RdRP (FAM) + N (Cy5)	RdRP	19.05	18554	12.64	22613	35.74	14778
		N	7.23	10383	12.03	4803	6.12	16188
	E (Hex) + N (Cy5)	E	29.21	10780	14.04	14255	54.28	1484
		N	7.39	8410	11.6	3775	6.76	11479
	RdRP (FAM) + E (Hex) + N (Cy5)	RdRP	13.84	16578	14.48	14187	17.53	11088
		E	35.13	1546	17.22	7820	18.51	8421
		N	9.39	7877	15.99	2907	21.19	2038

the most stable graph. In the case of the RdRP/E primer set and RdRP/E/N primer set, the ratio of 1:1 and 0.8:1:0.5 showed faster Ct values (13.41/11.07 and 14.48/17.22/15.99, respectively). Next, temperature-gradient tests (60, 62 and 65°C) showed that the optimum temperature was 60°C (Table 40.3), which is early Ct values of all four combination LAMP primer sets (RdRP/E: 13.41/11.07, RdRP/N: 12.77/12.85, E/N: 14.04/11.6, RdRP/E/N: 15.97/15.14/13.67).




Figure 40.1 Limit of detection for the monoplex SARS CoV-2 RT-LAMP assay. The limit of detection for the monoplex SARS CoV-2 RdRP (A), E (B) and N (C) RT-LAMP assay was tested with synthetic RdRP, E and N plasmid ranging from 10^8 to 10^0 copies/ μ L, respectively. Numbers (1–10) indicated plasmid copy numbers/ μ L (1.0×10^8 – 1.0×10^0 copies/ μ L) and negative control (distilled water (DW) as non-template control).

Table 40.3 Temperature gradient tests (60, 62 and 65°C) of the four multiplex combination RT-LAMP assay

Temperature (°C)			60°C		62°C		65°C	
Primer set	Plasmid (10 ⁷)		CT	RFU	CT	RFU	CT	RFU
Monoplex RT-LAMP	RdRP (FAM)	RdRP	11.01	31987	11.09	27937	15.94	21763
	E (Hex)	E	11.11	10860	13.65	10250	31.87	7281
	N (Cy5)	N	7.51	10689	7.53	10238	9.61	7086
Multiplex RT-LAMP	RdRP (FAM)	RdRP	13.41	9145	13.06	10589	22.01	7694
	+ E (Hex)	E	11.07	3950	16.55	1388	25.64	949
	RdRP (FAM) + N (Cy5)	RdRP	12.77	22613	12.24	20545	16.42	15942
		N	12.85	4803	13.28	4442	14.88	4201
	E (Hex) + N (Cy5)	E	14.04	14255	15.32	14261	Neg	324
		N	11.6	3775	11.78	4411	14.44	3869
	RdRP (FAM) + E (Hex) + N (Cy5)	RdRP	15.97	14608	15.12	13649	25.2	7986
		E	15.14	11522	18.75	6030	Neg	687
		N	13.67	3757	13.85	3791	17.93	3504

40.3.2 Comparison of Detection Limits of the Multiplex SARS CoV-2 RT-LAMP Assay with Two Commercial RT-qPCR Assays for SARS CoV-2 Clinical Samples

The detection limits of monoplex SARS CoV-2 LAMP primer sets were compared to those of two commercial RT-qPCR kits (Allplex™ 2019-nCoV Assay and PowerChek™ 2019-nCoV Real-time PCR kit) for 10-fold serial dilutions of SARS CoV-2 NP samples (range of 10⁻³–10⁻⁷) (Table 40.4 and Fig. 40.2). Monoplex RdRP, E and N RT-LAMP primer sets showed detection limits of 10⁻⁵, 10⁻⁵ and 10⁻⁶. The combination of RdRP/E and RdRP/N primer sets showed detection limits of 10⁻⁵/10⁻⁵ and 10⁻⁵/10⁻⁶, respectively, whereas combination of E/N and RdRP/E/N primer sets showed detection limits of 10⁻³/10⁻⁴ and 10⁻³/10⁻³/10⁻⁴, respectively. In addition, the multiplex SARS CoV-2 RdRP (FAM)/N (Cy5)/internal control (IC, actin beta, HEX) RT-LAMP assay is also developed to confirm the success of the extraction step. Adding internal control (actin β) LAMP primer set to RdRP and N (ratio of RdRP/N/IC = 1:0.5:0.5) LAMP assay did not affect the detection limits of RdRP and N LAMP assay. The SARS CoV-2 RdRP (FAM)/N (Cy5)/IC (Hex) RT-LAMP assay showed the detection limit of 10⁻⁵/10⁻⁶ for RdRP and N (Table 40.4 and Fig. 40.2C) but signal of IC was not detected. Although the signal of IC in SARS CoV-2 RdRP (FAM)/N (Cy5)/IC (Hex) RT-LAMP is unstable in SARS CoV-2 clinical samples, signal of IC in the RT-LAMP assay was specifically detected until 10⁻² diluted samples for non-infected clinical samples (Fig. S1). Among five combination LAMP primer sets, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay showed the lowest detection limits.

Furthermore, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay showed comparable sensitivities with those of the Allplex™ 2019-nCoV Assay and lower detection limits than those of the PowerChek™ 2019-nCoV Real-time PCR kit. Thus, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assays were further tested with SARS CoV-2 clinical samples.




Figure 40.2 Limit of detection (LOD) tests of the monoplex and multiplex RT-LAMP assay, Allplex™ 2019-nCoV Assay and PowerChek™ 2019-nCoV Real-time PCR kit for clinical SARS CoV-2 NP sample (range of 10^{-3} – 10^{-7}). (A) Detection limits of monoplex SARS CoV-2 RdRP (left), E (middle) and N (right) LAMP primer sets. (B) Detection limits of the multiplex SARS CoV-2 RdRP/E (upper left), RdRP/N (upper middle), E/N (upper right), RdRP/E/N (lower left) and RdRP/N/IC (lower middle) LAMP primer sets (C) Detection limits of Allplex™ 2019-nCoV assay (Left) and PowerChek™ 2019-nCoV Real-time PCR kit (Right).

Table 40.4 Limit of detection (LOD) tests of the monoplex and multiplex RT-LAMP assay, Allplex™ 2019-nCoV Assay and PowerChek™ 2019-nCoV Real-time PCR kit for clinical SARS CoV-2 NP sample (range of 10^{-3} – 10^{-7}).

		Nasopharyngeal swab clinical sample											
		Dilution		10^{-3}		10^{-3}		10^{-3}		10^{-6}		10^{-7}	
		Primer set		CT	RFU	CT	RFU	CT	RFU	CT	RFU	CT	RFU
Monoplex RT-LAMP	RdRP (FAM) RdRP	RdRP	15.15	8685	18.02	8580	21.03	8305	Neg	-	Neg	-	
	E (Hex) E	E	12.24	15456	14.05	15202	17.22	15812	Neg	-	Neg	-	
	N (Cy5) N	N	14.87	5023	17.08	4938	19.7	4725	22.56	4963	Neg	-	
Multiplex RT-LAMP	RdRP (FAM) RdRP	RdRP	14.23	7180	15.47	7586	17.49	7680	Neg	-	Neg	-	
	+ E (Hex) E	E	15.25	4997	17.56	5372	20.25	4535	Neg	-	Neg	-	
	RdRP (FAM) + N (Cy5)	RdRP	RdRP	15.18	7967	18.19	8148	25.18	7567	Neg	-	Neg	-
		N	N	13.25	5196	15.05	5344	17.2	5687	19.77	6746	Neg	-
	E (Hex) + N (Cy5)	E	E	24.84	14481	Neg	-	Neg	-	Neg	-	Neg	-
		N	N	16.31	14517	25.2	15850	Neg	-	Neg	-	Neg	-
	RdRP (FAM) + E (Hex) + N (Cy5)	RdRP	RdRP	25.9	6840	Neg	-	Neg	-	Neg	-	Neg	-
		E	E	30.61	2478	Neg	-	Neg	-	Neg	-	Neg	-
		N	N	22.01	3825	25.19	4233	Neg	-	Neg	-	Neg	-
	RdRP (FAM) + N (Cy5) + Internal control (Hex)	RdRP	RdRP	17.56	6555	23.33	6350	27.84	5890	Neg	-	Neg	-
		N	N	17.22	4444	19.92	4750	23.46	4753	29.03	4986	Neg	-
		IC	IC	Neg	-	Neg	-	Neg	-	Neg	-	Neg	-
Allplex™ 2019-nCoV Assay	E (FAM) + RdRP (Texas red) + N (Cy5)	E	27.74	4639	32.05	4421	37.85	2148	38.88	1710	Neg	-	
	RdRP	RdRP	29.47	5824	33.73	4631	39.06	1964	Neg	-	Neg	-	
	N	N	29.59	2982	33.79	2805	38.46	2115	Neg	-	Neg	-	
PowerChek™ 2019-nCoV Real-time PCR kit	RdRP (FAM)/E (FAM)	RdRP	27.09	14627	31.85	9908	Neg	-	Neg	-	Neg	-	
	E	E	28.51	14404	33.26	6377	Neg	-	Neg	-	Neg	-	

40.3.3 Comparison of the Clinical Performance of the Multiplex SARS CoV-2 RdRP/N/IC RT-LAMP Assay with That of Allplex™ 2019-nCoV Assay, and PowerChek™ 2019-nCoV Real-time PCR Kit Using Clinical Samples

To confirm the clinical performance of the multiplex SARS CoV-2 RdRP/E and RdRP/N/IC RT-LAMP, the sensitivities and specificities of the assays were compared to those of the Allplex™ 2019-nCoV Assay, and PowerChek™ 2019-

nCoV Real-time PCR kit for 130 clinical samples from 91 SARS CoV-2 patients and 162 NP specimens from individuals with (72) and without (90) viral respiratory infections (Table 40.5). For the SARS CoV-2 clinical samples ($n = 130$), the sensitivities of the Allplex™ 2019-nCoV Assay for RdRP, E, and N gene were all 100%, excepted for internal control (IC, 97.69%) and those of PowerChek™ 2019-nCoV Real-time PCR kit for RdRP, E and RdRP/E were 92.31%, 93.85% and 95.38%, respectively. The sensitivities of the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP were 93.85% in the RdRP channel (FAM), 94.62% in the N channel (Cy5), 50.77% in the internal control channel (HEX) and 96.92% in RdRP or N channels. The specificities of two assays for SARS CoV-2 negative clinical samples ($n = 162$) were 100%, excepted for PowerChek™ 2019-nCoV Real-time PCR kit (99.38%) (Table 40.5). The sensitivity of the internal control channel of the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay, Allplex™ 2019-nCoV Assay, and PowerChek™ 2019-nCoV Real-time PCR kit for SARS CoV-2 negative clinical samples was 100%. Overall, the sensitivity for SARS CoV-2 clinical samples were the highest in the test of the Allplex™ 2019-nCoV Assay, followed by the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay and finally the PowerChek™ 2019-nCoV Real-time PCR kit.

Table 40.5 Comparison of clinical performance of the multiplex SARS CoV-2 RT-LAMP assay with Allplex™ 2019-nCoV Assay and Powerchek™ 2019-nCoV Real-time PCR kit for SARS CoV-2 in clinical samples

Clinical samples		2019-nCoV ($n = 130$)		Non-infection ($n = 162$)		
		P/N	Sensitivity	P/N	Sensitivity	Specificity
Allplex™ 2019-nCoV Assay	E (FAM)	130/0	100%	0/162		100%
	RdRP (Texas red)	130/0	100%	0/162		100%
	N (Cy5)	130/0	100%	0/162		100%
	IC (Hex)	127/3	97.69%	162/0	100%	
	E/RdRP/N	130/0	100%	0/162		100%
SARS CoV-2 RdRP/N/IC RT-LAMP assay	RdRP (FAM)	122/8	93.85%	0/162		100%
	N (Cy5)	123/7	94.62%	0/162	-	100%
	IC (Hex)	66/64	50.77%	162/0	100%	
	RdRP/N	126/4	96.92%	0/162	-	100%
Powerchek™ 2019-nCoV Real-time PCR kit	RdRP (FAM)	120/10	92.31%	0/162	-	100%
	IC (Hex)	130/0	100%	162/0	100%	-
	E (FAM)	122/8	93.85%	1/161	-	99.38%
	IC (Hex)	130/0	100%	162/0	100%	-
	RdRP/E	124/6	95.38%	1/161		99.38%

Note: Sensitivity and specificity were calculated by taking Allplex™ 2019-nCoV Assay as standard.

Abbreviation: P/N, Positive/negative ratio.

40.3.4 Cross-Reactivity Tests of the Multiplex SARS CoV-2 RdRP/N/IC RT-LAMP, Allplex™ 2019-nCoV Assay and PowerChek™ 2019-nCoV Real-Time PCR Kit with Other Respiratory Viruses

To confirm the absence of cross-reactivity with other common respiratory viruses, NP swabs from 72 patients with known infections with 39 Coronavirus (229E, NL63 and OC43), 6 influenza virus A/B, 6 RSV A/B, 3 adenovirus, 3 PIV, 3 HBoV, 3 HEV, 3 HRV and 3 MPV were tested by the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay, Allplex™ 2019-nCoV Assay (Seegene, Inc., Seoul, South Korea) and PowerChek™ 2019-nCoV Real-time PCR kit (Kogenebiotech, Seoul, Korea) (Table 40.6). As a result, all three molecular diagnostic tests showed no cross-reactivity with other infectious viruses. Particularly, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay do not cross-react with human coronavirus 229E, NL63 and OC43.

Table 40.6 Cross-reactivity of the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay with Allplex™ 2019-nCoV Assay and Powerchek™ 2019-nCoV Real-time PCR kit for SARS CoV-2 against other human infectious viruses

Virus	No	SARS CoV-2 RdRP/N/IC RT-LAMP assay		Allplex™ 2019-nCoV assay			Powerchek™ 2019-nCoV Real-time PCR kit	
		RdRP (FAM)	N (Cy5)	E (FAM)	RdRP (Texas red)	N (Cy5)	RdRP (FAM)	E (FAM)
CoV 229E	13	0/13	0/13	0/13	0/13	0/13	0/13	0/13
CoV NL63	13	0/13	0/13	0/13	0/13	0/13	0/13	0/13
CoV OC43	13	0/13	0/13	0/13	0/13	0/13	0/13	0/13
Inf A/H1N1	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
Inf A/H3N2	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
Inf B	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
HEV	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
AdV	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
PIV	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
MPV	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
HboV	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
HRV	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
RSV A	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
RSV B	3	0/3	0/3	0/3	0/3	0/3	0/3	0/3

Abbreviations: CoV 229E, Human coronavirus 229E; CoV NL63, Human coronavirus NL63; CoV OC43, Human coronavirus OC43; Inf A/H1N1, Influenza A type H1N1; Inf A/H3N2, Influenza A type H3N2; Inf B, Influenza B; HEV, Human enterovirus; AdV, Adenovirus; PIV, Parainfluenza virus; MPV, Human metapneumovirus; HboV, Human bocavirus; HRV, Human rhinovirus; RSV A, Respiratory syncytial virus A; RSV B, Respiratory syncytial virus B.

40.4 Discussion

SARS CoV-2 (family *Coronaviridae*, genus *Betacoronavirus*) is a positive-sense, single-stranded RNA virus [17], and it represents the seventh coronavirus known to infect humans, the others being 229E, NL63, OC43, HKU1, Middle East Respiratory Syndrome Coronavirus (MERS CoV) and severe acute respiratory syndrome coronavirus (SARS CoV) [18, 19]. The genome of SARS CoV-2 consists of approximately 30,000 bases [20, 21]. A phylogenetic analysis revealed that genome sequences of SARS CoV-2 from different patients were extremely similar (with 99.98% identity) and that SARS CoV-2 was closely related (with 88% identity) to two bat-derived SARS-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, in eastern China [22].

Commercial SARS CoV-2 diagnostic RT-PCR kits detect 2–3 genes to produce a more accurate diagnosis of SARS CoV-2. Since the sensitivity of each primer set in clinical samples may be different, it is diagnosed as a positive sample when 2–3 genes are all positive, and if only one is identified, it is re-tested with another kit. Therefore, the multiplex primer set to detect two more genes is important in developing the SARS CoV-2 LAMP kit. Currently, several SARS CoV-2 LAMP primer sets were reported [23–26]. They were mostly developed with fast colorimetric detection of one or two genes suitable for on-site diagnosis [27–30]. However, it has disadvantages in not producing diagnosis with multiplex testing and having to test each primer set individually. In particular, the LAMP assay has been reported to be highly susceptible to contamination [31, 32], and the recently reported SARS CoV-2 RT-LAMP assay has also pointed out such a problem [33]. Therefore, if an RT-LAMP test for one clinical sample is performed with three or four LAMP primer sets (including internal control) individually, the degree of contamination may also increase. In addition, when conducting clinical tests in large quantities, the number of clinical trials more than doubles, and the advantage of a rapid diagnosis of the LAMP assay may be diluted. Therefore, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay developed in this study has an advantage in minimizing the contamination and enabling a mass diagnosis.

In this study, we have developed the multiplex SARS CoV-2 RT-LAMP assay, including an internal control (actin beta, IC) to detect detection the RdRP and N gene of SARS CoV-2 using strand-displaceable probes. In sensitivity test for SARS CoV-2 clinical samples, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay showed RdRP: 93.85%, N:94.62% and RdRP/N: 96.92% for SARS CoV-2 clinical samples ($n = 130$). This result is comparable to that (100%) of the commercial Allplex™ 2019-nCoV Assay (Seegene, Inc., Seoul, South Korea) and superior to that (RdRP: 92.31%, E: 93.85% and RdRP/E: 95.38%) of the PowerChek™ 2019-nCoV Real-time PCR kit (Kogenebiotech, Seoul, South Korea). Furthermore, the detection limits for the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP was similar to that of the Allplex™ 2019-nCoV Assay (Seegene, Inc., Seoul, South Korea) and superior to that of the commercial PowerChek™ 2019-nCoV Real-time PCR kit (Kogenebiotech, Seoul, South Korea).

Finally, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay showed 100% specificity, with no cross reactivity for NP samples from patients infected with other respiratory viruses (including Coronavirus 229E, NL63 and OC43) and from uninfected healthy controls. Unfortunately, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay was not tested for cross reactivity against SARS CoV or other bat-derived SARS-like coronaviruses.

While the two types of RT-qPCR kit take 2 h and 30 min of assay time, the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay is very fast and produces results within 40 min, so if we use a 15 min nucleic acid auto-extractor, it is possible to finish an assay within 1 h. Therefore, if used with multi-channel isothermal equipment, such as a T16-ISO Instrument (Axxin, Australia), it will be useful for airports, ports, emergency rooms, and drive thru type SARS CoV-2 testing systems.

Here, we have developed a multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay capable of detecting RdRP, N genes and IC (actin beta, IC) in a single tube. Since the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay takes less time (approximately 40 min), compared to the commercial Allplex™ 2019-nCoV Assay and PowerChek™ 2019-nCoV Real-time PCR kit (usually 2–3 h), it shows promise for deployment as an on-site molecular diagnostic test.

Supporting Information

S1 Fig. Limit of detection of the multiplex SARS CoV-2 RdRP/N/IC RT-LAMP assay for non-infected clinical samples (ranging from 1 to 10^{-3} copies/ μ L). Numbers (1–5) indicated diluted samples/ μ L ($1.0-1.0 \times 10^{-3}$ copies/ μ L) and negative control (distilled water (DW) as non-template control). <https://doi.org/10.1371/journal.pone.0248042.s001>.

Abbreviations

AdV:	adenovirus
CoV 229E:	human coronavirus 229E
CoV NL63:	human coronavirus NL63
CoV OC43:	human coronavirus OC43
COVID-19:	Coronavirus Disease 2019
HboV:	human bocavirus
HEV:	human enterovirus
HRV:	human rhinovirus
Inf A/H3N2:	Influenza A type H3N2
Inf A/H1N1:	Influenza A type H1N1
Inf B:	influenza B
IRB:	institutional review board
LAMP:	loop-mediated isothermal amplification
LOD:	limit of detection
MERS CoV:	Middle East Respiratory Syndrome Coronavirus
MPV:	human metapneumovirus

NP:	nasopharyngeal
OP:	oropharyngeal
PIV:	Parainfluenza virus
RdRP:	RNA-dependent RNA polymerase
RSV A:	Respiratory syncytial virus A
RSV B:	Respiratory syncytial virus B
RT-LAMP:	reverse-transcription loop-mediated isothermal amplification
SARS CoV-2:	Severe Acute Respiratory Syndrome Coronavirus 2
WHO:	World Health Organization

Disclosures and Conflict of Interest

This chapter was originally published as: Jang, W. S., Lim, D. H., Yoon, J., Kim, A., Lim, M., Nam, J., et al. (2021). Development of a multiplex loop-mediated isothermal amplification (LAMP) assay for on-site diagnosis of SARS CoV-2. *PLoS ONE*, **16**(3), e0248042, <https://doi.org/10.1371/journal.pone.0248042>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: All relevant data are within the chapter and its Supporting Information files.

Funding: This study was supported by a government-wide R&D fund project for infectious disease research (HG18C0012), National Research Foundation of Korea (NRF-2016R1A5A1010148), and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HR20C0021).

Competing interests: None of the authors has competing interests.

Woong Sik Jang and Da Hye Lim contributed equally to this work.

Conceptualization: Woong Sik Jang, Jung Yoon, Jeonghun Nam, Nam-Hee Ryoo, Chae Seung Lim; Data curation: Woong Sik Jang, Ahran Kim, Richard Yanagihara, Nam-Hee Ryoo, Chae Seung Lim; Formal analysis: Woong Sik Jang, Bo Kyeung Jung, Nam-Hee Ryoo, Chae Seung Lim; Funding acquisition: Chae Seung Lim; Investigation: Da Hye Lim, Minsup Lim, Sook-Won Ryu, Nam-Hee Ryoo; Methodology: Da Hye Lim, Minsup Lim; Project administration: Chae Seung Lim; Resources: Nam-Hee Ryoo; Supervision: Chae Seung Lim; Validation: Nam-Hee Ryoo; Writing – original draft: Woong Sik Jang; Writing – review & editing: Jung Yoon, Jeonghun Nam, Richard Yanagihara, Nam-Hee Ryoo, Chae Seung Lim.

References

1. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet*. 2020; 395(10223): 514–23.

2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* 2020; 25(3): 2000045.
3. Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis.* 2020; 91: 264–6.
4. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol.* 2020; 94(7): e00127-20.
5. Wassenaar TM, Zou Y. 2019_nCoV/SARS-CoV-2: rapid classification of betacoronaviruses and identification of Traditional Chinese Medicine as potential origin of zoonotic coronaviruses. *Lett Appl Microbiol.* 2020; 70(5): 342–8.
6. Xiao SY, Wu Y, Liu H. Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring. *J Med Virol.* 2020; 92(5): 464–7.
7. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. *World J Pediatr.* 2020; 16(3): 240–6.
8. Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 Novel Coronavirus (2019-nCoV): a systematic review. *J Clin Med.* 2020; 9(3): 623.
9. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* 2000; 28(12): E63.
10. Nagamine K, Hase T, Notomi T. Accelerated reaction by loop-mediated isothermal amplification using loop primers. *Mol Cell Probes.* 2002; 16(3): 223–9.
11. Baek YH, Cheon HS, Park SJ, Lloren KKS, Ahn SJ, Jeong JH, et al. Simple, rapid and sensitive portable molecular diagnosis of SFTS virus using reverse transcriptional loop-mediated isothermal amplification (RT-LAMP). *J Microbiol Biotechnol.* 2018; 28(11): 1928–36.
12. Ghosh DK, Warghane A, Biswas KK. Rapid and sensitive detection of *Citrus tristeza* virus using reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay. *Methods Mol Biol.* 2019; 2015: 143–50.
13. Dhama K, Karthik K, Chakraborty S, Tiwari R, Kapoor S, Kumar A, et al. Loop-mediated isothermal amplification of DNA (LAMP): a new diagnostic tool lights the world of diagnosis of animal and human pathogens: a review. *Pak J Biol Sci.* 2014; 17(2): 151–66.
14. Singh R, Singh DP, Savargaonkar D, Singh OP, Bhatt RM, Valecha N. Evaluation of SYBR green I based visual loop-mediated isothermal amplification (LAMP) assay for genus and species-specific diagnosis of malaria in *P. vivax* and *P. falciparum* endemic regions. *J Vector Borne Dis.* 2017; 54(1): 54–60.
15. Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, et al. Evaluation of diagnostic tests for infectious diseases: general principles. *Nat Rev Microbiol.* 2006; 4(12): S20–32.
16. Poon LL, Leung CS, Chan KH, Lee JH, Yuen KY, Guan Y, et al. Detection of human influenza A viruses by loop-mediated isothermal amplification. *J Clin Microbiol.* 2005; 43(1): 427–30.

17. Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur Rev Med Pharmacol Sci.* 2020; 24(4): 2012–9.
18. Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) Coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. *Viruses.* 2020; 12(2): 194.
19. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. *Clin Chem.* 2020; 66(4): 549–55.
20. Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. *J Med Virol.* 2020; 92(5): 522–8.
21. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. *Cell Host Microbe.* 2020; 27(3): 325–8.
22. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet.* 2020; 395(10224): 565–74.
23. Lamb LE, Bartolone SN, Ward E, Chancellor MB. Rapid detection of novel coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification. *PLoS ONE.* 2020; 15(6): e0234682.
24. Yan C, Cui J, Huang L, Du B, Chen L, Xue G, et al. Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect.* 2020; 26(6): 773–9.
25. Park GS, Ku K, Baek SH, Kim SJ, Kim SI, Kim BT, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *J Mol Diagn.* 2020; 22(6): 729–35.
26. Jiang M, Pan W, Arasthfer A, Fang W, Ling L, Fang H, et al. Development and validation of a rapid, single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19. *Front Cell Infect Microbiol.* 2020; 10: 331.
27. El-Tholoth M, Bau HH, Song J. A single and two-stage, closed-tube, molecular test for the 2019 novel coronavirus (COVID-19) at home, clinic, and points of entry. *ChemRxiv.* 2020.
28. Lu R, Wu X, Wan Z, Li Y, Jin X, Zhang C. A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. *Int J Mol Sci.* 2020; 21(8): 2826.
29. Baek YH, Um J, Antigua KJC, Park JH, Kim Y, Oh S, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. *Emerg Microbes Infect.* 2020; 9(1): 998–1007.
30. Dao Thi VL, Herbst K, Boerner K, Meurer M, Kremer LP, Kirrmaier D, et al. A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Sci Transl Med.* 2020; 12(556): eabc7075.

31. Hsieh K, Mage PL, Csordas AT, Eisenstein M, Soh HT. Simultaneous elimination of carryover contamination and detection of DNA with uracil-DNA-glycosylase-supplemented loop-mediated isothermal amplification (UDG-LAMP). *Chem Commun (Camb)*. 2014; 50(28): 3747–9.
32. Kil EJ, Kim S, Lee YJ, Kang EH, Lee M, Cho SH, et al. Advanced loop-mediated isothermal amplification method for sensitive and specific detection of Tomato chlorosis virus using a uracil DNA glycosylase to control carry-over contamination. *J Virol Methods*. 2015; 213: 68–74.
33. Huang WE, Lim B, Hsu CC, Xiong D, Wu W, Yu Y, et al. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2. *Microb Biotechnol*. 2020; 13(4): 950–61.

Chapter 41

A Proteomics-Based Method for Identifying Antigen within Immune Complexes

Stephanie Menikou, PhD, Andrew J. McArdle, MD, Ming-Shi Li, PhD, Myrsini Kaforou, PhD, Paul R. Langford, PhD, and Michael Levin, PhD

Department of Infectious Disease, Section of Paediatric Infectious Disease, Imperial College London, London, UK

s.menikou@imperial.ac.uk

Keywords: affinity chromatography, bioinformatics, data analysis, Fc gamma receptors (FcγRs), immune complexes (ICs), high molecular weight (HMW), horseradish peroxidase (HRP), immunoglobulins, influenza, intensity based absolute quantification (iBAQ), liquid chromatography tandem mass spectrometry (LC MS/MS), molecular weight cut-off (MWCO), polyethylene glycol (PEG), proteomics, size exclusion chromatography (SEC), Western blotting

41.1 Introduction

Immune complexes (ICs) are formed when antibodies bind to antigens. Antigen(s) may be endogenous as occurs in autoimmune disorders or exogenous (i.e., drugs, toxins or infectious agents). ICs are formed during many inflammatory and infectious processes, and an extensive literature documents their pathophysiological role in disease processes, as we have previously reviewed [1]. ICs are cleared from the circulation by uptake into cells following binding of the immunoglobulin heavy chain Fc region to Fc gamma receptors (FcγRs) expressed by numerous cells (e.g., mast cells, monocytes, macrophages, neutrophils and basophils) [2]. The binding of ICs to FcγRs may lead to either activation or suppression of inflammatory cells depending on the type of FCGR gene expressed [2], and IC-induced cellular activation or suppression has been documented in many disease processes [3, 4].

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

ICs may also precipitate in tissues, leading to local inflammation or organ damage, influx of inflammatory cells and complement activation [5]. Their importance is well established in renal diseases [6]; inflammatory disorders such as rheumatoid arthritis [7] and systemic lupus erythematosus; infectious diseases such as dengue, sclerosing panencephalitis, hepatitis and malignancies [5, 8]. Although many studies report identification of ICs during disease processes, only a few have reported identification of antigens within ICs [9–12].

ICs may contain any class of immunoglobulin but mainly comprise IgM, IgA and IgG [5]. The major immunoglobulin class that is responsible for agglutination is IgM [5]. Methods for IC detection are typically based on their physicochemical properties, such as their size, antibody class, affinity for specific cellular receptors and susceptibility to phagocytosis by macrophages [13]. A variety of methods are available for isolation of ICs or identifying elements associated with but not directly identifying ICs and are summarized in Menikou et al. [1]. Examples include methods that are based on the attachment of ICs to specific cellular receptors such as Fc receptors, binding to platelets or macrophages, or binding to complement component 3 receptors on Raji cells. Other methods include binding of soluble complexes to C1q [5], or addition of radiolabelled anti-human IgG to determine the amount of bound ICs [14]. Further methods include detection of ICs by their ability to agglutinate platelets [15, 16], gel filtration using Sepharose 6B [17], or radiolabelled C1q in combination with polyethylene glycol (PEG) precipitation for removal of free C1q [18]. Methods using labelled aggregated IgG and labelled macrophages to study IC inhibition have also been used [19]. Examples of methods directly identifying ICs include purification by magnetic beads (Protein G or Protein A) with immobilized Protein G followed by nano liquid chromatography tandem mass spectrometry (LC MS/MS) analysis [9, 20–22]. However, when using magnetic beads there is the possibility of nonspecific binding of proteins and the sensitivity of detection of the antigens identified is considered low [9, 20].

ICs can be precipitated from serum using PEG [13], and it was later confirmed that low concentrations of PEG selectively precipitate ICs with minimal free IgG, probably by steric hindrance effects [23, 24]. Large proteins or complexes are precipitated by PEG by steric exclusion only if they are surrounded by linear PEG chains [25, 26]. Although numerous methods are available for recovery of ICs by PEG precipitation [5, 7, 23–32], very few studies have identified the antigen within ICs.

Here we present a method that enables recovery of ICs from serum, as well as the isolation and identification of the antigen that is bound to the ICs. We tested the performance of the method with artificially created complexes of immunoglobulin and influenza peptides, and compared size exclusion and affinity chromatography, versus conventional PEG precipitation for recovery of the ICs, linked to LC MS/MS for identification of the antigen (Fig. 41.1). In both cases, we detected influenza proteins in the recovered fractions. We also characterized the immunoglobulin molecules and other proteins which were isolated.




Figure 41.1 Experimental workflow showing the strategy involved to recover and purify ICs.

41.2 Materials and Methods

41.2.1 Sample Collection

Serum was recovered from venous blood from seven healthy adult donors. Specific approval for the present study was given by Central Office for Research Ethics Committees, St Mary's NHS Trust, U.K. under reference number REC 12/WA/0196 with an Imperial College Healthcare Tissue Bank project R13062. Verbal informed consent was obtained from healthy volunteers at the time of the experiments. All volunteers have subsequently given written acknowledgments of their verbal consent, and these acknowledgments have been filed along with a Note to File appended to the Investigator Site File and signed by the Investigator, which conforms to the ethics approval. All seven volunteers had been vaccinated with influenza vaccine Split Virion BP 2014/2015 (strains: A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2) and B/Massachusetts/2/2012 from Sanofi Pasteur) at 6–10 weeks prior to sample collection. In addition to the seven volunteers above, serum from two healthy individuals who had been immunized with the Split Virion BP 2015/2016 vaccine (A/California/7/2009 (H1N1) pdm09,

A/Switzerland/971593/2013(H3N2), B/Phuket/3073/2013) 6 months prior to serum collection was used. Inclusion criteria for the volunteers were prior vaccination with influenza vaccine 6–10 weeks prior to sample collection, and exclusion criteria were that volunteers had no ongoing flu like or other illness, and were not taking any medication. The age range of the volunteers was 20–49 years of age. Ten patients with febrile illness within 10 days of onset of fever were recruited at University of California San Diego (UCSD) with parental consent and approval of the local research ethics committee (Human Research Protection Program #140220). Table 41.1 provides additional information the demographic details of the febrile patients.

Table 41.1 Demographic details of the study patients

Variable	Number of patients <i>n</i> = 10
Gender	
Male, <i>n</i> (%)	9 (90)
Female, <i>n</i> (%)	1 (10)
Median Age	2.8 (range 1.5–9.1)
Ethnic background	
Caucasian, <i>n</i> (%)	4 (40)
Hispanic, <i>n</i> (%)	2 (20)
Asian, <i>n</i> (%)	3 (30)
Mixed, <i>n</i> (%)	1 (10)

41.2.2 Sample Preparation

Volunteers' venous whole blood was collected in serum-separating tube (SST) II advance bottles (Becton Dickinson), kept at room temperature (RT) for 30 min and centrifuged at 4°C at 3000 *g* for 10 min for serum separation and recovery.

In vitro ICs were created by adding 40 µl of influenza vaccine to 160 µl of serum. For PEG precipitation studies, two different volumes of influenza vaccine were evaluated—4 µl and 40 µl. Serum and influenza vaccine were mixed, incubated at 37°C for 1 h to allow antibody-antigen binding, and then processed either by size exclusion chromatography (SEC) or PEG precipitation.

41.2.3 Isolation of ICs from Human Sera

SEC. Serum spiked with influenza vaccine as above was fractionated on a Superdex 200 10/300 GL (GE Healthcare) pre-packed Tricorn column attached to an AKTA purifier 10 chromatography system (GE Healthcare). Samples were loaded and eluted in 50 mM NaPO₄, 150 mM NaCl (pH 7.0) buffer. Sample elution was monitored by 280 nm Ultraviolet (UV) absorbance. Molecular mass standards (High Molecular Weight Kit, GE Healthcare) were used to construct calibration curves. All fractions after the void volume (24 ml) were collected.

PEG precipitation. Equal 200 μl volumes of serum and 6% PEG 6000 (BDH) were mixed and dissolved in borate buffer comprising 100 mM boric acid (Sigma Aldrich), 75 mM NaCl (BDH), 25 mM sodium tetraborate (Sigma Aldrich), and incubated statically at 4°C overnight. The resulting precipitate was centrifuged at 2000 g for 20 min at 4°C. After decanting the supernatant, precipitates were washed once with a 400 μl PEG solution of the same final concentration (3%). Supernatant was decanted and the pellet dissolved in 200 μl of 1x phosphate buffer solution (PBS) (Sigma Aldrich) which was left to stand at 4°C overnight and stored at -80°C until analysed.

SDS-PAGE. Samples from PEG precipitation were separated on polyacrylamide gels; 3–8% Tris-acetate mini gels 1.5 mm (Life Technologies). Ten microliters of HiMark pre-stained high molecular weight (HMW) protein standard (Life Technologies) was used per gel to determine the molecular weight of the proteins that were loaded on the Tris-acetate mini gels.

Protein staining. After migration, gels were stained with Zinc reversible stain kit (Thermo Fisher Scientific) and then transferred to a nitrocellulose membrane for Western blotting.

Affinity chromatography. To further purify the proteins in the fractions collected by SEC, the two initial peaks of SEC were pooled individually and applied separately to a 5 ml HiTrap Protein G column (GE Healthcare) in 20 mM sodium phosphate buffer (pH 7.0). Samples were eluted with 0.1 M glycine-HCl (pH 2.7) buffer and neutralized with 1 M Tris-HCl buffer (pH 9.0).

Protein concentration. Centrifugal filter membranes (GE Healthcare) were prepared according to the manufacturer's instructions. Membranes were rinsed in deionized water (Milli-Q water, HPLC grade, Acros). Vivaspin 20 membranes with 3,000 molecular weight cut-off (MWCO) were used. Each sample was centrifuged at 5,000 g for 15 min at 4°C using a swing bucket rotor.

Protein quantification. For total protein quantification of the resulting PEG precipitated samples, Coomassie Plus (Pierce) was used. The standard microplate protocol (working range = 100–1,500 $\mu\text{g}/\text{ml}$) was followed. Absorbance at 595 nm of each well was determined using a VERSAmax tunable microplate reader.

Western blotting. For detection of influenza proteins, samples were denatured and electrophoresed on 3–8% Tris-acetate gels (Thermo Fisher Scientific). Proteins were transferred onto polyvinylidene difluoride membrane (Thermo Fisher Scientific), probed with primary and secondary horseradish peroxidase (HRP)-conjugated antibody and then detected using enzyme chemiluminescent reagents (GE Healthcare). The primary antibody used for immunoblotting was rabbit polyclonal anti-H1N1 influenza A virus nucleocapsid protein (Ab104870, Abcam). The secondary antibody was goat anti-rabbit immunoglobulin HRP (P0448, Dako). Influenza vaccine (Split Virion BP 2015/2016) was used as a positive control.

Protein sequencing. Following protein quantification, the samples from affinity chromatography and PEG precipitation were sequenced by LC-MS/MS at the University of Bristol Proteomics Facility (UK) by in-gel digestion [33].

41.2.4 Bioinformatic Analysis

Mass spectrometry data were analysed using MaxQuant 1.6.6.10 [34]. In brief, spectra were searched against the UniProt human proteome (February 2019), immunoglobulin sequences (January 2018 Kabat and NCBI databases) from the abYisis database (Prof Andrew Martin, Personal Communication and [35]), and MaxQuant's standard contaminant database. Trypsin was selected as the enzyme with full specificity and up to two missed cleavages. Peptide precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was set at 0.5 Da. Search criteria included carbamidomethylation of cysteine (+57.0214) as a fixed modification and oxidation of methionine (+15.9949) as a variable modification. Intensity based absolute quantification (iBAQ) was employed. Match-between-runs was activated with default settings. False discovery rate was set at 0.01 for peptides and 1 for proteins (to prevent exclusion of immunoglobulin variable peptides which would be distributed between many protein sequences).

Downstream analysis was undertaken in R for Windows 3.5.1 [36]. Full gene names for UniProt proteins were determined by InterMineR. Individual proteins were classified using string matching as keratin, trypsin, complement, albumin, fibrinogen, immunoglobulin, other, contaminant and influenza. Individual peptides were then classified according to their corresponding protein(s). Where multiple classes matched, the first in the list preceding was selected.

iBAQ normalises total MS1 intensity per protein based on the number of tryptic peptides, approximating molar ratios of proteins within samples. We sought to calculate mass ratios and recalculate immunoglobulin results using constant region peptides only. We therefore calculated modified iBAQ-based values at peptide level.

Immunoglobulin peptides were classed as belonging to the constant region based on edit distance of two or below to a UniProt human constant immunoglobulin sequence (approximate Levenshtein distance algorithm).

For each protein, including immunoglobulin constant sequences, the number of tryptic peptides per kDa was calculated. Normalized peptide intensities were calculated by dividing the original intensities by the corresponding ratios. Non-constant region immunoglobulin peptide intensities were set to zero. Normalized constant immunoglobulin peptide intensities were then multiplied by the ratio between the molecular weight (MW) of the (sub)class and its constant region. Where a peptide corresponded to multiple immunoglobulin subclasses, the mean of each correction was taken.

Normalized intensities were summarized by class and sample, with the total for each sample normalized to correspond to the proportion of MS1 intensity belonging to identified features. In this way, differences in identification rates between samples remains informative.

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [37] partner repository with the dataset identifier PXD021575 and 10.6019/PXD021575.

41.3 Results

41.3.1 Analysis of Protein Complex Formation by SEC, SDS-PAGE Gels, Protein Staining and Western Blots

SEC of the mixed serum with influenza revealed a consistent pattern of peaks representing the eluted proteins on the chromatogram; a representative one is shown in Fig. 41.2. Three major peaks were identified: a peak at c. 600 kDa (HMW1), a separate peak >150 kDa (HMW2), and an albumin peak (67 kDa). SDS-PAGE followed by Western blotting for IgG and IgM detection showed that the HMW1 peak mainly contained IgM, and the HMW2 contained IgG. However, IgG was also detected within HMW1, suggesting the presence of ICs in HMW complexes.




Figure 41.2 Experimental workflow used to recover and purify each peak from the affinity purification step prior to protein sequencing.

41.3.2 Affinity Chromatography of Selected Fractions from SEC

To further purify the IgM, IgG and other possible antigens bound to the immunoglobulins prior to peptide sequencing, affinity chromatography was undertaken. A pool of fractions from SEC was generated that corresponded to the

HMW1 and HMW2 peaks and each pool was applied to a HiTrap Protein G column (Fig. 41.2). Unbound proteins were washed off, and bound proteins recovered by pH 2.7 elution buffer (0.1 M glycine-HCl). Both the bound and eluted fractions were collected, the eluted fractions were neutralized to restore pH to 7.3 and then concentrated to original volume.

41.3.3 Mass Spectrometry Analysis and Data Evaluation

Four pools of fractions of the recovered proteins were made from the affinity chromatography fractionation: bound and unbound fractions of the HMW1; bound and unbound pools of the HMW2 peaks (Fig. 41.2).

After dialysis and concentration of the pooled fractions to their original volume, in-solution digestion was carried out on 1 µg of protein and the samples analysed by LC MS/MS.

41.3.4 Identification of Influenza Antigens by Western Blotting after SDS-PAGE

After denaturation and separation of the PEG precipitated proteins in 3–8% Tris-acetate mini SDS-PAGE gels, proteins were visualized by Coomassie Blue staining and compared with the protein profile of unprecipitated serum, and the influenza vaccine proteins.

Figure 41.3 shows that influenza proteins were only detected in influenza vaccine spiked PEG precipitated samples, and in PEG precipitated samples where the concentration of the vaccine was highest (40 µl, Lanes 4 and 10). Additional bands that were present in the control samples are due to non-specific reactivity because the primary antibody is raised in rabbit and has IgG as an isotype.

Having shown that influenza antigens can be detected by Western blotting in PEG precipitated vaccine spiked in two donor serum samples (Fig. 41.3, Lanes 4 and 10), additional experiments were performed to compare the detection of influenza antigens in vaccine spiked serum without PEG precipitation. As shown in Fig. 41.4, influenza antigen was detected by Western blotting only in the serum samples spiked with influenza vaccine that were subjected to PEG precipitation (Lanes 6 and 12), and not when the unprecipitated serum spiked with same concentration of vaccine was used, nor in the unspiked (Lanes 5 and 11) or negative controls (Lanes 12 and 13).

These Western blotting experiments using anti-H1N1 antibodies (Fig. 41.3), confirmed that PEG precipitation can capture influenza proteins in ICs (Lanes 4 and 10), and none of the negative controls (unspiked serum) showed detectable bands (Lanes 2 and 8). Serum that was spiked with 40 µl of vaccine and not subjected to PEG precipitation had barely detectable bands. Thus, we concluded that PEG precipitation concentrated the influenza proteins during the precipitation of the ICs.




Figure 41.3 H1N1 Western blotting of PEG precipitates from two healthy adult control samples, healthy adult sera, PBS as a negative control and flu vaccine as a positive control, showed that PEG can precipitate *in vitro* ICs. Lane one is the Precision Plus protein standard ranging from 31 to 460 kDa. Three µg of protein per lane was loaded on a 3–8% Tris-acetate denaturing SDS-PAGE gel, blotted to nitrocellulose membrane and incubated with rabbit anti-H1N1 influenza A virus (primary antibody), goat anti-rabbit Immunoglobulin HRP (secondary antibody) and stained using the ECL kit. D stands for Donor, V for Vaccine and Negative control (Lane 7) is PEG with PBS. Lane 15 is a positive control, the influenza vaccine.




Figure 41.4 H1N1 Western blotting of healthy adult serum and serum spiked with vaccine, PEG precipitates from two healthy adult donor samples showed that influenza antigen was only detected in the PEG precipitated serum samples spiked with vaccine. Lane 1 of the gel is the Precision Plus protein standard ranging from 31 to 460 kDa. Three μg of protein per lane was loaded on a 3–8% Tris-acetate denaturing SDS-PAGE gel, blotted to nitrocellulose membrane and incubated with rabbit anti-H1N1 influenza A virus (primary antibody), goat anti-rabbit immunoglobulin HRP (secondary antibody) and stained using the ECL kit. D stands for Donor, V for vaccine. Negative control (Lane 13) is PEG with H_2O and 40 μl of vaccine and negative control (Lane 14) is PEG with PBS.

41.3.5 Mass Spectrometry Analysis

1. Identification of protein classes. We applied a modified iBAQ approach to obtain relative mass-based quantification of different classes of protein in the samples (Fig. 41.5A). The proportion of MS1 intensity belonging to identified




Figure 41.5 Quantification of different protein classes and identification of immunoglobulins. V indicates samples to which influenza vaccine was added. HMW1 refers to the highest molecular weight peak and HMW2 refers to the second peak. Febrile HMW1 eluant, wash-through and Febrile HMW2 eluant and wash-through are not spiked with vaccine. (A) Relative quantities of different classes of protein as calculated through a modified iBAQ-based approach. The total height of each bar is the proportion of MS1 intensity belonging to each identified feature. Samples come from two donors (Donor 1 and Donor 2). (B) Proportion of immunoglobulin mass by class as estimated using a modified iBAQ-based approach and extrapolated from constant peptides only. *Abbreviations:* HA, IgA heavy chain; HD, IgD heavy chain; HE, IgE heavy chain; HG, IgG heavy chain; HM, IgM heavy chain.

features is lowest (around 30%) in the samples with the highest proportion of immunoglobulin (Control & V HMW2 eluant and Febrile HMW2 eluant columns in Fig. 41.5A), which is expected due to the limited feature identification expected for variable immunoglobulin peptides.

The highest proportion of immunoglobulin is identified in the HMW2 peak from SEC that was eluted from the affinity column (94% and 98%). The unbound fractions have low proportions of IgG (11% and 29%) indicating that the HiTrap Protein G column efficiently bound IgG. Complement effectively passed into the wash-through (0.2% and 0.5% in eluant vs. 21% and 34% in wash-through).

The HMW1 eluants, which should be enriched for IgM and ICs also had high proportions of immunoglobulin (76% and 82%), and the wash-throughs were similarly depleted (19% and 27%). Complement components were in low abundance overall and mostly passed into the eluant (0.4% and 0.9% vs. 7% and 10%).

The PEG precipitates contained intermediate proportions of immunoglobulin (38–47%) with complement being the other major constituent (27–44%). The proportion of immunoglobulin was increased in the vaccine-spiked samples compared to controls (46% and 47% vs. 38% and 41%).

IgG dominated in the HMW2 eluant (99.4% and 99.7%) and was nearly absent in the febrile wash-through (2%) (Fig. 41.5B). In the influenza spiked wash-through a larger proportion of immunoglobulins was IgG. This suggests that the column may have been saturated. The remainder in both cases was predominantly IgM. IgG also dominated in the HMW1 eluants (85% and 89%), with IgM (6% and 9%), and IgA (4% and 6%) present. The wash-throughs were dominated by IgM and IgA.

The identification of IgG subclasses (HG1, HG2, HG3, HG4) was further explored (Fig. 41.6). Some peptides could not be uniquely assigned to a subclass (accounting for 51–80% of estimated mass). IgG1, as expected, was in the greatest abundance across all samples. Notably, in the PEG precipitates the proportion of IgG1 was increased in the influenza vaccine spiked samples vs the PEG Donor 1 and 2 samples that were not spiked (83% and 90% vs. 68% and 58% respectively).

2. Identification of Influenza proteins. Influenza peptides were detected in all vaccine-spiked samples (Fig. 41.7), the greatest number of spectra being in the PEG precipitates. More spectra mapped to influenza peptides were identified in the eluant of the HMW1 eluant fraction, suggesting they had been captured in ICs. The estimated mass contribution of influenza protein was also higher in the spiked PEG samples (2.4% and 3.2%) than the HMW1 eluant (0.02%). The five spectra that matched to influenza in unspiked samples corresponded to high abundance influenza peptides from spiked samples, suggesting some potential sample crossover.




Figure 41.6 Proportion of estimated IgG mass by subclass (excluding contributions by non-specific peptides). PEG precipitated samples come from two donors (D1 and D2) and V indicates samples to which influenza vaccine was added. HMW1 refers to the highest molecular weight peak and HMW2 refers to the second peak. Febrile HMW1 eluant, wash-through and Febrile HMW2 eluant and wash-through are not spiked with vaccine. *Abbreviations:* HG1, heavy chain of IgG subclass 1; HG2, heavy chain of IgG subclass 2; HG3, heavy chain of IgG subclass 3; HG4, heavy chain of IgG subclass 4.

41.4 Discussion

The pipeline of SEC followed by affinity chromatography and LC MS/MS successfully recovered and identified spiked influenza peptides. Influenza peptides were not identified in the non-spiked febrile controls apart from five peptides in one fraction, most likely carry over from the spiked sample. The healthy adult controls spiked with influenza vaccine were used to confirm that it is possible to recreate *in vitro* ICs and identify the antigen within the IC.

Protein sequencing by LC MS/MS detected influenza peptides indicating that the procedure followed for recreation of ICs *in vitro* was successful. The results from experiments using sera from healthy adult controls previously immunized with influenza vaccine that were spiked with influenza vaccine to recreate ICs *in vitro*, identified the presence of influenza antigen in HMW pools from affinity

chromatography. Identification of the influenza antigen principally in the highest molecular weight protein G purified fraction (HMW1) supports their presence and recovery from IC.




Figure 41.7 Number of MS2 spectra assigned to influenza peptides in each sample. MS1 features matched by run are excluded. Samples come from two donors (D1 and D2). V indicates samples to which influenza vaccine was added. SEC-AP V HMW1 eluant, wash-through, and SEC-AP HMW2 eluant and wash-through are the control samples spiked with vaccine. SEC-AP Febrile HMW1 eluant, wash-through and SEC-AP Febrile HMW2 eluant and wash-through are not spiked with vaccine.

Although the combination of SEC and affinity chromatography resulted in highly enriched immunoglobulin fractions, with co-recovery of the influenza proteins bound to immunoglobulin, the procedure is slow and not suitable for high throughput analysis. We found the simpler PEG precipitation method, although precipitating other high molecular weight proteins, also successfully recovered influenza proteins bound to immunoglobulin. Western blotting demonstrated that precipitation of influenza vaccine alone was limited. The PEG procedure is thus more suitable for analysis of large numbers of individual samples, whereas the SEC/affinity purification may be more suited for identifying antigens within a large pool of samples.

We have shown that our procedure can identify the influenza antigen within ICs produced *in vitro* after spiking the sample with the vaccine. This sequence of experiments can enrich and detect antigens within ICs.

There is controversy as to whether PEG preferentially precipitates only circulating ICs. Our results, showed that this is not the case and are consistent with other earlier studies [31]. In our results, there were PEG precipitated proteins and, in particular, IgM and IgG in samples, without *in vitro* ICs. In addition to immune proteins, a number of studies demonstrated that PEG precipitated sera not only contain free immunoglobulins and C3 but other proteins such as albumin and fibronectin [7, 38].

The general mechanism of the action of PEG is not yet understood but it can be used to precipitate proteins from complex mixtures. The experiments described in this chapter show that this simple and well-established approach can be used to recover ICs and identify the antigen within the complexes. PEG precipitation is a simple method; it does not involve many steps that could introduce contamination and has potential advantages in searching for an unknown antigen. For example, PEG does not denature proteins as much as other organic solvents and the PEG is used in a low concentration (3%) as most of it is in the supernatant of the solution [26]. LC MS/MS results showed that PEG precipitation preferentially precipitates immunoglobulin and complement regardless of the presence of ICs. The addition of influenza vaccine resulted in greater precipitation of immunoglobulin and increased proportion of IgG1, consistent with formation of ICs, since it is known that the response to IIV (inactivated influenza vaccine) is mostly IgG1 [39–41].

In conclusion, we have shown that this procedure can identify the influenza antigen within ICs produced *in vitro* after spiking the sample with the vaccine. The procedure may be useful in identifying the target antigen in many diseases involving ICs.

Supporting Information

S1 Raw images. <https://doi.org/10.1371/journal.pone.0244157.s001>.

Abbreviations

FcγRs:	Fc gamma receptors
HA:	IgA heavy chain
HD:	IgD heavy chain
HE:	IgE heavy chain
HG:	IgG heavy chain
HG1:	heavy chain of IgG subclass 1
HG2:	heavy chain of IgG subclass 2
HG3:	heavy chain of IgG subclass 3
HG4:	heavy chain of IgG subclass 4

HM:	IgM heavy chain
HMW:	high molecular weight
HRP:	horseradish peroxidase
iBAQ:	intensity based absolute quantification
ICs:	immune complexes
LC MS/MS:	liquid chromatography tandem mass spectrometry
MW:	molecular weight
MWCO:	molecular weight cut-off
PBS:	phosphate buffer solution
PEG:	polyethylene glycol
RT:	room temperature
SEC:	size exclusion chromatography
SST:	serum-separating tube
UCSD:	University of California San Diego
UV:	ultraviolet

Disclosures and Conflict of Interest

This chapter was originally published as: Menikou, S., McArdle, A. J., Li, M.-S., Kaforou, M., Langford, P. R., Levin, M. (2020). A proteomics-based method for identifying antigens within immune complexes. *PLoS ONE*, **15**(12), e0244157, <https://doi.org/10.1371/journal.pone.0244157>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: All relevant data are within the chapter and its Supporting Information files. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [37] partner repository with the dataset identifier PXD021575 and 10.6019/PXD021575.

Funding: This work supported in part by the UK National Institute for Health Research (NIHR) Imperial Biomedical Research Centre at Imperial College (WMNP_P69099, the Javon Charitable Trust, the Children of St Mary's Intensive Care Kawasaki Disease Research Fund.) AJM is funded through a Wellcome Trust/Imperial College London 4i PhD Fellowship.

Competing interests: The authors have declared that no competing interests exist.

Acknowledgments: The authors thank the participating volunteers and patients involved in this study. We also thank Professor J. C. Burns and Dr C. Shimizu, Department of Pediatrics, University of California San Diego USA, without whose help we could never have the samples required for this study. The authors thank Dr G. Maertens, Faculty of Medicine, Department of Infectious Disease, Imperial College London for her outstanding support on protein purification method. The authors also thank Dr M. S. Hamilton, Dr V. Wright, Dr J. Herberg and other members in the Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London for discussions throughout.

We thank Dr K. J. Heesom from the Proteomics Facility, University of Bristol for the Mass Spectrometry services.

Conceptualization: Stephanie Menikou, Paul R. Langford, Michael Levin; Data curation: Stephanie Menikou, Andrew J. McArdle, Myrsini Kaforou; Formal analysis: Andrew J. McArdle, Myrsini Kaforou; Investigation: Stephanie Menikou, Ming-Shi Li, Paul R. Langford, Michael Levin; Methodology: Stephanie Menikou, Andrew J. McArdle, Ming-Shi Li, Michael Levin; Supervision: Stephanie Menikou, Ming-Shi Li, Paul R. Langford, Michael Levin; Validation: Stephanie Menikou; Visualization: Stephanie Menikou, Paul R. Langford, Michael Levin; Writing – original draft: Stephanie Menikou; Writing – review & editing: Stephanie Menikou, Andrew J. McArdle, Ming-Shi Li, Myrsini Kaforou, Paul R. Langford, Michael Levin.

References

1. Menikou S, Langford PR, Levin M. Kawasaki Disease: The role of immune complexes revisited. *Front Immunol.* 2019; 10: (1156).
2. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. *Nat Rev Immunol.* 2008; 8(1): 34–47.
3. Ronnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcγRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. *Ann Rheum Dis.* 2003; 62(1): 37–42.
4. Jiang K, Chen Y, Xu CS, Jarvis JN. T cell activation by soluble C1q-bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis. *Clin Exp Immunol.* 2003; 131(1): 61–7.
5. Chia D, Barnett EV, Yamagata J, Knutson D, Restivo C, Furst D. Quantitation and characterization of soluble immune complexes precipitated from sera by polyethylene glycol (PEG). *Clin Exp Immunol.* 1979; 37(3): 399–407.
6. Levinsky RJ. Role of circulating immune complexes in renal diseases. *J Clin Pathol.* 1981; 34(11): 1214–22.
7. Mathsson L, Lampa J, Mullazehi M, Ronnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcγRIIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-α by peripheral blood mononuclear cells. *Arthritis Res Ther.* 2006; 8(3): R64.
8. Theofilopoulos AN, Wilson CB, Dixon FJ. The Raji cell radioimmune assay for detecting immune complexes in human sera. *J Clin Invest.* 1976; 57(1): 169–82.
9. Aibara N, Ichinose K, Baba M, Nakajima H, Satoh K, Atarashi R, et al. Proteomic approach to profiling immune complex antigens in cerebrospinal fluid samples from patients with central nervous system autoimmune diseases. *Clin Chim Acta.* 2018; 484: 26–31.
10. Coyle PK. Detection and isolation of immune complexes in multiple sclerosis cerebrospinal fluid. *J Neuroimmunol.* 1987; 15(1): 97–107.
11. Przybylski G, Golda R. Research on the occurrence of *Mycobacterium tuberculosis* antigens in the circulating immune complexes, isolated from serum of patients with tuberculosis. *Med Sci Monit.* 2014; 20: 6–10.

12. Mannik M, Nardella FA, Sasso EH. Rheumatoid factors in immune complexes of patients with rheumatoid arthritis. *Springer Semin Immunopathol.* 1988; 10(2-3): 215-30.
13. Morrow WJ, Wharton M, Stricker RB, Levy JA. Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. *Clin Immunol Immunopathol.* 1986; 40(3): 515-24.
14. Hay FC, Nineham LJ, Roitt IM. Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q. *Clin Exp Immunol.* 1976; 24(3): 396-400.
15. Myllyla G, Vaheri A, Penttinen K. Detection and characterization of immune complexes by the platelet aggregation test. II. Circulating complexes. *Clin Exp Immunol.* 1971; 8(3): 399-408.
16. Biberfeld G, Norberg R. Circulating immune complexes in *Mycoplasma pneumoniae* infection. *J Immunol.* 1974; 112(1): 413-5.
17. Jewell DP, MacLennan IC. Circulating immune complexes in inflammatory bowel disease. *Clin Exp Immunol.* 1973; 14(2): 219-26.
18. Nydegger UE, Lambert PH, Gerber H, Miescher PA. Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q. *J Clin Invest.* 1974; 54(2): 297-309.
19. Onyewotu II, Holborow EJ, Johnson GD. Detection and radioassay of soluble circulating immune complexes using guinea pig peritoneal exudate cells. *Nature.* 1974; 248(5444): 156-9.
20. Ohyama K, Baba M, Tamai M, Aibara N, Ichinose K, Kishikawa N, et al. Proteomic profiling of antigens in circulating immune complexes associated with each of seven autoimmune diseases. *Clin Biochem.* 2015; 48(3): 181-5.
21. Ohyama K, Huy NT, Yoshimi H, Kishikawa N, Nishizawa JE, Roca Y, et al. Proteomic profile of circulating immune complexes in chronic Chagas disease. *Parasite Immunol.* 2016; 38(10): 609-17.
22. Ohyama K, Yoshimi H, Aibara N, Nakamura Y, Miyata Y, Sakai H, et al. Immune complexome analysis reveals the specific and frequent presence of immune complex antigens in lung cancer patients: a pilot study. *Int J Cancer.* 2017; 140(2): 370-80.
23. Digeon M, Laver M, Riza J, Bach JF. Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol. *J Immunol Methods.* 1977; 16(2): 165-83.
24. Creighton WD, Lambert PH, Miescher PA. Detection of antibodies and soluble antigen-antibody complexes by precipitation with polyethylene glycol. *J Immunol.* 1973; 111(4): 1219-27.
25. Coppock JS, Scott DL, Carter SD, Moreland TM, Robinson MW. Fibronectin in polyethylene glycol precipitates: evidence for a role in immune complexes. *Rheumatol Int.* 1986; 6(2): 79-83.
26. Sharma VK, Kalonia DS. Polyethylene glycol-induced precipitation of interferon alpha-2a followed by vacuum drying: development of a novel process for obtaining a dry, stable powder. *AAPS PharmSci.* 2004; 6(1): E4.

27. Levin M, Holland PC, Nokes TJ, Novelli V, Mola M, Levinsky RJ, et al. Platelet immune complex interaction in pathogenesis of Kawasaki disease and childhood polyarteritis. *BMJ*. 1985; 290(6480): 1456–60.
28. Elshafie AI, Ahlin E, Mathsson L, ElGhazali G, Ronnelid J. Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in Sudanese patients with acute visceral *Leishmania donovani* infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis. *J Immunol*. 2007; 178(8): 5383–9.
29. Harkiss. Detection of immune complexes by a new assay, the polyethylene glycol precipitation-complement consumption test (PEG-CC). *Clin Exp Immunol*. 1979; 36: 117–29.
30. Rønnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcγRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. *Ann Rheum Dis*. 2003; 62: 37–42.
31. Robinson MW, Scott DGI, Bacon PA, Walton KW, Coppock JS, Scott DL. What proteins are present in polyethylene glycol precipitates from rheumatic sera? *Ann Rheum Dis*. 1989; 48: 496–501.
32. Chen Y, Wang H, Yang W, Jin W, Yu W, Wang W, et al. A new method of using polyethylene glycol (PEG) precipitation of macroprolactin to detect genuine hyperprolactinemia. *J Clin Lab Anal*. 2016; 30(6): 1169–74.
33. Calvopina K, Hinchliffe P, Brem J, Heesom KJ, Johnson S, Cain R, et al. Structural/mechanistic insights into the efficacy of nonclassical beta-lactamase inhibitors against extensively drug resistant *Stenotrophomonas maltophilia* clinical isolates. *Mol Microbiol*. 2017; 106(3): 492–504.
34. Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat Protoc*. 2016; 11(12): 2301–19.
35. Swindells MB, Porter CT, Couch M, Hurst J, Abhinandan KR, Nielsen JH, et al. abYsis: integrated antibody sequence and structure-management, analysis, and prediction. *J Mol Biol*. 2017; 429(3): 356–64.
36. Team RC. A language and environment for statistical computing. R Foundation for Statistical Computing. 2017. Available at: <https://www.R-project.org/> (accessed on October 15, 2022).
37. Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res*. 2019; 47(D1): D442–50.
38. Crowley-Nowick PA, Campbell E, Schrohenloher RE, Mestecky J, Mestecky J, Jackson S. Polyethylene glycol precipitates of serum contain a large proportion of uncomplexed immunoglobulins and C3. *Immunol Invest*. 1996; 25(1–2): 91–101.
39. Manenti A, Tete SM, Mohn KG, Jul-Larsen A, Giancchetti E, Montomoli E, et al. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. *Vaccine*. 2017; 35(1): 191–8.
40. Pedersen GK, Hoschler K, Oie Solbak SM, Bredholt G, Pathirana RD, Afsar A, et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. *Vaccine*. 2014; 32(35): 4550–7.

41. El-Madhun AS, Cox RJ, Haaheim LR. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. *J Infect Dis.* 1999; 180(4): 1356–60.

Chapter 42

Avidin-Biotin Complex-Based Capture Coating Platform for Universal Influenza Virus Immobilization and Characterization

Micaela Trexler, PhD,^{a,b} Michelle Brusatori, PhD,^{a,b,c} and Gregory Auner, PhD^{a,b,c}

^a*Smart Sensors and Integrated Microsystems,
Wayne State University, Detroit, Michigan, USA*

^b*Department of Biomedical Engineering, Wayne State University College of Engineering,
Detroit, Michigan, USA*

^c*Michael and Marian Illitch Department of Surgery,
Wayne State University School of Medicine, Detroit, Michigan, USA*

mtrexler@wayne.edu

Keywords: atomic force microscopy (AFM), avidin, avidin-biotin complex (ABC), biotin, biotinylated bovine serum albumin (bBSA), capture coating, capture efficiency (CEff), detection sensitivity, dynamic binding, enzyme-linked immunoassay (ELISA), fluorescein isothiocyanate (FITC), genome amplification, geometric standard deviation (GSD), glycoproteins, hemagglutinin (HA), influenza neuraminidase (NA), polyethylene glycol (PEG), real-time PCR (RT-PCR), sialic acid (SA), surface enhanced Raman spectroscopy (SERS), relative fluorescence units (RFU)

42.1 Introduction

Influenza virus mutates quickly and unpredictably creating emerging pathogenic strains that are difficult to detect, diagnosis, and characterize. Each year there are millions of flu cases and tens of thousands of deaths in the United States alone [1]. The wide variety of circulating strains of Influenza virus at any given time contributes to the difficulty of selecting candidate strains for yearly seasonal flu vaccine development as well as making the study of Influenza virus as a species challenging. Strains may suddenly emerge through antigenic shift (reassortment) and become pandemic, such as the 1918 H1N1 “Spanish flu”, 1957 H2N2 “Asian flu”, or 2009 H1N1 “swine flu” [2]. These pandemic strains often remain

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

circulating in the population for decades, undergoing gradual antigenic drift to cause milder, yearly epidemics until they completely disappear from circulation.

Influenza virus relies on two glycoproteins on its enveloped surface to successfully bind to and later release from epithelial cells of the host respiratory tract—hemagglutinin (HA) and neuraminidase (NA). Influenza HA's are known to multivalently bind to sialic acid (SA) residues of the host cell's glycocalyx during the first step of the viral infection cycle [3–5]. This SA binding triggers viral entry through endocytosis and mediates subsequent endosomal membrane fusion resulting in the release of viral ribonucleoprotein into the host cell [6]. One of the major differences among HA subtypes of Influenza virus is the preferential binding to a specific conformation of the sialic acid glycosidic linkage to glycolipids and glycoproteins of the host cell glycocalyx. For instance, HA subtypes of human Influenza A virus preferentially bind to sialic acid with an α 2,6 glycosidic linkage which are abundant on the human pulmonary epithelium [7]. Whereas HA subtypes of avian Influenza A strains prefer an α 2,3 glycosidic linkage. This preferential receptor binding is likely one of the major barriers preventing the spread of highly pathogenic avian influenza A virus in humans [8]. Conversely, Influenza B is an exclusively human circulating class of Influenza virus that has a much lower mutation rate in the HA encoded region of its genetic material. The Influenza B virus HA contains a conserved, narrower sialic acid binding site that preferentially binds to the α 2,6 glycosidic conformation by discriminating against the avian α 2,3 glycosidic linkage [6].

However, there is evidence that the sialic acid residue preference of HA is not absolute. Species crossover has been proven to begin before changes in the HA binding domain occurs, such as during the 1997 Hong Kong bird flu outbreak caused by an avian H5N1 influenza A virus [9]. All eight gene segments of the virus were of avian origin and maintained preference for binding the avian α 2,3 glycosidic linkage, yet were able to cause significant pathogenicity in the human population. Better tools are needed to elucidate the mechanism of infection for these crossover events. Conventional tools to study and characterize virus, such as next generation sequencing, genome amplification (real-time polymerase chain reaction [RT-PCR]), and serological antibody testing, are not adequately suited to rapidly mutating pathogens like Influenza virus where the success of infection heavily depends on the phenotypic expression of surface glycoproteins. Bridging the gap between genome and pathogenic expression remains a challenge. Mutations in PCR primer or probe binding regions significantly impact diagnostic sensitivity and often result in false-negative results [10]. And producing and harvesting strain specific antibodies is a labor and time intensive process plagued by low sensitivities [11, 12]. However, these techniques remain the gold standard for Influenza virus diagnosis, providing guidance for current epidemiological tracking and vaccine strain selection. Recent incremental progress on more complex techniques, such as digital electrochemical enzyme-linked immunoassay (ELISA), for Influenza virus which has a low detection limit [13, 14]. In addition, glycan microarrays are employed to determine binding specificities

on a diverse set on glycan configurations [15, 16], but the synthesis and/or purification of well characterized oligosaccharides may be time consuming and prohibitively complex for many diagnostic device labs.

There remains a great need for a paradigm shift in approach to influenza virus diagnostic and characterization techniques. The future of single-molecule biosensors depends on high spatial resolution and immobilization of viable virus to achieve enhanced molecular information, dynamic interactions, and detection sensitivity [17]. The development of open platform technologies is sorely needed to allow for the rapid testing of a variety of unconventional tools, from novel antigenic testing to spectroscopy techniques. Some groups have demonstrated the merit of such techniques by immobilizing isolated Influenza virus sourced antigens to study binding affinity and dynamic binding of Influenza HA and NA to sialic acid [18, 19]. Others have used an impedimetric-based detector to differentiate between species of Influenza A virus [20, 21]. Yet, to the best of our knowledge, universal Influenza binding for glycoprotein characterization studies on viable, whole virus has not been realized without the use of serotype specific antibodies or species-specific galactose residues. These studies would require the capture and immobilization of all Influenza virus present, agnostic to the specific strain or serotype. This has motivated the development of the novel capture coating in this study, allowing for universal Influenza virus immobilization.

In addition, the evolution of the capture coating design was particularly motivated by the advancement of vibrational spectroscopy techniques, such as infrared spectroscopy, Raman spectroscopy, surface enhanced Raman spectroscopy, and tip enhanced Raman spectroscopy. These techniques are capable of detecting molecular-level phenotypic changes such as those that occur during a viral envelope protein mutation. For example, Sun et al. used surface enhanced Raman spectroscopy (SERS) based immunosensing techniques to detect clinically isolated Influenza A down to 10 pfu/mL [22]. For the cleanest spectra, consideration must be given to the potential background signal created by the immobilization technique used. This motivated the pursuit of an avidin-biotin complex-based technique that can be layered onto optical spectroscopy compatible substrates, such as glass and sapphire, for greater flexibility in data acquisition techniques. Furthermore, application directly to glass and similar substrates would facilitate a variety of microfluidic integrations that benefit from virus immobilization, including interrogation for virus characterization and diagnosis or high throughput drug screening.

Towards this end, this study demonstrates the successful development of a novel universal Influenza virus capture coating that harnesses sialic acid binding to capture viable whole Influenza virus. A strong base layer of avidin biotin complex (ABC) binding combined with a biomimicking pegylated sialic acid tether is utilized to capture and immobilize the virus relative to the substrate in an aqueous environment without compromising the structural or functional integrity of the virus itself. In this study we confirm virus capture using fluorescent probes and atomic force microscopy (AFM).

42.2 Materials and Methods

42.2.1 Reagents and Biologics

Biotinylated bovine serum albumin (bBSA), avidin, blocker BSA, and serotype specific anti-Influenza virus fluorescein isothiocyanate (FITC) antibody probes were sourced from Thermo Fisher Scientific (PA1-73044, PA1-73047, PA1-73036). The custom assay probes are biotinylated polyethylene glycol (MW 2000) conjugated with sialic acid (bPEG_{2k}SA), produced by Nanocs, Inc. The non-binding assay probe control is biotinylated polyethylene glycol (MW 2000) conjugated with thiol (bPEG_{2k}SH), also produced by Nanocs, Inc. Virus strains were acquired from ATCC (IAV H1N1 A/Virginia/ATCC1/2009, IAV H3N2 A/Victoria/3/75, B Yamagata B/Wisconsin/1/2010, and B Victoria B/Florida/78/2015), rehydrated and diluted in PBS 1× and stored at -80°C with glycerol until thawed for experimental use.

42.2.2 Avidin-Biotin Sialic Acid Capture Coating Fabrication

1000 µg/mL bBSA in PBS was adsorbed onto hydrophobic substrate (black-walled non-treated polystyrene microplate or sapphire slide) via incubation at 37°C for 2 h. Substrate was then rinsed with PBS and incubated with 40 mg/mL blocker BSA in PBS for 1 h at 37°C. Substrate was again rinsed and incubated with 100 µg/mL avidin in PBS for 1 h at 4°C followed by another rinse and incubation with 10 µM bPEG_{2k}SA (or 10 µM bPEG_{2k}SH) in PBS for 1 h at 4°C. Substrate underwent a final rinse with PBS, sealed, and stored at 4°C for up to four weeks without noticeable capture efficiency loss.

42.2.3 Virus Preparation

On testing days, virus stock was removed from -80°C storage and thawed in a 37°C water bath. All stocks consisted of PBS-diluted active virus originating from either pooled allantoic fluid or MDCK propagation supernatant sourced from the supplier, ATCC. Prepared substrates were removed from 4°C storage at this time and brought to room temperature. Once thawed, virus stocks were further diluted in PBS as required to achieve final concentration and incubated on capture coated substrate at 37°C for 1 h followed by a PBS wash.

42.2.4 Capture Coating Optimization

Concentrations of bBSA and avidin were systematically varied from 0 µg/mL to 1000 µg/mL and bPEG_{2k}SA varied from 0 µM to 100 µM to optimize capture coating efficiency to the final concentrations described under Avidin-Biotin Sialic Acid Capture Coating Fabrication (Table 42.1 and Table S1). Serotype specific (H1N1, H3N2, B) anti-Influenza virus FITC conjugated antibody probes were used to detect Influenza virus immobilized on the capture coating. Fluorescent images

were captured for each well of a black walled microplate during exposure with an X-CITE 120 fluorescent illuminator fitted with a 480 nm excitation filter with a focal point power of 8.1 mW. Emission was imaged with a SPOT Insight camera through a 40× Nikon Plan Fluor objective and SPOTAdvanced software set to a 519 nm monochrome colorizing palette. Relative fluorescent unit measurements were made using ImageJ opensource software on the captured images. Statistical p values shown in Table 42.1 and Fig. S1 were calculated using a Welch's t -test with a threshold of $\alpha = 0.05$ on the \log_{10} transformation of the fluorescence data. Fluorophore-conjugated antibodies have been determined to have intensity measurements that follow a lognormal distribution [23]. The geometric mean was then calculated by taking the antilog of the mean \log_{10} transformed data and reported with the geometric standard deviation in Table 42.1 and Fig. S1.

Table 42.1 Fluorescence readings from anti-influenza FITC probes reveal the optimal bPEG_{2k}SA concentration to be 10 μ M

bPEG _{2k} SA	Influenza A H1N1 (A/Virginia/ATCC1/2009)	Influenza A H3N2 (A/Victoria/3/75)	Influenza B Yamagata (B/Wisconsin/1/2010)
100 μ M	241.2 \times/\div 6.6	13222.3 \times/\div 1.2*	638.9 \times/\div 12.2
10 μ M	15948.3 \times/\div 1.1*	16321.4 \times/\div 1.1*	11679.1 \times/\div 1.6*
1 μ M	1282.0 \times/\div 2.6	-925.8 \times/\div 2.3	-54.0 \times/\div 1.1
0 μ M	0.0 \times/\div 2.5	0.0 \times/\div 1.6	0.0 \times/\div 1.4

Note: All measurements taken on a base of 1000 μ g/mL bBSA and 100 μ g/mL avidin. Fluorescence values were obtained by subtracting residual fluorescence values from the 0 μ M bPEG_{2k}SA control and colorimetrically scaled. All cells were incubated with either 10⁴ CEID₅₀/mL (IAV H3N2 and IBV Yamagata) or 10⁴ PFU/mL (IAV H1N1). $n = 3$ for each cell with geometric standard deviation shown.

* $p < 0.05$ compared to respective 0 μ M bPEG_{2k}SA control.

42.2.5 Atomic Force Microscopy

As an additional confirmation of capture coating efficacy, AFM was used to image Influenza virus immobilized on the capture coating. A double side polished 460 μ m thick c-plane sapphire wafer (MSE Supplies) was cut into approximately 3/4" square pieces and layered with capture coating according to Avidin-Biotin Sialic Acid Capture Coating Fabrication protocol and incubated with Influenza virus according to Virus Preparation. Following incubation, slides were gently washed with sterile DI water and allowed to dry under the hood. Sapphire slides with immobilized virus were then placed on the stage of a Park Systems XE series AFM and imaged in soft non-contact mode using an approximately 30 nm diameter cantilever probe (Applied NanoStructures, Inc.) with Park Systems XE software. AFM images were processed, and influenza virus particles counted and characterized using Gwyddion open source software for SPM data analysis. Each AFM image was leveled using Gwyddion mean plane subtraction, scars

corrected, and background subtracted such that the minimum value was set at zero microns. Using the mark grains feature, a threshold was set to 100 nm height and a 70 nm equivalent radius (r_{eq}) filter applied to account for the 30 nm radius AFM probe tip causing broadening edge artefacts of the typically 40–100 nm radius Influenza virus particles. Particles were counted by their r_{eq} properties. Those with an r_{eq} larger than 150 nm were double counted as a clustered pair of viruses. An example of this process is depicted in Fig. S3. In addition to the r_{eq} height above capture coating was recorded for each virus.

42.3 Results and Discussion

42.3.1 Capture Coating Development and Optimization

The virus capture coating of the immobilization platform (Fig. 42.1) is comprised of bPEG_{2k}SA linked to bBSA with avidin. Concentration combinations of the three coating components (bBSA, avidin, and bPEG_{2k}SA) were investigated to find the optimal concentration based on viral binding performance. This was accomplished by first determining effective combinations of bBSA and avidin. Twenty-five concentration combinations of immobilized bBSA and FITC-conjugated avidin were evaluated by fluorescence imaging. Black-walled non-treated polystyrene microplates were used to prevent fluorescence emission from leaking into adjacent wells during imaging. Fluorescence readings for the FITC-biotin probe provided many promising combinations, as shown by high levels of fluorescence (green) in the upper left triangle of the test matrix, S1 Table. Higher fluorescence readings indicate a higher quantity of potential binding sites for the next layer of bPEG_{2k}SA tether. This agrees with other similar ABC based protocols in literature commonly using avidin to biotin ratios ranging from 1:1 to 1:10 [24–26]. Avidin-biotin binding was chosen as the base of our capture coating because of its many advantageous properties. It is one of the strongest known non-covalent bonds between a protein and ligand with a high degree of affinity ($K_D \approx 10^{-15}$ M) and specificity [27]. Avidin and biotin are widely available reagents with an interaction that is stable over a wide range of temperatures and pH, providing a robust base that would allow for a variety of downstream testing on captured virus.

Next, substrates were prepared with candidate bBSA/avidin combinations and incubated with different concentrations of bPEG_{2k}SA. The binding performance of each coating was assessed for three influenza virus strains (A H1N1, A H3N2, and B Yamagata) using serotype specific FITC conjugated anti-influenza probes. The FITC conjugated anti-influenza probes were raised against similar strains as each of the three used in this work (anti-H1N1, anti-H3N2, and anti-B Yamagata). Table 42.1 shows the relative fluorescence intensity values for different concentrations of bPEG_{2k}SA with 10^4 CEID₅₀/mL (IAV H3N2 and IBV Yamagata) or 10^4 PFU/mL (IAV H1N1) of virus. These experimental strains were chosen as representatives of major Influenza serotypes currently endemic in the

human population–IAV H1N1, IAV H3N2, and IBV Yamagata, respectively. Results indicate that each of the experimental strains of Influenza virus were best immobilized using 10 μM of bPEG_{2k}SA receptor with 1000 $\mu\text{g}/\text{mL}$ BBSA and 100 $\mu\text{g}/\text{mL}$ avidin, as indicated by having significantly higher fluorescent reading compared to the 0 μM bPEG_{2k}SA controls (IAV H1N1 $p = 0.041$, IAV H3N2 $p = 0.032$, IBV Yamagata $p < 0.001$). In addition, IAV H3N2 showed significant capture via fluorescence detection at 100 μM bPEG_{2k}SA ($p = 0.031$), however this was not the case for the other two strains at the same receptor concentration. The high standard deviation of these fluorescence tests, especially at the higher 100 μM bPEG_{2k}SA concentration, may be due to steric hindrance effects caused by a high concentration of receptors. Steric hindrance may be why 10 μM of bPEG_{2k}SA receptor significantly outperformed a higher concentration of 100 μM bPEG_{2k}SA receptor. Other less successful avidin/bBSA combinations with bPEG_{2k}SA are not shown.




Figure 42.1 Capture coating schematic depicting the layers of the custom avidin-biotin complex adsorbed to optically polished, c-cut sapphire slide windows. The hemagglutinin (HA) glycoproteins on the envelope of the Influenza virus bind sialic acid of the functionalized biotin-PEG linker (structural formula shown, insert, was provided by the supplier, Nanocs, Inc.).

Successful immobilization of the representative strains demonstrates proof of concept for this novel capture coating technique to be used universally with Influenza viruses type A and B. Furthermore, detection of Influenza in the concentration demonstrated, 10^4 PFU/mL or CEID₅₀/mL depending on strain used, points toward potential clinical use of this novel immobilization platform. The limit of detection for point of care Influenza virus detection tests has been found to range from 5.4 to 8.9 log copies/mL and 4.8 to 7.3 log copies/mL for Influenza H3N2v and H7N9 viruses strains, respectively [28]. These findings track well with 10^5 to 10^7 RNA copies per mL of mean viral load found in human

nasopharyngeal isolates [29]. Using an established conversion rate of 20–60 viral genome copies needed per PFU [30], this amounts to a typical clinical range of 10^4 to 10^6 PFU/mL in a clinical isolate. A control experiment using an alternative thiol-functionalized bPEG_{2k}SH tether was used to ensure that the Influenza virions were binding to the sialic acid tether and not simply being caught in the tendril-like structures of the capture coating. Results, Fig. S1, show consistently lower fluorescence values in this non-binding control coating for all Influenza strains tested compared to the bPEG_{2k}SA tether. Using FITC probes as a quantitative analog to virus concentration was not possible because the different serotype specific anti-Influenza FITC probes used may vary in binding affinity and fluorescence levels across strains.

To our knowledge, this is the first known successful use of the bPEG_{2k}SA molecule in an ABC-based capture coating designed specifically for universal immobilizing infectious virus. Past studies have often used fetuin and/or mucin as a viral receptor, due to an abundance of endogenous sialic acid end chains, in order to study Influenza virus binding characteristics [31–33]. In these cases, the endogenous receptors do not permanently immobilize the virus due to the release mechanism of the viral NA protein. While useful to study binding kinetics, this release mechanism would hinder interrogation by any technique that requires a highly spatially resolved location of the virus, such as super resolution microscopies and spectroscopies. This effect may notably be incompatible in a high laminar flow environment such as a microfluidic. Specifically, in the case of molecular spectroscopies such as Raman spectroscopy and infrared spectroscopy, molecules like fetuin and mucin add an uncontrolled layer of variable molecular makeup that is much more difficult to deconvolve from spectra than well-regulated proteins and molecules like biotin, avidin, and PEG.

A related pegylated sialic acid was recently used to study dynamic binding of HA and NA to sialic acid, including a demonstration of the irreversibility of HA binding in the absence of NA cleaving activity [18], also previously described by Guo et al. [34]. Similarly, our biotinylated polyethylene glycol (MW 2000) conjugated with sialic acid (bPEG_{2k}SA) for virus capture was configured without the addition of a galactose-sialic acid linkage to prevent NA cleaving the virus from the pegylated sialic acid tether. This cleaving allows for the severance of progeny virus from the infected host cell *in vivo* [35]. However, it has been shown that this action causes unstable binding of virus *in vitro* as HA mediated binding competes with NA mediated cleaving [36]. Future iterations of this platform may explore incorporating a galactose-sialic acid functionalized end chain with either an $\alpha 2,6$ or $\alpha 2,3$ glycosidic linkage. This may allow for studying the HA mediated binding and NA mediated cleaving of Influenza strains originating from different host species. However, for the scope of this research, only human strains preferential to $\alpha 2,6$ were used, and the glycosidic linkage was not included in the bPEG_{2k}SA probe to prevent NA mediated cleaving.

42.3.2 AFM Visualization and Analysis

The developed capture coating was characterized using AFM imaging and topography analysis. While AFM is not practical in a clinical diagnostic setting, it provides valuable validation of Influenza virus capture and allows for characterization of the capture coating itself which lead to the calculation of the coating's capture efficiency. Figure 42.2 displays topographical images and profile analysis results comparing images of the sapphire substrate (Fig. 42.2A), capture coating on sapphire substrate without virus (Fig. 42.2B), a cluster of Influenza A H3N2 virions immobilized by capture coating on sapphire substrate (Fig. 42.2C), and a single Influenza A H3N2 virion immobilized by capture coating on sapphire substrate (Fig. 42.2D). The measured height of the individual virion, 36 nm, and diameter, 160 nm, agree well with the known size of Influenza virus given the relatively large diameter (~ 30 nm) of the AFM probe tip causing a broadening edge artefact in the diameter measurement [37–40]. Throughout these studies multiple $50 \times 50 \mu\text{m}$, $10 \times 10 \mu\text{m}$, and $1 \times 1 \mu\text{m}$ AFM images were taken. Using Gwyddion software, virus height and radius were taken for each virus captured. These distributions are plotted in Fig. S4.




Figure 42.2 3D AFM topography images with corresponding 1D profiles through dashed lines as shown. (A) $460 \mu\text{m}$ sapphire c-cut slide. (B) Capture coating on sapphire slide. (C) Influenza A H3N2 virus cluster immobilized in capture coating on sapphire slide. The tendrils of the capture coating bPEG_{2k}SA receptor tethers are clearly seen. (D) A 2D example image of one of many single virions (this one Influenza A H3N2) immobilized in capture coating. 2DFFT analysis for all four AFM scans shown in Fig. S2.

Further, roughness parameters were extracted from these profiles using Gwyddion software and are summarized in Table 42.2. Differences in sapphire substrate and capture coating profiles support successful deposition of the capture coating onto the substrate. The average roughness (R_a) increased by approximately 24 nm which agrees well with the estimated 20–30 nm thickness of the bBSA-avidin-bPEG_{2k}SA coating combination. The regularly spaced and spiked profile of the capture coating also indicates successful adsorption of the bBSA and subsequent orientation of the avidin and bPEG_{2k}SA binding to create tendril-like

protrusions from the substrate surface. These protrusions are better visualized surrounding the AFM image of a cluster of influenza virions (Fig. 42.2C) which support the capture coating design and execution first depicted in Fig. 42.1. The apparent embedding of the virus into the capture coating is likely due to the brief drying out of the slides before AFM interrogation, causing the PEG tethers to crumple under the weight of the virion. It should be noted that features in the AFM topography images and subsequent roughness parameters may be smaller than they appear due to the relatively large diameter (~ 30 nm) of the AFM probe tip causing broadening edge artefacts [37].

Table 42.2 Parameters characterizing surface features and roughness of samples from Fig. 42.2

Characterizing surface features and roughness	460 μm sapphire slide	Capture coating	IAV H3N2 cluster (ATCC VR-822)	IAV H3N2 virion (ATCC VR-822)
Roughness average (Ra) [nm]	7.7	32.0	29.9	1.5
Root mean square roughness (Rq) [nm]	9.2	38.1	37.1	2.0
Maximum roughness height (Rt) [nm]	43.4	191.1	186.3	9.5
Avg maximum height (Rtm) [nm]	35.8	154.6	105.0	6.4
Mean spacing of peaks (Sm) [nm]	588.3	333.3	49.2	45.1

42.3.3 Capture Efficiency

The capture coating of the virus immobilization platform utilized a unique bPEG_{2k}SA linker that provides a biomimicking sialic acid receptor for Influenza HA to bind to. Capture efficiency was calculated for each of the four virus strains. When the total number of virus particles applied to the substrate is less than that which can fully occupy the substrate surface, capture efficiency (C_{Eff}) is defined as the ratio of virus particles captured over virus particles applied, Eq. 42.1.

$$C_{\text{Eff}} = \frac{P_{\text{bound}}}{P_{\text{total}}} = \frac{S * C}{n * 1}, \quad (42.1)$$

where the number of virus particles bound to the substrate, $P_{\text{bound}} = S * C$ with S being the substrate size factor (total substrate area/size of the AFM scan area) and C the virus particle count from AFM image. To determine the virus particle count from an AFM image, a $10 \times 10 \mu\text{m}^2$ AFM scan was analyzed for each of the four Influenza virus strains. Virus particles present were counted using Gwyddion's mark grain feature with minimum thresholds set at 120 nm height and 70 nm equivalent radius to account for the 30 nm radius AFM probe tip causing broadening edge artefacts. A demonstration of particle counting via AFM image with Gwyddion mark grain feature is provided as Fig. S3. For each Influenza strain, $n = 3$ AFM images were analyzed for particle count and the mean

taken. The total number of virus particles applied to the substrate $P_{\text{total}} = n \cdot I$, where n is the number density of virus particles in the stock solution and I is the volume of sample applied to the substrate. The number density is calculated from the infectious virus concentration of the virus stock $[V]$ multiplied by a conversion factor. For virus concentration in PFU/ml, $n = [V] \cdot \text{CTPR}$, where CTPR is the virus particle “count to PFU ratio” found in previous studies [41, 42]. When the virus concentration is CEID₅₀/ml, $n = [V] \cdot \text{PtC} \cdot \text{CTPR}$, where PtC is the PFU to CEID₅₀ ratio conversion factor.

Results and inputs parameters used to calculate the *capture coating efficiency* are detailed in Table 42.3. For this work, it is estimated that the total number of virus particles incubated for 1 h on a functionalized slide ($P_{\text{total}} = 2.29 \times 10^7$, 5.14×10^6 , 2.00×10^8 , 1.39×10^8) was less than the total number of available binding sites ($I_{\text{total}} = 1.03 \times 10^{10}$, 9.02×10^8 , 1.03×10^{10} , 1.03×10^{10}) for IAV H3N2, IAV H1N1, IBV Yamagata, and IBV Victoria, respectively. Capture efficiency (C_{Eff}) ranged from 90.0% to 99.7%. These promising results are likely due to the irreversibility of HA binding to sialic acid in absence of active NA cleaving [18] or due to strong avidity from bivalent [43] or multivalent binding of sialic acid by individual Influenza virions [36, 44–46]. Multivalent binding of Influenza virus to our capture coating may be caused by multiple bPEG_{2k}SA binding to a single avidin molecule in the ABC complex. Alternatively, the 333 nm peak spacing found via the AFM topography data had a standard deviation of 90 nm. The influenza virus may also be showing preference to binding locations where multiple bPEG_{2k}SA binding locations are within reach, providing access for multivalent binding. These results demonstrate the strong immobilization capability of this novel bPEG_{2k}SA capture coating. However, this strong binding capability was generated under ideal, static incubation conditions and should be further vetted through flow cell observations beyond the scope of this study.

Table 42.3 Parameters and calculated values of capture efficiency (C_{Eff}) for each Influenza strain

Strain	Stock concentration	Volume (mL)	Slide size (mm ²)	Mean particle count ($n = 3$)	CTPR [41, 42] (count to PFU ratio)	PtC (PFU to CEID ₅₀ conversion ratio)	Estimated capture efficiency (C_{Eff})
IAV H3N2 (A/Victoria/3/75)	1.6×10^5 CEID ₅₀ /mL	0.500	1140	2.0 ± 1	200	1.429	0.997 (99.7%)
IAV H1N1 (A/Virginia/ATCC1/2009)	2.9×10^4 PFU/mL	0.300	100	5.0 ± 1	591	N/A	0.972 (97.2%)
IBV Yamagata (B/Wisconsin/1/2010)	2.8×10^5 CEID ₅₀ /mL	0.500	1140	16.0 ± 2	1000	1.429	0.912 (91.2%)
IBV Victoria (B/Florida/78/2015)	7.8×10^5 CEID ₅₀ /mL	0.500	1140	11.0 ± 4	250	1.429	0.900 (90.0%)

Sialic acid is a common binding receptor used by a variety of viruses to initiate host cell entry. Since the goal of this research was to create a universal infectious virus Influenza immobilization platform, the sialic acid functionalized bPEG probe was synthesized without galactose and, therefore, without the NA glycosidic linkage cleaving site. While this work was limited to just a single conformation of bPEG_{2k}SA, advanced binding studies may be done by altering the glycan chemistry, such as functionalizing the PEG with a α 2,6 glycosidic conformation favored by human pathogenic Influenza virus or, alternatively, an avian Influenza favored α 2,3 glycosidic linkage. In addition, further studies may open the possibility to use this capture coating with other SA binding virus families such as adenovirus and coronavirus, amongst others [43, 47]. Like Influenza virus ($K_d = \mu\text{M}$ -pM) [48], adenovirus ($K_d = 19 \mu\text{M}$) [47], and some coronaviruses ($K_d = 49.1 \mu\text{M}$) [49] *multivalently* bind to SA with K_d in a high affinity range.

Together, these fluorescence and AFM studies show the first successful use of a novel ABC based sialic acid capture coating for universal Influenza virus immobilization and its potential as a diagnostic tool platform. An avidin-biotin complex base with a biotin-PEG-sialic acid functionalized surface was utilized to create an Influenza virus capture coating capable of immobilizing whole virus while keeping the virion intact. Atomic Force Microscopy studies confirmed and described the profile of the capture coating as well as demonstrated the ability of using the capture coating to help characterize a single Influenza virus by AFM topography. From AFM topography data we were able to determine the capture efficiency of the capture coating to be above 90% of virus particles at a concentration of 10^5 CEID₅₀/mL. We hope this capture coating technique creates an adaptable platform for further characterization of virus and development of novel phenotype diagnostic techniques.

Supporting Information

S1 Fig. Fluorescent tagging was used to assess the novel bPEG_{2k}SA capture coating against a non-binding control (bPEG_{2k} functionalized with a thiol group, SH). (A) Schematic of experimental set up. Influenza virus were incubated on capture coating or control coating, rinsed, and tagged using FITC conjugated anti-Influenza HA antibodies. (B) Fluorescence results in relative fluorescence units (RFU). Numbers reported as geometric mean and geometric standard deviation (GSD) (* = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$). <https://doi.org/10.1371/journal.pone.0247429.s001>.

S2 Fig. Corresponding 2D FFT analysis on AFM images from Fig. 4.2.2. (A) 460 μm c-cut sapphire slide. Image suggest spatial features of a repeated, relatively smooth texture. (B) Capture coating on sapphire slide. Image suggests spatial features of a repeated, dotted, and quite messy texture. (C) Clump of Influenza A H3N2 virion immobilized by capture coating on sapphire slide. The image suggests the virion has a gaussian-like shape with a randomly rough texture within a small variation

of the larger gaussian surface. Similarly, (D) shows a single Influenza A H3N2 virion immobilized by capture coating on sapphire slide. All 2D FFT analysis was conducted using Gwyddion open source SPM analysis software on captured AFM.tiff images. <https://doi.org/10.1371/journal.pone.0247429.s002>.

S3 Fig. Virus particle counting for C_{Eff} calculations was carried out using the Gwyddion SPM analysis software. A $10\ \mu\text{m} \times 10\ \mu\text{m}$ AFM image of immobilized 10^5 CEID₅₀/mL IBV Yamagata on capture coating was imported processed. (A) The image was leveled using Gwyddion mean plane subtraction, scars corrected, and background subtracted such that the minimum value was set at zero microns. (B) Using the mark grains feature, a threshold was set to 100 nm height and a 70 nm equivalent radius (r_{eq}) filter applied to account for the 30 nm radius AFM probe tip causing broadening edge artefacts of the typically 40–100 nm radius Influenza virus particles. The mask is colored in pink against a grey excluded background. (C) Particles were counted by their r_{eq} properties. Those with an r_{eq} larger than 150 nm were double counted as a clustered pair of viruses. This image resulted in a count of 16 IBV Yamagata particles in the given frame. <https://doi.org/10.1371/journal.pone.0247429.s003>.

S4 Fig. Height and radius distributions of virus immobilized by capture coating. The mean radius and height of each strain was not significantly different than each other strain and were as follows (height, radius): IAV H1N1 (34.16 nm, 42.98 nm), IAV H3N2 (57.75 nm, 53.52 nm), IBV Victoria (41.44 nm, 47.78 nm), and IBV Yamagata (37.68 nm, 51.59 nm). <https://doi.org/10.1371/journal.pone.0247429.s004>.

S1 Table. Fluorescence readings from FITC-biotin probes used to screen for acceptable bBSA and avidin concentration combinations used for further capture coating testing. Fluorescence values were obtained by subtracting residual fluorescence values from the 0 $\mu\text{g}/\text{mL}$ bBSA and 0 $\mu\text{g}/\text{mL}$ avidin control and colorimetrically scaled. Fluorescent images were captured for each well of a black walled microplate during exposure with an X-CITE 120 fluorescent illuminator fitted with a 480 nm excitation filter with a focal point power of 8.1 mW. Emission was imaged with a SPOT Insight camera through a 40 \times Nikon Plan Fluor objective and SPOTAdvanced software set to a 519 nm monochrome colorizing palette. Fluorescent unit measurements were made using ImageJ open-source software on the captured images. <https://doi.org/10.1371/journal.pone.0247429.s005>.

Disclosures and Conflict of Interest

This chapter was originally published as: Trexler, M., Brusatori, M., Auner, G. (2021). Avidin-biotin complex-based capture coating platform for universal *Influenza virus* immobilization and characterization. *PLoS ONE*, **16**(2), e0247429, <https://doi.org/10.1371/journal.pone.0247429>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Data Availability: All relevant data are within the chapter and its Supporting Information files.

Funding: M.T., M.B., and G.A.'s work in this study was funded by the Paul U. Strauss endowed chair position and the Smart Sensors and Integrated Microsystems Program (<http://www.ssim.wayne.edu/index.asp>) at the Wayne State University School of Medicine (<https://www.med.wayne.edu/>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

Acknowledgments: The authors would like to acknowledge the contributions of Dr. Gina Shreve and Chris Thrush.

Conceptualization: Micaela Trexler, Gregory Auner; Data curation: Micaela Trexler; Formal analysis: Micaela Trexler, Michelle Brusatori; Funding acquisition: Gregory Auner; Investigation: Micaela Trexler; Methodology: Micaela Trexler, Gregory Auner; Resources: Gregory Auner; Supervision: Gregory Auner; Validation: Micaela Trexler; Visualization: Micaela Trexler; Writing – original draft: Micaela Trexler; Writing – review & editing: Micaela Trexler, Michelle Brusatori, Gregory Auner.

References

1. Garten R, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, et al. Update: influenza activity in the United States during the 2017–18 season and composition of the 2018–19 influenza vaccine. *Morbidity and Mortality Weekly Report*. 2018; 67(22): 634–642.
2. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. *Revista Biomedica*. 2006; 17(1): 69–79.
3. Wasilewski S, Calder LJ, Grant T, Rosenthal PB. Distribution of surface glycoproteins on influenza A virus determined by electron cryotomography. *Vaccine*. 2012; 30(51): 7368–73.
4. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. *Annual Review of Biochemistry*. 2000; 69(1): 531–69.
5. Ivanovic T, Harrison SC. Distinct functional determinants of influenza hemagglutinin-mediated membrane fusion. *Elife*. 2015; 4: e11009.
6. Luo M. Influenza Virus Entry. In: Rossmann MG, Rao VB, editors. *Viral Molecular Machines*. Boston, MA: Springer US; 2012. p. 201–21.
7. Thompson CI, Barclay WS, Zambon MC, Pickles RJ. Infection of human airway epithelium by human and avian strains of influenza a virus. *Journal of Virology*. 2006; 80(16): 8060–8.
8. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. *Nature*. 2006; 444(7117): 378.

9. Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JM. Evolving complexities of influenza virus and its receptors. *Trends in Microbiology*. 2008; 16(4): 149–57.
10. Klungthong C, Chinnawirotpisan P, Hussem K, Phonpakobsin T, Manasatienkij W, Ajariyakhajorn C, et al. The impact of primer and probe-template mismatches on the sensitivity of pandemic influenza A/H1N1/2009 virus detection by real-time RT-PCR. *Journal of Clinical Virology*. 2010; 48(2): 91–5.
11. Allwinn R, Preiser W, Rabenau H, Buxbaum S, Stürmer M, Doerr H. Laboratory diagnosis of influenza—virology or serology? *Medical Microbiology and Immunology*. 2002; 191(3–4): 157–60.
12. Kim D-K, Poudel B. Tools to detect influenza virus. *Yonsei Medical Journal*. 2013; 54(3): 560–6.
13. Wu Z, Guo W-J, Bai Y-Y, Zhang L, Hu J, Pang D-W, et al. Digital single virus electrochemical enzyme-linked immunoassay for ultrasensitive H7N9 avian influenza virus counting. *Analytical Chemistry*. 2018; 90(3): 1683–90.
14. Leirs K, Tewari Kumar P, Decrop D, Pérez-Ruiz E, Leblebici P, Van Kelst B, et al. Bioassay development for ultrasensitive detection of influenza a nucleoprotein using digital ELISA. *Analytical Chemistry*. 2016; 88(17): 8450–8.
15. Council NR. *Transforming Glycoscience: A Roadmap for the Future*. National Academies Press; 2012.
16. Stevens J, Blixt O, Paulson JC, Wilson IA. Glycan microarray technologies: tools to survey host specificity of influenza viruses. *Nature Reviews Microbiology*. 2006; 4(11): 857–64.
17. Akkic N, Geschwindner S, Höök F. Single-molecule biosensors: recent advances and applications. *Biosensors and Bioelectronics*. 2020; 151: 111944.
18. Reiter-Scherer V, Cuellar-Camacho JL, Bhatia S, Haag R, Herrmann A, Lauster D, et al. Force spectroscopy shows dynamic binding of influenza hemagglutinin and neuraminidase to sialic acid. *Biophysical Journal*. 2019; 116(8): 1577.
19. Xiong X, Coombs PJ, Martin SR, Liu J, Xiao H, McCauley JW, et al. Receptor binding by a ferret-transmissible H5 avian influenza virus. *Nature*. 2013; 497(7449): 392.
20. Wicklein B, del Burgo MÁM, Yuste M, Carregal-Romero E, Llobera A, Darder M, et al. Biomimetic architectures for the impedimetric discrimination of influenza virus phenotypes. *Advanced Functional Materials*. 2013; 23(2): 254–62.
21. Hushegyi A, Pihíková D, Bertok T, Adam V, Kizek R, Tkac J. Ultrasensitive detection of influenza viruses with a glycan-based impedimetric biosensor. *Biosensors and Bioelectronics*. 2016; 79: 644–9.
22. Sun Y, Xu L, Zhang F, Song Z, Hu Y, Ji Y, et al. A promising magnetic SERS immunosensor for sensitive detection of avian influenza virus. *Biosensors and Bioelectronics*. 2017; 89: 906–12.
23. Mutch SA, Fujimoto BS, Kuyper CL, Kuo JS, Bajjalieh SM, Chiu DT. Deconvolving single-molecule intensity distributions for quantitative microscopy measurements. *Biophysical Journal*. 2007; 92(8): 2926–43.
24. Farina L, Iacobello C, Orlandini S, Ius A, Albertini A. The effect of the concentration ratio of avidin and biotin on a single step sandwich enzyme immunoassay. *Annals of Clinical Biochemistry*. 1993; 30(1): 87–9.

25. Kuhn P, Eyer K, Robinson T, Schmidt FI, Mercer J, Dittrich PS. A facile protocol for the immobilisation of vesicles, virus particles, bacteria, and yeast cells. *Integrative Biology*. 2012; 4(12): 1550–5.
26. Stamou D, Duschl C, Delamarche E, Vogel H. Self-assembled microarrays of attoliter molecular vessels. *Angewandte Chemie International Edition*. 2003; 42(45): 5580–3.
27. Green N. Avidin. 1. The use of [¹⁴C] biotin for kinetic studies and for assay. *Biochemical Journal*. 1963; 89(3): 585.
28. Chan K-H, To KK, Chan JF, Li CP, Chen H, Yuen K-Y. Analytical sensitivity of seven point-of-care influenza virus detection tests and two molecular tests for detection of avian origin H7N9 and swine origin H3N2 variant influenza A viruses. *Journal of Clinical Microbiology*. 2013; 51(9): 3160–1.
29. Granados A, Peci A, McGeer A, Gubbay JB. Influenza and rhinovirus viral load and disease severity in upper respiratory tract infections. *Journal of Clinical Virology*. 2017; 86: 14–9.
30. Yoshikawa T, Matsuo K, Matsuo K, Suzuki Y, Nomoto A, Tamura S-i, et al. Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice. *Journal of General Virology*. 2004; 85(8): 2339–46.
31. Lai JCC, Karunarathna HM, Wong HH, Peiris JS, Nicholls JM. Neuraminidase activity and specificity of influenza A virus are influenced by haemagglutinin-receptor binding. *Emerging Microbes & Infections*. 2019; 8(1): 327–38.
32. Onkhonova G, Maltsev S, Ryzhikov A. Determination of the binding affinity of virions of pandemic Influenza A/California/7/2009 (H1N1pdm09) virus for fetuin and mucin by the competitive and kinetic methods. *Biophysics*. 2019; 64(4): 522–7.
33. Sakai T, Nishimura SI, Naito T, Saito M. Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery. *Scientific Reports*. 2017; 7: 45043.
34. Guo H, Rabouw H, Slomp A, Dai M, van der Vegt F, van Lent JW, et al. Kinetic analysis of the influenza A virus HA/NA balance reveals contribution of NA to virus-receptor binding and NA-dependent rolling on receptor-containing surfaces. *PLoS Pathogens*. 2018; 14(8): e1007233.
35. Krammer F, Smith GJ, Fouchier RA, Peiris M, Kedzierska K, Doherty PC, et al. Influenza (Primer). *Nature Reviews: Disease Primers*. 2018; 4(1): 3.
36. Müller M, Lauster D, Wildenauer HH, Herrmann A, Block S. Mobility-based quantification of multivalent virus-receptor interactions: new insights into Influenza A virus binding mode. *Nano Letters*. 2019; 19(3): 1875–82.
37. Raposo M, Ferreira Q, Ribeiro P. A guide for atomic force microscopy analysis of soft-condensed matter. *Modern Research and Educational Topics in Microscopy*. 2007; 1: 758–69.
38. de Pablo PJ. Atomic force microscopy of virus shells. *Seminars in Cell & Developmental Biology*. 2017; 73: 199–208.
39. Li S, Sieben C, Ludwig K, Höfer CT, Chiantia S, Herrmann A, et al. pH-Controlled two-step uncoating of influenza virus. *Biophysical Journal*. 2014; 106(7): 1447–56.
40. Marchetti M, Wuite G, Roos W. Atomic force microscopy observation and characterization of single virions and virus-like particles by nano-indentation. *Current Opinion in Virology*. 2016; 18: 82–8.

41. Tabata KV, Minagawa Y, Kawaguchi Y, Ono M, Moriizumi Y, Yamayoshi S, et al. Antibody-free digital influenza virus counting based on neuraminidase activity. *Scientific Reports*. 2019; 9(1): 1–13.
42. Triana-Baltzer GB, Sanders RL, Hedlund M, Jensen KA, Aschenbrenner LM, Larson JL, et al. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. *Journal of Antimicrobial Chemotherapy*. 2011; 66(1): 15–28.
43. Neu U, Bauer J, Stehle T. Viruses and sialic acids: rules of engagement. *Current Opinion in Structural Biology*. 2011; 21(5): 610–8.
44. Xu H, Shaw DE. A simple model of multivalent adhesion and its application to influenza infection. *Biophysical Journal*. 2016; 110(1): 218–33.
45. Benton DJ, Martin SR, Wharton SA, McCauley JW. Biophysical measurement of the balance of influenza a hemagglutinin and neuraminidase activities. *Journal of Biological Chemistry*. 2015; 290(10): 6516–21.
46. Cuellar-Camacho JL, Bhatia S, Reiter-Scherer V, Lauster D, Liese S, Rabe P Jr, et al. Quantification of multivalent interactions between sialic acid and Influenza A Virus spike proteins by single-molecule force spectroscopy. *Journal of the American Chemical Society*. 2020; 142(28): 12181–92.
47. Nilsson EC, Storm RJ, Bauer J, Johansson SM, Lookene A, Ångström J, et al. The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis. *Nature Medicine*. 2011; 17(1): 105–9.
48. Casalegno J-S, Ferraris O, Escuret V, Bouscambert M, Bergeron C, Linès L, et al. Functional balance between the hemagglutinin and neuraminidase of influenza A (H1N1) pdm09 HA D222 variants. *PLoS ONE*. 2014; 9(8): e104009.
49. Tortorici MA, Walls AC, Lang Y, Wang C, Li Z, Koerhuis D, et al. Structural basis for human coronavirus attachment to sialic acid receptors. *Nature Structural & Molecular Biology*. 2019; 26(6): 481–9.

Chapter 43

Visualization of Sympathetic Neural Innervation in Human White Adipose Tissue

Aliki Perdikari, PhD, Tessa Cacciottolo, MD, PhD, Elana Henning, RN, Edson Mendes de Oliveira, PhD, Julia M. Keogh, and I. Sadaf Farooqi, PhD

*Wellcome-MRC Institute of Metabolic Science,
University of Cambridge Metabolic Research Laboratories
and NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK*
isf20@cam.ac.uk

Keywords: adipocytes, adipose tissue expansion, clear, unobstructed brain/body imaging cocktails and computational analysis (CUBIC) protocol, extracellular matrix (ECM), formaldehyde (FA), haematoxylin and eosin (H & E) staining, immunolabelling-enabled three-dimensional imaging of solvent-cleared organs (iDISCO) protocol, immunolabelling, neural intervention, neutral buffered formalin (NBF), optical clearing, three-dimensional visualization, tissue biopsy, type 2 diabetes, fatty liver disease, tyrosine hydroxylase (TH), white adipose tissue (WAT), whole tissue staining

43.1 Introduction

Obesity-related complications such as type 2 diabetes and fatty liver disease represent a significant disease burden. As people gain weight, white adipose tissue (WAT) mass expands to store energy-rich triglycerides. Studies in rodents and in humans with inherited disorders of adipose tissue development have shown that there is considerable variability in how much adipose tissue expansion can take place [1]. Once the adipose tissue expansion limit is reached, adipose tissue ceases to store triglycerides efficiently and lipids begin to accumulate ectopically in other tissues and organs such as the liver and skeletal muscle, causing lipotoxicity, insulin resistance, cellular apoptosis and inflammation, mechanisms that underpin the development of obesity-associated metabolic complications [2].

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

To date, much of our understanding of adipocyte biology has emerged from histological studies that have revealed changes in adipocyte cell size, extracellular matrix (ECM) flexibility and fibrosis, and macrophage infiltration in obesity [3], while the development of whole-mount immunolabelling has provided insights into adipocyte precursor cell development [4]. A major function of adipose tissue is the release of stored triglycerides in WAT by lipolysis in times of nutrient insufficiency, a process that is regulated by activation of the sympathetic nervous system. However, the neural innervation of WAT has been difficult to visualize due to the presence of large cells filled with lipids [5]. In classical studies in rodents, Bartness and colleagues used retrograde tracers to perform neuronal tracing between adipose tissue and the brain in order to determine the central circuits that innervate various adipose tissue depots [6]. Recent studies in mice have shown for the first time that white adipocytes are directly innervated by sympathetic neurons and that sympathetic innervation of WAT is necessary and sufficient to drive leptin-mediated lipolysis [7, 8]. Further studies using whole tissue immunolabelling, optical clearing and three-dimensional volume microscopy have revealed important information regarding the innervation of mouse adipose tissue and pathways responsible for the regulation of sympathetic innervation [9]. Here we set out to optimize optical clearing techniques and whole-mount immunolabelling protocols used in mice to visualize sympathetic neural circuits innervating WAT in humans. By contrast to optical clearing and whole tissue immunolabelling protocols previously described in mice [7, 10], the protocol reported here uses inexpensive, simple-to-make and non-hazardous solutions which are compatible with different light sheet confocal microscopes, enabling the analysis of human adipose tissue morphology and neural innervation.

43.2 Results

43.2.1 Subcutaneous Adipose Tissue from Obese Individuals Retains Most of Its Original Biopsy Size During Whole Mount Immunolabelling and Optical Clearing

We performed open biopsies of abdominal subcutaneous adipose tissue from individuals with severe obesity. Two grams of adipose tissue were immediately placed on dry ice and cut into two pieces. One piece was immersed in 4% formaldehyde (FA) and 10% sucrose in phosphate buffer saline (PBS) and kept at 4°C for 24 h for whole-mount immunolabelling, optical clearing and three-dimensional volume imaging. The second piece was immersed in 10% neutral buffered formalin solution (NBF) and kept at room temperature for histology and hematoxylin and eosin staining (H & E) (Fig. 43.1a). We then optimized the immunolabelling-enabled three-dimensional imaging of solvent-cleared organs (iDISCO) technique for whole-mount immunolabelling, which is based on dehydration and rehydration of the tissue in methanol to increase adipose tissue permeability [7, 11]. After multiple rounds of organic solvent-based dehydration/rehydration to remove lipids and enhance tissue permeabilization, bleaching with

hydrogen peroxide to reduce tissue auto-fluorescence was performed, followed by immunolabelling with primary antibody against tyrosine hydroxylase (TH) and secondary antibody, and optical clearing with hyperhydrating solutions (Fig. 43.1b). Although during dehydration the human adipose tissue biopsy reduced in size, it regained most of its original size during the rehydration steps. A small change in size was observed by the end of the dehydration/rehydration process, as measured by tissue area; further analysis is needed to assess whether there was a significant change in tissue volume (electronic supplementary material, Fig. S1). Moreover, while the tissue became more rigid during the whole process it regained its original texture upon incubation for 1 h in phosphate-buffered saline (PBS) and during subsequent washing, permeabilization and blocking steps. For immunolabelling, we used an antibody against TH, which is the rate-limiting enzyme of catecholamine biosynthesis and a marker for sympathetic nervous system neurons. Since lipids are a major source of auto-fluorescence, we used Alexa-568 fluorophore in the red spectrum as a secondary antibody, avoiding blue-green fluorophores, which generate more scatter when passing through tissue.




Figure 43.1 Processing of human adipose tissue (a) Schematic representation of processing of human adipose tissue including immunolabelling, optical clearing and three-dimensional volume imaging as well as hematoxylin and eosin (H & E) staining. (b) Schematic representation of the immunolabelling protocol for human adipose tissue. (c) Representative images for the optical clearing process (ScaleCUBIC 1 and ScaleCUBIC 2) for human adipose tissue at different time-points, scale bar: 1 cm.

43.2.2 Whole Adipose Tissue Optical Clearing Performed Using the Advanced CUBIC Method

We performed adipose tissue clearing using the advanced clear, unobstructed brain/body imaging cocktails and computational analysis (CUBIC) method, which is based on simple immersion in two different reagents to minimize light scattering [12]. Tissue was immersed in ScaleCUBIC-1 reagent, which can remove lipids, the main light scattering material inside the tissue and ScaleCUBIC-2 a reagent to further minimize light scattering and match the refractive indices (RIs) between the sample and the reagent, minimizing reflection or refraction and leading to a higher resolution image (Fig. 43.1c). Tissue texture was altered after optical clearing, leading to a more gel-like consistency due to the clearance of lipids, changing the shape of the tissue as well as its size (electronic supplementary material, Fig. S1), as reported for other tissues cleared with the CUBIC protocol [13].

43.2.3 Optical Clearing with the CUBIC Protocol Retains Adipose Tissue Morphology and Increases Whole Adipose Tissue Light Transmittance

We used H & E staining of tissue sections to confirm the presence of intact adipocytes comprised large lipid droplets (Fig. 43.2a). Moreover, we showed that




Figure 43.2 Morphology and light transmittance of human adipose tissue biopsies. (a) Representative hematoxylin and eosin (H & E) staining of human adipose tissue depicting lipid droplets within adipocytes. (b) Representative confocal image of human adipose tissue before clearing; adipocytes stained with perilipin (green) compared to secondary antibody only (negative control); scale bar, 100 μm . (c) Maximum intensity projection images of cleared human adipose tissue without (left) or with (right) tyrosine hydroxylase (TH) staining obtained using a light sheet microscope. Red: tyrosine hydroxylase, scale bar: 200 μm . (d) Maximum intensity projection image of autofluorescence of cleared human adipose tissue, scale bar: 200 μm . (e) Quantification of light transmittance of uncleared and optically cleared adipose tissue. Data presented as percentage transmittance, mean of three individual measurements of the same tissue, normalized to blank.

the adipose tissue remained intact after the biopsy as indicated by the presence of adipocytes (perilipin staining) and imaging with a conventional confocal microscope (Fig. 43.2b). After immunolabelling and optical clearing of human adipose tissue, we tested the specificity of the TH antibody to label sympathetic neural arborizations. We observed immunolabelling of neural connections in the optically cleared adipose tissue incubated with the TH antibody in comparison with tissue incubated only with the secondary antibody (Fig. 43.2c). Furthermore, using the auto-fluorescent properties of human adipose tissue, we could show that the overall tissue architecture remained intact even after the lengthy protocol of permeabilization, immunolabelling and clearing (Fig. 43.2d). Lastly, we examined light transmittance in the optically cleared whole adipose tissue after using the CUBIC protocol to assess the degree of tissue clearance (Fig. 43.2e). We could show that there is an increase of about 40% in light transmittance in the cleared sample in comparison to the light transmittance observed prior to optical clearing.

43.2.4 Quantification of Sympathetic Neural Innervation Using Whole Adipose Tissue Three-Dimensional Images

We analyzed cleared immunolabelled tissue from two severely obese people stained for TH using a light sheet confocal microscope that revealed in three dimension the presence of sympathetic neural networks in human adipose tissue (Fig. 43.3a–f; electronic supplementary material, movies S1 and S2). We used the three-dimensional images obtained to calculate the density of neural arborizations (relative number of TH+ fibres) and the mean fibre surface (Fig. 43.3g), which revealed variation in fibre size between subjects and also between different areas within the same piece of tissue (electronic supplementary material, Fig. S2).

43.3 Discussion

Until recently, the ability to study adipose tissue innervation has been limited by the technical properties of conventional microscopy. For several decades there has been doubt as to whether direct innervation of adipose tissue exists. The combination of tissue clearing techniques with immunolabelling and advanced three-dimensional volume microscopy has made it possible to image whole organs and study sympathetic innervation in murine adipose tissue at single fibre resolution [7–10]. In this study, we obtained human adipose tissue biopsies from severely obese people and developed a protocol for immunolabelling, optical clearing and three-dimensional visualization of neural networks within human WAT using a light sheet confocal microscope. We quantified the density of TH positive fibres in human adipose tissue samples by analyzing the three-dimensional images obtained. Although different protocols exist for whole adipose tissue immunostaining and three-dimensional imaging of mouse adipose tissue [7, 10], this is the first report of successful three-dimensional imaging of sympathetic

neuronal connections in human adipose tissue. Further studies of small sections of adipose tissue at higher magnification will be needed to quantify innervation by fine nerve fibres.




Figure 43.3 Imaging of sympathetic neural arborizations in human adipose tissue. (a–f) Representative images of the neural network in human adipose tissue obtained with light sheet microscopy from two subjects. (a, d) xy plane; (b,e) yz plane; (c, f) xz plane; scale bar: 1 mm. (g) Quantification of TH fibres presented as relative TH fibres and fibre surface, $n = 4$ tissue areas, mean \pm standard deviation (error bars).

For optical clearing of human WAT, we optimized the advanced CUBIC protocol, which is based on delipidation and hyperhydration of the tissue followed by RI matching. The advantage of using the CUBIC method, despite the lengthy protocol required and decreased clearance performance for large amounts of tissue in comparison to other protocols [12], is that the solutions used are based on urea and Triton X-100, and are non-hazardous, compared to organic solvents used in the benzyl alcohol/benzyl benzoate (BABB), AdipoClear and iDISCO protocols used for murine adipose tissue clearing [10, 11, 14]. A major disadvantage of this protocol is that clearing of the tissue takes several days, which may decrease staining intensity; notably, the tissue becomes highly fragile and difficult to handle in the clearing solution. The use of smaller samples would minimize the time needed for optical clearing.

This technique can be applied to study human adipose tissue biology and address important questions such as the differences between lean and obese people, the role of leptin in adipose tissue innervation, and the impact of weight loss on adipose tissue structure and function. There are a number of technical considerations when adapting this protocol for studies in larger clinical cohorts. Prior to immunolabelling, an antibody needs to be tested for compatibility with the methanol present in the dehydration/rehydration steps of the tissue, while antibody concentration may need further adjustment. Additionally, the size of the WAT sample will determine the time needed for effective permeabilization and blocking, as well as the length of incubation with the primary and secondary antibody. For the tissue mass used here, we required 5 days of permeabilization and blocking and 8 days of incubation in the antibody solutions. We obtained human adipose tissue biopsies surgically, which retained the morphology of the adipose tissue. We did not try the same protocol with adipose tissue obtained by other means, such as using fine needle biopsies, where the needle bore and application of suction may damage tissue structure. Moreover, we obtained tissue from severely obese people, where the amount of lipid and presence of tissue inflammation/fibrosis (compared to lean people) may have impacted on immunolabelling and tissue clearing. We observed a reduced antibody signal in the center of the adipose tissue biopsy (electronic supplementary material, movie S1) that probably results from decreased antibody penetration caused by incomplete clearing of lipids. Studies using smaller samples and increased antibody concentration may improve clearing and staining.

In summary, we have developed a protocol for the optical clearing and immunolabelling of human WAT that permits the direct visualization and quantification of sympathetic neural innervation for the first time. Given the importance of sympathetic neural connections in mediating lipolysis and potentially other functions, the method proposed here represents a powerful tool to further understand human adipose tissue structure and function, and its disturbance in obesity and metabolic disease.

43.4 Material and Methods

43.4.1 Subjects

Both male participants had a history of severe childhood obesity. At the time of the study, subject 1 was 22 years old with a BMI of 40.6 kg m⁻², subject 2 was 24 years old with a BMI of 42.7 kg m⁻². They had refrained from smoking, alcohol, caffeine and strenuous exercise for 24 h prior to the biopsy. Biopsies were carried out 3 h after the consumption of a standardized lunch (35% of total energy requirements; 50% carbohydrate, 30% fat, 20% protein). Studies were performed at the Wellcome MRC Institute of Metabolic Science Translational Research Facility.

43.4.2 Adipose Tissue Biopsy

Subcutaneous adipose tissue biopsies were obtained from the left iliac fossa, using a non-diathermy surgical biopsy method, under local anaesthesia. Participants were positioned in the supine position on a surgical couch. The skin was cleaned with 2% chlorhexidine in 70% isopropyl alcohol (ChlorPrep) and covered with surgical drapes to create a sterile field. The skin was infiltrated with a maximum of 10 ml local anaesthetic (1% lidocaine with 1 : 200 000 adrenaline). A 2–3 cm skin incision was made; skin flaps were raised on either side of the incision and the superficial fascia incised. Adipose tissue was grasped with atraumatic forceps; approximately 2 g of tissue was excised and washed in PBS. Hemostasis was achieved using manual compression. A subcuticular suture (3/0 Vicryl Rapid 19 mm) was passed and reinforced with histoacryl tissue adhesive.

43.4.3 Adipose Tissue Preparation

For whole-mount immunolabelling adipose tissue biopsies were fixed in 20 ml PBS with 4% formaldehyde (Fisher Chemical) and 10% sucrose (Sigma) in a 50 ml falcon tube overnight at 4°C with gentle shaking. Tissue was then washed 3 times with 5 ml PBS for 1 hour each time at room temperature and then either processed immediately for whole-mount immunolabelling, or kept in 70% ethanol at 4°C for maximum one month. For histology and hematoxylin and eosin staining (H & E) adipose tissue biopsies were fixed in 10% NBF in 25 ml histology pots at room temperature until further processing.

43.4.4 Whole-Mount Tissue Immunolabelling

The whole-mount immunolabelling protocol was adapted from Jiang et al. [7]. Fixed adipose tissue was cut into 1–2 cm³ pieces. All steps were performed in 2 ml Eppendorf tubes unless stated otherwise. Adipose tissue dehydration was performed at room temperature, with gentle shaking and serial incubation in 1.5 ml 20% methanol (Sigma) in double-distilled water (ddH₂O) for 30 min, 40% methanol in ddH₂O for 30 min, 60% methanol in ddH₂O for 30 min, 80% methanol in ddH₂O for 30 min and twice in 100% methanol in ddH₂O for 30 min. Dehydrated tissue was then bleached with gentle shaking at 4°C for 48 h in 1.5 ml of 5% H₂O₂ (Sigma) in methanol (1 volume of 30% H₂O₂ in 5 volumes of 100% methanol) supplemented with 10 mM EDTA and adjusted for pH 8 with Na. Tissue rehydration was performed at room temperature and with gentle shaking by serial incubation in 1.5 ml 80% methanol in ddH₂O for 30 min, 60% methanol in ddH₂O for 30 min, 40% methanol in ddH₂O for 30 min, 20% methanol in ddH₂O for 30 min and twice in 1.5 ml PBS supplemented with 0.2% Triton X 100 (Fisher Chemical) for 1 h. Tissue was permeabilized in 1.5 ml of PBS with 0.2% Triton X 100, 20% dimethyl sulfoxide (DMSO) (Sigma) and 0.3 M glycine (Sigma) at 37°C for 48 h with gentle rotation and then blocked in 1.5 ml of PBS

with 0.2% Triton X 100, 10% DMSO and 5% donkey serum (D9663 Sigma) at 37°C for 72 h with gentle rotation. Tissue was then immunolabelled with 1 : 100 anti-rabbit TH antibody (Millipore, AB152) or 1 : 500 anti-goat perilipin antibody (Abcam, ab61682) in 1.5 ml of PBS with 0.2% Tween20 (Sigma), 5% DMSO, 5% donkey serum and 10 µg ml⁻¹ heparin (Sigma) at 4°C for 96 h with gentle rotation, washed five times in 1.5 ml of PBS with 0.2% Tween20, and 10 µg ml⁻¹ heparin for 1 h each time with gentle rotation and labelled with the secondary antibody donkey anti-rabbit Alexa 568 (Invitrogen, A-31573) or donkey anti-goat Alexa 488 (Invitrogen, A-11055) in 1.5 ml of PBS with 0.2% Tween20, 5% DMSO, 5% donkey serum and 10 µg ml⁻¹ heparin at 4°C for 96 h with gentle rotation. Tissue was washed 5 times in PBS with 0.2% Tween20 and 10 µg ml⁻¹ heparin at room temperature for 2 h each time with gentle rotation and then kept in 1.5 ml PBS at 4°C until optical clearing.

43.4.5 Tissue Optical Clearing and Refractive Index Match

The optical clearing protocol was adapted from Susaki et al. [12]. In detail, ScaleCUBIC1 (reagent 1) was prepared by mixing 25 wt% (weight percent = weight of solute/weight of solvent × 100) final concentration Urea (Sigma), 25 wt% final concentration Quadrol 80% (Aldrich Chemical) and 15 wt% final concentration Triton X 100 in ddH₂O and kept at room temperature for maximum one month. ScaleCUBIC2 (reagent 2) was prepared by mixing 25 wt% final concentration Urea, 50 wt% final concentration sucrose (Sigma) and 10 wt% final concentration triethanolamine (Aldrich Chemistry) in ddH₂O and kept at room temperature for maximum one month. All steps for optical clearing were performed in 2 ml Eppendorf tubes. Immunolabelled adipose tissue was incubated in 1.5 ml 1 : 1 Reagent 1/ddH₂O solution at 37°C for 3–6 h with gentle rotation and then transferred in 1.5 ml Reagent 1 solution and incubated at 37°C with gentle rotation between 8 and 15 days. Reagent 1 solution was refreshed every second day until tissue looked clear. After that, adipose tissue was incubated in 1.5 ml 1 : 1 Reagent 2/PBS solution at 37°C for 3–6 h with gentle rotation and then transferred in 1.5 ml Reagent 2 solution at 37°C for 72 h with gentle rotation until imaged in the microscope.

43.4.6 Measurement of Tissue Light Absorbance, Calculation of Transmittance and Measurement of Tissue Biopsy Area

Uncleared and cleared adipose tissue was immersed in 100 µl of CUBIC2 reagent in a 96-well clear-bottomed microplate (Greiner). Tissue absorbance measurements were taken every 2 nm between 400 nm and 1000 nm with the Spark M10 Microplate Reader (Tecan). Blank measurements were taken from an equal volume of CUBIC2 reagent in the same 96 well plates. To calculate tissue transmittance (T) from absorbance (A) we used the equation $T = 10^{(-A)}$ and calculated the mean of three individual measurements of the same tissue.

Results are presented as percentage of normalized transmittance to blank, which is set at 100%.

Measurement of tissue biopsy area before, during and after dehydration and rehydration steps and optical clearing was made with ImageJ. The length of the scale bar in the images (1 cm) was used to set the reference scale for measurements. The tissue perimeter was drawn using the area selection tool and the area was calculated in cm^2 using the measure function.

43.4.7 Three-Dimensional Volume Fluorescent Imaging, Confocal Imaging, Image Processing and Density Quantification

Optically cleared adipose tissue was imaged on a Zeiss Z1 light sheet microscope in clearing configuration using a single or a dual-side illumination, with the EC Plan-Neofluar $5\times/0.16$ Air immersion objective, a 561 nm laser illumination and the BP 575–615 nm emission filter. Tissue was attached with glue in the edge of a syringe in order to be immobilized and immersed in the imaging chamber filled with ScaleCUBIC 2 (Reagent 2) solution carefully to avoid bubble formation. Acquisition and initial image processing were performed using ZEN black software (Zeiss, 2014 service pack 1 v. 9.2.6.54), stitching was performed in Arivis software (Arivis) and further image processing in Fiji and ZEN lite (Zeiss). Imaging of perilipin in uncleared adipose tissue was performed using a Leica SP8 confocal microscope (Leica Microsystems).

Quantification of TH fibre density and fibre surface (μm^2) was performed using the Arivis Vision4D software (Arivis). Fibre volume was calculated (μm^3) in 4 Z-stack areas per subject using the fluorescent signal and the 'blob finder' function. The diameter of fibres was calculated (blob finder) and the threshold was adjusted for object segmentation and splitting sensitivity to identify fibres. As a last step, the volume of all objects identified was calculated. Fibres with volume less than $600 \mu\text{m}^3$ were not included in the analysis. Fibre volume (μm^3) was divided by total volume (μm^3) to calculate the relative proportion of TH fibres. Tissue surface area (μm^2) was calculated with ImageJ (Fiji). Graphs were prepared with Prism 7 (Graph Pad Software).

43.4.8 Graphic Representations

Schematics used in the figures and supplementary figures were created with Biorender (BioRender.com).

43.5 Ethics

This study was approved by the Cambridge South Research Ethics Committee (18/EE/0032) and was conducted in accordance with the principles of the Declaration of Helsinki. Subjects were recruited from the Genetics of Obesity

Study (GOOS; www.goos.org.uk) and provided written informed consent prior to inclusion in the study.

Abbreviations

BABB: benzyl alcohol/benzyl benzoate
 CUBIC: clear, unobstructed brain/body imaging cocktails and computational analysis
 ddH₂O: double-distilled water
 DMSO: dimethyl sulfoxide
 ECM: extracellular matrix
 FA: formaldehyde
 H & E: hematoxylin and eosin staining
 iDISCO: immunolabelling-enabled three-dimensional imaging of solvent-cleared organs
 NBF: neutral buffered formalin solution
 PBS: phosphate buffer saline
 RIs: refractive indices
 TH: tyrosine hydroxylase
 WAT: white adipose tissue

Disclosures and Conflict of Interest

This chapter was originally published as: Perdikari, A., Cacciottolo, T., Henning, E., Mendes de Oliveira, E., Keogh, J. M., Farooqi, I. S. (2022). Visualization of sympathetic neural innervation in human white adipose tissue. *Open Biol.*, **12**, 210345, <https://doi.org/10.1098/rsob.210345>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>), and appears here with edits and updates.

Data accessibility: All data supporting our research are included in the submission.

Authors' contributions: A.P.: conceptualization, formal analysis, investigation, visualization, writing—original draft, writing—review and editing; T.C.: resources, writing—original draft; E.H.: resources, writing—original draft; E.M.d.O.: investigation, writing—original draft; J.M.K.: project administration, resources, writing—original draft; I.S.F.: conceptualization, project administration, resources, writing—original draft, writing—review and editing.

All authors gave final approval for publication of this chapter and agreed to be held accountable for the work performed therein.

Competing interests: The authors have no competing interests.

Funding: A.P. was supported by the Swiss National Science Foundation (P400PB_186783). I.S.F. was supported by the Wellcome Trust (207462/Z/17/Z), the NIHR (National Institute for Health Research) Cambridge Biomedical Research

Centre, Botnar Foundation, the Bernard Wolfe Health Neuroscience Endowment and a NIHR Senior Investigator Award.

Acknowledgements: The authors thank the research participants for their involvement. Clinical studies were performed in the Wellcome-MRC IMS Translational Research Facility (TRF), which is supported by a Wellcome Trust Major Award (208363/Z/17/Z). Light sheet confocal microscopy was performed in the Gurdon Institute Imaging Facility in Cambridge, UK. Histology was performed in the Wellcome-MRC IMS Histopathology Core Facility and confocal and histology imaging were performed in the Wellcome-MRC IMS Image Core Facility in Cambridge, UK. The authors would like to thank Nicola Lawrence and Alex Sossick at the Gurdon Institute Imaging Facility for microscopy and image analysis support and Sarah Kohnke (IMS) for support with the clearing protocol. The funding bodies had no role in the design or conduct of the study, collection, management, analysis or interpretation of the data, preparation, review or approval of the chapter, nor the decision to submit it for publication.

References

1. Vegiopoulos A, Rohm M, Herzig S. 2017. Adipose tissue: between the extremes. *EMBO J.* **36**, 1999–2017.
2. Rutkowski JM, Stern JH, Scherer PE. 2015. The cell biology of fat expansion. *J Cell Biol.* **208**, 501–512.
3. Lee M-J, Wu Y, Fried SK. 2010. Adipose tissue remodeling in pathophysiology of obesity. *Curr Opin Clin Nutr Metab Care.* **13**, 371–376.
4. Berry R, Rodeheffer MS. 2013. Characterization of the adipocyte cellular lineage *in vivo*. *Nat Cell Biol.* **15**, 302–308.
5. Berry R, Church CD, Gericke MT, Jeffery E, Colman L, Rodeheffer MS. 2014. Imaging of adipose tissue. *Methods Enzymol.* **537**, 47–73.
6. Bartness TJ, Song CK. 2007. Sympathetic and sensory innervation of white adipose tissue. *J Lipid Res.* **48**, 1655–1672.
7. Jiang H, Ding X, Cao Y, Wang H, Zeng W. 2017. Dense intra-adipose sympathetic arborizations are essential for cold-induced beiging of mouse white adipose tissue. *Cell Metab.* **26**, 686–92.e3.
8. Zeng W, et al. 2015. Sympathetic neuro-adipose connections mediate leptin-driven lipolysis. *Cell.* **163**, 84–94.
9. Wang P, et al. 2020. A leptin–BDNF pathway regulating sympathetic innervation of adipose tissue. *Nature.* **583**, 839–844.
10. Chi J, Crane A, Wu Z, Cohen P. 2018. Adipo-clear: a tissue clearing method for three-dimensional imaging of adipose tissue. *J Vis Exp.* **137**, 58271.
11. Renier N, Wu Z, Simon David J, Yang J, Ariel P, Tessier-Lavigne M. 2014. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. *Cell.* **159**, 896–910.
12. Susaki EA, Tainaka K, Perrin D, Yukinaga H, Kuno A, Ueda HR. 2015. Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging. *Nat Protoc.* **10**, 1709.

13. Gómez-Gavero MV, Sanderson D, Ripoll J, Desco M. 2020. Biomedical applications of tissue clearing and three-dimensional imaging in health and disease. *iScience*. **23**, 101432.
14. Costa EC, Silva DN, Moreira AF, Correia IJ. 2019. Optical clearing methods: an overview of the techniques used for the imaging of 3D spheroids. *Biotechnol Bioeng*. **116**, 2742-2763.

Chapter 44

Brainstem fMRI

Pengxu Wei, PhD,^{a,b} Zhi Lan, PhD,^b Zeping Lv, PhD,^{a,b} and Yubo Fan, PhD^{a,b}

^a*School of Biological Science and Medical Engineering
and Beijing Advanced Innovation Center for Biomedical Engineering,
Beihang University, Haidian District, Beijing, China*

^b*Beijing Key Laboratory of Rehabilitation Technical Aids for Old-Age Disability,
Key Laboratory of Neuro-functional Information and Rehabilitation Engineering
of the Ministry of Civil Affairs, National Research Center for Rehabilitation Technical Aids, Beijing, China*

yubofan@buaa.edu.cn

Keywords: analysis of functional neuroimages (AFNI), automated image registration (AIR), blood-oxygen-level-dependent (BOLD) fMRI, brainstem, brainstem oscillation, cerebrospinal fluid (CSF), cuneiform nucleus (CN), cytoarchitectonic probability maps, echo-pair imaging (EPI), FMRIB software library (FSL), functional magnetic resonance imaging (fMRI), functional magnetic resonance imaging of the brain (FMRIB), head motion, magnetic susceptibility, normalization, statistical parametric mapping (SPM), temporal signal-to-noise ratio (tSNR)

44.1 Introduction

The human brainstem plays important roles in maintaining basic vital functions, e.g., respiration, swallowing, and walking. The brainstem nuclei play essential roles in the regulation of behavior and cognition via cortical/subcortical projections and nerves originating from the nuclei [1]. For instance, the brainstem nuclei for vagal motor innervation are the nucleus ambiguus and dorsal motor nucleus of the vagus, and the final motoneurons are the ganglia in the lower respiratory tract and lung, the cardiac ganglion, and enteric neurons in the abdominal organs. The vagus nerve supplies the pharynx, larynx, and esophagus (general motor and sensory); the thorax and abdomen (visceral); and the thoracic and abdominal organs (parasympathetic nerve endings). Parasympathetic neurons in the dorsal vagus motor nucleus innervate the ganglia in the gastrointestinal wall and other abdominal organs. The motor nucleus modulates visceral motor function,

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

e.g., activities of the gastrointestinal smooth muscle. The brainstem nucleus for the vagal sensory innervation is the nucleus tractus solitarius. As for the swallowing function, most of the motor or sensory nerves supplying to the pharynx originate from the pharyngeal plexus. The plexus consists of the branches of the glossopharyngeal nerve, vagus nerves, and superior cervical sympathetic ganglia. The pharyngeal muscles are innervated from the pharyngeal plexus (through the vagal pharyngeal branch), except the stylopharyngeus (innervated by the glossopharyngeal nerve) [2, 3].

However, unlike a large amount of brain functional magnetic resonance imaging (fMRI) research, only a much smaller number of fMRI studies investigating the brainstem have been reported until now due to various technical challenges. This entry briefly introduces technical difficulties, recent advances, and further directions of brainstem fMRI in humans.

44.2 Technical Challenges of Brainstem fMRI

44.2.1 Motion Artifacts

Motion artifacts of the brainstem are a big challenge for fMRI research. Movements of brain tissues during fMRI scanning lead to displacements of voxels and thus influence voxel intensity. Motion artifacts stem from a number of sources including head movements, movements of the brainstem itself, cerebrospinal fluid (CSF) flux, and blood flow [4].

Head movements during MRI scanning cannot be totally avoided and are often treated with a rigid-body motion correction approach. In comparison with the voxel size, even a small amplitude of head motion can lead to the variation of voxel intensity in blood-oxygen-level-dependent (BOLD) fMRI images, thereby interfering with the detection of signal changes originating from cerebral activities. Motion correction tools including those in Automated Image Registration (AIR), Analysis of Functional NeuroImages (AFNI), FMRIB Software Library (FSL), and Statistical Parametric Mapping (SPM) can lead to improvements in the magnitude (up to 20%) and cluster size (up to 100%) of brain activations. Most motion correction methods apply a rigid-body algorithm, assuming that the shape of the brain is constant across volumes collected at different time points for the same subject. This rigid-body approach corrects translational and rotational motion [5].

Head motion correction may lead to acceptable results for motions of cerebral hemispheres and cerebellum if the amplitude of head movements fluctuates slightly. However, similar to the spinal cord, human brainstem has a thin profile. It is surrounded by cerebrospinal fluid, which cannot restrain small extents of brainstem motion relative to other parts of the brain, or motion of one part relative to other parts of the brainstem. The brainstem is therefore easily distorted by movements of various sources, in addition to rigid-body translational

and rotational motions. The caudal part of the brainstem connects the cervical spinal cord, a structure nearly “floating” in the vertebral canal and highly influenced by motion [6]; movements of the cervical spinal cord result in brainstem motions, such as the elongation-contraction movement, which enhances distortion of the brainstem [7].

Both cardiac and pulmonary activities lead to brainstem distortions. Respiration evokes brainstem oscillation, in which the cranial and caudal parts of brainstem displacements do not synchronize but correspond with different respiratory phases (expiration or inspiration) [8–10]. Ventilatory chest movement may drive brainstem movements through spinal cord movements (e.g., chest motion→vertebral canal and nerve roots from the spinal cord→spinal cord→brainstem) or through CSF motion driven by respiratory circles.

Brainstem motion originated from cardiac activities also presents non synchronized displacements between caudal and rostral structures of the brainstem [11]. The cardiac activity leads to pulsatility of arteries supplying the brainstem including the basilar artery and vertebral artery, which causes brainstem movements.

Note that distortion includes changes in both shape and size of the brainstem, which cannot be corrected by using a rigid-body model.

44.2.2 Physiological Noise

Here, the physiological noise is introduced as factors except brainstem motion, although the physiological noise and brainstem motion may stem from the same sources (e.g., cardiac and pulmonary activities). For brainstem fMRI, both cardiac and pulmonary activities are also main sources of physiologically originated noise, that is, BOLD signal changes in acquired images caused by the subject’s physiological factors but not brain activities. For example, the respiratory cycle is associated with lung volume changes and chest wall movements, which leads to a varying main static magnetic field (B_0) originating from variations of oxygen concentration/spatial distribution in the lungs. Such respiratory-induced instability of BOLD-fMRI signals in the brainstem and cervical spinal cord is higher than the instability in more cranial regions of the brain [4]. In addition, the respiratory cycle also has impact on arterial CO_2 partial pressure. The cardiac cycle influences cerebral blood flow and volume [12]. BOLD signal changes originating from these factors are noise contaminating signal variations induced by brain function changes.

44.2.3 Susceptibility-Induced BOLD Signal Losses/Distortions

The magnetic susceptibility of an object indicates its tendency to be magnetized when placed into a magnetic field. At 37°C, the susceptibility of water is -9.05×10^{-6} , and the susceptibilities of most human tissues are within $\pm 10\text{--}20\%$ of this value. At 20°C and normal pressure (1013 mbar), the susceptibility of air

is 0.36×10^{-6} [13, 14]. Susceptibility artifacts originate from the difference in the magnetic susceptibility arising at an air-tissue or metal implant-tissue interface, resulting in changes in both location and intensity of voxels.

In BOLD fMRI, susceptibility-related field inhomogeneities near the interface of tissues/air with strong different magnetic susceptibilities produce signal losses and/or image distortions. These susceptibility-induced BOLD signal losses and distortions influence sensitivity of spinal cord fMRI and brainstem fMRI [15]. Even in less-affected regions such as the primary motor hand area, voxel shift values in raw echo-planar imaging (EPI) images may reach 5 mm [16].

The sphenoid and the air-filled sphenoid sinus are adjacent to the brainstem, causing magnetic susceptibility-induced BOLD sensitivity losses of the medulla and especially ventral pons [17]. The FieldMap toolbox calculates an unwrapped field map with collected field maps during data acquisition, converts the created field map to the voxel displacement map, and then unwarps geometrically distorted BOLD-fMRI images. This method or similar tools are helpful but can hardly achieve a satisfactory correction for the ventral part of the pons (Fig. 44.1) [18].




Figure 44.1 Susceptibility-induced BOLD signals loss of the ventral pons in functional magnetic resonance imaging (fMRI) images. Normalized brainstem fMRI (A) and T1 images (B) of one subject in [18] are presented. The ventral pons appears to be “dark” in fMRI images because of susceptibility-induced loss of BOLD signals after correction with field maps. Thus, BOLD signal changes in this area cannot be reliably measured. These images are displayed with the SPM12 software (<https://www.fil.ion.ucl.ac.uk/spm>). The crosshairs in BOLD and T1 images indicate the same point in the Montreal Neurological Institute (MNI) space. BOLD signal losses are also obvious in the medial side of the temporal lobe besides in the ventral pons.

44.2.4 Thermal Noise and Low-Frequency Drift

The temporal signal-to-noise ratio (tSNR) is a ratio between the average BOLD signal intensity during an fMRI session and the standard deviation of the BOLD signal intensity of the session. The brainstem presents much lower tSNR than cerebral and cerebellar tissues, demonstrating relatively small magnitudes of BOLD signal changes compared to noise in the brainstem [12].

Thermal fluctuations of scanned subjects and MR electronics during an fMRI session are sources of noise. In comparison with the cortex, a longer distance of the brainstem from the MR coil reduces coil sensitivity, which may increase impacts from the thermal noise at a higher spatial resolution [4]. SNR driven by thermal fluctuations varies linearly with voxel sizes [12]. A higher spatial resolution of fMRI images (i.e., a smaller voxel size) increases the capability to differentiate anatomical details but reduces the SNR. A large voxel size can increase SNR but reduce tSNR gains due to worse impacts from physiologic noise. To acquire the highest SNR at the cost of the minimum loss in spatial resolution, suggested voxel sizes for gray matter, white matter, and cerebral CSF at 3T MR images have been provided as 1.8 mm³, 2.1 mm³, and 1.4 mm³, respectively [19].

The baseline of BOLD signal drifts during an fMRI session, which is usually considered to originate from the instability of MR instruments [20]. The signal drift may be caused by intrinsic brain physiology [21] whereas the impact of this factor on the brainstem remains unknown.

44.2.5 Localizing Brainstem Nuclei

Prior to group data analysis, individual MRI data needs to be transformed to match a template (e.g., MNI standard brains) through affine registration, e.g., “normalization” with SPM software or linear intra- and inter-modal brain image registration with FMRIB’s Linear Image Registration Tool. Such a process aims to facilitate accurate coregistration of anatomical structures across all subjects. After normalization, the locations, scopes, and sizes of brain regions in each subject correspond to those in the template. The MNI or other templates can therefore establish a common three-dimensional coordinate system as a reference to consistently communicate and compare the functional anatomy across studies [22, 23]. Since a number of nuclei are densely situated in the brainstem, small coregistration errors result in increased variance/decreased significance in detected activations [24].

The cross-sectional size of the brainstem is much smaller than that of brain hemispheres, and a number of brainstem nuclei have very small volumes [25]. Thus, differentiating brainstem nuclei is much harder than parcellating brain areas in cerebral hemispheres during fMRI data analysis. Cytoarchitectonic probability maps have been developed from the analysis of post-mortem human brain to correlate microscopically anatomical data and functional imaging data of the cerebral cortex [26]. However, there is no cytoarchitectonic probability map for human brainstem by now, and thus it is impossible to automatically

determine anatomical correspondence to a brainstem template. Manually localizing/labeling brainstem nuclei is a common approach to establish anatomical correspondence in brainstem fMRI studies. Such a manual process may be time and resource consuming and lack a consistent standard.

44.3 Advances in Brainstem fMRI

After motion correction, brainstem and spinal cord fMRI data still need to remove effects of physiological noise by using physiological (e.g., pulse and respiratory) recordings as regressors in the General Linear Model. This approach needs to take physiological recordings during fMRI scanning (e.g., using a pulse oximeter and a respiratory bellows [27]), better with the concurrent recording of scanner triggers [28].

Cardiac gating can be applied to reduce cardiogenic noise when collecting brainstem fMRI data. However, this technique has several disadvantages: (1) Fluctuations in the duration of the repetition time (TR) induced by heart rate variability cause temporal fluctuations of the intensity in fMRI images. (2) Due to non-constant TRs in cardiac gating, a mean TR is needed during data analysis, which may not be supported by commonly used fMRI software. (3) The cardiac gating method leads to relatively longer TR values, e.g., ranged approximately between 3.6 s and 4.6 s (an average value of 4.1 s) [7], which limits the time resolution of fMRI. Thus, collecting data with a standard fMRI sequence has been advocated. Independent component analysis finds that physiological noise is mainly detected at the junction area between the brainstem tissues and the adjacent CSF and blood vessels [4]. Brainstem masks are therefore used to prevent impacts driven by noise from the interface between the brainstem and surrounding tissues. The masked analysis has been applied successfully to resting-state brainstem fMRI data [29] and then used to analyze task-induced activations in the brainstem [18]. These brainstem masks are manually delineated on the basis of mean BOLD images, whereas a CSF mask can be automatically generated to extract nuisance regressors for the aCompCor-based method. The aCompCor approach regresses signal changes in the CSF out of BOLD signals in the statistical model because these signal changes are unlikely elicited by neuronal activities [30].

To reduce effects of small coregistration errors on detecting brainstem activations, the 2-stage mask guided registration technique has been developed to improved brainstem coregistration, and proven to generate a more consistent overlap of individual brainstem borders when compared to whole-brain coregistration methods [24]. Smoothing with a 4.5 mm-kernel combined with this mask guided registration method is proven to be sensitive for detecting activation of brainstem nuclei [7]. When using FSL normalization, activation of the trigeminal motor nucleus was detected by using 3 or 4.5 mm-kernel smoothing but not 6 mm-kernel smoothing [7]. Evidently, smoothing with a large kernel may “blur” localized activations and thus lead to loss in sensitivity. On the other hand, no smoothing or using small kernels may not well enable

inter-subject consistency, which also reduces sensitivity. For example, compared to a 3 or 4 mm-kernel, smoothing with a 5 mm-kernel resulted in larger task-evoked activations in the brainstem [18]. No smoothing also resulted in more dispersed activation clusters in cortical areas and therefore appeared to be less sensitive in comparison with smoothing with a 6 mm-kernel [31].

To achieve brainstem segmentation, tissue probability maps for four classes of brainstem tissues (three gray-matters and one white-matter) acquired with 3 T MRI scanners have been generated, based on a brain specimen of a 57-year-old male subject. These four classes of brainstem tissues are well consistent with brainstem anatomy shown in MR microscopy at 9.4 T [32]. This method can be used to quantitatively analyze the internal architecture of the brainstem [33]. To study functional connectivity between the brainstem and cortical regions [34] or between different nuclei of the brainstem [35, 36], it is necessary to define the exact scopes of brainstem nuclei. The cuneiform nucleus (CN) is located at the lateral side of the periaqueductal gray matter, and the pedunculopontine nucleus (PPN) is located at the lateral side of the CN. The CN controls high-speed locomotion whereas the PPN mediates slow/exploratory locomotion in vertebrates [37, 38]. Localizing individual nuclei, e.g., the CN or the PPN on the basis of a histochemically defined atlas [25] has also been reported [18]. With higher magnetic susceptibility, iron-rich structures including the red nucleus and substantia nigra can be defined by using quantitative susceptibility mapping [39]. Visual correspondence between detected brainstem activations and an atlas has also been used to estimate the location of brainstem nuclei, e.g., in a study to explore the effect of stimulating the auricular branch of the vagus nerve on the nucleus tractus solitarii in humans [40]. Ultrahigh field (7T) MR scanners can provide a high spatial resolution (e.g., 1.2 mm isotropic voxels) and strong tissue contrast in BOLD images, thereby reducing misalignments between functional and anatomical MR images [41].

44.4 Further Directions

High quality of fMRI data is of primary importance for research. Head movements during scanning are the main issue for brain fMRI studies. The real-time amplitude of head motion can be monitored [42] as an index to restart fMRI scanning. Notably, such real-time monitoring and a routine motion correction procedure in the pipeline of fMRI data analysis target movements of the entire head. However, the acceptable amplitude of head motion during scanning, e.g., less than 1- or 2-mm translation in x, y, and z axes, does not necessarily correspond to the same amplitude of brainstem motion. An accurate estimation of the extent of brainstem motion should originate from calculating displacements of the brainstem rather than the entire brain. As a precondition of such estimation, precise automatic segmentation of the brainstem and its surrounding tissues may be needed, similar to a skull-stripping process for brain images.

For the cervical spinal cord, slice-wise motion correction is better than volume-wise correction since the distortion of spinal cord driven by the cardiac and respiratory cycle varies along the cranial-caudal direction [43]. Similarly, because of nonsynchronized motions between different parts of the brainstem [8–10] and more localized impacts such as artery pulsations, rigid-body alignments across volumes of fMRI images (e.g., intrasubject registration) may not achieve accurate motion correction. Linear/nonlinear algorithms (e.g., affine models) [44] are therefore worthy to be tried to correct deformation of the brainstem. In previous studies, improvements after modeling of physiological noise [43] or using masks to exclude brainstem margins [18, 29] may also benefit from eliminating effects of residual brainstem distortions after motion-correction process.

Brain [26, 45] and spinal cord atlases [46, 47] provide standard reference spaces for projecting functional changes to anatomical structures in fMRI studies. Although the brainstem atlas has not been developed, the relationship of histological staining-structure MRI [48] or detailed histological staining of the brainstem [25] have been reported. A brainstem template is needed to achieve an accurate corresponding relationship between histologically defined nuclei/white matter fiber and high-resolution MRI. Notably, brain templates generated from different populations (Caucasian and Chinese people) exhibit dramatic differences in supramarginal gyri and inferior frontal gyri in terms of deformation variability, which can reduce the performance of the brain segmentation and registration when a mismatched template is applied during spatial normalization. The sample size during template constructing process also influences the deformation variability in some brain regions, i.e., the frontoparietal control network and dorsal attention network [49].

Subject-specific functional organization of brainstem nuclei should also be noted. Inter-subject variability in functional mapping of cortical regions has been identified. Such cortical functional regions present strong inter-subject variation in size, location, and connectivity. Furthermore, the size and location of the cortical regions as well as the resting-state functional connectivity among these regions are related to the performance of human behavior. Interestingly, the inter-subject differences in size, location, or connectivity of cortical regions can bring dissociated information to explain the behavior of subjects [50, 51]. Therefore, it is worthy to determine individual-specific functional organization of brainstem nuclei and evaluate the relationship between inter-subject variation and behavioral performance.

Abbreviations

AFNI: analysis of functional neuroimages
AIR: automated image registration
BOLD: blood-oxygen-level-dependent
CN: cuneiform nucleus

CSF: cerebrospinal fluid
 EPI: echo-planar imaging
 fMRI: functional magnetic resonance imaging
 FSL: FMRIB Software Library
 MNI: Montreal Neurological Institute
 PPN: pedunclopontine nucleus
 SPM: statistical parametric mapping
 TR: repetition time
 tSNR: temporal signal-to-noise ratio

Disclosures and Conflict of Interest

This chapter was originally published as: Wei, P., Lan, Z., Lv, Z., Fan, Y. (2021). Brainstem fMRI. *Encyclopedia*, **1**, 4–11, <https://dx.doi.org/10.3390/encyclopedia1010003>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>) and appears here with edits and updates.

Funding: This research was funded by The National Key R&D Program of China (Grant Nos. 2018YFC2001400 and 2018YFC2001700), the National Nature Science Foundation of China (Grant No. 81972160), and the Beijing Natural Science Foundation (Grant No. 17L20019).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Beissner, F. Baudrexel, S. Investigating the human brainstem with structural and functional MRI. *Front. Hum. Neurosci.*, 2014, **8**, 116.
2. Ramachandran, V. S. (Ed.) *Encyclopedia of the Human Brain*, 1st ed., Academic Press: San Diego, USA, 2002, Volume 4, pp. 543–906.
3. Standring, S. *Gray's Anatomy: Churchill Livingstone*: London, UK, 2004, pp. 441–724.
4. Sclocco, R., Beissner, F., Bianciardi, M., Polimeni, J. R., Napadow, V. Challenges and opportunities for brainstem neuroimaging with ultrahigh field MRI. *Neuroimage*, 2018, **168**, 412–426.
5. Oakes, T. R., Johnstone, T., Walsh, K. O., Greischar, L. L., Alexander, A. L., Fox, A. S., Davidson, R. J. Comparison of fMRI motion correction software tools. *Neuroimage*, 2005, **28**, 529–543.
6. Wei, P., Li, J., Gao, F., Ye, D., Zhong, Q., Liu, S. Resting state networks in human cervical spinal cord observed with fMRI. *Eur. J. Appl. Physiol.* 2010, **108**, 265–271.
7. Beissner, F., Deichmann, R., Baudrexel, S. fMRI of the brainstem using dual-echo EPI. *Neuroimage*, 2011, **55**, 1593–1599.
8. Whedon, J. M., Glassey, D. Cerebrospinal fluid stasis and its clinical significance. *Altern. Ther. Health Med.*, 2009, **15**, 54–60.
9. Budgell, B. S., Bolton, P. S. Cerebrospinal fluid pressure in the anesthetized rat. *J. Manip. Physiol. Ther.*, 2007, **30**, 351–356.

10. Maier, S. E., Hardy, C. J., Jolesz, F. A. Brain and cerebrospinal fluid motion: Real-time quantification with M-mode MR imaging. *Radiology*, 1994, 193, 477–483.
11. Enzmann, D. R., Pelc, N. J. Brain motion: Measurement with phase-contrast MR imaging. *Radiology*, 1992, 185, 653–660.
12. Brooks, J. C., Faull, O. K., Pattinson, K. T., Jenkinson, M. Physiological noise in brainstem fMRI. *Front. Hum. Neurosci.*, 2013, 7, 623.
13. Petersch, B., Bogner, J., Fransson, A., Lorang, T., Pötter, R. Effects of geometric distortion in 0.2T MRI on radiotherapy treatment planning of prostate cancer. *Radiother. Oncol.*, 2004, 71, 55–64.
14. Schenck, J. F. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. *Med. Phys.*, 1996, 23, 815–850.
15. Cordes, D., Turski, P. A., Sorenson, J. A. Compensation of susceptibility-induced signal loss in echo-planar imaging for functional applications. *Magn. Reson. Imaging*, 2000, 18, 1055–1068.
16. Lima Cardoso, P., Dymerska, B., Bachratá, B., Fischmeister, F. P. S., Mahr, N., Matt, E., Trattinig, S., Beisteiner, R., Robinson, S. D. The clinical relevance of distortion correction in presurgical fMRI at 7T. *Neuroimage*, 2018, 168, 490–498.
17. Weiskopf, N., Hutton, C., Josephs, O., Deichmann, R. Optimal EPI parameters for reduction of susceptibility-induced BOLD sensitivity losses: A whole-brain analysis at 3 T and 1.5 T. *Neuroimage*, 2006, 33, 493–504.
18. Wei, P., Zou, T., Lv, Z., Fan, Y. Functional MRI reveals locomotion-control neural circuits in human brainstem. *Brain Sci.*, 2020, 10, 757.
19. Bodurka, J., Ye, F., Petridou, N., Murphy, K., Bandettini, P. A. Mapping the MRI voxel volume in which thermal noise matches physiological noise--implications for fMRI. *Neuroimage*, 2007, 34, 542–549.
20. Evans, J. W., Kundu, P., Horovitz, S. G., Bandettini, P. A. Separating slow BOLD from non-BOLD baseline drifts using multi-echo fMRI. *Neuroimage*, 2015, 105, 189–197.
21. Yan, L., Zhuo, Y., Ye, Y., Xie, S. X., An, J., Aguirre, G. K., Wang, J. Physiological origin of low-frequency drift in blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI). *Magn. Reson. Med.*, 2009, 61, 819–827.
22. Klein, A., Andersson, J., Ardekani, B. A., Ashburner, J., Avants, B., Chiang, M.-C., Christensen, G. E., Collins, D. L., Gee, J., Hellier, P., et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. *Neuroimage*, 2009, 46, 786–802.
23. Dadar, M., Fonov, V. S., Collins, D. L. Alzheimer's Disease neuroimaging initiative. A comparison of publicly available linear MRI stereotaxic registration techniques. *Neuroimage*, 2018, 174, 191–200.
24. Napadow, V., Dhond, R., Kennedy, D., Hui, K. K., Makris, N. Automated brainstem co-registration (ABC) for MRI. *Neuroimage*, 2006, 32, 1113–1119.
25. Paxinos, G., Huang, X. F. *Atlas of the Human Brainstem*, 1st ed., Academic Press: San Diego, USA, 1995.
26. Eickhoff, S. B., Stephan, K. E., Mohlberg, H., Grefkes, C., Fink, G. R., Amunts, K., Zilles, K. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. *Neuroimage*, 2005, 25, 1325–1335.

27. Oliva, V., Gregory, R., Davies, W. E., Harrison, L., Moran, R., Pickering, A. E., Brooks, J. C. Parallel cortical-brainstem pathways to attentional analgesia. *Neuroimage*, 2020, 226, 117548.
28. Brooks, J. C., Beckmann, C. F., Miller, K. L., Wise, R. G., Porro, C. A., Tracey, I., Jenkinson, M. Physiological noise modelling for spinal functional magnetic resonance imaging studies. *Neuroimage*, 2008, 39, 680–692.
29. Beissner, F., Schumann, A., Brunn, F., Eisentrager, D., Bar, K. J. Advances in functional magnetic resonance imaging of the human brainstem. *Neuroimage*, 2014, 86, 91–98.
30. Matt, E., Fischmeister, F. P. S., Amini, A., Robinson, S. D., Weber, A., Foki, T., Gizewski, E. R., Beisteiner, R. Improving sensitivity, specificity, and reproducibility of individual brainstem activation. *Brain Struct. Funct.*, 2019, 224, 2823–2838.
31. Bao, R., Wei, P., Li, K., Lu, J., Zhao, C., Wang, Y., Zhang, T. Within-limb somatotopic organization in human SI and parietal operculum for the leg: An fMRI study. *Brain Res.*, 2012, 1445, 30–39.
32. Lambert, C., Lutti, A., Helms, G., Frackowiak, R., Ashburner, J. Multiparametric brainstem segmentation using a modified multivariate mixture of Gaussians. *Neuroimage Clin.*, 2013, 2, 684–694.
33. Lambert, C., Chowdhury, R., Fitzgerald, T. H. B., Fleming, S. M., Lutti, A., Hutton, C., Draganski, B., Frackowiak, R. S., Ashburner, J. Characterizing aging in the human brainstem using quantitative multimodal MRI analysis. *Front. Hum. Neurosci.*, 2013, 7, 462.
34. Zhu, J., Wang, J., Xu, C., Zhang, X., Qiao, L., Wang, X., Zhang, X., Yan, X., Ni, D., Yu, T., et al. The functional connectivity study on the brainstem-cortical/subcortical structures in responders following cervical vagus nerve stimulation. *Int. J. Dev. Neurosci.*, 2020, 80, 679–686.
35. Mills, E. P., Akhter, R., Di Pietro, F., Murray, G. M., Peck, C. C., Macey, P. M., Henderson, L. A. Altered brainstem pain modulating circuitry functional connectivity in chronic painful temporomandibular disorder. *J. Pain.*, 2020, doi: 10.1016/j.jpain.2020.08.002.
36. Mills, E. P., Alshelh, Z., Kosanovic, D., Di Pietro, F., Vickers, E. R., Macey, P. M., Henderson, L. A. Altered brainstem pain-modulation circuitry connectivity during spontaneous pain intensity fluctuations. *J. Pain Res.*, 2020, 13, 2223–2235.
37. Caggiano, V., Leiras, R., Goñi-Erro, H., Masini, D., Bellardita, C., Bouvier, J., Caldeira, V., Fisone, G., Kiehn, O. Midbrain circuits that set locomotor speed and gait selection. *Nature*, 2018, 553, 455–460.
38. Ferreira-Pinto, M. J., Ruder, L., Capelli, P., Arber, S. Connecting circuits for supraspinal control of locomotion. *Neuron*, 2018, 100, 361–374.
39. Li, X., Chen, L., Kuttan, K., Ceritoglu, C., Li, Y., Kang, N., Hsu, J. T., Qiao, Y., Wei, H., Liu, C., et al. Multi-atlas tool for automated segmentation of brain gray matter nuclei and quantification of their magnetic susceptibility. *Neuroimage*, 2019, 191, 337–349.
40. Frangos, E., Ellrich, J., Komisaruk, B. R. Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. *Brain Stimul.*, 2015, 8, 624–636.
41. Sclocco, R., Garcia, R. G., Kettner, N. W., Isenburg, K., Fisher, H. P., Hubbard, C. S., Ay, I., Polimeni, J. R., Goldstein, J., Makris, N., et al. The influence of respiration on brainstem

- and cardiovascular response to auricular vagus nerve stimulation: A multimodal ultrahigh-field (7T) fMRI study. *Brain Stimul.*, 2019, 12, 911–921.
42. Cox, R. W., Jesmanowicz, A. Real-time 3D image registration for functional MRI. *Magn. Reson. Med.*, 1999, 42, 1014–1018.
 43. Eippert, F., Kong, Y., Winkler, A. M., Andersson, J. L., Finsterbusch, J., Büchel, C., Brooks, J. C., Tracey, I. Investigating resting-state functional connectivity in the cervical spinal cord at 3T. *Neuroimage*, 2017, 147, 589–601.
 44. Woods, R. P., Grafton, S. T., Holmes, C. J., Cherry, S. R., Mazziotta, J. C. Automated image registration: I. General methods and intrasubject, intramodality validation. *J. Comput. Assist. Tomogr.*, 1998, 22, 139–152.
 45. Eickhoff, S. B., Paus, T., Caspers, S., Grosbras, M.-H., Evans, A. C., Zilles, K., Amunts, K. Assignment of functional activations to probabilistic cytoarchitectonic areas revisited. *Neuroimage*, 2007, 36, 511–521.
 46. Fonov, V., Le Troter, A., Taso, M., De Leener, B., Lévêque, G., Benhamou, M., Sdika, M., Benali, H., Pradat, P.-F., Collins, D. L., et al. Framework for integrated MRI average of the spinal cord white and gray matter: The MNI-Poly-AMU template. *Neuroimage*, 2014, 102, 817–827.
 47. De Leener, B., Lévy, S., Dupont, S. M., Fonov, V. S., Stikov, N., Collins, D. L., Callot, V., Cohen-Adad, J. SCT: Spinal Cord Toolbox, an open-source software for processing spinal cord MRI data. *Neuroimage*, 2017, 145, 24–43.
 48. Naidich, T. P., Duvernoy, H. M., Delman, B. N., Sorensen, A. G., Kollias, S. S., Haacke, E. M. *Duvernoy's Atlas of the Human Brain Stem and Cerebellum*, 1st ed., Springer-Verlag/Wien: Vienna, Austria, 2009, pp. 63–89.
 49. Yang, G., Zhou, S., Bozek, J., Dong, H.-M., Han, M., Zuo, X.-N., Liu, H., Gao, J.-H. Sample sizes and population differences in brain template construction. *Neuroimage*, 2020, 206, 116318.
 50. Li, M., Wang, D., Ren, J., Langs, G., Stoeklein, S., Brennan, B. P., Lu, J., Chen, H., Liu, H. Performing group-level functional image analyses based on homologous functional regions mapped in individuals. *PLoS Biol.*, 2019, 17, e2007032.
 51. Kong, R., Li, J., Orban, C., Sabuncu, M. R., Liu, H., Schaefer, A., Sun, N., Zuo, X.-N., Holmes, A. J., Eickhoff, S. B., et al. Spatial topography of individual-specific cortical networks predicts human cognition, personality, and emotion. *Cereb. Cortex*, 2019, 29, 2533–2551.

Chapter 45

Electrodes for Neural Stimulation and Monitoring

Jonathan R. Tomshine, PhD,^a and Kevin E. Bennet, PhD^{a,b}

^a*Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, USA*

^b*Division of Engineering, Mayo Clinic, Rochester, Minnesota, USA*

kbennet@mayo.edu

Keywords: biocompatible polymers, carbon fiber, current density, deep brain stimulation (DBS), dynamic response, elastomeric materials, electrical noise, electrochemical reactions, electrode corrosion, electrodes, electrophysiology, endogenous voltages, fast-scan cyclic voltammetry (FSCV), glial scar, lead designs, magnetic resonance imaging (MRI), multi-conductor array, neural stimulation, neuromodulation techniques, neurotransmitter, reactive species, redox chemistry, spatial precision, surface chemistry, wireless instantaneous neurotransmitter concentration system (WINCS)

45.1 Introduction

Electrodes used in neural stimulation and monitoring serve a crucial role as the point of interface between an engineered electronic system and natural biological tissue. While an electrode may be as simple as a section of exposed conductive material, in practice, an array of considerations constrain the engineering of practical neural electrodes. Among these considerations are size and shape, current density, electronic impedance, surface chemistry, material biocompatibility, lifetime/longevity, and surgical practicality of installation and removal.

Electrodes also differ relative to their intended use, which defines the direction of electrical current and information flow. Some electrodes are purely passive and serve only to monitor and record endogenous voltages (signals). In such cases, current and information flows from the biological tissue through the electrode to the electronic system. Other electrodes are designed for application of voltage (and therefore current) from the electronic system to neural tissue for the purpose of stimulation. Finally, there are electrodes designed to serve both purposes, or to serve a hybrid purpose. For example, in fast-scan

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

cyclic voltammetry (FSCV), a small transient voltage is applied for the purpose of monitoring neurotransmitter concentration via oxidation/reduction chemistry, measured by current flow. Here, the electronic system applies a voltage to a carbon-based electrode within neural tissue, for diagnostic and monitoring purposes rather than for the purpose of neural stimulation.

45.2 Electrode Design Considerations

45.2.1 Electronic Implications of Design

The most obvious differences between neural electrode designs are the construction material and the size and shape of the overall electrode and its individual electrical contacts. Electrodes differ in the number of distinct (electrically isolated) contacts or “channels” they contain generally from one to dozens. The greater the number of channels or contacts, the greater the number of distinct areas of the brain or of an individual nerve (contiguous volume) they can stimulate or monitor. However, electrodes with more channels are necessarily larger and thus more difficult to implant and more disruptive to the host tissue. Electrodes with many channels are also more difficult to fabricate than single channel electrodes and require more complex wiring harnesses, connectors, and interface electronics.

Each distinct electrically isolated channel of an electrode is associated with an electrical conductor which interfaces electrically with the neural tissue. The size of this conductor impacts the size of the area of neural tissue in contact with the electrode, and hence the volume of associated tissue stimulated or sampled and the spatial precision of the stimulation or monitoring. Electrode sizes can vary from the low single-digit micrometers (10^{-6} m) to low single-digit millimeters (10^{-3} m). Electrodes at the smaller end of this spectrum are capable of interacting with individual neurons but tend to be very fragile, short-lived, and yield very weak (high impedance) signals that are suitable only for monitoring or research use. Electrodes at the larger end of this spectrum are more robust and more suited for chronic surgical implantation into patients for purposes of stimulation.

The size (area) of an electrode also affects its electrical properties. In the case of stimulating electrodes, larger electrodes deliver current over a larger area, thus decreasing the “current density” (the number of electrons flowing between the electrode and the tissue per unit area per unit time). This is important because high-current densities may damage the electrode, the neural tissue, or both. In engineering and regulatory practice, various empirical safety limits on current density are observed, such as that published by Shannon [1]. On the other hand, excessively large electrodes may stimulate too large a volume of tissue, leading to undesirable off-target effects. However, advanced stimulation electrodes can be made to apply different voltages to a patterned array of channels so as to “steer” the resulting electrical field in a defined way. This technique can be used to refine the exact volume that is subject to stimulation [2].

Monitoring/recording electrodes, on the other hand, are faced with a problem on the opposite (small-signal) end of the spectrum. The amount of electrical charge produced endogenously by the brain or other neural tissue is comparatively small. That is, as a high-impedance voltage source, it cannot deliver a large current. An excessively large monitoring electrode would act as a capacitor, thus requiring too much charge to change its potential, leading to a slow dynamic response and temporally ambiguous data (i.e., the electrode would act as a low-pass filter). Additionally, large electrodes monitor a large number of neurons with potentially heterogeneous behavior, leading to spatially ambiguous data. On the other hand, excessively small electrodes lead to higher impedance (as well as higher thermal noise) which reduce data quality [3].

Electrodes are also commonly formed into multi-conductor arrays so as to monitor or introduce electric potentials over a grid of points. By recording voltages at several adjacent points in the grid, triangulation can be used to estimate the position of individual active neurons—even if the neuron in question is not in direct contact with one of the grid point contacts.

45.2.2 Biological Considerations: Acute and Chronic

Since the electrode is the point of contact between delicate neural tissue and the engineered electronic device, the electrode must be designed so as not to cause excessive damage or disruption for the length of time that it is present. These considerations become particularly important in chronic electrode implantation.

In acute electrode placement, the primary consideration is acute injury to the brain or nerve tissue. For example, implanting a deep brain stimulation (DBS) electrode requires the careful selection of an insertion path to avoid disrupting blood vessels and other functionally important regions of the brain. Clinically, this is accomplished with the aid of a brain atlas and magnetic resonance images of the patient's brain to select an electrode insertion trajectory.

In chronic electrode design, additional considerations come into play. For example, the brain or nerve tissue is not entirely stationary with respect to the skull due to pulsation of the circulatory system and the resumption of normal movement following surgery. Additionally, brain and nerve tissues are soft, with a Young's modulus in the range of 0.1–1.5 kPa, which is similar to jelly [4–8]. To prevent irritation to the delicate neural tissue, electrodes should be designed using the softest, most elastomeric (lowest Young's modulus) materials that are practical. The use of metal, while critical as an electrical conductor, should be minimized. In addition to being inelastic, metallic parts of electrodes can also interfere with magnetic resonance imaging (MRI) scans. Common materials for the construction of electrode bodies (the non-conductive parts) are parylene, polyimide, silicone polymers (e.g., PDMS), fluoropolymers (e.g., PFA), and others. Sharp edges must also be avoided where possible. Any anchorage between the electrode and the skull must also be somewhat flexible, so that the electrode body can move with the brain so as to avoid inflammation of and damage to the neural tissue or damage to the electrode.

Even with a well-designed electrode, however, penetration of nerve tissue will tend to lead to formation of a “glial scar” that encapsulates the penetrating electrode and acts as a local electrical insulator, thus isolating the electrode from the neurons that it is designed to record or stimulate. This reaction can lead to failure of an electrode over time, even if that electrode functioned well immediately following insertion, and even if the electrode itself is functioning normally [9]. This is especially true even under ideal conditions in the case of recording electrodes, which usually are of a higher impedance design than stimulating electrodes. In the case of stimulation electrodes, the increase in impedance can be overcome by increasing the stimulation voltage. In the FSCV electrode, the glial scar increases the time constant of the electrode area reaching equilibrium with the surrounding active neural tissue.

Finally, the electrode should not exert excessive pressure on the brain or nerve tissue once the surgical wound is closed. Pressures exceeding 2.5–8.0 kPa or strain exceeding 8–15% should not be exceeded, as this can limit blood perfusion and flow [10, 11]. Additionally, the brain is delicate and subject to mechanical stimulation, which can produce effects similar to electrical stimulation.

45.2.3 Surface Chemistry and Materials

As a general rule, an ideal electrode will not itself undergo electrochemical reactions across the voltage range it is subjected to, and electrode materials should be selected with this in mind. Independent of their electrochemical behavior, electrode materials must also be inert within the body and must not chemically degrade when exposed to the water, salt, protein, etc., of tissue. Electrochemical reactions within the tissue are generally unavoidable. For instance, above a potential of about 1.5 V, water will be separated into hydrogen and oxygen (electrolysis) at the electrode surfaces, thus providing small quantities of reactive species (such as oxygen and hydroxide ion) that can contribute to electrode corrosion. Short of limiting the applied voltage, reactions of this type cannot be avoided.

Common electrode materials that are in wide use are the noble metals, such as gold, platinum, platinum-iridium alloys, as well as tungsten. These metals tend to be inert across a range of common voltages. Carbon (in various allotropes) is also coming into use for neural electrodes, particularly for FSCV, because it is relatively inert over the wide range of positive and negative potentials encountered in that technique. Silicon is also used in some electrodes due to the wide variety of techniques (borrowed from the electronics industry) available for etching and coating it. However, it is also a very hard and brittle material. Modification of surfaces and surface chemistry is the next logical extension of stimulation electrodes. These coating materials include allotropes of carbon (such as graphite and diamond), polymer surfaces, such as conductive polymers, hydrogels, and biologically active compounds) [12].

In addition to the material chosen for the electrode, the applied voltage has a strong impact on the chemistry that may occur at the electrode surface and within

the adjacent tissue. Almost any electrode material, no matter how inert within some range of voltages, will become reactive outside that range. Since an accurate *ab initio* prediction of the complete chemical behavior at an electrode surface is quite difficult, laboratory tests to check for corrosion are required before using a novel electrode material or before using an established material outside its established voltage/current range. As a general rule, the higher the applied voltage, the wider the variety of (generally undesirable) chemical reactions that are thermodynamically possible at the electrode surface. Higher currents will tend to increase the rates of those reactions. Finally, electrochemical reactions are temperature-dependent, although this is rarely an issue *in vivo*, where temperature is closely regulated by homeostasis.

45.2.4 Wiring and Connectors

The wiring and proximal electronic connector of the neural electrode must also be considered in design. While these components are not as intuitively important as the distal end of the electrode that interfaces directly with the neural tissue, they nevertheless can introduce problems if neglected in the engineering process.

The wiring may be called upon to penetrate membranes (e.g., the meninges or perineurium), and such penetrations must be kept as small as possible. Leads must also be surgically tractable, that is, flexible enough to route, but sturdy enough to withstand the process of implantation. Leads for monitoring small signals must also be kept as short as possible with the largest possible conductors to avoid introducing excessive electrical impedance and noise into an already-weak signal. Many of these requirements are contradictory, so intelligent trade-offs must be made to arrive at an optimal design.

It should also be remembered that unshielded wires act as antennas. In the case of monitoring/recording leads carrying small signals, this may lead to electrical noise (spurious voltages) in the recorded signal. In a worst-case scenario, a patient in the presence of a very strong time-varying electromagnetic field (e.g., from a nearby radio transmitter or an MR scanner) could theoretically experience unintended neural stimulation with unpredictable results—regardless of whether the electrode was originally intended for stimulation or recording. Keeping leads short and electrically shielded may help prevent this. Various techniques of twisting the conductors can also help mitigate the problem of induced voltages. For more information on antennas and shielding, consult a specialist text on electrical (particularly radiofrequency) engineering. New lead designs intended for chronic implantation should be tested to characterize their behavior in the presence of strong radio frequency radiation.

45.3 Neural Electrode Examples

Any practical electrode design must balance the various considerations mentioned above. The particular designs discussed below illustrate the ways in

which different engineers have approached these issues and arrived at different electrode designs intended for different purposes.

45.3.1 Medtronic 3387 and 3389 Deep Brain Stimulation Electrodes

The Medtronic 3387 and 3389 DBS electrodes are commercially available and currently in clinical use for chronic implantation into patients (Fig. 45.1). These electrodes are intended for stimulation rather than monitoring. They contain four independent channels and are relatively large. The electrode shaft is 1.27 mm in diameter with four platinum-iridium contacts at the distal end. The contacts are annular, 1.5 mm in length, and they are spaced 1.5 mm (model 3387) or 0.5 mm (model 3389) apart (Fig. 45.2).




Figure 45.1 A composite of MRI and CT images of DBS electrodes implanted bilaterally in the thalamus of a patient with Tourette syndrome. These electrodes (manufactured by Medtronic and discussed in detail later in this chapter) contain four annular platinum-iridium contacts within the last centimeter of their distal ends. They are connected to an electronics package that is implanted in the patient’s chest (not shown).




Figure 45.2 Medtronic 3387 deep brain stimulation electrode (image courtesy of Medtronic).

The insulating components are made of various biocompatible polymers with the “shaft” of the electrode primarily composed of silicone rubber. This makes the electrode pliable so as to avoid damage to the brain, while a removable metal “stylet” runs down the central axis of the electrode to make it stiff enough for

surgical implantation. The four electrical conductors inside this shaft are twisted in a helical pattern so as to reduce the possibility of electrical interference.

This electrode is connected to an implantable deep brain stimulation unit that is implanted in the chest. The Medtronic Activa® stimulators that mate to these electrodes produce pulses ranging 0–10.5 V and currents up to 25.5 mA, with polarity being programmatically adjustable.

45.3.2 Electrophysiology Targeting Electrode

Prior to placement of a DBS electrode such as the Medtronic 3387 or 3389, it is common practice to confirm the targeted brain structure with passive electrophysiology recording in the operating room using a disposable electrode such as the D-Zap series by FHC, Inc. (Fig. 45.3). The electrode used for this task is not implanted chronically, but is utilized for a short time intraoperatively to sense neuronal firing activity at its tip. The electronic signal indicating firing of the “correct” neurons is monitored auditorily during electrode insertion and is used to identify the exact location for the chronically implanted DBS electrode. The intraoperative targeting electrode is then removed and the DBS electrode is implanted permanently in the same location (same stereotactic coordinates).



Figure 45.3 Electrophysiology targeting electrode. The exposed tungsten tip is at right (though too small to see at this resolution), the electrical contacts at left. The red contact at left is connected to the tungsten tip, while the white contact at left-bottom is connected to a stainless-steel jacket coaxial with the tungsten tip. In use, this electrode is inserted into the brain through a stainless-steel cannula, which is held in place by a stereotactic surgical frame. The black scale bar at the lower-right is 1 cm.

Materials of construction for these electrodes include tungsten or stainless steel insulated along their lengths with only a small tip exposed. These cores are often on the order of a few hundred micrometers in nominal diameter, sharpened to a fine point. A stainless-steel sheath (electrically insulated from the interior sensing electrode) is used as a counter-electrode and as protection for the thin interior electrode core.

Since these electrodes are only used for a few minutes during surgery, wiring is temporary and provided by clip-leads similar to those used in electronics laboratories.

45.3.3 Utah Multi-Electrode Array

The Utah Array is a relatively well-known recording and stimulating electrode array originally developed at the University of Utah and produced commercially by

Blackrock Microsystems, Salt Lake City, Utah (Fig. 45.4). Many different versions of this array have been produced, but all are on the order of about 0.5–4.0 mm square and contain on the order of 100 distinct channels. The bulk of the electrode is made from a silicon wafer that is sawed, etched, and processed using techniques borrowed from the semiconductor industry. The individual needles (channels) are insulated with polyimide, with only their tips exposed (via chemical etching) [13]. These arrays are currently available, but their use is limited to experimental work.




Figure 45.4 The Utah neural electrode array (at 30× magnification). The bulk of the array is made from etched silicon, with glass (fused frit) and parylene comprising the insulating portions.

45.3.4 Carbon Fiber Fast-Scan Cyclic Voltammetry Electrode

FSCV is a powerful analytical method that places unique demands on an electrode. While the technique involves the application of a small voltage to the electrode, the intent is not to supply sufficient voltage or current to produce neural stimulation. Rather, the voltage causes chemical oxidation/reduction reactions in neurotransmitter and other molecules near the electrode surface. Since these redox reactions occur at specific voltages for specific molecules, the amount of current drawn at a particular voltage (the I - V curve, in the electrical engineering parlance) can be used to infer the concentrations of specific molecules at the electrode.

Because the voltages and currents are small (on the order of 100 s of mV and 100 s of nA), and because the applied waveform is alternating rather than direct current (typically a pulsed triangular wave above a non-zero negative baseline), the complex impedance of the electrode and cable must be considered. Given the small signals involved, it is possible for capacitive “charging current” to overwhelm and mask the small current drawn by the redox chemistry.

Additionally, because endogenous concentrations of neurotransmitters are so small, it is important to consider the effect of electrode material on sensitivity. Certain materials, such as gold (or other metals), may be chemically inert, but they generally do not adsorb molecules of the analyte of interest (such as dopamine) on their surface, thus producing a relatively weak signal [14]. Carbon provides a surface with favorable neurotransmitter adsorption characteristics leading to enhanced sensitivity, so it is the material of choice in neural FSCV electrodes [15].

Laboratory *in vitro* carbon fiber FSCV microelectrodes have been fabricated from carbon fiber, often the exact same material used to construct carbon fiber components for aircraft, bicycles, etc. Since these electrodes are not commercialized, but are built as-needed in the laboratory, the particulars of their designs (dimensions, insulation and structural materials, etc.) differ widely. An example electrode for acute studies is depicted in Figs. 45.5 and 45.6. These electrodes cannot be used for chronic implantation in humans due to the fragility of thin carbon fibers, but they have been used extensively in acute and chronic animal studies and limited acute human studies [16].



Figure 45.5 Carbon fiber electrode constructed by the Mayo Clinic Neural Engineering Laboratory. The exposed carbon fiber tip is at right.

An example of a modern carbon fiber-based chronic FSCV electrode used for large-animal studies at the Mayo Clinic Neural Engineering Laboratory can be seen in Fig. 45.7. This electrode is designed to be used in conjunction with the wireless instantaneous neurotransmitter concentration system (WINCS) [17–22].

The electrode in Fig. 45.7 consists of a carbon fiber with a diameter on the order of 10 micrometers (of the type commonly used in the aerospace industry) held in place inside a small silica tube. This tube is secured inside an annular stainless-steel counter-electrode, while supporting non-conductive structures are made of polyimide (internally) and silicone rubber (externally, in contact with tissue). The leads are stainless steel and are wound helically inside a silicone rubber tube. The electrode is fabricated with a Nitinol wire stylet running down the center of the lead (much like the Medtronic 3387 and 3389). This stylet is removed during the implantation surgery after the electrode is placed. After the

stylet is removed, the remaining structure is flexible and able to move and flex in order to accommodate motion of the brain inside the skull.




Figure 45.6 Scanning electron micrograph of a carbon fiber electrode tip (at right) with glass insulation (at left).




Figure 45.7 Carbon fiber electrode for fast scan cyclic voltammetry recording designed at the Mayo Clinic. The carbon fiber for analysis is at the right (distal) end.

While the number of electrodes that have been developed for research and clinical use is enormous, these few examples illustrate the key issues that engineers and scientists must consider when designing electrodes to introduce voltages into neural tissue (stimulation) or record signals from tissue (electrophysiology and FSCV).

45.4 Summary

As the clinical use of neuromodulation techniques expands, so too will the need for advanced neural electrodes. Not only will new electrodes for neural stimulation be required, but new techniques of neuromodulation (such as closed-loop deep brain stimulation, which requires monitoring and recording brain activity)

will require fundamentally different electrode designs than those currently used in clinical practice. As work on this field progresses, engineers will be forced to address the various inherent design trade-offs between neural stimulation and the recording/sensing of neural activity. The current state-of-the-art in clinical practice is limited primarily to platinum/iridium electrodes and fairly large contact areas, but this will inevitably change as the limits of sensitivity, longevity, and tissue compatibility are encountered.

Disclosures and Conflict of Interest

This chapter was originally published as: Tomshine, J. R., Bennet, K. E. (2017). Electrodes for neural stimulation and monitoring. In: Lee, K. H., Duffy, P. S., Bieber, A. J., eds. *Deep Brain Stimulation: Indications and Applications*, Jenny Stanford Publishing Pte. Ltd., Singapore, chapter 20, pp. 373–388. It appears here, with edits and kind permission of the publisher.

References

1. Shannon RV (1992). A model of safe levels for electrical-stimulation. *IEEE Trans Bio-Med Eng*, **39**(4), 424–426.
2. Duker AP, Espay AJ (2013). Surgical treatment of Parkinson disease: past, present, and future. *Neurol Clin*, **31**(3), 799–808.
3. Hughes MP, Bustamante K, Banks DJ, Ewins DJ, eds. (2000). Effects of electrode size on the performance of neural recording micro-electrodes. *Microtechnologies in Medicine and Biology*, Lyon, France.
4. Shen F, Tay TE, Li JZ, Nigen S, Lee PV, Chan HK (2006). Modified Bilston nonlinear viscoelastic model for finite element head injury studies. *J Biomech Eng*, **128**(5), 797–801.
5. Taylor Z, Miller K (2004). Reassessment of brain elasticity for analysis of biomechanisms of hydrocephalus. *J Biomech*, **37**(8), 1263–1269.
6. Miller K (1999). Constitutive model of brain tissue suitable for finite element analysis of surgical procedures. *J Biomech*, **32**(5), 531–537.
7. Miller K, Chinzei K, Orssengo G, Bednarz P (2000). Mechanical properties of brain tissue in-vivo: experiment and computer simulation. *J Biomech*, **33**(11), 1369–1376.
8. Prange MT, Margulies SS (2002). Regional, directional, and age-dependent properties of the brain undergoing large deformation. *J Biomech Eng*, **124**(2), 244–252.
9. Polikov VS, Tresco PA, Reichert WM (2005). Response of brain tissue to chronically implanted neural electrodes. *J Neurosci Methods*, **148**(1), 1–18.
10. Lundborg G, Rydevik B (1973). Effects of stretching the tibial nerve of the rabbit. A preliminary study of the intraneural circulation and the barrier function of the perineurium. *J Bone Joint Surg Br*, **55**(2), 390–401.
11. Rydevik B, Lundborg G, Bagge U (1981). Effects of graded compression on intraneural blood flow. An *in vivo* study on rabbit tibial nerve. *J Hand Surg Am*, **6**(1), 3–12.

12. Aregueta-Robles UA, Woolley AJ, Poole-Warren LA, Lovell NH, Green RA (2014). Organic electrode coatings for next-generation neural interfaces. *Front Neuroeng*, **7**, 15.
13. Jones KE, Campbell PK, Normann RA (1992). A glass/silicon composite intracortical electrode array. *Ann Biomed Eng*, **20**(4), 423–437.
14. Zachek MK, Hermans A, Wightman RM, McCarty GS (2008). Electrochemical dopamine detection: comparing gold and carbon fiber microelectrodes using background subtracted fast scan cyclic voltammetry. *J Electroanal Chem (Lausanne Switz)*, **614**(1–2), 113–120.
15. Rice ME, Richards CD, Nedergaard S, Hounsgaard J, Nicholson C, Greenfield SA (1994). Direct monitoring of dopamine and 5-HT release in substantia nigra and ventral tegmental area in vitro. *Exp Brain Res*, **100**(3), 395–406.
16. Kasasbeh A, Lee K, Bieber A, Bennet K, Chang SY (2013). Wireless neurochemical monitoring in humans. *Stereotact Funct Neurosurg*, **91**(3), 141–147.
17. Agnesi F, Tye SJ, Bledsoe JM, Griessenauer CJ, Kimble CJ, Sieck GC, et al. (2009). Wireless instantaneous neurotransmitter concentration system-based amperometric detection of dopamine, adenosine, and glutamate for intraoperative neurochemical monitoring. *J Neurosurg*, **111**(4), 701–711.
18. Bledsoe JM, Kimble CJ, Covey DP, Blaha CD, Agnesi F, Mohseni P, et al. (2009). Development of the wireless instantaneous neurotransmitter concentration system for intraoperative neurochemical monitoring using fast-scan cyclic voltammetry. *J Neurosurg*, **111**(4), 712–723.
19. Kimble CJ, Johnson DM, Winter BA, Whitlock SV, Kressin KR, Horne AE, et al. (2009). Wireless instantaneous neurotransmitter concentration sensing system (WINCS) for intraoperative neurochemical monitoring. *Conf Proc IEEE Eng Med Biol Soc*, 4856–4859.
20. Van Gompel JJ, Chang SY, Goerss SJ, Kim IY, Kimble C, Bennet KE, et al. (2010). Development of intraoperative electrochemical detection: wireless instantaneous neurochemical concentration sensor for deep brain stimulation feedback. *Neurosurg Focus*, **29**(2), E6.
21. Griessenauer CJ, Chang SY, Tye SJ, Kimble CJ, Bennet KE, Garris PA, et al. (2010). Wireless instantaneous neurotransmitter concentration system: electrochemical monitoring of serotonin using fast-scan cyclic voltammetry—a proof-of-principle study. *J Neurosurg*, **113**(3), 656–665.
22. Chang SY, Jay T, Munoz J, Kim I, Lee KH (2012). Wireless fast-scan cyclic voltammetry measurement of histamine using WINCS—a proof-of-principle study. *Analyst*, **137**(9), 2158–2165.

Chapter 46

Imaging and Visualizing SARS-CoV-2 in a New Era for Structural Biology

Kendra E. Leigh, PhD,^{a,b} and Yorgo Modis, PhD^{a,b}

^a*Molecular Immunity Unit, Department of Medicine, MRC Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK*

^b*Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, UK*

ymodis@mrc-lmb.cam.ac.uk

Keywords: 3'-azido-3'-deoxythymidine (AZT), angiotensin converting enzyme 2 (ACE2), complementary metal-oxide semiconductor (CMOS), coronavirus disease 2019 (COVID-19), cryo-electron microscopy (cryo-EM), cryo-electron tomography, cryo-EM reconstruction, fluorescence microscopy, fluorescent light microscopy, multiscale imaging, nuclear magnetic resonance (NMR), receptor binding domain (RBD), RNA-dependent RNA polymerase (RdRp), scanning electron microscopy (SEM), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), stimulated emission depletion (STED), structural biology, subtomogram averaging (STA), tomographic slice, transmembrane protease serine 2 (TMPRSS2), transmission electron microscopy (TEM), X-ray crystallography

46.1 Introduction

The SARS-CoV-2 pandemic has had a global impact and has put scientific endeavour in the spotlight, perhaps more than any previous viral outbreak. Fortuitously, the pandemic came at a time when decades of research in multiple scientific fields could be rapidly brought to bear, and a new generation of vaccine platforms was on the cusp of clinical maturity. SARS-CoV-2 also emerged at the inflection point of a technological revolution in macromolecular imaging by cryo-electron microscopy (cryo-EM), fuelled by a confluence of major technological advances in sample preparation, optics, detectors and image processing software, that complemented pre-existing techniques. Together, these advances enabled us to visualize SARS-CoV-2 and its components more rapidly, in greater detail, and in

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

a wider variety of biologically relevant contexts than would have been possible even a few years earlier. The resulting ultrastructural information on SARS-CoV-2 and how it interacts with the host cell has played a critical role in the much-needed accelerated development of COVID-19 vaccines and therapeutics. Here, we review key imaging modalities used to visualize SARS-CoV-2 and present select example data, which have provided us with an exceptionally detailed picture of this virus.

46.2 Background

COVID-19 grew to pandemic scale with alarming speed and has continued to claim a heavy toll. However, the advent of the pandemic in late 2019 was fortuitous in more ways than one. A new generation of vaccine platforms was on the cusp of clinical maturity, making it possible for multiple highly effective vaccines to be developed and approved within a year of the outbreak. Perhaps just as importantly, SARS-CoV-2 emerged at the inflection point of a technological revolution in macromolecular imaging by cryo-EM, fuelled by a confluence of major advances in sample preparation, optics, detectors and image processing software for electron microscopy [1–3]. Together, these advances enabled us to visualize the molecular structure of SARS-CoV-2 and its components more rapidly, in greater detail, and in a wider variety of biologically relevant contexts than would have been possible even a few years earlier. The resulting wealth of ultrastructural information on SARS-CoV-2 and how it interacts with the host cell played a critical role in the remarkable and much-needed acceleration in the development of COVID-19 vaccines and therapeutics. Here, we review the key imaging modalities used to visualize SARS-CoV-2 and present select example data that have provided us with an exceptionally detailed picture of SARS-CoV-2 on a wide range of scales at every stage of the viral life cycle.

46.3 The Resolution Spectrum

Microscopes have been used to image viruses since viruses were discovered in the late nineteenth century [4], but only in the last decade or so have technological advances in electron microscopy allowed us to image viruses on a continuous resolution spectrum. With dimensions smaller than the wavelength of visible light, viruses could not be visualized directly until the invention of the electron microscope in the 1930s [5, 6] (Fig. 46.1). Since then, electron microscopy has been the method of choice for identifying viruses, based on their size, shape, ultrastructural features and tissue distribution. Our first glimpses of SARS-CoV-2 were in electron micrographs taken within weeks of the outbreak (Fig. 46.2) [11].

The images derived from electron microscopy are often noisy, making the features contained therein appear fuzzy and indistinct. This effect can be

compounded by the treatments that samples must be subjected to prior to imaging in a conventional transmission electron microscope. Chemical fixation, use of contrast agents (e.g. uranyl acetate), drying and embedding of the sample in plastic resin limit the imaging resolution and distort the sample, yielding results that fall short of the molecular detail needed to be useful in vaccine and antiviral drug design. X-ray crystallography of viral proteins, macromolecular assemblies and occasionally entire viruses can provide the necessary resolution but requires the object of interest to be crystallized. In practice, this limits crystallographic structure determination to homogeneous, highly soluble and relatively small (rarely larger than 200 kDa) macromolecules. The irregular, non-spherical shape of SARS-CoV-2 virions, therefore, precludes crystallization.




Figure 46.1 Recent technological advances have allowed us to image SARS-CoV-2 and its components on a continuous resolution spectrum up to the near-atomic scale. From left to right: a schematic of spike protein on the surface of cells as it would appear if visualized by fluorescent light microscopy; a schematic of a SARS-CoV-2 virion as it would appear if visualized by cryo-electron tomography; a cryo-EM reconstruction of the spike protein trimer (EMD-21374); a model based on the crystal structure of ACE2 (angiotensin-converting enzyme 2) in complex with the receptor binding domain (RBD) of spike protein (PDB 6M0J).

Up until the mid-2010s, in most cases, the limitations of these techniques left a large gap in achievable imaging resolutions between conventional transmission electron microscopy (with resolutions on the order of nanometres) and X-ray crystallography (with resolutions on the order of angstroms). For the most part, determining the structure of an entire virion, alone or in the context of a host cell, remained inaccessible to high resolution structure determination by any method. This began to change with the Nobel-prize-winning development by Dubochet and colleagues [12] of cryogenic vitrification of aqueous samples, including viruses, for cryo-EM imaging. These early cryo-EM micrographs were essentially free of preservation artefacts but still suffered from blurring and poor signal-to-noise ratios. Additional developments, most notably direct electron detectors, maximum likelihood image classification and averaging algorithms, and improved tomographic reconstruction and subtomogram averaging (STA) algorithms, which became widely available from 2013 onwards, really brought




Figure 46.2 SARS-CoV-2 and the cell. (a) Electron microscopy plays an important confirmatory role in diagnosis and determining subcellular localization. A false-colour transmission electron micrograph of SARS-CoV-2 isolated from a patient. Coronaviruses are approximately 80–120 nm in diameter [7]. (b) A false-colour scanning electron micrograph of an apoptotic cell (green) infected with SARS-CoV-2 isolated from a patient. The virions can be observed as small yellow spheres. (a) and (b) are adapted from images of ‘Novel Coronavirus SARS-CoV-2’ published by NIAID and licensed under CC BY 2.0 [8, 9]. (c) Fluorescence microscopy can show subcellular localization. Co-localization of FLAG-tagged SARS-CoV-2 protein Orf6 with nuclear pore complex protein Nup358 in HEK293T cells as imaged by stimulated emission depletion (STED) super-resolution microscopy. Scale bar in the left-most panel is 5 μm . Scale bar in the magnified panels is 1 μm . This panel is adapted from ref. [10] and licensed under CC BY 4.0.

the field to the fore [1–3]. These advances ushered in a new era in structural biology in which the structures of large asymmetric macromolecular assemblies can now be reconstructed at a resolution sufficient to build atomic models (between 0.1 nm and 1 nm resolution). While the use of contrast reagents and conventional electron microscopy on chemically fixed samples continues to be the method of choice for rapid identification of viruses, particularly, within infected cells or tissues, cryo-EM extends our ability to obtain high-resolution information of entire viruses and macromolecular assemblies that cannot be crystallized. When SARS-CoV-2 emerged, these tools had matured, allowing them to be rapidly applied to the virus and its components on a continuous resolution spectrum, through a combination of conventional electron microscopy, cryo-EM and X-ray crystallography (Fig. 46.1). The snapshots from these structural studies have

been provided a more dynamic biological context through the use of light microscopy, which can be used to track and identify viruses in real-time as they move through the host cell (Fig. 46.2).

46.4 Finding and Tracking SARS-CoV-2 in the Cell

Transmission electron microscopy (TEM) of tissue or fluid samples has historically played a key role in the identification of new viruses. SARS-CoV-2 was first imaged by TEM within weeks of the initial outbreak (Fig. 46.2a) [11]. Micrographs provided important visual confirmation of sequencing data that the new virus, displaying the prototypic ‘corona’ of glycoproteins, was a coronavirus. TEM also supported biochemical data suggesting that virus entry can occur at the plasma membrane or via endosomes [13–15]. Scanning electron microscopy (SEM) of infected cells showed large numbers of virus particles released from a single cell indicating that infection was acute and highly productive (Fig. 46.2b). However, these TEM and SEM micrographs alone cannot provide the molecular detail needed to understand the specific protein–protein interactions at the heart of the biological processes essential to the virus life cycle; for example, how SARS-CoV-2 recognizes host cells or how antibodies neutralize the virus. Moreover, these images are static, yielding no clues about the timescales of virus-cell entry, establishment of replication sites—‘virus factories’, and emergence of newly replicated virions from the cell.

Electron microscopy samples must be imaged in a vacuum to prevent scattering of the electron beam, thus making it impossible to study the dynamics of biological processes in living specimens. By contrast, light microscopy can be performed on live cells, allowing for example, tracking of fluorescently labelled viruses in real-time as they travel through the cell. Despite its lower imaging resolutions, light microscopy powerfully complements electron microscopy by providing a time dimension. Moreover, the use of genetically or chemically encoded fluorescent labels allows targets of interest, such as viral proteins, to be identified among the tens of thousands of other proteins that make up the cell (Fig. 46.2c). Fluorescence microscopy of virus-infected cells has been used to identify possible cell entry pathways for SARS-CoV-2, the architecture and subcellular location of virus replication sites, the effects of infection on cell morphology and the timings of each of these steps [16, 17]. For example, fluorescence microscopy revealed that lentiviruses pseudotyped with SARS-CoV-2 spike glycoprotein can take advantage of clathrin-mediated endocytosis pathways, where ubiquitous cathepsins take the place of TMPRSS2 (transmembrane protease serine 2) and prime the spike glycoprotein for entry within endosomes [13]. Fluorescence microscopy imaging had also shed light on other biological properties such as the membrane fusion activity of the spike glycoprotein, subcellular localization of viral proteins and inhibitor activity [10, 18, 19].

Complementary light and electron microscopy modalities, such as cryo-CLEM (cryo-correlative light and electron microscopy), have been applied to multiple viruses to gain an understanding of virus life cycles at the lower end of the resolution spectrum. Application of these modalities to SARS-CoV-2 allowed rapid identification, tracking of infection within the cell, including co-localization with cellular components, and ultrastructural characterization of larger virus-associated assemblies (such as replication sites). This type of information is necessary, not only to provide biological context but also to gain an understanding that can be leveraged in the development of antiviral approaches.

46.5 The Cryo-EM Revolution—Impact on SARS-CoV-2 Imaging

What sets the imaging and visualization of SARS-CoV-2 apart from work done on previous epidemics is the astonishing amount of high-resolution structural information that was gleaned and the pace at which it was delivered. This was made possible largely by transformative technological advances in cryo-EM (reviewed in [1–3]), and by an unprecedented mobilization of the scientific enterprise towards COVID-19-related research across public and private sectors. The majority of the cryo-EM-derived structural information on SARS-CoV-2 has come from image reconstructions determined by single-particle averaging (SPA). In SPA, thousands, or even millions, of images of a protein or macromolecular assembly in different orientations, but ideally in identical conformations, are extracted from cryo-EM micrographs, classified, aligned and then averaged to calculate a three-dimensional structure. The power of this averaging process greatly reduces the high background noise present in cryo-EM images, which have low signal to noise ratios due to the low scattering potential and therefore low inherent contrast of biological material, compounded by sample movement and radiation damage caused by the microscope's electron beam.

Cryo-EM has existed for decades as a structural technique, but more recent advances have taken the field to a state where near-atomic resolutions are readily achievable. Maximum likelihood statistical algorithms, as implemented for example in the RELION software package [20], greatly improve the alignment accuracy, and hence the effective resolution, of SPA image reconstruction. However, this process is computationally expensive. Computation and data storage requirements that would have been prohibitive even 10 years ago have recently become tractable through more affordable data storage, GPU (graphics processing unit)-based parallelization and the development of faster CPUs (central processing units). In parallel, the introduction of direct electron detectors, based on the principles behind the active-pixel CMOS (complementary metal-oxide-semiconductor) sensors used in consumer digital cameras, has significantly reduced detector noise and allowed for the acquisition of movies rather than still images [21]. With data acquired as a set of movies, some of the obstacles to

high-resolution reconstructions, such as blurring, can be overcome with computational approaches including motion-correction algorithms [22]. Together these advances, along with improved sample preparation workflows and hardware, have dramatically improved the capability of cryo-EM image reconstruction by SPA. As a result, resolutions comparable to those achieved in X-ray crystallography can now routinely be achieved by cryo-EM. The key advantage of cryo-EM over crystallography, however, is that cryo-EM can be used to determine structures of a wide variety of macromolecules that cannot be readily crystallized because they are too large, too flexible, insufficiently soluble (for example because they contain transmembrane domains or lipid anchors) or simply because they are not available in sufficient quantity or purity.

46.5.1 The SARS-CoV-2 Spike Structure

The cumulative technological advances in multiple fields of structure determination mean that within little over a year of the outbreak, structures have been determined of nearly all of the constituent proteins in SARS-CoV-2 at resolutions sufficient to allow atomic models to be built [23]. Arguably, the best example of the speed at which structural biology, and cryo-EM in particular, can now operate is illustrated by structures of the spike (S) glycoprotein of SARS-CoV-2. In March 2020, only a few months after the sequencing of the new virus, McLellan and colleagues [24] reported a cryo-EM structure of the soluble ectodomain of S in a stabilized trimeric prefusion conformation, determined by SPA to 3.5-Å resolution (Fig. 46.3a). Additional cryo-EM structures of the spike trimer quickly followed (for example, [25–29]), including those in complex with neutralizing antibody fragments [30] or other binding partners, at a pace that would not have been possible using crystallography or other previously available approaches. To date, there are well over 100 cryo-EM structures of the spike or its subcomponents [31], and the highest resolution structure currently available was determined to a resolution of 2.4 Å, which is at least on par with the average resolution of crystal structures of similarly sized molecules [32].

S is the single most important antigen on the virion surface and is the primary target of most neutralizing antibodies against SARS-CoV-2 [33]. Consequently, S was the expressed antigen selected for the first wave of SARS-CoV-2 vaccines, including those from Pfizer/BioNTech, Moderna and Oxford–AstraZeneca. Several of the S protein constructs used for cryo-EM structure determination contain various stabilizing mutations, most notably proline substitutions at residues 986 and 987, which also help preserve S in the pre-fusion conformation [24, 26, 29, 32, 34]. Previous structural and immunological studies on spike proteins from other coronaviruses have shown that such stabilizing mutations can result in improved expression stability and immunogenicity [35]. This previous work was fortuitous because knowledge of these mutations could be directly and rapidly applied to SARS-CoV-2 vaccine formulations [29, 36], highlighting how in this case structural biology and vaccinology mutually benefitted each other. The spike

structures have also served as excellent platforms for the analysis and prediction of the effects of any point mutations acquired by new isolates or variants of the virus [37, 38]. Furthermore, the rapid turnaround in cryo-EM structure determination means that spike structures can continue to be determined to address specific contexts, for example with antibodies or inhibitors bound, and thus continue to inform treatment and prevention strategies.




Figure 46.3 A technological revolution in cryo-EM has opened new imaging frontiers. (a) Cryo-EM map of stabilized trimeric spike ectodomain (EMD-21375) fitted with its corresponding atomic model (PDB 6VSB). Inset shows a closer view of the correspondence between the map and the model. N-terminal domain, blue: RBD, purple, C-terminal domain, green; fusion peptide, red; HR1, yellow. (b) Cryo-EM map of the apo RNA-dependent RNA polymerase (EMD-11007) fitted with its corresponding atomic model (PDB 6YYT). Remdesivir is shown in purple, positioned at the end of the RNA product. Its position is based on the alignment of a remdesivir-bound structure (PDB 7BV2) with the apo model. A clipped perspective of the remdesivir binding site is highlighted in the inset. nsp7, blue; nsp8, green; polymerase domains: ‘fingers’, yellow; ‘palm’, orange; ‘thumb’, red.

46.5.2 The RNA Polymerase Structure

SARS-CoV-2 relies on an RNA-dependent RNA polymerase (RdRp) to replicate and transcribe its positive-stranded RNA genome. Viral RNA polymerases have historically proven to be attractive drug targets. Various small molecules have been identified that inhibit specific viral RNA polymerases without affecting our essential cellular RNA polymerases. AZT (3'-azido-3'-deoxythymidine), which inhibits the reverse transcriptase of HIV (a type of RNA polymerase), paved the way for the successful clinical suppression of chronic HIV infection we have achieved today [39]. The cure for hepatitis C virus (HCV) developed by Gilead Sciences, one of the pharmaceutical industry's most notable recent successes

in the treatment of infectious diseases, includes the use of an HCV RdRp inhibitor [40, 41].

The SARS-CoV-2 RdRp was, therefore, immediately identified as one of the most important targets for structure-based drug discovery. With a molecular mass under 150 kDa, the SARS-CoV-2 RdRp would until recently have been too small to image by cryo-EM. With current technology, however, two groups were able to independently determine cryo-EM structures of the SARS-CoV-2 RdRp with an RNA template-product complex bound at 2.9 Å resolution by early 2020 (Fig. 46.3b) [42, 43]. The structure revealed the active site architecture and served as the ideal platform to accelerate the search for small molecule inhibitors of RdRp activity. Remdesivir, originally developed by Gilead as a potential treatment for RNA viruses and used in clinical trials against Ebola virus [44], became the first treatment for COVID-19 requiring hospitalization to be approved by the U.S. Food and Drug Administration in October 2020 [45, 46]. Shortly afterwards, cryo-EM structures of SARS-CoV-2 RdRp with remdesivir bound in the active site showed how the incorporation of remdesivir by the RdRp into nascent RNA products blocks translocation of the transcript and thereby stalling transcription (Fig. 46.3b) [47, 48]. This example illustrates how the availability of high-resolution target structures allows not only structure-based drug design but also elucidation of drug mechanisms, which in turn allows for future improvement of specificity and function.

46.5.3 Cryo-Electron Tomography of Intact Virions

Although cryo-EM structures of soluble purified recombinant spike proteins were rapidly determined by SPA, visualizing the structure and distribution of S trimer in the context of intact virions required a different approach. Cryo-EM structure determination by SPA relies on averaging two-dimensional images of many highly similar copies of a macromolecule. But larger biological assemblies tend to be more structurally heterogeneous, due to the intrinsic flexibility of their protein, lipid or nucleic acid constituents. For example, no two mitochondria, bacterial flagella or nuclear pores are exactly identical. Similarly, many viruses, including SARS-CoV-2, have intrinsically heterogeneous structures. Because each SARS-CoV-2 virion has a slightly different shape and spike distribution, structure determination by SPA is not feasible. However, asymmetric assemblies can be visualized by another EM-based approach: tomography. Tomographic reconstruction of cryo-EM micrographs taken of the same region of interest with the sample tilted through a series of angles results in a three-dimensional volume (tomogram) that can then be analysed. Recent advances in image processing algorithms for cryo-electron tomography (cryo-ET) have improved image alignment accuracy and allowed for averaging of repeating objects within a volume reconstruction, a process analogous to SPA known as STA [49, 50]. These advances have allowed for STA reconstructions of macromolecules found within large asymmetric assemblies to be determined to remarkably high

resolutions in some cases (3.4 Å for an HIV capsid structure, for example [51, 52]), although subnanometre resolutions are still not routine.




Figure 46.4 Cryo-electron tomography (cryo-ET) allows visualization *in situ*. (a) Three-dimensional volume rendering of a single virion derived from cryo-ET. The spike glycoprotein (purple) and viral ribonucleoprotein complexes (cyan) are subtomogram averages placed at their corresponding locations in the tomogram with vRNP orientations randomized. This panel is adapted from ref. [53] and licensed under CC BY 4.0. (b) Subtomogram averages of spike protein from the surface of virions. From left to right: closed conformation (EMD-11494), one RBD up (EMD-11495), two RBDs up (EMD-11496). RBDs in the up conformation are indicated by arrows. The position of the membrane relative to the glycoprotein is indicated by the double grey lines. (c) A tomographic slice showing SARS-CoV-2 budding events at ER-Golgi intermediate compartment membranes in VeroE6 cells (EMD-11863) with segmentation of different membrane events at right. The segmentation is adapted from ref. [53] and licensed under CC BY 4.0.

Leveraging the improved technologies described above, cryo-ET image reconstructions yielded exquisitely detailed structures of intact SARS-CoV-2 virions. Subtomogram averages of the spike trimers within these reconstructions were determined to subnanometre resolutions (Fig. 46.4a,b) [53–56]. Tomography combined with STA advantageously not only provides the protein structure but also the protein distribution, and the SARS-CoV-2 tomograms reveal the varying orientations and distributions of spike trimers on the virion surface, in addition to ultrastructural information on ribonucleoprotein assemblies within the virus [55]. Analysis of the tomograms showed that the spike trimers were more flexible than expected, with multiple hinge points resulting in various tilt angles relative to the lipid membrane [54, 56]. Some trimers were also seen to adopt the postfusion conformation rather than the prefusion conformation, suggesting premature triggering of the metastable glycoprotein [54]. The presence of the postfusion trimer has clinical implications, not only because the prefusion state is needed for the virion to be infectious but also because different antigenic epitopes are exposed in the pre- and postfusion conformations.

Cryo-ET has also been used to image SARS-CoV-2 virions *in situ*, inside infected cells. Frozen vitrified cells were milled down to 200 nm-thick lamella using a focused ion beam (FIB) to generate a sample thin enough to be penetrated by an electron beam. Viruses were then imaged within the subcellular compartments associated with viral replication [53]. Individual viral RNAs with branched secondary structures were observed and viral proteins were found at sites with increased membrane curvature in the cryo-ET reconstructions, representing nascent virus particles captured at intermediate assembly steps (Fig. 46.4c) [53]. Hence, these types of cryo-ET visualizations have provided invaluable mechanistic insights on vital processes in the life cycle of SARS-CoV-2.

46.6 X-Ray Crystallography

The proportion of cryo-EM structures being determined at resolutions sufficient to support drug design (approx. 3 Å) is increasing but remains a minority. Thus, most structure-guided drug discovery efforts continue to rely on crystallographic structure determination. Using crystal structures to help identify small molecules targeting SARS-CoV-2 proteins has been an active and productive area of research. Crystal structures of the proteases from HIV and HCV contributed to the development of antiviral protease inhibitors. In combination with some of the polymerase inhibitors mentioned above, protease inhibitors are essential components of current treatments against HIV and HCV. Crystal structures of the papain-like protease (PL^{pro}) and the main protease M^{pro} (also known as 3CL^{pro}) from SARS-CoV-2 have been determined, including some in complex with candidate inhibitors (Fig. 46.5a,b) [57–61]. These structures provide a powerful basis for the design of SARS-CoV-2 protease inhibitors. This structure-based

design strategy remains one of our best hopes for developing an effective pharmaceutical treatment for COVID-19.




Figure 46.5 Crystal structures still provide the most detailed protein structures. (a) A cartoon representation of the crystal structure of the papain-like protease (PL^{pro}) from nsp3 of SARS-CoV-2 (PDB 6WZU) with red spheres indicating the residues of the catalytic triad and the prototypic ‘thumb-palm-fingers’ architecture annotated in blue, teal and green. Three different inhibitors that bind to the same pocket are shown in the insets (PDB 7JIR, 7JIT, 7JIW). (b) The crystal structure of the SARS-CoV-2 M^{pro} (nsp5) homodimer bound to the 11b inhibitor in teal (PDB 6M0 K). The inset shows how density for the inhibitor can be observed in the crystallographic map. (c) Cartoon representations of the SARS-CoV-2 receptor binding domain (RBD; blue) bound to three different ligands. From top to bottom: ACE2 (sea green), EY6A Fab (green), CR3022 Fab (purple).

In addition to the protease structures, landmark structures of the spike receptor-binding domain (RBD) were determined by X-ray crystallography. The RBD is the region of the S protein that recognizes and binds the host cell, through

the ACE2 (angiotensin-converting enzyme 2) receptor [62]. Many neutralizing antibodies halt infection by preventing receptor binding. Several of the SARS-CoV-2 variants of concern contain mutations in the RBD, most notably E484K, that increase ACE2 binding affinity or decrease antibody binding affinities (or both) [63, 64]. The crystal structures of RBD bound to a soluble fragment of ACE2 are, therefore, some of the most important structures for understanding how SARS-CoV-2 recognizes host cells and how mutations in new virus isolates are likely affect this recognition (Fig. 46.5c) [65–67]. Several crystal structures of the RBD with various mutations bound to neutralizing antibody fragments are also available [30]. Together, the crystal structures of SARS-CoV-2 proteins paint a picture of the sites of vulnerability within the virus, and the extent to which they are conserved in different isolates or variants. This information can be used to develop therapeutics such as monoclonal antibodies or immunogens that are effective against a specific variant or set of variants.

46.7 Outlook

The spread of SARS-CoV-2, accelerated by global interconnectedness in our transport and trade links, has taken a calamitous toll and changed the way we live. However, the timing of the outbreak was fortuitous in that it followed technological breakthroughs in vaccinology and structural biology of a rare magnitude. These breakthroughs allowed us to visualize how SARS-CoV-2 interacts with cellular components in greater detail and at a faster pace than would have been possible even only a few years earlier. High-resolution imaging of SARS-CoV-2 has powerfully catalysed efforts to develop vaccines and therapeutics, giving structural studies a central role in enabling delivery of new COVID-19 vaccines and therapies with unprecedented speed. Here, we have reviewed the principal approaches that have been applied to visualize SARS-CoV-2, the structures they generated, and why they were important. Recent advances, particularly in cryo-EM and cryo-ET, have opened a new era in structural biology, making many previously intractable targets amenable to molecular-level visualization. The uses and imaging power of the techniques described here will continue to grow, yielding invaluable mechanistic insights on vital processes in the life cycle of SARS-CoV-2 and other viruses.

Another trend that can be expected going forward is an increase in the number of integrative multiscale imaging studies that combine different approaches to obtain a more complete picture of a biological process. Cryo-EM and cryo-ET imaging fill a gap in the resolution spectrum of imaging modalities. Cryo-ET allows imaging of intact biological assemblies *in situ*, cryo-EM allows more detailed visualization of macromolecule assemblies, and the resulting structures from both techniques are constantly improving in resolution due to ongoing developments in the field. Flanking these approaches, light microscopy allows us to explore the time dimension and probe subcellular localization of multiple components

using fluorescent markers at lower resolution scales. A current limitation of light microscopy is that the timescales are still relatively short compared to the timescale of infection. While this means it is difficult to definitively link characteristics of a tracked virion to observations later in infection, improvements in both length and resolution of such imaging may someday make this possible. For applications requiring the highest resolution, such as structure-based drug design, X-ray crystallography remains the gold standard, but nuclear magnetic resonance (NMR), a powerful technique for identifying binding interfaces and measuring protein dynamics, also has the potential to make future contributions [68]. A beautiful example of multiscale imaging applied to SARS-CoV-2 is the study by Bartenschlager and colleagues [16] combining fluorescence microscopy, TEM, SEM and cryo-ET image reconstruction to visualize the ultrastructural changes in cellular structures induced by SARS-CoV-2 infection. The imaging work carried out so far on SARS-CoV-2 has already yielded an exquisitely detailed picture of the virus and its interactions with the host [69, 70]. Further integrative imaging studies are still needed, however, in order to improve our understanding of the SARS-CoV-2 life cycle at the molecular level.

The scientific community's exceptional mobilization on SARS-CoV-2 research and the confluence of technological advances in multiple areas, particularly electron microscopy, have led to progress in visualization of SARS-CoV-2 at a pace that exceeded all expectations. Imaging studies of SARS-CoV-2 have informed vaccine design and helped identify new treatment strategies. The momentum gathered in this field must be sustained if we want to control this pandemic and treat its aftermath. At the same time, we need further method development in electron microscopy and other areas of structural biology to continue at a full pace so that we are even better prepared for future outbreaks. While the emergence of new viruses is inevitable, if we continue on this trajectory of technological progress and prioritized resourcing of virus research, we will be better positioned to deal with future epidemics.

Abbreviations

ACE2:	angiotensin-converting enzyme 2
AZT:	deoxythymidine
CMOS:	complementary metal-oxide-semiconductor
COVID-19:	coronavirus disease 2019
cryo-CLEM:	cryo-correlative light and electron microscopy
cryo-EM:	cryo-electron microscopy
cryo-ET:	cryo-electron tomography
FIB:	focused ion beam
GPU:	graphics processing unit
HCV:	hepatitis C virus
M ^{pro} :	main protease
NMR:	nuclear magnetic resonance

PL ^{pro} :	papain-like protease
RBD:	receptor binding domain
RdRp:	RNA-dependent RNA polymerase
S:	spike
SARS-CoV-2:	severe acute respiratory syndrome coronavirus 2
SEM:	scanning electron microscopy
SPA:	single-particle averaging
STA:	subtomogram averaging
STED:	stimulated emission depletion
TEM:	transmission electron microscopy
TMPRSS2:	transmembrane protease serine 2

Disclosure and Conflict of Interest

This chapter was originally published as: Leigh, K. E., Modis, Y. (2021). Imaging and visualizing SARS-CoV-2 in a new era for structural biology. *Interface Focus*, **11**, 20210019. <https://doi.org/10.1098/rsfs.2021.0019>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>), and appears here with edits and updates.

Data accessibility: This chapter has no additional data.

Authors' contributions: K.E.L. prepared the figures. Y.M. wrote the first draft. Both authors edited and approved the chapter.

Competing interests: The authors have no competing interests.

Funding: Y.M. is supported by a Senior Research Fellowship 217191/Z/19/Z from the Wellcome Trust.

References

1. Crowther RA (ed.). 2016. The resolution revolution: recent advances in CryoEM, vol. 579, *Methods in Enzymology*. London, UK: Academic Press.
2. Merk A, et al. 2016. Breaking cryo-EM resolution barriers to facilitate drug discovery. *Cell*. 165, 1698–1707.
3. Blundell TL, Chaplin AK. 2021. The resolution revolution in X-ray diffraction, cryo-EM and other technologies. *Prog Biophys Mol Biol*. 160, 2–4.
4. Iwanowski D. 1903. Über die Mosaikkrankheit der Tabakspflanze. *Z. Pflanzenkrankh. Pflanzenschutz*. 13, 1–41.
5. Marton L. 1934. Electron microscopy of biological objects. *Nature*. 133, 911.
6. Kausche GA, Pfankuch E, Ruska H. 1939. Die Sichtbarmachung von pflanzlichem Virus im Übermikroskop. *Naturwissenschaften*. 27, 292–299.
7. Masters PS. 2006. The molecular biology of coronaviruses. *Adv Virus Res*. 66, 193–292.
8. NIAID. Novel coronavirus SARS-CoV-2. Available at: <https://www.flickr.com/photos/54591706@N02/49597768457> (accessed on September 10, 2022).

9. NIAID. Novel coronavirus SARS-CoV-2. Available at: <https://www.flickr.com/photos/niaid/49727106598/in/album-72157712914621487/> (accessed on September 10, 2022).
10. Miorin L, et al. 2020. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. *Proc Natl Acad Sci USA*. 117, 28344–28354.
11. NIAID. SARS-CoV-2. Available at: <https://www.flickr.com/photos/niaid/albums/72157712914621487> (accessed on September 10, 2022).
12. Adrian M, Dubochet J, Lepault J, McDowell AW. 1984. Cryo-electron microscopy of viruses. *Nature*. 308, 32–36.
13. Bayati A, Kumar R, Francis V, McPherson PS. 2021. SARS-CoV-2 infects cells following viral entry via clathrin-mediated endocytosis. *J Biol Chem*. 296, 100306.
14. Ou X, et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun*. 11, 1620.
15. Brahim Belhaouari D, Fontanini A, Baudoin J-P, Haddad G, Le Bideau M, Bou Khalil JY, Raoult D, La Scola B. 2020. The strengths of scanning electron microscopy in deciphering SARS-CoV-2 infectious cycle. *Front Microbiol*. 11, 2014.
16. Cortese M, et al. 2020. Integrative imaging reveals SARS-CoV-2-induced reshaping of subcellular morphologies. *Cell Host Microbe*. 28, 853–866.
17. Pahmeier F, et al. 2021. A versatile reporter system to monitor virus-infected cells and its application to dengue virus and SARS-CoV-2. *J Virol*. 95, e01715–20.
18. Wang S, et al. 2020. Cholesterol 25-hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. *EMBO J*. 39, e106057.
19. Stebbing J, et al. 2021. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. *Sci Adv*. 7, abe4724.
20. Scheres SHW. 2012. RELION: implementation of a Bayesian approach to cryo-EM structure determination. *J Struct Biol*. 180, 519–530.
21. McMullan G, Faruqi AR, Henderson R. 2016. Direct electron detectors. In *The resolution revolution: recent advances in cryoEM*, vol. 579, *Methods in Enzymology* (ed. RA Crowther), pp. 1–17. London, UK: Academic Press.
22. Li X, Mooney P, Zheng S, Booth CR, Braunfeld MB, Gubbens S, Agard DA, Cheng Y. 2013. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. *Nat Methods*. 10, 584–590.
23. Mariano G, Farthing RJ, Lale-Farjat SLM, Bergeron JRC. 2020. Structural characterization of SARS-CoV-2: where we are, and where we need to be. *Front Mol Biosci*. 7, 5236.
24. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*. 367, 1260–1263.
25. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veerles D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*. 181, 281–292.
26. Hsieh C-L, et al. 2020. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science*. 369, 1501–1505.

27. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. 2020. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. *Nat Struct Mol Biol.* 27, 763–767.
28. Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM, Rawson S, Rits-Volloch S, Chen B. 2020. Distinct conformational states of SARS-CoV-2 spike protein. *Science.* 369, 1586–1592.
29. Bangaru S, et al. 2020. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. *Science.* 370, 1089–1094.
30. Yuan M, Liu H, Wu NC, Wilson IA. 2020. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. *Biochem Biophys Res Commun.* 538, 192–203.
31. Coronavirus Structural Task Force. Available at: https://github.com/thorn-lab/coronavirus_structural_task_force/tree/master/pdb/surface_glycoprotein/SARS-CoV-2 (accessed on September 20, 2022).
32. Zhou T, et al. 2020. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. *Cell Host Microbe.* 28, 867–879.
33. Piccoli L, et al. 2020. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. *Cell.* 183, 1024–1042.
34. Xiong X, et al. 2020. A thermostable, closed SARS-CoV-2 spike protein trimer. *Nat Struct Mol Biol.* 27, 934–941.
35. Pallesen J, et al. 2017. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci USA.* 114, E7348–E7357.
36. Krammer F. 2020. SARS-CoV-2 vaccines in development. *Nature.* 586, 516–527.
37. Zhang L, et al. 2020. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. *Nat Commun.* 11, 6013.
38. Kemp SA, et al. 2021. SARS-CoV-2 evolution during treatment of chronic infection. *Nature.* 592, 277–282.
39. De Clercq E, Li G. 2016. Approved antiviral drugs over the past 50 years. *Clin Microbiol Rev.* 29, 695–747.
40. Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA. 2015. Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. *Viruses.* 7, 5206–5224.
41. Picarazzi F, Vicenti I, Saladini F, Zazzi M, Mori M. 2020. Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge. *Molecules.* 25, 5695.
42. Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. 2020. Structure of replicating SARS-CoV-2 polymerase. *Nature.* 584, 154–156.
43. Gao Y, et al. 2020. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science.* 368, 779–782.
44. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. 2020. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS Cent Sci.* 6, 672–683.
45. Grein J, et al. 2020. Compassionate use of remdesivir for patients with severe Covid-19. *N Engl J Med.* 382, 2327–2336.

46. FDA. FDA approves first treatment for COVID-19. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19> (accessed on September 10, 2022).
47. Yin W, et al. 2020. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science*. 368, 1499–1504.
48. Kokic G, et al. 2021. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. *Nat Commun*. 12, 279.
49. Asano S, Engel BD, Baumeister W. 2016. *In situ* cryo-electron tomography: a post-reductionist approach to structural biology. *J Mol Biol*. 428, 332–343.
50. Wan W, Briggs JA. 2016. Cryo-electron tomography and subtomogram averaging. *Methods Enzymol*. 579, 329–367.
51. Mattei S, Glass B, Hagen WJ, Krausslich HG, Briggs JA. 2016. The structure and flexibility of conical HIV-1 capsids determined within intact virions. *Science*. 354, 1434–1437.
52. Turoňová B, Schur FKM, Wan W, Briggs JAG. 2017. Efficient 3D-CTF correction for cryo-electron tomography using NovaCTF improves subtomogram averaging resolution to 3.4Å. *J Struct Biol*. 199, 187–195.
53. Klein S, et al. 2020. SARS-CoV-2 structure and replication characterized by *in situ* cryo-electron tomography. *Nat Commun*. 11, 5885.
54. Ke Z, et al. 2020. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. *Nature*. 588, 498–502.
55. Yao H, et al. 2020. Molecular architecture of the SARS-CoV-2 virus. *Cell*. 183, 730–738.
56. Turoňová B, et al. 2020. *In situ* structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. *Science*. 370, 203–208.
57. Dai W, et al. 2020. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. *Science*. 368, 1331–1335.
58. Hattori SI, et al. 2021. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. *Nat Commun*. 12, 668.
59. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. 2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. *Science*. 368, 409–412.
60. Shin D, et al. 2020. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. *Nature*. 587, 657–662.
61. Klemm T, et al. 2020. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. *EMBO J*. 39, e106275.
62. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science*. 367, 1444–1448.
63. Yi C, et al. 2020. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. *Cell Mol Immunol*. 17, 621–630.
64. Xie X, et al. 2021. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484 K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat Med*. 27, 620–621.

65. Lan J, et al. 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*. 581, 215–220.
66. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. 2020. Structural basis of receptor recognition by SARS-CoV-2. *Nature*. 581, 221–224.
67. Wang Q, et al. 2020. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. *Cell*. 181, 894–904.e899.
68. COVID19-NMR Project. Welcome to the COVID19-NMR project. Available at: <https://covid19-nmr.de/> (accessed on September 10, 2022).
69. Zimmer C. 2020. The Coronavirus unveiled. *The New York Times*. Available at: <https://www.nytimes.com/interactive/2020/health/coronavirus-unveiled.html> (accessed on September 10, 2022).
70. Fischetti M. 2021. Inside the coronavirus. *Scientific American*. Available at: <https://www.scientificamerican.com/interactive/inside-the-coronavirus/> (accessed on September 10, 2022).

Chapter 47

Super-Resolution Microscopy: A Brief History and New Avenues

Kirti Prakash, PhD,^a Benedict Diederich, PhD,^b Rainer Heintzmann, PhD,^{b,c} and Lothar Schermelleh, PhD^d

^a*Integrated Pathology Unit, Centre for Molecular Pathology, The Royal Marsden Trust and Institute of Cancer Research, Sutton, UK*

^b*Leibniz Institute for Photonic Technology, Jena, Germany*

^c*Institute of Physical Chemistry and Abbe Center of Photonics, Friedrich-Schiller-University, Jena, Germany*

^d*Department of Biochemistry, University of Oxford, Oxford, UK*

kirtiprakash2.71@gmail.com, lothar.schermelleh@bioch.ox.ac.uk

Keywords: 4Pi single-molecule switching (4Pi-SMS), adaptive optics (AO), artificial intelligence (AI), computational imaging, frugal microscopy, image processing, image scanning microscopy (ISM), numerical aperture (NA), random illumination microscopy (RIM), single-molecule localization microscopy (SMLM), spatial resolution, stimulated emission depletion (STED), structured illumination microscopy (SIM), super-resolution microscopy (SRM)

47.1 Introduction

Super-resolution microscopy (SRM) is a fast-developing field that encompasses fluorescence imaging techniques with the capability to resolve objects below the classical diffraction limit of optical resolution. Acknowledged with the Nobel prize in 2014, numerous SRM methods have meanwhile evolved and are being widely applied in biomedical research, all with specific strengths and shortcomings. While some techniques are capable of nanometre-scale molecular resolution, others are geared towards volumetric three-dimensional multi-colour or fast live-cell imaging. In this chapter, we pick on the latest trends in the field. We start with a brief historical overview of both conceptual and commercial developments. Next, we highlight important parameters for imaging successfully with a particular super-resolution modality. Finally, we discuss the importance of reproducibility and quality control and the significance of open-source tools in microscopy.

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

47.2 A Brief History of Super-Resolution Microscopy


Optical fluorescence microscopy is a key method in modern biological and biomedical research. However, it has for the longest time suffered from the fundamental limitation of optical resolution imposed by the numerical aperture (NA) of the objective and the wavelength of light following fundamental laws of diffraction as described by Ernst Abbe [1]. Electron microscopy on the other hand, despite its ability to achieve orders of magnitude better resolution, has traditionally been hampered by the challenges in sample preparation and the difficulty in labeling and identifying specific molecules and structures, as well as a very low throughput. Hence physicists sought for ways to overcome the resolution barrier and bridge the gap between light and electron microscopy. Early works were confined to near-field scanning methods which had only very specialized and limited applicability in biology [2]. The first basic concepts to surpass the optical diffraction limit in far-field fluorescence microscopy were conceived in the early 1990s (see timeline in Fig. 47.1a). Along with optical sectioning through out-of-focus light rejection, slight improvements in the lateral resolution were already achieved by confocal microscopy [3]. Early super-resolution microscopy (SRM) developments initially addressed the inferior axial (z) resolution in far-field epifluorescence microscopy to achieve close to isotropic three-dimensional resolution by standing wave illumination [4] using opposing objectives in confocal (4Pi) [5, 6] or widefield (I5M) [7] microscopy. In the lateral direction, the theoretical foundations of stimulated emission depletion (STED) [8–10], structured illumination microscopy (SIM) [11–14] and single-molecule localization microscopy (SMLM) [15, 16]. Yet it required the maturation of underlying laser, photo-detector and computer technology to trigger the ‘Cambrian explosion’ of practical implementations of SR techniques seen a few years later in the 2000s [17–23]. For SMLM, the d STORM variant, which works with conventional fluorophores, became most popular [24, 25]. At this point, three major SRM techniques were established, i.e. STED, SIM and SMLM (now the widely accepted umbrella term for a raft of techniques that essentially follow the same principle and only distinguished themselves by the mechanism of stochastic switching of dye excitation states; see also Table 47.1).

After ‘overcoming’ the fundamental limits of optical resolution, subsequent developments were mainly driven by the demands of biologists, that is to (i) enhance resolution in all spatial dimensions and/or enable volumetric imaging [26–35], (ii) improve temporal resolution and reduce photodamage at the expense of spatial resolution to enable live-cell SR imaging [36–51], and (iii) increase imaging depth and penetration for three-dimensional tissue imaging [52–57]. As a logical consequence, commercial implementation into turn-key instruments followed with a few years’ delay (Fig. 47.1b), as did the widespread application as seen by the development of the number of publications (Fig. 47.1c).

Table 47.1 Overview of major SRM techniques and their characteristics.

Technique	Implementations & related methods	Principle / detection	Response	Diffraction	Resolution	Merits	Limitations	Deconvolution
STED	2D/3D STED Time-gated STED DYMIN STED Tau-STED STED-FCS	Point scanning + PSF shaping Photo-detector	Non-linear	Yes	Structural resolution typically 40-60 nm (xy) and ~600 nm (z) for 2D STED, or ~100 nm (xy) and ~250 nm (z) in 3D STED; excitation/depletion power-dependent	<ul style="list-style-type: none"> Excellent lateral resolution increase for sparse/isolated structures Routine 2-colour imaging No postprocessing required High penetration depth Variable resolution increase 	<ul style="list-style-type: none"> Low dynamic range Sensitivity to out-of-focus background -> Less good for dense 3D features High power density -> phototoxicity Low imaging speed per field of view Tricky to image more than 2 colours Trade-off between z-resolution increase and xy-resolution in 3D STED 	Routinely applied to improve signal to noise
SMLM	2D/3D/TIRF/HILO STORM gSTORM PALM DNA-PAINT (EM)CCD/sCMOS	Widefield + temporal separation of stochastic emission	Non-linear	Yes	Localisation precision typically 10-20 nm (xy); dependent on detected photons Structural resolution at least 2-fold lower; dependent on labelling-density	<ul style="list-style-type: none"> Single-molecule sensitivity Highest potential resolution 	<ul style="list-style-type: none"> Over-representation of sparse background, under-representation of very dense features Typically, no more than 2-colour imaging (except Exchange PAINT) Limited z-range in 3D SMLM Very slow -> low throughput 	Not typically applied
SOFI	SRRF ESI	Widefield + fluctuation autocorrelation	Non-linear	Yes	Typically 100-150 nm (xy)	<ul style="list-style-type: none"> No molecule identification needed Enables live cell imaging 	<ul style="list-style-type: none"> Only moderate lateral resolution increase SRRF particularly suited for fibres 	Not typically applied
SIM ^a	TIRF-SIM GI-SIM 2/3-beam (2D/3D SIM) 5-beam Lattice SIM RIM	Widefield + moiré interference & frequency shifting (EM)CCD/sCMOS	Linear	No	Structural resolution max. 2-fold better than the diffraction limit, typically ~110 nm (xy) and ~320 nm (z) (1.4 NA, 488 nm excitation) NA- and modulation contrast-dependent	<ul style="list-style-type: none"> High sensitivity Rel. high speed per field of view Efficient optical sectioning with much-increased contrast Works with rel. dense features Volumetric live-cell imaging Routine 3/4-colour imaging 	<ul style="list-style-type: none"> Sensitivity to aberrations Best results with measured OTFs and regular calibration Resolution increase wavelength-dependent 	Linear deconvolution (Wiener) typically applied Zeiss SIM ^a adds non-linear iterative deconvolution to further improve resolution
ISM	Re-Scan AiryScan iSIM	Single- or multi-point scanning Photo-detector (array) or sCMOS	Linear	No	Structural resolution 1.4-1.7-fold better than diffraction limit ("soft super-resolution")	<ul style="list-style-type: none"> Easy applicability Simple add-on to confocal system Robust against artefacts 	<ul style="list-style-type: none"> Less efficient high-frequency transfer than interference-based SIM Less contrast improvement than interference-based SIM 	Non-linear iterative deconvolution typically applied to improve resolution
LLS	Bessel beam	Lattice light-sheet & mono-dimensional SIM sCMOS	Linear	No	Structural resolution 250 x 250 x 200 nm	<ul style="list-style-type: none"> Highest temporal resolution per volume Low phototoxicity Fast & long-term volumetric live cell imaging Near isotropic resolution 	<ul style="list-style-type: none"> Sub-diffraction resolution only in one dimension 	Richardson-Lucy deconvolution typically applied

^aLinear super-resolution SIM, as opposed to conventional resolution optical sectioning SIM (OS-SIM, e.g. Zeiss Aptome), or higher-resolving saturated SIM (SSIM), non-linear SIM (NL-SIM), and 3D pRESOLFT.






Figure 47.1 A brief history of far-field SRM. (a) Timelines highlighting crucial milestones in the development of SRM techniques (top) and the corresponding introduction of commercial turn-key super-resolution systems (bottom). For each SRM technique, the corresponding authors of the subsequent publication have been listed. (c) The number of publications extracted from the Web of Science database. (d) Correlation between the approximate purchase costs and the nominal lateral (xy) resolution or localization precision (SMLM-based systems) achievable under ideal conditions, for commercial and open-source microscopy systems, respectively.

The latest development push has come from combining SMLM with illumination principles of other SRM techniques, like 4Pi single-molecule switching (4Pi-SMS) [58], MINFLUX [59] and SIMFLUX type methods [60–63] to further increase either lateral or axial localization precision (Fig. 47.1a). Most recently, in random illumination microscopy (RIM), principles of SIM and SOFI are combined to enable 3D SRM in a more robust and user-friendly way that is less affected by aberrations [64]. In Table 47.1, we provide an overview of major SRM techniques and their characteristics. For a more in-depth explanation of their functioning, we would like to refer to recent reviews [65–67]. Readers are also pointed to the following for further reference on this topic [68–72].

47.3 New Avenues for Super-Resolution Microscopy

No matter what leads to the development of a particular microscopy technique, whether it is the curiosity to build something new, to achieve the highest possible resolution, to gain new insights in natural, material or other sciences, to prove new physical phenomena or simply the joy of the technical interaction between man and machine—microscopy is almost always the result of many different disciplines working together. Nobel Prize-winning methods such as Cryo-EM, PALM or STED show that with the combination of new technology, the clever use of photophysical dye properties or computational tools, the optical resolution limit once described by Ernst Abbe can be circumvented.

Nonetheless, there is still plenty of room for ongoing and future improvements. Importantly, current progress is mainly geared towards promoting the reliability and applicability of these advanced techniques, rather than to further increasing resolution. On the instrument side, the wider-spread implementation of adaptive optics (AO) to correct (sample-induced) aberrations will benefit all the above-mentioned techniques to achieve their theoretical resolution in less ideal optical conditions, e.g. in thick cells and tissues [73–78].

Major advances are expected from the development of correlative microscopy approaches that seek to combine the strengths of different complementary imaging techniques [79–81]. For instance, recent advances in super-resolution cell imaging under cryo-conditions [82–84] and three-dimensional electron microscopy using advanced FIB-SEM [85] open up a potential pathway for developing new powerful three-dimensional CLEM workflows. Also, the consecutive application of SIM and single-molecule imaging techniques (SMLM, SPT) on the same widefield imaging platform holds the promise of getting the best of two worlds: single-molecule localization and contextual and structural three-dimensional information from SIM.

Major progress has been and continues to be provided by improvement in fluorescent dyes, probe design and labelling tools, such as in DNA-PAINT [86], Halo-tag JF dyes [87, 88] and nanobody reagents [89]. These have been specifically designed with SRM in mind, to improve specificity and photon yield

and live-cell imaging or, in combination with microfluidics or waveguide-based SRM imaging, enable multiplexing for future development [90–93].

Any progress on the instrument and labelling side will be accompanied by the massive utilization of bespoke Artificial Intelligence (AI) enhanced software solutions, implementing machine learning or neural networks to simplify and improve data post-processing/analysis [94, 95] and bridging the gap to electron microscopy by correlative (cryo) super-resolution CLEM [96]. Accelerating data acquisition speed for fast, long-term imaging will be vital as the field moves towards live imaging [57, 97–99]. A last important aspect is to continue to better understand the artefacts and limitations of individual SR approaches [100–102] and educate current and future users of SRM. A broader discussion of frequently asked questions in SRM can be found here [103–105].

47.4 Biological Application of SRM: What Have We Learned?

Still, to this date, many SRM publications are generated in specialist physics/optics labs. These often display images of previously well-characterized macromolecules or biological structures, such as microtubules, nuclear pores, or actin filaments, as examples for biological applications. This led to the widespread impression that the applicability of SRM is somewhat limited, provoking the question ‘What have we learned from SRM?’ On closer examination, this is a misperception and SRM has become a genuine tool for discovery. However, what has also become clear over the past years is that, despite the promises of microscopy companies, most SRM is still not yet ‘turn-key’ in the same way conventional widefield and confocal microscopy is today. Particular expertise is required, not necessarily in how to ‘press the right buttons’ on any given commercial system, but for the typically more complex experimental design, the higher demands on the quality of sample preparations, the more delicate system calibration, and the complexity in data postprocessing and quantitative analyses. Therefore, the amount of time and commitment required to do SRM meticulously has been (and still is) a barrier for many biological and biomedical labs to move into this field. Recognizing this fact, the establishment of centralized core facilities has become a popular path to not only make advanced imaging systems available to a wider number of research labs but also to provide the expertise to run those systems effectively. Secondly, microscopy companies and developers are meanwhile turning their efforts into making SRM more accessible and reliable, which explains the success of ‘soft super-resolution’ methods, like rescan confocal, photon reassignment, Airy scan or iSIM [36, 106, 107], that come as easy-to-apply add-on features to standard confocal systems.

It is also important to realize that a biological discovery does not necessarily mean revealing a new structure. Rather than creating ‘nice-looking’ pictures

(although that might be a pleasant side effect), the aim of an imaging experiment is rather to generate meaningful and reproducible quantitative data that helps to explain a biological phenomenon. Here, the ability to resolve events in time is as important as distinguishing objects or (macro)molecules in space as is their relationship to other molecules and structural features. High(er) throughput/content, along with elaborate data analyses, are becoming increasingly important for cutting-edge research involving SRM, and whatever the new findings, these need then be confirmed with orthogonal methods. Ideally, super-resolved images and data spark researchers to think differently about their particular biological problem and to question long-held assumptions.

With over a thousand SRM papers meanwhile published each year (Fig. 47.1a), it becomes increasingly difficult to pick out highlights of new discoveries, without doing injustice to many others. Good examples can be found in the field of chromatin and RNA biology, where single-cell 3D-SIM and SMLM studies lead to fundamentally new insights and models on how nucleosomes assemble higher-order structures and topological domains to define the functional modulus of genome organization [108–113], the crucial involvement of nanodomain formation in DNA repair [114], or how Xist RNA molecules spread during X-chromosome inactivation [115]. Larger macromolecular structures and enzyme complexes, such as synaptonemal complexes, centrosomes, kinetochores, DNA repair complexes, cytoskeleton, subcellular organelles, etc. lend themselves particularly well to super-resolution studies (for recent reviews see [65, 116]).

After more than one decade of development, SRM has shown that different modalities have different biological application areas and specific sweet spots of individual methods are complementary to each other. However, there is still a prevalent lack of understanding of the general benefits and limitations of one method over the other, that goes beyond comparing nominal resolution numbers (see Table 47.1). This applies, e.g. to the crucial trade-offs in SRM often depicted as ‘magical tetrahedron’ of spatial resolution, temporal resolution, photodamage, and imaging depth. Beyond this, there are further less-known trade-offs. For instance, in SMLM, the ability to localize molecules with high precision does not necessarily enable the ability to visualize and resolve macromolecular structures with enough sampling density. Increasing precision can come at the cost of decreased probability to detect localizations [69]. Moreover, both SMLM and STED employ non-linear excitation/detection to become diffraction-unlimited which comes at the price of undercounting fluorescent signals/molecules in some areas of the sample while overestimating them in others. In contrast, in linear SIM relative intensities between features with fewer or higher labeling densities are retained, allowing valid intensity quantifications. Yet this advantage gets lost when non-linear iterative three-dimensional deconvolution is added on top, which renders the data useless for particular analyses as well as generating oversharpening artifacts.

Besides biological research, SRM also has the potential to be applied in other fields, such as clinical diagnostics, e.g. using SIM through the eye lens to image the human retina with increased detail [117], or in food research using AO-assisted SMLM to investigate the characteristics of oil droplets in emulsions [118].

47.5 Open Technology Developments for Super-Resolution Microscopy

Historically, SRM developments have not been open-source, e.g. due to the demand for commercialization. However, more recently the philosophy of 'opening up' development projects to the entire research community and harnessing communal powers to accelerate progress, has gained traction. Projects like the Openflexure Microscope [119], the Fiji Image Analysis Software [120], the cellphone-based SMLM set-up 'cellSTORM' [121], the three-dimensionally printed modular toolbox UC2 [93, 122]) demonstrate the importance of an open and active community for scientific discovery and collaboration. Users can use, modify and build on top of existing solutions [123–125] to acquire new data, analyse them and propose new theories or questions for future generations of scientists.

The sharing of data and resources has the immense advantage of enabling other researchers to reproduce the results or even recreate entire experiments. Hence, it picks up on a currently widely discussed debate: the reproduction crisis and the associated loss of society in scientific work. On top of open-source, 'frugal science' aims to make scientific instruments available at low to no costs. The core idea is to replace complex and usually expensive laboratory-grade devices with do-it-yourself or consumer-grade solutions. Wang et al. [122] succeeded in this in the manuscript 'UCsim2: 2D Structured Illumination Microscopy using UC2', in which the open-source three-dimensionally printed optics kit 'UC2' (You.See.Too.) is extended by super-resolution functionality using SIM and image scanning microscopy (ISM). The open-source documentation allows others to build a device themselves, e.g. for teaching purposes. A device that costs only 5000€ instead of one million also contributes to the fact that several experiments are carried out in many more places in the world (Fig. 47.1d). This allows laboratories in financially less well-equipped institutes to keep up with cutting-edge science and contribute to scientific progress. This approach also demonstrates the beauty of open-sourcing ideas.

In addition to the possibility of providing other scientists with the tools necessary for research to increase the reproducibility of scientific results, corresponding quality standards are of great importance for carrying out the experiments. Several initiatives such as the QUAREP-LiMi [126, 127] recently proposed guidelines for good practice in (light) microscopic imaging and sample preparation. The standards developed together with the scientific community promise increased reproducibility across laboratories.

In this special issue on SRM, we pick up on these trends, show new advances in super-resolution imaging and also show how important it can be to focus not only on optical resolution but also on the reproducibility of scientific results, how quality standards and the creation of communities can help, and how scientific communities can be brought closer together so that tools can be developed that can be used to make breakthroughs.

Disclosure and Conflict of Interest

This chapter was originally published as: Prakash, K., Diederich, B., Heintzmann, R., Schermelleh, L. (2022). Super-resolution microscopy: a brief history and new avenues. *Phil. Trans. R. Soc. A*, **380**, 20210110. <https://doi.org/10.1098/rsta.2021.0110>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>), and appears here with edits and updates.

Competing interests: The authors have no competing interests.

Funding: L.S. acknowledges support by the Wellcome Trust Strategic Award 107457 and the European Research Council MSC ITN grant no. 766181. R.H. acknowledges support by the Collaborative Research Center SFB 1278 (PolyTarget, project C04) funded by the Deutsche Forschungsgemeinschaft. The authors thank the BMWi for funding B.D. by the ZIM project 'ZF4006820DF9'.

Data accessibility: This chapter has no additional data.

Authors' contributions: K.P. and L.S.: conceptualization, writing—original draft, writing—review and editing; B.D.: writing—review and editing; R.H.: writing—review and editing.

All authors gave final approval for publication and agreed to be held accountable for the work performed in this chapter.

Acknowledgements: This chapter is part of Theo Murphy international scientific meeting organized by the Royal Society called SIMposium: recent advancements in structured illumination microscopy. The authors would like to thank Timo Zimmermann for inspiring the timeline displayed in Fig. 47.1a,b.

References

1. Abbe E. 1873. Beitrage zur Theorie des Mikroskops und der mikroskopischen Wahrnehmung. *Arch Mikr Anat*, **9**, 413–468.
2. Betzig E, Lewis A, Harootunian A, Isaacson M, Kratschmer E. 1986. Near field scanning optical microscopy (NSOM): development and biophysical applications. *Biophys J*, **49**, 269–279.
3. Pawley J (ed.) 2006. *Handbook of Biological Confocal Microscopy*, vol. 236. Berlin, Germany: Springer Science & Business Media.
4. Bailey B, Farkas DL, Taylor DL, Lanni F. 1993. Enhancement of axial resolution in fluorescence microscopy by standing-wave excitation. *Nature*, **366**, 44–48.

5. Hell S, Stelzer EH. 1992. Properties of a 4Pi confocal fluorescence microscope. *JOSA A*. **9**, 2159–2166.
6. Hell SW, Lindek S, Cremer C, Stelzer EH. 1994. Measurement of the 4Pi-confocal point spread function proves 75 nm axial resolution. *Appl Phys Lett*. **64**, 1335–1337.
7. Gustafsson MG, Agard DA, Sedat JW. 1995. Sevenfold improvement of axial resolution in 3D wide-field microscopy using two objective-lenses. In *Three-Dimensional Microscopy: Image Acquisition and Processing II*, vol. 2412 (eds Wilson T, Cogswell CJ), pp. 147–156. Bellingham, WA: SPIE.
8. Okhonin V. 1991. A method of examination of sample microstructure. SU 1374922 A1. Priority 10.04.1986, doi:10.13140/2.1.2588.1922.
9. Hell SW, Wichmann J. 1994. Breaking the diffraction resolution limit by stimulated emission: stimulated-emission-depletion fluorescence microscopy. *Opt Lett*. **19**, 780–782.
10. Baer SC. 1999. Method and apparatus for improving resolution in a scanned optical system. US Patent No. 5,866,911.
11. Heintzmann R, Cremer CG. 1999. Laterally modulated excitation microscopy: improvement of resolution by using a diffraction grating. In *Optical Biopsies and Microscopic Techniques III*, vol. 3568 (eds Bigio IJ, Schneckenburger H, Slavik J, Svanberg K, Viallet PM), pp. 185–196. Bellingham, WA: SPIE.
12. Gustafsson MG. 2000. Surpassing the lateral resolution limit by a factor of two using structured illumination microscopy. *J Microsc*. **198**, 82–87.
13. Heintzmann R, Jovin TM, Cremer C. 2002. Saturated patterned excitation microscopy—a concept for optical resolution improvement. *JOSA A*. **19**, 1599–1609.
14. Gustafsson MG. 2005. Nonlinear structured-illumination microscopy: wide-field fluorescence imaging with theoretically unlimited resolution. *Proc Natl Acad Sci USA*. **102**, 13 081–13 086.
15. Betzig E. 1995. Proposed method for molecular optical imaging. *Opt Lett*. **20**, 237–239.
16. Dickson RM, Cubitt AB, Tsien RY, Moerner WE. 1997. On/off blinking and switching behaviour of single molecules of green fluorescent protein. *Nature*. **388**, 355–358.
17. Klar TA, Jakobs S, Dyba M, Egner A, Hell SW. 2000. Fluorescence microscopy with diffraction resolution barrier broken by stimulated emission. *Proc Natl Acad Sci USA*. **97**, 8206–8210.
18. Lidke KA, Rieger B, Jovin TM, Heintzmann R. 2005. Superresolution by localization of quantum dots using blinking statistics. *Opt Express*. **13**, 7052–7062.
19. Betzig E, Patterson GH, Sougrat R, Lindwasser OW, Olenych S, Bonifacino JS, Davidson MW, Lippincott-Schwartz J, Hess HF. 2006. Imaging intracellular fluorescent proteins at nanometer resolution. *Science*. **313**, 1642–1645.
20. Rust MJ, Bates M, Zhuang X. 2006. Stochastic optical reconstruction microscopy (storm) provides sub-diffraction-limit image resolution. *Nat Methods*. **3**, 793–796.
21. Hess ST, Girirajan TP, Mason MD. 2006. Ultra-high resolution imaging by fluorescence photoactivation localization microscopy. *Biophys J*. **91**, 4258–4272.
22. Rego EH, Shao L, Macklin JJ, Winoto L, Johansson GA, Kamps-Hughes N, Davidson MW, Gustafsson MG. 2012. Nonlinear structured-illumination microscopy with a

- photoswitchable protein reveals cellular structures at 50 nm resolution. *Proc Natl Acad Sci USA*. **109**, E135–E143.
23. Jungmann R, Steinhauer C, Scheible M, Kuzyk A, Tinnefeld P, Simmel FC. 2010. Single-molecule kinetics and super-resolution microscopy by fluorescence imaging of transient binding on DNA origami. *Nano Lett.* **10**, 4756–4761.
 24. Lemmer P, et al. 2008. SPDM: light microscopy with single-molecule resolution at the nanoscale. *Appl Phys B*. **93**, 1–12.
 25. Heilemann M, Van De Linde S, Schüttelz M, Kasper R, Seefeldt B, Mukherjee A, Tinnefeld P, Sauer M. 2008. Subdiffraction-resolution fluorescence imaging with conventional fluorescent probes. *Angew Chem Int Ed*. **47**, 6172–6176.
 26. Gustafsson MG, Shao L, Carlton PM, Wang CJR, Golubovskaya IN, Cande WZ, Agard DA, Sedat JW. 2008. Three-dimensional resolution doubling in wide-field fluorescence microscopy by structured illumination. *Biophys J*. **94**, 4957–4970.
 27. Schermelleh L, et al. 2008. Subdiffraction multicolor imaging of the nuclear periphery with 3d structured illumination microscopy. *Science*. **320**, 1332–1336.
 28. Huang B, Jones SA, Brandenburg B, Zhuang X. 2008. Whole-cell 3D STORM reveals interactions between cellular structures with nanometer-scale resolution. *Nat Methods*. **5**, 1047–1052.
 29. Juette MF, Gould TJ, Lessard MD, Mlodzianoski MJ, Nagpure BS, Bennett BT, Hess ST, Bewersdorf J. 2008. Three-dimensional sub-100 nm resolution fluorescence microscopy of thick samples. *Nat Methods*. **5**, 527–529.
 30. Dertinger T, Colyer R, Iyer G, Weiss S, Enderlein J. 2009. Fast, background-free, 3D super-resolution optical fluctuation imaging (SOFI). *Proc Natl Acad Sci USA*. **106**, 22 287–22 292.
 31. Hajj B, Wisniewski J, El Beheiry M, Chen J, Revyakin A, Wu C, Dahan M. 2014. Whole-cell, multicolor superresolution imaging using volumetric multifocus microscopy. *Proc Natl Acad Sci USA*. **111**, 17 480–17 485.
 32. Abrahamsson S, et al. 2017. Multifocus structured illumination microscopy for fast volumetric super-resolution imaging. *Biomed Opt Express*. **8**, 4135–4140.
 33. Shtengel G, et al. 2009. Interferometric fluorescent super-resolution microscopy resolves 3D cellular ultrastructure. *Proc Natl Acad Sci USA*. **106**, 3125–3130.
 34. Pavani SR, Thompson MA, Biteen JS, Lord SJ, Liu N, Twieg RJ, Piestun R, Moerner WE. 2009. Three-dimensional, single-molecule fluorescence imaging beyond the diffraction limit by using a double-helix point spread function. *Proc Natl Acad Sci USA*. **106**, 2995–2999.
 35. Willig KI, Harke B, Medda R, Hell SW. 2007. STED microscopy with continuous wave beams. *Nat Methods*. **4**, 915–918.
 36. York AG, Parekh SH, Dalle Nogare D, Fischer RS, Temprine K, Mione M, Chitnis AB, Combs CA, Shroff H. 2012. Resolution doubling in live, multicellular organisms via multifocal structured illumination microscopy. *Nat Methods*. **9**, 749–754.
 37. Kner P, Chhun BB, Griffis ER, Winoto L, Gustafsson MG. 2009. Super-resolution video microscopy of live cells by structured illumination. *Nat Methods*. **6**, 339–342.
 38. Hirvonen LM, Wicker K, Mandula O, Heintzmann R. 2009. Structured illumination microscopy of a living cell. *Eur Biophys J*. **38**, 807–812.

39. Shao L, Kner P, Rego EH, Gustafsson MG. 2011. Super-resolution 3d microscopy of live whole cells using structured illumination. *Nat Methods*. **8**, 1044–1046.
40. Li D, et al. 2015. Extended-resolution structured illumination imaging of endocytic and cytoskeletal dynamics. *Science*. **349**, aab3500.
41. Caron J, Fallet C, Tinevez JY, Moisan L, Braitbart LP, Sirat GY, Shorte SL. 2014. Conical diffraction illumination opens the way for low phototoxicity super-resolution imaging. *Cell Adhesion & Migration*. **8**, 430–439.
42. Zhao W, et al. 2022. Sparse deconvolution improves the resolution of live-cell super-resolution fluorescence microscopy. *Nature Biotechnol*. **40**, 606–661.
43. Manley S, Gillette JM, Patterson GH, Shroff H, Hess HF, Betzig E, Lippincott-Schwartz J. 2008. High-density mapping of single-molecule trajectories with photoactivated localization microscopy. *Nat Methods*. **5**, 155–157.
44. Gustafsson N, Culley S, Ashdown G, Owen DM, Pereira PM, Henriques R. 2016. Fast live-cell conventional fluorophore nanoscopy with ImageJ through super-resolution radial fluctuations. *Nature Commun*. **7**, 1–9.
45. Eggeling C, et al. 2009. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. *Nature*. **457**, 1159–1162.
46. Caron J, Fallet C, Tinevez JY, Moisan L, Braitbart LP, Sirat GY, Shorte SL. 2014. Conical diffraction illumination opens the way for low phototoxicity super-resolution imaging. *Cell Adh Migr*. **8**, 430–439.
47. Moffitt JR, Osseforth C, Michaelis J. 2011. Time-gating improves the spatial resolution of STED microscopy. *Opt Express*. **19**, 4242–4254.
48. Vicidomini G, Moneron G, Han KY, Westphal V, Ta H, Reuss M, Engelhardt J, Eggeling C, Hell SW. 2011. Sharper low-power STED nanoscopy by time gating. *Nat Methods*. **8**, 571–573.
49. Grotjohann T, Testa I, Leutenegger M, Bock H, Urban NT, Lavoie-Cardinal F, Willig KI, Eggeling C, Jakobs S, Hell SW. 2011. Diffraction-unlimited all-optical imaging and writing with a photochromic GFP. *Nature*. **478**, 204–208.
50. Guo Y, et al. 2018. Visualizing intracellular organelle and cytoskeletal interactions at nanoscale resolution on millisecond timescales. *Cell*. **175**, 1430–1442.
51. Huang X, et al. 2018. Fast, long-term, super-resolution imaging with Hessian structured illumination microscopy. *Nature Biotechnol*. **36**, 451–459.
52. York AG, Chandris P, Dalle Nogare D, Head J, Wawrzusin P, Fischer RS, Chitnis A, Shroff H. 2013. Instant super-resolution imaging in live cells and embryos via analog image processing. *Nat Methods*. **10**, 1122–1126.
53. Sheppard CJ. 2021. Structured illumination microscopy and image scanning microscopy: a review and comparison of imaging properties. *Phil Trans R Soc A*. **379**, 20200154.
54. Chen F, Tillberg PW, Boyden ES. 2015. Expansion microscopy. *Science*. **347**, 543–548.
55. Ingaramo M, York AG, Wawrzusin P, Milberg O, Hong A, Weigert R, Shroff H, Patterson GH. 2014. Two-photon excitation improves multifocal structured illumination microscopy in thick scattering tissue. *Proc Natl Acad Sci USA*. **111**, 5254–5259.
56. Chen B-C, et al. 2014. Lattice light-sheet microscopy: imaging molecules to embryos at high spatiotemporal resolution. *Science*. **346**, 1257998.

57. Liu T-L, et al. 2018. Observing the cell in its native state: imaging subcellular dynamics in multicellular organisms. *Science*. **360**, eaaq1392.
58. Huang F, et al. 2016. Ultra-high resolution 3D imaging of whole cells. *Cell*. **166**, 1028–1040.
59. Balzarotti F, Eilers Y, Gwosch KC, Gynnå AH, Westphal V, Stefani FD, Elf J, Hell SW. 2017. Nanometer resolution imaging and tracking of fluorescent molecules with minimal photon fluxes. *Science*. **355**, 606–612.
60. Cnossen J, Hinsdale T, Thorsen RØ, Siemons M, Schueder F, Jungmann R, Smith CS, Rieger B, Stallinga S. 2020. Localization microscopy at doubled precision with patterned illumination. *Nat Methods*. **17**, 59–63.
61. Reymond L, Ziegler J, Knapp C, Wang F-C, Huser T, Ruprecht V, Wieser S. 2019. Simple: structured illumination based point localization estimator with enhanced precision. *Opt Express*. **27**, 24578–24590.
62. Gu L, Li Y, Zhang S, Xue Y, Li W, Li D, Xu T, Ji W. 2019. Molecular resolution imaging by repetitive optical selective exposure. *Nat Methods*. **16**, 1114–1118.
63. Jouchet P, Cabriel C, Bourg N, Bardou M, Poüs C, Fort E, Lévêque-Fort S. 2021. Nanometric axial localization of single fluorescent molecules with modulated excitation. *Nat Photonics*. **15**, 297–304.
64. Mangeat T, et al. 2021. Super-resolved live-cell imaging using Random Illumination Microscopy. *Cell Reports Methods*. **1**, 100009.
65. Schermelleh L, Ferrand A, Huser T, Eggeling C, Sauer M, Biehlmaier O, Drummen GP. 2019. Super-resolution microscopy demystified. *Nat Cell Biol*. **21**, 72–84.
66. Wu Y, Shroff H. 2018. Faster, sharper, and deeper: structured illumination microscopy for biological imaging. *Nat Methods*. **15**, 1011–1019.
67. Heintzmann R, Huser T. 2017. Super-resolution structured illumination microscopy. *Chem Rev*. **117**, 13890–13908.
68. Reymond L, Huser T, Ruprecht V, Wieser S. 2020. Modulation-enhanced localization microscopy. *J Phys Photonics*. **2**, 041001.
69. Prakash K. 2022. At the molecular resolution with MINFLUX? *Phil Trans R Soc A*. **380**, 20200145.
70. Cremer C, Birk U. 2022. Spatially modulated illumination microscopy: application perspectives in nuclear nanostructure analysis. *Phil Trans R Soc A*. **380**, 20210152.
71. Prakash K, Curd A. 2021. Assessment of 3D MINFLUX data for quantitative structural biology in cells. *bioRxiv*. Available at: <https://doi.org/10.1101/2021.08.10.455294> (accessed on September 10, 2022).
72. Jouchet P, Poüs C, Fort E, Lévêque-Fort S. 2022. Time-modulated excitation for enhanced single-molecule localization microscopy. *Phil Trans R Soc A*. **380**, 20200299.
73. Débarre D, Botcherby EJ, Booth MJ, Wilson T. 2008. Adaptive optics for structured illumination microscopy. *Opt Express*. **16**, 9290–9305.
74. Booth M, Andrade D, Burke D, Patton B, Zurauskas M. 2015. Aberrations and adaptive optics in super-resolution microscopy. *Microscopy*. **64**, 251–261.
75. Gould TJ, Burke D, Bewersdorf J, Booth MJ. 2012. Adaptive optics enables 3D STED microscopy in aberrating specimens. *Opt Express*. **20**, 20998–21009.

76. Thomas B, Wolstenholme A, Chaudhari SN, Kipreos ET, Kner P. 2015. Enhanced resolution through thick tissue with structured illumination and adaptive optics. *J Biomed Opt.* **20**, 026006.
77. Zheng W, et al. 2017. Adaptive optics improves multiphoton super-resolution imaging. *Nat Methods.* **14**, 869–872.
78. Zdankowski P, Trusiak M, McGloin D, Swedlow JR. 2019. Numerically enhanced stimulated emission depletion microscopy with adaptive optics for deep-tissue super-resolved imaging. *ACS Nano.* **14**, 394–405.
79. Liu F, Li Q, Jiang S, Zhou L, Zhang J, Zhang H. 2021. Two-photon structured illumination microscopy imaging using Fourier ptychography scheme. *Opt Commun.* **489**, 126872.
80. Keller PJ, Schmidt AD, Santella A, Khairy K, Bao Z, Wittbrodt J, Stelzer EH. 2010. Fast, high-contrast imaging of animal development with scanned light sheet-based structured illumination microscopy. *Nat Methods* **7**, 637–642.
81. Chang B-J, Meza VDP, Stelzer EH. 2017. csLSFM combines light-sheet fluorescence microscopy and coherent structured illumination for a lateral resolution below 100 nm. *Proc Natl Acad Sci USA.* **114**, 4869–4874.
82. Kaufmann R, Schellenberger P, Seiradake E, Dobbie IM, Jones EY, Davis I, Hagen C, Grünewald K, et al. 2014. Super-resolution microscopy using standard fluorescent proteins in intact cells under cryo-conditions. *Nano Lett.* **14**, 4171–4175.
83. Hoffman DP, et al. 2020. Correlative three-dimensional super-resolution and block-face electron microscopy of whole vitreously frozen cells. *Science.* **367**, eaaz5357.
84. Wolff G, Hagen C, Grünewald K, Kaufmann R. 2016. Towards correlative super-resolution fluorescence and electron cryo-microscopy. *Biol Cell.* **108**, 245–258.
85. Xu CS, et al. 2017. Enhanced FIB-SEM systems for large-volume 3D imaging. *Elife.* **6**, e25916.
86. Jungmann R, Avedaño MS, Woehrstein JB, Dai M, Shih WM, Yin P. 2014. Multiplexed 3D cellular super-resolution imaging with DNA-PAINT and Exchange-PAINT. *Nat Methods.* **11**, 313–318.
87. Grimm JB, et al. 2015. A general method to improve fluorophores for live-cell and single-molecule microscopy. *Nat Methods.* **12**, 244–250.
88. Liu Z, Lavis LD, Betzig E. 2015. Imaging live-cell dynamics and structure at the single-molecule level. *Mol Cell.* **58**, 644–659.
89. Fridy PC, et al. 2014. A robust pipeline for rapid production of versatile nanobody repertoires. *Nat Methods.* **11**, 1253–1260.
90. Oleksiievets N, et al. 2022. Fluorescence lifetime DNA-PAINT for multiplexed super-resolution imaging of cells. *Commun Biol.* **5**, 1–8.
91. Lin G, Baker MA, Hong M, Jin D. 2018. The quest for optical multiplexing in bio-discoveries. *Chem.* **4**, 997–1021.
92. Helle ØI, Dullo FT, Lahrberg M, Tinguely J-C, Hellesø OG, Ahluwalia BS. 2020. Structured illumination microscopy using a photonic chip. *Nat Photonics.* **14**, 431–438.
93. Diederich B, Lachmann R, Carlstedt S, Marsikova B, Wang H, Uwurukundo X, Mosig AS, Heintzmann R. 2020. A versatile and customizable low-cost 3D-printed open standard for microscopic imaging. *Nat Commun.* **11**, 5979.

94. Boland MA, Cohen EA, Flaxman SR, Neil MA. 2021. Improving axial resolution in Structured Illumination Microscopy using deep learning. *Phil Trans R Soc A*. **379**, 20200298.
95. Gong H, Guo W, Neil MA. 2021. GPU-accelerated real-time reconstruction in Python of three-dimensional datasets from structured illumination microscopy with hexagonal patterns. *Phil Trans R Soc A*. **379**, 20200162.
96. Phillips MA, et al. 2020. Cryosim: super-resolution 3d structured illumination cryogenic fluorescence microscopy for correlated ultrastructural imaging. *Optica*. **7**, 802–812.
97. Huang X, et al. 2018. Fast, long-term, super-resolution imaging with hessian structured illumination microscopy. *Nat Biotechnol*. **36**, 451–459.
98. Song L, Lu-Walther H-W, Förster R, Jost A, Kielhorn M, Zhou J, Heintzmann R. 2016. Fast structured illumination microscopy using rolling shutter cameras. *Meas Sci Technol*. **27**, 055401.
99. Appelt D, Ehler E, Mukherjee SS, Heintzmann R, Wicker K. 2022. Polarized illumination coded structured illumination microscopy (picoSIM): experimental results. *Phil Trans R Soc A*. **380**, 20210193.
100. Mo Y, Feng F, Mao H, Fan J, Chen L. 2021. Structured illumination microscopy artefacts caused by illumination scattering. *Phil Trans R Soc A*. **379**, 20200153.
101. Ball G, Demmerle J, Kaufmann R, Davis I, Dobbie IM, Schermelleh L. 2015. Simcheck: a toolbox for successful super-resolution structured illumination microscopy. *Sci Rep*. **5**, 1–12.
102. Demmerle J, et al. 2017. Strategic and practical guidelines for successful structured illumination microscopy. *Nat Protoc*. **12**, 988–1010.
103. Prakash K, Diederich B, Reichelt S, Heintzmann R, Schermelleh L. 2021. Super-resolution structured illumination microscopy: past, present and future. *Phil Trans R Soc A*. **379**, 20200143.
104. Heintzmann R. 2021. Answers to fundamental questions in superresolution microscopy. *Phil Trans R Soc A*. **379**, 20210105.
105. Manton JD. 2022. Answering some questions about structured illumination microscopy. *Phil Trans R Soc A*. **380**, 20210109.
106. Roth S, Sheppard CJ, Wicker K, Heintzmann R. 2013. Optical photon reassignment microscopy (OPRA). *Opt Nanoscopy*. **2**, 1–6.
107. De Luca GM, et al. 2013. Re-scan confocal microscopy: scanning twice for better resolution. *Biomed Opt Express*. **4**, 2644–2656.
108. Miron E, et al. 2020. Chromatin arranges in chains of mesoscale domains with nanoscale functional topography independent of cohesin. *Sci Adv*. **6**, eaba8811.
109. Bintu B, Mateo LJ, Su JH, Sinnott-Armstrong NA, Parker M, Kinrot S, Yamaya K, Boettiger AN, Zhuang X. 2018. Super-resolution chromatin tracing reveals domains and cooperative interactions in single cells. *Science*, **362**.
110. Kirmes I, et al. 2015. A transient ischemic environment induces reversible compaction of chromatin. *Genome Biol*. **16**, 1–19.

111. Ricci MA, Manzo C, García-Parajo MF, Lakadamyali M, Cosma MP. 2015. Chromatin fibers are formed by heterogeneous groups of nucleosomes *in vivo*. *Cell*. **160**, 1145–1158.
112. Szabo Q, et al. 2018. TADs are 3D structural units of higher-order chromosome organization in *Drosophila*. *Sci Adv*. **4**, eaar8082.
113. Prakash K, et al. 2015. Superresolution imaging reveals structurally distinct periodic patterns of chromatin along pachytene chromosomes. *Proc Natl Acad Sci USA*. **112**, 14635–14640.
114. Ochs F, et al. 2019. Stabilization of chromatin topology safeguards genome integrity. *Nature*. **574**, 571–574.
115. Rodermund L, et al. 2021. Time-resolved structured illumination microscopy reveals key principles of Xist RNA spreading. *Science*. **372**, doi:10.1126/science.abe7500.
116. Bond C, Santiago-Ruiz AN, Tang Q, Lakadamyali M. 2022. Technological advances in super-resolution microscopy to study cellular processes. *Mol Cell*. **82**, 315–332.
117. Schock F, Best G, Celik N, Heintzmann R, Dithmar S, Cremer C. 2022. Structured illumination ophthalmoscope: super-resolution microscopy on the living human eye. *Phil Trans R Soc A*. **380**, 20210151.
118. Jabermoradi A, Yang S, Gobes MI, van Duynhoven JPM, Hohlbein J. 2022. Enabling single-molecule localization microscopy in turbid food emulsions. *Phil Trans R Soc A*. **380**, 20200164.
119. Collins JT, et al. 2020. Robotic microscopy for everyone: the OpenFlexure microscope. *Biomed. Opt Express*. **11**, 2447–2460.
120. Schindelin J, et al. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods*. **9**, 676–682.
121. Diederich B, Then P, Jügler A, Förster R, Heintzmann R. 2019. cellSTORM—Cost-effective super-resolution on a cellphone using dSTORM. *PLoS ONE*. **14**, e0209827.
122. Wang H, Lachmann R, Marsikova B, Heintzmann R, Diederich B. 2022. UCsim2: 2D structured illumination microscopy using UC2. *bioRxiv*. doi:10.1101/2021.01.08.425840.
123. Prakash K. 2021. Laser-free super-resolution microscopy. *Phil Trans R Soc A*. **379**, 20200144.
124. Pilger C, Pospíšil J, Müller M, Ruoff M, Schütte M, Spiecker H, Huser T. 2021. Super-resolution fluorescence microscopy by line-scanning with an unmodified two-photon microscope. *Phil Trans R Soc A*. **379**, 20200300.
125. McFadden D, Amos B, Heintzmann R. 2022. Quality control of image sensors using gaseous tritium light sources. doi:10.22443/rms.elmi2021.71.
126. Boehm U, et al. 2021. QUAREP-LiMi: a community endeavor to advance quality assessment and reproducibility in light microscopy. *Nat Methods*. **18**, 1423–1426.
127. Hohlbein J, Diederich B, Marsikova B, et al. 2022. Open microscopy in the life sciences: quo vadis? *Nat Methods*. **19**, 1020–1025.

Chapter 48

End-to-End System for Rapid and Sensitive Early-Detection of SARS-CoV-2 for Resource-Poor and Field-Test Environments Using a \$51 Lab-in-a-Backpack

E. Emily Lin, MSc, Umar A. Razzaque, MSc, Stephen A. Burrows, PhD,
and Stoyan K. Smoukov, PhD

School of Engineering and Materials Science, Queen Mary University of London, London, UK
s.smoukov@qmul.ac.uk

Keywords: CentriDrive, Coronavirus Disease 2019 (COVID-19), lab-in-a-backpack, pandemic, phosphate-buffered saline (PBS), point-of-care (POC), polylactic acid (PLA), polymerase chain reaction (PCR), recycled/repurposed electronics, reliability, reproducibility, reverse transcription loop-mediated isothermal amplification (RT-LAMP), SARS-CoV-2 RNA, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

48.1 Introduction/Background

Globally, as of September 15 2022, there have been over 607 million confirmed cases of Coronavirus Disease 2019 (COVID-19), including close to 6.5 million deaths, reported to the WHO [1]. International efforts, such as UN- and WHO-led COVAX are encouraging, but full vaccination is still a few years away. There are real concerns about overwhelming the health-care systems in many countries. With over half of 54 countries reaching less than 2% only 15 countries reaching 10% COVID-19 vaccination by October 2021, the goal of protective vaccination in Africa will be one for the future [2]. Cheap and fast testing is needed in both home environments and point-of-care (POC) facilities, and in both resource-rich and resource-poor countries, for accurately distinguishing COVID-19 from other respiratory illnesses [3, 4]. Such a testing system is needed for safeguarding front-line healthcare workers, for identifying and contact-tracing of infections,

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

for enabling travel, and for providing more measured pandemic responses where limited test administration necessitates complete lockdowns [5]. Similar per-test costs as in the UK are supplemented by extraordinary costs for on-site personnel at US\$ 5000–6000/ person per day in California [6].

In addition to the high costs, the invasiveness and pain of the test itself puts up extra barriers to compliance and frequent testing. Currently, the gold standard for COVID-19 detection [7–9], the PCR test requires the uncomfortable feeling of jabbing probes deep into the nostrils, turning people away from testing. To improve experience, speed, and cost, other methods are starting to be used around the world [10, 11]. The reverse transcription loop-mediated isothermal amplification (RT-LAMP) is a one-step nucleic acid amplification method that has a similar sensitivity to the multi-cycle PCR [12, 13] and can be performed on saliva samples [14, 15]. Since the pioneering work of Notomi [14] it is widely used in the diagnosis of infectious diseases [16–21]. The LAMP reaction of DNA amplification at constant temperature has been combined in an assay with a reverse transcription process (RT-LAMP) to target and detect RNA sequences, specifically also the SARS-CoV-2 RNA [22–25]. It is a high sensitivity and high specificity test, and its minimal requirements for equipment and reagents make it a suitable candidate for economic and rapid viral detection on site. Still, such 120-min on-site “fly-safe” LAMP tests at Heathrow cost £85 (\$118) and more [26]. Additionally, such tests assume the availability of high value instruments, such as centrifuges, or fluorescence readers, making them inappropriate for in-home testing and remote locations. For such environments, the low-cost of the entire system must be considered too.

Inexpensive tests carried out in residential facilities can increase testing compliance. Furthermore so would non-invasive tests in countries and cultures where the cost or fear of the procedure would prevent testing [27, 28]. In addition to the marginal cost per sample, for many lower-volume sites, one has to also consider the additional cost of infrastructure and staff training. Low-cost approaches have been advocated for both RT-LAMP and RT-qPCR tests [29].

These range from extremely low-cost (\$10) device sets that could be operated even without electricity [30], to more expensive \$300 equipment that can be used to run concurrent tests in 96-well plates and then reading out fluorescent results with a UV source and a smart phone or a tablet [29]. The appropriate (fixed capital) cost for such instruments depends strongly on the required number of tests to be run at a time, longevity and stable operation of the equipment, and situation-specific factors. Such factors include the distance of test subjects from other amenities, e.g. ability to charge via grid or automobile batteries, refrigeration for RNA primers, etc. Education and training of workers is another component of the fixed (human) capital costs of these tests. Therefore, procedures should be easy to follow, even with only basic literacy skills and minimal training, and ideally with instructions in multiple languages. Thus to maximize the availability and impact of COVID-19 testing around the world, instruments and protocols need to be tailored to situations to minimize local testing system cost [31].

In this chapter we report a non-invasive, rapid, low-cost system for COVID-19 testing to replace or complement PCR tests. It consists of a \$51 lab-in-a-backpack system (including a high-performance \$28 electronic centrifuge made from recycled waste computer hard drives, a thermometer, a thermos bottle, and \$20 for two micropipettes), and an RT-LAMP protocol from Harvard Medical School [32] integrated into a single test kit that can be used reliably and reproducibly at home or in remote field conditions (Fig. 48.1). The system instructions include a visual protocol with disposable reagent packs, enabled by graphical instructions for mixing numbered, color-coded packages which can be followed by minimally trained staff. It takes around 80 min to test one sample, or 90 min to test 6 samples. The test achieves SARS-CoV-2 detection that costs in reagents and consumables approximately \$3.5 per sample. Such a widely available non-invasive, rapid, sensitive, and reliable test for COVID has the potential to alleviate stresses in many health care systems.



Figure 48.1 CentriDrive and reagents for LAMP assay. (a) The CentriDrive. (b) Circuit diagram of the CentriDrive. 1. Switch. 2. Power input. 3. LCD. 4. Breadboard. 5. Geekcreit Nano. 6. Infrared sensor. 7. ESC. 8. Potentiometer. 9. Motor. (c) List of all reagents for LAMP assay. Chemical A, Lysis/Inactivation buffer. Chemical B.1, NaI powder. Chemical B.2, 1 N HCl. Chemical B.3, Triton X-100. Chemical C, Silica binding suspension. Chemical D, 80% ethanol solution. Chemical E.1, PBS buffer. Chemical E.2, Primer solution. Chemical E.3, WarmStart® Colorimetric LAMP 2X Master Mix. Chemical E.4, SARS-CoV-2 solution. *The Arduino nano is shown in the figure due to limitations of the drawing software, but the Geekcreit Nano was used in the final test.

48.2 Equipment/Materials and Methods

48.2.1 Components for the CentriDrive

The CentriDrive (Fig. 48.1a) is an inexpensive medical device, assembled from low-cost new and recycled components at an approximate cost of \$28. In addition to the current use in the covid test, this centrifuge has been used for the demonstration of DNA separation in UK high schools. This low-cost device can be used in a wide variety of resource-poor settings. It can be assembled in local workshops and enterprises using the wiring diagram in Fig. 48.1b along with the following tools: a soldering iron, a T6 screwdriver. The major components are listed below.

48.2.2 Spinning Hard Drive

Hard drives with rotating spindles are engineered so well that usually they are disposed with unwanted computers in working order. In cloud computing farms, where they are used constantly, their failure rate is only 1–2% per year on average. Of the non-functioning hard drives the vast majority fail due to head damage or plate seizure. Therefore, after dismantling the head arm and plate (for separate disposal, removing any data/privacy concerns), the motor, controls, and chassis of the hard drive can be used for a centrifuge. The spindle motors in hard drives are designed to operate at high speeds, having a long lifespan of 3–5 years on average. They are well balanced and control their speed of rotation well, making them ideal for the diagnostic centrifuge.

48.2.3 3D Printed Centrifuge Rotor

The rotor was designed to hold 6×1.5 mL microfuge tubes and has a rotor radius of 3.5 cm. It is printed from 22 g of PLA (polylactic acid) plastic filament using an Ultimaker 3.0, with printing taking approximately 4 h. The rotor is mounted to the motor with the screws that initially held the plate. Using a commonly available standard 7200 rpm hard drive, the hard drive centrifuge can reach a maximum speed of 11650 rpm (5320 rcf) and 7600 rpm (2260 rcf) when loaded with the microfuge tubes. With 10000 rpm server hard drives, it can reach over 4000 rcf. The speed is controlled by a potentiometer, measured by an IR sensor mounted within range of the rotor, and displayed on an LCD (liquid crystal display) driven by a microcontroller Geekcreit Nano. The consistency of the CentriDrive speed was tested every minute for 15 min (see Fig. S7 in S1 File).

48.2.3.1 Other electronic components (commercially available)

Generic descriptions of components are given, with more details, costs, and sources listed in the Supplementary Material. Components: 5–12 V brushless DC (BLDC), 30 A electronic speed controller (ESC), Geekcreit Nano, 10K potentiometers, 12 V power supply, a rocker switch, and an infrared sensor.

48.2.4 Materials for the Detection

TCEP-HCl, TritonX-100 were purchased from Tokyo Chemical Industry. EDTA, NaI, silicon dioxide, K_2HPO_4 , KH_2PO_4 , and nuclease-free water were purchased from Sigma-Aldrich Company. Primers were purchased from Thermo-Fisher. SARS-CoV-2 Template viral RNA was purchased from Twist Bioscience. WarmStart® Colorimetric LAMP 2X Master Mix was purchased from New England Biolabs. All chemicals were of reagent grade and were used without further purification.

48.3 Modified RT-LAMP Reaction Components [32]

Chemical A. Lysis/Inactivation buffer. To a 1.5 mL centrifuge tube, 0.5 mL 0.5 M TCEP-HCl, 0.1 mL 0.5 M EDTA (pH = 8), 0.115 mL 10 N NaOH, and 0.285 mL tap water were added to form 1 mL of the 100× inactivation buffer. Stored at 4°C for later use.

Chemical B. NaI binding solution. To a 10 mL tube, Chemical B.1 450 mg NaI power and 4 mL water were added to form 10 wt% NaI solution, then Chemical B.2 50 μ L 1 N HCl, Chemical B.3 100 μ L TritonX-100 were added to form the Chemical B NaI binding solution. The Chemical B should be freshly prepared before testing.

Chemical C. Silica binding suspension. To a 100 mL centrifuge tube, added 5 g 325 mesh silicon dioxide and 50 mL water. Pour off the supernatant after the silica has settled for 1 h. Another portion of 50 mL water was added to make the silica suspension. This suspension works in conjunction with the NaI binding solution, added in ratios of 50:1.

Chemical D. 80% ethanol solution. The ethanol washing solution was made by diluting the 80 mL of absolute ethanol with 20 mL of water.

Chemical E.1 PBS buffer. Phosphate-buffered saline (PBS) buffer was made by dissolving 0.2798 g K_2HPO_4 and 0.0205 g KH_2PO_4 to 50 mL water to make the pH \approx 7.8. If the pH is too high, it won't show the color change from pink to yellow. If the pH is too low, the color change would not be easy to distinguish. Store at 4°C for later use.

Chemical E.2 primer solution. The primers (Table 48.1) were dissolved with nuclease-free water or tap water separately. The sequences are from Rabe and Cepko 2020 [32]. The primer mix were combined with 16 μ L FIP, 16 μ L BIP, 2 μ L F3, 2 μ L B3, 4 μ L LF, 4 μ L LB, and brought to 100 μ L with water to make the 10X solution. They were stored at 4°C for later use.

Chemical E.3 WarmStart® colorimetric LAMP 2X master mix. Used as purchased and stored at -20°C. The mix is a special low-buffer reaction solution containing phenol red as a visible pH indicator for rapid and easy detection of reverse transcription loop-mediated isothermal amplification (RT-LAMP) reactions [33]. The whole system is designed to provide a fast, clear visual detection of amplification based on the production of acid and subsequent drop in pH [34], producing a change in solution color from pink to yellow [35].

Table 48.1 Sequence of custom primers from 5' to 3'

Primer	Sequence (5'–3')
F3	CGGTGGACAAATTGTCAC
B3	CTTCTCTGGATTTAACACACTT
FIP	TCAGCACACAAAGCCAAAAATTTATCTGTGCAAAGGAAATTAAGGAG
BIP	TATTGGTGGAGCTAAACTTAAAGCCCTGTACAATCCCTTTGAGTG
LF	TTACAAGCTTAAAGAATGTCTGAACACT
LB	TTGAATTTAGGTGAAACATTTGTCACG

Chemical E.4 template viral RNA. Diluted with both nuclease-free water and tap water, separately. Stored at -80°C for later use. Although we used this template viral RNA as the positive reference, it doesn't need to be used in the real test.

48.3.1 Ethics Statement

For solutions where saliva was used in mixture with buffers, only authors' own self-collected saliva was used. After the experiment it was safely discarded as biowaste. The protocol was deemed not to require approval by the Queen Mary University Ethics of Research Committee.

48.4 Results

SARS-CoV-2 RNA was mixed with saliva at varying concentrations and tested with the CentriDrive system to determine the sensitivity of virus detection. The results showed that the RT-LAMP reaction, after the centrifugation, could detect SARS-CoV-2 at 4 viral genome copies/ μL . The experiment was repeated nine times, and in all cases the detection was successful. The control experiment contained no virus SARS-CoV-2 RNA and produced no color change of the LAMP solution (Fig. 48.2). Though we usually used nuclease-free water to make the stock solution of the SARS-CoV-2 RNA, we verified that for detection of virus RNA soon after collection, tap water achieved a sensitivity of 8 copies/ μL . On both the CentriDrive and the commercial centrifuge (SciSpin—Micro, Cat. No:911315410035) tests, the lowest concentration detected was 4 viral genome copies/ μL . The illustrated procedure uses minimal hardware and an easy-to-follow procedure that could be followed both at home and in field point-of-care (POC) centers.

48.4.1 Detection Procedure

Collect around 500 μL of saliva in a 1.5 mL centrifuge tube. It should be ensured that participants do not chew gum, smoke, eat or drink for 30 min before submitting the sample. Add 5 μL Chemical A (Lysis inactive solution), mix them and put the tube into boiling water and incubate for 5 min, then use the CentriDrive

to spin for 1 min at the maximum speed (~7600 rpm). Collect the supernatant into a new 1.5 mL centrifuge tube.




Figure 48.2 LAMP reaction results. After centrifugation, the LAMP protocol can effectively detect synthetic viral RNA down to 4 copies per μL in saliva. (a) The tubes show the successful amplification of 100, 200, 400, 2000, 20000 copies of the COVID control RNA genomes, respectively. The leftmost sample shows the control color in the absence of LAMP reaction with 0 COVID control RNA genomes. (b) Control and viral RNA samples amplified by LAMP reaction using tap water give comparable results to nuclease-free water.

To the supernatant solution, add 250 μL of Chemical B (NaI binding reagent) and 5 μL of Chemical C (silica slurry), mix them and incubate at room temperature for 10 min. Then centrifuge for 30 s and pour off the supernatant and keep the precipitation.

Add 700 μL of Chemical D (80% ethanol) to the tube with the precipitation, mix them and centrifuge for 30 s at the maximum speed. Pour off the ethanol and keep the lid open to evaporate the residual ethanol at room temperature. Do not try to heat higher than 70°C to speed up the evaporation process, as it might cause RNA degradation. Do not use gas to blow on the tube which may blow the RNA away.

To the tube with silica precipitate, add 2.5 μL Chemical E.2 (LAMP primers), 12.5 μL Chemical E.4 (WarmStart® Colorimetric LAMP 2X Master Mix), Chemical E.3 (SARS-CoV-2 solution, add as a positive comparison), and enough Chemical

E.1 (PBS solution) to bring the solution to 25 μL , mix them using a vortexer at around 800 rpm/min for 5 s or violently shake manually for 30–60 s, followed by centrifuging at 2000 rcf for 30 s to ensure all material collects at the bottom of the tube. Otherwise, the reaction may not happen. Then incubate the reaction mix at 65°C for 30 min. Positive reactions will turn yellow while negative controls should remain pink (Fig. 48.3).




Figure 48.3 Methods and steps for CentriDrive-LAMP reaction assay process. The following reagents are denoted by letters: A. 5 μL Chemical A; B. 250 μL Chemical B; C. 5 μL Chemical C; D. 700 μL Chemical D; E. 2.5 μL Chemical E.2, 12.5 μL Chemical E.4, Chemical E.1 and Chemical E.3 are 10 μL in total to bring the solution to 25 μL .

48.4.2 Mechanism of the LAMP Assay

Under alkaline conditions and high temperature, membranes and proteins will be denatured rapidly, while covalently bonded circular plasmid DNA will remain intact in the supernatant. Obtain the required nucleic acid by collecting the supernatant after centrifugation (Fig. 48.4a).

The nucleic acids will bind to the silica in the presence of chaotropic salts, such as NaI used here [36, 37]. Obtain the nucleic acid bound with silica by collecting the precipitate after centrifugation (Fig. 48.4b).

In the LAMP reaction, the target sequence is amplified at a constant temperature of 60–65°C, using three sets of primers) and a polymerase. The first step is the reverse transcription of RNA to DNA in the presence of reverse transcriptase. Then each of the primer possesses a sequence complementary to one chain of the amplification region at the 3'-terminal and identical to the inner region of the same chain at the 5'-terminal, finally forms the dumbbell-like structure [15].

The addition of loop primers to the reaction accelerates the DNA amplification [38]. The amplified products again pass through repeated elongation reactions, which generate amplified DNA products of various stem lengths [39] (Fig. 48.4c).




Figure 48.4 Mechanism of the LAMP assay. (a) Inactivation of the saliva. (b) Binding the nucleic acid. (c) LAMP reaction process. (d) Mechanism of the generation of the proton.

The DNA synthesis process is the formation of a phosphodiester bond between the incoming deoxynucleoside triphosphate and the terminal primer

nucleotide catalyzed by DNA polymerases. It will release a pyrophosphate (PPi) [40]. (Fig. 48.4d) Hydrolysis of pyrophosphate will generate two hydrogen protons which lower the solution pH and is detected by color change in the pH color indicator.

48.5 Conclusions

By using the LAMP test method in combination with our \$51 lab-in-a-backpack system, pictured in Fig S11 (included in S1 File), we can successfully detect SARS-CoV-2 at 4 viral genomes/ μL . This detection sensitivity is much lower than found in infected individuals [41] and compares favorably to commercial LAMP tests, which detect 4 viral genomes/ μL [42]. Commercial LAMP test kits sold to testing companies cost £5–17 (\$7–24) in bulk. The test is fast and cheap taking < 90 min at \$3.5 per sample. The test and hardware reported here could be the basis of a stand-alone system and an end-to-end solution for COVID-19 testing. The centrifuge described above could also be used as part of another commercial LAMP test to complete a hardware system and an end-to-end solution.

Supporting information

S1 File. Supplementary materials. Including Assay time for one sample and six samples, The hard drive centrifuge recipe, The consistence of the CentriDrive speed, Rotational speed characterization of CentriDrive at different voltage, LAMP reaction results using commercial centrifuge instead of the CentriDrive, A prototype kit with vials in several pouches.

<https://doi.org/10.1371/journal.pone.0259886.s001> (PDF)

S1 Graphical abstract.

<https://doi.org/10.1371/journal.pone.0259886.s002>.

Disclosures and Conflict of Interest

This chapter was originally published as: Lin, E. E., Razzaque, U. A., Burrows, S. A., Smoukov, S. K. (2022). End-to-end system for rapid and sensitive early-detection of SARS-CoV-2 for resource-poor and field-test environments using a \$51 lab-in-a-backpack. *PLoS ONE*, **17**(1), e0259886. <https://doi.org/10.1371/journal.pone.0259886>, under the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>), and appears here, with edits and updates.

Funding: The authors thank the CSC for the scholarship to E Lin, the EPSRC fellowship EP/R028915/1 and European Space Agency MAP PROJECT WHISKIES. to S.K.S, and the Queen Mary University of London SEMS Undergraduate Research Fund.

Competing interests: The authors have declared that no competing interests exist.

Author Contributions:

Conceptualization: Stoyan K. Smoukov; Data curation: E. Emily Lin, Umar A. Razzaque, Stoyan K. Smoukov; Formal analysis: E. Emily Lin, Stephen A. Burrows, Stoyan K. Smoukov; Funding acquisition: Stoyan K. Smoukov; Investigation: E. Emily Lin, Umar A. Razzaque; Methodology: Umar A. Razzaque, Stoyan K. Smoukov; Software: Umar A. Razzaque; Supervision: Stoyan K. Smoukov; Validation: E. Emily Lin, Umar A. Razzaque, Stephen A. Burrows, Stoyan K. Smoukov; Visualization: E. Emily Lin, Umar A. Razzaque, Stephen A. Burrows, Stoyan K. Smoukov; Writing – original draft: E. Emily Lin, Stoyan K. Smoukov; Writing – review & editing: E. Emily Lin, Umar A. Razzaque, Stephen A. Burrows, Stoyan K. Smoukov.

Acknowledgments: The authors thank Belinda Nedjai, Director of the Molecular Epidemiology laboratory for opinions on commercial LAMP test incorporation in the thousands of COVID-19 tests done daily at QMUL. The authors thank Jianxin Chen and David Gould for initial discussions of the LAMP experiments. The authors wish to thank Fabien PiuZZi for helpful discussions on his low-cost centrifuge designed around a drone motor.

References

1. WHO Coronavirus Disease (COVID-19) Dashboard: World Health Organization. Available at: <https://covid19.who.int> (accessed on September 15, 2022).
2. Fifteen African countries hit 10% COVID-19 vaccination goal: World Health Organization. Available at: <https://www.afro.who.int/news/fifteen-african-countries-hit-10-covid-19-vaccination-goal> (accessed on September 15, 2022).
3. Songok E. A locally sustainable approach to COVID-19 testing in Africa. *Lancet Microbe*. 2020; 1(5): e197.
4. Adepoju P. Africa's struggle with inadequate COVID-19 testing: the lancet microbe; 2020. Available at: [https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247\(20\)30014-8/fulltext](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30014-8/fulltext) (accessed on September 15, 2022).
5. Wang YC, Lee YT, Yang T, Sun JR, Shen CF, Cheng CM. Current diagnostic tools for coronaviruses—From laboratory diagnosis to POC diagnosis for COVID-19. *Bioeng Transl Med*. 2020; 5(3): e10177.
6. STANDARD AGREEMENT; 2020. Available at: <https://files.covid19.ca.gov/pdf/Verily-life-sciences-LLC-OES-6155.pdf> (accessed on September 15, 2022).
7. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. *Expert Rev Mol Diagn*. 2020; 20(5): 453–4.
8. Oliveira BA, Oliveira LCD, Sabino EC, Okay TS. SARS-CoV-2 and the COVID-19 disease: a mini review on diagnostic methods. *Rev Inst Med Trop São Paulo*. 2020; 62: e44.
9. Bustin SA, Nolan T. RT-qPCR testing of SARS-CoV-2: a primer. *Int J Mol Sci*. 2020; 21(8): 3004.
10. Ward S, Lindsley A, Courter J, Assa'ad A. Clinical testing for COVID-19. *J Allergy Clin Immunol*. 2020; 146(1): 23–34.

11. Chau CH, Strobe JD, Figg WD. COVID-19 clinical diagnostics and testing technology. *Pharm J Human Pharm Drug Ther.* 2020; 40(8): 857–68.
12. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription–loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. *J Clin Microbiol.* 2020; 58(9): e01438–20.
13. Baek YH, Um J, Antigua KJC, Park JH, Kim Y, Oh S, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. *Emerg Microbes Infect.* 2020; 9(1): 998–1007.
14. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* 2000; 28(12): e63–e.
15. Notomi T, Mori Y, Tomita N, Kanda H. Loop-mediated isothermal amplification (LAMP): principle, features, and future prospects. *J Microbiol.* 2015; 53(1): 1–5.
16. Fukuta S, Iida T, Mizukami Y, Ishida A, Ueda J, Kanbe M, et al. Detection of Japanese yam mosaic virus by RT-LAMP. *Arch Virol.* 2003; 148(9): 1713–20.
17. Aonuma H, Yoshimura A, Kobayashi T, Okado K, Badolo A, Nelson B, et al. A single fluorescence-based LAMP reaction for identifying multiple parasites in mosquitoes. *Exp Parasitol.* 2010; 125(2): 179–83.
18. Fukuta S, Takahashi R, Kuroyanagi S, Miyake N, Nagai H, Suzuki H, et al. Detection of *Pythium aphanidermatum* in tomato using loop-mediated isothermal amplification (LAMP) with species-specific primers. *Eur J Plant Pathol.* 2013; 136(4): 689–701.
19. Caipang CM, Haraguchi I, Ohira T, Hirono I, Aoki T. Rapid detection of a fish iridovirus using loop-mediated isothermal amplification (LAMP). *J Virol Methods.* 2004; 121(2): 155–61.
20. Hsieh K, Mage PL, Csordas AT, Eisenstein M, Soh HT. Simultaneous elimination of carryover contamination and detection of DNA with uracil-DNA-glycosylase-supplemented loop-mediated isothermal amplification (UDG-LAMP). *Chem Commun (Camb).* 2014; 50(28): 3747–9.
21. Duan Y, Ge C, Zhang X, Wang J, Zhou M. A rapid detection method for the plant pathogen *Sclerotinia sclerotiorum* based on loop-mediated isothermal amplification (LAMP). *Australas Plant Pathol.* 2013; 43(1): 61–6.
22. Yu L, Wu S, Hao X, Li X, Liu X, Ye S, et al. Rapid colorimetric detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform: iLACO. *medRxiv*; 2020. Available at: <https://doi.org/10.1101/2020.02.20.20025874> (accessed on September 15, 2022).
23. Zhang Y, Odiwuor N, Xiong J, Sun L, Nyaruaba RO, Wei H, et al. Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP. *medRxiv.* 2020:2020.02.26.20028373.
24. Kashir J, Yaqinuddin A. Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19. *Med Hypotheses.* 2020; 141: 109786.
25. Thompson D, Lei Y. Mini review: recent progress in RT-LAMP enabled COVID-19 detection. *Sens Actuators Rep.* 2020; 2(1). Available at: <https://doi.org/10.1016/j.snr.2020.100017> (accessed on September 15, 2022).

26. Heathrow Airport. 2021. Covid 19 test: Heathrow; 2021. Available at: <https://www.heathrow.com/at-the-airport/fly-safe/covid-19-test> (accessed on September 15, 2022).
27. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Suksuwan W, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. *Clin Microbiol Infect.* 2020; 27(2): 285.e1–285.e4.
28. Vaz SN, Santana DSD, Netto EM, Pedrosa C, Wang W-K, Santos FDA, et al. Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection. *Braz J Infect Dis.* 2020; 24(5): 422–7.
29. Arumugam A, Faron ML, Yu P, Markham C, Wong S. A rapid COVID-19 RT-PCR detection assay for low resource settings. *Diagnostics (Basel).* 2020; 10(10): 739.
30. Li E, Larson A, Kothari A, Prakash M. Handyfuge-LAMP: low-cost and electricity-free centrifugation for isothermal SARS-CoV-2 detection in saliva. *medRxiv.* 2020:2020.06.30.20143255.
31. Manero A, Smith P, Koontz A, Dombrowski M, Sparkman J, Courbin D, et al. Leveraging 3D printing capacity in times of crisis: recommendations for COVID-19 distributed manufacturing for medical equipment rapid response. *Int J Environ Res Public Health.* 2020; 17(13): 4634.
32. Rabe BA, Cepko C. SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive protocol for sample inactivation and purification. *Proc Natl Acad Sci.* 2020; 117(39): 24450–8.
33. WarmStart® Colorimetric LAMP 2X Master Mix: NEW ENGLAND BioLabs. Available at: <https://international.neb.com/products/m1800-warmstart-colorimetric-lamp-2x-master-mix-dna-rna> (accessed on September 15, 2022).
34. Mori Y, Kitao M, Tomita N, Notomi T. Real-time turbidimetry of LAMP reaction for quantifying template DNA. *J Biochem Biophys Methods.* 2004; 59(2): 145–57.
35. Salk JE, Youngner J, Ward EN. Use of color change of phenol red as the indicator in titrating poliomyelitis virus or its antibody in a tissue-culture system. *Am J Hyg.* 1954; 60(2): 214–30.
36. Vogelstein B, Gillespie D. Preparative and analytical purification of DNA from agarose. *Proc Natl Acad Sci.* 1979; 76(2): 615–9.
37. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-Van Dillen PM, Van Der Noordaa J. Rapid and simple method for purification of nucleic acids. *J Clin Microbiol.* 1990; 28(3): 495–503.
38. Nagamine K, Hase T, Notomi T. Accelerated reaction by loop-mediated isothermal amplification using loop primers. *Mol Cell Probes.* 2002; 16(3): 223–9.
39. Hardinge P, Murray JA. Reduced false positives and improved reporting of loop-mediated isothermal amplification using quenched fluorescent primers. *Sci Rep.* 2019; 9(1): 1–13.
40. Kottur J, Nair DT. Pyrophosphate hydrolysis is an intrinsic and critical step of the DNA synthesis reaction. *Nucleic Acids Res.* 2018; 46(12): 5875–85.
41. Sender R, Bar-On YM, Gleizer S, Bernshtein B, Flamholz A, Phillips R, et al. The total number and mass of SARS-CoV-2 virions. *Proc Natl Acad Sci.* 2021; 118(25): e2024815118.

42. Butler DJ, Mozsary C, Meydan C, Danko D, Foux J, Rosiene J, et al. Shotgun transcriptome and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. *bioRxiv*. 2020:2020.04.20.048066.

Chapter 49

A Review of the Leishmanin Skin Test: A Neglected Test for a Neglected Disease

Jessica Carstens-Kass, Kayla Paulini, Patrick Lypaczewski, MSc,
and Greg Matlashewski, PhD

Department of Microbiology and Immunology, McGill University, Montreal, Canada

greg.matlashewski@mcgill.ca

Keywords: Bacille Calmette–Guérin (BCG) vaccine, ballpoint pen method, cross-reactivity, cutaneous leishmaniasis (CL), delayed-type hypersensitivity (DTH), diagnostic test, diffuse cutaneous leishmaniasis (DCL), disseminated cutaneous leishmaniasis (DsCL), enzyme-linked immunosorbent assay (ELISA), epidemiology, exposure monitoring, false positives, Good Manufacturing Practice (GMP), immunogenic epitopes, interferon- γ (IFN- γ), interferon- γ release assay (IGRA), *Leishmania amazonensis*, *Leishmania antigens*, *Leishmania braziliensis*, *Leishmania donovani*, *Leishmania guyanensis*, *Leishmania infantum*, *Leishmania major*, leishmaniasis, leishmaniasis recidivans (LR), leishmanin, leishmanin skin test (LST), limit of sensitivity, Montenegro skin test, mucocutaneous leishmaniasis (MCL), post-kala-azar dermal leishmaniasis (PKDL), protective immunity, QuantiFERON, sample preparation, serology, standardization, tuberculin skin test (TST), vaccines, validation, visceral leishmaniasis (VL)

49.1 Introduction

Leishmaniasis is caused by intracellular protozoan parasites of the genus *Leishmania*, which are transmitted by sand flies in endemic regions of Asia, Africa, Southern Europe, and Latin America [1]. More than 1 billion people are at risk of infection, and up to 1 million new cases occur annually [2]. Leishmaniasis is the second most deadly parasitic disease after malaria and is classified by the World Health Organization as a neglected tropical disease [3]. Depending on the species of *Leishmania* one becomes infected with, the severity of the disease can range from a self-healing cutaneous infection to a life-threatening visceral infection

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

(Table 49.1) [1]. Cutaneous leishmaniasis (CL) is characterized by nodules and ulcers—usually on the face, arms, and/or legs—which usually self-heal within 3 to 18 months but leave scars, which can be stigmatizing [1, 2]. Up to 10% of CL cases progress to leishmaniasis recidivans, diffuse CL, disseminated CL, or mucocutaneous leishmaniasis [1]. In cases of mucocutaneous leishmaniasis, the most disabling form of CL, the infection destroys the mucosal surfaces of the nose, mouth, and throat, leading to disfigurement, stigmatization, and, in some cases, death [2]. Visceral leishmaniasis (VL), or kala-azar, is a systemic manifestation of the disease and is the most severe. VL causes fever, weight loss, anemia, immunosuppression, and enlargement of the spleen and liver and is fatal unless treated [1, 2]. Following cure of VL from *Leishmania donovani* infection, patients may develop post-kala-azar dermal leishmaniasis (PKDL), which presents as a rash caused by an immune response against residual parasites in the skin [1]. PKDL is usually self-healing in Africa but is rarely self-healing in the Indian subcontinent [4, 5]. Although PKDL is most often an esthetic problem, it can be debilitating in some patients [1] and is thought to be a reservoir of the disease [6, 7].

Table 49.1 Clinical and epidemiological characteristics of selected *Leishmania* species

	Clinical form	High-burden countries or regions
<i>Leishmania donovani</i>	VL and PKDL	India, Bangladesh, Ethiopia, Sudan, and South Sudan
<i>Leishmania major</i>	CL	Iran, Saudi Arabia, North Africa, the Middle East, Central Asia, and West Africa
<i>Leishmania infantum</i>	VL and CL	China, Southern Europe, Brazil, and South America for VL and CL; Central America for CL
<i>Leishmania mexicana</i>	CL, DCL, and DsCL	South America
<i>Leishmania amazonensis</i>	CL, DCL, and DsCL	South America
<i>Leishmania braziliensis</i>	CL, DCL, LR, and MCL	South America
<i>Leishmania guyanensis</i>	CL, DsCL, and MCL	South America

Note: Adapted from Burza et al. (2018) [1].

Abbreviations: CL, cutaneous leishmaniasis; DCL, diffuse cutaneous leishmaniasis; DsCL, disseminated cutaneous leishmaniasis; LR, leishmaniasis recidivans; MCL, mucocutaneous leishmaniasis; PKDL, post-kala-azar dermal leishmaniasis; VL, visceral leishmaniasis.

The leishmanin skin test (LST; otherwise known as the Montenegro skin test) is performed via intradermal injection of *Leishmania* antigens (leishmanin) to induce and visualize the adaptive immune response in individuals who have been previously infected with *Leishmania*. The test is analogous to the better-known Mantoux tuberculin skin test (TST) [8], which is widely used as a diagnostic test for tuberculosis. Both the LST and TST are based on the principle that the injection of antigens into an individual who has been previously infected

causes the classical T cell-mediated inflammatory reaction known as the delayed-type hypersensitivity (DTH) response. In this response, antigen-specific T_H1 cells are activated by antigen-presenting cells, causing the T_H1 cells to secrete the inflammatory cytokine interferon- γ (IFN- γ), which recruits macrophages and other inflammatory cells to the site of the injection, resulting in a visible induration [9]. The DTH response is called “delayed” because the maximal influx of T_H1 cells and other inflammatory cells occurs 24 to 72 hours after exposure to antigens [10]; thus, this is the time at which the size of the induration peaks and is measured. In the case of the LST, an induration of at least 5 mm in diameter at 48 hours is typically considered a positive test [11], indicating that previous exposure to *Leishmania* has resulted in the development of cell-mediated immunity. Since the protective immune response to *Leishmania* is primarily mediated by T_H1 cells [12], a positive LST result signifies a level of immunity against the disease.

The LST has been a useful tool in epidemiological studies to monitor exposure and immunity to *Leishmania* as well as in vaccine studies as a surrogate marker of immunity. However, a standardized and reliable leishmanin product is currently not available; thus, the use of the LST has recently declined. In this review, we present the history of the LST and call for developing a standardized leishmanin that is produced under Good Manufacturing Practice (GMP) conditions and obtains the World Health Organization diagnostic prequalification for use in endemic countries.

49.2 History of the Leishmanin Skin Test

49.2.1 Development of the Leishmanin Skin Test

The LST was introduced in 1923 when it was demonstrated that intradermal injection of *Leishmania* extracts into an immunized guinea pig results in a cutaneous reaction [13]. This result was then reproduced in humans by João Montenegro, for whom the test is named, who showed that the reaction is positive in patients with active CL in a sensitive and specific manner [13]. It was soon demonstrated that the LST can detect cellular immunity even in cases in which parasites are too scarce to be found by microscopy in biological samples; thus, the LST became the preferred diagnostic tool for CL [14]. In 1966, it was observed that the LST is often positive in individuals lacking scars to indicate previous infection and who do not recall ever having had symptoms, and it was suggested that these individuals had asymptomatic infections [15]. This observation has since been repeated [16, 17], and it is now believed that of all people infected with *Leishmania*, symptomatic cases represent merely the tip of the iceberg. Although the LST was historically used to help diagnose skin lesions as cases of active CL, its use as a diagnostic tool is questionable due to the fact that the test does not distinguish between active and cured CL. Thus, use of the LST for diagnosis has declined since the emergence of alternative diagnostic tools that detect *Leishmania* DNA [18, 19]. However, the LST is currently still used in epidemiological studies of CL

and is often recommended as a complimentary diagnostic test in endemic regions in South America [8, 20].

The application of the LST to VL was more complex. In 1944, it was reported that the LST is negative in patients with active VL [21]. This was believed to be due to cellular anergy [1] and eliminated the possibility of using the LST as a diagnostic tool for VL. At the time, this finding led to the belief that the skin retains a sensitivity to leishmanin following CL but not VL. Therefore, it was believed that the LST was only useful to CL. Fifteen years later, it was hypothesized that the LST would be positive in cases of PKDL due to the presence of parasites in the skin [21]. Surprisingly, it was shown that the LST is positive once VL is cured regardless of whether the patient develops PKDL [21], unleashing a wave of new possible applications of the LST in the context of cured VL. Furthermore, it was quickly demonstrated that, like in CL, the LST is positive in individuals with asymptomatic VL infections, and it was proposed that these asymptomatic cases are reservoirs of *Leishmania* and perpetuate its transmission undetected [22]. This idea led to the first suggestion that the LST be used for surveillance of VL in endemic regions [22]. Since then, the LST has been used for monitoring exposure to VL-causing *Leishmania* species in epidemiological studies [23–26].

49.2.2 Past Sources of Leishmanin

When Montenegro first demonstrated the use of the LST in humans, he warned against accepting the results of the test without first evaluating the antigen preparation [13], highlighting the need for a standardized leishmanin. Still, despite repeated attempts at standardization and distribution, there is currently no standardized GMP-grade leishmanin available to researchers or clinicians. In many of the earliest studies, leishmanin was locally produced using varying techniques to obtain a suspension of killed whole promastigotes. The result was that studies used leishmanin products of differing composition and variable quality; thus, these studies could not be compared for analysis [27]. The Wellcome Trust resolved this issue when it began producing the first standardized leishmanin [28] (date unknown). However, production ended in the early 1980s, again forcing researchers either to prepare their own leishmanin or to stop using the LST. In the early 1990s, another attempt at standardization was made when the Special Program for Research and Training in Tropical Diseases (TDR) at the World Health Organization asked for leishmanin submissions from institutions around the world [28]. The 3 submissions received were a *Leishmania amazonensis*-derived leishmanin from the University of Minas Gerais in Brazil, a *Leishmania infantum*-derived leishmanin from the Istituto Superiore de Sanità in Italy, and a *Leishmania major*-derived leishmanin from the Pasteur Institute in Iran [28, 29]. The latter 2 products were found to be more potent, and TDR selected the Iranian leishmanin to support a developing country [28]. TDR began wide distribution of the Iranian leishmanin, resolving the need for a standardized and reliable antigen [27, 28]. TDR eventually ceased the distribution of the Iranian

leishmanin for unknown reasons. However, some institutions, including those mentioned above, briefly continued to produce leishmanin on a smaller scale. The Iranian leishmanin was still used in studies until recently [30, 31], but it is no longer available today (personal communication, Professor Alimohammadian). The leishmanin from the Istituto Superiore de Sanità was produced until a study suggested that the sensitivity of the product declines over time [29]. The Centro de Produção e Pesquisa de Imunobiológicos (CPPI, Immunobiology Production and Research Center) was the last company producing the Brazilian leishmanin; production of the Brazilian leishmanin ended in 2017 when the Agência Nacional de Vigilância Sanitária (ANVISA, National Health Surveillance Agency), a regulatory agency belonging to the Brazilian Ministry of Health, redefined its requirements for the manufacturing of the reagent [32]. The Wellcome Trust also resumed its production of leishmanin for a time, but eventually stopped once again. Consequently, researchers today have no source of standardized leishmanin.

49.2.3 Production, Storage, and Use of Leishmanin: What Can Be Learned from the Tuberculin Skin Test?

Few studies have compared the various methods of production, storage, and use of leishmanin, which is important for ensuring that studies using leishmanin are reliable and comparable. In this section, we will present the various techniques that have been employed in these 3 areas. When possible, we will attempt to identify which methods are optimal. Since tuberculin is standardized, extensively studied, and widely used, it is often a helpful benchmark for comparison.

49.2.4 Production and Storage of Leishmanin

Cross-reactivity between *Leishmania* species has been observed [33–35], although the extent of such cross-reactivity is unknown. While more studies are needed to elucidate the level of cross-reactivity between *Leishmania* species in the LST, there does appear to be a consensus that cross-reactivity is strongest within CL-causing and VL-causing subsets of *Leishmania* species, respectively [35, 36]. Although it would be difficult to make multiple versions of leishmanin for different endemic regions, for maximum sensitivity, it may be useful to make an *L. donovani*-derived leishmanin for VL and a leishmanin derived from an Old World and a New World species for CL.

While leishmanin was originally made of killed whole promastigotes, it has since been reported that soluble *Leishmania* antigen is more sensitive and potent [27, 37]. The preparation of soluble leishmanin involves the disruption of parasites, and it has been suggested that this process causes immunogenic epitopes to be more available for uptake by antigen-presenting cells, resulting in the increased sensitivity [27]. There are further advantages of using soluble antigen rather than killed whole promastigotes: It can be sterilized by filtration; the protein content can be determined and standardized; and the homogeneity

of the solution allows it to be delivered with greater uniformity [38]. However, the preparation of soluble leishmanin is inconsistent across studies. To begin preparing leishmanin, harvested parasites are centrifuged, washed, and the pellet is then resuspended. The media in which the pellet is resuspended is a source of discordance between studies. A few examples of media that have been used are sterile water [27, 37]; phenol solution [8]; saline solution containing 0.0001% thimerosal (merthiolate) [39]; and Tris-HCl, EDTA, leupeptin, α -2-macroglobulin, and phenylmethylsulfonyl fluoride [40]. Once the pellet has been resuspended, the next step is the disruption of the parasites, which has been accomplished in these studies by freeze-thaw cycles [27, 37], sonication [39, 40], or both. The disrupted parasite lysate is clarified by centrifugation, and the supernatant is collected. Sometimes, this supernatant is further dialyzed [40] or sterilized by filtration through 0.22 μ m pores [8, 27, 40]. These various techniques should be compared to establish consistency in the production of soluble leishmanin. Once the methodology has been established, it will be essential to manufacture leishmanin under GMP certification, which ensures the integrity of the manufacturing process and compliance with safety regulations. GMP-grade leishmanin must then be validated for safety and sensitivity in previously infected and relevant control populations.

The volume of leishmanin injected during the LST is consistently 0.1 ml in previous studies, but the amount of leishmanin protein delivered by the injection is often inconsistent due to the different preparation techniques described above. The sensitivity of leishmanin plateaus near 100% as dose increases [37, 41]. Also, size of induration increases as dose increases [27, 42]. However, very high doses of leishmanin have been associated with vesiculation, ulceration, and necrosis, which may lead to false-positive readings [42]. This underlines the need to deliver an optimal dose of leishmanin in the LST. The first study using soluble leishmanin reported that 25 μ g was the better dose compared to 5 μ g and 50 μ g [37], and a recent study using the LST delivered a 25 μ g dose [43].

To prevent its degradation during storage, leishmanin should be prepared with preservatives. Phenol prevents contamination but reportedly does not stabilize proteins [42], while the surfactant polysorbate 80 serves as a stabilizer as well as an excipient [44]. In tuberculin, a concentration of 0.0005% polysorbate 80 is sufficient to prevent adsorption of proteins, especially to the inner walls of glass or plastic containers, helping to maintain potency for skin testing [45]. Tuberculin prepared with phenol (0.3%) and polysorbate 80 (0.0005%) has been found to be stable following up to 3 years of storage at 4°C [46]. Accordingly, the first soluble leishmanin contained phenol (0.28%) and polysorbate 80 (0.0005%) [37]. Presumably, phenol and polysorbate 80 have the same preservative effects on leishmanin as they do on tuberculin.

The temperature at which leishmanin is stored also affects its stability. In the field, temperature control may be spotty or unavailable during transportation and storage. It is therefore necessary for leishmanin to be stable when stored refrigerated as a liquid. Even more ideal would be for leishmanin to be stable at the high ambient temperatures of endemic regions, which, for example, reach 29°C

to 38°C during summer months in the Middle East [47]. Tuberculin is stored in liquid form at 2°C to 8°C [48]. However, soluble leishmanin containing phenol (0.28%, w/v) and polysorbate 80 (0.0005%, w/v) stored at 2°C to 8°C for 5 years displayed significant protein degradation [38]. Additionally, lyophilization (freeze drying) extends the shelf life of tuberculin [49] and increases the heat stability of the Bacille Calmette–Guérin (BCG) vaccine for tuberculosis [50], but lyophilization has not been explored as an option for leishmanin. Studies could be performed in experimental animal models such as guinea pigs [51] to compare the stability and immunogenicity of liquid or lyophilized soluble leishmanin stored at various temperatures over assorted time periods.

49.2.5 Standardization of the LST

Once a standardized soluble leishmanin is produced, the LST itself should be standardized. Studies using the LST have measured induration at different time points ranging from 48 to 72 hours after injection of leishmanin [27, 52–54]. If only one reading is possible, it would be ideal to measure induration 48 hours after the injection of leishmanin, as this is the time at which peak induration is most likely to occur for skin tests in general [55]. In a study of the LST in 2,500 participants, indurations were largest 48 hours after the injection of leishmanin but were not statistically significant in size from indurations measured 72 hours after the injection of leishmanin [56]. Future studies should take into consideration the kinetics of the cellular immune response in the LST.



Figure 49.1 Ballpoint pen method for reading transverse diameter of induration. A ballpoint pen is placed a few centimeters from the edge of the induration and lightly moved across the skin toward the induration, drawing a line on the skin. When the tip of the pen reaches the boundary of the induration, added pressure is felt by the hand holding the pen, at which point the pen is lifted from the skin. Thus, the end of the line marks a boundary of the induration. Image from CDC Public Health Image Library [58].

Various studies have used different measurements and calculations to determine the size of an induration: One diameter [20]; the mean of 2 perpendicular

diameters [27, 30, 39, 57] except in cases of highly asymmetric reactions [10]; and the mean of the longest diameter and its perpendicular [42] have all been used. Additionally, there is reader-to-reader variability in skin tests, mainly due to the fact that induration boundaries can be difficult to define [55]. This issue can be somewhat resolved within studies by the consistent use of a single experienced reader [55] and across studies by clearly defining induration boundaries using the ballpoint pen method [10, 58] (Fig. 49.1). The ballpoint pen method is widely used in the TST [59].

49.2.6 Advantages of LST Over Serology for Epidemiological Studies

The goal of many epidemiological studies of leishmaniasis is to track and monitor the exposure of a certain population to *Leishmania*. Since their development, serological assays such as the direct agglutination test or the enzyme-linked immunosorbent assay (ELISA) have often been used for this purpose [60]. There are, however, 2 reasons why the LST is advantageous over serology for determining exposure to *Leishmania*. First, cell-mediated immunity lasts longer than antibody-mediated immunity following cured leishmaniasis [61]. In the case of CL, parasites are confined to the skin and therefore elicit a predominantly cell-mediated immune response [62]. This explains why antibody titers are low during and following even severe CL infection [62, 63]. Thus, the LST would be more effective than serology at determining past exposure to CL-causing *Leishmania* species. In the case of VL, LST positivity can last anywhere from 20 years to a lifetime [17, 23], while humoral immunity nearly disappears by the completion of treatment [64]. In many populations residing in CL- and VL-endemic regions, LST positivity trends upward with age while seropositivity does not [25, 30, 31, 52, 56]. It is unclear whether LST positivity increases with age due to naturally long-lasting cellular immunity or increased cumulative exposure to *Leishmania* or both. Nevertheless, this illustrates the longevity of cell-mediated immunity and supports the claim that the LST is a better indicator than serology of past exposure to both CL- and VL-causing *Leishmania* species. Accordingly, studies conducted around the world have found that the LST is more sensitive than serology [52, 65, 66].

Second, in the case of VL, cell-mediated immunity is more indicative of protection against reinfection compared to antibody-mediated immunity [57]. LST-positive individuals are largely immunologically protected against VL [25, 26, 29, 67] and are less likely to be reinfected compared to seropositive individuals [25]. Conversely, asymptomatic seropositive individuals in Bihar, India are considered to be at higher risk of developing VL [68]. With respect to New World CL, the size of induration produced by the LST-induced DTH response is negatively correlated with probability of reinfection, as incidence decreases by 17.9% per mm [56]. Thus, not only does a positive LST response indicate protection against reinfection but may also indicate the degree of protection.

49.2.7 LST in Vaccine Trials

Promising new vaccines for leishmaniasis are emerging [69, 70]. A major challenge for developing a vaccine for leishmaniasis will be how to measure efficacy. Development of disease has been traditionally used as a primary endpoint in human vaccine studies [71]. However, endpoint efficacy trials will be difficult to conduct in areas where there are fewer than 5 cases per 10,000 persons due to the success of ongoing VL elimination programs [72]. Therefore, a surrogate marker of immunity is needed to determine vaccine efficacy. As discussed above, LST positivity following natural infection is associated with long-lasting protection against VL [25, 26, 29, 67]. LST conversion has been used as an endpoint for protective immunity in trials involving first-generation vaccines with heat-killed parasites in the Old World [73] and in the New World [74, 75]. Overall, since these vaccines were not protective and poor at producing a positive LST, it was not possible to firmly conclude that a positive LST was associated with protective immunity. Reintroducing the LST with a standardized leishmanin will nevertheless be required as a surrogate marker of protective immunity for future trials with the newer and potentially more effective vaccine candidates [69, 70]. The live-attenuated vaccine that is advancing toward human clinical trials [70] provides an excellent opportunity to make leishmanin under GMP conditions.

For vaccine trials, LST negativity can be used to identify individuals who have not been previously exposed to *Leishmania* and therefore are good candidates for the trial. However, there is concern that leishmanin itself has a sensitizing effect, meaning an LST could cause positivity in subsequent LSTs resulting in a false-positive interpretation of vaccine efficacy. There is some evidence that the LST does not sensitize persons to leishmanin when leishmanin is prepared from whole promastigotes [42, 76]. However, repeated LSTs using a leishmanin prepared from whole promastigotes of a mixture of *L. amazonensis*, *Leishmania braziliensis*, and *Leishmania guyanensis* was reported to be sensitizing [77]. Once a standardized soluble leishmanin is prepared, it should be tested for sensitizing effects. If soluble leishmanin is not sensitizing, then the LST may be used prior to vaccination to determine previous exposure and again after vaccination. If soluble leishmanin is sensitizing, then the LST should only be used after vaccination to determine the vaccine-induced immune response. In the latter case, an *in vitro* version of the LST could be used prior to vaccination to determine previous exposure, as discussed in the following section.

49.3 Potential Application of Leishmanin to the Interferon- γ Release Assay

The development of monoclonal antibodies against IFN- γ in 1990 [78] made it possible to design a sandwich ELISA to detect IFN- γ in the supernatants of whole blood samples stimulated with tuberculin (also referred to as purified protein derivative or PPD) [79]. This was the first IFN- γ release assay (IGRA),

developed to diagnose bovine tuberculosis and later used to diagnose human tuberculosis. The cell-mediated immune response against *Mycobacterium tuberculosis* is driven by the activation of macrophages by IFN- γ [80]. An IGRA detects whether immune cells increase production of IFN- γ in response to stimulation with a particular antigen; an increase in IFN- γ production indicates the presence of antigen-specific cell-mediated immunity. Thus, like a skin test, the IGRA shows whether an individual has cell-mediated immunity against the antigens of a specific pathogen, and this could have advantages for some leishmaniasis applications.

The IGRA is quick, easy to perform, and more sensitive and specific than any other tests available for the diagnosis of bovine and human tuberculosis, including the TST [79, 81, 82]. Thus, the IGRA emerged as a new diagnostic tool for human tuberculosis and a commercially produced IGRA called QuantiFERON was subsequently developed. To perform the QuantiFERON test, 1 ml of blood is collected directly in QuantiFERON tubes in the field and transported to a laboratory testing facility. Within 24 hours, tuberculin antigens are added to the tubes, and the IFN- γ concentration of the supernatants is measured using a 1-step ELISA kit [83]. Field use is possible because the only components required are the QuantiFERON tubes (with *Leishmania* antigen) and a hot water bath to incubate at 37°C. In 2001, the Food and Drug Administration (FDA) approved a commercial QuantiFERON-TB test [84], providing researchers with a standardized tool with which to diagnose tuberculosis *in vitro* in the field [35]. Since then, the QuantiFERON and updated versions have been widely used for diagnosis and in epidemiological studies of tuberculosis.

Similar to the immune response against *M. tuberculosis*, the protective immune response against *Leishmania* is cell mediated and relies on the activation of macrophages by IFN- γ [12]. In 2010, in response to the lack of standardization of leishmanin for use in the LST, a modified QuantiFERON was investigated as an alternative to the LST for epidemiological studies [85]. Tuberculin antigens were replaced with *Leishmania* peptide antigens in the QuantiFERON-TB Gold In-Tube test. Whole blood stimulated with specific *Leishmania* peptides released IFN- γ in a sensitive and specific manner. A similar study showed that the test has even higher sensitivity when soluble leishmanin is used for stimulation instead of *Leishmania* peptides [83]. When this study was repeated with a larger participant pool, the modified QuantiFERON using soluble leishmanin for stimulation was 85% sensitive and 100% specific and detected asymptomatic, active, and cured cases of VL [86]. These findings illustrate that the IGRA could be an additional application for soluble leishmanin, providing yet another compelling reason to develop a standardized leishmanin product.

The level of concordance between the LST and modified QuantiFERON has been evaluated in studies that measured the levels of IFN- γ released by stimulated peripheral blood mononuclear cells [35, 87]; however, studies are needed which evaluate the levels of IFN- γ released by stimulated whole blood, as this is a better reflection of disease status for VL for reasons that are currently unknown [86, 88]. A study should be conducted in which the LST and the IGRA are performed on

the same cohort to determine concordance between the modern versions of these tests. The results will help in determining whether it is appropriate to replace the LST with the modified QuantiFERON in certain scenarios, such as prior to vaccination trials. Regardless of which test is chosen in future studies, researchers are in need of a standardized soluble leishmanin product.

49.4 Future Directions

In this review, we have discussed the past uses of the LST, the motivation for reintroducing the LST, and the need for a standardized leishmanin product. We will now consider how the LST may be applied once a standardized leishmanin product is available.

An urgent application of the LST is to support the effort to eliminate VL in the Indian subcontinent. Elimination of VL from this region has been deemed achievable for the following reasons [89]: *L. donovani*, the causative species of VL in the region, has no nonhuman reservoirs; *Phlebotomus argentipes*, the sole vector of *L. donovani* in the region, is susceptible to insecticides; transmission is geographically restricted to a focused area; there are effective options for diagnosis (rk39 rapid diagnostic test [90]) and treatment (oral miltefosine and liposomal amphotericin B) [1]; and immunity is protective and long lasting. In 2005, Bangladesh, India, and Nepal launched a 10-year initiative to eliminate VL with a target of less than 1 case per 10,000 at the block level [91]. This initiative contributed to an impressive 75% decline in incidence by 2015 [92]. However, the countries have yet to achieve sustainable elimination in 2020, with India being the furthest from the target [93]. A lack of effective surveillance has been a persistent constraint since the launch of the initiative [94, 95]. Specifically, studies are needed to understand why VL tends to cluster in shifting and tightly localized areas and how the parasite reservoir is maintained in locations where there are few VL cases [96]. The LST could be used to conduct epidemiological studies to establish the levels of ongoing and previous transmission in districts with varying numbers of cases. For these studies, it may be necessary to consider using a leishmanin derived from *L. donovani*, the species endemic in these regions, to increase sensitivity of the LST. A high level of LST positivity, particularly in the young, would identify areas of active transmission where increased resources such as active case detection and vector control efforts could be focused.

The development of a vaccine would advance the elimination of VL from the Indian subcontinent and Africa as well as help prevent all forms of leishmaniasis worldwide. As promising vaccines advance to clinical trials, it would be valuable to use the LST as a surrogate marker of immunity and protection. This would greatly reduce the number of participants and time required to show vaccine-induced protective immunity, simplifying Phase III trials. The eligibility of participants for vaccine trials should be based on the negative result of a modified QuantiFERON, because this test does not expose study participants to leishmanial antigens. This will ensure that an LST performed after vaccination will not be

affected by a participant’s exposure to anything other than the vaccine itself, making the LST a more reliable surrogate marker of immunity.

In summary, the LST is an effective surveillance tool for detecting exposure and immunity to *Leishmania*, but a standardized GMP-grade leishmanin antigen is not currently available anywhere in the world. In this review, we have outlined some of the major considerations required to prepare, store, and use leishmanin, as well as the studies required to standardize these steps (Fig. 49.2, Table 49.2). We have also discussed the benefits of the LST compared to serological tests for epidemiological studies, the use of the LST in vaccine trials, and the potential application of leishmanin to the IGRA. In conclusion, the reintroduction of the LST is urgently needed for ongoing surveillance and elimination programs and future vaccine trials.




Figure 49.2 Steps required for the production, validation, and application of leishmanin. Green = method is standardized. Yellow = method requires confirmational studies. Red = method is not standardized. Symbols (#, †, ¥, and ¢) correspond to recommendations in Table 49.2. Abbreviations: ELISA, enzyme-linked immunosorbent assay; GMP, Good Manufacturing Practice; IFN-γ, interferon-γ; LST, leishmanin skin test.

Table 49.2 Recommendations for future development and studies

Standardization of the production and storage of leishmanin
Determine cross-reactivity of <i>Leishmania</i> species in leishmanin preparations (#)
Establish standardized methodology for production of leishmanin under GMP guidelines (#)
Standardize the use of safe preservatives in leishmanin and determine whether lyophilization of leishmanin improves storage and heat stability (†)
Administration of the LST
Standardize the metric used to measure size of induration (¥)
Future applications of leishmanin and the LST
Use the LST alone or in combination with serological assays for surveillance and epidemiological studies
Use the LST for the diagnosis of CL
Use the LST as a surrogate marker of immunity in vaccine trials
Use leishmanin in the modified QuantiFERON (an IGRA)
Determine the best positive reference value for the modified QuantiFERON (¢)
Determine the level of concordance between the LST and modified QuantiFERON

Note: Symbols (#, †, ¥, and ¢) correspond to steps in Fig. 49.2.

Abbreviations: CL, cutaneous leishmaniasis; IGRA, interferon- γ release assay; LST, leishmanin skin test.

Key Learning Points

- The leishmanin skin test (LST) has been used for almost 1 century to detect exposure and immunity to *Leishmania* parasites, which cause the disease leishmaniasis.
- The LST is better than serological tests for detecting exposure and immunity to *Leishmania* and can be used for epidemiological studies, surveillance, and as a surrogate marker of protective immunity for human vaccine trials.
- *Leishmania* antigen (leishmanin), the reagent used in the LST, is not currently produced under Good Manufacturing Practice (GMP) conditions anywhere in the world. As a result, the LST is seldom used in the field today.
- A standardized leishmanin is defined as an antigen that is produced under GMP conditions and obtains the World Health Organization prequalification.
- A standardized leishmanin product can also be investigated for use in an interferon- γ release assay (IGRA), which may serve as an in vitro version of the LST.

Top Five Papers

1. Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S. Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for *Leishmania donovani*, a proof of concept study. *PLoS Negl Trop Dis*. 2011 Apr 19; 5(4): e1042.
2. Montenegro J. Cutaneous reactions in leishmaniasis. *Arch Derm Syphilol*. 1926 Feb 1; 13(2): 187–94.
3. Reed SG, Badaró R, Masur H, Carvalho EM, Lorencó R, Lisboa A et al. Selection of a skin test antigen for American visceral leishmaniasis. *Am J Trop Med Hyg*. 1986 Jan 1; 35(1): 79–85.
4. Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. *Am J Trop Med Hyg*. 1991 Mar 1; 44(3): 260–71.
5. Zijlstra EE, El-Hassan AM, Ismael A, Ghalib HW. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. *Am J Trop Med Hyg*. 1994 Dec 1; 51(6): 826–36.

Abbreviations

ANVISA:	Agência Nacional de Vigilância Sanitária
BCG:	bacille Calmette–Guérin
CL:	cutaneous leishmaniasis
CPPI:	Centro de Produção e Pesquisa de Imunobiológicos
DCL:	diffuse cutaneous leishmaniasis
DsCL:	disseminated cutaneous leishmaniasis
DTH:	delayed-type hypersensitivity
ELISA:	enzyme-linked immunosorbent assay
FDA:	Food and Drug Administration
GMP:	Good Manufacturing Practice
IFN- γ :	inflammatory cytokine interferon- γ
IGRA:	interferon- γ release assay
LR:	leishmaniasis recidivans
LST:	leishmanin skin test
MCL:	mucocutaneous leishmaniasis
PKDL:	post-kala-azar dermal leishmaniasis
TDR:	WHO Special Programme for Research and Training in Tropical Diseases
TST:	tuberculin skin test
VL:	visceral leishmaniasis

Disclosures and Conflict of Interest

This chapter was originally published as: Carstens-Kass, J., Paulini, K., Lypaczewski, P., Matlashewski, G. (2021). A review of the leishmanin skin test: A neglected test for a neglected disease. *PLoS Negl. Trop. Dis.*, **15**(7), e0009531, <https://doi.org/10.1371/journal.pntd.0009531>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>) and appears here with edits and updates.

Funding: This research was supported by grants from the Canadian Institutes of Health Research (CIHR) to GM and the Global Health Innovation Technology Fund (GHIT) to GM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

References

1. Burza S, Croft SL, Boelaert M. Leishmaniasis. *Lancet*. 2018; 392(10151): 951–70.
2. WHO. Leishmaniasis. Available at: <https://www.who.int/health-topics/leishmaniasis> (accessed on September 20, 2022).
3. WHO. Neglected tropical diseases. Available at: https://www.who.int/health-topics/neglected-tropical-diseases#tab=tab_1 (accessed on September 20, 2022).
4. Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, Kroeger A, et al. Enhanced case detection and improved diagnosis of PKDL in a Kala-azar-endemic area of Bangladesh. *PLoS Negl Trop Dis*. 2010; 4(10): e832.
5. Zijlstra EE, Hassan AM, Ismael A. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. *Am J Trop Med Hyg*. 1995; 52(4): 299–305.
6. Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, et al. Quantifying the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies. *Clin Infect Dis*. 2019; 69(2): 251–8.
7. Singh OP, Tiwary P, Kushwaha AK, Singh SK, Singh DK, Lawyer P, et al. Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. *Lancet Microbe*. 2021; 2(1): e23–31.
8. Krolewiecki AJ, Almazan MC, Quipildor M, Juarez M, Gil JF, Espinosa M, et al. Reappraisal of leishmanin skin test (LST) in the management of American cutaneous leishmaniasis: a retrospective analysis from a reference center in Argentina. *PLoS Negl Trop Dis*. 2017; 11(10): e0005980.
9. Murphy K, Weaver C. *Janeway's Immunobiology*. 9th ed., Taylor & Francis, 2017.
10. Sokal JE. Editorial: measurement of delayed skin-test responses. *N Engl J Med*. 1975; 293(10): 501–2.
11. Skraba CM, de Mello TF, Pedroso RB, Ferreira ÉC, Demarchi IG, Aristides SM, et al. Evaluation of the reference value for the Montenegro skin test. *Rev Soc Bras Med Trop*. 2015; 48(4): 437–44.

12. Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. *Curr Opin Immunol*. 1993; 5(4): 524–31.
13. Montenegro J. Cutaneous reaction in leishmaniasis. *Arch Derm Syphilol*. 1926; 13(2): 187–94.
14. Dostrovsky A, Sagher F. The intracutaneous test in cutaneous leishmaniasis. *Ann Trop Med Parasitol*. 1946; 40(3–4): 265–9.
15. Chalmers AH, Harris JC, Swanton RH, Thorley AP. A survey of the distribution of dermal leishmaniasis in British Honduras. *Trans R Soc Trop Med Hyg*. 1968; 62(2): 213–20.
16. Aston DL, Thorley AP. Leishmaniasis in Central Brazil: results of a Montenegro skin test survey among Amerindians in the Xingu National Park. *Trans R Soc Trop Med Hyg*. 1970; 64(5): 671–8.
17. Pampiglione S, Manson-Bahr PE, La Placa M, Borgatti MA, Micheloni F. Studies on Mediterranean leishmaniasis. IV. The leishmanin skin test in cutaneous leishmaniasis. *Trans R Soc Trop Med Hyg*. 1976; 70(1): 62–5.
18. Adams ER, Schoone GJ, Ageed AF, Safi SE, Schallig HD. Development of a reverse transcriptase loop-mediated isothermal amplification (LAMP) assay for the sensitive detection of *Leishmania* parasites in clinical samples. *Am J Trop Med Hyg*. 2010; 82(4): 591–6.
19. Mary C, Faraut F, Lascombe L, Dumon H. Quantification of *Leishmania infantum* DNA by a real-time PCR assay with high sensitivity. *J Clin Microbiol*. 2004; 42(11): 5249–55.
20. Pinheiro ABS, Kurizky PS, Ferreira MF, Mota MAS, Ribeiro JS, Oliveira Filho EZ, et al. The accuracy of the Montenegro skin test for leishmaniasis in PCR-negative patients. *Rev Soc Bras Med Trop*. 2020; 53: e20190433.
21. Manson-Bahr PE, Heisch RB, Garnham PC. Studies in leishmaniasis in East Africa. IV. The Montenegro test in kala-azar in Kenya. *Trans R Soc Trop Med Hyg*. 1959; 53: 380–3.
22. Manson-Bahr PE. East African kala-azar with special reference to the pathology, prophylaxis and treatment. *Trans R Soc Trop Med Hyg*. 1959; 53 (2): 123–36. discussion 36–7.
23. Pampiglione S, Manson-Bahr PE, La Placa M, Borgatti MA, Musumeci S. Studies in Mediterranean leishmaniasis. 3. The leishmanin skin test in kala-azar. *Trans R Soc Trop Med Hyg*. 1975; 69(1): 60–8.
24. Yangzom T, Cruz I, Bern C, Argaw D, den Boer M, Vélez ID, et al. Endemic transmission of visceral leishmaniasis in Bhutan. *Am J Trop Med Hyg*. 2012; 87(6): 1028–37.
25. Hailu A, Gramiccia M, Kager PA. Visceral leishmaniasis in Aba-Roba, south-western Ethiopia: prevalence and incidence of active and subclinical infections. *Ann Trop Med Parasitol*. 2009; 103(8): 659–70.
26. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. *Am J Trop Med Hyg*. 1994; 51(6): 826–36.
27. Alimohammadian MH, Fariba Kojori Z, Darabi H, Malekzadeh S, Yousef-Beig M, Irvani-Nia F. Soluble leishmanin as an ideal reagent for skin testing in human leishmaniasis. *IBJ*. 1997; 1(4): 39–47.

28. Tropical disease research: progress 1975–94, highlights 1993–94, twelfth programme report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). World Health Organization; 1995. p. 146.
29. Bern C, Amann J, Haque R, Chowdhury R, Ali M, Kurkjian KM, et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. *Am J Trop Med Hyg.* 2006; 75(4): 744–8.
30. Chapman LAC, Morgan ALK, Adams ER, Bern C, Medley GF, Hollingsworth TD. Age trends in asymptomatic and symptomatic *Leishmania donovani* infection in the Indian subcontinent: a review and analysis of data from diagnostic and epidemiological studies. *PLoS Negl Trop Dis.* 2018; 12(12): e0006803.
31. Traoré B, Oliveira F, Faye O, Dicko A, Coulibaly CA, Sissoko IM, et al. Prevalence of cutaneous leishmaniasis in districts of high and low endemicity in mali. *PLoS Negl Trop Dis.* 2016; 10(11): e0005141.
32. Braz LMA. Tegumentary leishmaniasis diagnosis: what happened with MST (Montenegro Skin Test) in Brazil? *Rev Inst Med Trop Sao Paulo.* 2019; 61: e17.
33. Akuffo H, Darce M, Maasho K, Berhan TY. In vivo evaluation of immune responses in leishmaniasis: the use of cross-species leishmanin preparations for skin testing. *Am J Trop Med Hyg.* 1995; 53(1): 16–22.
34. Tonui WK, Titus RG. Cross-protection against *Leishmania donovani* but not *L. braziliensis* caused by vaccination with *L. major* soluble promastigote exogenous antigens in BALB/c mice. *Am J Trop Med Hyg.* 2007; 76(3): 579–84.
35. Alimohammadian MH, Jones SL, Darabi H, Riazirad F, Ajdary S, Shabani A, et al. Assessment of interferon-gamma levels and leishmanin skin test results in persons recovered for leishmaniasis. *Am J Trop Med Hyg.* 2012; 87(1): 70–5.
36. Gidwani K, Rai M, Chakravarty J, Boelaert M, Sundar S. Evaluation of leishmanin skin test in Indian visceral leishmaniasis. *Am J Trop Med Hyg.* 2009; 80(4): 566–7.
37. Reed SG, Badaro R, Masur H, Carvalho EM, Lorenco R, Lisboa A, et al. Selection of a skin test antigen for American visceral leishmaniasis. *Am J Trop Med Hyg.* 1986; 35(1): 79–85.
38. Badaró R, Pedral-Sampaio D, Johnson WD Jr, Reed SG. Evaluation of the stability of a soluble intradermal skin test antigen preparation in American visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 1990; 84(2): 226–7.
39. da Costa CA, de Toledo VP, enaro O, Williams P, Mayrink W. Montenegro skin test—evaluation of the composition and stability of the antigen preparation. *Mem Inst Oswaldo Cruz.* 1996; 91(2): 193–4.
40. Scott P, Pearce E, Natovitz P, Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. *J Immunol.* 1987; 139(9): 3118–25.
41. Cuba CAC, Marsden PD, Barretto AC, Jones TC, Richards F. The use of different concentrations of leishmanial antigen in skin testing to evaluate delayed hypersensitivity in American cutaneous leishmaniasis. *Rev Soc Bras Med Trop.* 1985; 18: 231–6.

42. Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. Leishmanin skin test standardization and evaluation of safety, dose, storage longevity of reaction and sensitization *Am J Trop Med Hyg.* 1991; 44(3): 260–71.
43. Rodrigues-Neto JF, Monteiro GR, Keesen TSL, Lacerda HG, Carvalho EM, SMB J. CD45RO+ T cells and T cell activation in the long-lasting immunity after *Leishmania infantum* infection. *Am J Trop Med Hyg.* 2018; 98(3): 875–82.
44. Ita K. Progress in the use of microemulsions for transdermal and dermal drug delivery. *Pharm Dev Technol.* 2017; 22(4): 467–75.
45. Landi S, Held HR, Tseng MC. Disparity of potency between stabilized and nonstabilized dilute tuberculin solutions. *Am Rev Respir Dis.* 1971; 104(3): 385–93.
46. Landi S, Held HR. Stability of dilute solutions of tuberculin purified protein derivative. *Tubercle.* 1978; 59(2): 121–33.
47. Monthly weather forecast and climate 2020. Available at: <https://www.weather-atlas.com/> (accessed on September 20, 2022).
48. Product monograph including patient medication information: TUBERSOL; Tuberculin Purified Protein Derivative (Mantoux), 2016. Available at: https://pdf.hres.ca/dpd_pm/00065105.PDF (accessed on September 20, 2022).
49. Bharnthong T, Prachayasittikul V, Isarankura Na Ayudhya C, Premchaiporn P, Khow O, Sitprija V. A lyophilized formulation to extend the shelf-life of tuberculin PPD. *Southeast Asian J Trop Med Public Health.* 2005; 36(4): 970–5.
50. Wright D, Muggleton PW, Griffiths MI. Evaluation of the stability of dried BCG vaccine. *Tubercle.* 1972; 53(2): 92–9.
51. Guedes DC, Minozzo JC, Pasquali AKS, Faulds C, Soccol CR, Thomaz-Soccol V. New strategy to improve quality control of Montenegro skin test at the production level. *Rev Soc Bras Med Trop.* 2017; 50(6): 788–94.
52. Bekele F, Belay T, Zeynudin A, Hailu A. Visceral leishmaniasis in selected communities of Hamar and Banna-Tsamai districts in Lower Omo Valley, South West Ethiopia: sero-epidemiological and leishmanin skin test surveys. *PLoS ONE.* 2018; 13(5): e0197430.
53. Guirges SY. Natural and experimental re-infection of man with Oriental sore. *Ann Trop Med Parasitol.* 1971; 65(2): 197–205.
54. Tadese D, Hailu A, Bekele F, Belay S. An epidemiological study of visceral leishmaniasis in North East Ethiopia using serological and leishmanin skin tests. *PLoS ONE.* 2019; 14(12): e0225083.
55. Bates SE, Suen JY, Tranum BL. Immunological skin testing and interpretation: a plea for uniformity. *Cancer.* 1979; 43(6): 2306–14.
56. Davies CR, Llanos-Cuentas EA, Pyke SD, Dye C. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. *Epidemiol Infect.* 1995; 114(2): 297–318.
57. Gadisa E, Custodio E, Cañavate C, Sordo L, Abebe Z, Nieto J, et al. Usefulness of the rK39-immunochromatographic test, direct agglutination test, and leishmanin skin test for detecting asymptomatic *Leishmania* infection in children in a new visceral leishmaniasis focus in Amhara State. *Ethiopia Am J Trop Med Hyg.* 2012; 86(5): 792–8.

58. CDC, Benenson G. Public Health Image Library 2004. Available at: <https://phil.cdc.gov/Details.aspx?pid=6807> (accessed on September 20, 2022).
59. Pai M, Kunimoto D, Jamieson F, Menzies D. Chapter 4: Diagnosis of latent tuberculosis infection. In: *Canadian Tuberculosis Standards 7th Edition: 2014*, Public Health Agency of Canada. Available at: <https://www.canada.ca/en/public-health/services/infectious-diseases/canadian-tuberculosis-standards-7th-edition/edition-16.html>. (accessed on September 20, 2022).
60. Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 1990; 84(5): 673–5.
61. Shiddo SA, Akuffo HO, Mohamed AA, Huldt G, Nilsson LA, Ouchterlony O, et al. Visceral leishmaniasis in Somalia: prevalence of leishmanin-positive and seropositive inhabitants in an endemic area. *Trans R Soc Trop Med Hyg.* 1995; 89(1): 21–4.
62. Nation CS, Dondji B, Stryker GA. Previous exposure to a low infectious dose of *Leishmania major* exacerbates infection with *Leishmania infantum* in the susceptible BALB/c mouse. *Parasitol Res.* 2012; 111(3): 1407–15.
63. Adler S, Nelken D. Attempts to transfer delayed hypersensitivity to *Leishmania tropica* by leucocytes and whole blood. *Trans R Soc Trop Med Hyg.* 1965; 59: 59–63.
64. Singla N, Singh GS, Sundar S, Vinayak VK. Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India. *Trans R Soc Trop Med Hyg.* 1993; 87(3): 276–8.
65. Jones TC, Johnson WD Jr, Barretto AC, Lago E, Badaro R, Cerf B, et al. Epidemiology of American cutaneous leishmaniasis due to *Leishmania braziliensis braziliensis*. *J Infect Dis.* 1987; 156(1): 73–83.
66. Riera C, Fisa R, López-Chejade P, Serra T, Girona E, Jiménez M, et al. Asymptomatic infection by *Leishmania infantum* in blood donors from the Balearic Islands (Spain). *Transfusion.* 2008; 48(7): 1383–9.
67. Khalil EA, Zijlstra EE, Kager PA, El Hassan AM. Epidemiology and clinical manifestations of *Leishmania donovani* infection in two villages in an endemic area in eastern Sudan. *Trop Med Int Health.* 2002; 7(1): 35–44.
68. Sinha PK, Bimal S, Pandey K, Singh SK, Ranjan A, Kumar N, et al. A community-based, comparative evaluation of direct agglutination and rK39 strip tests in the early detection of subclinical *Leishmania donovani* infection. *Ann Trop Med Parasitol.* 2008; 102(2): 119–25.
69. Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S, et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. *PLoS Negl Trop Dis.* 2017; 11(5): e0005527.
70. Zhang W-W, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, et al. A second generation leishmanization vaccine with a markerless attenuated *Leishmania major* strain using CRISPR gene editing. *Nat Commun.* 2020; 11(1): 3461.
71. WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations 2016. Available at: <https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9> (accessed on September 20, 2022).
72. Rijal S, Sundar S, Mondal D, Das P, Alvar J, Boelaert M. Eliminating visceral leishmaniasis in South Asia: the road ahead. *BMJ.* 2019; 364: k5224.

73. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomised vaccine trial of single dose of killed *Leishmania major* plus BCG against anthroponotic cutaneous leishmaniasis in Bam. *Iran Lancet*. 1998; 351(9115): 1540–3.
74. Antunes CM, Mayrink W, Magalhaes PA, Costa CA, Melo MN, Dias M, et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. *Int J Epidemiol*. 1986; 15(4): 572–80.
75. Mayrink W, Magalhães PA, Dias M, Da Costa CA, Melo MN, Lima AO. Responses to Montenegro antigen after immunization with killed *Leishmania* promastigotes. *Trans R Soc Trop Med Hyg*. 1978; 72(6): 676.
76. Satti I, el Hassan A, Khalil el TA, Akuffo H. The effect of repeated leishmanin skin testing on the immune responses to *Leishmania* antigen in healthy volunteers. *Trans R Soc Trop Med Hyg*. 2002; 96(5): 565–7.
77. Nascimento MD, Alcântara-Neves NM, Muniz ME, Nunes SF, Paranhos M, de Carvalho LC. Induction and modulation of the immune response to *Leishmania* by Montenegro's skin test. *Trans R Soc Trop Med Hyg*. 1993; 87(1): 91–3.
78. Wood PR, Rothel JS, McWaters PG, Jones SL. Production and characterization of monoclonal antibodies specific for bovine gamma-interferon. *Vet Immunol Immunopathol*. 1990; 25(1): 37–46.
79. Rothel JS, Jones SL, Corner LA, Cox JC, Wood PR. A sandwich enzyme immunoassay for bovine interferon-gamma and its use for the detection of tuberculosis in cattle. *Aust Vet J*. 1990; 67(4): 134–7.
80. Braverman J, Stanley SA. Nitric oxide modulates macrophage responses to *Mycobacterium tuberculosis* infection through activation of HIF-1 α and repression of NF- κ B. *J Immunol*. 2017; 199(5): 1805–16.
81. Wood PR, Corner LA, Rothel JS, Baldock C, Jones SL, Cousins DB, et al. Field comparison of the interferon-gamma assay and the intradermal tuberculin test for the diagnosis of bovine tuberculosis. *Aust Vet J*. 1991; 68(9): 286–90.
82. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent *Mycobacterium tuberculosis* infection. *JAMA*. 2001; 286(14): 1740–7.
83. Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S. Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for *Leishmania donovani* a proof of concept study. *PLoS Negl Trop Dis*. 2011; 5(4): e1042.
84. Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent *Mycobacterium tuberculosis* infection. Centers for disease control and prevention. *MMWR Recomm Rep*. 2003; 52(Rr-2): 15–8.
85. Turgay N, Balcioğlu IC, Toz SO, Ozbel Y, Jones SL. Quantiferon-*Leishmania* as an epidemiological tool for evaluating the exposure to *Leishmania* infection. *Am J Trop Med Hyg*. 2010; 83(4): 822–4.
86. Singh OP, Gidwani K, Kumar R, Nylén S, Jones SL, Boelaert M, et al. Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. *Clin Vaccine Immunol*. 2012; 19(6): 961–6.
87. Khalil EA, Ayed NB, Musa AM, Ibrahim ME, Mukhtar MM, Zijlstra EE, et al. Dichotomy of protective cellular immune responses to human visceral leishmaniasis. *Clin Exp Immunol*. 2005; 140(2): 349–53.

88. Singh OP, Sundar S. Whole blood assay and visceral leishmaniasis: challenges and promises. *Immunobiology*. 2014; 219(4): 323–8.
89. Bhattacharya SK, Sur D, Sinha PK, Karbwang J. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable. *Indian J Med Res*. 2006; 123(3): 195–6.
90. Badaró R, Benson D, Eulálio MC, Freire M, Cunha S, Netto EM, et al. rK39: a cloned antigen of *Leishmania chagasi* that predicts active visceral leishmaniasis. *J Infect Dis*. 1996; 173(3): 758–61.
91. WHO Regional Office for South-East Asia Regional strategic framework for elimination of kala azar from the South-East Asia Region (2005–2015). New Delhi: WHO Regional Office for South-East Asia; 2005.
92. WHO NTD. South-East Asia poised to defeat visceral leishmaniasis (kala-azar) 2015 Oct 19. Available at: https://www.who.int/neglected_diseases/news/SEARO_poised_to_defeat_VL/en/ (accessed on September 20, 2022).
93. WHO. Leishmaniasis 2020 March 2. Available at: <https://www.who.int/news-room/fact-sheets/detail/leishmaniasis> (accessed on September 20, 2022).
94. Singh OP, Hasker E, Boelaert M, Sundar S. Elimination of visceral leishmaniasis on the Indian subcontinent. *Lancet Infect Dis*. 2016; 16(12): e304–e9.
95. WHO. Eliminating visceral leishmaniasis: India takes decisive steps to overcome last-mile challenges. Available at: <https://www.who.int/news-room/detail/05-03-2020-VL-India-takes-decisive-steps-overcome-last-mile-challenges> (accessed on September 20, 2022).
96. Das VN, Pandey RN, Siddiqui NA, Chapman LA, Kumar V, Pandey K, et al. Longitudinal study of transmission in households with visceral leishmaniasis, asymptomatic infections and PKDL in highly endemic villages in Bihar, India. *PLoS Negl Trop Dis*. 2016; 10(12): e0005196.

Chapter 50

Current Issues in Age-Related Macular Degeneration¹

*National Eye Institute,
National Institutes of Health, Bethesda, Maryland, USA*

Keywords: age-related macular degeneration (AMD), Amsler grid, anti-vascular endothelial growth factor (VEGF) drugs, Age-Related Eye Disease Studies 2 (AREDS2) trial, beta-carotene, Byooviz, Charles Bonnet syndrome, conjunctival hemorrhage, dilated eye exam, dry AMD, early AMD, endophthalmitis, first Age-Related Eye Disease Studies (AREDS) trial, fluorescein angiogram, genetic testing, geographic atrophy, implantable miniature telescope (IMT), interchangeable biosimilar, intermediate AMD, intraocular pressure, iris, late AMD, Lucentis, lutein, macula, macula, neovascular age-related macular degeneration (nAMD), omega-3 fatty acids, optic nerve, optical coherence tomography, photodynamic therapy, pupil, ranibizumab, retina, retinal detachments, thromboembolic, vascular endothelial growth factor (VEGF), visual acuity test, visual hallucinations, wet AMD, zeaxanthin



¹This chapter is organized and edited by the Series Editor, Raj Bawa, PhD, MD. It is based on information and materials kindly provided to Dr. Bawa by the National Eye Institute (NEI). The NEI conducts and supports research that leads to sight-saving treatments and plays a key role in reducing visual impairment and blindness. The NEI is part of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. This chapter is a patient education tool for health professionals and community-based educators.

Advances in Medical Imaging, Detection, and Diagnosis


Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com


50.1 What Is AMD?



Age-related macular degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 60 and older. It causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp, central vision, which lets us see objects that are straight ahead.

In some people, AMD advances so slowly that vision loss does not occur for a long time. In others, the disease progresses faster and may lead to a loss of vision in one or both eyes. As AMD progresses, a blurred area near the center of vision is a common symptom. Over time, the blurred area may grow larger or you may develop blank spots in your central vision. Objects also may not appear to be as bright as they used to be.

AMD by itself does not lead to complete blindness, with no ability to see. However, the loss of central vision in AMD can interfere with simple everyday activities, such as the ability to see faces, drive, read, write, or do close work, such as cooking or fixing things around the house.



50.2 Who Is at Risk?

Age is a major risk factor for AMD. The disease is most likely to occur after age 60, but it can occur earlier. Other risk factors for AMD include:

Smoking. Research shows that smoking doubles the risk of AMD.

Race. AMD is more common among Caucasians than among African-Americans or Hispanics/Latinos.

Family History and Genetics. People with a family history of AMD are at higher risk. At last count, researchers had identified nearly 20 genes that can affect the risk of developing AMD. Many more genetic risk factors are suspected.

You may see offers for genetic testing for AMD. Because AMD is influenced by so many genes, plus environmental factors such as smoking and nutrition, there are currently no genetic tests that can diagnose AMD, or predict with certainty who will develop it.

The American Academy of Ophthalmology currently recommends against routine genetic testing for AMD, and insurance generally does not cover such testing.

50.3 How Is AMD Detected?

The early and intermediate stages of AMD usually start without symptoms. Only a comprehensive dilated eye exam can detect AMD. The eye exam may include the following:

Visual Acuity Test. This eye chart measures how well you see at distances.


Dilated Eye Exam. Your eye care professional places drops in your eyes to widen or dilate the pupils. This provides a better view of the back of your eye. Using a special magnifying lens, he or she then looks at your retina and optic nerve for signs of AMD and other eye problems.


Does lifestyle make a difference?

Researchers have found links between AMD and some lifestyle choices, such as smoking. You might be able to reduce your risk of AMD or slow its progression by making these healthy choices:


- Avoid smoking
- Exercise regularly
- Maintain normal blood pressure and cholesterol levels
- Eat a healthy diet rich in green, leafy vegetables and fish

Amsler Grid. Your eye care professional also may ask you to look at an Amsler grid. Changes in your central vision may cause the lines in the grid to disappear or appear wavy, a sign of AMD.





Here is what an Amsler grid normally looks like.



This is what an Amsler grid might look like to someone with AMD.

Fluorescein Angiogram. In this test, which is performed by an ophthalmologist, a fluorescent dye is injected into your arm. Pictures are taken as the dye passes through the blood vessels in your eye. This makes it possible to see leaking blood vessels, which occur in a severe, rapidly progressive type of AMD. In rare cases, complications to the injection can arise, from nausea to more severe allergic reactions.

Optical Coherence Tomography (OCT). You have probably heard of ultrasound, which uses sound waves to capture images of living tissues. OCT is similar except that it uses light waves, and can achieve very high-resolution images of any tissues that can be penetrated by light—such as the eyes. After your eyes are dilated, you'll be asked to place your head on a chin rest and hold still for several seconds while the images are obtained. The light beam is painless. During the exam, your eye care professional will look for drusen, which are yellow deposits beneath the retina. Most people develop some very small drusen as a normal part of aging. The presence of medium-to-large drusen may indicate that you have AMD.

Another sign of AMD is the appearance of pigmentary changes under the retina. In addition to the pigmented cells in the iris (the colored part of the eye), there are pigmented cells beneath the retina. As these cells break down and release their pigment, your eye care professional may see dark clumps of released pigment and later, areas that are less pigmented. These changes will not affect your eye color.

50.4 What Are the Stages of AMD?

There are three stages of AMD defined in part by the size and number of drusen under the retina. It is possible to have AMD in one eye only, or to have one eye with a later stage of AMD than the other.

Early AMD. Early AMD is diagnosed by the presence of medium-sized drusen, which are about the width of an average human hair. People with early AMD typically do not have vision loss.

Intermediate AMD. People with intermediate AMD typically have large drusen, pigment changes in the retina, or both. Again, these changes can only be detected during an eye exam. Intermediate AMD may cause some vision loss, but most people will not experience any symptoms.

Late AMD. In addition to drusen, people with late AMD have vision loss from damage to the macula. There are two types of late AMD:

- In geographic atrophy (also called dry AMD), there is a gradual breakdown of the light-sensitive cells in the macula that convey visual information to the brain, and of the supporting tissue beneath the macula. These changes cause vision loss.
- In neovascular AMD (also called wet AMD), abnormal blood vessels grow underneath the retina. (“neovascular” means “new vessels.”) These vessels can leak fluid and blood, which may lead to swelling and damage of the macula. The damage may be rapid and severe, unlike the more gradual course of geographic atrophy. It is possible to have both geographic atrophy and neovascular AMD in the same eye, and either condition can appear first.

AMD has few symptoms in the early stages, so it is important to have your eyes examined regularly. If you are at risk for AMD because of age, family history, lifestyle, or some combination of these factors, you should not wait to experience changes in vision before getting checked for AMD.

Not everyone with early AMD will develop late AMD. For people who have early AMD in one eye and no signs of AMD in the other eye, about five percent will develop advanced AMD after 10 years. For people who have early AMD in both eyes, about 14 percent will develop late AMD in at least one eye after 10 years. With prompt detection of AMD, there are steps you can take to further reduce your risk of vision loss from late AMD.

If you have late AMD in one eye only, you may not notice any changes in your overall vision. With the other eye seeing clearly, you may still be able to drive, read, and see fine details. However, having late AMD in one eye means you are at increased risk for late AMD in your other eye. If you notice distortion or blurred vision, even if it doesn't have much effect on your daily life, consult an eye care professional.

50.5 How Is AMD Treated?

Early AMD

Currently, no treatment exists for early AMD, which in many people shows no symptoms or loss of vision. Your eye care professional may recommend that you get a comprehensive dilated eye exam at least once a year. The exam will help determine if your condition is advancing.

As for prevention, AMD occurs less often in people who exercise, avoid smoking, and eat nutritious foods including green leafy vegetables and fish. If you already have AMD, adopting some of these habits may help you keep your vision longer.

Intermediate and Late AMD

Researchers at the National Eye Institute tested whether taking nutritional supplements could protect against AMD in the Age-Related Eye Disease Studies (AREDS and AREDS2). They found that daily intake of certain high-dose vitamins and minerals can slow progression of the disease in people who have intermediate AMD, and those who have late AMD in one eye.

The first AREDS trial showed that a combination of vitamin C, vitamin E, beta-carotene, zinc, and copper can reduce the risk of late AMD by 25 percent. The AREDS2 trial tested whether this formulation could be improved by adding lutein, zeaxanthin or omega-3 fatty acids. Omega-3 fatty acids are nutrients enriched in fish oils. Lutein, zeaxanthin and beta-carotene all belong to the same family of vitamins, and are abundant in green leafy vegetables.

The AREDS2 trial found that adding lutein and zeaxanthin or omega-3 fatty acids to the original AREDS formulation (with beta-carotene) had no overall effect on the risk of late AMD. However, the trial also found that replacing beta-carotene with a 5-to-1 mixture of lutein and zeaxanthin may help further reduce the risk of late AMD. Moreover, while beta-carotene has been linked to an increased risk of lung cancer in current and former smokers, lutein and zeaxanthin appear to be safe regardless of smoking status.

Here are the clinically effective doses tested in AREDS and AREDS2:

- 500 milligrams (mg) of vitamin C
- 400 international units of vitamin E
- 80 mg zinc as zinc oxide (25 mg in AREDS2)
- 2 mg copper as cupric oxide
- 15 mg beta-carotene, OR 10 mg lutein and 2 mg zeaxanthin

A number of manufacturers offer nutritional supplements that were formulated based on these studies. The label may refer to “AREDS” or “AREDS2.”

If you have intermediate or late AMD, you might benefit from taking such supplements. But first, be sure to review and compare the labels. Many of the supplements have different ingredients, or different doses, from those tested in the AREDS trials. Also, consult your doctor or eye care professional about which supplement, if any, is right for you. For example, if you smoke regularly, or used to, your doctor may recommend that you avoid supplements containing beta-carotene.

Even if you take a daily multivitamin, you should consider taking an AREDS supplement if you are at risk for late AMD. The formulations tested in the AREDS trials contain much higher doses of vitamins and minerals than what is found in multivitamins. Tell your doctor or eye care professional about any multivitamins you are taking when you are discussing possible AREDS formulations.

You may see claims that your genotype can influence how you will respond to AREDS supplements. Some recent studies have claimed that, depending on genotype, some patients will benefit from AREDS supplements and others could be harmed. These claims are based on a portion of data from the AREDS research. NEI investigators have done comprehensive analyses of the complete AREDS data. Their findings to date indicate that AREDS supplements are beneficial for patients of all tested genotypes. Based on the overall data, the American Academy of Ophthalmology does not support the use of genetic testing to guide treatment for AMD.

Finally, remember that the AREDS formulation is not a cure. It does not help people with early AMD, and will not restore vision already lost from AMD. But it may delay the onset of late AMD. It also may help slow vision loss in people who already have late AMD.

Advanced neovascular AMD

Neovascular AMD typically results in severe vision loss. However, eye care professionals can try different therapies to stop further vision loss. You should remember that the therapies described below are not a cure. The condition may progress even with treatment.

Injections. One option to slow the progression of neovascular AMD is to inject drugs into the eye. With neovascular AMD, abnormally high levels of vascular endothelial growth factor (VEGF) are secreted in your eyes. VEGF is a protein that promotes the growth of new abnormal blood vessels. Anti-VEGF injection therapy blocks this growth. If you get this treatment, you may need multiple monthly injections. Before each injection, your eye will be numbed and cleaned with antiseptics. To further reduce the risk of infection, you may be prescribed antibiotic drops. A few different anti-VEGF drugs are available. They vary in cost and in how often they need to be injected, so you may wish to discuss these issues with your eye care professional.

Photodynamic Therapy. This technique involves laser treatment of select areas of the retina. First, a drug called verteporfin will be injected into a vein in your arm. The drug travels through the blood vessels in your body, and is absorbed by new, growing blood vessels. Your eye care professional then shines a laser beam into your eye to activate the drug in the new abnormal blood vessels, while sparing normal ones. Once activated, the drug closes off the new blood vessels, slows their growth, and slows the rate of vision loss. This procedure is less common than anti-VEGF injections, and is often used in combination with them for specific types of neovascular AMD.

Laser Surgery. Eye care professionals treat certain cases of neovascular AMD with laser surgery, though this is less common than other treatments. It involves aiming an intense “hot” laser at the abnormal blood vessels in your eyes to destroy them. This laser is not the same one used in photodynamic therapy which may be referred to as a “cold” laser. This treatment is more likely to be used when blood

vessel growth is limited to a compact area in your eye, away from the center of the macula, that can be easily targeted with the laser. Even so, laser treatment also may destroy some surrounding healthy tissue. This often results in a small blind spot where the laser has scarred the retina. In some cases, vision immediately after the surgery may be worse than it was before. But the surgery may also help prevent more severe vision loss from occurring years later.

50.6 What Are Some Low Vision Devices?

Because low vision varies from person to person, specialists have different tools to help patients deal with vision loss. They include:

- Reading glasses with high-powered lenses
- Computers with large-print and speech-output systems
- Large-print reading materials
- Talking watches, clocks, and calculators
- Computer aids and other technologies, such as a closed-circuit television, which uses a camera and television to enlarge printed text

For some patients with end-stage AMD, an Implantable Miniature Telescope (IMT) may be an option. This FDA-approved device can help restore some lost vision by refocusing images onto a healthier part of the retina. After the surgery to implant the IMT, patients participate in an extensive vision rehabilitation program.

Keep in mind that low vision aids without proper diagnosis, evaluation, and training may not work for you. It is important that you work closely with your low vision team to get the best device or combination of aids to help improve your ability to see.

50.7 What Is Charles Bonnet Syndrome (Visual Hallucinations)?

People with impaired vision sometimes see things that are not there, called visual hallucinations. They may see simple patterns of colors or shapes, or detailed pictures of people, animals, buildings, or landscapes. Sometimes these images fit logically into a visual scene, but they often do not.

This condition can be alarming, but don't worry—it is not a sign of mental illness. It is called Charles Bonnet syndrome, and it is similar to what happens to some people who have lost an arm or leg. Even though the limb is gone, these people still feel their toes or fingers or experience itching. Similarly, when the brain loses input from the eyes, it may fill the void by generating visual images on its own.

Charles Bonnet syndrome is a common side effect of vision loss in people with AMD. However, it often goes away a year to 18 months after it begins. In the

meantime, there are things you can do to reduce hallucinations. Many people find the hallucinations occur more frequently in evening or dim light. Turning on a light or television may help. It may also help to blink, close your eyes, or focus on a real object for a few moments.

50.8 Byooviz

The U.S. Food and Drug Administration in 2021 approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions, including wet or neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older. Byooviz is also approved to treat macular edema (fluid build-up) following retinal vein occlusion (blockage of veins in the retina) and myopic choroidal neovascularization, a vision-threatening complication of myopia (nearsightedness).

As discussed earlier in this chapter, wet or neovascular age-related macular degeneration destroys the sharp, central vision needed to see clearly and can affect daily activities like reading, driving and watching television. While dry AMD is more common, wet AMD leads to vision loss at a faster rate. Both macular edema and myopic choroidal neovascularization can also lead to visual impairment.

Biological products are generally derived from a living organism and can come from many sources, including animals and microorganisms, such as bacteria or yeast. A biosimilar is a biological product that is approved based on data showing that it is highly similar to a biological product already approved by the FDA (reference product) and has no clinically meaningful differences in terms of safety, purity and potency (i.e., safety and effectiveness) from the reference product, in addition to meeting other criteria specified by law. Patients can expect the same safety and effectiveness from the biosimilar over the course of treatment as from the reference product.

The FDA's approval of Byooviz was based on a review of evidence that included extensive structural and functional characterization, comparative clinical efficacy and safety evaluations, including potential immunogenicity (type of immune response) that demonstrated Byooviz is biosimilar to Lucentis. To date, the FDA has approved 31 biosimilars, including one interchangeable biosimilar (<https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products>), for the treatment of a variety of health conditions.

Byooviz is administered by intravitreal injection (delivered into the vitreous humor of the eye) once a month. Administration of Byooviz may cause serious side effects, including: endophthalmitis (infection inside the eye) and retinal detachments; increases in intraocular pressure; and thromboembolic (obstruction of a blood vessel by a blood clot) events. The most common side effects of Byooviz include conjunctival hemorrhage (broken blood vessel), eye pain, vitreous floaters (black spots that drift across the eye) and increased intraocular fluid pressure. The FDA granted approval of Byooviz to Samsung Bioepis.

What can you do to protect your vision?

T	Take your medications as prescribed by your doctor.	
R	Reach and maintain a healthy weight.	
A	Add more physical activity to your daily routine.	
C	Control your ABCs—A1C, blood pressure, and cholesterol levels.	
K	Kick the smoking habit.	

Chapter 51

On-Chip Liquid Chromatography

Makoto Tsunoda, PhD

Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan

makotot@mol.f.u-tokyo.ac.jp

Keywords: collocated monolith support structures (COMOSS), device capacity, electrochromatography, electrophoresis, hemoglobin A_{1c} (HbA_{1c}), hydrophilic interaction chromatography (HILIC), hydrophobic interaction chromatography (HIC), integrated systems, ion exchange, lab-on-a-chip, liquid chromatography (LC), liquid chromatography mass spectrometry (LC-MS), micro total analysis system (microTAS), monolithic, on-chip chromatography, open tubular, packed particle, pillar array, pillar-distribution controlled (PDC), reduced plate height, reverse phase, sol-gel synthesis, solid-phase extraction (SPE)

51.1 Introduction

Liquid chromatography (LC) is an indispensable separation technique with many biological, clinical, environmental, forensic, and pharmaceutical applications. Various stationary phases can be used for LC, and this technique provides highly reproducible results. In omics research, such as proteomics and metabolomics, LC coupled to mass spectrometry (LC-MS) is an effective analytical method for highly sensitive and accurate mass determination. However, it is still difficult to achieve satisfactory separation, particularly in complex mixtures such as biological samples (tissue, plasma, serum, and urine). In metabolomics, thousands of metabolites must be measured simultaneously. Furthermore, some important biological compounds are present only in small amounts, along with high concentrations of other endogenous compounds that may present interference. These challenges can be overcome through LC miniaturization.

In recent years, micro total analysis systems (microTAS), also known as lab-on-a-chip, have emerged as an attractive area of research. In a microTAS,

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

sampling, sample transport, necessary chemical reactions, separation, and detection are all performed on a chip. Separation is one of the key processes in a microTAS. Therefore, extensive research has been conducted to realize on-chip separation using miniaturized LC.

Previous studies have examined on-chip separation using electrophoresis or electrochromatography. However, there are relatively few examples of chip-based LC. Four different on-chip LC approaches have been developed to date: use of open-tubular, packed-particle, monolithic, and pillar array columns (Fig. 51.1). These techniques enable fast analysis, while offering the advantages of high throughput, very small sample volumes, and low reagent consumption. Each method is described in the following section.




Figure 51.1 Four approaches for on-chip LC: use of (a) open-tubular [1], (b) packed-particle [2], (c) monolithic [3], and (d) pillar array columns [4]. Reproduced with permission from references [1–4].

51.2 Approaches

51.2.1 Open-Tubular Chromatography

Open-tubular chromatography is the simplest way to realize chromatography on a chip and is the first published example of on-chip LC; this technique was first reported by Manz et al. [1]. In their study, an open-tubular column with a length of 15 cm, width of 6 μm , and depth of 2 μm was fabricated, but no separations were attempted.

The channel wall of the chip was directly modified and used as the stationary phase to obtain the desired retention capacity. A notable advantage of open-tubular chromatography is the low backpressure. A device with an integrated micropump that employs sodium-silicate-based sol-gel membranes for generating pressure-driven flow was employed for reverse-phase LC separation of three rhodamine B derivatives. Separation was achieved in 60 s in an open-tubular channel [5]. An open-tubular column coated with a C8 stationary phase and pressure-driven gated injection were used to achieve baseline separation of phenol and 2,6-dimethylphenol; vitamin A and vitamin E were also partially separated [6].

The main disadvantage of this method is the low column capacity due to the low surface-to-volume ratio. To increase the capacity of open-tubular columns, the specific surface area of the stationary phase must be increased. Although not chip-based, a capillary application was used to increase the relevant surface area by introducing an open-tubular monolithic porous polymer layer through ultraviolet photoinitiated fabrication [7].

51.2.2 Packed-Particle Columns

In conventional LC, most columns are packed with particles. In on-chip LC, conventional-type stationary phases are transferred to the microfluidic chip. Hence, on-chip LC systems packed with particles represent one of the more straightforward options for achieving separation. Pre-prepared particles can flow into the microchannel on a chip, resulting in the formation of a packed bed. Numerous particle types with different modifications, e.g., C8, C18, ion exchange, hydrophilic interaction chromatography (HILIC), are available; these particles can be used to develop particle-packed chips. These particle-packed columns have a much larger specific surface area than open-tubular columns.

On-chip cation-exchange chromatography was used to separate hemoglobin A_{1c} (HbA_{1c}), one of the most important marker proteins for diabetes [8]. The chip was packed with cation exchange beads (particle diameter 30 μm), which could separate HbA_{1c} from other Hbs.

The first commercially available chips were packed with particles. However, they have only been used for specific equipment configurations, for example, in combination with a mass spectrometer. The packed particles are required to eliminate the dead volumes that result from the connection between the column and the mass spectrometer.

The Agilent LC particle-packed chip includes an on-chip microvalve, an enrichment column, a packed-particle analytical column, and a nanospray emitter on a single multilayer polymer chip [2]. It has been extensively utilized for proteome research and for analyzing small molecules such as 7-aminoflunitrazepam in human urine, 8-isoprostaglandin F_{2α} in human urine, hepcidin (a peptide marker of clinical disorders linked to iron metabolism) in human plasma, pharmaceutical drugs covering a wide range of hydrophilicities, fluoxetine,

and norfluoxetine in rat serum, illicit drugs and metabolites in human hair, and 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma.

The ionKey and iKey (Waters) chips are ceramic. These chips contain 1.7 μm silica-particles packed in a 150 or 300 μm microchannel, an electrical column heater, a nebulization gas channel, and a post-column mobile-phase-modifier channel. The post-column makeup-flow design allows the post-column addition of solvents to enhance the electrospray ionization and increase the sensitivity of the mass spectrometer. An Ionkey/MS system was used to quantify infliximab in rat serum [9]. Compared to conventional LC, the sensitivity was higher. An online analysis system for evaluating intestinal absorption and the formation of unknown products was developed by coupling a flow-through Transwell system with an online iKeyChip-QTOF-MS system [10].

cHiPLC (SCIEX (Eksigent)) is another commercially available chip-based platform, which acts as a “docking station” for up to three quartz microfluidic chips. The system’s flexible design and built-in 10-port nanovalve allow for easy switching between different modes, such as direct injection and trap loading. cHiPLC was recently used to investigate LGALS3BP/90K glycoprotein in the cerebrospinal fluid of patients with neurological diseases [11].

The performance of particle-packed on-chip LC devices depends critically on the packing conditions of the particles. Because the chip channels are not cylindrical, as in a conventional LC column, and the pressure applied for packing is limited, it is challenging to achieve reproducible packing as in conventional LC columns. Some studies have shown that for particle-packed on-chip LC columns, high bed densities are critical for achieving good separation performance in noncylindrical packed beds [12], and that the desired high packing densities can be much more easily achieved using 3 μm particles than with the use of 5 μm particles [13].

The preparation of packed beds in chips requires the installation of packed particles in the microchannels. A common method for immobilizing the particles is to construct a frit structure inside the chip channels by the microfabrication of bottleneck-shaped channels or by synthesizing thin monolith layers. Porous polymeric monoliths have been utilized as retaining elements in common slurry-packing procedures [14]. By using laser-assisted photopolymerization, the frits can be precisely defined to have lengths less than 100 μm .

Particle-packed LC chips were recently reviewed in detail elsewhere [15].

51.2.3 Monoliths

Monoliths consist of a single rod of porous material that is easily synthesized *in situ* by a polymerization reaction. Unlike particle-packed columns, monoliths do not require frits and have high permeability. Compared to open-tubular columns, monoliths have a higher specific surface area and greater column capacity.

Solutions containing monomers and functional groups can be introduced into the microchannels for thermally or via photoinduced polymerization, resulting

in a highly porous material. Ericson et al. first demonstrated anion-exchange chromatography of proteins by filling narrow channels with continuous polymer beds [3]. A monolithic nano-porous polymer chip was fabricated by packing the channels with poly(methyl acrylate) monoliths [16]. The monolith consisted of a number of globes, with a diameter of approximately 2 μm . Neurotransmitters, 5-hydroxyindole-3-acetic acid (5-HIAA) and 5-hydroxytryptamine (serotonin), were successfully separated.

Ion-exchange chromatographic separation of protein-isoforms and sensitive immunoassay detection were combined in a porous nitrocellulose monolith chip [17]. The chip could discriminate between transferrin isoforms differing by only 0.1 pH units in pI and was used to specifically quantify the separated transferrin isoforms.

The use of a reverse-phase polymethacrylate monolith (15 cm long) as the separation column and a 5 mm long methacrylate monolith as the solid-phase extraction (SPE) element for sample cleanup and enrichment enabled the separation of fluorescein-labeled model peptides [18]. Online removal of free fluorescein was achieved using the on-chip SPE column, resulting in a 150-fold improvement in the sensitivity.

A chip-based polymer monolithic column was coupled with a valveless gated sample injection method [19]. Two fluorescently labeled amines (butylamine and cyclohexylamine) were successfully separated in less than 220 s with a column length of 1 cm. The valveless gated sample injection method enabled nanoliter-scale sample injection without the need for a mechanical valve.

A microfluidic device was designed for comprehensive spatial two-dimensional LC [20]. A hydrophobic methacrylate ester-based monolithic stationary phase was polymerized *in situ* in the second-dimension channels. In addition, a photomask was used to localize monolith formation in the parallel second-dimension channels. The pore and globule sizes were in the range of 0.8–1.5 and 1–2 μm , respectively.

Recently, 3D printing technology has been used to fabricate LC chips. Selective laser melting was used to fabricate titanium-based LC columns [21, 22]. In-column thermal polymerization of mechanically stable poly(BuMA-co-EDMA) monoliths was achieved, without any structural changes. The monolith in the complex internal channels (~ 0.9 mm I.D. and 600 mm length) was found to be mechanically stable, and was used to separate intact proteins, including the A and B components of β -lactoglobulin and peptides, from complex mixtures.

Considering its practical uses, the main disadvantage is column-to-column reproducibility because the polymerization reaction cannot be completely controlled. In addition, the overall size of the monolithic beds often decreases after polymerization.

51.2.4 Pillar Array

A pillar array column can also be used to achieve LC separation on a chip. Before introducing pillar array columns, the theoretical aspects of LC should be

considered. According to Giddings's theory, three processes contribute to band dispersion, and the plate height can be expressed as the sum of three terms. The reduced plate height depends on the reduced velocity, as shown in the following equation:

$$h = A + B/v + Cv,$$

where A , B , and C are constants, h is the reduced plate height (plate height divided by dp , i.e., the particle diameter of the packing material), and v is the reduced velocity (expressed as udp/Dm , where u is the mobile phase linear velocity and Dm is the diffusion coefficient of the analyte in the mobile phase). The terms A , B , and C relate to flow in interparticle spaces, axial diffusion, and slow equilibration between the mobile and stationary phases, respectively. Knox pointed out that A -term dispersion is by far the most important phenomenon to consider, and that this feature is limited when using particle-packed columns due to packing technology constraints [23]. He also stated that much lower h values could be obtained by decreasing the A -term dispersion, if the stationary phase was constructed to be highly ordered; for example, by micromachining the entire column.

In 1998, Regnier et al. first introduced pillar array columns (referred to as collocated monolith support structures (COMOSS)) [24]. They reported that direct fabrication with photolithography using deep-reactive ion-etching techniques could be used to simultaneously position and define pillars. However, such columns have only been evaluated in electro-driven chromatography.

The first successful pressure-driven LC separation using pillar array columns was performed by Desmet et al. [25]. Nonporous silicon pillars with a diameter of approximately 4.4 μm were fabricated and covalently coated with a hydrophobic monolayer to enable reverse-phase LC separations. The separation of three dyes (C440, C460, and C480) was achieved in 3 s. A plate height of ~ 4 μm , which is much smaller than those of conventional LC columns, was obtained under weak retention conditions. This result clearly shows that the ordered structure of the stationary phase can enhance the separation performance of the column.

However, there is a limit to the length of the linear flow path that can be fabricated on a small substrate, making multicomponent analysis of biomolecules difficult. To realize better separation, a long separation column with a turn structure is required. Tapered turn structures with equal distances between the inner and outer peripheries (low-dispersion turn) were found to be effective for preventing turn-induced sample dispersion [4]. With the low-dispersion-turn geometry, a pillar array column with a width of 400 μm and a column length of 110 mm was fabricated on a 20 \times 20 mm microchip. Under non-retained conditions, the solute bands obtained for fluorescent dyes remained almost unchanged, even after passing through the low-dispersion turns. Two coumarin dyes (C525 and C545) were well resolved under reverse-phase conditions, and a

maximum theoretical plate number of 8000 was obtained. Branched-chain amino acids (valine, isoleucine, and leucine), other amino acids (phenylalanine and tyrosine), and keto acids in human plasma samples could be quantified, demonstrating for the first time that pillar array columns can be applied to the analysis of biological samples [26–28]. When biological compounds were quantified using the pillar array columns, the relative standard deviation of the peak intensity was high (>30%) because the injection volume of the sample was of the order of nanoliters. Adding an internal standard improved the reproducibility [26]. The feasibility of quantitative analysis of samples using pillar array columns with the help of an internal standard was demonstrated. Furthermore, an automated sample injection system for pillar array columns was developed to maintain a constant sample injection volume [29]. The system was composed of two pumps (one for the sample and another for the mobile phase), a six-way valve that can be controlled by a PC, and an autosampler.

The turn structure described above has a high flow resistance due to the narrow channel width of the turn, making it difficult to achieve high-speed separation at high flow rates. Hence, a new turn structure with low dispersion and low flow resistance (pillar-distribution controlled (PDC) turn) was designed as a constant-radius turn, filled with octagonal pillars that were arranged to control the linear velocity of the mobile phase in the radial direction [30]. Upon introducing the PDC turn structure into the pillar array columns, separation at high flow rates became possible, and five fluorescently derivatized amino acids (proline, valine, 6-aminocaproic acid, leucine, and phenylalanine), could be separated within 24 s. The PDC turn structure offers the advantages of longer pillar array columns for the fast analysis of complex samples.

However, analysis of biological compounds using a single mobile phase is still difficult as biological samples are very complex and the polarity of the components exhibit large differences. In conventional LC, this problem is solved by utilizing a gradient elution system that can accelerate the elution of strongly retained solutes. Hence, a gradient elution system with pillar array columns was developed [31]. The essential component of the gradient elution system is the mixer, which is used to mix two kinds of mobile phases. A cross-Tesla structure with a 3 mm mixing length was effective for mixing two liquids. The gradient elution system using a cross-Tesla mixer and pillar array columns improved the separation efficiency of the pillar array columns, as evidenced by the gradient chromatographic separation of the fluorescent derivatives of four aliphatic amines (pentylamine, hexylamine, heptylamine, and octylamine) within 110 s.

To increase the retention of nonporous pillar array columns, pillars with thick layers of mesoporous silicon were produced [32]. A 550 nm thick porous layer on the pillar array generated by anodization increased the available surface area by at least two orders of magnitude. Sol-gel synthesis of silica monoliths with the pillar array column technology afforded porous-shell coated pillars [33]. The thickness of the porous layer on the 2.4 μm pillars was

480 nm, with relatively large through-pores of 2.2 μm . A minimal plate height of 3.9 μm was obtained under non-retained conditions. Another approach involves the direct growth of carbon nanotubes on the pillar surface [34]. The retention was improved relative to that of pillar array columns grafted with an octadecyl stationary phase only.

Two pillar array columns (200 and 50 cm in length) are currently commercially available from PharmaFluidics. The chip can be connected to any micro/nano LC system with a connector through a capillary tube. These chips are applied to proteomics and lipidomics studies. Very recently, pillar array columns (200 cm) coupled with mass spectrometers were used to identify 340,000 proteins, doubling the number of proteins identified hitherto [35]. With the pillar array system, the coefficient of variation for the peptide retention times was improved 2.5-fold, and high interlaboratory reproducibility was achieved compared to conventional LC. Moreover, pillar array columns (50 cm) were effective for separating some permethylated glycan isomers [36].

51.3 Conclusions

In this chapter, the recent advances in the development of on-chip LC were reviewed. Thirty years have elapsed since the first example of a chip-based LC device. Since then, four different on-chip LC approaches have been developed: open-tubular, packed-particle, monolithic, and pillar array. These methods have been applied to proteomics, as well as the analysis of small molecules and drugs in various biological samples. These devices enable fast analysis, with the advantages of high throughput, very small sample volumes, and low reagent consumption. Pillar array columns also afford highly efficient separation, overcoming the limitations of the conventional column, and may be helpful for omics studies such as metabolomics and proteomics, which require the separation of many kinds of compounds.

On-chip chromatography technology still remains largely in the basic research stage, although some devices based on particle-packed and pillar array columns are commercially available. Further advancements, described below, can be expected.

The main separation mode for on-chip LC is currently the reverse-phase mode. Other separation modes such as ion exchange, HILIC, and size exclusion can be developed for analyzing many kinds of biomolecules, including protein and DNA. User-friendly systems including pumps, injectors, and detectors should be developed. Currently, commercially available on-chip LC systems are connected to MS. Chip-based LC-MS does not require connections between the column and mass spectrometer, which reduces extra column band broadening. Other detection approaches coupled with on-chip LC are interesting alternatives to MS. For micro-scale fluids, reducing the channel size and increasing the column length significantly increase the back pressure. Hence, new kinds of substrate materials should be developed using microfabrication technology

such as 3D printing technology. MicroTAS using on-chip LC is also important for enabling new applications in a variety of research areas. In pharmaceutical analysis, MicroTAS using on-chip LC is not just faster and more efficient than LC separation, but also enables automation of the entire analytical process. Hence, this technique can overcome the limitations of current pharmaceutical analyses. On-chip LC is expected to find extensive applications due to its portability, where application to clinical diagnosis is one of the important examples. In clinical diagnosis, on-chip LC can be performed in hospitals and even at the bedside.

Abbreviations

5-HIAA:	5-hydroxyindole-3-acetic acid
COMOSS:	collocated monolith support structures
HbA _{1c} :	hemoglobin A _{1c}
HIC:	hydrophobic interaction chromatography
HILIC:	hydrophilic interaction chromatography
LC:	liquid chromatography
LC-MS:	LC coupled to mass spectrometry
microTAS:	micro total analysis systems
PDC:	pillar-distribution controlled
SPE:	solid-phase extraction

Disclosures and Conflict of Interest

This chapter was originally published as: Tsunoda, M. On-chip liquid chromatography. *Encyclopedia*, 2022, **2**, 617–624. <https://doi.org/10.3390/encyclopedia2010041>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>) and appears here with edits and updates.

Funding: This research was funded in part by grants from the Japan Society for the Promotion of Science (JSPS; grant numbers 17K08234 and 21H02613).

Conflicts of Interest: The author declares no conflict of interest.

References

1. Manz, A., Miyahara, Y., Miura, J., Watanabe, Y., Miyagi, H., Sato, K. Design of an open-tubular column liquid chromatograph using silicon chip technology. *Sens. Actuators B Chem.*, 1990, **1**, 249–255.
2. Yin, H. F., Killeen, K., Brennen, R., Sobek, D., Werlich, M., van de Goor, T. Microfluidic chip for peptide analysis with an integrated HPLC column, sample enrichment column, and nanoelectrospray tip. *Anal. Chem.*, 2005, **77**, 527–533.
3. Ericson, C., Holm, J., Ericson, T., Hjertén, S. Electroosmosis- and pressure-driven chromatography in chips using continuous beds. *Anal. Chem.*, 2000, **72**, 81–87.

4. Aoyama, C., Saeki, A., Noguchi, M., Shirasaki, Y., Shoji, S., Funatsu, T., Mizuno, J., Tsunoda, M. Use of folded micromachined pillar array column with low-dispersion turns for pressure-driven liquid chromatography. *Anal. Chem.*, 2010, 82, 1420–1426.
5. Toh, G. M., Corcoran, R. C., Dutta, D. Sodium silicate based sol-gel structures for generating pressure-driven flow in microfluidic channels. *J. Chromatogr. A*, 2010, 1217, 5004–5011.
6. Schlund, M., Gilbert, S. E., Schnydrig, S., Renaud, P. Continuous sampling and analysis by on-chip liquid/solid chromatography. *Sens. Actuators B*, 2007, 123, 1133–1141.
7. Collins, D. A., Nesterenko, E. P., Brabazon, D., Paull, B. Controlled ultraviolet (UV) photoinitiated fabrication of monolithic porous layer open tubular (monoPLOT) capillary columns for chromatographic applications. *Anal. Chem.*, 2012, 84, 3465–3472.
8. Tanaka, T., Izawa, K., Okochi, M., Lim, T.-K., Watanabe, S., Harada, M., Matsunaga, T. On-chip type cation-exchange chromatography with ferrocene-labeled anti-hemoglobin antibody and electrochemical detector for determination of hemoglobin A_{1c} level. *Anal. Chim. Acta*, 2009, 638, 186–190.
9. Kleinnijenhuis, A. J., Ingola, M., Toersche, J. H., van Holthoon, F. L., van Dongen, W. D. Quantitative bottom up analysis of infliximab in serum using protein A purification and integrated μ LC-electrospray chip IonKey MS/MS technology. *Bioanalysis*, 2016, 8, 891–904.
10. Santbergen, M. J. C., van der Zande, M., Gerssen, A., Bouwmeester, H., Nielen, M. W. F. Dynamic *in vitro* intestinal barrier model coupled to chip-based liquid chromatography mass spectrometry for oral bioavailability studies. *Anal. Bioanal. Chem.*, 2020, 412, 1111–1122.
11. Costa, J., Pronto-Laborinho, A., Pinto, S., Gromicho, M., Bonucci, S., Tranfield, E., Correia, C., Alexandre, B. M., de Carvalho, M. Investigating LGALS3BP/90 K glycoprotein in the cerebrospinal fluid of patients with neurological diseases. *Sci. Rep.*, 2020, 10(1), 5649.
12. Ehlert, S., Kraiczek, K., Mora, J. A., Dittmann, M., Rozing, G. P., Tallarek, U. Separation efficiency of particle-packed HPLC microchips. *Anal. Chem.*, 2008, 80, 5945–5950.
13. Jung, S., Hölzel, A., Ehlert, S., Mora, J. A., Kraiczek, K., Dittmann, M., Rozing, G. P., Tallarek, U. Impact of conduit geometry on the performance of typical particulate microchip packings. *Anal. Chem.*, 2009, 81, 10193–10200.
14. Thurmann, S., Mauritz, L., Heck, C., Belder, D. High-performance liquid chromatography on glass chips using precisely defined porous polymer monoliths as particle retaining elements. *J. Chromatogr. A*, 2014, 1370, 33–39.
15. Kecskemeti, A., Gasper, A. Particle-based liquid chromatographic separations in microfluidic devices—A review. *Anal. Chim. Acta*, 2018, 1021, 1–19.
16. Kim, J.-H., O'Hare, D. Monolithic nano-porous polymer in microfluidic channels for lab-chip liquid chromatography. *Nano Converg.*, 2018, 5, 19.
17. Lönnberg, M., Carlsson, J. Lab-on-a-chip technology for determination of protein isoform profiles. *J. Chromatogr. A*, 2006, 1127, 175–182.
18. Liu, J., Chen, C.-F., Tsao, C.-W., Chang, C.-C., Chu, C.-C., DeVoe, D. L. Polymer microchips integrating solid-phase extraction and high-performance liquid chromatography using reversed-phase polymethacrylate monoliths. *Anal. Chem.*, 2009, 81, 2545–2554.

19. Wang, X.-L., Zhu, Y., Fang, Q. Valveless gated injection for microfluidic chip-based liquid chromatography system with polymer monolithic column. *J. Chromatogr. A*, 2012, 1246, 123–128.
20. Wouters, B., De Vos, J., Desmet, G., Terryn, H., Schoenmakers, P. J., Eeltink, S. Design of a microfluidic device for comprehensive spatial two-dimensional liquid chromatography. *J. Sep. Sci.*, 2015, 38, 1123–1129.
21. Gupta, V., Talebi, M., Deverell, J., Sandron, S., Nesterenko, P. N., Heery, B., Thompson, F., Beirne, S., Wallace, G. G., Paull, B. 3D printed titanium micro-bore columns containing polymer monoliths for reversed-phase liquid chromatography. *Anal. Chim. Acta*, 2016, 910, 84–94.
22. Gupta, V., Beirne, S., Nesterenko, P. N., Paull, B. Investigating the effect of column geometry on separation efficiency using 3D printed liquid chromatographic columns containing polymer monolithic phases. *Anal. Chem.*, 2018, 90, 1186–1194.
23. Knox, J. H. Band dispersion in chromatography – a new view of A-term dispersion. *J. Chromatogr. A*, 1999, 831, 3–15.
24. He, B., Tait, N., Regnier, F. Fabrication of nanocolumns for liquid chromatography. *Anal. Chem.*, 1998, 70, 3790–3797.
25. De Malsche, W., Eghbali, H., Clicq, D., Vangelooen, J., Gardeniers, H., Desmet, G. Pressure-driven reverse-phase liquid chromatography separations in ordered nonporous pillar array columns. *Anal. Chem.*, 2007, 79, 5915–5926.
26. Song, Y., Takatsuki, K., Isokawa, M., Sekiguchi, T., Mizuno, J., Funatsu, T., Shoji, S., Tsunoda, M. Fast and quantitative analysis of branched-chain amino acids in biological samples using a pillar array column. *Anal. Bioanal. Chem.*, 2013, 405, 7993–7999.
27. Song, Y., Takatsuki, K., Sekiguchi, T., Funatsu, T., Shoji, S., Tsunoda, M. Rapid quantitative method for the detection of phenylalanine and tyrosine in human plasma using pillar array columns and gradient elution. *Amino Acids*, 2016, 48, 1731–1735.
28. Fujiwara, T., Funatsu, T., Tsunoda, M. Fast analysis using pillar array columns: Quantification of branched-chain α -keto acids in human plasma samples. *J. Pharm. Biomed. Anal.*, 2021, 198, 114019.
29. Kuroki, H., Koyama, H., Nakatani, Y., Funatsu, T., Horiike, S., Tsunoda, M. Development of an automated sample injection system for pillar array columns. *Chromatography*, 2021, 41, 59–62.
30. Isokawa, M., Takatsuki, K., Song, Y., Shih, K., Nakanishi, K., Xie, Z., Yoon, D. H., Sekiguchi, T., Funatsu, T., Shoji, S., et al. Liquid chromatography chip with low-dispersion and low-pressure-drop turn structure utilizing a distribution-controlled pillar array. *Anal. Chem.*, 2016, 88, 6485–6491.
31. Song, Y., Noguchi, M., Takatsuki, K., Sekiguchi, T., Mizuno, J., Funatsu, T., Shoji, S., Tsunoda, M. Integration of pillar array columns into a gradient elution system for pressure-driven liquid chromatography. *Anal. Chem.*, 2012, 84, 4739–4745.
32. De Malsche, W., Clicq, D., Verdoold, V., Gzil, P., Desmet, G. Integration of porous layers in ordered pillar arrays for liquid chromatography. *Lab Chip*, 2007, 7, 1705–1711.
33. Detobel, F., De Bruyne, S., Vangelooen, J., De Malsche, W., Aerts, T., Terryn, H., Gardeniers, H., Eeltink, S., Desmet, G. Fabrication and chromatographic performance of porous-shell pillar-array columns. *Anal. Chem.*, 2010, 82, 7208–7217.

34. Fonverne, A., Ricoul, F., Demesmay, C., Delattre, C., Fournier, A., Dijon, J., Vinet, F. *In situ* synthesized carbon nanotubes as a new nanostructured stationary phase for microfabricated liquid chromatographic column. *Sens. Actuators B*, 2008, 129, 510–517.
35. Müller, J. B., Geyer, P. E., Colaço, A. R., Treit, P. V., Strauss, M. T., Oroshi, M., Doll, S., Winter, S. V., Bader, J. M., Köhler, N., et al. The proteome landscape of the kingdoms of life. *Nature*, 2020, 582, 592–596.
36. Cho, B. G., Jiang, P., Goli, M., Gautam, S., Mechref, Y. Using micro pillar array columns (μ PAC) for the analysis of permethylated glycans. *Analyst*, 2021, 146, 4374–4383.

Chapter 52

Studying Metabolism with Multi-Organ Chips: New Tools for Disease Modelling, Pharmacokinetics and Pharmacodynamics

Tanvi Shroff, MSc,^{a,b} Kehinde Aina, MSc,^c Christian Maass, PhD,^d
Madalena Cipriano, PhD,^b Joeri Lambrecht, PhD,^e Frank Tacke, MD, PhD,^c
Alexander Mosig, PhD,^c and Peter Loskill, PhD^{a,b,f}

^aNMI Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany

^bDepartment for Microphysiological Systems, Institute for Biomedical Engineering,
Faculty of Medicine, Eberhard Karls University Tübingen, Tübingen, Germany

^cInstitute of Biochemistry II, Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany

^desqLABS GmbH, Saterland, Germany

^eDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin,
Campus Virchow Klinikum and Campus Charité Mitte, Berlin, Germany

^f3R-Center for In vitro Models and Alternatives to Animal Testing,
Eberhard Karls University Tübingen, Tübingen, Germany

alexander.mosig@med.uni-jena.de, peter.loskill@uni-tuebingen.de

Keywords: adiponectin (APN), glycolysis, adsorption, distribution, metabolism, excretion and toxicity (ADMET), adverse outcome pathway (AOP), asthma, autocrine, biomarker, cyclic olefin copolymer (COC), drug metabolism, fatty acid oxidation, free fatty acids (FFAs), gluconeogenesis, hepatocytes, homeostasis, human-on-a-chip, hydrocortisone (HC), *in silico* models, *in situ* readout, *in vitro* to *in vivo* extrapolation (IVIVE), *in vitro-in vivo* translation (IVIVT), induced pluripotent stem cells (iPSCs), inflammatory bowel disease, kidney-injury marker (KIM-1), liver disease, metabolic disease, metabolic regulation, microfabrication, microfluidics, microphysiological system (MPS), multi-analyte biosensor, multi-organ chip (MOC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), organ crosstalk, organ-on-chip (OoC), paracrine, pharmacodynamics (PD), pharmacokinetics (PK), physiologically based PK-PD (PBPK-PD), polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), quantitative systems pharmacology (QSP), reactive oxygen species, signaling pathways, tricarboxylic acid (TCA), type 2 diabetes mellitus (T2D), vasculature-like perfusion

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

52.1 Introduction

Metabolism consists of three categories of life-supporting functions [1]. The first involves the biochemical events across tissues that generate or consume energy to maintain homeostasis. The second involves the production of building blocks such as proteins and lipids from food, to support body functions. The final aspect of metabolism involves the elimination of metabolic waste and xenobiotics. The primary organs involved in metabolism include the gut, liver, adipose tissue, pancreas, kidney and muscles. During metabolic regulation, these organs interact through different signalling pathways elicited by hormones and morphogens, providing the body with the appropriate amount of energy it needs. Immune-related processes also affect metabolic function through multiple mechanisms [2].

Metabolism is regulated by complex signalling pathways that centrally involve hormones such as insulin and glucagon secreted by the pancreas, provoking effects in energy-consuming organs including the muscle, liver and adipose tissue. The secretion of these signalling molecules differs with glucose availability, which regulates the adaptive metabolic response. Dysfunction of metabolism has been linked to the onset of a variety of diseases caused by disturbance of homeostatic mechanisms required to maintain proper cell function.

52.1.1 Types of Metabolism

Carbohydrate metabolism is closely regulated by insulin and glucagon, both of which are secreted by the pancreas. When glucose-containing meals are ingested, the pancreas secretes insulin, leading to elevated glucose uptake by the muscles and liver; under fasting conditions, the pancreas secretes glucagon, promoting glucose metabolism from stored glycogen. This regulation forms the basis of glucose metabolism. Stored lactate is a hydroxycarboxylic acid produced from glucose by glycolysis or the pentose phosphate pathway or by the transamination of alanine. Monocarboxylate transporter 4 is responsible for the secretion of lactate from cells. While exercising or during a state of starvation, lactate becomes a precursor for gluconeogenesis [3]. Lipid metabolism involves the uptake and release of free fatty acids (FFAs) into the circulation, mediated by pathways involved in signalling with adipose tissue. Adipokines, secreted by adipose tissue, have been implicated in the progression of insulin resistance during obesity. Lipids make up many key cell components but the dysregulation of lipid metabolic pathways leads to intracellular lipid deposition and functional dysregulation of cells [4]. Protein metabolism is influenced by various factors such as food, hormones, inflammatory stimuli and age. Some hormones have catabolic effects (glucagon, glucocorticoids and catecholamines), others have anabolic effects (insulin, insulin-like growth factor 1 and growth hormone) and the effects of some are unknown [5]. Essential amino acids are consumed in the diet and subsequently acted upon by branched chain amino acid transferase, after which they undergo a series of transformations to finally become products that get

rerouted to the tricarboxylic acid (TCA) cycle, like succinyl CoA, *etc.* Valine is glucogenic; isoleucine is glucogenic and ketogenic while leucine is ketogenic. Protein synthesis and protein breakdown determine the homeostasis of proteins in the body [6]. Drug biotransformation refers to the process by which xenobiotics are enzymatically converted to make them readily excretable and to eliminate pharmacological activity [7]. This mainly involves changes to the drug iso-form or addition of functional groups, making the parent drug molecule more hydrophilic and prone to elimination. The liver is one of the key organs where drug metabolism occurs, closely followed by the intestine and kidneys and other organs to a lesser degree (e.g., heart, blood, skin and brain). Drug-metabolizing enzymes can be classified into two phases (phase 1 and phase 2) depending on the type of metabolism they carry out.

52.1.2 Physiology of Inter-Organ Communication and the Disruption of Metabolic Pathways

Metabolism involves harmonious signalling between multiple organs and, depending upon the type of metabolism to be studied, it is imperative to understand the physiology of organ interactions. Human metabolism involves multiple organs and specialized tissues to digest, store and retrieve energy from nutrition. One of the central metabolizing organs is the liver. The broad range of different biotransformation processes is mainly executed by hepatocytes. Liver parenchymal cells (i.e., hepatocytes and cholangiocytes) are surrounded by a network of non-parenchymal cells (e.g., liver macrophages (Kupffer cells), sinusoidal endothelial cells and hepatic stellate cells) in the hepatic sinusoid that contribute to and regulate metabolic activities and immunological responses. Depending on their localization in periportal, mid- and pericentral zones of the hepatic lobules, hepatocytes are exposed to various biophysical and biochemical cues. The liver and the adipose tissue are specialized organs for storing energy. Adipose tissue makes up 20–50% of body weight and functions as a storage organ for fatty acids in addition to being a powerful endocrine organ. There is evidence that the visceral fat influences metabolism via the secretion of adipokines and FFAs [8]. Skeletal muscle tissue represents the most abundant muscle type in the human body and constitutes about 40–45% of total body weight, but 70–80% of cell mass. Besides providing mechanical forces for movement, muscle tissue also serves as an energy depot. It is a vital storage site for proteins and free amino acids, which represent a major source for generating glucose through gluconeogenesis to ensure a glucose supply for the brain during starvation. The pancreas is a compound gland that discharges digestive enzymes into the gut and secretes the hormones insulin and glucagon, which play important roles in glucose metabolism, into the bloodstream. These two hormones influence the rate of glucose breakdown in the body [9]. The small intestine covers a considerable length and is one of the first sites of absorption of nutrients and xenobiotics into the bloodstream [10]. The intestinal epithelial cells have a large surface area

for absorption and metabolism, and the ability to regenerate, thus maintaining intestinal function. The presence of immune cells and the gut microbiota contributes significantly to the intestine's metabolizing capabilities [11].

The various metabolizing organs in our body interact synchronously to maintain homeostasis. The liver and adipose tissue are the vital metabolic organs necessary for energy utilization and storage. Both organs interact for the regulation of the metabolism of lipid and glucose by secreting various growth factors with a vast range of metabolic regulatory effects, including fibroblast growth factor 21, adiponectin (APN) and the pro-inflammatory factors adipose fatty acid-binding protein-4 and lipocalin-2 [12]. The pancreatic islets of Langerhans are endocrine structures distributed throughout the exocrine portion of the pancreas. They consist of five distinct cell types: α cells (secreting glucagon), β cells (insulin), γ /PP cells (pancreatic polypeptide), δ cells (somatostatin) and ϵ cells (ghrelin). In the liver, insulin plays a major role in glycogen synthesis and inhibits glycogen breakdown. Additionally, it regulates glycolysis and inhibits gluconeogenesis, which influences glucose metabolism. Insulin also performs different anabolic functions in the liver, stimulating lipid synthesis and release and protein synthesis and inhibiting the breakdown of these substances [13]. Skeletal muscles secrete myokines and peptides that can perform autocrine, paracrine and endocrine actions. Exercise contributes to their release and is shown to produce adipocyte browning. Myonectin is involved in fatty acid uptake and oxidation in adipose tissue and liver. Insulin resistance in the skeletal muscle changes the expression of these myokines and influences fatty acid metabolism in the body [14]. Myokines counteract the effects of adipokines. Myostatin is one such myokine and is important for the maintenance of metabolic homeostasis and in regulating the size and function of adipose tissue. Interleukin 6 (IL-6) is secreted into the bloodstream in response to muscle contractions during exercise, not because of immune responses in this state [15]. IL-6 is also hypothesized to increase fatty acid oxidation through AMP-activated protein kinase and is responsible for glucose production during exercise but might worsen insulin resistance between liver and adipose tissue.

Adipose tissue has revealed itself as a major endocrine regulator, impacting the metabolic balance in the body and hence leading to numerous pathophysiologies downstream. The link between obesity and the metabolic syndrome is critically dependent on the distribution of body fat. Clinical data show that abdominal obesity is more strongly associated with the development of the metabolic syndrome than peripheral body fat distribution, proving the critical role of visceral fat in the development of metabolic diseases. Obese adipose tissue secretes adipokines, thereby causing damage to pancreatic β cells [16]. Thus, the crosstalk between pancreatic adipocytes and islets is defined by the metabolic status, which in turn regulates the secretion of adipocytes and islet activity and, therefore, the paracrine effects. Adipocytes secrete leptin and APN. Leptin is a peptide that is produced by mature adipocytes and that acts mainly on the central nervous system. Leptin release is regulated by cross-communication of fat tissue,

brain and bone and acts on the β cells of the pancreas by negatively regulating pancreatic β cell function and cell mass [17, 18]. However, some of the endocrine actions of leptin on β cells are not mediated via its receptors on β cells. Leptin regulates bone metabolism, which demonstrates that bone may exert feedback control on β -cell function [19]. APN target organs include the liver, where the hormone counteracts gluconeogenesis; the skeletal muscle, where it stimulates oxidation of fatty acids; and the brain, where it ensures a continuous energy supply [20]. Under diseased conditions, adipokines, pro-inflammatory cytokines, FFAs and other substances are released by adipose tissue, thereby contributing to a hepatic acute-phase response. The secreted pro-inflammatory cytokines stimulate liver resident macrophages (Kupffer cells), which mediate inflammation that interferes with the secretion of regulatory factors of lipid and glucose metabolism. This pathophysiological effect is thought to be causative for the observed association between dysregulation in lipid and glucose metabolism and deregulation of metabolic signalling pathways in gluco-metabolic diseases [21].

Immuno-metabolism represents a key mechanism central to innate and adaptive immune regulations. Early studies identified inflammatory cytokines secreted in obese adipose tissue as drivers of metabolic disease by initiating the crosstalk between immune cells and metabolism, resulting in aggravation of the inflammatory loop [22, 23]. Metabolic pathways are intricately linked to cell signalling and differentiation, giving rise to different immune cell subsets that adapt in response to biochemical and biophysical cues of their micro-environments, inducing unique metabolic fates.

52.1.3 Non-Clinical Models to Study Metabolism

Metabolism has been intensively studied in various *in vitro* models, including precision-cut tissue slices as well as cell lines and primary cells that could be genetically engineered for the expression of specific enzymes [24]. Advanced *in vitro* systems such as three-dimensional cultures and organ-on-chip (OoC) systems could present advantages for metabolism-based studies, in being able to isolate certain pathways and study disease pathophysiology. Organs-on-chips recreating specific organotypic functions can enable the understanding of the development of a certain disease pathophysiology through the lens of one specific target organ for a specific donor [25]. Furthermore, they can be specifically tailored to study a specific organ function by integrating non-parenchymal cells that improve the physiological relevance of the organ model [26]. On one hand, single-organ chips could serve as a framework to identify vital biological mechanisms such as disease progression and immune-organ interactions to identify key biological pathways and new targets for drug testing. This leads to the next application of organ chips to test drug efficacy and metabolism in target organs at the pre-clinical development stage, thus providing a reliable data source for clinical trials [27].

To study the full range of inter-organ interactions and identify potential toxicity of drugs and metabolites, two-dimensional cultures and animal models are widely used in biomedical research and drug development. However, these models are limited in physiological relevance and often differ significantly in (drug) metabolism from humans. Systemic studies have so far mostly been performed by use of *in vivo* models, i.e., rodent models, which show considerable interspecies variability in metabolic specificity, hormone regulation and thermal biology [28, 29]. Two-dimensional models lack the complexity of the three-dimensional tissue microenvironment and the important crosstalk between different cell types and the extracellular matrix. Studies involving animals are often challenging to extrapolate to humans as different animal species give conflicting results, e.g., on drug toxicity. *In vitro* models that are able to recapitulate the crosstalk between metabolic tissues would be a major step forward for metabolism-associated research. Especially to model metabolic diseases, complex bioengineered three-dimensional model systems that are physiologically representative of the tissue microenvironment are urgently required [30]. Although the systemic clinical manifestation of metabolic disease cannot be fully recapitulated in a single tissue or organ model, understanding the basic processes can still show useful information about the whole disease mechanism. To model the spatio-temporal dynamic processes in the human body and disease pathogenesis, integration of these three-dimensional models by linking multiple organs together with functional vasculature will be crucial.

OoC systems belong to a new wave of *in vitro* models, which have the potential to better recapitulate metabolic physiology *in vitro* by allowing reliable control of cellular, biochemical and biophysical cues in a precise and accurate manner [31, 32]. This highly interdisciplinary technology combines microfabrication techniques, tissue engineering and (stem) cell biology to create perfused species-specific *in vitro* models to answer specific scientific questions related to disease mechanisms or drug response [33]. The underlying technological concept of microfluidics paves the way for the linkage of individual organ models by connecting perfused microchannels. Further applying mathematical modelling principles to the data from multi-organ chips (MOCs) will enable the generation of predictive *in silico* models that could predict human-scale metabolic responses.

In this chapter, we comprehensively review MOC models relevant for metabolism research towards clinically relevant predictions of disease progression, and pharmacokinetics and pharmacodynamics (PK-PD; Fig. 52.1). We introduce the technical aspects of MOC design and strategies to correlate MOC data to predict *in vivo* outcomes, as well as further discuss specific application of OoCs in disease modelling, applications for mechanistic studies in ADMET and quantitative PK-PD modelling.



Figure 52.1 Schematic overview of the focus of this review—the study of metabolism spans many organs via various pathways. MOCs coupled with *in silico* models provide a strong platform in the prediction of disease progression, PK and PD.

52.2 Concepts for Linking Multi-Organ Chips

Single-organ chips enable the study of organ-specific questions [34–36]. These include organ-specific PK aspects such as absorption in the gut, partitioning of the drug into adipose tissue, liver metabolism of the drug or excretion of the drug in the kidney. They also enable the study of disease mechanisms triggered in different organs, such as inflammatory bowel disease, asthma or liver disease [36–38]. Complex (patho)physiological processes can be captured by models integrating organ-specific extracellular matrix, multiple cell types or aspects of the immune system. The interconnection of OoCs to MOCs presents the opportunity to investigate organ crosstalk and address questions in a highly controlled manner, on a systemic level that can be compared with animal experimentation. Individual OoCs have metabolic attributes and can interact with each other and exchange substances via microchannel systems. Compared with the isolated culture of individual organ models, the organotypic functions in MOCs could be improved by their close interaction with other organs. To link multiple organ models, complex connection strategies are required. This section provides an overview of connection approaches. For more specific reviews of technical design, the reader is referred to additional literature focusing on designing organ chips, connection strategies for multiple organ models and approaches for appropriate organ scaling [39–41].

A physiologically relevant connection strategy of OoCs involves organ communication via simulated vasculature structures. This can be achieved by enabling flow of medium from one tissue chamber to another via a common fluidic channel. A monolayer of endothelial cells lining the connection channel

could further allow for physiological exchange of signalling molecules across the endothelial barrier. Connections can be built into one single chip, where compartments for various tissues with a fixed cell ratio are perfused with a common cell medium flowing through fluidic channels built directly into the chip [42]. Since each tissue requires a different microenvironment, interconnected OoCs can be limited in terms of design flexibility [43, 44]. Modular connections enable the culture of organ chips separately until the tissue is fully formed. Tissue models can be linked in a modular and flexible fashion. This type of system has several detachable parts and, hence, a higher likelihood of leaks, but provides a high degree of flexibility, allowing, for example, the insertion of sensors into the modular connection. Some examples of this methodology include Lego-inspired capillary connectors [45, 46], insert-based connectors [47], three-dimensional bioreactors connected via tubing [48] or magnetic snap-fit connection systems [49]. In the case of fluidic interfaces, multiple chips can be plugged into a common interface with one inlet and outlet, while the chips are connected to each other via the fluidics built into the interface. The MOC designer is, however, restricted to the dimensions of the fluidic interface in terms of locating ports to connect the chip to the interface. This system makes it easier for automation and robotic handling owing to the fixed spatial arrangement of sampling ports, as demonstrated by Novak et al. [50].

A variety of perfusion approaches exist to flow media through MoCs. Passive flow represents an approach to using gravitational hydrostatic pressure difference, or surface tension to guide flow through channels [41]. This perfusion approach allows direct access to reservoirs at the inlet and outlet for medium change or effluent collection. The passive flow is usually created by rocking the devices back and forth [51]. Syringe or peristaltic pumps as well as centrifugal or pneumatic systems are able to create active, mechanically driven perfusion of medium. Syringe and peristaltic systems require the use of tubing, leading to a larger dead volume than passive flow and a higher tendency of leakage and bubble formation [52]. Syringe pumping is commonly used to circulate fresh medium in a unidirectional manner, allowing for the study of downstream effects of individual OoCs. Peristaltic pumping allows the recirculation of medium or mixing of recirculated and fresh media in a controlled ratio [53]. Centrifugal force represents a novel, innovative method that uses a spinning mechanism to perfuse medium and allows for the control of flow rates by regulation of the rotation speed [54]. Pneumatic pressure flow does not require the use of tubing and thus reduces the amount of required medium volume. However, these systems rely on gas supply channels to drive medium flow by membranes and need to be airtight in order to prevent pressure imbalance causing unpredicted detrimental flow conditions [55]. Electromagnetic actuators enable automated flow control for unidirectional or recirculating flow [56, 57]. A more detailed overview of pumping approaches for an OoC platform is provided in a recent review by Byun et al. [58].

During the prototyping phase, the choice of material of construction of MOCs depends on the scientific application of the organ chips and scale of operation. Polydimethylsiloxane (PDMS) is gas permeable and ensures that the medium is saturated with gases at the same rate as the environment around it. Rigid plastics such as polymethyl methacrylate (PMMA) or cyclic olefin copolymer (COC) allow for locally tunable gas concentrations around the tissue depending upon the requirements of the study (e.g., anaerobic microbes in the gut or oxygen-dependent zonation in the liver) [59, 60]. The absorption and adsorption of small molecules into the material of construction of the MOC must be monitored in order to ensure adequate dose exposures to the tissues for PK and PD studies [61].

An optimized combination medium is essential to ensure the proper functional state of each tissue in the MOC. This was demonstrated in a four-organ system by Oleaga et al. [62], who connected functional cardiac, neuronal, muscle and liver modules over an extended time period of 14 days via vascular perfusion of a common medium. Liver function was confirmed via albumin and urea production, cardiac and skeletal microtissue function was assessed in their contractile response to broad-field electrical stimulation and neuronal function was analyzed using patch clamp electrophysiology. The integrated modules were exposed to drugs with known side effects for 7 days to show correlation with published human and animal data. The authors also attempted to investigate animal serum-free medium to ensure better control over MOC culture conditions [62]. In a similar approach, Miller & Shuler [43] presented a 14-organ MOC which remained functional over a 7-day period and was perfused via gravity-driven flow. While these systems lacked an endothelial barrier layer across which nutrient exchange could take place, they provide insights into functional MOCs with common circulating media.

To monitor metabolic activity in MOCs, the effluent or perfused medium is typically analyzed outside the chip. A number of approaches, however, integrate in-line sensors, which can be used for *in situ* readout of metabolic function [63]. An interesting development is the integration of enzyme-based multi-analyte biosensors into a multi-tissue culture platform for MOC application. Misun et al. [64] developed a multi-tissue platform with integrated sensors for lactate metabolism. The sensor modules were designed as small glass plug-ins featuring platinum working electrodes, coupled with oxidase enzymes to allow continuous measurement of lactate and glucose. The biosensors recorded high sensitivities of $443 \pm 37 \text{ nA mM}^{-1} \text{ mm}^{-2}$ for lactate; the corresponding limits of detection were below $10 \text{ }\mu\text{MT}$. The model enabled tissue-size-dependent, real-time measurement of lactate secretion from the three-dimensional microtissues cultured in a hanging drop configuration [64]. Gliberman et al. [65] demonstrated a high-throughput pancreatic islet capture chip with in-line insulin sensing during glucose-stimulated insulin secretion experiments. Taken together, the use of integrated sensors for glucose, ammonia, insulin, oxygen [66] and reactive oxygen species [67], among others, will allow for in-line data acquisition that can support *in silico* modelling. That being said, in-line sensing

is still an important challenge for the field, owing to the limited number of analytes, sensor robustness and fabrication limitations.

52.3 Multi-Organ Chips to Study Metabolism

This section provides an overview of the literature involving MOCs that study the four previously described types of metabolism—carbohydrate, lipid, protein and drug metabolism (Fig. 52.2).

Lee et al. [69] designed a three-organ chip system of pancreas, muscle and liver models to mimic glucose metabolism and homeostasis. An *in silico* model of glucose metabolism was developed for the quantification of glucose uptake based on experimental data obtained from the MOC. The organs were allometrically scaled with respect to each other, and the flow rates were calculated based on physiological residence time of blood in each organ chamber [69]. The usage of automated robotic systems to study metabolism in multiple organ models has recently been proposed by Novak et al. [50]. The robotic interrogator maintained the viability and organ-specific functions of eight vascularized, two-channel organ chips (intestine, liver, kidney, heart, lung, skin, blood–brain barrier and brain) for three weeks in culture. The robotic interrogator and a physiological multi-compartmental model of the experimental system was used to quantitatively predict the glucose metabolism and distribution of an inulin tracer, a complex sugar, perfused through the platform [50]. Bauer et al. [70] presented a pancreas–liver MOC which allowed for the co-culture of human pancreatic islet microtissues and liver spheroids in an insulin-free medium. Similar to *in vivo*, hepatocytes take up glucose at a low level in the absence of insulin. Upon exposure to glucose, insulin was released by pancreatic islet microtissues, which stimulated an increased glucose uptake by liver spheroids. As the glucose concentration decreased, insulin secretion subsided, showing an efficient feedback loop between the liver and the insulin-secreting islet microtissues [70]. Glucose metabolism was also studied in another MOC integrating hepatocytes, adipose tissue and endothelial cells. This platform sustained glucose and fatty acid homeostasis *in vitro* over a period of 72 h. Afterwards, it was challenged with insulin and high glucose concentrations to mimic hyperglycemia, and the ability to retain or restore physiological circulating glucose concentrations in response to insulin was investigated to determine the effects of these conditions on other metabolites involved in glucose and lipid metabolism. The authors demonstrated the impact of high glucose levels and their significant effects on the metabolic profile and insulin response [68]. In a follow-up study by the same group, two different scaling models were implemented in a hepatocyte–endothelial model—one based on cell numbers and the other based on metabolic rates and cell surface areas. An analysis of the metabolic response of the two configurations showed varying glucose and lipid balance, with the cell number-based scaling model displaying higher glucose consumption per hepatocyte and higher functional activity per cell than the metabolic rate-based scaling model [75].




Figure 52.2 MOCs to study the various types of metabolism. Carbohydrate metabolism—(a) a three-way connected organ system featuring adipose, liver and vascular tissue (adapted from [68] (CC BY 4.0)), (b) a connected pancreas–muscle tissue model to study insulin-dependent glucose uptake (adapted from [69] with permission from Wiley Periodicals, Inc.) and (c) a model connecting pancreatic islets and liver spheroids to study insulin signalling between the cell types (reprinted from [70] (CC BY 4.0)). Lipid metabolism—(d) the study of cholesterol dysregulation using a gut–liver–on–chip model (adapted from [71] with permission from 2021 the American Chemical Society). Protein metabolism—(e) connected gut–liver–cardiac system for the study of protein metabolism (adapted from [72] (CC BY 4.0)). Drug metabolism—(f) a neurotoxicity study involving the interaction between liver and neurospheres (reprinted from [73] with permission from Elsevier) and (g) accumulation, distribution and toxicity in a liver–fat–lung–on–chip system (adapted from [74] (CC BY 4.0)).

In another system reflecting gut–liver–vascular interaction, Duan et al. [71] tested the hypothesis of fine particulate matter (PM_{2.5}) influencing lipid metabolism. The main forms of exposure that were tested included gut to liver and liver to gut, highlighting oral and systemic delivery, respectively. In both cases, the PM_{2.5} particles were able to infiltrate the liver and gut cells and contribute to dysregulation of the cholesterol pathway in the liver first, followed by a dysregulation of the bile acid metabolism in the liver and gut [71].

Carbohydrate and protein metabolism was captured in a study by Maass et al. [72], who monitored gut, liver and cardiac OoCs over a period of one week in order to gauge nutrient consumption and metabolic profiles. Starting with the long-term assessment of the gut microphysiological system (MPS), the study was extended to a computational model of the gut, liver and heart MOC, highlighting the importance of understanding the metabolic needs of the individual OoCs not just from the perspective of carbohydrate metabolism but also from the perspective of metabolism of other species such as proteins [72].

For many years now, increased lactate levels have been consistently associated with morbidity and mortality in a wide range of metabolic disease states. To measure lactate consumption, a co-culture of human artificial liver microtissues and human neurospheres were exposed to fluid flow over two weeks in a multi-organ platform. Daily monitoring of lactate dehydrogenase (LDH) activity measurements in the medium and immunofluorescence endpoint staining showed the viability of the tissues and the preservation of differentiated cell phenotypes. Moreover, the lactate production and glucose consumption values of the tissues cultured indicated that a stable steady state was achieved after 6 days of co-cultivation. Toxicity testing was performed with the exposure of the system to the neurotoxin 2,5-hexanedione, which showed that the MOC responded with increased LDH release compared with the individual tissue cultures [73].

In a publication by Viravaidya and Shuler [74], a micro-scale cell culture analogue device was used to study drug metabolism. Their four-organ MOC captured physiologically based PK in a rat model on a microfluidic chip, highlighting drug toxicity, bioaccumulation and distribution [74].

52.4 Applications of Metabolism-Focused Multi-Organ Chips

The previous chapters covered the fundamentals related to setting up MOCs to study a specific type of metabolism, along with some examples of state-of-the-art MOCs used to study metabolism. This section highlights case studies where the MOCs were applied towards two main areas—metabolic disease modelling and ADME/PD.

52.4.1 Metabolic Liver Disease Modelling

Metabolic diseases represent a spectrum of disorders ranging from obesity, coronary artery disease, cardiovascular diseases, non-alcoholic fatty liver disease

(NAFLD) and type 2 diabetes. Owing to an ageing population and the rise of obesity, this disease spectrum belongs to one of the fastest growing epidemics globally [76]. The pathophysiology of metabolic diseases is multifactorial and complex, with an increased incidence in industrialized countries because of the numerous environmental and genetic factors. NAFLD represents the most common chronic hepatic disorder in which fat is deposited in the hepatocytes. Metabolic injury to hepatocytes can lead to non-alcoholic steatohepatitis (NASH), which can result in liver fibrosis and cirrhosis. Although recent findings identified liver inflammation and toxic accumulation of lipids as the main molecular drivers for disease progression, it is not clear whether NASH develops sequentially based on fatty liver formation or whether it is a *de novo* event in a lipotoxic environment [77].

Developing new approaches to prevent or treat these diseases requires an understanding of the molecular mechanisms and signalling pathways that contribute to the disease. Although great progress has been made through genome-wide association studies in the identification of genetic variants or loci which play a part in metabolic diseases, the challenge remains to unravel the molecular mechanisms through which these genes contribute to pathophysiology. Animal models have been used to recapitulate metabolic diseases, but interspecies differences make it difficult to fully mimic human pathophysiology in clinical findings [78]. Furthermore, high failure rates have been observed, when efficacious concepts from pre-clinical testing were tested in clinical trials in patients, in which most of these drugs failed to provide convincing data regarding efficacy [79].

Here, we highlight what has been learnt from different models in which multi-tissue interaction has been shown to impact metabolic disease phenotype, with a focus on NAFLD and diabetes using MOC platforms.

52.4.1.1 Multi-organ chips towards modelling non-alcoholic fatty liver disease

In a recent study by Yang et al. [80], a gut–liver-on-a-chip platform was created to study the initiation and progression of NAFLD. Microscopic high-content analysis and mRNA sequencing was combined to study the crosstalk between the gut and liver in the context of NAFLD. More so, NAFLD-induced FFA build-up was observed in the liver cells, alongside upregulated gene expressions linked with retinol metabolism and glucuronidation. Furthermore, accumulation of intracellular lipid droplets in the FFA-treated liver cells and gene expression patterns in relation to cellular endoplasmic reticulum stress was observed [80].

FFA uptake in the liver with subsequent lipid deposition in a liver model was also studied by Lee & Sung [81] to investigate processes of lipid absorption and induction of hepatic steatosis. In this model, anti-steatotic compounds mediated an improvement in a dysfunctional gut barrier and were able to ameliorate hepatic steatosis. By contrast, tumour necrosis factor α (TNF- α) treatment induced the progression of hepatic steatosis owing to compromised gut barrier function [81].

Further, Hughes and colleagues [82] established a combined gut–liver model to mimic NAFLD. In this study, the gut cultures were susceptible to inflammatory stimuli that decreased gut integrity, a similar process known to occur *in vivo* during NASH [82].

Although these *in vitro* NASH models served as ideal tools to understand the basic mechanisms of human NASH, none of these models served as a useful tool for assessing the efficacy of novel anti-NASH therapeutic compounds against a wide range of targeted pathways. The utilization of these micro-physiological three-dimensional steatosis liver platforms in an MOC would enable the study of crosstalk with organs involved in the development of NAFLD and provide valuable insights into glucose homeostasis in a physiologically relevant scale. Other notable models proposed include the liver–pancreatic islet communication by InSphero AG to study NASH.

A major limitation of the above models is that several NAFLD-associated organs such as the pancreas, white adipose tissue and kidney are neglected. To address this, previously established OoC modules integrating adipose [83], pancreatic [84], kidney tissue [85] and hepatic tissue [86] could be linked together. Thus far, organ crosstalk via bacterial metabolites, exosomes, miRNA, *etc.* has not been mimicked. In order to study the impact of immune cell recruitment for disease progression, there is an added requirement of blood flow, cell sources from genetically diverse donors (e.g., PNPLA3, TM6SF2, MBOAT7, *etc.*) and bile acid recirculation (and modification by gut microbiota). Fibrosis as the main clinically relevant endpoint develops *in vivo* over years or decades and recapitulating this phenotype faithfully *in vitro* remains challenging. More scope for future study also relates to changes in bio-mechanics due to fibrosis and in identifying novel biomarkers to indicate the progression of NAFLD.

52.4.1.2 Multi-organ chips towards modelling diabetes

Type 2 diabetes mellitus (T2D) is often linked with a high incidence of hepatic comorbidities, e.g., NAFLD. It is still debatable whether NAFLD is a consequence or a cause of pancreatic disorders [87]. Understanding the mechanisms which lead to T2D is important in the search for novel molecular drug targets to prevent and control this disease. Although the development of pancreatic chip models to study diabetes is still in the early stages, different pancreas-on-chip platforms are incorporated as co-cultures with other cell types [70, 88]. A comprehensive overview of existing OoC models to study T2D research has been given by Rogal et al. [33].

Recently, a thermoplastic microfluidic-based pancreatic islet which automates islet loading and insulin sensing was used to deliver glucose pulses to positioned islets. Beyond glucose monitoring, the islets responded to other functionally relevant stimuli such as glucagon and amino acids. A perfusion with the suspension of human cadaveric islets confirms the capture of pancreatic islets in an automated manner with precise fluid control [65].

Zbinden et al. [84] recently developed an endocrine pancreas-on-chip model based on a tailored microfluidic approach, which allowed for self-guided entrapping of single human pseudo-islets. Human pseudo-islets were derived from the immortalized EndoC- β H3 cell line. This platform enabled precise control of vasculature-like perfusion, enabling prompt delivery of nutrients to the pseudo-islets and the excretion of metabolites. A unique addition is the incorporation of Raman spectroscopy to monitor the functionality of human pseudo-islets [84].

In another study, human pancreatic islet organoids generated from hiPSCs were perfused in a microfluidic platform. The islet organoids showed a similar tissue morphology and multi-tissue complexity mimicking human pancreatic islets *in vivo*. Moreover, the derived pancreatic organoids showed improved expression and maturation of β -cell-associated genes, insulin secretion and influx of calcium ions in response to glucose under dynamic culture conditions. This highlighted the role of biomimetic biophysical cues improving the islet organoid function and maturation, therefore serving as a promising tool for modelling diabetes *in vitro* and testing drugs for T2D therapy [89].

Substantial progress has been made in the development of multi-organ platforms emulating diabetes *in vitro*. Nguyen et al. [90] established an endocrine-on-chip system to model diabetes and to screen drugs for the treatment of diabetes by measuring insulin release over time. In this model, pancreatic and intestinal cells were co-cultured to quantify the effect of glucose on the release of glucagon-like peptide in the intestinal cells and insulin secretion from the pancreatic cell. In the study, glucose concentrations in response to different stimuli and change in the profiles of diabetes-associated genes were investigated. Despite the prospects that this model holds for diabetic therapy, a major limitation of this platform is the absence of a hepatic component, since T2D is often linked with hepatic comorbidities. Future platforms should incorporate liver cells to gain a better understanding of the multi-organ interplay in the disease process [90].

Mechanisms of T2D were further recapitulated in liver spheroids co-cultured with pancreatic islet microtissues to study liver–pancreas crosstalk, based on the regulation of glucose and insulin.

To assess the functionality of this model, the feedback loop between the liver and the insulin-secreting islet microtissues was recapitulated *in vitro*. The model served as a useful tool in understanding the mechanisms and comorbidities of T2D-associated diseases, including β -cell failure, insulin resistance, steatohepatitis and liver cirrhosis. However, the incorporation of other cell types such as white adipose tissue or kidney would be more metabolically representative [70].

Recently, the Leclerc group developed a pancreas–liver chip using rat islets and hepatocytes. The characteristic functions of the hepatocyte–islet co-culture model were evaluated and compared with monoculture conditions of the individual cell type. To assess pancreatic activity, the hepatocytes improved the islet response to hormonal cues as there was an increase in the secretion of insulin and changes

in the expression patterns of the genes involved in regulating insulin and glucagon balance [91].

52.4.2 Absorption, Distribution, Metabolism and Excretion/ Pharmacodynamics

Mechanistic toxicology is the identification and understanding of the cellular, biochemical and molecular mechanisms by which chemicals or drugs exert toxic effects. Mechanistic data are required to demonstrate adverse outcomes in risk assessment or to measure the relative toxic potential among the different species. In drug development, mechanistic studies are the key for repurposing studies of molecules that have an adequate PK profile (e.g., thalidomide).

MOCs allow for new perspectives in mechanistic toxicology that in the past could only have been addressed by animal or clinical studies. These platforms allow for the collection of data on biotransformation and the effect on target organs. They also allow for the simulation of kinetics in coordination with *in silico* data [92, 93]. The possibility to monitor the generation of bioactive metabolites and their effect and/or accumulation in off-target organs within the same MOC allows for the generation of complex human-relevant information before any *in vivo* study is performed. MOCs allow for designing ADMET studies that support mechanistic toxicology approaches because it is possible to use common *in vitro* toxicity methods such as cytotoxicity, cell viability and apoptosis, gene expression of metabolic enzymes and transporters, and combine them with non-invasive and clinically used toxicity biomarkers and advanced live imaging techniques. Additionally, diverse administration or exposure routes can be mimicked and compared, which could support future decisions on the ideal exposure route for a specific drug.

In the drug discovery process, the emergence of unexpected toxicity is often a problem resulting from a poor understanding of different drug metabolites. To assess the relevance of MOC for drug metabolism, several models have been developed. Materne et al. [73] presented a liver–neurosphere model which remained stable when connected, over a period of two weeks. The connected system seemed to be more sensitive to the neurotoxic drug 2,5-hexanedione than individual OoCs [73]. In a system reported by Wagner et al. [94], human liver microtissues and skin biopsies were studied for drug metabolism and inter-tissue crosstalk for up to 14 days of co-culture with troglitazone [94]. Maschmeyer et al. [95] reported a complex system, capturing the absorption aspect via small intestine and skin models, the metabolism aspect via the liver and excretion via a kidney-on-chip system. They showed stable culture for up to 28 days, with two streams of circulating media—one circulating nutrients across the four organs, and the other ensuring drainage of effluent from the kidney epithelial compartment [95].

In a human-on-a-chip platform comprising models of the brain, pancreas, liver, lung, heart, gut and endometrium, with a mixer channel for the systemic circulation of tolcapone, tolcapone metabolism was investigated by analyzing

the supernatants in the medium using mass spectrometry. In this study, 12 different metabolites were identified, three of which were novel. These metabolites showed that reduction, oxidation and conjugation reactions are significant routes of drug metabolism [96]. In another study, four tissues—liver, heart, muscle and neurons—were integrated as a functional unit. In this model, primary cells and hiPSC-derived cells were used in the system under perfusion for 14 days, after functional analysis of the readouts in the system, interchange of metabolites and signalling molecules were exhibited. Furthermore, heart rate, muscle contractility, neuro-electrophysiology and production of liver albumin and urea were quantified and assessed; this served as an accurate model for predicting metabolism in different human organs [62]. In a follow-up study, the effect of cyclophosphamide on hepatic metabolic function was assessed. In a liver–heart co-culture cyclophosphamide induced cardiotoxic effects only after metabolism. Interestingly, the toxicity in the heart could be significantly reduced for the initially cardiotoxic terfenadine through metabolization [97].

Furthermore, Lee-Montiel et al. [98] recently created a multi-organ system consisting of hiPSC-derived hepatocytes and cardiomyocytes to study the metabolic conversion of cisapride to non-arrhythmogenic norcisapride through cytochrome P450 enzyme. This cisapride metabolism led to arrhythmia in the cardiac model. The authors were able to show functional integration of these systems allowing drug–drug screening and testing for toxicity [98]. Rajan et al. [99] developed an integrated system to accommodate six tissue constructs including liver, cardiac, lung, endothelium, brain and testes organoids. The tissues were incubated for 14 days; they were able to show that the metabolism of ifosfamide in their liver organoid produced chloroacetaldehyde and induced neurotoxicity. The platform represents an expandable, multi-organoid body-on-a-chip system that can be used for flexible characterization of drug interactions *in vitro* in a modular approach combining different organoid models [99].

A multi-layered chip was also proposed by Li et al. [100] that included tissues recapitulating functions of the liver, tumour, breast, lung and gastric tract. The system was used to assess drug metabolism, drug efficacy and toxicity in different organ-specific cells in parallel. The biomimetic organs-on-a-chip model not only captured the primary and secondary metabolism of capecitabine in different organs, but also enhanced the characterization of drug metabolism in a dynamic manner and its bioactivity on different organs in a simple approach [100].

In all these models, basic aspects of *in vivo* crosstalk of metabolic drug activity, their efficacy, mode of action and potential toxicity of off-target effects, which is critical for therapeutic interventions, could be mimicked with two or three organs in an *in vitro* platform. Most of these studies emphasized the inclusion of the liver because of its crucial role in entero-hepatic circulation as a central metabolizing organ to adequately mimic drug metabolization.

Lin et al. [101] studied the metabolism and toxicity of ciclosporin A in a liver–kidney MOC for its chronic nephrotoxicity and its role as substrate and inhibitor of CYP3A4 and p-gp. A 14-day repeated-dose systemic administration of ciclosporin A in combination with rifampicin from day 6 onwards showed the modulation of the biotransformation by the second drug at the hepatic

level reducing mediated chronic nephrotoxicity. In this study, the authors used several clinical biomarkers for liver toxicity demonstrating the potential of MOC platforms for translational medical research [101].

The use of MOCs in mechanistic toxicology still faces numerous challenges, related to the confidence in the models, the perfusion settings, the selection of the 'universal medium', the inclusion of key components (endothelization and immune component) and the combination with systems biology approaches.

A recent assessment of the adoption of advanced cell culture systems (like OoCs) for toxicology studies and regulatory purposes revealed that model adoption depends on a detailed assessment of the model performance [102]. Ishida [103] defined the minimal requirements for systems mimicking the liver, small intestine and kidney epithelium covering cell culture properties such as transporter activity, membrane permeability and the capacity to withstand long-term culture. Cong et al. [104] reviewed the toxicity biomarkers already used in established single OoC systems covering hepatotoxicity, nephrotoxicity, cardiotoxicity and neurotoxicity. Indeed, the combination of physiological requirements and the use of translatable endpoints are essential for the application of MOCs in biomedical research, drug development and chemical toxicity [104].

A key consideration in the use of MOCs for ADMET studies is the perfusion system, which can be arranged as single pass or recirculating (reviewed in detail by Ronaldson-Bouchard et al. [105]). The use of complementary platforms that allow for both perfusion settings and the flexibility to test several directions of circulation would be beneficial to better answer questions related to bioactivation and positive or negative feedback responses. Also, the recapitulation of endothelial barrier functionality remains a challenge that should be addressed in future studies because of its relevance for systemic distribution and biotransformation of drugs in the 'first-pass' organ, the liver. Several single-organ chip models include an endothelial component but very few MOC models do. An initial approach of endothelization in a two-organ (liver and skin) model in 2015 enabled the evaluation of oral exposure with troglitazone to liver–intestine co-cultures as well systemic liver–skin co-cultures [106]. There exist other instances of ADMET studies being performed in MOCs [70, 95, 101, 107–110]; however, no ADMET study has been performed so far with the presence of the endothelial component. More recently, Ingber and colleagues described a quantitative PK study in a vascularized organ-chip, characterizing the data from a first-pass MOC model perfusing a universal blood substitute between endothelium-lined vascular channels [50, 111]: an arteriovenous reservoir enabled mimicry of drug distribution and dilution through the entire vasculature. The data compared closely with clinical data of cisplatin PK. This reinforces the importance of the commonly overlooked endothelial component contributing towards mitigating the challenge of a universal medium.

Most of the MOC publications addressing toxicological questions are focused on drug development [97, 104, 112]. Indeed, these cell culture platforms can provide valuable information in regard to chemical risk assessments here, but a significant need exists for replacing animal tests in (i) skin sensitization;

(ii) repeated-dose toxicity; (iii) carcinogenicity; (iv) reproductive toxicity; and (v) toxicokinetics and quantitative *in vitro*–*in vivo* extrapolation (qIVIVE). Replacing these five systemic toxicity testing schemes requires a deep understanding of the possible mechanism of toxicity and the animal experiment cannot be replaced by an *in vitro* or *in silico* method on a one-to-one basis. As recently discussed by Veening-Griffioen [113], ‘Tradition, not science, is the basis of animal model selection in translational and applied research’. MOCs and especially those combined with *in silico* modelling offer the possibility for a transition from current to future toxicology in safety science [114]. Also, the recent report from an EPAA Blue Sky Workshop suggested a workflow that allows for identification of suitable analogues for a target chemical and integration of toxicokinetic data to establish an acceptable level of exposure, or the incorporation of *in vitro* data to support the decision [115].

The contribution of MOCs for skin sensitization could be substantial. The general mechanisms of skin sensitization are well defined. A two-organ model with an immunocompetent skin chip [116] connected to a lymph node chip [117–119] allowing for topical exposure and for the perfusion of immune cells would suffice to quantify the four key events and adverse outcomes of the skin sensitization adverse outcome pathway (AOP) [120]. Carcinogenicity, especially of non-genotoxic chemicals, could be screened on MOCs combining the key administration and metabolism routes (e.g., gut, liver, skin and lung) connected to other key tissues when carcinogenesis is more likely to happen (e.g., pancreas, brain and kidney) and addressing the issues of metabolic activation of xenobiotics, causing immunosuppression or changes in cell death and proliferation at the tissue level [121]. The potential of using MOCs for repeated-dose toxicity comes hand in hand with carcinogenicity (recently reviewed by Yang et al. [122]). MOCs can be cultured under perfusion for many weeks and allow different combinations of organs that can be included to investigate their role on the toxicity and its molecular mechanisms. This is particularly important for *ab initio* studies of chemicals where other data and read-across methods do not provide sufficient information [115]. A current challenge in mechanistic toxicology is to bridge the data obtained from availability of advanced cell culture systems with systems biology (i.e., toxicogenomics) [123]. Addressing these challenges as well as the costs of these technologies will pave the way for merging MOCs with toxicogenomic approaches, high-content imaging as well as untargeted metabolomic approaches [124, 125] covering cell products as well as chemical- or drug-related metabolites. These would place MOCs as essential tools for animal-free chemical risk assessment of human hazards.

Integrating *in silico* models with data from MOCs would create a powerful predictive tool for *in vivo* drug response or disease development. Table 52.1 summarizes the MOCs mentioned above. In the next section, we outline the framework to set up *in silico* models and potential applications for *in vitro*–*in vivo* translation.

Table 52.1 Summary of MOCs with applications in disease modelling and ADMET

Application	Ref.	Organ models involved	Cell types	Drugs studied	Endpoints and assays performed
Disease modelling (NAFLD)	[80]	Gut, liver	Caco-2, HepG2	—	<ul style="list-style-type: none"> • microscopic high-content analysis • mRNA sequencing • gene expression
Disease modelling (hepatic steatosis)	[81]	Gut, liver	Caco-2, HepG2	Turofexorate isopropyl (XL-335), metformin	<ul style="list-style-type: none"> • cell viability • permeability assay, • gut–liver chip-based drug screening
Disease modelling (diabetes)	[65]	Pancreas	Human cadaveric islet and SC-β cell	—	<ul style="list-style-type: none"> • hydrodynamic islet trapping • insulin quantification
	[91]	Pancreas–liver	Primary rat islets and hepatocytes	—	<ul style="list-style-type: none"> • RTqPCR assays
	[90]	Intestine–pancreas	Rat β-cell line INS-1, GLUTag cell line	GLP-1 analogues and natural insulin and GLP-1	<ul style="list-style-type: none"> • ELISA • immunofluorescence staining
ADMET	[73]	Liver, brain	Human liver spheroids and neurospheres	2,5-hexanedione	<ul style="list-style-type: none"> • qRT-PCR • toxicity assay • endpoint tissue culture analysis
	[94]	Liver, skin	HepaRG cell line, skin biopsies	Troglitazone	<ul style="list-style-type: none"> • multi-tissue sensitivity assay • LDH assay
	[95]	Human intestine, liver, skin, kidney	Primary human intestinal constructs, HepaRG, skin biopsy construct, human proximal tubule cell line	Selected drug candidates.	<ul style="list-style-type: none"> • RNA quantification • systemic tissue viability and barrier • organ integrity
	[96]	Brain, pancreas, liver, lung, heart, gut, endometrium	Tissue constructs	Tolcapone	<ul style="list-style-type: none"> • metabolite profiling • metabolomics

Application	Ref.	Organ models involved	Cell types	Drugs studied	Endpoints and assays performed
	[97]	Liver, heart	iPS-derived cardiomyocytes, primary hepatocytes	Cyclophosphamide, terfenadine	<ul style="list-style-type: none"> • biomarker and enzyme expression • electrical activity measurements • drug quantification via HPLC-MS
	[98]	Liver, heart	hiPSCs	Cisapride, norcisapride, ketoconazole	<ul style="list-style-type: none"> • drug transport studies, qPCR • Drug metabolism assays
	[99]	Liver, heart, lung, endothelium, brain, testes	Primary human cells, hiPSCs, cell line	Capecitabine	<ul style="list-style-type: none"> • Drug toxicity assays
	[100]	Liver, breast, lung, intestine	Primary cells and cell lines	Capecitabine	<ul style="list-style-type: none"> • PK-PD studies, toxicity, and metabolism studies
	[101]	Liver, kidney	Cell line	Ciclosporin, rifampicin	<ul style="list-style-type: none"> • Biomarker analysis • Protein expression
	[107]	Testes, liver	Primary human testicular organoids, HepaRG cells	Cyclophosphamide	<ul style="list-style-type: none"> • Immunofluorescence • Hormone measurements
	[109]	Liver, skin	Human epidermal cells, HepaRG	Hyperforin, permethrin	<ul style="list-style-type: none"> • Gene expression • qPCR • Mass spectrometry
	[111]	Intestine, liver, kidney; bone marrow, liver, kidney	Caco-2, primary human hepatocytes, human renal proximal tubule cells, primary bone marrow progenitor cells	Nicotine, cisplatin	<ul style="list-style-type: none"> • Barrier function assessment • Mass spectrometry • Flow cytometry

Abbreviations: GLP-1, glucagon-like peptide-1; GLUT, glucose transporter; hiPSC, human induced pluripotent stem cell; qPCR, quantitative polymerase chain reaction.

52.5 *In silico* Modelling of Multi-Organ Chips and *in vitro*–*in vivo* Translation

Pre-clinical and clinical drug development calls for the investigation of PK-PD parameters of a drug candidate by testing with a variety of *in vitro* and *in vivo* models. Experimental and computational models could complement each other in the prediction of drug–body interactions. Computational models could also enable the prediction of potential metabolic pathway disruptions, leading to diseases.

MOCs are now being used to define PK parameters for various drugs [32, 111]. They allow for the study of the fate of a drug when exposed to a functional organ tissue, to determine PK properties such as absorption, distribution, metabolism and excretion. This opportunity comes from the advantage of the ability to monitor effluents and to study response parameters in real time with the help of sensors or downstream effluent analysis and hence complete control over the characterization of a model and the parameters that go with it. This has led to the investigation of multi-compartment bioreactor models to demonstrate pharmacological interactions between organ models [43]. In order to use these pharmacological data to be able to predict the dose requirements in a clinical setting, there arises a need to create integrated models which require more inputs than flow rate and PK parameters. These inputs include metabolites, externally administered and secreted soluble factors, and a model shift from PK-PD to a more physiologically based PK (PBPK)-PD model where the outputs consist of response markers such as cytokines and growth factors which could then influence the progression of the drug response. Yu et al. [126] demonstrated this with an example of a traditional PK model and a mechanistic model for concentrations of hydrocortisone (HC), which when not bound to human serum albumin (HSA) can be metabolized by the liver. The mechanistic PK model accounted for HC-HSA binding and produced a constant value of $k_{\text{metabolism}}$ for different values of initial bound/unbound HC ratio, which could be used to study drug PK *in vivo*, compared with the traditional PK model, which did not consider the mechanism of HSA binding [65]. Such studies lay the foundation work for *in vitro* to *in vivo* extrapolation (IVIVE), where MOCs could be used to predict *in vivo* PK properties of the drug [127].

So far, *in silico* models have evolved along a spectrum in terms of the amount of detail that they capture. A mini-review on these models by Helmlinger et al. [128] displays the evolution of *in silico* modelling approaches depending upon the application. There exist models that focus solely on intracellular mechanisms, and these follow the principles of systems biology. At the other end of the spectrum there exist computational models which represent a human as a collection of organ ‘compartments’ and these are the PBPK models, where the functions of the compartments are quantified on a large scale, and this general interaction can predict PD of the drug when interacting with this system [129]. Quantitative system pharmacology (QSP) models allow for intracellular detail depending

upon the scientific question and can still maintain the broad interaction between different organs within the model undergoing said interaction. The European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM) is heavily involved in understanding the current state of affairs of *in silico* modelling and requirements to bridge the gaps in regulatory acceptance of *in silico* models [114, 129–132].

52.5.1 Framework of *in silico* Modelling in Multi-Organ Chips

The process of correlating MOC data and *in silico* models with *in vivo* responses consists of three blocks (Fig. 52.3).




Figure 52.3 Framework for the integration of MOCs and computational model data to predict *in vivo* outcomes.

52.1.1.1 Block 1—study decisions and multi-organ chip development

In block 1, the MOC is developed, based on the type of study and organs involved. The mechanism of action of the drug or disease pathophysiology is determined, in addition to the decisions about the involvement of the immune component.

To use MOCs for PBPK-PD studies, the organ models should be designed and appropriately scaled to maintain a physiological relation similar to the

in vivo situation. A compilation of scaling approaches has been provided by Ahluwalia [133]. Simple allometric scaling relies on using the quarter power law to scale weight/volume of organs down from macro-scale to micro-scale in correlation with the whole-body weight [134]. Wikswo et al. demonstrated that this approach leads to disproportionately sized micro-organs with respect to each other and fails to capture how organ functions scale with respect to each other [39]. Shuler and colleagues did some fundamental work on organ model scaling considering specific organ mass and the residence time of blood within the organs. Briefly, each organ was scaled according to organ mass or volume and the blood flow into each chamber based on *in vivo* residence times, then ordinary differential equations were used to calculate time-specific concentrations per compartment of drugs and metabolites [42, 66, 74]. For unknown mechanisms of toxicity, it is crucial to scale tissues with respect to their functionality. The third method of scaling accounts for the functional property of the organ and aims to scale that to the micro-scale, while additionally considering the spatial arrangement of cells in an MPS platform. An important aspect of this approach involves accounting for the distribution of resources to the organ tissues *in vitro* compared with *in vivo*. *In vitro*, the cells are in a resource-rich environment, and this would cause them to behave differently from their *in vivo* counterparts. Moraes et al. [135] investigated insulin-dependent glucose uptake in adipose tissue and discussed how the spatial arrangement of cells could influence the functional activity, for example the metabolic activity. They also highlighted considerations for scaling organs based on volume or surface area (three- or two-dimensional) depending on whether the organ is functionally three-dimensional (secretory, storage functions of glands, bone marrow and fat) or functionally two-dimensional (filtration, absorption, molecular transport functions for membrane organs such as endothelial cells, kidney, the blood–brain barrier and lungs) [135]. Other work on functional scaling has been done by West et al. [136] and Toussiant et al. [137]. The organ scaling process is iterative and requires the use of computational mechanistic models to validate the quantitative data obtained from the model and, in the process, helps to refine the scaling parameters to iterate the model [136, 137]. Maass et al. [72] show that mechanistic computational models enable an improved design of MOCs by highlighting the medium component requirements of each connected organ at a steady state to enable longer term pharmacological studies. In a novel computational multi-organ scaling approach, the functional scaling in comparison with allometric and direct scaling approaches was investigated. In the study, an objective function was defined that represents the biological functions of interest and aims to minimize the discrepancy between model-derived and previously established data [138].

To expand the effectiveness of the IVIVE study, it is important to consider the following points about the system: age, sex and body mass index could change the extent of organ function—a number of studies demonstrate that plasma concentrations of glucocorticoids and progestins are significantly lower for obese women than for women of normal weight. Immune responses—drug treatment

could trigger the immune system and the pathways for these processes have not been well defined. Many drugs that were not intended for immune modulation could trigger immune side effects [139]. Traditional PK models can capture their effect only to a limited extent, while PBPK-PD models or mechanistic PK models could be coupled with multi-organ MOCs to predict the impact of the drug-related immune response on the metabolism. Trapecar et al. [140] show this as well in a multi-organ ulcerative colitis model including liver, gut and circulating Treg and Th17 cells. They note that short-chain fatty acids incite an immune response from CD4+ cells, which in turn leads to a disrupted gut barrier and reduced liver function [140].

52.5.1.2 Block 2—gathering multi-organ chip data and *in silico* model design

Experimental data derived from MOCs under highly reproducible conditions provides a valuable basis for mechanistic *in silico* modelling of the observed metabolic effects. Essential parameters such as glucose turnover and oxygen consumption could be continuously monitored by integrated glucose and oxygen sensors and its change linked to treatments with different drug dosages. These data could be complemented by specific biomarkers, cytokine profiles and drug metabolite formation. Maass et al. [72] studied the effects of medium renewal on tissue function and validated their quasi-steady-state model by performing experiments to observe the effect of medium change on tissue function. These data were correlated to observed and predicted concentrations of medium components such as glucose and lactate. For their study, the glucose and lactate concentrations were kept within physiological ranges (a glucose concentration of 4–7 mM and lactate concentration below 20 mM). They reported that 15% of medium change every 24 h is enough to maintain functional properties of the tissue cultures in their model (iPS-derived cardiomyocytes, primary human hepatocytes and differentiated Caco2 intestinal cell line), allowing for *in silico* models to predict strategies for the judicious use of medium components within a physiological range [72].

General considerations to be made while running metabolic *in vitro* studies include: (i) the role of serum present at different levels in the medium and the impact of drug binding, i.e., by albumin [141–143], (ii) concentrations of medium components and how they relate to the *in vivo* situation, (iii) differences between cell sources and functional variations between cell lines or cell types, and (iv) the material used for MOCs and its drug absorption/adsorption characteristics.

In order to characterize the PK-PD properties of the drug in the MOC, it is essential to set up a baseline drug profile within the system in the absence of cells, in order to establish a blank 'system control'. Partitioning of lipophilic compounds into PDMS could influence the initial drug concentration that the cells are exposed to. Rigid plastics mitigate this issue but have lower levels of oxygen permeability than PDMS.

52.5.1.3 Block 3—*in vitro* to *in vivo* translation

The *in silico* model can be used to predict *in vivo* outcomes based on physiologically based PK modelling or systems pharmacology approaches and validated against the *in vivo* situation based on clinical biomarkers and drug serum levels. Criteria for the MPS validation are the time-dependent changes of drug levels in blood against unbound drug levels in the medium perfusate of the MOC.

Quantitative systems PK has been extended from an approach to determine PK for therapeutic development to understanding relations between MOCs from a biological and physical dynamics standpoint. This can then aid defining appropriate experimental conditions and predict *in vivo* outcomes. Edington et al. [93] applied the principles of quantitative systems pharmacology (QSP) to determine the conditions required to maintain functionality of up to 10 organ tissues connected on a flow platform with a built-in pumping system. The platform was used to measure metabolite concentrations in effluents and to calculate metabolite formation rates. The organ model platform was further used to quantify diclofenac metabolism and the correlation of the effluent measurements with the PBPK model [93].

Arakawa et al. [144] created an MOC model of Caco2 cells and HepaRG cells representing crosstalk between intestine and liver tissue. The obtained data were used to predict plasma profiles of triazolam in humans. The authors used scaling factors to predict blood plasma concentration of metabolites and triazolam in humans [144].

Tsamandorous et al. [145] performed an array of tests on cryopreserved hepatocytes from five different donors to assess drug effects and the possibility, by using a simulation framework, to predict *in vivo* drug metabolism. They assessed hepatocyte functionality through albumin secretion and expression of metabolism-related genes upon exposure to six different drugs and were able to successfully predict *in vivo* clearance of drugs [145].

A number of software tools can be employed to solve the equations generated to set up the *in silico* model. Ordinary differential equations are generated to describe the time-dependent variation of concentration of a component within the MOC system. Common software for ordinary differential equation modelling includes R, Matlab, SAAM2, Berkeley Madonna [146] and others. Examples of more integrated platforms for PBPK modelling are the OSP Suite from Bayer/esqLABS [147], SimCYP [148] from Certara and GastroPlus [149]. For QSP modelling, the OSP Suite from Bayer/esqLABS is more widely used.

The MOC field is rapidly growing, proven by advances in hardware technology to culture cells, perfuse media and integrate multiple organs in a single platform with advanced sensor arrays. Likewise, the recapitulation of human physiology *in vitro* is rapidly advancing. However, an integrated software solution to streamline MOC experiments within the drug development process is still lacking. A software solution may guide experimental designs, provide model-informed selection of drug concentrations to analyze *in vitro* data and

translate it into clinical outcomes predictions by using human QSP/PBPK models. Individual reports have demonstrated the predictive power of such an approach over conventional methods already. Further adoption and development are now needed to fully demonstrate the impact of *in silico* and *in vitro* models on the drug development process with improved prediction of drug efficacy, a reduction of attrition rates and identification of as yet non-clinically detectable toxicity effects.

52.5.2 Case Studies

While there are a considerable number of publications on MPSs, publications of studies that combine computational modelling and MPS-derived experimental data are scarce. A PubMed query (pubmed.ncbi.nlm.nih.gov) including the search terms (OoC) or (MPS) resulted in 2733 entries from 2013 to 2021. When including search terms such as PK, PBPK and QSP, 103, 12 and 12 publications, respectively, were found (corresponds to 4%, 0.5% and 0.5% of the total entries). Thus, only a handful of reports directly report computational analysis of the biological data and the subsequent integration with human-based PK or PBPK/QSP models. In this section, we highlight two of these reports as example case studies.

52.5.2.1 Assessing the toxicodynamic effects of terfenadine on a heart–liver multi-organ chip

In a publication by McAleer and co-workers, the authors proposed a workflow integrating both experimental data and computational models to inform pre-clinical outcomes after terfenadine administration causing QT-prolongation [150]. They investigated the potential of MOCs to recapitulate pre-clinical PK-PD relationships of terfenadine. The toxicodynamic effects of terfenadine on the heart, which are pre-clinically and clinically well characterized, are caused by QT prolongation, which was quantified by changes in the field potential duration in a heart MPS. It is also known that mainly CYP3A4 enzymes metabolize terfenadine to fexofenadine, which does not cause any QT prolongation. The authors then fluidically coupled the heart MPS to a liver MPS. The aim was to demonstrate that, in the presence of a metabolically competent MPS, the toxicodynamic effects on the heart MPS were less pronounced, as soon as terfenadine was metabolized to fexofenadine. Therefore, they quantified generic biomarkers such as cell viability and MPS-specific biomarkers such as the heart-MPS beat rate or the field potential duration over the course of the experiment (24 h). Additionally, they quantified both terfenadine and fexofenadine concentrations in the cell medium and lysate of the liver and heart MPSs (multiple time points over 24 h). The authors confirmed the presence of fexofenadine and thus indirectly confirmed that the liverMPS was metabolically competent and could indeed metabolize terfenadine to fexofenadine via CYP3A4. The authors then developed a four-compartmental mathematical model of the multi-MPS to

describe the kinetics of both MPS-specific biomarkers and drug concentrations. They even accounted for the absorption of highly lipophilic compounds (such as terfenadine) to the multi-organ platform, which is mainly made of PDMS and would reduce the actual drug concentrations available for metabolism or adverse effects. After the mathematical model was calibrated to describe the heart–liver system biological data, the authors used this model to predict the change in FPD in animal models (guinea pig and dog) as well as humans. This was done by providing the *in vitro* model with terfenadine kinetics taken from available literature reports.

52.5.2.2 Predicting clinical outcomes after administration of cisplatin in a kidney immune *in silico* model

In a recent publication by Maass et al. [151], a different workflow was applied by integrating both experimental data and computational models to inform clinical outcomes after cisplatin administration causing acute kidney injury (AKI). A PBPK model was developed to describe the kinetics of cisplatin in humans (based on literature reports). Especially for the kidneys where damage is observed *in vivo*, the model was used to inform the drug concentrations that should be tested in organ chips. The toxicodynamic effect of cisplatin was quantified by measuring cell viability and the kidney-specific biomarker KIM-1 (kidney-injury molecule). This biomarker is routinely used in clinical studies for the assessment of AKI. KIM-1 profiles were compared between a kidney chip model and two-dimensional cell culture. Following the *in vitro* experiments, the authors developed another PBPK model to describe the distribution and synthesis of KIM-1 in humans. This model served as an *in silico* MOC model. This model included an immune system response (neutrophil recruitment) causing elevated KIM-1 levels. The experimentally derived biological data on KIM-1 kinetics after cisplatin administration (multiple time points over the course of the experiment) as well as the simulated drug concentration kinetics were used as inputs into this newly developed human PBPK model. The authors successfully described the kinetics of KIM-1 in humans as a function of drug concentrations at the site of action, which was informed by the *in vitro* experiments. The results were compared with a list of clinical reports on elevated KIM-1 levels in patients with AKI. This demonstrates the power of integrating *in vitro* and *in silico* approaches.

These two exemplary studies demonstrate the power of combination of MOC experimental data with computational modelling to identify drug-related toxicity in pre-clinical studies to inform the dosing regimen and to predict clinical outcomes.

The ability to precisely and accurately predict adverse events and efficacy in pre-clinical studies could help to reduce patient burden and drug attrition rates. Yet current animal models and state-of-the-art *in vitro* systems fail to do so. The examples presented above show the potential of the translational workflow in two specific applications. Future studies may extend the approach for various translational pharmacology applications, such as toxicity assessment, first-in-human dosing and metabolism. The adoption and validation of the presented

workflow would include testing a broader set of drugs, measure platform and medium binding of compounds routinely, and identify clinically relevant and organ-specific biomarkers. More studies highlighting the predictive power of an integrated approach over conventional methods (*in vitro*–*in vivo* correlation/extrapolation, two- versus three-dimensional or MPSs, animal testing) in the assessment of drug-related clinical toxicity and efficacy testing are needed.

52.6 Outlook

With advances in microfabrication techniques, three-dimensional cell culture methods, stem cell technologies and biomarkers, the development of OoC technology has been rapid over the last decade [25]. As a result, multiple ready-to-use OoC models are already commercially available, for biomedical research, toxicity screening and drug testing [152]. In a recent publication, the question of how much impact MPSs could have in early drug discovery (high-throughput screening) and pre-clinical studies was investigated and estimated to save up to 25% (approx. US\$700M) of total research and development costs per drug candidate [153]. While both industry partners and regulatory agencies are starting to recognize the impact and predictive power that OoC systems may have on drug testing, the full potential of the technology is not used yet.

Mastrangeli et al. [154] highlighted six components in the development of OoC technology that the field is making headway in, in one form or another. However, certain limitations are to be overcome for OoCs to get approval by regulatory bodies. Table 52.2 provides a summary of the challenges faced by the MOC field. Allwardt et al. [155] also conducted a survey consolidating the challenges of the OoC field. Alongside a roadmap of requirements for the technology, they highlighted challenges and these are considered at Technology Readiness Level 4 (technology validated in the laboratory) [155].

In order for OoCs to be taken up as a drug-screening platform, either an ‘evolutionary’ approach or ‘revolutionary’ approach is needed, as highlighted by Heringa et al. [156]. In the evolutionary approach, OoCs could be compared with animal data for toxicity endpoints, after which the validated OoC model could be used to derive safe limits for humans. The revolutionary approach seeks to redefine toxicity endpoints by the development of quantitative AOPs and to use OoC and *in silico* data to predict the drug response in humans. In both cases, *in silico* modelling could provide a bridge for *in vivo* prediction and strengthen the data obtained from the OoC.

To increase trust in the novel technological advances, collaborations of academics, industry partners and regulatory agencies should prove that OoCs are better predictors of human outcomes and establish best practices for using commercially available OoCs. There is an immediate need for an integrated workflow that combines both computational models and data derived from MPS experiments (i.e., *in vitro*–*in vivo* translation (IVIVT)). Such a translational

workflow may enable the assessment of toxicity and safety hazards, could inform first-in-human drug dosing and may help to identify potential drug failures pre-clinically, reducing time, cost and attrition rates.

Table 52.2 A summary of requirements of the MOCs and the current challenges that the field still faces

Challenge	Important aspects	Refer to section
Connection strategies	<ul style="list-style-type: none"> • Flexibility to allow modular connection of organ chips with different requirements/timelines for tissue formation and maturation • Minimizing dead volumes • Leak-proof and robust connection mechanisms 	52.2
Standardization	<ul style="list-style-type: none"> • Interfacing with automated sampling approaches and modular connection approaches • Connection of chips from different developers 	52.2
Physiologically relevant microanatomy	<ul style="list-style-type: none"> • Cell sourcing (human, autologous cell types) • Maintaining tissue complexity and homeostasis in individual organ modules in connected culture • Immune cell integration (resident and peripheral) 	52.1, 52.4
Chip material	<ul style="list-style-type: none"> • Biocompatibility • Tuneable gas permeability • Non-absorbing versus case-by-case small molecule absorption characterization • Transparency for imaging • Economical production for prototyping/pilot/large scale 	52.2
Time-resolved analyte quantification	<ul style="list-style-type: none"> • Limited number of analytes of in-line sensing strategies • Assay sensitivity and volume requirements of off-line assays 	52.2, 52.3, 52.4
Clinical translation	<ul style="list-style-type: none"> • Clinically relevant endpoints • <i>In silico</i> models for IVIVT and dosing predictions 	52.5

Note: The reader is referred to specific sections within the chapter for more details about each challenge.

Diseases associated with metabolism tend to be chronic, i.e., NAFLD and NASH, which could proceed to hepatocellular carcinoma not only in adults but also in children and adolescents, especially with the spike in obesity [157]. The global prevalence of NAFLD is 24% and these chronic illnesses are associated with metabolic syndrome, which is characterized by increased visceral fat, insulin resistance and circulating fatty acids. Another important facet of OoC technology is the ability to integrate immune cells, which are involved in many hepatotoxicity responses to drugs.

Current therapeutic regimes are primarily designed for the average patient, based on the observed benefits and success rates within the general population, without considering the tremendous genetic diversity between individuals [158]. Such a uniform treatment strategy bears the risk of significant adverse events and the administration of inappropriate drug dosages with insufficient drug efficacy. Therefore, the clinical need for patient-specific treatments, based on individual genomic backgrounds, remains [159]. Microfluidic MOCs, using patient-derived cells, represent a promising tool to such personalized medicine. While the utility of mature differentiated cells is often limited owing to their low regeneration, the use of induced pluripotent stem cells (iPSCs) may overcome this drawback. Indeed, iPSCs show a remarkable capacity of cell renewal and a potential to differentiate into a plethora of cell types. However, it should be mentioned that such iPSC-based techniques are not yet up to the mark, causing a high level of heterogeneity, or immature phenotype, in the derived cell types [160, 161]. Improved differentiation protocols are thus needed to generate more mature cell types with a higher homogeneity and lower batch-to-batch variation. Additionally, to allow for high-throughput screening of compounds, the parallelization of MoCs should be possible [162]. Once fully optimized, these personalized MoCs may provide a tool for long-term tests, mimicking the biological environment, to predict the response of multiple organs to a specific drug and to define appropriate dosage, therefore elevating the potential for a beneficial clinical outcome. For example, MoCs with integrated circulatory systems could have high potential in oncology, as they might predict the tissue to which metastatic cells will migrate [163].

The key values to obtain a high translational value of MOCs relies on the recreation of a biologically relevant on-chip environment, the use of suitable and sustainable cell models and the availability of sensitive and reliable readouts [164]. Indeed, while many of these features have been addressed by current research, significant improvements of the OoC models are still required to allow their integration into the drug development process and even diagnostics. A key asset in the adoption of OoC systems is the ability of *in silico* modelling to contribute to the predictability of the OoC system. Another aspect includes the cell source—while most OoC models still use cells from animal origin, more advanced models will integrate cells of human origin, i.e., primary cells or iPSC-derived cells. Current OoC models are not yet able to fully reflect the key characteristics of *in vivo* cellular homeostasis or pathology, such as zonation of tissues, zonal pressure, integration of a complex microbiome, physiological fluctuation of hormones or integration of a full-scale organ-specific immune response [105, 164, 165]. However, emerging techniques and materials, such as the use of novel biomaterials (considering the importance of cell–material communication), integration of high-throughput microfluidic systems (allowing parallel experimenting) and integration of novel sensor arrays will contribute to improving current OoC platforms [166]. We are thus confident that the significant advancements in MOC technology will enhance and encourage its

broader use in biological and clinical research and help to transform non-clinical research towards precision medicine with improved capabilities of personalized disease modelling and drug discovery.

Abbreviations

ADMET:	absorption, distribution, metabolism, excretion and toxicity
AOP:	adverse outcome pathway
APN:	adiponectin
COC:	cyclic olefin copolymer
FFAs:	free fatty acids
GLP-1:	glucagon-like peptide-1
GLUT:	glucose transporter
HC:	hydrocortisone
hiPSC:	human induced pluripotent stem cell
IVIVE:	<i>in vitro</i> to <i>in vivo</i> extrapolation
IVIVT:	<i>in vitro-in vivo</i> translation
iPSCs:	induced pluripotent stem cells
KIM-1:	kidney-injury marker
LDH:	lactate dehydrogenase
MOCs:	multi-organ chips
MPS:	microphysiological system
NAFLD:	non-alcoholic fatty liver disease
NASH:	non-alcoholic steatohepatitis
OoC:	organ-on-chip
PBPK-PD:	physiologically based PK-PD
PD:	pharmacodynamics
PDMS:	polydimethylsiloxane
PK:	pharmacokinetics
PMMA:	polymethyl methacrylate
qPCR:	quantitative polymerase chain reaction
QSP:	quantitative systems pharmacology
T2D:	Type 2 diabetes mellitus
TCA:	tricarboxylic acid
TNF- α :	tumour necrosis factor α

Disclosures and Conflict of Interest

This chapter was originally published as: Shroff, T., Aina, K., Maass, C., Cipriano, M., Lambrecht, J., Tacke, F., Mosig, A., Loskill, P. (2022). Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics. *Open Biol.*, **12**, 210333, <https://doi.org/10.1098/rsob.210333>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>) and appears here with edits and updates.

Tanvi Shroff and Kehinde Aina contributed equally to this study.

Data accessibility: This article has no additional data.

Authors' contributions: T.S.: conceptualization, data curation, formal analysis, project administration, writing—original draft and writing—review and editing; K.A.: conceptualization, data curation, formal analysis, writing—original draft and writing—review and editing; C.M.: data curation, writing—original draft and writing—review and editing; M.C.: conceptualization, data curation, writing—original draft and writing—review and editing; J.L.: data curation and writing—original draft; F.T.: supervision and writing—review and editing; A.M.: conceptualization, funding acquisition, resources, supervision and writing—review and editing; P.L.: conceptualization, funding acquisition, project administration, resources, supervision and writing—review and editing

All authors gave final approval for publication and agreed to be held accountable for the work performed herein.

Competing interests: The authors have no competing interests.

Funding: This research has been supported by the H2020, European Commission. In particular, the CSA - Coordination and support action (GA-766884-ORCHID), the MSCA-ITN-ETN - European Training Networks (GA-812954-EUROoC) and the MSCA-IF-EF-ST - Standard EF to M.C. (GA-845147-LIV-AD-ON-A-CHIP). Further financial support was given by the Ministry of Science, Research and the Arts of Baden-Württemberg.

References

1. Gilleron J, Gerdes JM, Zeigerer A. 2019. Metabolic regulation through the endosomal system. *Traffic*. **20**, 552–570.
2. Zmora N, Bashirdes S, Levy M, Elinav E. 2017. The role of the immune system in metabolic health and disease. *Cell Metab*. **25**, 506–521.
3. Bonen A. 2001. The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. *Eur J Appl Physiol*. **86**, 6–11.
4. Shah RV, et al. 2014. Visceral adiposity and the risk of metabolic syndrome across body mass index. *JACC Cardiovasc Imaging*. **7**, 1221–1235.
5. Rabasa C, Dickson SL. 2016. Impact of stress on metabolism and energy balance. *Curr Opin Behav Sci*. **9**, 71–77.
6. Duan Y. et al. 2016. The role of leucine and its metabolites in protein and energy metabolism. *Amino Acids*. **48**, 41–51.
7. Sane R, Sinz M. 2017. Introduction of drug metabolism and overview of disease effect on drug metabolism. In *Drug Metabolism in Diseases*, Amsterdam, The Netherlands: Elsevier, pp. 1–19.
8. Young B, O'Dowd G, Woodford P. 2013. *Wheater's Functional Histology*, 6th ed. Philadelphia, PA: Elsevier.

9. Gerich JE, Charles MA, Grodsky GM. 1976. Regulation of pancreatic insulin and glucagon secretion. *Annu Rev Physiol.* **38**, 353–388.
10. Kaminsky LS, Zhang QY. 2003. The small intestine as a xenobiotic-metabolizing organ. *Drug Metab Dispos.* **31**, 1520–1525.
11. Gu BH, Kim M, Yun CH. 2021. Regulation of gastrointestinal immunity by metabolites. *Nutrients.* **13**, 167.
12. Ye DW, Rong XL, Xu AM, Guo J. 2017. Liver-adipose tissue crosstalk: a key player in the pathogenesis of glucolipid metabolic disease. *Chin J Integr Med.* **23**, 410–414.
13. Cherrington AD, Moore MC, Sindelar DK, Edgerton DS. 2007. Insulin action on the liver *in vivo*. *Biochem Soc Trans.* **35**, 1171–1174.
14. Gamas L, Matafome P, Seiça R. 2015. Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk. *J Diabetes Res.* **2015**, 1–8.
15. Chung HS, Choi KM. 2018. Adipokines and myokines: a pivotal role in metabolic and cardiovascular disorders. *Curr Med Chem.* **25**, 2401–2415.
16. Lehr S, et al. 2012. Identification and validation of novel adipokines released from primary human adipocytes. *Mol Cell Proteomics.* **11**, M111.010504.
17. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, Mombaerts P, Friedman JM. 2001. Selective deletion of leptin receptor in neurons leads to obesity. *J Clin Invest.* **108**, 1113–1121.
18. Covey SD, et al. 2006. The pancreatic β cell is a key site for mediating the effects of leptin on glucose homeostasis. *Cell Metab.* **4**, 291–302.
19. Soedling H, Hodson DJ, Adrianssens AE, Gribble FM, Reimann F, Trapp S, Rutter GA. 2015. Limited impact on glucose homeostasis of leptin receptor deletion from insulin- or proglucagon-expressing cells. *Mol Metab.* **4**, 619–630.
20. Muoio DM, Dohn GL, Fiedorek FT, Tapscott EB, Coleman RA. 1997. Leptin directly alters lipid partitioning in skeletal muscle. *Diabetes.* **46**, 1360–1363.
21. Hui X, Feng T, Liu Q, Gao Y, Xu A. 2016. The FGF21–adiponectin axis in controlling energy and vascular homeostasis. *J Mol Cell Biol.* **8**, 110–119.
22. Lefere S, Tacke F. 2019. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism. *JHEP Rep Innov Hepatol.* **1**, 30–43.
23. Makowski L, Chaib M, Rathmell JC. 2020. Immunometabolism: from basic mechanisms to translation. *Immunol Rev.* **295**, 5–14.
24. Bale SS, Moore L, Yarmush M, Jindal R. 2016. Emerging *in vitro* liver technologies for drug metabolism and inter-organ interactions. *Tissue Eng Part B Rev.* **22**, 383–394.
25. Marx U, et al. 2020. Biology-inspired microphysiological systems to advance medicines for patient benefit and animal welfare. *ALTEX.* **37**, 365–394.
26. Deng J, Chen Z, Zhang X, Luo Y, Wu Z, Lu Y, Liu T, Zhao W, Lin B. 2019. A liver-chip-based alcoholic liver disease model featuring multi-non-parenchymal cells. *Biomed Microdevices.* **21**, 57.
27. Loskill P, Hardwick RN, Roth A. 2021. Challenging the pipeline. *Stem Cell Rep.* **16**, 2033–2037.

28. Reitman ML. 2018. Of mice and men - environmental temperature, body temperature, and treatment of obesity. *FEBS Lett.* **592**, 2098–2107.
29. Staiger H, Keuper M, Berti L, Hrabě De Angelis M, Häring HU. 2017. Fibroblast growth factor 21—metabolic role in mice and men. *Endocr Rev.* **38**, 468–488.
30. Breslin S, O’Driscoll L. 2013. Three-dimensional cell culture: the missing link in drug discovery. *Drug Discov Today.* **18**, 240–249.
31. Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA. 2020. Organs-on-chips: into the next decade. *Nat Rev Drug Discov.* **20**, 345–361.
32. Bhatia SN, Ingber DE. 2014. Microfluidic organs-on-chips. *Nature Biotechnol.* **32**, 760–772.
33. Rogal J, Zbinden A, Schenke-Layland K, Loskill P. 2019. Stem-cell based organ-on-a-chip models for diabetes research. *Adv Drug Deliv Rev.* **140**, 101–128.
34. Rennert K, et al. 2015. A microfluidically perfused three dimensional human liver model. *Biomaterials.* **71**, 119–131.
35. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. 2010. Reconstituting organ-level lung functions on a chip. *Science.* **328**, 1662–1668.
36. Jang KJ, et al. 2019. Reproducing human and cross-species drug toxicities using a liver-chip. *Sci Transl Med.* **11**, eax5516. doi:10.1126/scitranslmed.aax5516.
37. Kim HJ, Li H, Collins JJ, Ingber DE. 2016. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. *Proc Natl Acad Sci USA.* **113**, E7–15.
38. Bulutoglu B, Rey-Bedón C, Kang YB, Mert S, Yarmush ML, Usta OB. 2019. A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation. *Lab Chip.* **19**, 3022–3031.
39. Wikswo JP, et al. 2013. Engineering challenges for instrumenting and controlling integrated organ-on-chip systems NIH public access. *IEEE Trans Biomed Eng.* **60**, 682–690.
40. Rogal J, Probst C, Loskill P. 2017. Integration concepts for multi-organ chips: how to maintain flexibility?. *Future Sci OA.* **3**, FSO180. doi:10.4155/fsoa-2016-0092.
41. Wang YI, Oleaga C, Long CJ, Esch MB, Mcaleer CW, Miller PG, Hickman JJ, Shuler ML. 2017. Minireview. Self-contained, low-cost body-on-a-chip systems for drug development. *Exp Biol Med.* **242**, 1701–1713.
42. Sung JH, Kam C, Shuler ML. 2010. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. *Lab Chip.* **10**, 446–455.
43. Miller PG, Shuler ML. 2016. Design and demonstration of a pumpless 14 compartment microphysiological system. *Biotechnol Bioeng.* **113**, 2213–2227.
44. Materne EM, et al. 2015. The multi-organ chip—a microfluidic platform for long-term multi-tissue coculture. *J Vis Exp.* **98**, e52526.
45. Loskill P, Marcus SG, Mathur A, Reese WM, Healy KE. 2015. μ Organo: A Lego®-like plug & play system for modular multi-organ-chips. *PLoS ONE.* **10**, e0139587.
46. An F, Qu Y, Luo Y, Fang N, Liu Y, Gao Z, Zhao W, Lin B. 2016. A laminated microfluidic device for comprehensive preclinical testing in the drug ADME process. *Sci Rep.* **6**, 1–8.

47. Schimek K, et al. 2020. Human multi-organ chip co-culture of bronchial lung culture and liver spheroids for substance exposure studies. *Sci Rep.* **10**, 7865.
48. Ahluwalia A, Misto A, Vozzi F, Magliaro C, Mattei G, Marescotti MC, Avogaro A, Iori E. 2018. Systemic and vascular inflammation in an in-vitro model of central obesity. *PLoS ONE.* **13**, e0192824.
49. Ong LJY, Ching T, Chong LH, Arora S, Li H, Hashimoto M, Dasgupta R, Yuen PK, Toh YC. 2019. Self-aligning Tetris-like (TILE) modular microfluidic platform for mimicking multi-organ interactions. *Lab Chip.* **19**, 2178–2191.
50. Novak R, et al. 2020. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. *Nat Biomed Eng.* **4**, 407–420.
51. Lee H, Kim DS, Ha SK, Choi I, Lee JM, Sung JH. 2017. A pumpless multi-organ-on-a-chip (MOC) combined with a pharmacokinetic-pharmacodynamic (PK-PD) model. *Biotechnol Bioeng.* **114**, 432–443.
52. Maoz BM, et al. 2018. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. *Nat Biotechnol.* **36**, 865–877.
53. Wang YI, Shuler ML. 2018. UniChip enables long-term recirculating unidirectional perfusion with gravity-driven flow for microphysiological systems. *Lab Chip.* **18**, 2563–2574.
54. Satoh T, Sugiura S, Shin K, Onuki-Nagasaki R, Ishida S, Kikuchi K, Kakiki M, Kanamori T. 2017. A multi-throughput multi-organ-on-a-chip system on a plate formatted pneumatic pressure-driven medium circulation platform. *Lab Chip.* **18**, 115–125.
55. Schneider S, Bubeck M, Rogal J, Weener HJ, Rojas C, Weiss M, Heymann M, Van Der Meer AD, Loskill P. 2021. Peristaltic on-chip pump for tunable media circulation and whole blood perfusion in PDMS-free organ-on-chip and organ-disc systems. *Lab Chip.* **21**, 3963–3978.
56. Tandon V, et al. 2016. Microfabricated reciprocating micropump for intracochlear drug delivery with integrated drug/fluid storage and electronically controlled dosing. *Lab Chip.* **16**, 829–846.
57. Coppeta JR, et al. 2017. A portable and reconfigurable multi-organ platform for drug development with onboard microfluidic flow control. *Lab Chip.* **17**, 134–144.
58. Byun CK, Abi-Samra K, Cho YK, Takayama S. 2014. Pumps for microfluidic cell culture. *Electrophoresis.* **35**, 245–257.
59. Jalili-Firoozinezhad S, et al. 2019. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. *Nat Biomed Eng.* **3**, 520–531.
60. Tonon F, Giobbe GG, Zambon A, Luni C, Gagliano O, Floreani A, Grassi G, Elvassore N. 2019. In vitro metabolic zonation through oxygen gradient on a chip. *Sci Rep.* **9**, 13557.
61. Wang JD, Douville NJ, Takayama S, Elsayed M. 2012. Quantitative analysis of molecular absorption into PDMS microfluidic channels. *Ann Biomed Eng.* **40**, 1862–1873.
62. Oleaga C, et al. 2016. Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. *Sci Rep.* **6**, 1–17.

63. Fuchs S, Johansson S, Tjell AØ, Werr G, Mayr T, Tenje M. 2021. In-line analysis of organ-on-chip systems with sensors: integration, fabrication, challenges, and potential. *ACS Biomater. Sci Eng.* **7**, 2926–2948.
64. Misun PM, Rothe J, Schmid YRF, Hierlemann A, Frey O. 2016. Multi-analyte biosensor interface for real-time monitoring of 3D microtissue spheroids in hanging-drop networks. *Microsyst Nanoeng.* **2**, 16022.
65. Gliberman AL, et al. 2019. Synchronized stimulation and continuous insulin sensing in a microfluidic human islet on a chip designed for scalable manufacturing. *Lab Chip.* **19**, 2993–3010.
66. Sin A, Chin KC, Jamil MF, Kostov Y, Rao G, Shuler ML. 2004. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. *Biotechnol Prog.* **20**, 338–345.
67. Ali M, Kim YS, Khalid MAU, Soomro AM, Lee JW, Lim JH, Choi KH, Ho LS. 2020. On-chip real-time detection and quantification of reactive oxygen species in MCF-7 cells through an in-house built fluorescence microscope. *Microelectron Eng.* **233**, 111432.
68. Iori E, Vinci B, Murphy E, Marescotti MC, Avogaro A, Ahluwalia A. 2012. Glucose and fatty acid metabolism in a 3 tissue in-vitro model challenged with normo- and hyperglycaemia. *PLoS ONE.* **7**, e34704.
69. Lee DW, Lee SH, Choi N, Sung JH. 2019. Construction of pancreas–muscle–liver microphysiological system (MPS) for reproducing glucose metabolism. *Biotechnol Bioeng.* **116**, 3433–3445.
70. Bauer S, et al. 2017. Functional coupling of human pancreatic islets and liver spheroids on-a-chip: towards a novel human ex vivo type 2 diabetes model. *Sci Rep.* **7**, 14620.
71. Duan X, Zheng L, Zhang X, Wang B, Xiao M, Zhao W, Liu S, Sui G. 2020. A membrane-free liver-gut-on-chip platform for the assessment on dysregulated mechanisms of cholesterol and bile acid metabolism induced by PM2.5. *ACS Sensors.* **5**, 3483–3492.
72. Maass C, Dallas M, Labarge ME, Shockley M, Valdez J, Geishecker E, Stokes CL, Griffith LG, Cirit M. 2018. Establishing quasi-steady state operations of microphysiological systems (MPS) using tissue-specific metabolic dependencies. *Sci Rep.* **8**, 1–13.
73. Materne EM, et al. 2015. A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing. *J Biotechnol.* **205**, 36–46.
74. Viravaidya K, Shuler ML. 2008. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. *Biotechnol Prog.* **20**, 590–597.
75. Ucciferri N, Sbrana T, Ahluwalia A. 2014. Allometric scaling and cell ratios in multi-organ in vitro models of human metabolism. *Front Bioeng Biotechnol.* **2**, 42113.
76. Younossi Z, et al. 2019. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology.* **69**, 2672–2682.
77. Hundertmark J, Tacke F. 2020. How effective are nonalcoholic fatty liver disease models for drug discovery? *Expert Opin Drug Discov.* **15**, 1237–1240.

78. Reimer KC, Wree A, Roderburg C, Tacke F. 2020. New drugs for NAFLD: lessons from basic models to the clinic. *Hepatol Int.* **14**, 8–23.
79. Fogel DB. 2018. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. *Contemp Clin Trials Commun.* **11**, 156–164.
80. Yang J, et al. 2020. Integrated gut–liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease. *bioRxiv.* 2020.06.10.141606.
81. Lee SY, Sung JH. 2018. Gut–liver on a chip toward an in vitro model of hepatic steatosis. *Biotechnol Bioeng.* **115**, 2817–2827.
82. Kostrzewski T, et al. 2017. A microphysiological system for studying nonalcoholic steatohepatitis. *Hepatol Commun.* **4**, 77–91.
83. Rogal J, Binder C, Kromidas E, Roosz J, Probst C, Schneider S, Schenke-Layland K, Loskill P. 2020. WAT-on-a-chip integrating human mature white adipocytes for mechanistic research and pharmaceutical applications. *Sci Rep.* **10**, 6666.
84. Zbinden A, et al. 2020. Non-invasive marker-independent high content analysis of a microphysiological human pancreas-on-a-chip model. *Matrix Biol.* **85–86**, 205–220.
85. Jang KJ, Mehr AP, Hamilton GA, Mcpartlin LA, Chung S, Suh KY, Ingber DE. 2013. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. *Integr Biol.* **5**, 1119–1129.
86. Nawroth JC, et al. 2021. Modeling alcohol-associated liver disease in a human liver-chip. *Cell Rep.* **36**, 109393.
87. Perry RJ, Samuel VT, Petersen KF, Shulman GI. 2014. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. *Nature.* **510**, 84–91.
88. Li X, Brooks JC, Hu J, Ford KI, Easley CJ. 2017. 3D-templated, fully automated microfluidic input/output multiplexer for endocrine tissue culture and secretion sampling. *Lab Chip.* **17**, 341–349.
89. Tao T, Wang Y, Chen W, Li Z, Su W, Guo Y, Deng P, Qin J. 2019. Engineering human islet organoids from iPSCs using an organ-on-chip platform. *Lab Chip.* **19**, 948–958.
90. Nguyen DTT, Van Noort D, Jeong IK, Park S. 2017. Endocrine system on chip for a diabetes treatment model. *Biofabrication.* **9**, 015021.
91. Essaouiba A, Okitsu T, Kinoshita R, Jellali R, Shinohara M, Danoy M, Legallais CÂ, Sakai Y, Leclerc E. 2020. Development of a pancreas-liver organ-on-chip coculture model for organ-to-organ interaction studies. *Biochem Eng J.* **164**, 107783.
92. Tsamandouras N, Chen WLK, Edington CD, Stokes CL, Griffith LG, Cirit M. 2017. Integrated gut and liver microphysiological systems for quantitative *in vitro* pharmacokinetic studies. *AAPS J.* **19**, 1499–1512.
93. Edington CD, et al. 2018. Interconnected microphysiological systems for quantitative biology and pharmacology studies. *Sci Rep.* **8**, 4530.
94. Wagner I, et al. 2013. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. *Lab Chip.* **13**, 3538–3547.
95. Maschmeyer I, et al. 2015. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. *Lab Chip.* **15**, 2688–2699.

96. Wang X, Cirit M, Wishnok JS, Griffith LG, Tannenbaum SR. 2019. Analysis of an integrated human multiorgan microphysiological system for combined tolcapone metabolism and brain metabolomics. *Anal Chem.* **91**, 8667–8675.
97. Oleaga C, et al. 2018. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system. *Biomaterials.* **182**, 176–190.
98. Lee-Montiel F, et al. 2020. Integrated hiPSC-based liver and heart microphysiological systems predict unsafe drug-drug interaction. *bioRxiv.* 2020.05.24.112771 doi:10.1101/2020.05.24.112771.
99. Rajan SAP, et al. 2020. Probing prodrug metabolism and reciprocal toxicity with an integrated and humanized multi-tissue organ-on-a-chip platform. *Acta Biomater.* **106**, 124–135.
100. Li Z, Guo Y, Yu Y, Xu C, Xu H, Qin J. 2016. Assessment of metabolism-dependent drug efficacy and toxicity on a multilayer organs-on-a-chip. *Integr Biol (United Kingdom).* **8**, 1022–1029.
101. Lin N, et al. 2020. Repeated dose multi-drug testing using a microfluidic chip-based coculture of human liver and kidney proximal tubules equivalents. *Sci Rep.* **10**, 8879.
102. Batista Leite S, Cipriano M, Carpi D, Coecke S, Holloway M, Corvi R, Worth A, Barroso J, Whelan M. 2021. *Establishing the Scientific Validity of Complex In Vitro Models: Results of a EURL ECVAM Survey.* Publications Office of the European Union, pp. 1–28. Available at: <https://op.europa.eu/en/publication-detail/-/publication/3824b024-5621-11eb-b59f-01aa75ed71a1/language-en> (accessed on September 17, 2022).
103. Ishida S. 2018. Organs-on-a-chip: current applications and consideration points for in vitro ADME-Tox studies. *Drug Metab Pharmacokinet.* **33**, 49–54.
104. Cong Y, et al. 2020. Drug toxicity evaluation based on organ-on-a-chip technology: a review. *Micromachines.* **11**, 1–24.
105. Ronaldson-Bouchard K, Vunjak-Novakovic G. 2018. Organs-on-a-chip: a fast track for engineered human tissues in drug development. *Cell Stem Cell.* **22**, 310–324.
106. Maschmeyer I, et al. 2015. Chip-based human liver–intestine and liver–skin co-cultures – a first step toward systemic repeated dose substance testing in vitro. *Eur J Pharm Biopharm.* **95**, 77–87.
107. Baert Y, Ruetschle I, Cools W, Oehme A, Lorenz A, Marx U, Goossens E, Maschmeyer I. 2020. A multi-organ-chip co-culture of liver and testis equivalents: a first step toward a systemic male reprotoxicity model. *Hum Reprod.* **35**, 1029–1044.
108. Tavares RSN, et al. 2020. Toxicity of topically applied drugs beyond skin irritation: static skin model vs. two organs-on-a-chip. *Int J Pharm.* **589**, 119788.
109. Kühnl J, et al. 2021. Characterization of application scenario-dependent pharmacokinetics and pharmacodynamic properties of permethrin and hyperforin in a dynamic skin and liver multi-organ-chip model. *Toxicology.* **448**, 152637.
110. Tao TP, et al. 2021. Demonstration of the first-pass metabolism in the skin of the hair dye, 4-amino-2-hydroxytoluene, using the Chip2 skin–liver microphysiological model. *J Appl Toxicol.* **41**, 1553–1567.
111. Herland A, et al. 2020. Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips. *Nat Biomed Eng.* **4**, 421–436.

112. Esch MB, Smith AST, Prot JM, Oleaga C, Hickman JJ, Shuler ML. 2014. How multi-organ microdevices can help foster drug development. *Adv Drug Deliv Rev.* **69–70**, 158–169.
113. Veening-Griffioen D. 2020. Tradition, not science, is the basis of animal model selection in translational and applied research. *ALTEX.* **38**, 49–62.
114. Leist M. 2014. Consensus report on the future of animal-free systemic toxicity testing. *ALTEX.* **31**, 341–356.
115. Mahony C, et al. 2020. New ideas for non-animal approaches to predict repeated-dose systemic toxicity: report from an EPAA Blue Sky Workshop. *Regul Toxicol Pharmacol.* **114**, 104668.
116. Risueño I, Valencia L, Jorcano JL, Velasco D. 2021. Skin-on-a-chip models: general overview and future perspectives. *APL Bioeng.* **5**, 030901.
117. Goyal G, et al. 2019. Lymph node follicle formation and vaccination responses reconstituted *in vitro* in a human organ chip. *bioRxiv.* 806505 doi: <https://doi.org/10.1101/806505>.
118. Shanti A, et al. 2020. Multi-compartment 3D-cultured organ-on-a-chip: towards a biomimetic lymph node for drug development. *Pharmaceutics.* **12**, 464.
119. Hallfors N, Shanti A, Sapudom J, Teo J, Petroianu G, Lee SM, Planelles L, Stefanini C. 2021. Multi-compartment lymph-node-on-a-chip enables measurement of immune cell motility in response to drugs. *Bioengineering.* **8**, 19.
120. Mackay C. 2013. From pathways to people: applying the adverse outcome pathway (AOP) for skin sensitization to risk assessment. *ALTEX.* **30**, 473–486.
121. Madia F, Pillo G, Worth A, Corvi R, Prieto P. 2021. Integration of data across toxicity endpoints for improved safety assessment of chemicals: the example of carcinogenicity assessment. *Arch Toxicol.* **95**, 1971–1993.
122. Yang S, Chen Z, Cheng Y, Liu T, Lihong Yin G, Pu Y, Liang G. 2021. Environmental toxicology wars: organ-on-a-chip for assessing the toxicity of environmental pollutants. *Environ Pollut.* **268**, 115861.
123. Serras AS, Rodrigues JS, Cipriano M, Rodrigues AV, Oliveira NG, Miranda JP. 2021. A critical perspective on 3D liver models for drug metabolism and toxicology studies. *Front Cell Dev Biol.* **9**, 626805.
124. Zhang YY, et al. 2020. A comprehensive automatic data analysis strategy for gas chromatography-mass spectrometry based untargeted metabolomics. *J Chromatogr A.* **1616**, 460787.
125. Chen L, Zhong F, Zhu J. 2020. Bridging targeted and untargeted mass spectrometry-based metabolomics via hybrid approaches. *Metabolites.* **10**, 348.
126. Yu J, et al. 2015. Quantitative systems pharmacology approaches applied to microphysiological systems (MPS): data interpretation and multi-MPS integration. *CPT Pharmacometrics Syst Pharmacol.* **4**, 585–594.
127. Fowler S, et al. 2020. Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization. *Lab Chip.* **20**, 446–467.
128. Helmlinger G, et al. 2017. Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet. *Eur J Pharm Sci.* **109**, S39–S46.

129. Paini A, Leonard JA, Kliment T, Tan YM, Worth A. 2017. Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications. *Regul Toxicol Pharmacol.* **90**, 104–115.
130. Worth AP. 2020. Computational modelling for the sustainable management of chemicals. *Comput Toxicol.* **14**, 100122.
131. Pletz J, et al. 2020. Physiologically based kinetic (PBK) modelling and human bio-monitoring data for mixture risk assessment. *Environ Int.* **143**, 105978.
132. Pistollato F, Carpi D, Mendoza-De Gyves E, Paini A, Bopp SK, Worth A, Bal-Price A. 2021. Combining in vitro assays and mathematical modelling to study developmental neurotoxicity induced by chemical mixtures. *Reprod Toxicol.* **105**, 101–119.
133. Ahluwalia A. 2017. Allometric scaling in-vitro. *Sci Rep.* **7**, 42113.
134. Kleiber M. 1947. Body size and metabolic rate. *Physiol Rev.* **27**, 511–541.
135. Moraes C, Labuz JM, Leung BM, Inoue M, Chun TH, Takayama S. 2013. On being the right size: scaling effects in designing a human-on-a-chip. *Integr Biol.* **5**, 1149.
136. West GB, Woodruff WH, Brown JH. 2002. Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals. *Proc Natl Acad Sci USA.* **99**(Suppl. 1), 2473–2478.
137. Toussaint O, Weemaels G, Debacq-Chainiaux F, Scharffetter-Kochanek K, Wlaschek M. 2011. Artefactual effects of oxygen on cell culture models of cellular senescence and stem cell biology. *J Cell Physiol.* **226**, 315–321.
138. Maass C, Stokes CL, Griffith LG, Cirit M. 2017. Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS). *Integr Biol UK.* **9**, 290–302.
139. Kidd BA, Wroblewska A, Boland MR, Agudo J, Merad M, Tatonetti NP, Brown BD, Dudley JT. 2016. Mapping the effects of drugs on the immune system. *Nat Biotechnol.* **34**, 47–54.
140. Trapecar M, et al. 2020. Gut-liver physiomechanics reveal paradoxical modulation of IBD-related inflammation by short-chain fatty acids. *Cell Syst.* **10**, 223–239.e9.
141. Munar MY, Singh H. 2007. Drug dosing adjustments in patients with chronic kidney disease. *Am Fam Phys.* **75**, 1487–1496.
142. De Marinis E, Ceccherelli A, Quattrocchi A, Leboffe L, Polticelli F, Nervi C, Ascenzi P. 2019. Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models. *Sci Rep.* **9**, 16379.
143. Sung JH, Wang YI, Sriram NN, Jackson M, Long C, Hickman JJ, Shuler ML. 2019. Recent advances in body-on-a-chip systems. *Anal Chem.* **91**, 330–351.
144. Arakawa H, Sugiura S, Kawanishi T, Shin K, Toyoda H, Satoh T, Sakai Y, Kanamori T, Kato Y. 2020. Kinetic analysis of sequential metabolism of triazolam and its extrapolation to humans using an entero-hepatic two-organ microphysiological system. *Lab Chip.* **20**, 537–547.
145. Tsamandouras N, Kostrzewski T, Stokes CL, Griffith LG, Hughes DJ, Cirit M. 2017. Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system. *J Pharmacol Exp Ther.* **360**, 95–105.

146. Berkeley Madonna. Modeling and analysis of dynamic systems. Available at: <http://www.berkeleymadonna.com/> (accessed on September 17, 2022).
147. Lippert J, et al. 2019. Open systems pharmacology community—an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. *CPT Pharmacometrics Syst Pharmacol*. **8**, 878–882.
148. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. 2009. The Simcyp[®] population-based ADME simulator. *Expert Opin Drug Metab Toxicol*. **5**, 211–223.
149. Simulations Plus. Available at: <http://www.simulations-plus.com/> (accessed on September 17, 2022).
150. Mcaleer CW, et al. 2019. On the potential of *in vitro* organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships. *Sci Rep*. **9**, 1–14.
151. Maass C, Sorensen NB, Himmelfarb J, Kelly EJ, Stokes CL, Cirit M. 2019. Translational assessment of drug-induced proximal tubule injury using a kidney microphysiological system. *CPT Pharmacometrics Syst Pharmacol*. **8**, 316–325.
152. Zhang B, Radisic M. 2017. Organ-on-a-chip devices advance to market. *Lab Chip*. **17**, 2395–2420.
153. Franzen N, Van Harten WH, Retèl VP, Loskill P, Van Den Eijnden-Van Raaij J, Ijzerman M. 2019. Impact of organ-on-a-chip technology on pharmaceutical R&D costs. *Drug Discov Today*. **24**, 1720–1724.
154. Mastrangeli M, Millet S, Van Den Eijnden-Van Raaij J. 2019. Organ-on-chip in development: towards a roadmap for organs-on-chip. Available at: www.h2020-orchid.eu (accessed on September 17, 2022).
155. Allwardt V, Ainscough AJ, Viswanathan P, Sherrod SD, Mclean JA, Haddrick M, Pensabene V. 2020. Translational roadmap for the organs-on-a-chip industry toward broad adoption. *Bioengineering*. **7**, 1–27.
156. Heringa MB, Park MVDZ, Kienhuis AS, Vandebriel RJ. 2020. The value of organs-on-chip for regulatory safety assessment. *ALTEX*. **37**, 208–222.
157. Hursting SD, Dunlap SM. 2012. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. *Ann NY Acad Sci*. **1271**, 82–87.
158. Kankala RK, Wang SB, Chen AZ. 2019. Microengineered organ-on-a-chip platforms towards personalized medicine. *Curr Pharm Des*. **24**, 5354–5366.
159. Mathur S, Sutton J. 2017. Personalized medicine could transform healthcare (Review). *Biomed Rep*. **7**, 3–5.
160. Volpato V, Webber C. 2020. Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. *Dis Models Mech*. **13**, dmm042317.
161. Geraili A, et al. 2018. Controlling differentiation of stem cells for developing personalized organ-on-chip platforms. *Adv Healthc Mater*. **7**.
162. Caballero D, Kaushik S, Correlo VM, Oliveira JM, Reis RL, Kundu SC. 2017. Organ-on-chip models of cancer metastasis for future personalized medicine: from chip to the patient. *Biomaterials*. **149**, 98–115.

163. Skardal A, Devarasetty M, Forsythe S, Atala A, Soker S. 2016. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. *Biotechnol Bioeng.* **113**, 2020–2032.
164. Haddrick M, Simpson PB. 2019. Organ-on-a-chip technology: turning its potential for clinical benefit into reality. *Drug Discov Today.* **24**, 1217–1223.
165. Esch EW, Bahinski A, Huh D. 2015. Organs-on-chips at the frontiers of drug discovery. *Nat Rev Drug Discov.* **14**, 248–260.
166. Zhao Y, Kankala R, Wang SB, Chen AZ. 2019. Multi-organs-on-chips: towards long-term biomedical investigations. *Molecules.* **24**, 675.

Chapter 53

From *Animaculum* to Single Molecules: 300 Years of the Light Microscope

**Adam J. M. Wollman, D. Phil., Richard Nudd, PhD, Erik G. Hedlund, PhD,
and Mark C. Leake, PhD**

*Biological Physical Sciences Institute,
Departments of Physics and Biology, University of York, York, UK*
mark.leake@york.ac.uk

Keywords: Abbe condenser, Abbe diffraction limit, Abbe number, Airy disc, aperture, astigmatism, brightfield images, combinatorial microscopy, contrast, differential interference contrast (DIC), diffraction, double-helix PSF (DH-PSF), dynamic fluorescence imaging, electron microscopy, epi-fluorescence, fluorescein, fluorescence imaging with one nanometer accuracy (FIONA), fluorescence recovery after photobleaching (FRAP), fluorescent staining, Förster resonance energy transfer (FRET), Gram staining, green fluorescent protein (GFP), imaging, interference, interferometric methods, Laguerre-Gauss (LG) beams, laser-scanning confocal microscope, light-sheet microscopy (LSM), mathematical fitting, Nomarski–Wollaston prism, optical diffraction gratings, optical microscope, phase contrast, photo-activated localization microscopy (PALM), point spread function (PSF), polarized light, ptychography, resolution, resolving power, scanning near-field optical microscopy (SNOM), spatial light modulator (SLM), stimulated emission depletion microscopy (STED), stochastic optical reconstruction microscopy (STORM), structured illumination microscopy, total internal reflection fluorescence (TIRF), two-photon excitation (2PE), two-photon microscopy, ultraviolet (UV)

53.1 Summary

Although not laying claim to be the inventor of the light microscope, Antonj van Leeuwenhoek (1632–1723) was arguably the first person to bring this new technological wonder of the age properly to the attention of natural scientists

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

interested in the study of living things (people we might now term 'biologists'). He was a Dutch draper with no formal scientific training. From using magnifying glasses to observe threads in cloth, he went on to develop over 500 simple single lens microscopes (Baker & Leeuwenhoek 1739 *Phil. Trans.* 41, 503–519. (doi:10.1098/rstl.1739.0085)) which he used to observe many different biological samples. He communicated his findings to the Royal Society in a series of letters (Leeuwenhoek 1800 *The select works of Antony Van Leeuwenhoek, containing his microscopical discoveries in many of the works of nature*, vol. 1) including the one republished in this edition of *Open Biology*. Our chapter here begins with the work of van Leeuwenhoek before summarizing the key developments over the last *ca* 300 years, which has seen the light microscope evolve from a simple single lens device of van Leeuwenhoek's day into an instrument capable of observing the dynamics of single biological molecules inside living cells, and to tracking every cell nucleus in the development of whole embryos and plants.

53.2 Antonj van Leeuwenhoek and Invention of the Microscope

Prior to van Leeuwenhoek, lenses had existed for hundreds of years but it was not until the seventeenth century that their scientific potential was realized with the invention of the light microscope. The word 'microscope' was first coined by Giovanni Faber in 1625 to describe an instrument invented by Galileo in 1609. Galileo's design was a compound microscope—it used an objective lens to collect light from a specimen and a second lens to magnify the image, but this was not the first microscope invented. In around 1590, Hans and Zacharias Janssen had created a microscope based on lenses in a tube [1]. No observations from these microscopes were published and it was not until Robert Hooke and Antonj van Leeuwenhoek that the microscope, as a scientific instrument, was born.

Robert Hooke was a contemporary of van Leeuwenhoek. He used a compound microscope, in some ways very similar to those used today with a stage, light source and three lenses. He made many observations which he published in his *Micrographia* in 1665 [2]. These included seeds, plants, the eye of a fly and the structure of cork. He described the pores inside the cork as 'cells,' the origin of the current use of the word in biology today.

Unlike Hooke, van Leeuwenhoek did not use compound optics but single lenses. Using only one lens dramatically reduced problems of optical aberration in lenses at the time, and in fact van Leeuwenhoek's instruments for this reason generated a superior quality of image to those of his contemporaries. His equipment was all handmade, from the spherical glass lenses to their bespoke fittings. His many microscopes consisted mainly of a solid base, to hold the single spherical lens in place, along with adjusting screws which were mounted and glued in place to adjust the sample holding pin, and sometimes an aperture placed before the sample to control illumination [3] (see Fig. 53.1 for an illustration). These

simple instruments could be held up to the sun or other light source such as a candle and did not themselves have any light sources inbuilt. His microscopes were very lightweight and portable, however, allowing them to be taken into the field to view samples as they were collected. Imaging consisted of often painstaking mounting of samples, focusing and then sketching, with sometimes intriguing levels of imagination, or documenting observations.




Figure 53.1 Optical microscope designs through the ages. (a) One design of a simple compound microscope used by Hooke while writing *Micrographia*. (b) An example of the single spherical lens mount system that van Leeuwenhoek used, approximately 5 cm in height. (c) A simple epi-fluorescence system. (d) A simple modern-day confocal microscope. Also see chapter 10 in this volume by Dr. Raj Bawa, titled “Medical Imaging, Detection, and Diagnosis: A Journey in Pictures.”

Van Leeuwenhoek’s studies included the microbiology and microscopic structure of seeds, bones, skin, fish scales, oyster shell, tongue, the white matter upon the tongues of feverish persons, nerves, muscle fibres, fish circulatory system, insect eyes, parasitic worms, spider physiology, mite reproduction, sheep fetuses, aquatic plants and the ‘animalcula’—the microorganisms described in his letter [4]. As he created the microscopes with the greatest magnification of his time, he pioneered research into many areas of biology. He can arguably be credited with the discovery of protists, bacteria, cell vacuoles and spermatozoa.

53.3 The Development of the Microscope and Its Theoretical Underpinnings

It was not until the nineteenth century that the theoretical and technical underpinnings of the modern light microscope were developed, most notably diffraction-limit theory, but also aberration-corrected lenses and an optimized illumination mode called Köhler illumination.

There is a fundamental limit to the resolving power of the standard light microscope; these operate by projecting an image of the sample a distance of several wavelengths of light from the sample itself, known as the ‘far-field’ regime. In this regime, the diffraction of light becomes significant, for example, through the circular aperture of the objective lens. This diffraction causes ‘point sources’ in the sample which scatter the light to become blurred spots when viewed through a microscope, with the level of blurring determined by the imaging properties of the microscope known as the point spread function (PSF). Through a circular aperture, such as those of lenses in a light microscope, the PSF can be described by a mathematical pattern called an Airy disc, which contains a central peak of light intensity surrounded by dimmer rings moving away from the center (Fig. 53.2a). This phenomenon was first theoretically characterized by George Airy in 1835 [5]. Later, Ernst Abbe would state that the limit on the size of the Airy disc was roughly half the wavelength of the imaging light [6], which agrees with the so-called Raleigh criterion for the optical resolution limit [7] which determines the minimum distance between resolvable objects (Fig. 53.2b). This became the canonical limit in microscopy for over a hundred years, with the only attempts to improve spatial resolution being through the use of lower wavelength light or using electrons rather than photons, as in electron microscopy, which have a smaller effective wavelength by approximately four orders of magnitude.

Ernst Abbe also helped solve the problem of chromatic aberration. A normal lens focuses light to different points depending on its wavelength. In the eighteenth century, Chester Moore Hall invented the achromatic lens, which used two lenses of different materials fused together to focus light of different wavelengths to the same point. In 1868, Abbe invented the apochromatic lens, using more fused lenses, which better corrected chromatic and spherical aberrations [8]. Abbe also created the world’s first refractometer and we still use the ‘Abbe Number’ to quantify how diffraction varies with wavelength [9]. He also collaborated with Otto Schott, a glass chemist, to produce the first lenses that were engineered with sufficiently high quality to produce diffraction-limited microscopes [10]. Their work in 1883 set the limits of far-field optics for over a century, until the advent of the 4π microscope in 1994 [11].

Another eponymous invention of Abbe was the Abbe condenser—a unit that focuses light with multiple lenses which improved sample illumination but was quickly superseded by Köhler Illumination, the modern standard for

'brightfield' light microscopy. August Köhler was a student of many fields of the 'natural sciences.' During his PhD studying limpet taxonomy, he modified his illumination optics to include a field iris and also an aperture iris with a focusing lens to produce the best illumination with the lowest glare, which aided in image collection using photosensitive chemicals [12]. Owing to the slow nature of photography of the period, good images required relatively long exposure times and Köhler Illumination greatly aided in producing high-quality images. He joined the Zeiss Optical Works in 1900, where his illumination technique coupled with the optics already developed by Abbe and Schott went on to form the basis of the modern brightfield light microscope.




Figure 53.2 Mathematically generated PSF images from different light microscope designs. (a) The Airy pattern, a disc and one of the rings produced by a point source emitter imaged using a spherical lens. (b) Two such Airy discs separated by less than the Abbe limit for optical resolution. (c) The lateral xy stretching exhibited in astigmatic imaging systems when the height z of a point source emitter is above or below the focal plane, the degree of stretching a metric for z . (d) Expected pattern when a point source emitter is defocused. (e) Two-lobed PSF used in double-helix PSF techniques, where the rotation of the lobes about the central point is used to calculate z .

53.4 Increasing Optical Contrast

One of the greatest challenges in imaging biological samples is their inherently low contrast, due to their refractive index being very close to water and thus generating little scatter interaction with incident light. A number of different methods for increasing contrast have been developed including imaging phase and polarization changes, staining and fluorescence, the latter being possibly the most far-reaching development since the invention of the light microscope.

Biological samples generate contrast in brightfield microscopy by scattering and absorbing some of the incident light. As they are almost transparent, the contrast is very poor. One way around this, is to generate contrast from phase (rather than amplitude) changes in the incident light wave. Fritz Zernike developed phase contrast microscopy in the 1930s [13] while working on diffraction gratings. Imaging these gratings with a telescope, they would 'disappear' when in focus [14]. These observations led him to realize the effects of phase in imaging, and their application to microscopy subsequently earned him the Nobel prize in 1953. Phase contrast is achieved by manipulating the transmitted, background light differently from the scattered light, which is typically phase-shifted 90° by the sample. This scattered light contains information about the sample. A circular annulus is placed in front of the light source, producing a ring of illumination. A ring-shaped phase plate below the objective shifts the phase of the background light by 90° such that it is in phase (or sometimes completely out of phase, depending on the direction of the phase shift) with the scattered light, producing a much higher contrast image.

An alternative to phase contrast is differential interference contrast (DIC). It was created by Smith [15] and further developed by Georges Nomarski in 1955 [16]. It makes use of a Nomarski–Wollaston prism through which polarized light is sheared into two beams polarized at 90° to each other. These beams then pass through the sample and carry two brightfield images laterally displaced a distance equal to the offset of the two incoming beams at the sample plane. Both beams are focused through the objective lens and then recombined through a second Nomarski–Wollaston prism. The emergent beam goes through a final analyser, emerging with a polarization of 135° . The coaxial beams interfere with each other owing to the slightly different path lengths of the two beams at the same point in the image, giving rise to a phase difference and thus a high-contrast image. The resultant image appears to have bright and dark spots which resemble an illuminated relief map. This faux relief map should not be interpreted as such, however, as the bright and dark spots contain information instead about path differences between the two sheared beams. The images produced are exceptionally sharp compared with other transmission modes. DIC is still the current standard technique for imaging unstained microbiological samples in having an exceptional ability to reveal the boundaries of cells and subcellular organelles.

Contrast can also be improved in biological samples by staining them with higher contrast material, for example dyes. This also allows differential contrast, where only specific parts of a sample, such as the cell nucleus, are stained. In 1858 came one of the earliest documented reports of staining in microscopy when Joseph von Gerlach demonstrated differential staining of the nucleus and cytoplasm in human brain tissue soaked in the contrast agent carmine [17]. Other notable examples include silver staining introduced by Camillo Golgi in 1873 [18], which allowed nervous tissue to be visualized, and Gram staining invented by Hans Christian Gram in 1884 [19], which allowing differentiation of

different types of bacteria. Sample staining is still widely in use today, including many medical diagnostic applications. However, the advent of fluorescent staining would revolutionize contrast enhancement in biological samples.

The word 'fluorescence' to describe emission of light at a different wavelength to the excitation wavelength was first made by Stokes in 1852 [20]. Combining staining with fluorescence detection allows for enormous increases in contrast, with the first fluorescent stain fluorescein being developed in 1871 [21]. In 1941, Albert Coons published the first work on immunofluorescence. This technique uses fluorescently labelled antibodies to label specific parts of a sample. Coons used a fluorescein-derivative-labelled antibody and showed that it could still bind to its antigen [22]. This opened the way to using fluorescent antibodies as a highly specific fluorescent stain.

Green fluorescent protein (GFP) was first isolated from the jellyfish *Aequorea victoria* in 1962 [23], but it was not until 1994 that Chalfie et al. [24] showed that it could be expressed and fluoresce outside of the jellyfish. They incorporated it into the promoter for a gene that encoded β -tubulin and showed that it could serve as a marker for expression levels. The discovery and development of GFP by Osamu Shimomura, Martin Chalfie and Roger Tsien was recognized in 2008 by the Nobel prize in chemistry.

By mutating GFP, blue, cyan and yellow derivatives had been manufactured [25] but orange and red fluorescent proteins proved difficult to produce until the search for fluorescent proteins was expanded to non-bioluminescent organisms. This led to the isolation of dsRed from *Anthozoa*, a species of coral [26]. Brighter and more photostable fluorescent proteins were subsequently produced by directed evolution [27]. The discovery of spectrally distinct fluorescent proteins allowed multichannel (dual and multi-color) fluorescence imaging and opened the way to studying the interaction between different fluorescently labelled proteins.

Early work with fluorescent proteins simply co-expressed GFP on the same promoter as another gene to monitor expression levels. Proteins could also be chemically labelled outside of the cell and then inserted using microinjection [25, 28]. A real breakthrough, with the discovery of GFP, was optimizing a method to fuse the genes of a protein of interest with a fluorescent protein and express this in a cell—thus leaving the cell relatively unperturbed. This was first demonstrated [29] on a GFP fusion to the *bcd* transcription factor in *Drosophila* [30].

Fluorescent dyes have been used not just as high-contrast markers, but as part of molecular probes which can readout dynamics between molecules and also environmental factors such as pH. In 1946, Theodore Förster posited that if a donor and acceptor molecule were sufficiently close together, non-radiative transfer of energy could occur between the two, now known as Förster resonance energy transfer (FRET), with efficiency proportional to the sixth power of the distance between them [31]. If such molecules are themselves fluorescent dyes, then fluorescence can be used as a metric of putative molecular interaction through FRET. In 1967, Stryer and Haugland [32] showed this phenomenon could

be used as a molecular ruler over a length scale of approximately 1–10 nm. Since then, FRET is used routinely to image molecular interactions and the distances between biological molecules, and also in fluorescence lifetime imaging [33]. Fluorescent probes have also been developed to detect cell membrane voltages, local cellular viscosity levels and the concentration of specific ions, with calcium ion probes, for example, first introduced by Roger Tsien in 1980 [34].

53.5 The Fluorescence Microscope

The fluorescence microscope has its origins in ultraviolet (UV) microscopy. Abbe theory meant that better spatial resolution could be achieved using shorter wavelengths of light. August Köhler constructed the first UV microscope in 1904 [35]. He found that his samples would also emit light under UV illumination (although he noted this as an annoyance). Not long after, Oskar Heimstaedt realized the potential for fluorescence and had a working instrument by 1911 [36]. These transmission fluorescence microscopes were greatly improved in 1929 when Philipp Ellinger and August Hirt placed the excitation and emission optics on the same side as the sample and invented the ‘epi-fluorescence’ microscope [37]. With the invention of dichroic mirrors in 1967 [38], this design would become the standard in fluorescence microscopes. Several innovative illumination modes have also been developed for the fluorescence microscope, which have allowed it to image many different samples over a wide range of length scales. These modes include confocal, fluorescence recovery after photobleaching (FRAP), total internal reflection fluorescence (TIRF) and two-photon and light-sheet microscopy (LSM).

In conventional fluorescence microscopy, the whole sample is illuminated and emitted light collected. Much of the collected light is from parts of the sample that are out of focus. In confocal microscopy, a pinhole is placed after the light source such that only a small portion of the sample is illuminated and another pinhole placed before the detector such that only in-focus light is collected (Fig. 53.1). This can reduce the background in a fluorescence image and allow imaging further into a sample. The latter even enables optical sectioning and three-dimensional reconstruction. The first confocal microscope was patented by Marvin Minsky in 1961 [39]. This instrument preceded the laser so the incident light was not bright enough for fluorescence. With laser-scanning confocal microscopes [40], much better fluorescence contrast is achievable, as explored by White who compared the contrast in different human and animal cell lines [41].

Fluorophores only emit light for a short time before they are irreversibly photobleached, and so microscopists must limit their sample’s exposure to excitation light. Photobleaching can be used to reveal kinetic information about a sample by fluorescence recovery. In the earliest fluorescence recovery study, in 1974, Peters et al. [42] bleached one-half of fluorescein-labelled human erythrocyte plasma membranes and found that no fluorescence returned,

indicating no observable mean diffusive process of the membrane over the experimental time scales employed. Soon after, analytical work by Axelrod et al. [43] (on what they termed fluorescence photobleaching recovery) allowed them to characterize different modes of diffusion in intracellular membrane trafficking. The term FRAP appears to have been coined by Jacobson, Wu and Poste in 1976 [44]. With FRAP capabilities commercially available on confocal systems, it is now widely used for measuring turnover kinetics in live cells.

When imaging features that are thin or peripheral such as cell membranes and molecules embedded in these, a widely used method is TIRF microscopy. This technique uses a light beam introduced above the critical angle of the interface between the (normally) glass microscope coverslip and the water-based sample. The beam itself will be reflected by total internal reflection due to the differences in refractive index between the water and the glass, but at the interface an evanescent wave of excitation light is generated which penetrates only approximately 100 nm into the sample, thus only fluorophores close to the coverslip surface are excited, producing much higher signal-to-noise than conventional epi-fluorescence microscopy. It was first demonstrated on biological samples by Axelrod in 1981 to image membrane proteins in rat muscle cells and lipids in human skin cells [45].

In conventional epifluorescence or even confocal, there is a limit to how far into the sample it is possible to image because of incident light scattering from the sample, creating a fluorescent background. This is particularly problematic when imaging tissues. Longer wavelength light scatters much less but few fluorophores can be excited by this with standard single photon excitation. In her doctoral thesis, in 1931, Maria Goppert-Mayer theorized that two photons with half the energy needed can excite emission of one photon whose energy was the sum of the two photons during a narrow time window for absorption of approximately 10^{-18} s [46]. The phenomenon of two-photon excitation (2PE) was not observed experimentally for another 30 years, until Kaiser and Garrett demonstrated it in CaF crystals [47]. The probability of 2PE occurring in a sample is low due to the very narrow time window of coincidence with respect to the two excitation photons, so high-intensity light with a large photon flux is required to use the phenomenon in microscopy. In 1990, Denk used a laser in a confocal scanning microscope to image human kidney cells with 2PE [48]. Since then, it has become a powerful technique for observing molecular processes in live tissues, particularly in neuroscience, where the dynamics of neurons within a live rat brain were first observed by Svoboda et al. [49].

Another method of reducing background in fluorescent samples is to only illuminate the sample through the plane that is in focus. This can be achieved by shining a very flat excitation beam through the sample perpendicular to the optical axis. Voie et al. [50] first demonstrated this using LSM in 1993. LSM can be used to take fluorescence images through slices of a sample, allowing a stack of images to build a three-dimensional reconstruction. One caveat of LSM is that samples need to be specially mounted to allow an unobstructed excitation beam as well as a

perpendicular detection beam, so a bespoke microscope is required. The technique was pioneered and developed by Ernst Stelzer in 2004, and termed selective plane illumination microscopy; it was used to image live embryos in three dimensions [51]. Stelzer's group went on to image and track every nucleus in a developing zebrafish over 24 h [52] and also the growth of plant roots at the cellular level in *Arabidopsis* [53]. LSM has proved itself a powerful tool for developmental biology, the potential of which is only now being realized (Fig. 53.3).



Figure 53.3 By chance, in the last days of finishing this chapter, the corresponding author was staying approximately 100 m from Leeuwenhoek's final resting place in the Oude Kerk, Delft, and captured these images.

53.6 Improving Resolution in Length and Time

Fluorescence microscopy set new standards of contrast in biological samples that have enabled the technique to achieve possibly the ultimate goal of microscopy in biology and visualize single molecules in live cells. The Abbe diffraction limit, thought unbreakable for over one hundred years, has been circumvented by ever more inventive microscopy techniques which are now extending into three spatial dimensions.

The first single biological molecules detected were observed by Cecil Hall in the 1950s [54], using electron microscopy of filamentous molecules including DNA and fibrous proteins using metallic shadowing of dried samples in a vacuum. The very first detection of a single biological molecule in its functional

aqueous phase was made by Boris Rotman, his seminal work published in 1961 involving the observation of fluorescently labelled substrates of β -galactosidase suspended in water droplets. The enzyme catalyzed the hydrolysis of galactopyranose labelled with fluorescein to the sugar galactose plus free fluorescein, which had a much greater fluorescence intensity than when attached to the substrate. He could detect single molecules because each enzyme could turn over thousands of fluorescent substrate molecules [55]. A more direct measurement was made by Thomas Hirschfield, in work published in 1976, who managed to see single molecules of globulin, labelled with approximately 100 fluorescein dyes, passing through a focused laser [56]. Single dye molecules were not observable directly until the advent of scanning near-field optical microscopy (SNOM) developed by Eric Betzig and Robert Chichester, allowing them to image individual cyanine dye molecules in a sub-monolayer [57]. SNOM uses an evanescent wave from a laser incident on an approximate 100 nm probe aperture which illuminates a small section and penetrates only a small distance into the sample. Images are generated by scanning this probe over the sample. This is technically challenging as the probe must then be very close to the sample.

Single molecules were shown to be observable with less challenging methods when, using TIRF microscopy, single ATP turnover reactions in single myosin molecules was observed in 1995 [58]. Other studies observed single F1-ATPase rotating using fluorescently labelled actin molecules in 1997 [59] and the dynamics of single cholesterol oxidase molecules [60]. In a landmark study, the mechanism and step size of the myosin motor was determined by labelling one foot, observing and using precise Gaussian fitting to obtain nanometre resolution (termed 'fluorescence imaging with one nanometer accuracy'—FIONA) [61]. This localization microscopy could effectively break the diffraction limit by using mathematical fitting algorithms to pinpoint the center of a dye molecule's PSF image, as long as they are resolvable such that the typical nearest-neighbor separation of dye molecules in the sample is greater than the optical resolution limit. These techniques were soon applied to image single molecules in living cells [62, 63] and now it is possible to count the number of single molecules in complexes inside cells [64, 65].

Stefan Hell showed that it was possible to optically break the diffraction limit with a more deterministic technique which modified the actual shape of the PSF, called Stimulated emission depletion microscopy (STED), which he proposed with Jan Wichmann in 1994 [66] and implemented with Thomas Klar in 1999 [67]. STED works by depleting the population of excited energy state electrons through stimulated emission. Fluorescence emission only occurs subsequently from a narrow central beam inside the deactivation annulus region which is scanned over the sample. The emission region is smaller than the diffraction limit (approx. 100 nm in the original study), thus allowing a superresolution image to be generated.

The development of STED showed that the diffraction limit could be broken, and many new techniques followed. In 2002, Ando et al. [68] isolated a fluorescent protein from the stony coral, *Trachyphyllia geoffroyi*, which they named Kaede. They found that if exposed to UV light its fluorescence would change from green to red, and demonstrated this in Kaede protein expressed in HeLa cells. Photoactivatable proteins such as this were used in 2006 by Hess et al. [69] in photo-activated localization microscopy (PALM) using TIRF and by Betzig et al. in fluorescence photo-activated localization microscopy using confocal. Both methods use low-intensity long UV laser light to photoactivate a small subset of sample fluorophores then another laser to excite them to emit and photobleach. This is repeated to build a superresolution image. A related method uses stochastic photoblinking of fluorescent dyes, which for example can be used to generate superresolution structures of DNA [70].

Other notable superresolution techniques include structured illumination microscopy [71]. In 1993, Bailey et al. showed that structured stripes of light could be used to generate a spatial 'beat' pattern in the image which could be used to extract spatial features in the underlying sample image, which had a resolution of approximately two times that of the optical resolution limit. In 2006, Zhuang and co-workers [72] demonstrated stochastic optical reconstruction microscopy (STORM), which used a Cy5/Cy3 pair as a switchable probe. A red laser keeps Cy5 in a dark state and excites fluorescence, while a green laser brings the pair back into a fluorescent state. Thus, similarly to PALM, a superresolution image can be generated.

Improvements in *dynamic* fluorescence imaging have been significant over the past few decades. For example, using essentially the same localization algorithms as developed for PALM/STORM imaging, fluorescent dye tags can be tracked in a cellular sample in real-time, for example tracking of membrane protein complexes in bacteria to nanoscale precision [73], which has been extended into high time resolution dual-color microscopy *in vivo* to monitor dynamic co-localization with a spatial precision of approximately 10–100 nm [74]. Modifications to increase the laser excitation of several recent bespoke microscope systems have also improved the time resolution of fluorescence imaging down to the millisecond level, for example using narrow-field and slim field microscopy [64].

Three-dimensional information can be obtained in many ways including using interferometric methods [75] or multiplane microscopy [76], which image multiple focal planes simultaneously. Another method of encoding depth information in images is to distort the PSF image in an asymmetrical but measurable way as the light source moves away from the imaging plane. Astigmatism and double-helix microscopy accomplish this using different methods and are compatible with many modes of fluorescence illumination as the equipment used is placed between the objective lens and the camera. As such, it is a viable way to extract three-dimensional data from many currently developed fluorescence microscopes.

Astigmatism microscopy is a simple three-dimensional microscopy technique, first demonstrated by Kao and Verkman in 1994 [77]. An asymmetry is introduced in the imaging path by placing a cylindrical lens before the camera detector. The introduced astigmatism offsets the focal plane along one lateral axis slightly, resulting in a controlled image distortion. When imaging singular or very small aggregates of fluorophores, the distortion takes the form of an ellipse, extending along either the x - or y -axis in the lateral plane of a camera detector conjugate to the microscope focal plane, depending on whether the fluorophore is above or below the focal plane. Values of 30 nm resolution in the lateral plane and 50 nm in the axial dimension have been reported using astigmatism with STORM [78].

Double-helix PSF (DH-PSF) microscopy is a similar three-dimensional microscopy technique using controlled PSF distortion. It exploits optical vortex beams, beams of light with angular momentum, and works by placing a phase mask—an object which modifies the phase of the beam differently at different points along a cross section—between the camera and the objective lens to turn the laser beam intensity profile from a Gaussian beam to a mixture of higher order optical vortex beams—a superposition of two so-called Laguerre-Gauss (LG) beams. These two beams interfere with each other at the point that the light hits the camera, creating two bright lobes [79]. The fields rotate as a function of distance propagated. As the two beams are superposed, the distance is the same; if the two LG beams are slightly different the electric fields will rotate at different rates thanks to different so-called ‘Gouy Phase’ components. This means that the interference pattern produced rotates as a function of the distance of the point source from the image plane only [80]. The distance from the focal plane can be determined by measuring the rotation angle of the two lobes.

The phase mask can be created using transparent media such as etched glass or using a spatial light modulator (SLM). An SLM is a two-dimensional array of microscale bit components, each of which can be used to change the phase of the incident light across a beam profile. A liquid-crystal-on-silicon SLM retards light as a function of the input voltage to each bit. As such, a phase mask can be applied and changed in real-time using computer control. One major drawback is that they are sensitive to the polarization of light [81], limiting the efficiency of light propagation through the SLM. Alternatively, a fixed glass phase plate can be etched using nanolithography. This is phase-independent and much more photon efficient. The phase is retarded simply by the thickness of the glass at each point in the beam. However, glass phase plates are less precise than SLM due to limitations in the lithography. Still, these are much easier to implement and can be purchased commercially or custom-built and used with almost any microscope set-up with minimal detrimental impact. DH-PSF microscopy has been shown to have some of the smallest spatial localization errors of any three-dimensional localization mode in high signal-to-noise systems [82].

The power of beam-shaping combined with light-sheet illumination has been recently used to create lattice LSM [83]. Using Bessel beams, which focus laser profiles with minimal divergence due to diffraction, they create different bound

optical lattices with different properties allowing them to image across four orders of magnitude in space and time and in diverse samples including diffusing transcription factors in stem cells, mitotic microtubules and embryogenesis in *Caenorhabditis elegans*.

53.7 The Future

Although it is over 300 years since the pioneering work of van Leeuwenhoek, many of the major developments in light microscopy have occurred in just the past few decades and their full impact may not yet be felt. There are several technologies currently in development which may have a profound impact on microscopy. These include, for example, adaptive optics, lens-free microscopy, super lenses, miniaturization and combinational microscopy approaches.

A biological sample itself adds aberration through spatial variation in the refractive index. This is even more of a problem when imaging deep into tissues. Adaptive optics uses so-called dynamic correction elements such as deformable mirrors or SLMs to correct for this aberration, increasing spatial resolution and contrast. There have been many recent developments, reviewed comprehensively by Martin Booth [84], but the technology is still yet to be widely adopted.

The archetypal lens used in light microscopy is made of glass, however this is not the only type of lens available. Optical diffraction gratings (optical gratings) can be used to focus, steer and even reflect light. Recognizing the need for miniaturization, researchers have been investigating the use of diffraction gratings in place of glass to help reduce the necessary size of optical components. While glass is great for large applications, it is extremely bulky when compared with the minimum size of a diffraction grating [85]. Optical gratings can be used as equivalent to lenses under some circumstances, for example a Fresnel zone plate can be used to focus light to a point as a convex lens does. Optical gratings all rely on the interaction of electromagnetic waves as they pass through the spaces in the gratings. This is fundamentally linked to the wavelength of propagating light making achromatic optical gratings very difficult to achieve in practice. Only recently have scientists been able to produce achromatic glass analogues such as an achromatic grating quarter-wave plates, for example, with good operational ranges [86].

Ptychography completely removes the need for imaging optics, lenses or gratings, and directly reconstructs real-space images from diffraction patterns captured from a beam scanned over a sample. In many cases, this allows higher contrast images than DIC or phase contrast and three-dimensional reconstruction [87, 88].

All optics currently used in microscopes are diffraction-limited but it is theoretically possible to construct, using so-called 'metamaterials', a perfect lens or super lens which could image with perfect sharpness. This was thought to require a material with negative refractive index [89] but it has now been shown that ordinary positive refractive index materials can also be used [90]. Even if super

lenses are not achievable, new materials may revolutionize microscope lenses, still mostly composed of the same materials used by van Leeuwenhoek.

It is interesting to note the return of microscopes such as van Leeuwenhoek's which use only a single lens, in the foldscope developed by Manu Prakash at Stanford University [91]. Using cardboard (an essential and surprisingly cheap component of some of the most advanced bespoke light microscopes found in our own laboratory) and simple filters and lenses, a near indestructible microscope with both normal transmission modes and fluorescence modes has been created that can be used by scientists and physicians working in areas far from expensive laboratory equipment.

Combinatorial microscopy is an interesting recent advance, which shows significant future potential. Here, several different microscopy methods are implemented on the same light microscope device. Many advances are being made at the level of single-molecule biophysics coupled to light microscopy in this regard. For example, methods are being developed that can permit simultaneous superresolution imaging of DNA coupled to magnetic tweezers manipulation [92].

The ultimate practical limits at the other end of the length scale for imaging tissues and whole organisms in the future are difficult to determine. Recent technological developments such as the light-sheet imaging of *Arabidopsis* or lattice LSM discussed previously have enabled imaging of ever larger samples in greater detail. What limits the largest possible sample and to what level of detail it can be imaged is unknown. And, just as importantly, is computing technology used to store and analyze these data up to the challenge?

It is unquestionable that light microscopy has advanced enormously since the days of Antonj van Leeuwenhoek. The improvements have been, in a broad sense, twofold. Firstly, in length-scale precision: this has been a 'middling-out' improvement, in that superresolution methods have allowed unprecedented access to nanoscale biological features, whereas light-sheet approaches and multiphoton deep imaging methods in particular have allowed incredible detail to be discerned at the much larger length-scale level of multicellular tissues. Secondly, there has been an enormous advance, almost to the level of a paradigm shift, towards faster imaging in light microscopy, to permit truly dynamic biological processes to be investigated, right down to the millisecond level. Not only can we investigate detailed biological structures using light microscopy, but we can watch them change with time.

And yet, equally so, the basic principles of light microscopy for the study of biology remain essentially unchanged. These were facilitated in no small part by the genius and diligence of van Leeuwenhoek. It is perhaps the finest legacy for a true pioneer of light microscopy.

Abbreviations

2PE:	two-photon excitation
DH-PSF:	double-helix PSF
DIC:	differential interference contrast

FIONA:	fluorescence imaging with one nanometer accuracy
FRAP:	fluorescence recovery after photobleaching
FRET:	Förster resonance energy transfer
GFP:	green fluorescent protein
LG:	Laguerre-Gauss
LSM:	light-sheet microscopy
PALM:	photo-activated localization microscopy
PSF:	point spread function
SLM:	spatial light modulator
SNOM:	scanning near-field optical microscopy
STED:	stimulated emission depletion microscopy
STORM:	stochastic optical reconstruction microscopy
TIRF:	total internal reflection fluorescence
UV:	ultraviolet

Disclosures and Conflict of Interest

This chapter was originally published as: Wollman, A. J. M., Nudd, R., Hedlund, E. G., Leake, M. C. (2015). From *Animaculum* to single molecules: 300 years of the light microscope. *Open Biol.*, **5**, 150019, <http://dx.doi.org/10.1098/rsob.150019>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>), and appears here with edits and updates.

Funding statement: M.C.L. is supported by a Royal Society University Research Fellowship (UF110111). E.G.H. was supported by Marie Curie EU FP7 ITN 'ISOLATE' ref 289995. R.N. was supported by the White Rose Consortium. The work was supported by the Biological Physics Sciences Institute (BPSI).

Author contributions: All authors contributed to the drafting and revision of the chapter, and gave their final approval for publication.

References

1. Orchard G, Nation B. 2014. *Cell Structure & Function*, Oxford, UK: Oxford University Press, p. 448.
2. Hooke R. 1665. *Micrographia: or Some Physiological Descriptions of Minute Bodies Made by Magnifying Glasses, with Observations and Inquiries Thereupon*. Courier Corporation. Available at: <https://tile.loc.gov/storage-services/service/rbc/rbctos/2017rosen1511/2017rosen1511.pdf> (accessed on September 20, 2022).
3. Baker H, Leeuwenhoek M. 1739. An account of Mr. Leeuwenhoek's microscopes; by Mr. Henry Baker F. R. S. 1739. *Phil. Trans.* **41**, 503–519.
4. van Leeuwenhoek A, Hoole S. 1800. *The Select Works of Antony Van Leeuwenhoek, Containing His Microscopical Discoveries in Many of the Works of Nature*, Vol. **1**. Gale ECCO. DOI: <https://doi.org/10.5962/bhl.title.5700>, OCLC: 8875257.
5. Airy GB. 1835. On the diffraction of an object-glass with circular aperture. *Trans Camb Phil Soc.* **5**, 239–291.

6. Abbe E. 1873. Beiträge zur Theorie des Mikroskops und der mikroskopischen Wahrnehmung. *Arch Mikrosk Anat.* **9**, 413–418.
7. Lord Rayleigh FRS. 1879. XXXI investigations in optics, with special reference to the spectroscope. *Phil Mag Ser 5.* **8**, 261–274.
8. Mansuripur M. 2002. *Classical Optics and Its Applications*, Cambridge, UK: Cambridge University Press, p. 502.
9. Abbe E. 1881. VII.-On the estimation of aperture in the microscope. *JR Microsc Soc.* **1**, 388–423.
10. Abbe E. 1883. XV.-The relation of aperture and power in the microscope. *JR Microsc Soc.* **3**, 790–812.
11. Hell SW, Stelzer EHK, Lindek S, Cremer C. 1994. Confocal microscopy with an increased detection aperture: type-B 4Pi confocal microscopy. *Opt Lett.* **19**, 222.
12. Köhler A. 1893. Ein neues Beleuchtungsverfahren für mikrophotographische Zwecke. *Z Wiss Mikrosk.* **10**, 433–440.
13. Zernike F. 1942. Phase contrast, a new method for the microscopic observation of transparent objects. *Physica.* **9**, 686–698.
14. Zernike F. 1955. How I discovered phase contrast. *Science.* **121**, 345–349.
15. Smith F. 1955. Microscopic interferometry. *Research.* **8**, 385–395.
16. Nomarski G, Weill A. 1955. Application à la métallographie des méthodes interférentielles à deux ondes polarisées. *Rev Met.* **2**, 121–128.
17. Gerlach J. 1858. *Mikroskopische Studien aus dem Gebiete der menschlichen Morphologie*. Enke.
18. Golgi C. 1873. Sulla struttura della grigia del cervello. *Gaz Med Intalianna Lomb.* **6**, 244–246.
19. Gram H. 1884. Über die isolierte Färbung der Schizomyceten in Schnitt-und Trockenpräparaten. *Fortschr Med.* **2**, 185–189.
20. Stokes GG. 1852. On the change of refrangibility of light. *Phil Trans R Soc Lond.* **142**, 463–562.
21. Baeyer A. 1871. Über eine neue Klasse von Farbstoffen. *Berichte der Dtsch Chem Gesellschaft.* **4**, 555–558.
22. Coons AH, Creech HJ, Jones RN. 1941. Immunological properties of an antibody containing a fluorescent group. *Exp Biol Med.* **47**, 200–202.
23. Shimomura O, Johnson FH, Saiga Y. 1962. Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, aequorea. *J Cell Comp Physiol.* **59**, 223–239.
24. Chalfie M, Tu Y, Euskirchen G, Ward W, Prasher D. 1994. Green fluorescent protein as a marker for gene expression. *Science.* **263**, 802–805.
25. Heim R, Prasher DC, Tsien RY. 1994. Wavelength mutations and posttranslational autoxidation of green fluorescent protein. *Proc Natl Acad Sci USA.* **91**, 12 501–12 504.
26. Matz MV, Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, Markelov ML, Lukyanov SA. 1999. Fluorescent proteins from nonbioluminescent Anthozoa species. *Nat Biotechnol.* **17**, 969–973.

27. Shaner NC, Campbell RE, Steinbach PA, Giepmans BNG, Palmer AE, Tsien RY. 2004. Improved monomeric red, orange and yellow fluorescent proteins derived from *Discosoma* sp. red fluorescent protein. *Nat Biotechnol.* **22**, 1567–1572.
28. Taylor D, Amato P, Luby-Phelps K, McNeil P. 1984. Fluorescent analog cytochemistry. *Trends Biochem Sci.* **9**, 88–91.
29. Gerdes H-H, Kaether C. 1996. Green fluorescent protein: applications in cell biology. *FEBS Lett.* **389**, 44–47.
30. Wang S, Hazelrigg T. 1994. Implications for bcd mRNA localization from spatial distribution of exu protein in *Drosophila oogenesis*. *Nature.* **369**, 400–403.
31. Förster T. 1946. Energiewanderung und Fluoreszenz. *Naturwissenschaften.* **33**, 166–175.
32. Stryer L, Haugland RP. 1967. Energy transfer: a spectroscopic ruler. *Proc Natl Acad Sci USA.* **58**, 719–726.
33. Clegg RM, Feddersen BA, Gratton E, Jovin TM. 1992. Time-resolved imaging fluorescence microscopy. *Proc SPIE.* **1640**, 448–460.
34. Tsien RY. 1980. New calcium indicators and buffers with high selectivity against magnesium and protons: design, synthesis, and properties of prototype structures. *Biochemistry.* **19**, 2396–2404.
35. Köhler A, Rohr MJ. 1905. Photomicrography with ultra-violet light. *JR Microsc Soc.* **25**, 513.
36. Heimstadt O. 1911. Das Fluoreszenzmikroskop. *Z Wiss Mikrosk.* **28**, 330–337.
37. Ellinger P, Hirt A. 1929. Mikroskopische Beobachtungen an lebenden Organen mit Demonstrationen (Intravitalmikroskopie). *Arch Exp Pathol Pharmacol.* **147**, 63.
38. Ploem JS. 1967. The use of a vertical illuminator with interchangeable dichroic mirrors for fluorescence microscopy with incidental light. *Z Wiss Mikrosk.* **68**, 129–142.
39. Minsky M. 1961. *Microscopy Apparatus*. US Patent No. 3,013,467.
40. Wilke V. 1985. Optical scanning microscopy: the laser scan microscope. *Scanning.* **7**, 88–96.
41. White JG. 1987. An evaluation of confocal versus conventional imaging of biological structures by fluorescence light microscopy. *J Cell Biol.* **105**, 41–48.
42. Peters R, Peters J, Tews KH, Bähr W. 1974. A microfluorimetric study of translational diffusion in erythrocyte membranes. *Biochim Biophys Acta Biomembr.* **367**, 282–294.
43. Axelrod D, Koppel DE, Schlessinger J, Elson E, Webb WW. 1976. Mobility measurement by analysis of fluorescence photobleaching recovery kinetics. *Biophys J.* **16**, 1055–1069.
44. Jacobson K, Wu E, Poste G. 1976. Measurement of the translational mobility of concanavalin A in glycerol-saline solutions and on the cell surface by fluorescence recovery after photobleaching. *Biochim Biophys Acta.* **433**, 215–222.
45. Axelrod D. 1981. Cell-substrate contacts illuminated by total internal reflection fluorescence. *J Cell Biol.* **89**, 141–145.
46. Göppert-Mayer M. 1931. Über Elementarakte mit zwei Quantensprüngen. *Ann Phys.* **401**, 273–294.
47. Kaiser W, Garrett C. 1961. Two-photon excitation in $\text{CaF}_2: \text{Eu}^{2+}$. *Phys Rev Lett.* **7**, 229–231.

48. Denk W, Strickler JH, Webb WW. 1990. Two-photon laser scanning fluorescence microscopy. *Science*. **248**, 73–76.
49. Svoboda K, Denk W, Kleinfeld D, Tank DW. 1997. *In vivo* dendritic calcium dynamics in neocortical pyramidal neurons. *Nature*. **385**, 161–165.
50. Voie AH, Burns DH, Spelman FA. 1993. Orthogonal-plane fluorescence optical sectioning: three-dimensional imaging of macroscopic biological specimens. *J Microsc*. **170**, 229–236.
51. Huisken J, Swoger J, Del Bene F, Wittbrodt J, Stelzer EHK. 2004. Optical sectioning deep inside live embryos by selective plane illumination microscopy. *Science*. **305**, 1007–1009.
52. Keller PJ, Schmidt AD, Wittbrodt J, Stelzer EHK. 2008. Reconstruction of zebrafish early embryonic development by scanned light sheet microscopy. *Science*. **322**, 1065–1069.
53. Maizel A, von Wangenheim D, Federici F, Haseloff J, Stelzer EHK. 2011. High-resolution live imaging of plant growth in near physiological bright conditions using light sheet fluorescence microscopy. *Plant J*. **68**, 377–385.
54. Hall CE. 1956. Method for the observation of macromolecules with the electron microscope illustrated with micrographs of DNA. *J Biophys Biochem Cytol*. **2**, 625–628.
55. Rotman B. 1961. Measurement of activity of single molecules of beta-D-galactosidase. *Proc Natl Acad Sci USA*. **47**, 1981–1991.
56. Hirschfeld T. 1976. Optical microscopic observation of single small molecules. *Appl Opt*. **15**, 2965–2966.
57. Betzig E, Chichester RJ. 1993. Single molecules observed by near-field scanning optical microscopy. *Science*. **262**, 1422–1425.
58. Funatsu T, Harada Y, Tokunaga M, Saito K, Yanagida T. 1995. Imaging of single fluorescent molecules and individual ATP turnovers by single myosin molecules in aqueous solution. *Nature*. **374**, 555–559.
59. Noji H, Yasuda R, Yoshida M, Kinosita K. 1997. Direct observation of the rotation of F1-ATPase. *Nature*. **386**, 299–302.
60. Lu HP. 1998. Single-molecule enzymatic dynamics. *Science*. **282**, 1877–1882.
61. Yildiz A, et al. 2003. Myosin V walks hand-over-hand: single fluorophore imaging with 1.5 nm localization. *Science*. **300**, 2061–2065.
62. Byassee T, Chan W, Nie S. 2000. Probing single molecules in single living cells. *Anal Chem*. **72**, 5606–5611.
63. Sako Y, Minoghchi S, Yanagida T. 2000. Single-molecule imaging of EGFR signalling on the surface of living cells. *Nat Cell Biol*. **2**, 168–172.
64. Reyes-Lamothe R, Sherratt DJ, Leake MC. 2010. Stoichiometry and architecture of active DNA replication machinery in *Escherichia coli*. *Science*. **328**, 498–501.
65. Leake MC, Chandler JH, Wadhams GH, Bai F, Berry RM, Armitage JP. 2006. Stoichiometry and turnover in single, functioning membrane protein complexes. *Nature*. **443**, 355–358.
66. Hell SW, Wichmann J. 1994. Breaking the diffraction resolution limit by stimulated emission: stimulated-emission-depletion fluorescence microscopy. *Opt Lett*. **19**, 780–782.

67. Klar TA, Hell SW. 1999. Subdiffraction resolution in far-field fluorescence microscopy. *Opt Lett.* **24**, 954.
68. Ando R, Hama H, Yamamoto-Hino M, Mizuno H, Miyawaki A. 2002. An optical marker based on the UV-induced green-to-red photoconversion of a fluorescent protein. *Proc Natl Acad Sci USA.* **99**, 12 651–656.
69. Hess ST, Girirajan TPK, Mason MD. 2006. Ultra-high resolution imaging by fluorescence photoactivation localization microscopy. *Biophys J.* **91**, 4258–4272.
70. Miller H, Zhaokun Z, Wollman AJM, Leake MC. 2015. Superresolution imaging of single DNA molecules using stochastic photoblinking of minor groove and intercalating dyes. *Methods.* **88**, 81–88.
71. Bailey B, Farkas DL, Taylor DL, Lanni F. 1993. Enhancement of axial resolution in fluorescence microscopy by standing-wave excitation. *Nature.* **366**, 44–48.
72. Rust MJ, Bates M, Zhuang X. 2006. Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). *Nat Methods.* **3**, 793–795.
73. Leake MC, Greene NP, Godun RM, Granjon T, Buchanan G, Chen S, Berry RM, Palmer T, Berks BC. 2008. Variable stoichiometry of the TatA component of the twin-arginine protein transport system observed by *in vivo* single-molecule imaging. *Proc Natl Acad Sci USA.* **105**, 15376–15381.
74. Llorente-Garcia I, et al. 2014. Single-molecule *in vivo* imaging of bacterial respiratory complexes indicates delocalized oxidative phosphorylation. *Biochim Biophys Acta.* **1837**, 811–824.
75. Shtengel G, et al. 2009. Interferometric fluorescent super-resolution microscopy resolves 3D cellular ultrastructure. *Proc Natl Acad Sci USA.* **106**, 3125–3130.
76. Juette MF, Gould TJ, Lessard MD, Mlodzianoski MJ, Nagpure BS, Bennett BT, Hess ST, Bewersdorf J. 2008. Three-dimensional sub-100 nm resolution fluorescence microscopy of thick samples. *Nat Methods.* **5**, 527–529.
77. Kao HP, Verkman AS. 1994. Tracking of single fluorescent particles in three dimensions: use of cylindrical optics to encode particle position. *Biophys J.* **67**, 1291–1300.
78. Huang B, Wang W, Bates M, Zhuang X. 2008. Three-dimensional super-resolution imaging by stochastic optical reconstruction microscopy. *Science.* **319**, 810–813.
79. Pavani SRP, Thompson MA, Biteen JS, Lord SJ, Liu N, Twieg RJ, Piestun R, Moerner WE. 2009. Three-dimensional, single-molecule fluorescence imaging beyond the diffraction limit by using a double-helix point spread function. *Proc Natl Acad Sci USA.* **106**, 2995–2999.
80. Schechner Y, Piestun R, Shamir J. 1996. Wave propagation with rotating intensity distributions. *Phys Rev E.* **54**, R50–R53.
81. Carbone L, Fulda P, Bond C, Brueckner F, Brown D, Wang M, Lodhia D, Palmer R, Freise A. 2013. The generation of higher-order Laguerre-Gauss optical beams for high-precision interferometry. *J Vis Exp.* **78**, e50564.
82. Badieirostami M, Lew MD, Thompson MA, Moerner WE. 2010. Three-dimensional localization precision of the double-helix point spread function versus astigmatism and biplane. *Appl Phys Lett.* **97**, 161103.

83. Chen B-C, et al. 2014. Lattice light-sheet microscopy: imaging molecules to embryos at high spatiotemporal resolution. *Science*. **346**, 1257998.
84. Booth MJ. 2014. Adaptive optical microscopy: the ongoing quest for a perfect image. *Light Sci Appl*. **3**, e165.
85. Chrostowski L. 2010. Optical gratings: nano-engineered lenses. *Nat Photonics*. **4**, 413–415.
86. Passilly N, Ventola K. 2008. Achromatic phase retardation by subwavelength gratings in total internal reflection. *J Opt A Pure Appl Opt*. **10**, 015001.
87. Marrison J, Rätty L, Marriott P, O'Toole P. 2013. Ptychography—a label free, high-contrast imaging technique for live cells using quantitative phase information. *Sci Rep*. **3**, 2369.
88. Rodenburg JM, Hurst AC, Cullis AG. 2007. Transmission microscopy without lenses for objects of unlimited size. *Ultramicroscopy*. **107**, 227–231.
89. Pendry J. 2000. Negative refraction makes a perfect lens. *Phys Rev Lett*. **85**, 3966–3969.
90. Leonhardt U. 2009. Perfect imaging without negative refraction. *New J Phys*. **11**, 093040.
91. Cybulski JS, Clements J, Prakash M. 2014. Foldscope: origami-based paper microscope. *PLoS ONE*. **9**, e98781.
92. Wollman AJM, Miller H, Zhaokun Z, Leake MC. 2015. Probing DNA interactions with proteins using a single-molecule toolbox: inside the cell, in a test tube, and in a computer. *Biochem Soc Trans*. **43**, 139–145.

Chapter 54

Ultrastructure Expansion Microscopy in *Trypanosoma Brucei*

Ana Kalichava, MSc,^{a,b} and Torsten Ochsenreiter, PhD^a

^a*Institute of Cell Biology, University of Bern, Switzerland*

^b*Graduate School for Cellular and Biomedical Sciences, University of Bern, Switzerland*

torsten.ochsenreiter@izb.unibe.ch

Keywords: ammonium persulfate (APS), archaic protein translocase of the outer membrane (ATOM), basal body (bb), centrins, confocal imaging, 4',6-diamidino-2-phenylindole (DAPI) stain, flagellar attachment zone (FAZ), flagellum, Golgi, high-resolution imaging, immunofluorescence, kinetoplast DNA (kDNA), mitochondria, organelles, polyelectrolyte gel, pro-basal body (probb), protozoan, segregation machinery, sodium dodecyl sulfate (SDS), tripartite attachment complex (TAC), *Trypanosoma brucei*, trypanosomes, ultrastructure expansion microscopy (U-ExM)

54.1 Introduction

Trypanosoma brucei is a unicellular flagellated protozoan parasite and the causative agent of human African sleeping sickness and Nagana in cattle. The highly polarized parasite cell body is about 25 µm in length and is shaped by the subpellicular microtubule corset [1, 2]. The *T. brucei* cell contains at least eight single-copy organelles, including the (i) flagellum that emanates from the (ii) flagellar pocket in the posterior region of the cell and is attached along the entire cell body by the (iii) flagellar attachment zone (FAZ) [3]. The axoneme of the flagellum nucleates at the (iv) basal body, which aside from the well-conserved microtubule organization also associates with the (v) microtubule quartet that has an orientation (posterior to anterior) opposite of the microtubule corset [4]. Additional single-copy organelles are the (vi) Golgi and the (vii) mitochondrion [5, 6] with its (viii) single mitochondrial genome named the kinetoplast DNA (kDNA). The kDNA is the feature structure of the Kinetoplastea and in *T. brucei* is organized in a complex structure of approximately 5000 interlocked mini-

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

and approximately 25 maxicircles [7, 8]. Replication and segregation of the mitochondrial genome has been studied in some detail, and it is thought that more than 100 proteins are likely to be involved in these two processes [9, 10]. In recent years, a number of studies have started to deconstruct the segregation machinery (tripartite attachment complex, TAC) connecting the basal body of the flagellum to the kDNA.

Expansion microscopy is based on a series of chemical steps to physically magnify the cell and visualize ultrastructures by optical microscopy (for details see [11–13]; Fig. 54.1; Table 54.1 summarizes details of antibodies used in this study). In the first step, the precursor molecules formaldehyde and acrylamide are introduced to functionalize the cellular components allowing the subsequent linkage of swellable polyelectrolyte gel (sodium acrylate). The gel formation is accomplished analogously to polyacrylamide gels by using oxidizing reagents like tetramethylethylenediamine and ammonium persulfate (APS). After the gel is formed, the cell contents are denatured and thus homogenized through the use of sodium dodecyl sulfate (SDS) and heat. At this point, the sample is ready for the application of standard immunofluorescence techniques. Expansion microscopy has been applied to a wide range of organisms and scientific questions, including membrane biology in bacteria, neuronal development in fish and cell structure of protozoan parasites, to name just a few [11, 14–16].

Table 54.1 Antibodies used in this study

Primary antibody	Target	Source/Reference	Dilution for U-ExM	Dilution for IF
TAC102 (mouse)	TAC102	[29]	1 : 500	1 : 5000
20H5 (mouse)	basal body and pro-basal body	Millipore Sigma (04-1624)	1 : 500	1 : 2000
SAS6 (rabbit)	basal body and pro-basal body	[23]	1 : 500	1 : 2000
YL1/2 (rat)	tyrosinated tubulin	[30]	1 : 2000	1 : 50 000
Bip (rabbit)	endoplasmic reticulum	[27]	1 : 500	1 : 2000
alpha-tubulin (guinea pig)	alpha-tubulin	Geneva Antibody Facility	1 : 500	1 : 2000
Secondary antibody	Source	Dilution for U-ExM	Dilution for IF	Used for
Alexa Fluor 594 (mouse)	Sigma SAB4600180	1 : 500	1 : 2000	alpha-tubulin
Oregon Green 488 (rabbit)	Invitrogen A32744	1 : 500	1 : 2000	20H5, TAC102
Alexa Fluor 488 (rat)	Thermofisher O-11038	1 : 500	1 : 2000	SAS6
Alexa Fluor 647 (guinea pig)	Thermofisher A-11006	1 : 500	1 : 2000	YL1/2




Figure 54.1 Schematic representation of the ultrastructure expansion microscopy concept in *T. brucei*. First, cells were settled at room temperature on coverslips. Then, the coverslips were incubated in a 24-well plate filled with a solution of formaldehyde and acrylamide in PBS. Cells were subsequently prepared for gelation by carefully transferring coverslips into a gel solution supplemented with APS and TEMED. After gelation, the cell components were denatured using heat and SDS, which was followed by first round of expansion and gel shrinkage in PBS. Then, cells were stained with primary and secondary antibodies followed by dialyzing in water for the final expansion.

We now provide data to validate this new sample preparation technique in *T. brucei* and give an overview of the opportunities and challenges with ultrastructure expansion microscopy (U-ExM) in the protozoan model system.

54.2 Results and Discussion

The use of ultrastructure expansion microscopy was first demonstrated in Kinetoplastea localizing a component of the mitochondrial genome segregation machinery (TAP110) relative to its interaction partner TAC102 [17]. In that study, the isotropicity was measured using the basal body, the kDNA and the nucleus as references. The expansion factors of those cellular compartments/complexes varied less than 10% between 3.61 and 3.86. In the current study, we were able to increase the expansion factor to 4.2–4.6 as measured by the expansion of the kDNA, nucleus and cytoskeleton maintaining the variation at about 10% (Fig. 54.2a–c). Aside from the measurements of cellular compartments, the isotropicity of the expansion becomes obvious in the maintenance of the overall cell shape when compared to the non-expanded trypanosomes (Fig. 54.2a,b).

The ability to image DNA in the nucleus and the mitochondrion of expanded cells will in future allow the precise localization of expressed genes, centromeric sequences or overall chromatin architecture. Thus, we evaluated the use of the minor groove AT-rich DNA binder 4',6-diamidino-2-phenylindole (DAPI) in U-ExM in *T. brucei*. The mitochondrial DNA of *T. brucei* and for most Kinetoplastea is organized in a complex structure of interlocked minicircles and maxicircles. Depending on the imaging angle, this results in the DAPI stain to appear as a homogeneous cylinder or 'disc-like' structure (Fig. 54.3a,b) [18]. In the kDNA, the minicircles are parallel to each other and stretched out maximally thereby defining the height of the cylinder. As a consequence of this organization, the kDNA cylinder can be isotropically expanded in its diameter but not in its height (Fig. 54.3a). With U-ExM, we can visualize individual regions within the kDNA disc that have previously only been detected by electron microscopy. This includes the inner unilateral filament region, a DNA containing domain between the kDNA disc and the inner mitochondrial membrane (Fig. 54.3b) [19]. If the 'cloudy' DAPI signal at the basal body proximal face of the kDNA disc is made up of minicircle replication intermediates as could be predicted by the current replication model [9] or potentially maxicircle segments remains to be investigated (Fig. 54.3a,b, asterisk). Furthermore, during replication and prior to segregation, the kinetoplast assumes a conformation that from the side resembles a V. In this conformation, the DAPI signal seems strongly concentrated in the middle between the two newly developing kDNAs (late kDNA replication phase), which is likely a combination of the imaging angle and the replication of maxicircles that potentially occurs at the interphase of the two replicating kDNAs [20] (Fig. 54.3b).




Figure 54.2 Isotropy and the expansion factor. (a) Non-expanded and expanded PCF cells stained with α -tubulin (magenta; Alexa Fluor 647), kDNA and nuclear DNA (cyan; DAPI). Imagery was deconvolved using Huygens Professional and visualized using Imaris. (b,c) Magnified views and measurements of the cytoskeleton length, kDNA length and nucleus diameter in non-expanded and expanded cells were done in ImageJ. Expansion factor was calculated as the ratio between non-expanded and expanded cell compartments.




Figure 54.3 Representative confocal images of kDNA during different stages of the cell cycle. (a) Comparative confocal images of expanded and non-expanded *T. brucei* kDNA (DAPI, cyan). (b) Representative images of the kDNA and basal bodies during different kDNA replication steps. DNA stained with DAPI (cyan); cytoskeleton stained with a monoclonal alpha-tubulin antibody (magenta; Alexa Fluor 647). Asterisk marks the 'cloudy' part of the kDNA. Imagery was deconvolved using Huygens Professional and visualized using Imaris.

In *T. brucei*, the cytoskeleton is dominated by microtubules that can be visualized by an alpha-tubulin antibody. Aside from the subpellicular microtubules, the antibody also allows detection of the entire axoneme from the base of the flagellum to its tip, revealing its continuous attachment to the cell body as previously described [21] (Fig. 54.2a). By using higher zoom factors, we can visualize the pro- and mature basal bodies with their associated microtubule quartet in proximity to the kDNA (Fig. 54.2a). The basal body is the central organizer of the cell cycle specifically involved in the duplication of the Golgi and the mitochondrion, including its singular genome [4, 6, 22]. Although the precise number remains unknown, probably more than 100 proteins are involved in the biogenesis and structure of the basal body, all concentrated in a small area. Thus, precise localization of the individual components will be key for understanding their role in basal body biogenesis. Centrin, for example, are calcium-binding proteins that are highly conserved in all centrosomes. The monoclonal antibody 20H5 that was raised against the centrin in *Chlamydomonas* binds to centrin 1 and 2 at the basal body and the bilobe region in *T. brucei*, [6] (Fig. 54.4a). Using U-ExM, we can now show that centrin1/2 are found in expanded cells at the mature basal body, and a region of about 500 nm between the maturing basal body and the associated growing microtubule quartet (Fig. 54.4a, arrowhead; quantification in Fig. 54.4d). To a lesser degree, there is also a signal at the old basal body (Fig. 54.4a, asterisk) and at the bilobe (Fig. 54.4a, asterisk). A second very prominent protein of the basal body is SAS6, a structural component of the cartwheel, that in trypanosomes is present at the pro- and the mature basal body [23] (Fig. 54.4b). U-ExM confirms that similar to the recent data from cryo-tomography SAS6 is in the center of the cartwheel and protrudes at the proximal end of the basal body [24]. We measured the protrusion to be 170 and 210 nm at the pro-basal body and mature basal body, respectively (Fig. 54.4e). In non-expanded cells, this would translate to 40–50 nm that the cartwheel would protrude from the proximal end of the basal body (Fig. 54.4e). Another commonly used reagent to label the basal body is the antibody YL1/2 that binds to tyrosinated α -tubulin and also cross-reacts with the basal body protein TbrP2 [25, 26]. With U-ExM and at high dilutions of the primary antibody, we find tyrosinated tubulin to be more or less equally distributed at the old and new basal body. At these concentrations, the previously described cross-reactivity of YL1/2 with TbrP2 cannot be detected (Fig. 54.4, asterisks).

One question that we wished to address was whether membrane-bound organelles could be analyzed using U-ExM in *T. brucei*. To test this, we localized the archaic protein translocase of the outer membrane (ATOM), which is part of the mitochondrial protein import machinery in the outer mitochondrial membrane, TAC102 which is a TAC protein inside the mitochondrion and the luminal ER component binding protein (BiP) [27–29]. In regular confocal microscopy, ATOM is continuously distributed throughout the entire mitochondrial membrane. In expansion microscopy, the distribution of the protein is visible in several hundred individual spots per cell, suggesting individual complexes can be visualized (Fig. 54.5a). The ER-resident protein BiP on the other hand seems to be more

continuously distributed throughout the ER lumen even in U-ExM (Fig. 54.5b), which is in good agreement with its function as a chaperone. TAC102 that was previously shown to reside inside the mitochondrion in proximity to the kDNA disc can be visualized using a monoclonal antibody (Fig. 54.5c).




Figure 54.4 Representative confocal images of basal body associated structures in U-ExM. (a) Centrin stained with anti-centrin antibody 20H5 (green), anti- α -tubulin antibody (magenta), kDNA and nucleus with DAPI (cyan). Arrowheads mark the centrin signal at the maturing basal body and microtubule quartet. Asterisk represents centrin signal at the old basal body and bilobe structure. (b) Anti-SAS6 antibody (green) localization at the basal body and pro-basal body (magenta). (c) Tyrosinated tubulin distribution (YL1/2, green) at the bb and probb (magenta). (d) Boxplot quantification of the length of 20H5 signal at the pro-basal body. (e) Quantification of SAS6 protrusion at the pro-basal body (the left graph) and basal body (the right graph). Imagery was deconvolved using Huygens Professional and visualized using Imaris.




Figure 54.5 Expansion microscopy targeting different compartments of *T. brucei*. (a) Mitochondrial protein complexes (anti-ATOM antibody, green) distribution in *T. brucei*. (b) BIP (anti-BIP antibody, green) distribution in *T. brucei*. (c) TAC protein (anti-TAC102 monoclonal antibody, green) localization at the kDNA. Imagery was deconvolved using Huygens Professional and visualized using Imaris.

54.2.1 Ultrastructure Expansion Microscopy Challenges and Opportunities

U-ExM offers several technical advantages for visualizing ultrastructures, but it also faces significant challenges. One of the main chemicals used in U-ExM is sodium acrylate. Its quality varies from batch to batch, and impurities negatively affect polymerization and ultimately the expansion factor. Another key challenge in expansion microscopy is the imaging process. The transparent aqueous gel starts shrinking after some time due to laser power and the evaporation of water out of the gel, which results in shifted images. Furthermore, sample storage is not as simple as for immunofluorescence slides. While immunofluorescence slides can be kept at four degrees for a long period of time, gel quality drops rapidly. It should also be noted that U-ExM requires significantly more antibody than typical immunofluorescence staining. Also, we have experienced potentially due to the denaturation of epitopes that not all antibodies that work in regular immunofluorescence microscopy can be used in U-ExM. U-ExM enables super-resolution imaging through the improvement of axial and lateral effective resolution by an isotropic increase in the distance between individual molecules

to be analyzed. Correspondingly, expansion by a factor of four increases resolution from around 200 nm to less than 50 nm using regular confocal microscopy and significantly further by super-resolution techniques. In future, this will allow us to precisely visualize and characterize biomolecular structures that are in close proximity to each other such as components within the basal body and nuclear pore complexes. In contrast with other high-resolution imaging techniques, U-ExM is accessible without the need of special equipment. In combination with protease treatment, the technique will likely allow improved intra-molecular resolution leading to *in situ* structure analysis, while using established reagents. Many antibodies and stains used for regular immunofluorescence microscopy show good results also in U-ExM. Furthermore, by tuning the sample functionalization steps and increasing the expansion factor, resolution in the single-digit nanometer range seems feasible. In summary, U-ExM has developed into a very powerful tool bridging the gap between light and electron microscopy.

54.3 Material and Methods

54.3.1 *Trypanosoma Brucei* Cell Culture Conditions

Procyclic form (PCF, 29–13) asynchronous *T. brucei* cells were cultured in semi-defined medium-79 (SDM-79) supplemented with 10% FCS, 15 $\mu\text{g ml}^{-1}$ geneticin and 25 $\mu\text{g ml}^{-1}$ hygromycin at 27°C.

54.3.2 Immunofluorescence Analyses

One million cells were washed twice with 200 μl phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na_2HPO_4 , and 1.8 mM KH_2PO_4 . PBS) and centrifuged for 3 min at 1800g, then resuspended in 100 μl of PBS and settled for 15 min at room temperature on coverslips. Then, the excess liquid is removed with tissue paper. Then, 200 μl of 4% paraformaldehyde (PFA; Sigma P6148) were overlaid on the cells adhered on coverslips and incubated at room temperature for 5 min. Coverslips were then washed 3 times with 200 μl PBS and then permeabilized with 0.2% Triton X-100/PBS for 4 min. After blocking coverslips with PBS containing 4% BSA for 0.5 h, trypanosomes were stained in 4% BSA/PBS with primary antibodies: guinea pig tubulin detecting α -tubulin (AA345, Geneva Antibody Facility) 1 : 2000; YL1/2 antibody detecting tyrosinated tubulin as present in the basal body [30] 1 : 100 000; monoclonal mouse TAC102 antibody (Trikin et al. [29]) 1 : 2000; polyclonal rabbit ATOM (gift from Andre Schneider) 1 : 2000; mouse 20H5 (Millipore 04–1624) 1 : 2000; polyclonal rabbit SAS6 (gift from Ziyin Li) 1 : 2000; rabbit p67 and rabbit BIP (gift from James Bangs) 1 : 2000. After thoroughly washing with 200 μl PBS, cells were incubated with 100 μl secondary antibodies Alexa Fluor 488 Goat-anti-Rabbit IgG (H + L) (Invitrogen), Alexa Fluor 594 Goat-anti-Mouse IgG (H + L) (Molecular Probes), Alexa Fluor 647

Goat-anti-Rat IgG (H + L) (Life Technologies), anti-guinea pig 594 (Abcam 150188) and 647 (Abcam 150187) diluted all 1 : 10 000 in 4% BSA/PBS for 1 h. The cells were counterstained with DAPI before mounting with Gold ProLong Gold antifade reagent (Molecular Probes D1306). Fluorescent optical images were taken on a Leica TCS SP8 using a 63 × 1.4 NA oil objective. LAS X software (Leica Microsystems), Huygens Professionals and ImageJ were used to analyze the images.

54.3.3 Ultrastructure Expansion Microscopy

Two million cells were washed twice with 200 μ l PBS and centrifuged for 3 min at 1800g, then resuspended in 150 μ l of PBS and settled for 20 min at room temperature on poly-D-lysine functionalized coverslips (12 mm, Menzel-Glaser). Coverslips were transferred into a 24-well plate filled with a solution of 0.7% Formaldehyde (FA, 36.5–38%, Sigma) with 0.15% or 1% acrylamide (AA, 40%, Sigma) in PBS and incubated for 5 h at 37°C. Cells were then prepared for gelation by carefully putting coverslips (cells facing down to the monomer solution) into 35 μ l of monomer solution (AK Scientific 7446-81-3) 10% (wt/wt) AA, 0.1% (wt/wt) N,N'-methylenebisacrylamide (BIS, SIGMA) in PBS supplemented with 0.5% APS and 0.5% tetramethylethylenediamine (TEMED) on parafilm in a pre-cooled humid chamber. Gelation proceeded for 5 min on ice, and then samples were incubated at 37°C in the dark for 1 h. Coverslips with gels were then transferred into a six-well plate filled with denaturation buffer (200 mM SDS, 200 mM NaCl and 50 mM Tris in ultrapure water, pH 9) for 15 min at room temperature. Gels were then detached from the coverslips with tweezers and moved into a 1.5 ml Eppendorf centrifuge tube filled with denaturation buffer and incubated at 95°C for 1 h and 30 min. After denaturation, gels were placed in beakers filled with deionized water for the first round of expansion. Water was exchanged at least twice every 30 min at room temperature, and then gels were incubated overnight in deionized water. Next day, gels were washed two times for 30 min in PBS and subsequently incubated on a shaker (gentle) with primary antibody diluted as follows: guinea pig tubulin detecting α -tubulin (AA345, Geneva Antibody Facility) 1 : 500; YL1/2 antibody detecting tyrosinated tubulin as present in the basal body [30] 1 : 100 000; monoclonal mouse TAC102 antibody [29] 1 : 1000; polyclonal rabbit ATOM (gift from Andre Schneider) 1 : 500; 20H5 (Millipore 04-1624) 1 : 500; polyclonal rabbit SAS6 (gift from Ziyin Li) 1 : 1000; rabbit p67 and rabbit BIP (gift from James Bangs) 1 : 500; all antibodies were diluted in 2% PBS/BSA and gels were incubated for 3 h at 37°C. Gels were then washed in PBST three times for 10 min while gently shaking and subsequently incubated with secondary antibodies Alexa Fluor 488 Goat-anti-Rabbit IgG (H + L) (Invitrogen), Alexa Fluor 594 Goat-anti-Mouse IgG (H + L) (Molecular Probes), Alexa Fluor 647 Goat-anti-Rat IgG (H + L) (Life Technologies), anti-guinea pig 594 (Abcam 150188) and 647 (Abcam 150187) all 1 : 1000 and 4',6-diamidino-2-phenylindole (DAPI, Thermofisher D1306) 1 : 5000. All antibodies were diluted in 2% PBS/BSA and gels were incubated for approximately 3 h at 37°C. Gels

were then washed in PBST three times for 10 min while gently shaking and finally placed in beakers filled with deionized water for expansion. Water was exchanged at least twice every 30 min before gels were incubated in deionized water overnight. Gel expanded between $4.1 \times$ and $4.4 \times$ depending on SA purity.

54.3.4 Mounting and Image Acquisition

After the final expansion, gel size was measured with a caliper to calculate the fold expansion. The gel was then cut with a razor blade in pieces that fit in a 36 mm metallic chamber for imaging. The piece of gel was then mounted on a 24 mm round poly-D-lysine functionalized coverslip, already inserted in the metallic chamber and gently pressed with a brush to ensure adherence of the gel to the coverslip. Confocal microscopy was performed on a Leica TCS SP8 using a 63×1.4 NA oil objective, with the following parameters: z step size at $0.3 \mu\text{m}$ interval with a pixel size of 35 nm. LAS X software (Leica Microsystems), Huygens Professionals and ImageJ were used to analyze the images.

54.3.5 Calculation of Expansion from Ultrastructure Expansion Microscopy

The expansion factor was determined by comparing the ratio of expanded cell length, kDNA and nucleus to non-expanded cell length, kDNA and nucleus. For unexpanded kDNA and nucleus measurements, $n = 20$ cells from immunofluorescence imagery were analyzed. The length of the kDNA was determined by measuring the maximum length of the kDNA observed in each cell. The diameter of the nucleus was determined by measuring the widest diameter observed in each cell. The length of the cell structure was determined by measuring the cell length from anterior to posterior end in each cell.

Abbreviations

APS:	ammonium persulfate
ATOM:	archaic protein translocase of the outer membrane
bb:	basal body
BiP:	binding protein
FAZ:	flagellar attachment zone
kDNA:	kinetoplast DNA
probb:	pro-basal body
SDS:	sodium dodecyl sulfate
TAC:	tripartite attachment complex
TEMED:	tetramethylethylenediamine
U-ExM:	ultrastructure expansion microscopy

Disclosures and Conflict of Interest

This chapter was originally published as: Kalichava, A., Ochsenreiter, T. (2021). Ultrastructure expansion microscopy in *Trypanosoma brucei*. *Open Biol.*, **11**, 210132, <https://doi.org/10.1098/rsob.210132>, under the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>), and appears here with edits and updates.

Data accessibility: Data are all in the chapter. Original imagery is available on request.

Authors' contributions: Conceptualization was done by A.K. and T.O. Formal analysis was done by A.K. Funding acquisition was done by T.O. Investigation was done by A.K. Methodology was done by A.K. Project administration was done by T.O. Resources were done by T.O. Supervision was done by T.O. Visualization was done by A.K. Writing the original draft was done by A.K. and T.O. Writing-review and editing were done by A.K. and T.O.

Competing interests: The authors have no competing interests.

Funding: The work in this chapter was supported by Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (grant no. 179454) and Uniscientia Foundation. The Ochsenreiter lab was supported by grants from Swiss National Science Foundation and the Uniscientia foundation.

Acknowledgements: The authors thank Ziyin Li for the SAS6 and Jay Bangs for the BiP antibodies, André Schneider for the ATOM antibody and Keith Gull for the YL1/2 antibody. The authors acknowledge the Microscopy Imaging Center (MIC) of the University of Bern.

References

1. Sherwin T, Gull K. 1989. Visualization of detyrosination along single microtubules reveals novel mechanisms of assembly during cytoskeletal duplication in trypanosomes. *Cell*. **57**, 211–221.
2. Robinson DR, Sherwin T, Ploubidou A, Byard EH, Gull K. 1995. Microtubule polarity and dynamics in the control of organelle positioning, segregation, and cytokinesis in the trypanosome cell cycle. *J Cell Biol.* **128**, 1163–1172.
3. Lacomble S, Vaughan S, Gadelha C, Morpew MK, Shaw MK, McIntosh JR, Gull K. 2009. Three-dimensional cellular architecture of the flagellar pocket and associated cytoskeleton in trypanosomes revealed by electron microscope tomography. *J Cell Sci.* **122**, 1081–1090.
4. Vaughan S, Gull K. 2015. Basal body structure and cell cycle-dependent biogenesis in *Trypanosoma brucei*. *Cilia*. **5**, 5.
5. Matthews KR. 2005. The developmental cell biology of *Trypanosoma brucei*. *J Cell Sci.* **118**, 283–290.
6. He CY, Pypaert M, Warren G. 2005. Golgi duplication in *Trypanosoma brucei* requires Centrin2. *Science*. **310**, 1196–1198.

7. Borst P, Hoeijmakers JH. 1979. Kinetoplast DNA. *Plasmid*. **2**, 20–40.
8. Shapiro TA, Englund PT. 1995. The structure and replication of kinetoplast DNA. *Ann Rev Microbiol*. **49**, 117–143.
9. Jensen RE, Englund PT. 2012. Network news: the replication of kinetoplast DNA. *Annu Rev Microbiol*. **66**, 473–491.
10. Schneider A, Ochsenreiter T. 2018. Failure is not an option: mitochondrial genome segregation in trypanosomes. *J Cell Sci*. **131**, jcs221820.
11. Wassie AT, Zhao Y, Boyden ES. 2019. Expansion microscopy: principles and uses in biological research. *Nat Methods* **16**, 33–41.
12. Gambarotto D, et al. 2019. Imaging cellular ultrastructures using expansion microscopy (U-ExM). *Nat Methods*. **16**, 71–74.
13. Chen F, Tillberg PW, Boyden ES. 2015. Expansion microscopy. *Science*. **347**, 543–548.
14. Bertiaux E, Balestra AC, Bournonville L, Louvel V, Maco B, Soldati-Favre D, Brochet M, Guichard P, Hamel V. 2021. Expansion microscopy provides new insights into the cytoskeleton of malaria parasites including the conservation of a conoid. *PLoS Biol*. **19**, e3001020.
15. Freifeld L, et al. 2017. Expansion microscopy of zebrafish for neuroscience and developmental biology studies. *Proc Natl Acad Sci USA*. **114**, E10 799–E10 808.
16. Zhang YS, et al. 2016. Hybrid microscopy: enabling inexpensive high-performance imaging through combined physical and optical magnifications. *Sci Rep*. **6**, 1.
17. Amodeo S, Kalichava A, Fradera-Sola A, Bertiaux-Lequoy E, Guichard P, Butter F, Ochsenreiter T. 2021. Characterization of the novel mitochondrial genome segregation factor TAP110 in *Trypanosoma brucei*. *J Cell Sci*. **134**, jcs254300.
18. Lukeš J, Guilbride DL, Votýpka J, Zíková A, Benne R, Englund PT. 2002. Kinetoplast DNA network: evolution of an improbable structure. *Eukaryot Cell*. **1**, 495–502.
19. Gluenz E, Shaw MK, Gull K. 2007. Structural asymmetry and discrete nucleic acid subdomains in the *Trypanosoma brucei* kinetoplast. *Mol Microbiol*. **64**, 1529–1539.
20. Gluenz E, Povelones ML, Englund PT, Gull K. 2011. The kinetoplast duplication cycle in *Trypanosoma brucei* is orchestrated by cytoskeleton-mediated cell morphogenesis. *Mol Cell Biol*. **31**, 1012–1021.
21. Vickerman K. 1969. On the surface coat and flagellar adhesion in trypanosomes. *J Cell Sci*. **5**, 163–193.
22. Robinson DR, Gull K. 1991. Basal body movements as a mechanism for mitochondrial genome segregation in the trypanosome cell cycle. *Nature*. **352**, 731–733.
23. Hu H, Liu Y, Zhou Q, Siegel S, Li Z. 2015. The centriole cartwheel protein SAS-6 in *trypanosoma brucei* is required for probasal body biogenesis and flagellum assembly. *Eukaryot Cell*. **14**, 898–907.
24. LeGuennec M, Klena N, Aeschlimann G, Hamel V, Guichard P. 2021. Overview of the centriole architecture. *Curr Opin Struct Biol*. **66**, 58–65.
25. Sherwin T, Schneider A, Sasse R, Seebeck T, Gull K. 1987. Distinct localization and cell cycle dependence of COOH terminally tyrosinolated alpha-tubulin in the microtubules of *Trypanosoma brucei*. *J Cell Biol*. **104**, 439–446.

26. Andre J, Kerry L, Qi X, Hawkins E, Drizyte K, Ginger ML, McKean PG. 2014. An alternative model for the role of RP2 protein in flagellum assembly in the African trypanosome. *J Biol Chem.* **289**, 464–475.
27. Bangs JD, Uyetake L, Brickman MJ, Balber AE, Boothroyd JC. 1993. Molecular cloning and cellular localization of a BiP homologue in *Trypanosoma brucei*: divergent ER retention signals in a lower eukaryote. *J Cell Sci.* **105**(Pt 4), 1101–1113.
28. Pusnik M, Schmidt O, Perry AJ, Oeljeklaus S, Niemann M, Warscheid B, Lithgow T, Meisinger C, Schneider A. 2011. Mitochondrial preprotein translocase of trypanosomatids has a bacterial origin. *Curr Biol.* **21**, 1738–1743.
29. Trikin R, Doiron N, Hoffmann A, Haenni B, Jakob M, Schnauffer A, Schimanski B, Zuber B, Ochsenreiter T. 2016. TAC102 Is a novel component of the mitochondrial genome segregation machinery in trypanosomes. *PLoS Pathog.* **12**, e1005586.
30. Kilmartin JV, Wright B, Milstein C. 1982. Rat monoclonal antitubulin antibodies derived by using a new nonsecreting rat cell line. *J Cell Biol.* **93**, 576–582.

Chapter 55

Pathogenic Prion Structures at High Resolution

Byron Caughey, PhD,^a Heidi G. Standke,^b Efrosini Artikis, PhD,^a Forrest Hoyt, MSc,^c and Allison Kraus, PhD^b

^aRocky Mountain Laboratories,

National Institutes of Health, Hamilton, Montana, USA

^bDepartment of Pathology and Cleveland Center for Membrane and Structural Biology,

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

^cResearch Technologies Branch, Rocky Mountain Laboratories,

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA

bcaughey@nih.gov, alk127@case.edu

Keywords: Alzheimer's, amyloid fibrils, conformational variations, cryogenic electron microscopy (cryo-EM), fibril core, glycoposphatidylinositol (GPI), GPI anchors, high-resolution structures, infectivity, N-linked glycans, native prion protein (PrP^C), parallel in-register intermolecular β -sheets (PIRIBS), Parkinson's, prion propagation, prion protein (PrP), proteinopathies, protofilaments, PrP fibrils, PrP scrapie (PrP^{Sc}), transmissibility, wild type (wt)

Numerous proteins are known to form ordered, self-propagating aggregates as underlying causes of neurodegeneration in proteinopathies such as Alzheimer's, Parkinson's, and prion diseases [1, 2]. The prion-like properties of such aggregates can promote spreading within and, sometimes, between hosts as pathogens. Prions are protein-based transmissible agents that, unlike other types of pathogens, do not carry a specific nucleic acid genome. Classical prions are formed from the hosts' native prion protein (PrP^C) and have long been known to be highly transmissible in many mammalian species (reviewed in [2, 3]). Other more common proteinopathies have also been shown to be transmissible from humans to experimental, and usually transgenic "humanized," animals, but the extent to which any such transmission occurs between humans remains under investigation and debate [4]. Extensive comparisons of brain-derived versus synthetic PrP aggregates with *in vitro* self-propagating (seeding) activities have shown that conformational differences can profoundly affect their *in vivo* transmissibilities

Advances in Medical Imaging, Detection, and Diagnosis

Edited by Raj Bawa, Gerald F. Audette, S. R. Bawa, Bela Patel, Bruce D. Johnson, and Rajeev Khanna

Copyright © 2023 Jenny Stanford Publishing Pte. Ltd.

ISBN 978-981-4877-46-6 (Hardcover), 978-1-003-29803-8 (eBook)

www.jennystanford.com

and pathogenicities, or lack thereof (e.g., [2, 5]). For example, whereas approximately 10^{-15} g of brain-derived prions can be lethal, inoculation of a $>10^9$ -fold larger amount of synthetic recombinant PrP fibrils can be innocuous [2]. Thus, in evaluating and understanding the risks posed by various self-replicative protein assemblies, it is crucial to consider conformational details. Fortunately, although the structures of prions and other proteopathic aggregates eluded high-resolution determination for decades, recent applications of cryogenic electron microscopy (cryo-EM) have begun to reveal these structures (e.g., [6–11]). Within the last year and a half, the first 3 near-atomic resolution cryo-EM structures of highly pathogenic brain-derived prions have been reported [6–10]. Here, we highlight how these new prion structures have begun to address fundamental, long-standing questions in prion biology.

55.1 What Structures Allow Prions to Propagate as Deadly Infectious Pathogens?

Although divergent ultrastructures have been observed in *ex vivo* preparations of infectious prions, the high-resolution prion structures that are available so far are amyloid fibrils (Fig. 55.1) [6–10]. These structures are of the hamster scrapie strain 263K [6, 7] and the mouse wild type (wt) [10] and glycosylphosphatidylinositol (GPI)-anchorless (a) [8, 9] RML scrapie strains. As for most amyloids, these prion fibrils have highly ordered core structures with PrP molecules stacked parallel and in register such that each monomer provides 1 rung along the fibril axis and any given amino acid residue in 1 monomer is aligned axially with the analogous residues of other monomers. Whereas most amyloid fibrils have 2 or more protofilaments, these prion fibrils consist primarily of 1 protofilament, the cross-section of which is spanned by a single monomer (Fig. 55.1B and 55.1C). To accommodate up to 137 residues within the ordered core cross-sections, the PrP polypeptide backbone of each rung folds back on itself in a serpentine fashion, forming a series of β -sheet sections called parallel in-register intermolecular β -sheets (PIRIBS) that are stabilized by hydrogen bonds between backbone carbonyls and amides. The β -sheets are interspersed with loops or turns. The structurally diverse N-linked glycans, and GPI anchors, if present, are not well resolved in these cryo-EM analyses and are presumed to decorate the periphery of the fibril (Fig. 55.2). Also poorly resolved are the less ordered, primarily N-terminal amino acid residues.

The ends of the prion fibrils provide templates for the addition of new monomers as the fibrils grow [6–10]. Inherent in these structures is the fact that the templating surfaces at opposite ends of a given fibril are not equivalent, raising the possibility of different elongation kinetics at these sites. Given that the normal PrP^C precursor of the infectious prion isoform (generically called PrP^{Sc} for PrP-scrapie) is monomeric with predominantly disordered and α -helical secondary structural domains (Fig. 55.1A), a wholesale refolding occurs upon recruitment of new monomers into fibrils [6, 7]. Much remains to be determined about the




Figure 55.1 Two prion strains are amyloid fibrils with distinct templating surfaces on the ends where incoming monomers are refolded. (A) PrP^C molecules (disordered N-terminal residues not shown) undergo conversion and assembly into the prion forms shown here for hamster 263K (blue, PDB: 7LNA, [6, 7]) and mouse aRML (red, PDB: 7TD6, [8, 9]) prions. PDB accession codes 1B10 and 1XYZ were used for hamster and mouse PrP^C, respectively. (B) Polypeptide backbones of the fibril cross-sections (colored) as they fit within the cryo-EM density maps (gray). Open arrowheads: densities outside the polypeptide backbone that coincide with attachment sites of glycans (green) or glycolipid anchors (orange). Closed green arrowheads: densities of unknown origin outside the amyloid cores, often adjacent to cationic residues. (C) Similar shared β -arch motifs/topologies distinguished by color. Variations within these topologies and other features, including distinct orientations of the C-terminal tails, distinguish these strains. (D) Extended lateral views of fibril density maps, with brackets indicating the relative cross-over distances. *Abbreviations:* cryo-EM, cryogenic electron microscopy; PrP, prion protein.




Figure 55.2 Cross-sectional depictions of membrane-bound 263K and RML prions. For simplicity, only short pentameric segments of the fibrils are shown. The natural glycans and GPI moieties are much more heterogeneous than those shown. The RML structure shown was assembled using the aRML pdb coordinates (PDB: 7TD6) because the wtRML pdb coordinates were not yet publically available. Although the aRML and wtRML cores are similar overall, there are detailed features of the wtRML core structure that differ from that depicted. See [10]. *Abbreviation:* GPI, glycosphosphatidylinositol.

steps involved, but among the key events are the peeling of the loop containing helix 1 away from helices 2 and 3 of PrP^C [12] and stretching of the helices into extended strands within the prion fibril core [6, 7]. A clearer understanding of this conversion mechanism should aid in the rational design of therapeutic strategies aimed at limiting prion propagation.

55.2 What Is the Structural Basis of Prion Strain Variation?

Comparison of the 263K and RML prion structures gives initial insights into prion strain variation [6–10]. These rodent-adapted scrapie strains share structural motifs including N (N-proximal), middle, and disulfide β -arches, and a steric zipper that glues the N-terminal residues of the core to the head of the middle β -arch (Fig. 55.1C). However, otherwise, there are striking differences in the detailed conformations of these and other features, as well as the overall fibril morphologies (Fig. 55.1B–55.1D). Particularly notable are the different orientations of the C-terminal residues linked to the GPI anchor in the 263K and wtRML prions [6–10]. In 263K, these residues flank the disulfide β -arch but extend in the opposite direction in the RML structures. In addition, the amino acid sequences within the cores of 263K and RML prions differ at 8 positions in their respective hamster

and mouse PrP molecules. The extent to which the conformational differences between 263K and RML prions are dictated by sequence differences versus conformational templating remains to be determined. Nonetheless, although only 3 high-resolution infectious prion structures are currently available, we can already surmise that major determinants of prion strains are conformational variations in common motifs and other structural elements [8, 9]. However, there are more than 30 different types of PrP-based prions in mammals including various strains, sequences, and combinations thereof. Thus, much remains to be done to explain the full range of prion structures and how those structures underpin strain-specific disease phenotypes.

55.3 How Might Prion Structures Explain Prion Transmission (and Species) Barriers?

Many lines of evidence indicate that a primary factor controlling the transmissibility of prions between hosts of different genotypes is sequence compatibility between the infecting PrP^{Sc} and the host's PrP^C (e.g., [7] and references therein). While some sequence differences have little impact, others can result in high, and seemingly insurmountable, barriers to transmission. The structural bases for these effects remain poorly understood, but the new high-resolution prion structures provide initial insights into potential transmission barrier mechanisms [7]. Each of these PIRIBS-based structures has tightly packed regions in which the substitution of a heterologous residue might cause unfavorable steric clashes, electrostatic interactions, changes in hydrogen bonding, or other perturbations that could slow or prevent full conformational conversion of incoming monomers. On the other hand, other areas of these fibril cores are less packed or otherwise more tolerant of heterologous residues. Even if heterologous conversion can occur sustainably in the new host, an altered or partial conversion product might be less pathogenic or more easily cleared than the original prion strain in its original host, and therefore, less causative of clinical disease within the natural lifespan of the new host.

55.4 How Might GPI Anchors and N-Linked Glycans Affect Prion Structure and Interactions with Tissue Environments?

GPI anchors and N-linked glycans are prominent features of wild-type prions that are unusual among the many pathologic protein amyloids of mammals. Although these post-translational modifications are not required for prion infectivity or pathogenicity, they can profoundly affect the routes of prion spreading within the host [13] and the resulting clinical and neuropathological phenotypes of disease [14]. In the 263K and wtRML prion structures, the anchors and glycans can be inferred to project outward from the fibril cores (Fig. 55.2) [6, 7, 10].

The resulting array of GPI anchors along the fibril axis would likely interact with cellular membranes, perhaps causing distorted membrane lesions that are indicative of prion-infected brain tissue [6, 7]. Such lesions might in turn mediate disruptions of cellular functions such as membrane trafficking, signaling, and homeostasis. The attached membranes, as well as N-linked glycans, should obscure at least the C-terminal cores of the prion fibrils in a manner that would limit interactions with other macromolecules. Disease progression is often faster in wild-type versus anchorless PrP transgenic mice [15], suggesting that GPI-mediated membrane interactions contribute significantly to the neuropathogenic process. However, it is important to emphasize that both wild-type and GPI-anchorless prions, the latter of which are also deficient in N-linked glycans, can be lethal to the host [14, 15]. Indeed, after multiple serial passes of scrapie strains in anchorless PrP transgenic mice, survival times can become as short as those in wild-type mice [16, 17]. Thus, there must be both GPI-dependent and -independent mechanisms by which prions disrupt brain function.

55.5 What Are Structural Determinants of Prion Transmissibility and Pathogenicity?

Structural features correlating with infectivity are already suggested by comparisons of cryo-EM structures of brain-derived infectious prions [6–10] to presumably much less, if at all, infectious synthetic PrP fibrils that also all have PIRIBS-based cores [18–22]. Assessments of the infectivity of latter synthetic structures have not been reported, but most recombinant PrP preparations with similarly small protease-resistant cores have lacked pathogenicity. However, we note that one of these high-resolution cryo-EM structures is of fibrils of human PrP 23–144, and a fibrillar preparation of the analogous murine fragment induces prion disease in PrP-overexpressing transgenic mice [23], albeit with long incubation periods suggestive of low titer. In any case, whereas the high-titered infectious PrP fibrils (approximately 10^8 to 10^{10} 50% lethal doses per mg) have large ordered amyloid core structures with an N-proximal steric zipper as well as N, middle, and disulfide β -arches [6–10], the available synthetic fibril structures have only either an N or a disulfide β -arch without the other major features. Importantly, however, even seemingly subtle differences in the size of PrP fibril cores (e.g., as little as approximately 1 kDa [5, 24]) have correlated with large differences in infectivity [2]. Thus, much remains to be learned about the structure–function relationships that discriminate lethal from innocuous assemblies of PrP molecules.

Disclosure and Conflict of Interest

This chapter was originally published as: Caughey, B., Standke, H. G., Artikis, E., Hoyt, F., Kraus, A. (2022). Pathogenic prion structures at high resolution. *PLoS Pathog*, **18**(6), e1010594, <https://doi.org/10.1371/journal.ppat.1010594>, under

the Creative Commons Attribution 4.0 license (<http://creativecommons.org/licenses/by/4.0/>), and appears here with edits and updates.

Funding: This work was supported in part by the Intramural Research Program of the NIAID, grant number ZIA AI000580 (to B.C.) and the Britton Fund, CWRU School of Medicine, and the Clifford V. Harding and Mina K. Chung Professorship (to A. K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the chapter.

Competing interests: The authors have declared that no competing interests exist.

References

1. Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. *Annu Rev Biochem.* 2017; 109: 27–68.
2. Caughey B, Kraus A. Transmissibility versus pathogenicity of self-propagating protein aggregates. *Viruses.* 2019; 11(11): 1044.
3. Kraus A, Groveman BR, Caughey B. Prions and the potential transmissibility of protein misfolding diseases. *Annu Rev Microbiol.* 2013; 67: 543–64.
4. Asher DM, Belay E, Bigio E, Brandner S, Brubaker SA, Caughey B, et al. Risk of transmissibility from neurodegenerative disease-associated proteins: experimental knowns and unknowns. *J Neuropathol Exp Neurol.* 2020; 79(11): 1141–6.
5. Wang F, Wang X, Orru CD, Groveman BR, Surewicz K, Abskharon R, et al. Self-propagating, protease-resistant, recombinant prion protein conformers with or without in vivo pathogenicity. *PLoS Pathog.* 2017; 13(7): e1006491.
6. Kraus A, Hoyt F, Schwartz CL, Hansen B, Hughson AG, Artikis E, et al. Structure of an infectious mammalian prion. *bioRxiv.* 2021. Available at: <https://doi.org/10.1101/2021.02.14.431014> (accessed on September 15, 2022).
7. Kraus A, Hoyt F, Schwartz CL, Hansen B, Artikis E, Hughson AG, et al. High-resolution structure and strain comparison of infectious mammalian prions. *Mol Cell.* 2021; 81(21): 4540–51.
8. Hoyt F, Standke HG, Artikis E, Schwartz CL, Hansen B, Li K, et al. Structure of anchorless RML prion reveals motif variation between strains. *bioRxiv.* 2021. Available at: <https://doi.org/10.1101/2021.12.22.473909> (accessed on September 15, 2022).
9. Hoyt F, Standke HG, Artikis E, Schwartz CL, Hansen B, Li K, et al. Cryo-EM structure of anchorless RML prion reveals variations in shared motifs between distinct strains. *Nat Commun.* 2022; 13, Article number: 4005.
10. Manka SW, Zhang W, Wenborn A, Betts J, Joiner S, Saibil HR, et al. 2.7 Å cryo-EM structure of *ex vivo* RML prion fibrils. *Nat Commun.* 2022; 13, Article number: 4004.
11. Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, et al. Structure-based classification of tauopathies. *Nature.* 2021; 598(7880): 359–63.
12. Adrover M, Pauwels K, Prigent S, de Chiara C, Xu Z, Chapis C, et al. Prion Fibrillization Is Mediated by a Native Structural Element That Comprises Helices H2 and H3. *J Biol Chem.* 2010; 285(27): 21004–12.

13. Rangel A, Race B, Phillips K, Striebel J, Kurtz N, Chesebro B. Distinct patterns of spread of prion infection in brains of mice expressing anchorless or anchored forms of prion protein. *Acta Neuropathol Commun.* 2014; 2: 8.
14. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. *Science.* 2005; 308(5727): 1435–9.
15. Chesebro B, Race B, Meade-White K, LaCasse R, Race R, Klingeborn M, et al. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. *PLoS Pathog.* 2010; 6(3): e1000800.
16. Aguilar-Calvo P, Sevillano AM, Bapat J, Soldau K, Sandoval DR, Altmeppen HC, et al. Shortening heparan sulfate chains prolongs survival and reduces parenchymal plaques in prion disease caused by mobile, ADAM10-cleaved prions. *Acta Neuropathol.* 2020; 139(3): 527–46.
17. Aguilar-Calvo P, Xiao X, Bett C, Erana H, Soldau K, Castilla J, et al. Post-translational modifications in PrP expand the conformational diversity of prions in vivo. *Sci Rep.* 2017; 7: 43295.
18. Glynn C, Sawaya MR, Ge P, Gallagher-Jones M, Short CW, Bowman R, et al. Cryo-EM structure of a human prion fibril with a hydrophobic, protease-resistant core. *Nat Struct Mol Biol.* 2020; 27(5): 417–23.
19. Li Q, Jaroniec CP, Surewicz W. Cryo-EM structure of disease-related prion fibrils provides insights into seeding barriers. *Nat Struct Mol Biol.* 2022. Available at: <https://doi.org/10.1038/s41594-022-00833-4> (accessed on September 15, 2022).
20. Wang LQ, Zhao K, Yuan HY, Wang Q, Guan Z, Tao J, et al. Cryo-EM structure of an amyloid fibril formed by full-length human prion protein. *Nat Struct Mol Biol.* 2020; 27(6): 598–602.
21. Wang LQ, Zhao K, Yuan HY, Li XN, Dang HB, Ma Y, et al. Genetic prion disease-related mutation E196K displays a novel amyloid fibril structure revealed by cryo-EM. *Sci Adv.* 2021; 7(37): eabg9676.
22. Gallagher-Jones M, Glynn C, Boyer DR, Martynowycz MW, Hernandez E, Miao J, et al. Sub-angstrom cryo-EM structure of a prion protofibril reveals a polar clasp. *Nat Struct Mol Biol.* 2018; 25(2): 131–4.
23. Choi JK, Cali I, Surewicz K, Kong Q, Gambetti P, Surewicz WK. Amyloid fibrils from the N-terminal prion protein fragment are infectious. *Proc Natl Acad Sci USA.* 2016; 113(48): 13851–6.
24. Noble GP, Wang DW, Walsh DJ, Barone JR, Miller MB, Nishina KA, et al. A Structural and Functional Comparison Between Infectious and Non-Infectious Autocatalytic Recombinant PrP Conformers. *PLoS Pathog.* 2015; 11(6): e1005017.

Index

- 3'-azido-3'-deoxythymidine (AZT) 1175, 1182
- 3D mammography 133, 155–156
- 4-*N,N*-dimethyls-amino-1,8-naphthalimide-trehalose (DMN-trehalose) 935, 939, 945, 949–950
- 4',6-diamidino-2-phenylindole (DAPI) stain 1339
- 4Pi single-molecule switching (4Pi-SMS) 1195, 1200
- 8-hydroxy-2'-deoxyguanosine 597, 599
- 8-hydroxyguanine 597, 599
- 8-oxoguanine 813, 816, 819–822
- 16S rRNA 656, 658, 817–818, 873–874, 878, 882–883
- $\alpha_5\beta_3$ integrin receptors 683, 685–686
- Abbe condenser 1317, 1320
- Abbe diffraction limit 1317, 1326
- Abbe number 1317, 1320
- abnormal bronchial sound 853, 855, 861
- acceleration time (AoAT) 829, 832
- Achilles' tendinopathy (AT) 747
- acoustic radiation force impulse imaging (ARFI) 133, 172, 181, 195
- acousticians 853, 855–856
- active targeting 256, 683, 685–686, 731
- acute renal injury 829, 845
- adaptive optics (AO) 1195, 1200, 1330
- adenocarcinoma 18, 24, 276, 401, 476, 685–686, 729, 829, 837
- adenosine triphosphate (ATP) 133, 136, 195, 619, 636, 640
- adipocytes 1137–1138, 1140–1141, 1276
- adiponectin (APN) 1273, 1276, 1304
- adipose tissue expansion 1137
- adsorption 625, 627, 631, 687, 1127, 1171, 1232, 1273, 1281, 1297
- adsorption, distribution, metabolism, excretion and toxicity (ADMET) 1273, 1304
- advanced polycystic kidney disease 829, 834
- adverse outcome pathway (AOP) 1273, 1291, 1304
- affinity chromatography 1099–1100, 1103, 1105–1106, 1111–1112
- Age-Related Eye Disease Studies 2 (AREDS2) trial 1249
- age-related macular degeneration (AMD) 112, 1249–1258
- Airy disc 1317, 1320
- Alzheimer's 140, 160, 177, 195, 286, 296, 731, 1355
- ammonium persulfate (APS) 1339–1340, 1350
- amperometry 813
- amplification refractory mutation system (ARMS) 567, 576, 580, 583
- Amsler grid 1249, 1252
- amyloid fibrils 1355–1357
- analysis of functional neuroimages (AFNI) 1151–1152, 1158
- ancillary testing 907–908, 925
- anesthesia 167, 274, 847
- angiomyofibroma 829, 837
- angiotensin converting enzyme 683, 690, 703, 1175
- angiotensin converting enzyme 2 (ACE2) 1175
- annexin A3 597, 599
- anti-programmed cell death 1 (PD-1) 567, 570
- anti-vascular endothelial growth factor (anti-VEGF) drugs 1249
- antibiotic resistance 480, 657, 813, 823, 886
- antibiotics 21, 64, 109, 121, 125, 138, 480, 600, 657, 661, 813–815, 819, 823, 873–874, 879–880, 883–886, 911, 945, 1256
- antibody fragment 303, 305–306
- antibody labels 303
- antibody purification 303, 305

- antibody structure 303, 307
antigen-antibody binding 597
antimicrobial resistance 535, 950, 1025, 1042–1043
antiretroviral therapy (ART) 957, 962, 1053, 1055–1056, 1061–1062, 1073
antiviral 199, 206, 211–212, 1177, 1180, 1185
aperture 949, 1195–1196, 1317–1318, 1320–1321, 1327
apolipoprotein A1 (Apo-A1) 597, 599, 612
apolipoprotein E 683, 690, 703
aptamer-linked immunosorbent assays 907, 913
aptamers 260, 436–437, 634, 683, 685–686, 783, 785, 787–788, 799–803, 825, 907, 910, 913
archaic protein translocase of the outer membrane (ATOM) 1339, 1345, 1350
area under the curve (AUC) 285, 293, 295, 298, 487, 489, 500
artemisinin-based combination therapy (ACT) 979, 981–982, 993, 996
arterial blood oxygen saturation 667–668
artificial intelligence (AI) 133, 176–178, 181, 195, 269, 281–282, 389, 1195, 1201
Ashbya gossypii (Ag) 1025, 1035, 1044
asialoglycoprotein 683, 686, 703
Aspergillus 1037
Aspergillus fumigatus (Af) 1025–1026, 1034, 1036, 1044
Aspergillus spp. 1025
assay workflow 487, 497
asthma 177, 1273, 1279
astigmatism 1317, 1328–1329
asymptomatic carrier 211, 225
atomic force microscopy (AFM) 67, 318, 323, 390, 597, 601, 603, 612, 1119, 1121, 1123, 1130
atopic disease 655
atrial fibrillation (AF) 133, 180, 195
attenuated total reflectance Fourier transform infrared spectroscopy 597
autocrine 1273, 1276
autoimmune diseases 176, 655
automated image registration (AIR) 1151–1152, 1158
autonomously replicating sequence (ARS) 1025, 1032, 1035, 1044
avidin 1119, 1121–1127, 1129–1131
avidin-biotin complex 1119, 1121, 1125, 1130–1131
 β -lactam antibiotics 813, 819
b-type cytochromes 655–656
Bacille-Calmette-Guérin (BCG) vaccine 1227, 1233
backward internal primer (BIP) 211, 227
bacteraemia 873–874
bacterial pathogens 873–874, 878
ballpoint pen method 1227, 1233–1234
basal body (bb) 1339–1340, 1342, 1345–1346, 1348–1350
bedside testing 907–908, 925
Beer-Lambert law 683
beta-carotene 1249, 1255
bioaerosols 935–950
bioavailability 251–253, 263, 632
biocompatible polymers 699, 1163, 1168
bioinformatics 182, 194, 487, 491–492, 496, 499, 513, 516, 520–522, 525, 538, 891, 900, 1099
bioluminescence 303, 314, 316–317, 725, 736, 740
biomarker-based PoC tests 907, 910, 913
biomarkers 189, 269, 286, 297, 399, 487–500, 547, 557, 567, 569–575, 578–583, 597–612, 618, 633–637, 695, 756, 802, 873, 885, 907, 910, 913–919, 1002, 1273, 1286, 1288, 1290, 1293, 1297–1301
biomimetic 18-F fluorodeoxyglucose (FDG) 1001–1002, 1011
biopsies 18, 24, 98, 147, 153–154, 157, 168, 171–172, 185, 269, 271, 273–275, 281–282, 401, 446, 478, 487, 490, 492, 500–501, 511, 513, 523, 569, 576–577, 583, 761–766, 771, 796, 829, 838, 846, 1137–1141, 1143–1146, 1288, 1292

- biotin 625, 736, 791, 818–819, 1020, 1119, 1121–1126, 1130–1131
 blood oxygen delay 667, 674–675, 678
 blood-oxygen-level-dependent (BOLD) fMRI 1151–1152
 blood oxygen saturation (SpO₂) 667–680
 blood pool agents (BPAs) 683, 689, 703
 bone scans 269, 273
 Bosniak classification 829, 833
 bottom-up proteomics 545
 brain tissue micromovements 285
 brainstem 296, 1151–1159
 brainstem oscillation 1151, 1153
 breast computed tomography scanner (bCT) 133, 153, 156, 164
 brightfield images 987, 993, 1317, 1322
 broadly neutralizing antibodies (bnABs) 197, 202
 bronchoscopy 12, 269, 274
 Byooviz 1249, 1258–1259
- C-reactive protein (CRP) 597, 599, 604–605, 607–609, 612, 873, 878, 886, 913
 cancer 18, 22–24, 42, 49, 51, 98, 105, 137–138, 147, 152–156, 159–160, 164, 168–169, 178, 188, 251, 254–261, 269–283, 287, 319, 324, 336, 397, 399–401, 459, 473, 475–479, 482, 487–490, 492–501, 507–509, 511–513, 519, 521–524, 545, 567–584, 598–599, 622, 631, 633–635, 637, 655, 685–686, 690, 695, 697–701, 731–732, 734, 740, 803
 cancer staging 269, 275–277, 575
Candida albicans (Ca) 1025, 1030, 1032, 1044
Candida parapsilosis (Cp) 878, 1025, 1027–1028, 1035, 1040, 1044
Candida spp. 873
 canine leishmaniasis (CanL) 755, 757, 763, 766, 774, 795
 capture coating 1119, 1121–1131
 capture coating efficiency 1122
- carbapenemase-producing carbapenem-resistant *Enterobacteriaceae* (CP-CRE) 813, 817, 822, 825
 carbon fiber 1163, 1170–1172
 carbon nanotubes (CNTs) 260–261, 263, 319, 323, 437, 619, 627, 640, 683–684, 696–697, 699, 703–704, 789, 803, 1268
 cardiac troponin T (cTnT) 619, 636, 640
 CD4-dependent hazard rates 1053, 1055
 CentriDrive 1213, 1215–1216, 1218, 1220, 1222
 centrinins 1339, 1345–1346
 cerebrospinal fluid (CSF) 640, 959, 1151–1152, 1159, 1264
 Cetuximab 507–508, 571–573, 575, 685
 charge-coupled device (CCD) 512, 725, 736, 740
 Charles Bonnet syndrome 1249, 1257
 checkpoint inhibitors 524, 567–568, 570, 572
 chemiluminescence 303, 313–316, 323
 chemotherapy 105, 147, 156–157, 476, 567–568, 570, 575, 936, 945, 947
 chest radiography scores 935, 946
 China Food and Drug Administration 487, 496, 500
 chromogenic *in situ* hybridization (CISH) 521, 525
 chronic kidney disease (CKD) 829, 843, 845
 circulating free DNA (cfDNA) 567, 569, 577, 583
 circulating tumor cells (CTCs) 479, 567, 577, 583
 circulating tumor DNA (ctDNA) 487, 492, 500–501
 clear, unobstructed brain/body imaging cocktails and computational analysis (CUBIC) 1137
 clear, unobstructed, brain/body imaging cocktails and computational analysis (CUBIC) 1140–1142, 1147
 clinical accuracy 487, 489, 492
 clinical diagnosis 687, 790, 873, 1065, 1068, 1071, 1269

- Clinical Laboratory Improvement
 Amendments 507–508, 525, 533, 825
- clinical performance 491, 496, 533, 541, 1081, 1090–1091
- clinical practice 12, 532–533, 538, 737, 751, 879, 885, 967, 973, 976, 989, 1173
- clinical validity 531–536, 539–541, 543–544
- Clostridium difficile* 480, 655, 657
- clustered regularly interspaced short palindromic repeats (CRISPR) 907, 912, 927, 1025–1026, 1030, 1032, 1034, 1043–1044
- coarse crackles 853, 855, 861, 863, 866–868
- coefficient of variation (CV) 233, 238, 247, 1268
- collocated monolith support structures (COMOSS) 1261, 1266, 1269
- colonoscopy 269, 274, 655, 660
- colony forming unit (CFU) 639, 935, 950
- colorectal cancer (CRC) 178, 478–479, 507–509, 523, 567–584
- combinatorial microscopy 1317, 1331
- combinatorial probe-anchor ligation 507, 516, 525
- community-based exposure 935–936
- community healthcare worker (CHW) 907, 924, 927
- companion diagnostics 269, 282, 473, 475, 482, 489, 494–495, 500–501, 507–526
- competitive assay 303, 308
- complement factor H-related 1 (CFHR1) 597, 612
- complement fixation reaction (CFR) 783, 786, 803
- complementary DNA (cDNA) 783, 789, 794, 796, 803, 892, 900–901
- complementary metal-oxide semiconductor (CMOS) 1175
- composite reference standard (CRS) 956, 960–961, 963, 967–968
- computational imaging 1195
- computed tomography (CT) 92–93, 95, 100, 133, 152, 157–158, 161, 163–164, 166, 183, 189, 193, 195–196, 256, 269, 272, 285, 296, 683–684, 693–694, 703–704, 725, 728, 732, 740–741, 829, 833
- computer tomography colonography 655, 660
- confidence interval (CI) 233, 238, 247, 293–295, 606, 1001, 1004, 1011
- confocal imaging 68, 1146, 1339
- conformational variations 1355, 1359
- congestive heart failure (HF) 133, 180, 196
- conjunctival hemorrhage 1249, 1258
- Consensus Molecular Subtypes (CMS) 567, 573–574, 583
- contrast 43–44, 91–93, 95, 150, 152–156, 160–161, 163–164, 166–167, 171, 173, 181, 184–185, 188, 190, 252, 256–258, 272, 291, 296, 345, 347, 379, 382, 387, 389, 572, 575, 631, 633, 636, 659, 661, 683–696, 698–702, 727–732, 736–737, 739, 767, 771, 829, 833, 847–848, 884–885, 985, 988, 1177–1180, 1317, 1321–1324, 1326, 1330–1331
- contrast agents 92, 133, 152–153, 156, 160–161, 163–164, 166–167, 181, 184, 188, 190, 252, 256–258, 272, 631, 633, 636, 684, 686–692, 694–696, 698–702, 728–730, 732, 736–737, 739, 1177, 1322
- contrast-enhanced computed tomography (CECT) 829, 833
- contrast-enhanced ultrasound (CEUS) 829, 833, 848
- convolutional neural networks (CNNs) 979, 981, 985, 996
- Coronavirus Disease 2019 (COVID-19) 84, 123, 179, 184, 193, 216–217, 233–234, 241, 244–247, 393, 447, 481, 597, 667–668, 679, 825, 892, 895, 898–899, 901, 1081–1082, 1094, 1175–1176, 1180, 1183, 1186–1188, 1213–1215, 1222
- coronaviruses 81, 83–84, 197, 199, 205, 211–212, 228, 233, 238, 240, 247, 391–392, 481–482, 597, 667–668, 825, 892–893, 895–896, 901, 1081–1082, 1092–1095, 1130, 1175, 1178–1179, 1181, 1188–1189, 1213

- cortical thickness 829–830, 832, 839, 843
 credible interval (CrI) 1053, 1057–1063, 1073
 crepitus 853–855, 861, 863, 866
 CRISPR-mediated marker excision (CRIME) 1025, 1030, 1044
 CRISPR-RNA (crRNA) 1026, 1032, 1034, 1044
 cross-reactivity 130, 233, 238, 240, 247, 312, 756, 765, 793, 802, 907, 911, 916–917, 956, 966, 1081, 1092, 1094, 1227, 1231, 1239, 1345
 cross-sectional area (CSA) 747, 749
 cross-sectional B-mode imaging 285
 cross-sectional images 40, 133, 152, 162, 183, 728
 cross-validation 487, 491
 cryo-electron microscopy/cryogenic electron microscopy (cryo-EM) 133, 142, 195, 382, 1175, 1188, 1355–1357
 cryo-electron tomography 46, 1175, 1177, 1183–1184, 1188
 cryo-EM reconstruction 1175, 1177
Cryptococcus neoformans (Cn) 1025–1026, 1034, 1044
Cryptococcus spp. 1025–1026, 1037–1038, 1040
 cuneiform nucleus (CN) 1151, 1157–1158
 current density 603, 616–617, 1163–1164
 customized PoC diagnostics 907
 cutaneous leishmaniasis (CL) 755–757, 760, 763–764, 774, 783–784, 796, 803, 920–921, 923, 1227–1228, 1239–1240
 cyber-physically assistive clothing (CPAC) 133, 178, 195
 cycle threshold (Ct) 233, 235, 238, 242, 247, 892, 894–896, 901
 cyclic olefin copolymer (COC) 948, 1273, 1281, 1304
 cyclic reversible termination 507–510, 519, 525
 cysteine 638, 761, 763, 774, 1017–1022, 1104
 cysts 18, 92, 154, 829, 833–835, 847, 915
 cytoarchitectonic probability maps 1151, 1155
 data administrator 531, 535
 data analysis 238, 248, 507, 511–513, 517, 520–521, 525, 673, 804, 960, 1099, 1123, 1155–1157
 data preservation 531, 536, 542
de novo classification 534
 deep brain stimulation (DBS) 184, 1163, 1165, 1168–1169, 1172
 deep learning (DL) 133, 177, 184, 195, 979, 985–986, 988, 991–993, 995–997
 deep-learning system (DLS) 979, 985–987, 996
 deep-vein thrombosis (DVT) 133, 173, 195
 delayed-type hypersensitivity (DTH) 786, 1227, 1229, 1240
 demographics 216, 499, 570, 956
 dendrimers 251, 255–256, 435, 683, 686–688, 690–692, 701–702, 729, 738, 783, 789, 792–793, 804
 dendritic cell 725, 735, 740
 densitometry 473, 475
 detection 1–248, 308–313, 316–322, 473–474, 478–481, 487–489, 492–493, 500–501, 507–508, 515–517, 519, 521–523, 547–548, 550, 554–555, 569–570, 575–581, 583, 597–612, 625–629, 633–639, 677, 689–690, 732–734, 755–757, 760–761, 765–771, 773–775, 785–802, 813–816, 818–826, 873–886, 894–896, 898–900, 910–913, 915–916, 935–937, 944–947, 979–980, 993–995, 1020, 1042–1043, 1081–1082, 1085–1090, 1093–1094, 1099–1100, 1105–1106, 1119–1121, 1125, 1213–1222
 detection sensitivity 178, 237, 550, 761, 771, 1119, 1121, 1222
 device capacity 1261
 diabetes 112, 131, 179, 661, 1263, 1285–1287, 1292
 type 1 655
 type 2 1137, 1273, 1285–1286, 1304
 diagnostic magnetic resonance (DMR) 619, 639–640
 diagnostic reliability 286, 873–874, 885
 diagnostic test 37, 193, 285, 475, 489, 491, 495, 498–500, 761, 766, 772–773,

- 914, 922, 925, 1094, 1227–1228, 1230, 1237
- diagnostic ultrasound 133, 169–170, 172
- diagnostics 37, 152, 160, 169–170, 172, 179–181, 190–191, 193, 195–196, 211, 227, 251–252, 285–298, 304, 321–322, 473, 475, 487–501, 507–526, 531–532, 567–570, 572–584, 597–598, 600, 611–613, 619–640, 755–758, 761, 764–766, 771–775, 785–787, 793, 799–800, 802–803, 849, 873–875, 885, 907–927, 955–956, 959–960, 962, 964–969, 975–976, 979–981, 994–997, 1053–1074, 1092–1094, 1120–1121, 1130, 1227–1230
- diastolic velocity (Vd) 829, 832
- dielectric constant (ϵ) 597, 602, 620–621
- differential interference contrast (DIC) 1317, 1322, 1331
- diffraction 200, 397, 1189, 1195–1196, 1202, 1317, 1320, 1322, 1326–1330
- diffuse cutaneous leishmaniasis (DCL) 1227–1228, 1240
- diffuse optical tomography (DOT) 133, 145, 195
- digital breast tomosynthesis 133, 155
- digital medicine 655, 660
- digitization 287, 979–980, 982, 984, 994–995, 997
- dilated eye exam 1249, 1251–1252, 1254
- diminished breath sound 853, 856, 861
- direct agglutination test (DAT) 755–756, 763, 774, 783, 786, 803, 1234
- disability-adjusted life year (DALY) 907, 909
- disease diagnostics 597
- displaceable probe (DP) 211, 213, 217–218, 223, 227
- displacement waveform 285, 296
- disseminated cutaneous leishmaniasis (DsCL) 760, 774, 1227–1228, 1240
- DNA biosensor 813
- dopamine 634, 655, 659, 661, 1171
- Doppler examination 829, 831
- Doppler ultrasound 171, 829, 832, 841
- double-helix PSF (DH-PSF) 1317, 1321, 1329, 1331
- double-stranded break 1025–1026, 1044
- downstream (DW) 475, 525, 577, 910–912, 937, 946, 948, 1025, 1030–1032, 1037, 1041, 1044, 1104, 1124, 1276, 1280, 1294
- DP-RT-LAMP 211, 213–214, 216, 219–220, 222–223, 227
- drug delivery 184, 186, 190, 251, 253–255, 436–437, 633, 694, 741
- drug metabolism 1273, 1282–1284, 1288–1289, 1293, 1298
- drug resistance 121, 473, 480–481, 945, 1026, 1040, 1043, 1071
- dry AMD 1249, 1254, 1258
- Dual Path Platform (DPP) 907, 927
- dynamic binding 1119, 1121, 1126
- dynamic fluorescence imaging 1317
- dynamic response 1163, 1165
- dysbiosis 655–656, 658, 1022
- early AMD 1249, 1254, 1256
- early onset sepsis (EOS) 873–886
- ease of use 211, 576, 815, 908
- echo-pair imaging (EPI) 1151
- echogenic 829–830
- elastography 133, 168, 171–172, 181, 184, 188, 196, 829, 847–849
- elastomeric materials 1163
- electrical noise 669, 1163, 1167
- electrochemical biosensors 597, 600, 611, 633–634, 801, 816
- electrochemical detection 598, 635, 813, 816, 824
- electrochemical impedance spectroscopy (EIS) 597, 600, 607–608, 612
- electrochemical reactions 320, 1163, 1166–1167
- electrochemical sensors 597, 603, 633
- electrochemistry 320, 813
- electrochromatography 1262
- electrode corrosion 1163, 1166
- electrodes 35, 37, 320–321, 323, 600–604, 606, 610–612, 616–617, 625, 627–629, 633–635, 637, 783, 792, 796–799, 802, 804, 816, 819, 823–825, 1163–1173, 1281

- electroencephalography (EEG) 184, 195, 667
 electron microscopy 47, 72–73, 75–76, 81, 84, 133, 142, 195, 200, 205, 314, 318, 323, 382, 387–389, 392–395, 399, 402–404, 426–427, 429, 431–432, 434, 442, 460, 597, 601, 603, 613, 619, 626, 640, 689, 1175–1180, 1188–1189, 1196, 1200–1201, 1317, 1320, 1326, 1342, 1348, 1355–1357
 electrophoresis 546, 556, 558, 579, 770, 794, 1261–1262
 electrophoretic mobility 597, 601–602
 electrophysiology 33, 1163, 1169, 1172, 1281, 1289
 encapsulation 251–253, 257
 endogenous voltages 1163
 endophthalmitis 1249, 1258
 endoplasmic reticulum (ER) 133, 136, 196, 1285
 endoscopy 11–12, 106, 133, 145, 167, 269, 274, 660
 energy dispersive x-ray spectroscopy (EDAX) 597, 601, 603, 612
 engrailed-2 (EN2) protein 597
 enhanced permeability and retention (EPR) 684, 703, 725, 729, 740
 enzyme-linked aptamer assays 907, 913
 enzyme-linked immunoassays 1119–1120
 enzyme-linked immunosorbent assay (ELISA) 303, 308, 323, 487–488, 501, 755–756, 774, 783, 803, 1227, 1234, 1238, 1240
 enzyme-linked oligonucleotide assays 907, 913
 epidemiology 269, 279, 582, 785, 891, 936, 947, 1001, 1004, 1012, 1053, 1062, 1227
 epidermal growth factor 567, 571, 573–574, 583, 619, 635, 640, 683, 685, 703, 725, 732, 740
 epidermal growth factor receptors (EGFRs) 683, 685, 703
 epifluorescence 1317, 1319, 1324–1325
 epifluorescent illumination 935, 949
 episomal plasmids 1025, 1027, 1031, 1035
 epitope 303–304, 311–312
 Erlotinib 507–508
Escherichia coli 66, 161, 305, 386, 473, 480, 639, 801, 817, 821–822, 873, 1021, 1043
 European Medicines Agency (EMA) 487, 495, 501
 expiratory wheezes 853, 855, 861, 865, 867
 exposure monitoring 1227
 external oblique (EO) 747, 750
 extracellular matrix (ECM) 185, 195, 1137–1138, 1147, 1278–1279
 extraction control (EC) 223, 233, 236, 240, 247

 faecal microbiota transplantation (FMT) 655, 657
 false positives 130, 212, 481, 577, 793, 821, 862, 885, 911, 913, 960, 963–964, 968, 1227
 Faraday Cage 667, 669
 fast agglutination screening test (FAST) 783, 786, 803
 fast-scan cyclic voltammetry (FSCV) 1163, 1170
 fatty acid oxidation 1273, 1276
 fatty liver disease 1137, 1273, 1284–1285, 1304
 Fc gamma receptors (FcγRs) 1099, 1113
 Federal Food Drug & Cosmetic Act (FD&C Act) 531
 Federal Policy for the Protection of Human Subjects 531, 537
 fibril core 1355, 1358
 field-deployable 211, 220, 909, 912, 914–918, 922, 925
 field of view (FOV) 58, 202, 979, 984, 996
 fine crackles 853, 855, 860–861, 863, 866, 868
 first Age-Related Eye Disease Studies (AREDS) trial 1249
 flagellar attachment zone (FAZ) 1339, 1350
 flagellum 799, 1339–1340, 1345
 flavin adenine dinucleotide (FAD) 619, 628, 640

- Flinders Technology Associates (FTA) 755, 761, 763, 774
- flu 976, 1102, 1107, 1119–1120
- fluorescein 251, 256, 263, 314, 323, 692, 1119, 1122, 1249, 1253, 1265, 1317, 1323–1324, 1327
- fluorescein angiogram 1249, 1253
- fluorescein isothiocyanate (FITC) 251, 256, 263, 314, 323, 692, 1119, 1122
- fluorescence 185, 189, 197–207, 213, 217–218, 220, 222, 224, 260, 262, 303, 308, 313–318, 320, 322–323, 474–475, 507, 509, 517, 521, 526, 619, 625, 636–638, 640, 692–698, 736, 740, 769, 786, 789–791, 935, 937, 939–940, 943–949, 979–998, 1085, 1119, 1123–1126, 1130–1131, 1139, 1175, 1178–1179, 1188, 1195–1196, 1317, 1319, 1321, 1323–1328, 1331–1332
- fluorescence imaging 725, 736, 740, 1124, 1195, 1317, 1323, 1327–1328, 1332
- fluorescence imaging with one nanometer accuracy (FIONA) 1317, 1327, 1332
- fluorescence *in situ* hybridization (FISH) 67, 507, 521, 526
- fluorescence microscopy/fluorescent light microscopy 81, 197–207, 392, 697, 935, 937, 944, 949, 959, 995, 1175, 1177–1179, 1188, 1196, 1324–1326
- fluorescence recovery after photobleaching (FRAP) 1317, 1324, 1332
- fluorescence super-resolution (FSR) 197, 200–201, 205
- fluorescent detection reagents (FDR) 755, 769, 774
- fluorescent staining 980, 993, 995, 1317, 1323
- fluoroscopy 96, 98, 133, 152, 181
- FMRIB software library (FSL) 1151–1152, 1159
- folic acid 256, 635, 683, 686, 704, 729
- formaldehyde (FA) 633, 1137–1138, 1144, 1147, 1340–1341, 1349
- Förster/fluorescence resonance energy transfer (FRET) 260, 263, 619, 625, 640, 1317, 1323, 1332
- forward internal primer (FIP) 211, 227
- Foundation for Innovative New Diagnostics (FIND) 755, 765, 774, 1053
- free fatty acids (FFAs) 1273–1274, 1304
- frugal microscopy 1195
- functional imaging 1001–1002, 1155
- functional magnetic resonance imaging (fMRI) 133, 166, 186, 196, 1151–1152, 1154, 1159
- functional magnetic resonance imaging of the brain (fMRIB) 1151
- fungal diseases 1025
- gadolinium-diethylenetriaminepentaacetic acid 683, 701, 704
- gas-filled microbubbles (MBs) 725, 732
- gene expression 473, 475–478, 493, 523, 573, 579–581, 1042, 1285, 1288, 1292–1293
- general practitioner 853
- Genetic Information Non-discrimination Act 531
- genetic testing 532, 1249, 1251, 1256
- genetic variants 521, 523–525, 531–544, 1285
- GeneXpert MTB/RIF 1053, 1074
- genome amplification 1119–1120
- genome editing 1025–1026, 1028–1029, 1031, 1033, 1035, 1037, 1039, 1041, 1043
- Genomic Data Commons 269, 282
- genomics 282, 473, 476, 487–488, 492, 494, 500, 515–516, 519, 537
- genosensors 783, 787–789, 794, 796–797
- genotype 307, 531–532, 534–536, 538–540, 543, 1041, 1256
- genotype-phenotype associations 531–532, 534, 536, 540
- geographic atrophy 1249, 1254
- germ-free mice 655, 657
- glial scar 1163, 1166
- global initiative on sharing avian influenza data (GISAID) 892
- glomerular sclerosis 829, 843
- gluconeogenesis 1273–1277
- glucose oxidase (GOx) 314, 619, 628, 634, 640

- glycolic chitosan 683, 686, 704
glycolysis 1273–1274, 1276
glycophosphatidylinositol (GPI)
1355–1356, 1358
glycoproteins 61, 82, 202, 393, 634, 638,
786, 1119–1121, 1125, 1179, 1181,
1184–1185, 1264
Golgi 54–55, 136, 1184, 1322, 1339, 1345
Good Manufacturing Practice (GMP) 1227,
1229, 1238–1240
GPI anchors 1355–1356, 1358–1360
Gram staining 1317, 1322
graphene 251, 260–262, 319, 436, 619,
629–630, 638, 640, 683, 693, 704,
725, 734, 740, 789, 803
graphene oxide 693, 704, 725, 734, 740,
789, 803
green fluorescent protein (GFP) 148, 197,
201, 206, 736, 1317, 1323, 1332
Group A Streptococcus (GAS) 873, 886
Group B Streptococcus (GBS) 873, 886
guanine 1, 458, 813, 816, 818, 826
gut microbial community 655–656
- haematoxylin and eosin (H & E) staining
1137
hammerhead (HH) 1025, 1034–1035, 1044
hands-on time 497–498, 576, 771–772
head motion 1151–1152, 1157
Health Insurance Portability and
Accountability Act (HIPAA) 531, 537
heat-inactivated virus isolate 211, 219
hemagglutinin 61, 1119–1120, 1125
hemoglobin A_{1c} (HbA_{1c}) 1261, 1263, 1269
hepatic imaging 692, 694, 1001, 1008
hepatocellular carcinoma 683, 686, 704,
1302
hepatocytes 1273, 1275, 1282, 1285, 1287,
1289, 1292–1293, 1297–1298
heteroechoic 829–830
high-density antibody microarrays
487–488
high intensity focused ultrasound (HIFU)
133, 172, 196
high molecular weight (HMW) 217, 1099,
1102–1103, 1112, 1114
high-resolution imaging 9, 200, 636, 689,
697, 1187, 1339, 1348
high-resolution structures 1355
high-throughput 233, 235, 245, 549, 575,
619, 629, 640, 727, 736, 768, 1281,
1301, 1303
high-throughput screening (HTS) 619, 629,
640, 727, 768, 1301, 1303
HIV protease 133, 141–142
HIV/TB coinfection 1053, 1055
holobiont 655, 658
homeostasis 1167, 1273–1276, 1282,
1286, 1302–1303, 1360
homology-directed repair (HDR)
1025–1026, 1030, 1032, 1034,
1043–1044
horizontal gene transfer (HGT) 655–656,
661, 815
host-microbe interface 1017
human chorionic gonadotrophin (HCG)
619, 627, 640
human epidermal growth factor receptor
567, 573–574, 685, 725, 732, 740
human epidermal growth factor receptor
2/human epidermal growth factor 2
(HER2) 508, 523, 567, 573–574, 581,
583, 619, 635, 640, 732, 740
human hepatitis delta virus (HDV) 1025,
1032, 1034
human immunodeficiency virus (HIV) 65,
201, 310, 323, 390, 473, 481–482,
619, 626, 640, 766, 774, 908
human-on-a-chip 1273, 1288
hydrocortisone (HC) 1273, 1294, 1304
hydrogen peroxide (H₂O₂) 313, 597, 599,
625, 1017–1018, 1139
hydronephrosis 829, 838–842, 847
hydrophilic interaction chromatography
(HILIC) 1261, 1263, 1269
hydrophobic interaction chromatography
(HIC) 1261, 1269
hydroxy-2 599
hygromycin marker 1025, 1036, 1038
hyperechoic 829–830, 837, 841, 844
hypoechoic 829–830, 836
hypoxia 131, 667–668, 679, 878–879
hypoxic SpO₂ levels 667–668

- identikit 935, 938
- image generation 973
- image-guided biopsy 269, 282
- image processing 973, 975, 1146, 1175–1176, 1183, 1195
- image scanning microscopy (ISM) 1195, 1203
- imaging 1–206, 251–263, 269, 271–272, 281–282, 285–287, 289–290, 292, 294–295, 298, 318, 507, 509, 520, 545, 547, 555, 631, 633, 636, 638, 683–704, 725–740, 747–750, 829, 845, 847, 942–947, 949, 973–976, 979–980, 982–983, 1001–1012, 1124, 1137–1142, 1146–1148, 1151–1152, 1154–1155, 1159, 1163, 1175–1184, 1186–1189, 1195–1196, 1200–1204, 1317, 1319–1325, 1327–1332, 1339, 1342, 1347–1348
- imipenemase (IMP) 813–814, 826
- immobilization 303, 312, 318, 322, 619–620, 627, 793, 796, 1119–1132
- IMMray™ 489, 491–492, 496–497, 500
- immune complexes (ICs) 1099–1114
- immunoassay 303, 308–315, 317, 320–323, 601–602, 635–636, 783, 795, 804, 825, 1119–1120, 1265
- immunochromatographic test 783, 786
- immunofluorescence 186, 581, 755–756, 774, 783, 786, 804, 1284, 1292–1293, 1323, 1339–1340, 1347–1348
- immunofluorescence antibody test (IFAT) 755–756, 774
- immunofluorescence assay (IFA) 783, 786, 804
- immunogen 303, 305
- immunogenic epitopes 1227, 1231
- immunoglobulin (Ig) 303–305, 323, 1099–1100, 1103–1105, 1107–1110, 1112–1113
- immunohistochemistry (IHC) 487, 489–490, 501, 507, 521, 526, 567, 569, 572, 580–581, 583
- immunolabelling 432, 1137–1139, 1141, 1143–1144, 1147
- immunolabelling-enabled three-dimensional imaging of solvent-cleared organs (iDISCO) 1137–1138
- immunological PoC tests 907, 910–911, 913–914
- immunosensing 303, 319, 322, 1121
- immunosensors 320, 635–636, 783, 787–788, 793, 911
- immunotherapy 524, 567–568, 571
- implantable miniature telescope 1249, 1257
- in silico* models 1279, 1291, 1294, 1297–1298, 1300
- in vitro* diagnostics (IVDs) 487, 494, 501, 576, 959
- in vitro-in vivo* translation (IVIVT) 1273, 1301–1302, 1304
- in vitro* to *in vivo* extrapolation (IVIVE) 1273, 1294, 1296, 1304
- individual patient data (IPD) 956, 968
- induced blood-stage malaria (IBSM) 1001–1002, 1011
- induced pluripotent stem cells (iPSCs) 1273, 1303–1304
- infected red blood cells (iRBCs) 984, 990–992, 1001–1002, 1011
- infectious disease 14, 180, 434, 473, 475, 479, 598–599, 873, 891, 913, 935, 946, 955, 1053, 1099, 1114, 1175
- infectivity 1355, 1359–1360
- inflammatory biomarkers 597–612, 618
- inflammatory bowel disease 1273, 1279
- influenza 110, 176, 199, 201, 205, 481–482, 626, 892, 1081, 1092, 1094, 1099–1113, 1119–1132
- influenza neuraminidase 1119
- infrared radiation 973
- ingestible sensors 655–656, 658–662
- inspiratory wheezes 853, 855, 861, 865, 867
- institutional review board (IRB) 233, 235, 247, 892, 898, 901, 958, 1081, 1094
- insulin-like growth factor-1 567, 569
- integrated systems 1261
- intensity based absolute quantification (iBAQ) 1099, 1104, 1114
- inter-recti distance (IRD) 747, 749–750
- interchangeable biosimilar 1249, 1258
- interference 198, 200, 398, 418, 598, 695–696, 1042, 1169, 1261, 1317, 1322, 1329, 1331
- interferometric methods 1317, 1328

- interferon- γ (IFN- γ) 1227, 1229, 1235, 1238–1240
- interferon- γ release assay (IGRA) 1227, 1235, 1239–1240
- interleukin-6 (IL-6) 597, 599–602, 604–612, 616–619, 635, 640, 1276
- intermediate AMD 1249, 1254–1255
- internal control 213, 216–217, 219–221, 223–224, 233–234, 244, 247, 875, 1082, 1085, 1088, 1090–1091, 1093
- internal oblique (IO) 747, 750
- Internet of Things (IoT) 597–598
- interstitial fibrosis 829, 843
- intraocular pressure 1249, 1258
- intrinsically conducting polymers (ICP) 783, 789, 804
- ion exchange 1261, 1263, 1268
- iris 926, 1249, 1253, 1321
- iron oxide nanoparticles 251, 254–257, 263–264, 437, 638, 683, 689, 700, 704, 725, 730–731, 740–741
- isobaric tags for relative and absolute quantification (iTRAQ) 548, 558
- isoelectric focusing (IEF) 545–546, 553, 558
- isolation culture 813, 816
- isotopic tandem orthogonal proteolysis–activity-based protein profiling (isoTOP–ABPP) 1020–1021
- jaundice 269, 271
- kidney disease 829, 833–834, 843, 845
- kidney-injury marker (KIM-1) 1273, 1304
- kinetoplast DNA (kDNA) 755, 761, 763, 774, 793–794, 1339, 1350
- Kirsten rat sarcoma viral oncogene homolog* (KRAS) 567, 571, 574
- Klebsiella pneumoniae* carbapenemase (KPC) 813, 817, 822, 826
- lab-in-a-backpack 1213–1222, 1226
- lab-on-a-chip 124, 133, 173, 322, 907–908, 910, 1261
- Laguerre-Gauss (LG) beams 1317, 1329
- laser ablation 251, 258
- laser-scanning confocal microscope 1317
- late AMD 1249, 1254–1256
- lateral flow biosensors (LFBs) 783, 793, 804
- lateral flow immunoassay (LFIA) 783, 795, 804
- lead designs 1163, 1167
- Leidenfrost transfer system 973
- Leishmania amazonensis* 766, 1227–1228, 1230
- Leishmania* antigens 1227–1228, 1231, 1239
- Leishmania braziliensis* 1227–1228, 1235
- Leishmania donovani* 1227–1228, 1231, 1240
- Leishmania guyanensis* 761, 1227–1228, 1235
- Leishmania infantum* 774, 1227–1228
- Leishmania major* 760, 1227–1228, 1230
- Leishmania* spp. 786, 788–789, 793
- leishmaniasis 637, 755–757, 760–761, 763–768, 771–775, 783–787, 795–796, 802–804, 907, 909, 914–916, 918–921, 923, 927, 1227–1228, 1234–1237, 1239–1240
- leishmaniasis recidivans 1227–1228, 1240
- leishmanin skin test (LST) 1227–1240
- light-sheet microscopy (LSM) 1317, 1324, 1332
- limit of detection (LOD) 211, 213, 219, 227, 233, 237–238, 247, 487–488, 501, 507, 550, 578, 597, 606, 612, 761, 788–789, 792–793, 796, 798, 800, 802, 896, 899, 1081, 1085–1087, 1089–1090, 1094, 1125, 1281
- limit of quantification 487–488, 501
- limit of sensitivity 1227
- lipid nanoparticles 251, 254, 264
- lipoarabinomannan (LAM) 955–970, 1053–1054, 1064, 1066–1068, 1073
- liposomes 251, 254, 260, 314, 734, 792
- liquid biopsy 269, 281–282, 490, 500–501, 511, 569, 583
- liquid chromatography (LC) 545, 556, 558, 1017, 1020–1022, 1099–1100, 1114, 1261–1262, 1264, 1266, 1268–1269

- liquid chromatography mass spectrometry (LC-MS) 1261
- liquid chromatography tandem mass spectrometry (LC MS/MS) 1099–1100, 1114
- liver disease 168, 188, 1137, 1273, 1279, 1284–1285, 1304
- logistic regression 285, 291, 293–295, 298
- loop-mediated isothermal amplification (LAMP) 211, 217, 227, 755–775, 907, 910, 912, 918, 927, 979–980, 996, 1081–1082, 1094–1095, 1213–1214, 1217
- loop primers 211, 217–218, 758, 1082, 1221
- loss of heterozygosity 1025, 1040, 1043–1044
- louder breath sound 853, 855, 861, 864, 866–867
- low back pain (LBP) 178, 747–749
- Lucentis 1249, 1258
- lutein 1249, 1255
- lymphoma 700, 829, 836–837, 1002
- machine learning 133, 176–178, 184, 187, 190, 196, 598, 981, 1201
- macula 36, 1249–1250, 1254, 1257
- magnetic nanoparticles (MNPs) 252, 619, 638, 640, 683–684, 700, 704, 725, 730, 739–740
- magnetic resonance elastography (MRE) 133, 168, 188, 196
- magnetic resonance imaging (MRI) 39, 58–59, 70, 92, 95, 108, 133, 165–167, 186, 188–189, 196, 251–252, 263, 269, 272, 285–286, 289, 292, 294–295, 298, 633, 683, 686, 704, 725, 729, 740, 829, 845, 1001–1002, 1011–1012, 1151–1152, 1154, 1159, 1163, 1165
- magnetic susceptibility 1151, 1153–1154, 1157
- malaria 193, 757, 772, 908, 923, 979–981, 985, 989, 991, 993–996, 1001–1006, 1008–1012, 1227
- mammography 22, 133, 152–157, 188
- Markov chain Monte Carlo (MCMC) 1053, 1063, 1072–1073
- mass spectrometry (MS) 487–488, 501, 545–546, 552, 556–558, 815, 826, 1017, 1019, 1021–1022, 1099–1100, 1104, 1106, 1108, 1114, 1261, 1269, 1289, 1293
- mathematical fitting 1317, 1327
- medical device 160, 487–489, 495–496, 498, 501, 541, 1216
- medical subject headings (MeSH) 907, 925, 927
- medium crackles 853–855, 861, 863
- membrane-proximal external region (MPER) 197, 202, 206
- metabolic disease 1143, 1273, 1277–1278, 1284–1285
- metabolic regulation 1273–1274
- metabolism 95, 188, 661, 685, 729, 801, 1001–1012, 1018, 1021, 1263, 1273–1304
- metadata 531, 537–538, 946
- metastasis 23, 269, 276–277, 473, 476, 478, 482, 700, 734
- metastatic bone tumors 269, 273
- methylated Septin9 (mSEPT9) 567, 569
- Meyerozyma guilliermondii* (Mg) 1025, 1032, 1035, 1044
- micro-RNA (miRNA) 473, 567, 573–574, 584
- micro total analysis system (microTAS) 1261
- microarray 487, 489, 492, 497, 523, 579–581, 815–816
- microbial-animal interaction 655
- microbial diversity 655
- microbiological reference standard (MRS) 956, 960–961, 963–964, 967–968, 1071
- microbiome 66, 386, 480, 655–662, 874, 940, 1303
- microfabrication 190, 1264, 1268, 1273, 1278, 1301
- microfluidics 188, 322, 514, 1201, 1273, 1278
- microhomology-mediated end joining (MMEJ) 1025–1026, 1034, 1044
- microphysiological system (MPS) 1273, 1284, 1304

- microsatellite instability (MSI) 508, 523, 567, 570, 574, 578, 584
 microscopy 28–29, 45, 47, 72–73, 75–76, 81, 105, 107, 110, 133, 146, 189, 194–207, 318, 323, 378–380, 382, 387–390, 392–395, 398–399, 402–404, 426–429, 431–432, 434, 449–450, 597–598, 601, 603, 612–613, 761–763, 765–768, 771–772, 935, 937, 947, 949, 959–960, 979–998, 1119, 1141–1142, 1148, 1175–1180, 1187–1189, 1195–1204, 1317, 1320–1322, 1324–1332, 1339–1342, 1344–1350, 1355–1357
 Middle East Respiratory Syndrome (MERS) 211, 227, 1093–1094
 minimal residual disease (MRD) 473, 477, 482
 mismatch repair (MMR) 567, 570, 574, 584
 mitochondria 45, 73, 79, 103, 136, 395–396, 1183, 1339
 mobile genetic elements (MGEs) 655–656, 815
 molecular biology 185, 190, 371, 378, 426–428, 473–474, 1175, 1189
 molecular detection 233
 molecular diagnostics 567–584, 755–756, 771
 molecular PoC tests 907, 912
 molecular xenomonitoring (MX) 755, 767, 774
 monoclonal 119, 124, 303–306, 437, 513, 567–568, 571, 583, 602, 685, 791–792, 799, 1187, 1235, 1344–1349
 monoclonal antibodies (mAbs) 119, 124, 305–306, 437, 567–568, 792, 799, 1187, 1235
 monolithic 1261–1263, 1265, 1268
 Montenegro skin test 1227–1228
 mucocutaneous leishmaniasis (MCL) 755–757, 774, 783–784, 804, 1227–1228, 1240
 multi-analyte biosensor 1273
 multi-conductor array 1163
 multi-drug resistant (MDR) 935–936, 950
 multi-organ chip (MOC) 1273, 1295, 1297, 1299
 multifidus muscles 747–749, 751
 multiple reaction monitoring (MRM) 487–488, 501
 multiplex 211, 220, 223, 233–248, 310, 322, 515, 579, 873, 875, 878, 881, 883–884, 891–892, 894–900, 1042, 1081–1086, 1088–1094
 multiplex detection 211, 223, 1042
 multiplex PCR 515, 579, 873, 875, 878, 881, 883–884, 897
 multiplex RT-LAMP 1083, 1085–1086, 1088–1090
 multiplexed testing 907
 multiplexing 319, 321, 487, 491–492, 496, 498–500, 520, 629, 639, 698, 911–912, 919, 922, 1041, 1201
 multiscale imaging 1175, 1187–1188
 musculoskeletal disorders 747, 752
Mycobacterium tuberculosis (Mtb) 935–950, 956, 959, 968

 N-linked glycans 1355–1356, 1359–1360
 NADPH oxidases (NOX) 1017–1018
 nanobubbles 725, 732, 740
 nanocarbons 251, 260–262
 nanocarriers 251–253, 436, 798
 nanocrystals 251, 257, 259, 314, 435, 695
 nanomaterials 260, 303, 318, 619, 629, 639, 683–704, 734, 783, 785, 787–803
 nanomechanical sensors 303, 320
 nanomedicine 251–253, 263, 434, 640, 704, 725–727, 730, 734, 740
 nanoparticles (NPs) 82–83, 189–190, 195, 201, 251–252, 254–258, 261, 263–264, 303, 310, 314, 318, 323, 392, 436–437, 567, 579–581, 601, 605, 619, 640, 683–685, 687, 689, 691, 693, 700, 702, 704, 725, 728, 730, 733, 735, 737–738, 740–741, 783, 789, 793–796, 798, 801–802, 804
 nanopore sequencing 507, 518
 nanorods 251, 259, 619, 624, 640, 687

- nanowell array 935, 942, 944
 nanowell-arrayed microscope 935, 938
 nasopharyngeal 211, 214–216, 223, 227,
 233–234, 241–242, 245–247,
 898–899, 1081, 1090, 1095, 1126
 nasopharyngeal swab (NPS) 233–234,
 247, 1090
 native prion protein (PrPc) 1355
 near-infrared 145, 153, 157, 190, 192,
 251, 257, 263, 624, 640, 694, 704,
 725, 736, 740
 near-patient laboratory testing 907–908,
 925
 negative percentage agreement (NPA) 233,
 247
 negative predictive value (NPV) 233, 238,
 244, 247, 567, 578, 600
 neglected tropical diseases (NTDs)
 783–784, 804, 907–927
Neisseria meningitidis 473, 480
 neonatal 677, 873–886
 neovascular age-related macular
 degeneration (nAMD) 1249, 1258
 neural intervention 1137
 neural networks 133, 177–178, 184, 190,
 979, 981, 985, 996, 1141–1142, 1201
 neural stimulation 1163–1173
 neuraminidase 1119–1120
 neurological deficit 285, 287
 neuromodulation techniques 1163, 1172
 neurotransmitter 1163–1164, 1170–1171
 neutral buffered formalin (NBF)
 1137–1138, 1147
 New Delhi metallo- β -lactamase (NDM)
 813–814, 826
 next-generation sensor 597
 next-generation sequencing (NGS)
 487–488, 490, 501, 507–526, 531,
 567–568, 580–581, 584, 907, 910,
 912, 927, 1042–1044, 1120
 Nomarski–Wollaston prism 1317, 1322
 nomenclature 251, 537, 853–854, 856,
 862, 866–868
 non-alcoholic fatty liver disease (NAFLD)
 1273, 1284–1285, 1304
 non-alcoholic steatohepatitis (NASH) 1273,
 1285, 1304
 non-communicable disease 655
 non-homologous end joining (NHEJ)
 1025–1026, 1034, 1044
 non-neoplastic factors 567, 570
 non-small cell lung cancer (NSCLC) 473,
 476, 482, 497, 507–508, 522–523
 non-spherical gold nanoparticles (nsAuNPs)
 783, 796, 804
 non-tuberculous mycobacteria (NTM) 956,
 965, 968
 normal bronchial sound 853, 855, 861,
 864, 866
 normalization 523, 1151, 1155–1156,
 1158
 Northern Blot 473, 475
 Nourseothricin resistant (NTC R) 1025,
 1030, 1044
 Nourseothricin susceptible (NTC S) 1025,
 1030, 1044
 nuclear magnetic resonance (NMR) 94,
 133, 142, 196, 431, 1175, 1188
 nuclear medicine 48–50, 95, 157–160, 191,
 193, 738, 1001–1003, 1012
 nuclear mitotic apparatus protein 1
 (NUMA1) 597, 599, 613
 nuclear scans 269, 272–273
 nucleic acid amplification test (NAAT)
 755, 757, 775, 825, 907, 912, 927,
 979–980, 996
 nucleic-acid-based PoC tests 907
 nucleic acid hybridization assay 567, 577
 nucleic acid sequence-based amplification
 (NASBA) 755, 758, 775
 nucleotide extraction 473–474
 numerical aperture 949, 1195–1196
 omega-3 fatty acids 1249, 1255
 Omnipaque® 683, 688, 690–692
 on-chip chromatography 1261, 1268
 oncocytoma 829, 837
 open reading frame (ORF) 892, 1025,
 1030, 1044
 open tubular 1261
 optic nerve 56, 1249, 1252
 optical clearing 1137–1143, 1145–1146
 optical coherence tomography (OCT) 112,
 133, 145, 191, 196, 1249, 1253

- optical diffraction gratings 1317, 1330
optical imaging 133, 144–146, 189, 191, 736–737, 739
optical microscope 382, 1317, 1319
optical properties 251, 258–260, 262, 637, 737
organ crosstalk 1273, 1279, 1286
organ-on-chip (OoC) 1273, 1277, 1304
organelles 79, 135–137, 142, 379, 396, 404, 739, 1202, 1322, 1339, 1345
oropharyngeal 216, 233–234, 246–247, 898, 1081, 1095
oropharyngeal swab (OPS) 233–234, 246–247, 898
Osimertinib 507–508
osteoclasts 725, 731, 740
oxacillinase-48 (OXA-48) 813–814, 826
oxidation (ox) 258, 320, 628, 631, 816, 818–822, 1017–1022, 1104, 1164, 1170, 1273, 1276–1277, 1289
oxidative posttranslational modifications (OxiPTMs) 1017–1018
- packed particle 1261
palliative chemotherapies 567–568
PAMAM dendrimers 256, 683, 686–688, 690, 692, 701–702
pandemic 179, 211–212, 225, 233–234, 481, 976, 1082, 1119, 1175–1176, 1188, 1213–1214
panning 307–308
para-benzoquinone (p-BQ) 619, 638, 640
paracrine 428, 1273, 1276
parallel in-register intermolecular β -sheets (PIRIBS) 1355–1356
parasitic diseases 783, 1227
parenchymal thickness 829–830, 832
Parkinson's disease 140, 159, 161, 184, 285–298, 1355
pathology reports 269, 273, 275–276, 278
paucibacillary 935, 937, 956, 1071
PCR-restriction fragment length polymorphism (PCR-RFLP) 755, 771, 775
PDQ[®] cancer treatment summaries 269–271, 275, 277
- PEGylated AuNPs 683, 685, 687, 690
PEGylated perfluorooctyl bromide 683, 694, 704
Pembrolizumab 490–491, 567, 570–572
people living with HIV (PLHIV) 955–970, 1053–1055, 1061–1062, 1074
peptide mass fingerprint (PMF) 545–546, 556
personal protective equipment (PPE) 233–234, 247
personalized medicine 532, 567, 1303
personalized treatment 251
phage display 303, 307–308
pharmacodynamics 1273, 1278, 1288, 1304
pharmacokinetics (PK) 1273, 1278, 1304
phase contrast 91, 379, 427, 1317, 1322, 1330
phenotype 307, 531–532, 534–536, 538–540, 543, 942, 1010, 1041, 1130, 1285–1286, 1303
phosphatase and tensin homolog (PTEN) 567, 572, 574, 584
phosphate-buffered saline (PBS) 600, 948, 950, 1139, 1213, 1217, 1348
photo-activated localization microscopy (PALM) 197, 206, 1317, 1328, 1332
photo-bleaching 197, 200–202, 205
photoacoustic 133, 145, 631, 636–637, 683, 692, 694–695, 698–699, 725, 739–740
photoacoustic imaging (PAI) 133, 145, 631, 636, 683, 692, 694–695, 698–699, 725, 739–740
photodynamic therapy 251, 259, 262, 264, 1249, 1256
photomultiplier tube 725, 733, 740
photoplethysmogram 667, 669, 676, 678
photoplethysmography (PPG) 667–671, 676
photothermal therapy (PTT) 619, 622, 640
phototoxicity 197, 200–203, 205
physiologically based PK-PD (PBPK-PD) 1273, 1304
piezoelectric mass sensors 303, 320
pillar array 1261–1262, 1265–1268
pillar-distribution controlled (PDC) 1261, 1267, 1269

- Plasmodium falciparum* 979–998, 1001, 1011, 1042
- Plasmodium vivax* 1001, 1012
- pleural rub 853, 856
- point-of-care (POC) 133, 176, 179–180, 191, 196, 303, 318, 321, 567, 580, 597–598, 600, 608, 611–613, 619, 640, 755, 761, 773, 775, 783, 786, 790, 793, 804, 813, 824, 826, 907–970, 979–980, 983, 996–997, 1042, 1054, 1081–1082, 1125, 1213, 1218
- point-of-care circulating cathodic antigen (POC-CCA) 907, 918, 927
- point-of-care diagnostics (POCD) 597–598, 612–613, 907–926
- point-of-care test 567, 580, 773, 1042, 1054
- point spread function (PSF) 1317, 1320, 1332
- polarized light 623, 1317, 1322
- poly(lactic-co-glycolic acid) 725
- polyamidoamine (PAMAM) 251, 256, 263, 683, 686–688, 690–692, 701, 704, 783, 788–789, 792–793, 804
- polyclonal 124, 130, 303–305, 626, 791, 958, 966, 1103, 1348–1349
- polydimethylsiloxane (PDMS) 1273, 1281, 1304
- polyelectrolyte complex (PEC) 683, 702, 704
- polyelectrolyte complex nanoparticles (PEC NPs) 683, 702
- polyelectrolyte gel 1339–1340
- polyethylene glycol 306, 323, 437, 688, 697, 1099–1100, 1114, 1119, 1122, 1126
- polyethylene terephthalate 783, 789, 804
- polylactic acid (PLA) 694, 1213, 1216
- polymerase chain reaction (PCR) 123, 184, 211, 227, 233–234, 247, 473–482, 490, 501, 507–508, 526, 575, 655, 658, 755–756, 763, 775, 783, 787, 804, 815–816, 826, 873, 886, 907, 910, 912, 927, 979–980, 996, 1001, 1003, 1012, 1081, 1120, 1213, 1293, 1304
- polymeric nanoparticles 251, 255
- polymethyl methacrylate (PMMA) 1273, 1281, 1304
- positive percentage agreement (PPA) 233, 247
- positive predictive value (PPV) 233, 238, 244, 247, 567, 578
- positron emission tomography 43, 95, 133, 153, 156–158, 189, 192, 196, 269, 273, 285, 683, 694, 704, 725, 733, 740, 1001–1002, 1007, 1011–1012
- post kala-azar dermal leishmaniasis (PKDL) 755, 757, 763–764, 775
- post-translational modification (PTM) 545, 556, 558
- precision medicine 473–482, 501, 507–526, 531, 533, 568, 575, 1304
- premarket approval 487, 495, 501, 507, 519, 526
- premarket clearance 531, 534
- premarket submission 531, 534, 536, 540–541, 543
- prion propagation 1355, 1358
- prion protein (PrP) 1355, 1357
- Privacy Act 531, 537
- pro-basal body (probb) 1339–1340, 1345–1346, 1350
- probiotics 655–657
- professional training 531, 540
- profiling 123, 487–488, 492, 494, 498, 500, 939, 1017, 1019–1022, 1043, 1226, 1292
- prognosis 13, 153, 252, 269, 278–280, 389, 476–479, 570–573
- Programmed Death-Ligand 1 (PD-L1) 567, 572, 574, 584
- progression-free survival (PFS) 279, 567, 572, 584
- prolonged expiratory phase 853, 855
- prospective study 282, 567, 570, 967
- prostate-specific antigen (PSA) 619, 626, 640
- protective immunity 1227, 1235, 1237, 1239
- protein speciation 545
- protein species 545–547, 550, 552–553
- proteinopathies 1355
- proteoform 545–552, 554–558
- proteoliosomes 792

- proteomes 488, 545–558, 1017,
 1019–1022, 1104, 1263
 proteomics 473, 476, 487–489, 491–492,
 494, 497–500, 545, 547, 550,
 1099–1114, 1261, 1268
 protofilaments 1355–1356
 protospacer adjacent motif 1025–1026,
 1044
 protozoa 110, 755, 783, 791, 793, 799,
 1227, 1339–1340, 1342
 PrP fibrils 1355–1356, 1360
 PrP scrapie (PrPSc) 1355
 ptychography 1317, 1330
 pulmonary 43, 88, 163, 635, 853,
 1053–1056, 1058–1059, 1120, 1153
 pulmonologists 853–854, 856, 858,
 860–861, 867–868
 pulse oximeter 133, 1156
 pulse oximetry 667–670, 674, 677, 679
 pupil 7, 451, 1249
 pyonephrosis 829, 840
 pyrithiamine resistance cassette (*PTRA*)
 1025, 1037, 1044
- quadruplex 800, 813, 816–817, 819–825
 QuantiFERON 1227, 1236–1237,
 1239–1240
 quantitative polymerase chain reaction
 (qPCR) 211, 227, 473–482, 501,
 507–508, 526, 567, 575, 755, 763,
 775, 783, 787, 804, 873, 886, 892,
 894–896, 901, 944, 979–980, 990,
 996, 1001, 1003, 1012, 1081, 1293,
 1304
 quantitative reverse transcription PCR
 567, 575, 581, 584
 quantitative reverse transcription
 polymerase chain reaction 1081
 quantitative systems pharmacology (QSP)
 1273, 1298, 1304
 QuantiVirus™ 233
 quantum dots (QDs) 197, 201, 206, 251,
 254, 259, 264, 303, 314, 318, 323,
 619, 637, 640, 683–684, 695, 704,
 737, 783, 789, 791, 796, 803
- Quencher-Trehalose-Fluorophore (QTF)
 935, 946, 950
- radiofrequency ultrasound 285–298
 radiometry 973
 radionuclide scan 269, 272
 Raman spectroscopy 133, 145, 192, 1119,
 1121, 1126, 1287
 random illumination microscopy (RIM)
 1195, 1200
 ranibizumab 1249, 1258
 rapid detection 211–228, 597, 757, 798,
 883
 rapid diagnostic tests (RDTs) 191, 193,
 196, 756, 775, 925, 959, 979–980, 996
 reaction monitoring 487–488, 501,
 557–558
 reactive oxygen species (ROS) 692, 1017,
 1022, 1273, 1281
 reactive species 1163, 1166
 real-time polymerase chain reaction
 220, 237, 474, 498, 580–581, 799,
 815–816, 826, 873–875, 878–879,
 883, 900, 1082, 1085, 1088–1094,
 1119–1120
 real-time quantitative polymerase chain
 reaction 783, 787, 804
 real-time reverse transcription polymerase
 chain reaction 184, 233–234, 247
 receiver operating characteristic (ROC)
 285, 291, 298, 487, 489
 receptor binding domain (RBD) 1175,
 1177, 1186, 1189
 recombinant 303–305, 307, 317, 322, 763,
 775, 783, 786, 788, 793, 795,
 799–801, 804, 1183, 1356, 1360
 recombinase polymerase amplification
 (RPA) 755, 758, 775, 907, 910, 912,
 918, 927
 rectus abdominis (RA) 747, 750
 recycled/repurposed electronics 1213
 red blood cells (RBCs) 16, 20, 29, 109, 116,
 129, 135, 157, 667, 979, 984–987,
 989–992, 996, 1001–1002, 1011
 redox chemistry 1163, 1170
 redox signaling 1017–1022

- reduced plate height 1261, 1266
- region of interest (ROI) 285, 288–289, 292, 298, 730, 975, 1001–1003, 1005, 1012, 1183
- regulatory considerations 487, 493–495
- reliability 252, 286, 475, 480, 496, 570, 751, 771, 873–874, 885, 914, 1200, 1213
- remote patient monitoring (RPM) 133, 179, 196
- remote rapid testing 907–908, 925
- renal anatomy 829
- renal calculi 829, 841
- renal cell carcinoma (RCC) 829, 835–836, 847–848
- repair template (RT) 1025, 1030, 1035, 1044
- reproducibility 233, 238–240, 247, 322, 447–448, 546, 626, 795, 914, 1195, 1203–1204, 1213, 1265, 1267–1268
- resistive index (RI) 829, 831–832
- resolving power 1317, 1320
- respiration rate 667, 669
- respiratory aerosol sampling chamber (RASC) 935
- respiratory sounds 853–854, 856, 861, 866, 868
- responsiveness 487, 491
- reticuloendothelial system (RES) 683, 687, 702, 704
- retina 36–37, 56, 68, 112, 145, 191, 427, 1203, 1249–1250, 1252–1254, 1256–1258
- retinal detachments 1249, 1258
- reverse phase 1261
- reverse transcriptase quantitative polymerase chain reaction 892
- reverse transcription loop-mediated isothermal amplification (RT-LAMP) 211, 217, 227, 1081, 1095, 1213–1214, 1217
- reverse transcription polymerase chain reaction 567, 575, 581, 584
- rheumatology 873, 973, 976
- rhonchi 2, 853, 855, 860–862, 865–868
- ribosomal RNA (rRNA) 658, 755, 761, 775
- ribozymes 1025, 1027, 1031–1032, 1034–1035, 1037–1038
- risk prediction 169, 531–532
- RNA-dependent RNA polymerase (RdRP) 1081, 1095, 1175, 1182, 1189
- RNA-Cas9 protein complex (RNP) 1025, 1032, 1034
- rolling circle amplification 507, 516, 526
- Saccharomyces cerevisiae* 1025–1026, 1032, 1034, 1044
- sample manipulation 211–212
- sample pooling 233, 236, 244
- sample preparation 200, 212–214, 217, 220–223, 226, 245, 517, 525, 825, 911, 915–916, 920, 980, 1102, 1175–1176, 1181, 1196, 1203, 1227, 1342
- sandwich assay 303
- scanning electron microscopy (SEM) 318, 323, 597, 601, 603, 613, 689, 1175, 1179, 1189
- scanning near-field optical microscopy (SNOM) 1317, 1327, 1332
- screen-printed carbon electrodes (SPCEs) 783, 798–799, 804
- segregation machinery 1339–1340, 1342
- selected reaction monitoring 487–488, 501, 557–558
- semiochemical 655, 659, 662
- sensitivity 130, 211–212, 220–222, 224–226, 237–241, 244–247, 297, 315–316, 321–322, 478–482, 488–489, 491–492, 547–548, 550–551, 555, 569–570, 576–578, 621, 625–627, 698–699, 733–735, 737, 756–757, 761–763, 765–769, 771–773, 785–787, 792–797, 823–825, 894–895, 912–913, 944–945, 956, 960, 962–968, 980, 993–995, 1054–1055, 1063–1065, 1071–1072, 1091, 1093, 1119–1121, 1154–1157, 1171, 1214, 1218, 1230–1232, 1236–1237, 1264–1265
- sentinel cells 655–657
- sentinel lymph node biopsy 269, 275
- sentinel lymph nodes (SLN) 269, 473, 478, 482

- septin 9 567, 569, 574, 584
 sequence variations 473, 481
 sequencing 123, 487–488, 490, 497, 501,
 507–526, 531–532, 534, 538,
 567–568, 575–577, 580–581, 584,
 878, 882–883, 891–892, 894,
 897–898, 900, 907, 910, 912, 927,
 1025, 1042–1044, 1103, 1105,
 1111, 1120, 1179, 1181, 1285, 1292
 sequencing by ligation 507, 509, 515, 526
 sequencing by synthesis 507–510, 512,
 514, 519, 526
 serological test 755
 serology 756, 761, 1227, 1234
 serotonin 655, 659, 661, 1265
 serum 15–16, 25, 128–129, 304–305,
 310–311, 477, 487, 492, 500, 546,
 569, 598, 626, 635–638, 687, 689,
 756, 767, 790, 792–793, 795,
 1100–1103, 1105–1106, 1108, 1114,
 1119, 1122, 1145, 1261, 1264, 1281,
 1294, 1297–1298
 Severe Acute Respiratory Syndrome
 Coronavirus 2 (SARS-CoV-2) 81–85,
 184, 197–199, 205–206, 211–220,
 222–228, 233–238, 240–248,
 392–393, 481–482, 891–901, 1081,
 1095, 1175–1189, 1213–1220, 1222,
 1226
 Sexually Transmitted Diseases Diagnostics
 Initiative (SDI) 907, 909, 927
 sialic acid 1119–1123, 1125–1126,
 1128–1130
 signal generation 303, 313, 315–318, 821
 signal-to-noise ratio 725, 728, 741, 1151,
 1155, 1159
 signal transduction 303, 319, 321–322,
 785, 1022
 signaling pathways 101, 1022, 1273
 silicon nanoparticles (SiNPs) 683, 702
 silicon photomultipliers 725, 733, 740
 single-guide RNA (sgRNA) 1025–1026,
 1030, 1032, 1034, 1044
 single-molecule localization microscopy
 (SMLM) 1195–1196
 single-molecule switching microscopy
 (SMSM) 197, 200, 206
 single-nucleotide addition (SNA) 507, 512,
 514, 519, 526
 single-nucleotide variants 507, 511, 523,
 526
 single-photon emission computed
 tomography (SPECT) 157–158, 189,
 193, 196, 285, 683, 694, 704, 725,
 732, 741
in situ readout 1273
 size exclusion chromatography (SEC)
 1099, 1102, 1114
 sleep apnea 667–668, 670, 677, 679
 sodium dodecyl sulfate (SDS) 545, 552,
 558, 1339–1340, 1350
 sol-gel synthesis 1261, 1267
 solid-phase extraction (SPE) 1261, 1265,
 1269
 sound classes 853–856, 860, 862, 866, 868
 Southern Blot 473, 475
 spatial light modulator (SLM) 1317, 1329,
 1332
 spatial precision 1163–1164, 1328
 spatial resolution 197, 199, 201, 203–204,
 297, 728, 730–731, 733, 735, 737,
 983, 989, 1121, 1155, 1157,
 1195–1196, 1202, 1320, 1324, 1330
 specific signal threshold (SST) 597,
 606–608, 613
 specificity 130, 178, 217, 238, 240–241,
 244–246, 252, 291, 293, 295, 297,
 305, 307, 479–480, 482, 487–489,
 569–570, 573, 578, 581, 598, 607,
 617, 619, 626, 637, 756–757,
 761–763, 765–768, 772–773,
 786–787, 792, 794–795, 799, 803,
 823–824, 841, 911–913, 915–916,
 956, 960, 963–967, 1041–1042, 1054,
 1063–1064, 1071–1072, 1085, 1091,
 1094, 1104
 spike gene target failure (SGTF) 892–893,
 901
 splenic imaging 1001, 1007, 1009
 splenic tropism 1001, 1009–1010
 splicing 545, 547, 550
 squamous cell carcinoma 276, 477, 635,
 685–686, 829, 836
 squawk 853, 856
 stable isotope labeling of amino acids in
 cell culture (SILAC) 548, 558
 standard operating procedures (SOPs)
 531, 536

- standardization 473, 482, 500, 525, 537, 583, 787, 803, 907, 975–976, 1227, 1230, 1233, 1236, 1239–1240, 1302
- standardized uptake values (SUVs) 1001, 1003, 1012
- Staphylococcus aureus* 21, 80, 125, 386, 473, 695, 814, 876
- statistical parametric mapping (SPM) 1151–1152, 1159
- stethoscope 2–4, 9, 35, 853, 856–858, 866
- stimulated emission depletion (STED) 81, 197, 201, 206, 392, 1175, 1178, 1189, 1195–1196, 1317, 1327, 1332
- stimulated emission depletion microscopy (STED) 197, 201, 206, 1317, 1327, 1332
- stochastic optical reconstruction microscopy (STORM) 197, 201, 206, 1317, 1328, 1332
- stridor 853, 855, 860–861
- structural biology 73, 138–139, 141, 143, 194, 382, 395, 1175–1189, 1355
- Structural Similarity Index (SSIM) 979, 986, 996
- structured illumination microscopy (SIM) 194, 196, 1195–1196, 1203–1204, 1317, 1328
- sub-clinical infections 935, 937
- substantia nigra (SN) 285, 289, 294, 298, 1157
- subtomogram averaging (STA) 1175, 1177, 1189
- super-resolution microscopy 81, 110, 133, 146, 206, 392, 1178, 1195–1200, 1202–1204
- superparamagnetic iron oxide NPs (SPIONs) 254–256, 683, 689, 700, 704, 725, 731
- superparamagnetic iron oxide NPs ultrasound 725
- surface chemistry 601, 1163, 1166
- surface-enhanced Raman scattering (SERS) 619, 625, 640, 683, 692, 704
- surface-enhanced Raman spectroscopy 1119, 1121
- surface plasmon resonance (SPR) 619–620, 640, 783, 793, 804
- surrogate marker 655, 660–661, 1229, 1235, 1237–1239
- surveillance 269, 279, 476–479, 481, 496, 500, 757, 767–768, 814, 885–886, 891–901, 908, 914, 917, 926, 936, 1082, 1230–1231, 1237–1239
- Surveillance, Epidemiology and End Results (SEER) Program 269, 279–280
- systematic evolution of ligands by exponential enrichment (SELEX) 783, 799, 804
- systolic acceleration (Ao Accel) 829, 832
- systolic velocity (Vs) 829, 831–832
- tandem mass spectrometry 545–546, 552, 556, 558, 1099–1100, 1114
- tandem mass tags (TMT) 545, 548, 558
- TaqMan 218, 234, 475
- telehealth 133, 177–180, 194
- temporal resolution 197, 199, 202, 204–205, 728, 735, 1196, 1202
- temporal signal-to-noise ratio (tSNR) 1151, 1155, 1159
- terahertz tomography 133, 146
- theranostics 194, 251–264, 740
- therapeutic ultrasound 133, 169, 171–172
- thermal cycler 473–474
- thermal sensors 973
- thermographic index 973, 975
- thermography 973, 975–976
- three-dimensional visualization 1137, 1141
- thromboembolic 1249, 1258
- time-resolved fluorescence 303, 314
- tissue biopsy 569, 762–764, 1137, 1139, 1143–1146
- TMN staging system 269
- tomographic slice 1175, 1184
- top-down proteomics 545
- total internal reflection fluorescence (TIRF) 197, 204, 207, 507, 509, 526, 1317, 1324, 1332
- trans*-activating RNA (tracrRNA) 1025, 1034
- transcranial sonography (TCS) 285–287, 289, 292, 294–295, 298
- transient CRISPR-Cas9 coupled with electroporation 1025, 1039, 1044

- transitional cell carcinoma 829, 836
- transmembrane protease serine 2 (TMPRSS2) 1175, 1179, 1189
- transmissibility 83, 898, 1355, 1359–1360
- transmission electron microscopy (TEM) 76, 432, 619, 626, 640, 1175, 1177, 1179, 1189
- transversus abdominis (TrAb) 747, 750
- tricarboxylic acid (TCA) 1273, 1275, 1304
- tripartite attachment complex (TAC) 1339–1340, 1350
- Trypanosoma brucei* 1339–1350
- trypanosomes 1339, 1342, 1345, 1348
- Tsimane 655, 662
- tuberculin skin test (TST) 1227–1228, 1231, 1240
- tuberculosis (TB) 2, 128, 434, 757, 907–908, 927, 935–970, 1026, 1053–1074, 1228, 1233, 1236
- tuberous sclerosis 829, 835, 837
- tubular atrophy 829, 843
- tumor 39, 58, 105, 147, 152–154, 156–157, 168–169, 171, 185, 191, 256, 260–263, 269, 272, 274–277, 282, 473, 476–479, 482, 487–488, 491–492, 500–501, 508, 523–524, 538, 567–575, 577, 582–584, 598, 633, 636, 684–689, 692–693, 695, 700–702, 729, 732, 734–735, 739, 835–836, 838, 847, 979
- tumor grade 269, 276–277
- tumor markers 269, 272, 275, 492
- tumor-node metastasis (TNM) 473
- turnaround time (TAT) 236, 487, 497, 507, 511, 519, 526, 567, 578, 772, 815, 907–908
- two-dimensional gel electrophoresis (2DE) 545–558
- two-photon excitation (2PE) 1317, 1325, 1331
- two-photon microscopy 1317
- type 2 diabetes mellitus (T2D) 1273, 1286, 1304
- tyrosine hydroxylase (TH) 1137, 1139–1140, 1147
- tyrosine kinase inhibitor (TKI) therapy 567–568
- ultrasonogram (USG) 631, 683, 692, 704
- ultrasonography 86, 731, 747, 829–850
- ultrasound (US) 18, 52–53, 70, 112, 133, 153, 157, 169–173, 179, 181, 185–186, 188–189, 191, 195–196, 255, 269, 273, 285–298, 725, 727, 731, 741, 747–750, 829, 832–833, 848, 1253
- ultrasound-guided biopsy 829, 838
- ultrasound-guided interventions 829
- ultrasound imaging (USI) 727, 747–750
- ultrastructure expansion microscopy (U-ExM) 1339–1350
- ultraviolet (UV) 144–145, 187, 192, 737, 983, 1102, 1114, 1263, 1317, 1324, 1332
- Unified Parkinson's Disease Rating Scale (UPDRS) 285, 287, 292, 298
- up-converting phosphor lateral flow circulating anodic antigen (UCP-LF CAA) 907, 918, 927
- upper limit of normal 1001, 1009, 1012
- uric acid 102, 597, 599
- urinary lactoferrin 597, 599
- urinary obstruction 829, 838
- urinary tract 102, 597, 599, 613, 616, 815, 956, 966
- urinary tract infections (UTIs) 597, 599, 613, 815
- urine-based diagnostic 1053–1054
- urine creatinine 597, 599
- urine dipstick probe 597–612, 618
- urine-noninvasive body fluid 597
- uroolithiasis 829, 838, 841
- US Food and Drug Administration (FDA) 111, 119, 155, 157, 160, 172, 234–235, 239, 241, 245–247, 255, 263, 275, 281–282, 434, 487–490, 494–496, 500–501, 507–509, 511–512, 519, 521–525, 531–544, 567–571, 575–576, 583, 1183, 1236, 1240, 1257–1258
- v-raf murine sarcoma viral oncogene homolog B1 (BRAF)* 571, 574
- vaccines 119–120, 126, 202, 206, 212, 1101–1103, 1106–1113, 1119–1120,

- 1175–1177, 1181, 1187–1188, 1227, 1229, 1233, 1235, 1237–1239
- validated protocols 531, 538–539
- validation 33, 223, 228, 238–239, 248, 487, 491, 494, 542, 569, 573, 582–583, 680, 870, 899, 914–919, 922, 970, 986, 989, 993, 997, 1041, 1127, 1132, 1227, 1238, 1298, 1300
- variant evaluation 531, 533, 538–539, 542
- variants of concern (VOC) 891–901, 1187
- variants of interest (VOI) 892, 895–896, 901
- variants with unknown significance 507, 524, 526
- vascular endothelial growth factor (VEGF) 1249, 1256
- vasculature-like perfusion 1273, 1287
- Verona integron-encoded metallo- β -lactamase (VIM) 813–814, 826
- vertebral bone marrow imaging 1001, 1007
- vesicoureteric reflux 829, 838–839
- vesicular breath sound 853, 855, 861, 864, 866
- viral dynamics 197
- viral transport medium (VTM) 211, 223, 227, 899–900
- visceral leishmaniasis (VL) 755–757, 763–764, 774–775, 783–784, 795, 804, 907, 918–919, 927, 1227–1228, 1240
- visceral leishmaniasis-lateral flow device (VL-LFD) 907
- visual acuity test 1249, 1251
- visual hallucinations 1249, 1257
- von Hippel-Lindau disease 829
- wearable sensors 133, 174, 178
- Western blot (WB) 557, 783, 786, 799–801, 804
- Western blotting 756, 1099, 1103, 1105–1108, 1112
- wet AMD 1249, 1254, 1258
- white adipose tissue (WAT) 1137–1148, 1286–1287
- white blood cells (WBCs) 20, 131, 135, 137, 979, 981, 996
- whole-genome sequencing (WGS) 507, 518–519, 526
- whole tissue staining 1137
- wild type (wt) 1355–1356
- wireless instantaneous neurotransmitter concentration system (WINCS) 1163, 1171
- World Health Organization (WHO) 126, 233, 668, 755, 757, 772, 907–909, 919, 921, 926–927, 956, 962, 980, 996, 1074, 1081–1082, 1095, 1227, 1229–1230, 1239
- X-ray crystallography 133, 142–143, 148, 1175, 1177–1178, 1181, 1185–1186, 1188
- X-ray imaging 17, 154, 161, 166, 181, 183, 188, 725–727, 729
- X-rays 17–18, 30–32, 39–41, 95–97, 100, 113, 131, 133, 142–145, 147–156, 160–164, 166–167, 172, 181, 183–184, 187–189, 191, 194–195, 272–273, 275, 397, 446–447, 597, 601, 603, 612, 684, 686–687, 693, 725–730, 734, 737, 1175, 1177–1178, 1181, 1185–1186, 1188–1189
- Xpert MTB/RIF 956, 959, 968
- yogurt-derived microbes 655, 657
- your favorite gene (*YFG*) 1025, 1030, 1032, 1034, 1044
- ζ -potential 597, 600–602, 605–606, 610
- zeaxanthin 1249, 1255
- zero-mode waveguides 507, 517, 526

Also Read

Current Issues in Medicine – Volume 1

Advances in Medical Biochemistry, Genomics, Physiology, and Pathology

Raj Bawa, PhD, MD, Esther H. Chang, PhD, Gerald F. Audette, PhD, Anil R. Diwan, PhD, and Saadia A. Faiz, MD (Editors)

978-981-4877-44-2 (Hardcover), 978-1-003-18044-9 (eBook)
696 pages



The pace and sophistication of advances in medicine in the past two decades have necessitated a growing need for a comprehensive reference that highlights current issues in medicine. Each volume in the Current Issues in Medicine series is a stand-alone text that provides a broad survey of various critical topics—all accomplished in a user-friendly yet interconnected format. The series not only highlights current advances but also explores related topics such as translational medicine, regulatory science, neglected diseases, global pandemics, patent law, immunotoxicology, theranostics, big data, artificial intelligence, novel imaging tools, combination drug products, and novel therapies. While bridging the gap between basic research and clinical medicine, this series provides a thorough understanding of medicine's potential to address health problems from both the patient's and the provider's perspectives in a healthcare setting. The range of topics covered, and the expertise of the contributing authors accurately reflect the rapidly evolving areas within medicine—from basic medical sciences to clinical specialties.

Each volume is essential reading for physicians, medical students, nurses, fellows, residents, undergraduate and graduate students, educators, policymakers, and biomedical researchers. The multidisciplinary approach of the series makes it a valuable reference resource for the pharmaceutical industry, academia, and governments. However, unlike other series on medicine or medical textbooks, this series focuses on current trends, perspectives, and issues in medicine that are central to healthcare delivery in the 21st century. Volume 1 focuses on the current issues in basic medical sciences, subjects that are fundamental to the practice of medicine. Specifically, it covers medical biochemistry, genomics, physiology, and pathology. These subjects, traditionally taught in the first two years of medical school that precede clinical instruction and training, provide a core of basic knowledge critical to the success in clinical medicine during rotations, training, and medical practice.

Current Issues in Medicine – Volume 2

Advances in Clinical Immunology, Medical Microbiology, COVID-19, and Big Data

Raj Bawa, PhD, MD (Editor)

978-981-4877-84-8 (Hardcover), 978-1-003-18043-2 (eBook)
930 pages

The pace and sophistication of advances in medicine in the past two decades have necessitated a growing need for a comprehensive reference that highlights current issues in medicine. Each volume in the Current Issues in Medicine series is a stand-alone text that provides a broad survey of various critical topics—all accomplished in a user-friendly yet interconnected format. The series not only highlights current advances but also explores related topics such as translational medicine, regulatory science, neglected diseases, global pandemics, patent law, immunotoxicology, theranostics, big data, artificial intelligence, novel imaging tools, combination drug products, and novel therapies. While bridging the gap between basic research and clinical medicine, this series provides a thorough understanding of medicine's potential to address health problems from both the patient's and the provider's perspectives in a healthcare setting. The range of topics covered, and the expertise of the contributing authors accurately reflect the rapidly evolving areas within medicine—from basic medical sciences to clinical specialties.



Each volume is essential reading for physicians, medical students, nurses, fellows, residents, undergraduate and graduate students, educators, policymakers, and biomedical researchers. The multidisciplinary approach of the series makes it a valuable reference resource for the pharmaceutical industry, academia, and governments. However, unlike other series on medicine or medical textbooks, this series focuses on current trends, perspectives, and issues in medicine that are central to healthcare delivery in the 21st century. Volume 2 focuses on the current issues in basic medical sciences, subjects that are fundamental to the practice of medicine. Specifically, it discusses clinical immunology, medical microbiology, COVID-19, and big data. These subjects, traditionally taught in the first two years of medical school that precede clinical instruction, provide a core of basic knowledge critical to the success in clinical medicine during rotations, training, and medical practice.

Advances in Surgical and Medical Specialties

Raj Bawa, PhD, MD (Editor)

978-981-4877-45-9 (Hardcover), 978-1-003-29830-4 (eBook)

1378 pages



The pace and sophistication of advances in medicine in the past two decades have been truly breathtaking. This has necessitated a growing need for comprehensive references that highlight current issues in specific sectors of medicine. Keeping this in mind, each volume in the *Current Issues in Medicine* series is a stand-alone text that provides a broad survey of various critical topics in a focused area of medicine—all accomplished in a user-friendly yet interconnected format. However, unlike other series on medicine or medical texts, this series focuses on current trends, perspectives, and issues in medicine that are central to healthcare delivery in the 21st century. Medical practitioners today continue to improve upon techniques and technologies to provide procedures for patients that are safer, faster, less invasive, and more accurate—a direct consequence of advances in technological breakthroughs from a variety of medical and engineering fields. In order to render modern patient care, it is imperative that surgeons and medical practitioners stay current with these latest advances in their respective specialties. Given this backdrop, the specific topics covered in this volume and the expertise of the contributing authors accurately reflect the rapidly evolving areas within surgical and medical specialties. While recognizing how expansive and multifaceted medicine is, *Advances in Surgical and Medical Specialties* addresses crucial recent advances in surgical and medical specialties, integrating the knowledge and experience of experts from academia and practicing surgeons. The multidisciplinary approach reflected here makes this volume a valuable reference resource for medical practitioners, medical students, nurses, fellows, residents, undergraduate and graduate students, educators, venture capitalists, policymakers, and biomedical researchers. A wide audience will benefit from having this volume on their bookshelf: health care systems, the pharmaceutical industry, academia, and government.

Handbook of Clinical Nanomedicine – Volume 1


Nanoparticles, Imaging, Therapy, and Clinical Applications

Raj Bawa, PhD, MD, Gerald F. Audette, PhD, and Israel Rubinstein, MD (Editors)

978-981-4669-20-7 (Hardcover), 978-981-4669-21-4 (eBook)

1662 pages

This handbook (55 chapters) provides a comprehensive roadmap of basic research in nanomedicine as well as clinical applications. However, unlike other texts in nanomedicine, it not only highlights current advances in diagnostics and therapeutics but also explores related issues like nomenclature, historical developments, regulatory aspects, nanosimilars and 3D nanofabrication. While bridging the gap between basic biomedical research, engineering, medicine and law, the handbook provides a thorough understanding of nano's potential to address (i) medical problems from both the patient and health provider's perspective, and (ii) current applications and their potential in a healthcare setting.



"Dr. Bawa and his team have meticulously gathered the distilled experience of world-class researchers, clinicians and business leaders addressing the most salient issues confronted in product concept development and translation."

Gregory Lanza, MD, PhD

Professor of Medicine and Oliver M. Langenberg Distinguished Professor
Washington University Medical School, USA

"This is an outstanding, comprehensive volume that crosscuts disciplines and topics fitting individuals from a variety of fields looking to become knowledgeable in medical nanotech research and its translation from the bench to the bedside."

Shaker A. Mousa, PhD, MBA

Vice Provost and Professor of Pharmacology
Albany College of Pharmacy and Health Sciences, USA

"Masterful! This handbook will have a welcome place in the hands of students, educators, clinicians and experienced scientists alike. In a rapidly evolving arena, the authors have harnessed the field and its future by highlighting both current and future needs in diagnosis and therapies. Bravo!"

Howard E. Gendelman, MD

Margaret R. Larson Professor and Chair
University of Nebraska Medical Center, USA

"It is refreshing to see a handbook that does not merely focus on preclinical aspects or exaggerated projections of nanomedicine. Unlike other books, this handbook not only highlights current advances in diagnostics and therapies but also addresses critical issues like terminology, regulatory aspects and personalized medicine."

Gert Storm, PhD

Professor of Pharmaceutics
Utrecht University, The Netherlands

Handbook of Clinical Nanomedicine – Volume 2

Law, Business, Regulation, Safety, and Risk

**Raj Bawa, PhD, MD, (Editor), Gerald F. Audette, PhD, and
Brian E. Reese, PhD, MBA, JD (Assistant Editors)**

978-981-4669-22-1 (Hardcover), 978-981-4669-23-8 (eBook)
1448 pages

This unique handbook (60 chapters) examines the entire “product life cycle,” from the creation of nanomedical products to their final market introduction. While focusing on critical issues relevant to nanoproduct development and translational activities, it tackles topics such as regulatory science, patent law, FDA law, ethics, personalized medicine, risk analysis, toxicology, nano-characterization and commercialization activities. A separate section provides fascinating perspectives and editorials from leading experts in this complex interdisciplinary field.



“The distinguished editors have secured contributions from the leading experts in nanomedicine law, business, regulation and policy. This handbook represents possibly the most comprehensive and advanced collections of materials on these critical topics. An invaluable standard resource.”

Gregory N. Mandel, JD

Peter J. Liacouras Professor of Law and Associate Dean
Temple University Beasley School of Law, USA

“This is an outstanding volume for those looking to become familiar with nanotechnology research and its translation from the bench to market. Way ahead of the competition, a standard reference on any shelf.”

Shaker A. Mousa, PhD, MBA

Vice Provost and Professor of Pharmacology
Albany College of Pharmacy, USA

“The editors have gathered the distilled experience of leaders addressing the most salient issues confronted in R&D and translation. Knowledge is power, particularly in nanotechnology translation, and this handbook is an essential guide that illustrates and clarifies our way to commercial success.”

Gregory Lanza, MD, PhD

Professor of Medicine and Oliver M. Langenberg Distinguished Professor
Washington University Medical School, USA

“The title of the handbook reflects its broad-ranging contents. The intellectual property chapters alone are worthy of their own handbook. Dr. Bawa and his coeditors should be congratulated for gathering the important writings on nanotech law, business and commercialization.”

Richard J. Apley, JD

Chief Patent Officer
Litman Law Offices/Becker & Poliakoff, USA

“It is clear that this handbook will serve the interdisciplinary community involved in nanomedicine, pharma and biotech in a highly comprehensive way. It not only covers basic and clinical aspects but the often missing, yet critically important, topics of safety, risk, regulation, IP and licensing. The section titled ‘Perspectives and Editorials’ is superb.”


Yechezkel (Chezy) Barenholz, PhD

Professor Emeritus of Biochemistry and Daniel Miller Professor of Cancer Research
Hebrew University-Hadassah Medical School, Israel

Immune Aspects of Biopharmaceuticals and Nanomedicines

Raj Bawa, PhD, MD, János Szebeni, MD, PhD, DSc, Thomas J. Webster, MS, PhD, and Gerald F. Audette, PhD (Editors)

978-981-4774-52-9 (Hardcover), 978-0-203-73153-6 (eBook)
1038 pages



The enormous advances in the immunologic aspects of biotherapeutics and nanomedicines in the past two decades has necessitated an authoritative and comprehensive reference source that can be relied upon by immunologists, biomedical researchers, clinicians, pharmaceutical companies, regulators, venture capitalists, and policy makers alike. This text provides a thorough understanding of immunology, therapeutic potential, clinical applications, adverse reactions, and approaches to overcoming immunotoxicity of biotherapeutics and nanomedicines. It also tackles critical, yet often overlooked topics such as immune aspects of nano-bio interactions, current FDA regulatory guidances, complement activation-related pseudoallergy (CARPA), advances in nanovaccines, and immunogenicity testing of protein therapeutics.

"This outstanding volume represents a review of the various effects of biopharmaceuticals and nanomedicines on the immune system: immunotherapy, vaccines, and drug delivery; challenges and overcoming translational barriers stemming from immunotoxicity; strategies to designing more immunologically friendly formulations."

África González-Fernández, PhD, MD

Professor of Immunology and President of the Spanish Society of Immunology,
University of Vigo, Spain

"For those who are specialists, and for those interested in a broader understanding of biologics and nanomedicines, this is a superb book, with internationally accomplished contributors. It serves both as a reference and as a practical guide to the newest advances in these important fields. Highly recommended!"

Carl R. Alving, MD

Emeritus Senior Scientist, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

"A skillfully produced book that addresses an often-missed topic: immune aspects of biologicals and nanoscale therapeutics, with an emphasis on clinical relevance and applications."

Rajiv R. Mohan, PhD

Professor and Ruth M. Kraeuchi Missouri Endowed Chair Professor,
University of Missouri, Columbia, USA

"An indispensable masterpiece! It represents a rich source of information on interactions of biologics and nanodrugs with the immune system—all critical for medical applications. Volume 3, once again, achieves the series' high standards."

László Rosivall, MD, PhD, DSc Med, Med habil.

Széchenyi Prize Laureate and Professor, Faculty of Medicine, Semmelweis University,
Budapest, Hungary

"Hats off to Dr. Bawa for producing yet another impressive volume in terms of scope, timeliness, and relevance. With expert contributions from around the globe, this book addresses topics germane to researchers, clinicians, drug and biotherapeutic companies, regulators, policymakers, and patients."

Sara Brenner, MD, MPH


Associate Professor and Assistant Vice President, SUNY Polytechnic Institute, Albany,
New York, USA

The Road from Nanomedicine to Precision Medicine

Shaker A. Mousa, PhD, MBA, Raj Bawa, PhD, MD, and Gerald F. Audette, PhD (Editors)

978-981-4800-59-4 (Hardcover), 978-0-429-29501-0 (eBook)

1208 pages



The enormous advances in nanomedicine and precision medicine in the past two decades has necessitated a growing need for an authoritative and comprehensive reference source that can be relied upon by biomedical researchers, clinicians, pharmaceutical scientists, regulators, and lawyers alike. This stand-alone, full-color book provides a broad survey of various interconnected topics, all accomplished in a user-friendly format. Each chapter contains key words, tables, and figures in color, future projections, and an extensive list of references. It is intended to be a standalone reference volume that broadly surveys and highlights innovative technologies and advances pertaining to nanomedicine and precision medicine. In addition, it also addresses often-neglected yet key issues such as translational medicine, intellectual property law, FDA regulatory issues, nanomedicine nomenclature, and artificial nanomachines—all accomplished in a user-friendly, broad yet interconnected format. The book is essential reading for the novice and expert alike in diverse fields such as medicine, law, genomics, pharmaceutical sciences, biomedical sciences, ethics, and regulatory science. The book's multidisciplinary approach will attract a global audience. It will serve as a valuable reference resource for the industry, academia, and government.

"The carefully selected range of topics in this masterpiece is perfect for academia, physicians, drug industry, healthcare systems, policymakers, regulatory bodies, and governments. In the coming decade, efforts in nanomedicine and precision medicine will be translated from the bench to the bedside, paving the way for more accurate diagnosis and more precise therapeutics. This volume is a standard reference for anyone involved in the coming healthcare revolution."

Tatiana K. Bronich, PhD

Parke-Davis Professor, University of Nebraska Medical Center, USA
Editor, *Nanomedicine* (Elsevier)

"The first 3 volumes in this wonderful series have been inspirational. They form the most definitive and useful references about the clinical, technical, legal, and business aspects of nano. This fourth volume was awaited with great interest."

Peter J. Dobson, PhD, OBE

Academic Director, Begbroke Science Park, and Professor (retd), University of Oxford, UK

"Ehrlich's vision of 'magic bullets' postulated in 1908 will be realized along the road from nanomedicine to precision medicine. The power unleashed by elucidation of the genome coupled with the elegance of site-specific drug delivery will revolutionize healthcare in the next century. In my 70-year career as a researcher and university professor, nothing has held greater potential to diagnose and treat diseases in a more customizable, targeted manner. This book reflects innovations, potential applications, and possible bottlenecks in these two interrelated fields."

S. R. Bawa, MSc, PhD

Founding Head and Professor of Biophysics (retd), Panjab University, India

"Precision medicine and targeted nanomedicines are the 'Holy Grail' of medicine and drug delivery; this comprehensive volume highlights their salient features and interconnectivity. A team of distinguished editors and authors have done a superb job focusing on the critical and current issues, masterfully dissecting hype from reality."

János Szebeni, MD, PhD, DSc

Director, Nanomedicine Research & Education Center, Semmelweis University
CEO, SeroScience, Hungary

"The growth, opportunity, and promise of nanomedicine have become breathtaking, which is why this book is my 'go to' reference. It puts cutting-edge nano-developments in context of precision medicine, and the lessons learned from applications in one clinical challenge may serve as a template for other challenges. Use this volume as a reference, but be sure to read it for inspiration."

Nicholas Borys, MD

Senior Vice President and Chief Medical Officer, Celsion Corporation, USA

Medical care is the most critical issue of our time and will be so for the foreseeable future. In this regard, the pace and sophistication of advances in medicine in the past two decades have been truly breathtaking. This has necessitated a growing need for comprehensive reference resources that highlight current issues in specific sectors of medicine. Keeping this in mind, each volume in the *Current Issues in Medicine* series is a stand-alone text that provides a broad survey of various important topics in a focused area of medicine—all accomplished in a user-friendly yet interconnected format. This volume addresses advances in medical imaging, detection, and diagnostic technologies. Technological innovations in these sectors of medicine continue to provide for safer, more accurate, and faster diagnosis for patients. This translates into superior prognosis and better patient compliance, while reducing morbidity and mortality. Hence, it is imperative that practitioners stay current with these latest advances to provide the best care for nursing and clinical practices. While recognizing how expansive and multifaceted these areas of medicine are, *Advances in Medical Imaging, Detection, and Diagnosis* addresses crucial recent progress, integrating the knowledge and experience of experts from academia and the clinic. The multidisciplinary approach reflected makes this volume a valuable reference resource for medical practitioners, medical students, nurses, fellows, residents, undergraduate and graduate students, educators, venture capitalists, policymakers, and biomedical researchers. A wide audience will benefit from having this volume on their bookshelf: health care systems, the pharmaceutical industry, academia, and government.

About the Series Editor



Raj Bawa, PhD, MD, is president of Bawa Biotech LLC (founded 2002), a biotech/pharma consultancy and patent law firm based in Ashburn, Virginia. Trained as a microbiologist and biochemist, he is an inventor, author, entrepreneur, professor, and registered patent agent licensed to practice before the US Patent & Trademark Office. He is currently scientific advisor to Teva Pharmaceutical Industries, Israel; visiting research scholar at Pharmaceutical Research Institute of Albany Pharmacy, Albany, New York; and full professor (adjunct) at NOVA in Annandale, Virginia. He is VP/chief IP officer at Guanine, Inc., in Rensselaer, New York, a company focused on rapid, accurate detection of infectious pathogens. Dr. Bawa has served as a principal investigator of various NCI research grants, and most recently as a principal investigator of a CDC grant to develop an assay for *Klebsiella pneumoniae* carbapenemase (KPC)-producing bacteria. Previously, he was an adjunct professor at Rensselaer Polytechnic Institute, Troy, New York, from 1998 to 2018. He held various positions at the US Patent Office, including primary examiner from 1996 to 2002. He earned a BSc (Honors School) in microbiology, MS in cancer biology, PhD in biophysics/biochemistry, and MD. Currently, he is a life member of Sigma Xi, cochair of the nanotech and precision medicine committees of the American Bar Association and founding director of the American Society for Nanomedicine (established 2008). He has authored over 100 publications, edited 10 texts, and serves on the editorial boards of numerous peer-reviewed journals, including serving as an associate editor of *Nanomedicine* (Elsevier).